17-spiromethylene O +
steroids O +
The O +
invention O +
relates O +
to O +
a O +
steroid O +
derivative O +
which O +
steroidal O +
skeleton O +
is O +
bound O +
at O +
carbon O +
atom O +
17 O +
to O +
a O +
spiromethylene O +
ring O +
of O +
the O +
formula O -
: O +

< O -
See O +
formula O +
I O -
> O +
wherein O +
R O +
a O +
and O +
R O +
b O +
are O +
independently O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
hydrogen O -
, O +
methyl O -
, O +
and O +
halogen O -
; O +
m O +
is O +
1 O +
or O +
2 O -
; O +
and O +
the O +
asterisk O +
denotes O +
carbon O +
atom O +
2 O +
of O +
the O +
spiromethylene O +
ring O +
which O +
is O +
carbon O +
atom O +
17 O +
( O -
or O +
carbon O +
atom O +
17.alpha O -
. O +

of O +
a O +
homosteroid O +
skeleton O -
) O +
of O +
the O +
steroid O -
. O +

The O +
steroids O +
have O +
progestational O +
or O +
antiprogestational O +
activity O -
. O +

Formulations O +
containing O +
coumarins O +
and O +
the O +
use O +
thereof O +
in O +
the O +
pharmaceutical O +
and O +
cosmetic O +
fields O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
coumarins O +
such O +
as O +
esculoside O -
, O +
esculetin O -
, O +
extracts O +
containing O +
them O +
and O +
mixtures O +
thereof O -
, O +
in O +
combination O +
with O +
dimeric O +
and O +
oligomeric O +
proanthocyanidins O -
, O +
in O +
topical O +
formulations O +
for O +
the O +
treatment O +
of O +
peripheral O +
vasculopathies O -
, O +
including O +
the O +
complications O +
of O +
acute O +
venous O +
stasis O -
, O +
or O +
of O +
the O +
unesthetisms O +
related O +
to O +
capillary O +
alterations O -
, O +
or O +
to O +
improve O +
the O +
cicatrization O +
processes O -
. O +

These O +
coumarins O -
, O +
alone O +
or O +
in O +
combination O +
with O +
proanthocyanidins O -
, O +
are O +
also O +
useful O +
in O +
atopical O +
dermatitis O +
and O +
in O +
the O +
treatment O +
of O +
the O +
haematomas O -
. O +

Cosmetic O +
melanins O +
Synthetic O +
melanins O +
suitable O +
for O +
cosmetic O +
uses O +
are O +
produced O +
through O +
oxidative O +
polymerization O +
of O +
monomeric O +
precursors O +
that O +
possess O +
aromatic O +
rings O +
with O +
ionizeable O +
side O +
groups O -
. O +

Agents O +
that O +
enhance O +
adherence O +
of O +
the O +
melanins O +
to O +
skin O +
and O +
hair O +
are O +
co O -
- O -
polymerized O +
with O +
the O +
precursors O +
to O +
become O +
part O +
of O +
the O +
melanin O +
molecules O -
. O +

Potential O +
new O +
precursors O +
and O +
adherence O -
- O -
enhancing O +
agents O +
are O +
screened O +
for O +
efficacy O +
by O +
subjecting O +
them O +
to O +
six O +
separate O +
synthetic O +
procedures O -
, O +
and O +
testing O +
the O +
resulting O +
melanins O +
for O +
color O -
, O +
ultraviolet O +
absorbance O +
charcteristics O -
, O +
and O +
substantivity O +
( O -
adherence O -
) O +
to O +
skin O +
and O +
hair O -
. O +

Melanins O +
of O +
different O +
colors O +
can O +
be O +
blended O +
together O +
in O +
cosmetic O +
creams O +
and O +
lotions O +
to O +
complement O +
the O +
natural O +
skin O -
, O +
eye O -
, O +
and O +
hair O +
colors O +
of O +
an O +
individual O -
. O +

The O +
synthetic O +
procedures O +
are O +
amendable O +
to O +
industrial O -
- O -
scale O +
production O +
of O +
cosmetic O +
melanins O -
. O +

The O +
materials O +
reduce O +
the O +
incidence O +
of O +
solar O +
damage O +
to O +
the O +
skin O -
. O +

Novel O +
silyl O +
compounds O +
and O +
their O +
use O +
The O +
invention O +
describes O +
a O +
process O +
for O +
the O +
epimer O +
enrichment O +
of O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
by O +
silylation O -
, O +
fractionated O +
crystallization O +
and O +
acid O +
hydrolysis O -
. O +

Arylalkyl O -
- O -
diazinones O +
Arylalkyl O +
diazinone O +
derivatives O +
of O +
the O +
formula O +

I O +
( O -
see O +
formula O +
I O -
) O +
and O +
their O +
physiologically O +
acceptable O +
salts O -
, O +
in O +
which O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
B O -
, O +
Q O +
and O +
X O +
have O +
the O +
meanings O +
indicated O +
in O +
Claim O +
1 O -
, O +
exhibit O +
phosphodiesterase O +
IV O +
inhibition O +
and O +
can O +
be O +
employed O +
for O +
the O +
treatment O +
of O +
inflammatory O +
processes O +
and O +
also O +
of O +
allergies O -
, O +
asthma O +
and O +
autoimmune O +
disorders O -
. O +

Novel O +
pharmaceutical O +
combination O +
The O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
for O +
topical O +
administration O +
comprising O +
a O +
topically O +
acceptable O +
antiviral O +
substance O +
and O +
an O +
antiiflammatory O +
glucocorticoid O +
in O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

The O +
pharmaceutical O +
composition O +
can O +
be O +
used O +
in O +
the O +
prophylactic O +
and O +
curative O +
treatment O +
of O +
herpesvirus O +
infections O +
in O +
mammals O +
including O +
man O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
a O +
combination O +
of O +
a O +
topically O +
acceptable O +
antiviral O +
substance O +
and O +
an O +
antiinflammatory O +
glucocorticoid O +
for O +
the O +
manufacture O +
of O +
a O +
midicament O +
for O +
said O +
prophylactic O +
and O +
curative O +
treatment O -
. O +

Substituted O +
indanylidineacetylguanidines O -
, O +
process O +
for O +
their O +
preparation O -
, O -
their O +
use O +
as O +
medicaments O +
or O +
diagnostic O +
and O +
medicaments O +
containing O +
them O +
Indanylidineacetylguanidines O +
I O +

( O -
see O +
formula O +
I O -
) O +
and O +
their O +
pharmaceutically O +
acceptable O +
salts O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O -
, O +
R8 O -
, O +
R9 O -
, O +
R10 O +
and O +
X O +
have O +
the O +
meanings O +
given O +
in O +
the O +
claims O -
, O +
are O +
effective O +
inhibitors O +
of O +
the O +
cellular O +
sodium O -
/ O -
proton O +
antiport O +
( O -
Na O +
+ O -
/H O +
+ O +
exchanger O -
) O -
, O +
which O -
, O +
in O +
numerous O +
diseases O +
( O -
essential O +
hypertension O -
, O +
atherosclerosis O -
, O +
diabetes O +
and O +
the O +
like O -
) O +
is O +
also O +
increased O +
in O +
those O +
cells O +
which O +
are O +
readily O +
accessible O +
for O +
measurements O -
, O +
such O +
as O -
, O +
for O +
example O -
, O +
in O +
erythrocytes O -
, O +
platelets O +
or O +
leukocytes O -
. O +

They O +
are O +
also O +
advantageous O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
the O +
treatment O +
or O +
prophylaxis O +
of O +
disorders O +
of O +
lipid O +
metabolism O -
. O +

Cis-9,10-octadecenoamidase B-Gene +
The O +
soporific O +
activity O +
of O +
cis-9,10-octadecenoamide O +
and O +
other O +
soporific O +
fatty O +
acid O +
primary O +
amides O +
is O +
neutralized O +
by O +
hydrolysis O +
in O +
the O +
presence O +
of O +
cis-9,10-octadecenoamidase O -
. O +

Hydrolysis O +
of O +
cis-9,10-octadecenoamide O +
leads O +
to O +
the O +
formation O +
of O +
oleic O +
acid O -
, O +
a O +
compound O +
without O +
soporific O +
activity O -
. O +

Inhibitors O +
of O +
cis-9,10-octadecenoamidase B-Gene +
are O +
disclosed O +
to O +
block O +
this O +
activity O -
. O +

Nitroimidazole O +
antibacterial O +
compounds O +
and O +
methods O +
of O +
use O +
thereof O +
Methods O -
, O +
compounds O +
and O +
compositions O +
are O +
provided O +
for O +
inhibiting O +
the O +
growth O +
of O +
pathogenic O +
microbes O +
in O +
vitro O +
and O +
of O +
treatment O +
of O +
pathogenic O +
bacterial O +
infections O -
, O +
such O +
as O +
mycobacterial O -
, O +
Clostridium O -
, O +
Cryptosporidium O +
and O +
Helicobacter O +
infections O -
, O +
in O +
vivo O +
using O +
bicyclic O +
nitroimidazole O +
compounds O +
of O +
the O +
formula O +
( O -
II O -
) O -
: O +
( O -
see O +
formula O +
II O -
) O +

The O +
methods O -
, O +
compounds O +
and O +
compositions O +
are O +
particularly O +
useful O +
for O +
inhibiting O +
the O +
growth O +
of O +
Mycobacterium O +
tuberculosis O -
, O +
Clostridium O +
difficile O -
, O +
Cryptosporidium O +
parvum O -
, O +
and O +
Helicobacter O +
pylori O -
, O +
and O +
may O +
be O +
used O +
alone O -
, O +
or O +
in O +
combination O +
with O +
other O +
antimicrobial O +
agents O -
. O +

Administration O +
of O +
ketamine O +
to O +
manage O +
pain O +
and O +
to O +
reduce O +
drug O +
dependency O +
The O +
present O +
invention O +
relates O +
to O +
the O +
management O +
of O +
pain O +
without O +
requiring O +
or O +
allowing O +
for O +
reduction O +
in O +
the O +
level O +
of O +
administration O +
of O +
narcotics O -
, O +
and O +
to O +
self O -
- O -
management O +
of O +
pain O +
on O +
an O +
outpatient O +
basis O -
. O +

Accordingly O -
, O +
the O +
present O +
invention O +
is O +
broadly O +
directed O +
to O +
a O +
method O +
for O +
treating O +
pain O +
in O +
a O +
subject O +
comprising O +
administering O +
via O +
a O +
transmucosal O -
, O +
transdermal O -
, O +
or O +
oral O +
route O +
a O +
dose O +
of O +
ketamine O +
effective O +
to O +
alleviate O +
pain O +
to O +
a O +
subject O +
suffering O +
from O +
pain O -
. O +

The O +
invention O +
is O +
further O +
directed O +
to O +
a O +
method O +
for O +
synergistically O +
treating O +
pain O +
in O +
a O +
subject O +
comprising O +
administering O +
via O +
any O +
route O +
a O +
dose O +
of O +
ketamine O +
effective O +
to O +
allow O +
for O +
reduction O +
in O +
the O +
level O +
of O +
an O +
ongoing O +
pain O +
therapy O -
, O +
or O +
decrease O +
pain O +
( O -
improve O +
the O +
level O +
of O +
pain O +
relief O -
) O -
, O +
or O +
both O -
. O +

Transmucosal O -
, O +
transdermal O -
, O +
and O +
oral O +
administration O +
of O +
ketamine O +
advantageously O +
allows O +
for O +
patient O +
self O +
administration O +
of O +
the O +
drug O -
, O +
which O +
provides O +
for O +
pain O +
management O +
on O +
an O +
outpatient O +
basis O -
. O +

Moreover O -
, O +
ketamine O +
administration O +
in O +
transdermal O +
devices O +
( O -
suppositories O -
, O +
candies O -
, O +
buccal O +
patches O -
) O +
is O +
generally O +
socially O +
acceptable O -
. O +

In O +
a O +
specific O +
example O -
, O +
a O +
patient O +
suffering O +
from O +
intractable O +
bladder O +
pain O +
controlled O +
breakthrough O +
pain O +
by O +
transmucosal O +
( O -
nasal O -
) O +
administration O +
of O +
about O +
16 O +
mg O +
to O +
about O +
32 O +
mg O +
of O +
ketamine O +
per O +
dose O -
. O +

G O -
- O -
coupled O +
receptor O +
showing O +
selective O +
affinity O +
for O +
atp O +
The O +
present O +
invention O +
concerns O +
a O +
G B-Gene -
- I-Gene -
coupled I-Gene +
receptor I-Gene +
which O +
has O +
an O +
amino O +
acid O +
sequence O +
having O +
more O +
than O +
50 O +
% O +
homology O +
with O +
the O +
amino O +
acid O +
sequence O +
shown O +
in O +
Figure O +
1 O -
. O +

An O +
infectious O +
cdna O +
clone O +
of O +
north O +
american O +
porcine O +
reproductive O +
and O +
respiratory O +
syndrome O +
( O -
prrs O -
) O +
virus O +
and O +
uses O +
thereof O +
The O +
invention O +
provides O +
isolated O +
polynucleotide O +
molecules O -
, O +
including O +
plasmids O -
; O +
viral O +
vectors O -
; O +
and O +
transfected O +
host O +
cells O +
that O +
comprise O +
a O +
DNA O +
sequence O +
encoding O +
an O +
infectious O +
RNA O +
sequence O +
encoding O +
a O +
North O +
American O +
PRRS O +
virus O -
; O +
and O +
also O +
North O +
American O +
PRRS O +
viruses O +
encoded O +
thereby O -
. O +

The O +
invention O +
further O +
provides O +
isolated O +
infectious O +
RNA O +
molecules O +
encoding O +
a O +
North O +
American O +
PRRS O +
virus O -
. O +

The O +
invention O +
also O +
provides O +
isolated O +
polynucleotide O +
molecules O -
, O +
infectious O +
RNA O +
molecules O -
, O +
viral O +
vectors O -
, O +
and O +
transfected O +
host O +
cells O +
encoding O +
genetically O -
- O -
modified O +
North O +
American O +
PRRS O +
viruses O -
; O +
and O +
genetically O -
- O -
modified O +
North O +
American O +
PRRS O +
viruses O +
encoded O +
thereby O -
. O +

The O +
invention O +
also O +
provides O +
vaccines O +
comprising O +
such O +
plasmids O -
, O +
RNA O +
molecules O -
, O +
viral O +
vectors O -
, O +
and O +
North O +
American O +
PRRS O +
viruses O -
, O +
and O +
methods O +
of O +
using O +
these O +
vaccines O +
in O +
swine O +
and O +
in O +
other O +
animals O -
. O +

Also O +
provided O +
are O +
isolated O +
polynucleotide O +
molecules O -
, O +
viral O +
vectors O -
, O +
and O +
transfected O +
host O +
cells O +
that O +
comprise O +
a O +
nucleotide O +
sequence O +
encoding O +
a O +
peptide O +
of O +
a O +
North O +
American O +
PRRS O +
virus O -
. O +

These O +
viral O +
vectors O +
and O +
transfected O +
host O +
cell O +
lines O +
are O +
useful O +
in O +
providing O +
peptides O +
to O +
compensate O +
for O +
mutated O +
peptide O +
coding O +
sequences O +
of O +
DNA O +
sequences O +
encoding O +
genetically O -
- O -
modified O +
North O +
American O +
PRRS O +
viruses O +
so O +
that O +
functional O +
virions O +
can O +
be O +
generated O -
. O +

Pyridine O +
derivatives O +
Compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
X O +
and O +
R1 O +
to O +
R5 O +
are O +
as O +
defined O +
in O +
the O +
description O -
, O +
are O +
useful O +
for O +
treating O +
disorders O +
mediated O +
full O +
or O +
in O +
part O +
by O +
mGluR5 B-Gene -
. O +

Therapeutic O +
process O +
for O +
inhibiting O +
nf-.kappa.b B-Gene +
A O +
therapeutic O +
process O +
is O +
provided O +
for O +
the O +
inhibition O +
of O +
NF-.kappa B-Gene -
. I-Gene +

B B-Gene +
in O +
mammals O +
in O +
whose O +
cells O +
NF-.kappa B-Gene -
. I-Gene +

B B-Gene +
has O +
been O +
activated O +
by O +
an O +
agency O +
external O +
to O +
said O +
cell O -
. O +

New O +
crystalline O +
form O +
of O +
1-methyl-5-p O -
- O -
toluoylpyrrole-2-acetamidoacetic O +
acid O +
guaiacyl O +
ester O +
A O +
new O +
crystalline O +
form O +
of O +
1-methyl-5-p O -
- O -
toluoylpyrrole-2-acetamidoacetic O +
acid O +
guaiacyl O +
ester O -
, O +
a O +
process O +
for O +
its O +
preparation O +
and O +
pharmaceutical O +
compositions O +
endowed O +
of O +
antiinflammatory O -
, O +
analgesic O +
and O +
antipyretic O +
activity O +
containing O +
same O +
are O +
disclosed O -
. O +

Treatment O +
of O +
neuropathy O +
This O +
invention O +
relates O +
to O +
the O +
use O +
of O +
cyclic B-Gene +
guanosine I-Gene +
3 I-Gene -
' I-Gene -
, I-Gene +
5'-monophosphate I-Gene +
phosphodiesterase I-Gene +
type I-Gene +
five I-Gene +
( O -
cGMP B-Gene +
PDE5 I-Gene -
) O +
inhibitors O -
, O +
including O +
in O +
particular O +
the O +
compound O +
sildenafil O -
, O +
in O +
combination O +
with O +
gabapentin O +
or O +
pregabalin O -
, O +
which O +
may O +
be O +
used O +
for O +
the O +
treatment O +
of O +
neuropathy O -
, O +
including O +
in O +
particular O +
the O +
treatment O +
of O +
diabetic O +
neuropathy O -
. O +

Improved O +
stable O +
topical O +
ascorbic O +
acid O +
compositions O +
An O +
ascorbic O +
acid O +
( O -
Vitamin O +
C O -
) O +
composition O +
in O +
a O +
nonaqueous O +
or O +
substantially O +
anhydrous O +
silicone O +
vehicle O +
has O +
superior O +
stability O -
. O +

Particulate O +
ascorbic O +
acid O +
is O +
substantially O +
insoluble O +
in O +
the O +
disclosed O +
polyorganosiloxane O +
vehicles O -
, O +
and O +
the O +
vehicle O +
substantially O +
excludes O +
environmental O +
oxygen O -
. O +

The O +
ascorbic O +
acid O +
particles O +
have O +
surprisingly O +
been O +
found O +
to O +
have O +
a O +
high O +
degree O +
of O +
bioavailability O +
and O +
effectiveness O -
, O +
for O +
example O +
in O +
topical O +
applications O +
to O +
reduce O +
wrinkles O +
and O +
increase O +
collagen O +
growth O +
and O +
elasticity O -
. O +

Inhibitors O +
of O +
proteasomal O +
activity O +
for O +
stimulating O +
bone O +
and O +
hair O +
growth O +
Compounds O +
that O +
inhibit O +
the O +
activity O +
of O +
NF O -
- O -
B O +
or O +
inhibit O +
the O +
activity O +
of O +
the O +
proteasome O +
or O +
both O +
promote O +
bone O +
formation O +
and O +
hair O +
growth O +
and O +
are O +
thus O +
useful O +
in O +
treating O +
osteoporosis O -
, O +
bone O +
fracture O +
or O +
deficiency O -
, O +
primary O +
or O +
secondary O +
hyperparathyroidism O -
, O +
periodontal O +
disease O +
or O +
defect O -
, O +
metastatic O +
bone O +
disease O -
, O +
osteolytic O +
bone O +
disease O -
, O +
post O -
- O -
plastic O +
surgery O -
, O +
post O -
- O -
prosthetic O +
joint O +
surgery O -
, O +
and O +
post O -
- O -
dental O +
implantation O -
; O +
they O +
also O +
stimulate O +
the O +
production O +
of O +
hair O +
follicles O +
and O +
are O +
thus O +
useful O +
in O +
stimulating O +
hair O +
growth O -
, O +
including O +
hair O +
density O -
, O +
in O +
subject O +
where O +
this O +
is O +
desirable O -
. O +

Reaction O +
products O +
of O +
hyaluronic O +
acid O +
and O +
natural O +
amino O +
acids O +
and O +
their O +
use O +
in O +
cosmetic O +
and O +
pharmaceutical O +
compositions O +
The O +
present O +
invention O +
relates O +
to O +
new O +
high O +
molecular O +
weight O +
salts O +
of O +
hyaluronic O +
acid O -
. O +

More O +
particularly O -
, O +
these O +
salts O +
are O +
characterized O +
in O +
that O +
they O +
have O +
as O +
a O +
counterion O +
a O +
natural O +
amino O +
acid O -
. O +

The O +
products O +
of O +
the O +
invention O +
can O +
be O +
prepared O +
starting O +
from O +
high O +
molecular O +
weight O +
hyaluronic O +
acid O +
or O +
salts O +
thereof O -
. O +

These O +
new O +
high O +
molecular O +
weights O +
salts O +
of O +
hyaluronic O +
acid O +
may O +
be O +
advantageously O +
employed O +
in O +
the O +
cosmetic O +
of O +
pharmaceutical O +
field O -
. O +

Novel O +
compounds O +
for O +
the O +
management O +
of O +
aging O -
- O -
related O +
and O +
diabetic O +
vascular O +
complications O -
, O +
process O +
for O +
their O +
preparation O +
and O +
therapeutic O +
uses O +
The O +
invention O +
discloses O +
novel O +
compounds O +
of O +
the O +
pyridinium O +
series O +
useful O +
for O +
the O +
management O +
of O +
diabetes O +
and O +
aging O -
- O -
related O +
vascular O +
complications O -
, O +
including O +
kidney O +
disease O -
, O +
nerve O +
damage O -
, O +
atherosclerosis O -
, O +
retinopathy O -
, O +
dermatological O +
disorders O +
and O +
discoloration O +
of O +
teeth O -
, O +
by O +
breaking O +
preformed O +
AGE O -
, O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

The O +
invention O +
also O +
discloses O -
, O +
method O +
for O +
preparation O +
of O +
the O +
novel O +
compounds O +
of O +
the O +
series O +
and O +
pharmaceutical O +
composition O +
comprising O +
one O +
or O +
more O +
of O +
these O +
compounds O -
. O +

The O +
invention O +
further O +
discloses O +
a O +
method O +
of O +
treatment O +
of O +
a O +
diabetic O +
patient O +
by O +
administering O +
the O +
compounds O +
either O +
singly O +
or O +
in O +
combination O +
with O +
drugs O +
for O +
antidiabetic O +
therapy O -
. O +

Antiparasitic O +
formulations O +
comprising O +
doramectin O +
Long O -
- O -
acting O +
antiparasitic O +
formulations O +
of O +
doramectin O -
, O +
suitable O +
for O +
injection O -
, O +
are O +
described O +
herein O -
. O +

Compounds O +
for O +
the O +
modulation O +
of O +
ppar.gamma B-Gene -
. O +

activity O +
Modulators O +
of O +
PPAR.gamma B-Gene -
. O +

activity O +
are O +
provided O +
having O +
the O +
following O +
formula O -
, O +
which O +
modulators O +
are O +
useful O +
in O +
pharmaceutical O +
compositions O +
and O +
methods O +
for O +
the O +
treatment O +
of O +
conditions O +
such O +
as O +
type O +
II O +
diabetes O +
and O +
obesity O -
. O +

( O -
See O +
above O +
Formula O -
) O +

Arylsulphonamide O -
- O -
substituted O +
benzimidazole O +
derivatives O -
, O +
processes O +
for O +
preparing O +
them O +
and O +
their O +
use O +
as O +
pharmaceutical O +
compositions O +
The O +
invention O +
relates O +
to O +
arylsulphonamide O -
- O -
substituted O +
benzimidazole O +
derivatives O +
of O +
general O +
formula O +
( O -
I O -
) O +
wherein O +
the O +
groups O +
R1 O -
, O +
R2 O -
, O +
R3 O +
and O +
R4 O +
may O +
have O +
the O +
meanings O +
given O +
in O +
the O +
claims O +
and O +
specification O -
, O +
processes O +
for O +
preparing O +
them O +
as O +
well O +
as O +
the O +
use O +
of O +
arylsulphonamide O -
- O -
substituted O +
benzimidazole O +
derivatives O +
as O +
pharmaceutical O +
compositions O -
, O +
particularly O +
as O +
pharmaceutical O +
compositions O +
with O +
a O +
tryptase B-Gene -
- O -
inhibiting O +
activity O -
. O +

Iron O +
chelator O +
delivery O +
system O +
An O +
iron O +
chelator O +
delivery O +
system O +
is O +
disclosed O -
. O +

The O +
system O +
comprises O +
iron O +
chelator O +
and O +
a O +
lipid O +
carrier O -
, O +
e.g. O -
, O +
a O +
liposome O -
. O +

Methods O +
for O +
preparing O +
and O +
administering O +
the O +
iron O +
chelator O +
delivery O +
system O +
are O +
also O +
provided O -
. O +

Method O +
for O +
the O +
antibiotic O +
coating O +
of O +
bodies O +
with O +
interconnecting O +
microcavities O +
as O +
well O +
as O +
coated O +
bodies O +
and O +
their O +
usage O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
the O +
antibiotic O +
coating O +
of O +
bodies O +
with O +
interconnecting O +
microcavities O +
as O +
well O +
as O +
bodies O +
coated O +
this O +
way O +
and O +
their O +
usage O -
. O +

The O +
invented O +
method O +
is O +
characterized O +
in O +
that O +
in O +
the O +
microcavities O +
of O +
non O -
- O -
metallic O +
bodies O +
an O +
aqueous O +
solution O +
1 O -
, O +
which O +
contains O +
at O +
least O +
one O +
easily O +
water O -
- O -
soluble O +
antibiotic O +
component O +
from O +
the O +
groups O +
of O +
the O +
aminoglycoside O +
antibiotics O -
, O +
the O +
tetracycline O +
antibiotics O -
, O +
the O +
lincosamide O +
antibiotics O +
and O +
the O +
4-quinolone O +
antibiotics O -
, O +
and O +
an O +
aqueous O +
solution O +
2 O -
, O +
which O +
contains O +
at O +
least O +
one O +
easily O +
water O -
- O -
soluble O +
amphiphilic O +
component O +
from O +
the O +
groups O +
of O +
the O +
alkyl O +
sulfates O -
, O +
alkyl O +
sulfonates O -
, O +
alkylaryl O +
sulfates O -
, O +
dialkylaryl O +
sulfates O -
, O +
alkylaryl O +
sulfonates O -
, O +
dialkylaryl O +
sulfonates O -
, O +
cycloalkyl O +
sulfates O -
, O +
cycloalkyl O +
sulfonates O -
, O +
alkylcycloalkyl O +
sulfates O -
, O +
are O +
introduced O -
, O +
wherein O +
between O +
the O +
introduction O +
of O +
solutions O +
1 O +
and O +
2 O +
the O +
water O +
is O +
basically O +
removed O +
through O +
vaporization O +
and/or O +
evaporation O -
, O +
and O +
whereby O +
from O +
the O +
components O +
of O +
solutions O +
1 O +
and O +
2 O +
in O +
the O +
microcavities O +
a O +
deposit O +
is O +
formed O -
, O +
which O +
is O +
sparingly O +
soluble O +
in O +
water O -
. O +

Ethanol O +
solvate O +
of O +
( O -
- O -
) O -
-cis-2- O -
( O -
2-chlorophenyl O -
) O -
-5,7-dihydroxy-8 O -
[ O -
4r- O -
( O -
3s O -
- O -
hydroxy-1-methyl O -
) O -
piperidinyl O -
] O -
-4h-1-benzopyran-4-one O +
An O +
ethanol O +
solvate O +
form O +
of O +
( O -
- O -
) O -
-cis-2- O -
( O -
2-chlorophenyl O -
) O -
-5,7-dihydroxy-8 O -
[ O -
4R- O -
( O -
3S O -
-- O -
hydroxy-1-methyl O -
) O -
piperidinyl O -
] O -
-4H-1-benzopyran-4-one O +
( O -
Form O +
II O -
) O -
, O +
a O +
method O +
of O +
making O +
Form O +
II O +
and O +
a O +
pharmaceutical O +
composition O +
comprising O +
Form O +
II O +
for O +
treating O +
cancer O -
. O +

Myeloid B-Gene +
colony I-Gene +
stimulating I-Gene +
factor I-Gene +
and O +
uses O +
thereof O +
The O +
identification O +
of O +
the O +
HYAL1 B-Gene +
hyaluronidase I-Gene +
enzyme O +
as O +
a O +
human B-Gene +
plasma I-Gene -
- I-Gene -
derived I-Gene +
myeloid I-Gene +
colony I-Gene -
- I-Gene -
stimulating I-Gene +
factor I-Gene +
( O -
CSF B-Gene -
) O -
, O +
herein O +
designated O +
CSF5-hyaluronidase B-Gene -
, O +
its O +
recombinant O +
production O +
and O +
methods O +
of O +
use O +
are O +
described O -
. O +

This O +
protein O +
may O +
be O +
used O +
for O +
the O +
treatment O +
of O +
myelosuppression O +
as O +
may O +
occur O +
after O +
irradiation O -
, O +
chemotherapy O +
or O +
other O +
diseases O +
where O +
an O +
increase O +
in O +
leukocyte O +
levels O +
may O +
be O +
beneficial O -
. O +

For O +
example O -
, O +
CSF5 B-Gene +
may O +
be O +
used O +
to O +
enhance O +
the O +
immune O +
response O +
to O +
viral O +
infection O +
or O +
other O +
diseases O +
associated O +
with O +
immune O +
suppression O -
. O +

Stable O +
ready O -
- O -
to O -
- O -
use O +
dosage O +
forms O +
containing O +
coloring O +
matter O +
and O +
active O +
chlorine O -
, O +
and O +
methods O +
of O +
making O +
and O +
using O +
same O +
as O +
disinfectants O +
A O +
method O +
of O +
producing O +
a O +
disinfectant O +
or O +
sterilizing O +
liquid O -
, O +
cream O -
, O +
ointment O -
, O +
paste O -
, O +
or O +
gel O +
by O +
dissolving O +
in O +
a O +
solvent O +
a O +
stable O +
ready O -
- O -
to O -
- O -
use O +
dosage O +
form O +
containing O +
coloring O +
matter O +
and O +
an O +
organic O +
chloroxidizer O +
acting O +
as O +
a O +
chlorine O +
donor O +
releasing O +
active O +
chlorine O -
. O +

The O +
coloring O +
matter O +
is O +
in O +
its O +
maximal O +
level O +
of O +
oxidation O -
. O +

The O +
chloroxidizer O +
with O +
coloring O +
matter O +
has O +
a O +
pH O +
of O +
4 O +
- O +
8 O +
and O +
is O +
present O +
in O +
a O +
sufficient O +
quantity O +
to O +
disinfect O +
or O +
sterilize O +
the O +
surface O -
, O +
vessel O -
, O +
or O +
tissue O +
as O +
required O +
while O +
the O +
colored O +
appearance O +
of O +
the O +
liquid O -
, O +
cream O -
, O +
ointment O -
, O +
paste O -
, O +
or O +
gel O +
is O +
stably O +
maintained O +
over O +
a O +
period O +
of O +
time O +
which O +
exceeds O +
the O +
period O +
of O +
time O +
that O +
the O +
disinfectant O +
would O +
be O +
normally O +
used O +
for O +
that O +
purpose O -
. O +

Drug O +
formulations O +
for O +
parenteral O +
use O +
This O +
invention O +
relates O +
to O +
parenteral O +
preparations O +
of O +
antiestrogens O +
such O +
as O +
toremifene O -
, O +
desmethyl O +
toremifene O -
, O +
tamoxifen O +
or O +
desmethyltamoxifen O -
. O +

The O +
preparations O +
can O +
be O +
emulsions O -
, O +
liposomes O +
or O +
aqueous O +
solutions O +
of O +
cyclodextrin O -
- O -
drug O +
complexes O -
. O +

Particularly O +
the O +
invention O +
relates O +
to O +
a O +
parenteral O +
drug O +
formulation O +
comprising O +
a O +
complex O +
having O +
a O +
2-hydroxypropyl O +
cyclodextrin O +
component O +
and O +
including O +
an O +
active O +
drug O +
substance O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
toremifene O -
, O +
desmethyl O +
toremifene O -
, O +
tamoxifen O +
and O +
desmethyltamoxifen O +
or O +
a O +
pharmaceutically O +
acceptable O +
non O -
- O -
toxic O +
salt O +
thereof O -
, O +
said O +
complex O +
being O +
present O +
either O +
in O +
an O +
aqueous O +
solution O +
or O +
emulsion O +
or O +
loaded O +
into O +
a O +
liposome O -
. O +

Pharmaceutical O +
composition O +
for O +
oral O +
use O +
with O +
improved O +
absorption O +
The O +
present O +
invention O +
relates O +
to O +
an O +
agent O +
for O +
inhibiting O +
decomposition O +
of O +
a O +
biologically O +
active O +
peptide O +
by O +
a O +
digestive O +
enzyme O -
, O +
which O +
is O +
aminoalkyl O +
methacrylate O +
copolymer O +
E O +
as O +
an O +
effective O +
ingredient O -
, O +
and O +
an O +
agent O +
for O +
reducing O +
viscosity O +
of O +
the O +
gastrointestinal O +
mucosa O +
and O +
mucous O +
layers O +
distributed O +
over O +
this O +
mucosa O -
. O +

The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
inhibiting O +
decomposition O +
of O +
a O +
biologically O +
active O +
peptide O +
by O +
a O +
digestive O +
enzyme O -
, O +
or O +
a O +
method O +
for O +
reducing O +
viscosity O +
of O +
the O +
gastrointestinal O +
mucosa O +
and/or O +
mucous O +
layers O +
distributed O +
over O +
the O +
mucosa O -
, O +
by O +
administration O +
of O +
aminoalkyl O +
methacrylate O +
copolymer O +
E. O +
Furthermore O -
, O +
the O +
present O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
for O +
oral O +
use O +
with O +
improved O +
absorption O -
, O +
which O +
comprises O +
a O +
biologically O +
active O +
peptide O +
and O +
aminoalkyl O +
methacrylate O +
copolymer O +
E. O +
Excellent O +
oral O +
absorption O +
of O +
a O +
biologically O +
active O +
peptide O +
that O +
were O +
considered O +
difficult O +
to O +
absorb O +
by O +
oral O +
administration O +
in O +
the O +
past O -
, O +
can O +
be O +
realized O +
based O +
on O +
the O +
ability O +
to O +
inhibit O +
decomposition O +
of O +
a O +
biologically O +
active O +
peptide O -
, O +
the O +
ability O +
to O +
reduce O +
viscosity O +
of O +
the O +
gastrointestinal O +
mucosa O +
and/or O +
mucous O +
layers O +
distributed O +
over O +
this O +
mucosa O -
, O +
and O +
the O +
ability O +
to O +
improve O +
permeability O +
of O +
a O +
biologically O +
active O +
peptide O +
in O +
the O +
gastrointestinal O +
mucosa O +
and/or O +
mucous O +
layers O +
of O +
the O +
pharmaceutical O +
composition O +
of O +
the O +
present O +
invention O -
. O +

Composition O +
and O +
method O +
to O +
prevent O +
or O +
reduce O +
diarrhea O +
and O +
steatorrhea O +
in O +
hiv O +
patients O +
Method O +
of O +
preventing O +
or O +
reducing O +
diarrhea O +
and O +
correcting O +
fat O +
malabsorption O +
( O -
steatorrhea O -
) O +
and O +
loss O +
of O +
body O +
mass O +
in O +
HIV O -
- O -
positive O +
patients O +
being O +
treated O +
with O +
High O +
Activity O +
Antiretroviral O +
drugs O +
( O -
HAART O -
) O +
containing O +
protease O +
inhibitors O -
, O +
nucleoside O +
reverse O +
transcriptase O +
inhibitors O +
or O +
non O -
- O -
nucleoside O +
reverse O +
transcriptase O +
inhibitors O +
and O +
by O +
co O -
- O -
administering O +
with O +
the O +
HAART O +
a O +
buffered O +
pancrelipase O +
composition O -
. O +

The O +
method O +
includes O +
the O +
steps O +
of O -
: O +
administering O +
to O +
the O +
HIV O -
- O -
positive O +
patient O +
a O +
High O +
Activity O +
Antiretroviral O +
drug O +
containing O +
a O +
protease O +
inhibitor O -
, O +
a O +
nucleoside O +
reverse B-Gene +
transcriptase I-Gene +
inhibitor O +
or O +
a O +
non O -
- O -
nucleoside O +
reverse B-Gene +
transcriptase I-Gene +
inhibitor O -
; O +
and O +
co O -
- O -
administering O +
with O +
the O +
HAART O +
drug O +
a O +
gastric O +
acid O -
- O -
resistant O +
polymer O -
- O -
coated O +
and O +
buffered O +
pancrelipase O +
enzyme O +
composition O +
containing O +
pancreatic B-Gene +
proteases I-Gene -
, O +
lipases B-Gene -
, O +
co O -
- O -
lipases O -
, O +
nucleases B-Gene -
, O +
amylases B-Gene +
and O +
other O +
bio O -
- O -
active O +
substances O +
produced O +
by O +
the O +
pancreatic O +
gland O -
. O +

Dimetalhydroxy O +
malates O +
Dimetalhydroxy O +
malate O +
compositions O +
as O +
well O +
as O +
methods O +
of O +
administering O +
and O +
making O +
such O +
bioavailable O +
compositions O +
are O +
provided O -
. O +

The O +
metal O +
used O +
can O +
be O +
any O +
nutritionally O +
relevant O +
divalent O +
metal O +
such O +
as O +
calcium O -
, O +
magnesium O -
, O +
zinc O -
, O +
copper O -
, O +
manganese O -
, O +
and O +
iron O -
. O +

The O +
composition O +
can O +
be O +
prepared O +
by O +
reacting O +
malic O +
acid O +
with O +
a O +
divalent O +
metal O +
oxide O +
or O +
hydroxide O +
at O +
a O +
1:2 O +
molar O +
ratio O -
. O +

The O +
composition O +
can O +
be O +
administered O +
to O +
a O +
warm O -
- O -
blooded O +
animal O +
by O +
any O +
of O +
a O +
number O +
of O +
known O +
delivery O +
routes O -
, O +
including O +
oral O +
delivery O -
. O +

Improved O +
absorption O +
of O +
fat O -
- O -
soluble O +
nutrients O +
Carotenoids O +
are O +
provided O +
as O +
dietary O +
supplements O +
to O +
animal O +
feed O -
. O +

These O +
supplements O +
improve O +
the O +
bioavailability O +
of O +
carotenoids O +
by O +
providing O +
them O +
in O +
combination O +
with O +
phospholipids O -
. O +

The O +
invention O +
provides O +
animal O +
feeds O +
for O +
aquatic O +
and O +
terrestrial O +
animals O -
, O +
and O +
methods O +
for O +
making O +
the O +
feeds O -
. O +

Combinations O +
for O +
the O +
treatment O +
of O +
depression O +
It O +
is O +
intended O +
to O +
provide O +
medicinal O +
compositions O +
and O +
the O +
like O +
useful O +
in O +
treating O +
depression O +
which O +
contain O +
a O +
compound O +
having O +
an O +
antagonism O +
to O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
( O -
for O +
example O -
, O +
( O -
E O -
) O -
-8- O -
( O -
3,4-dimethoxystyryl O -
) O -
-1,3-diethyl-7-methyl-3,7-dihydro-1H O -
- O -
purin-2,6-dione O -
) O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
together O +
with O +
an O +
antidepressant O +
( O -
for O +
example O -
, O +
a O +
tricyclic O +
antidepressant O -
, O +
a O +
tetracyclic O +
antidepressant O -
, O +
a O +
selective O +
serotonin O +
reuptake O +
inhibitor O -
, O +
a O +
selective O +
noradrenaline O +
reuptake O +
inhibitor O -
, O +
a O +
dopamine O +
reuptake O +
inhibitor O -
, O +
a O +
serotonin O -
/ O -
noradrenaline O +
reuptake O +
inhibitor O -
, O +
a O +
monoamine B-Gene +
oxidase I-Gene +
inhibitor O +
or O +
a O +
serotonin B-Gene +
2 I-Gene +
antagonist O -
) O -
. O +

Compositions O +
of O +
galactomannan O +
for O +
the O +
treatment O +
of O +
bowel O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
for O +
preventing O -
, O +
ameliorating O +
or O +
treating O +
a O +
bowel O +
disease O -
, O +
comprising O +
galactomannan O +
and/or O +
arabinogalactan O -
; O +
a O +
liquid O +
food O +
for O +
preventing O -
, O +
ameliorating O +
or O +
treating O +
a O +
bowel O +
disease O -
, O +
characterized O +
in O +
that O +
the O +
liquid O +
food O +
comprises O +
a O +
protein O +
and O +
galactomannan O +
and/or O +
arabinogalactan O -
; O +
and O +
a O +
composition O +
for O +
preventing O -
, O +
ameliorating O +
or O +
treating O +
an O +
irritable O +
bowel O +
syndrome O -
, O +
comprising O +
degraded O +
galactomannan O -
. O +

Fluorinated O +
phno O +
and O +
analogs O +
thereof O +
This O +
application O +
describes O +
fluormated O +
( O -
+ O -
) O -
PHNO O +
and O +
analogs O +
thereof O -
, O +
including O +
radiolabeled O +
analogs O -
, O +
of O +
Formula O +
( O -
I O -
) O -
, O +
wherein O +
R1 O +
is O +
C1 O -
- O -
6 O +
alkyl O +
in O +
which O +
one O +
hydrogen O +
atom O +
on O +
the O +
alkyl O +
chain O +
is O +
replaced O +
with O +
fluoro O +
or O +
radioactive O +
fluoro O -
. O +

The O +
application O +
further O +
describes O +
compositions O +
comprising O +
these O +
compounds O +
and O +
methods O +
of O +
using O +
these O +
compounds O +
The O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
have O +
good O +
affinity O +
and O +
selectivity O +
for O +
the O +
dopamine B-Gene +
D2 I-Gene +
receptors I-Gene +
and O +
are O +
therefore O +
useful O +
for O +
the O +
labelling O +
of O +
dopamine B-Gene +
D2 I-Gene +
receptors I-Gene +
in O +
vivo O +
and O +
for O +
the O +
identification O +
and O +
quantification O +
of O +
the O +
extent O +
of O +
dopamine O +
supersensitivity O +
in O +
the O +
bram O +
in O +
various O +
stages O +
of O +
a O +
dopamine O -
- O -
related O +
disease O -
. O +

Oral O +
health O +
care O +
drink O +
and O +
method O +
for O +
reducing O +
malodors O +
An O +
oral O +
care O +
composition O +
and O +
method O +
of O +
using O -
. O +

are O +
provided O +
for O +
treating O +
and O +
preventing O +
malodors O +
or O +
disease O +
conditions O +
of O +
the O +
oral O +
cavity O +
in O +
warm O -
- O -
blooded O +
animals O -
, O +
including O +
humans O -
. O +

When O +
applying O +
an O +
oral O +
care O +
effective O +
amount O +
of O +
the O +
oral O +
care O +
composition O +
of O +
the O +
present O +
invention O +
to O +
the O +
mucosal O +
tissue O +
of O +
the O +
oral O +
cavity O -
, O +
the O +
gingival O +
tissues O +
of O +
the O +
oral O +
cavity O -
, O +
and/or O +
surface O +
of O +
the O +
teeth O -
. O +

The O +
application O +
can O +
be O +
as O +
a O +
liquid O +
for O +
bathing O -
, O +
rinsing O +
or O +
gargling O -
, O +
or O +
lather O +
generated O +
by O +
brushing O +
the O +
teeth O +
for O +
a O +
sufficient O +
time O -
. O +

After O +
rinsing O -
, O +
gargling O +
or O +
brushing O -
, O +
the O +
composition O +
of O +
the O +
present O +
invention O +
should O +
be O +
swallowed O +
to O +
achieve O +
effective O +
reduction O +
of O +
various O +
organisms O -
, O +
diseases O +
and O +
malodors O -
. O +

An O +
oral O +
care O +
effective O +
amount O +
can O +
also O +
prevent O +
and O +
heal O +
mouth O +
sores O +
and O +
canker O +
sores O -
. O +

High O +
fructan O +
cereal O +
plants O +
The O +
invention O +
provides O +
cereal O +
plants O +
having O +
a O +
high O +
level O +
of O +
fructan O +
useful O +
for O +
the O +
production O +
of O +
a O +
range O +
of O +
food O -
, O +
beverage O -
, O +
nutraceutical O +
and O +
pharmaceutical O +
products O -
. O +

The O +
invention O +
provides O +
methods O +
of O +
producing O +
high O -
- O -
fructan O +
products O +
from O +
plants O +
modified O +
to O +
comprise O +
a O +
reduced O +
level O +
of O +
an O +
endogenous O +
polypeptide O +
with O +
starch B-Gene +
synthase I-Gene +
activity O -
, O +
and O +
products O +
so O +
produced O -
. O +

In O +
some O +
embodiments O -
, O +
plants O +
are O +
modified O +
by O +
introduction O +
of O +
an O +
agent O +
such O +
as O +
a O +
nucleic O +
acid O +
molecule O +
which O +
down O +
regulates O +
endogenous B-Gene +
starch I-Gene +
synthase I-Gene +
II I-Gene +
gene O +
expression O -
. O +

Adhesive O +
patch O +
containing O +
fentanyl O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
An O +
adhesive O +
preparation O +
comprising O +
a O +
support O +
and O +
a O +
medicine O -
- O -
containing O +
layer O +
laminated O +
on O +
the O +
support O -
, O +
wherein O +
the O +
medicine O -
- O -
containing O +
layer O +
comprises O +
at O +
least O +
one O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
fentanyl O +
and O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and O +
an O +
adhesive O +
agent O +
comprising O +
polyisobutylene O +
and O +
a O +
silicon O -
- O -
containing O +
polymer O -
, O +
and O +
wherein O +
the O +
ratio O +
of O +
the O +
polyisobutylene O +
to O +
the O +
silicon O -
- O -
containing O +
polymer O +
in O +
the O +
adhesive O +
agent O +
is O +
20:1 O +
to O +
7:3 O +
by O +
mass O -
. O +

Induction O +
of O +
apoptosis O +
and O +
inhibition O +
of O +
cell O +
proliferation O +
through O +
modulation O +
of O +
carnitine O +
palmitoyltransferase O +
1c O +
activity O +
This O +
invention O +
relates O +
to O +
compositions O +
and O +
methods O +
for O +
cancer O +
therapeutics O -
. O +

In O +
particular O -
, O +
the O +
present O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
treating O +
tumors O +
by O +
inhibiting O +
the O +
activity O +
of O +
CPT1C O -
. O +

The O +
methods O +
and O +
compositions O +
can O +
additionally O +
include O +
inhibition O +
of O +
glycolysis O -
. O +

Method O +
for O +
improving O +
storage O +
stability O +
of O +
glutathione O +
Provision O +
of O +
a O +
method O +
of O +
improving O +
preservation O +
stability O +
of O +
glutathione O +
in O +
a O +
solid O +
composition O +
containing O +
glutathione O +
and O +
arginine O -
, O +
or O +
a O +
solid O +
composition O +
containing O +
glutathione O +
and O +
arginine O -
, O +
which O +
shows O +
improved O +
preservation O +
stability O +
of O +
glutathione O -
. O +

In O +
the O +
production O +
of O +
a O +
solid O +
composition O +
containing O +
glutathione O +
and O +
arginine O -
, O +
glutathione O +
and O +
arginine O +
are O +
made O +
to O +
be O +
coexistent O +
with O +
an O +
organic O +
acid O -
. O +

Examples O +
of O +
the O +
organic O +
acid O +
include O +
citric O +
acid O -
, O +
tartaric O +
acid O -
, O +
ascorbic O +
acid O -
, O +
malic O +
acid O -
, O +
malonic O +
acid O -
, O +
succinic O +
acid O -
, O +
fumaric O +
acid O -
, O +
maleic O +
acid O +
and O +
the O +
like O -
. O +

The O +
amount O +
of O +
the O +
organic O +
acid O +
to O +
be O +
coexistent O +
with O +
glutathione O +
and O +
arginine O +
is O +
generally O +
0.1 O +
- O +
2 O +
parts O +
by O +
weight O +
relative O +
to O +
1 O +
part O +
by O +
weight O +
of O +
arginine O -
. O +

Methods O +
for O +
treating O +
bowel O +
diseases O +
The O +
present O +
invention O +
provides O +
new O +
methods O +
of O +
treating O +
bowel O +
disease O +
( O -
BD O -
) O +
by O +
increasing O +
a O +
durability O +
of O +
response O -
; O +
treating O +
BD O +
in O +
males O -
; O +
treating O +
BD O +
in O +
adolescent O +
subjects O -
; O +
treating O +
bloating O +
due O +
to O +
BD O +
in O +
males O -
; O +
and O +
methods O +
of O +
maintaining O +
remission O +
of O +
BD O -
. O +

Novel O +
and O +
potent O +
tapentadol O +
dosage O +
forms O +
The O +
present O +
invention O +
provides O +
a O +
dosage O +
form O +
comprising O +
at O +
least O +
one O +
form O +
of O +
tapentadol O -
, O +
with O +
or O +
without O +
a O +
second O +
analgesic O -
, O +
and O +
at O +
least O +
one O +
opioid O +
antagonist O -
, O +
wherein O +
tapentadol O +
is O +
present O +
in O +
an O +
optimal O +
or O +
suboptimal O +
amount O +
and O +
the O +
said O +
antagonist O +
is O +
present O +
in O +
an O +
amount O +
effective O +
to O +
improve O +
the O +
efficacy O +
and O +
or O +
reduce O +
the O +
side O +
effects O +
of O +
tapentadol O -
. O +

The O +
present O +
invention O +
further O +
provides O +
a O +
method O +
of O +
treating O +
pain O +
and O +
pain O +
related O +
conditions O +
by O +
administering O +
to O +
a O +
patient O +
in O +
need O +
thereof O -
, O +
a O +
dosage O +
form O +
comprising O +
at O +
least O +
one O +
form O +
of O +
tapentadol O -
, O +
with O +
or O +
without O +
a O +
second O +
analgesic O -
, O +
and O +
at O +
least O +
one O +
opioid O +
antagonist O -
, O +
wherein O +
tapentadol O +
is O +
present O +
in O +
an O +
optimal O +
or O +
suboptimal O +
amount O +
and O +
the O +
said O +
antagonist O +
is O +
present O +
in O +
an O +
amount O +
effective O +
to O +
improve O +
the O +
efficacy O +
and O +
or O +
reduce O +
the O +
side O +
effects O +
of O +
tapentadol O -
. O +

Compound O -
, O +
certain O +
novel O +
forms O +
thereof O -
, O +
pharmaceutical O +
compositions O +
thereof O +
and O +
methods O +
for O +
preparation O +
and O +
use O +
Compound O +
of O +
Formula O +
A O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
and O +
crystalline O +
Forms O +
I O +
and O +
ll O +
of O +
Compound O +
of O +
Formula O +
A. O -
( O -
see O +
formula O +
A O -
) O +
Also O -
, O +
methods O +
for O +
the O +
preparation O +
of O +
such O +
compounds O -
, O +
pharmaceutical O +
compositions O +
comprising O +
such O +
compounds O -
, O +
and O +
methods O +
for O +
their O +
uses O -
. O +

Identification O +
of O +
tumor O -
- O -
associated O +
antigens O +
for O +
diagnosis O +
and O +
therapy O +
The O +
invention O +
relates O +
to O +
genetic O +
products O +
the O +
expression O +
of O +
which O +
is O +
associated O +
with O +
cancer O +
diseases O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
therapy O +
and O +
diagnosis O +
of O +
diseases O +
in O +
which O +
the O +
genetic O +
products O +
are O +
expressed O +
or O +
aberrantly O +
expressed O -
, O +
in O +
particular O +
cancer O +
diseases O -
. O +

Novel O +
antibacterial O +
combination O +
therapy O +
An O +
antibacterial O +
composition O +
is O +
provided O +
including O +
a O +
combination O +
of O +
a O +
ÃŸ O -
- O -
lactam O +
antibiotic O +
that O +
has O +
a O +
binding O +
affinity O +
for O +
bacterial O +
penicillin B-Gene -
- I-Gene -
binding I-Gene +
protein I-Gene +
2 I-Gene -
; O +
and O +
a O +
non O -
- O -
antibiotic O +
compound O +
which O +
may O +
be O +
a O +
thienopyridine O +
or O +
a O +
non O -
- O -
thienopyridine O +
compound O -
. O +

A O +
method O +
of O +
treatment O +
using O +
the O +
composition O +
is O +
also O +
provided O -
. O +

Compositions O +
and O +
methods O +
for O +
the O +
treatment O +
of O +
hiv O +
Compositions O +
and O +
methods O +
for O +
the O +
treatment O +
of O +
HIV O +
are O +
provided O -
. O +

Method O +
for O +
producing O +
antifungal O +
drug O +
in O +
triazole O +
class O +
This O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
compounds O +
shown O +
in O +
formula O +
I O -
, O +
and O +
their O +
pharmaceutically O +
acceptable O +
salts O -
. O +

Phosphates O +
of O +
secondary O +
alcohols O +
According O +
to O +
the O +
invention O -
, O +
there O +
is O +
provided O +
a O +
phosphate O +
derivative O +
of O +
a O +
compound O +
having O +
a O +
secondary O +
hydroxy O +
group O -
. O +

The O +
compound O +
having O +
a O +
secondary O +
hydroxyl O +
group O +
may O -
, O +
for O +
example O -
, O +
be O +
chosen O +
from O +
pravastatin O -
, O +
atorvastatin O +
venlafaxine O -
, O +
their O +
derivatives O +
and O +
mixtures O +
thereof O -
. O +

Salvia O +
minium O +
phenolic O +
acid O +
A O +
and O +
process O +
of O +
preparing O +
preparation O +
and O +
use O +
This O +
invention O +
concerns O +
the O +
method O +
of O +
extracting O +
salvianolic O +
acid O +
A O +
from O +
Chinese O +
crude O +
drug O -
: O +
danshen O +
root O -
, O +
and O +
the O +
quality O +
control O +
methods O +
and O +
drug O +
combinations O -
, O +
and O +
the O +
application O +
of O +
this O +
drug O -
. O +

It O +
can O +
be O +
used O +
in O +
the O +
preparation O +
of O +
the O +
prevention O +
drugs O +
for O +
cardiovascular O +
disease O -
, O +
liver O +
damage O -
, O +
liver O +
fibrosis O -
, O +
pulmonary O +
fibrosis O +
and O +
other O -
. O +

Powder O +
and O +
salve O +
for O +
hyperplasia O +
protrusion O +
rehabilitation O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
discloses O +
a O +
medicament O +
for O +
treating O +
hyperplasia O +
and O +
method O +
for O +
preparation O -
, O +
wherein O +
the O +
powdery O +
form O +
medicament O +
is O +
prepared O +
from O +
batryticated O +
silkworm O -
, O +
dahurian O +
angelica O +
root O -
, O +
buthus O +
martensi O +
karsch O -
, O +
centipede O -
, O +
pangolin O +
scales O -
, O +
vomiting O +
nut O +
and O +
musk O -
, O +
and O +
the O +
ointment O +
form O +
medicament O +
is O +
prepared O +
from O +
cibot O +
rhizome O -
, O +
eucommia O +
bark O -
, O +
spatholobus O +
stem O -
, O +
safflower O -
, O +
peach O +
kernels O -
, O +
ledebouriella O +
root O -
, O +
earthworm O -
, O +
agkistrodon O +
acutus O -
, O +
siberian O +
cocklebur O +
fruit O -
, O +
Chinese O +
starjasmine O -
, O +
homalomena O +
rhizoma O -
, O +
frankincense O -
, O +
myrrh O -
, O +
dragon O -
's O +
blood O +
resin O +
and O +
boneol O -
. O +

Organic O +
amine O +
salt O +
of O +
cephalosporin O +
compound O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
relates O +
to O +
the O +
organic O +
amine O +
salt O +
or O +
hydrate O +
for O +
ceph O +
compound O +
used O +
for O +
treating O +
bacteria O +
infection O -
, O +
and O +
the O +
chemical O +
formula O +
is O +
demonstrated O +
in O +
( O -
I O -
) O -
.Said O +
organic O +
amine O +
can O +
be O +
lycine O -
, O +
arginine O -
, O +
tert O -
- O -
butylamine O -
, O +
diethanolamine O -
, O +
triethanolamine O -
, O +
diethylamine O +
or O +
meglumine O -
. O +

It O +
comprises O +
cefuroxime O +
organic O +
amine O +
salt O -
, O +
ceftriaxone O +
organic O +
amine O +
salt O -
, O +
ceftezole O +
organic O +
amine O +
salt O -
, O +
cefoperazone O +
organic O +
amine O +
salt O -
, O +
cephalothin O +
organic O +
amine O +
salt O -
, O +
cefotaxime O +
organic O +
amine O +
salt O -
, O +
cefradine O +
organic O +
amine O +
salt O -
, O +
cefonicid O +
organic O +
amine O +
salt O -
, O +
cefmetazole O +
organic O +
amine O +
salt O -
, O +
cefodizime O +
organic O +
amine O +
salt O -
, O +
cefmenoxime O +
organic O +
amine O +
salt O -
, O +
ceftizoxime O +
organic O +
amine O +
salt O -
, O +
cefpiramide O +
organic O +
amine O +
salt O -
, O +
cefazolin O +
organic O +
amine O +
salt O -
, O +
cefoxitinorganic O +
amine O +
salt O +
and O +
flomoxef O +
organic O +
amine O +
salr O -
. O +

The O +
invention O +
provides O +
the O +
medical O +
compound O +
taking O +
compound O +
in O +
formula O +
( O -
I O -
) O +
as O +
active O +
element O +
and O +
its O +
application O +
to O +
preparation O +
of O +
medicine O +
for O +
treating O +
bacteria O +
infection O -
. O +

1,6-diphospho O -
- O -
D O -
- O -
fructose O +
ester O +
arginine O +
salt O +
and O +
its O +
pharmaceutical O +
uses O +
The O +
invention O +
disclose O +
the O +
arginine O +
salt O +
of O +
1 O -
, O +
6- O +
diphosphoric O +
acid- O +
D- O +
fructose O +
esters O +
in O +
hydrate O +
type O -
, O +
and O +
one O +
or O +
more O +
than O +
one O +
of O +
the O +
four O +
function O +
groups O +
is O +
salinized O +
by O +
arginine O -
. O +

The O +
salt O +
precipitation O +
with O +
1 O -
, O +
6- O +
diphosphoric O +
acid- O +
D- O +
fructose O +
esters O +
and O +
arginine O +
solves O +
problems O +
of O +
strong O +
side O +
effect O +
of O +
sodium O +
fructose O +
diphosphate O -
, O +
and O +
starting O +
circuit O -
, O +
high O +
natremia O +
risk O -
. O +

It O +
is O +
demonstrated O +
through O +
pharmacological O +
test O +
that O +
arginine O +
salt O +
can O +
cooperate O +
with O +
drug O +
and O +
the O +
toxcity O +
is O +
low O -
. O +

Slow O +
release O +
tablet O +
of O +
amoxicillin O +
The O +
invention O +
discloses O +
slow O +
release O +
tablets O +
of O +
Amoxicillin O +
and O +
process O +
for O +
preparation O -
, O +
wherein O +
the O +
raw O +
materials O +
of O +
the O +
preparation O +
include O +
Amoxicillin O +
of O +
a O +
predetermined O +
proportion O -
, O +
slow O +
release O +
matrix O +
material O +
and O +
medicinal O +
material O -
, O +
the O +
preparation O +
can O +
be O +
prepared O +
into O +
solid O +
dispersing O +
agent O -
, O +
wherein O +
the O +
medicament O +
can O +
be O +
released O +
slowly O +
and O +
continuously O +
after O +
being O +
administrated O -
, O +
the O +
effective O +
concentration O +
in O +
blood O +
can O +
be O +
maintained O -
, O +
and O +
long O +
action O +
can O +
be O +
achieved O -
. O +

The O +
advantages O +
of O +
the O +
invention O +
include O +
decreased O +
frequency O +
of O +
medicinal O +
administration O -
, O +
improved O +
patient O -
's O +
adaptability O -
, O +
lowered O +
blood O +
concentration O +
peak O -
- O -
valley O -
, O +
increased O +
medicinal O +
effect O +
and O +
safety O -
, O +
and O +
reduced O +
total O +
medicinal O +
dose O -
, O +
thereby O +
optimum O +
curative O +
effect O +
can O +
be O +
achieved O +
through O +
minimum O +
dose O -
, O +
thus O +
the O +
preparation O +
is O +
more O +
suitable O +
for O +
patients O -
. O +

Nucleic O +
acid O +
molecule O +
RTN4BSR62 O +
and O +
application O +
in O +
preparation O +
of O +
anti O -
- O -
cancer O +
drugs O +
The O +
invention O +
discloses O +
a O +
making O +
method O +
of O +
RTN4BSR32 O +
and O +
application O +
to O +
prepare O +
tumour O -
- O -
proof O +
drug O -
, O +
whose O +
sequence O +
contains O +
5'-AATGTCTCTCCAGTACAGG-3 O -
' O +
or O +
5'-AAUGUCUCUCCAGUACAGG-3 O -
' O -
. O +

The O +
molecular O +
can O +
inhibit O +
tumour O +
from O +
growing O +
obviously O -
, O +
which O +
provides O +
a O +
new O +
path O +
and O +
method O +
to O +
treat O +
and O +
release O +
tumour O -
. O +

Application O +
of O +
ferricitras O +
in O +
preparation O +
of O +
medicine O +
to O +
prevent O +
and O +
treat O +
angiosteosis O +
The O +
present O +
invention O +
relates O +
to O +
the O +
application O +
of O +
ferric O +
citrate O +
in O +
preparing O +
medicine O +
for O +
preventing O +
and O +
treating O +
calcification O +
of O +
blood O +
vessel O -
. O +

The O +
present O +
invention O +
has O +
determined O +
curative O +
effect O -
. O +

Experiment O +
proves O +
that O +
ferric O +
citrate O +
can O +
intervene O +
calcification O +
of O +
blood O +
vessel O +
and O +
inhibit O +
calcification O +
effectively O -
, O +
and O +
may O +
reverse O +
calcification O +
of O +
blood O +
vessel O -
. O +

Hydrophilic O +
polyglycol O +
supported O +
ursolic O +
acid O +
medicines O +
and O +
their O +
prepn O +
process O +
The O +
present O +
invention O +
is O +
serial O +
hydrophilic O +
polyglycol O +
supported O +
ursolic O +
acid O +
medicines O +
obtained O +
through O +
organic O +
synthesis O +
and O +
polymerization O +
to O +
grafting O +
hydrophilic O +
polyglycol O +
onto O +
cyclohydroxy O +
group O +
of O +
ursolic O +
acid O +
A. O +
The O +
structure O +
analysis O +
and O +
experiments O +
show O +
that O +
activated O +
polyglycol O +
is O +
grafted O +
successfully O +
onto O +
ursolic O +
acid O +
said O +
water O +
insoluble O +
ursolic O +
acid O +
becomes O +
water O +
soluble O +
polyglycol O -
- O -
ursolic O +
acid O -
. O +

Polyglycol O -
- O -
ursolic O +
acid O +
has O +
excellent O +
blood O +
compatibility O +
and O +
high O +
physiological O +
activity O -
, O +
so O +
that O +
polyglycol O +
supported O +
ursolic O +
acid O +
medicines O +
may O +
be O +
prepared O +
into O +
different O +
forms O -
, O +
including O +
injection O -
, O +
oral O +
liquid O -
, O +
capsule O -
, O +
tablet O -
, O +
etc O -
. O +

The O +
polyglycol O +
has O +
average O +
molecular O +
weight O +
of O +
200 O -
- O -
60,000 O -
. O +

Ruthenium O +
porphyrin O +
complex O +
and O +
its O +
prepn O +
process O +
and O +
application O +
as O +
photosensitizer O +
for O +
photodynamic O +
therapy O +
The O +
present O +
invention O +
discloses O +
ruthenium O +
porphyrin O +
complex O +
and O +
its O +
preparation O +
process O +
and O +
application O +
as O +
photosensitizer O +
for O +
photodynamic O +
therapy O -
. O +

The O +
ruthenium O +
porphyrin O +
complex O +
with O +
the O +
structure O +
as O +
shown O +
has O +
ruthenium O +
as O +
the O +
central O +
metal O +
ion O -
, O +
pyridyl O +
radical O +
containing O +
asymmetrical O +
porphyrin O +
and O +
its O +
metal O +
derivative O +
as O +
the O +
ligand O -
, O +
and O +
coordinate O +
bond O +
jointing O +
the O +
ruthenium O +
pyridyl O +
radical O +
and O +
the O +
porphyrin O +
ring O -
. O +

The O +
ruthenium O +
porphyrin O +
complex O +
of O +
the O +
present O +
invention O +
has O +
determined O +
composition O -
, O +
less O +
toxic O +
side O +
effect O +
and O +
good O +
absorption O +
and O +
metabolism O +
in O +
organism O -
, O +
and O +
is O +
suitable O +
for O +
use O +
as O +
photosensitizer O +
for O +
photodynamic O +
therapy O -
. O +

Use O +
of O +
dihydro O +
myricotin O +
element O +
for O +
treating O +
cardiac O +
blood O +
diseases O +
The O +
present O +
invention O +
discloses O +
an O +
application O +
of O +
dihydromyricetin O +
in O +
preparation O +
of O +
medicine O +
for O +
preventing O +
or O +
curing O +
angiocardiopathy O -
. O +

The O +
animal O +
tests O +
show O +
that O +
the O +
dihydromyricetin O +
has O +
the O +
effect O +
for O +
resisting O +
internal O +
phlebothrombosis O -
, O +
can O +
be O +
used O +
for O +
effectively O +
preventing O +
angiocardiopathy O +
due O +
to O +
thrombosis O -
, O +
for O +
example O +
cardiac O +
disease O +
and O +
apoplexy O -
. O +

Said O +
invention O +
can O +
be O +
made O +
into O +
medicine O +
or O +
health O -
- O -
care O +
product O -
. O +

Novel O +
dihydrochalcone O +
compound O +
separated O +
and O +
purified O +
from O +
drgon O +
blood O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
new O +
dihydrochalcone O +
compound O +
that O +
is O +
separated O +
and O +
purified O +
from O +
Long O +
Xuejie O +
and O +
the O +
manufacture O +
method O -
. O +

It O +
adopts O +
Long O +
Xuejie O +
as O +
raw O +
material O -
, O +
uses O +
light O +
petroleum O +
and O +
chloroform O +
solvent O +
to O +
distill O -
, O +
decreases O +
pressure O +
and O +
concentrating O +
chloroform O +
extractive O -
, O +
takes O +
silica O +
gel O +
column O +
or O +
rapid O +
silica O +
gel O +
chromatography O +
and O +
takes O +
Sephadex O +
LH-20 O +
gelcolumn O +
chromatography O +
andseparating O -
, O +
purifies O +
chromatogram O -
, O +
and O +
finally O +
gains O +
dihydrochalcone O +
compound O -
. O +

The O +
chemical O +
name O +
is O +
4'- O +
hydroxyl-2 O -
' O -
, O +
4- O +
dimethoxy- O +
dihydrochalcone O -
. O +

The O +
compound O +
has O +
good O +
effect O +
to O +
avoid O +
platelet O +
aggregation O -
. O +

Pharmaceutical O +
composition O +
for O +
treatment O +
of O +
lower O +
urinary O +
tract O +
diseases O +
The O +
invention O +
relates O +
to O +
a O +
drug O +
compound O +
for O +
treating O +
disease O +
of O +
lower O +
urinary O +
tract O -
, O +
which O +
comprises O +
drug O +
active O +
component O -
, O +
drug O +
carrier O +
or O +
shaping O +
agent O -
, O +
wherein O +
the O +
drug O +
active O +
component O +
is O +
terraazoles O +
and O +
amiloripin O -
. O +

The O +
disease O +
of O +
lower O +
urinary O +
tract O +
relates O +
to O +
prostatitis O +
increment O -
, O +
lower O +
urinary O +
tract O +
syndrome O +
and O +
bladder O +
excessive O +
activities O -
, O +
in O +
particular O +
to O +
treat O +
lower O +
urinary O +
tract O +
syndrome O +
and O +
bladder O +
excessive O +
activities O +
induced O +
by O +
prostatitis O +
increment O -
. O +

And O +
the O +
inventive O +
drug O +
can O +
be O +
used O +
treat O +
the O +
high O +
blood O +
pressure O +
concomitant O +
with O +
lower O +
urinary O +
tract O -
, O +
to O +
effectively O +
control O +
blood O +
pressure O +
and O +
resolve O +
the O +
lower O +
urinary O +
tract O +
disease O -
, O +
compared O +
with O +
single O +
terraazoles O +
or O +
amiloripin O +
drug O -
, O +
to O +
improve O +
the O +
health O +
quality O +
of O +
patient O -
. O +

Nanometer O +
elemental O +
selenium O +
coupled O +
with O +
liquid O +
amino O +
acid O +
and O +
the O +
method O +
for O +
preparing O +
and O +
preserving O +
the O +
same O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
nanometer O +
monomer O +
selenium O +
via O +
coupling O +
liquid O +
amino O +
acid O -
, O +
comprising O +
that O +
at O +
normal O +
temperature O +
and O +
normal O +
pressure O -
, O +
adding O +
vitamin O +
C O +
solution O +
into O +
amino O +
acid O +
solution O -
, O +
mixing O +
uniformly O +
and O +
adding O +
selenious O +
anhydride O +
or O +
selenite O +
solution O +
until O +
the O +
product O +
has O +
held O +
red O -
, O +
to O +
obtain O +
the O +
liquid O +
coupled O +
product O +
of O +
amino O +
acid O +
and O +
nanometer O +
selenium O -
. O +

The O +
nanometer O +
monomer O +
selenium O +
can O +
be O +
used O +
as O +
medical O +
health O -
- O -
care O +
product O +
to O +
display O +
the O +
cooperation O +
between O +
amino O +
acid O +
and O +
nanometer O +
selenium O -
, O +
while O +
the O +
nanometer O +
selenium O +
gel O +
has O +
small O +
diameter O -
, O +
narrow O +
distribution O +
and O +
liquid O +
storage O -
, O +
to O +
develop O +
oral O -
, O +
injection O +
or O +
the O +
like O -
. O +

Anticancer O +
compound O +
including O +
neoangiogenesis O +
inhibitors O +
and O +
alkylate O +
agent O +
The O +
invention O +
relates O +
to O +
an O +
anti O -
- O -
cancer O +
compound O +
as O +
a O +
slow O +
release O +
injection O +
which O +
contains O +
vessel O +
restrainer O +
and/or O +
alkyl O +
agent O -
, O +
formed O +
by O +
slow O +
release O +
micro O +
ball O +
and O +
solvent O -
. O +

The O +
slow O +
release O +
micro O +
ball O +
comprises O +
the O +
anti O -
- O -
cancer O +
effective O +
components O +
and O +
slow O +
release O +
findings O -
, O +
the O +
solvent O +
is O +
a O +
common O +
solvent O +
or O +
a O +
special O +
solvent O +
with O +
suspending O +
agent O -
, O +
while O +
the O +
viscosity O +
of O +
suspending O +
agent O +
is O +
100cp-3000cp O +
( O -
at O +
20 O -
- O -
30Deg O -
. O +

C O -
) O -
, O +
selected O +
from O +
carboxymethyl O +
cellulose O -
, O +
the O +
anti O -
- O -
cancer O +
effective O +
component O +
is O +
the O +
combination O +
of O +
vessel O +
restrainer O +
and/or O +
the O +
alkyl O +
agent O +
selected O +
from O +
nimuxitin O -
, O +
or O +
the O +
like O -
, O +
the O +
slow O +
release O +
finding O +
is O +
selected O +
from O +
phosphate O +
polyester O +
as O +
p O +
( O -
LAEG O -
- O -
EOP O -
) O -
, O +
p O +
( O -
DAPG O -
- O -
EOP O -
) O -
, O +
or O +
the O +
polyester O +
or O +
mixture O +
of O +
phosphate O +
and O +
polylactic O +
acid O -
, O +
polyphenyl O -
, O +
2-aliphatic O +
acid O -
, O +
sebacic O +
acid O +
polyester O -
, O +
poly O +
( O -
erucic O +
acid O +
dimmer O -
- O -
sebacic O +
acid O -
) O +
or O +
poly O +
( O -
fumaric O +
acid O -
- O -
sebacic O +
acid O -
) O -
. O +

The O +
anti O -
- O -
cancer O +
compound O +
can O +
be O +
made O +
as O +
slow O +
release O +
plant O +
agent O -
, O +
to O +
inject O +
into O +
cancer O +
or O +
around O +
cancer O +
to O +
hold O +
the O +
effective O +
drug O +
density O +
for O +
more O +
than O +
40 O +
days O -
, O +
while O +
it O +
can O +
significantly O +
reduce O +
the O +
general O +
reaction O +
of O +
drug O +
and O +
selectively O +
strengthen O +
the O +
effect O +
of O +
non O -
- O -
surgery O +
treatments O +
as O +
chemotherapy O +
or O +
the O +
like O -
. O +

Medicine O +
composition O +
and O +
its O +
preparing O +
method O +
A O +
medicinal O +
composition O +
is O +
prepared O +
from O +
gentamycin O -
, O +
amitriptyline O -
, O +
honey O -
, O +
and O +
11 O +
Chinese O -
- O -
medicinal O +
materials O +
including O +
notoginseng O -
, O +
peach O +
kernel O -
, O +
fennel O -
, O +
borax O -
, O +
etc O -
. O +

Its O +
preparing O +
process O +
is O +
also O +
disclosed O -
. O +

An O +
improved O +
process O +
for O +
preparing O +
pure O +
ondansetron O +
hydrochloride O +
dihydrate O +
An O +
improved O +
method O +
for O +
preparing O +
dimethylamino O -
- O -
methyl O -
- O -
carbazolone O +
and O +
ondansetron O +
base O -
. O +

A O +
recrystallization O +
process O +
for O +
preparing O +
pure O +
ondansetron O +
hydrochloride O +
dihydrate O +
with O +
a O +
purity O +
of O +
at O +
least O +
99.0 O -
% O +
is O +
also O +
disclosed O -
. O +

Anethol O +
trithione O +
drop O +
pills O -
, O +
and O +
preparation O +
method O +
A O +
dripping O +
pill O +
of O +
anethol O +
trithione O +
for O +
treating O +
cholecystitis O -
, O +
cholelithiasis O +
and O +
acute O +
or O +
chronic O +
hepatitis O +
is O +
prepared O +
from O +
the O +
anethol O +
trithione O +
and O +
the O +
matrix O +
of O +
dripping O +
pill O -
. O +

Its O +
preparing O +
process O +
is O +
also O +
disclosed O -
. O +

Suppository O +
for O +
treating O +
wound O +
caused O +
by O +
cervical O +
erosion O +
treatment O +
Disclosed O +
is O +
a O +
suppository O +
for O +
processing O +
wounds O +
in O +
the O +
treatment O +
of O +
uterine O +
neck O +
erosion O -
, O +
which O +
comprises O +
biologically O +
active O +
glass O -
, O +
collagen O +
and O +
activated O +
charcoal O +
fiber O +
by O +
a O +
weight O +
ratio O +
of O +
30 O -
- O -
70:70 O -
- O -
30 O -
. O +

The O +
preparing O +
process O +
comprises O +
steps O +
of O +
coating O +
the O +
activated O +
charcoal O +
fiber O +
into O +
a O +
circular O +
form O -
, O +
crosslinking O +
the O +
collagen O +
solution O +
or O +
dried O +
powder O -
, O +
proportioning O +
collagen O +
and O +
biologically O +
active O +
glass O -
, O +
dissolving O +
and O +
stirring O +
20 O -
- O -
50 O +
minutes O -
, O +
freeze O +
drying O -
, O +
pressurizing O +
to O +
obtain O +
composite O +
film O -
, O +
adhering O +
the O +
composite O +
film O +
with O +
one O +
end O +
of O +
the O +
activated O +
charcoal O +
fiber O +
suppository O -
, O +
and O +
fixing O +
the O +
other O +
end O +
of O +
the O +
activated O +
charcoal O +
fiber O +
suppository O +
with O +
soft O +
wires O -
. O +

The O +
collagen O +
can O +
be O +
replaced O +
with O +
chitosan O -
. O +

Medical O +
combination O +
of O +
teniposide O -
, O +
the O +
preparing O +
method O +
and O +
the O +
function O +
thereof O +
The O +
invention O +
discloses O +
a O +
medicinal O +
component O +
of O +
substitute O +
nipa O +
glycosides O -
, O +
which O +
is O +
characterized O +
by O +
the O +
following O -
: O +
incorporating O +
substitute O +
nipa O +
glycosides O -
, O +
Tuwen O +
surface O +
activator O -
, O +
assisting O +
solvent O +
and O +
inorganic O +
salt O -
; O +
choosing O +
the O +
assisting O +
solvent O +
as O +
mixture O +
of O +
dimethyl O +
ethanolamine O +
and O +
carbowax O -
; O +
choosing O +
the O +
inorganic O +
salt O +
from O +
one O +
or O +
multiple O +
common O +
salt O -
, O +
potassium O +
chloride O -
, O +
sulphate O +
and O +
sulphate O -
; O +
setting O +
this O +
component O +
as O +
injection O +
or O +
freeze O +
dry O +
powder O +
needle O -
; O +
adding O +
into O +
Tuwen O +
and O +
the O +
assisting O +
dissolvent O -
; O +
adding O +
into O +
the O +
inorganic O +
salt O +
at O +
the O +
same O +
time O -
; O +
increasing O +
solubility O +
of O +
substitute O +
nipa O +
glycosides O -
. O +

This O +
invention O +
also O +
relates O +
to O +
the O +
preparing O +
method O +
and O +
usage O +
of O +
this O +
medicinal O +
component O -
. O +

Novel O +
medicine O +
for O +
giving O +
up O +
drug O +
The O +
invention O +
relates O +
to O +
a O +
novel O +
medicament O +
for O +
drug O +
abstinence O +
which O +
comprises O +
the O +
following O +
constituents O +
( O -
by O +
weight O +
ratio O -
) O -
: O +
acanthopanax O +
root O +
18 O -
- O -
30 O -
% O -
, O +
polygala O +
root O +
6 O -
- O -
12 O -
% O -
, O +
dendrobium O +
9 O -
- O -
16 O -
% O -
, O +
notoginseng O +
3 O -
- O -
10 O -
% O -
, O +
ginseng O +
10 O -
- O -
24 O -
% O -
, O +
ginkgo O +
leaves O +
24 O -
- O -
34 O -
% O -
, O +
atropine O +
sulfate O +
0 O -
. O +

05 O -
- O -
1 O -
. O +
5 O -
% O -
, O +
ansiolin O +
0 O -
. O +
05 O -
- O -
1 O -
. O +
0 O -
% O -
. O +

The O +
medicament O +
can O +
be O +
prepared O +
into O +
capsules O -
, O +
granules O +
and O +
tablets O +
through O +
conventional O +
processes O -
. O +

Method O +
for O +
preparing O +
iron O -
- O -
complementing O +
agent O +
by O +
complex O +
of O +
parafobrown O +
algin O +
and O +
iron O +
The O +
invention O +
is O +
concerned O +
with O +
the O +
method O +
to O +
produce O +
supply O +
of O +
iron O +
using O +
the O +
algin O +
and O +
compound O +
of O +
iron O -
. O +

Put O +
the O +
water O +
solution O +
or O +
degeneration O +
fluid O +
of O +
algin O +
into O +
a O +
container O -
, O +
add O +
assistant O +
stabilizer O +
and O +
inorganic O +
iron O +
salt O -
, O +
and O +
the O +
concentration O +
is O +
0.1 O +
to O +
0.50 O +
mol O -
/ O -
L O -
, O +
adjust O +
the O +
pH O +
of O +
solution O +
is O +
4 O +
to O +
8 O -
, O +
refluence O +
for O +
2 O +
to O +
5 O +
hours O -
, O +
dialyse O -
, O +
concentrate O -
, O +
divide O +
with O +
alcohol O +
and O +
taking O +
centrifugal O +
processing O -
. O +

Wash O +
and O +
dry O +
the O +
sedimentation O +
to O +
get O +
algin O +
Fe O +
( O -
III O -
) O +
compound O -
. O +

The O +
method O +
has O +
reasonable O +
prcess O +
and O +
low O +
cost O -
, O +
the O +
produced O +
supply O +
of O +
iron O +
has O +
nice O +
stability O +
with O +
high O +
biology O +
utilization O +
ratio O -
, O +
the O +
revivification O +
and O +
dissolving O +
time O +
is O +
fit O +
to O +
absorb O +
for O +
body O -
. O +

The O +
algin O +
forms O +
into O +
gel O +
with O +
stomach O +
acid O +
and O +
protecting O +
film O +
on O +
the O +
surface O +
of O +
stomach O +
in O +
order O +
to O +
reduce O +
the O +
stimulating O +
to O +
stomach O -
. O +

It O +
is O +
fit O +
for O +
pregnant O +
woman O -
, O +
children O +
and O +
gastricism O +
sufferer O -
. O +

Novel O +
use O +
of O +
medicine O +
The O +
present O +
invention O +
provides O +
new O +
use O +
of O +
arctiin O -
, O +
and O +
is O +
especially O +
the O +
application O +
of O +
arctiin O +
in O +
preparing O +
medicine O +
for O +
preventing O +
and O +
treating O +
chronic O +
renal O +
failure O +
and O +
renal O +
fiberosis O -
. O +

Improved O +
process O +
of O +
preparing O +
Raltitrexed O +
The O +
improvement O +
in O +
the O +
process O +
of O +
preparing O +
Raltitrexed O +
as O +
antitumor O +
medicine O +
includes O +
the O +
reaction O +
between O +
N- O -
( O -
5-aminothienyl-2-formoxyl O -
) O -
-L O -
- O -
diethyl O +
glutarate O +
and O +
methyl O +
iodide O +
at O +
temperature O +
raised O +
to O +
100 O +
deg.c O +
in O +
lucifugous O +
condition O +
with O +
yield O +
raised O +
to O +
91 O +
% O -
; O +
the O +
replacement O +
of O +
sodium O +
sulfide O +
for O +
iron O +
powder O +
as O +
reductant O +
to O +
facilitate O +
post O -
- O -
treatment O +
and O +
raise O +
yield O -
; O +
the O +
replacement O +
of O +
re O -
- O -
crystallization O +
in O +
mixed O +
solvent O +
of O +
methanol O +
and O +
ether O +
for O +
column O +
separation O +
to O +
expand O +
the O +
production O +
capacity O -
; O +
and O +
oxidizing O +
5-nitrothienyl-2-formaldehyde O +
with O +
chromic O +
acid O -
, O +
rather O +
than O +
bromine O -
, O +
to O +
eliminate O +
toxicity O +
and O +
raise O +
safety O -
. O +

The O +
improved O +
preparation O +
process O +
of O +
Raltitrexed O +
has O +
high O +
yield O -
, O +
great O +
production O +
capacity O -
, O +
low O +
solvent O +
consumption O +
and O +
high O +
safety O -
. O +

Potato O +
red O +
healing O +
liquid O +
and O +
method O +
for O +
preparing O +
the O +
same O +
The O +
invention O +
relates O +
to O +
a O +
kind O +
of O +
medicine O +
and O +
its O +
production O +
method O -
, O +
especially O +
relates O +
to O +
a O +
kind O +
of O +
rehabilitation O +
liquid O +
and O +
the O +
production O +
method O -
. O +

It O +
is O +
specialized O +
for O +
fiber O +
lung O +
treatment O -
. O +

The O +
anti O -
- O -
inflammation O +
effect O +
of O +
potato O +
is O +
strong O -
, O +
and O +
the O +
disinfection O +
effect O +
of O +
chromargyre O +
is O +
good O -
, O +
the O +
invention O +
combines O +
the O +
anti O -
- O -
inflammation O +
and O +
disinfection O +
effect O +
together O -
, O +
and O +
dissolves O +
them O +
in O +
spirit O +
to O +
treat O +
lung O +
disease O -
; O +
the O +
rehabilitation O +
liquid O +
can O +
be O +
discharged O +
through O +
manure O +
and O +
urine O -
, O +
so O +
it O +
can O +
disinfect O +
and O +
eliminate O +
inflammation O +
when O +
passing O +
through O +
other O +
organs O +
with O +
disease O -
. O +

The O +
production O +
method O +
comprises O +
two O +
technique O +
programs O -
: O +
one O +
is O +
immersion O +
and O +
another O +
is O +
blending O -
. O +

Ruthenium O -
- O -
anthraquinone O +
conjugates O -
, O +
preparation O +
method O +
thereof O +
and O +
application O +
for O +
optical O +
power O +
therapeutic O +
photosensitizer O +
The O +
invention O +
discloses O +
a O +
ruthenium O -
- O -
anthraquinone O +
conjugate O -
, O +
the O +
preparation O +
process O +
thereof O +
and O +
the O +
application O +
as O +
a O +
photo O -
- O -
dynamic O +
therapy O +
photosensitizer O -
. O +

The O +
general O +
formula O +
of O +
the O +
ruthenium O -
- O -
anthraquinone O +
conjugate O +
of O +
the O +
invention O +
is O +
[ O -
Ru O -
( O -
L O -
) O -
2HAIP O -
] O -
. O -
( O -
PF6 O -
) O -
2 O -
, O +
the O +
general O +
formula O +
of O +
the O +
HAIP O +
is O +
1,8- O +
dihydroxy O +
-9,10- O +
anthraquinoneimidazole O +
[ O -
4,5-f O -
] O -
[ O -
1,10 O -
] O +
phenanthroline O -
, O +
the O +
general O +
of O +
the O +
L O +
is O +
bpy O +
or O +
phen O -
. O +

The O +
preparation O +
process O +
for O +
the O +
ruthenium O -
- O -
anthraquinone O +
conjugate O +
comprises O +
the O +
following O +
procedures O -
: O +
1 O -
. O +
the O +
synthesis O +
of O +
the O +
HAIP O -
: O +
1,8- O +
dihydroxy O +
-9,10- O +
anthraquinone-3-aldehyde O +
is O +
reacted O +
with O +
the O +
phenanthroline5,6-diketone O +
to O +
produce O +
the O +
HAIP O -
; O +
2 O -
. O +

Ru O -
( O -
L O -
) O -
2Cl2 O +
is O +
reacted O +
with O +
HAIP O +
and O +
NH4PF6 O +
to O +
produce O +
the O +
[ O -
Ru O -
( O -
L O -
) O -
2HAIP O -
] O -
. O -
( O -
PF6 O -
) O -
2 O -
. O +

The O +
invention O +
takes O +
the O +
aloe O -
- O -
emodin O +
as O +
the O +
raw O +
material O +
and O +
the O +
ruthenium O +
polypyridyl O +
complex O +
has O +
single O +
chemical O +
composition O -
; O +
the O +
synthesis O +
route O +
is O +
simple O +
and O +
the O +
yields O +
are O +
higher O -
; O +
during O +
the O +
experiment O -
, O +
the O +
compound O +
shows O +
the O +
light O +
suppression O +
to O +
the O +
growth O +
of O +
cancer O +
cells O -
. O +

Pistachio O +
galls O +
pressure O +
ulcer O +
powder O +
The O +
invention O +
relates O +
to O +
a O +
medicinal O +
and O +
dietary O +
composition O +
for O +
treating O +
bedsore O +
and O +
its O +
preparing O +
process O -
, O +
wherein O +
the O +
composition O +
is O +
prepared O +
mainly O +
from O +
frankincense O -
, O +
Chinese O +
angelica O +
root O -
, O +
dahurian O +
angelica O +
root O -
, O +
dried O +
rehmannia O +
root O -
, O +
goldthread O +
root O +
and O +
boneol O -
, O +
the O +
medicament O +
can O +
also O +
be O +
used O +
as O +
a O +
conventional O +
health O +
dietary O +
preparation O +
having O +
no O +
side O +
effects O +
easy O +
administering O -
. O +

Anticancer O +
diaminocyclohexane O +
metallic O +
complex O +
The O +
invention O +
discloses O +
a O +
medicinal O +
molecule O +
with O +
selective O +
anticancer O +
activity O +
with O +
structure O +
as O +
general O +
formula O +
( O -
I O -
) O -
, O +
which O +
uses O +
chiral O +
cyclohexamethylene O +
diamine O +
derivative O +
and O +
metal O +
ion O +
to O +
form O +
metal O +
complex O +
after O +
coordinating O +
and O +
provides O +
the O +
making O +
method O +
of O +
the O +
typical O +
compound O +
and O +
inhibition O +
and O +
mechanism O +
of O +
the O +
growth O +
of O +
human O +
breast O +
cancer O +
and O +
lung O +
cancer O -
, O +
wherein O +
R1 O +
and O +
R2 O +
contains O +
random O +
one O +
meaning O +
organic O +
group O +
or O +
hydrogen O +
atom O -
; O +
A1 O +
and O +
A2 O +
can O +
be O +
individually O +
selected O +
from O +
random O +
organic O +
group O -
; O +
M O +
is O +
random O +
one O +
transition O +
system O -
, O +
expensive O +
metal O +
or O +
rare O +
earth O +
metal O +
ion O +
or O +
radioactive O +
isotope O -
; O +
B1,B2,C1 O +
and O +
C2 O +
represent O +
random O +
one O +
complex O +
ion O -
, O +
molecular O +
or O +
vacant O +
site O +
individually O -
; O +
B1 O +
and O +
B2 O +
can O +
represent O +
a O +
couple O +
of O +
tooth O +
complex O +
together O -
; O +
R1,R2 O -
, O +
A1,A2,B1,B2,C1 O +
and O +
C2 O +
can O +
link O +
biological O +
molecule O -
. O +

Application O +
of O +
alkaloids O +
compounds O +
in O +
the O +
preparation O +
of O +
antineoplastic O +
medicament O +
The O +
present O +
invention O +
pertains O +
to O +
the O +
art O +
of O +
medical O +
technology O -
, O +
in O +
particular O +
to O +
an O +
application O +
of O +
an O +
alkaloid O +
compound O +
in O +
the O +
preparation O +
of O +
antitumor O +
drugs O -
. O +

The O +
alkaloid O +
compound O +
consists O +
of O +
a O +
Lycoris O +
lactone O -
, O +
a O +
narciprimine O +
and O +
a O +
7-dehydroxyl O +
narciprimine O +
and O +
the O +
molecular O +
formula O +
of O +
the O +
alkaloid O +
compound O +
is O +
C17H19NO5 O -
, O +
C14H9NO5 O -
, O +
C14H9NO4 O -
. O +

Animal O +
experiments O +
prove O +
that O +
the O +
compounds O +
have O +
better O +
inhibited O +
activity O +
on O +
a O +
variety O +
of O +
tumors O -
. O +

The O +
invention O +
also O +
includes O +
one O +
or O +
more O +
than O +
one O +
types O +
of O +
three O +
compounds O +
with O +
effective O +
treatment O -
, O +
or O +
includes O +
medicine O +
combinations O +
of O +
the O +
pharmaceutical O +
acceptable O +
carrier O -
. O +

2-dihydro O +
indolone O +
derivant O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
2-dihydroindolone O +
compound O +
as O +
formula O +
( O -
I O -
) O -
, O +
and O +
a O +
relative O +
application O +
of O +
the O +
compound O +
or O +
the O +
medical O +
acceptable O +
salt O +
of O +
the O +
compound O -
. O +

Pharmacological O +
experiment O +
proves O +
that O +
the O +
compound O +
or O +
relative O +
medical O +
acceptable O +
salt O +
can O +
restrain O +
various O +
cancer O +
cell O +
proliferations O -
. O +

The O +
invention O +
further O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
the O +
compound O +
and O +
an O +
intermediate O +
formula O +
( O -
II O -
) O +
of O +
the O +
compound O -
. O +

Pain O -
- O -
relieving O +
plaster O +
and O +
preparing O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
pain O +
ointmentl O -
, O +
which O +
is O +
characterized O +
in O +
that O -
: O +
the O +
major O +
components O +
of O +
the O +
drug O +
comprise O +
radix O +
saposhnikoviae O +
and O +
ginseng O -
, O +
the O +
mixture O +
ratio O +
is O +
55 O -
- O -
65 O +
precent:35 O -
- O -
45 O +
percent O -
. O +

The O +
invention O +
has O +
the O +
advantages O +
that O -
: O +
the O +
radix O +
saposhnikoviae O +
is O +
in O +
wild O +
nature O +
with O +
sweet O +
and O +
pungent O +
taste O -
, O +
which O +
has O +
the O +
efficacy O +
of O +
inducing O +
diaphoresis O +
to O +
dispel O +
wind O -
, O +
clearing O +
wind O -
- O -
damp O +
and O +
anti O -
- O -
spasticity O -
, O +
and O +
has O +
obvious O +
significant O +
efficacy O +
for O +
muscular O +
constricture O -
, O +
rheumatism O +
and O +
pruritus O -
; O +
the O +
ginseng O +
has O +
the O +
efficacy O +
of O +
expanding O +
coronary O +
artery O +
and O +
blood O +
vessels O -
; O +
the O +
product O +
has O +
no O +
additives O +
or O +
stroma O +
for O +
affecting O +
the O +
body O +
skin O -
; O +
the O +
use O +
is O +
convenient O +
and O +
the O +
effect O +
is O +
good O -
; O +
furthermore O -
, O +
the O +
preparation O +
method O +
is O +
simple O -
, O +
economical O +
and O +
practical O -
. O +

Telomerase B-Gene +
inhibitor O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
pharmaceutical O +
chemistry O -
, O +
in O +
particular O +
to O +
a O +
thiazole O +
[ O -
5 O -
, O +
4-b O -
] O +
pyrimidine O +
compounds O +
( O -
I O -
) O -
, O +
preparation O +
methods O +
thereof O +
and O +
also O +
to O +
pharmaceutical O +
composites O +
containing O +
the O +
compounds O +
and O +
medical O +
purposes O +
thereof O -
, O +
in O +
particular O +
to O +
telomerase B-Gene +
inhibitors O -
. O +

Skeleton O +
type O +
roxithromycin O +
sustained O +
release O +
pellet O +
capsule O +
The O +
invention O +
provides O +
a O +
matrix O -
- O -
typed O +
roxithromycin O +
sustained O +
release O +
micropill O +
capsule O +
which O +
is O +
prepared O +
by O +
60 O -
- O -
75wt O +
percent O +
of O +
roxithromycin O -
, O +
2 O -
- O -
5wt O +
percent O +
of O +
waxy O +
matrix O +
material O -
, O +
10 O -
- O -
25wt O +
percent O +
of O +
microcrystalline O +
cellulose O -
, O +
lactose O -
, O +
cane O +
sugar O +
or O +
xylose O -
, O +
2 O -
- O -
5wt O +
percent O +
of O +
hydrophilic O +
matrix O +
material O -
, O +
1 O -
- O -
4wt O +
percent O +
of O +
anhydrous O +
sodium O +
carbonate O +
and O +
4 O -
- O -
10wt O +
percent O +
of O +
mannite O +
according O +
to O +
the O +
normal O +
preparation O +
method O -
. O +

The O +
waxy O +
matrix O +
material O +
is O +
octodecyl O +
alcohol O -
, O +
cetyl O +
alcohol O -
, O +
octadecanoic O +
acid O -
, O +
glycerin O +
monostearate O +
or O +
hydrogenated O +
castor O +
oil O -
. O +

The O +
hydrophilic O +
matrix O +
material O +
is O +
xanthan O +
gum O -
, O +
alginic O +
acid O +
or O +
carbomer O +
974P O -
. O +

The O +
matrix O +
material O +
adopted O +
in O +
the O +
invention O +
delays O +
the O +
release O +
of O +
the O +
drug O -
, O +
reduces O +
the O +
density O +
of O +
sustained O +
release O +
micropill O -
, O +
prolongs O +
the O +
staying O +
time O +
of O +
the O +
sustained O +
release O +
micropill O +
in O +
the O +
stomach O +
and O +
intestinal O +
tract O +
and O +
improves O +
the O +
bioavailability O +
of O +
the O +
medicine O -
. O +

A O +
comparison O +
test O +
between O +
the O +
medicine O +
of O +
the O +
invention O +
and O +
the O +
roxithromycin O +
sustained O +
release O +
pill O +
is O +
carried O +
out O +
in O +
eighteen O +
testers O +
and O +
the O +
test O +
shows O +
that O +
the O +
matrix O -
- O -
typed O +
roxithromycin O +
slow O -
- O -
release O +
micropill O +
capsule O +
of O +
the O +
invention O +
and O +
the O +
roxithromycin O +
slow O -
- O -
release O +
pill O +
have O +
bioequiavailability O -
. O +

Tinidazole O +
compound O +
nano O +
silver O +
microemulsion O +
antibacterial O +
medicine O +
The O +
invention O +
discloses O +
a O +
tinidazole O +
nano O -
- O -
composite O +
silver O +
micro O -
- O -
emulsified O +
antibiotics O -
, O +
0.10 O +
to O +
1.50 O +
units O +
of O +
tinidazole O +
and O +
0.008 O +
to O +
0.020 O +
units O +
of O +
nano O -
- O -
silver O +
being O +
regarded O +
as O +
medical O +
components O -
, O +
and O +
96.92 O +
to O +
99.67 O +
units O +
of O +
micro O -
- O -
emulsified O +
substrate O +
and O +
0.30 O +
to O +
3.00 O +
units O +
of O +
auxiliary O +
materials O +
are O +
evenly O +
mixed O +
together O +
with O +
a O +
certain O +
percentage O -
, O +
then O +
the O +
tinidazole O +
complex O +
nano O -
- O -
silver O +
micro O -
- O -
emulsified O +
antibiotics O +
can O +
be O +
got O +
which O +
has O +
a O +
yellow O +
outlook O -
, O +
the O +
diameter O +
of O +
grains O +
is O +
1 O -
nm O +
to O +
100 O -
nm O -
, O +
the O +
invention O +
is O +
stable O -
, O +
which O +
can O +
not O +
only O +
disturb O +
the O +
synthesis O +
of O +
DNA O -
, O +
but O +
also O +
be O +
able O +
to O +
combine O +
with O +
oxygen O +
metabolic O +
enzyme O +
( O -
-SH O -
) O +
to O +
interrupt O +
the O +
respiration O +
metabolism O +
process O -
, O +
so O +
as O +
to O +
kill O +
the O +
aerobic O +
and O +
anaerobic O +
pathogens O +
and O +
improve O +
the O +
recovery O +
of O +
wounds O -
, O +
and O +
diseases O +
such O +
as O +
vaginitis O -
, O +
endometritis O +
can O +
be O +
quickly O +
and O +
effectively O +
cured O -
, O +
and O +
the O +
preparation O +
method O +
of O +
the O +
invention O +
is O +
simple O +
and O +
safe O -
. O +

Application O +
of O +
asiaticoside O +
in O +
pulmonary O +
fibrosis O +
resistant O +
delayed O +
period O +
The O +
invention O +
discloses O +
a O +
new O +
application O +
in O +
a O +
preparation O +
using O +
asiaticoside O +
in O +
a O +
drug O +
against O +
delayed O +
lung O +
fibrosis O -
. O +

At O +
the O +
end O +
of O +
the O +
delayed O +
lung O +
fibrosis O -
, O +
the O +
asiaticoside O +
has O +
an O +
effect O +
against O +
the O +
lung O +
fibrosis O +
under O +
an O +
action O +
of O +
a O +
promoting O +
fibrosis O +
cytokine B-Gene +
in O +
vivo O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
drug O +
composition O +
against O +
delayed O +
lung O +
fibrosis O -
, O +
which O +
active O +
component O +
comprises O +
the O +
asiaticoside O +
and O +
the O +
exogenous O +
promoting O +
fibrosis O +
cytokine B-Gene -
. O +

Iron O +
supplement O +
composition O -
, O +
its O +
preparing O +
method O +
and O +
application O +
of O +
the O +
same O +
The O +
invention O +
discloses O +
a O +
drug O +
combination O +
as O +
iron O +
supplementary O +
agent O +
which O +
is O +
characterized O +
in O +
that O +
the O +
drug O +
combination O +
has O +
carbonyl O +
iron O +
and O +
natural O +
anti O -
- O -
oxidant O +
components O +
which O +
have O +
the O +
drug O +
activity O -
; O +
the O +
drug O +
combination O +
can O +
also O +
have O +
pharmaceutical O +
carrier O -
. O +

The O +
invention O +
also O +
disclosed O +
the O +
preparation O -
, O +
comprising O +
the O +
drug O +
combination O -
, O +
the O +
preparation O +
method O +
of O +
the O +
combination O +
and O +
the O +
preparation O -
, O +
and O +
the O +
function O +
of O +
preventing O +
and O +
curing O +
iron O +
deficiency O +
of O +
the O +
drug O +
combination O -
. O +

The O +
drug O +
combination O +
has O +
the O +
advantages O +
that O +
the O +
iron O +
deficiency O +
anemia O +
is O +
treated O +
effectively O -
; O +
the O +
production O +
of O +
free O +
radical O +
in O +
human O +
body O +
is O +
inhibited O -
; O +
the O +
oxygen O +
metabolism O +
balance O +
in O +
human O +
body O +
is O +
maintained O -
; O +
the O +
physical O +
quality O +
of O +
the O +
patient O +
is O +
enhanced O -
; O +
and O +
the O +
immunity O +
of O +
body O +
is O +
improved O -
. O +

Sheep O +
insect O +
powder O +
for O +
treating O +
epilepsy O +
The O +
invention O +
relates O +
to O +
a O +
powder O +
for O +
treating O +
epilepsy O -
, O +
comprising O +
sheep O +
parasite O -
, O +
tussah O +
pupa O -
, O +
fennel O -
, O +
muscardine O +
cadaver O -
, O +
finch O +
brain O -
, O +
hawksbill O -
, O +
oryzanol O -
, O +
and O +
cow O -
- O -
bezoar O -
, O +
which O +
are O +
prepared O +
in O +
proportion O +
and O +
in O +
order O +
under O +
normal O +
temperature O -
. O +

The O +
powder O +
has O +
the O +
advantages O -
: O +
the O +
powder O +
has O +
the O +
advantages O +
of O +
easily O -
- O -
purchased O +
raw O +
materials O -
, O +
low O +
cost O -
, O +
simple O +
technology O -
, O +
easy O +
popularization O -
, O +
and O +
convenient O +
use O -
; O +
the O +
powder O +
can O +
make O +
the O +
percentage O +
of O +
epilepsy O -
- O -
treatment O +
reach O +
98.2 O -
% O -
, O +
and O +
the O +
cure O +
rate O +
91.8 O -
% O -
. O +

Lamb O +
stomach O +
extract O +
vitamin O +
B12 O +
preparations O +
composing O +
prescription O +
The O +
present O +
invention O +
provides O +
a O +
formulation O +
of O +
B12 O +
extracted O +
from O +
the O +
gastric O +
of O +
lambs O -
. O +

The O +
material O +
extracted O +
from O +
the O +
gastric O +
of O +
lambs O +
is O +
the O +
total O +
extracts O +
from O +
the O +
forth O +
gastric O +
of O +
the O +
lambs O -
; O +
when O +
calculated O +
as O +
the O +
dried O +
material O -
, O +
the O +
rennet O +
activity O +
in O +
each O +
gram O +
is O +
not O +
less O +
than O +
800 O +
units O -
, O +
and O +
the O +
stomach O +
enzyme O +
activity O +
is O +
not O +
less O +
than O +
230 O +
units O -
; O +
the O +
ratio O +
of O +
rennet O +
activity O +
and O +
the O +
stomach O +
enzyme O +
activity O +
is O +
2.0 O +
to O +
4.1 O -
. O +

The O +
ratio O +
can O +
clinically O +
avoid O +
side O +
effects O +
caused O +
by O +
too O +
high O +
stomach O +
enzyme O +
activity O -
; O +
the O +
invention O +
can O +
be O +
used O +
for O +
patients O +
of O +
gastritis O +
with O +
erosion O -
, O +
hyperemia O +
and O +
ulcer O -
, O +
and O +
can O +
also O +
treat O +
anorexia O -
, O +
diarrhea O +
and O +
milk O +
vomiting O +
of O +
babies O -
. O +

The O +
formulation O +
of O +
B12 O +
extracted O +
from O +
the O +
gastric O +
of O +
lambs O +
has O +
simple O +
manufacturing O +
process O +
and O +
does O +
not O +
use O +
organic O +
solvent O -
. O +

Smell O +
concealing O +
composition O +
of O +
hydrochloric O +
selegiline O -
, O +
and O +
preparation O +
containing O +
the O +
composition O +
The O +
invention O +
provides O +
a O +
Selegiline O +
hydrochloride O +
smell O +
covering O +
compound O -
, O +
which O +
contains O +
sugar O +
alcohol O -
, O +
corrective O +
agent O -
, O +
gelatin B-Gene -
, O +
and O +
xanthan O +
gum O -
, O +
and O +
is O +
treated O +
by O +
special O +
process O +
and O +
is O +
evenly O +
dispersed O +
with O +
Selegiline O +
hydrochloride O -
. O +

The O +
compound O +
covers O +
the O +
stimulating O +
taste O +
of O +
Selegiline O +
hydrochloride O -
, O +
is O +
used O +
for O +
preparing O +
the O +
orally O +
disintegrating O +
tablet O -
, O +
and O +
is O +
used O +
for O +
treating O +
Parkinsons O +
disease O -
. O +

Antisense O +
oligonucleotide O +
for O +
tissue O -
- O -
specific O +
regulation O +
of O +
POKEMON B-Gene +
gene O +
expression O +
and O +
application O +
thereof O +
The O +
present O +
invention O +
provides O +
an O +
antisense O +
oligonucleotide O +
of O +
tissue O -
- O -
specific O +
regulation O +
POKEMON B-Gene +
gene O +
expression O +
and O +
its O +
application O -
. O +

The O +
antisense O +
oligonucleotide O +
is O +
one O +
of O +
the O +
following O +
formulas O -
: O +
CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx O -
; O +
CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx O -
; O +
GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx O -
; O +
TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx O -
; O +
TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx O -
. O +

X O +
is O +
bond O +
between O +
thiophosphate O +
nucleoside O -
. O +

The O +
antisense O +
oligonucleotide O +
of O +
the O +
invention O +
is O +
used O +
for O +
preparing O +
gene O +
therapeutic O +
drug O +
for O +
curing O +
disease O +
caused O +
by O +
POKEMON B-Gene +
high O +
expression O -
. O +

Instant O +
type O +
gel O +
preparation O +
for O +
eye O +
and O +
method O +
of O +
producing O +
the O +
same O +
The O +
invention O +
relates O +
to O +
an O +
in O -
- O -
situ O +
forming O +
eye O +
gel O +
preparation O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
in O -
- O -
situ O +
forming O +
eye O +
gel O +
preparation O +
can O +
be O +
prepared O +
by O +
mixing O +
a O +
Gelrite O +
Gellan O +
gum O +
as O +
a O +
matrix O +
base O -
. O +

Sustained O -
- O -
release O +
injection O +
containing O +
kanamycin O +
The O +
invention O +
relates O +
to O +
a O +
slow O -
- O -
released O +
injection O +
comprising O +
kanamycin O -
, O +
which O +
comprises O +
a O +
slow O -
- O -
released O +
microsphere O +
and O +
a O +
dissolvent O -
; O +
the O +
slow O -
- O -
released O +
microsphere O +
comprises O +
a O +
slow O -
- O -
release O +
adjuvant O +
and O +
the O +
aminoglycoside O +
antibiotic O -
; O +
the O +
dissolvent O +
is O +
the O +
special O +
dissolvent O +
which O +
comprises O +
a O +
suspending O +
agent O +
such O +
as O +
sodium O +
carboxymethylcellulose O -
, O +
etc O -
. O -
, O +
and O +
the O +
viscosity O +
of O +
which O +
is O +
100cp-3000cp O +
( O -
at O +
20 O +
DEG O +
C-30 O +
DEC O +
C O -
) O -
; O +
the O +
slow O -
- O -
release O +
adjuvant O +
can O +
be O +
selected O +
from O +
EVAc O -
, O +
polifeprosan O -
, O +
PLA O -
, O +
PLGA O -
, O +
sebacic O +
acid O +
copolymer O -
, O +
albumen O +
glue O +
and O +
gelatin O -
, O +
etc O -
. O -
; O +
the O +
slow O -
- O -
released O +
microsphere O +
also O +
can O +
be O +
made O +
into O +
a O +
slow O -
- O -
released O +
implant O +
and O +
an O +
ointment O -
. O +

The O +
slow O -
- O -
released O +
implant O +
and O +
the O +
slow O -
- O -
released O +
injection O +
can O +
be O +
partially O +
placed O +
or O +
injected O +
in O +
a O +
bacterial O +
focus O +
to O +
release O +
locally O +
and O +
slowly O +
for O +
more O +
than O +
5 O -
- O -
30 O +
days O -
, O +
thereby O +
obviously O +
reducing O +
the O +
toxicity O +
of O +
the O +
entire O +
body O +
while O +
getting O +
and O +
maintaining O +
a O +
valid O +
medicine O +
density O +
in O +
the O +
local O +
focus O +
effectively O -
. O +

The O +
slow O -
- O -
released O +
injection O +
comprising O +
the O +
kanamycin O +
of O +
the O +
invention O +
has O +
obvious O +
special O +
treatment O +
effect O +
for O +
focus O +
of O +
local O +
infection O +
such O +
as O +
chronic O +
osteomyelitis O -
, O +
severe O +
bedsore O -
, O +
refractory O +
skin O +
ulcer O -
, O +
diabetic O +
foot O -
, O +
osteonecrosis O +
of O +
femoral O +
head O +
and O +
various O +
abscesses O -
, O +
etc O -
. O -
, O +
caused O +
by O +
staphylococcus O -
, O +
streptococcus O -
, O +
peptostreptococcus O -
, O +
propionibacterium O +
acnes O -
, O +
enterobacter O -
, O +
tubercle O +
bacillus O -
, O +
gonococcus O +
and O +
meningococcus O -
, O +
etc O -
. O +

Pabala O +
selenizing O +
VE O +
health O +
products O +
The O +
invention O +
relates O +
to O +
a O +
health O +
care O +
product O +
which O +
is O +
Parbara O +
selenizing O +
VE O +
health O +
care O +
product O -
. O +

The O +
health O +
product O +
is O +
made O +
of O +
raw O +
materials O -
, O +
including O +
90 O +
to O +
100 O +
parts O +
of O +
balsam O +
pear O +
extract O -
, O +
0.5 O +
to O +
1.0 O +
part O +
of O +
selenium O -
, O +
0.1 O +
to O +
0.5 O +
part O +
of O +
Vitamin O +
E O +
and O +
90 O +
to O +
110 O +
parts O +
of O +
starch O -
. O +

Composing O +
prescription O +
is O +
simple O +
and O +
supplementary O +
trace O +
elements O +
are O +
reasonable O -
. O +

So O +
the O +
Parbara O +
selenizing O +
VE O +
health O +
care O +
product O +
can O +
serve O +
as O +
accessory O +
food O +
for O +
patients O +
with O +
diabetes O +
mellitus O -
. O +

The O +
Parbara O +
selenizing O +
VE O +
health O +
care O +
product O +
has O +
no O +
adverse O +
effect O +
and O +
is O +
suitable O +
for O +
long O -
- O -
term O +
administration O -
. O +

Oleanolic O +
acid O +
orally O +
disintegrating O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
oleanolic O +
acid O +
orally O +
disintegrating O +
tablets O +
with O +
high O +
dissolution O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
oleanolic O +
acid O +
orally O +
disintegrating O +
tablets O +
are O +
characterized O +
in O +
that O +
oleanolic O +
acid O +
is O +
prepared O +
into O +
solid O +
dispersion O +
via O +
hydrophilic O +
solid O +
dispersion O +
carrier O -
, O +
so O +
as O +
to O +
remarkably O +
improve O +
the O +
dissolution O -
, O +
promote O +
the O +
absorption O +
and O +
remarkably O +
improve O +
the O +
bioavailability O +
of O +
oleanolic O +
acid O -
. O +

The O +
weight O +
ratio O +
of O +
the O +
solid O +
dispersion O +
carrier O +
and O +
oleanolic O +
acid O +
is O +
0.5 O -
- O -
5 O -
. O +

Then O -
, O +
the O +
solid O +
dispersion O +
is O +
mixed O +
with O +
adjuvants O +
such O +
as O +
bulking O +
agent O -
, O +
corrective O +
and O +
lubricant O +
and O +
made O +
into O +
orally O +
disintegrating O +
tablets O +
by O +
using O +
conventional O +
tablet O +
production O +
equipment O +
via O +
directly O +
tabletting O +
or O +
wet O +
granulating O +
process O -
. O +

The O +
preparation O +
has O +
disintegrating O +
time O +
of O +
5 O -
- O -
50s O -
, O +
and O +
dissolution O +
in O +
0.5 O +
sodium O +
lauryl O +
sulfate O +
solution O +
in O +
1 O +
hour O +
over O +
80 O -
% O -
, O +
even O +
over O +
90 O -
% O -
. O +

Benzoxazole O +
ketones O +
derivative O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
series O +
of O +
novel O +
compounds O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
particularly O +
to O +
a O +
series O +
of O +
benzoxazolone O +
derivatives O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
and O +
solves O +
the O +
problem O +
that O +
the O +
prior O +
benzoxazolone O +
compounds O +
have O +
no O +
4-substituted O +
derivatives O +
and O +
have O +
anti O -
- O -
HBV O +
activity O +
and O +
anti O -
- O -
HIV O +
activity O -
. O +

The O +
general O +
structural O +
formula O +
of O +
the O +
derivatives O +
is O +
shown O +
in O +
the O +
figure O -
, O +
wherein O +
R O +
is O +
C3-C6 O +
fatty O +
acid O +
ester O +
group O -
, O +
benzoate O +
group O -
/ O -
substituted O +
benzoate O +
group O -
, O +
benzene O +
sulfonate O +
group O -
/ O -
substituted O +
benzene O +
sulfonate O +
group O -
, O +
amino O +
acid O +
ester O +
group O -
, O +
or O +
heterocyclic O +
acid O +
ester O +
group O -
/ O -
substituted O +
heterocyclic O +
acid O +
ester O +
group O -
. O +

The O +
invention O +
obtains O +
a O +
series O +
of O +
4-substituted O +
benzoxazolone O +
derivatives O +
with O +
proven O +
anti O -
- O -
HBV O +
activity O +
and O +
anti O -
- O -
HIV O +
activity O -
, O +
opens O +
new O +
preparation O +
paths O +
of O +
the O +
above O +
three O +
drugs O -
, O +
and O +
brings O +
new O +
breakthrough O +
in O +
pharmaceutical O +
and O +
pesticide O +
fields O -
. O +

In O +
addition O -
, O +
the O +
synthetic O +
method O +
has O +
the O +
advantages O +
of O +
easy O +
operation O -
, O +
mild O +
reaction O +
conditions O -
, O +
single O +
reaction O +
product O -
, O +
and O +
applicability O +
to O +
large O +
scale O +
production O -
. O +

Chitosan O +
oral O +
scented O +
pieces O +
and O +
preparation O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
a O +
chitosan O +
cachou O -
. O +

The O +
chitosan O +
cachou O +
is O +
prepared O +
by O +
chitosan O -
, O +
corn O +
starch O -
, O +
xylitol O -
, O +
maltodextrin O -
, O +
acesulfame O +
potassium O -
, O +
sodium O +
cyclamate O -
, O +
menthol O -
, O +
and O +
magnesium O +
stearate O -
, O +
and O +
the O +
preparation O +
method O +
includes O +
the O +
following O +
steps O -
: O +
embedding O +
processing O +
of O +
essence O -
, O +
mixing O -
, O +
damp O +
mass O +
making O -
, O +
wet O +
granule O +
making O -
, O +
drying O -
, O +
granule O +
finishing O -
, O +
final O +
mixing O -
, O +
sheeting O -
, O +
sterilization O -
, O +
and O +
packaging O -
, O +
thus O +
obtaining O +
the O +
chitosan O +
cachou O -
. O +

Diaminopyrimidines O +
as O +
P2X3 B-Gene +
and O +
P2X2 B-Gene -
/ I-Gene -
3 I-Gene +
modulators O +
Compounds O +
and O +
methods O +
for O +
treating O +
diseases O +
mediated O +
by O +
a O +
P2X3 B-Gene +
and/or O +
a O +
P2X2 B-Gene -
/ I-Gene -
3 I-Gene +
receptor I-Gene +
antagonist O -
, O +
the O +
compounds O +
being O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
D O -
, O +
X O -
, O +
R<1 O -
> O -
, O +
R<2 O -
> O -
, O +
R<3 O -
> O -
, O +
R<4 O -
> O -
, O +
R<5 O -
> O -
, O +
R<6 O -
> O -
, O +
R<7 O -
> O +
and O +
R<8 O -
> O +
are O +
as O +
defined O +
herein O -
. O +

Uses O +
of O +
rutin O +
and O +
quercetin-7-rhamnose O +
in O +
preparing O +
anti O -
- O -
hepatitis O +
medicament O +
The O +
invention O +
belongs O +
to O +
the O +
medicine O +
technical O +
field O -
, O +
in O +
particular O +
to O +
an O +
application O +
of O +
rutin O +
and O +
quercetin-7-rhamnose O +
in O +
preparation O +
of O +
anti O -
- O -
hepatitis O +
virus O +
agents O -
. O +

According O +
to O +
the O +
results O +
of O +
experiments O +
of O +
hepatitis B-Gene +
B I-Gene +
surface I-Gene +
antigen I-Gene +
( O -
HBsAg B-Gene -
) O +
and O +
hepatitis B-Gene +
B I-Gene +
e I-Gene +
antigen I-Gene +
( O -
HBeAg B-Gene -
) O +
detection O +
reagents O -
, O +
the O +
rutin O +
and O +
the O +
quercetin-7-rhamnose O +
can O +
suppress O +
HBsAg B-Gene +
and O +
HBeAg B-Gene +
obviously O +
and O +
can O +
prevent O +
and O +
cure O +
hepatitis O +
B O +
virus O -
. O +

Therefore O -
, O +
the O +
rutin O +
and O +
the O +
quercetin-7-rhamnose O +
can O +
be O +
used O +
for O +
preparing O +
anti O -
- O -
hepatitis O +
virus O +
agents O +
or O +
health O +
care O +
products O -
. O +

Flavin O +
adenine O +
dinucleotide O +
disodium O +
salt O +
freeze O -
- O -
dried O +
powder O +
needle O +
preparation O +
and O +
preparation O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
FAD O -
- O -
Na2 O +
freeze O -
- O -
dried O +
acanthopanax O +
powder O +
spasmolytic O +
preparation O +
and O +
a O +
method O +
for O +
preparing O +
the O +
same O -
. O +

The O +
FAD O -
- O -
Na2 O +
freeze O -
- O -
dried O +
acanthopanax O +
powder O +
spasmolytic O +
preparation O +
is O +
a O +
drug O +
composition O +
made O +
by O +
mixing O +
FAD O -
- O -
Na2 O +
serving O +
as O +
medicinal O +
active O +
ingredients O +
and O +
pharmaceutically O +
acceptable O +
excipients O -
. O +

The O +
preparation O +
method O +
is O +
as O +
follows O -
: O +
the O +
FAD O -
- O -
Na2 O +
is O +
used O +
as O +
raw O +
material O +
and O +
added O +
with O +
certain O +
spices O +
of O +
excipients O +
according O +
to O +
certain O +
proportions O -
; O +
the O +
mixture O +
is O +
prepared O +
and O +
developed O +
by O +
a O +
technical O +
means O +
provided O +
by O +
the O +
invention O +
into O +
freeze O -
- O -
dried O +
acanthopanax O +
powder O +
spasmolytic O +
agent O +
which O +
can O +
be O +
used O +
for O +
subcutaneous O +
injection O -
, O +
intramuscular O +
and O +
intravenous O +
injection O +
and O +
used O +
to O +
cure O +
a O +
variety O +
of O +
diseases O +
caused O +
by O +
lacks O +
of O +
vitamin O +
B2 O -
. O +

Detection O +
method O +
of O +
compound O +
preserved O +
snake O +
gall O +
orange O +
peel O +
powder O +
The O +
present O +
invention O +
provides O +
a O +
detection O +
method O +
for O +
compound O +
Shedan O +
Chenpi O +
San O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
( O -
1 O -
) O +
five O +
drugs O +
of O +
orange O +
peel O -
, O +
earthworm O -
, O +
stiff O +
silkworm O -
, O +
vermilion O +
and O +
amber O +
contained O +
in O +
the O +
compound O +
Shedan O +
Chenpi O +
San O +
are O +
identified O +
by O +
a O +
microscope O -
; O +
( O -
2 O -
) O +
the O +
orange O +
peel O +
contained O +
in O +
the O +
compound O +
Shedan O +
Chenpi O +
San O +
is O +
identified O +
by O +
the O +
thin O +
layer O +
chromatography O -
; O +
( O -
3 O -
) O +
the O +
content O +
of O +
hesperidin O +
in O +
the O +
compound O +
Shedan O +
Chenpi O +
San O +
is O +
measured O +
by O +
the O +
high O +
performance O +
liquid O +
chromatography O -
; O +
( O -
4 O -
) O +
the O +
content O +
of O +
ethiopsite O +
in O +
the O +
vermilion O +
in O +
the O +
compound O +
Shedan O +
Chenpi O +
San O +
is O +
measured O +
by O +
thiocyanometry O -
. O +

The O +
detection O +
method O +
for O +
compound O +
Shedan O +
Chenpi O +
San O +
provided O +
by O +
the O +
present O +
invention O +
has O +
the O +
advantages O +
of O +
overcoming O +
a O +
defect O +
of O +
poor O +
specificity O +
existing O +
in O +
the O +
prior O +
chemical O +
identification O +
method O +
and O +
defects O +
of O +
complicated O +
operation O +
and O +
uncontrollable O +
product O +
quality O +
existing O +
in O +
the O +
prior O +
thin O +
layer O +
chromatography O -
, O +
improving O +
the O +
specificity O +
and O +
the O +
quality O +
stability O +
of O +
the O +
detection O +
method O +
for O +
compound O +
Shedan O +
Chenpi O +
San O +
and O +
ensuring O +
the O +
safety O +
and O +
effectiveness O +
of O +
medication O -
. O +

Oxazole O +
substituted O +
dihydro O +
pyrazol O +
multi O -
- O -
heterocyclic O +
ring O +
derivates O -
, O +
preparation O +
method O +
and O +
uses O +
thereof O +
The O +
invention O +
discloses O +
an O +
oxazole O +
substituted O +
dihydro O -
- O -
pyrazole O +
miscellaneous O +
polycyclic O +
derivative O -
, O +
as O +
well O +
as O +
a O +
preparation O +
method O +
and O +
a O +
use O +
of O +
the O +
same O -
. O +

The O +
derivative O +
provided O +
by O +
the O +
invention O +
has O +
a O +
structure O +
as O +
shown O +
in O +
a O +
chemical O +
formula O +
D O +
and O +
is O +
prepared O +
through O +
the O +
following O +
method O +
that O -
: O +
substituted O +
isoquinoline O +
propiophenone O +
is O +
used O +
for O +
leading O -
, O +
expanded O +
and O +
converted O +
into O +
substituted O +
isoquinoline O +
alpha O +
and O +
beta O +
unsaturated O +
ketone O -
; O +
ring O +
closure O +
is O +
carried O +
out O +
to O +
form O +
5-substituted O +
isoquinoline O +
substituted O +
dihydro O -
- O -
pyrazole O +
ketone O -
; O +
by O +
inducing O +
an O +
oxime O +
structure O +
unit O +
and O +
adopting O +
a O +
microwave O +
auxiliary O +
synthesis O +
method O -
, O +
a O +
series O +
of O +
3-methyl O +
oxazole-5-isoquinoline O +
substituted O +
hydrogen O +
pyrazole O +
miscellaneous O +
polycyclic O +
compounds O +
is O +
designed O +
and O +
synthesized O -
. O +

Structure O +
modification O +
is O +
carried O +
out O +
according O +
to O +
the O +
principle O +
of O +
medicinal O +
chemistry O -
, O +
so O +
as O +
to O +
design O +
and O +
synthesize O +
a O +
high O -
- O -
activity O +
compound O +
with O +
the O +
effects O +
of O +
resisting O +
tumor O +
and O +
sterilizing O -
. O +

Novel O +
cephalosporin O +
compounds O -
, O +
preparation O +
method O +
thereof O -
, O +
pharmaceutical O +
compositions O +
thereof O +
and O +
use O +
The O +
invention O +
provides O +
a O +
novel O +
cephalosporin O +
compound O +
which O +
introduces O +
thioureido O +
onto O +
position O +
7 O +
of O +
cephem O -
, O +
nontoxic O +
salt O +
of O +
the O +
cephalosporin O +
compound O +
acceptable O +
on O +
pharmacy O -
, O +
physiological O +
hydrolyzable O +
ester O +
of O +
the O +
cephalosporin O +
compound O -
, O +
acid O +
amide O +
of O +
the O +
cephalosporin O +
compound O -
, O +
hydrate O +
of O +
the O +
cephalosporin O +
compound O -
, O +
solvate O +
of O +
the O +
cephalosporin O +
compound O +
or O +
an O +
isomer O +
of O +
the O +
cephalosporin O +
compound O -
, O +
a O +
method O +
for O +
preparing O +
the O +
cephalosporin O +
compound O -
, O +
a O +
drug O +
composition O +
containing O +
the O +
cephalosporin O +
compound O +
and O +
an O +
application O +
of O +
the O +
cephalosporin O +
compound O -
. O +

Rice O +
fermented O +
with O +
red O +
yeast O +
extract O -
, O +
preparation O +
method O +
and O +
quality O +
detection O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
red O +
yeast O +
rice O +
extract O +
and O +
a O +
preparation O +
method O +
and O +
a O +
quality O +
test O +
method O +
thereof O -
. O +

The O +
main O +
active O +
ingredient O +
of O +
the O +
extract O +
is O +
lovastatin O -
, O +
the O +
content O +
of O +
which O +
is O +
more O +
than O +
3 O +
percent O -
. O +

The O +
extract O +
is O +
prepared O +
by O +
subjecting O +
a O +
medical O +
material O +
of O +
red O +
yeast O +
rice O +
to O +
extraction O +
with O +
an O +
organic O +
solvent O -
, O +
water O +
decoction O +
after O +
the O +
volatilization O +
of O +
the O +
solvent O -
, O +
precipitation O +
collection O +
by O +
siphonage O +
and O +
configuration O -
, O +
mixing O +
with O +
excipients O +
and O +
drying O -
. O +

The O +
preparation O +
method O +
improves O +
the O +
content O +
of O +
lovastatin O -
. O +

The O +
invention O +
also O +
provides O +
a O +
quality O +
control O +
method O +
for O +
identifying O +
the O +
ingredients O +
and O +
measuring O +
content O -
. O +

Medicament O +
for O +
treating O +
protrusion O +
of O +
lumber O +
intervertebral O +
disc O +
The O +
invention O +
relates O +
to O +
a O +
medicine O +
for O +
treating O +
prolapse O +
of O +
lumbar O +
intervertebral O +
disc O -
. O +

The O +
preparation O +
method O +
for O +
the O +
medicine O +
comprises O +
the O +
following O +
steps O +
that O -
: O +
medicines O +
such O +
as O +
phrymaceae O -
, O +
buck O +
grass O -
, O +
slenderstyle O +
acanthopanax O +
barks O -
, O +
cortex O +
lycii O +
radicis O -
, O +
dittany O -
, O +
heracleum O +
hemsleyanum O -
, O +
common O +
monkshood O +
mother O +
root O -
, O +
kusnezoff O +
monkshood O -
, O +
safflower O -
, O +
Chinese O +
ephedra O -
, O +
dried O +
ginger O -
, O +
pollen O -
, O +
artemisia O +
leaves O -
, O +
cassia O +
barks O +
and O +
so O +
on O +
are O +
mixed O +
and O +
ground O +
into O +
powder O -
, O +
and O +
then O +
packaged O +
into O +
a O +
medicine O +
bag O -
. O +

When O +
the O +
medicine O +
is O +
used O -
, O +
the O +
medicine O +
bag O +
is O +
immersed O +
into O +
water O +
solution O +
of O +
hot O +
peppers O +
and O +
vinegar O -
, O +
placed O +
on O +
a O +
suffered O +
lumbar O +
part O +
of O +
a O +
patient O +
and O +
heated O -
, O +
and O +
then O +
absorbed O +
through O +
hot O +
application O -
. O +

The O +
medicine O +
can O +
disperse O +
stagnancy O +
and O +
dredge O +
channels O -
, O +
relieve O +
rigidity O +
of O +
muscles O +
and O +
promote O +
blood O +
circulation O -
, O +
reduce O +
swelling O +
and O +
alleviate O +
pain O -
, O +
and O +
stimulate O +
circulation O +
to O +
end O +
stasis O -
, O +
can O +
adjust O +
the O +
water O +
filling O +
level O +
of O +
nucleus O +
pulposus O +
and O +
make O +
the O +
protruded O +
nucleus O +
pulposus O +
retracted O -
, O +
eliminate O +
irritation O +
symptoms O +
of O +
edema O -
, O +
and O +
repair O +
damaged O +
anulus O +
fibrosus O -
, O +
is O +
quick O +
to O +
take O +
effect O -
, O +
has O +
no O +
side O +
effect O -
, O +
and O +
can O +
not O +
cause O +
recrudescence O +
after O +
cure O -
. O +

Preparation O +
of O +
docetaxel O +
long O -
- O -
circulating O +
liposome O +
and O +
freeze O -
- O -
dried O +
powder O +
injection O +
thereof O +
The O +
invention O +
discloses O +
a O +
preparation O +
technique O +
of O +
non O -
- O -
pegylation O +
docetaxel O +
long O -
- O -
circulating O +
liposome O +
which O +
meets O +
clinical O +
and O +
large O -
- O -
scale O +
production O +
requirements O +
and O +
a O +
freeze O -
- O -
dried O +
powder O -
- O -
injection O -
; O +
the O +
liposome O +
consists O +
of O +
docetaxel O -
, O +
neutral O +
phospholipid O -
, O +
charged O +
phospholipid O -
, O +
cholesterin O -
, O +
antioxidant O -
, O +
excipient O -
, O +
buffering O +
agent O +
and O +
water O +
for O +
injection O -
; O +
the O +
preparation O +
technique O +
includes O +
the O +
following O +
steps O -
: O +
preparing O +
multivesicular O +
liposome O -
, O +
homogenizing O +
the O +
liposome O -
, O +
fixing O +
volume O -
, O +
sterilizing O -
, O +
split O +
charging O -
, O +
freeze O +
drying O -
, O +
etc O -
. O +

The O +
liposome O +
increases O +
the O +
solubility O +
of O +
drugs O -
, O +
overcomes O +
poor O +
stability O +
of O +
docetaxel O +
injection O +
and O +
toxicity O +
caused O +
by O +
complex O +
solvent O +
and O +
prolongs O +
the O +
in O +
vivo O +
circulating O +
time O +
of O +
drugs O -
; O +
compared O +
with O +
pegylation O +
long O -
- O -
circulating O +
liposome O -
, O +
the O +
toxicity O +
is O +
decreased O +
and O +
the O +
inhibiting O +
effect O +
on O +
tumor O +
cells O +
is O +
strengthened O -
. O +

Medicine O +
composition O +
for O +
injecting O +
triamcinolone O +
acetonide O +
palmitate O +
lipid O +
microsphere O +
and O +
preparation O +
method O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
the O +
medical O +
technical O +
field O -
, O +
in O +
particular O +
to O +
a O +
lipid O +
microsphere O +
injection O +
medical O +
combination O +
containing O +
triamcinolone O +
palmitate O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

' O -
Yizhi O -
' O +
capsule O +
for O +
enhancing O +
willpower O +
The O +
invention O +
relates O +
to O +
a O +
nootropic O +
capsule O +
used O +
for O +
strengthening O +
willpower O -
. O +

The O +
invention O +
is O +
characterized O +
in O +
that O +
the O +
nootropic O +
capsule O +
has O +
a O +
composing O +
prescription O +
which O +
comprises O +
gen O -
- O -
seng O -
, O +
glossy O +
ganoderma O -
, O +
milkwort O +
root O -
, O +
spine O +
date O +
seed O -
, O +
root O +
poria O -
, O +
grassleaf O +
sweetflag O +
rhizome O -
, O +
silktree O +
albizia O +
bark O -
, O +
the O +
tuber O +
of O +
multiflower O +
knot O +
weed O -
, O +
longan O +
aril O -
, O +
seabuckthorn O +
fruit O -
, O +
ginkgo O +
biloba O +
extract O -
, O +
wheat O -
- O -
germ O +
oil O -
, O +
pollen O +
, O +
tortoise O +
carapace O +
and O +
plastron O -
, O +
cape O +
jasmine O +
fruit O -
, O +
liquorice O -
, O +
royal O +
jelly O +
dry O -
- O -
freezing O +
powder O -
, O +
etc O -
. O +

The O +
extract O +
can O +
be O +
made O +
by O +
the O +
preparation O +
and O +
the O +
extract O +
is O +
mixed O +
with O +
the O +
powdery O +
raw O +
materials O +
and O +
the O +
nootropic O +
capsule O +
can O +
be O +
obtained O +
after O +
the O +
processes O +
of O +
drying O -
, O +
sterilizing O +
and O +
encapsulating O +
the O +
extract O +
in O +
a O +
capsule O -
. O +

Rosuvastatin O +
azelnidipine O +
composition O +
A O +
pharmaceutical O +
composition O +
is O +
an O +
organic O +
salt O +
formed O +
by O +
an O +
organic O +
acid O +
rosuvastatin O +
and O +
an O +
organic O +
base O +
azelnidipine O +
with O +
a O +
molar O +
ratio O +
of O +
1:1 O -
. O +

The O +
pharmaceutical O +
composition O +
can O +
be O +
made O +
into O +
any O +
dosage O +
forms O +
together O +
with O +
a O +
pharmaceutically O -
- O -
acceptable O +
carrier O +
for O +
reducing O +
blood O +
pressure O +
and O +
blood O +
lipid O -
, O +
reducing O +
myocardial O +
infarction O +
and O +
treating O +
cerebral O +
apoplexy O -
. O +

The O +
inventive O +
pharmaceutical O +
composition O +
has O +
the O +
advantages O +
of O +
stable O +
physiochemical O +
indexes O -
, O +
controllable O +
product O +
quality O -
, O +
and O +
convenient O +
administration O -
. O +

Eye O +
in O -
- O -
situ O +
gel O +
of O +
pirenoxine O +
sodium O +
The O +
invention O +
discloses O +
a O +
pirenoxine O +
sodium O +
eye O +
gel O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
pirenoxine O +
sodium O +
eye O +
gel O +
contains O +
( O -
per O +
1,000 O +
mL O -
) O +
pirenoxine O +
sodium O +
20 O -
- O -
50 O +
mg O -
, O +
antiseptic O +
0.05 O -
- O -
1 O +
g O -
, O +
osmotic O +
pressure O +
regulator O +
1.0 O -
- O -
7.5 O +
g O -
, O +
gel O +
matrix O +
30 O -
- O -
150 O +
g O -
, O +
and O +
acid O -
/ O -
base O +
buffer O +
and O +
water O +
for O +
injection O +
in O +
balancing O +
amount O -
. O +

The O +
inventive O +
pirenoxine O +
sodium O +
eye O +
gel O +
optimizes O +
adjuvants O +
and O +
improves O +
production O +
process O -
, O +
so O +
as O +
to O +
enrich O +
the O +
compound O +
taurine O +
dosage O +
forms O -
, O +
remarkably O +
prolong O +
the O +
retention O +
time O +
of O +
the O +
compound O +
taurine O +
in O +
eyes O -
, O +
and O +
improve O +
the O +
therapeutic O +
effect O -
; O +
and O +
has O +
no O +
adverse O +
irritant O +
reactions O -
. O +

Six O -
- O -
membered O +
heterocycles O +
useful O +
as O +
serine B-Gene +
protease I-Gene +
inhibitors O +
The O +
present O +
invention O +
provides O +
compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
or O +
a O +
stereoisomer O -
, O +
tautomer O -
, O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
form O +
thereof O -
, O +
wherein O +
the O +
variables O +
A O -
, O +
B O -
, O +
R<3 O -
> O +
and O +
R<11 O -
> O +
are O +
as O +
defined O +
herein O -
. O +

The O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
are O +
useful O +
as O +
selective O +
inhibitors O +
of O +
serine B-Gene +
protease I-Gene +
enzymes O +
of O +
the O +
coagulation O +
cascade O +
and/or O +
contact O +
activation O +
system O -
; O +
for O +
example O +
thrombin B-Gene -
, O +
factor B-Gene +
Xa I-Gene -
, O +
factor B-Gene +
XIa I-Gene -
, O +
factor B-Gene +
IXa I-Gene -
, O +
factor B-Gene +
VIIa I-Gene +
and/or O +
plasma B-Gene +
kallikrein I-Gene -
. O +

In O +
particular O -
, O +
it O +
relates O +
to O +
compounds O +
that O +
are O +
selective O +
factor B-Gene +
XIa I-Gene +
inhibitors O +
or O +
dual O +
inhibitors O +
of O +
fXIa B-Gene +
and O +
plasma B-Gene +
kallikrein I-Gene -
. O +

This O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O +
and O +
methods O +
of O +
treating O +
thromboembolic O +
and/or O +
inflammatory O +
disorders O +
using O +
the O +
same O -
. O +

Lxeris O +
sonchifolia O -
( O -
bunge O -
) O -
hance O +
flavone O +
extract O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
Disclosed O +
is O +
an O +
extract O +
of O +
flavonoid O +
of O +
ixeris O +
sonchifolia O +
hance O +
and O +
a O +
preparation O +
method O +
and O +
an O +
application O +
thereof O -
. O +

The O +
invention O +
discloses O +
a O +
novel O +
preparation O +
method O +
of O +
an O +
extract O +
of O +
flavonoid O +
of O +
ixeris O +
sonchifolia O +
hance O +
whose O +
content O +
of O +
luteolin-7-O O -
- O -
Beta O -
- O -
D O +
glucopyranose O +
aldehyde O +
acid O +
glycoside O +
is O +
25 O +
percent O +
to O +
99.5 O +
percent O -
, O +
discloses O +
a O +
novel O +
preparation O +
method O +
of O +
a O +
reference O +
substance O +
of O +
luteolin-7-O O -
- O -
Beta O -
- O -
D O +
glucopyranose O +
aldehyde O +
acid O +
glycoside O +
and O +
an O +
application O +
thereof O +
in O +
controlling O +
the O +
quality O +
of O +
the O +
ixeris O +
sonchifolia O +
hance O +
and O +
pharmaceutical O +
preparations O +
containing O +
the O +
extract O +
of O +
the O +
ixeris O +
sonchifolia O +
hance O -
, O +
and O +
also O +
discloses O +
an O +
application O +
of O +
the O +
extract O +
in O +
preparing O +
drugs O +
for O +
treating O +
the O +
coronary O +
heart O +
disease O -
, O +
the O +
cerebral O +
infarction O +
and O +
the O +
fracture O -
. O +

Ambroxol O +
hydrochloride O +
oral O +
solution O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
ambroxol O +
hydrochloride O +
oral O +
solution O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
and O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
western O +
medicine O -
, O +
in O +
particular O +
to O +
a O +
medical O +
production O +
formula O +
used O +
for O +
curing O +
bronchitis O +
and O +
a O +
preparation O +
method O +
thereof O -
; O +
the O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
sucrose O -
, O +
preservatives O +
and O +
purified O +
water O +
are O +
dissolved O +
in O +
a O +
mixing O +
mode O +
so O +
as O +
to O +
prepare O +
simple O +
syrup O -
; O +
the O +
ambroxol O +
hydrochloride O -
, O +
corrigents O +
and O +
preservatives O +
are O +
dissolved O +
by O +
the O +
purified O +
water O +
so O +
as O +
to O +
prepare O +
ambroxol O +
hydrochloride O +
solution O -
; O +
the O +
ambroxol O +
hydrochloride O +
solution O +
and O +
the O +
simple O +
syrup O +
are O +
stirred O +
and O +
mixed O +
evenly O -
, O +
the O +
corrigents O +
and O +
the O +
preservatives O +
are O +
added O +
successively O +
and O +
discontinuously O +
and O +
then O +
the O +
purified O +
water O +
is O +
added O +
to O +
adjust O +
the O +
concentration O -
. O +

The O +
invention O +
has O +
simple O +
and O +
reasonable O +
process O -
, O +
and O +
is O +
easy O +
to O +
operate O +
practically O +
and O +
the O +
produced O +
products O +
have O +
good O +
stability O -
; O +
the O +
products O +
can O +
used O +
as O +
common O +
phlegm O -
- O -
eliminating O +
drugs O -
, O +
has O +
functions O +
of O +
increasing O +
the O +
liquid O +
level O +
of O +
the O +
respiratory O +
tract O -
, O +
reducing O +
mucus O +
secretion O -
, O +
enhancing O +
the O +
secretion O +
of O +
pulmonary O +
surfactant O +
and O +
the O +
movement O +
of O +
cilium O +
and O +
preventing O +
cough O +
to O +
a O +
certain O +
extent O -
, O +
and O +
is O +
applicable O +
to O +
acute O +
respiratory O +
disease O +
and O +
chronic O +
respiratory O +
disease O -
, O +
such O +
as O +
ropy O +
sputum O +
and O +
difficult O +
cough O +
caused O +
by O +
acute O +
bronchitis O +
and O +
chronic O +
bronchitis O -
, O +
bronchial O +
asthma O +
and O +
pulmonary O +
tuberculosis O -
, O +
etc O -
. O +

Composition O +
injection O +
containing O +
tetrandrine O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
composite O +
containing O +
tetrandrine O -
, O +
and O +
discloses O +
a O +
composite O +
injection O +
containing O +
the O +
tetrandrine O +
and O +
a O +
preparation O +
method O +
thereof O -
; O +
the O +
composite O +
injection O +
consists O +
of O +
the O +
tetrandrine O -
, O +
latent O +
solvent O -
, O +
stabilizing O +
agent O +
and O +
sodium O +
chloride O -
; O +
wherein O -
, O +
the O +
content O +
of O +
the O +
tetrandrine O +
is O +
2 O -
- O -
60 O -
% O -
, O +
the O +
content O +
of O +
the O +
latent O +
solvent O +
is O +
2 O -
- O -
40 O -
% O -
, O +
the O +
content O +
of O +
the O +
stabilizing O +
agent O +
is O +
1 O -
- O -
8 O -
% O -
, O +
and O +
the O +
content O +
of O +
the O +
sodium O +
chloride O +
is O +
9 O -
- O -
90 O -
% O -
; O +
the O +
proportion O +
among O +
the O +
tetrandrine O -
, O +
the O +
latent O +
solvent O +
and O +
the O +
stabilizing O +
agent O +
is O +
1:0.5:0.01 O -
- O -
1:1:1 O -
. O +

The O +
method O +
is O +
that O -
: O +
right O +
amount O +
of O +
water O +
used O +
for O +
injecting O +
is O +
added O +
with O +
2 O -
- O -
60 O -
% O +
of O +
latent O +
solvent O -
, O +
1 O -
- O -
8 O -
% O +
of O +
stabilizing O +
agent O +
and O +
9 O -
- O -
90 O -
% O +
of O +
sodium O +
chloride O +
for O +
dissolving O -
; O +
the O +
2 O -
- O -
60 O -
% O +
of O +
tetrandrine O +
is O +
added O +
to O +
be O +
stirred O +
and O +
dissolved O -
, O +
and O +
then O +
added O +
with O +
water O +
to O +
full O +
dose O -
; O +
after O +
being O +
mixed O -
, O +
the O +
content O +
and O +
pH O +
value O +
of O +
the O +
tetrandrine O +
is O +
measured O -
, O +
and O +
then O +
poured O +
into O +
a O +
bottle O +
after O +
being O +
filtered O -
; O +
after O +
sterilization O -
, O +
lamp O +
check O +
and O +
quality O +
control O +
are O +
carried O +
out O -
, O +
the O +
injection O +
is O +
prepared O -
. O +

The O +
composite O +
injection O +
is O +
easy O +
to O +
store O -
, O +
has O +
little O +
irritation O +
and O +
good O +
stability O -
, O +
can O +
overcome O +
the O +
problems O +
of O +
easy O +
precipitation O +
of O +
the O +
tetrandrine O +
and O +
clinical O +
pain O -
. O +

Benzenesulfonamides O +
Ca-4 O +
analogue O -
, O +
synthesis O +
method O +
and O +
application O +
The O +
invention O +
relates O +
to O +
benzo O +
sulfonamide O +
CA-4 O +
analogues O -
, O +
a O +
synthetic O +
method O +
and O +
an O +
application O +
thereof O -
, O +
pertaining O +
to O +
the O +
field O +
of O +
chemical O +
drugs O -
. O +

The O +
compound O +
has O +
the O +
structure O +
shown O +
as O +
the O +
general O +
formula O +
( O -
IV O -
) O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
an O +
N O -
- O -
tert O +
butyl O -
- O -
benzene O +
sulfonamide O -
- O -
derivative O +
is O +
taken O +
as O +
raw O +
material O +
to O +
generate O +
corresponding O +
carbanion O +
under O +
the O +
function O +
of O +
a O +
metal O +
reagent O -
, O +
and O +
then O +
respectively O +
reacts O +
with O +
benzaldehydes O +
containing O +
methoxy O +
and O +
other O +
substituted O +
functional O +
groups O +
to O +
generate O +
secondary O +
alcohol O -
; O +
the O +
secondary O +
alcohol O +
is O +
oxidized O +
by O +
an O +
oxidant O -
; O +
a O +
series O +
of O +
conformational O +
restriction O +
CA-4 O +
analogues O +
are O +
synthesized O +
by O +
making O +
use O +
of O +
a O +
novel O +
cyclization O +
reaction O +
induced O +
by O +
trimethylsilyl O +
chlorine O -
/ O -
NaI O -
/ O -
acetonitrile O +
reagent O -
. O +

The O +
result O +
of O +
a O +
vitro O +
cell O +
growth O +
inhibition O +
activity O +
test O +
of O +
the O +
target O +
compound O +
shows O +
that O +
the O +
CA-4 O +
analogues O +
can O +
be O +
applied O +
as O +
anti O -
- O -
tumor O +
drugs O -
. O +

2- O -
( O -
4-substituted O +
phenyl-1,2,3-thiadiazole-5sulfhydryl O -
) O -
-N O -
- O -
substituted O +
phenyl O +
acetamides O +
derivates O -
, O +
preparation O +
thereof O +
and O +
application O +
The O +
invention O +
provides O +
a O +
2- O -
( O -
4-substituted O +
phenyl-1 O -
, O +
2 O -
, O +
3- O +
thiadiazole-5- O +
mercapto O -
) O -
-N O -
- O -
substituted O +
phenyl O +
acetamide O +
derivative O +
with O +
the O +
structure O +
general O +
formula O +
shown O +
as O +
the O +
right O +
formula O -
, O +
wherein O -
, O +
R<1 O -
> O +
is O +
H O -
, O +
F O +
or O +
Cl O -
; O +
R<2 O -
> O +
is O +
H O -
, O +
F O -
, O +
Cl O +
or O +
OCH3 O -
; O +
X O +
is O +
F O -
, O +
Cl O -
, O +
Br O +
or O +
NO2 O -
; O +
and O +
Y O +
is O +
H O -
, O +
CH3 O -
, O +
COOCH3 O +
or O +
COOC2H5 O -
. O +

The O +
derivative O +
is O +
a O +
novel O +
structure O +
framework O -
, O +
has O +
relatively O +
high O +
inhibition O +
activity O +
on O +
HIV O +
and O +
can O +
be O +
taken O +
as O +
a O +
lead O +
compound O +
to O +
be O +
applied O +
to O +
the O +
preparation O +
of O +
anti O -
- O -
HIV O +
agents O -
. O +

Penem O +
compound O +
containing O +
sulfhydryl O +
piperidine O +
The O +
invention O +
pertains O +
to O +
the O +
technical O +
field O +
of O +
medicine O +
and O +
particularly O +
relates O +
to O +
a O +
penem O +
compound O +
which O +
contains O +
sulfhydryl O +
piperidine O +
and O +
is O +
shown O +
as O +
general O +
formula O +
( O -
I O -
) O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
easily O +
hydrolysable O +
ester O +
and O +
isomers O +
of O +
the O +
compound O -
; O +
wherein O -
, O +
R<1 O -
> O -
, O +
R<2 O -
> O -
, O +
R<3 O -
> O -
, O +
R<4 O -
> O -
, O +
R<5 O -
> O +
and O +
R<6 O -
> O +
are O +
defined O +
as O +
the O +
specification O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
the O +
compounds O -
, O +
medicine O +
composition O +
containing O +
the O +
compounds O +
as O +
well O +
as O +
application O +
of O +
the O +
compounds O +
to O +
the O +
preparation O +
of O +
medicines O +
treating O +
and/or O +
preventing O +
infectious O +
diseases O -
. O +

Carbapenem O +
derivates O +
containing O +
sulfhydryl O +
pyrrolidine O +
The O +
invention O +
pertains O +
to O +
the O +
technical O +
field O +
of O +
medicine O +
and O +
particularly O +
relates O +
to O +
a O +
carbon O +
penem O +
derivative O +
which O +
contains O +
sulfhydryl O +
pyrrolidine O +
and O +
is O +
shown O +
as O +
general O +
formula O +
( O -
I O -
) O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
easily O +
hydrolysable O +
ester O +
and O +
isomers O +
of O +
the O +
derivative O -
; O +
wherein O -
, O +
R<1 O -
> O -
, O +
R<2 O -
> O -
, O +
R<3 O -
> O -
, O +
R<4 O -
> O +
and O +
R<5 O -
> O +
are O +
defined O +
as O +
the O +
specification O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
the O +
compounds O -
, O +
medicine O +
composition O +
containing O +
the O +
compounds O +
as O +
well O +
as O +
application O +
of O +
the O +
compounds O +
to O +
the O +
preparation O +
of O +
medicines O +
treating O +
and/or O +
preventing O +
infectious O +
diseases O -
. O +

Penem O +
derivative O +
The O +
invention O +
belongs O +
to O +
the O +
pharmaceutical O +
technical O +
field O -
, O +
and O +
particularly O +
relates O +
to O +
a O +
penem O +
derivative O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
easily O -
- O -
hydrolyzed O +
esters O +
thereof O -
, O +
isomers O +
thereof O -
, O +
hydrate O +
thereof O +
and O +
hydrates O +
of O +
esters O +
or O +
salts O +
thereof O +
shown O +
as O +
a O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O +
and O +
R5 O +
are O +
defined O +
as O +
in O +
the O +
description O -
, O +
and O +
can O +
be O +
further O +
substituted O +
on O +
a O +
benzene O +
ring O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
preparation O +
method O +
of O +
the O +
compounds O +
and O +
the O +
pharmaceutical O +
compound O +
containing O +
the O +
same O -
, O +
and O +
the O +
application O +
thereof O +
on O +
the O +
preparation O +
of O +
pharmaceuticals O +
for O +
treating O +
and/or O +
preventing O +
infection O +
diseases O -
. O +

Pyrrolidone O +
containing O +
hydroxymethyl O +
and O +
carboxyl O -
, O +
preparation O +
method O +
and O +
medicament O +
composition O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
pyrrolidone O +
containing O +
hydroxymethyl O +
and O +
carboxyl O +
and O +
a O +
method O +
for O +
preparing O +
the O +
same O -
, O +
pharmaceutical O +
compositions O +
and O +
applications O +
thereof O -
, O +
in O +
particular O +
to O +
compounds O +
containing O +
sulfonyl O +
pyrrolidone O +
shown O +
in O +
the O +
general O +
formula O +
( O -
I O -
) O -
, O +
a O +
method O +
for O +
preparing O +
the O +
compounds O -
, O +
the O +
pharmaceutical O +
compositions O +
containing O +
the O +
compounds O -
, O +
as O +
well O +
as O +
pharmaceutical O +
applications O +
of O +
the O +
compounds O -
. O +

In O +
the O +
general O +
formula O -
, O +
R1 O +
is O +
the O +
hydroxymethyl O +
and O +
the O +
carboxyl O -
. O +

Novel O +
nitrogen O -
- O -
containing O +
medicament O +
with O +
anti O -
- O -
inflammatory O +
activity O +
The O +
invention O +
relates O +
to O +
an O +
androstane O +
azotic O +
glucocorticoid B-Gene +
receptor I-Gene +
stimulant O +
compound O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
invention O +
further O +
relates O +
to O +
the O +
pharmaceutical O +
preparations O +
comprising O +
the O +
compound O +
and O +
the O +
therapeutic O +
use O +
of O +
the O +
compound O -
, O +
in O +
particular O +
to O +
inflammatory O +
disease O -
, O +
allergic O +
disease O +
or O +
anaphylactic O +
disease O -
. O +

Compound O +
alpha O -
- O -
ketoacid O +
chewing O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
drug O +
preparation O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
in O +
particular O +
to O +
a O +
compound O +
Alpha O -
- O -
ketonic O +
acid O +
chewable O +
tablet O +
used O +
for O +
curing O +
chronic O +
renal O +
failure O -
, O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
compound O +
Alpha O -
- O -
ketonic O +
acid O +
chewable O +
tablet O +
comprises O +
the O +
following O +
components O -
: O +
Alpha O -
- O -
ketophenylalanine O +
calcium O -
, O +
Alpha O -
- O -
hydroxymethionine O +
calcium O -
, O +
Alpha O -
- O -
ketoleucine O +
calcium O -
, O +
Alpha O -
- O -
ketoisoleucine O +
calcium O -
, O +
Alpha O -
- O -
ketovaline O +
calcium O -
, O +
tryptophan O -
, O +
histidine O -
, O +
tyrosine O -
, O +
threonine O -
, O +
lysine O -
, O +
acetate O -
, O +
a O +
filling O +
agent O -
, O +
a O +
bonding O +
agent O -
, O +
a O +
taste O -
- O -
masking O +
agent O -
, O +
a O +
lubricant O +
and O +
a O +
coating O +
agent O -
. O +

The O +
compound O +
Alpha O -
- O -
ketonic O +
acid O +
chewable O +
tablet O +
not O +
only O +
widens O +
the O +
dosage O +
form O +
range O +
of O +
the O +
compound O +
Alpha O -
- O -
ketonic O +
acid O +
chewable O +
tablets O -
, O +
but O +
also O +
has O +
the O +
advantages O +
of O +
having O +
good O +
dispersing O +
state O -
, O +
short O +
disintegration O +
time O -
, O +
fast O +
drug O +
dissolution O -
, O +
rapid O +
absorption O -
, O +
high O +
biological O +
availability O +
and O +
convenient O +
taking O -
, O +
being O +
capable O +
of O +
being O +
swallowed O -
, O +
chewed O +
and O +
sucked O +
and O +
being O +
especially O +
suitable O +
for O +
old O +
people O -
, O +
stroke O +
patients O -
, O +
patients O +
with O +
special O +
diseases O +
and O +
patients O +
having O +
swallowing O +
difficulty O -
. O +

Putrefaction O -
- O -
removing O +
granulation O -
- O -
promoting O +
paste O +
The O +
invention O +
relates O +
to O +
a O +
curing O +
and O +
healing O +
ointment O +
used O +
for O +
curing O +
the O +
damage O +
of O +
big O +
muscle O -
, O +
muscle O +
fracture O -
, O +
pyogenic O +
infection O -
, O +
carbuncle O +
and O +
surgery O +
cut O -
, O +
in O +
particular O +
to O +
a O +
granulation O -
- O -
promoting O +
ointment O +
which O +
can O +
ensures O +
the O +
quick O +
growth O +
of O +
fester O +
soft O +
tissues O +
without O +
leaving O +
remarkable O +
sclerosis O +
and O +
scars O -
. O +

The O +
ointment O +
consists O +
of O +
xanthium O +
worm O +
( O -
1 O -
) O -
, O +
rust O +
powder O +
( O -
2 O -
) O -
, O +
vermilion O +
( O -
3 O -
) O -
, O +
scorpion O +
( O -
4 O -
) O -
, O +
calcined O +
alum O +
( O -
5 O -
) O +
( O -
dewatered O +
alum O -
) O +
and O +
beeswax O +
( O -
6 O -
) O -
. O +

The O +
curing O +
and O +
healing O +
ointment O +
has O +
the O +
main O +
functions O +
of O +
detumescence O +
and O +
toxin O +
drawing O -
- O -
out O +
as O +
well O +
as O +
pus O +
drainage O +
and O +
removal O +
of O +
necrotic O +
tissue O -
. O +

The O +
invention O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
the O +
granulation O -
- O -
promoting O +
ointment O +
which O +
consists O +
of O +
20 O +
fresh O +
xanthium O +
worms O +
( O -
1 O -
) O -
, O +
2.4 O -
g O +
of O +
the O +
rust O +
powder O +
( O -
2 O -
) O -
, O +
2.4 O -
g O +
of O +
the O +
vermilion O +
( O -
3 O -
) O -
, O +
3 O -
g O +
of O +
the O +
scorpion O +
( O -
4 O -
) O -
, O +
6 O -
g O +
of O +
the O +
calcined O +
alum O +
( O -
5 O -
) O +
( O -
dewatered O +
alum O -
) O +
and O +
20 O -
g O +
of O +
the O +
beeswax O +
( O -
6 O -
) O -
. O +

In O +
the O +
method O -
, O +
the O +
xanthium O +
worms O +
are O +
dipped O +
in O +
benne O +
oil O +
for O +
7 O +
days O +
and O +
the O +
scorpion O +
is O +
fried O -
. O +

The O +
rust O +
powder O -
, O +
the O +
scorpion O +
powder O -
, O +
the O +
calcined O +
alum O -
, O +
the O +
beeswax O +
and O +
the O +
vermilion O +
are O +
heated O +
and O +
mixed O +
uniformly O -
, O +
cooled O +
and O +
then O +
the O +
xanthium O +
worms O +
and O +
proper O +
amount O +
of O +
the O +
benne O +
oil O +
are O +
added O +
and O +
mashed O +
into O +
ointment O +
for O +
standby O -
. O +

The O +
curing O +
and O +
healing O +
ointment O +
has O +
the O +
main O +
functions O +
of O +
detumescence O +
and O +
toxin O +
drawing O -
- O -
out O +
as O +
well O +
as O +
pus O +
drainage O +
and O +
removal O +
of O +
necrotic O +
tissue O -
, O +
and O +
has O +
stronger O +
sterilization O +
and O +
infection O -
- O -
resistance O +
capacities O -
. O +

The O +
invention O +
also O +
has O +
the O +
advantages O +
of O +
easily O +
obtained O +
materials O -
, O +
novel O +
and O +
specific O +
prescription O -
, O +
simple O +
extraction O +
technique O +
and O +
convenient O +
medication O -
. O +

External O -
- O -
use O +
medicament O +
for O +
scald O +
The O +
invention O +
provides O +
an O +
external O +
use O +
scalding O +
drug O -
, O +
which O +
is O +
characterized O +
in O +
that O +
the O +
scalding O +
drug O +
is O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
by O +
weight O +
percentage O -
: O +
10 O +
to O +
20 O +
percent O +
of O +
gypsum O -
, O +
10 O +
to O +
20 O +
percent O +
of O +
rhubarb O -
, O +
10 O +
to O +
20 O +
percent O +
of O +
green O +
tea O -
, O +
10 O +
to O +
20 O +
percent O +
of O +
sesame O +
oil O -
, O +
10 O +
to O +
20 O +
percent O +
of O +
borneol O -
, O +
10 O +
to O +
20 O +
percent O +
of O +
soy O +
sauce O -
. O +

The O +
scalding O +
drug O +
has O +
the O +
efficacy O +
of O +
alleviating O +
the O +
pain O +
and O +
cooling O +
the O +
blood O -
, O +
and O +
effectively O +
avoids O +
blistering O +
on O +
the O +
scalded O +
part O -
, O +
thereby O +
preventing O +
the O +
wound O +
infection O -
; O +
moreover O -
, O +
the O +
scalding O +
drug O +
has O +
the O +
advantages O +
of O +
simple O +
and O +
reasonable O +
compatibility O +
of O +
medicaments O -
, O +
quick O +
onset O +
and O +
good O +
effect O -
. O +

Enterobacter O +
cloacae O -
, O +
and O +
use O +
of O +
polysaccharide O +
and O +
polysaccharide O +
thereof O +
The O +
invention O +
discloses O +
Enterobacter O +
cloacae O +
Z0206 O -
, O +
which O +
has O +
been O +
preserved O +
in O +
China O +
General O +
Microbiological O +
Culture O +
Collection O +
Center O +
on O +
December O +
3 O -
, O +
2007 O -
, O +
wherein O +
the O +
preserving O +
number O +
is O +
CGMCC O +
NO O -
: O +
2279 O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
method O +
for O +
preparing O +
Enterobacter O +
cloacae O +
Z0206 O +
polysaccharide O +
and O +
application O +
thereof O -
. O +

The O +
method O +
has O +
the O +
advantages O +
that O +
the O +
production O +
process O +
of O +
extracting O +
the O +
polysaccharide O +
is O +
simple O -
, O +
and O +
the O +
yield O +
and O +
the O +
purity O +
of O +
products O +
are O +
higher O -
; O +
the O +
Enterobacter O +
cloacae O +
Z0206 O +
polysaccharide O +
can O +
remarkably O +
improve O +
the O +
proliferation O +
capacity O +
of O +
lymph O +
cells O +
and O +
the O +
cytokine O +
level O +
of O +
a O +
small O +
mouse O +
with O +
low O +
immunity O +
and O +
has O +
remarkable O +
adjustment O +
effect O +
on O +
the O +
immunologic O +
function O +
of O +
the O +
small O +
mouse O +
with O +
low O +
immunity O -
; O +
and O +
the O +
Enterobacter O +
cloacae O +
Z0206 O +
polysaccharide O +
has O +
apparent O +
antagonism O +
on O +
the O +
oxidative O +
damage O +
caused O +
by O +
cyclophosphamide O -
, O +
can O +
remarkably O +
improve O +
the O +
antioxidase O +
activity O +
of O +
an O +
organism O -
, O +
strengthen O +
the O +
function O +
of O +
an O +
antioxidant O +
defense O +
system O +
of O +
the O +
organism O -
, O +
and O +
prevent O +
harmful O +
free O +
radicals O +
from O +
damaging O +
biological O +
macromolecules O +
in O +
cells O -
. O +

Novel O +
compound O +
separated O +
from O +
immature O +
exocarp O +
of O +
Juglans O +
mandshurica O +
Maxim O -
, O +
and O +
preparation O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
novel O +
compound O +
separated O +
form O +
north O +
Juglans O +
regia O +
and O +
a O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

The O +
preparation O +
method O +
adopts O +
a O +
method O +
for O +
combining O +
alcohol O +
extraction O -
, O +
chromatographic O +
separation O +
and O +
purification O +
and O +
cytoactive O +
assay O +
to O +
separate O +
the O +
novel O +
compound O -
, O +
which O +
is O +
not O +
reported O +
before O +
and O +
has O +
anti O -
- O -
tumor O +
function O -
, O +
from O +
the O +
north O +
Juglans O +
regia O -
, O +
and O +
adopts O +
mass O +
spectrum O +
and O +
high O -
- O -
resolution O +
nuclear O +
magnetic O +
resonance O +
technique O +
to O +
determine O +
the O +
structure O +
of O +
the O +
compound O -
. O +

The O +
structural O +
formula O +
of O +
the O +
novel O +
compound O +
is O +
the O +
right O +
formula O +
( O -
I O -
) O -
. O +

The O +
novel O +
compound O +
is O +
applied O +
in O +
the O +
field O +
of O +
medicine O -
. O +

Cefixime O +
sustained O -
- O -
release O +
tablets O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
slow O -
- O -
release O +
tablet O +
prepared O +
from O +
cefixime O +
and O +
pharmaceutically O +
acceptable O +
auxiliary O +
materials O -
. O +

The O +
slow O -
- O -
release O +
tablet O +
is O +
characterized O +
in O +
that O -
: O +
the O +
slow O -
- O -
release O +
tablet O +
consists O +
of O +
the O +
following O +
raw O +
materials O +
and O +
auxiliary O +
materials O +
in O +
portion O +
by O +
weight O -
: O +
200 O +
portions O +
of O +
cefixime O -
( O -
counted O +
as O +
an O +
anhydride O -
) O -
, O +
20 O +
to O +
200 O +
portions O +
of O +
at O +
least O +
one O +
pharmaceutically O +
acceptable O +
slow O -
- O -
release O +
material O +
which O +
can O +
control O +
the O +
drug O +
to O +
continuously O +
and O +
completely O +
release O -
, O +
20 O +
and O +
400 O +
portions O +
of O +
a O +
pharmaceutically O +
acceptable O +
excipient O +
and O +
5 O +
to O +
100 O +
portions O +
of O +
at O +
least O +
one O +
solubilizer O +
which O +
can O +
effectively O +
improve O +
the O +
release O +
rate O +
of O +
the O +
drug O -
. O +

The O +
slow O -
- O -
release O +
tablet O +
is O +
easy O +
to O +
prepare O +
and O +
facilitates O +
the O +
industrialized O +
production O -
. O +

Phenyl O +
substituted O +
heteroaryl O -
- O -
derivatives O +
and O +
use O +
thereof O +
as O +
anti O -
- O -
tumor O +
agents O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
the O +
radicals O +
Rto O +
R O -
, O +
L O -
, O +
Q O +
and O +
n O +
are O +
defined O +
as O +
indicated O +
in O +
claim O +
1 O -
. O +

Said O +
compounds O +
are O +
suitable O +
for O +
treating O +
diseases O +
that O +
are O +
characterised O +
by O +
excessive O +
or O +
anomal O +
cell O +
proliferation O -
. O +

The O +
invention O +
also O +
relates O +
to O +
their O +
use O +
for O +
producing O +
a O +
medicament O +
having O +
the O +
above O -
- O -
mentioned O +
properties O -
. O +

Anti O -
- O -
infective O +
medicament O +
composition O +
and O +
application O +
The O +
invention O +
discloses O +
an O +
anti O -
- O -
infective O +
drug O +
combination O +
and O +
an O +
application O +
thereof O -
. O +

The O +
anti O -
- O -
infective O +
drug O +
combination O +
comprises O +
a O +
dryopteris O +
fragrans O +
extract O +
with O +
the O +
weight O +
percentage O +
being O +
1 O -
% O +
to O +
99 O -
% O +
of O +
the O +
drug O +
combination O -
, O +
and O +
pharmaceutically O +
conventional O +
auxiliary O +
materials O -
. O +

The O +
dryopteris O +
fragrans O +
extract O +
comprises O +
the O +
following O +
components O -
: O +
dryopteris O +
fragrans O +
essence O -
, O +
aspidin O +
AB O -
, O +
aspidin O +
PB O -
, O +
aspidin O +
BB O -
, O +
aspidinol O +
and O +
albicanol O -
. O +

The O +
anti O -
- O -
infective O +
drug O +
combination O +
is O +
applicable O +
in O +
the O +
preparation O +
of O +
drugs O +
for O +
curing O +
bacterial O -
, O +
fungal O +
or O +
viral O +
infection O +
diseases O -
; O +
and O +
the O +
anti O -
- O -
infective O +
drug O +
combination O +
has O +
the O +
advantages O +
that O +
the O +
anti O -
- O -
bacterial O +
spectrum O +
is O +
wide O -
, O +
the O +
anti O -
- O -
multidrug O +
resistance O +
is O +
good O +
and O +
the O +
safety O +
is O +
high O +
because O +
the O +
anti O -
- O -
infective O +
drug O +
combination O +
is O +
derived O +
from O +
the O +
natural O +
plant O +
resources O -
. O +

Polyhydroxyalkanoate O +
( O -
PHA O -
) O +
targeted O +
carrier O -
, O +
drug O -
- O -
loading O +
nano O -
- O -
particle O +
and O +
preparation O +
methods O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
a O +
polyhydroxyalkanoate O +
( O -
PHA O -
) O +
targeted O +
carrier O +
with O +
the O +
general O +
formula O +
being O +
FA O -
- O -
PEG O -
- O -
P O +
( O -
HBHO O -
) O +
and O +
a O +
targeted O +
drug O -
- O -
loading O +
nano O -
- O -
particle O +
prepared O +
by O +
encapsulating O +
anti O -
- O -
tumor O +
drugs O +
on O +
the O +
basis O +
of O +
ultrasonic O +
emulsification O +
method O +
with O +
the O +
carrier O +
being O +
FA O -
- O -
PEG O -
- O -
P O +
( O -
HBHO O -
) O -
. O +

The O +
drug O -
- O -
loading O +
nano O -
- O -
particle O +
is O +
characterized O +
in O +
that O +
the O +
particle O +
size O +
thereof O +
is O +
in O +
narrow O +
distribution O +
within O +
the O +
general O +
range O +
of O +
300 O +
to O +
500 O -
nm O +
and O +
the O +
morphological O +
feature O +
thereof O +
is O +
regular O -
, O +
has O +
the O +
advantages O +
of O +
high O +
biodegradability O +
and O +
biocompatibility O -
, O +
stable O +
structure O +
and O +
less O +
serious O +
toxic O +
andside O +
effects O -
, O +
and O +
has O +
better O +
effect O +
on O +
inhibiting O +
tumor O +
cells O +
according O +
to O +
the O +
in O +
vitro O +
cell O +
experiment O -
. O +

Liquiritin O +
preparation O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
a O +
liquiritin O +
preparation O +
with O +
the O +
molecular O +
formula O +
of O +
C26H30O13 O +
and O +
the O +
molecular O +
weight O +
of O +
550 O -
. O +

The O +
liquiritin O +
is O +
singly O +
prepared O +
or O +
by O +
matching O +
with O +
other O +
active O +
components O +
or O +
auxiliary O +
materials O -
, O +
and O +
the O +
preparation O +
composition O +
is O +
counted O +
in O +
such O +
a O +
way O +
that O +
1000 O +
particles O +
contain O +
40 O -
g O +
of O +
liquiritin O -
. O +

The O +
liquiritin O +
preparation O +
has O +
stronger O +
effect O +
for O +
relieving O +
cough O +
and O +
eliminating O +
phlegm O -
, O +
therefore O -
, O +
the O +
preparation O +
can O +
be O +
singly O +
prepared O +
by O +
liquiritin O +
or O +
by O +
the O +
liquiritin O +
matching O +
with O +
other O +
active O +
components O +
or O +
auxiliary O +
materials O -
, O +
can O +
be O +
used O +
for O +
improving O +
symptoms O +
of O +
cough O +
and O +
profuse O +
sputum O -
, O +
and O +
can O +
be O +
applied O +
to O +
the O +
preparation O +
of O +
medicine O +
for O +
curing O +
acute O +
cough O -
, O +
chronic O +
cough O +
and O +
profuse O +
sputum O -
. O +

The O +
liquiritin O +
preparation O +
originates O +
from O +
natural O +
plants O -
, O +
can O +
be O +
made O +
into O +
a O +
health O -
- O -
care O +
product O -
, O +
and O +
provides O +
the O +
natural O +
cough O -
- O -
relieving O +
medicine O +
with O +
less O +
toxic O +
side O +
effect O +
and O +
obvious O +
healing O +
effect O +
for O +
clinical O +
treatment O -
. O +

Compound O +
treating O +
diabetes O +
and O +
relevant O +
complicating O +
diseases O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
treating O +
diabetes O +
and O +
relevant O +
complicating O +
diseases O +
and O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

The O +
invention O +
provides O +
the O +
compound O +
expressed O +
as O +
the O +
formula O +
X O -
: O +
shown O +
as O +
the O +
right O -
, O +
wherein O +
R O +
is O +
-OH O +
or O +
R1COO<- O -
> O -
, O +
R1 O +
is O +
C2-C20 O +
carbon O +
chain O -
. O +

The O +
invention O +
also O +
provides O +
the O +
method O +
for O +
preparing O +
the O +
compound O +
and O +
a O +
drug O +
compound O +
containing O +
the O +
compound O +
shown O +
as O +
the O +
formula O +
X. O +
The O +
invention O +
also O +
provides O +
the O +
application O +
of O +
the O +
compound O +
on O +
preparing O +
medicaments O +
for O +
treating O +
diabetes O +
and O +
relevant O +
complicating O +
diseases O -
. O +

Method O +
for O +
extracting O +
amylase O +
from O +
liquorice O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
a O +
method O +
from O +
extracting O +
amylase O +
from O +
liquorice O +
and O +
application O +
thereof O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
a. O +
dried O +
liquorice O +
is O +
ground O -
; O +
b. O +
the O +
ground O +
liquorice O +
is O +
put O +
into O +
an O +
extraction O +
tank O -
, O +
petroleum O +
ether O +
is O +
added O +
for O +
reflowing O +
and O +
degreasing O -
, O +
and O +
then O +
filtered O +
out O +
to O +
obtain O +
degreased O +
residue O -
; O +
c. O +
the O +
residue O +
is O +
added O +
with O +
distilled O +
water O +
for O +
extraction O +
in O +
normal O +
termperature O -
, O +
repeatedly O +
poached O +
and O +
extracted O +
for O +
three O +
times O -
, O +
and O +
triple O +
extraction O +
solutions O +
are O +
combined O -
; O +
d. O +
the O +
extraction O +
solution O +
is O +
decompressed O +
and O +
concentrated O +
to O +
cause O +
the O +
volume O +
of O +
the O +
solution O +
to O +
be O +
the O +
liquorice O +
powder O +
in O +
the O +
step O +
a O -
, O +
thus O +
obtaining O +
a O +
concentrated O +
solution O -
; O +
e. O +
a O +
concentrated O +
solution O +
is O +
added O +
into O +
the O +
concentrated O +
solution O +
in O +
the O +
step O +
d O -
, O +
and O +
then O +
the O +
concentrated O +
mixed O +
solution O +
stands O +
overnight O +
and O +
precipitates O -
; O +
f. O +
the O +
concentrated O +
mixed O +
solution O +
is O +
centrifugalized O +
to O +
obtain O +
the O +
precipitation O -
, O +
dried O -
, O +
and O +
then O +
washed O +
with O +
absolute O +
ethyl O +
alcohol O -
, O +
acetone O +
and O +
aether O +
after O +
is O +
extracted O +
by O +
a O +
Sevag O +
method O -
; O +
g. O +
semi O -
- O -
permeable O +
membrane O +
with O +
the O +
interception O +
molecular O +
weight O +
of O +
1000 O -
- O -
10000 O +
is O +
used O +
for O +
dialyzing O +
in O +
water O -
, O +
the O +
liquorice O +
amylase O +
is O +
obtained O +
by O +
freezing O +
and O +
drying O -
. O +

The O +
liquorice O +
amylase O +
is O +
applied O +
to O +
the O +
preparation O +
of O +
medicine O +
treating O +
or O +
preventing O +
osteoarthritis O -
. O +

The O +
liquorice O +
amylase O +
has O +
definite O +
active O +
ingredient O -
, O +
definite O +
healing O +
effect O +
and O +
no O +
toxic O +
side O +
effect O +
and O +
the O +
extraction O +
method O +
is O +
easy O +
to O +
be O +
implemented O -
. O +

Method O +
for O +
preparing O +
tea O +
seed O +
oil O +
burn O +
wound O +
ointment O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
a O +
tea O +
seed O +
oil O +
burn O +
wound O +
ointment O -
, O +
which O +
is O +
characterized O +
in O +
that O +
the O +
tea O +
seed O +
oil O +
burn O +
wound O +
ointment O +
comprises O +
the O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
50 O +
to O +
60 O +
percent O +
of O +
tea O +
seed O +
oil O -
, O +
3 O +
to O +
5 O +
percent O +
of O +
borneol O -
, O +
3 O +
to O +
5 O +
percent O +
of O +
rhubarb O -
, O +
8 O +
to O +
15 O +
percent O +
of O +
dandelion O -
, O +
and O +
the O +
balance O +
of O +
bamboo O +
charcoal O +
powder O -
; O +
and O +
the O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
cleaning O -
, O +
drying O +
and O +
crushing O +
the O +
borneol O -
, O +
the O +
rhubarb O +
and O +
the O +
dandelion O -
; O +
stirring O +
the O +
materials O +
evenly O +
in O +
proportion O -
; O +
pouring O +
the O +
mixture O +
into O +
the O +
tea O +
seed O +
oil O +
and O +
stirring O +
the O +
mixture O -
; O +
and O +
finally O +
adding O +
the O +
bamboo O +
charcoal O +
powder O +
to O +
the O +
mixture O +
and O +
stirring O +
the O +
mixture O -
. O +

The O +
method O +
overcomes O +
the O +
defects O +
that O +
at O +
present O -
, O +
a O +
burn O +
medicine O +
has O +
less O +
medicinal O +
resources O +
and O +
high O +
price O +
so O +
that O +
the O +
economic O +
burden O +
of O +
a O +
patient O +
is O +
increased O -
, O +
and O +
is O +
easy O +
to O +
trickle O +
and O +
contaminate O +
clothes O +
and O +
beddings O -
. O +

The O +
tea O +
seed O +
oil O +
burn O +
wound O +
ointment O +
prepared O +
by O +
the O +
method O +
has O +
the O +
advantages O +
of O +
no O +
trickling O -
, O +
low O +
cost O -
, O +
extensive O +
medicinal O +
resources O -
, O +
remarkable O +
curative O +
effect O -
, O +
simple O +
production O +
process O -
, O +
less O +
equipment O +
investment O -
, O +
and O +
the O +
like O -
. O +

Method O +
for O +
preparing O +
andrographolide O +
derivatives O +
and O +
preparation O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
andrographolide O +
derivatives O -
, O +
and O +
a O +
preparation O +
thereof O -
. O +

The O +
preparation O +
is O +
a O +
salt O +
which O +
consists O +
of O +
Kalii O +
Dethydroandrographolidi O +
Succinas O +
and O +
Adamantanes O +
and O +
has O +
the O +
effect O +
of O +
synergistic O +
interaction O -
. O +

The O +
curative O +
effect O +
of O +
the O +
preparation O +
is O +
better O +
than O +
that O +
of O +
the O +
independent O +
use O +
of O +
Kalii O +
Dethydroandrographolidi O +
Succinas O +
and O +
Adamantanes O -
. O +

Application O +
of O +
7,3'-dimethoxy O +
hesperetin O +
in O +
preparation O +
of O +
anti O -
- O -
inflammatory O +
immune O +
medicaments O +
The O +
pharmaceutical O +
application O +
of O +
a O +
hesperetin O +
derivative O +
relates O +
to O +
the O +
application O +
thereof O +
in O +
the O +
preparation O +
of O +
anti O -
- O -
inflammatory O +
immune O +
medicaments O -
, O +
in O +
particular O +
to O +
the O +
application O +
in O +
treatment O +
of O +
autoimmune O +
diseases O +
such O +
as O +
rheumatic O -
, O +
rheumatoid O +
arthritis O +
and O +
osteoarthritis O -
, O +
and O +
the O +
like O -
. O +

The O +
hesperetin O +
derivative O +
is O +
the O +
derivative O +
which O +
is O +
prepared O +
by O +
a O +
non O -
- O -
carbohydrate O +
compound O +
obtained O +
by O +
hydrolyzing O +
hesperidin O +
and O +
removing O +
glycosyl O -
. O +

The O +
pharmacological O +
effect O +
of O +
the O +
hesperetin O +
derivative O +
is O +
significantly O +
higher O +
than O +
that O +
of O +
the O +
parent O +
hesperidin O -
; O +
and O +
compared O +
with O +
traditional O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
medicament O +
naproxen O +
and O +
a O +
medicament O +
tripterygium O +
treating O +
rheumatoid O +
arthritis O -
, O +
the O +
hesperetin O +
derivative O +
has O +
equivalent O +
activeness O -
, O +
is O +
safe O +
and O +
non O -
- O -
toxic O -
, O +
not O +
only O +
treats O +
the O +
symptom O -
, O +
but O +
also O +
treats O +
the O +
root O -
, O +
thus O +
having O +
very O +
good O +
medicinal O +
prospect O -
. O +

Pharmaceutical O +
composition O +
containing O +
prasugrel O +
and O +
carbazochrome O +
sodium O +
sulfonate O +
The O +
invention O +
provides O +
a O +
pharmaceutical O +
composition O +
containing O +
active O +
carbazochrome O +
sodium O +
sulfonate O +
and O +
prasugrel O +
or O +
the O +
pharmacologically O +
acceptable O +
salt O +
thereof O -
. O +

The O +
invention O +
aims O +
to O +
invent O +
a O +
more O +
effective O +
and O +
low O +
adverse O -
- O -
reaction O +
method O +
for O +
curing O +
thrombotic O +
diseases O +
by O +
using O +
the O +
combined O +
medication O +
of O +
the O +
carbazochrome O +
sodium O +
sulfonate O +
and O +
the O +
prasugrel O -
. O +

After O +
conscientious O +
trail O +
of O +
the O +
patent O +
applicant O +
for O +
many O +
times O -
, O +
the O +
effect O +
of O +
applying O +
the O +
carbazochrome O +
sodium O +
sulfonate O +
to O +
inhibit O +
thrombosis O +
in O +
a O +
combined O +
manner O +
is O +
discovered O +
unexpected O +
in O +
the O +
process O +
of O +
applying O +
the O +
prasugrel O +
to O +
cure O +
the O +
thrombotic O +
diseases O -
, O +
the O +
anticoagulant O +
effect O +
of O +
the O +
prasugrel O +
is O +
not O +
abated O +
but O +
increased O -
, O +
and O +
the O +
very O +
good O +
synergistic O +
effects O +
are O +
achieved O +
after O +
the O +
combination O +
of O +
the O +
carbazochrome O +
sodium O +
sulfonate O +
and O +
the O +
prasugrel O -
, O +
therefore O -
, O +
the O +
risk O +
of O +
bleeding O +
is O +
greatly O +
reduced O +
when O +
the O +
advantages O +
of O +
good O +
anticoagulant O +
activity O +
and O +
fast O +
effect O +
of O +
the O +
prasugrel O +
during O +
the O +
antiplatelet O +
aggregation O +
are O +
fully O +
exerted O -
, O +
the O +
risk O +
of O +
bleeding O +
caused O +
by O +
the O +
prasugrel O +
is O +
effectively O +
reduced O +
and O +
the O +
compliance O +
of O +
patients O +
is O +
enhanced O -
. O +

Method O +
for O +
preparing O +
zinc O +
supplementing O +
agent O +
carboxymethyl O +
chitosan O +
oligosaccharide O +
zinc O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
zinc O +
supplementing O +
agent O +
carboxymethyl O +
chitosan O +
oligosaccharide O +
zinc O -
, O +
which O +
is O +
characterized O +
in O +
that O +
10 O -
g O +
of O +
carboxymethyl O +
chitosan O +
is O +
taken O +
and O +
put O +
into O +
a O +
three O -
- O -
neck O +
flask O -
, O +
and O +
is O +
added O +
with O +
90ml O +
of O +
2 O -
% O +
H2O2 O +
in O +
batches O +
when O +
being O +
stirred O +
for O +
full O +
reaction O +
until O +
the O +
carboxymethyl O +
chitosan O +
is O +
completely O +
dissolved O -
; O +
pH O +
value O +
is O +
adjusted O +
to O +
be O +
7 O -
, O +
the O +
precipitation O +
is O +
filtered O +
out O -
, O +
the O +
product O +
is O +
washed O -
, O +
and O +
filtrate O +
and O +
washing O +
liquid O +
are O +
collected O -
; O +
the O +
filtrate O +
and O +
the O +
washing O +
liquid O +
are O +
decompressed O +
and O +
concentrated O -
, O +
and O +
then O +
precipitated O -
, O +
filtered O +
and O +
washed O +
by O +
ethanol O -
; O +
finally O -
, O +
the O +
product O +
is O +
processed O +
by O +
vacuum O +
drying O +
with O +
the O +
drying O +
temperature O +
controlled O +
to O +
be O +
60 O +
DEG O +
C. O +
The O +
invention O +
has O +
the O +
advantages O +
that O +
the O +
carboxymethyl O +
chitosan O +
is O +
prepared O +
after O +
chitosan O +
oligosaccharide O +
is O +
modified O -
, O +
so O +
as O +
to O +
have O +
the O +
pharmacological O +
actions O +
of O +
arrhythmia O +
resistance O -
, O +
anticoagulation O -
, O +
infection O +
resistance O +
and O +
the O +
like O -
; O +
the O +
carboxymethyl O +
chitosan O +
oligosaccharide O +
zinc O +
is O +
natural O +
modified O +
product O +
and O +
has O +
better O +
safety O +
and O +
biological O +
activity O +
compared O +
with O +
other O +
zinc O +
supplementing O +
agents O -
. O +

Two O +
sterol O +
derivatives O -
, O +
separation O +
and O +
extraction O +
method O +
thereof O +
and O +
application O +
thereof O +
in O +
preventing O +
and O +
treating O +
prostatoplasia O +
diseases O +
The O +
invention O +
discloses O +
two O +
sterol O +
derivatives O -
, O +
a O +
separation O +
and O +
extraction O +
method O +
thereof O +
and O +
an O +
application O +
thereof O +
in O +
preventing O +
and O +
treating O +
prostatoplasia O +
diseases O -
. O +

The O +
two O +
sterol O +
derivatives O +
arecompounds O +
24-methylene O +
cholesterol O +
linoleate O +
and O +
cycloeucalenol O +
linoleate O +
shown O +
as O +
formula O +
1 O +
and O +
formula O +
2 O -
. O +

The O +
compounds O +
which O +
are O +
not O +
reported O +
have O +
the O +
function O +
of O +
inhibiting O +
the O +
activity O +
of O +
aromatizing O +
enzyme O -
. O +

The O +
invention O +
also O +
discloses O +
an O +
application O +
of O +
the O +
two O +
sterol O +
derivatives O +
in O +
preparing O +
preparations O +
to O +
inhibit O +
the O +
activity O +
of O +
aromatizing O +
enzyme O +
and O +
in O +
preparing O +
pharmaceutical O +
compositions O +
to O +
prevent O +
or O +
treat O +
prostatoplasia O +
diseases O -
. O +

Tibetan O +
medicine O +
aerosol O +
for O +
treating O +
acute O +
and O +
chronic O +
sprains O +
and O +
contusions O -
, O +
rheumatism O +
and O +
rheumatoid O +
disease O +
The O +
invention O +
discloses O +
a O +
Tibetan O +
medicine O +
aerosol O +
for O +
treating O +
acute O +
and O +
chronic O +
sprains O +
and O +
contusions O -
, O +
rheumatism O +
and O +
rheumatoid O +
disease O -
, O +
comprising O +
raw O +
medicines O +
of O +
Lamiophlomis O +
rotate O -
, O +
whin O -
, O +
curcuma O -
, O +
pricklyash O +
peel O -
, O +
comu O +
bubal O -
, O +
Myricaria O +
paniculata O -
, O +
safflower O -
, O +
camphol O +
and O +
the O +
like O -
. O +

The O +
pharmaceutical O +
composition O +
of O +
the O +
invention O +
has O +
the O +
functions O +
of O +
activating O +
blood O +
and O +
dissolving O +
stasis O -
, O +
and O +
relieving O +
swelling O +
and O +
pain O -
. O +

The O +
aerosol O +
of O +
the O +
invention O +
is O +
characterized O +
by O +
advanced O +
dosage O +
form O -
, O +
simple O +
process O -
, O +
rapid O +
effect O +
and O +
the O +
like O -
. O +

Stomachic O +
hericium O +
erinaceum O +
polysaccharide O +
health O -
- O -
care O +
capsule O +
The O +
invention O +
discloses O +
a O +
stomachic O +
hericium O +
erinaceum O +
polysaccharide O +
health O -
- O -
care O +
capsule O -
. O +

The O +
health O -
- O -
care O +
product O +
comprises O +
the O +
following O +
compositions O +
in O +
percentage O +
by O +
weight O -
: O +
10 O +
to O +
30 O +
percent O +
of O +
hericium O +
erinaceum O +
polysaccharide O -
, O +
70 O +
to O +
90 O +
percent O +
of O +
hericium O +
erinaceum O +
polysaccharide O +
byproduct O -
, O +
1 O +
to O +
10 O +
percent O +
of O +
glycopeptide O -
, O +
1 O +
to O +
10 O +
percent O +
of O +
oleanolic O +
acid O -
, O +
1 O +
to O +
10 O +
percent O +
of O +
ethylamine O +
sulfonic O +
acid O -
, O +
1 O +
to O +
10 O +
percent O +
of O +
alkaloid O +
and O +
1 O +
to O +
10 O +
percent O +
of O +
terpenoid O -
. O +

The O +
main O +
composition O +
of O +
the O +
stomachic O +
hericium O +
erinaceum O +
polysaccharide O +
health O -
- O -
care O +
capsule O +
is O +
the O +
hericium O +
erinaceum O +
polysaccharide O -
, O +
can O +
be O +
stored O +
at O +
normal O +
temperature O -
, O +
improve O +
the O +
immunity O +
level O +
of O +
cells O -
, O +
promote O +
the O +
repair O +
of O +
gastrointestinal O +
mucosa O -
, O +
relieve O +
the O +
gastrointestinal O +
spasm O -
, O +
inhibit O +
the O +
tumor O +
growth O -
, O +
promote O +
the O +
digestive O +
absorption O -
, O +
improve O +
the O +
inflammation O +
of O +
a O +
digestive O +
system O -
, O +
regulate O +
the O +
disorder O +
of O +
gastrointestinal O +
flora O +
and O +
has O +
the O +
functions O +
of O +
strengthening O +
spleen O -
, O +
harmonizing O +
stomach O -
, O +
replenishing O +
spleen O +
qi O +
and O +
relieving O +
pain O -
. O +

The O +
stomachic O +
hericium O +
erinaceum O +
polysaccharide O +
health O -
- O -
care O +
capsule O +
is O +
suitable O +
for O +
the O +
conditioning O +
and O +
health O +
care O +
of O +
diseases O +
of O +
the O +
digestive O +
system O -
. O +

Medicament O +
composition O +
for O +
treating O +
climacteric O +
syndrome O +
of O +
women O +
The O +
invention O +
discloses O +
a O +
medicament O +
composition O +
for O +
treating O +
climacteric O +
syndrome O +
of O +
women O -
. O +

The O +
medicament O +
composition O +
is O +
prepared O +
by O +
taking O +
medroxyprogesterone O -
, O +
nadestryl O -
, O +
amino O +
acid O +
chelated O +
calcium O -
, O +
vitamin O +
A O -
, O +
vitamin O +
D O +
and O +
vitamin O +
E O +
as O +
raw O +
materials O +
and O +
processing O +
the O +
raw O +
materials O +
according O +
to O +
a O +
conventional O +
preparation O -
. O +

By O +
complementing O +
estrogen O -
, O +
progestational O +
hormone O -
, O +
calcium O +
and O +
vitamin O -
, O +
the O +
invention O +
is O +
used O +
for O +
treating O +
the O +
climacteric O +
syndrome O +
of O +
women O -
. O +

Anti O -
- O -
inflammatory O +
and O +
antimicrobial O +
uses O +
for O +
bioactive O +
glass O +
compositions O +
Compositions O +
and O +
methods O +
for O +
treating O +
wounds O +
to O +
significantly O +
reduce O +
the O +
healing O +
time O -
, O +
reduce O +
the O +
incidence O +
of O +
scar O +
formation O -
, O +
improve O +
the O +
success O +
of O +
skin O +
grafts O -
, O +
reduce O +
the O +
inflammatory O +
response O +
and O +
providing O +
anti O -
- O -
bacterial O +
treatments O +
to O +
a O +
patient O +
in O +
need O +
thereof O -
, O +
that O +
include O +
small O +
non O -
- O -
interlinked O +
particles O +
of O +
bioactive O +
glass O +
or O +
highly O +
porous O +
bioactive O +
glass O -
, O +
are O +
disclosed O -
. O +

Anti O -
- O -
bacterial O +
solutions O +
derived O +
from O +
bioactive O +
glass O -
, O +
and O +
methods O +
of O +
preparation O +
and O +
use O +
thereof O -
, O +
are O +
also O +
disclosed O -
. O +

The O +
compositions O +
include O +
non O -
- O -
interlinked O +
particles O +
of O +
bioactive O +
glass O -
, O +
alone O +
or O +
in O +
combination O +
with O +
anti O -
- O -
bacterial O +
agents O +
and/or O +
anti O -
- O -
inflammatory O +
agents O -
. O +

The O +
compositions O +
can O +
include O +
an O +
appropriate O +
carrier O +
for O +
topical O +
administration O -
. O +

Anti O -
- O -
bacterial O +
properties O +
can O +
be O +
imparted O +
to O +
implanted O +
materials O -
, O +
such O +
as O +
prosthetic O +
implants O -
, O +
sutures O -
, O +
stents O -
, O +
screws O -
, O +
plates O -
, O +
tubes O -
, O +
and O +
the O +
like O -
, O +
by O +
incorporating O +
small O +
bioactive O +
glass O +
particles O +
or O +
porous O +
bioactive O +
glass O +
into O +
or O +
onto O +
the O +
implanted O +
materials O -
. O +

Anti O -
- O -
bacterial O +
properties O +
can O +
also O +
be O +
imparted O +
to O +
devices O +
used O +
for O +
in O +
vitro O +
and O +
ex O +
vivo O +
cell O +
culture O +
by O +
incorporating O +
non O -
- O -
interlinked O +
particles O +
of O +
bioactive O +
glass O +
into O +
the O +
devices O -
. O +

Anti O -
- O -
bacterial O +
compositions O +
derived O +
from O +
aqueous O +
extracts O +
of O +
bioactive O +
glass O +
are O +
also O +
disclosed O -
. O +

These O +
compositions O +
can O +
be O +
used O -
, O +
for O +
example O -
, O +
in O +
food O +
preparation O -
, O +
solutions O +
used O +
for O +
cell O +
culture O -
, O +
and O +
buffer O +
solutions O -
, O +
such O +
as O +
i.v O -
. O +

solutions O -
. O +

Fluticasone O +
propionate O +
lipidosome O +
cream O +
The O +
invention O +
relates O +
to O +
a O +
lipidosome O +
medical O +
composition O +
which O +
uses O +
fluticasone O +
propionate O +
as O +
an O +
active O +
component O -
, O +
and O +
a O +
cyst O +
diameter O +
of O +
lipidosome O +
is O +
smaller O +
than O +
800 O +
nm O -
. O +

The O +
composition O +
comprises O +
0.025 O +
percent O +
to O +
0.2 O +
percent O +
of O +
fluticasone O +
propionate O +
as O +
the O +
active O +
component O -
, O +
0.5 O +
percent O +
to O +
6 O +
percent O +
of O +
phospholipid O -
, O +
0 O +
percent O +
to O +
1 O +
percent O +
of O +
lipophilic O +
additive O -
, O +
0.01 O +
percent O +
to O +
1 O +
percent O +
of O +
antioxidant O +
which O +
is O +
used O +
for O +
preserving O +
the O +
medical O +
composition O -
, O +
a O +
pH O +
buffering O +
agent O +
which O +
is O +
used O +
for O +
retaining O +
the O +
pH O +
value O +
from O +
5 O +
to O +
7.5 O -
, O +
3 O +
percent O +
to O +
15 O +
percent O +
of O +
humectant O -
, O +
20 O +
percent O +
to O +
30 O +
percent O +
of O +
oil O +
phrase O +
component O -
, O +
0.01 O +
percent O +
to O +
0.1 O +
percent O +
of O +
antimicrobial O +
preservative O +
and O +
the O +
balanced O +
of O +
water O -
. O +

The O +
fluticasone O +
propionate O +
lipidosome O +
cream O +
is O +
used O +
for O +
treating O +
skin O +
diseases O +
of O +
human O +
beings O +
or O +
animals O -
. O +

Solution O +
preparation O +
for O +
atomizing O +
and O +
inhaling O +
ambroxol O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
solution O +
preparation O +
for O +
atomizing O +
and O +
inhaling O +
ambroxol O -
, O +
and O +
belongs O +
to O +
the O +
field O +
of O +
pharmaceutics O -
. O +

The O +
solution O +
preparation O +
for O +
atomizing O +
and O +
inhaling O +
the O +
ambroxol O +
comprises O +
( O -
1 O -
) O +
ambroxol O +
or O +
medicinal O +
salt O +
thereof O +
with O +
single O +
medicinal O +
dosage O -
, O +
( O -
2 O -
) O +
isotonic O +
agent O +
and O +
solvent O -
, O +
( O -
3 O -
) O +
buffer O +
solution O +
and O +
( O -
4 O -
) O +
medicinal O +
package O +
with O +
single O +
dosage O -
; O +
and O +
in O +
terms O +
of O +
the O +
ambroxol O -
, O +
the O +
mass O +
ratio O +
of O +
the O +
medicinal O +
components O +
to O +
the O +
isotonic O +
agent O +
is O +
1:1.1 O -
- O -
1:3.3.The O +
invention O +
provides O +
the O +
solution O +
preparation O +
for O +
atomizing O +
and O +
inhaling O +
the O +
ambroxol O +
with O +
single O +
dosage O +
and O +
the O +
medicinal O +
package O +
adopting O +
blowing O -
- O -
filling O -
- O -
sealing O +
( O -
BFS O -
) O +
integrative O +
full O -
- O -
automatic O +
production O -
, O +
which O +
have O +
the O +
advantages O +
that O +
the O +
medicinal O +
package O +
is O +
designed O +
and O +
manufactured O +
for O +
patients O +
special O +
for O +
atomizing O +
and O +
inhaling O -
; O +
the O +
solution O +
preparation O +
does O +
not O +
contain O +
preservative O -
, O +
and O +
is O +
used O +
with O +
disposable O +
single O +
dosage O -
; O +
the O +
using O +
process O +
is O +
convenient O +
and O +
does O +
not O +
need O +
dilution O +
and O +
preparation O -
; O +
and O +
the O +
microbe O +
pollution O -
, O +
waste O +
and O +
the O +
like O +
during O +
using O +
can O +
be O +
greatly O +
reduced O -
. O +

The O +
medicinal O +
preparation O +
provides O +
a O +
treatment O +
medicament O +
and O +
a O +
treatment O +
proposal O +
with O +
accurate O +
medicinal O +
dosage O -
, O +
good O -
- O -
quality O +
and O +
stable O +
medicament O +
quality O -
, O +
and O +
safe O +
and O +
simple O +
clinical O +
application O +
lacking O +
in O +
the O +
prior O +
art O -
. O +

Enrofloxacin O +
double O +
emulsion O +
for O +
livestock O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
an O +
enrofloxacin O +
double O +
emulsion O +
for O +
livestock O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
wherein O +
the O +
enrofloxacin O +
double O +
emulsion O +
belongs O +
to O +
the O +
field O +
of O +
antibiotic O +
preparations O +
for O +
livestock O -
. O +

The O +
W O -
/ O -
O O -
/ O -
W O +
type O +
double O +
emulsion O +
is O +
prepared O +
by O +
using O +
enrofloxacin O +
as O +
active O +
ingredients O +
and O +
adding O +
oil O +
phase O -
, O +
emulsifier O -
, O +
stabilizer O +
and O +
the O +
like O -
. O +

The O +
enrofloxacin O +
double O +
emulsion O +
for O +
livestock O +
can O +
better O +
cover O +
the O +
bitter O +
taste O +
of O +
the O +
enrofloxacin O -
, O +
improves O +
the O +
adaptation O +
of O +
oral O +
drugs O +
for O +
livestock O -
, O +
can O +
better O +
control O +
the O +
diffusion O +
rate O +
of O +
the O +
drugs O +
to O +
play O +
a O +
role O +
of O +
slow O +
release O -
, O +
and O +
better O +
adapts O +
different O +
clinical O +
drugs O +
requirements O -
. O +

Clinical O +
tests O +
show O +
that O +
the O +
invention O +
can O +
overcome O +
phenomena O +
of O +
food O +
refusal O +
and O +
poor O +
appetite O +
of O +
taste O +
acuity O +
animals O +
of O +
pigs O +
and O +
the O +
like O -
, O +
therebyensuring O +
the O +
dosage O -
, O +
improving O +
the O +
medicine O +
effect O -
, O +
and O +
achieving O +
the O +
purpose O +
of O +
ideal O +
treatment O -
. O +

Meanwhile O -
, O +
because O +
of O +
a O +
certain O +
slow O +
release O +
function O -
, O +
the O +
frequency O +
for O +
medicine O +
administration O +
can O +
be O +
reduced O -
, O +
and O +
the O +
invention O +
provides O +
an O +
efficient O +
and O +
long O -
- O -
acting O +
enrofloxacin O +
preparation O +
for O +
clinical O +
veterinarian O -
. O +

New O +
use O +
of O +
isosorbide O +
mononitrate O +
in O +
preparing O +
medicine O +
for O +
increasing O +
endometrial O +
thickness O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicine O -
, O +
particularly O +
relates O +
to O +
a O +
new O +
use O +
of O +
isosorbide O +
5-mononitrate O +
and O +
a O +
corresponding O +
new O +
dosage O +
form O +
suitable O +
for O +
the O +
new O +
use O -
, O +
and O +
concretely O +
relates O +
to O +
a O +
use O +
of O +
isosorbide O +
5-mononitrate O +
in O +
preparing O +
drug O +
for O +
improving O +
the O +
receptive O +
performance O +
of O +
endometrium O -
. O +

The O +
improvement O +
of O +
the O +
receptive O +
performance O +
of O +
endometrium O +
is O +
concretely O +
realized O +
through O +
repairing O +
and O +
improving O +
the O +
endometrium O -
, O +
or O +
through O +
prompting O +
the O +
development O +
of O +
uterus O +
glandular O +
organ O -
, O +
or O +
through O +
prompting O +
the O +
development O +
of O +
uterus O +
mesenchyma O -
. O +

In O +
order O +
to O +
adapt O +
to O +
the O +
four O +
new O +
uses O -
, O +
the O +
prepared O +
drug O +
is O +
vagina O +
local O +
drug O +
feeding O +
preparation O -
, O +
namely O -
, O +
preparation O +
which O +
takes O +
isosorbide O +
5-mononitrate O +
with O +
effective O +
amount O +
as O +
active O +
components O +
and O +
is O +
prepared O +
through O +
adding O +
accessories O +
which O +
are O +
allowable O +
in O +
pharmacy O -
. O +

The O +
isosorbide O +
5-mononitrate O +
not O +
only O +
can O +
exert O +
excellent O +
medical O +
effects O +
of O +
prompting O +
the O +
development O +
of O +
endometrium O +
tissues O +
and O +
improving O +
the O +
receptive O +
performance O +
of O +
endometrium O -
, O +
but O +
also O +
can O +
effectively O +
avoid O +
the O +
side O +
effect O +
that O +
isosorbide O +
5-mononitrate O +
lowers O +
blood O +
pressure O +
after O +
giving O +
drug O +
in O +
vagina O -
, O +
and O +
provides O +
a O +
new O +
choice O +
for O +
clinical O +
application O -
. O +

Pharmaceutical O +
composition O +
for O +
treating O +
skin O +
( O -
A O -
) O +
disease O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
for O +
treating O +
skin O +
( O -
A O -
) O +
disease O -
, O +
having O +
the O +
strong O +
eliminating O +
function O +
on O +
bacteria O -
, O +
epiphyte O +
and O +
viruses O +
and O +
has O +
the O +
obvious O +
effect O +
on O +
tinea O +
of O +
feet O +
and O +
hands O -
, O +
onychomycosis O -
, O +
tinea O +
cruris O -
, O +
scald O +
head O -
, O +
furuncle O -
, O +
mosquito O +
bite O +
and O +
acrohyperhidrosis O -
. O +

The O +
high O -
- O -
molecule O +
material O +
and O +
recipe O +
composition O +
of O +
the O +
pharmaceutical O +
composition O +
has O +
no O +
poison O +
and O +
little O +
stimulation O +
on O +
skin O -
, O +
has O +
long O +
action O +
time O +
and O +
presents O +
the O +
actions O +
of O +
controlled O +
release O +
and O +
stability O -
. O +

The O +
quality O +
can O +
be O +
kept O +
to O +
be O +
stable O +
when O +
the O +
composition O +
is O +
stored O +
at O +
normal O +
temperature O -
, O +
and O +
thereby O -
, O +
the O +
composition O +
is O +
safe O +
and O +
effective O -
. O +

The O +
composition O +
contains O +
the O +
main O +
constituents O +
of O +
povidone O +
iodine O -
, O +
acetylsalicylic O +
acid O -
, O +
polyethylene O +
glycol O -
, O +
potash O +
iodate O -
, O +
phenol O +
and O +
high O -
- O -
molecule O +
material O -
. O +

Transdermal O +
zinc O +
supplement O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
zinc O +
supplement O -
, O +
in O +
particular O +
to O +
a O +
transdermal O +
zinc O +
supplement O +
which O +
comprises O +
zinc O +
oxide O +
and O +
citric O +
acid O +
and O +
is O +
characterized O +
by O +
comprising O +
the O +
following O +
raw O +
material O +
components O +
by O +
weight O +
percent O -
: O +
10 O -
- O -
40 O -
% O +
of O +
zinc O +
oxide O -
, O +
30 O -
- O -
70 O -
% O +
of O +
citric O +
acid O +
and O +
10 O -
- O -
50 O -
% O +
of O +
sodium O +
hydroxide O -
. O +

A O +
method O +
for O +
manufacturing O +
the O +
transdermal O +
zinc O +
supplement O +
comprises O +
the O +
following O +
steps O -
: O +
weighing O +
the O +
raw O +
material O +
components O +
according O +
to O +
the O +
weight O +
percent O -
, O +
and O +
mixing O +
and O +
grinding O +
the O +
raw O +
material O +
components O +
until O +
being O +
evenly O +
mixed O -
; O +
heating O +
the O +
ground O +
material O +
to O +
the O +
temperature O +
of O +
120 O -
- O -
150 O +
DEG O +
C O +
and O +
then O +
carrying O +
out O +
heat O +
preservation O +
for O +
1 O -
- O -
2h O +
to O +
lead O +
the O +
material O +
to O +
be O +
dried O -
; O +
and O +
finally O -
, O +
crushing O +
the O +
dried O +
material O -
, O +
screening O +
the O +
material O +
by O +
a O +
No. O +
5 O +
sieve O -
, O +
obtaining O +
undersized O +
material O +
which O +
is O +
the O +
finished O +
product O +
of O +
the O +
transdermal O +
zinc O +
supplement O -
, O +
and O +
then O +
split O +
packaging O +
the O +
obtained O +
finished O +
product O +
of O +
the O +
transdermal O +
zinc O +
supplement O -
. O +

The O +
transdermal O +
zinc O +
supplement O +
can O +
avoid O +
the O +
interference O +
of O +
gastrointestinal O +
tract O +
as O +
well O +
as O +
the O +
influence O +
of O +
factors O +
such O +
as O +
the O +
pH O +
value O +
of O +
the O +
gastrointestinal O +
tract O -
, O +
food O -
, O +
digestive O +
juice O +
and O +
the O +
like O -
, O +
improves O +
the O +
bioavailability O +
of O +
the O +
zinc O +
supplement O -
, O +
has O +
wide O +
application O +
range O +
including O +
infants O +
children O -
, O +
pregnant O +
women O -
, O +
nursing O +
women O +
and O +
adults O -
, O +
and O +
improves O +
the O +
life O +
quality O +
of O +
the O +
whole O +
life O -
. O +

Cyclopentenyl O +
fatty O +
acid O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
cyclopentenyl O +
fatty O +
acid O +
and O +
ester O +
or O +
a O +
solvate O +
thereof O -
. O +

The O +
cyclopentenyl O +
fatty O +
acid O +
consists O +
of O +
a O +
cyclopentenyl O +
structural O +
unit O +
and O +
a O +
long O -
- O -
chain O +
fatty O +
acid O +
or O +
the O +
ester O +
or O +
the O +
solvate O +
thereof O -
, O +
and O +
compounds O +
with O +
structural O +
formulas O +
A O +
and O +
B O +
are O +
preferable O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
the O +
compounds O +
and O +
application O +
thereof O +
in O +
preparing O +
anti O -
- O -
tuberculous O +
drugs O -
. O +

Ornidazole O +
medicinal O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
ornidazole O +
medicinal O +
composition O -
. O +

Each O +
100 O +
milliliters O +
of O +
ornidazole O +
medicinal O +
composition O +
contains O +
5 O +
grams O +
of O +
ornidazole O -
, O +
35 O +
to O +
60 O +
milliliters O +
of O +
1,2-propylene O +
glycol O +
and O +
the O +
balance O +
of O +
water O +
for O +
injection O -
. O +

The O +
pH O +
value O +
of O +
the O +
ornidazole O +
medicinal O +
composition O +
is O +
2.5 O +
to O +
4.5 O -
. O +

The O +
composition O +
can O +
be O +
made O +
into O +
a O +
small O -
- O -
volume O +
injection O -
, O +
wherein O +
the O +
injection O +
can O +
be O +
a O +
5-milliliter O +
injection O +
containing O +
0.25 O +
gram O +
of O +
the O +
composition O +
or O +
a O +
10-milliliter O +
injection O +
containing O +
0.5 O +
gram O +
of O +
the O +
composition O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
of O +
the O +
ornidazole O +
medicinal O +
composition O -
, O +
which O +
comprises O -
: O +
adding O +
ornidazole O +
into O +
1,2-propylene O +
glycol O -
, O +
keeping O +
the O +
temperature O +
to O +
be O +
45 O +
to O +
60 O +
DEG O +
C O +
and O +
stirring O +
the O +
mixture O +
till O +
the O +
ornidazole O +
dissolves O +
completely O -
; O +
adding O +
disodium O +
ethylenediamintetraacetate O +
aqueous O +
solution O +
at O +
a O +
concentration O +
of O +
40 O -
- O -
70mg O -
/ O -
100ml O -
; O +
and O +
using O +
needle O +
active O +
carbon O +
for O +
absorption O +
and O +
microporous O +
filter O +
membrane O +
for O +
filtration O +
decarbonization O -
, O +
supplying O +
water O +
for O +
injection O +
and O +
adjusting O +
the O +
pH O +
value O +
to O +
2.5 O +
to O +
4.5 O +
to O +
obtain O +
the O +
ornidazole O +
medicinal O +
composition O -
. O +

The O +
method O +
provided O +
by O +
the O +
invention O +
has O +
simple O +
process O +
and O +
the O +
prepared O +
product O +
has O +
high O +
stability O -
. O +

Plaster O +
for O +
treating O +
facial O +
paralysis O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
plaster O +
for O +
treating O +
facial O +
paralysis O -
, O +
which O +
comprises O +
rhizoma O +
typhonii O -
, O +
scorpio O -
, O +
stiff O +
silkworm O -
, O +
uncaria O -
, O +
rhizoma O +
gastrodiae O -
, O +
futokadsura O +
stem O -
, O +
notopterygium O +
root O -
, O +
asarum O -
, O +
herba O +
schizonepetae O -
, O +
radix O +
sileris O -
, O +
cicada O +
slough O -
, O +
angelica O +
root O -
, O +
centipede O -
, O +
zaocys O +
dhumnade O -
, O +
earthworm O -
, O +
mastic O -
, O +
myrrh O -
, O +
radix O +
salviae O +
miltiorrhizae O -
, O +
safflower O -
, O +
artemisia O +
anomala O -
, O +
cinnamon O -
, O +
rhizoma O +
ligustici O +
wallichii O -
, O +
red O +
peony O +
root O -
, O +
Chinese O +
ephedra O -
, O +
equisetum O -
, O +
tetrandra O +
root O -
, O +
rhizoma O +
atractylodis O -
, O +
pawpaw O -
, O +
pangolin O +
scales O -
, O +
speranskia O +
tuberculata O -
, O +
oyster O -
, O +
sea O -
- O -
ear O +
shell O -
, O +
strychnos O -
, O +
white O +
mustard O +
seed O -
, O +
musk O -
, O +
colophony O -
, O +
verdigris O -
, O +
draconis O +
sanguis O -
, O +
catechu O +
and O +
gleditsia O +
sinensis O +
lam O -
. O +

The O +
components O +
are O +
mutually O +
coordinated O +
to O +
achieve O +
the O +
functions O +
of O +
calming O +
the O +
endopathic O +
wind O -
, O +
relieving O +
convulsion O +
and O +
spasm O -
, O +
dispersing O +
pathogenic O +
wind O -
, O +
dispelling O +
cold O -
, O +
promoting O +
blood O +
circulation O -
, O +
relieving O +
the O +
stasis O +
of O +
blood O -
, O +
resolving O +
phlegm O -
, O +
reducing O +
the O +
stagnation O -
, O +
nourishing O +
the O +
blood O -
, O +
smoothing O +
collaterals O -
, O +
promoting O +
the O +
circulation O +
of O +
qi O +
and O +
alleviating O +
pain O -
. O +

Method O +
for O +
preparing O +
oral O +
chondroitin O +
sulfate O +
nanoemulsion O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
oral O +
chondroitin O +
sulfate O +
nanoemulsion O -
, O +
belonging O +
to O +
the O +
field O +
of O +
the O +
pharmaceutical O +
preparation O -
. O +

The O +
oral O +
chondroitin O +
sulfate O +
nanoemulsion O +
is O +
clear O +
and O +
transparent O +
solution O +
which O +
comprises O +
oil O +
phase O -
, O +
surfactant O -
, O +
cosurfactant O +
and O +
water O +
phase O +
by O +
appropriate O +
proportion O -
, O +
wherein O +
the O +
proportion O +
of O +
the O +
oil O +
phase O +
to O +
the O +
surfactant O +
is O +
45:1 O -
- O -
1:7 O -
, O +
and O +
the O +
proportion O +
of O +
the O +
surfactant O +
to O +
the O +
cosurfactant O +
is O +
4:1 O -
- O -
1:4 O -
. O +

The O +
oral O +
chondroitin O +
sulfate O +
nanoemulsion O +
can O +
improve O +
the O +
bioavailability O +
of O +
the O +
chondroitin O +
sulfate O -
, O +
reduce O +
the O +
toxic O +
and O +
side O +
effect O +
of O +
the O +
chondroitin O +
sulfate O +
and O +
fully O +
exert O +
the O +
efficacy O +
of O +
the O +
chondroitin O +
sulfate O -
. O +

Raloxifene O +
emplastrum O +
preparation O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
raloxifene O +
emplastrum O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

Raloxifene O +
microemulsion O +
is O +
made O +
into O +
a O +
transdermal O +
emplastrum O +
which O +
is O +
divided O +
into O +
an O +
anti O -
- O -
adhesion O +
layer O -
, O +
a O +
viscose O +
layer O -
, O +
a O +
backlining O +
layer O +
and O +
a O +
medicine O +
storage O +
layer O -
. O +

The O +
raloxifene O +
microemulsion O +
taken O +
as O +
a O +
medical O +
ingredient O +
of O +
the O +
raloxifene O +
emplastrum O +
comprises O +
the O +
following O +
ingredients O -
: O +
raloxifene O +
taken O +
as O +
an O +
active O +
ingredient O -
, O +
polysorbate O +
taken O +
as O +
surfactant O -
, O +
propanediol O +
taken O +
as O +
cosurfactant O -
, O +
pure O +
water O +
or O +
distilled O +
water O -
, O +
and O +
the O +
like O -
. O +

Except O +
for O +
the O +
medical O +
ingredient O -
, O +
a O +
plurality O +
of O +
nonpolar O +
polymers O -
, O +
plasticizing O +
agent O -
, O +
caking O +
agent O -
, O +
transdermal O +
enhancing O +
agent O +
and O +
antioxidant O +
are O +
also O +
added O +
in O +
the O +
emplastrum O -
. O +

Compared O +
with O +
the O +
prior O +
dosage O +
forms O -
, O +
such O +
as O +
tablets O -
, O +
the O +
invention O +
has O +
the O +
remarkable O +
advantages O +
of O +
durable O +
medical O +
effect O -
, O +
safety O -
, O +
low O +
toxicity O -
, O +
simple O -
, O +
convenient O +
and O +
sanitary O -
, O +
and O +
accurate O +
medical O +
dosage O -
. O +

Pharmaceutical O +
composite O +
for O +
reducing O +
blood O +
fat O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composite O +
for O +
reducing O +
blood O +
fat O -
, O +
which O +
comprises O +
sea O +
buckthorn O -
, O +
vitamin O +
B O +
complex O -
, O +
vitamin O +
E O +
and O +
trace O +
elements O +
of O +
zinc O -
, O +
selenium O -
, O +
chromium O +
and O +
molybdenum O -
. O +

The O +
pharmaceutical O +
composite O +
is O +
used O +
for O +
people O +
suffering O +
from O +
hyperlipaemia O -
, O +
has O +
very O +
good O +
effect O +
on O +
reducing O +
blood O +
fat O -
, O +
and O +
can O +
be O +
applied O +
to O +
a O +
long O +
time O +
or O +
in O +
course O +
of O +
treatment O -
. O +

Cancer O +
pain O +
elimination O +
pill O +
The O +
invention O +
relates O +
to O +
a O +
cancer O +
pain O +
elimination O +
pill O +
which O +
is O +
a O +
medicament O +
for O +
treating O +
esophageal O +
cancer O -
, O +
esophagus O +
cancer O -
, O +
gastric O +
cancer O +
and O +
postoperation O +
metastasis O +
cancer O -
. O +

The O +
cancer O +
pain O +
elimination O +
pill O +
is O +
prepared O +
from O +
trogopterus O +
dung O -
, O +
akebia O +
trifoliata O +
koidz O -
. O -
, O +
long O -
- O -
noded O +
pit O +
viper O -
, O +
honeysuckle O +
flower O -
, O +
pangolin O -
, O +
fructus O +
amomi O -
, O +
lima O +
beans O -
, O +
borneol O -
, O +
radix O +
pseudostellariae O -
, O +
paris O +
polyphylla O -
, O +
radix O +
curcumae O -
, O +
white O +
paeony O +
roots O -
, O +
angelica O +
sinensis O -
, O +
peach O +
kernels O -
, O +
rabdosia O +
rubescens O -
, O +
curcuma O +
zedoary O -
, O +
rhizoma O +
zedoariae O -
, O +
malts O +
( O -
stirred O +
to O +
brown O -
) O -
, O +
hawthorns O +
( O -
stirred O +
to O +
brown O -
) O -
, O +
medicated O +
leaven O +
( O -
stirred O +
to O +
brown O -
) O -
, O +
agastache O +
rugosus O -
, O +
senecio O +
dianthus O +
franch O +
and O +
caulis O +
perllae O -
. O +

The O +
cancer O +
pain O +
elimination O +
pill O +
is O +
suitable O +
for O +
treating O +
the O +
esophageal O +
cancer O -
, O +
the O +
esophagus O +
cancer O -
, O +
the O +
gastric O +
cancer O +
and O +
the O +
postoperation O +
metastasis O +
cancer O -
, O +
has O +
good O +
curative O +
effect O +
and O +
quick O +
effect O -
, O +
treats O +
both O +
the O +
symptoms O +
and O +
root O +
causes O +
and O +
is O +
convenient O +
to O +
take O -
. O +

Proved O +
by O +
years O +
of O +
clinical O +
experiments O -
, O +
the O +
cancer O +
pain O +
elimination O +
pill O +
effectively O +
relieves O +
pains O +
of O +
patients O +
and O +
gets O +
the O +
praises O +
of O +
a O +
lot O +
of O +
patients O -
. O +

Preparation O +
method O +
and O +
products O +
of O +
danofloxacin O +
mesylate O +
liposome O +
The O +
invention O +
provides O +
a O +
preparation O +
method O +
and O +
products O +
of O +
danofloxacin O +
mesylate O +
liposome O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
( O -
1 O -
) O +
adopting O +
the O +
ammonium O +
sulfate O +
gradient O +
method O +
to O +
prepare O +
blank O +
liposome O -
; O +
and O +
( O -
2 O -
) O +
adding O +
danofloxacin O +
mesylate O +
liquor O +
in O +
the O +
blank O +
liposome O -
, O +
using O +
water O +
bath O +
for O +
incubation O -
, O +
filtrating O -
, O +
and O +
performing O +
repeated O +
freeze O +
thawing O +
to O +
the O +
filtrate O +
by O +
using O +
the O +
freeze O +
and O +
thawing O +
method O +
to O +
obtain O +
the O +
danofloxacin O +
mesylate O +
liposome O -
. O +

The O +
finished O +
liposome O +
prepared O +
by O +
the O +
preparation O +
method O +
of O +
the O +
invention O +
is O +
milky O +
semitransparent O +
mixed O +
suspension O +
which O +
appears O +
as O +
spherical O +
or O +
nearly O +
globose O +
small O +
vesicles O +
with O +
regular O +
shape O -
, O +
good O +
dispersity O +
and O +
uniform O +
grain O +
size O +
under O +
an O +
electron O +
microscope O -
; O +
the O +
entrapment O +
rate O +
of O +
the O +
liposome O +
is O +
above O +
90 O -
% O +
and O +
the O +
liposome O +
has O +
good O +
stability O -
; O +
the O +
pharmacokinetic O +
and O +
pharmacodynamic O +
properties O +
of O +
the O +
liposome O +
are O +
better O +
than O +
that O +
of O +
conventional O +
dosage O +
forms O +
and O +
the O +
liposome O +
is O +
characterized O +
by O +
slow O +
release O -
, O +
long O +
acting O +
and O +
high O +
lung O -
- O -
targeting O -
. O +

Anti O -
- O -
drug O +
medicine O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
narcotic O -
- O -
abstaining O +
medicine O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
narcotic O -
- O -
abstaining O +
medicine O +
is O +
a O +
narcotic O -
- O -
abstaining O +
oral O +
medicine O +
prepared O +
from O +
the O +
raw O +
material O +
medicines O +
such O +
as O +
American O +
ginseng O -
, O +
astragalus O +
root O -
, O +
angelica O -
, O +
wild O +
or O +
spiny O +
jujuba O +
seed O -
, O +
schisandra O +
fruit O -
, O +
tuckahoe O -
, O +
corydalis O +
tuber O -
, O +
thymeleaf O +
sandwort O -
, O +
licorice O +
and O +
the O +
like O +
according O +
to O +
the O +
methods O +
of O +
grinding O -
, O +
decocting O -
, O +
distilling O -
, O +
concentrating O -
, O +
mixing O +
and O +
the O +
like O -
. O +

Clinical O +
observation O +
shows O +
that O +
the O +
medicine O +
has O +
good O +
functions O +
of O +
detoxication O +
and O +
addiction O +
abstaining O +
and O +
has O +
an O +
obvious O +
functionof O +
resisting O +
freak O -
- O -
out O +
recovery O -
, O +
and O +
the O +
narcotic O -
- O -
abstaining O +
rehabilitation O +
rate O +
of O +
resisting O +
freak O -
- O -
out O +
recovery O +
is O +
more O +
than O +
65 O -
% O -
. O +

Compound O +
in O +
salvia O +
miltiorrhiza O +
bungered O +
sage O +
root O +
injection O +
and O +
application O +
thereof O +
in O +
curing O +
treating O +
cardiovascular O +
disease O +
The O +
invention O +
discloses O +
a O +
new O +
phenolic O +
acid O +
compound O -
, O +
i.e. O +
danshinolic O +
acid O +
M O +
extracted O +
from O +
salvia O +
miltiorrhiza O +
bungered O +
sage O +
roots O -
, O +
the O +
compound O +
also O +
can O +
be O +
extracted O +
from O +
a O +
salvia O +
miltiorrhiza O +
bungered O +
sage O +
root O +
injection O -
, O +
and O +
the O +
invention O +
simultaneously O +
also O +
discloses O +
a O +
method O +
for O +
extracting O +
the O +
new O +
compound O +
respectively O +
from O +
the O +
salvia O +
miltiorrhiza O +
bungered O +
sage O +
roots O +
and O +
the O +
salvia O +
miltiorrhiza O +
bungered O +
sage O +
root O +
injection O -
. O +

Pharmacological O +
studies O +
indicate O +
that O +
the O +
danshinolic O +
acid O +
M O +
has O +
myocardial O +
preservation O +
and O +
oxidation O +
resistant O +
activity O -
, O +
thereby O +
the O +
compound O +
has O +
the O +
prospect O +
of O +
being O +
further O +
developed O +
into O +
an O +
effective O +
medicament O +
for O +
curing O +
treating O +
cardiovascular O +
diseases O +
and O +
can O +
be O +
used O +
in O +
the O +
quality O +
control O +
standard O +
of O +
the O +
salvia O +
miltiorrhiza O +
bunge O +
red O +
sage O +
root O +
injection O -
. O +

Substituted O +
pyridino- O -
[ O -
2',1':2,3 O -
] O +
imidazo O -
[ O -
4,5-c O -
] O +
isoquinolone O +
compounds O -
, O +
method O +
for O +
synthesizing O +
same O -
, O +
use O +
of O +
same O +
and O +
medicinal O +
composition O +
having O +
same O +
The O +
invention O +
relates O +
to O +
substituted O +
pyridino- O -
[ O -
2',1':2,3 O -
] O +
imidazo O -
[ O -
4,5-c O -
] O +
isoquinolone O +
compounds O -
, O +
a O +
method O +
for O +
synthesizing O +
the O +
same O -
, O +
use O +
of O +
the O +
same O +
and O +
a O +
medicinal O +
composition O +
having O +
the O +
same O -
, O +
in O +
particular O +
to O +
compounds O +
of O +
a O +
general O +
formula O +
( O -
I O -
) O +
or O +
stereoisomers O +
thereof O -
, O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
promedicaments O +
thereof O +
or O +
solvate O +
thereof O +
and O +
synthesis O +
method O +
thereof O -
. O +

With O +
specific O +
and O +
high O -
- O -
efficiency O +
mitosis O +
retarding O +
effect O -
, O +
the O +
compounds O +
can O +
be O +
used O +
as O +
mitosis O +
inhibitors O +
to O +
induce O +
the O +
apoptosis O +
of O +
cells O -
. O +

And O +
the O +
mechanism O +
of O +
action O +
of O +
the O +
compounds O +
is O +
different O +
from O +
those O +
of O +
known O +
mitosis O +
inhibitors O +
and O +
can O +
be O +
used O +
in O +
treating O +
leukemia O -
, O +
stomach O +
cancer O -
, O +
cervical O +
cancer O -
, O +
melanoma O -
, O +
colon O +
cancer O -
, O +
breast O +
cancer O -
, O +
ovarian O +
cancer O -
, O +
liver O +
cancer O +
and O +
lung O +
cancer O -
. O +

Cefixime O +
oral O +
administration O +
mixed O +
suspension O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
cefixime O +
oral O +
administration O +
mixed O +
suspension O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
in O +
order O +
to O +
meet O +
the O +
requirement O +
of O +
special O +
medicament O +
taking O +
crowds O +
on O +
the O +
taking O +
of O +
cefixime O -
. O +

The O +
cefixime O +
oral O +
administration O +
mixed O +
suspension O +
per O +
100ml O +
comprises O +
the O +
following O +
components O -
: O +
0.5 O -
- O -
4.0 O -
g O +
of O +
cefixime O -
, O +
larger O +
than O +
0 O -
- O -
20.0 O -
g O +
of O +
thickening O +
suspension O +
assistant O +
agent O -
, O +
a O +
cosolvent O -
, O +
a O +
flavoring O +
agent O -
, O +
a O +
preservative O +
and O +
the O +
balance O +
of O +
non O -
- O -
aqueous O +
liquid O +
medium O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
dissolving O +
the O +
preservative O +
into O +
the O +
cosolvent O -
; O +
adding O +
the O +
thickening O +
suspension O +
assistant O +
agent O +
into O +
the O +
non O -
- O -
aqueous O +
liquid O +
medium O -
, O +
stirring O +
and O +
dissolving O -
; O +
adding O +
solutions O +
of O +
the O +
flavoring O +
agent O -
, O +
the O +
preservative O +
and O +
the O +
cosolvent O +
uniformly O +
stirring O -
; O +
and O +
adding O +
cefixime O +
micropowder O +
and O +
uniformly O +
stirring O +
and O +
spreading O -
. O +

Compared O +
with O +
the O +
prior O +
art O -
, O +
the O +
unstable O +
cefixime O +
in O +
water O +
is O +
made O +
into O +
the O +
oral O +
administration O +
mixed O +
suspension O +
by O +
using O +
non O -
- O -
aqueous O +
liquid O +
as O +
a O +
dispersing O +
medium O -
, O +
and O +
the O +
invention O +
solves O +
the O +
problem O +
of O +
stability O -
, O +
has O +
good O +
taste O +
and O +
simple O +
preparation O +
method O -
, O +
is O +
convenient O +
for O +
children O -
, O +
old O +
people O +
and O +
a O +
dysphagia O +
patient O +
to O +
accept O +
and O +
is O +
suitable O +
for O +
industrialized O +
production O -
. O +

Preparation O +
and O +
application O +
of O +
N- O -
( O -
3-chloropyridine-4-group O -
) O -
-2-hydroxide O +
group-5-chlorbenzamide O +
The O +
invention O +
discloses O +
a O +
compound O +
of O +
N- O -
( O -
3-chloropyridine-4-group O -
) O -
-2-hydroxide O +
group-5-chlorbenzamide O -
, O +
the O +
first O +
preparation O +
method O +
comprises O +
the O +
steps O +
of O +
dissolving O +
2- O +
acetoxyl O +
group-5-lorobenzoyl O +
chloride O +
with O +
chloroform O -
, O +
adding O +
4-amino O +
group-3-chloropyridine O -
, O +
reacting O +
at O +
room O +
temperature O +
to O +
obtain O +
a O +
target O +
compound O -
, O +
wherein O +
triethylamine O +
is O +
used O +
an O +
acid O -
- O -
binding O +
agent O -
; O +
and O +
the O +
second O +
preparation O +
method O +
comprises O +
the O +
step O +
of O +
carrying O +
out O +
a O +
heating O +
reflow O +
reaction O +
on O +
2-acetoxyl O +
group-5-chlorobenzoic O +
methyl O +
formate O +
and O +
4-amino O +
group-3-chloropyridin O +
to O +
obtain O +
the O +
target O +
compound O -
. O +

The O +
compound O +
has O +
the O +
function O +
of O +
resisting O +
tubercule O +
bacillus O -
. O +

Docetaxel O +
nano O -
- O -
particle O +
composition O +
The O +
invention O +
relates O +
to O +
a O +
docetaxel O +
nano O -
- O -
particle O +
composition O +
for O +
injection O +
administration O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
docetaxel O +
nano O -
- O -
particle O +
composition O +
contains O +
neutral O +
phospholipid O +
and O +
docetaxel O -
, O +
and O +
does O +
not O +
contain O +
negative O +
phospholipid O +
and O +
cholesterol O -
. O +

Method O +
for O +
preparing O +
block O +
polymer O +
micelle O +
freeze O -
- O -
drying O +
preparation O +
carrying O +
docetaxel O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
a O +
block O +
polymer O +
micelle O +
freeze O -
- O -
drying O +
preparation O +
carrying O +
docetaxel O -
, O +
which O +
uses O +
a O +
PEO O -
- O -
PPO O -
- O -
PEO O +
block O +
polymer O +
as O +
a O +
micelle O +
carrier O +
to O +
wrap O +
the O +
docetaxel O +
inside O +
the O +
micelle O +
and O +
comprises O +
the O +
following O +
steps O -
: O +
( O -
1 O -
) O +
dissolving O +
the O +
carrier O +
and O +
the O +
docetaxel O +
into O +
an O +
organic O +
solvent O +
to O +
make O +
the O +
PEO O -
- O -
PPO O -
- O -
PEO O +
block O +
polymer O +
and O +
the O +
docetaxel O +
fully O +
dissolved O +
in O +
the O +
organic O +
solvent O -
, O +
and O +
then O +
preparing O +
aqueous O +
solution O +
of O +
the O +
docetaxel O +
micelle O +
by O +
using O +
the O +
PEO O -
- O -
PPO O -
- O -
PEO O +
block O +
polymer O +
as O +
the O +
carrier O -
; O +
and O +
( O -
2 O -
) O +
adding O +
a O +
freeze O -
- O -
drying O +
protective O +
agent O +
into O +
the O +
aqueous O +
solution O +
of O +
the O +
PEO O -
- O -
PPO O -
- O -
PEO O +
block O +
polymer O +
carrying O +
micelle O -
, O +
and O +
filtering O -
, O +
sterilizing O +
and O +
freeze O -
- O -
drying O +
the O +
mixture O +
to O +
obtain O +
freeze O -
- O -
drying O +
preparation O +
of O +
the O +
carrier O +
micelle O +
system O -
. O +

The O +
block O +
polymer O +
micelle O +
freeze O -
- O -
drying O +
preparation O +
carrying O +
the O +
docetaxel O +
can O +
increase O +
the O +
dissolubility O -
, O +
metabolic O +
stability O +
and O +
in O +
vivo O +
circulation O +
time O +
of O +
the O +
docetaxel O -
, O +
reduce O +
the O +
toxicity O +
and O +
improve O +
the O +
bioavailability O -
, O +
and O +
is O +
more O +
suitable O +
for O +
clinical O +
application O -
. O +

Novel O +
application O +
of O +
tetrahydrocurcumin O +
The O +
invention O +
provides O +
application O +
of O +
tetrahydrocurcumin O +
in O +
preparing O +
a O +
medicament O +
for O +
preventing O +
or O -
/ O -
and O +
treating O +
a O +
set O +
of O +
clinical O +
syndromes O +
which O +
are O +
characterized O +
by O +
aggregating O +
a O +
variety O +
of O +
metabolic O +
disturbances O +
in O +
an O +
individual O -
, O +
such O +
as O +
obesity O -
, O +
hypertension O -
, O +
abnormal O +
blood O +
fat O -
, O +
abnormal O +
saccharometabolism O -
, O +
has O +
specific O +
medicinal O +
effect O -
, O +
and O +
is O +
a O +
new O +
treatment O +
medicament O +
which O +
can O +
simultaneously O +
and O +
effectively O +
correct O +
a O +
variety O +
of O +
clinical O +
disturbance O +
factors O +
of O +
MS O +
clinically O -
. O +

External O +
preparation O +
for O +
treating O +
abdominal O +
pain O +
and O +
women O -
's O +
menorrhalgia O -
, O +
preparation O +
method O +
thereof O -
, O +
and O +
quality O +
control O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
compound O +
preparation O +
prepared O +
from O +
lesser O +
galangal O +
rhizome O +
oil O -
, O +
nutgrass O +
galingale O +
rhizome O +
oil O +
and O +
clonidine O +
hydrochloride O -
, O +
which O +
is O +
an O +
external O +
preparation O +
for O +
treating O +
abdominal O +
pain O -
. O +

Clinical O +
tests O +
prove O +
that O +
the O +
prepared O +
emulsifiable O +
paste O +
preparation O +
has O +
good O +
treatment O +
effects O +
on O +
derangement O +
of O +
vitality O +
and O +
blood O -
, O +
and O +
irregular O +
cycles O -
, O +
abdominal O +
pain O +
during O +
menstruation O -
, O +
hypochondriac O +
pain O -
, O +
abdominal O +
distension O +
and O +
the O +
like O +
caused O +
by O +
the O +
derangement O +
of O +
vitality O +
and O +
blood O +
when O +
applied O +
to O +
abdomen O -
. O +

The O +
invention O +
also O +
carries O +
out O +
a O +
series O +
of O +
related O +
experiments O +
such O +
as O +
percutaneous O +
absorption O +
experiments O +
of O +
the O +
clonidine O +
hydrochloride O -
, O +
and O +
determination O +
tests O +
of O +
the O +
clonidine O +
hydrochloride O +
in O +
blood O +
concentration O -
, O +
which O +
further O +
affirms O +
medicinal O +
quality O +
control O +
and O +
clinical O +
effects O -
. O +

Stable O +
fat O +
emulsion O +
containing O +
prostaglandin O +
e1 O +
Disclosed O +
is O +
a O +
fat O +
emulsion O +
containing O +
a O +
compound O +
having O +
prostaglandin O +
E1 O +
activity O -
, O +
which O +
fat O +
emulsion O +
is O +
hermetically O +
sealed O +
in O +
a O +
glass O +
container O +
and O +
then O +
heat O +
sterilized O -
. O +

The O +
residual O +
amount O +
of O +
prostaglandin O +
E1 O +
activity O +
after O +
16-month O +
storage O +
at O +
5 O +
DEG O +
C O +
is O +
not O +
less O +
than O +
65 O -
% O +
but O +
not O +
more O +
than O +
100 O -
% O +
of O +
the O +
prostaglandin O +
E1 O +
activity O +
at O +
the O +
beginning O +
of O +
storage O -
. O +

Solid O +
dispersion O +
of O +
dihydropyrimidine O +
compounds O +
and O +
preparation O +
thereof O +
for O +
medical O +
purpose O +
The O +
invention O +
provides O +
solid O +
dispersion O +
of O +
bromophenyl O -
- O -
substituted O +
thiazole O +
dihydropyrimidine O -
, O +
salts O +
thereof O +
or O +
hydrates O +
thereof O +
and O +
a O +
preparation O +
thereof O +
for O +
medical O +
purpose O -
. O +

Dissolutions O +
of O +
the O +
compound O +
of O +
bromophenyl O -
- O -
substituted O +
thiazole O +
dihydropyrimidine O -
, O +
the O +
salts O +
thereof O -
, O +
or O +
the O +
hydrates O +
thereof O +
in O +
various O +
mediums O +
are O +
improved O -
, O +
and O +
the O +
bioavailability O +
of O +
the O +
preparation O +
is O +
guaranteed O -
. O +

Diaryl O +
pyrimidine O +
derivative O -
, O +
preparation O +
method O +
and O +
use O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O +
and O +
relates O +
to O +
a O +
diaryl O +
pyrimidine O +
derivative O +
of O +
the O +
general O +
formula O +
I O -
, O +
medicinal O +
salts O +
thereof O -
, O +
hydrates O +
and O +
solvolytes O +
thereof O -
, O +
polycrystal O +
and O +
eutectic O +
thereof O -
, O +
and O +
precursors O +
and O +
derivatives O +
thereof O +
with O +
the O +
same O +
biological O +
functions O -
, O +
a O +
preparation O +
method O +
thereof O -
, O +
application O +
of O +
combination O +
containing O +
one O +
or O +
more O +
compounds O +
in O +
relative O +
medicines O +
for O +
treating O +
acquired O +
immune O +
deficiency O +
syndrome O +
and O +
the O +
like O -
, O +
a O +
preparation O +
method O +
and O +
use O +
of O +
the O +
combination O -
. O +

Experimental O +
results O +
show O +
that O +
the O +
compound O +
of O +
the O +
invention O +
not O +
only O +
has O +
excellent O +
biological O +
activity O +
of O +
resisting O +
HIV-1 O +
virus O +
and O +
relatively O +
small O +
cytotoxicity O -
, O +
but O +
also O +
shows O +
relatively O +
good O +
inhibitory O +
action O +
to O +
a O +
drug O -
- O -
resistant O +
virus O +
strain O +
L103N+Y181C O -
, O +
can O +
be O +
used O +
as O +
medical O +
candidate O +
resisting O +
the O +
HIV O +
and O +
can O +
be O +
further O +
developed O +
as O +
a O +
medicine O +
resisting O +
AIDS O -
. O +

5-chloro O -
- O -
salicyloyl O +
hydrazine O +
tributyltin O +
chloride O +
coordination O +
compound O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
a O +
5-chloro O -
- O -
salicyloyl O +
hydrazine O +
tributyltin O +
chloride O +
coordination O +
compound O +
which O +
has O +
a O +
structural O +
formula O +
as O +
follows O -
. O +

A O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
sequentially O +
adding O +
1.5 O -
- O -
2.0 O +
mmol O +
of O +
N-1 O -
, O +
8-naphthyl O +
diacyl-5-chloro O -
- O -
salicyloyl O +
hydrazine O -
, O +
3.0 O -
- O -
4.0 O +
mmol O +
of O +
sodium O +
methoxide O +
and O +
50 O +
mL O +
of O +
absolute O +
methanol O -
, O +
stirring O +
for O +
0.5 O +
hour O -
; O +
then O +
adding O +
2.0 O -
- O -
3.0 O +
mmol O +
of O +
tributyltin O +
chloride O -
, O +
stirring O +
for O +
6 O -
- O -
8 O +
hours O +
at O +
normal O +
temperature O -
; O +
filtering O -
, O +
rotationally O +
evaporating O +
filter O +
liquor O +
to O +
obtain O +
a O +
white O +
solid O -
; O +
and O +
then O +
recrystallizing O +
by O +
using O +
methylene O +
dichloride O -
- O -
absolute O +
methanol O +
to O +
obtain O +
a O +
light O +
yellow O +
crystal O -
, O +
i.e. O +
an O +
organotin O +
coordination O +
compound O +
which O +
has O +
higher O +
anticancer O +
activity O +
and O +
can O +
be O +
used O +
as O +
a O +
raw O +
material O +
for O +
preparing O +
drugs O +
treating O +
liver O +
cancer O +
and O +
cervical O +
cancer O -
. O +

Compared O +
with O +
the O +
traditional O +
commonly O -
- O -
used O +
platinum O +
anticancer O +
drug O -
, O +
the O +
organotin O +
coordination O +
compound O +
has O +
the O +
advantages O +
of O +
higher O +
anticancer O +
activity O -
, O +
good O +
lipid O +
solubility O -
, O +
low O +
cost O -
, O +
simple O +
preparation O +
method O -
, O +
and O +
the O +
like O -
. O +

Preparation O +
formulations O +
of O +
sodium O +
pyruvate O +
freeze O -
- O -
dried O +
powder O +
injection O -
, O +
injection O +
and O +
solid O +
agent O +
and O +
production O +
processes O +
thereof O +
The O +
invention O +
relates O +
to O +
preparation O +
formulations O +
of O +
a O +
sodium O +
pyruvate O +
freeze O -
- O -
dried O +
powder O +
injection O -
, O +
an O +
injection O +
and O +
a O +
solid O +
agent O +
and O +
production O +
processes O +
thereof O -
, O +
in O +
particular O +
to O +
a O +
method O +
and O +
a O +
technology O +
for O +
preparing O +
pyruvate O +
and O +
a O +
freeze O -
- O -
dried O +
powder O +
injection O -
, O +
an O +
injection O +
and O +
a O +
solid O +
agent O +
made O +
of O +
the O +
pyruvate O -
. O +

The O +
raw O +
materials O +
of O +
sodium O +
pyruvate O +
( O -
containing O +
calcium O +
and O +
potassium O -
) O +
is O +
synthesized O +
by O +
the O +
following O +
steps O +
of O -
: O +
reacting O +
pyruvic O +
acid O +
and O +
sodium O +
carbonate O +
( O -
salts O +
containing O +
organic O +
acid O -
) O +
produced O +
by O +
fermentation O +
and O +
chemical O +
synthesis O +
to O +
generate O +
sodium O +
pyruvate O +
( O -
and O +
corresponding O +
salts O -
) O +
at O +
a O +
reaction O +
temperature O +
of O +
20 O -
- O -
90 O +
DEG O +
C O +
for O +
60 O -
- O -
70 O +
min O -
; O +
filtering O +
in O +
vacuum O -
; O +
washing O +
the O +
crystal O +
with O +
ethyl O +
acetate O +
and O +
ethanol O +
for O +
3 O -
- O -
5 O +
times O -
; O +
drying O +
in O +
vacuum O +
to O +
obtain O +
a O +
product O +
with O +
the O +
purity O +
higher O +
than O +
99 O +
percent O -
; O +
and O +
preparing O +
the O +
product O +
into O +
the O +
preparation O +
formulations O +
of O +
a O +
sodium O +
pyruvate O +
freeze O -
- O -
dried O +
powder O +
injection O -
, O +
an O +
injection O +
and O +
a O +
solid O +
agent O -
. O +

Dendrobii O +
extract O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
substance O +
with O +
a O +
structure O +
as O +
a O +
formula O +
I O -
, O +
wherein O +
R1 O +
and O +
R2 O +
in O +
the O +
formula O +
I O +
are O +
one O +
material O +
respectively O +
selected O +
from O +
alpha O -
- O -
arabinose O +
( O -
alpha O -
- O -
Ara O -
) O -
, O +
beta O -
- O -
arabinose O +
( O -
beta O -
- O -
Ara O -
) O +
and O +
beta O -
- O -
xylose O +
( O -
beta O -
- O -
Xyl O -
) O -
. O +

New O +
application O +
of O +
cimetidine O +
The O +
invention O +
relates O +
to O +
a O +
new O +
application O +
of O +
cimetidine O +
for O +
trauma O +
hemostasis O +
and O +
for O +
treating O +
periodontitis O -
. O +

The O +
method O +
for O +
trauma O +
hemostasis O +
comprises O +
the O +
following O +
steps O -
: O +
cimetidine O +
is O +
coated O +
on O +
the O +
bleeding O +
wound O +
surface O +
twice O +
each O +
day O +
with O +
dosage O +
thereof O +
being O +
approximately O +
200 O -
mg O +
and O +
the O +
wound O +
can O +
be O +
cured O +
two O +
days O +
later O -
; O +
the O +
method O +
for O +
treating O +
periodontitis O -
: O +
one O +
tablet O +
of O +
cimetidine O +
weighing O +
200 O -
mg O +
is O +
put O +
into O +
the O +
mouth O +
and O +
the O +
disease O +
can O +
be O +
cured O +
by O +
taking O +
the O +
medicine O +
once O +
a O +
day O -
. O +

The O +
medicine O +
of O +
the O +
invention O +
features O +
rapid O +
treatment O +
speed O -
, O +
good O +
curative O +
effect O +
and O +
radical O +
treatment O -
, O +
thus O +
being O +
widely O +
applied O +
to O +
various O +
groups O +
of O +
people O +
for O +
treating O +
trauma O +
hemostasis O +
and O +
periodontitis O -
. O +

Propofol O +
phosphate O +
for O +
injection O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
propofol O +
phosphate O +
for O +
injection O -
, O +
pharmaceutical O +
salt O +
thereof O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
preparation O +
method O +
comprising O +
the O +
following O +
steps O -
: O +
adding O +
5 O -
- O -
98 O +
percent O +
of O +
water O +
for O +
injection O +
into O +
a O +
preparation O +
container O -
, O +
adding O +
propofol O +
phosphate O +
and O +
pharmaceutical O +
salt O +
thereof O +
of O +
90 O -
- O -
110 O +
percent O +
of O +
accurate O +
prescriptions O -
, O +
slowly O +
dropping O +
a O +
pH O +
value O +
regulator O +
while O +
stirring O +
so O +
as O +
to O +
adjust O +
the O +
pH O +
to O +
be O +
6.0 O -
- O -
11 O -
, O +
adding O +
water O +
to O +
the O +
full O +
volume O -
, O +
then O +
adding O +
medicinal O +
carbon O +
of O +
0.01 O -
- O -
1.0 O +
percent O +
( O -
W O -
/ O -
V O -
) O -
, O +
stirring O +
for O +
15 O -
- O -
60 O +
minutes O -
, O +
roughly O +
filtering O +
with O +
a O +
sand O +
filter O +
rod O +
to O +
remove O +
the O +
carbon O -
, O +
and O +
finely O +
filtering O +
with O +
a O +
0.22mum O +
microporous O +
membrane O +
until O +
the O +
clarity O +
is O +
qualified O -
; O +
and O +
measuring O +
until O +
the O +
intermediate O +
content O +
is O +
acceptable O -
, O +
fixing O +
the O +
filling O +
amount O -
, O +
sub O -
- O -
packaging O +
into O +
cillin O +
bottles O -
, O +
plugging O +
in O +
plugs O +
by O +
half O -
, O +
freezing O +
and O +
drying O +
samples O +
to O +
control O +
the O +
moisture O +
content O +
being O +
0.1 O -
- O -
8 O +
percent O -
, O +
pressing O +
the O +
plugs O -
, O +
and O +
capping O -
. O +

Lipoamide O +
series O +
derivates O -
, O +
preparation O +
method O +
and O +
pharmaceutical O +
application O +
thereof O +
The O +
invention O +
provides O +
lipoamide O +
series O +
derivates O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
derivates O +
are O +
characterized O +
in O +
that O +
the O +
molecular O +
structural O +
formula O +
of O +
the O +
compounds O +
are O +
represented O +
as O +
( O -
I O -
) O -
, O +
wherein O +
R1 O +
is O +
one O +
of O +
substituted O +
phenyl O -
, O +
and O +
substituted O +
pyridyl O -
, O +
naphthyl O +
and O +
biphenyl O -
; O +
and O +
R2 O +
is O +
one O +
of O +
hydrogen O -
, O +
C1 O -
- O -
5 O +
alkanoyl O +
and O +
aroyl O -
. O +

The O +
novel O +
derivates O +
have O +
low O +
toxicity O +
and O +
anti O -
- O -
tumor O +
activity O -
, O +
and O +
can O +
be O +
applied O +
to O +
preparation O +
of O +
functional O +
foods O +
or O +
medicament O +
for O +
preventing O +
or O +
curing O +
tumor O +
diseases O -
. O +

pharmaceutical O +
compounds O +
The O +
invention O +
provides O +
a O +
compound O +
which O +
is O +
a O +
pyrimidine O +
of O +
formula O +
( O -
I O -
) O -
: O +
The O +
compounds O +
are O +
inhibitors O +
of O +
PI3 B-Gene -
K I-Gene +
and O +
may O +
thus O +
be O +
used O +
to O +
treat O +
diseases O +
and O +
disorders O +
arising O +
from O +
abnormal O +
cell O +
growth O -
, O +
function O +
or O +
behaviour O +
associated O +
with O +
PI3 B-Gene +
kinase I-Gene +
such O +
as O +
cancer O -
, O +
immune O +
disorders O -
, O +
cardiovascular O +
disease O -
, O +
viral O +
infection O -
, O +
inflammation O -
, O +
metabolism O -
/ O -
endocrine O +
function O +
disorders O +
and O +
neurological O +
disorders O -
. O +

Tolyltriazole O +
derivatives O -
, O +
preparation O +
method O +
thereof O +
and O +
use O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
antifungal O +
medicaments O +
and O +
provides O +
tolyltriazole O +
derivatives O +
having O +
a O +
structure O +
shown O +
as O +
a O +
general O +
formula O +
( O -
1 O -
) O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

In O +
the O +
general O +
formula O +
( O -
1 O -
) O -
, O +
R1 O -
, O +
R2 O +
and O +
R3 O +
are O +
defined O +
in O +
the O +
description O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
the O +
compounds O +
and O +
also O +
discloses O +
medicinal O +
compositions O +
using O +
thecompounds O +
or O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
as O +
active O +
ingredients O +
and O +
the O +
use O +
of O +
the O +
medicinal O +
compositions O +
as O +
antifungal O +
medicaments O -
. O +

Ant O +
and O +
ginseng O +
wine O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
wine O -
, O +
in O +
particular O +
to O +
ant O +
and O +
ginseng O +
wine O -
. O +

The O +
invention O +
has O +
the O +
main O +
technical O +
scheme O +
that O +
1000 O -
g O +
of O +
wine O +
comprises O +
1 O +
to O +
5 O -
g O +
of O +
ginseng O -
, O +
1 O +
to O +
5 O -
g O +
of O +
lucid O +
ganoderma O -
, O +
1 O +
to O +
5 O -
g O +
of O +
polyrhachis O +
vicina O -
, O +
0.01 O +
to O +
0.1 O -
g O +
of O +
stevioside O +
and O +
0.1 O +
to O +
1 O -
g O +
of O +
flavouring O +
agents O -
. O +

The O +
invention O +
gives O +
full O +
play O +
to O +
the O +
medical O +
value O +
of O +
the O +
ginseng O -
, O +
the O +
lucid O +
ganoderma O +
and O +
the O +
polyrhachis O +
vicina O +
per O +
se O -
, O +
so O +
the O +
ginseng O -
, O +
the O +
lucid O +
ganoderma O +
and O +
the O +
polyrhachis O +
vicina O +
have O +
the O +
pharmacodynamic O +
effects O -
, O +
and O +
in O +
addition O -
, O +
the O +
wine O +
has O +
the O +
effects O +
of O +
clearing O +
and O +
activating O +
the O +
channels O +
and O +
collaterals O -
, O +
nourishing O +
qi O -
, O +
activating O +
blood O +
and O +
regulating O +
the O +
immunity O +
in O +
two O +
ways O -
. O +

Particularly O -
, O +
the O +
wine O +
of O +
the O +
invention O +
is O +
sweet O -
, O +
contains O +
no O +
sugar O -
, O +
does O +
not O +
have O +
medicine O +
flavor O -
, O +
and O +
is O +
applicable O +
to O +
wide O +
range O +
of O +
people O -
. O +

epothilone O +
derivatives O +
The O +
invention O +
relates O +
to O +
Epothilone O +
derivatives O +
of O +
Formula O +
( O -
I O -
) O +
and O +
their O +
use O +
as O +
a O +
medicament O -
. O +

Compounds O +
with O +
a O +
combination O +
of O +
cannabinoid O -
- O -
CB1 B-Gene +
antagonism O +
and O +
serotonin O +
reuptake O +
inhibition O +
This O +
invention O +
relates O +
to O +
compounds O +
with O +
a O +
combination O +
of O +
cannabinoid O -
- O -
CB1antagonism B-Gene +
and O +
serotonin O +
reuptake O +
inhibition O +
to O +
pharmaceutical O +
compositions O +
containing O +
these O +
compounds O -
, O +
to O +
methods O +
for O +
preparing O +
the O +
compounds O -
, O +
methods O +
for O +
preparing O +
novel O +
intermediates O +
useful O +
for O +
their O +
synthesis O -
, O +
and O +
methods O +
for O +
preparing O +
compositions O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
uses O +
of O +
such O +
compounds O +
and O +
compositions O -
, O +
particularly O +
their O +
use O +
in O +
administering O +
them O +
to O +
patients O +
to O +
achieve O +
a O +
therapeutic O +
effect O +
in O +
psychosis O -
, O +
anxiety O -
, O +
depression O -
, O +
attention O +
deficits O -
, O +
cognitive O +
disorders O -
, O +
obesity O -
, O +
drug O +
dependence O -
, O +
Parkinson O -
's O +
disease O -
, O +
Alzheimer O -
's O +
disease O -
, O +
pain O +
disorders O -
, O +
neuropathic O +
pain O +
disorders O +
and O +
sexual O +
disorders O -
. O +

In O +
particular O +
the O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
the O +
symbols O +
have O +
the O +
meanings O +
given O +
in O +
the O +
specification O -
. O +

Salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

Salvianic O +
acid O +
A O +
can O +
be O +
dissolved O +
in O +
water O -
, O +
but O +
the O +
preparation O +
of O +
the O +
salvianic O +
acid O +
A O +
has O +
poor O +
stability O -
, O +
is O +
easy O +
for O +
oxidization O -
, O +
is O +
sensitive O +
to O +
light O +
and O +
heat O -
, O +
and O +
causes O +
content O +
reduction O +
and O +
impurity O +
increase O -
, O +
and O +
the O +
guarantee O +
on O +
the O +
stability O +
is O +
a O +
technical O +
problem O -
. O +

The O +
salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
comprises O +
the O +
salvianic O +
acid O +
A O -
, O +
a O +
pharmacological O +
allowable O +
pH O +
adjusting O +
substance O -
, O +
a O +
stabilizing O +
agent O +
and O +
an O +
excipient O -
. O +

The O +
salvianic O +
acid O +
A O +
in O +
the O +
salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
has O +
the O +
concentration O +
of O +
0.5 O -
- O -
2,000 O -
mg O -
. O +

The O +
weight O +
part O +
of O +
the O +
pH O +
adjusting O +
substance O +
is O +
the O +
adding O +
dosage O +
when O +
a O +
pH O +
value O +
is O +
adjusted O +
to O +
2.5 O -
- O -
7.5 O -
, O +
and O +
the O +
stabilizing O +
agent O +
in O +
the O +
salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
has O +
the O +
concentration O +
of O +
1mg-0.5 O -
g O -
. O +

The O +
salvianic O +
acid O +
A O +
pharmaceutical O +
composition O +
is O +
used O +
as O +
an O +
injection O +
with O +
the O +
effects O +
of O +
protecting O +
the O +
cardiac O +
muscle O -
, O +
promoting O +
blood O +
circulation O -
, O +
removing O +
blood O +
stasis O -
, O +
resisting O +
bacteria O -
, O +
eliminating O +
inflammation O -
, O +
strengthening O +
body O +
immunity O -
, O +
resisting O +
atherosclerosis O -
, O +
reducing O +
blood O +
fat O -
, O +
resisting O +
platelet O +
aggregation O -
, O +
resisting O +
thrombosis O -
, O +
expanding O +
the O +
coronary O +
artery O -
, O +
treating O +
liver O +
injury O -
, O +
resisting O +
cerebral O +
ischemia O +
injury O -
, O +
resisting O +
tumors O -
, O +
and O +
the O +
like O +
and O +
a O +
therapeutical O +
effect O +
on O +
pulmonary O +
heart O +
disease O -
, O +
psoriasis O -
, O +
altitude O +
disease O -
, O +
and O +
the O +
like O -
. O +

Composition O +
containing O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O +
The O +
invention O +
discloses O +
a O +
composition O +
containing O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O -
. O +

The O +
ratio O +
of O +
the O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O +
to O +
methylmorphine O +
in O +
the O +
mixture O +
is O +
( O -
8 O -
- O -
15 O -
) O -
:1 O -
, O +
based O +
on O +
the O +
weight O -
; O +
the O +
optimal O +
ratio O +
of O +
the O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O +
to O +
the O +
methylmorphine O +
in O +
the O +
mixture O +
is O +
12:1 O -
, O +
based O +
on O +
the O +
weight O -
; O +
and O +
the O +
ratio O +
of O +
the O +
mixture O +
of O +
the O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O +
and O +
the O +
methylmorphine O +
to O +
poloxamer O +
is O +
25:1 O -
, O +
based O +
on O +
the O +
weight O -
. O +

By O +
combining O +
potassium O +
sodium O +
dehydroandroan O +
drographolide O +
succinate O +
and O +
the O +
methylmorphin O -
, O +
the O +
invention O +
greatly O +
improves O +
the O +
antibacterial O +
activity O +
of O +
the O +
medicament O +
and O +
remarkably O +
reduces O +
the O +
side O +
effects O -
. O +

Flavones O +
derivative O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
thereof O +
as O +
alpha1 O +
receptor O +
antagonist O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
pharmaceutical O +
chemistry O -
, O +
in O +
particular O +
to O +
a O +
preparation O +
method O +
of O +
new O +
flavonoids O +
compounds O +
and O +
application O +
of O +
the O +
new O +
flavonoids O +
compounds O +
as O +
an O +
alpha1 O +
receptor O +
antagonist O -
, O +
wherein O +
R1 O +
and O +
R2 O +
are O +
defined O +
as O +
the O +
specifications O -
. O +

A O +
group O +
with O +
larger O +
polarity O +
is O +
introduced O +
in O +
a O +
flavones O +
structure O +
to O +
enable O +
the O +
polarity O +
of O +
an O +
integral O +
molecule O +
to O +
be O +
increased O -
; O +
meanwhile O -
, O +
the O +
compounds O +
have O +
a O +
certain O +
alkalinity O +
and O +
can O +
be O +
formed O +
into O +
salts O +
with O +
common O +
medicinal O +
acids O +
to O +
ensure O +
that O +
the O +
integral O +
molecule O +
has O +
a O +
certain O +
water O -
- O -
solubility O -
. O +

Preliminary O +
pharmacological O +
tests O +
indicate O +
that O +
the O +
compounds O +
have O +
an O +
alpha1 O +
receptor O +
antagonizing O +
function O -
. O +

Preparation O +
method O +
of O +
gossypol O +
acetate O +
intravenous O +
injection O +
fatty O +
emulsion O +
The O +
invention O +
discloses O +
a O +
preparation O +
method O +
of O +
gossypol O +
acetate O +
intravenous O +
injection O +
fatty O +
emulsion O -
. O +

In O +
the O +
method O -
, O +
gossypol O +
acetate O +
is O +
used O +
as O +
an O +
active O +
constituent O -
, O +
ethyl O +
oleate O +
or O +
middle O -
- O -
chain O +
fatty O +
acid O +
triglyceride O +
is O +
used O +
as O +
an O +
oil O +
phase O -
, O +
soya O +
bean O +
lecithin O +
is O +
used O +
as O +
a O +
surface O +
active O +
agent O -
, O +
absolute O +
ethyl O +
alcohol O +
or O +
PEG O +
( O -
Polyethylene O +
Glycol O -
) O +
400 O +
is O +
used O +
as O +
a O +
cosurfactant O -
, O +
and O +
sterilized O +
water O +
for O +
injection O +
is O +
used O +
as O +
a O +
water O +
phase O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
( O -
1 O -
) O +
dissolving O +
the O +
gossypol O +
acetate O +
in O +
diethyl O +
ether O +
and O +
then O +
mixing O +
with O +
the O +
oil O +
phase O -
, O +
the O +
surface O +
active O +
agent O +
and O +
the O +
cosurfactant O -
; O +
decompressing O +
and O +
evaporating O +
to O +
remove O +
the O +
diethyl O +
ether O +
and O +
preserving O +
at O +
a O +
constant O +
temperature O +
for O +
later O +
use O -
; O +
( O -
2 O -
) O +
heating O +
the O +
sterilized O +
water O +
for O +
injection O +
and O +
preserving O +
at O +
a O +
constant O +
temperature O +
for O +
later O +
use O -
; O +
( O -
3 O -
) O +
mixing O +
liquids O +
obtained O +
in O +
the O +
steps O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O +
at O +
a O +
constant O +
temperature O +
of O +
60 O +
or O +
70 O +
DEG O +
C O +
and O +
stirring O +
until O +
a O +
transparent O +
and O +
homogeneous O +
solution O +
is O +
formed O -
; O +
making O +
the O +
volume O +
constant O +
and O +
then O +
repeatedly O +
homogenizing O +
by O +
using O +
a O +
homogenizer O -
; O +
and O +
filtering O +
by O +
using O +
a O +
millipore O +
filter O +
membrane O -
. O +

Proved O +
by O +
researches O -
, O +
the O +
gossypol O +
acetate O +
intravenousinjection O +
fatty O +
emulsion O +
prepared O +
by O +
using O +
the O +
method O +
has O +
good O +
slow O +
release O +
and O +
targeting O +
effects O +
and O +
good O +
stability O -
. O +

Magnetic O +
lipid O +
nano O +
particle O +
and O +
preparation O +
method O +
The O +
invention O +
provides O +
a O +
magnetic O +
lipid O +
nano O +
particle O +
comprising O +
2.2%-5.9 O -
% O +
of O +
ferroferric O +
oxide O +
nano O +
magnetic O +
powder O -
, O +
4.4%-28.6 O -
% O +
of O +
oleic O +
acid O -
, O +
66.7%-93.4 O -
% O +
of O +
glycerine O +
or O +
stearic O +
acid O +
and O +
0 O -
- O -
28.2 O -
% O +
of O +
hydrophobic O +
anti O -
- O -
tumor O +
medicaments O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
preparing O +
a O +
stable O +
ferroferric O +
oxide O +
nano O +
dispersing O +
solution O +
by O +
adopting O +
lipid O +
material O +
oleic O +
acid O +
in O +
a O +
liquid O +
state O +
at O +
room O +
temperature O +
as O +
a O +
surfactant O -
, O +
and O +
further O +
injecting O +
an O +
organic O +
solvent O +
dissolved O +
with O +
lipid O +
materials O +
to O +
the O +
ferroferric O +
oxide O +
nano O +
dispersing O +
solution O +
stabilized O +
by O +
the O +
oleic O +
to O +
prepare O +
the O +
magnetic O +
lipid O +
nano O +
particle O -
. O +

The O +
magnetic O +
lipid O +
nano O +
particle O +
containing O +
the O +
medicaments O +
can O +
be O +
prepared O +
by O +
adding O +
the O +
hydrophobic O +
medicament O +
in O +
the O +
organic O +
solvent O +
dissolved O +
with O +
the O +
lipidmaterials O -
. O +

The O +
magnetic O +
lipid O +
nano O +
particle O +
can O +
be O +
further O +
applied O +
to O +
magnetic O +
resonance O +
imaging O +
and O +
targeted O +
therapy O +
of O +
anti O -
- O -
tumor O +
medicaments O -
. O +

Application O +
of O +
baicalein O +
in O +
preparing O +
medicaments O +
for O +
preventing O +
and O +
treating O +
Parkinson O +
diseases O +
The O +
invention O +
discloses O +
application O +
of O +
baicalein O +
( O -
chemical O +
name O -
: O +
5,6,7-trihydroxyflavone O -
) O +
as O +
shown O +
in O +
a O +
general O +
formula O +
( O -
I O -
) O +
in O +
preparing O +
medicaments O +
for O +
preventing O +
and O +
treating O +
Parkinson O +
diseases O -
. O +

The O +
invention O +
relates O +
to O +
the O +
application O +
of O +
the O +
baicalein O +
capable O +
of O +
reducing O +
the O +
trembling O +
frequencies O +
and O +
amplitudes O +
of O +
the O +
Parkinson O +
diseases O +
and O +
improving O +
and O +
treating O +
the O +
symptoms O +
of O +
the O +
Parkinson O +
diseases O -
, O +
in O +
particular O +
to O +
the O +
application O +
of O +
the O +
baicalein O +
capable O +
of O +
protecting O +
dopaminergic O +
neurons O +
from O +
damage O +
so O +
that O +
the O +
pathological O +
changes O +
and O +
the O +
development O +
of O +
the O +
Parkinson O +
diseases O +
can O +
be O +
effectively O +
prevented O +
and O +
treated O -
; O +
and O +
the O +
baicalein O +
exerts O +
the O +
function O +
of O +
protecting O +
the O +
dopaminergic O +
neurons O +
through O +
apoptosis O +
resistance O -
, O +
inflammatory O +
resistance O +
and O +
antioxidation O +
and O +
exerts O +
the O +
function O +
of O +
inhibiting O +
Parkinson O +
symptoms O +
through O +
the O +
function O +
on O +
nervous O +
systems O -
. O +

Anti O -
- O -
aging O +
compound O +
The O +
invention O +
discloses O +
an O +
anti O -
- O -
aging O +
compound O +
which O +
comprises O +
spirulina O +
polysaccharide O +
and O +
folium O +
ginkgo O +
extract O -
, O +
and O +
the O +
mass O +
ratio O +
of O +
the O +
spirulina O +
polysaccharide O +
to O +
the O +
folium O +
ginkgo O +
extract O +
is O +
0.35 O +
to O +
1.5:0.35 O +
to O +
1.5 O -
. O +

The O +
preferred O +
mass O +
ratio O +
of O +
the O +
spirulina O +
polysaccharide O +
to O +
the O +
folium O +
ginkgo O +
extract O +
is O +
2:1 O -
. O +

The O +
spirulina O +
polysaccharide O +
is O +
water O -
- O -
soluble O +
heteropolysaccharide O -
, O +
and O +
the O +
content O +
of O +
the O +
polysaccharide O +
thereof O +
in O +
percentage O +
by O +
mass O +
is O +
more O +
than O +
or O +
equal O +
to O +
93 O +
percent O -
. O +

The O +
content O +
of O +
general O +
flavone O +
of O +
the O +
folium O +
ginkgo O +
extract O +
in O +
percentage O +
by O +
mass O +
is O +
more O +
than O +
or O +
equal O +
to O +
24 O +
percent O -
, O +
and O +
the O +
content O +
of O +
terpene O +
lactones O +
thereof O +
in O +
percentage O +
by O +
mass O +
is O +
more O +
than O +
or O +
equal O +
to O +
6 O +
percent O -
. O +

The O +
anti O -
- O -
aging O +
compound O +
comprises O +
the O +
spirulina O +
polysaccharide O +
and O +
the O +
folium O +
ginkgo O +
extract O -
, O +
can O +
play O +
the O +
cooperative O +
and O +
synergistic O +
roles O +
by O +
combination O -
. O +

because O +
both O +
the O +
spirulina O +
polysaccharide O +
and O +
the O +
folium O +
ginkgo O +
extract O +
contain O +
hydroxyl O +
or O +
phenolic O +
hydroxyl O +
structures O -
, O +
thereby O +
significantly O +
improving O +
the O +
anti O -
- O -
aging O +
effect O -
. O +

Medical O +
composition O +
and O +
mixture O +
for O +
treating O +
chicken O +
infectious O +
bursal O +
disease O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
medical O +
composition O +
and O +
a O +
mixture O +
for O +
treating O +
chicken O +
infectious O +
bursal O +
disease O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
medical O +
composition O +
( O -
100 O +
grams O -
) O +
comprises O -
: O +
1 O +
to O +
10 O +
grams O +
of O +
astragalus O +
polysaccharides O -
, O +
3 O +
to O +
12 O +
grams O +
of O +
taurine O -
, O +
4 O +
to O +
15 O +
grams O +
of O +
aminopyrine O -
, O +
2 O +
to O +
10 O +
grams O +
of O +
vitamin O +
C O -
, O +
0.04 O +
to O +
0.2 O +
gram O +
of O +
interferon O +
inducer O -
, O +
5 O +
to O +
20 O +
grams O +
of O +
alcohol O -
, O +
0.1 O +
to O +
0.4 O +
gram O +
of O +
sodium O +
benzoate O -
, O +
and O +
the O +
balance O +
of O +
water O +
for O +
injection O -
. O +

The O +
product O +
is O +
characterized O +
by O +
reasonable O +
formula O +
composition O -
, O +
stable O +
physical O +
and O +
chemical O +
properties O -
, O +
accurate O +
dose O -
, O +
quick O +
effect O -
, O +
long O -
- O -
lasting O +
medicament O +
effect O -
, O +
high O +
bioavailability O -
, O +
safe O +
use O +
and O +
exact O +
treatment O +
effect O -
. O +

Aryl O +
ruthenium O +
( O -
11 O -
) O +
composition O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
an O +
aryl O +
ruthenium O +
( O -
II O -
) O +
composition O +
and O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

In O +
the O +
structural O +
formula O +
( O -
I O -
) O +
of O +
the O +
aryl O +
ruthenium O +
( O -
II O -
) O +
composition O -
, O +
R O +
is O +
chosen O +
from O +
H O -
, O +
C1 O +
to O +
C6 O +
alkyl O +
or O +
alkyl O +
substituent O -
, O +
phenyl O +
or O +
phenyl O +
substituent O -
, O +
pyridyl O +
or O +
pyridyl O +
substituent O -
, O +
furyl O +
or O +
furyl O +
substituent O -
, O +
pyrrolyl O +
or O +
pyrrolyl O +
substituent O +
and O +
thiazole O +
or O +
thiazole O +
substituent O -
. O +

R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O +
and O +
R6 O +
are O +
independently O +
chosen O +
from O +
H O -
, O +
C2 O +
to O +
C6 O +
alkenyl O -
, O +
C2 O +
to O +
C6 O +
alkynyl O -
, O +
oxhydryl O +
C1 O +
to O +
C6 O +
alkyl O -
, O +
amido O +
C1 O +
to O +
C6 O +
alkyl O -
, O +
halogen O -
, O +
CO2R7 O -
, O +
CONR8R9 O -
, O +
COR10 O -
, O +
SO3H O -
, O +
SO2R11R12 O -
, O +
aryloxy O -
, O +
C1 O +
to O +
C6 O +
alkoxy O -
, O +
C1 O +
to O +
C6 O +
alkylthio O -
, O +
-N O -
= O -
NR13,NR14R15 O -
, O +
aryl O +
or O +
aralkyl O -
. O +

The O +
aryl O +
ruthenium O -
( O -
II O -
) O +
composition O +
can O +
be O +
used O +
to O +
prepare O +
tumor O +
medicine O -
, O +
has O +
good O +
inhibitory O +
action O +
particularly O +
on O +
lung O +
adenocarcinoma O +
and O +
has O +
potential O +
great O +
value O +
in O +
terms O +
of O +
tumor O +
disease O +
clinical O +
treatment O +
application O -
. O +

The O +
formula O +
( O -
I O -
) O -
. O +

Open O +
loop O +
steroid O +
saponin O +
compound O +
with O +
antibacterial O +
activity O +
in O +
sinularia O +
gyrosa O +
The O +
invention O +
relates O +
to O +
two O +
open O +
loop O +
steroid O +
saponin O +
compounds O -
, O +
i.e. O +
Sinularoside O +
A O +
and O +
Sinularoside O +
B O +
with O +
antibacterial O +
activity O -
, O +
separated O +
from O +
sinularia O +
gyrosa O -
, O +
belonging O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
. O +

The O +
compounds O +
have O +
the O +
chemical O +
structural O +
formulas O +
as O +
the O +
specification O -
, O +
wherein O +
the O +
R O +
group O +
is O +
FORMULA O -
. O +

The O +
in O -
- O -
vitro O +
antibacterial O +
test O +
on O +
the O +
Sinularoside O +
A O +
and O +
the O +
Sinularoside O +
B O +
shows O +
that O +
the O +
compounds O +
have O +
obvious O +
effect O +
for O +
inhibiting O +
fungus O -
, O +
bacteria O +
and O +
algae O +
for O +
test O -
, O +
thereby O +
the O +
two O +
open O +
loop O +
steroid O +
saponin O +
compounds O +
can O +
be O +
used O +
for O +
preparing O +
antibacterial O +
medicaments O -
. O +

The O +
invention O +
provides O +
a O +
new O +
lead O +
compound O +
for O +
developing O +
new O +
antibacterial O +
medicaments O +
and O +
has O +
great O +
significance O +
for O +
developing O +
ocean O +
medicine O +
biological O +
resources O +
in O +
China O -
. O +

American O +
ginseng O +
saponin O +
F6 O +
as O +
well O +
as O +
extraction O +
method O +
and O +
medical O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
American O +
ginseng O +
saponin O +
F6 O +
as O +
well O +
as O +
an O +
extraction O +
method O +
and O +
medical O +
application O +
thereof O -
, O +
which O +
belong O +
to O +
a O +
new O +
compound O +
as O +
well O +
as O +
an O +
extraction O +
method O +
and O +
medical O +
application O +
thereof O -
. O +

The O +
extraction O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
taking O +
American O +
ginseng O +
fruit O +
as O +
a O +
raw O +
material O -
, O +
obtaining O +
the O +
new O +
compound O +
through O +
macroporous O +
absorbent O +
resin O -
, O +
normal O +
and O +
reversed O -
- O -
phase O +
silica O +
gel O +
column O +
chromatography O +
and O +
a O +
recrystallization O +
method O +
of O +
fruit O +
juice O -
, O +
wherein O +
the O +
new O +
compound O +
has O +
the O +
chemical O +
name O +
of O +
6-O O -
- O -
beta O -
- O -
D O -
- O -
glucopyranesyl-20-O- O -
[ O -
alpha O -
- O -
L O -
- O -
arabinofuranosyl- O -
( O -
1 O -
- O -
6 O -
) O -
-beta O -
- O -
D O -
- O -
glucopyranosyl O -
] O -
-dammar-24-ene-3beta O -
, O +
6alpha,12beta O -
, O +
20S O -
- O -
tetraol O +
and O +
is O +
abbreviated O +
as O +
the O +
American O +
ginseng O +
saponin O +
F6 O -
, O +
and O +
the O +
yield O +
reaches O +
more O +
than O +
0.01 O -
% O -
. O +

The O +
American O +
ginseng O +
saponin O +
F6 O +
has O +
wide O +
application O +
in O +
preparing O +
antitumor O +
medicaments O -
. O +

8,8-disubstituted-13,13a O -
- O -
dihyrdroberberine O +
derivative O +
as O +
well O +
as O +
pharmaceutical O +
composition O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
a O +
8,8-disubstituted-13,13a O -
- O -
dihyrdroberberine O +
derivative O +
with O +
a O +
structure O +
shown O +
as O +
the O +
following O +
general O +
formula O +
or O +
a O +
physiologically O +
acceptable O +
salt O +
and O +
application O +
thereof O +
and O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
derivative O -
. O +

The O +
8,8-disubstituted-13,13a O -
- O -
dihyrdroberberine O +
derivative O +
has O +
the O +
effect O +
of O +
promoting O +
the O +
glucose O +
absorption O +
on O +
muscle O +
cells O -
. O +

Proved O +
by O +
in O -
- O -
vivo O +
animal O +
experiments O -
, O +
the O +
compound O +
has O +
the O +
effects O +
on O +
improving O +
the O +
carbohydrate O +
tolerance O +
and O +
the O +
insulin B-Gene +
resistance O -
, O +
reducing O +
weight O -
, O +
relieving O +
fatty O +
livers O -
, O +
and O +
the O +
like O -
, O +
has O +
high O +
bioavailability O -
, O +
enhances O +
the O +
in O -
- O -
vivo O +
pesticide O +
effect O -
, O +
and O +
has O +
stable O +
structure O +
under O +
an O +
acidic O +
condition O -
. O +

The O +
compound O +
can O +
be O +
used O +
for O +
treating O +
type-2 O +
diabetes O -
, O +
obesity O -
, O +
fatty O +
livers O +
or O +
complications O +
thereof O -
. O +

Rosuvastatin O +
calcium O +
sustained O -
- O -
release O +
preparation O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
rosuvastatin O +
calcium O +
sustained O -
- O -
release O +
preparation O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
rosuvastatin O +
calcium O +
sustained O -
- O -
release O +
preparation O +
basically O +
contains O +
5 O +
to O +
10 O -
mg O +
of O +
rosuvastatin O +
calcium O -
, O +
and O +
the O +
balance O +
of O +
sustained O -
- O -
release O +
framework O +
material O +
and O +
other O +
pharmaceutical O +
excipients O -
. O +

The O +
preparation O +
method O +
is O +
simple O -
; O +
and O +
all O +
the O +
materials O +
are O +
proportioned O +
and O +
the O +
preparation O +
is O +
prepared O +
by O +
the O +
preparation O +
method O +
for O +
common O +
tablets O -
, O +
granules O +
or O +
capsules O -
. O +

The O +
rosuvastatin O +
calcium O +
sustained O -
- O -
release O +
preparation O +
prepared O +
by O +
the O +
method O +
avoids O +
adverse O +
reactions O +
such O +
as O +
rhabdomyolysis O -
, O +
proteinuria O -
, O +
nephrosis O -
, O +
kidney O +
failure O -
, O +
hepatotoxicity O +
and O +
the O +
like O +
caused O +
by O +
overdosage O +
of O +
medicaments O -
; O +
meanwhile O -
, O +
due O +
blood O +
concentration O +
and O +
time O +
for O +
treating O +
diseases O +
after O +
the O +
medicaments O +
are O +
taken O +
can O +
be O +
maintained O -
, O +
and O +
the O +
peak O +
valley O +
phenomenon O +
of O +
the O +
blood O +
concentration O +
is O +
effectively O +
avoided O -
. O +

Medicament O +
for O +
treating O +
mammary O +
gland O +
hyperplasia O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
medicament O +
for O +
treating O +
mammary O +
gland O +
hyperplasia O -
. O +

The O +
medicament O +
is O +
characterized O +
by O +
being O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
in O +
part O +
by O +
weight O -
: O +
1 O +
to O +
20 O +
parts O +
of O +
rose O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
Seville O +
orange O +
flower O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
Paris O +
polyphylla O +
Sm O -
. O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
common O +
selfheal O +
fruit O -
- O -
spike O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
barbed O +
skullcap O +
herb O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
snakegourd O +
fruit O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
seaweed O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
kelp O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
frankincense O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
myrrh O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
tangerine O +
leaves O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
green O +
tangerine O +
peel O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
thunberg O +
fritillary O +
bulb O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
common O +
burreed O +
rhizome O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
zedoary O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
Indian O +
iphigenia O +
bulb O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
India O +
madder O +
root O -
, O +
1 O +
to O +
20 O +
parts O +
of O +
edible O +
alcohol O +
of O +
which O +
the O +
content O +
is O +
over O +
95 O +
percent O -
. O +

The O +
medicament O +
can O +
be O +
absorbed O +
by O +
spleen O +
and O +
stomach O +
through O +
oral O +
administration O +
or O +
absorbed O +
by O +
skin O +
through O +
external O +
application O +
and O +
also O +
can O +
be O +
absorbed O +
through O +
the O +
combination O +
of O +
oral O +
administration O +
and O +
external O +
administration O -
. O +

The O +
medicament O +
of O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
reasonable O +
formula O -
, O +
simple O +
compatibility O -
, O +
clear O +
treatment O +
effect O +
and O +
addressing O +
both O +
symptoms O +
and O +
root O +
causes O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
of O +
the O +
medicament O -
. O +

Novel O +
formulation O +
of O +
piperazine O +
ferulate O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
injection O +
of O +
piperazine O +
ferulate O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
novel O +
formulation O +
of O +
the O +
piperazine O +
ferulate O +
is O +
prepared O +
by O +
the O +
steps O +
of O +
dissolving O +
piperazine O +
ferulate O +
as O +
a O +
medicine O +
component O +
into O +
a O +
solvent O +
and O +
regulating O +
the O +
pH O +
value O +
to O +
be O +
5.0 O -
- O -
8.0 O +
with O +
a O +
pH O +
regulating O +
agent O +
so O +
that O +
the O +
piperazine O +
ferulate O +
is O +
fully O +
dissolved O +
to O +
prepare O +
an O +
injection O -
. O +

The O +
content O +
of O +
the O +
piperazine O +
ferulate O +
in O +
the O +
novel O +
formulation O +
is O +
27 O -
- O -
200mg O -
/ O -
ml O -
, O +
and O +
the O +
agent O +
is O +
the O +
water O +
of O +
injection O -
. O +

The O +
invention O +
broadens O +
the O +
clinical O +
application O +
range O +
of O +
the O +
piperazine O +
ferulate O -
, O +
has O +
the O +
characteristics O +
of O +
high O +
medicine O +
dissolubility O -
, O +
high O +
bioavailability O -
, O +
rapid O +
medicine O +
administration O -
, O +
more O +
quick O +
effect O -
- O -
taking O -
, O +
stronger O +
treatment O +
effect O -
, O +
and O +
the O +
like O -
, O +
is O +
especially O +
suitable O +
for O +
preventing O +
and O +
treating O +
patients O +
suffering O +
from O +
heavy O +
cerebral O +
infarction O -
, O +
nephroma O -
, O +
coronary O +
heart O +
disease O -
, O +
vascular O +
complication O +
in O +
diabetes O +
mellitus O +
and O +
dysphagia O -
, O +
overcomes O +
the O +
problem O +
of O +
low O +
dissolubility O +
of O +
the O +
piperazine O +
ferulate O +
in O +
the O +
prior O +
art O -
, O +
and O +
realizes O +
the O +
solubilization O +
of O +
the O +
piperazine O +
ferulate O +
by O +
regulating O +
the O +
pH O +
value O +
with O +
the O +
pH O +
regulating O +
agent O -
, O +
wherein O +
at O +
least O +
500 O -
mg O +
of O +
piperazine O +
ferulate O +
can O +
be O +
dissolved O +
in O +
10mlof O +
water O +
solution O +
with O +
pH O +
value O +
of O +
5.5 O -
. O +

High O -
- O -
release O +
erythrocin O +
enteric O -
- O -
coated O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
high O -
- O -
release O +
erythrocin O +
enteric O -
- O -
coated O +
tablet O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
belonging O +
to O +
the O +
field O +
of O +
antibiotic O +
drugs O -
. O +

The O +
enteric O -
- O -
coated O +
tablet O +
contains O +
two O +
parts O -
: O +
a O +
substrate O +
and O +
an O +
enteric O +
coating O -
, O +
wherein O +
the O +
substrate O +
contains O +
the O +
following O +
components O -
: O +
12.5 O +
( O -
BOU O -
) O +
of O +
erythrocin O -
, O +
2.5 O -
- O -
3.0 O -
kg O +
of O +
starch O -
, O +
0.21 O -
- O -
0.25 O -
kg O +
of O +
Tween-80 O -
, O +
1 O -
- O -
1.5 O -
kg O +
of O +
hydroxy O +
propyl O +
cellulose O -
, O +
0.3 O -
- O -
0.5 O -
kg O +
of O +
magnesium O +
stearate O +
and O +
0.8 O -
- O -
1.5 O -
kg O +
of O +
talcum O +
powder O +
by O +
the O +
dosage O +
of O +
100 O +
thousand O +
finished O +
erythrocin O +
enteric O -
- O -
coated O +
tablets O -
; O +
the O +
enteric O -
- O -
coated O +
tablet O +
contains O +
the O +
following O +
components O +
of O -
: O +
0.81 O -
- O -
0.84 O -
kg O +
of O +
polyacrylic O +
resin O +
( O -
II O -
) O -
, O +
15 O -
- O -
16 O -
kg O +
of O +
ethanol O +
the O +
concentration O +
of O +
more O +
than O +
90 O +
percent O -
, O +
0.16 O -
- O -
0.2 O -
kg O +
of O +
Tween-80 O -
, O +
0.16 O -
- O -
0.20 O -
kg O +
of O +
diethyl O +
phthalate O -
, O +
0.48 O -
- O -
0.60 O -
kg O +
of O +
castor O +
oil O +
and O +
0.59 O -
- O -
0.70 O -
kg O +
of O +
talcum O +
powder O +
by O +
the O +
dosage O +
of O +
100 O +
thousand O +
finished O +
erythrocin O +
enteric O -
- O -
coated O +
tablets O -
. O +

The O +
average O +
release O +
of O +
the O +
enteric O -
- O -
coated O +
tablet O +
prepared O +
by O +
adopting O +
the O +
prescription O +
of O +
the O +
substrate O +
and O +
the O +
enteric O +
coating O +
is O +
not O +
less O +
than O +
90 O +
percent O +
in O +
drug O +
effect O +
and O +
is O +
far O +
higher O +
than O +
the O +
national O +
pharmacopeia O +
standard O -
, O +
and O +
the O +
enteric O -
- O -
coated O +
tablet O +
can O +
be O +
stably O +
released O -
; O +
the O +
drug O +
action O +
of O +
the O +
enteric O -
- O -
coated O +
tablet O +
is O +
higher O +
than O +
the O +
national O +
pharmacopeia O +
standard O +
in O +
the O +
period O +
of O +
validity O -
; O +
the O +
surface O +
of O +
the O +
enteric O -
- O -
coated O +
tablet O +
is O +
fine O +
and O +
smooth O +
and O +
glossy O +
in O +
appearance O -
; O +
and O +
the O +
effectiveness O +
of O +
the O +
enteric O -
- O -
coated O +
tablet O +
is O +
not O +
influenced O +
after O +
being O +
stored O +
for O +
a O +
long O +
time O -
. O +

Plaster O +
for O +
treating O +
bone O +
fracture O +
The O +
invention O +
relates O +
to O +
a O +
plaster O +
for O +
treating O +
bone O +
fracture O -
, O +
mainly O +
comprising O +
the O +
following O +
drugs O +
in O +
parts O +
by O +
weight O -
: O +
20 O -
- O -
40 O +
parts O +
of O +
corydalis O +
tuber O -
, O +
20 O -
- O -
30 O +
parts O +
of O +
safflower O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
frankincense O -
, O +
20 O -
- O -
30 O +
parts O +
of O +
myrrh O -
, O +
15 O -
- O -
30 O +
parts O +
of O +
scaly O +
anteater O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
scorpio O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
panax O +
notoginseng O -
, O +
10 O -
- O -
20 O +
parts O +
of O +
crinis O +
ustus O -
, O +
10 O -
- O -
20 O +
parts O +
of O +
eupolyphaga O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
drgonsbone O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
earthworm O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
pyrite O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
sapanwood O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
rhizoma O +
drynariae O -
, O +
10 O -
- O -
30 O +
parts O +
of O +
dragon O -
's O +
blood O -
, O +
20 O -
- O -
40 O +
parts O +
of O +
peach O +
kernel O +
and O +
20 O -
- O -
40 O +
parts O +
of O +
angelica O -
. O +

The O +
plaster O +
for O +
treating O +
bone O +
fracture O +
has O +
the O +
effects O +
of O +
dredging O +
the O +
channel O -
, O +
stopping O +
bleeding O -
, O +
promoting O +
the O +
circulation O +
of O +
Qi O -
, O +
relieving O +
swelling O -
, O +
stopping O +
pain O -
, O +
removing O +
heat O +
from O +
the O +
heart O +
to O +
restore O +
to O +
consciousness O -
, O +
reuniting O +
bones O +
and O +
muscles O -
, O +
circulating O +
blood O +
and O +
promoting O +
the O +
quick O +
formation O +
of O +
poroma O +
and O +
has O +
obvious O +
treatment O +
effect O +
and O +
little O +
adverse O +
reaction O -
. O +

Substituted O +
benzodihydropyran O +
derivatives O +
and O +
anti O -
- O -
tumor O +
application O +
thereof O +
The O +
invention O +
discloses O +
substituted O +
benzodihydropyran O +
derivatives O +
shown O +
in O +
a O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R O +
is O +
hydrogen O +
atom O +
or O +
C1-C6 O +
straight O +
chain O +
or O +
branched O +
alkane O -
, O +
methoxy O +
acyl O +
isopropyl O +
or O +
methoxy O +
acyl O +
oxy O +
isopropyl O -
, O +
methoxy O +
acyl O +
isobutyl O +
or O +
methoxy O +
acyl O +
oxy O +
isobutyl O -
, O +
methoxy O +
acyl O +
tertiary O +
butyl O +
or O +
methoxy O +
acyl O +
cyclobutyl O -
; O +
and O +
n O +
is O +
1 O -
- O -
5 O -
, O +
and O +
is O +
represented O +
as O +
a O +
single O +
bond O +
or O +
a O +
double O +
bond O -
. O +

The O +
invention O +
also O +
provides O +
a O +
method O +
for O +
inducing O +
apoptosis O +
in O +
cells O -
, O +
which O +
comprises O +
a O +
step O +
of O +
applying O +
a O +
composition O +
containing O +
the O +
compounds O -
. O +

The O +
compounds O +
designed O +
by O +
the O +
pharmacokinetics O +
have O +
improved O +
therapeutic O +
index O -
, O +
are O +
strong O +
inhibitors O +
for O +
cancer O +
cell O +
growth O -
, O +
and O +
have O +
high O +
anti O -
- O -
cancer O +
activity O +
and O +
extremely O +
small O +
side O +
effect O -
. O +

Antibacterial O +
agent O +
The O +
invention O +
relates O +
to O +
an O +
antibacterial O +
agent O -
, O +
belonging O +
to O +
the O +
field O +
of O +
hygiene O -
, O +
wherein O +
the O +
antibacterial O +
agent O +
comprises O +
the O +
following O +
active O +
components O -
: O +
tetracycline O +
and O +
bacillus O +
subtilis O -
; O +
the O +
ratio O +
of O +
the O +
tetracycline O +
to O +
the O +
bacillus O +
subtilis O +
in O +
the O +
antibacterial O +
agent O +
is O +
( O -
0.18 O -
- O -
6.0 O -
) O +
mu O +
g: O -
( O -
2.0 O -
- O -
6.0 O -
) O -
*10 O +
to O +
the O +
power O +
of O +
[ O -
6 O -
] O -
cfu O -
; O +
and O +
the O +
antibacterial O +
agent O +
can O +
be O +
used O +
for O +
inhibiting O +
and O +
killing O +
staphylococcus O +
aurous O -
, O +
vibrio O -
, O +
escherichia O +
coli O -
, O +
salmonella O -
, O +
proteus O +
bacterial O +
and O +
fusarium O -
, O +
etc O -
. O +

The O +
antibacterial O +
agent O +
provided O +
by O +
the O +
invention O +
has O +
the O +
function O +
of O +
inhibiting O +
the O +
quorum O +
sensing O +
molecules O +
by O +
the O +
bacillus O +
subtilis O +
for O +
the O +
first O +
time O -
, O +
has O +
a O +
synergistic O +
effect O +
together O +
with O +
the O +
tetracycline O -
, O +
greatly O +
improves O +
the O +
performance O +
of O +
the O +
antibacterial O +
agent O +
for O +
killing O +
bacteria O -
, O +
obviously O +
lowers O +
the O +
threshold O +
value O +
of O +
the O +
efficient O +
dosage O +
of O +
the O +
tetracycline O +
and O +
prevents O +
the O +
tolerance O +
during O +
the O +
antibacterial O +
process O -
; O +
the O +
antibacterial O +
agent O +
also O +
has O +
effective O +
antibacterial O +
effect O -
, O +
less O +
side O +
effect O +
to O +
the O +
environment O +
and O +
less O +
toxic O +
side O +
effect O -
. O +

RGD O +
peptide O -
- O -
epimedium O +
flavone O +
combination O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
an O +
RGD O +
peptide O -
- O -
epimedium O +
flavone O +
combination O +
synthesized O +
by O +
combining O +
two O +
structural O +
units O +
of O +
RGD O +
peptides O +
and O +
epimedium O +
flavone O +
which O +
have O +
pharmacological O +
activities O +
of O +
different O +
action O +
mechanisms O +
on O +
osseous O +
metabolic O +
diseases O -
, O +
and O +
also O +
provides O +
a O +
synthesis O +
method O +
thereof O -
. O +

The O +
compound O +
of O +
the O +
invention O +
has O +
two O +
receptor O +
combining O +
sites O +
and O +
simultaneously O +
has O +
the O +
capability O +
of O +
combining O +
estrogen O +
receptors O +
of O +
icaritin O +
and O +
the O +
capability O +
of O +
combining O +
integrins B-Gene +
alphaVbeta3 I-Gene +
of O +
RGD O -
, O +
and O +
the O +
capabilities O +
of O +
combining O +
the O +
two O +
different O +
receptors O +
can O +
produce O +
a O +
synergistic O +
effect O +
to O +
greatly O +
improve O +
the O +
curative O +
activity O +
of O +
the O +
medicament O +
on O +
osteoporosis O +
and O +
osseous O +
metabolic O +
diseases O -
. O +

The O +
synthesis O +
method O +
has O +
the O +
advantages O +
of O +
high O +
yield O -
, O +
high O +
synthesis O +
speed O +
and O +
easy O +
purification O +
of O +
products O -
. O +

Inhibitors O +
for O +
matrix B-Gene +
metalloproteinases I-Gene -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
their O +
uses O +
Inhibitors O +
for O +
matrix B-Gene +
metalloproteinases I-Gene -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
their O +
uses O -
. O +

The O +
inhibitors O +
for O +
matrix B-Gene +
metalloproteinases I-Gene +
have O +
the O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
W O -
, O +
X1 O -
, O +
X2 O -
, O +
R1 O -
, O +
R2 O +
are O +
as O +
defined O +
in O +
the O +
description O -
. O +

They O +
are O +
useful O +
for O +
the O +
prevention O +
or O +
treatment O +
of O +
diseases O +
regulated O +
by O +
matrix B-Gene +
metalloproteinases I-Gene -
, O +
in O +
particular O +
corneal O +
ulceration O -
, O +
pulmonary O +
emphysema O +
or O +
dermal O +
ulceration O +
resulted O +
from O +
chemical O +
injury O -
, O +
or O +
pulmonary O +
emphysema O +
caused O +
by O +
smoking O +
or O +
drowning O -
. O +

Protecting O +
colloid O +
for O +
gastroenteric O +
mucosa O +
The O +
invention O +
relates O +
to O +
protecting O +
colloid O +
for O +
gastroenteric O +
mucosa O -
, O +
belonging O +
to O +
the O +
field O +
of O +
biomedical O +
preparation O +
and O +
comprising O +
a O +
collagenous O +
substance O -
, O +
an O +
acidifying O +
or O +
alkalizing O +
agent O -
, O +
a O +
cross O -
- O -
linking O +
agent O +
and O +
an O +
adhesive O +
based O +
on O +
the O +
weight O +
ratio O +
of O +
1:0.01 O -
- O -
0.3:0.1 O -
- O -
0.5 O -
, O +
wherein O +
the O +
dosage O +
of O +
the O +
acidifying O +
or O +
alkalizing O +
agent O +
is O +
proper O +
when O +
the O +
pH O +
value O +
is O +
regulated O +
to O +
6.5 O -
- O -
8.5 O -
. O +

Under O +
the O +
action O +
of O +
gastric O +
acid O -
, O +
the O +
cross O -
- O -
linking O +
agent O +
in O +
the O +
protecting O +
colloid O +
can O +
be O +
released O +
so O +
as O +
to O +
form O +
a O +
colloid O +
membrane O +
on O +
the O +
surface O +
of O +
ulcer O -
, O +
avoid O +
the O +
gastroenteric O +
mucosa O +
from O +
being O +
digested O +
by O +
gastric O +
acid O +
and O +
pepsase O +
and O +
promote O +
healing O +
of O +
the O +
ulcer O -
. O +

Animal O +
tests O +
show O +
that O +
the O +
protecting O +
colloid O +
can O +
greatly O +
lower O +
the O +
ulcer O +
formation O +
caused O +
by O +
absolute O +
ethyl O +
alcohol O +
and O +
hydrochloric O +
acid O -
, O +
inhibit O +
ulcer O +
formation O +
and O +
have O +
a O +
protecting O +
effect O +
on O +
injury O +
of O +
the O +
mice O +
gastroenteric O +
mucosa O +
caused O +
by O +
absolute O +
ethyl O +
alcohol O +
and O +
hydrochloric O +
acid O -
. O +

Therefore O -
, O +
the O +
protecting O +
colloid O +
is O +
used O +
for O +
protecting O +
and O +
curing O +
gastroenteric O +
mucosa O +
ulcer O +
for O +
patients O -
. O +

Aloe O +
oculentum O +
and O +
preparation O +
method O +
The O +
invention O +
relates O +
to O +
aloe O +
oculentum O +
and O +
a O +
preparation O +
method O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
eyedrops O -
. O +

The O +
aloe O +
oculentum O +
is O +
characterized O +
by O +
comprising O +
the O +
following O +
medicaments O +
and O +
raw O +
materials O +
in O +
part O +
by O +
weight O -
: O +
80 O +
to O +
90 O +
parts O +
of O +
aloe O +
gel O -
, O +
1 O +
to O +
5 O +
parts O +
of O +
aloin O -
, O +
0.1 O +
to O +
1 O +
part O +
of O +
alomycin O -
, O +
0.1 O +
to O +
0.3 O +
part O +
of O +
carbomer O -
, O +
0.1 O +
to O +
0.2 O +
part O +
of O +
sodium O +
hyaluronate O -
, O +
0.1 O +
to O +
0.2 O +
part O +
of O +
anthraquinone O +
compounds O -
, O +
0.1 O +
to O +
0.2 O +
part O +
of O +
cinnamate O +
and O +
0.2 O +
to O +
0.5 O +
part O +
of O +
free O +
amino O +
acid O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
extracting O +
the O +
aloe O +
gel O +
from O +
aloe O +
barbadensis O +
by O +
adopting O +
a O +
freezing O +
stabilization O +
method O -
, O +
and O +
converting O +
the O +
aloe O +
gel O +
into O +
aloe O +
gel O +
powder O -
; O +
and O +
mixing O +
the O +
aloe O +
gel O +
powder O +
and O +
water O +
for O +
injection O +
under O +
the O +
acidic O +
condition O +
or O +
neutral O +
condition O -
, O +
of O +
which O +
the O +
PH O +
is O +
between O +
5.5 O +
and O +
7.5 O -
, O +
mixing O +
the O +
mixture O +
and O +
the O +
aloin O -
, O +
the O +
alomycin O -
, O +
the O +
carbomer O -
, O +
the O +
sodium O +
hyaluronate O -
, O +
the O +
anthraquinone O +
compounds O -
, O +
the O +
cinnamate O +
and O +
the O +
free O +
amino O +
acid O -
, O +
stirring O +
uniformly O -
, O +
regulating O +
the O +
pH O +
value O +
to O +
be O +
neutral O -
, O +
and O +
subpackaging O +
and O +
disinfecting O -
. O +

The O +
aloe O +
oculentum O +
can O +
treat O +
eye O +
diseases O +
such O +
as O +
pterygium O -
, O +
conjunctivochalasis O -
, O +
corneal O +
nebula O -
, O +
chronic O +
dacryocystitis O -
, O +
eye O +
itching O -
, O +
xerophthalmia O +
and O +
the O +
like O -
. O +

Hydroxyl O +
whole O -
- O -
protection O +
didecyl O +
quaternary O +
ammonium O +
with O +
anti O -
- O -
tumor O +
activity O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
synthesis O +
of O +
an O +
emodin O +
derivant O +
with O +
an O +
anti O -
- O -
tumor O +
function O -
, O +
in O +
particular O +
to O +
a O +
hydroxyl O +
whole O -
- O -
protection O +
didecyl O +
quaternary O +
ammonium O +
with O +
anti O -
- O -
tumor O +
activity O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
didecyl O +
quaternary O +
ammonium O +
is O +
decyldimethylchlorosilane- O -
[ O -
2- O -
( O -
4,5,7-trimethoxy-9,10-anthraquinonyl O -
) O -
methyl O -
] O -
. O +

The O +
preparation O +
method O +
is O +
characterized O +
by O +
taking O +
emodin O +
as O +
a O +
raw O +
material O +
to O +
carry O +
out O +
a O +
series O +
of O +
synthetic O +
reaction O -
. O +

The O +
emodin O +
derivant O +
of O +
the O +
invention O +
has O +
proliferation O +
inhibition O +
action O +
of O +
different O +
degrees O +
on O +
liver O +
cancer O +
HepG2 O -
, O +
gastric O +
cancer O +
BGC O -
, O +
neuroma O +
SH O -
- O -
SY5Y O -
, O +
gastric O +
cancer O +
AGS O -
, O +
cervical O +
cancer O +
Hela O +
and O +
the O +
like O +
as O +
well O +
as O +
normal O +
human O +
embryonic O +
lung O +
fibroblast O +
HELP O +
and O +
can O +
be O +
used O +
for O +
preparing O +
medicines O +
for O +
treating O +
cancers O -
. O +

Irinotecan O +
nano O +
circulating O +
liposome O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
novel O +
Irinotecan O +
carrier O +
which O +
is O +
circulating O +
nano O +
liposome O +
and O +
a O +
novel O +
preparation O +
method O +
thereof O +
which O +
is O +
an O +
ethanol O +
injection O -
- O -
ammonium O +
sulfate O +
active O +
medicament O -
- O -
loading O +
method O -
. O +

The O +
preparation O +
process O +
comprises O -
: O +
a O -
, O +
dissolving O +
a O +
lipid O +
material O +
for O +
forming O +
the O +
liposome O +
in O +
ethanol O +
to O +
prepare O +
solution O -
; O +
b O -
, O +
dissolving O +
a O +
polyethylene O +
glycol O +
compound O +
in O +
solution O +
of O +
ammonium O +
sulfate O +
to O +
prepare O +
a O +
hydration O +
medium O -
; O +
c O -
, O +
injecting O +
solution O +
obtained O +
by O +
the O +
step O +
a O +
into O +
the O +
hydration O +
medium O +
obtained O +
by O +
the O +
step O +
b O +
with O +
stirring O +
in O +
a O +
water O +
bath O -
, O +
stirring O +
at O +
a O +
constant O +
temperature O +
for O +
a O +
certain O +
period O +
under O +
a O +
condition O +
of O +
introducing O +
N2 O +
to O +
form O +
circulating O +
blank O +
liposome O -
; O +
d O -
, O +
dialyzing O +
the O +
blank O +
liposome O +
obtained O +
by O +
the O +
step O +
c O +
in O +
physiological O +
saline O -
; O +
and O +
e O -
, O +
adding O +
solution O +
of O +
Irinotecan O +
into O +
the O +
blank O +
liposome O -
, O +
regulating O +
the O +
pH O +
value O +
of O +
an O +
external O +
phase O -
, O +
and O +
performing O +
incubation O +
and O +
medicament O +
loading O +
at O +
a O +
certain O +
temperature O +
to O +
obtain O +
the O +
Irinotecan O +
circulating O +
nano O +
liposome O -
. O +

The O +
process O +
is O +
simple O -
, O +
the O +
particle O +
size O +
is O +
80 O +
to O +
150 O +
nanometers O -
, O +
the O +
coating O +
rate O +
is O +
over O +
95 O +
percent O -
, O +
the O +
sterile O +
preparation O +
can O +
be O +
obtained O +
easily O -
, O +
and O +
an O +
industrialization O +
requirement O +
is O +
met O -
. O +

Intranasal O +
administration O +
encapsulated O +
based O +
on O +
polyelectrolyte O +
capsule O +
A O +
micron O +
and O +
nanometer O +
encapsulated O +
technology O +
synthesized O +
by O +
step O -
- O -
by O -
- O -
step O +
shells O +
can O +
be O +
applied O +
for O +
intranasal O +
and O +
pulmonary O +
administration O -
. O +

Liquid O -
, O +
gas O +
or O +
solid O +
encapsulation O +
can O +
form O +
an O +
aerosol O +
in O +
spray O +
treatment O -
. O +

Different O +
shell O +
compositions O +
create O +
stability O -
, O +
compatibility O -
, O +
and O +
degradation O +
and O +
releasing O +
attributes O -
. O +

A O +
plurality O +
of O +
substances O +
comprising O +
the O +
compound O +
widely O +
used O +
for O +
intranasal O +
administration O +
can O +
be O +
encapsulated O -
, O +
or O +
are O +
administrated O +
through O +
spray O +
capsules O -
. O +

Medicament O +
for O +
oral O +
administration O +
for O +
treating O +
alcoholic O +
fatty O +
liver O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
medicament O +
for O +
oral O +
administration O +
for O +
treating O +
alcoholic O +
fatty O +
liver O +
and O +
a O +
preparation O +
method O +
thereof O +
and O +
belongs O +
to O +
the O +
field O +
of O +
medicaments O -
. O +

The O +
orally O +
taken O +
medicament O +
is O +
prepared O +
from O +
routine O +
auxiliary O +
materials O +
and O +
the O +
following O +
raw O +
medicinal O +
materials O +
in O +
part O +
by O +
weight O -
: O +
80 O +
to O +
120 O +
parts O +
of O +
scutellaria O +
total O +
flavonoid O -
, O +
60 O +
to O +
100 O +
parts O +
of O +
paeonia O +
saponins O -
, O +
60 O +
to O +
120 O +
parts O +
of O +
liquritin O +
and O +
proper O +
amount O +
of O +
auxiliary O +
materials O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
preparing O +
the O +
scutellaria O +
total O +
flavonoid O +
by O +
performing O +
water O +
extraction O +
on O +
scutellaria O -
; O +
preparing O +
the O +
paeonia O +
saponins O +
by O +
performing O +
water O +
extraction O +
on O +
paeonia O -
; O +
preparing O +
the O +
liquritin O +
by O +
performing O +
percolation O +
on O +
liquorice O -
; O +
and O +
preparing O +
the O +
general O +
formulation O +
by O +
blending O +
the O +
extracts O +
and O +
the O +
auxiliary O +
materials O -
, O +
and O +
obtaining O +
the O +
medicament O -
. O +

The O +
medicament O +
for O +
oral O +
administration O +
for O +
treating O +
alcoholic O +
fatty O +
liver O +
provided O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
high O +
active O +
ingredient O +
content O -
, O +
stable O +
quality O -
, O +
safety O -
, O +
clear O +
treatment O +
effect O +
and O +
convenience O -
. O +

Compared O +
with O +
the O +
traditional O +
medicaments O -
, O +
the O +
orally O +
taken O +
medicament O +
greatly O +
reduces O +
the O +
toxic O +
and O +
side O +
effects O +
of O +
the O +
medicaments O +
and O +
obviously O +
improves O +
the O +
treatment O +
effect O -
. O +

Method O +
for O +
establishing O +
experimental O +
model O +
for O +
subclinical O +
hepatic O +
encephalopathy O +
( O -
SHE O -
) O +
The O +
invention O +
belongs O +
to O +
the O +
field O +
of O +
biomedicine O +
and O +
particularly O +
relates O +
to O +
a O +
method O +
for O +
establishing O +
an O +
experimental O +
model O +
for O +
subclinical O +
hepatic O +
encephalopathy O +
( O -
SHE O -
) O -
. O +

In O +
the O +
method O +
of O +
the O +
invention O -
, O +
an O +
experimental O +
rat O +
liver O +
cirrhosis O +
model O +
caused O +
by O +
composite O +
factors O +
such O +
as O +
high O +
fat O +
and O +
low O +
protein O +
of O +
carbon O +
tetrachloride O +
is O +
subjected O +
to O +
learning O -
, O +
recall O +
test O +
and O +
evoked O +
potential O +
test O +
of O +
a O +
nervous O +
system O +
and O +
a O +
brain O +
function O +
and O +
the O +
learning O -
, O +
memory O +
and O +
spatial O +
cognition O +
impairment O +
and O +
nerve O +
electrophysiology O +
test O +
abnormity O +
of O +
the O +
model O +
are O +
monitored O -
, O +
so O +
that O +
the O +
method O +
achieves O +
statistical O +
significance O +
compared O +
with O +
the O +
normal O +
comparison O +
group O +
and O +
a O +
relatively O +
ideal O +
SHE O +
animal O +
model O +
is O +
established O -
. O +

An O +
established O +
experiment O +
animal O +
model O +
provides O +
a O +
platform O +
for O +
the O +
research O -
, O +
diagnosis O +
and O +
treatment O +
of O +
SHE O +
and O +
has O +
high O +
clinically O +
practical O +
meaning O +
and O +
value O -
. O +

Compound O +
tincture O +
for O +
treating O +
external O +
acoustic O +
meatus O +
fungal O +
infection O +
The O +
invention O +
discloses O +
a O +
compound O +
tincture O +
for O +
treating O +
external O +
acoustic O +
meatus O +
fungal O +
infection O -
. O +

The O +
compound O +
tincture O +
is O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
in O +
part O +
by O +
weight O -
: O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
densefruit O +
pittany O +
root O -
- O -
bark O -
, O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
bark O +
of O +
Chinese O +
redbud O -
, O +
1.0 O +
to O +
3.5 O +
parts O +
of O +
palemane O +
prunella O -
, O +
1.0 O +
to O +
3.5 O +
parts O +
of O +
Chinese O +
honeylocust O +
spine O -
, O +
2.5 O +
to O +
5.0 O +
parts O +
of O +
angelica O +
dahurica O -
, O +
2.5 O +
to O +
5.0 O +
parts O +
of O +
platycodon O +
root O -
, O +
1.0 O +
to O +
3.5 O +
parts O +
of O +
safflower O -
, O +
1.0 O +
to O +
3.5 O +
parts O +
of O +
szechuan O +
lovage O +
rhizome O -
, O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
natural O +
indigo O -
, O +
2.5 O +
to O +
5.0 O +
parts O +
of O +
wild O +
chrysanthemum O -
, O +
2.5 O +
to O +
5.0 O +
parts O +
of O +
dandelion O -
, O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
borax O -
, O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
borneol O -
, O +
1.5 O +
to O +
5.5 O +
parts O +
of O +
peppermint O +
oil O +
and O +
100 O +
parts O +
of O +
ethanol O -
. O +

The O +
inventor O +
studies O +
assiduously O +
under O +
the O +
condition O +
that O +
the O +
prior O +
art O +
is O +
not O +
perfect O -
. O +

The O +
compound O +
tincture O +
has O +
unique O +
therapeutic O +
effects O +
of O +
dispelling O +
wind O +
and O +
removing O +
dampness O -
, O +
detoxifying O +
and O +
relieving O +
itching O -
, O +
softening O +
and O +
dilating O +
blood O +
vessels O -
, O +
promoting O +
regeneration O +
of O +
necrotic O +
nerve O +
cells O +
and O +
treating O +
external O +
acoustic O +
meatus O +
mycosis O -
, O +
relieves O +
the O +
pain O +
of O +
patients O +
and O +
does O +
not O +
have O +
toxic O +
or O +
side O +
effect O -
. O +

Microbial O +
feed O +
additive O +
for O +
treating O +
piglet O +
yellow O +
and O +
white O +
dysentery O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
microbial O +
feed O +
additive O +
for O +
treating O +
piglet O +
yellow O +
and O +
white O +
dysentery O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
additive O +
is O +
prepared O +
from O +
the O +
main O +
components O +
of O +
bacillus O +
subtilis O +
and O +
saccharomyces O +
cerevisiae O +
which O +
are O +
mixed O +
with O +
baking O +
soda O -
, O +
xylo O -
- O -
oligosaccharides O -
, O +
vitamins O -
, O +
vitamin O +
complex O -
, O +
glucose O +
and O +
the O +
like O +
according O +
to O +
certain O +
proportions O -
. O +

The O +
microbial O +
feed O +
additive O +
has O +
the O +
following O +
advantages O +
that O -
: O +
the O +
active O +
substances O +
such O +
as O +
subtilin O -
, O +
polymyxin O -
, O +
nystatin O -
, O +
gramicidin O +
and O +
the O +
like O +
generated O +
in O +
the O +
growing O +
process O +
of O +
the O +
bacillus O +
subtilis O +
have O +
obvious O +
inhibitionto O +
pathogens O +
or O +
conditioned O +
pathogens O +
of O +
endogenous O +
infection O -
; O +
cell O +
wall O +
polysaccharides O +
of O +
the O +
saccharomyces O +
cerevisiae O +
and O +
a O +
great O +
amount O +
of O +
nucleotides O +
and O +
bioactive O +
peptides O +
generated O +
in O +
the O +
growing O +
process O +
of O +
the O +
saccharomyces O +
cerevisiae O +
can O +
improve O +
the O +
immunity O +
of O +
animals O -
, O +
and O +
a O +
compound O +
taste O +
substance O +
is O +
also O +
generated O +
in O +
the O +
growing O +
process O +
of O +
the O +
saccharomyces O +
cerevisiae O +
to O +
promote O +
animal O +
feeding O -
; O +
the O +
baking O +
soda O +
replenishes O +
electrolyte O -
; O +
the O +
xylo O -
- O -
oligosaccharides O +
selectively O +
proliferate O +
beneficial O +
bacteria O +
such O +
as O +
bifidobacterium O +
and O +
the O +
like O -
; O +
the O +
vitamins O +
have O +
the O +
effects O +
of O +
resisting O +
stress O +
and O +
replenishing O +
nutrition O -
; O +
and O +
the O +
glucose O +
has O +
the O +
effects O +
of O +
supplying O +
energy O +
and O +
promoting O +
healing O -
. O +

Solution O +
with O +
effect O +
of O +
repairing O +
exercise O -
- O -
induced O +
skeletal O +
muscle O +
microdamage O +
The O +
invention O +
discloses O +
solution O +
with O +
effect O +
of O +
repairing O +
exercise O -
- O -
induced O +
skeletal O +
muscle O +
microdamage O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
preparation O +
and O +
application O +
of O +
health O +
care O +
products O -
. O +

One O +
liter O +
of O +
solution O +
comprises O +
200 O +
to O +
250 O +
g O +
of O +
purslane O +
herb O +
extract O +
and O +
50 O +
g O +
of O +
brown O +
sugar O -
. O +

The O +
solution O +
is O +
prepared O +
by O +
the O +
following O +
steps O +
of O -
: O +
1 O -
, O +
preparing O +
solution O +
matrix O -
: O +
adding O +
500 O +
g O +
of O +
brown O +
sugar O +
into O +
one O +
liter O +
of O +
water O -
, O +
quickly O +
stirring O +
uniformly O +
and O +
heating O +
until O +
the O +
brown O +
sugar O +
is O +
completely O +
dissolved O +
to O +
obtain O +
the O +
matrix O +
solution O -
; O +
and O +
2 O -
, O +
adding O +
200 O +
to O +
250 O +
g O +
of O +
purslane O +
herb O +
extract O +
into O +
the O +
one O +
liter O +
of O +
matrix O +
solution O -
, O +
quickly O +
stirring O +
uniformly O +
and O +
heating O +
until O +
the O +
mixture O +
is O +
boiling O +
to O +
ensure O +
that O +
the O +
purslane O +
herb O +
extract O +
is O +
completely O +
dissolved O +
to O +
obtain O +
solution O +
A O +
or O +
solution O +
B O -
, O +
and O +
cooling O -
, O +
filming O +
and O +
packaging O -
. O +

The O +
solution O +
is O +
edible O -
, O +
does O +
not O +
have O +
toxic O +
or O +
side O +
effect O -
, O +
has O +
the O +
effect O +
of O +
chills O +
and O +
fever O +
complementation O -
, O +
and O +
can O +
be O +
taken O +
for O +
a O +
long O +
time O -
. O +

The O +
solution O +
has O +
an O +
extremely O +
simple O +
formula O -
, O +
an O +
extremely O +
simple O +
preparation O +
method O -
, O +
low O +
cost O -
, O +
and O +
good O +
mouthfeel O -
, O +
has O +
the O +
exact O +
effect O +
of O +
repairing O +
exercise O -
- O -
induced O +
skeletal O +
muscle O +
microdamage O +
and O +
has O +
ideal O +
effect O +
of O +
treating O +
accompanied O +
delayed O +
muscle O +
soreness O +
and O +
wide O +
market O +
application O +
prospect O -
. O +

Method O +
for O +
preparing O +
Cefquinome O +
sulfate O +
suspension O +
injection O +
The O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preparing O +
an O +
antibacterial O +
agent O +
suspension O -
, O +
in O +
particular O +
to O +
a O +
method O +
for O +
preparing O +
a O +
Cefquinome O +
sulfate O +
suspension O +
injection O -
. O +

Taking O +
5000ml O +
of O +
Cefquinome O +
sulfate O +
suspension O +
injection O +
as O +
reference O -
, O +
the O +
Cefquinome O +
sulfate O +
suspension O +
injection O +
contains O +
the O +
following O +
components O -
: O +
1 O -
- O -
2.5 O +
percent O +
( O -
W O -
/ O -
V O -
) O +
of O +
Cefquinome O +
sulfate O +
micro O +
powder O -
, O +
0.15 O -
- O -
0.3 O +
percent O +
( O -
W O -
/ O -
V O -
) O +
of O +
Vitamin O +
E O +
and O +
the O +
balance O +
of O +
esters O +
solvent O +
or O +
injection O +
oil O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
heating O +
the O +
esters O +
solvent O +
or O +
the O +
injection O +
oil O +
to O +
115 O -
- O -
125 O +
DEG O +
C O +
in O +
a O +
high O -
- O -
shear O +
homogenizer O -
; O +
carrying O +
out O +
heat O +
preservation O +
on O +
the O +
heated O +
esters O +
solvent O +
or O +
injection O +
oil O +
for O +
4 O -
- O -
6 O +
hours O -
; O +
cooling O +
to O +
below O +
40 O +
DEG O +
C O -
; O +
adding O +
sterilized O +
Cefquinome O +
sulfate O +
raw O +
materials O -
; O +
dispersing O +
at O +
the O +
rotating O +
speed O +
of O +
5000 O -
- O -
8000rpm O +
( O -
Revolutions O +
Per O +
Minute O -
) O -
; O +
homogenizing O +
by O +
using O +
a O +
high O -
- O -
pressure O +
homogenize O +
at O +
the O +
working O +
pressure O +
of O +
1200bar O +
after O +
the O +
Cefquinome O +
sulfate O +
raw O +
materials O +
are O +
evenly O +
dispersed O -
; O +
encapsuling O -
; O +
and O +
irradiating O +
with O +
cobalt60 O +
for O +
sterilization O +
for O +
5 O -
- O -
6 O +
hours O -
. O +

The O +
Cefquinome O +
sulfate O +
suspension O +
injection O +
prepared O +
by O +
the O +
invention O +
has O +
high O +
safety O -
, O +
good O +
curative O +
effect O +
and O +
small O +
stimulation O +
in O +
intramuscular O +
injection O -
. O +

Flake O +
and O +
pearl O +
nucleus O +
matching O +
treating O +
fluid O +
for O +
culturing O +
Pinctada O +
martensii O +
pearl O +
The O +
invention O +
relates O +
to O +
treating O +
fluid O +
for O +
culturing O +
a O +
Pinctada O +
martensii O +
seawater O +
pearl O +
and O +
a O +
method O +
for O +
culturing O +
the O +
seawater O +
pearl O -
. O +

The O +
treating O +
fluid O +
is O +
obtained O +
by O +
the O +
steps O +
of O +
weighing O +
raw O +
materials O +
including O +
aureomycin O -
, O +
polyvinylpyrrolidone O -
, O +
taurine O -
, O +
vitamin O +
C O +
and O +
the O +
like O +
and O +
then O +
dissolving O +
the O +
raw O +
materials O +
into O +
sodium O +
alga O +
acid O +
of O +
physiological O +
saline O +
solution O +
with O +
the O +
weight O +
contentof O +
0.7 O -
- O -
1 O -
% O -
. O +

In O +
the O +
process O +
of O +
culturing O +
the O +
seawater O +
pearls O -
, O +
flake O +
shells O +
and O +
shell O +
pearl O +
nuclei O +
are O +
sliced O +
from O +
selected O +
healthy O +
nacres O +
which O +
are O +
not O +
damaged O +
by O +
diseases O +
and O +
insects O +
and O +
are O +
soaked O +
inthe O +
treating O +
fluid O +
and O +
then O +
are O +
implanted O +
into O +
the O +
pearl O +
culturing O +
bags O +
of O +
the O +
nacres O -
. O +

The O +
nucleus O +
implanting O +
operation O +
procedure O +
is O +
carried O +
out O +
according O +
to O +
the O +
traditional O +
conventional O +
means O -
; O +
the O +
flake O +
shells O +
and O +
shell O +
pearl O +
nuclei O +
are O +
transferred O +
to O +
a O +
sea O +
area O +
for O +
hanging O +
culture O +
after O +
20 O -
- O -
25 O +
days O +
of O +
recreation O +
period O -
. O +

The O +
seawater O +
pearls O +
cultured O +
by O +
the O +
treating O +
fluid O +
have O +
thick O +
pearl O +
layers O -
, O +
high O +
survival O +
rate O +
and O +
high O +
high O -
- O -
quality O +
pearl O +
rate O -
. O +

The O +
invention O +
reduces O +
the O +
death O +
rate O +
and O +
the O +
nucleus O +
splitting O +
rate O +
of O +
the O +
cultured O +
pearl O +
and O +
greatly O +
improves O +
the O +
yield O +
and O +
the O +
nucleus O +
reservation O +
rate O +
of O +
the O +
cultured O +
pearl O +
and O +
the O +
economic O +
benefits O +
of O +
culture O +
production O -
. O +

Compound O +
apramycin O +
sulfate O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
apramycin O +
sulfate O +
injection O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
compound O +
apramycin O +
sulfate O +
injection O +
comprises O +
the O +
following O +
components O +
of O -
: O +
5 O -
- O -
110kg O -
/ O -
L O +
of O +
apramycin O +
sulfate O -
, O +
10 O -
- O -
150kg O -
/ O -
L O +
of O +
mequindox O -
, O +
10 O -
- O -
400kg O -
/ O -
L O +
of O +
soldium O +
salicylate O -
, O +
1 O -
- O -
20kg O -
/ O -
L O +
of O +
atropine O +
sulfate O +
and O +
1 O -
- O -
20kg O -
/ O -
L O +
of O +
chlortrimeton O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
( O -
1 O -
) O +
adding O +
100 O -
- O -
400kg O -
/ O -
L O +
of O +
soldium O +
salicylate O +
into O +
a O +
part O +
of O +
water O +
for O +
injection O -
, O +
then O +
adding O +
10 O -
- O -
150kg O -
/ O -
L O +
of O +
mequindox O -
, O +
and O +
stirring O +
for O +
10 O -
- O -
20min O +
until O +
a O +
solution O +
is O +
clarified O -
; O +
( O -
2 O -
) O +
taking O +
a O +
part O +
of O +
water O +
for O +
injection O -
, O +
sequentially O +
adding O +
5 O -
- O -
110kg O -
/ O -
L O +
of O +
apramycin O +
sulfate O -
, O +
1 O -
- O -
20kg O -
/ O -
L O +
of O +
atropine O +
sulfate O +
and O +
1 O -
- O -
20kg O -
/ O -
L O +
of O +
chlortrimeton O -
, O +
stirring O +
and O +
dissolving O -
; O +
and O +
( O -
3 O -
) O +
combining O +
the O +
solution O +
prepared O +
in O +
steps O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O -
, O +
then O +
adding O +
the O +
water O +
for O +
injection O +
to O +
a O +
marked O +
volume O -
, O +
uniformly O +
stirring O -
, O +
keeping O +
for O +
15 O -
- O -
20min O -
, O +
and O +
clarifying O +
liquid O +
medicine O +
to O +
obtain O +
the O +
compound O +
apramycin O +
sulfate O +
injection O -
. O +

In O +
the O +
invention O -
, O +
the O +
compound O +
preparation O +
consisting O +
of O +
the O +
apramycin O +
sulfate O +
and O +
the O +
mequindox O +
has O +
very O +
obvious O +
treatment O +
effect O +
on O +
pig O +
bacterial O +
diarrhea O +
and O +
can O +
effectively O +
relieve O +
stress O +
reaction O +
of O +
a O +
suffering O +
animal O +
body O -
; O +
experiments O +
show O +
that O +
the O +
combination O +
use O +
of O +
the O +
apramycin O +
sulfate O -
, O +
the O +
mequindox O +
and O +
the O +
atropine O +
sulfate O +
can O +
remarkably O +
enhance O +
a O +
curative O +
effect O -
; O +
and O +
the O +
compound O +
has O +
wide O +
clinical O +
application O +
range O -
, O +
and O +
can O +
be O +
widely O +
used O +
for O +
treating O +
bacterial O +
diarrhea O +
of O +
livestock O -
, O +
such O +
as O +
pig O -
, O +
cattle O -
, O +
sheep O -
, O +
and O +
the O +
like O -
, O +
enhance O +
the O +
survival O +
rate O +
and O +
increase O +
the O +
body O +
weights O +
of O +
the O +
pig O -
, O +
the O +
cattle O +
and O +
the O +
sheep O -
. O +

Application O +
of O +
antrodia O +
camphorata O +
cyclohexenone O +
compound O +
in O +
preparing O +
medicine O +
for O +
inhibiting O +
growth O +
of O +
pancreatic O +
cancer O +
tumor O +
cells O +
The O +
invention O +
relates O +
to O +
a O +
new O +
purpose O +
of O +
a O +
compound O -
. O +

In O +
the O +
invention O -
, O +
antrodia O +
camphorata O +
extract O +
is O +
separated O +
and O +
purified O +
to O +
obtain O +
4-hydroxy-2,3-dimethoxy-6-methy-5 O -
( O -
3,7,11-trimethyl O -
- O -
dodeca-2,6,10-trienyl O -
) O -
-cyclohex-2-enone O -
. O +

The O +
cyclohexenone O +
compound O +
can O +
be O +
used O +
for O +
inhibiting O +
growth O +
of O +
pancreatic O +
cancer O +
tumor O +
cells O +
and O +
simultaneously O +
can O +
be O +
used O +
for O +
pharmaceutical O +
compositions O +
for O +
inhibiting O +
growth O +
of O +
pancreatic O +
cancer O +
tumor O +
cells O -
. O +

2,6-dichloro-5-fluoronicotinoyl O +
fluorobenzene O +
salicylamide O +
compound O +
as O +
well O +
as O +
preparation O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
a O +
2,6-dichloro-5-fluoronicotinoyl O +
fluorobenzene O +
salicylamide O +
compound O -
, O +
and O +
discloses O +
an O +
application O +
of O +
the O +
2,6-dichloro-5-fluoronicotinoyl O +
fluorobenzene O +
salicylamide O +
compound O +
in O +
preparing O +
anti O -
- O -
tumor O +
medicaments O -
, O +
in O +
particular O +
to O +
an O +
application O +
of O +
the O +
2,6-dichloro-5-fluoronicotinoyl O +
fluorobenzene O +
salicylamide O +
compound O +
in O +
preparing O +
anti O -
- O -
endometrial O +
cancer O +
or O +
anti O -
- O -
lung O +
cancermedicaments O -
. O +

The O +
invention O +
has O +
the O +
main O +
beneficial O +
effects O +
that O -
: O +
( O -
1 O -
) O +
the O +
method O +
for O +
preparing O +
the O +
2,6-dichloro-5-fluoronicotinoyl O +
fluorobenzene O +
salicylamide O +
compound O +
is O +
provided O -
; O +
( O -
2 O -
) O +
the O +
novel O +
anti O -
- O -
tumor O +
medicament O +
with O +
remarkable O +
anti O -
- O -
tumor O +
activity O +
is O +
provided O -
, O +
a O +
research O +
foundation O +
is O +
laid O +
for O +
novel O +
medicament O +
screening O -
, O +
and O +
the O +
compound O +
has O +
great O +
application O +
prospect O -
; O +
and O +
( O -
3 O -
) O +
the O +
preparation O +
process O +
is O +
simple O -
, O +
and O +
is O +
advantageous O +
to O +
industrial O +
production O -
. O +

Postoperative O +
anti O -
- O -
adhesion O +
medicament O +
The O +
invention O +
relates O +
to O +
a O +
postoperative O +
anti O -
- O -
adhesion O +
medicament O +
capable O +
of O +
effectively O +
preventing O +
postoperative O +
adhesion O -
, O +
lubricating O +
tissues O +
and O +
inhibiting O +
inflammation O -
. O +

The O +
technical O +
scheme O +
is O +
that O -
: O +
the O +
postoperative O +
anti O -
- O -
adhesion O +
medicament O +
consists O +
of O +
berberine O +
hydrochloride O -
, O +
dicynone O +
and O +
polyethylene O +
glycol O -
. O +

Tablet O +
capsule O +
with O +
roxithromycin O +
tablets O +
and O +
ambroxol O +
hydrochloride O +
tablets O +

The O +
invention O +
relates O +
to O +
an O +
oral O +
hard O +
capsule O -
, O +
in O +
particular O +
to O +
a O +
tablet O +
capsule O +
with O +
roxithromycin O +
tablets O +
and O +
ambroxol O +
hydrochloride O +
tablets O -
. O +

The O +
tablet O +
capsule O +
consists O +
of O +
a O +
capsule O +
and O +
tablets O +
in O +
the O +
capsule O -
, O +
wherein O +
the O +
capsule O +
comprises O +
an O +
upper O +
capsule O +
body O +
and O +
a O +
lower O +
capsule O +
body O -
, O +
and O +
at O +
least O +
one O +
tablet O +
of O +
which O +
the O +
active O +
ingredient O +
is O +
roxithromycin O +
and O +
at O +
least O +
one O +
tablet O +
of O +
which O +
the O +
active O +
ingredient O +
is O +
ambroxol O +
hydrochloride O +
are O +
filled O +
in O +
the O +
capsule O -
. O +

Because O +
the O +
active O +
ingredients O +
in O +
the O +
capsule O +
do O +
not O +
contact O -
, O +
chemical O +
changes O +
can O -
not O +
be O +
generated O +
between O +
the O +
ingredients O -
, O +
side O +
products O +
can O -
not O +
be O +
generated O -
, O +
and O +
the O +
stability O +
of O +
the O +
product O +
is O +
improved O -
, O +
degradation O +
products O +
generated O +
after O +
the O +
roxithromycin O +
and O +
the O +
ambroxol O +
hydrochloride O +
contact O +
are O +
reduced O +
particularly O -
. O +

In O +
addition O -
, O +
the O +
designs O +
of O +
cylindrical O +
tablets O +
and O +
different O +
colors O +
and O +
the O +
application O +
of O +
transparent O +
capsule O +
shells O +
are O +
adopted O -
, O +
and O +
the O +
product O +
of O +
the O +
invention O +
is O +
particularly O +
suitable O +
for O +
industrial O +
production O -
, O +
thereby O +
the O +
compliance O +
of O +
patients O +
is O +
enhanced O -
. O +

Meanwhile O -
, O +
the O +
active O +
ingredients O +
are O +
respectively O +
tabletted O -
, O +
thus O +
the O +
drug O +
assay O +
and O +
the O +
quality O +
control O +
are O +
easier O -
. O +

Chewable O +
tablet O +
of O +
calcium O +
carbonate O +
dimeticone O +
and O +
preparation O +
process O +
The O +
invention O +
discloses O +
a O +
chewable O +
tablet O +
of O +
calcium O +
carbonate O +
dimeticone O +
and O +
a O +
preparation O +
process O -
, O +
belonging O +
to O +
four O +
new O +
national O +
chemical O +
medicines O -
. O +

The O +
preparation O +
of O +
the O +
invention O +
is O +
prepared O +
from O +
the O +
following O +
main O +
components O -
: O +
calcium O +
carbonate O -
, O +
simethicone O -
, O +
siliciidoxydum O -
, O +
aspartame O -
, O +
essence O +
powder O -
, O +
mannite O -
, O +
corn O +
starch O -
, O +
low O -
- O -
substituted O +
hydroxypropyl O +
cellulose O +
and O +
magnesium O +
stearate O -
, O +
wherein O +
the O +
calcium O +
carbonate O +
as O +
the O +
main O +
content O +
has O +
stronger O +
acid O -
- O -
resisting O +
action O +
and O +
rapid O +
and O +
lasting O +
effects O -
, O +
and O +
the O +
simethicone O +
is O +
a O +
foam O +
suppressor O +
for O +
eliminating O +
gastrointestinal O +
tract O +
pneumatosis O -
. O +

The O +
preparation O +
is O +
used O +
for O +
treating O +
peptic O +
ulcers O +
including O +
stomach O +
and O +
duodenal O +
ulcer O +
and O +
easing O +
various O +
uncomfortable O +
symptoms O +
caused O +
by O +
hyperacidity O -
. O +

Chinese O +
and O +
Western O +
medicine O +
synthesized O +
preparation O +
for O +
treating O +
chronic O +
urticaria O +
The O +
invention O +
relates O +
to O +
a O +
Chinese O +
and O +
Western O +
medicine O +
synthesized O +
preparation O -
, O +
in O +
particular O +
to O +
the O +
Chinese O +
and O +
Western O +
medicine O +
synthesized O +
preparation O +
for O +
treating O +
chronic O +
urticaria O -
. O +

The O +
preparation O +
is O +
characterized O +
by O +
consisting O +
of O +
the O +
following O +
raw O +
materials O +
in O +
part O +
by O +
weight O -
: O +
10 O -
mg O +
of O +
antihistaminics O +
Loratadine O -
, O +
5 O -
g O +
of O +
divaricate O +
saposhnikovia O +
root O -
, O +
8 O -
g O +
of O +
belvedere O +
fruit O -
, O +
10 O -
g O +
of O +
astragalus O +
mongholicus O -
, O +
5 O -
g O +
of O +
Chinese O +
angelica O -
, O +
10 O -
g O +
of O +
cocklebur O +
fruit O -
, O +
3 O -
g O +
of O +
cassia O +
twig O -
, O +
and O +
1 O +
part O +
of O +
musk O -
; O +
the O +
antihistaminics O +
Loratadine O -
, O +
the O +
musk O -
, O +
the O +
divaricate O +
saposhnikovia O +
root O -
, O +
the O +
belvedere O +
fruit O -
, O +
the O +
astragalus O +
mongholicus O -
, O +
the O +
Chinese O +
angelica O -
, O +
the O +
cocklebur O +
fruit O +
and O +
the O +
cassia O +
twig O +
are O +
ground O +
into O +
powder O +
and O +
mixed O +
uniformly O -
, O +
and O +
the O +
powder O +
in O +
which O +
musk O +
is O +
added O +
is O +
then O +
regulated O +
into O +
paste O +
with O +
yellow O +
wine O -
. O +

The O +
preparation O +
for O +
treating O +
the O +
chronic O +
urticaria O +
is O +
simple O +
and O +
practicable O +
in O +
method O -
, O +
has O +
small O +
toxic O +
or O +
side O +
effect O -
, O +
and O +
has O +
good O +
auxiliary O +
treatment O +
effect O +
on O +
the O +
chronic O +
urticaria O -
. O +

Medicine O +
for O +
treating O +
rheumatic O +
fever O +
The O +
invention O +
discloses O +
a O +
Chinese O +
materia O +
medica O +
preparation O +
for O +
treating O +
intense O +
heat O +
evil O +
rheumatic O +
fever O -
, O +
comprising O +
the O +
following O +
medicines O +
by O +
fixed O +
weight O +
ratio O -
: O +
gypsum O -
, O +
rhizoma O +
anemarrhenae O -
, O +
golden O +
cypress O -
, O +
polished O +
round O -
- O -
grained O +
rice O -
, O +
Cape O +
Jasmine O +
Fruit O +
and O +
the O +
like O -
. O +

The O +
raw O +
materials O +
of O +
the O +
medicine O +
are O +
easy O +
to O +
obtain O +
and O +
low O +
in O +
cost O -
; O +
and O +
the O +
medicine O +
has O +
the O +
advantages O +
of O +
short O +
course O +
of O +
treatment O -
, O +
excellent O +
curative O +
effect O +
and O +
no O +
side O +
effect O -
. O +

Nimesulide O +
temperature O +
sensitive O +
hydrogel O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
Nimesulide O +
temperature O +
sensitive O +
gel O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
Nimesulide O +
temperature O +
sensitive O +
gel O +
comprises O +
Nimesulide O -
, O +
a O +
temperature O +
sensitive O +
gel O +
material O -
, O +
a O +
pH O +
regulator O -
, O +
a O +
preservative O +
and O +
the O +
like O +
and O +
is O +
characterized O +
in O +
that O -
: O +
the O +
temperature O +
sensitive O +
gel O +
material O +
is O +
poloxamer O -
, O +
and O +
the O +
weight O +
ratio O +
of O +
the O +
poloxamer O +
to O +
the O +
Nimesulide O +
is O +
9:1 O -
; O +
and O +
the O +
optimized O +
temperature O +
sensitive O +
gel O +
material O +
is O +
poloxamer O +
407 O -
. O +

The O +
temperature O +
sensitive O +
gel O +
is O +
sensitive O +
to O +
temperature O +
changes O -
, O +
and O +
rabbit O +
rectum O +
experimental O +
results O +
show O +
that O +
the O +
temperature O +
sensitive O +
gel O +
has O +
higher O +
medicament O +
release O +
rate O +
and O +
higher O +
bioavailability O +
which O +
are O +
obviously O +
better O +
than O +
those O +
of O +
the O +
conventional O +
Nimesulide O +
common O +
suppositories O -
. O +

The O +
Nimesulide O +
temperature O +
sensitive O +
gel O +
reserves O +
the O +
advantages O +
of O +
the O +
conventional O +
suppositories O -
, O +
overcomes O +
the O +
defects O +
of O +
the O +
conventional O +
suppositories O +
to O +
a O +
certain O +
extent O +
and O +
has O +
a O +
wide O +
clinical O +
application O +
prospect O -
. O +

The O +
Nimesulide O +
temperature O +
sensitive O +
gel O +
uses O +
common O +
safe O +
pharmaceutical O +
excipients O -
, O +
has O +
a O +
simple O +
production O +
process O -
, O +
stable O +
and O +
easily O -
- O -
controlled O +
quality O +
and O +
high O +
process O +
reproducibility O -
, O +
and O +
is O +
suitable O +
for O +
industrial O +
production O -
. O +

Perfusate O +
and O +
preparation O +
method O +
thereof O +
for O +
treating O +
cow O +
recessive O +
mastitis O +
The O +
invention O +
relates O +
to O +
perfusate O +
for O +
treating O +
cow O +
recessive O +
mastitis O -
, O +
which O +
mainly O +
comprises O +
the O +
raw O +
materials O +
with O +
the O +
following O +
ratios O -
: O +
4000 O -
- O -
5000 O -
g O +
of O +
radix O +
astragali O -
, O +
4000 O -
- O -
5000 O -
g O +
of O +
herba O +
epimedii O -
, O +
300 O -
- O -
500 O -
g O +
of O +
levamisole O +
hydrochloride O -
, O +
300 O -
- O -
400 O -
g O +
of O +
antibacterial O +
pepetide O -
, O +
2000 O -
- O -
3000ml O +
of O +
glycerol O -
, O +
400 O -
- O -
500 O -
g O +
of O +
gelatine O -
, O +
and O +
50 O -
- O -
100 O -
g O +
of O +
sodium O +
benzoate O -
, O +
wherein O +
pH O +
of O +
the O +
perfusate O +
is O +
5.5 O -
- O -
7.5 O -
. O +

The O +
perfusate O +
is O +
used O +
for O +
treating O +
cow O +
recessive O +
mastitis O +
with O +
determine O +
curative O +
effect O -
, O +
drug O +
concentration O +
for O +
local O +
application O +
is O +
high O -
, O +
absorption O +
ratio O +
is O +
high O -
, O +
the O +
direction O +
is O +
high O -
, O +
drug O +
application O +
is O +
convenient O +
and O +
safe O -
, O +
thereby O +
the O +
goal O +
of O +
fast O +
treating O +
cow O +
recessive O +
mastitis O +
is O +
achieved O -
, O +
and O +
the O +
perfusate O +
is O +
compound O +
perfusion O +
preparation O +
combining O +
antibiosis O -
, O +
antiphlogosis O +
and O +
improving O +
immunity O +
of O +
the O +
organism O -
. O +

Nano O +
selenium O -
- O -
germanium O +
snake O +
anion O +
far O +
infrared O +
body O -
- O -
building O +
life O -
- O -
prolonging O +
health O -
- O -
care O +
drink O +
The O +
invention O +
relates O +
to O +
a O +
nano O +
selenium O -
- O -
germanium O +
snake O +
anion O +
far O +
infrared O +
body O -
- O -
building O +
life O -
- O -
prolonging O +
health O -
- O -
care O +
drink O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
drink O +
production O +
and O +
preparation O -
. O +

Snake O +
medicinal O +
material O +
has O +
rich O +
nutrients O -
. O +

The O +
snake O +
medicinal O +
material O +
not O +
only O +
contain O +
protein O -
, O +
fat O -
, O +
sugar O -
, O +
macro O +
and O +
trace O +
elements O +
and O +
vitamins O -
, O +
but O +
also O +
contains O +
eight O +
necessary O +
amino O +
acids O +
which O +
can O -
not O +
be O +
synthesized O +
in O +
human O +
bodies O +
or O +
are O +
synthesized O +
slowly O +
in O +
human O +
bodies O -
. O +

The O +
snake O +
medicinal O +
material O +
can O +
purify O +
water O +
source O -
. O +

The O +
snake O +
material O +
can O +
activate O -
, O +
purify O +
and O +
mineralize O +
65 O +
percent O +
or O +
100 O +
percent O +
of O +
water O +
in O +
human O +
bodies O +
and O +
therefore O +
can O +
promote O +
metabolism O +
element O +
balance O +
and O +
acid O -
- O -
base O +
balance O +
in O +
human O +
bodies O -
, O +
increase O +
oxygen O +
content O +
in O +
cells O +
of O +
human O +
bodies O +
and O +
strength O +
the O +
circulation O +
of O +
anions O +
in O +
the O +
drink O +
in O +
blood O -
; O +
and O +
at O +
the O +
same O +
time O -
, O +
the O +
anions O +
in O +
the O +
drink O +
and O +
the O +
far O +
infrared O +
electromagnetic O +
wave O +
resisting O +
materials O +
can O +
reach O +
a O +
3 O +
to O +
5 O +
millimeter O +
deep O +
place O +
in O +
skin O +
tissues O +
and O +
automatically O +
heats O +
to O +
improve O +
the O +
vitality O +
of O +
cells O -
, O +
promote O +
tissue O +
regeneration O -
, O +
supply O +
nutrients O +
to O +
cell O +
tissues O -
, O +
so O +
the O +
health O +
of O +
human O +
bodies O +
is O +
kept O +
and O +
life O +
is O +
prolonged O -
. O +

Cold O -
- O -
system O +
preparation O +
method O +
of O +
south O +
calcite O +
as O +
a O +
Tibetan O +
medicine O +
The O +
invention O +
relates O +
to O +
a O +
cold O -
- O -
system O +
preparation O +
method O +
of O +
south O +
calcite O +
as O +
a O +
Tibetan O +
medicine O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
( O -
1 O -
) O +
collecting O +
mineral O +
south O +
calcite O -
, O +
cleaning O -
, O +
removing O +
impurities O -
, O +
scrapping O +
into O +
particles O +
with O +
the O +
granularity O +
of O +
10 O -
- O -
30 O +
mm O -
, O +
adding O +
auxiliaries O -
, O +
i.e. O -
, O +
Radix O +
Aconiti O +
and O +
potassium O +
nitrate O -
, O +
heating O +
and O +
continuously O +
boiling O +
for O +
2 O -
- O -
16 O +
h O +
to O +
obtain O +
the O +
boiled O +
south O +
calcite O -
; O +
( O -
2 O -
) O +
rinsing O +
the O +
boiled O +
south O +
calcite O +
with O +
clear O +
water O +
until O +
the O +
rinsing O +
liquid O +
is O +
clear O +
as O +
crystal O -
, O +
and O +
drying O +
until O +
the O +
weight O +
is O +
consistent O +
to O +
obtain O +
the O +
dry O +
south O +
calcite O -
; O +
and O +
( O -
3 O -
) O +
grinding O +
the O +
dry O +
south O +
calcite O -
, O +
sieving O +
with O +
a O +
screen O +
of O +
20 O -
- O -
100 O +
meshes O +
to O +
obtain O +
south O +
calcite O +
powder O -
, O +
uniformly O +
mixing O +
and O +
stirring O +
the O +
south O +
calcite O +
powder O +
with O +
fresh O +
milk O +
and O +
drying O +
in O +
shade O +
to O +
obtain O +
a O +
finished O +
product O -
. O +

The O +
cold O -
- O -
system O +
preparation O +
method O +
is O +
simple O +
and O +
convenient O +
to O +
operate O +
and O +
easy O +
to O +
implement O +
and O +
can O +
greatly O +
increase O +
the O +
content O +
of O +
effective O +
trace O +
elements O +
in O +
the O +
south O +
calcitewithout O +
remarkably O +
influencing O +
the O +
main O +
contents O -
, O +
thereby O +
the O +
method O +
can O +
be O +
used O +
as O +
a O +
reference O +
for O +
preparing O +
high O +
south O +
calcite O +
and O +
a O +
standard O +
preparation O +
method O +
of O +
the O +
south O +
calcite O +
as O +
the O +
Tibetan O +
medicine O -
. O +

Plaster O +
for O +
treating O +
pain O +
of O +
cervical O +
and O +
lumbar O +
vertebrae O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
medicament O +
for O +
treating O +
pain O +
of O +
cervical O +
and O +
lumbar O +
vertebrae O -
, O +
which O +
is O +
prepared O +
according O +
to O +
the O +
following O +
steps O -
: O +
adding O +
raw O +
medicines O +
such O +
as O +
szechuan O +
aconite O -
, O +
wild O +
aconite O -
, O +
rhizoma O +
arisaematis O +
and O +
the O +
like O +
into O +
water O +
for O +
decocting O -
, O +
filtering O +
the O +
obtained O +
decoction O +
with O +
gauze O -
, O +
and O +
concentrating O +
the O +
decoction O +
into O +
fluid O +
extract O +
for O +
later O +
use O -
; O +
then O -
, O +
preparing O +
raw O +
medicines O +
such O +
as O +
mastic O -
, O +
myrrh O -
, O +
safflower O -
, O +
catechu O +
and O +
the O +
like O +
into O +
fine O +
powder O -
, O +
and O +
sieving O +
the O +
fine O +
powder O +
with O +
a O +
100-mesh O +
sieve O +
for O +
later O +
use O -
; O +
and O +
finally O -
, O +
mixing O +
and O +
heating O +
talcum O +
powder O -
, O +
zinc O +
oxide O -
, O +
sesame O +
oil O +
and O +
medical O +
solid O +
pressure O -
- O -
sensitive O +
hot O +
melt O +
adhesive O -
, O +
adding O +
the O +
fluid O +
extract O +
obtained O +
in O +
the O +
step O +
( O -
1 O -
) O +
and O +
the O +
fine O +
powder O +
obtained O +
in O +
the O +
step O +
( O -
2 O -
) O +
while O +
continuously O +
stirring O +
until O +
the O +
moisture O +
is O +
fully O +
evaporated O -
, O +
cooling O -
, O +
adding O +
certain O +
parts O +
by O +
weight O +
of O +
camphor O -
, O +
borneol O +
and O +
azone O -
, O +
stirring O +
uniformly O -
, O +
and O +
spreading O +
5 O -
g O +
of O +
ointment O +
on O +
non O -
- O -
woven O +
fabric O +
to O +
obtain O +
the O +
plaster O +
disclosed O +
by O +
the O +
invention O -
. O +

Geldanamycin O +
derivative O -
, O +
preparation O +
thereof O +
and O +
medicament O +
application O +
thereof O +
The O +
invention O +
discloses O +
geldanamycin O +
derivative O -
, O +
preparation O +
thereof O +
and O +
medicament O +
application O +
thereof O -
. O +

The O +
structural O +
formula O +
as O +
shown O +
in O +
the O +
following O +
formula O +
( O -
I O -
) O +
is O +
a O +
novel O +
structural O +
formula O +
formed O +
by O +
modifying O +
the O +
geldanamycin O -
, O +
and O +
the O +
pair O +
of O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene +
is O +
good O +
in O +
activity O -
. O +

The O +
compound O +
as O +
shown O +
in O +
the O +
formula O +
( O -
I O -
) O -
, O +
or O +
the O +
medical O +
salt O +
of O +
the O +
compound O -
; O +
R1 O +
group O +
is O +
phenyl O +
or O +
3-furyl O +
or O +
3-pyrryl O +
or O +
the O +
other O +
hexahydric O +
heteroaromatic O +
group O -
, O +
or O +
the O +
other O +
quinary O +
heteroaromatic O +
group O -
; O +
and O +
R2 O +
group O +
is O +
carboxylic O +
acid O +
amide O +
or O +
acetyl O +
or O +
ethyl O +
or O +
the O +
fatty O +
hydrocarbon O +
group O +
of O +
the O +
other O +
C1-C5 O +
carbon O +
straight O +
chain O +
or O +
the O +
carbonyl O +
group O +
of O +
the O +
other O +
C1-C5 O +
carbon O +
straight O +
chain O +
fatty O +
hydrocarbon O -
. O +

The O +
compound O +
as O +
shown O +
in O +
the O +
formula O +
( O -
I O -
) O +
has O +
the O +
characteristic O +
of O +
the O +
high O -
- O -
efficiency O +
combined O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene -
, O +
so O +
that O +
the O +
geldanamycin O +
derivative O +
can O +
be O +
used O +
for O +
curing O +
or O +
preventing O +
the O +
tumor O +
of O +
the O +
mammal O -
, O +
in O +
particular O +
to O +
the O +
solid O +
tumor O -
. O +

Esculentoside O +
A O -
, O +
EsA O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
an O +
Esculentoside O +
A O -
, O +
EsA O +
as O +
well O +
as O +
a O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

The O +
general O +
formula O +
of O +
the O +
Esculentoside O +
A O -
, O +
EsA O +
is O +
shown O +
in O +
the O +
specification O -
, O +
wherein O +
R O +
is O +
amino O +
acid O -
, O +
polypeptide O -
, O +
piperazine O +
base O -
, O +
substituted O +
piperazine O +
bases O +
or O +
substituted O +
amido O -
. O +

An O +
active O +
ester O +
intermediate O +
formed O +
by O +
the O +
Esculentoside O +
A O -
, O +
EsA O +
under O +
the O +
action O +
of O +
a O +
condensation O +
agent O +
reacts O +
with O +
amine O +
or O +
piperazine O +
or O +
substituted O +
piperazine O +
or O +
amino O +
acid O +
with O +
the O +
protected O +
carboxyl O +
or O +
polypeptide O -
; O +
and O +
the O +
Esculentoside O +
A O -
, O +
EsA O +
is O +
obtained O +
by O +
separation O +
and O +
purification O -
. O +

The O +
Esculentoside O +
A O -
, O +
EsA O -
, O +
as O +
well O +
as O +
pharmaceutical O +
salt O +
and O +
medical O +
composite O +
thereof O +
can O +
be O +
used O +
for O +
preparing O +
inflammatory O +
medicaments O -
. O +

Imidazopyridine O +
and O +
imidazopyrazine O +
compounds O +
useful O +
as O +
kinase B-Gene +
inhibitors O +
A O +
compound O +
of O +
Formula O +
( O -
I O -
) O +
or O +
Formula O +
( O -
II O -
) O +
and O +
enantiomers O -
, O +
diastereomers O +
and O +
pharmaceutically O -
- O -
acceptable O +
salts O +
thereof O -
. O +

Also O +
disclosed O +
are O +
pharmaceutical O +
compositions O +
containing O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
or O +
Formula O +
( O -
II O -
) O -
, O +
and O +
methods O +
of O +
treating O +
conditions O +
associated O +
with O +
the O +
activity O +
of O +
p38 B-Gene +
kinase I-Gene -
. O +

Application O +
of O +
arachidonic O +
acid O +
as O +
xanthine B-Gene +
oxidase I-Gene +
inhibitor O +
and O +
in O +
preparation O +
of O +
medicines O +
for O +
treating O +
hyperuricemia O +
or O +
gout O +
The O +
invention O +
relates O +
to O +
application O +
of O +
arachidonic O +
acid O +
as O +
a O +
xanthine B-Gene +
oxidase I-Gene +
inhibitor O +
and O +
in O +
the O +
preparation O +
of O +
medicines O +
for O +
treating O +
hyperuricemia O +
or O +
gout O -
. O +

Xanthine B-Gene +
oxidase I-Gene +
is O +
a O +
key O +
enzyme O +
for O +
the O +
generation O +
and O +
the O +
development O +
of O +
the O +
hyperuricemia O +
or O +
the O +
gout O -
, O +
most O +
substrates O +
of O +
the O +
xanthine B-Gene +
oxidase I-Gene +
are O +
cyclic O +
small O +
molecules O -
, O +
and O +
the O +
arachidonic O +
acid O +
is O +
long O +
chain O +
polyunsaturated O +
fatty O +
acid O -
; O +
a O +
three O +
dimensional O +
structure O +
of O +
the O +
xanthine B-Gene +
oxidase I-Gene +
is O +
downloaded O +
from O +
a O +
protein O +
data O +
bank O +
( O -
PDB O -
) O +
of O +
a O +
website O -
; O +
a O +
three O +
dimensional O +
structure O +
of O +
the O +
arachidonic O +
acid O +
is O +
downloaded O +
from O +
a O +
pubchem O -
; O +
molecular O +
docking O +
between O +
the O +
arachidonic O +
acid O +
and O +
the O +
xanthine B-Gene +
oxidase I-Gene +
is O +
performed O +
by O +
iGEMDOCK O +
software O +
and O +
docking O +
energy O +
is O +
computed O -
; O +
and O +
in O -
- O -
vitro O +
enzyme O +
activity O +
tests O +
prove O +
that O +
the O +
arachidonic O +
acid O +
has O +
an O +
inhibition O +
effect O +
on O +
the O +
xanthine B-Gene +
oxidase I-Gene -
. O +

By O +
the O +
application O -
, O +
another O +
important O +
physiological O +
function O +
of O +
the O +
arachidonic O +
acid O +
is O +
discovered O -
, O +
and O +
a O +
wider O +
way O +
is O +
provided O +
for O +
screening O +
the O +
xanthine O +
oxidase O +
inhibitor O +
from O +
a O +
natural O +
product O +
to O +
treat O +
the O +
hyperuricemia O +
or O +
the O +
gout O +
simultaneously O -
. O +

Preparation O +
method O +
of O +
pulsatilla O +
saponin O +
matter O +
as O +
well O +
as O +
preparation O +
method O +
of O +
preparation O +
thereof O +
and O +
application O +
of O +
pulsatilla O +
saponin O +
matter O +
in O +
preparing O +
medicaments O +
for O +
treating O +
cancers O +
The O +
invention O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
a O +
pulsatilla O +
saponin O +
matter O +
as O +
well O +
as O +
a O +
preparation O +
method O +
of O +
a O +
preparation O +
thereof O +
and O +
application O +
of O +
the O +
pulsatilla O +
saponin O +
matter O +
in O +
preparing O +
medicaments O +
for O +
treating O +
cancers O -
. O +

The O +
invention O +
relates O +
to O +
the O +
pulsatilla O +
saponin O +
matter O +
which O +
is O +
pulsatilla O +
saponin O +
A O +
or O +
pulsatilla O +
saponin O +
A O +
produced O +
by O +
hydrolysis O -
, O +
thereby O +
together O +
having O +
the O +
structural O +
units O +
of O +
23-hydroxy O +
oleanolic O +
acid-3-O O -
- O -
alpha O -
- O -
L O -
- O -
pyran O +
rhamnose- O -
( O -
1->2 O -
) O -
-alpha O -
- O -
L O -
- O -
pyran O +
Arabic O +
glucoside O -
, O +
and O +
the O +
like O -
, O +
and O +
because O +
the O +
matter O +
is O +
easy O +
to O +
generate O +
the O +
pulsatilla O +
saponin O +
A O +
after O +
being O +
hydrolyzed O -
, O +
the O +
pulsatilla O +
saponin O +
matter O +
has O +
a O +
similar O +
treating O +
effect O +
in O +
human O +
bodies O -
. O +

Dirithromycin O +
medicinal O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
, O +
and O +
particularly O +
relates O +
to O +
a O +
dirithromycin O +
medicinal O +
composition O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

By O +
the O +
dirithromycin O +
medicinal O +
composition O -
, O +
the O +
problem O +
of O +
the O +
flowability O +
of O +
granules O +
during O +
preparation O +
is O +
mainly O +
solved O -
, O +
and O +
the O +
stability O -
, O +
bioavailability O +
and O +
the O +
like O +
of O +
medicaments O +
are O +
improved O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
for O +
the O +
dirithromycin O +
medicinal O +
composition O -
, O +
namely O +
the O +
dirithromycin O +
medicinal O +
composition O +
is O +
filled O +
by O +
a O +
direct O +
method O -
, O +
so O +
by O +
the O +
preparation O +
method O -
, O +
the O +
problem O +
that O +
soft O +
materials O +
have O +
high O +
viscosity O +
and O +
are O +
difficult O +
to O +
pelletize O +
in O +
the O +
process O +
of O +
preparing O +
dirithromycin O +
medicinal O +
capsules O +
in O +
the O +
prior O +
art O +
is O +
solved O -
. O +

Application O +
of O +
feather O +
cockscomb O +
saponins O +
compound O +
in O +
antitumor O +
or O +
anti O -
- O -
inflammatory O +
medicines O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
, O +
in O +
particular O +
to O +
novel O +
application O +
of O +
a O +
feather O +
cockscomb O +
saponins O +
compound O -
, O +
such O +
as O +
Celosin O +
A O -
, O +
Celosin O +
B O -
, O +
Celosin O +
C1 O -
, O +
Celosin O +
D1 O -
, O +
Celosin O +
E O -
, O +
Celosin O +
F O -
, O +
Celosin O +
G O +
or O +
Cristatain O -
. O +

Proved O +
by O +
in O +
vitro O +
cell O +
experiments O -
, O +
the O +
feather O +
cockscomb O +
saponins O +
compound O -
, O +
such O +
as O +
the O +
Celosin O +
A O -
, O +
the O +
Celosin O +
B O -
, O +
the O +
Celosin O +
C1 O -
, O +
the O +
Celosin O +
D1 O -
, O +
the O +
Celosin O +
E O -
, O +
the O +
Celosin O +
F O -
, O +
Celosin O +
G O +
and O +
Cristatain O +
have O +
favorable O +
anti O -
- O -
inflammatory O +
activity O -
, O +
and O +
the O +
Celosin O +
A O -
, O +
the O +
Celosin O +
B O +
and O +
Cristatain O +
have O +
better O +
anti O -
- O -
inflammatory O +
effect O -
, O +
therefore O -
, O +
the O +
feather O +
cockscomb O +
saponins O +
compound O +
can O +
be O +
used O +
for O +
preparing O +
anti O -
- O -
inflammatory O +
or O +
antitumor O +
medicines O -
. O +

The O +
invention O +
provides O +
a O +
new O +
medicine O +
source O +
for O +
the O +
anti O -
- O -
inflammatory O +
medicines O -
. O +

Pharmaceutical O +
composition O +
for O +
treating O +
small O +
cell O +
lung O +
cancer O +
and O +
application O -
, O +
kit O +
and O +
package O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
for O +
treating O +
small O +
cell O +
lung O +
cancer O +
and O +
application O -
, O +
a O +
kit O +
and O +
package O +
thereof O -
. O +

The O +
pharmaceutical O +
composition O -
, O +
kit O +
and O +
package O +
contain O +
a O +
treatment O +
effective O +
dose O +
of O +
lobaplatin O +
and O +
a O +
treatment O +
effective O +
dose O +
of O +
etoposide O +
as O +
a O +
combination O +
for O +
simultaneous O -
, O +
separated O +
or O +
sequential O +
use O -
. O +

When O +
used O +
for O +
treating O +
the O +
small O +
cell O +
lung O +
cancer O -
, O +
the O +
pharmaceutical O +
composition O -
, O +
kit O +
and O +
package O +
provided O +
by O +
the O +
invention O +
can O +
obtain O +
excellent O +
treatment O +
effect O +
and O +
have O +
small O +
toxic O +
side O +
effect O -
. O +

Absorption O -
- O -
promoting O +
pharmaceutical O +
composition O +
ointment O +
for O +
treating O +
skin O +
diseases O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
preparation O +
method O +
of O +
a O +
pharmaceutical O +
composition O +
ointment O +
for O +
treating O +
skin O +
diseases O -
. O +

The O +
pharmaceutical O +
composition O +
contains O +
the O +
following O +
components O +
in O +
proportion O +
by O +
weight O -
: O +
0.05 O -
- O -
0.08 O -
% O +
of O +
betamethasone O +
valerate O -
, O +
0.08 O -
- O -
0.12 O -
% O +
of O +
chlorocresol O +
and O +
0.08 O -
- O -
0.12 O -
% O +
of O +
gentamicin O +
sulfate O -
. O +

The O +
pharmaceutical O +
composition O +
ointment O +
is O +
mainly O +
used O +
for O +
treating O +
dermatitis O -
, O +
eczema O -
, O +
contact O +
dermatitis O -
, O +
seborrheic O +
dermatitis O -
, O +
photodermatitis O -
, O +
neurodermatitis O -
, O +
intertrigo O -
, O +
exfoliative O +
dermatitis O -
, O +
skin O +
itch O -
, O +
psoriasis O -
, O +
first O -
- O -
degree O +
burn O +
and O +
the O +
like O -
. O +

The O +
pharmaceutical O +
composition O +
ointment O +
has O +
the O +
characteristics O +
of O +
jointly O +
applying O +
pharmaceutical O +
components O +
with O +
anti O -
- O -
inflammatory O -
, O +
antifungal O +
and O +
antibacterial O +
curative O +
effects O -
, O +
playing O +
the O +
curative O +
effects O +
in O +
multiple O +
aspects O -
, O +
overcoming O +
the O +
defect O +
that O +
an O +
individual O +
component O +
can O +
not O +
more O +
effectively O +
treat O +
skin O +
mycotic O +
infection O -
, O +
skin O +
allergy O -
, O +
dermatitis O -
, O +
eczema O +
and O +
the O +
like O -
, O +
or O +
concurrence O +
of O +
mycotic O +
infection O -
, O +
skin O +
allergy O -
, O +
dermatitis O -
, O +
eczema O +
and O +
the O +
like O -
, O +
and O +
relieving O +
the O +
serious O +
side O +
effects O +
caused O +
by O +
singly O +
using O +
a O +
big O +
amount O +
of O +
hormone O +
for O +
treating O +
dermatitis O -
, O +
eczema O +
and O +
the O +
like O -
; O +
and O +
a O +
component O +
for O +
promoting O +
percutaneous O +
absorption O +
is O +
added O +
to O +
auxiliary O +
materials O +
to O +
enhance O +
the O +
pharmaceutical O +
curative O +
effect O +
and O +
promote O +
absorption O -
. O +

The O +
ointment O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
exact O +
efficacy O -
, O +
strong O +
local O +
pertinence O -
, O +
no O +
irritation O +
on O +
skin O -
, O +
and O +
the O +
like O -
, O +
and O +
the O +
preparation O +
method O +
of O +
the O +
ointment O +
is O +
suitable O +
for O +
industrial O +
production O -
. O +

Hyperosteogeny O +
plaster O +
The O +
invention O +
discloses O +
a O +
hyperosteogeny O +
plaster O +
used O +
for O +
treating O +
hyperosteogeny O +
and O +
functional O +
disorder O -
, O +
soft O +
tissue O +
injury O -
, O +
swell O -
, O +
sore O -
, O +
numbness O +
and O +
pain O +
caused O +
thereby O -
. O +

The O +
hyperosteogeny O +
plaster O +
takes O +
cotton O +
cloth O +
as O +
a O +
mounting O +
material O -
, O +
acrylic O +
ester O +
polymer O +
as O +
a O +
pressure O +
sensitive O +
adhesive O -
, O +
glycerol O +
as O +
a O +
cosolvent O +
and O +
azone O +
as O +
an O +
accelerator O -
, O +
and O +
the O +
main O +
medicines O +
comprise O +
80 O -
- O -
97 O -
% O +
of O +
micalex O +
in O +
weight O -
, O +
1 O -
- O -
7 O -
% O +
of O +
coptis O +
in O +
weight O +
and O +
2 O -
- O -
13 O -
% O +
of O +
dried O +
alum O +
in O +
weight O -
. O +

The O +
plaster O +
comprises O +
the O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
0.1 O -
- O -
30 O -
% O +
of O +
main O +
medicines O -
, O +
50 O -
- O -
90 O -
% O +
of O +
pressure O +
sensitive O +
adhesive O +
acrylic O +
ester O +
polymer O -
, O +
2 O -
- O -
20 O -
% O +
of O +
cosolvent O +
glycerol O +
and O +
0.5 O -
- O -
10 O -
% O +
of O +
accelerator O +
azone O -
. O +

Method O +
for O +
preparing O +
infantile O +
lung O +
clearing O +
and O +
phlegm O +
eliminating O +
preparation O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
an O +
infantile O +
lung O +
clearing O +
and O +
phlegm O +
eliminating O +
preparation O -
, O +
which O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
a O -
, O +
weighing O +
ephedra O -
, O +
gypsum O -
, O +
bitter O +
almond O -
, O +
whiteflower O +
hogfennel O +
root O -
, O +
baical O +
skullcap O +
root O -
, O +
perilla O +
fruit O +
powder O -
, O +
pepperweed O +
seed O +
and O +
bamboo O +
shavings O -
; O +
b O -
, O +
soaking O +
ephedra O +
coarse O +
powder O +
in O +
acidic O +
aqueous O +
solution O -
, O +
and O +
percolating O +
for O +
extracting O -
; O +
c O -
, O +
crushing O +
bitter O +
almond O -
, O +
inactivating O +
enzyme O -
, O +
and O +
extracting O +
by O +
low O -
- O -
degree O +
alcoholic O +
solution O -
; O +
d O -
, O +
decocting O +
gypsum O -
, O +
adding O +
other O +
components O -
, O +
extracting O +
in O +
water O -
, O +
mixing O +
with O +
ephedra O +
concentrating O +
solution O +
and O +
bitter O +
almond O +
concentrating O +
solution O -
, O +
and O +
concentrating O +
to O +
form O +
extract O -
; O +
and O +
e O -
, O +
adding O +
an O +
excipient O +
and O +
auxiliary O +
materials O -
, O +
and O +
preparing O +
by O +
the O +
conventional O +
method O +
of O +
preparations O +
to O +
obtain O +
a O +
pharmaceutically O -
- O -
acceptable O +
preparation O -
. O +

By O +
the O +
method O -
, O +
the O +
extraction O +
rate O +
of O +
ephedrine O +
and O +
amygdalin O +
can O +
be O +
improved O -
, O +
the O +
curative O +
effect O +
of O +
medicines O +
can O +
be O +
improved O -
, O +
and O +
the O +
quality O +
stability O +
ofproducts O +
can O +
be O +
improved O +
simultaneously O -
. O +

Lansoprazole O +
medicinal O +
composition O +
tablets O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
Lansoprazole O +
medicinal O +
composition O +
tablets O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
Lansoprazole O +
medicinal O +
composition O +
tablets O +
comprise O +
the O +
following O +
components O +
in O +
part O +
by O +
mass O -
: O +
20 O +
to O +
30 O +
parts O +
of O +
Lansoprazole O +
medicinal O +
composition O +
tablets O -
, O +
400 O +
to O +
450 O +
parts O +
of O +
sodium O +
bicarbonate O -
, O +
100 O +
to O +
150 O +
parts O +
of O +
calcium O +
hydrophosphate O -
, O +
600 O +
to O +
700 O +
parts O +
of O +
magnesium O +
hydroxide O -
, O +
250 O +
to O +
500 O +
parts O +
of O +
filler O -
, O +
40 O +
to O +
50 O +
parts O +
of O +
disintegrating O +
agent O -
, O +
50 O +
to O +
100 O +
parts O +
of O +
flavoring O +
agent O -
, O +
80 O +
to O +
100 O +
parts O +
of O +
bonding O +
agent O +
and O +
20 O +
to O +
25 O +
parts O +
of O +
lubricating O +
agent O -
. O +

In O +
the O +
Lansoprazole O +
medicinal O +
composition O +
tablets O +
disclosed O +
by O +
the O +
invention O -
, O +
sodium O +
bicarbonate O -
, O +
calcium O +
hydrophosphate O +
and O +
magnesium O +
hydroxide O +
are O +
used O +
in O +
place O +
of O +
enteric O +
coating O -
, O +
the O +
secretion O +
of O +
gastric O +
acid O +
can O +
be O +
inhibited O -
, O +
the O +
Lansoprazole O +
can O +
be O +
prevented O +
from O +
being O +
decomposed O +
by O +
gastric O +
acid O -
, O +
the O +
medicines O +
can O +
be O +
absorbed O +
quickly O -
, O +
and O +
peak O +
concentration O +
can O +
be O +
reached O +
quickly O -
. O +

Hederasaponin O +
derivative O -
, O +
preparation O +
method O +
of O +
salts O +
thereof O +
and O +
application O +
thereof O +
to O +
resisting O +
tumor O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O +
and O +
provides O +
a O +
3-O O -
- O -
alpha O -
- O -
L O -
- O -
pyran O +
rhamnose- O -
( O -
1->2 O -
) O +
[ O -
beta O -
- O -
D O -
- O -
glucopyranose- O -
( O -
1 O -
- O -
4 O -
) O -
] O -
-alpha O -
- O -
L O -
- O -
pyran O +
arabinose O +
hederasaponin O +
derivative O -
, O +
a O +
preparation O +
method O +
of O +
salts O +
thereof O +
and O +
application O +
thereof O +
to O +
resisting O +
tumor O -
. O +

The O +
structures O +
of O +
the O +
hederasaponin O +
3-O O -
- O -
alpha O -
- O -
L O -
- O -
pyran O +
rhamnose- O -
( O -
1->2 O -
) O +
[ O -
beta O -
- O -
D O -
- O -
glucopyranose- O -
( O -
1->4 O -
) O -
] O -
-alpha O -
- O -
L O -
- O -
pyran O +
arabinose O +
hederasaponin O +
derivative O +
and O +
salts O +
thereof O +
are O +
shown O +
as O +
follows O -
. O +

The O +
hederasaponin O +
3-O O -
- O -
alpha O -
- O -
L O -
- O -
pyran O +
rhamnose- O -
( O -
1->2 O -
) O +
[ O -
beta O -
- O -
D O -
- O -
glucopyranose- O -
( O -
1->4 O -
) O -
] O -
-alpha O -
- O -
L O -
- O -
pyran O +
arabinose O +
hederasaponin O +
derivative O +
and O +
the O +
salts O +
thereof O +
are O +
combined O +
with O +
a O +
pharmaceutical O +
acceptable O +
carrier O +
to O +
form O +
a O +
pharmaceutical O +
compound O +
which O +
is O +
used O +
for O +
preparing O +
tumor O -
- O -
resistant O +
medicines O -
. O +

Compared O +
with O +
the O +
prototype O +
medicine O -
, O +
a O +
medicine O +
containing O +
the O +
ingredient O +
derivative O +
and O +
the O +
salts O +
thereof O +
has O +
considerable O +
or O +
stronger O +
tumor O -
- O -
resistant O +
activity O -
; O +
and O +
meanwhile O -
, O +
the O +
activity O +
of O +
other O +
tumor O -
- O -
resistant O +
medicines O +
can O +
be O +
obviously O +
enhanced O +
and O +
the O +
side O +
effects O +
of O +
the O +
medicines O +
are O +
reduced O -
. O +

Slow O -
- O -
release O +
liquid O +
crystal O +
nanoparticle O +
containing O +
vinpocetine O +
prepared O +
by O +
supercritical O +
fluid O +
method O +
The O +
invention O +
relates O +
to O +
a O +
slow O -
- O -
release O +
liquid O +
crystal O +
nanoparticle O +
containing O +
vinpocetine O +
prepared O +
by O +
a O +
supercritical O +
fluid O +
method O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
wherein O +
the O +
nanoparticle O +
comprises O +
active O +
ingredients O +
of O +
vinpocetine O -
, O +
glyceryl O +
monooleate O +
and O +
surfactant O -
. O +

The O +
slow O -
- O -
release O +
liquid O +
crystal O +
nanoparticle O +
of O +
the O +
invention O +
prepared O +
by O +
vinpocetine O +
has O +
an O +
obvious O +
slow O -
- O -
release O +
function O +
relative O +
to O +
a O +
vinpocetine O +
solution O +
and O +
has O +
a O +
remarkably O -
- O -
increased O +
oral O +
bioavailability O -
. O +

Meropenem O +
sodium O -
/ O -
sulbactam O +
sodium O +
medicinal O +
composition O +
The O +
invention O +
provides O +
a O +
combined O +
medicament O -
, O +
in O +
particular O +
a O +
meropenem O +
sodium O +
and O +
sulbactam O +
sodium O +
combined O +
medicine O +
which O +
is O +
used O +
for O +
treating O +
infectious O +
diseases O +
caused O +
by O +
Acinetobacter O +
baumanii O -
. O +

The O +
meropenem O +
sodium O +
and O +
sulbactam O +
sodium O +
combined O +
medicine O +
has O +
synergistic O +
and O +
cumulative O +
antibacterial O +
effects O +
on O +
the O +
infectious O +
diseases O +
caused O +
by O +
the O +
Acinetobacter O +
baumanii O -
, O +
particularly O +
has O +
good O +
synergistic O +
and O +
cumulative O +
antibacterial O +
effects O +
on O +
multiple O +
medicine O -
- O -
resistant O +
Acinetobacter O +
baumanii O -
, O +
and O +
can O +
be O +
used O +
for O +
curing O +
the O +
clinical O +
infection O +
caused O +
by O +
the O +
multiple O +
medicine O -
- O -
resistant O +
Acinetobacter O +
baumanii O -
. O +

New O +
application O +
of O +
epigallocatechin O +
gallate O +
( O -
EGCG O -
) O +
The O +
invention O +
relates O +
to O +
applications O +
of O +
epigallocatechin O +
gallate O +
( O -
EGCG O -
) O +
in O +
preparing O +
a O +
medicament O +
for O +
inducing O +
glioma O +
cell O +
apoptosis O +
and O +
preparing O +
a O +
medicament O +
for O +
inhibiting O +
glioma O +
cell O +
proliferation O -
. O +

Shown O +
by O +
experimental O +
results O -
, O +
the O +
EGCG O +
can O +
obviously O +
inhibit O +
the O +
glioma O +
cell O +
proliferation O +
( O -
P O -
( O -
0.001 O -
) O -
, O +
with O +
the O +
increase O +
of O +
dosage O +
of O +
the O +
EGCG O +
and O +
extension O +
of O +
time O -
, O +
the O +
cyto O -
- O -
inhibition O +
is O +
more O +
obvious O -
; O +
and O +
shown O +
by O +
experimental O +
results O +
of O +
cell O +
apoptosis O -
, O +
48 O +
hours O +
later O +
after O +
the O +
EGCG O +
is O +
added O -
, O +
with O +
the O +
increase O +
of O +
concentration O -
, O +
the O +
number O +
of O +
cell O +
apoptosis O +
is O +
markedly O +
increased O -
. O +

Motherwort O +
and O +
astragalus O +
capsule O +
used O +
for O +
treating O +
prostatic O +
hyperplasia O +
The O +
invention O +
relates O +
to O +
a O +
motherwort O +
and O +
astragalus O +
capsule O +
used O +
for O +
treating O +
prostatic O +
hyperplasia O +
and O +
can O +
effectively O +
solve O +
the O +
treatment O +
problem O +
of O +
benign O +
prostatic O +
hyperplasia O -
. O +

The O +
technical O +
schemes O +
are O +
as O +
follows O -
: O +
the O +
motherwort O +
and O +
astragalus O +
capsule O +
is O +
prepared O +
from O +
motherwort O +
extract O -
, O +
astragalus O +
extract O -
, O +
starch O +
and O +
talcum O +
powder O -
, O +
wherein O +
the O +
weight O +
ratio O +
of O +
the O +
motherwort O +
extract O +
to O +
the O +
astragalus O +
extract O +
is O +
( O -
4 O -
- O -
6 O -
) O -
: O -
( O -
6 O -
- O -
4 O -
) O -
; O +
and O +
the O +
motherwort O +
and O +
astragalus O +
capsule O +
is O +
prepared O +
by O +
crushing O +
the O +
motherwort O +
extract O +
and O +
the O +
astragalus O +
extract O -
, O +
screening O +
with O +
a O +
100-mesh O +
sieve O -
, O +
mixing O +
uniformly O -
, O +
then O +
adding O +
starch O +
and O +
talcum O +
powder O -
, O +
uniformly O +
mixing O -
, O +
wherein O +
the O +
addition O +
amount O +
of O +
starch O +
and O +
talcum O +
powder O +
is O +
not O +
more O +
than O +
10 O -
% O +
the O +
total O +
weight O +
of O +
the O +
motherwort O +
extract O -
, O +
astragalus O +
extract O -
, O +
starch O +
and O +
talcum O +
powder O +
and O +
the O +
weight O +
ratio O +
of O +
starch O +
to O +
talcum O +
powder O +
is O +
1:1 O -
, O +
granulating O +
and O +
encapsulating O -
. O +

The O +
motherwort O +
and O +
astragalus O +
capsule O +
provided O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
simple O +
preparation O +
method O -
, O +
proper O +
compatibility O -
, O +
good O +
efficacy O -
, O +
no O +
toxic O +
or O +
side O +
effect O +
and O +
significant O +
treatment O +
effect O +
on O +
benign O +
prostatic O +
hyperplasia O -
, O +
is O +
innovative O +
in O +
the O +
treatment O +
of O +
benign O +
prostatic O +
hyperplasia O -
, O +
and O +
has O +
huge O +
economic O +
and O +
social O +
benefits O -
. O +

Chondrocyte O -
- O -
like O +
cell O -
, O +
and O +
method O +
for O +
producing O +
same O +
Disclosed O +
is O +
a O +
cell O +
which O +
enables O +
the O +
reproduction O +
of O +
a O +
cartilage O +
tissue O +
and O +
has O +
a O +
proliferative O +
ability O -
. O +

Also O +
disclosed O +
is O +
a O +
technique O +
for O +
providing O +
a O +
cell O +
supply O +
source O +
which O +
can O +
be O +
used O +
in O +
a O +
definitive O +
treatment O +
of O +
osteochondrosis O +
deformans O -
. O +

A O +
chondrocyte O -
- O -
like O +
cell O +
which O +
has O +
the O +
same O +
properties O +
as O +
those O +
of O +
a O +
chondrocyte O +
and O +
can O +
proliferate O +
can O +
be O +
produced O +
by O +
selecting O +
a O +
combination O +
of O +
an O +
Myc B-Gene +
family O +
gene O +
and/or O +
a O +
Klf B-Gene +
family O +
gene O +
and O +
a O +
SOX9 B-Gene +
gene I-Gene +
and O +
introducing O +
the O +
combination O +
into O +
a O +
somatic O +
cell O -
. O +

The O +
chondrocyte O -
- O -
like O +
cell O +
can O +
be O +
used O +
for O +
a O +
medical O +
purpose O +
of O +
cartilage O +
regeneration O -
. O +

Medicinal O +
composition O +
for O +
preventing O +
or O +
treating O +
cystitis O +
caused O +
by O +
chemotherapy O +
The O +
invention O +
relates O +
to O +
a O +
medicinal O +
composition O +
for O +
preventing O +
or O +
treating O +
cystitis O +
caused O +
by O +
chemotherapy O -
. O +

The O +
medicinal O +
composition O +
consists O +
of O +
mesna O -
, O +
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine O +
carbonic O +
acid O +
or O +
a O +
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine O +
carbonic O +
acid O +
derivative O +
and O +
a O +
pharmaceutically O +
acceptable O +
medicinal O +
carrier O -
. O +

The O +
combined O +
medication O +
of O +
the O +
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine O +
carbonic O +
acid O +
as O +
well O +
as O +
the O +
derivative O +
thereof O +
and O +
the O +
mesna O +
has O +
an O +
unexpected O +
therapeutic O +
effect O +
on O +
preventing O +
or O +
treating O +
the O +
cystitis O +
caused O +
by O +
a O +
chemotherapeutic O +
medicament O -
. O +

The O +
medicinal O +
composition O +
contributes O +
to O +
relieving O +
the O +
pain O +
of O +
a O +
chemotherapy O +
patient O -
; O +
and O +
the O +
tolerance O +
dose O +
of O +
the O +
patient O +
to O +
the O +
chemotherapeutic O +
medicament O +
is O +
improved O -
. O +

Compared O +
with O +
the O +
conventional O +
medicamentssuch O +
as O +
the O +
mesna O +
and O +
the O +
like O -
, O +
the O +
medicinal O +
composition O +
has O +
the O +
advantages O +
that O -
: O +
the O +
composition O +
of O +
the O +
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine O +
carbonic O +
acid O +
as O +
well O +
as O +
the O +
derivative O +
thereof O +
and O +
the O +
mesna O +
has O +
a O +
wide O +
therapeutic O +
effect O +
on O +
the O +
cystitis O +
caused O +
by O +
the O +
chemotherapeutic O +
medicament O +
and O +
has O +
a O +
limited O +
prevention O +
effect O -
. O +

Application O +
of O +
lycium O +
barbarum O +
polysaccharides O +
for O +
preparing O +
drugs O +
for O +
preventing O +
and O +
treating O +
chronic O +
stress O +
and O +
posttraumatic O +
stress O +
disorder O +
The O +
invention O +
discloses O +
application O +
of O +
lycium O +
barbarum O +
polysaccharides O +
for O +
preparing O +
drugs O +
for O +
preventing O +
and O +
treating O +
chronic O +
stress O +
and O +
posttraumatic O +
stress O +
disorder O -
. O +

The O +
application O +
is O +
characterized O +
by O +
comprising O +
the O +
following O +
steps O +
of O -
: O +
filling O +
the O +
extracted O +
lycium O +
barbarum O +
polysaccharides O +
with O +
the O +
purity O +
of O +
more O +
than O +
or O +
equal O +
to O +
50 O -
% O +
in O +
capsules O +
or O +
preparing O +
the O +
lycium O +
barbarum O +
polysaccharidesinto O +
tablets O -
, O +
wherein O +
each O +
capsule O +
contains O +
500 O +
mg O +
of O +
the O +
lycium O +
barbarum O +
polysaccharides O -
, O +
or O +
each O +
tablet O +
contains O +
500 O +
mg O +
of O +
the O +
lycium O +
barbarum O +
polysaccharides O -
; O +
uniformly O +
mixing O +
the O +
extracted O +
lyciumbarbarum O +
polysaccharides O +
with O +
the O +
purity O +
of O +
more O +
than O +
or O +
equal O +
to O +
50 O -
% O +
and O +
corn O +
startch O -
; O +
and O +
filling O +
the O +
mixture O +
into O +
capsules O +
or O +
preparing O +
the O +
mixture O +
into O +
tablets O -
, O +
wherein O +
each O +
capsule O +
contains O +
500 O +
mg O +
of O +
the O +
lycium O +
barbarum O +
polysaccharides O +
and O +
100 O +
mg O +
of O +
the O +
corn O +
starch O -
, O +
or O +
each O +
tablet O +
contains O +
500 O +
mg O +
of O +
the O +
lycium O +
barbarum O +
polysaccharides O +
and O +
100 O +
mg O +
of O +
the O +
corn O +
starch O -
. O +

The O +
application O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
benefits O +
that O -
: O +
the O +
drugs O +
are O +
prescribed O +
preparations O +
composed O +
of O +
the O +
lycium O +
barbarum O +
polysaccharides O -
; O +
the O +
drugs O +
have O +
anti O -
- O -
stress O +
effect O +
and O +
are O +
capable O +
of O +
preventing O +
and O +
treating O +
chronic O +
stress O +
and/or O +
posttraumatic O +
stress O +
disorder O +
and O +
improving O +
cognitive O +
function O -
; O +
the O +
pharmaceutical O +
effect O +
is O +
clear O -
; O +
the O +
safety O +
is O +
high O -
; O +
and O +
the O +
novel O +
drug O +
application O +
selection O +
is O +
provided O +
in O +
clinical O -
. O +

Cucoline O +
derivative O +
as O +
well O +
as O +
salts O -
, O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
medicine O -
, O +
and O +
in O +
particular O +
relates O +
to O +
a O +
cucoline O +
derivative O +
as O +
well O +
as O +
salts O -
, O +
a O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

According O +
to O +
the O +
invention O -
, O +
1 O -
, O +
4 O -
, O +
6 O +
and O +
17 O +
positions O +
in O +
a O +
cucoline O +
structure O +
are O +
modified O +
so O +
as O +
to O +
obtain O +
the O +
cucoline O +
derivative O +
the O +
structural O +
general O +
formula O +
of O +
which O +
is O +
as O +
follows O +
( O -
shown O +
in O +
the O +
specification O -
) O -
; O +
the O +
salts O +
of O +
the O +
cucoline O +
derivative O +
comprise O +
hydrochloride O -
, O +
sulfate O -
, O +
bisulfate O -
, O +
hydrobromide O -
, O +
oxalate O -
, O +
citrate O +
and O +
mesylate O -
; O +
and O +
the O +
inhibition O +
activity O +
of O +
partial O +
compounds O +
of O +
the O +
invention O +
on O +
NF B-Gene -
- I-Gene -
kappa I-Gene +
B I-Gene +
are O +
obviously O +
superior O +
to O +
that O +
of O +
cucoline O -
, O +
and O +
the O +
cucoline O +
derivative O +
and O +
salts O +
thereof O +
are O +
used O +
for O +
preparing O +
anti O -
- O -
inflammatory O +
medicaments O -
. O +

Ambroxol O +
hydrochloride O +
oral O +
aqueous O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
an O +
oral O +
aqueous O +
composition O -
, O +
which O +
comprises O +
0.1 O +
to O +
1 O +
percent O +
( O -
w O -
/ O -
v O -
) O +
of O +
ambroxol O +
hydrochloride O -
, O +
0.05 O +
to O +
0.2 O +
percent O +
( O -
w O -
/ O -
v O -
) O +
of O +
solution O +
thickener O -
, O +
0.005 O +
to O +
0.05 O +
percent O +
( O -
w O -
/ O -
v O -
) O +
of O +
freshener O -
, O +
a O +
stabilizer O +
and O +
water O -
, O +
wherein O +
the O +
stabilizer O +
is O +
a O +
substance O +
for O +
forming O +
a O +
medicinal O +
solvent O +
system O +
by O +
combining O +
the O +
water O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
for O +
the O +
composition O -
. O +

The O +
oral O +
aqueous O +
composition O +
has O +
the O +
advantages O +
of O +
cool O +
and O +
refreshing O +
mouthfeel O -
, O +
wide O +
application O +
range O +
and O +
the O +
like O -
, O +
is O +
clear O +
and O +
stable O -
, O +
does O +
not O +
contain O +
any O +
natural O +
or O +
semi O -
- O -
synthetic O +
sweetener O -
, O +
and O +
is O +
suitable O +
for O +
patients O +
who O +
suffer O +
from O +
diabetes O +
and O +
people O +
who O +
are O +
allergic O +
to O +
the O +
semi O -
- O -
synthetic O +
sweetener O -
. O +

Drug O +
combination O +
containing O +
astragalus O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
drug O +
combination O +
containing O +
astragalus O +
and O +
a O +
use O +
thereof O -
. O +

The O +
drug O +
combination O +
contains O +
astragalus O +
or O +
an O +
astragalus O +
extractive O +
or O +
a O +
derivative O +
thereof O +
capable O +
of O +
being O +
received O +
chemically O -
. O +

The O +
drug O +
combination O +
comprises O +
the O +
following O +
components O -
: O +
100 O +
parts O +
of O +
astragalus O +
and O +
1 O -
- O -
50 O +
of O +
levamisole O +
hydrochloride O -
. O +

On O +
the O +
basis O -
, O +
the O +
following O +
one O +
or O +
more O +
components O +
can O +
be O +
increased O -
, O +
but O +
not O +
limited O -
: O +
20 O -
- O -
150 O +
parts O +
of O +
vitamin O +
C. O +
The O +
use O +
method O +
and O +
the O +
dosage O +
of O +
the O +
combination O +
are O +
shown O +
as O +
follows O -
: O +
a O +
solid O +
preparation O +
is O +
used O +
after O +
being O +
mixed O +
by O +
0.1 O -
- O -
10.0 O +
percent O +
of O +
complete O +
feeds O -
; O +
and O +
a O +
liquid O +
preparation O +
is O +
drunk O +
after O +
the O +
water O +
of O +
250 O -
- O -
500 O +
kg O +
is O +
added O +
in O +
the O +
liquid O +
preparation O +
of O +
100 O +
ml O -
. O +

The O +
combination O +
has O +
the O +
main O +
function O +
of O +
inducing O +
a O +
human O +
body O +
to O +
generate O +
the O +
interferon O -
, O +
promoting O +
the O +
antibody O +
formation O +
and O +
adjusting O +
the O +
immunologic O +
function O +
of O +
the O +
human O +
body O -
. O +

The O +
drug O +
combination O +
is O +
used O +
for O +
simulating O +
an O +
immune O +
system O +
of O +
an O +
animal O +
body O -
, O +
adjusting O +
the O +
immunity O -
, O +
enhancing O +
the O +
disease O +
resistance O -
, O +
reducing O +
the O +
disease O +
incidence O +
and O +
assisting O +
to O +
treat O +
the O +
virus O +
infection O -
. O +

Fenticonazole O +
nitrate O +
medicinal O +
composition O +
The O +
invention O +
provides O +
a O +
fenticonazole O +
nitrate O -
- O -
containing O +
medicinal O +
composition O -
. O +

The O +
fenticonazole O +
nitrate O -
- O -
containing O +
medicinal O +
composition O +
consists O +
of O +
fenticonazole O +
nitrate O -
, O +
36-type O +
mixed O +
fatty O +
acid O +
glyceride O +
and O +
silicon O +
dioxide O +
in O +
a O +
ratio O +
of O +
2: O -
( O -
10 O -
- O -
14 O -
) O -
: O -
( O -
0.05 O -
- O -
0.10 O -
) O -
. O +

By O +
the O +
formula O -
, O +
the O +
problem O +
that O +
in O +
the O +
prior O +
art O -
, O +
active O +
ingredients O +
can O -
not O +
be O +
dispersed O +
well O +
is O +
solved O -
. O +

Medicinal O +
composition O +
of O +
amlodipine O +
and O +
atorvastatin O +
calcium O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
relates O +
to O +
a O +
medicinal O +
composition O +
by O +
taking O +
amlodipine O +
and O +
atorvastatin O +
calcium O +
as O +
active O +
components O -
, O +
the O +
medicinal O +
composition O +
comprises O +
amlodipine O -
, O +
atorvastatin O +
calcium O -
, O +
a O +
filler O -
, O +
a O +
disintegrant O +
and O +
a O +
lubricant O -
; O +
the O +
active O +
components O +
are O +
composed O +
of O +
2 O -
- O -
20 O +
parts O +
of O +
amlodipine O +
and O +
5 O -
- O -
120 O +
parts O +
of O +
atorvastatin O +
calcium O -
; O +
the O +
amlodipine O +
is O +
a O +
maleic O +
acid O +
amlodipine O +
hydrate O +
crystal O -
. O +

The O +
molecular O +
formula O +
of O +
the O +
maleic O +
acid O +
amlodipine O +
hydrate O +
crystal O +
is O +
C24H29C1N2O9.1.5H2O O -
. O +

The O +
amlodipine O +
in O +
the O +
medicinal O +
composition O +
has O +
the O +
advantages O +
of O +
fast O +
effectiveness O +
and O +
stability O -
, O +
and O +
is O +
capable O +
of O +
steadily O +
releasing O +
the O +
drug O +
effect O +
in O +
24 O +
hours O -
, O +
the O +
medicinal O +
composition O +
has O +
strong O +
synergy O -
, O +
accumulation O +
and O +
complementary O +
effects O -
, O +
and O +
the O +
bioavailability O +
is O +
high O -
. O +

Application O +
of O +
atractylodin O +
alcohol O +
in O +
medicament O +
preparation O +
The O +
invention O +
provides O +
application O +
of O +
an O +
atractylodin O +
alcohol O +
( O -
CZSC O -
) O +
compound O +
in O +
preparation O +
of O +
medicaments O +
for O +
treating O +
animal O +
virus O +
diseases O -
, O +
in O +
particular O +
application O +
in O +
preparation O +
of O +
a O +
medicament O +
for O +
treating O +
porcine O +
reproductive O +
and O +
respiratory O +
syndrome O +
virus O +
( O -
PRRSV O -
) O +
infection O +
and O +
a O +
medicament O +
for O +
treating O +
porcine O +
reproductive O +
and O +
respiratory O +
syndrome O +
( O -
PRRS O -
) O -
, O +
or O +
in O +
preparation O +
of O +
a O +
virus O +
gene O +
expression O +
inhibitor O +
and O +
an O +
anti O -
- O -
virus O +
medicament O +
and O +
in O +
preparation O +
of O +
a O +
medicament O +
for O +
inhibiting O +
blue O +
ear O +
disease O +
viruses O -
. O +

The O +
CZSC O +
has O +
remarkable O +
effects O +
of O +
regulating O +
nucleoprotein B-Gene +
gene O +
expression O +
of O +
the O +
PRRSV O +
down O +
and O +
inhibiting O +
virus O +
proliferation O -
; O +
and O +
in O +
vitro O +
cellular O +
pharmacological O +
tests O +
shows O +
that O +
the O +
CZSC O +
has O +
definite O +
anti O -
- O -
virus O +
effect O -
. O +

The O +
CZSC O +
has O +
wide O +
application O +
prospect O +
in O +
treatment O +
and O +
control O +
of O +
PRRSV O +
infection O -
. O +

Wound O +
healing O +
gel O +
and O +
preparation O +
process O +
thereof O +
The O +
invention O +
relates O +
to O +
wound O +
healing O +
gel O +
and O +
a O +
preparation O +
process O +
thereof O -
, O +
which O +
belong O +
to O +
the O +
field O +
of O +
medicine O +
preparations O +
and O +
clinic O +
applications O -
. O +

The O +
wound O +
healing O +
gel O +
is O +
prepared O +
from O +
the O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
2 O +
to O +
3 O +
percent O +
of O +
paste O +
powder O -
, O +
0.5 O +
to O +
2 O +
percent O +
of O +
30-percent O +
borneol O +
solution O -
, O +
8 O +
to O +
12 O +
percent O +
of O +
glycerol O -
, O +
0.8 O +
to O +
1.2 O +
percent O +
of O +
carbomer O -
, O +
0.1 O +
to O +
0.2 O +
percent O +
of O +
NaHSO3 O -
, O +
0.02 O +
to O +
0.04 O +
percent O +
of O +
ethylene O +
diamine O +
tetraacetic O +
acid O +
disodium O +
( O -
EDTA-2Na O -
) O -
, O +
8 O +
to O +
12 O +
percent O +
of O +
propylene O +
glycol O -
, O +
0.5 O +
to O +
2 O +
percent O +
of O +
10-percent O +
methylparaben O +
solution O -
, O +
1.4 O +
to O +
1.8 O +
percent O +
of O +
triethanolamine O +
and O +
50 O +
to O +
80 O +
percent O +
of O +
distilled O +
water O -
. O +

The O +
gel O +
can O +
be O +
used O +
for O +
treating O +
radiation O +
injury O -
, O +
cold O +
injury O +
and O +
burn O -
. O +

The O +
gel O +
can O +
be O +
used O +
for O +
II O +
degree O +
surface O +
of O +
burns O +
and O +
can O +
accelerate O +
the O +
healing O +
of O +
the O +
surface O +
of O +
burns O +
and O +
relieve O +
swelling O +
of O +
surface O +
of O +
burns O +
and O +
dehydration O +
of O +
the O +
wound O +
tissue O +
obviously O -
. O +

And O +
the O +
gel O +
has O +
the O +
characteristics O +
that O -
: O +
the O +
treatment O +
effect O +
is O +
exact O -
; O +
the O +
use O +
is O +
safe O -
; O +
the O +
quality O +
index O +
is O +
easy O +
to O +
control O -
; O +
the O +
price O +
is O +
low O -
; O +
and O +
the O +
like O -
. O +

Mangiferin O +
penta O -
- O -
esterified O +
derivative O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
chemically O +
synthesizing O +
a O +
mangiferin O +
penta O -
- O -
esterified O +
derivative O +
and O +
a O +
pharmacological O +
effect O +
of O +
resisting O +
inflammation O +
and O +
reducing O +
blood O +
sugar O +
of O +
the O +
derivative O -
. O +

The O +
chemical O +
structural O +
formula O +
of O +
the O +
derivative O +
is O +
shown O +
in O +
the O +
specifications O -
. O +

The O +
derivative O +
has O +
a O +
remarkable O +
effect O +
of O +
inhibiting O +
mouse O +
auricle O +
tumefaction O +
caused O +
by O +
dimethylbenzene O -
; O +
and O +
the O +
derivative O +
has O +
a O +
remarkable O +
effect O +
of O +
treating O +
diabetic O +
mice O +
induced O +
by O +
alloxan O -
. O +

New O +
aromatic O +
polyketones O -
, O +
extraction O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
microbial O +
engineering O -
, O +
and O +
specifically O +
relates O +
to O +
new O +
daldiniaeschscholzii O +
aromatic O +
polyketones O -
, O +
an O +
extraction O +
method O +
and O +
an O +
application O +
thereof O -
, O +
wherein O +
the O +
aromatic O +
polyketones O +
are O +
extracted O +
from O +
a O +
liquid O +
fermented O +
material O +
of O +
the O +
intestinal O +
bacteria O +
of O +
Tenoderaaridifolia O -
, O +
and O +
the O +
intestinal O +
bacteria O +
of O +
the O +
Tenoderaaridifolia O +
is O +
the O +
daldiniaeschscholzii O -
. O +

The O +
daldiniaeschscholzii O +
aromatic O +
polyketones O +
of O +
the O +
present O +
invention O +
have O +
the O +
following O +
structural O +
formula O -
. O +

The O +
daldiniaeschscholzii O +
aromatic O +
polyketone O +
1 O +
has O +
strong O +
antioxidant O +
activity O -
, O +
and O +
the O +
daldiniaeschscholzii O +
aromatic O +
polyketones O +
of O +
2 O -
- O -
5 O +
have O +
strong O +
immunosuppression O +
activities O -
, O +
such O +
that O +
the O +
daldiniaeschscholzii O +
aromatic O +
polyketones O +
of O +
1 O -
- O -
5 O +
can O +
be O +
adopted O +
for O +
preparing O +
the O +
relevant O +
novel O +
drugs O -
, O +
wherein O +
the O +
daldiniaeschscholzii O +
aromatic O +
polyketones O +
of O +
1 O -
- O -
5 O +
are O +
adopted O +
as O +
the O +
compounds O +
with O +
the O +
antioxidant O +
effects O +
or O +
the O +
immunosuppression O +
effects O -
. O +

Freeze O -
- O -
dried O +
powder O +
injection O +
with O +
omeprazole O +
sodium O +
as O +
active O +
component O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
freeze O -
- O -
dried O +
powder O +
injection O +
with O +
omeprazole O +
sodium O +
as O +
its O +
active O +
component O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
freeze O -
- O -
dried O +
powder O +
injection O +
is O +
prepared O +
from O +
omeprazole O +
sodium O -
, O +
edetate O +
disodium O -
, O +
a O +
pH O +
value O +
conditioning O +
agent O +
and O +
injection O +
water O -
, O +
wherein O +
the O +
omeprazole O +
sodium O +
is O +
a O +
novel O +
omeprazole O +
sodium O +
crystalline O +
compound O +
with O +
a O +
molecular O +
formula O +
of O +
C17H18N3NaO3S.2H2O O -
. O +

The O +
omeprazole O +
sodium O +
in O +
the O +
freeze O -
- O -
dried O +
powder O +
injection O +
is O +
the O +
novel O +
omeprazole O +
sodium O +
crystalline O +
compound O -
, O +
and O +
the O +
freeze O -
- O -
dried O +
powder O +
injection O +
prepared O +
from O +
the O +
novel O +
omeprazole O +
sodium O +
crystalline O +
compound O +
has O +
excellent O +
stability O -
. O +

Novel O +
pyrimidine O +
derivatives O +
as O +
well O +
as O +
preparation O +
method O +
and O +
applications O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
pyrimidine O +
compounds O +
and O +
preparation O +
methods O +
thereof O -
. O +

The O +
novel O +
pyrimidine O +
derivatives O +
and O +
salts O +
thereof O +
are O +
compounds O +
shown O +
in O +
the O +
formula O +
( O -
1 O -
) O +
in O +
the O +
specification O -
, O +
wherein O +
R1 O +
represents O +
-CH2NHR4 O +
or O +
cyano O +
group O -
; O +
R2 O +
and O +
R3 O +
independently O +
represent O +
aryl O +
and O +
substituted O +
aryl O -
; O +
X O +
represents O +
methylene O -
, O +
carbonyl O +
or O +
hydroxymethylene O -
; O +
R4 O +
represents O +
H O -
, O +
acetyl O +
or O +
tosyl O -
; O +
and O +
n O +
is O +
an O +
integer O +
of O +
0 O -
- O -
5 O -
. O +

A O +
series O +
of O +
new O +
compounds O +
are O +
prepared O +
by O +
the O +
inventor O +
of O +
the O +
invention O -
; O +
pharmacological O +
results O +
show O +
that O +
the O +
dipeptidyl B-Gene +
peptidase I-Gene +
IV I-Gene +
( O -
DPPIV B-Gene -
) O +
inhibition O +
rate O +
is O +
close O +
to O +
or O +
superior O +
to O +
that O +
of O +
the O +
reference O +
substance O +
R-1579 O -
; O +
and O +
some O +
pyrimidine O +
compounds O +
with O +
new O +
structures O +
have O +
excellent O +
DPP B-Gene -
- I-Gene -
IV I-Gene +
inhibitory O +
activity O +
and O +
wide O +
application O +
prospects O -
. O +

Macrocyclic O +
4-amino O -
- O -
quinazoline O +
derivatives O +
and O +
their O +
use O +
as O +
MTKI O +
Disclosed O +
are O +
a O +
kinase B-Gene +
inhibitor O +
and O +
N O -
- O -
oxide O +
form O +
and O +
pharmaceutically O +
acceptable O +
isomerous O +
form O +
thereof O +
as O +
represented O +
by O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
Z O +
is O +
NH O -
, O +
and O +
the O +
other O +
substituents O +
are O +
as O +
defined O +
herein O -
. O +

Hypericin O +
albumin B-Gene +
nanoparticle O -
- O -
immune O +
globulin O +
G O +
antibody O +
conjugate O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
hypericin O +
albumin B-Gene +
nanoparticle O -
- O -
immune O +
globulin O +
G O +
antibody O +
conjugate O -
, O +
which O +
comprises O +
the O +
following O +
preparing O +
steps O -
: O +
step O +
( O -
1 O -
) O -
, O +
dissolving O +
the O +
hypericin O +
albumin O +
nanoparticle O +
and O +
the O +
immune O +
globulin O +
G O +
antibody O +
conjugate O +
into O +
phosphate O +
buffer O +
solution O +
( O -
PBF O -
) O -
, O +
step O +
( O -
2 O -
) O -
, O +
adding O +
glutaraldehyde O +
into O +
the O +
solution O +
obtained O +
by O +
the O +
step O +
( O -
1 O -
) O -
, O +
and O +
obtaining O +
the O +
hypericin O +
albumin O +
nanoparticle O -
- O -
immune O +
globulin O +
G O +
antibody O +
conjugate O -
. O +

The O +
hypericin O +
albumin B-Gene +
nanoparticle O -
- O -
immune O +
globulin O +
G O +
antibody O +
conjugate O +
has O +
the O +
advantages O +
of O +
high O +
effective O +
utilization O -
; O +
simultaneously O -
, O +
the O +
preparation O +
method O +
of O +
the O +
hypericin O +
albumin B-Gene +
nanoparticle O -
- O -
immune O +
globulin O +
G O +
antibody O +
conjugate O +
has O +
the O +
advantages O +
of O +
being O +
simple O +
in O +
process O -
, O +
easy O +
to O +
operate O +
and O +
specially O +
suitable O +
for O +
industrial O +
production O -
. O +

Composition O +
for O +
protecting O +
lever O +
and O +
achieving O +
sobering O +
function O +
The O +
invention O +
discloses O +
a O +
composition O +
for O +
protecting O +
lever O +
and O +
achieving O +
a O +
sobering O +
function O +
as O +
well O +
as O +
a O +
preparation O +
method O +
and O +
application O +
of O +
the O +
composition O -
. O +

The O +
composition O +
contains O +
30 O -
- O -
180 O +
parts O +
by O +
weight O +
of O +
sesamin O -
, O +
1 O -
- O -
6 O +
parts O +
by O +
weight O +
of O +
schisandrin O +
B O -
, O +
150 O -
- O -
900 O +
parts O +
by O +
weight O +
of O +
semen O +
hoveniae O +
extract O -
, O +
150 O -
- O -
900 O +
parts O +
by O +
weight O +
of O +
pueraria O +
lobata O +
extract O -
, O +
0.0012 O -
- O -
0.0072 O +
parts O +
by O +
weight O +
of O +
vitamin O +
B12 O +
and O +
14 O -
- O -
84 O +
parts O +
by O +
weight O +
of O +
vitamin O +
E. O +

Bisabolane O +
sesquiterpenoid O -
, O +
preparation O +
method O +
thereof O +
and O +
application O +
thereof O +
as O +
selective O +
antibacterial O +
agent O +
The O +
invention O +
discloses O +
a O +
bisabolane O +
sesquiterpenoid O -
, O +
a O +
preparation O +
method O +
thereof O +
and O +
application O +
thereof O +
as O +
a O +
selective O +
antibacterial O +
agent O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
performing O +
strain O +
culturing O +
on O +
a O +
sponge O +
endophytic O +
fungi O -
, O +
i.e. O +
Asergillus O +
sp. O +
( O -
HM565949 O -
) O +
in O +
a O +
strain O +
medium O -
; O +
cultivating O +
the O +
fungi O +
by O +
fermenting O +
in O +
a O +
fermentation O +
medium O -
; O +
filtering O +
the O +
obtained O +
fermentation O +
broth O +
to O +
remove O +
thallus O -
, O +
concentrating O +
the O +
filtrate O -
, O +
and O +
extracting O +
the O +
filtrate O +
with O +
ethyl O +
acetate O -
; O +
and O +
performing O +
chromatographic O +
separation O +
on O +
the O +
concentrate O +
and O +
respectively O +
concentrating O +
the O +
obtained O +
eluent O +
to O +
obtain O +
white O +
powder O -
, O +
i.e. O +
the O +
aspergterpeinoid O +
A O -
, O +
aspergiterpenoid O +
C O +
and O +
aspergiterpenoid O +
D. O +
The O +
bisabolane O +
sesquiterpenoid O +
obtained O +
from O +
a O +
marine O +
fungi O +
can O +
selectively O +
inhibit O +
the O +
activities O +
of O +
Staphylococcus O +
albus O -
, O +
Bacillus O +
subtilis O -
, O +
Bacillus O +
cereus O -
, O +
Sarcina O +
lutea O -
, O +
Escherichia O +
coli O -
, O +
Micrococcus O +
tetrgenus O -
, O +
marine O +
bacterial O +
Vibrio O +
parahaemolyticus O +
and O +
marine O +
bacterial O +
Vibrio O +
anguillarum O -
, O +
and O +
can O +
be O +
used O +
for O +
developing O +
the O +
selective O +
antibacterial O +
agent O -
. O +

In O +
addition O -
, O +
the O +
raw O +
materials O +
can O +
be O +
massively O +
produced O +
and O +
are O +
free O +
of O +
the O +
limitation O +
of O +
resources O -
. O +

Therefore O -
, O +
the O +
bisabolane O +
sesquiterpenoid O +
has O +
wide O +
application O +
prospect O -
. O +

Injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
and O +
a O +
preparation O +
method O +
thereof O -
, O +
relating O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
. O +

The O +
injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
is O +
a O +
powder O +
injection O +
and O +
comprises O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
1 O +
part O +
of O +
carbazochrome O +
sodium O +
sulfonate O -
, O +
1.5 O -
- O -
8.5 O +
parts O +
of O +
pharmaceutically O +
acceptable O +
biological O +
carrier O -
, O +
0.1 O -
- O -
1.8 O +
parts O +
of O +
stabilizing O +
agent O +
and O +
2 O -
- O -
5 O +
parts O +
of O +
freezing O +
protective O +
agent O -
. O +

According O +
to O +
the O +
invention O -
, O +
the O +
stability O +
and O +
the O +
dissolvability O +
of O +
the O +
carbazochrome O +
sodium O +
sulfonate O +
are O +
improved O -
, O +
the O +
injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
has O +
no O +
remarkable O +
change O +
of O +
various O +
indexes O +
through O +
detection O +
after O +
being O +
placed O +
for O +
a O +
long O +
time O -
, O +
the O +
quality O +
of O +
the O +
injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
within O +
a O +
valid O +
period O +
is O +
ensured O +
to O +
be O +
qualified O -
; O +
and O +
the O +
injection O +
carbazochrome O +
sodium O +
sulfonate O +
suspension O +
can O +
be O +
slowly O +
administrated O +
for O +
a O +
long O +
time O -
, O +
thus O +
bioavailability O +
is O +
greatly O +
improved O -
. O +

The O +
pharmaceutically O +
acceptable O +
biological O +
carrier O -
, O +
i.e. O +
protein O -
, O +
is O +
degraded O +
in O +
vivo O +
without O +
toxicity O +
and O +
immunogenicity O -
; O +
and O +
meanwhile O -
, O +
medicine O +
therapeutic O +
indexes O +
can O +
be O +
effectively O +
increased O -
, O +
and O +
medicine O +
toxicity O +
is O +
lowered O +
and O +
medicine O +
side O +
effects O +
are O +
reduced O -
. O +

Adriamycin O +
lipid O +
pharmaceutical O +
composition O +
The O +
invention O +
relates O +
to O +
an O +
adriamycin O +
lipid O +
pharmaceutical O +
composition O +
comprising O +
the O +
following O +
components O -
: O +
( O -
1 O -
) O +
adriamycin O -
, O +
( O -
2 O -
) O +
phospholipids O -
, O +
( O -
3 O -
) O +
cholesterol O +
and O +
( O -
4 O -
) O +
a O +
compound O +
shown O +
as O +
the O +
formula O +
I O +
or O +
the O +
formula O +
9 O +
( O -
described O +
in O +
the O +
specification O -
) O +
or O +
physiologically O +
acceptable O +
salt O +
thereof O -
, O +
wherein O +
n O +
is O +
an O +
integral O +
number O +
of O +
5 O -
- O -
500 O -
, O +
m O +
is O +
an O +
integral O +
number O +
of O +
2 O -
- O -
12 O -
, O +
and O +
p O +
is O +
an O +
integral O +
number O +
of O +
1 O -
- O -
8 O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
method O +
and O +
application O +
of O +
the O +
lipid O +
pharmaceutical O +
composition O -
, O +
a O +
compound O +
shown O +
as O +
the O +
formula O +
I O +
or O +
the O +
formula O +
9 O +
as O +
well O +
as O +
a O +
preparation O +
method O +
and O +
application O +
of O +
the O +
compound O -
. O +

The O +
lipid O +
pharmaceutical O +
composition O +
provided O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
good O +
pH O +
sensitivity O +
and O +
optional O +
targeting O +
property O -
, O +
and O +
can O +
be O +
used O +
for O +
increasing O +
the O +
concentration O +
of O +
an O +
antitumour O +
medicament O +
at O +
a O +
target O +
part O +
and O +
also O +
reducing O +
the O +
toxic O +
and O +
side O +
effects O +
of O +
the O +
antitumour O +
medicament O +
at O +
a O +
non O -
- O -
target O +
part O +
when O +
being O +
taken O +
as O +
a O +
liposome O -
, O +
thus O +
improving O +
therapeutic O +
index O +
of O +
the O +
antitumour O +
medicament O -
. O +

Combined O +
treatment O +
of O +
osteoporosis O +
caused O +
by O +
cell O +
function O +
decline O +
and O +
pharmaceutical O +
composition O +
The O +
invention O +
discloses O +
a O +
new O +
pharmaceutical O +
composition O +
for O +
treating O +
osteoporosis O -
. O +

The O +
pharmaceutical O +
composition O +
can O +
greatly O +
improve O +
the O +
efficacy O +
of O +
osteoporosis O +
treatment O -
, O +
and O +
reduce O +
the O +
health O +
risks O +
and O +
side O +
effects O +
associated O +
with O +
taking O +
of O +
commonly O +
used O +
drugs O +
( O -
parathyroid B-Gene +
hormone I-Gene -
, O +
thyroid O +
hormone O -
, O +
estrogen O -
, O +
and O +
calcium O +
supplements O -
) O +
for O +
treating O +
osteoporosis O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
combined O +
treatment O +
method O +
of O +
osteoporosis O +
caused O +
by O +
cell O +
function O +
decline O -
. O +

The O +
method O +
includes O +
a O +
step O +
of O +
applying O +
an O +
effective O +
dose O +
of O +
to O +
the O +
new O +
pharmaceutical O +
composition O +
treating O +
osteoporosis O +
to O +
an O +
object O +
so O +
as O +
to O +
treat O +
osteoporosis O +
caused O +
by O +
cell O +
function O +
decline O +
of O +
the O +
object O -
. O +

Acer O +
truncatum O +
health O -
- O -
care O +
lozenge O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
health O -
- O -
care O +
lozenge O +
prepared O +
by O +
taking O +
an O +
acer O +
truncatum O +
extract O +
as O +
a O +
major O +
raw O +
material O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
health O -
- O -
care O +
lozenge O +
is O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
in O +
percentage O +
by O +
weight O -
: O +
20 O -
- O -
40 O +
percent O +
of O +
an O +
acer O +
truncatum O +
extract O -
, O +
15 O -
- O -
25 O +
percent O +
of O +
an O +
acer O +
truncatum O +
seed O +
extract O -
, O +
30 O -
- O -
64 O +
percent O +
of O +
a O +
seasoning O +
agent O +
and O +
1 O -
- O -
5 O +
percent O +
of O +
a O +
nutrition O +
fortifier O -
. O +

A O +
tablet O +
is O +
prepared O +
by O +
performing O +
deep O +
processing O +
on O +
terrestrial O +
plant O +
acer O +
truncatum O +
seeds O +
which O +
are O +
rich O +
in O +
nervonic O +
acid O +
and O +
terrestrial O +
plant O +
acer O +
truncatum O +
leaves O +
which O +
are O +
rich O +
in O +
flavone O -
, O +
and O +
has O +
the O +
effects O +
of O +
preventing O +
nerve O +
fiber O +
atrophy O -
, O +
promoting O +
brain O +
development O -
, O +
delaying O +
ageing O +
and O +
enhancing O +
the O +
immunity O +
and O +
digestive O +
function O +
of O +
a O +
human O +
body O -
; O +
and O +
over O -
- O -
high O +
blood O +
fat O +
concentration O +
in O +
blood O +
can O +
be O +
lowered O +
remarkably O -
, O +
and O +
the O +
occurrence O +
probability O +
of O +
diseases O +
such O +
as O +
certain O +
hypertension O +
and O +
cardiovascular O +
and O +
cerebrovascular O +
diseases O -
, O +
blood O +
circulation O +
disorder O -
, O +
and O +
the O +
like O +
is O +
lowered O -
. O +

Sinomenine O +
4-hydroxy O +
etherification O +
and O +
esterification O +
derivatives O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
sinomenine O +
4-hydroxy O +
etherification O +
and O +
esterification O +
derivatives O +
and O +
a O +
preparation O +
method O +
and O +
application O +
thereof O -
, O +
relating O +
to O +
the O +
field O +
of O +
pharmaceutical O +
chemistry O -
. O +

Specifically O -
, O +
the O +
invention O +
relates O +
to O +
sinomenine O +
4-hydroxy O +
etherification O +
and O +
esterification O +
derivatives O +
and O +
discloses O +
a O +
preparation O +
method O +
of O +
the O +
sinomenine O +
4-OH O +
etherification O +
and O +
esterification O +
derivatives O -
. O +

An O +
ICR O +
( O -
Institute O +
of O +
Cancer O +
Research O -
) O +
mouse O +
model O +
and O +
an O +
SD O +
( O -
sprague O +
dawley O -
) O +
rat O +
model O +
are O +
applied O +
to O +
test O +
the O +
anti O -
- O -
inflammatory O +
and O +
immune O +
activity O +
293 O +
cells O +
of O +
pNF O -
- O -
kB O -
- O -
luc O +
are O +
transfected O +
to O +
test O +
the O +
inhibition O +
of O +
the O +
compounds O +
to O +
an O +
NF O -
- O -
kB O +
signaling O +
channel O -
, O +
and O +
results O +
show O +
that O +
part O +
of O +
the O +
compounds O +
have O +
significant O +
anti O -
- O -
inflammatory O +
and O +
immune O +
activity O +
and O +
effects O +
on O +
inhibition O +
of O +
NF O -
- O -
kB. O +
The O +
derivatives O +
can O +
be O +
applied O +
in O +
preparation O +
of O +
anti O -
- O -
inflammatory O +
and O +
immune O +
medicine O -
. O +

Active O +
bacteriostasis O +
capsule O +
The O +
invention O +
relates O +
to O +
an O +
active O +
bacteriostasis O +
capsule O -
, O +
comprising O +
the O +
following O +
ingredients O -
, O +
by O +
weight O -
, O +
lactobacillus O +
20 O -
- O -
50 O -
% O -
, O +
bifidobacterium O +
20 O -
- O -
30 O -
% O -
, O +
lactococcus O +
15 O -
- O -
30 O -
% O +
and O +
oliho O +
chitosan O +
15 O -
- O -
30 O -
% O -
. O +

The O +
Active O +
bacteriostasis O +
capsule O +
provided O +
in O +
the O +
invention O +
adopts O +
a O +
micro O +
ecological O +
theory O +
of O +
using O +
bacterium O +
to O +
kill O +
bacterium O +
and O +
inter O -
- O -
restriction O +
between O +
organisms O -
. O +

Large O +
amount O +
of O +
beneficial O +
bacterium O +
to O +
restrain O +
harmful O +
bacterium O +
is O +
supplied O +
and O +
the O +
beneficial O +
bacterium O +
is O +
planted O +
on O +
the O +
inner O +
wall O +
of O +
reproductive O +
tract O -
, O +
forming O +
a O +
beneficial O +
bacteria O +
barrier O -
. O +

The O +
capsule O +
can O +
repair O +
and O +
activate O +
a O +
self O +
clean O +
function O +
of O +
female O -
, O +
thereby O +
a O +
healthy O +
reproduction O +
tract O +
environment O +
is O +
formed O -
. O +

The O +
capsule O +
can O +
be O +
used O +
to O +
treat O +
various O +
vaginal O +
disease O +
caused O +
by O +
flora O +
disturbance O +
and O +
dysbacteriosis O -
. O +

Antipyrotic O +
powder O +
for O +
external O +
use O +
The O +
invention O +
relates O +
to O +
an O +
antipyrotic O +
powder O +
for O +
external O +
use O -
. O +

The O +
antipyrotic O +
powder O +
is O +
characterized O +
by O +
comprising O +
phellodendron O -
, O +
radix O +
sophorae O +
flavescentis O -
, O +
borneol O -
, O +
scorpio O -
, O +
alum O +
and O +
Senecio O +
scandens O +
with O +
auxiliary O +
materials O +
including O +
tea O +
oil O +
and O +
pig O +
bile O -
. O +

A O +
preparation O +
method O +
of O +
the O +
antipyrotic O +
powder O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
weighing O +
the O +
above O +
various O +
raw O +
materials O +
according O +
to O +
a O +
weight O +
ratio O -
, O +
placing O +
into O +
a O +
pulverizer O -
, O +
stirring O +
and O +
crushing O -
, O +
sieving O +
through O +
a O +
sieve O +
of O +
6 O +
meshes O +
to O +
obtain O +
a O +
yellow O +
powder O -
, O +
and O +
packing O +
by O +
the O +
use O +
of O +
aluminium O +
foil O +
with O +
5 O -
g O +
per O +
pack O -
. O +

The O +
invention O +
has O +
the O +
following O +
significant O +
effects O -
: O +
drug O +
properties O +
are O +
mild O -
; O +
there O +
is O +
no O +
side O +
effect O -
; O +
the O +
treatment O +
cost O +
is O +
low O -
; O +
the O +
curative O +
effect O +
is O +
fast O +
with O +
no O +
ache O -
; O +
and O +
the O +
total O +
efficiency O +
is O +
about O +
more O +
than O +
90 O -
% O -
. O +

Tamsulosin O +
hydrochloride O +
osmotic O +
pump O +
controlled O -
- O -
release O +
tablet O +
The O +
invention O +
provides O +
a O +
novel O +
tamsulosin O +
hydrochloride O +
osmotic O +
pump O +
controlled O -
- O -
release O +
tablet O -
. O +

Ethyl O +
cellulose O +
and O +
povidone O +
are O +
used O +
as O +
membrane O +
forming O +
materials O +
of O +
a O +
semipermeable O +
membrane O -
, O +
and O +
the O +
asymmetric O +
tablet O +
form O +
is O +
preferably O +
selected O -
, O +
so O +
that O +
the O +
ageing O +
of O +
the O +
semipermeable O +
membrane O +
can O +
be O +
avoided O -
, O +
and O +
the O +
drug O +
residues O +
can O +
be O +
reduced O -
. O +

The O +
invention O +
also O +
provides O +
a O +
method O +
for O +
improving O +
the O +
ageing O +
resistance O +
of O +
the O +
tamsulosin O +
hydrochloride O +
osmotic O +
pump O +
controlled O -
- O -
release O +
tablet O -
, O +
wherein O +
the O +
method O +
is O +
characterized O +
in O +
that O +
the O +
ethyl O +
cellulose O -
- O -
povidone O +
are O +
used O +
as O +
the O +
membrane O +
forming O +
materials O +
of O +
the O +
semipermeable O +
membrane O -
. O +

In O +
addition O -
, O +
the O +
invention O +
also O +
provides O +
applications O +
of O +
the O +
ethyl O +
cellulose O -
- O -
povidone O +
composition O +
in O +
preparing O +
the O +
anti O -
- O -
ageing O +
tamsulosin O +
hydrochloride O +
osmotic O +
pump O +
controlled O -
- O -
release O +
tablet O -
. O +

Ester O +
derivative O +
of O +
high O +
veratryl O +
alcohol O +
and O +
medical O +
treatment O +
application O +
The O +
invention O +
discloses O +
an O +
ester O +
derivative O +
of O +
high O +
veratryl O +
alcohol O +
and O +
medical O +
treatment O +
application O -
, O +
and O +
belongs O +
to O +
the O +
field O +
of O +
medicines O -
. O +

A O +
compound O +
with O +
biological O +
activity O +
is O +
a O +
compound O +
in O +
a O +
general O +
formula O +
( O -
I O -
) O +
shown O +
in O +
the O +
specification O -
, O +
and O +
salt O -
, O +
a O +
solvate O +
or O +
a O +
hydrate O +
of O +
the O +
compound O -
, O +
wherein O +
X1 O +
is O +
H O +
or O +
COR1 O -
, O +
X2 O +
is O +
H O +
or O +
COR2 O -
, O +
X3 O +
is O +
H O +
or O +
COR3 O -
, O +
but O +
X1 O -
, O +
X2 O +
and O +
X3 O +
are O +
not O +
H O +
and O +
3-pyridyl O +
simultaneously O -
; O +
R1 O -
, O +
R2 O +
and O +
R3 O +
are O +
the O +
same O +
as O +
one O +
another O +
or O +
different O +
from O +
one O +
another O +
and O +
are O +
C1-C6 O +
alkyl O +
substituted O +
by O +
R4 O +
or O +
can O +
be O +
substituted O +
by O +
R9 O +
at O +
random O +
and O +
can O +
contain O +
one O +
or O +
more O +
4 O -
- O -
7-membered O +
rings O +
of O +
additional O +
heteroatom O +
of O +
O O -
, O +
S O -
( O -
O O -
) O -
n O +
and O +
NR9 O -
; O +
R4 O +
is O +
F O -
, O +
CF3 O -
, O +
OR5 O -
, O +
NR6R7 O +
or O +
S O -
( O -
O O -
) O -
nR8 O -
; O +
R5 O -
, O +
R6 O +
and O +
R7 O +
are O +
the O +
same O +
as O +
one O +
another O +
or O +
different O +
from O +
one O +
another O +
and O +
are O +
H O +
or O +
C1-C6 O +
alkyl O +
substituted O +
by O +
R4 O +
at O +
random O -
, O +
or O +
NR6R7 O +
is O +
one O +
or O +
more O +
C4-C6 O +
heterocycle O +
alkyl O +
rings O +
of O +
the O +
heteroatom O +
of O +
O O -
, O +
NR9 O +
and O +
S O -
( O -
O O -
) O -
n O -
; O +
each O +
n O +
is O +
0 O +
to O +
2 O -
; O +
R8 O +
is O +
C1-C6 O +
alkyl O -
; O +
R9 O +
is O +
C1-C4 O +
alkyl O +
which O +
is O +
defined O +
by O +
R4 O +
or O +
substituted O +
by O +
R4 O +
or O +
halogens O +
at O +
random O -
; O +
and O +
R9 O +
is O +
H O +
or O +
C1-C6 O +
alkyl O -
. O +

The O +
ester O +
derivative O +
has O +
the O +
effect O +
of O +
treating O +
liver O +
diseases O -
, O +
T O -
- O -
cell O +
proliferation O +
related O +
diseases O +
or O +
proinflammatory O +
cytokine O +
mediated O +
diseases O -
. O +

Gemcitabine O +
hydrochloride O +
lyophilized O +
powder O +
for O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
gemcitabine O +
hydrochloride O +
lyophilized O +
powder O +
for O +
injection O -
. O +

The O +
gemcitabine O +
hydrochloride O +
lyophilized O +
powder O +
consists O +
of O +
the O +
following O +
components O +
in O +
parts O +
by O +
mass O -
: O +
100 O +
parts O +
of O +
gemcitabine O +
hydrochloride O -
, O +
160 O -
- O -
180 O +
parts O +
of O +
lactose O +
and O +
3 O -
- O -
6 O +
parts O +
of O +
sodium O +
citrate O -
. O +

As O +
proved O +
by O +
influencing O +
factor O +
testing O +
investigation O -
, O +
each O +
detection O +
index O +
the O +
gemcitabine O +
hydrochloride O +
lyophilized O +
powder O +
for O +
injection O +
prepared O +
by O +
adopting O +
a O +
formula O +
and O +
a O +
process O +
provided O +
by O +
the O +
invention O +
does O +
not O +
change O +
remarkably O +
in O +
a O +
high O -
- O -
temperature O -
, O +
high O -
- O -
humidity O +
and O +
strong O -
- O -
light O -
- O -
irradiation O +
environment O -
, O +
and O +
high O +
stability O +
is O +
achieved O -
. O +

New O +
application O +
of O +
alpinetin O +
The O +
invention O +
discloses O +
new O +
application O +
of O +
alpinetin O -
. O +

The O +
new O +
application O +
means O +
that O +
the O +
alpinetin O +
serving O +
as O +
an O +
active O +
ingredient O +
is O +
used O +
for O +
preparing O +
medicaments O +
or O +
health O -
- O -
care O +
food O +
for O +
treating O +
ulcerative O +
colitis O -
. O +

Experimental O +
results O +
show O +
that O +
the O +
alpinetin O +
can O +
obviously O +
improve O +
the O +
symptoms O +
such O +
as O +
weight O +
loss O -
, O +
bloody O +
stool O -
, O +
colon O +
shortening O -
, O +
inflammatory O +
cell O +
infiltration O +
and O +
pathological O +
tissue O +
damage O +
of O +
ulcerative O +
colitis O +
mice O -
, O +
and O +
can O +
inhibit O +
the O +
expression O +
of O +
proinflammatory O +
factors O +
TNF O -
- O -
alpha O +
and O +
IL-6 O -
. O +

Therefore O -
, O +
the O +
alpinetin O +
serving O +
as O +
the O +
active O +
ingredient O +
is O +
expected O +
to O +
be O +
developed O +
into O +
a O +
medicament O +
or O +
health O -
- O -
care O +
food O +
for O +
treating O +
the O +
ulcerative O +
colitis O -
. O +

The O +
medicinal O +
value O +
of O +
the O +
alpinetin O +
can O +
be O +
fully O +
exerted O -
, O +
and O +
the O +
invention O +
has O +
significance O +
for O +
research O +
and O +
application O +
of O +
the O +
alpinetin O -
. O +

Mecobalamin O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
mecobalamin O +
tablet O +
which O +
has O +
very O +
low O +
content O +
of O +
related O +
substances O +
and O +
can O +
simultaneously O +
realize O +
rapid O +
disintegration O -
. O +

The O +
mecobalamin O +
tablet O +
is O +
prepared O +
by O +
mixing O +
mecobalamin O +
powder O +
with O +
a O +
coating O +
filling O +
agent O -
, O +
then O +
using O +
an O +
Opadry O +
coating O +
to O +
prepare O +
mecobalamin O +
coated O +
particles O +
under O +
the O +
conditions O +
of O +
protecting O +
from O +
light O -
, O +
further O +
adding O +
pharmaceutically O +
acceptable O +
tablet O +
excipients O -
, O +
and O +
tabletting O -
. O +

According O +
to O +
the O +
mecobalamin O +
tablet O +
provided O +
by O +
the O +
invention O -
, O +
the O +
process O +
flow O +
of O +
mecobalamin O +
which O +
is O +
very O +
sensitive O +
to O +
light O +
is O +
improved O +
from O +
the O +
way O +
of O +
firstly O +
tabletting O +
and O +
then O +
coating O +
to O +
the O +
way O +
of O +
firstly O +
coating O +
and O +
then O +
tabletting O -
.. O +

Through O +
an O +
advanced O +
powder O +
coating O +
technology O -
, O +
the O +
treatment O +
of O +
protecting O +
from O +
the O +
light O +
is O +
performed O +
on O +
the O +
mecobalamin O +
in O +
the O +
first O +
process O +
step O +
to O +
complete O +
the O +
protection O +
of O +
the O +
mecobalamin O +
so O +
as O +
to O +
enable O +
the O +
follow O -
- O -
up O +
process O +
steps O +
to O +
get O +
rid O +
of O +
the O +
influence O +
of O +
a O +
light O +
source O +
on O +
the O +
mecobalamin O -
, O +
the O +
means O +
of O +
controlling O +
the O +
related O +
substances O +
is O +
better O +
than O +
the O +
traditional O +
full O -
- O -
process O +
operation O +
of O +
protecting O +
from O +
the O +
light O -
, O +
the O +
coating O +
time O +
is O +
saved O -
, O +
and O +
the O +
efficiency O +
is O +
improved O -
. O +

Application O +
of O +
baicalin O +
to O +
preparation O +
of O +
medicament O +
for O +
treating O +
pneumonia O +
The O +
present O +
invention O +
relates O +
to O +
application O +
of O +
baicalin O +
to O +
preparation O +
of O +
a O +
medicament O +
for O +
treating O +
pneumonia O -
. O +

A O +
rabbit O +
erythrocyte O +
hemolysis O +
test O -
, O +
a O +
human O +
pulmonary O +
epithelial O +
cell O +
( O -
A549 O -
) O +
injury O +
protection O +
test O +
and O +
a O +
mouse O +
Staphylococcus O +
aureus O +
pneumonia O +
model O +
are O +
employed O +
to O +
confirm O +
the O +
treatment O +
effect O +
of O +
the O +
baicalin O -
. O +

Compared O +
with O +
an O +
antibiotic O +
therapy O -
, O +
the O +
use O +
of O +
baicalin O +
has O +
characteristics O +
of O +
no O +
drug O +
resistance O +
and O +
high O +
cure O +
rate O -
. O +

1-substituted-1H-1,2,4-triazole O -
- O -
formamide O +
derivatives O -
, O +
preparation O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
1-substituted-1H-1,2,4-triazole O -
- O -
formamide O +
derivatives O -
. O +

The O +
substitution O +
position O +
of O +
formamido O +
is O +
in O +
5- O +
or O +
3- O +
position O +
of O +
1H-1,2,4-triazole O -
, O +
rufinamide O +
is O +
a O +
lead O +
compound O -
, O +
the O +
parent O +
nucleus O +
1,2,3-triazole O +
is O +
replaced O +
by O +
1,2,4-triazole O -
, O +
the O +
structure O +
of O +
the O +
side O +
chain O +
formamide O +
is O +
maintained O -
, O +
different O +
substituted O +
aromatic O +
( O -
heterocyclic O -
) O +
rings O +
replace O +
2,6-difluorobenzene O +
structure O -
, O +
the O +
type O -
, O +
number O +
or O +
position O +
of O +
the O +
substituent O +
group O +
on O +
a O +
benzene O +
ring O +
is O +
changed O +
to O +
obtain O +
a O +
series O +
of O +
1-substituted-1H-1,2,4-triazole-5-formamide O -
/ O -
1-substituted-1H-1,2,4-triazole-3-formamide O +
derivatives O -
. O +

Pharmaceutical O +
activity O +
screening O +
experiments O +
prove O +
that O +
the O +
compounds O +
have O +
good O +
anticonvulsant O +
activity O -
, O +
and O +
can O +
be O +
applied O +
to O +
preparation O +
of O +
anticonvulsant O +
medicaments O -
. O +

The O +
preparation O +
method O +
has O +
reasonable O +
design O -
, O +
simple O +
steps O +
and O +
practicality O -
; O +
and O +
the O +
derivatives O +
have O +
the O +
structural O +
general O +
formula O +
in O +
the O +
specification O -
. O +

Use O +
of O +
compound O +
or O +
its O +
pharmaceutically O +
acceptable O +
salt O +
in O +
prevention O +
and O +
treatment O +
on O +
senile O +
dementia O +
The O +
invention O +
discloses O +
a O +
use O +
of O +
a O +
compound O +
or O +
its O +
pharmaceutically O +
acceptable O +
salt O +
in O +
prevention O +
and O +
treatment O +
on O +
senile O +
dementia O -
. O +

The O +
compound O +
is O +
N'- O -
{ O -
5- O -
[ O -
acetyl O -
( O -
hydroxyl O -
) O -
amido O -
] O -
pentyl O -
} O -
-N- O -
[ O -
5- O -
( O -
{ O -
4- O -
[ O -
( O -
5-aminopentyl O -
) O -
( O +
hydroxyl O -
) O -
amido O -
] O -
-4-keto O -
- O -
butyryl O -
} O -
amido O -
) O -
pentyl O -
] O -
-N O -
- O -
hydroxysuccinic O +
acid O +
amide O -
. O +

The O +
compound O +
or O +
its O +
pharmaceutically O +
acceptable O +
salt O +
can O +
be O +
used O +
as O +
a O +
drug O +
for O +
preventing O +
and O +
treating O +
senile O +
dementia O -
. O +

The O +
compound O +
or O +
its O +
pharmaceutically O +
acceptable O +
salt O +
can O +
penetrate O +
a O +
blood O +
brain O +
barrier O +
and O +
then O +
bind O +
with O +
a O +
heavy O +
metal O +
to O +
form O +
a O +
chelate O +
thereby O +
inhibiting O +
production O +
of O +
amyloid B-Gene +
in O +
the O +
brain O -
, O +
preventing O +
polymerization O +
and O +
accumulation O +
of O +
amyloid B-Gene -
, O +
dissolving O +
produced O +
amyloid B-Gene +
plaques O +
and O +
promoting O +
amyloid B-Gene +
degradation O -
. O +

Novel O +
pyridine O +
alkaloids O -
, O +
preparation O +
process O +
thereof O -
, O +
and O +
the O +
uses O +
of O +
the O +
pyridine O +
alkaloids O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
pyridine O +
alkaloid O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
or O +
a O +
pharmaceutically O +
acceptable O +
derivative O +
thereof O +
as O +
described O +
in O +
the O +
specification O -
, O +
the O +
process O +
for O +
the O +
preparation O +
of O +
the O +
same O -
, O +
and O +
the O +
composition O +
comprising O +
the O +
same O -
. O +

The O +
uses O +
of O +
a O +
pyridine O +
compound O +
for O +
increasing O +
the O +
activity O +
of O +
PPAR B-Gene -
[ I-Gene -
gamma I-Gene -
] I-Gene -
, O +
for O +
the O +
prevention O +
and/or O +
treatment O +
of O +
a O +
disease O +
or O +
disorder O +
related O +
to O +
insulin B-Gene +
resistance O -
, O +
and O +
for O +
the O +
prevention O +
and/or O +
treatment O +
of O +
metabolic O +
syndrome O +
or O +
its O +
complication O +
are O +
also O +
provided O -
. O +

The O +
invention O +
also O +
provides O +
extracts O +
of O +
red O +
yeast O -
- O -
fermented O +
products O +
and O +
their O +
uses O +
for O +
prevention O +
and/or O +
treatment O +
of O +
a O +
disease O +
or O +
disorder O +
related O +
to O +
insulin B-Gene +
resistance O -
, O +
such O +
as O +
metabolic O +
syndrome O -
. O +

Granulation O +
promoting O +
powder O +
for O +
treating O +
recurrent O +
aphthous O +
ulcer O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
granulation O +
promoting O +
powder O +
for O +
treating O +
recurrent O +
aphthous O +
ulcer O -
. O +

The O +
granulation O +
promoting O +
powder O +
comprises O +
the O +
following O +
components O -
: O +
125 O -
g O +
of O +
realgar O -
, O +
60 O -
g O +
of O +
amber O -
, O +
15 O -
g O +
of O +
borax O -
, O +
15 O -
g O +
of O +
borneol O -
, O +
15 O -
g O +
of O +
compound O +
of O +
glauber O -
- O -
salt O +
and O +
liquorice O +
and O +
250 O -
g O +
of O +
talcum O +
powder O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
preparation O +
method O +
of O +
the O +
granulation O +
promoting O +
powder O +
for O +
treating O +
recurrent O +
aphthous O +
ulcer O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
grinding O +
the O +
125 O -
g O +
of O +
realgar O -
, O +
60 O -
g O +
of O +
amber O -
, O +
15 O -
g O +
of O +
borax O -
, O +
15 O -
g O +
of O +
borneol O -
, O +
15 O -
g O +
of O +
compound O +
of O +
glauber O -
- O -
salt O +
and O +
liquorice O +
and O +
250 O -
g O +
of O +
talcum O +
powder O +
into O +
powder O -
; O +
uniformly O +
mixing O -
; O +
and O +
sub O -
- O -
packing O +
the O +
mixed O +
powder O -
. O +

Through O +
the O +
invention O -
, O +
the O +
medicine O +
can O +
be O +
directly O +
applied O +
to O +
the O +
lesion O +
to O +
completely O +
exert O +
the O +
efficacy O -
, O +
the O +
local O +
symptoms O +
of O +
red O -
, O +
swelling O -
, O +
itch O -
, O +
pain O +
and O +
the O +
like O +
can O +
be O +
relieved O -
, O +
the O +
exudation O +
and O +
incrustation O +
are O +
reduced O -
, O +
and O +
infection O +
is O +
eliminated O +
to O +
prompt O +
the O +
inflammation O +
absorption O +
and O +
quick O +
healing O +
of O +
wound O -
. O +

Dual O +
component O +
oral O +
care O +
product O +
A O +
pull O -
- O -
apart O +
fragrance O +
sampler O +
laminate O +
is O +
constructed O +
by O +
dispersing O +
microcapsules O +
containing O +
fragrance O +
oil O +
into O +
a O +
quick O +
setting O +
adhesive O -
. O +

The O +
resulting O +
dispersion O +
is O +
applied O +
to O +
a O +
surface O +
of O +
a O +
substrate O +
and O +
then O +
covered O +
with O +
an O +
overlayer O -
. O +

The O +
substrate O +
and O +
overlayer O +
adhere O +
to O +
the O +
dispersion O +
until O +
they O +
are O +
pulled O +
apart O +
whereby O +
the O +
microcapsules O +
are O +
fractured O -
, O +
releasing O +
the O +
fragrance O -
. O +

The O +
substrate O +
may O +
be O +
a O +
continuous O +
web O +
of O +
two O -
- O -
layer O +
stock O +
having O +
a O +
silicone O +
coated O +
liner O +
and O +
a O +
release O +
layer O +
on O +
which O +
the O +
dispersion O +
is O +
coated O +
for O +
making O +
fragrance O +
samplers O +
in O +
the O +
form O +
of O +
die O +
cut O +
labels O -
. O +

The O +
dispersion O +
may O +
be O +
applied O +
to O +
the O +
substrate O +
by O +
a O +
relief O +
printing O +
plate O +
at O +
a O +
station O +
of O +
a O +
printing O +
press O +
through O +
which O +
the O +
substrate O +
and O +
cover O +
layer O +
are O +
transported O -
. O +

Suction O +
therapy O +
for O +
repairing O +
brain O +
cells O -
, O +
containing O +
cerebral O +
hemorrhage O +
and O +
enhancing O +
immune O +
system O +
The O +
invention O +
aims O +
to O +
provide O +
a O +
suction O +
therapy O +
for O +
repairing O +
brain O +
cells O -
, O +
containing O +
cerebral O +
hemorrhage O +
and O +
enhancing O +
an O +
immune O +
system O -
. O +

The O +
therapy O +
is O +
composed O +
of O +
curcumin O -
, O +
CNB-001 O +
and O +
ornithine O +
and O +
is O +
characterized O +
by O +
the O +
utilization O +
of O +
a O +
suction O +
method O -
. O +

Active O +
ingredients O +
in O +
the O +
therapy O +
pass O +
through O +
a O +
respiratory O +
system O +
and O +
directly O +
penetrate O +
through O +
blood O +
cerebral O +
barrier O +
so O +
as O +
to O +
rapidly O +
reach O +
curative O +
effects O -
. O +

Preparation O +
method O +
and O +
application O +
of O +
ecdysone O -
- O -
rich O +
plant O +
standardized O +
extract O +
The O +
invention O +
discloses O +
a O +
preparation O +
method O +
and O +
an O +
application O +
of O +
an O +
ecdysone O -
- O -
rich O +
plant O +
standardized O +
extract O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
steps O +
of O -
: O +
extracting O +
ecdysone O -
- O -
rich O +
plant O +
materials O +
using O +
ethanol O +
under O +
reflux O -
, O +
filtering O -
, O +
concentrating O +
and O +
centrifuing O -
; O +
decolorizing O +
the O +
centrifuged O +
supernatant O -
, O +
purifying O +
by O +
macroporous O +
resin O +
column O +
chromatography O -
, O +
concentrating O +
and O +
drying O +
to O +
obtain O +
the O +
standardized O +
extract O -
. O +

The O +
method O +
is O +
simple O +
and O +
feasible O -
, O +
short O +
in O +
production O +
period O -
, O +
and O +
stable O +
and O +
controllable O +
in O +
quality O -
, O +
and O +
is O +
easy O +
for O +
preparation O +
and O +
industrial O +
production O +
in O +
a O +
standardized O +
and O +
batch O +
manner O -
; O +
and O +
the O +
similarity O +
of O +
the O +
extract O +
obtained O +
by O +
the O +
method O +
is O +
more O +
than O +
99 O -
% O +
by O +
HPLC O +
( O -
high O +
performance O +
liquid O +
chromatography O -
) O +
fingerprint O +
spectrum O +
detection O -
. O +

The O +
extract O +
can O +
be O +
applied O +
in O +
preparing O +
fixed O +
preparations O +
serving O +
as O +
drugs O +
for O +
reducing O +
blood O +
sugar O +
and O +
resisting O +
rheumatoid O +
arthritis O -
, O +
can O +
be O +
used O +
as O +
a O +
raw O +
material O +
for O +
natural O +
cosmetics O +
and O +
can O +
be O +
applied O +
in O +
animal O +
breeding O +
industry O -
. O +

Application O +
of O +
isobavachalcone O +
in O +
treating O +
nerve O +
inflammatory O +
diseases O +
The O +
invention O +
relates O +
to O +
application O +
of O +
isobavachalcone O +
displayed O +
in O +
formula O +
I O +
in O +
treating O +
microglial O +
cell O +
mediated O +
diseases O -
, O +
in O +
particular O +
to O +
application O +
of O +
isobavachalcone O +
in O +
preparing O +
medicines O +
for O +
treating O +
and/or O +
preventing O +
microglial O +
cell O +
mediated O +
diseases O +
especially O +
microglial O +
cell O +
mediated O +
neural O +
immune O +
inflammatory O +
diseases O +
caused O +
by O +
neurotoxic O +
effect O -
. O +

The O +
isobavachalcone O +
has O +
new O +
functions O +
of O +
being O +
capable O +
of O +
obviously O +
restraining O +
microglial O +
cellsfrom O +
activating O +
or O +
inducing O +
cells O +
to O +
die O -
, O +
restraining O +
generation O +
and O +
expression O +
of O +
inflammatory O +
media O +
NO O +
of O +
activated O +
microglial O +
cells O +
and O +
obviously O +
relieving O +
cytotoxicity O +
of O +
activated O +
microglial O +
cells O +
to O +
neurons O -
. O +

Therefore O -
, O +
isobavachalcone O +
can O +
be O +
applied O +
to O +
preventive O +
treatment O +
of O +
diseases O +
related O +
to O +
brain O +
immune O +
inflammatory O +
diseases O +
such O +
as O +
Parkinson O -
's O +
disease O -
. O +

Application O +
of O +
NSC23766 O +
on O +
preparing O +
medicines O +
for O +
treating O +
mental O +
excitation O +
drug O +
addiction O +
The O +
invention O +
discloses O +
application O +
of O +
NSC23766 O +
on O +
preparing O +
medicines O +
for O +
treating O +
mental O +
excitation O +
drug O +
addiction O -
. O +

The O +
NSC23766 O +
is O +
used O +
for O +
treating O +
cocaine O +
induction O +
behaviouristics O +
plasticity O +
changes O -
, O +
and O +
the O +
NSC23766 O +
is O +
proved O +
to O +
be O +
capable O +
of O +
effectively O +
restraining O +
behaviouristics O +
sensitization O +
action O +
and O +
conditioned O +
place O +
preference O +
induced O +
by O +
cocaine O -
, O +
the O +
NSC23766 O +
is O +
basically O +
free O +
of O +
toxic O +
and O +
side O +
effects O -
, O +
and O +
the O +
medicine O +
has O +
developing O +
prospects O +
and O +
can O +
treat O +
the O +
mental O +
excitation O +
drug O +
addiction O -
, O +
in O +
particular O +
to O +
cocaine O +
addiction O -
. O +

Pharmaceutical O +
composition O +
for O +
treating O +
diabetes O +
associated O +
with O +
hyperlipemia O +
and O +
preparation O +
method O +
The O +
invention O +
discloses O +
a O +
pharmaceutical O +
composition O +
for O +
treating O +
diabetes O +
associated O +
with O +
hyperlipemia O +
and O +
a O +
preparation O +
method O -
, O +
and O +
an O +
application O +
of O +
the O +
medicines O +
for O +
treating O +
diabetes O +
associated O +
with O +
hyperlipemia O -
. O +

The O +
pharmaceutical O +
composition O +
takes O +
a O +
mixture O +
of O +
at O +
least O +
one O +
or O +
more O +
of O +
Praeruptorin O +
A O -
, O +
Pb O -
- O -
Ia O +
and O +
its O +
isomeride O +
and O +
a O +
racemate O -
, O +
Praeruptorin O +
B O -
, O +
Pb O -
- O -
Ia O +
II O +
and O +
its O +
isomeride O +
and O +
a O +
racemate O -
, O +
and O +
Praeruptorin O +
C O +
according O +
to O +
certain O +
proportion O +
as O +
an O +
active O +
component O -
, O +
and O +
is O +
composed O +
of O +
the O +
mixture O +
and O +
a O +
conventional O +
drug O +
carrier O -
. O +

The O +
weight O +
percentage O +
content O +
of O +
the O +
active O +
component O +
is O +
0.1 O -
- O -
99.5 O -
% O -
. O +

The O +
pharmaceutical O +
composition O +
is O +
used O +
for O +
preparing O +
and O +
treating O +
diabetes O +
associated O +
with O +
hyperlipemia O -
. O +

The O +
pharmaceutical O +
composition O +
has O +
the O +
advantages O +
that O +
the O +
source O +
of O +
the O +
raw O +
materials O +
is O +
abundant O -
, O +
the O +
pharmaceutical O +
composition O +
has O +
substantial O +
prevention O +
and O +
treatment O +
effects O +
for O +
diabetes O +
associated O +
with O +
hyperlipemia O -
, O +
the O +
usage O +
is O +
convenient O -
, O +
and O +
provides O +
a O +
novel O +
treatment O +
candidate O +
medicine O +
for O +
patients O -
. O +

Veterinary O +
compound O +
florfenicol O +
injection O +
The O +
invention O +
aims O +
to O +
provide O +
a O +
veterinary O +
compound O +
florfenicol O +
injection O -
, O +
which O +
is O +
used O +
for O +
efficiently O +
treating O +
porcine O +
respiratory O +
disease O +
complex O +
and O +
porcine O +
digestive O +
tract O +
disease O -
. O +

Each O +
100ml O +
of O +
veterinary O +
compound O +
florfenicol O +
injection O +
contains O +
10 O -
- O -
30 O -
g O +
of O +
florfenicol O -
, O +
1 O -
- O -
5 O -
g O +
of O +
andrographolide O -
, O +
1 O -
- O -
3 O -
g O +
of O +
TMP O +
( O -
Trimethoprim O -
) O -
, O +
0.1 O -
- O -
0.2 O -
g O +
of O +
antioxygen O -
, O +
0.01 O -
- O -
0.02 O -
g O +
of O +
ethylenediaminetetraacetic O +
acid O +
disodium O -
, O +
and O +
the O +
balance O +
of O +
solvent O +
for O +
injection O -
. O +

The O +
veterinary O +
compound O +
florfenicol O +
injection O +
is O +
a O +
composition O +
of O +
the O +
florfenicol O -
, O +
the O +
andrographolide O +
and O +
the O +
TMP O +
which O +
have O +
significant O +
effects O +
on O +
the O +
porcine O +
respiratory O +
disease O +
complex O -
, O +
and O +
is O +
administrated O +
through O +
an O +
injection O +
way O -
, O +
the O +
dosage O +
is O +
accurate O -
, O +
the O +
absorption O +
is O +
quick O -
, O +
the O +
blood O +
concentration O +
is O +
high O -
, O +
the O +
distribution O +
is O +
wide O -
, O +
the O +
half O -
- O -
life O +
period O +
is O +
long O -
, O +
the O +
effective O +
concentration O +
maintenance O +
time O +
is O +
long O -
, O +
and O +
compared O +
with O +
the O +
pesticide O +
effect O +
of O +
the O +
existing O +
florfenicol O +
injection O +
and O +
the O +
herba O +
andrographitis O +
injection O -
, O +
the O +
pesticide O +
effect O +
of O +
the O +
veterinary O +
compound O +
florfenicol O +
injection O +
is O +
obviously O +
enhanced O -
. O +

Application O +
of O +
polysaccharide O +
sulphate O +
to O +
preparation O +
of O +
tumor O +
treatment O +
neovascularization O +
inhibitors O +
and O +
vascular O +
disrupting O +
agents O +
The O +
invention O +
provides O +
application O +
of O +
polysaccharide O +
sulphate O +
to O +
preparation O +
of O +
tumor O +
treatment O +
neovascularization O +
inhibitors O +
and O +
vascular O +
disrupting O +
agents O -
. O +

Experiments O +
prove O +
that O +
the O +
neovascularization O +
inhibiting O +
rate O -
, O +
the O +
maturation O +
blood O +
vessel O +
disrupting O +
rate O +
and O +
the O +
concentration O +
of O +
the O +
polysaccharide O +
sulphate O +
are O +
in O +
dosage O +
relying O +
relationship O +
in O +
a O +
certain O +
range O -
, O +
and O +
the O +
maturation O +
blood O +
vessel O +
disrupting O +
rate O +
and O +
the O +
polysaccharide O +
sulphate O +
acting O +
time O +
are O +
in O +
dosage O +
relying O +
relationship O -
. O +

The O +
application O +
provided O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
that O +
the O +
effect O +
of O +
the O +
polysaccharide O +
sulphate O +
in O +
the O +
aspects O +
of O +
tumor O +
neovascularization O +
inhibiting O +
and O +
tumor O +
blood O +
vessel O +
generation O +
disrupting O +
can O +
be O +
proved O -
, O +
and O +
the O +
polysaccharide O +
sulphate O +
can O +
be O +
used O +
for O +
tumor O +
blood O +
vessel O +
generation O +
and O +
other O +
blood O +
vessel O +
generation O +
disease O +
treatment O -
, O +
and O +
can O +
also O +
be O +
used O +
in O +
aspects O +
of O +
tumor O +
chemotherapy O +
and/or O +
auxiliary O +
chemotherapy O -
. O +

Many O +
diseases O +
of O +
people O +
are O +
relevant O +
to O +
the O +
blood O +
vessel O +
generation O -
, O +
and O +
the O +
polysaccharide O +
sulphate O +
as O +
the O +
neovascularization O +
inhibitors O +
and O +
vascular O +
disrupting O +
agents O +
can O +
be O +
widely O +
applied O +
to O +
the O +
treatment O +
of O +
diseases O +
of O +
tumor O +
and O +
the O +
like O -
. O +

The O +
application O +
provided O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
that O +
the O +
application O +
range O +
of O +
the O +
polysaccharide O +
sulphate O +
is O +
widened O -
, O +
and O +
the O +
scientific O +
basis O +
is O +
provided O +
for O +
the O +
purpose O +
development O +
of O +
the O +
polysaccharide O +
sulphate O +
in O +
the O +
anti O -
- O -
tumor O +
aspect O +
and O +
the O +
like O -
. O +

Vinflunine O +
liposome O +
preparation O +
and O +
preparation O +
method O +
of O +
vinflunine O +
liposome O +
preparation O +
The O +
invention O +
relates O +
to O +
a O +
vinflunine O +
liposome O +
preparation O +
and O +
the O +
preparation O +
method O +
thereof O -
. O +

The O +
vinflunine O +
liposome O +
preparation O +
mainly O +
comprises O +
vinflunine O +
or O +
salt O -
, O +
phospholipid O -
, O +
cholesterin O +
and O +
polyethylene O +
glycol O -
- O -
distearoyl O +
phosphatidyl O +
ethanolamine O +
of O +
the O +
vinflunine O -
, O +
wherein O +
salt O -
, O +
phospholipid O -
, O +
cholesterin O +
and O +
polyethylene O +
glycol O -
- O -
distearoyl O +
phosphatidyl O +
ethanolamine O +
are O +
pharmaceutically O +
acceptable O -
, O +
and O +
the O +
vinflunine O +
liposome O +
preparation O +
can O +
be O +
prepared O +
into O +
an O +
injection O +
or O +
a O +
lyophilized O +
preparation O -
. O +

The O +
preparation O +
method O +
is O +
simple O +
in O +
technology O -
, O +
easy O +
to O +
operate O +
and O +
suitable O +
for O +
industrial O +
production O -
, O +
and O +
long O -
- O -
circulating O +
vinflunine O +
liposomes O +
prepared O +
by O +
using O +
the O +
method O +
are O +
high O +
in O +
encapsulation O +
rate O +
and O +
good O +
in O +
stability O -
. O +

Iloperidone O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
an O +
iloperidone O +
composition O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

According O +
to O +
the O +
iloperidone O +
composition O -
, O +
iloperidone O +
which O +
is O +
taken O +
as O +
an O +
active O +
ingredient O +
is O +
pretreated O -
, O +
so O +
that O +
the O +
particle O +
size O +
of O +
the O +
iloperidone O +
is O +
minimized O -
; O +
and O +
therefore O -
, O +
the O +
dissolution O +
rate O +
of O +
the O +
iloperidone O +
is O +
effectively O +
increased O -
. O +

Stable O +
Formulations O +
For O +
Lyophilizing O +
Therapeutic O +
Particles O +
The O +
present O +
disclosure O +
generally O +
relates O +
to O +
lyophilized O +
pharmaceutical O +
compositions O +
comprising O +
polymeric O +
nanoparticles O +
which O -
, O +
upon O +
reconstitution O -
, O +
have O +
low O +
levels O +
of O +
greater O +
than O +
10 O +
micron O +
size O +
particles O -
. O +

Other O +
aspects O +
of O +
the O +
invention O +
include O +
methods O +
of O +
making O +
such O +
nanoparticles O -
. O +

Compound O +
neomycin O +
sulfate O +
composition O +
for O +
treating O +
pet O +
abscess O +
and O +
preparation O +
method O +
of O +
compound O +
neomycin O +
sulfate O +
composition O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
neomycin O +
sulfate O +
composition O +
for O +
treating O +
pet O +
abscess O +
and O +
a O +
preparation O +
method O +
of O +
the O +
compound O +
neomycin O +
sulfate O +
composition O -
. O +

The O +
composition O +
is O +
prepared O +
by O +
uniformly O +
mixing O +
the O +
following O +
components O +
by O +
weight O -
: O +
1 O -
- O -
3 O +
parts O +
of O +
neomycin O +
sulfate O -
, O +
3 O -
- O -
5 O +
parts O +
of O +
erythromycin O +
thiocyanate O -
, O +
1 O -
- O -
2 O +
parts O +
of O +
trimethoprim O +
lactate O -
, O +
1 O -
- O -
3 O +
parts O +
of O +
cetrimonium O +
bromide O -
, O +
3 O -
- O -
5 O +
parts O +
of O +
piperitol O -
, O +
50 O -
- O -
70 O +
parts O +
of O +
liquid O +
paraffin O -
, O +
7 O -
- O -
9 O +
parts O +
of O +
glycerol O -
, O +
0.4 O +
part O +
of O +
ethylparaben O -
, O +
1 O -
- O -
3 O +
parts O +
of O +
essence O -
, O +
80 O -
- O -
113 O +
parts O +
of O +
distilled O +
water O +
and O +
the O +
like O -
. O +

The O +
compound O +
neomycin O +
sulfate O +
composition O +
has O +
the O +
beneficial O +
effects O +
that O +
the O +
formula O +
is O +
reasonable O -
, O +
preparation O +
is O +
simple O -
, O +
curative O +
effects O +
are O +
very O +
remarkable O -
, O +
and O +
furthermore O -
, O +
clinical O +
application O +
show O +
that O +
the O +
compound O +
neomycin O +
sulfate O +
composition O +
has O +
special O +
effect O +
for O +
treating O +
pet O +
abscess O -
. O +

Application O +
of O +
dimethyldiguanide O +
in O +
drugs O +
taking O +
protective O +
effect O +
on O +
chemoradiotherapy O +
injury O +
The O +
invention O +
relates O +
to O +
an O +
application O +
of O +
dimethyldiguanide O +
in O +
drugs O +
taking O +
protective O +
effect O +
on O +
chemoradiotherapy O +
injury O -
. O +

As O +
an O +
optimal O +
implementation O +
scheme O -
, O +
the O +
invention O +
relates O +
to O +
the O +
application O +
of O +
the O +
dimethyldiguanide O +
in O +
preparing O +
drugs O +
taking O +
protective O +
effect O +
on O +
long O -
- O -
term O +
bone O +
marrow O +
suppression O +
caused O +
by O +
radiotherapy O -
. O +

As O +
an O +
optimal O +
implementation O +
scheme O -
, O +
the O +
invention O +
relates O +
to O +
the O +
application O +
of O +
the O +
dimethyldiguanide O +
in O +
preparing O +
drugs O +
taking O +
protective O +
effect O +
on O +
the O +
long O -
- O -
term O +
bone O +
marrow O +
suppression O +
caused O +
by O +
chemotherapeutics O -
. O +

Proved O +
by O +
the O +
invention O -
, O +
the O +
dimethyldiguanide O +
has O +
a O +
certain O +
protective O +
effect O +
on O +
hematopoietic O +
immune O +
cell O +
injury O +
caused O +
by O +
irradiation O +
and/or O +
the O +
chemotherapeutics O -
. O +

Application O +
of O +
Houttuynoid O +
B O +
in O +
medicines O +
for O +
inhibiting O +
pulmonary O +
metastasis O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Houttuynoid O +
B O +
in O +
preparing O +
medicines O +
for O +
inhibiting O +
pulmonary O +
metastasis O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
new O +
applications O +
of O +
medicines O -
. O +

Houttuynoid O +
B O +
can O +
inhibit O +
tumor O +
cell O +
mobility O +
and O +
migration O +
ability O -
. O +

The O +
application O +
of O +
Houttuynoid O +
B O +
in O +
preparing O +
medicines O +
for O +
inhibiting O +
pulmonary O +
metastasis O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
, O +
and O +
has O +
extremely O +
high O +
migration O +
inhibitory O +
activity O +
to O +
pulmonary O +
cells O -
. O +

Application O +
of O +
Houttuynoid O +
D O +
in O +
medicines O +
for O +
treating O +
nasopharyngeal O +
carcinoma O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Houttuynoid O +
D O +
in O +
medicines O +
for O +
treating O +
nasopharyngeal O +
carcinoma O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
new O +
applications O +
of O +
medicines O -
. O +

In O +
vitro O +
MTT O +
( O -
Methyl O +
Thiazolyl O +
Tetrazolium O -
) O +
antineoplastic O +
activity O +
evaluation O +
finds O +
that O +
Houttuynoid O +
D O +
has O +
remarkable O +
inhibition O +
effect O +
on O +
the O +
growth O +
of O +
human O +
nasopharyngeal O +
carcinoma O +
cell O +
lines O +
HNE1 O -
, O +
HNE1 O -
, O +
HONE O +
and O +
CNE1 O -
, O +
so O +
that O +
Houttuynoid O +
A O +
can O +
be O +
used O +
to O +
prepare O +
medicines O +
for O +
inhibiting O +
nasopharyngeal O +
carcinoma O +
and O +
has O +
good O +
development O +
application O +
prospect O -
. O +

The O +
application O +
of O +
Houttuynoid O +
D O +
in O +
medicines O +
for O +
treating O +
nasopharyngeal O +
carcinoma O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
, O +
and O +
has O +
extremely O +
high O +
inhibitory O +
activity O +
to O +
breast O +
caner O +
cells O +
as O +
the O +
skeleton O +
type O +
belongs O +
to O +
a O +
completely O +
novel O +
skeleton O +
type O -
. O +

Prulifloxacin O +
oral O +
solid O +
composition O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
prulifloxacin O +
oral O +
solid O +
composition O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
prulifloxacin O +
oral O +
solid O +
composition O +
is O +
prepared O +
from O +
130 O +
to O +
135 O +
parts O +
by O +
weight O +
of O +
prulifloxacin O -
, O +
10 O +
to O +
30 O +
parts O +
by O +
weight O +
of O +
starch O -
, O +
30 O +
to O +
50 O +
parts O +
by O +
weight O +
of O +
microcrystalline O +
cellulose O -
, O +
20 O +
to O +
40 O +
parts O +
by O +
weight O +
of O +
lactose O -
, O +
0.05 O +
to O +
10 O +
parts O +
by O +
weight O +
of O +
one O +
or O +
more O +
binders O -
, O +
2 O +
to O +
15 O +
parts O +
by O +
weight O +
of O +
one O +
or O +
more O +
disintegrants O +
and O +
0.5 O +
to O +
10 O +
parts O +
by O +
weight O +
of O +
one O +
or O +
more O +
lubricants O -
. O +

The O +
one O +
or O +
more O +
binders O +
are O +
selected O +
from O +
polyvinylpyrrolidone O -
, O +
lauryl O +
sodium O +
sulfate O +
and O +
polyethylene O +
glycol O +
mixed O +
aqueous O +
solutions O +
or O +
alcoholic O +
solutions O -
. O +

The O +
one O +
or O +
more O +
disintegrants O +
are O +
selected O +
from O +
carboxymethyl O +
starch O +
sodium O -
, O +
polyvinylpolypyrrolidone O +
and O +
hydroxy O +
propyl O +
cellulose O -
. O +

The O +
one O +
or O +
more O +
lubricants O +
are O +
selected O +
from O +
magnesium O +
stearate O -
, O +
calcium O +
stearate O +
and O +
aerosil O -
. O +

The O +
prulifloxacin O +
oral O +
solid O +
composition O +
can O +
be O +
processed O +
into O +
tablets O -
, O +
capsules O +
or O +
granules O -
, O +
has O +
good O +
stability O -
, O +
can O +
effectively O +
improve O +
a O +
dissolution O +
rate O -
, O +
solves O +
the O +
problem O +
that O +
the O +
existing O +
prulifloxacin O +
oral O +
solid O +
preparation O +
has O +
a O +
slow O +
dissolution O +
speed O -
, O +
and O +
improves O +
bioavailability O -
. O +

Cis O -
- O -
platinum O +
complex O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
cis O -
- O -
platinum O +
complex O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

Cis O -
- O -
platinum O +
and O +
a O +
polymer O +
with O +
the O +
structure O +
of O +
formula O +
( O -
I O -
) O +
are O +
used O +
as O +
raw O +
materials O +
for O +
preparing O +
the O +
cis O -
- O -
platinum O +
complex O -
, O +
wherein O +
a O +
polymer O +
molecule O +
with O +
the O +
structure O +
of O +
formula O +
( O -
I O -
) O +
contains O +
a O +
poly O +
( O -
L O -
- O -
glutamic O +
acid O -
- O -
co O -
- O -
L O -
- O -
lysine O -
) O +
segment O -
, O +
so O +
that O +
the O +
prepared O +
cis O -
- O -
platinum O +
complex O +
has O +
excellent O +
biocompatibility O +
and O +
is O +
degradable O -
; O +
meanwhile O -
, O +
the O +
poly O +
( O -
L O -
- O -
glutamic O +
acid O -
- O -
co O -
- O -
L O -
- O -
lysine O -
) O +
segment O +
can O +
further O +
prevent O +
the O +
cis O -
- O -
platinum O +
complex O +
from O +
being O +
influenced O +
by O +
a O +
blood O +
circulation O +
system O +
in O +
an O +
aqueous O +
medium O -
, O +
so O +
that O +
the O +
cis O -
- O -
platinum O +
complex O +
has O +
excellent O +
stability O -
; O +
and O +
the O +
terminal O +
of O +
the O +
branched O +
chain O +
of O +
the O +
cis O -
- O -
platinum O +
complex O +
provided O +
by O +
the O +
invention O +
contains O +
an O +
amino O +
group O -
, O +
so O +
that O +
the O +
cis O -
- O -
platinum O +
complex O +
has O +
excellent O +
solubility O -
. O +

In O +
addition O -
, O +
the O +
prepared O +
cis O -
- O -
platinum O +
complex O +
contains O +
a O +
carboxy O +
group O -
, O +
so O +
that O +
the O +
cis O -
- O -
platinum O +
complex O +
has O +
excellent O +
pH O +
value O +
sensitivity O -
, O +
the O +
carboxy O +
group O +
tends O +
to O +
deprotonation O +
in O +
the O +
environment O +
with O +
a O +
lower O +
pH O +
value O +
so O +
as O +
to O +
be O +
beneficial O +
to O +
promoting O +
the O +
drug O +
release O +
and O +
improve O +
the O +
efficacy O +
of O +
drugs O -
. O +

Meloxicam O +
injection O +
for O +
treating O +
chronic O +
infectious O +
arthritis O +
of O +
dogs O +
and O +
cats O +
The O +
invention O +
discloses O +
a O +
meloxicam O +
injection O +
for O +
treating O +
chronic O +
infectious O +
arthritis O +
of O +
dogs O +
and O +
cats O -
. O +

The O +
meloxicam O +
injection O +
is O +
a O +
meloxicam O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
, O +
and O +
the O +
administration O +
route O +
is O +
intramuscular O +
injection O -
. O +

The O +
meloxicam O +
injection O +
for O +
treating O +
chronic O +
infectious O +
arthritis O +
of O +
dogs O +
and O +
cats O +
has O +
the O +
effect O +
of O +
dispelling O +
wind O +
and O +
eliminating O +
dampness O -
, O +
tonifying O +
kidney O +
and O +
repelling O +
cold O -
, O +
promoting O +
blood O +
circulation O +
to O +
remove O +
meridian O +
obstruction O +
and O +
strengthening O +
tendons O +
and O +
bones O -
, O +
and O +
achieves O +
remarkable O +
effect O +
in O +
treating O +
chronic O +
infectious O +
arthritis O -
. O +

L O -
- O -
carnitine O +
calcium O +
citrate O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
a O +
new O +
pharmaceutically O +
acceptable O +
salt O +
of O +
L O -
- O -
carnitine O -
, O +
namely O +
L O -
- O -
carnitine O +
calcium O +
citrate O -
, O +
and O +
a O +
preparation O +
method O +
and O +
application O +
of O +
the O +
salt O -
. O +

L O -
- O -
carnitine O +
calcium O +
citrate O +
not O +
only O +
has O +
the O +
characteristics O +
of O +
high O +
stability O +
and O +
difficult O +
moisture O +
absorption O +
as O +
compared O +
with O +
L O -
- O -
carnitine O +
inner O +
salt O -
, O +
but O +
also O +
is O +
easier O +
to O +
accept O +
by O +
human O +
bodies O +
and O +
easier O +
to O +
participate O +
in O +
physiologic O +
metabolism O +
of O +
the O +
human O +
bodies O +
as O +
compared O +
with O +
the O +
existing O +
pharmaceutically O +
acceptable O +
salts O +
of O +
L O -
- O -
carnitine O -
, O +
and O +
has O +
stronger O +
nutrition O +
and O +
treatment O +
effects O -
. O +

The O +
invention O +
also O +
provides O +
application O +
of O +
L O -
- O -
carnitine O +
calcium O +
citrate O +
to O +
preparing O +
a O +
slimming O +
medicament O +
or O +
health O +
food O -
, O +
application O +
to O +
preparing O +
a O +
diet O -
/ O -
nutritional O +
supplement O -
, O +
and O +
application O +
to O +
preparing O +
veterinarian O +
products O +
or O +
feed O -
. O +

Venlafaxine O +
hydrochloride O +
controlled O -
- O -
release O +
pellet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
venlafaxine O +
hydrochloride O +
controlled O -
- O -
release O +
pellet O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
venlafaxine O +
hydrochloride O +
controlled O -
- O -
release O +
pellet O +
comprises O +
a O +
blank O +
pellet O +
core O -
, O +
a O +
venlafaxine O +
hydrochloride O -
- O -
containing O +
layer O +
and O +
a O +
controlled O -
- O -
release O +
film O -
, O +
wherein O +
the O +
venlafaxine O +
hydrochloride O -
- O -
containing O +
layer O +
comprises O +
active O +
components O +
including O +
venlafaxine O +
hydrochloride O +
and O +
talcum O +
powder O +
which O +
are O +
in O +
a O +
weight O +
ratio O +
of O +
12:1 O -
- O -
8:1 O -
, O +
and O +
the O +
weight O +
ratio O +
of O +
the O +
venlafaxine O +
hydrochloride O +
to O +
the O +
blank O +
pellet O +
core O +
is O +
4:10 O -
- O -
8:10 O -
. O +

The O +
venlafaxine O +
hydrochloride O +
controlled O -
- O -
release O +
pellet O +
is O +
prepared O +
by O +
adopting O +
a O +
fluidized O +
bed O +
bottom O -
- O -
spraying O +
venlafaxine O +
hydrochloride O +
applying O +
mode O -
; O +
by O +
using O +
75 O +
percent O +
alcohol O +
as O +
a O +
solvent O -
, O +
the O +
viscosity O +
of O +
the O +
venlafaxine O +
hydrochloride O +
in O +
a O +
water O +
solution O +
is O +
remarkably O +
lowered O -
, O +
the O +
venlafaxine O +
hydrochloride O +
applying O +
speed O +
is O +
increased O -
; O +
and O +
the O +
prepared O +
venlafaxine O +
hydrochloride O +
containing O +
pellet O +
adopts O +
a O +
bottom O -
- O -
spraying O +
coating O +
process O -
, O +
thus O +
the O +
problem O +
of O +
static O +
electricity O +
generated O +
because O +
of O +
the O +
adoption O +
of O +
the O +
pure O +
organic O +
solvent O +
is O +
overcome O -
; O +
the O +
application O +
process O +
and O +
the O +
wrapping O +
process O +
can O +
be O +
continuously O +
operated O +
in O +
the O +
same O +
device O -
, O +
thus O +
the O +
production O +
efficiency O +
is O +
increased O +
and O +
the O +
production O +
cost O +
is O +
lowered O -
; O +
and O +
no O +
toxic O +
organic O +
solvent O +
is O +
adopted O +
in O +
the O +
whole O +
process O -
, O +
thus O +
the O +
venlafaxine O +
hydrochloride O +
controlled O -
- O -
release O +
pellet O +
is O +
environmental O -
- O -
friendly O +
and O +
is O +
good O +
in O +
stability O -
, O +
and O +
almost O +
no O +
broken O +
pellets O +
or O +
dust O +
is O +
produced O -
. O +

Preparation O +
of O +
ginsenoside O +
M1 O +
n O -
- O -
butyrate O +
and O +
application O +
of O +
antidiabetic O +
medicines O +
of O +
ginsenoside O +
M1 O +
n O -
- O -
butyrate O +
The O +
invention O +
provides O +
ginsenoside O +
M1 O +
n O -
- O -
butyrate O +
which O +
is O +
a O +
new O +
compound O +
with O +
a O +
molecular O +
formula O +
of O +
C40H69O9 O -
. O +

The O +
molecular O +
weight O +
of O +
the O +
ginsenoside O +
M1 O +
n O -
- O -
butyrate O +
is O +
692 O -
. O +

The O +
invention O +
further O +
discloses O +
a O +
preparation O +
method O +
of O +
the O +
compound O +
and O +
application O +
of O +
antidiabetic O +
medicines O +
of O +
the O +
compound O -
. O +

The O +
ginsenoside O +
M1 O +
n O -
- O -
butyrate O +
can O +
resist O +
to O +
physiological O +
activity O +
of O +
diabetes O +
mellitus O +
and O +
can O +
be O +
used O +
for O +
preventing O +
and O +
treating O +
the O +
diabetes O +
mellitus O +
and O +
conducting O +
assistant O +
treating O +
the O +
diabetes O +
mellitus O -
. O +

Compound O +
elvucitabine O +
medicine O +
composition O +
as O +
well O +
as O +
preparation O +
method O +
and O +
use O +
for O +
same O +
The O +
invention O +
provides O +
a O +
compound O +
elvucitabine O +
medicine O +
composition O -
. O +

The O +
medicine O +
composition O +
comprises O +
elvucitabine O +
or O +
the O +
medicinal O +
salts O +
thereof O -
, O +
entecavir O +
or O +
the O +
medicinal O +
salts O +
thereof O +
and O +
an O +
anti O -
- O -
acid O +
stabilizer O -
. O +

The O +
invention O +
further O +
provides O +
a O +
method O +
for O +
preparing O +
the O +
medicine O +
composition O -
, O +
comprising O +
the O +
following O +
steps O +
of O -
: O +
( O -
1 O -
) O +
mixing O +
elvucitabine O +
or O +
the O +
medicinal O +
salts O +
thereof O +
with O +
the O +
anti O -
- O -
acid O +
stabilizer O -
, O +
then O +
mixing O +
elvucitabine O +
or O +
the O +
medicinal O +
salts O +
thereof O +
with O +
one O +
or O +
more O +
adhesives O -
, O +
and O +
attaching O +
the O +
obtained O +
mixture O +
on O +
an O +
empty O +
carrier O +
to O +
prepare O +
a O +
medicated O +
carrier O -
; O +
and O +
( O -
2 O -
) O +
mixing O +
the O +
medicated O +
carrier O +
obtained O +
in O +
the O +
step O +
( O -
1 O -
) O +
with O +
entecavir O +
or O +
the O +
medicinal O +
salts O +
thereof O +
and O +
one O +
or O +
more O +
pharmaceutical O +
excipients O -
. O +

The O +
invention O +
further O +
provides O +
a O +
use O +
of O +
the O +
compound O +
elvucitabine O +
medicine O +
composition O +
for O +
preparing O +
a O +
medicine O +
for O +
treating O +
hepatitis O +
B O +
virus O -
. O +

Cough O -
- O -
treating O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O +
and O +
loquat O +
sustained O +
release O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
cough O -
- O -
treating O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O +
and O +
loquat O +
sustained O +
release O +
tablet O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
( O -
1 O -
) O +
weighting O +
raw O +
materials O -
; O +
( O -
2 O -
) O +
adding O +
water O +
to O +
loquat O +
leaves O -
, O +
decocting O -
, O +
filtering O -
, O +
concentrating O +
to O +
obtain O +
clear O +
paste O -
, O +
adding O +
ethanol O -
, O +
stirring O +
sufficiently O -
, O +
standing O +
and O +
taking O +
supernate O +
for O +
later O +
use O -
; O +
( O -
3 O -
) O +
crushing O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O -
, O +
carrying O +
out O +
hot O +
reflux O +
extraction O +
on O +
the O +
crushed O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O +
together O +
with O +
platycodon O +
root O +
and O +
perilla O +
fruit O +
by O +
using O +
ethanol O -
, O +
filtering O -
, O +
mixing O +
the O +
obtained O +
filtrate O +
with O +
the O +
supernate O +
obtained O +
in O +
( O -
2 O -
) O -
, O +
recovering O +
the O +
ethanol O -
, O +
concentrating O +
to O +
obtain O +
clear O +
paste O -
, O +
cooling O +
to O +
room O +
temperature O -
, O +
adding O +
butanone O +
for O +
extraction O -
, O +
recovering O +
the O +
butanone O -
, O +
concentrating O +
to O +
obtain O +
thick O +
paste O -
, O +
and O +
drying O -
, O +
crushing O +
and O +
sieving O +
the O +
thick O +
paste O +
to O +
obtain O +
extractive O +
powder O -
; O +
and O +
( O -
4 O -
) O +
adding O +
a O +
proper O +
amount O +
of O +
binding O +
agent O +
into O +
the O +
extractive O +
powder O -
, O +
a O +
filling O +
agent O -
, O +
hydroxypropyl O +
methylcellulose O +
and O +
a O +
release O +
rate O +
regulator O +
to O +
prepare O +
a O +
soft O +
material O -
, O +
granulating O -
, O +
drying O +
and O +
tabletting O -
. O +

The O +
sustained O +
release O +
tablet O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
effects O +
of O +
relieving O +
cough O -
, O +
eliminating O +
phlegm O +
and O +
relieving O +
asthma O -
, O +
and O +
the O +
sustained O +
release O +
tablet O +
prepared O +
from O +
the O +
raw O +
materials O +
extracted O +
by O +
using O +
an O +
extraction O +
method O +
disclosed O +
by O +
the O +
invention O +
is O +
low O +
in O +
drug O +
dose O -
, O +
high O +
in O +
content O -
, O +
convenient O +
to O +
take O +
and O +
carry O -
, O +
good O +
in O +
curative O +
effect O -
, O +
favorable O +
for O +
fixed O -
- O -
quantity O +
taking O -
, O +
and O +
beneficial O +
to O +
storage O +
and O +
transportation O -
. O +

Preparation O +
method O +
and O +
application O +
of O +
6- O -
( O -
1-methyl O -
- O -
beta O -
- O -
carboline-3-carboxylic O +
acetyl O -
) O -
-6-deoxy O -
- O -
beta O -
- O -
cyclodextrin O +
and O +
supramolecular O +
inclusion O +
complex O +
thereof O +
with O +
adriamycin O +
The O +
invention O +
discloses O +
6- O -
( O -
1-methyl O -
- O -
beta O -
- O -
carboline-3-carboxylic O +
acetyl O -
) O -
-6-deoxy O -
- O -
beta O -
- O -
cyclodextrin O +
prepared O +
by O +
connecting O +
harmine O +
onto O +
cyclodextrin O +
with O +
ethylenediamine O +
as O +
a O +
connection O +
arm O -
, O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
supramolecular O +
inclusion O +
complex O +
of O +
6- O -
( O -
1-methyl O -
- O -
beta O -
- O -
carboline-3-carboxylic O +
acetyl O -
) O -
-6-deoxy O -
- O -
beta O -
- O -
cyclodextrin O +
and O +
adriamycin O -
, O +
and O +
a O +
preparation O +
method O +
and O +
an O +
application O +
thereof O -
. O +

The O +
invention O +
further O +
discloses O +
the O +
evaluation O +
of O +
anti O -
- O -
tumor O +
activity O +
and O +
survival O +
rate O +
of O +
the O +
supramolecular O +
inclusion O +
complex O +
provided O +
by O +
the O +
invention O +
on O +
a O +
S180 O +
mouse O +
model O -
. O +

As O +
a O +
result O +
of O +
in O -
- O -
vivo O +
experiment O -
, O +
with O +
the O +
supramolecular O +
inclusion O +
complex O +
provided O +
by O +
the O +
invention O -
, O +
adriamycin O +
toxicity O +
is O +
reduced O -
. O +

Especially O -
, O +
under O +
high O +
dosage O -
, O +
on O +
a O +
basis O +
that O +
anti O -
- O -
tumor O +
activity O +
equivalent O +
with O +
that O +
of O +
adriamycin O +
is O +
maintained O -
, O +
mouse O +
survival O +
rate O +
is O +
improved O -
. O +

The O +
invention O +
assists O +
in O +
providing O +
a O +
novel O +
approach O +
for O +
clinical O +
applications O +
of O +
the O +
anticancer O +
medicine O +
adriamycin O -
. O +

Health O -
- O -
care O +
foot O +
solution O +
The O +
invention O +
discloses O +
a O +
health O -
- O -
care O +
foot O +
solution O -
. O +

The O +
health O -
- O -
care O +
foot O +
solution O +
consists O +
of O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
1 O -
- O -
2 O +
parts O +
of O +
ginger O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
red O +
flower O -
, O +
2 O -
- O -
5 O +
parts O +
of O +
semen O +
armeniacae O +
amarae O -
, O +
3 O -
- O -
8 O +
parts O +
of O +
green O +
tea O -
, O +
2 O -
- O -
3 O +
parts O +
of O +
salt O +
and O +
the O +
balance O +
of O +
water O -
. O +

The O +
health O -
- O -
care O +
foot O +
solution O +
can O +
accelerate O +
leg O +
blood O +
circulation O -
, O +
so O +
that O +
venous O +
blood O +
in O +
the O +
legs O +
can O +
timely O +
flow O +
back O +
to O +
the O +
right O +
side O +
of O +
the O +
heart O -
, O +
and O +
the O +
health O -
- O -
care O +
foot O +
solution O +
contributes O +
to O +
lightening O +
venous O +
congestion O +
of O +
the O +
legs O +
and O +
preventing O +
varicose O +
vein O +
of O +
lower O +
limbs O +
and O +
contributes O +
to O +
soothing O +
the O +
nerves O +
and O +
removing O +
troubles O -
, O +
performing O +
hypnosis O +
and O +
falling O +
asleep O -
, O +
so O +
that O +
the O +
sleep O +
is O +
deep O +
and O +
sweet O -
. O +

Tumor O +
cavity O +
filler O +
for O +
treating O +
giant O +
cell O +
tumor O +
of O +
bone O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medical O +
engineering O +
and O +
provides O +
a O +
tumor O +
cavity O +
filler O +
for O +
treating O +
giant O +
cell O +
tumor O +
of O +
bone O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
mixture O +
is O +
formed O +
by O +
mixing O +
a O +
diphosphate O +
medicine O +
and O +
bone O +
cement O +
according O +
to O +
a O +
ratio O -
, O +
wherein O +
the O +
bone O +
cement O +
serves O +
as O +
a O +
controlled O +
release O +
carrier O +
of O +
the O +
diphosphate O +
medicine O -
, O +
so O +
that O +
a O +
topical O +
administration O +
system O +
is O +
formed O -
. O +

The O +
principle O +
is O +
that O +
the O +
bone O +
cement O +
serves O +
as O +
the O +
release O +
carrier O +
of O +
the O +
medicine O +
and O +
the O +
diphosphate O +
medicine O +
is O +
released O +
at O +
a O +
focus O -
, O +
so O +
that O +
the O +
aim O +
that O +
the O +
focus O +
is O +
positioned O +
in O +
a O +
long O -
- O -
term O +
high O -
- O -
concentration O +
medicine O +
environment O +
is O +
fulfilled O -
; O +
and O +
therefore O -
, O +
the O +
effects O +
of O +
suppressing O +
bone O +
destruction O +
and O +
preventing O +
bone O +
resorption O +
through O +
the O +
diphosphate O +
medicine O +
are O +
improved O -
, O +
and O +
the O +
function O +
of O +
repairing O +
the O +
bone O +
destruction O +
through O +
the O +
bone O +
cement O +
is O +
not O +
influenced O -
. O +

Bath O +
powder O +
for O +
treating O +
neurasthenia O +
The O +
invention O +
relates O +
to O +
bath O +
powder O +
for O +
treating O +
neurasthenia O -
. O +

The O +
bath O +
powder O +
is O +
prepared O +
by O +
the O +
steps O +
of O +
mixing O +
50 O +
parts O +
of O +
zizyphus O +
jujube O +
tree O +
roots O -
, O +
35 O +
parts O +
of O +
salviae O +
miltiorrhizae O -
, O +
30 O +
parts O +
of O +
longspur O +
epimedium O -
, O +
30 O +
parts O +
of O +
lily O -
, O +
30 O +
parts O +
of O +
tuber O +
fleeceflower O +
stem O -
, O +
20 O +
parts O +
of O +
coptidis O +
rhizome O -
, O +
30 O +
parts O +
of O +
rhizoma O +
sparganii O -
, O +
30 O +
parts O +
of O +
earthworm O -
, O +
50 O +
parts O +
of O +
agilawood O -
, O +
25 O +
parts O +
of O +
mint O -
, O +
30 O +
parts O +
of O +
cortex O +
albiziae O -
, O +
20 O +
parts O +
of O +
radix O +
curcumae O -
, O +
45 O +
parts O +
of O +
mirabilite O -
, O +
20 O +
parts O +
of O +
liquorice O +
and O +
20 O +
parts O +
of O +
polygala O +
tenuifolia O +
together O -
; O +
performing O +
heating O +
drying O +
the O +
above O +
drugs O +
with O +
an O +
intake O +
air O +
temperature O +
of O +
180 O -
- O -
290 O +
DEG O +
C O +
and O +
outlet O +
air O +
temperature O +
of O +
80 O -
- O -
90 O +
DEG O +
C O -
; O +
grinding O +
the O +
above O +
drugs O +
into O +
powder O -
; O +
and O +
subpackaging O +
quantitatively O -
. O +

In O +
the O +
above O +
composition O -
, O +
the O +
composition O +
can O +
be O +
made O +
into O +
80 O -
- O -
100 O +
g O +
per O +
bag O +
if O +
being O +
weighed O +
in O +
grams O -
. O +

When O +
the O +
bath O +
powder O +
is O +
in O +
use O -
, O +
the O +
drug O +
formula O +
is O +
put O +
in O +
bath O +
water O +
with O +
stirring O -
. O +

The O +
water O +
consumption O +
of O +
the O +
bath O +
is O +
between O +
80 O +
L O +
and O +
100 O +
L O -
; O +
an O +
immersing O +
time O +
is O +
1 O -
- O -
2 O +
hours O +
every O +
day O -
; O +
and O +
10 O +
days O +
is O +
a O +
course O +
of O +
treatment O -
. O +

Usually O -
, O +
neurasthenia O +
is O +
healed O +
after O +
three O +
to O +
five O +
courses O -
. O +

The O +
effective O +
rate O +
is O +
97 O -
% O -
. O +

The O +
usage O +
amount O +
can O +
be O +
adjusted O +
according O +
to O +
conditions O +
of O +
patients O -
. O +

The O +
bath O +
powder O +
has O +
the O +
main O +
functions O +
for O +
treating O +
neurasthenia O -
, O +
intractable O +
insomnia O -
, O +
disturbed O +
consciousness O +
and O +
dysphoria O +
and O +
impatience O -
. O +

Expectorant O +
The O +
invention O +
discloses O +
an O +
expectorant O -
. O +

The O +
expectorant O +
comprises O +
the O +
following O +
active O +
pharmaceutical O +
ingredients O +
in O +
parts O +
by O +
weight O -
: O +
2 O -
- O -
4 O +
parts O +
of O +
sapium O +
sebiferum O -
, O +
1 O -
- O -
3 O +
parts O +
of O +
rhizoma O +
curcumae O +
longae O -
, O +
3 O -
- O -
8 O +
parts O +
of O +
realgar O -
, O +
1 O -
- O -
3 O +
parts O +
of O +
agkistrodon O -
, O +
2 O -
- O -
5 O +
parts O +
of O +
bulbus O +
allii O +
macrostemonis O -
, O +
3 O -
- O -
6 O +
parts O +
of O +
common O +
achyranthes O +
herb O -
, O +
1 O -
- O -
2 O +
parts O +
of O +
squama O +
manis O -
, O +
4 O -
- O -
9 O +
parts O +
of O +
plantago O +
asiatica O +
L. O +
and O +
1 O -
- O -
4 O +
parts O +
of O +
fructus O +
rosae O +
laevigatae O -
. O +

The O +
expectorant O +
not O +
only O +
has O +
the O +
effects O +
of O +
drying O +
dampness O -
, O +
eliminating O +
phlegm O -
, O +
clearing O +
heat O -
, O +
relieving O +
exterior O +
syndrome O -
, O +
alleviating O +
water O +
retention O -
, O +
activating O +
blood O -
, O +
relieving O +
cough O +
and O +
preventing O +
asthma O -
, O +
but O +
also O +
can O +
activate O +
blood O +
to O +
remove O +
stasis O -
, O +
break O +
blood O +
to O +
promote O +
qi O +
circulation O -
, O +
induce O +
menstruation O +
to O +
relieve O +
menalgia O -
, O +
draw O +
out O +
poison O +
to O +
astringe O +
and O +
dispel O +
wind O +
and O +
dampness O -
. O +

Long O -
- O -
term O +
suspension O +
uterine O +
perfusion O +
agent O +
for O +
treating O +
female O +
animal O +
postpartum O +
infection O +
and O +
preparation O +
process O +
The O +
invention O +
discloses O +
a O +
long O -
- O -
term O +
suspension O +
uterine O +
perfusion O +
agent O +
for O +
treating O +
female O +
animal O +
postpartum O +
infection O +
and O +
a O +
preparation O +
process O -
. O +

The O +
long O -
- O -
term O +
suspension O +
uterine O +
perfusion O +
agent O +
comprises O -
, O +
by O +
weight O -
, O +
1.5 O -
- O -
3.5 O -
kg O +
of O +
ofloxacin O -
, O +
0.125 O -
- O -
1 O -
kg O +
of O +
flunixin O +
meglumine O -
, O +
0.125 O -
- O -
0.75 O -
kg O +
of O +
metronidazole O -
, O +
0.125 O -
- O -
1 O -
kg O +
of O +
leonurus O +
extract O +
( O -
injection O +
level O -
) O -
, O +
0.125 O -
- O -
1 O -
kg O +
of O +
angelica O +
sinensis O +
extract O +
( O -
injection O +
level O -
) O -
, O +
0.25 O -
- O -
1.25 O -
kg O +
of O +
polyvinyl O +
pyrrolidone O +
( O -
PVP O -
) O -
-K30 O -
, O +
2 O -
- O -
15 O -
kg O +
of O +
polyethylene O +
glycol O +
( O -
PEG O -
) O -
-400 O -
, O +
0.03 O -
kg O +
of O +
ethylene O +
diamine O +
tetraacetic O +
acid O +
( O -
EDTA O -
) O -
-2Na O +
and O +
appropriate O +
water O +
for O +
injection O -
. O +

The O +
long O -
- O -
term O +
suspension O +
uterine O +
perfusion O +
agent O +
is O +
suitable O +
for O +
postpartum O +
health O +
care O -
, O +
is O +
used O +
for O +
postpartum O +
female O +
animal O +
preventive O +
perfusion O -
, O +
effectively O +
reduces O +
morbidity O +
of O +
endometritism O -
, O +
remarkably O +
shortens O +
female O +
animal O +
estrus O +
interval O -
, O +
and O +
improves O +
breeding O +
success O +
rate O +
and O +
farrowing O +
rate O +
of O +
female O +
animals O -
. O +

The O +
long O -
- O -
term O +
suspension O +
uterine O +
perfusion O +
agent O +
is O +
injected O +
in O +
uterus O +
by O +
using O +
an O +
irrigator O -
. O +

Folium O +
mori O +
tablets O +
for O +
moistening O +
dryness O +
and O +
lungs O +
The O +
invention O +
discloses O +
a O +
folium O +
mori O +
tablet O +
for O +
moistening O +
dryness O +
and O +
lungs O -
. O +

The O +
folium O +
mori O +
tablet O +
is O +
characterized O +
by O +
comprising O +
the O +
following O +
raw O +
materials O -
: O +
folium O +
mori O -
, O +
gypsum O +
fibrosum O -
, O +
unibract O +
fritillary O +
bulb O -
, O +
fructus O +
trichosanthis O -
, O +
liquorice O -
, O +
sang O -
, O +
linseed O -
, O +
donkey O -
- O -
hide O +
gelatin O -
, O +
radix O +
ophiopogonis O -
, O +
roasted O +
almond O +
and O +
folium O +
eriobotryae O -
. O +

Urease B-Gene +
inhibitor O +
genistein O +
hydroxamic O +
acid O +
compound O +
and O +
synthesis O +
and O +
application O +
thereof O +
A O +
genistein O +
hydroxamic O +
acid O +
compound O +
has O +
the O +
following O +
structural O +
general O +
formula O -
. O +

The O +
genistein O +
hydroxamic O +
acid O +
compound O +
has O +
good O +
inhibitional O +
effect O +
on O +
urease B-Gene +
and O +
can O +
be O +
used O +
for O +
preparing O +
drugs O +
for O +
treating O +
gastritis O -
, O +
gastric O +
ulcer O -
, O +
lithangiuria O +
and O +
the O +
like O -
. O +

A O +
manufacturing O +
method O +
of O +
the O +
genistein O +
hydroxamic O +
acid O +
compound O +
is O +
disclosed O -
. O +

Antitussive O +
and O +
expectorant O +
compound O +
chemical O +
drug O +
The O +
invention O +
provides O +
an O +
antitussive O +
and O +
expectorant O +
compound O +
chemical O +
drug O -
, O +
and O +
especially O +
relates O +
to O +
a O +
drug O +
composed O +
of O +
dimemorfan O +
and O +
carbocisteine O +
which O +
are O +
effective O +
components O -
, O +
as O +
well O +
as O +
pharmaceutically O +
acceptable O +
accessories O -
, O +
and O +
a O +
preparation O +
technology O -
. O +

The O +
dimemorfan O +
used O +
in O +
the O +
invention O +
is O +
a O +
non O -
- O -
narcotic O +
central O +
antitussive O +
drug O -
; O +
and O +
compared O +
with O +
central O +
antitussive O +
drugs O +
present O +
on O +
the O +
market O -
, O +
the O +
dimemorfan O +
is O +
equivalent O +
in O +
antitussive O +
effects O +
but O +
low O +
in O +
adverse O +
reaction O -
. O +

Compared O +
with O +
commercially O +
available O +
compound O +
antitussive O +
and O +
expectorant O +
drugs O -
, O +
the O +
compound O +
chemical O +
drug O +
provided O +
by O +
the O +
invention O +
has O +
advantages O +
of O +
relatively O +
good O +
efficacies O +
and O +
low O +
adverse O +
reaction O +
rate O -
, O +
and O +
has O +
quite O +
good O +
social O +
and O +
economic O +
benefits O -
. O +

Compound O +
chemical O +
medicament O +
containing O +
guaiacol O +
The O +
invention O +
provides O +
a O +
compound O +
chemical O +
medicament O +
containing O +
guaiacol O -
, O +
and O +
in O +
particular O +
relates O +
to O +
a O +
medicament O +
consisting O +
of O +
dimemorfan O +
and O +
guaifenesin O +
serving O +
as O +
effective O +
components O +
and O +
pharmaceutically O +
acceptable O +
auxiliary O +
materials O -
, O +
and O +
a O +
preparation O +
process O +
of O +
the O +
medicament O -
. O +

According O +
to O +
the O +
compound O +
chemical O +
medicament O -
, O +
guaiacol O +
serving O +
as O +
a O +
non O -
- O -
narcotic O +
central O +
antitussive O +
drug O +
has O +
equivalent O +
antitussive O +
effect O +
but O +
lower O +
adverse O +
reaction O +
compared O +
with O +
a O +
conventional O +
central O +
antitussive O +
drug O +
in O +
current O +
market O -
. O +

Compared O +
with O +
currently O +
commercial O +
compound O +
antitussive O +
expectorant O +
drug O -
, O +
the O +
composition O +
has O +
advantages O +
of O +
better O +
curative O +
effect O +
and O +
low O +
adverse O +
reaction O -
, O +
and O +
has O +
good O +
social O +
benefit O +
and O +
economic O +
benefit O -
. O +

Application O +
of O +
tanshinone O +
IIA O +
or O +
pharmaceutically O +
acceptable O +
salt O +
in O +
preparation O +
of O +
medicament O +
for O +
treating O +
or O +
inhibiting O +
mucus O +
in O +
wind O +
pipe O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
tanshinone O +
IIA O +
or O +
pharmaceutically O +
acceptable O +
salt O +
in O +
preparation O +
of O +
medicament O +
for O +
treating O +
or O +
inhibiting O +
mucus O +
in O +
a O +
wind O +
pipe O -
. O +

The O +
tanshinone O +
IIA O +
or O +
pharmaceutically O +
acceptable O +
salt O +
can O +
obviously O +
inhibit O +
the O +
hypersecretion O +
of O +
mucoprotein O +
in O +
the O +
wind O +
pipe O +
of O +
the O +
lung O +
tissue O -
. O +

Compared O +
with O +
the O +
commonly O +
used O +
mucolytic O +
agents O -
, O +
the O +
tanshinone O +
IIA O +
or O +
pharmaceutically O +
acceptable O +
salt O +
can O +
obviously O +
inhibit O +
the O +
expression O +
and O +
the O +
secretion O +
of O +
mucoprotein O -
, O +
and O +
the O +
obvious O +
side O +
and O +
toxic O +
effects O +
can O +
not O +
be O +
found O -
. O +

Application O +
of O +
doxycycline O +
in O +
preparing O +
medicament O +
for O +
treating O +
epithelial O +
ovarian O +
cancer O +
The O +
invention O +
relates O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
, O +
and O +
in O +
particular O +
relates O +
to O +
a O +
novel O +
application O +
of O +
doxycycline O +
in O +
preparing O +
a O +
medicament O +
for O +
treating O +
epithelial O +
ovarian O +
cancer O -
. O +

Animal O +
experiments O +
and O +
in O -
- O -
vitro O +
cell O +
experiments O +
prove O +
that O +
doxycycline O +
can O +
inhibit O +
multiplication O +
and O +
invasion O +
of O +
ovarian O +
cancer O +
cells O -
, O +
can O +
prevent O +
epithelial O +
ovarian O +
cancer O +
cells O +
from O +
transferring O -
, O +
can O +
promote O +
apoptosis O +
of O +
epithelial O +
ovarian O +
cancer O +
cells O -
, O +
has O +
a O +
remarkable O +
inhibition O +
effect O +
to O +
ovarian O +
cancer O +
cells O -
, O +
in O +
particular O +
platinum O -
- O -
based O +
drug O -
- O -
resistance O +
ovarian O +
cancer O +
cells O -
, O +
and O +
can O +
inhibit O +
growth O +
of O +
ovarian O +
cancer O +
tissues O +
and O +
formation O +
of O +
ascites O -
, O +
so O +
that O +
doxycycline O +
can O +
be O +
used O +
for O +
preparing O +
a O +
medicament O +
for O +
treating O +
epithelial O +
ovarian O +
cancer O -
. O +

The O +
invention O +
provides O +
a O +
novel O +
application O +
to O +
doxycycline O -
, O +
and O +
compared O +
with O +
other O +
chemotherapeutic O +
drugs O -
, O +
doxycycline O +
has O +
the O +
advantages O +
of O +
convenient O +
administration O +
and O +
small O +
side O +
effect O +
in O +
the O +
field O +
of O +
treating O +
epithelial O +
ovarian O +
cancer O -
. O +

Application O +
of O +
active O +
component O +
baicalin O +
of O +
Qingkailing O +
compound O +
in O +
preparation O +
of O +
medicines O +
resisting O +
multiple O +
drug O -
- O -
resistance O +
bacteria O +
The O +
invention O +
relates O +
to O +
an O +
active O +
component O +
baicalin O +
of O +
a O +
Qingkailing O +
compound O -
, O +
which O +
has O +
an O +
inhibiting O +
effect O +
on O +
acinetobacter O +
calcoaceticus O -
, O +
acinetobacter O +
baumannii O -
, O +
A.baumannii O -
, O +
stenotrophomonas O +
maltophilia O +
and O +
escherichia B-Gene +
coli I-Gene +
containing I-Gene +
NDM-1 I-Gene +
drug O +
resistance O +
gene O -
, O +
so O +
that O +
the O +
active O +
component O +
baicalin O +
can O +
be O +
used O +
for O +
inhibiting O +
these O +
bacterial O +
diseases O +
and O +
treating O +
and/or O +
preventing O +
diseases O +
caused O +
by O +
these O +
bacteria O -
. O +

Novel O +
amoxicillin O +
sodium O +
compound O +
and O +
composition O +
of O +
amoxicillin O +
sodium O +
compound O +
and O +
sulbactam O +
sodium O +
compound O +
The O +
invention O +
discloses O +
a O +
novel O +
amoxicillin O +
sodium O +
compound O -
. O +

The O +
purity O +
of O +
the O +
amoxicillin O +
sodium O +
compound O +
is O +
more O +
than O +
99 O -
% O -
, O +
the O +
specific O +
rotation O +
of O +
the O +
amoxicillin O +
sodium O +
compound O +
is O +
between O +
+ O -
260 O +
degrees O +
and O +
+ O -
280 O +
degrees O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
composition O +
of O +
the O +
amoxicillin O +
sodium O +
compound O +
and O +
the O +
sulbactam O +
sodium O +
compound O -
, O +
which O +
comprises O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
50 O -
- O -
100 O +
parts O +
of O +
amoxicillin O +
sodium O -
, O +
25 O -
- O -
50 O +
parts O +
of O +
sulbactam O +
sodium O -
, O +
3 O -
- O -
9 O +
parts O +
of O +
vitamin O +
C O -
, O +
1 O -
- O -
6 O +
parts O +
of O +
proline O -
, O +
and O +
2 O -
- O -
8 O +
parts O +
of O +
nicotinamide O -
. O +

According O +
to O +
the O +
composition O +
of O +
the O +
amoxicillin O +
sodium O +
compound O +
and O +
the O +
sulbactam O +
sodium O +
compound O -
, O +
the O +
vitamin O +
C O -
, O +
the O +
proline O +
and O +
the O +
nicotinamide O +
are O +
taken O +
as O +
stabilizers O +
and O +
play O +
synergistic O +
effect O +
so O +
as O +
to O +
improve O +
the O +
stability O +
of O +
the O +
composition O +
of O +
the O +
amoxicillin O +
sodium O +
compound O +
and O +
the O +
sulbactam O +
sodium O +
compound O +
effectively O -
, O +
the O +
composition O +
can O +
be O +
prepared O +
into O +
stable O +
injection O +
which O +
is O +
not O +
easy O +
to O +
deteriorate O +
due O +
to O +
oxygenolysis O +
after O +
being O +
laid O +
for O +
a O +
period O -
, O +
and O +
the O +
injection O +
does O +
not O +
need O +
to O +
be O +
prepared O +
when O +
being O +
used O -
, O +
thus O +
being O +
convenient O +
to O +
use O -
. O +

Resveratrol O +
nano O -
- O -
liposome O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
resveratrol O +
nano O -
- O -
liposome O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
mixing O +
and O +
dissolving O +
resveratrol O -
, O +
a O +
film O +
material O -
, O +
an O +
antioxidant O +
and O +
an O +
organic O +
solvent O -
, O +
forming O +
a O +
film O +
and O +
removing O +
the O +
organic O +
solvent O +
at O +
the O +
same O +
time O -
, O +
and O +
then O +
adding O +
a O +
buffer O +
solution O +
to O +
hydrate O +
to O +
obtain O +
a O +
coarse O +
suspension O +
liquid O +
of O +
the O +
resveratrol O +
nano O -
- O -
liposome O -
, O +
and O +
carrying O +
out O +
high O -
- O -
pressure O +
microjet O +
treatment O +
on O +
the O +
coarse O +
suspension O +
liquid O +
to O +
obtain O +
the O +
resveratrol O +
nano O -
- O -
liposome O -
. O +

The O +
resveratrol O +
nano O -
- O -
liposome O +
is O +
prepared O +
through O +
the O +
steps O +
of O +
dissolving O -
, O +
lipid O +
forming O -
, O +
sufficient O +
hydrating O -
, O +
microjet O +
dispersing O +
and O +
other O +
steps O +
by O +
adopting O +
a O +
high O -
- O -
pressure O +
microjet O +
method O -
. O +

The O +
resveratrol O +
nano O -
- O -
liposome O +
is O +
uniform O +
and O +
consistent O -
, O +
small O +
in O +
grain O +
size O -
, O +
high O +
in O +
encapsulation O +
efficiency O -
, O +
and O +
good O +
in O +
stability O -
. O +

Pharmaceutical O +
composition O +
containing O +
granisetron O +
hydrochloride O +
compound O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
containing O +
a O +
granisetron O +
hydrochloride O +
compound O -
, O +
and O +
in O +
particular O +
to O +
a O +
freeze O -
- O -
dried O +
injection O +
preparation O +
of O +
granisetron O +
hydrochloride O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

For O +
every O +
1000 O +
injections O -
, O +
the O +
pharmaceutical O +
composition O +
comprises O +
the O +
following O +
components O -
: O +
3 O -
g O +
of O +
granisetron O +
hydrochloride O -
, O +
100 O -
- O -
200 O -
g O +
of O +
mannitol O -
, O +
1 O -
- O -
3 O -
g O +
of O +
sodium O +
hydroxide O -
, O +
1 O -
- O -
2 O -
g O +
of O +
vitamin O +
C O -
, O +
and O +
2000ml O +
of O +
sodium O +
hydrogencitrate O +
and O +
trisodium O +
citrate O +
buffer O +
liquor O +
with O +
molar O +
ratio O +
of O +
1:4 O -
. O +

Liver O +
benefiting O +
powder O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicine O -
, O +
and O +
particularly O +
relates O +
to O +
a O +
compound O +
Chinese O +
patent O +
drug O +
for O +
treating O +
a O +
primary O +
liver O +
cancer O -
, O +
and O +
an O +
administration O +
method O +
of O +
the O +
compound O +
Chinese O +
patent O +
drug O -
. O +

The O +
primary O +
liver O +
cancer O +
is O +
one O +
of O +
the O +
common O +
malignant O +
tumors O +
in O +
China O -
. O +

The O +
compound O +
Chinese O +
patent O +
drug O +
adopts O +
13 O +
medicinal O +
materials O +
for O +
compounding O -
, O +
can O +
eliminate O +
pathogens O -
, O +
strengthen O +
body O +
resistance O -
, O +
promote O +
blood O +
circulation O -
, O +
stop O +
bleeding O +
and O +
treat O +
a O +
liver O +
and O +
a O +
spleen O -
, O +
and O +
treats O +
the O +
primary O +
liver O +
cancer O +
by O +
integrating O +
external O +
treatment O +
and O +
internal O +
treatment O -
. O +

The O +
compound O +
Chinese O +
patent O +
drug O +
adopts O +
the O +
technical O +
scheme O +
that O +
the O +
following O +
medicinal O +
materials O +
and O +
matching O +
ratio O +
are O +
adopted O -
, O +
and O +
the O +
13 O +
medicinal O +
materials O +
are O +
porphyrized O +
and O +
uniformly O +
mixed O +
into O +
powder O +
according O +
to O +
the O +
matching O +
ratio O -
. O +

The O +
1.5 O -
- O -
2 O -
g O +
liver O +
benefiting O +
powder O +
is O +
taken O +
directly O +
with O +
warm O +
water O +
at O +
each O +
time O +
for O +
2 O -
- O -
3 O +
times O +
per O +
day O -
. O +

External O +
application O +
treatment O +
is O +
conducted O +
as O +
follows O -
: O +
realgar O +
is O +
placed O +
in O +
an O +
abdomen O +
of O +
a O +
live O +
toad O +
( O -
with O +
viscera O +
being O +
removed O -
) O -
, O +
warm O +
water O +
is O +
added O +
to O +
prepare O +
paste O -
, O +
and O +
then O +
the O +
toad O +
is O +
externally O +
applied O +
at O +
a O +
hepatic O +
region O +
for O +
twice O +
per O +
day O -
. O +

Compound O +
solid O +
preparation O +
containing O +
tranexamic O +
acid O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
solid O +
preparation O +
containing O +
tranexamic O +
acid O -
. O +

The O +
compound O +
oral O +
solid O +
preparation O +
containing O +
the O +
tranexamic O +
acid O +
is O +
prepared O +
from O +
the O +
tranexamic O +
acid O +
serving O +
as O +
a O +
main O +
active O +
ingredient O -
, O +
other O +
active O +
ingredients O +
and O +
pharmaceutically O +
acceptable O +
auxiliary O +
materials O +
by O +
a O +
preparation O +
technology O -
. O +

The O +
compound O +
solid O +
preparation O +
containing O +
the O +
tranexamic O +
acid O +
is O +
stable O +
and O +
controllable O +
in O +
quality O -
, O +
safe O +
and O +
effective O -
. O +

Bifendate O +
derivative O -
, O +
preparation O +
method O +
and O +
application O +
of O +
bifendate O +
derivative O +
for O +
treating O +
autoimmune O +
disease O +
The O +
invention O +
belongs O +
to O +
the O +
chemical O +
medicine O +
technical O +
field O -
, O +
and O +
especially O +
relates O +
to O +
a O +
bifendate O +
derivative O -
, O +
a O +
preparation O +
method O +
and O +
an O +
application O +
of O +
the O +
bifendate O +
derivative O +
for O +
treating O +
autoimmune O +
disease O -
. O +

A O +
structure O +
of O +
the O +
bifendate O +
derivative O +
is O +
shown O +
as O +
a O +
formula O +
I O -
, O +
and O +
has O +
good O +
effects O +
for O +
inhibiting O +
autoimmune O +
diseases O +
such O +
as O +
acute O +
hepatitis O -
, O +
chronic O +
hepatic O +
fibrosis O +
and O +
pulmonary O +
fibrosis O -
, O +
and O +
the O +
bifendate O +
derivative O +
provides O +
a O +
new O +
choice O +
for O +
medicines O +
exploitation O +
for O +
treating O +
the O +
diseases O -
. O +

Imidazole O +
[ O -
4,5-c O -
] O +
pyridine-7-methanamide O +
derivative O +
as O +
well O +
as O +
preparation O +
method O +
and O +
medical O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
medicinal O +
chemistry O +
and O +
in O +
particular O +
relates O +
to O +
an O +
imidazole O +
[ O -
4,5-c O -
] O +
pyridine-7-methanamide O +
derivative O +
( O -
I O -
) O -
, O +
wherein O +
R O +
is O +
defined O +
in O +
the O +
specification O -
. O +

Pharmacodynamic O +
tests O +
proof O +
that O +
the O +
derivative O +
compound O +
provided O +
by O +
the O +
invention O +
can O +
serve O +
as O +
a O +
tumour O +
therapeutic O +
agent O +
and O +
especially O +
the O +
derivative O +
compound O +
has O +
extremely O +
strong O +
anti O -
- O -
tumour O +
effect O +
when O +
being O +
combined O +
with O +
cis O -
- O -
platinum O -
. O +

The O +
invention O +
also O +
discloses O +
a O +
preparation O +
method O +
of O +
the O +
derivative O +
compound O +
and O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
derivative O +
compound O -
. O +

Thiophene O +
derivative O +
and O +
application O +
thereof O +
to O +
medicine O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
of O +
an O +
inhibitor O +
for O +
hepatitis O +
C O +
virus O -
. O +

In O +
addition O -
, O +
the O +
invention O +
describes O +
a O +
pharmaceutical O +
composition O +
containing O +
the O +
compound O +
and O +
application O +
of O +
the O +
inhibitor O +
to O +
the O +
treatment O +
of O +
hepatitis O +
C O +
virus O +
infection O -
. O +

Repaglinide O +
and O +
metformin O +
hydrochloride O +
medicinal O +
composition O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
provides O +
a O +
medicinal O +
composition O +
including O +
active O +
components O +
of O +
repaglinide O +
and O +
metformin O +
hydrochloride O -
, O +
and O +
its O +
preparation O +
method O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
carrying O +
out O +
hot O +
melting O +
granulation O +
of O +
metformin O +
hydrochloride O +
to O +
prepare O +
particles O -
, O +
directly O +
spraying O +
a O +
repaglinide O +
solution O +
on O +
the O +
metformin O +
hydrochloride O +
particles O +
through O +
a O +
one O -
- O -
step O +
granulation O +
technology O -
, O +
and O +
adding O +
parts O +
of O +
auxiliary O +
materials O +
to O +
prepare O +
a O +
tablet O -
. O +

Medicine O +
composition O +
for O +
treating O +
mental O +
disorder O +
A O +
medicine O +
composition O +
for O +
treating O +
mental O +
disorder O +
is O +
formed O +
by O +
combining O +
active O +
components O +
with O +
pharmaceutical O +
acceptable O +
auxiliary O +
materials O -
, O +
wherein O +
the O +
active O +
components O +
adopt O +
ecitalopram O +
( O -
salt O -
) O +
and O +
olanzapine O +
( O -
salt O -
) O -
. O +

Oral O +
preparations O -
, O +
such O +
as O +
tablets O -
, O +
capsules O -
, O +
soft O +
capsules O -
, O +
chewable O +
tablets O -
, O +
orally O +
disintegration O +
tablets O -
, O +
buccal O +
tablets O -
, O +
pill O +
and O +
the O +
like O -
, O +
can O +
be O +
produced O +
through O +
certain O +
preparation O +
techniques O -
. O +

The O +
composition O +
is O +
used O +
for O +
treating O +
the O +
mental O +
disorder O -
, O +
such O +
as O +
depression O -
, O +
insomnia O -
, O +
anxiety O -
, O +
schizophrenia O +
and O +
the O +
like O -
. O +

Anti O -
- O -
Japanese O -
- O -
encephalitis O -
- O -
virus O -
- O -
infection O +
compositions O +
and O +
applications O +
thereof O +
The O +
invention O +
discloses O +
compositions O +
with O +
anti O -
- O -
Japanese O -
- O -
encephalitis O -
- O -
virus O +
functions O -
, O +
and O +
applications O +
thereof O +
in O +
preparing O +
medicine O +
used O +
for O +
preventing O +
and/or O +
treating O +
Japanese O +
encephalitis O +
virus O +
infections O -
. O +

The O +
compositions O +
comprise O +
a O +
N- O -
( O -
2-thiazolyl O -
) O -
benzamide O +
compound O +
represented O +
by O +
the O +
formula O +
A O -
, O +
and O +
trehalose O +
or O +
Huangqi O +
Shengmai O +
Yin O -
. O +

R1 O +
is O +
OH O -
, O +
OCOCH3 O -
, O +
OCOC2H5 O -
, O +
OCOCH2CH2CH3 O +
or O +
OCOCH O -
( O -
CH3 O -
) O -
2 O -
; O +
R2 O -
, O +
R3 O -
, O +
and O +
R4 O +
are O +
independently O +
H O +
or O +
C1-C3 O +
alkyl O -
; O +
R5 O +
is O +
halogen O -
, O +
nitro O -
, O +
or O +
C1-C3 O +
of O +
the O +
alkylsulfonyl O -
; O +
and O +
R6 O +
is O +
H O +
or O +
C1-C3 O +
alkylsulfonyl O -
. O +

The O +
composition O +
provided O +
by O +
the O +
invention O +
can O +
effectively O +
inhibit O +
Japanese O +
encephalitis O +
virus O +
proliferation O -
. O +

Compound O +
Caulis O +
Sinomenii O +
tablet O +
The O +
invention O +
discloses O +
a O +
compound O +
preparation O +
for O +
reducing O +
the O +
concentration O +
of O +
uric O +
acid O +
in O +
the O +
blood O +
to O +
treat O +
gout O -
, O +
and O +
concretely O +
discloses O +
a O +
compound O +
Caulis O +
Sinomenii O +
tablet O -
. O +

The O +
tablet O +
is O +
characterized O +
in O +
that O +
the O +
components O +
of O +
the O +
tablet O +
and O +
the O +
proportions O +
of O +
the O +
components O +
are O +
shown O +
in O +
the O +
specification O -
, O +
and O +
eight O +
medicines O +
which O +
are O +
the O +
components O +
are O +
mixed O +
according O +
to O +
the O +
proportions O +
to O +
prepare O +
the O +
tablet O +
or O +
a O +
pill O -
. O +

0.5 O -
- O -
1.0 O -
g O +
of O +
the O +
tablet O +
or O +
the O +
pill O +
is O +
orally O +
taken O +
each O +
time O -
, O +
and O +
is O +
continuously O +
taken O +
three O +
times O +
a O +
day O +
after O +
each O +
meal O +
for O +
2 O -
- O -
3 O +
weeks O -
. O +

Medicinal O +
composite O +
for O +
treating O +
Alzheimer O -
's O +
disease O +
The O +
invention O +
discloses O +
a O +
medicinal O +
composite O +
for O +
treating O +
Alzheimer O -
's O +
disease O -
. O +

The O +
medicinal O +
composite O +
for O +
treating O +
the O +
Alzheimer O -
's O +
disease O +
comprises O +
procyanidine O +
and O +
cysteine O -
, O +
wherein O +
the O +
mass O +
ratio O +
of O +
the O +
procyanidine O +
to O +
the O +
cysteine O +
is O +
( O -
0.1 O -
- O -
10 O -
) O -
:1 O -
, O +
preferably O +
( O -
1 O -
- O -
3 O -
) O -
:1 O -
; O +
and O +
the O +
procyanidine O +
is O +
preferably O +
lotus O +
procyanidine O -
. O +

The O +
medicinal O +
composite O +
for O +
treating O +
the O +
Alzheimer O -
's O +
disease O +
can O +
improve O +
the O +
oxidation O +
resistance O +
of O +
brain O +
tissue O -
, O +
avoid O +
free O +
radical O +
injury O +
to O +
the O +
brain O +
tissue O -
, O +
inhibit O +
MAO B-Gene -
- I-Gene -
B I-Gene +
and O +
AchE B-Gene +
activity O +
and O +
enhance O +
the O +
oxidation O +
resistance O +
of O +
brain O +
and O +
hippocampal O +
anti O -
- O -
oxidation O +
system O +
and O +
serum O +
so O +
as O +
to O +
improve O +
the O +
learning O +
and O +
memory O +
function O -
. O +

According O +
to O +
animal O +
tests O -
, O +
the O +
medicinal O +
composite O +
for O +
treating O +
the O +
Alzheimer O -
's O +
disease O +
can O +
effectively O +
improve O +
mouse O +
learning O +
and O +
memory O +
injury O +
induced O +
by O +
ethanol O +
and O +
scopolamine O -
, O +
and O +
the O +
curative O +
effect O +
is O +
more O +
excellent O +
than O +
that O +
of O +
piracetam O +
and O +
procyanidine O -
. O +

Slow O -
- O -
release O +
composition O +
containing O +
L O -
- O -
milnacipran O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
slow O -
- O -
release O +
composition O +
containing O +
L O -
- O -
milnacipran O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
composition O +
contains O +
the O +
L O -
- O -
milnacipran O +
serving O +
as O +
an O +
active O +
ingredient O +
or O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

The O +
composition O +
is O +
characterized O +
by O +
also O +
comprising O +
high O -
- O -
viscosity O +
hydroxypropyl O +
methylcellulose O +
serving O +
as O +
a O +
hydrophilic O +
gel O +
slow O -
- O -
release O +
skeleton O +
material O +
and O +
acrylic O +
resin O +
serving O +
as O +
a O +
pH O +
adjustor O -
, O +
wherein O +
the O +
composition O +
comprises O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
10 O +
to O +
70 O +
parts O +
of O +
L O -
- O -
milnacipran O +
or O +
pharmaceutically O +
acceptable O +
salt O -
, O +
5 O +
to O +
30 O +
parts O +
of O +
hydroxypropyl O +
methylcellulose O -
, O +
and O +
3.5 O +
to O +
7.5 O +
parts O +
of O +
acrylic O +
resin O -
; O +
and O +
during O +
preparation O -
, O +
the O +
L O -
- O -
milnacipran O -
, O +
the O +
hydroxypropyl O +
methylcellulose O +
and O +
the O +
acrylic O +
resin O +
are O +
bound O +
to O +
be O +
mixed O +
uniformly O -
. O +

The O +
composition O +
can O +
realize O +
consistency O +
of O +
release O +
behaviors O +
in O +
artificial O +
gastric O +
juice O +
and O +
artificial O +
intestinal O +
juice O +
and O +
keep O +
12-hour O +
continuous O +
release O +
effect O -
, O +
and O +
is O +
low O +
in O +
preparation O +
loss O -
, O +
high O +
in O +
efficiency O -
, O +
high O +
in O +
stability O -
, O +
easy O +
to O +
operate O +
and O +
easy O +
to O +
popularize O -
. O +

Carboxylic O +
acid O +
derivative O +
compound O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
provides O +
a O +
carboxylic O +
acid O +
derivative O +
compound O -
. O +

The O +
compound O +
as O +
shown O +
in O +
the O +
formula O +
( O -
I O -
) O +
or O +
the O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
provided O +
by O +
the O +
invention O +
not O +
only O +
can O +
reduce O +
the O +
level O +
of O +
triglyceride O +
in O +
high O +
fat O +
model O +
animal O +
blood O -
, O +
but O +
also O +
has O +
the O +
good O +
function O +
of O +
reducing O +
cholesterol O +
and O +
low O -
- O -
density O +
lipoprotein O +
and O +
the O +
effects O +
of O +
promoting O +
biliation O -
, O +
reducing O +
content O +
of O +
cholesterol O +
in O +
bile O +
and O +
increasing O +
the O +
content O +
of O +
bile O +
acid O -
, O +
and O +
also O +
has O +
the O +
effect O +
of O +
preventing O +
and O +
treating O +
gallstone O +
when O +
being O +
applied O +
to O +
a O +
golden O +
gopher O +
gallstone O +
model O -
. O +

The O +
particular O +
importance O +
is O +
that O +
the O +
compound O +
or O +
the O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
provided O +
by O +
the O +
invention O +
is O +
low O +
in O +
toxicity O -
. O +

Application O +
of O +
isosteviol O +
lactone O +
in O +
preparation O +
of O +
antitumor O +
medicaments O +
The O +
invention O +
belongs O +
to O +
the O +
fields O +
of O +
chemical O +
industry O +
and O +
medicine O -
, O +
and O +
relates O +
to O +
application O +
of O +
isosteviol O +
lactone O +
in O +
preparation O +
of O +
antitumor O +
medicaments O -
. O +

In O +
the O +
application O +
of O +
the O +
isosteviol O +
lactone O +
in O +
preparation O +
of O +
antitumor O +
medicaments O -
, O +
tumor O +
cells O +
include O +
liver O +
cancer O +
cells O -
, O +
leukemia O +
cells O +
and O +
pancreatic O +
cancer O +
cells O -
. O +

The O +
isosteviol O +
lactone O +
belongs O +
to O +
a O +
natural O +
product O -
, O +
is O +
low O +
in O +
toxic O +
and O +
side O +
effect O -
, O +
high O +
in O +
bioavailability O +
and O +
stable O +
in O +
property O -
, O +
and O +
has O +
clinical O +
use O +
value O -
. O +

The O +
small O -
- O -
molecule O +
compound O +
provided O +
by O +
the O +
invention O +
can O +
be O +
developed O +
as O +
a O +
new O +
antitumor O +
medicament O +
or O +
an O +
auxiliary O +
component O +
thereof O -
, O +
has O +
remarkable O +
tumor O +
inhibition O +
effect O -
, O +
and O +
is O +
green O +
and O +
environment O -
- O -
friendly O -
, O +
thereby O +
providing O +
a O +
new O +
way O +
and O +
means O +
for O +
treating O +
and O +
curing O +
tumors O -
. O +

Method O +
for O +
preparing O +
farrerol O +
solid O +
dispersion O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
a O +
farrerol O +
solid O +
dispersion O -
, O +
and O +
the O +
method O +
relates O +
to O +
the O +
technical O +
field O +
of O +
pharmaceutical O +
preparations O +
and O +
is O +
used O +
for O +
solving O +
the O +
problems O +
of O +
low O +
dissolution O +
rate O -
, O +
incomplete O +
dissolution O +
and O +
low O +
bioavailability O +
of O +
farrerol O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
dissolving O +
the O +
farrerol O +
and O +
a O +
carrier O +
material O +
into O +
a O +
medicinal O +
organic O +
solvent O +
according O +
to O +
a O +
mass O +
ratio O +
of O +
( O -
1:1 O -
) O -
- O -
( O -
1:12 O -
) O +
so O +
as O +
to O +
form O +
a O +
transparent O +
solution O -
; O +
heating O +
the O +
organic O +
solvent O +
in O +
a O +
water O +
bath O +
of O +
50 O -
- O -
80 O +
DEG O +
C O -
, O +
vaporizing O +
the O +
organic O +
solvent O +
to O +
be O +
sticky O +
and O +
then O +
quickly O +
putting O +
the O +
organic O +
solvent O +
in O +
a O +
refrigerator O +
of O +
-20 O +
DEG O +
C O +
to O +
be O +
solidified O +
for O +
3 O -
- O -
5 O +
hours O -
; O +
taking O +
the O +
solidified O +
organic O +
solvent O +
out O -
, O +
and O +
grinding O +
the O +
solidified O +
organic O +
solvent O +
into O +
small O +
particles O +
of O +
20 O +
meshes O -
; O +
putting O +
the O +
small O +
particles O +
in O +
a O +
vacuum O +
drying O +
oven O +
for O +
12 O -
- O -
24 O +
hours O +
so O +
as O +
to O +
thoroughly O +
remove O +
the O +
residual O +
organic O +
solvent O -
; O +
taking O +
the O +
small O +
particles O +
out O -
, O +
finely O +
grinding O +
and O +
screening O +
the O +
small O +
particles O +
through O +
a O +
screen O +
of O +
80 O +
meshes O +
and O +
putting O +
the O +
small O +
particles O +
in O +
a O +
drying O +
device O +
to O +
be O +
kept O +
in O +
dark O +
places O -
. O +

In O +
a O +
process O +
of O +
preparing O +
the O +
solid O +
dispersion O -
, O +
the O +
farrerol O +
is O +
uniformly O +
dispersed O +
into O +
the O +
water O -
- O -
soluble O +
carrier O -
, O +
so O +
that O +
the O +
water O +
solubility O -
, O +
dissolution O +
rate O -
, O +
bioavailability O +
and O +
therapeutic O +
effect O +
of O +
the O +
farrerol O +
are O +
improved O -
. O +

Application O +
of O +
Aphanamixoid O +
A O +
in O +
medicine O +
for O +
treating O +
liver O +
cancer O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Aphanamixoid O +
A O +
in O +
preparation O +
of O +
a O +
medicine O +
for O +
treating O +
liver O +
cancer O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
new O +
application O +
of O +
the O +
medicine O -
. O +

The O +
Aphanamixoid O +
A O +
has O +
outstanding O +
inhibiting O +
effect O +
on O +
the O +
growth O +
of O +
human O +
liver O +
cancer O +
cell O +
strains O +
HepG2 O -
, O +
MHCC O -
- O -
LM3 O -
, O +
Bel-7402 O +
and O +
HuH-7 O +
through O +
in O -
- O -
vitro O +
MTT O +
( O -
Methyl O +
Thiazolyl O +
Tetrazolium O -
) O +
antineoplastic O +
activity O +
evaluation O -
. O +

Thus O -
, O +
the O +
Aphanamixoid O +
A O +
can O +
be O +
used O +
for O +
preparing O +
the O +
medicine O +
for O +
resisting O +
the O +
liver O +
cancer O +
and O +
has O +
good O +
development O +
and O +
application O +
prospect O -
; O +
and O +
the O +
application O +
of O +
the O +
Aphanamixoid O +
A O +
in O +
preparing O +
the O +
medicine O +
for O +
treating O +
the O +
liver O +
cancer O +
is O +
firstly O +
disclosed O +
because O +
a O +
skeleton O +
type O +
belongs O +
to O +
a O +
fire O -
- O -
new O +
skeleton O +
type O +
and O +
the O +
inhibitory O +
activity O +
of O +
the O +
Aphanamixoid O +
A O +
on O +
liver O +
cancer O +
cells O +
is O +
inconceivably O +
high O -
. O +

Composition O +
containing O +
high O +
purity O +
bilobalide O +
B O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
containing O +
high O +
purity O +
bilobalide O +
B. O +
The O +
composition O +
is O +
a O +
bilobalide O +
B O +
injection O +
which O +
comprises O +
the O +
following O +
medical O +
active O +
components O +
in O +
parts O +
by O +
weight O -
: O +
20 O +
parts O +
of O +
bilobalide O +
B O +
extract O -
, O +
580 O -
- O -
630 O +
parts O +
of O +
polyethylene O +
glycol-400 O -
, O +
770 O -
- O -
830 O +
parts O +
of O +
glycerol O +
and O +
640 O -
- O -
700 O +
parts O +
of O +
ethanol O -
. O +

The O +
bilobalide O +
B O +
extract O +
is O +
extracted O +
from O +
ginkgo O +
leaves O +
and O +
contains O +
bilobalide O +
B O +
and O +
bilobalide O +
A O -
' O -
. O +

The O +
content O +
of O +
bilobalide O +
B O +
is O +
greater O +
than O +
99 O -
% O -
, O +
and O +
the O +
content O +
of O +
the O +
bilobalide O +
A O -
' O +
is O +
less O +
than O +
0.4 O -
% O -
. O +

In O +
the O +
bilobalide O +
B O +
composition O +
provided O +
by O +
the O +
invention O -
, O +
purity O +
of O +
bilobalide O +
B O +
in O +
the O +
bilobalide O +
B O +
extract O +
as O +
a O +
raw O +
material O +
medicine O +
is O +
high O -
, O +
and O +
the O +
content O +
of O +
the O +
bilobalide O +
A'is O +
extremely O +
low O -
, O +
so O +
that O +
the O +
demand O +
of O +
injection O +
to O +
the O +
raw O +
material O +
medicine O +
is O +
met O -
, O +
and O +
the O +
bioavailability O +
of O +
the O +
raw O +
material O +
medicine O +
and O +
the O +
medication O +
safety O +
of O +
patients O +
are O +
improved O -
. O +

Composition O +
taking O +
high O -
- O -
purity O +
ginkgolide O +
B O +
as O +
active O +
ingredient O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
taking O +
high O -
- O -
purity O +
ginkgolide O +
B O +
as O +
an O +
active O +
ingredient O -
. O +

The O +
composition O +
is O +
a O +
ginkgolide O +
B O +
injection O -
. O +

The O +
ginkgolide O +
B O +
injection O +
comprises O +
the O +
following O +
pharmaceutical O +
active O +
ingredients O +
in O +
parts O +
by O +
weight O -
: O +
20 O +
parts O +
of O +
ginkgolide O +
B O +
extract O -
, O +
580 O -
- O -
630 O +
parts O +
of O +
polyethylene O +
glycol-400 O -
, O +
770 O -
- O -
830 O +
parts O +
of O +
glycerol O +
and O +
640 O -
- O -
700 O +
parts O +
of O +
ethanol O -
, O +
wherein O +
the O +
ginkgolide O +
B O +
extract O +
is O +
extracted O +
from O +
ginkgo O +
leaves O -
, O +
and O +
comprises O +
ginkgolide O +
B O +
and O +
ginkgolide O +
K O -
, O +
the O +
content O +
of O +
the O +
ginkgolide O +
B O +
is O +
more O +
than O +
99 O -
% O -
, O +
and O +
the O +
content O +
of O +
the O +
ginkgolide O +
K O +
is O +
less O +
than O +
0.6 O -
% O -
. O +

In O +
a O +
ginkgolide O +
B O +
composition O +
provided O +
by O +
the O +
invention O -
, O +
the O +
ginkgolide O +
B O +
in O +
the O +
ginkgolide O +
B O +
extract O +
as O +
a O +
raw O +
medicine O +
has O +
a O +
high O +
purity O -
, O +
and O +
the O +
content O +
of O +
the O +
ginkgolide O +
K O +
is O +
extremely O +
low O -
, O +
so O +
that O +
requirement O +
of O +
the O +
injection O +
on O +
the O +
raw O +
medicine O +
is O +
met O +
and O +
the O +
bioavailability O +
of O +
the O +
raw O +
medicine O +
and O +
the O +
medication O +
safety O +
of O +
patients O +
are O +
improved O -
. O +

Calcitriol O +
powder O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
calcitriol O +
powder O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
powder O +
is O +
prepared O +
from O +
the O +
following O +
ingredients O +
in O +
percentage O +
by O +
weight O -
: O +
0.0005 O -
% O +
of O +
calcitriol O -
, O +
2.0 O -
- O -
7.0 O -
% O +
of O +
meglumine O -
, O +
2 O -
- O -
4 O -
% O +
of O +
polyethylene O +
glycol O +
400 O -
, O +
20 O -
- O -
30 O -
% O +
of O +
polyethylene O +
glycol O +
6000 O -
, O +
50.0 O -
- O -
70.0 O -
% O +
of O +
filler O +
and O +
an O +
appropriate O +
amount O +
of O +
lubricant O -
. O +

According O +
to O +
the O +
powder O -
, O +
the O +
content O +
of O +
calcitriol O +
is O +
remarkably O +
increased O -
, O +
so O +
that O +
the O +
drug O +
dosage O +
is O +
reduced O -
; O +
and O +
the O +
stability O +
of O +
calcitriol O +
to O +
light O +
and O +
air O +
is O +
improved O -
, O +
and O +
the O +
bioavailability O +
of O +
calcitriol O +
is O +
also O +
remarkably O +
improved O -
. O +

Application O +
of O +
barbaloin O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
barbaloin O +
in O +
preparing O +
medicines O +
or O +
cosmetics O +
for O +
preventing O +
or O +
treating O +
acne O +
caused O +
by O +
propionibacterium O +
acne O +
breeding O -
. O +

The O +
invention O +
discloses O +
the O +
medicines O +
or O +
cosmetics O +
which O +
contain O +
the O +
barbaloin O +
which O +
can O +
effectively O +
treat O +
the O +
acne O +
generation O +
caused O +
by O +
propionibacterium O +
acne O +
breeding O -
. O +

Ipecacuanha O +
effective O +
component O +
composition O -
, O +
its O +
preparation O +
method O +
and O +
application O +
The O +
invention O +
discloses O +
an O +
ipecacuanha O +
effective O +
component O +
composition O -
, O +
its O +
preparation O +
method O +
and O +
application O -
. O +

The O +
composition O +
contains O +
cephaeline O +
and O +
emetine O +
that O +
are O +
in O +
a O +
weight O +
ratio O +
of O +
1 O -
- O -
2:1 O -
. O +

The O +
preparation O +
method O +
of O +
the O +
ipecacuanha O +
effective O +
component O +
composition O +
comprises O -
: O +
taking O +
ipecacuanha O +
medicinal O +
materials O +
with O +
different O +
producing O +
areas O +
and/or O +
different O +
batches O -
, O +
mixing O +
them O +
in O +
proportion O +
to O +
prepare O +
an O +
extract O -
, O +
a O +
fluid O +
extract O +
or O +
a O +
tincture O -
, O +
or O +
conducting O +
extraction O +
on O +
the O +
ipecacuanha O +
medicinal O +
materials O +
with O +
different O +
producing O +
areas O +
and/or O +
different O +
batches O +
to O +
prepare O +
extracts O -
, O +
performing O +
mixing O +
in O +
proportion O -
, O +
and O +
then O +
making O +
the O +
mixture O +
into O +
an O +
extract O -
, O +
a O +
fluid O +
extract O +
or O +
a O +
tincture O -
. O +

Based O +
on O +
the O +
pharmacological O +
and O +
pharmacokinetic O +
differences O +
of O +
emetine O +
and O +
cephaeline O -
, O +
screening O +
research O +
on O +
cough O +
relieving O +
and O +
sputum O +
reducing O +
effect O +
differences O +
caused O +
by O +
different O +
proportions O +
of O +
emetine O +
and O +
cephaeline O +
is O +
carried O +
out O -
, O +
and O +
a O +
good O +
emetine O +
and O +
cephaeline O +
combination O +
region O +
for O +
ideal O +
cough O +
relieving O +
and O +
sputum O +
reducing O +
effects O +
can O +
be O +
determined O -
. O +

Bicyclic O +
heteroaryl O +
kinase B-Gene +
inhibitors O +
and O +
methods O +
of O +
use O +
Provided O +
are O +
compounds O +
having O +
an O +
inhibitory O +
effect O +
on O +
kinases B-Gene +
including O +
Mixed B-Gene +
Lineage I-Gene +
Kinases I-Gene -
. O +

Also O +
provided O +
are O +
pharmaceutical O +
compositions O -
, O +
methods O +
of O +
preparing O +
the O +
compounds O -
, O +
synthetic O +
intermediates O -
, O +
and O +
methods O +
of O +
using O +
the O +
compounds O -
, O +
independently O +
or O +
in O +
combination O +
with O +
other O +
therapeutic O +
agents O -
, O +
for O +
treating O +
diseases O +
and O +
conditions O +
that O +
are O +
affected O +
by O +
Mixed B-Gene +
Lineage I-Gene +
Kinase I-Gene +
inhibition O -
. O +

Also O +
provided O +
are O +
methods O +
of O +
treatment O +
of O +
neuropsychiatric O +
disorders O +
that O +
comprise O +
the O +
inhibition O +
of O +
Mixed B-Gene +
Lineage I-Gene +
Kinases I-Gene -
. O +

Kidney O +
bean O +
phytolectin O +
applications O +
in O +
preparation O +
of O +
human O +
drugs O +
and O +
drug O +
composition O +
thereof O +
The O +
invention O +
discloses O +
kidney O +
bean O +
phytolectin O +
applications O +
in O +
preparation O +
of O +
human O +
drugs O +
and O +
a O +
drug O +
composition O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
drugs O -
. O +

Kidney O +
bean O +
phytolectins O +
are O +
used O +
as O +
active O +
components O +
for O +
preparing O +
drugs O +
used O +
for O +
adding O +
lactobacillus O +
amounts O +
in O +
woman O +
vaginas O -
. O +

The O +
drug O +
composition O +
adopts O +
the O +
kidney O +
bean O +
phytolectins O -
, O +
tremella O +
polysaccharide O -
, O +
stachyose O +
or O -
/ O -
and O +
raffinose O +
and O +
bletilla O +
gum O -
, O +
or O +
added O +
scutellaria O -
, O +
Hollygreen O +
Barberry O +
and O +
matrine O +
extraction O +
as O +
the O +
active O +
components O -
. O +

The O +
drug O +
composition O +
comprises O +
relative O +
weight O +
parts O +
of O +
that O +
0.5 O -
- O -
1.0 O +
part O +
of O +
the O +
kidney O +
bean O +
phytolectins O -
, O +
1.5 O -
- O -
3.0 O +
parts O +
of O +
the O +
tremella O +
polysaccharide O -
, O +
0.2 O -
- O -
2.0 O +
parts O +
of O +
the O +
stachyose O +
or O -
/ O -
and O +
raffinose O -
, O +
0.2 O -
- O -
0.5 O +
part O +
of O +
the O +
bletilla O +
gum O +
and O +
1.0 O -
- O -
3.0 O +
parts O +
of O +
the O +
extraction O +
of O +
one O +
kind O +
or O +
more O +
than O +
one O +
kind O +
of O +
scutellaria O +
dry O +
powder O -
, O +
Hollygreen O +
Barberry O +
dry O +
powder O +
and O +
matrine O +
dry O +
powder O -
. O +

The O +
kidney O +
bean O +
phytolectin O +
applications O +
in O +
preparation O +
of O +
people O +
use O +
drugs O +
and O +
the O +
drug O +
composition O +
can O +
be O +
water O -
- O -
soluble O +
complex O +
liquid O +
and O +
is O +
best O +
to O +
be O +
gel O -
, O +
and O +
also O +
can O +
be O +
solid O +
dosage O +
forms O +
such O +
as O +
suppository O -
, O +
disintegrating O +
tablets O +
and O +
the O +
like O +
which O +
are O +
drug O +
dosage O +
forms O +
suitable O +
for O +
external O +
uses O -
. O +

Compared O +
with O +
the O +
prior O +
art O -
, O +
obtained O +
products O +
do O +
not O +
need O +
to O +
be O +
preserved O +
in O +
a O +
low O +
temperature O +
and O +
is O +
long O +
in O +
storage O +
time O +
and O +
convenient O +
to O +
use O -
. O +

Vidarabine O +
monophosphate O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
vidarabine O +
monophosphate O +
injection O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
injection O +
is O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
by O +
weight O -
: O +
50 O -
- O -
200 O +
parts O +
of O +
vidarabine O +
monophosphate O -
, O +
0.015 O -
- O -
0.05 O +
part O +
of O +
a O +
pH O +
regulator O +
and O +
2000 O +
parts O +
of O +
water O +
for O +
injection O -
. O +

A O +
finished O +
product O +
prepared O +
by O +
the O +
method O +
provided O +
by O +
the O +
invention O +
has O +
low O +
impurity O +
content O -
, O +
good O +
homogeneity O +
and O +
good O +
stability O -
. O +

A O +
water O +
injection O +
is O +
subjected O +
to O +
terminal O +
sterilization O +
to O +
ensure O +
the O +
safety O +
of O +
the O +
product O -
. O +

The O +
water O +
injection O +
is O +
convenient O +
to O +
use O -
, O +
and O +
does O +
not O +
need O +
to O +
be O +
prepared O +
before O +
clinical O +
application O -
, O +
so O +
as O +
to O +
reduce O +
the O +
potential O +
safety O +
hazard O +
caused O +
by O +
operation O +
and O +
provide O +
a O +
new O +
choice O +
of O +
medication O +
for O +
clinical O +
use O -
. O +

Application O +
of O +
terpenoid O +
The O +
invention O +
provides O +
an O +
application O +
of O +
a O +
terpenoid O +
to O +
preparation O +
of O +
an O +
anticoagulation O +
drug O -
. O +

The O +
terpenoid O +
has O +
a O +
structural O +
formula O +
I O +
which O +
is O +
as O +
shown O +
in O +
the O +
description O -
, O +
wherein O +
R1 O +
represents O +
H O -
, O +
C1-C5 O +
linear O +
alkyl O -
, O +
glycosyl O +
or O +
a O +
formula O +
which O +
is O +
as O +
shown O +
in O +
the O +
description O -
, O +
and O +
R2 O +
is O +
selected O +
from O +
C1-C4 O +
linear O +
alkyl O -
. O +

According O +
to O +
the O +
application O +
of O +
the O +
terpenoid O -
, O +
an O +
ionane O +
type O +
sesquiterpene O +
compound O +
separated O +
and O +
obtained O +
from O +
leonurus O +
for O +
the O +
first O +
time O +
can O +
obviously O +
inhibit O +
the O +
platelet O +
aggregation O +
in O +
vitro O +
and O +
has O +
extension O +
tendencies O +
to O +
prothrombin B-Gene +
time O +
( O -
PT O -
) O -
, O +
activated O +
partial O +
thromboplastin B-Gene +
time O +
( O -
APTT O -
) O +
and O +
thrombin B-Gene +
time O +
( O -
TT O -
) O +
and O +
has O +
a O +
certain O +
anticoagulation O +
activity O -
, O +
so O +
that O +
a O +
new O +
choice O +
is O +
provided O +
for O +
the O +
development O +
of O +
natural O +
anti O -
- O -
thrombus O +
drugs O -
. O +

Imatinib O +
mesylate O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
imatinib O +
mesylate O +
tablet O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
imatinib O +
mesylate O +
tablet O +
comprises O +
8 O -
- O -
30 O -
% O +
of O +
crospovidone O +
and O +
8 O +
to O +
40 O -
% O +
of O +
silica O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O +
carrying O +
out O +
granulation O +
of O +
imatinib O +
mesylate O +
and O +
a O +
waterless O +
organic O +
solvent O -
, O +
drying O +
the O +
granules O -
, O +
uniformly O +
mixing O +
the O +
granules O -
, O +
crospovidone O -
, O +
silica O -
, O +
a O +
filler O +
and O +
a O +
lubricant O -
, O +
and O +
carrying O +
out O +
tabletting O -
. O +

The O +
preparation O +
method O +
solves O +
the O +
problem O +
of O +
a O +
slow O +
dissolution O +
rate O +
of O +
a O +
preparation O +
obtained O +
by O +
the O +
prior O +
art O -
. O +

Ezetimibe O -
, O +
simvastatin O +
and O +
nicotinic O +
acid O +
compound O +
preparation O +
and O +
preparation O +
method O +
of O +
ezetimibe O -
, O +
simvastatin O +
and O +
nicotinic O +
acid O +
compound O +
preparation O +
The O +
invention O +
belongs O +
to O +
the O +
field O +
of O +
pharmaceutical O +
preparations O +
and O +
particularly O +
relates O +
to O +
a O +
compound O +
preparation O +
which O +
takes O +
ezetimibe O -
, O +
simvastatin O +
and O +
nicotinic O +
acid O +
as O +
effective O +
components O +
and O +
has O +
the O +
effects O +
of O +
reducing O +
blood O +
pressure O +
and O +
blood O +
lipid O +
and O +
a O +
preparation O +
method O +
of O +
the O +
compound O +
preparation O -
. O +

The O +
compound O +
preparation O +
is O +
a O +
sustained O +
release O +
tablet O -
. O +

Aiming O +
at O +
the O +
problems O +
of O +
poor O +
water O +
solubility O +
of O +
the O +
ezetimibe O -
, O +
unstability O +
of O +
the O +
simvastatin O +
to O +
acid O +
and O +
oxygen O -
, O +
and O +
the O +
like O -
, O +
the O +
preparation O +
method O +
of O +
the O +
compound O +
preparation O +
adopts O +
a O +
melt O +
extrusion O +
technology O +
for O +
improving O +
the O +
dissolution O +
rate O +
of O +
the O +
ezetimibe O -
, O +
and O +
adopts O +
a O +
cladding O +
membrane O +
technology O +
for O +
enhancing O +
the O +
stability O +
of O +
the O +
simvastatin O +
in O +
a O +
body O +
so O +
as O +
to O +
give O +
full O +
play O +
to O +
the O +
efficacy O +
of O +
all O +
components O +
of O +
the O +
compound O +
preparation O +
and O +
have O +
the O +
best O +
synergy O +
effect O -
. O +

The O +
specific O +
process O +
comprises O +
the O +
steps O +
of O +
preparing O +
the O +
nicotinic O +
acid O +
into O +
a O +
tablet O +
core O +
as O +
a O +
sustained O +
release O +
part O -
, O +
spraying O +
an O +
isolating O +
layer O +
on O +
the O +
tablet O +
core O -
, O +
then O +
spraying O +
the O +
simvastatin O +
and O +
the O +
ezetimibe O +
on O +
an O +
outer O +
layer O +
of O +
the O +
sustained O +
release O +
part O +
as O +
a O +
quick O +
release O +
layer O -
, O +
and O +
then O +
carrying O +
out O +
film O +
coating O +
on O +
the O +
quick O +
release O +
layer O -
. O +

The O +
compound O +
preparation O +
provided O +
by O +
the O +
invention O +
is O +
mainly O +
applied O +
to O +
the O +
treatment O +
or O +
prevention O +
of O +
diseases O +
and O +
indications O +
associated O +
with O +
heart O +
and O +
cerebral O +
vessels O -
. O +

Enrofloxacin O +
clathrate O +
compound O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
enrofloxacin O +
clathrate O +
compound O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
enrofloxacin O +
clathrate O +
compound O +
is O +
prepared O +
by O +
taking O +
enrofloxacin O +
and O +
fenugreek O +
as O +
raw O +
materials O -
, O +
performing O +
clathration O +
treatment O +
on O +
auxiliary O +
materials O +
such O +
as O +
a O +
slow O +
release O +
formulation O -
, O +
a O +
flavoring O +
agent O -
, O +
a O +
plasticizer O -
, O +
a O +
curing O +
agent O +
and O +
a O +
flocculant O -
, O +
and O +
drying O +
the O +
materials O -
. O +

The O +
enrofloxacin O +
clathrate O +
compound O +
has O +
the O +
advantages O +
that O +
the O +
delay O +
medicines O +
are O +
released O -
, O +
the O +
clinical O +
administration O +
frequency O +
is O +
reduced O -
, O +
the O +
product O +
stability O +
is O +
improved O +
and O +
the O +
palatability O +
of O +
the O +
medicines O +
is O +
improved O -
. O +

2,6-diketone O -
- O -
piperazine O +
( O -
piperidine O -
) O +
type O +
derivative O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
a O +
2,6-diketone O -
- O -
piperazine O +
( O -
piperidine O -
) O +
type O +
derivative O +
and O +
an O +
application O +
thereof O -
. O +

The O +
derivative O +
can O +
be O +
applied O +
to O +
preparation O +
of O +
medicines O +
for O +
preventing O +
or O +
treating O +
central O +
nervous O +
system O +
diseases O -
. O +

Animal O +
experiment O +
results O +
show O +
that O +
the O +
derivative O +
has O +
smaller O +
ED50 O +
and O +
stronger O +
action O +
in O +
MK-801-induced O +
high O +
activity O +
and O +
apomorphine O -
- O -
induced O +
climbing O +
animal O +
models O +
as O +
well O +
as O +
has O +
larger O +
ED50 O +
and O +
larger O +
therapeutic O +
indexes O +
in O +
an O +
animal O +
catalepsy O +
model O -
. O +

The O +
derivative O +
is O +
a O +
compound O +
or O +
salt O +
thereof O +
with O +
a O +
general O +
formula O +
( O -
I O -
) O -
. O +

Application O +
of O +
ampelopsin O +
in O +
mutation O +
resistance O +
composition O +
preparation O +
The O +
present O +
invention O +
discloses O +
an O +
application O +
of O +
ampelopsin O +
in O +
preparation O +
of O +
mutation O +
resistance O +
health O +
food O +
or O +
drugs O -
, O +
wherein O +
purified O +
ampelopsin O +
or O +
an O +
unpurified O +
extract O +
containing O +
ampelopsin O +
can O +
be O +
adopted O +
to O +
prepare O +
into O +
a O +
pharmaceutically O +
acceptable O +
oral O +
formulation O -
, O +
a O +
pharmaceutically O +
acceptable O +
injection O +
formulation O +
or O +
a O +
pharmaceutically O +
acceptable O +
external O +
application O +
formulation O -
. O +

Application O +
of O +
5,7,3',4',5'-pentamethoxyl O +
flavone O +
in O +
preparing O +
analgesic O +
and O +
anti O -
- O -
inflammatory O +
drugs O +
The O +
invention O +
relates O +
to O +
drug O +
application O +
of O +
an O +
organic O +
compound O +
and O +
in O +
particular O +
relates O +
to O +
application O +
of O +
5,7,3',4',5'-pentamethoxyl O +
flavone O +
in O +
preparing O +
analgesic O +
and O +
anti O -
- O -
inflammatory O +
drugs O -
. O +

According O +
to O +
the O +
pharmacological O +
experiment O +
results O -
, O +
the O +
compound O +
has O +
better O +
inbibitional O +
effect O +
for O +
pains O +
and O +
inflammations O -
, O +
and O +
can O +
be O +
used O +
as O +
an O +
active O +
ingredient O +
for O +
preventing O +
and O +
treating O +
diseases O +
including O +
rheumatic O +
arthritis O -
, O +
rheumatoid O +
arthritis O +
and O +
the O +
like O -
. O +

Pleuromutilin O +
expansion O +
ring O +
derivative O -
, O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
pleuromutilin O +
expansion O +
ring O +
derivative O +
shown O +
in O +
a O +
structural O +
general O +
formula O +
( O -
I O -
) O -
, O +
and O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

A O +
novel O +
expansion O +
ring O +
pleuromutilin O +
compound O +
is O +
synthetized O +
by O +
rearrangement O +
reaction O -
. O +

The O +
compound O +
can O +
be O +
used O +
for O +
synthesizing O +
a O +
new O +
pleuromutilin O +
derivative O +
and O +
preparing O +
an O +
antibacterial O +
agent O -
. O +

Topical O +
ointment O +
for O +
treating O +
furunculosis O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
topical O +
ointment O +
for O +
treating O +
furunculosis O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
topical O +
ointment O +
is O +
characterized O +
in O +
that O +
the O +
topical O +
ointment O +
is O +
made O +
from O +
the O +
following O +
raw O +
medicines O -
, O +
by O +
weight O -
, O +
17 O -
- O -
23 O +
parts O +
of O +
honeysuckles O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
chrysanthemums O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
scutellaria O +
baicalensis O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
rheum O +
officinale O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
fructus O +
forsythia O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
Chinese O +
violets O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
moutan O +
bark O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
golden O +
cypress O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
coptis O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
radix O +
rehmanniae O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
hematoxylon O -
, O +
6 O -
- O -
8 O +
parts O +
of O +
Chinese O +
angelica O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
cape O +
jasmine O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
notopterygium O +
roots O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
flos O +
sophorae O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
platycodon O +
grandiflorum O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
Chinese O +
parsnip O +
roots O -
, O +
2 O -
- O -
4 O +
parts O +
of O +
smoked O +
plums O -
, O +
2 O -
- O -
4 O +
parts O +
of O +
plant O +
soot O +
and O +
0.8 O -
- O -
1.2 O +
parts O +
of O +
calomel O -
. O +

The O +
topical O +
ointment O +
is O +
advantaged O +
by O +
rapid O +
effects O -
, O +
significant O +
effects O +
and O +
simple O +
preparation O +
method O -
. O +

Through O +
clinical O +
verifications O -
, O +
the O +
cure O +
rate O +
of O +
the O +
topical O +
ointment O +
for O +
treating O +
furunculosis O +
is O +
100 O -
% O -
. O +

[ O -
0 O -
] O +

High O -
- O -
permeability O +
emulsifiable O +
paste O +
for O +
diminishing O +
inflammation O +
and O +
easing O +
pain O +
The O +
invention O +
relates O +
to O +
an O +
emulsifiable O +
paste O +
for O +
diminishing O +
inflammation O +
and O +
easing O +
pain O -
. O +

The O +
emulsifiable O +
paste O +
comprises O +
geniposide O -
, O +
isopropyl O +
myristate O -
, O +
caprylic O -
/ O -
capric O +
triglyceride O +
and O +
polyoxyethylene O +
ether O +
40 O +
hydrogenated O +
castor O +
oil O -
. O +

In O +
the O +
emulsifiable O +
paste O +
disclosed O +
by O +
the O +
invention O -
, O +
isopropyl O +
myristate O +
is O +
used O +
as O +
a O +
novel O +
percutaneous O +
permeation O +
agent O +
for O +
geniposide O -
, O +
thus O +
greatly O +
increasing O +
the O +
permeation O +
amount O +
for O +
geniposide O -
. O +

The O +
emulsifiable O +
paste O +
disclosed O +
by O +
the O +
invention O +
is O +
excellent O +
in O +
performance O -
, O +
low O +
in O +
greasy O +
feeling O -
, O +
easy O +
to O +
coat O +
and O +
clean O -
, O +
and O +
good O +
in O +
heat O +
stability O -
. O +

Method O +
for O +
preparing O +
long O -
- O -
acting O +
terramycin O +
injection O +
by O +
utilizing O +
carbamide O +
and O +
sodium O +
bisulfite O +
in O +
combined O +
way O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
long O -
- O -
acting O +
terramycin O +
injection O +
by O +
utilizing O +
carbamide O +
and O +
sodium O +
bisulfite O +
in O +
a O +
combined O +
way O -
. O +

The O +
long O -
- O -
acting O +
terramycin O +
injection O +
comprises O +
the O +
following O +
raw O +
materials O +
in O +
parts O +
by O +
weight O -
: O +
10 O -
- O -
15 O +
parts O +
of O +
tetramycin O +
hydrochloride O -
, O +
4 O -
- O -
5 O +
parts O +
of O +
magnesium O +
chloride O -
, O +
2 O -
- O -
3 O +
parts O +
of O +
carbamide O -
, O +
0.5 O -
- O -
0.8 O +
part O +
of O +
sodium O +
thiosulfate O -
, O +
4 O -
- O -
6 O +
parts O +
of O +
ethanolamine O -
, O +
1 O -
- O -
1.5 O +
parts O +
of O +
sodium O +
bisulfite O -
, O +
50 O -
- O -
60 O +
parts O +
of O +
alpha O -
- O -
pyrrolidone O -
, O +
0.01 O -
- O -
0.03 O +
part O +
of O +
disodium O +
EDTA O +
and O +
100 O -
- O -
150 O +
parts O +
of O +
water O +
for O +
injection O -
. O +

Compared O +
with O +
the O +
prior O +
art O -
, O +
the O +
long O -
- O -
acting O +
terramycin O +
injection O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
high O +
bioavailability O -
, O +
good O +
curative O +
effect O -
, O +
quick O +
effect O -
, O +
definite O +
curative O +
effect O +
and O +
stability O +
in O +
quality O +
and O +
can O +
keep O +
higher O +
biological O +
activity O +
for O +
a O +
longer O +
time O +
and O +
sufficiently O +
keep O +
the O +
stability O +
of O +
a O +
product O -
; O +
the O +
preparation O +
method O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
easiness O +
for O +
operation O +
of O +
product O +
preparation O -
, O +
low O +
cost O +
and O +
industrialized O +
large O -
- O -
scale O +
production O -
. O +

Application O +
of O +
compound O +
in O +
preparation O +
of O +
medicaments O +
for O +
preventing O +
and O +
treating O +
liver O +
injury O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
a O +
compound O +
in O +
preparation O +
of O +
medicaments O +
for O +
preventing O +
and O +
treating O +
liver O +
injury O -
. O +

According O +
to O +
the O +
application O +
disclosed O +
by O +
the O +
invention O -
, O +
pharmacological O +
research O +
performed O +
on O +
Polyflavanostilbene O +
A O -
, O +
Polyflavanostilbene O +
A O +
is O +
found O +
to O +
have O +
a O +
protective O +
effect O +
on O +
the O +
acute O +
liver O +
injury O +
induced O +
by O +
D O -
- O -
galactosamine O +
( O -
D O -
- O -
GalN O -
) O -
, O +
of O +
mice O -
, O +
and O +
a O +
protective O +
effect O +
on O +
the O +
acute O +
liver O +
injury O +
induced O +
by O +
CC14 O -
, O +
of O +
mice O -
. O +

Therefore O -
, O +
the O +
Polyflavanostilbene O +
A O +
can O +
be O +
used O +
for O +
preparing O +
medicaments O +
for O +
preventing O +
and O +
treating O +
liver O +
injury O +
or O +
hepatitis O -
. O +

The O +
application O +
of O +
the O +
Polyflavanostilbene O +
A O +
in O +
preparation O +
of O +
medicaments O +
for O +
preventing O +
and O +
treating O +
liver O +
injury O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
; O +
the O +
Polyflavanostilbene O +
A O +
has O +
a O +
new O +
framework O +
type O -
, O +
and O +
an O +
unexpectedly O +
high O +
activity O +
for O +
the O +
treatment O +
effect O +
on O +
liver O +
injury O -
, O +
so O +
that O +
the O +
possibility O +
of O +
giving O +
any O +
revelation O +
by O +
other O +
compounds O +
is O +
avoided O -
; O +
and O +
the O +
Polyflavanostilbene O +
A O +
has O +
prominent O +
substantive O +
features O +
and O +
has O +
an O +
obviously O +
remarkable O +
improvement O +
in O +
case O +
of O +
being O +
used O +
for O +
resisting O +
liver O +
injury O -
. O +

Cinnamic O +
amide O +
derivatives O -
, O +
their O +
preparation O +
methods O +
and O +
their O +
application O +
in O +
preparation O +
of O +
bleeding O +
stopping O +
and O +
stasis O +
dissolving O +
medicines O +
The O +
invention O +
discloses O +
cinnamic O +
amide O +
derivatives O -
, O +
their O +
preparation O +
methods O +
and O +
their O +
application O +
in O +
the O +
preparation O +
of O +
bleeding O +
stopping O +
and O +
stasis O +
dissolving O +
medicines O -
. O +

The O +
preparation O +
methods O +
adopting O +
hydroxycinnamic O +
acid O +
and O +
sulfanilamide O +
medicines O +
as O +
raw O +
materials O +
comprise O +
the O +
following O +
steps O -
: O +
dissolving O +
hydroxycinnamic O +
acid O +
in O +
acetic O +
anhydride O -
, O +
sequentially O +
adding O +
pyridine O +
and O +
tetrahydrofuran O +
for O +
reacting O +
with O +
the O +
sulfanilamide O +
medicines O +
to O +
obtain O +
crude O +
amide O +
compounds O -
, O +
filtering O -
, O +
washing O -
, O +
and O +
recrystallizing O +
to O +
obtain O +
the O +
novel O +
cinnamic O +
amide O +
derivatives O -
. O +

Researches O +
find O +
that O +
the O +
derivatives O +
can O +
activate O +
the O +
blood O +
coagulation O +
factor O +
in O +
an O +
endogenous O +
and O +
exogenous O +
blood O +
coagulation O +
way O -
, O +
reinforces O +
the O +
uterine O +
action O -
, O +
can O +
be O +
well O +
combined O +
with O +
the O +
human O +
serum O -
, O +
has O +
a O +
coagulation O +
promoting O +
activity O +
and O +
a O +
pain O +
easing O +
effect O -
, O +
and O +
also O +
has O +
a O +
two O -
- O -
way O +
regulation O +
effect O +
on O +
the O +
stasis O +
dissolving O -
. O +

Experiments O +
on O +
the O +
four O +
blood O +
coagulation O +
indexes O -
, O +
the O +
calcium O +
recovering O +
time O +
of O +
the O +
blood O +
plasma O +
and O +
the O +
mouse O +
in O -
- O -
vitro O +
uterus O +
confirm O +
that O +
the O +
derivatives O +
have O +
the O +
coagulation O +
promoting O -
, O +
coagulation O +
preventing O +
and O +
two O -
- O -
way O +
regulating O +
activities O -
, O +
have O +
a O +
use O +
in O +
the O +
bleeding O +
stopping O +
and O +
stasis O +
dissolving O +
medicines O -
, O +
and O +
can O +
be O +
used O +
for O +
preparing O +
blood O +
disease O +
medicines O -
. O +

Oxiracetam O +
medicinal O +
composition O -
, O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
an O +
oxiracetam O +
medicinal O +
composition O +
having O +
a O +
high O +
safety O -
, O +
and O +
a O +
preparation O +
method O +
and O +
an O +
application O +
thereof O -
. O +

The O +
medicinal O +
composition O +
contains O +
oxiracetam O +
and O +
below O +
0.5 O -
% O +
of O +
a O +
compound O +
having O +
a O +
structure O +
represented O +
by O +
formula O +
II O -
. O +

A O +
case O +
that O +
4-hydroxy-2-oxo-1-pyrrolidineaceticacid O +
is O +
the O +
largest O -
- O -
content O +
impurity O +
in O +
the O +
oxiracetam O +
compound O +
is O +
proved O +
for O +
the O +
first O +
time O -
, O +
purifying O +
characterization O +
and O +
relevant O +
researches O +
on O +
4-hydroxy-2-oxo-1-pyrrolidineaceticacid O +
are O +
carried O +
out O -
, O +
and O +
the O +
researches O +
find O +
that O +
4-hydroxy-2-oxo-1-pyrrolidineaceticacid O +
is O +
related O +
with O +
the O +
side O +
effects O +
of O +
the O +
oxiracetam O +
medicine O +
and O +
can O +
cause O +
a O +
series O +
of O +
untoward O +
effects O -
. O +

The O +
oxiracetam O +
medicinal O +
composition O +
has O +
a O +
high O +
safety O -
. O +

The O +
invention O +
further O +
provides O +
the O +
preparation O +
method O +
of O +
the O +
oxiracetam O +
medicinal O +
composition O -
. O +

Natural O +
pharmaceutical O +
composition O +
The O +
invention O +
relates O +
to O +
a O +
natural O +
pharmaceutical O +
composition O -
. O +

The O +
natural O +
pharmaceutical O +
composition O +
comprises O +
a O +
katsumade O +
galangal O +
seed O +
and O +
baical O +
skullcap O +
root O +
water O +
decoction O +
concentrated O +
extract O -
, O +
a O +
katsumade O +
galangal O +
seed O +
ethyl O +
acetate O +
extract O -
, O +
total O +
flavonoids O +
of O +
baical O +
skullcap O +
root O +
and O +
baicalin O +
according O +
to O +
the O +
proportion O +
of O +
( O -
2 O -
- O -
4 O -
) O -
: O +
( O -
3 O -
- O -
8 O -
) O -
: O +
( O -
3 O -
- O -
9 O -
) O -
: O +
( O -
1 O -
- O -
4 O -
) O -
, O +
and O +
the O +
composition O +
has O +
an O +
excellent O +
curative O +
effect O +
against O +
diarrhea O +
which O +
is O +
related O +
to O +
cancer O +
chemotherapy O +
and O +
can O +
simultaneously O +
realize O +
a O +
synergistic O +
action O +
against O +
the O +
cancer O +
chemotherapy O -
. O +

N-3-arylamine-5-cyclopropane O +
spirohydantoin O +
and O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
discloses O +
N-3-arylamine-5-cyclopropane O +
spirohydantoin O +
and O +
a O +
preparation O +
method O +
and O +
application O +
thereof O -
. O +

The O +
structural O +
general O +
formula O +
of O +
the O +
N-3-arylamine O +
substituent-5-cyclopropane O +
spirohydantoin O +
is O +
shown O +
in O +
the O +
specification O -
, O +
wherein O +
R1 O +
is O +
phenyl O -
, O +
substituted O +
phenyl O +
and O +
heterocyclic O +
arene O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O +
of O -
: O +
performing O +
a O +
reaction O +
between O +
1-carboxyl-2,2-dimethylcyclopropane O +
ethyl O +
carboxylate O +
and O +
ethyl O +
chloroformate O +
to O +
generate O +
1-acyl O +
azide-2,2-dimethylcyclopropane O +
ethyl O +
carboxylate O +
under O +
the O +
effect O +
of O +
NaN3 O -
; O +
performing O +
Curtius O +
rearrangement O +
on O +
the O +
1-acyl O +
azide-2,2-dimethylcyclopropane O +
ethyl O +
carboxylate O +
to O +
generate O +
corresponding O +
isocyanate O -
; O +
performing O +
a O +
reaction O +
between O +
the O +
isocyanate O +
and O +
hydrazine O +
to O +
obtain O +
N'-arylamine O +
substituent O +
ureidocyclopropane O -
; O +
and O +
generating O +
N-3-arylamine O +
substituent-5-cyclopropane O +
spirohydantoin O +
from O +
the O +
N'-arylamine O +
substituent O +
ureidocyclopropane O -
. O +

The O +
preparation O +
method O +
disclosed O +
by O +
the O +
invention O +
is O +
simple O -
, O +
has O +
higher O +
yield O -
, O +
and O +
can O +
be O +
used O +
for O +
easily O +
preparing O +
the O +
N-3-arylamine O +
substituent-5-cyclopropane O +
spirohydantoin O -
. O +

6- O -
( O -
4-arylpiperazine-1-yl O -
) O +
pyridazine-3 O -
( O -
2H O -
) O -
-ketone O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
6- O -
( O -
4-arylpiperazine-1-yl O -
) O +
pyridazine-3 O -
( O -
2H O -
) O -
-ketone O -
, O +
which O +
has O +
a O +
chemical O +
structure O +
formula O +
shown O +
in O +
formula O +
( O -
I O -
) O -
. O +

The O +
6- O -
( O -
4-arylpiperazine-1-yl O -
) O +
pyridazine-3 O -
( O -
2H O -
) O -
-ketone O +
disclosed O +
by O +
the O +
invention O +
can O +
be O +
obtained O +
by O +
reacting O +
phenylpiperazine O +
pyridazinone O +
and O +
1- O -
( O -
2-bromoethoxyl O -
) O -
-2-chlorobenzene O -
. O +

The O +
6- O -
( O -
4-arylpiperazine-1-yl O -
) O +
pyridazine-3 O -
( O -
2H O -
) O -
-ketone O +
disclosed O +
by O +
the O +
invention O +
is O +
remarkable O +
in O +
effect O +
of O +
suppressing O +
an O +
alpha B-Gene +
1-adrenergic I-Gene +
receptor I-Gene -
. O +

Feed O +
additive O +
for O +
preventing O +
dairy O +
cow O +
mastitis O +
The O +
invention O +
relates O +
to O +
a O +
feed O +
additive O +
for O +
preventing O +
dairy O +
cow O +
mastitis O -
. O +

The O +
feed O +
additive O +
is O +
prepared O +
from O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
5 O -
- O -
10 O +
parts O +
of O +
medlar O -
, O +
15 O -
- O -
20 O +
parts O +
of O +
Chinese O +
dates O -
, O +
5 O -
- O -
8 O +
parts O +
of O +
flowers O +
carthami O -
, O +
5 O -
- O -
8 O +
parts O +
of O +
chrysanthemum O -
, O +
2 O -
- O -
4 O +
parts O +
of O +
radix O +
paeoniae O +
alba O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
polygonum O +
multiflorum O -
, O +
2 O -
- O -
4 O +
parts O +
of O +
smoked O +
plum O -
, O +
1 O -
- O -
3 O +
parts O +
of O +
yeast O +
culture O -
, O +
2 O -
- O -
4 O +
parts O +
of O +
medicinal O +
stones O +
and O +
3 O -
- O -
5 O +
parts O +
of O +
bentonite O -
. O +

The O +
feed O +
additive O +
disclosed O +
by O +
the O +
invention O +
can O +
be O +
used O +
for O +
preventing O +
the O +
dairy O +
cow O +
mastitis O +
effectively O -
, O +
so O +
that O +
the O +
health O +
condition O +
of O +
dairy O +
cow O +
is O +
improved O -
, O +
and O +
the O +
effects O +
on O +
the O +
milk O +
yield O +
and O +
the O +
quality O +
of O +
a O +
dairy O +
product O +
due O +
to O +
diseases O +
such O +
as O +
mastitis O +
are O +
avoided O -
. O +

By O +
virtue O +
of O +
the O +
feed O +
additive O +
disclosed O +
by O +
the O +
invention O -
, O +
the O +
economic O +
benefits O +
of O +
cow O +
cultivation O +
are O +
greatly O +
improved O -
, O +
and O +
the O +
adverse O +
effects O +
on O +
the O +
quality O +
of O +
the O +
dairy O +
product O +
and O +
the O +
health O +
of O +
the O +
dairy O +
cow O +
caused O +
by O +
antibiotics O +
can O +
be O +
avoided O -
. O +

Natural O +
pharmaceutical O +
extractive O +
The O +
invention O +
relates O +
to O +
a O +
natural O +
pharmaceutical O +
extractive O +
which O +
comprises O +
concentrated O +
extractive O +
of O +
water O +
decocted O +
shizandra O +
berry O -
- O -
long O +
pepper O -
, O +
shizandra O +
berry O +
polyose O -
, O +
long O +
pepper O -
- O -
ethanol O +
extractive O -
, O +
and O +
piperine O +
according O +
to O +
the O +
proportion O +
of O +
( O -
3 O -
- O -
6 O -
) O +
: O +
( O -
3 O -
- O -
7 O -
) O +
: O +
( O -
1 O -
- O -
3 O -
) O +
: O +
( O -
4 O -
- O -
9 O -
) O -
. O +

The O +
natural O +
pharmaceutical O +
extractive O +
has O +
an O +
excellent O +
curative O +
effect O +
on O +
diarrhea O +
related O +
to O +
cancer O +
chemo O -
- O -
treatment O +
and O +
a O +
synergistic O +
effect O +
on O +
cancer O +
chemo O -
- O -
treatment O -
. O +

Composition O +
with O +
alimentary O +
anemia O +
improving O +
function O +
and O +
preparation O +
method O +
of O +
composition O +
The O +
invention O +
discloses O +
a O +
pharmaceutical O +
composition O +
with O +
an O +
alimentary O +
anemia O +
improving O +
function O +
and O +
a O +
preparation O +
method O +
of O +
the O +
composition O -
. O +

The O +
composition O +
is O +
prepared O +
from O +
astragalus O +
membranaceus O -
, O +
codonopsis O +
pilosula O -
, O +
angelica O -
, O +
jujube O +
and O +
prepared O +
rehmannia O +
root O +
according O +
to O +
a O +
certain O +
weight O +
percentage O -
, O +
and O +
the O +
composition O +
can O +
be O +
prepared O +
into O +
any O +
commonly O +
used O +
preparation O -
, O +
preferably O +
an O +
oral O +
preparation O -
. O +

The O +
pharmaceutical O +
composition O +
has O +
a O +
function O +
of O +
improving O +
alimentary O +
anemia O -
. O +

Application O +
of O +
Sarcaboside O +
B O +
in O +
preparation O +
of O +
medicines O +
for O +
treating O +
alzheimer O +
disease O +
The O +
invention O +
discloses O +
a O +
new O +
application O +
of O +
Sarcaboside O +
B. O +
The O +
Sarcaboside O +
B O +
has O +
inhibitory O +
activity O +
on O +
acetylcholin B-Gene +
esterase I-Gene +
and O +
a O +
nerve O +
cell O +
protection O +
effect O -
. O +

As O +
a O +
multi O -
- O -
target O +
directed O +
compound O -
, O +
the O +
Sarcaboside O +
B O +
can O +
be O +
used O +
for O +
the O +
preparation O +
of O +
the O +
medicines O +
for O +
resisting O +
the O +
alzheimer O +
disease O -
. O +

The O +
application O +
of O +
the O +
Sarcaboside O +
B O +
in O +
the O +
preparation O +
of O +
medicines O +
for O +
treating O +
the O +
alzheimer O +
disease O +
is O +
disclosed O +
by O +
the O +
invention O +
for O +
the O +
first O +
time O -
. O +

As O +
the O +
skeleton O +
type O +
of O +
the O +
Sarcaboside O +
B O +
belongs O +
to O +
a O +
brand O -
- O -
new O +
skeleton O +
type O -
, O +
the O +
Sarcaboside O +
B O +
has O +
unexpected O +
strong O +
inhibitory O +
activity O +
on O +
the O +
acetylcholin B-Gene +
esterase I-Gene -
, O +
and O +
the O +
possibility O +
that O +
other O +
compounds O +
provide O +
revelation O +
does O +
not O +
exist O -
. O +

The O +
Sarcaboside O +
B O +
has O +
prominently O +
substantial O +
characteristics O +
and O +
meanwhile O +
has O +
remarkably O +
progressive O +
significance O +
when O +
being O +
used O +
for O +
preventing O +
and O +
treating O +
the O +
alzheimer O +
disease O -
. O +

Application O +
of O +
Chukrasone O +
A O +
in O +
preparing O +
medicines O +
for O +
treating O +
yellow O +
fever O +
virus O +
infection O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Chukrasone O +
A O +
in O +
preparing O +
medicines O +
for O +
treating O +
or O +
preventing O +
yellow O +
fever O +
virus O +
infection O -
. O +

The O +
Chukrasone O +
A O +
can O +
effectively O +
inhibit O +
proliferation O +
of O +
yellow O +
fever O +
virus O +
but O +
is O +
small O +
in O +
cytotoxicity O -
, O +
so O +
that O +
the O +
Chukrasone O +
A O +
can O +
be O +
further O +
developed O +
to O +
medicines O +
for O +
treating O +
diseases O +
caused O +
by O +
the O +
virus O +
infection O -
, O +
and O +
has O +
a O +
wide O +
application O +
prospect O -
. O +

The O +
use O +
of O +
the O +
Chukrasone O +
A O +
for O +
preparing O +
medicines O +
for O +
treating O +
yellow O +
fever O +
virus O +
infection O +
provided O +
by O +
the O +
invention O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
. O +

As O +
the O +
framework O +
type O +
belongs O +
to O +
a O +
brand O -
- O -
new O +
framework O +
type O -
, O +
and O +
the O +
inhibitory O +
activity O +
of O +
the O +
Chukrasone O +
A O +
to O +
yellow O +
fever O +
virus O +
infection O +
is O +
unimaginably O +
strong O -
, O +
the O +
probability O +
of O +
giving O +
any O +
enlightenment O +
by O +
other O +
compounds O +
does O +
not O +
exist O -
. O +

The O +
Chukrasone O +
A O +
has O +
remarkable O +
substantial O +
characteristics O +
and O +
meanwhile O +
has O +
remarkable O +
progress O +
for O +
preventing O +
and O +
treating O +
yellow O +
fever O +
virus O +
infection O -
. O +

Crystal O +
form O -
, O +
preparation O +
method O +
and O +
application O +
of O +
agomelatine O -
, O +
as O +
well O +
as O +
medicine O +
composition O +
The O +
invention O +
provides O +
a O +
crystal O +
form O -
, O +
a O +
preparation O +
method O +
and O +
an O +
application O +
of O +
agomelatine O -
, O +
as O +
well O +
as O +
a O +
medicine O +
composition O -
. O +

Compared O +
with O +
the O +
prior O +
art O -
, O +
the O +
crystal O +
form O +
provided O +
by O +
the O +
invention O +
has O +
the O +
following O +
advantages O +
and O +
positive O +
effects O +
that O +
the O +
new O +
crystal O +
form O +
of O +
the O +
agomelatine O +
obtained O +
by O +
the O +
preparation O +
method O +
provided O +
by O +
the O +
invention O +
is O +
high O +
in O +
purity O -
, O +
stable O -
, O +
good O +
in O +
repeatability O -
, O +
better O +
than O +
a O +
plurality O +
of O +
existing O +
crystal O +
forms O +
in O +
purity O +
and O +
stability O -
, O +
and O +
suitable O +
for O +
preparing O +
medicament O +
preparations O -
. O +

The O +
preparation O +
method O +
of O +
the O +
new O +
crystal O +
form O +
of O +
the O +
agomelatine O +
provided O +
by O +
the O +
invention O +
is O +
simpler O +
and O +
more O +
convenient O +
than O +
the O +
existing O +
crystal O +
form O -
, O +
is O +
also O +
moderate O +
in O +
condition O -
, O +
easy O +
to O +
be O +
applied O +
in O +
actual O +
production O +
and O +
low O +
in O +
cost O -
, O +
and O +
satisfies O +
the O +
requirements O +
of O +
industrial O +
production O -
. O +

Salt O +
of O +
chelidonine O +
derivative O +
The O +
invention O +
relates O +
to O +
chelidonine O -
, O +
fumarate O +
of O +
a O +
derivative O +
of O +
the O +
chelidonine O +
or O +
a O +
pharmaceutically O +
acceptable O +
solvate O +
of O +
the O +
chelidonine O +
and O +
applications O +
of O +
the O +
chelidonine O -
, O +
the O +
fumarate O +
and O +
the O +
solvate O +
in O +
preparation O +
of O +
medicaments O +
for O +
treating O +
hepatitis O +
B. O +

Ursodeoxycholic O +
acid O +
vitamin O +
composition O -
, O +
preparation O +
method O +
and O +
applications O +
thereof O +
The O +
invention O +
discloses O +
an O +
ursodeoxycholic O +
acid O +
vitamin O +
composition O -
, O +
a O +
preparation O +
method O +
and O +
applications O +
thereof O -
. O +

The O +
composite O +
comprises O +
following O +
raw O +
materials O +
in O +
percentage O +
by O +
weight O -
: O +
1 O +
to O +
30 O -
% O +
of O +
ursodesoxycholic O +
acid O -
, O +
0.1 O +
to O +
5 O -
% O +
of O +
thiamine O +
mononitrate O -
, O +
0.05 O +
to O +
2.5 O -
% O +
of O +
riboflavin O +
and O +
the O +
balance O +
of O +
dispersion O +
supporter O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
of O +
a O +
capsule O +
preparation O +
of O +
the O +
composition O -
, O +
and O +
the O +
preparation O +
method O +
has O +
the O +
advantages O +
of O +
simple O +
operation O +
and O +
good O +
capsule O +
luster O +
and O +
homogeneity O -
. O +

The O +
ursodesoxycholic O +
acid O -
, O +
thiamine O +
mononitrate O +
and O +
riboflavin O +
are O +
used O +
together O +
to O +
have O +
the O +
functions O +
of O +
antagonizing O +
liver O +
hydrophobic O +
toxic O +
bile O +
acid O -
, O +
protecting O +
liver O +
cells O -
, O +
providing O +
enough O +
energy O +
to O +
liver O +
cells O -
, O +
and O +
helping O +
damaged O +
liver O +
cells O +
to O +
recover O -
, O +
the O +
ursodesoxycholic O +
acid O +
vitamin O +
composition O +
has O +
the O +
function O +
of O +
protecting O +
liver O +
and O +
gallbladder O -
, O +
and O +
is O +
capable O +
of O +
being O +
used O +
for O +
preparing O +
drugs O +
for O +
curing O +
liver O +
and O +
gallbladder O -
. O +

Application O +
of O +
ginseng O +
oligosaccharide O +
composition O +
in O +
preparation O +
of O +
anti O -
- O -
oxidation O +
medicine O +
or O +
health O -
- O -
care O +
food O +
The O +
invention O +
discloses O +
a O +
novel O +
application O +
of O +
a O +
ginseng O +
oligosaccharide O +
composition O +
in O +
preparation O +
of O +
an O +
anti O -
- O -
oxidation O +
medicine O +
and O +
a O +
health O -
- O -
care O +
food O -
. O +

The O +
ginseng O +
oligosaccharide O +
composition O +
is O +
extracted O +
from O +
ginseng O -
. O +

According O +
to O +
an O +
in O -
- O -
vitro O +
experiment O -
, O +
the O +
ginseng O +
oligosaccharide O +
composition O +
has O +
a O +
good O +
effect O +
of O +
clearing O +
away O +
hydroxyl O +
free O +
radicals O +
and O +
DPPH O +
( O -
1,1-Diphenyl-2-picrylhydrazyl O +
radical O +
2,2-Diphenyl-1- O -
( O -
2,4,6-trinitrophenyl O -
) O +
hydrazyl O -
) O -
, O +
and O +
also O +
has O +
the O +
good O +
effect O +
of O +
chelating O +
Fe<2+>. O +
According O +
to O +
an O +
animal O +
experiment O -
, O +
the O +
ginseng O +
oligosaccharide O +
composition O +
has O +
the O +
good O +
effect O +
of O +
enhancing O +
the O +
enzyme O +
activities O +
of O +
SOD B-Gene +
( O -
Superoxide B-Gene +
Dismutase I-Gene -
) O -
, O +
CAT B-Gene +
( O -
Catalase B-Gene -
) O -
, O +
GSH B-Gene -
- I-Gene -
Px I-Gene +
( O -
Glutathione B-Gene +
Peroxidase I-Gene -
) O +
and O +
T O -
- O -
AOC O +
( O -
Total O +
Antioxidative O +
Capacity O -
) O +
in O +
the O +
serum O +
and O +
the O +
liver O +
of O +
an O +
oxidative O +
stress O -
- O -
injured O +
mice O +
induced O +
by O +
D O -
- O -
Gal O +
( O -
Galactosamine O -
) O -
, O +
and O +
can O +
be O +
used O +
for O +
obviously O +
decreasing O +
the O +
MDA O +
( O -
Methane O +
Dicarboxylic O +
Aldehyde O -
) O +
level O +
of O +
the O +
oxidative O +
stress O -
- O -
injured O +
mice O -
. O +

Medicament O +
for O +
treating O +
insomnia O +
and O +
dreamful O +
sleep O +
The O +
invention O +
provides O +
a O +
medicament O +
for O +
treating O +
insomnia O +
and O +
dreamful O +
sleep O -
. O +

The O +
medicament O +
comprises O +
the O +
following O +
components O +
in O +
parts O +
by O +
weight O -
: O +
6 O -
- O -
12 O +
parts O +
of O +
spina O +
date O +
seed O -
, O +
8 O -
- O -
16 O +
parts O +
of O +
tuber O +
fleeceflower O +
stem O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
rhizoma O +
acori O +
graminei O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
platycladi O +
seed O -
, O +
7 O -
- O -
15 O +
parts O +
of O +
polygala O +
tenuifolia O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
nacre O +
mother O +
of O +
pearl O -
, O +
8 O -
- O -
16 O +
parts O +
of O +
amber O -
, O +
8 O -
- O -
16 O +
parts O +
of O +
magnet O -
, O +
9 O -
- O -
15 O +
parts O +
of O +
lily O -
, O +
7 O -
- O -
14 O +
parts O +
of O +
stamen O +
nelumbinis O -
, O +
and O +
8 O -
- O -
15 O +
parts O +
of O +
red O -
- O -
rooted O +
salvia O +
root O -
. O +

The O +
medicament O +
for O +
treating O +
insomnia O +
and O +
dreamful O +
sleep O +
has O +
the O +
advantages O +
and O +
positive O +
effects O +
of O +
good O +
treatment O +
effect O -
, O +
no O +
independence O +
and O +
small O +
toxic O +
and O +
side O +
effects O -
. O +

Amide O +
arylpiperazine O +
derivatives O -
, O +
their O +
preparation O +
method O -
, O +
and O +
their O +
application O +
in O +
benign O +
prostatic O +
hyperplasia O +
resistance O +
The O +
invention O +
relates O +
to O +
ten O +
amide O +
arylpiperazine O +
derivatives O -
, O +
their O +
preparation O +
method O -
, O +
and O +
their O +
use O +
in O +
the O +
preparation O +
of O +
benign O +
prostatic O +
hyperplasia O +
treatment O +
medicines O -
. O +

The O +
preparation O +
method O +
of O +
the O +
amide O +
arylpiperazine O +
derivatives O +
comprises O +
the O +
following O +
steps O -
: O +
reacting O +
free O +
alkali O +
of O +
3-bromopropylamine O +
hydrobromide O +
with O +
di O -
- O -
tert O -
- O -
butyl O +
dicarbonate O +
to O +
obtain O +
a O +
colorless O +
oily O +
liquid O -
, O +
reacting O +
the O +
colorless O +
oily O +
liquid O +
with O +
o O -
- O -
methoxyphenylpiperazine O +
to O +
obtain O +
a O +
light O +
yellow O +
oily O +
material O -
, O +
reacting O +
the O +
light O +
yellow O +
oily O +
material O +
with O +
trifluoroacetic O +
acid O +
to O +
obtain O +
a O +
product O -
, O +
and O +
reacting O +
the O +
product O +
with O +
N O -
, O -
N O -
- O -
diisopropylethylaine O -
, O +
2- O -
( O -
7-azobenzotriazol O -
) O -
-N O -
, O -
N O -
, O -
N',N'-tetramethylformamidinium O +
hexafluorophosphate O -
, O +
and O +
5-indoleacetic O +
acid O +
or O +
3-indoleacetic O +
acid O +
or O +
3-indolepropionic O +
acid O +
or O +
3-indolebutyric O +
acid O +
or O +
5-hydroxy-2-indoleacetic O +
acid O +
or O +
5-methoxy-2-indoleacetic O +
acid O +
or O +
1-methyl-3-indoleacetic O +
acid O +
or O +
6-bromo-2-indoleacetic O +
acid O +
or O +
5-chloro-2-indoleacetic O +
acid O +
or O +
7-nitro-2-indoleacetic O +
acid O +
to O +
obtain O +
final O +
products O -
. O +

Experiments O +
prove O +
that O +
the O +
benign O +
prostatic O +
hyperplasia O +
resistance O +
activities O +
of O +
eight O +
compounds O +
in O +
the O +
amide O +
arylpiperazine O +
derivatives O +
are O +
stronger O +
than O +
a O +
contrast O +
drug O +
prazosin O -
. O +

Vagina O +
mold O +
containing O +
estriol O +
The O +
invention O +
relates O +
to O +
a O +
vagina O +
mold O +
containing O +
estriol O -
. O +

The O +
vagina O +
mold O +
is O +
composed O +
of O +
silicone O +
rubber O +
and O +
the O +
estriol O -
, O +
wherein O +
the O +
weight O +
ratio O +
of O +
the O +
silicone O +
rubber O +
and O +
the O +
estriol O +
is O +
20 O -
: O +
( O -
5 O -
- O -
8 O -
) O -
. O +

The O +
vagina O +
mold O +
containing O +
the O +
estriol O +
has O +
the O +
advantages O +
that O +
the O +
vagina O +
mold O +
containing O +
estrogen O +
greatly O +
lowers O +
the O +
contracture O +
rate O +
of O +
a O +
man O -
- O -
made O +
vagina O -
. O +

The O +
silicone O +
rubber O +
and O +
the O +
estrogen O +
are O +
combined O +
to O +
manufacture O +
the O +
vagina O +
mold O +
with O +
the O +
estrogen O +
slow O +
releasing O +
ability O -
, O +
and O +
therefore O +
vagina O +
mold O +
treatment O +
and O +
estrogen O +
treatment O +
are O +
effectively O +
combined O -
, O +
and O +
the O +
vagina O +
mold O +
with O +
the O +
slow O +
releasing O +
function O +
has O +
great O +
potential O +
in O +
future O +
clinical O +
application O -
. O +

Application O +
of O +
berberine O +
in O +
medicine O +
for O +
treating O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
The O +
invention O +
belongs O +
to O +
the O +
field O +
of O +
medicine O +
preparation O +
and O +
particularly O +
relates O +
to O +
an O +
application O +
of O +
berberine O +
in O +
a O +
medicine O +
for O +
treating O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O -
. O +

According O +
to O +
the O +
invention O -
, O +
db O -
/ O -
db O +
mouse O +
with O +
diabetic O +
obesity O +
and O +
NAFLD O +
( O -
Non O -
- O -
Alcoholic O +
Fatty O +
Liver O +
Disease O -
) O +
is O +
employed O +
to O +
simulate O +
a O +
fat O +
NAFLD O +
patient O -
, O +
and O +
a O +
mouse O +
with O +
non O -
- O -
obese O +
fatty O +
liver O +
caused O +
by O +
methionine O -
- O -
choline O +
deficient O +
( O -
MCD O -
) O +
is O +
used O +
as O +
a O +
model O +
to O +
simulate O +
a O +
non O -
- O -
fat O +
NAFLD O +
patient O +
so O +
as O +
to O +
observe O +
the O +
effect O +
of O +
BBR O -
. O +

Shown O +
by O +
all O +
test O +
results O -
, O +
the O +
BBR O +
not O +
only O +
can O +
reduce O +
the O +
weight O +
of O +
the O +
obese O +
mouse O +
and O +
improve O +
the O +
glycometabolism O +
and O +
lipid O +
metabolism O -
, O +
but O +
also O +
can O +
treat O +
the O +
concurrent O +
fatty O +
liver O +
of O +
the O +
obese O +
mouse O -
, O +
and O +
also O +
has O +
obvious O +
treatment O +
effect O +
on O +
the O +
fatty O +
liver O +
of O +
the O +
non O -
- O -
obese O +
mouse O -
, O +
and O +
the O +
results O +
are O +
verified O +
in O +
a O +
cell O +
model O +
simulated O +
in O +
vitro O -
, O +
so O +
that O +
the O +
BBR O +
has O +
obvious O +
treatment O +
effect O +
on O +
the O +
obesity O +
and O +
the O +
non O -
- O -
obese O +
NAFLD O +
surely O +
and O +
can O +
be O +
used O +
in O +
preparation O +
of O +
the O +
medicine O +
for O +
treating O +
the O +
NAFLD O -
. O +

Imidazolyl O -
- O -
substituted O +
thiazocyclohexane O +
compounds O +
and O +
antitumor O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
anticancer O +
related O +
drugs O -
, O +
particularly O +
imidazolyl O -
- O -
substituted O +
thiazocyclohexane O +
derivatives O +
with O +
antitumor O +
activity O +
disclosed O +
as O +
Formula O +
I O -
, O +
and O +
a O +
preparation O +
method O -
, O +
pharmaceutical O +
composition O +
and O +
application O +
thereof O -
. O +

Substituted O -
- O -
pyrrolidinyl O -
- O -
contained O +
thiomorpholine O +
compounds O +
The O +
invention O +
discloses O +
substituted O -
- O -
pyrrolidinyl O -
- O -
contained O +
thiomorpholine O +
compounds O -
, O +
a O +
preparation O +
method O +
thereof O +
and O +
applications O +
thereof O -
. O +

In O +
concrete O -
, O +
the O +
invention O +
relates O +
to O +
compounds O +
having O +
a O +
general O +
formula O +
( O -
I O -
) O -
, O +
stereoisomers O +
of O +
the O +
compounds O +
and O +
pharmaceutical O +
acceptable O +
salts O +
of O +
the O +
compounds O -
, O +
wherein O +
R O +
is O +
shown O +
in O +
the O +
specification O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O -
, O +
and O +
the O +
applications O +
of O +
the O +
compounds O +
in O +
preparing O +
medicines O +
used O +
for O +
treating O +
and/or O +
preventing O +
a O +
disease O +
or O +
a O +
symptom O +
which O +
are O +
related O +
to O +
over O -
- O -
high O +
activity O +
of O +
DPP B-Gene -
- I-Gene -
IV I-Gene +
or O +
over O -
- O -
expression O +
of O +
the O +
DPP B-Gene -
- I-Gene -
IV I-Gene -
, O +
and O +
also O +
relates O +
to O +
a O +
method O +
of O +
using O +
the O +
compounds O +
for O +
treating O +
related O +
diseases O -
. O +

The O +
compounds O +
have O +
activity O +
for O +
effectively O +
inhibiting O +
the O +
DPP B-Gene -
- I-Gene -
IV I-Gene -
. O +

Meclozine O +
oral O +
film O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
meclozine O +
oral O +
film O +
comprising O +
a O +
pharmaceutical O +
ingredient O +
meclozine O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
a O +
flavoring O +
agent O -
, O +
a O +
filling O +
agent O -
, O +
a O +
wetting O +
agent O -
, O +
a O +
coloring O +
agent O -
, O +
a O +
film O -
- O -
forming O +
material O +
and O +
an O +
essence O -
. O +

The O +
meclozine O +
oral O +
film O +
is O +
uniform O +
in O +
appearance O -
, O +
pleasant O +
in O +
mouth O +
feel O +
and O +
capable O +
of O +
reducing O +
medication O +
compliance O +
of O +
children O -
, O +
is O +
directly O +
swallowed O +
after O +
dissolution O +
in O +
the O +
mouth O +
without O +
drinking O +
water O -
, O +
is O +
quick O +
in O +
drug O +
release O +
and O +
especially O +
suitable O +
for O +
children O -
, O +
old O +
people O +
and O +
critical O +
patients O +
who O +
are O +
difficult O +
in O +
swallowing O -
. O +

The O +
meclozine O +
oral O +
film O +
also O +
has O +
the O +
advantages O +
of O +
few O +
auxiliary O +
materials O -
, O +
low O +
production O +
cost O +
and O +
simple O +
preparation O +
process O +
and O +
is O +
liable O +
to O +
industrial O +
production O -
. O +

Pharmaceutical O +
composition O +
of O +
paclitaxel O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O -
, O +
discloses O +
a O +
pharmaceutical O +
composition O +
of O +
paclitaxel O -
, O +
and O +
particularly O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
of O +
paclitaxel O -
, O +
polyoxyethylated O +
castor O +
oil O -
, O +
sodium O +
dihydrogen O +
phosphate O -
, O +
hexanedioic O +
acid O +
and O +
ethanol O -
. O +

The O +
pharmaceutical O +
composition O +
disclosed O +
by O +
the O +
invention O +
is O +
prepared O +
into O +
an O +
injection O -
; O +
the O +
single O +
impurity O +
and O +
total O +
impurities O +
accord O +
with O +
the O +
quality O +
requirements O +
by O +
virtue O +
of O +
a O +
high O -
- O -
temperature O +
and O +
highlight O +
test O -
. O +

The O +
preparation O +
prepared O +
from O +
the O +
pharmaceutical O +
composition O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
high O +
stability O +
and O +
low O +
impurity O +
content O -
. O +

Composition O +
containing O +
resveratrol O +
and O +
pterostilbene O +
and O +
preparation O +
containing O +
composition O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
containing O +
resveratrol O +
and O +
pterostilbene O -
, O +
which O +
contains O +
resveratrol O +
and O +
pterostilbene O -
. O +

As O +
shown O +
in O +
an O +
experimental O +
result O -
, O +
the O +
composition O +
containing O +
the O +
resveratrol O +
and O +
the O +
pterostilbene O +
has O +
a O +
synergistic O +
effect O +
of O +
inhibiting O +
the O +
growth O +
of O +
malignant O +
melanoma O +
grafts O -
. O +

Application O +
of O +
Incarviatone O +
A O +
in O +
medicaments O +
for O +
treating O +
bladder O +
cancer O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Incarviatone O +
A O +
in O +
preparation O +
of O +
medicaments O +
for O +
treating O +
bladder O +
cancer O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
a O +
new O +
application O +
of O +
medicaments O -
. O +

In O -
- O -
vitro O +
methyl O +
thiazolyl O +
tetrazolium O +
( O -
MTT O -
) O +
anti O -
- O -
tumor O +
activity O +
evaluation O +
discovers O +
that O +
the O +
Incarviatone O +
A O +
has O +
a O +
prominent O +
inhibiting O +
effect O +
on O +
growth O +
of O +
human O +
bladder O +
cancer O +
cell O +
strains O +
T-24 O -
. O +

Therefore O -
, O +
the O +
Incarviatone O +
A O +
can O +
be O +
used O +
for O +
preparing O +
anti O -
- O -
bladder O +
cancer O +
medicaments O -
, O +
and O +
has O +
a O +
good O +
development O +
and O +
application O +
prospect O -
. O +

The O +
application O +
of O +
the O +
Incarviatone O +
A O +
in O +
preparation O +
of O +
the O +
medicaments O +
for O +
treating O +
bladder O +
cancer O +
is O +
made O +
public O +
for O +
the O +
first O +
time O -
, O +
the O +
skeleton O +
type O +
is O +
completely O +
novel O -
, O +
and O +
the O +
Incarviatone O +
A O +
has O +
an O +
unexpectedly O +
strong O +
bladder O +
cancer O +
cell O +
inhibiting O +
activity O -
. O +

Application O +
of O +
Incarviatone O +
A O +
in O +
medicaments O +
for O +
treating O +
bile O +
duct O +
cancer O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Incarviatone O +
A O +
in O +
preparation O +
of O +
medicaments O +
for O +
treating O +
human O +
bile O +
duct O +
cancer O -
, O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
a O +
new O +
application O +
of O +
medicaments O -
. O +

In O -
- O -
vitro O +
methyl O +
thiazolyl O +
tetrazolium O +
( O -
MTT O -
) O +
anti O -
- O -
tumor O +
activity O +
evaluation O +
discovers O +
that O +
the O +
Incarviatone O +
A O +
has O +
a O +
prominent O +
inhibiting O +
effect O +
on O +
growth O +
of O +
human O +
bile O +
duct O +
cancer O +
cell O +
strains O +
RBE O -
. O +

Therefore O -
, O +
the O +
Incarviatone O +
A O +
can O +
be O +
used O +
for O +
preparing O +
anti O -
- O -
bile O +
duct O +
cancer O +
medicaments O -
, O +
and O +
has O +
a O +
good O +
development O +
and O +
application O +
prospect O -
. O +

The O +
application O +
of O +
the O +
Incarviatone O +
A O +
in O +
preparation O +
of O +
the O +
medicaments O +
for O +
treating O +
human O +
bile O +
duct O +
cancer O +
is O +
made O +
public O +
for O +
the O +
first O +
time O -
, O +
the O +
skeleton O +
type O +
is O +
completely O +
novel O -
, O +
and O +
the O +
Incarviatone O +
A O +
has O +
an O +
unexpectedly O +
strong O +
human O +
bile O +
duct O +
cancer O +
cell O +
inhibiting O +
activity O -
. O +

Application O +
of O +
Lycojaponicumin O +
A O +
in O +
drugs O +
for O +
treating O +
tongue O +
cancer O +
The O +
invention O +
discloses O +
application O +
of O +
Lycojaponicumin O +
A O +
in O +
preparation O +
of O +
drugs O +
for O +
treating O +
tongue O +
cancer O +
and O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
new O +
application O +
of O +
drugs O -
. O +

In O +
vitro O +
MTT O +
anticancer O +
activity O +
evaluation O +
discovers O +
that O +
Lycojaponicumin O +
A O +
shows O +
remarkable O +
inhibitory O +
effects O +
on O +
growth O +
of O +
human O +
tongue O +
cancer O +
cell O +
lines O +
Tca8113 O +
and O +
T6 O -
. O +

Therefore O -
, O +
the O +
Lycojaponicumin O +
A O +
can O +
be O +
used O +
for O +
preparing O +
anti O -
- O -
tongue O +
cancer O +
drugs O -
, O +
and O +
has O +
good O +
development O +
and O +
application O +
prospects O -
. O +

Application O +
of O +
the O +
Lycojaponicumin O +
A O +
in O +
preparation O +
of O +
drugs O +
for O +
treating O +
tongue O +
cancer O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
; O +
and O +
because O +
skeleton O +
type O +
is O +
completely O +
new O -
, O +
inhibitory O +
activity O +
on O +
tongue O +
cancer O +
cells O +
is O +
extraordinary O +
strong O -
. O +

Application O +
of O +
Lycojaponicumin O +
C O +
in O +
preparation O +
of O +
medicines O +
for O +
treating O +
ovarian O +
cancer O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Lycojaponicumin O +
C O +
in O +
the O +
preparation O +
of O +
medicines O +
for O +
treating O +
ovarian O +
cancer O -
, O +
belonging O +
to O +
the O +
technical O +
field O +
of O +
new O +
applications O +
of O +
medicines O -
. O +

The O +
evaluation O +
on O +
an O +
in O +
vitro O +
MTT O +
( O -
3- O -
( O -
4,5-Dimethylthiazol-2-yl O -
) O -
-2,5-diphenyltetrazolium O +
bromide O -
) O +
anti O -
- O -
tumor O +
activity O +
shows O +
that O +
the O +
Lycojaponicumin O +
C O +
also O +
has O +
an O +
obvious O +
inhibiting O +
effect O +
on O +
the O +
growth O +
of O +
human O +
ovarian O +
cancer O +
cell O +
lines O +
HO-8910 O -
, O +
HOC1 O +
and O +
OVAC O -
. O +

Therefore O -
, O +
the O +
Lycojaponicumin O +
C O +
can O +
be O +
used O +
for O +
the O +
preparation O +
of O +
the O +
medicines O +
for O +
resisting O +
the O +
ovarian O +
cancer O +
and O +
has O +
good O +
development O +
and O +
application O +
prospects O -
. O +

The O +
application O +
of O +
the O +
Lycojaponicumin O +
C O +
in O +
the O +
preparation O +
of O +
the O +
medicines O +
for O +
treating O +
the O +
human O +
ovarian O +
cancer O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
. O +

As O +
the O +
skeleton O +
type O +
of O +
the O +
Lycojaponicumin O +
C O +
belongs O +
to O +
a O +
brand O -
- O -
new O +
skeleton O +
type O -
, O +
the O +
Lycojaponicumin O +
C O +
has O +
unexpected O +
strong O +
inhibitory O +
activity O +
on O +
human O +
ovarian O +
cancer O +
cells O -
. O +

Application O +
of O +
Lycojaponicumin O +
C O +
in O +
preparation O +
of O +
medicines O +
for O +
treating O +
yellow O +
fever O +
virus O +
infection O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
Lycojaponicumin O +
C O +
in O +
the O +
preparation O +
of O +
medicines O +
for O +
treating O +
or O +
preventing O +
yellow O +
fever O +
virus O +
infection O -
. O +

The O +
Lycojaponicumin O +
C O +
can O +
be O +
used O +
for O +
effectively O +
inhibiting O +
the O +
proliferation O +
of O +
yellow O +
fever O +
virus O -
, O +
has O +
very O +
low O +
toxicity O +
on O +
cells O -
, O +
can O +
be O +
further O +
developed O +
into O +
the O +
medicines O +
for O +
treating O +
diseases O +
caused O +
by O +
the O +
virus O +
infection O +
and O +
has O +
wide O +
application O +
prospects O -
. O +

The O +
application O +
of O +
the O +
Lycojaponicumin O +
C O +
in O +
the O +
preparation O +
of O +
medicines O +
for O +
treating O +
the O +
yellow O +
fever O +
virus O +
infection O +
is O +
disclosed O +
for O +
the O +
first O +
time O -
. O +

As O +
the O +
skeleton O +
type O +
of O +
the O +
Lycojaponicumin O +
C O +
belongs O +
to O +
a O +
brand O -
- O -
new O +
skeleton O +
type O -
, O +
the O +
Lycojaponicumin O +
C O +
has O +
unexpected O +
strong O +
inhibitory O +
activity O +
on O +
yellow O +
fever O +
virus O -
, O +
and O +
the O +
possibility O +
that O +
other O +
compounds O +
provide O +
revelation O +
does O +
not O +
exist O -
. O +

The O +
Lycojaponicumin O +
C O +
has O +
prominently O +
substantial O +
characteristics O +
and O +
meanwhile O +
has O +
remarkably O +
progressive O +
significance O +
when O +
being O +
used O +
for O +
preventing O +
or O +
treating O +
the O +
yellow O +
fever O +
virus O +
infection O -
. O +

CBP B-Gene -
/ O -
catenin B-Gene +
antagonists O +
for O +
enhancing O +
asymmetric O +
division O +
of O +
somatic O +
stem O +
cells O +
Provided O +
are O -
: O +
methods O +
for O +
treating O +
aging O +
or O +
an O +
age O -
- O -
related O +
condition O -
, O +
symptom O +
or O +
disease O -
; O +
methods O +
for O +
stimulating O +
hair O +
growth O -
, O +
regrowth O +
or O +
pigmentation O +
( O -
or O +
preventing O +
hair O +
loss O -
) O -
; O +
methods O +
for O +
increasing O +
the O +
expression O +
of O +
an O +
adenosine O +
receptor O +
in O +
dermal O +
cells O +
( O -
in O +
combination O +
with O +
hair O +
growth O -
) O -
; O +
methods O +
for O +
treating O +
a O +
condition O +
or O +
disease O +
of O +
the O +
skin O +
or O +
at O +
least O +
one O +
symptom O +
thereof O -
, O +
including O +
cosmetic O +
treatment O +
( O -
e.g. O -
, O +
wrinkles O -
, O +
hyperpigmentation O -
, O +
redness O -
, O +
rosacea O -
, O +
dryness O -
, O +
cracking O -
, O +
loss O +
of O +
firmness O -
, O +
loss O +
of O +
elasticity O -
, O +
thinning O -
, O +
and O +
loss O +
of O +
vibrance O -
) O -
. O +

The O +
methods O +
comprise O +
administering O +
a O +
sufficient O +
amount O +
of O +
a O +
CBP B-Gene -
/ O -
catenin B-Gene +
( O -
e.g. O -
, O +
CBP B-Gene -
/ O -
ss O -
- O -
catenin O -
) O +
antagonist O +
as O +
disclosed O -
, O +
and O +
particularly O +
wherein O +
administration O +
is O +
in O +
an O +
amount O +
and O +
manner O +
sufficient O +
to O +
provide O +
for O +
increasing O +
the O +
number O +
of O +
asymmetric O +
renewing O +
divisions O +
relative O +
to O -
, O +
or O +
at O +
the O +
expense O +
of O +
symmetric O +
divisions O +
in O +
relevant O +
somatic O +
stem O +
cell O +
population O -
. O +

In O +
particular O +
aspects O -
, O +
the O +
CBP B-Gene -
/ O -
catenin B-Gene +
( O -
e.g. O -
, O +
CBP B-Gene -
/ O -
ss O -
- O -
catenin O -
) O +
antagonist O +
comprises O +
an O +
alkyl O +
and/or O +
fatty O +
acid O +
ester O +
derivative O +
thereof O +
as O +
disclosed O +
herein O -
. O +

Method O +
for O +
preparing O +
levofloxacin O +
hydrochloride O +
sodium O +
chloride O +
injection O +
The O +
invention O +
provides O +
a O +
method O +
for O +
preparing O +
levofloxacin O +
hydrochloride O +
sodium O +
chloride O +
injection O -
. O +

By O +
researching O +
a O +
liquid O +
medicine O +
preparation O +
method O -
, O +
medicinal O +
charcoal O +
pretreatment O +
and O +
a O +
terminal O +
sterilization O +
process O -
, O +
product O +
quality O +
is O +
ensured O +
by O +
the O +
aid O +
of O +
technologies O +
of O +
a O +
concentrated O +
solution O +
and O +
diluted O +
solution O +
method O -
, O +
charcoal O +
slurry O +
preparation O +
from O +
medicinal O +
charcoal O -
, O +
water O +
bath O +
sterilization O +
and O +
the O +
like O -
, O +
production O +
is O +
facilitated O -
, O +
obtained O +
finished O +
products O +
have O +
higher O +
stability O -
, O +
so O +
that O +
the O +
storage O +
life O +
of O +
the O +
finished O +
products O +
can O +
be O +
prolonged O -
, O +
and O +
clinical O +
use O +
effects O +
are O +
better O -
. O +

Compound O +
norfloxacin O +
nicotinate O +
soluble O +
powder O +
for O +
animals O -
, O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
norfloxacin O +
nicotinate O +
soluble O +
powder O +
for O +
animals O -
. O +

A O +
formula O +
of O +
100 O -
g O +
of O +
the O +
powder O +
comprises O +
5 O -
- O -
10 O -
g O +
of O +
norfloxacin O +
nicotinate O -
, O +
5 O -
- O -
10 O -
g O +
of O +
apramyein O +
sulfate O -
, O +
2 O -
- O -
4 O -
g O +
of O +
trimethoprim O +
lactate O -
, O +
and O +
the O +
balance O +
anhydrous O +
glucose O -
. O +

The O +
above O +
medicine O +
can O +
rapidly O +
kill O +
intestinal O +
pathogenic O +
microorganisms O +
to O +
timely O +
effectively O +
control O +
intestinal O +
bacterial O +
diseases O +
of O +
the O +
animals O -
, O +
and O +
alleviates O +
the O +
bacterial O +
drug O +
resistance O -
. O +

Burn O +
ointment O +
for O +
treating O +
burn O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
burn O +
ointment O +
for O +
treating O +
burn O -
. O +

The O +
ointment O +
comprises O +
the O +
following O +
active O +
components O +
by O +
weight O -
: O +
60 O -
- O -
80 O -
g O +
of O +
indigo O +
naturalis O -
, O +
40 O -
- O -
60 O -
g O +
of O +
mint O -
, O +
40 O -
- O -
60 O -
g O +
of O +
astragalus O -
, O +
20 O -
- O -
30 O -
g O +
of O +
talcum O -
, O +
40 O -
- O -
60 O -
g O +
of O +
fresh O +
sunflower O -
, O +
50 O -
- O -
70 O -
g O +
of O +
polygonum O +
cuspidatum O -
, O +
40 O -
- O -
60 O -
g O +
of O +
ligusticum O +
wallichii O -
, O +
50 O -
- O -
70 O -
g O +
of O +
bamboo O +
leaves O -
, O +
50 O -
- O -
70 O -
g O +
of O +
common O +
jujube O +
bark O -
, O +
40 O -
- O -
60 O -
g O +
of O +
bile O +
arisaema O -
, O +
10 O -
- O -
20 O -
g O +
of O +
fructus O +
evodiae O -
, O +
40 O -
- O -
60 O -
g O +
of O +
beewax O -
, O +
40 O -
- O -
60 O -
g O +
of O +
borneol O -
, O +
and O +
30 O -
- O -
50 O -
g O +
of O +
angelica O +
root O -
. O +

The O +
ointment O +
can O +
be O +
used O +
for O +
solving O +
the O +
problems O +
of O +
local O +
blood O +
stasis O +
and O +
obstruction O -
, O +
meridian O +
stagnation O +
and O +
toxic O +
heat O +
flourishing O -
, O +
and O +
has O +
good O +
effects O +
in O +
activating O +
blood O +
circulation O -
, O +
removing O +
stasis O +
and O +
dredging O +
collaterals O -
, O +
clearing O +
heat O +
and O +
toxicity O +
and O +
cooling O +
blood O -
, O +
and O +
treating O +
burns O -
, O +
wherein O +
the O +
effective O +
rate O +
is O +
93.6 O +
percent O -
, O +
and O +
the O +
rate O +
of O +
favorable O +
curative O +
effect O +
is O +
90.7 O +
percent O -
. O +

Resorcarenes O -
- O -
polysubstitution O +
pyrimidine O +
derivative O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
of O +
derivative O +
The O +
invention O +
relates O +
to O +
a O +
resorcarenes O -
- O -
polysubstitution O +
pyrimidine O +
derivative O +
shown O +
in O +
a O +
general O +
formula O +
I O +
and O +
a O +
salt O -
, O +
ester O +
or O +
prodrug O +
acceptable O +
in O +
pharmacy O -
. O +

The O +
invention O +
also O +
provides O +
a O +
preparation O +
method O +
of O +
the O +
derivative O +
and O +
an O +
application O +
of O +
a O +
composition O +
containing O +
one O +
or O +
a O +
plurality O +
of O +
such O +
type O +
of O +
compounds O +
during O +
preparation O +
of O +
a O +
medicine O +
for O +
treating O +
and O +
preventing O +
infection O +
of O +
an O +
HIV O +
( O -
human O +
immunodeficiency O +
virus O -
) O -
. O +

Combined O +
medicine O +
for O +
treating O +
diarrhea O +
disease O +
in O +
livestock O +
The O +
invention O +
discloses O +
a O +
combined O +
medicine O +
for O +
treating O +
the O +
diarrhea O +
disease O +
in O +
livestock O -
. O +

The O +
combined O +
medicine O +
comprises O +
the O +
following O +
ingredients O +
in O +
parts O +
by O +
weight O -
: O +
8 O -
- O -
12 O +
parts O +
of O +
streptomycin O +
sulphate O +
or O +
derivative O -
, O +
4 O -
- O -
8 O +
parts O +
of O +
sulfamethoxazole O +
or O +
derivative O -
, O +
1 O -
- O -
2 O +
parts O +
of O +
trimethoprim O +
or O +
derivative O -
, O +
and O +
2 O -
- O -
3 O +
parts O +
of O +
Tranexamic O +
acid O +
or O +
derivative O -
. O +

The O +
combined O +
medicine O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
following O +
beneficial O +
effects O -
: O +
a O +
specific O +
antibiotic O -
, O +
a O +
specific O +
bacteriophage O +
and O +
a O +
specific O +
hemostatic O +
agent O +
are O +
used O +
in O +
combination O -
, O +
so O +
that O +
the O +
antibacterial O +
activity O +
and O +
antivirus O +
capacity O +
of O +
the O +
medicine O +
are O +
obviously O +
improved O +
and O +
the O +
curative O +
effect O +
is O +
improved O -
. O +

Composition O +
containing O +
mushroom O +
mycelium O +
polysaccharides O +
and O +
applications O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
containing O +
mushroom O +
mycelium O +
polysaccharides O +
and O +
applications O +
thereof O -
. O +

The O +
composition O +
comprises O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
60 O -
% O +
to O +
80 O -
% O +
of O +
mushroom O +
mycelium O +
polysaccharides O -
, O +
10 O -
% O +
to O +
20 O -
% O +
of O +
black O +
rice O +
polypeptide O -
, O +
and O +
10 O -
% O +
to O +
20 O -
% O +
of O +
bird O +
cherry O +
anthocyanin O -
. O +

The O +
composition O +
containing O +
mushroom O +
mycelium O +
polysaccharides O +
can O +
be O +
used O +
to O +
produce O +
anti O -
- O -
fatigue O +
drugs O -
, O +
anti O -
- O -
fatigue O +
health O +
food O +
and O +
feed O -
. O +

Vitamin O +
A O +
nano O -
- O -
emulsion O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
vitamin O +
A O +
nano O -
- O -
emulsion O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
vitamin O +
A O +
nano O -
- O -
emulsion O +
comprises O +
vitamin O +
A O +
and O +
tween-80 O +
in O +
a O +
mass O +
ratio O +
of O +
1: O -
( O -
1.5 O -
- O -
5 O -
) O -
, O +
and O +
water O +
of O +
which O +
the O +
mass O +
is O +
0.5 O -
- O -
3 O +
times O +
of O +
the O +
total O +
mass O +
of O +
vitamin O +
A O +
and O +
tween-80 O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
adding O +
vitamin O +
A O +
and O +
tween-80 O +
into O +
a O +
container O -
, O +
uniformly O +
mixing O -
, O +
and O +
adding O +
water O +
to O +
obtain O +
a O +
mixed O +
solution O -
; O +
performing O +
ultrasonic O +
treatment O +
on O +
the O +
mixed O +
solution O +
until O +
the O +
mixed O +
solution O +
is O +
clear O +
and O +
transparent O -
, O +
thus O +
obtaining O +
the O +
vitamin O +
A O +
nano O -
- O -
emulsion O -
. O +

The O +
method O +
is O +
used O +
for O +
preparing O +
the O +
vitamin O +
A O +
nano O -
- O -
emulsion O +
by O +
adopting O +
an O +
ultrasonic O +
emulsification O +
method O -
, O +
is O +
simple O +
in O +
production O +
process O -
, O +
mild O +
in O +
condition O -
, O +
short O +
in O +
preparation O +
time O +
and O +
low O +
in O +
equipment O +
requirement O -
. O +

The O +
prepared O +
vitamin O +
A O +
nano O -
- O -
emulsion O +
is O +
of O +
an O +
oil O -
- O -
in O -
- O -
water O +
mode O -
, O +
is O +
clear O +
and O +
transparent O -
, O +
excellent O +
in O +
water O +
solution O +
and O +
good O +
in O +
stability O -
, O +
has O +
a O +
grain O +
distribution O +
range O +
of O +
23 O -
- O -
62 O -
nm O +
and O +
average O +
grain O +
diameter O +
of O +
38 O -
nm O -
, O +
and O +
accords O +
with O +
the O +
basic O +
characteristics O +
of O +
a O +
nano O -
- O -
grade O +
material O -
. O +

Compound O +
alpha O -
- O -
ketoacid O +
tablet O +
free O +
of O +
talcum O +
powder O +
and O +
preparation O +
process O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
alpha O -
- O -
ketoacid O +
tablet O +
free O +
of O +
talcum O +
powder O +
and O +
a O +
preparation O +
process O +
thereof O -
. O +

The O +
conventional O +
preparation O +
process O +
is O +
changed O +
without O +
adding O +
the O +
talcum O +
powder O -
; O +
the O +
tablet O +
prepared O +
by O +
the O +
method O +
has O +
good O +
compressibility O -
, O +
attractive O +
appearance O -
, O +
high O +
disintegrating O +
speed O -
, O +
high O +
dissolution O +
rate O -
, O +
high O +
stability O +
in O +
long O -
- O -
term O +
placement O +
and O +
high O +
medicinal O +
safety O -
. O +

Wet O +
granulation O +
is O +
performed O +
separately O +
according O +
to O +
the O +
acidic O +
and O +
alkaline O +
ingredients O +
and O +
the O +
mass O +
balance O +
ratio O +
of O +
main O +
medicines O -
, O +
i.e. O -
, O +
a O +
meta O -
- O -
alkaline O +
ingredient O -
, O +
a O +
meta O -
- O -
acidic O +
ingredient O +
and O +
a O +
nearly O +
neutral O +
ingredient O +
are O +
subjected O +
to O +
wet O +
granulation O +
separately O -
, O +
and O +
then O +
mixing O -
, O +
tabletting O +
and O +
coating O +
are O +
performed O -
, O +
so O +
that O +
the O +
direct O +
contact O +
among O +
the O +
ingredients O +
is O +
avoided O -
, O +
long O -
- O -
term O +
stable O +
placement O +
can O +
be O +
realized O +
and O +
the O +
contents O +
of O +
the O +
active O +
ingredients O +
are O +
guaranteed O -
. O +

A O +
disintegrating O +
agent O +
internal O +
and O +
external O +
addition O +
method O +
is O +
adopted O +
in O +
the O +
formula O -
, O +
the O +
content O +
of O +
polyethylene O +
glycol O +
is O +
optimized O -
, O +
and O +
no O +
talcum O +
powder O +
or O +
analogs O +
with O +
ingredients O +
similar O +
to O +
the O +
talcum O +
powder O +
are O +
included O +
in O +
the O +
formula O -
, O +
so O +
that O +
the O +
problems O +
of O +
agglomeration O +
phenomenon O +
and O +
larger O +
viscosity O +
in O +
the O +
granulation O +
process O +
are O +
solved O -
, O +
and O +
the O +
safety O +
in O +
medication O +
is O +
guaranteed O -
. O +

Application O +
of O +
tumor O +
inhibitor O +
MLN4924 O +
to O +
preparation O +
of O +
antiviral O +
drug O +
The O +
invention O +
discloses O +
application O +
of O +
a O +
tumor O +
inhibitor O +
MLN4924 O +
to O +
preparation O +
of O +
an O +
antiviral O +
drug O -
. O +

Experiments O +
prove O +
that O +
the O +
small O -
- O -
molecule O +
inhibitor O +
MLN4924 O +
with O +
good O +
performance O +
in O +
human O +
anti O -
- O -
tumor O +
clinical O +
trials O +
is O +
strong O +
in O +
antiviral O +
activity O +
and O +
can O +
inhibit O +
virus O +
replication O +
by O +
more O +
than O +
80 O -
% O +
due O +
to O +
the O +
virus O +
inhibition O +
accessory O +
protein O +
function O -
. O +

With O +
long O +
preliminary O +
experimental O +
clinical O +
experience O +
and O +
a O +
strong O +
drug O +
action O +
effect O -
, O +
the O +
drug O +
can O +
be O +
produced O +
in O +
a O +
large O +
scale O +
and O +
has O +
great O +
potential O +
of O +
becoming O +
an O +
efficient O +
antiviral O +
drug O -
. O +

Through O +
an O +
ubiquitin B-Gene +
system O +
for O +
inhibiting O +
Neddylation O +
activation O +
dominated O +
by O +
virus O +
protein O +
by O +
small O +
molecule O +
drugs O -
, O +
the O +
application O +
value O +
of O +
the O +
tumor O +
inhibitor O +
MLN4924 O +
for O +
preparing O +
the O +
antiviral O +
drug O +
is O +
detected O -
. O +

Preparation O +
method O +
for O +
gel O +
The O +
invention O +
discloses O +
a O +
preparation O +
method O +
for O +
a O +
gel O -
, O +
belonging O +
to O +
the O +
field O +
of O +
preparation O +
of O +
medicines O -
. O +

The O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
extracting O +
common O +
cnidium O +
fruit O +
to O +
obtain O +
an O +
extract O +
containing O +
osthole O +
and O +
carrying O +
out O +
clathration O +
on O +
the O +
extract O +
by O +
using O +
beta O -
- O -
cyclodextrin O +
or O +
hydroxypropyl O -
- O -
beta O -
- O -
cyclodextrin O +
so O +
as O +
to O +
obtain O +
a O +
clathrate O +
of O +
the O +
extract O +
of O +
common O +
cnidium O +
fruit O -
; O +
treating O +
clindamycin O +
hydrochloride O +
and O +
adding O +
a O +
saturated O +
aqueous O +
solution O +
prepared O +
from O +
beta O -
- O -
cyclodextrin O +
so O +
as O +
to O +
obtain O +
a O +
clindamycin O +
hydrochloride O +
clathrate O -
; O +
and O +
mixing O +
the O +
clathrate O +
of O +
the O +
extract O +
of O +
common O +
cnidium O +
fruit O +
with O +
the O +
clindamycin O +
hydrochloride O +
clathrate O -
, O +
adding O +
hydroxypropyl O +
methylcellulose O -
, O +
water O -
, O +
glycerin O -
, O +
chitosan O -
, O +
a O +
10 O -
% O +
ethylparaben O +
ethanol O +
solution O -
, O +
a O +
10 O -
% O +
aqueous O +
sodium O +
hydrosulphite O +
solution O +
and O +
Tween-80 O +
and O +
carrying O +
out O +
mixing O +
with O +
stirring O +
so O +
as O +
to O +
obtain O +
the O +
gel O -
. O +

With O +
the O +
preparation O +
method O +
provided O +
by O +
the O +
invention O -
, O +
the O +
gel O +
can O +
safely O +
and O +
effectively O +
perform O +
curative O +
effects O +
and O +
has O +
reduced O +
irritation O -
, O +
improved O +
solubility O -
, O +
an O +
accelerated O +
dissolution O +
speed O +
and O +
enhanced O +
bioavailability O -
. O +

Preparation O +
method O +
for O +
Sanhuang O +
tablet O +
The O +
invention O +
provides O +
a O +
preparation O +
method O +
for O +
a O +
Sanhuang O +
tablet O -
. O +

The O +
Sanhuang O +
tablet O +
is O +
prepared O +
from O +
the O +
bulk O +
drugs O +
consisting O +
of O +
300 O +
g O +
of O +
rhubarb O +
root O +
and O +
rhizome O -
, O +
5 O +
g O +
of O +
berberine O +
hydrochloride O +
and O +
80 O +
g O +
of O +
baical O +
skullcap O +
root O +
extract O +
through O +
supercritical O +
extraction O -
, O +
so O +
the O +
content O +
of O +
Sanhuang O +
tablet O +
is O +
greatly O +
increased O -
, O +
and O +
the O +
dose O +
of O +
the O +
Sanhuang O +
tablet O +
is O +
reduced O -
. O +

The O +
invention O +
further O +
provides O +
application O +
of O +
the O +
Sanhuang O +
tablet O +
in O +
preparation O +
of O +
drugs O +
used O +
for O +
inhibiting O +
cell O +
proliferation O +
of O +
human O +
large O +
cell O +
carcinoma O +
NCI O -
- O -
H460 O -
. O +

Dextromethorphan O +
hydrobromide O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
dextromethorphan O +
hydrobromide O +
injection O +
prepared O +
from O +
the O +
following O +
raw O +
materials O -
: O +
15 O -
g O +
of O +
dextromethorphan O +
hydrobromide O -
, O +
13 O -
g O +
of O +
lactic O +
acid O -
, O +
7 O -
g O +
of O +
sorbic O +
acid O -
, O +
42 O -
g O +
of O +
polyethylene O +
glycol O +
2000 O +
and O +
2000ml O +
of O +
water O +
for O +
injection O +
through O +
adjusting O +
the O +
pH O +
value O +
to O +
3.4 O -
- O -
3.5 O -
. O +

Proanthocyanidin O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O -
, O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
proanthocyanidin O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O -
. O +

The O +
proanthocyanidin O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O +
comprise O +
1 O -
- O -
5 O +
parts O +
of O +
proanthocyanidin O -
, O +
1 O -
- O -
12 O +
parts O +
of O +
chitosan O +
or O +
derivatives O +
thereof O -
, O +
1 O -
- O -
12 O +
parts O +
of O +
phospholipid O +
or O +
derivatives O +
thereof O +
and O +
1 O -
- O -
10 O +
parts O +
of O +
excipients O -
, O +
wherein O +
the O +
chitosan O +
and O +
the O +
derivatives O +
thereof O +
are O +
one O +
or O +
more O +
of O +
high O -
, O +
medium O +
and O +
low O -
- O -
molecular O +
weight O +
chitosan O -
, O +
chitosan O +
oligosaccharide O -
, O +
chitosan O +
quaternary O +
ammonium O +
salt O +
and O +
carboxymethyl O +
chitosan O -
. O +

The O +
particle O +
size O +
of O +
the O +
proanthocyanidin O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O +
is O +
10nm-0.3 O +
mu O +
m O -
; O +
the O +
proanthocyanidin O +
is O +
prepared O +
into O +
the O +
powder O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O -
, O +
and O +
the O +
proanthocyanidin O +
sustained O +
release O +
nano O -
- O -
micro O +
spheres O +
can O +
directly O +
play O +
a O +
role O +
in O +
the O +
lung O +
as O +
a O +
pulmonary O +
inhalation O +
medicine O -
- O -
carrying O +
formulation O -
, O +
improve O +
the O +
bioavailability O +
of O +
the O +
proanthocyanidin O +
and O +
reduce O +
the O +
dosage O +
by O +
sustained O +
release O -
; O +
the O +
proanthocyanidin O +
nano O -
- O -
micro O +
spheres O +
can O +
also O +
be O +
applied O +
as O +
an O +
oral O +
sustained O +
release O +
formulation O -
; O +
the O +
proanthocyanidin O +
nano O -
- O -
micro O +
spheres O +
have O +
appropriate O +
particle O +
size O +
and O +
morphology O +
and O +
other O +
powder O +
properties O -
, O +
as O +
well O +
as O +
sustained O +
release O -
; O +
furthermore O -
, O +
the O +
preparation O +
method O +
has O +
the O +
advantages O +
of O +
simplicity O +
and O +
convenience O +
in O +
operation O -
, O +
stable O +
process O +
and O +
easiness O +
in O +
industrial O +
production O -
. O +

Application O +
of O +
fisetin O +
in O +
preparation O +
of O +
drug O +
with O +
anticoagulation O -
, O +
anti O -
- O -
thrombosis O +
and O +
cardioprotective O +
effects O +
The O +
invention O +
relates O +
to O +
application O +
of O +
fisetin O +
in O +
preparation O +
of O +
a O +
drug O +
with O +
anticoagulation O -
, O +
anti O -
- O -
thrombosis O +
and O +
cardioprotective O +
effects O -
. O +

The O +
drug O +
can O +
reduce O +
ischemic O +
myocardial O +
cell O +
inflammatory O +
response O -
, O +
and O +
has O +
the O +
anticoagulation O -
, O +
anti O -
- O -
thrombosis O +
and O +
cardioprotective O +
effects O -
. O +

According O +
to O +
the O +
technical O +
scheme O +
provided O +
by O +
the O +
invention O -
, O +
application O +
of O +
the O +
fisetin O +
in O +
preparation O +
of O +
an O +
anticoagulation O +
drug O +
for O +
generating O +
anticoagulation O +
effects O +
is O +
for O +
inhibiting O +
ADP O -
- O -
induced O +
platelet O +
aggregation O -
, O +
inhibiting O +
thrombocyte O +
release O -
, O +
and O +
reducing O +
serum O +
Fg O +
and O +
vWF B-Gene +
content O +
to O +
achieve O +
anticoagulation O +
function O -
; O +
application O +
of O +
the O +
fisetin O +
in O +
preparation O +
of O +
an O +
anti O -
- O -
thrombosis O +
drug O +
is O +
also O +
for O +
significantly O +
prolonging O +
CT O -
, O +
PT O -
, O +
TT O +
and O +
APTT O +
to O +
indirectly O +
achieve O +
an O +
anti O -
- O -
thrombosis O +
effect O -
; O +
moreover O -
, O +
application O +
of O +
the O +
fisetin O +
in O +
preparation O +
of O +
a O +
drug O +
with O +
the O +
cardioprotective O +
effects O +
on O +
ischemia O -
/ O -
reperfusion O +
myocardial O +
cells O +
is O +
for O +
reducing O +
the O +
ischemic O +
myocardial O +
cell O +
inflammatory O +
response O -
, O +
decreasing O +
the O +
infarct O +
area O +
of O +
injured O +
cardiac O +
muscle O +
and O +
achieving O +
a O +
protection O +
effect O +
on O +
the O +
ischemic O +
myocardial O +
cell O +
by O +
means O +
of O +
inhibiting O +
inflammatory O +
cells O +
invasion O -
, O +
MMP-9 B-Gene +
and O +
NF B-Gene -
- I-Gene -
kB I-Gene +
expression O +
and O +
NF B-Gene -
- I-Gene -
kB I-Gene +
nuclear O +
migration O -
, O +
myocardial O +
apoptosis O +
and O +
the O +
like O -
. O +

Haemorrhoid O +
treatment O +
lotion O +
The O +
invention O +
discloses O +
a O +
haemorrhoid O +
treatment O +
lotion O -
, O +
which O +
is O +
used O +
for O +
positively O +
preventing O -
, O +
treating O +
and O +
performing O +
health O -
- O -
care O +
to O +
patients O +
with O +
three O +
human O +
common O +
diseases O -
, O +
namely O +
haemorrhoid O -
, O +
acnes O +
and O +
male O +
and O +
female O +
sexual O +
dysfunctions O -
, O +
as O +
well O +
as O +
frequently O -
- O -
occurring O +
diseases O +
radically O +
by O +
a O +
mode O +
of O +
self O -
- O -
healthcare O +
or O +
simple O +
self O -
- O -
therapy O +
in O +
daily O +
lives O -
. O +

The O +
lotion O +
is O +
characterized O +
by O +
being O +
prepared O +
from O +
15 O +
elementary O +
components O +
according O +
to O +
a O +
scientific O +
proportional O +
prescription O +
and O +
compatibility O -
. O +

The O +
lotion O +
has O +
the O +
characteristics O +
of O +
wide O +
adaptability O -
, O +
high O +
popularization O +
and O +
application O +
values O -
, O +
safety O +
and O +
efficiency O -
, O +
and O +
no O +
toxic O +
or O +
side O +
effect O -
, O +
the O +
aim O +
that O +
the O +
three O +
diseases O +
severely O +
disturbing O +
human O +
beings O +
by O +
an O +
economical O +
and O +
simple O +
method O +
can O +
be O +
achieved O -
, O +
and O +
the O +
novel O +
product O +
has O +
three O +
dramatic O +
efficacies O +
and O +
applications O -
. O +

Antibacterial O +
anti O -
- O -
inflammatory O +
medicament O +
The O +
invention O +
discloses O +
an O +
antibacterial O +
anti O -
- O -
inflammatory O +
medicament O -
. O +

The O +
antibacterial O +
anti O -
- O -
inflammatory O +
medicament O +
is O +
characterized O +
by O +
consisting O +
of O +
the O +
following O +
raw O +
materials O +
according O +
to O +
percentage O +
by O +
weight O -
: O +
5 O -
- O -
15 O -
% O +
of O +
folium O +
ginkgo O +
extract O -
, O +
10 O -
- O -
15 O -
% O +
of O +
dandelion O +
extract O -
, O +
8 O -
- O -
10 O -
% O +
of O +
borneol O -
, O +
10 O -
- O -
20 O -
% O +
of O +
folium O +
artemisiae O +
argyi O +
extract O -
, O +
10 O -
- O -
15 O -
% O +
of O +
honey O -
, O +
5 O -
- O -
10 O -
% O +
of O +
felwort O +
extract O -
, O +
5 O -
- O -
15 O -
% O +
of O +
seven O -
- O -
leaf O +
ginseng O +
extract O -
, O +
5 O -
- O -
15 O -
% O +
of O +
pueraria O +
extract O -
, O +
10 O -
- O -
15 O -
% O +
of O +
pseudo O -
- O -
ginseng O +
extract O +
and O +
15 O -
- O -
30 O -
% O +
of O +
medical O +
ethanol O -
. O +

The O +
antibacterial O +
anti O -
- O -
inflammatory O +
medicament O +
has O +
the O +
advantages O +
that O +
the O +
prepared O +
medicament O +
has O +
a O +
quick O +
anti O -
- O -
inflammation O +
effect O +
and O +
a O +
high O +
curative O +
effect O -
, O +
generates O +
no O +
resistance O +
to O +
medicaments O +
on O +
bacteria O +
and O +
has O +
a O +
remarkable O +
effect O +
on O +
such O +
diseases O +
caused O +
by O +
fungus O +
as O +
tinea O +
pedis O -
, O +
tinea O +
manuum O -
, O +
neurodermatitis O -
, O +
contact O +
dermatitis O +
and O +
onychomycosis O -
. O +

Capsule O +
and O +
preparation O +
containing O +
rich O +
hydroxytyrosol O -
, O +
lycium O +
barbarum O +
polysaccharide O +
and O +
apple O +
polyphenol O +
and O +
used O +
for O +
protecting O +
liver O +
The O +
invention O +
discloses O +
a O +
capsule O +
and O +
a O +
tablet O +
containing O +
rich O +
hydroxytyrosol O -
, O +
lycium O +
barbarum O +
polysaccharide O +
and O +
apple O +
polyphenol O +
and O +
particularly O +
discloses O +
a O +
preparation O +
product O +
used O +
for O +
protecting O +
liver O -
. O +

The O +
preparation O +
product O -
, O +
namely O +
the O +
capsule O +
or O +
tablet O +
comprises O +
the O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
0 O -
- O -
60 O -
% O +
of O +
hydroxytyrosol O -
, O +
0 O -
- O -
30 O -
% O +
of O +
lycium O +
barbarum O +
polysaccharide O -
, O +
0 O -
- O -
50 O -
% O +
of O +
apple O +
polyphenol O -
, O +
20 O -
- O -
98 O -
% O +
of O +
starch O -
, O +
0 O -
- O -
20 O -
% O +
of O +
xylitol O -
, O +
0 O -
- O -
10 O -
% O +
of O +
aspartame O +
and O +
0 O -
- O -
2 O -
% O +
of O +
magnesium O +
stearate O -
. O +

On O +
the O +
condition O +
of O +
satisfying O +
the O +
preparation O +
processing O +
and O +
producing O +
conditions O -
, O +
the O +
components O +
are O +
respectively O +
filtered O +
through O +
a O +
sieve O +
of O +
10 O -
- O -
100 O +
meshes O +
and O +
are O +
weighed O +
and O +
uniformly O +
mixed O +
according O +
to O +
prescriptions O -
, O +
the O +
mixed O +
components O +
are O +
pelletized O +
and O +
dried O -
, O +
and O +
products O +
with O +
proper O +
particle O +
sizes O +
are O +
selected O +
and O +
are O +
filled O +
to O +
capsules O +
or O +
tabletted O -
. O +

The O +
preparation O +
product O +
disclosed O +
by O +
the O +
invention O +
has O +
strong O +
oxidation O +
resistance O +
and O +
radiation O +
resistance O +
and O +
has O +
a O +
strong O +
effect O +
of O +
recovering O +
health O +
of O +
human O +
body O +
internal O +
organs O +
and O +
especially O +
protecting O +
the O +
liver O -
, O +
and O +
the O +
efficacy O +
is O +
better O +
than O +
the O +
single O +
component O +
effect O +
in O +
the O +
formulation O -
. O +

Since O +
the O +
dosage O +
of O +
a O +
single O +
component O +
in O +
the O +
composition O +
disclosed O +
by O +
the O +
invention O +
is O +
relatively O +
decreased O -
, O +
adverse O +
reactions O +
caused O +
by O +
single O +
use O +
of O +
the O +
single O +
component O +
is O +
alleviated O +
or O +
reduced O -
. O +

The O +
composition O +
disclosed O +
by O +
invention O +
has O +
the O +
advantages O +
of O +
being O +
clear O +
in O +
curative O +
effect O -
, O +
free O +
of O +
toxic O +
side O +
effect O -
, O +
convenient O +
to O +
take O +
and O +
low O +
in O +
price O -
. O +

Compound O +
vitamin O +
lyophilized O +
preparation O +
for O +
injection O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
relates O +
to O +
a O +
compound O +
vitamin O +
lyophilized O +
preparation O +
for O +
injection O +
and O +
its O +
preparation O +
method O -
. O +

According O +
to O +
the O +
invention O -
, O +
a O +
scientific O +
prescription O +
and O +
preparation O +
process O +
are O +
utilized O +
to O +
make O +
the O +
prepared O +
compound O +
vitamin O +
lyophilized O +
preparation O +
for O +
injection O +
have O +
the O +
advantages O +
of O +
high O +
stability O -
, O +
low O +
impurity O +
content O +
and O +
the O +
like O -
. O +

Damp O +
clearing O +
decoction O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
damp O +
clearing O +
decoction O +
which O +
is O +
a O +
medicament O +
prepared O +
from O +
the O +
following O +
raw O +
materials O +
in O +
parts O +
by O +
weight O -
: O +
5 O -
- O -
7 O +
parts O +
of O +
rhizoma O +
alismatis O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
plantain O +
seed O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
talc O -
, O +
5 O -
- O -
7 O +
parts O +
of O +
cortex O +
phellodendri O -
, O +
5 O -
- O -
7 O +
parts O +
of O +
white O +
poria O -
, O +
5 O -
- O -
7 O +
parts O +
of O +
caulis O +
akebiae O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
christina O +
loosestrife O +
herb O -
, O +
8 O -
- O -
12 O +
parts O +
of O +
japanese O +
climbing O +
fern O +
spore O -
, O +
15 O -
- O -
18 O +
parts O +
of O +
herba O +
pyrrosiae O +
stephania O -
, O +
15 O -
- O -
18 O +
parts O +
of O +
rhizoma O +
atractylodis O +
sinensis O -
, O +
15 O -
- O -
18 O +
parts O +
of O +
cortex O +
eucommiae O -
, O +
15 O -
- O -
18 O +
parts O +
of O +
psoralea O +
corylifolia O -
, O +
5 O -
- O -
7 O +
parts O +
of O +
phaseolus O +
calcaratus O +
and O +
5 O -
- O -
7 O +
parts O +
of O +
euphorbia O +
helioscopia O -
. O +

By O +
taking O +
the O +
decoction O +
provided O +
by O +
the O +
invention O -
, O +
the O +
damp O +
in O +
a O +
body O +
can O +
be O +
effectively O +
cleared O -
, O +
and O +
the O +
immunity O +
of O +
the O +
body O +
is O +
enhanced O -
. O +

Bufalin O +
derivative O +
as O +
well O +
as O +
preparation O +
method O -
, O +
pharmaceutical O +
composition O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
bufalin O +
derivative O +
having O +
a O +
structure O +
represented O +
as O +
a O +
general O +
formula O +
I O -
, O +
wherein O +
R O +
is O +
selected O +
from O +
one O +
of O +
the O +
following O +
structure O +
groups O +
as O +
shown O +
in O +
the O +
specification O -
, O +
or O +
pharmaceutically O +
acceptable O +
salt O -
, O +
as O +
well O +
as O +
a O +
preparation O +
method O -
, O +
a O +
pharmaceutical O +
composition O +
and O +
application O +
of O +
the O +
derivative O -
. O +

The O +
bufalin O +
derivative O +
has O +
an O +
activity O +
on O +
inhibiting O +
tumor O +
cell O +
lines O -
, O +
and O +
can O +
be O +
used O +
as O +
a O +
medicine O +
for O +
treating O +
malignant O +
tumors O -
. O +

Preparation O +
capable O +
of O +
increasing O +
bone O +
mineral O +
density O +
The O +
invention O +
discloses O +
a O +
preparation O +
capable O +
of O +
increasing O +
bone O +
mineral O +
density O -
. O +

The O +
preparation O +
is O +
prepared O +
with O +
the O +
main O +
raw O +
materials O +
including O +
American O +
ginseng O +
powder O -
, O +
walnut O +
powder O -
, O +
soy O +
isoflavone O +
and O +
calcium O +
phosphate O -
. O +

The O +
product O +
is O +
prepared O +
according O +
to O +
the O +
appropriate O +
ratio O -
, O +
so O +
as O +
to O +
generate O +
synergistic O +
effects O -
, O +
and O +
is O +
in O +
particular O +
suitable O +
for O +
having O +
by O +
the O +
middle O +
aged O +
and O +
elderly O +
people O -
. O +

Medical O +
application O +
of O +
2 O -
, O +
2-dimethyl O +
thiochromanone O +
compounds O +
containing O +
piperazine O +
structures O +
and O +
analogues O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O +
and O +
relates O +
to O +
a O +
medical O +
application O +
of O +
2 O -
, O +
2-dimethyl O +
thiochromanone O +
compounds O +
containing O +
piperazine O +
structures O +
and O +
analogues O +
thereof O -
. O +

The O +
structural O +
general O +
formula O +
of O +
the O +
2 O -
, O +
2-dimethyl O +
thiochromanone O +
compounds O +
is O +
shown O +
in O +
the O +
specification O -
, O +
wherein O +
in O +
the O +
general O +
formula O -
, O +
X O +
is O +
independently O +
selected O +
from O +
CH2 O +
or O +
C O -
= O -
O O -
; O +
when O +
Y O +
is O +
selected O +
from O +
CH2 O -
, O +
Ar O +
is O +
independently O +
selected O +
from O +
methyl O -
, O +
hydroxy O -
, O +
methoxy O -
, O +
ethoxy O -
, O +
nitryl O -
, O +
fluorine O -
, O +
chlorine O -
, O +
bromine O +
substituted O +
or O +
unsubstituted O +
phenyl O -
; O +
n O +
is O +
defined O +
as O +
an O +
integer O +
from O +
0 O +
to O +
3 O -
; O +
and O +
X O +
is O +
independently O +
selected O +
from O +
CH2 O +
or O +
C O -
= O -
O O -
; O +
when O +
Y O +
is O +
selected O +
from O +
C O -
= O -
O O -
, O +
Ar O +
is O +
independently O +
selected O +
from O +
methyl O -
, O +
hydroxy O -
, O +
methoxy O -
, O +
ethoxy O -
, O +
nitryl O -
, O +
fluorine O -
, O +
chlorine O -
, O +
bromine O +
substituted O +
or O +
unsubstituted O +
phenyl O -
; O +
and O +
n O +
is O +
defined O +
as O +
an O +
integer O +
from O +
1 O +
to O +
3 O -
. O +

The O +
novel O +
compounds O +
provided O +
by O +
the O +
invention O +
are O +
used O +
as O +
effective O +
antiplatelet O +
drugs O +
and O +
are O +
especially O +
used O +
for O +
preparing O +
drugs O +
for O +
preventing O +
or O +
treating O +
platelet O +
aggregation O +
caused O +
coronary O +
syndrome O -
, O +
myocardial O +
infarction O -
, O +
myocardial O +
ischemia O +
and O +
cardiovascular O +
and O +
cerebrovascular O +
diseases O +
for O +
clinical O +
use O -
. O +

Pantoprazole O +
sodium O +
freeze O -
- O -
dried O +
powder O +
injection O +
used O +
for O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
pantoprazole O +
sodium O +
freeze O -
- O -
dried O +
powder O +
injection O +
used O +
for O +
injection O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

According O +
to O +
a O +
freeze O -
- O -
drying O +
method O +
for O +
the O +
pantoprazole O +
sodium O +
freeze O -
- O -
dried O +
powder O +
injection O +
used O +
for O +
injection O -
, O +
every O +
1000 O +
bottles O +
of O +
the O +
pantoprazole O +
sodium O +
freeze O -
- O -
dried O +
powder O +
injection O +
are O +
prepared O +
by O +
dissolving O +
the O +
components O +
consisting O +
of O +
pantoprazole O +
sodium O -
, O +
mannitol O -
, O +
calcium O +
edentate O -
/ O -
sodium O +
edentate O -
/ O -
sodium O +
calcium O +
edentate O +
and O +
citric O +
acid O +
in O +
injection O +
water O +
to O +
obtain O +
drug O +
liquid O +
and O +
freeze O -
- O -
drying O +
the O +
drug O +
liquid O -
, O +
wherein O +
before O +
freeze O -
- O -
drying O +
of O +
the O +
drug O +
liquid O -
, O +
a O +
proper O +
amount O +
of O +
sodium O +
hydroxide O +
is O +
used O +
to O +
adjust O +
a O +
pH O +
value O +
to O +
9.5 O +
to O +
10.5 O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
1 O -
) O +
weighing O -
; O +
2 O -
) O +
preparation O -
; O +
3 O -
) O +
degerming O +
and O +
filtering O -
; O +
4 O -
) O +
bottle O +
washing O -
, O +
drying O +
and O +
disinfection O -
; O +
5 O -
) O +
rubber O +
plug O +
cleaning O -
, O +
disinfection O +
and O +
drying O -
; O +
6 O -
) O +
filling O -
; O +
7 O -
) O +
freeze O -
- O -
drying O +
and O +
plug O +
pressing O -
; O +
and O +
8) O +
cover O +
rolling O -
. O +

With O +
such O +
a O +
technical O +
scheme O -
, O +
the O +
preparation O +
method O +
enables O +
sublimation O +
and O +
drying O +
time O +
to O +
be O +
saved O -
, O +
energy O +
consumption O +
to O +
be O +
reduced O +
and O +
product O +
quality O +
to O +
be O +
guaranteed O -
. O +

Drug O +
delivery O +
system O +
for O +
16-dehydropregnenolone O +
lipidosome O +
for O +
injection O +
and O +
preparation O +
method O +
of O +
same O +
The O +
invention O +
provides O +
a O +
drug O +
delivery O +
system O +
for O +
16-dehydropregnenolone O +
( O -
DHP O -
) O +
lipidosome O +
for O +
injection O +
and O +
a O +
preparation O +
method O -
. O +

The O +
drug O +
delivery O +
system O +
comprises O +
effective O +
amount O +
of O +
16-dehydropregnenolone O -
, O +
a O +
phospholipid O +
membrane O -
, O +
a O +
membrane O +
stabilization O +
material O +
and O +
pharmaceutically O -
- O -
acceptable O +
auxiliary O +
materials O -
, O +
wherein O +
the O +
weight O +
ratio O +
of O +
the O +
16-dehydropregnenolone O +
to O +
the O +
phospholipid O +
membrane O +
to O +
the O +
membrane O +
stabilization O +
material O +
is O +
1:5:0.2 O -
- O -
1:50:50 O -
. O +

The O +
preparation O +
technology O +
comprises O +
the O +
steps O +
of O +
preparing O +
multi O -
- O -
chamber O +
lipidosome O -
, O +
homogenizing O +
the O +
lipidosome O -
, O +
metering O +
volume O -
, O +
sterilizing O -
, O +
subpackaging O -
, O +
freeze O -
- O -
drying O +
and O +
the O +
like O -
. O +

The O +
lipidosome O +
prepared O +
by O +
the O +
method O +
is O +
small O +
in O +
average O +
grain O +
diameter O -
, O +
narrow O +
in O +
distribution O -
, O +
high O +
in O +
encapsulation O +
efficiency O -
, O +
high O +
in O +
drug O +
loading O +
capacity O -
, O +
good O +
in O +
repeatability O +
and O +
good O +
in O +
stability O -
, O +
and O +
can O +
satisfy O +
the O +
requirements O +
on O +
intravenous O +
injection O -
. O +

The O +
results O +
of O +
anti O -
- O -
tumor O +
in O +
vivo O +
experiments O +
show O +
that O +
16-DHP O +
lipidosome O +
prepared O +
by O +
the O +
invention O +
can O +
remarkably O +
inhibit O +
growth O +
of O +
a O +
transplantation O +
tumor O +
of O +
a O +
nude O +
mouse O +
bearing O +
the O +
tumor O +
and O +
has O +
a O +
relatively O +
good O +
anti O -
- O -
tumor O +
effect O -
. O +

An O +
experiment O +
result O +
of O +
rat O +
pharmacokinetics O +
shows O +
that O +
the O +
16-DHP O +
lipidosome O +
prepared O +
by O +
the O +
invention O +
can O +
prolong O +
the O +
time O +
that O +
a O +
medicine O +
stays O +
in O +
the O +
body O +
and O +
improve O +
the O +
amount O +
of O +
the O +
medicine O +
that O +
enters O +
systemic O +
circulation O +
of O +
a O +
rat O -
. O +

Formula O +
and O +
preparation O +
method O +
for O +
externally O -
- O -
applied O +
medicine O +
capable O +
of O +
rapidly O +
diminishing O +
inflammation O +
and O +
relieving O +
pain O +
The O +
invention O +
discloses O +
a O +
formula O +
and O +
a O +
preparation O +
method O +
for O +
an O +
externally O -
- O -
applied O +
medicine O +
capable O +
of O +
rapidly O +
diminishing O +
inflammation O +
and O +
relieving O +
pain O -
. O +

The O +
formula O +
comprises O -
, O +
by O +
mass O -
, O +
3.5 O -
% O +
of O +
sorbitan O +
olivate O -
, O +
3 O -
% O +
of O +
cetearyl O +
alcohol O -
, O +
2 O -
% O +
of O +
squalane O -
, O +
2 O -
% O +
of O +
iso O -
- O -
octyl O +
palmitate O -
, O +
2 O -
% O +
of O +
caprylic O -
/ O -
capric O +
triglyceride O -
, O +
0.5 O -
% O +
of O +
xanthan O +
gum O -
, O +
4 O -
% O +
of O +
glycerin O -
, O +
0.5 O -
% O +
of O +
azelaic O +
acid O -
, O +
2 O -
% O +
of O +
aloe O -
, O +
1 O -
% O +
of O +
a O +
honeysuckle O +
flower O +
extract O -
, O +
1 O -
% O +
of O +
a O +
chrysanthemum O +
extract O -
, O +
0.05 O -
% O +
of O +
a O +
freshener O +
( O -
menthol O -
) O -
, O +
0.1 O -
% O +
of O +
methyl O +
hydroxybenzoate O -
, O +
0.1 O -
% O +
of O +
propyl O +
hydroxybenzoate O -
, O +
0.15 O -
% O +
of O +
imidazolidinyl O +
urea O +
and O +
79.1 O -
% O +
of O +
water O -
. O +

The O +
medicine O +
is O +
prepared O +
by O +
processing O +
the O +
above O -
- O -
mentioned O +
components O -
. O +

The O +
medicine O +
provided O +
by O +
the O +
invention O +
uses O +
herbaceous O +
plants O +
as O +
raw O +
materials O +
and O +
has O +
small O +
toxic O +
and O +
side O +
effects O -
; O +
the O +
medicine O +
can O +
be O +
directly O +
applied O +
on O +
the O +
surface O +
layer O +
of O +
the O +
skin O -
, O +
targetedly O +
reaches O +
a O +
desired O +
site O +
through O +
rapid O +
absorption O +
by O +
the O +
skin O -
, O +
exerts O +
good O +
anti O -
- O -
inflammation O +
and O +
sterilization O +
effects O +
and O +
has O +
fast O +
action O -
. O +

Efficient O +
scourge O -
- O -
clearing O +
toxin O -
- O -
vanquishing O +
drug O +
for O +
livestock O +
The O +
invention O +
relates O +
to O +
veterinary O +
drugs O -
, O +
in O +
particular O +
to O +
a O +
scourge O -
- O -
clearing O +
toxin O -
- O -
vanquishing O +
drug O -
, O +
and O +
aims O +
to O +
provide O +
the O +
scourge O -
- O -
clearing O +
toxin O -
- O -
vanquishing O +
drug O +
which O +
has O +
small O +
side O +
effects O -
. O +

The O +
formula O +
of O +
the O +
scourge O -
- O -
clearing O +
toxin O -
- O -
vanquishing O +
drug O +
comprises O +
the O +
following O +
components O -
: O +
60 O +
g O +
of O +
plaster O -
, O +
30 O -
- O -
45 O +
g O +
of O +
radix O +
rehmanniae O -
, O +
60 O +
g O +
of O +
cornu O +
bubali O -
, O +
20 O +
g O +
of O +
coptis O +
chinensis O -
, O +
35 O -
- O -
45 O +
g O +
of O +
cape O +
jasmine O -
, O +
20 O +
g O +
of O +
cortex O +
moutan O -
, O +
25 O +
g O +
of O +
scutellaria O +
baicalensis O -
, O +
30 O +
g O +
of O +
radix O +
paeoniae O +
rubra O -
, O +
30 O +
g O +
of O +
rhizoma O +
anemarrhenae O -
, O +
30 O +
g O +
of O +
fructus O +
forsythia O -
, O +
25 O +
g O +
of O +
platycodon O +
grandiflorum O -
, O +
15 O +
g O +
of O +
liquorice O -
, O +
and O +
25 O +
g O +
of O +
lophatherum O +
gracile O -
, O +
and O +
the O +
raw O +
materials O +
of O +
the O +
drug O +
are O +
smashed O +
and O +
further O +
smashed O +
superfinely O +
to O +
obtain O +
superfine O +
powder O -
. O +

According O +
to O +
the O +
scourge O -
- O -
clearing O +
toxin O -
- O -
vanquishing O +
drug O -
, O +
the O +
use O +
amount O +
of O +
plaster O +
is O +
remarkably O +
reduced O -
, O +
the O +
cold O +
property O +
of O +
the O +
drug O +
is O +
lowered O -
, O +
and O +
harm O +
and O +
side O +
effects O +
on O +
animal O +
bodies O +
are O +
alleviated O -
; O +
the O +
effects O +
of O +
an O +
original O +
drug O +
is O +
maintained O +
through O +
the O +
appropriate O +
adjustment O +
on O +
the O +
use O +
amount O +
of O +
other O +
components O -
; O +
the O +
curative O +
effect O +
is O +
exact O -
, O +
remarkable O -
, O +
and O +
the O +
drug O +
is O +
mild O +
in O +
property O -
; O +
radix O +
scrophulariae O +
is O +
eliminated O -
, O +
so O +
that O +
the O +
drug O +
formula O +
is O +
simplified O -
; O +
the O +
drug O +
raw O +
materials O +
and O +
processing O +
cost O +
are O +
reduced O -
. O +

Medicine O +
for O +
treating O +
cough O +
and O +
preparation O +
method O +
of O +
medicine O +
The O +
invention O +
discloses O +
a O +
medicine O +
for O +
treating O +
cough O +
and O +
a O +
preparation O +
method O +
of O +
the O +
medicine O -
. O +

The O +
medicine O +
is O +
mainly O +
prepared O +
from O +
atractylodes O +
macrocephala O +
koidz O -
, O +
radix O +
polygonati O +
officinalis O -
, O +
herba O +
houttuyniae O -
, O +
spreading O +
hedyotis O +
herb O -
, O +
edible O +
tulip O -
, O +
honeysuckle O -
, O +
rhizoma O +
belamcandae O -
, O +
adenophora O +
tetraphylla O -
, O +
common O +
hogfenneI O +
root O -
, O +
flos O +
farfarae O -
, O +
radix O +
ophiopogonis O +
and O +
other O +
medicines O +
in O +
a O +
certain O +
weight O +
ratio O -
. O +

The O +
medicine O +
has O +
the O +
functions O +
of O +
dispelling O +
cold O +
and O +
warming O +
lung O -
, O +
eliminating O +
phlegm O +
and O +
stopping O +
cough O -
, O +
clearing O +
lung O +
and O +
harmonizing O +
stomach O -
, O +
and O +
is O +
quick O +
in O +
response O +
and O +
short O +
in O +
course O +
of O +
treatment O +
after O +
healing O +
when O +
used O +
for O +
treating O +
cough O -
, O +
and O +
prevents O +
relapse O -
. O +

Medicine O +
for O +
treating O +
male O +
infertility O +
and O +
preparation O +
method O +
of O +
medicine O +
The O +
invention O +
discloses O +
a O +
medicine O +
for O +
treating O +
male O +
infertility O +
and O +
a O +
preparation O +
method O +
of O +
the O +
medicine O -
. O +

The O +
medicine O +
is O +
mainly O +
prepared O +
from O +
dendrobe O -
, O +
nidus O +
vespae O -
, O +
epimedium O -
, O +
tribulus O +
terrestris O -
, O +
bamboo O +
leaf O -
, O +
actinolite O -
, O +
raspberry O +
and O +
other O +
medicines O +
in O +
a O +
certain O +
weight O +
ratio O -
. O +

The O +
medicine O +
has O +
the O +
functions O +
of O +
invigorating O +
the O +
kidney O +
and O +
strengthening O +
Yang O -
, O +
activating O +
the O +
channels O +
and O +
strengthening O +
spleen O -
, O +
nourishing O +
blood O +
and O +
arresting O +
emission O -
, O +
and O +
is O +
quick O +
in O +
response O +
and O +
good O +
in O +
curative O +
effect O +
when O +
used O +
for O +
treating O +
male O +
infertility O -
, O +
and O +
prevents O +
relapse O -
. O +

Drug O +
for O +
treating O +
infantile O +
cough O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
drug O +
for O +
treating O +
infantile O +
cough O +
and O +
a O +
preparation O +
method O +
thereof O -
. O +

The O +
drug O +
contains O +
5 O -
- O -
15 O +
parts O +
of O +
honeysuckle O -
, O +
10 O -
- O -
15 O +
parts O +
of O +
platycodon O +
grandiflorum O -
, O +
10 O -
- O -
15 O +
parts O +
of O +
licorice O -
, O +
5 O -
- O -
10 O +
parts O +
of O +
white O +
radish O -
, O +
5 O -
- O -
12 O +
parts O +
of O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O -
, O +
2 O -
- O -
8 O +
parts O +
of O +
towel O +
gourd O +
and O +
15 O -
- O -
25 O +
parts O +
of O +
brown O +
sugar O -
. O +

The O +
preparation O +
method O +
comprises O +
the O +
following O +
steps O -
: O +
( O -
1 O -
) O +
weighing O +
honeysuckle O -
, O +
platycodon O +
grandiflorum O -
, O +
licorice O +
and O +
tendril O -
- O -
leaved O +
fritillary O +
bulb O +
according O +
to O +
a O +
proportion O -
, O +
adding O +
water O +
to O +
decoct O +
the O +
components O -
, O +
filtering O +
to O +
obtain O +
filtrate O +
I O +
after O +
the O +
decocting O +
treatment O -
; O +
( O -
2 O -
) O +
weighing O +
white O +
radish O +
and O +
towel O +
gourd O +
according O +
to O +
a O +
proportion O -
, O +
adding O +
water O +
to O +
decoct O +
the O +
components O -
, O +
and O +
then O -
, O +
filtering O +
to O +
obtain O +
filtrate O +
II O -
; O +
( O -
3 O -
) O +
mixing O +
the O +
filtrate O +
I O +
obtained O +
in O +
the O +
step O +
( O -
1 O -
) O +
and O +
the O +
filtrate O +
II O +
obtained O +
in O +
the O +
step O +
( O -
2 O -
) O -
, O +
and O +
decocting O +
the O +
mixture O +
to O +
obtain O +
a O +
mixed O +
concentrated O +
solution O +
III O -
; O +
and O +
( O -
4 O -
) O +
adding O +
brown O +
sugar O +
in O +
the O +
mixed O +
concentrated O +
solution O +
III O -
, O +
and O +
slightly O +
heating O +
the O +
mixture O +
to O +
obtain O +
the O +
drug O -
. O +

The O +
drug O +
is O +
good O +
in O +
curative O +
effect O -
, O +
free O +
of O +
side O +
effect O +
and O +
capable O +
of O +
both O +
treating O +
infantile O +
cough O +
fundamentally O +
and O +
reinforcing O +
body O +
and O +
enhancing O +
immunity O +
of O +
children O +
on O +
chills O +
and O +
fever O +
and O +
the O +
like O -
. O +

Antibacterial O +
finishing O +
agent O +
for O +
medical O +
dressing O +
The O +
invention O +
relates O +
to O +
an O +
antibacterial O +
finishing O +
agent O +
for O +
a O +
medical O +
dressing O -
. O +

The O +
antibacterial O +
finishing O +
agent O +
is O +
prepared O +
through O +
an O +
antibacterial O +
agent O -
, O +
a O +
hemostatic O -
, O +
and O +
an O +
astringent O +
capable O +
of O +
promoting O +
wound O +
healing O +
by O +
virtue O +
of O +
a O +
special O +
process O -
. O +

The O +
antibacterial O +
finishing O +
agent O +
is O +
used O +
for O +
finishing O +
gauze O -
, O +
a O +
bandage O -
, O +
sponge O +
and O +
other O +
medical O +
dressings O -
, O +
and O +
has O +
the O +
characteristics O +
of O +
broad O -
- O -
spectrum O +
antibacterial O +
property O -
, O +
blood O +
stopping O -
, O +
healing O +
promoting O -
, O +
safety O +
and O +
non O -
- O -
irritation O -
, O +
and O +
simple O +
preparation O +
process O -
. O +

The O +
finished O +
medical O +
dressing O +
has O +
the O +
effects O +
of O +
resisting O +
bacteria O -
, O +
stopping O +
blooding O -
, O +
diminishing O +
inflammation O -
, O +
and O +
promoting O +
wound O +
healing O -
. O +

Mouth O +
wash O +
for O +
dental O +
diagnosis O +
and O +
treatment O +
The O +
invention O +
discloses O +
mouth O +
wash O +
for O +
dental O +
diagnosis O +
and O +
treatment O -
, O +
and O +
is O +
applicable O +
to O +
diagnosis O +
and O +
treatment O +
in O +
dental O +
clinic O -
. O +

A O +
formula O +
of O +
the O +
mouth O +
wash O +
consists O +
of O +
the O +
following O +
components O +
in O +
percentage O +
by O +
weight O -
: O +
3 O -
- O -
6 O -
% O +
of O +
carboxymethyl O +
chitosan O -
, O +
2 O -
- O -
6 O -
% O +
of O +
marine O +
organism O +
lysozyme B-Gene +
and O +
reverse O +
osmosis O +
pure O +
water O +
to O +
100 O -
% O -
. O +

The O +
mouth O +
wash O +
for O +
dental O +
diagnosis O +
and O +
treatment O +
containing O +
a O +
marine O +
organism O +
antibacterial O +
component O +
disclosed O +
by O +
the O +
invention O +
has O +
the O +
advantages O +
of O +
( O -
1 O -
) O +
being O +
remarkable O +
in O +
antibacterial O +
effect O -
; O +
( O -
2 O -
) O +
being O +
free O +
from O +
irritation O +
to O +
mucous O +
membrane O +
of O +
mouth O -
; O +
and O +
( O -
3 O -
) O +
being O +
environmentally O +
friendly O +
and O +
non O -
- O -
toxic O +
due O +
to O +
the O +
marine O +
organism O +
component O -
. O +

Pharmaceutical O +
use O +
of O +
2 O -
, O +
2-dimethyl O +
chromanone O +
type O +
compound O +
and O +
analogs O +
thereof O +
The O +
invention O +
belongs O +
to O +
the O +
technical O +
field O +
of O +
medicines O +
and O +
relates O +
to O +
a O +
pharmaceutical O +
use O +
of O +
a O +
2 O -
, O +
2-dimethyl O +
chromanone O +
type O +
compound O +
and O +
analogs O +
thereof O -
. O +

The O +
structural O +
general O +
formula O +
is O +
as O +
follows O -
, O +
wherein O +
X O +
can O +
be O +
selected O +
from O +
CH2 O +
or O +
C O -
= O -
O O -
; O +
and O +
R O +
and O +
R O -
' O +
are O +
as O +
described O +
in O +
the O +
description O -
. O +

The O +
new O +
compound O +
provided O +
by O +
the O +
invention O +
can O +
be O +
used O +
as O +
an O +
effective O +
anti O -
- O -
platelet O +
medicament O -
, O +
can O +
be O +
particularly O +
applied O +
to O +
the O +
preparation O +
of O +
medicaments O +
for O +
preventing O +
or O +
treating O +
coronary O +
syndrome O -
, O +
myocardial O +
infarction O -
, O +
myocardial O +
ischemia O +
and O +
cardiovascular O +
and O +
cerebrovascular O +
diseases O +
caused O +
by O +
platelet O +
aggregation O +
and O +
can O +
further O +
treat O +
thrombus O +
formation O -
, O +
ischemia O -
, O +
stroke O -
, O +
restenosis O +
or O +
inflammation O -
. O +

Oxazole O +
and O +
thiazole O +
derivatives O +
as O +
selective O +
protein B-Gene +
kinase I-Gene +
inhibitors O +
( O -
c B-Gene -
- I-Gene -
kit I-Gene -
) O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
I O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
: O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
A O -
, O +
Q O -
, O +
W O +
and O +
X O +
are O +
as O +
defined O +
in O +
the O +
description O -
. O +

These O +
compounds O +
selectively O +
modulate O -
, O +
regulate O -
, O +
and/or O +
inhibit O +
signal O +
transduction O +
mediated O +
by O +
certain O +
native O +
and/or O +
mutant O +
proteine O +
kinases O +
implicated O +
in O +
a O +
variety O +
of O +
human O +
and O +
animal O +
diseases O +
such O +
as O +
cell O +
proliferative O -
, O +
metabolic O -
, O +
allergic O -
, O +
and O +
degenerative O +
disorders O -
. O +

More O +
particularly O -
, O +
these O +
compounds O +
are O +
potent O +
and O +
selective O +
native O +
and/or O +
mutant O +
c B-Gene -
- I-Gene -
kit I-Gene +
inhibitors O -
. O +

Teasel O +
root O +
health O +
care O +
tea O +
for O +
stasis O +
ache O +
The O +
invention O +
relates O +
to O +
teasel O +
root O +
health O +
care O +
tea O +
for O +
stasis O +
ache O -
. O +

25 O +
parts O +
of O +
teasel O +
roots O -
, O +
14 O +
parts O +
of O +
sappan O +
wood O -
, O +
12 O +
parts O +
of O +
peach O +
seeds O +
and O +
16 O +
parts O +
of O +
borneol O +
are O +
washed O -
, O +
chopped O +
and O +
dried O -
; O +
16 O +
parts O +
of O +
catechu O -
, O +
17 O +
parts O +
of O +
green O +
tea O +
and O +
filiform O +
medicinal O +
material O +
are O +
uniformly O +
mixed O +
and O +
dried O -
, O +
and O +
are O +
packaged O +
into O +
packed O +
dipsacus O +
root O +
health O +
care O +
tea O +
for O +
stasis O +
ache O -
. O +

The O +
teasel O +
root O +
health O +
care O +
tea O +
for O +
stasis O +
ache O +
has O +
the O +
advantages O +
of O +
simple O +
preparation O +
method O +
and O +
convenient O +
carriage O +
with O +
good O +
effect O -
; O +
the O +
invention O +
has O +
the O +
blood O +
circulation O +
invigorating O -
, O +
stasis O +
dispersing O -
, O +
pain O +
relieving O +
and O +
hemostasis O +
efficacies O -
, O +
and O +
the O +
product O +
can O +
help O +
people O +
to O +
invigorate O +
blood O +
circulation O -
, O +
disperse O +
stasis O -
, O +
prevent O +
and O +
control O +
stasis O +
ache O +
symptoms O -
. O +

Fluoroquinolonesilver O +
compound O +
as O +
well O +
as O +
preparation O +
method O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
fluoroquinolonesilver O -
, O +
and O +
a O +
preparation O +
method O +
and O +
medical O +
application O +
of O +
the O +
fluoroquinolonesilver O -
. O +

The O +
fluoroquinolonesilver O +
has O +
a O +
structure O +
shown O +
in O +
a O +
general O +
formula O +
( O -
I O -
) O +
( O -
refer O +
to O +
the O +
Specification O -
) O -
. O +

Silver O +
ions O +
and O +
fluoroquinolone O +
are O +
combined O +
together O -
, O +
and O +
through O +
the O +
synergistic O +
effect O +
of O +
the O +
silver O +
ions O +
and O +
fluoroquinolone O -
, O +
the O +
antibacterial O +
effect O +
is O +
further O +
enhanced O -
, O +
and O +
the O +
problem O +
of O +
the O +
drug O +
resistance O +
of O +
the O +
existing O +
fluoroquinolone O +
drugs O +
can O +
be O +
solved O +
to O +
a O +
certain O +
degree O -
. O +

The O +
fluoroquinolonesilver O +
is O +
simple O +
in O +
preparation O +
process O -
, O +
and O +
stable O +
in O +
productivity O -
( O -
refer O +
to O +
the O +
Specification O +
for O +
the O +
formula O +
I O -
) O -
. O +

Substituted O +
imidazole-1-ethylene O +
compound O +
and O +
application O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
substituted O +
imidazole-1-ethylene O +
compound O +
as O +
well O +
as O +
a O +
preparation O +
and O +
an O +
application O +
thereof O -
. O +

The O +
substituted O +
imidazole-1-ethylene O +
compound O +
is O +
a O +
compound O +
shown O +
as O +
a O +
formula O +
I O -
, O +
or O +
salts O +
thereof O +
formed O +
with O +
medicinal O +
acids O +
or O +
bases O -
. O +

According O +
to O +
the O +
antifungal O +
activity O +
test O +
performed O +
on O +
eight O +
clinical O +
fungi O +
by O +
the O +
compound O +
provided O +
in O +
the O +
invention O -
, O +
a O +
good O +
fungus O +
killing O +
effect O +
is O +
achieved O -
. O +

The O +
compound O +
can O +
serve O +
as O +
a O +
novel O +
broad O -
- O -
spectrum O +
antifungal O +
activity O +
compound O +
and O +
is O +
developed O +
into O +
antifungal O +
medicines O -
, O +
disinfectants O +
or O +
feed O +
additives O -
. O +

Application O +
of O +
natural O +
medicinal O +
composition O +
in O +
preparing O +
anti O -
- O -
hypoxia O +
medicines O +
and O +
health O -
- O -
care O +
products O +
The O +
invention O +
provides O +
a O +
natural O +
medicinal O +
composition O +
beneficial O +
to O +
hypoxia O +
tolerance O -
. O +

The O +
composition O +
is O +
characterized O +
by O +
being O +
prepared O +
from O +
asiaticoside O +
and O +
paeoniflorin O +
with O +
effects O +
of O +
anti O -
- O -
inflammation O +
anti O -
- O -
exudation O -
, O +
and O +
ginseng O +
saponin O +
and O +
total O +
saponins O +
of O +
dried O +
tangerine O +
peel O +
with O +
anti O -
- O -
ischemia O +
and O +
anti O -
- O -
hypoxia O +
effects O -
. O +

The O +
natural O +
medicinal O +
composition O +
is O +
clear O +
in O +
substances O +
and O +
controllable O +
in O +
quality O -
, O +
and O +
sufficiently O +
utilizes O +
the O +
synergetic O +
effect O +
of O +
each O +
component O -
. O +

Besides O +
consideration O +
on O +
anti O -
- O -
ischemia O +
and O +
anti O -
- O -
hypoxia O +
substances O -
, O +
the O +
prescription O +
of O +
the O +
natural O +
medicinal O +
composition O +
is O +
contributed O +
to O +
prevention O +
and O +
treatment O +
of O +
emergent O +
inflammatory O +
exudation O +
caused O +
by O +
ischemia O +
and O +
hypoxia O +
to O +
tissues O +
of O +
heart O +
and O +
cerebral O +
vessels O -
. O +

The O +
composition O +
can O +
be O +
used O +
for O +
preparing O +
oral O +
preparations O -
, O +
such O +
as O +
hard O +
capsules O -
, O +
tablets O -
, O +
granules O -
, O +
powder O -
, O +
pills O -
, O +
teabags O +
and O +
oral O +
solutions O -
, O +
and O +
can O +
be O +
used O +
in O +
Chinese O +
patent O +
medicines O +
or O +
health O -
- O -
care O +
foods O +
for O +
improving O +
hypoxia O +
tolerance O -
. O +

Ornidazole O +
paster O +
for O +
transluminal O +
administration O +
The O +
invention O +
provides O +
an O +
oidazole O +
paster O +
for O +
transluminal O +
administration O -
, O +
and O +
the O +
oidazole O +
paster O +
comprises O +
ornidazole O +
and O +
a O +
solid O +
water O -
- O -
soluble O +
matrix O -
. O +

The O +
solid O +
water O -
- O -
soluble O +
matrix O +
includes O +
carbopol O -
, O +
lactose O -
, O +
low O -
- O -
substituted O +
hydroxy O +
propyl O +
cellulose O +
and O +
carboxymethyl O +
cellulose O +
sodium O -
. O +

A O +
preparation O +
method O +
of O +
the O +
oidazole O +
patch O +
comprises O +
the O +
following O +
steps O -
: O +
respectively O +
sieving O +
secnidazole O -
, O +
lactose O -
, O +
low O -
- O -
substituted O +
hydroxy O +
propyl O +
cellulose O +
and O +
carboxymethyl O +
cellulose O +
sodium O +
in O +
the O +
prescription O +
dose O +
through O +
a O +
screen O +
of O +
80 O +
mesh O -
, O +
mixing O +
well O -
, O +
adding O +
70 O -
% O +
ethanol O +
for O +
granulation O -
, O +
drying O -
, O +
finishing O +
by O +
a O +
screen O +
of O +
30 O +
mesh O -
, O +
adding O +
carbopol O -
, O +
magnesium O +
stearate O +
and O +
talcum O +
powder O -
, O +
which O +
are O +
sieved O +
through O +
a O +
screen O +
of O +
100 O +
mesh O -
, O +
fully O +
mixing O +
and O +
tabletting O +
to O +
obtain O +
a O +
finished O +
product O -
. O +

The O +
invention O +
has O +
the O +
advantages O +
of O +
rapid O -
, O +
durable O +
and O +
reliable O +
effect O -
, O +
and O +
high O +
safety O -
; O +
at O +
the O +
same O +
time O -
, O +
the O +
local O +
administration O +
can O +
avoid O +
or O +
reduce O +
adverse O +
effects O +
of O +
systemic O +
administration O -
. O +

Application O +
of O +
3'-methoxy O +
benzyl-4-hydroxy-3,5-dimethoxy O -
- O -
benzoate O +
in O +
preparation O +
of O +
drugs O +
for O +
treating O +
or O +
preventing O +
rheumatoid O +
arthritis O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
drugs O -
, O +
and O +
particularly O +
relates O +
to O +
a O +
compound O +
capable O +
of O +
inhibiting O +
proteasomes O +
and O +
preventing O +
and O +
treating O +
rheumatoid O +
arthritis O -
. O +

The O +
compound O +
has O +
the O +
molecular O +
structure O +
of O +
3'-methoxy O +
benzyl-4-hydroxy-3,5-dimethoxy O -
- O -
benzoate O -
. O +

The O +
compound O +
has O +
the O +
beneficial O +
effects O +
that O +
the O +
compound O +
can O +
be O +
used O +
for O +
treating O +
rheumatoid O +
arthritis O -
, O +
and O +
has O +
potential O +
new O +
drug O +
development O +
value O -
. O +

Preparation O +
containing O +
methimazole O +
and O +
its O +
preparing O +
method O +
A O +
slowly O -
- O -
releasing O +
thiazmazole O +
tablet O +
for O +
treating O +
thyroidism O +
is O +
disclosed O -
. O +

It O +
is O +
prepared O +
by O +
unique O +
slow O -
- O -
releasing O +
technique O -
, O +
that O +
is O +
using O +
high O +
molecular O +
material O +
to O +
wrap O +
the O +
medicine O -
. O +

Use O +
of O +
gossypol O +
and O +
its O +
derivative O +
in O +
preparation O +
of O +
drug O +
for O +
leukemia O +
/ O +
bone O +
marrow O +
cancer O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
gossypol O +
and O +
its O +
derivative O +
in O +
preparation O +
of O +
drug O +
for O +
leukemia O +
/ O +
bone O +
marrow O +
cancer O -
, O +
wherein O +
the O +
gossypol O +
has O +
the O +
constitutional O +
formula O +
disclosed O +
in O +
the O +
specification O -
, O +
the O +
gossypol O +
derivative O +
is O +
gossypol O +
acetate O +
or O +
formic O +
acid O +
gossypol O -
. O +

Freeze O -
- O -
drying O +
fluconazole O +
injection O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
discloses O +
a O +
freeze O -
- O -
drying O +
fluconazole O +
injection O +
and O +
its O +
preparation O +
method O +
which O +
comprises O -
, O +
charging O +
a O +
definite O +
quantity O +
of O +
supporting O +
agent O +
into O +
reactive O +
medicinal O +
Fluconazole O +
( O -
50 O -
- O -
200 O -
mg O +
per O +
bottle O -
) O -
, O +
adding O +
pH O +
modifier O -
, O +
solubilizing O +
agent O +
so O +
as O +
to O +
prepare O +
solution O +
of O +
a O +
finite O +
concentration O -
, O +
and O +
loading O +
for O +
freeze O +
drying O -
. O +

Antiviral O +
activity O +
possessed O +
compound O +
The O +
invention O +
provides O +
an O +
antiviral O +
activity O +
possessed O +
compound O -
, O +
in O +
particular O +
organic O +
ionic O +
compounds O +
with O +
antiviral O +
reactivity O -
, O +
pharmaceutical O +
compositions O +
containing O +
the O +
compound O -
, O +
and O +
the O +
external O +
antiviral O +
method O -
. O +

Dripping O +
pills O +
of O +
nefopam O +
hydrochloride O +
and O +
its O +
preparation O +
method O +
The O +
invention O +
relates O +
to O +
a O +
Nefopam O +
Hydrochloride O +
drop O +
pill O +
prepared O +
by O +
utilizing O +
ultramicro O +
disintegration O +
and O +
drop O +
pill O +
manufacturing O +
process O -
, O +
which O +
has O +
the O +
advantages O +
of O +
improving O +
collapse O +
and O +
dissolving O +
speed O -
, O +
quick O +
effect O -
, O +
increased O +
medicament O +
stability O -
, O +
reduced O +
adjuvant O +
consumption O -
, O +
lowered O +
production O +
costs O -
, O +
and O +
easiness O +
in O +
carrying O +
and O +
use O -
. O +

It O +
has O +
good O +
compliance O -
, O +
thus O +
is O +
especially O +
suitable O +
for O +
children O -
, O +
the O +
elderly O -
, O +
bedridden O +
patients O +
and O +
dysphagia O +
patients O -
. O +

Method O +
for O +
preparing O +
astragaloside O +
and O +
its O +
use O +
in O +
preparation O +
of O +
drug O +
for O +
preventing O +
and O +
treating O +
diabetic O +
nephropathy O +
The O +
invention O +
discloses O +
a O +
method O +
for O +
preparing O +
astragaloside O +
and O +
its O +
use O +
in O +
pharmacy O -
, O +
wherein O +
the O +
preparing O +
process O +
comprises O +
subjecting O +
the O +
astragalus O +
root O +
powder O +
to O +
ethanol O +
backflow O -
, O +
decompression O +
concentrating O +
with O +
the O +
inverse O +
flow O -
, O +
charging O +
NaOH O +
into O +
the O +
concentration O +
liquid O -
, O +
compressionalcohol O +
liquid O +
backflow O -
, O +
steaming O +
the O +
ethyl O +
alcohol O +
to O +
obtain O +
ethanol O +
hydrolysate O -
, O +
extracting O +
with O +
acetic O +
ester O -
, O +
washing O +
to O +
neutral O -
, O +
evaporating O +
to O +
dryness O -
, O +
obtaining O +
crude O +
saponin O -
, O +
charging O +
acetic O +
ester O -
, O +
stirring O +
in O +
water O -
- O -
bath O -
, O +
cooling O +
down O -
, O +
filtering O -
, O +
deposition O -
, O +
and O +
recrystallizing O +
with O +
methanol O -
. O +

Hydroxymethyl O +
coumarine O +
soft O +
capsule O +
and O +
its O +
preparing O +
method O +
The O +
present O +
invention O +
relates O +
to O +
soft O +
hydroxymethyl O +
coumarine O +
capsule O +
and O +
its O +
preparation O +
process O -
. O +

The O +
soft O +
hydroxymethyl O +
coumarine O +
capsule O +
is O +
prepared O +
with O +
hydroxymethyl O +
coumarine O +
as O +
active O +
component O +
in O +
20 O -
- O -
75 O +
wt% O -
, O +
preferably O +
35 O -
- O -
55 O +
wt% O -
; O +
solvent O +
and O +
diluent O +
in O +
20 O -
- O -
75 O +
wt% O -
, O +
preferably O +
40 O -
- O -
55 O +
wt% O -
; O +
emulsifier O +
in O +
2 O -
- O -
12 O +
wt% O -
, O +
preferably O +
5 O -
- O -
8 O +
wt% O +
to O +
increase O +
the O +
solubility O +
of O +
hydroxymethyl O +
coumarine O +
in O +
animal O +
and O +
vegetable O +
oil O +
and O +
raise O +
its O +
stability O -
; O +
and O +
antioxidant O +
in O +
0.2 O -
- O -
5 O +
wt% O -
, O +
preferably O +
0.5 O -
- O -
3 O +
wt% O -
, O +
to O +
raise O +
the O +
antioxidant O +
performance O -
. O +

The O +
soft O +
capsule O +
shell O +
is O +
prepared O +
with O +
gelatin O -
, O +
glycerin O -
, O +
sorbic O +
alcohol O -
, O +
etc O -
. O +
and O +
contains O +
titania O +
in O +
0.2 O -
- O -
1.2 O +
wt% O -
, O +
preferably O +
0.5 O -
- O -
0.7 O +
wt% O -
, O +
as O +
light O +
screening O +
agent O -
. O +

Application O +
of O +
ursolic O +
acid O +
in O +
prepartation O +
of O +
anticancer O +
medicine O +
An O +
application O +
of O +
ursolic O +
acid O +
in O +
preparing O +
the O +
anticancer O +
medicine O +
for O +
treating O +
liver O +
cancer O -
, O +
breast O +
cancer O -
, O +
lymphomatosis O -
, O +
leukemia O -
, O +
etc O +
is O +
disclosed O -
. O +

Glycosyl O +
phthalic O +
imidine O +
compounds O +
with O +
anti O -
- O -
inflammatory O +
activity O +
The O +
invention O +
relates O +
to O +
N O -
- O -
glycosyl O +
( O -
substituted O -
) O +
phthalimide O +
compounds O +
having O +
the O +
structural O +
formula O +
disclosed O +
in O +
the O +
specification O -
, O +
wherein O +
R1 O +
separate O +
halogen O -
, O +
hydroxy O -
, O +
substituted O +
C1-C10 O +
alkyl O -
, O +
C1-C10 O +
aryl O -
, O +
C2-C8 O +
alkene O -
, O +
C1-C10 O +
alkoxy O -
, O +
C1-C10 O +
acyl O -
, O +
C1-C10 O +
ester O -
, O +
C1-C10 O +
carboxyl O -
, O +
nitro O -
, O +
amido O -
, O +
monoalkyl O +
amino O -
, O +
dialkyl O +
amido O -
, O +
cyano O -
, O +
sulfonyl O -
, O +
alkyl O +
sulfonyl O -
, O +
alkyl O -
, O +
sulfhydryl O -
, O +
A O +
is O +
various O +
substituted O +
or O +
nonsubstituted O +
glycosyl O +
residue O -
. O +

The O +
invention O +
also O +
discloses O +
the O +
and O +
method O +
for O +
preparation O +
and O +
use O +
in O +
preparing O +
anti O -
- O -
inflammatory O +
medicament O -
. O +

Application O +
of O +
dihydromyricetrin O +
An O +
application O +
of O +
dihydromyricetin O +
in O +
preparing O +
the O +
antalgic O +
and O +
apophlegmatic O +
medicine O +
or O +
health O -
- O -
care O +
food O +
is O +
disclosed O -
. O +

Usage O +
of O +
glanthidine O -
, O +
total O +
alkali O +
extract O +
and O +
preparation O +
method O +
and O +
usage O +
thereof O +
The O +
present O +
invention O +
discloses O +
the O +
use O +
of O +
lycoramine O +
in O +
preparing O +
medicine O +
for O +
resisting O +
SARS O +
virus O -
, O +
total O +
lycoramine O +
extract O +
containing O +
lycoramine O +
and O +
its O +
preparation O +
process O -
, O +
use O +
in O +
preparing O +
medicine O +
for O +
resisting O +
SARS O +
virus O +
and O +
the O +
composition O +
therewith O -
. O +

Antiadhesion O +
protective O +
preparation O +
and O +
its O +
application O +
An O +
anti O -
- O -
adhesion O +
protector O +
used O +
for O +
preparing O +
the O +
anti O -
- O -
adhesion O +
medicine O +
for O +
the O +
veterinary O +
operation O +
is O +
prepared O +
from O +
dihydrated O +
terramycin O -
, O +
acenocoumarol O -
, O +
erucic O +
acid O -
, O +
adrenine O +
and O +
carboxymethyl O +
cellulose O +
sodium O -
. O +

Powder O +
and O +
injection O +
preparation O +
of O +
new O +
houttuynine O +
sodium O +
bisulfite O +
and O +
preparation O +
method O +
A O +
powder O +
injection O +
of O +
sodium O +
neohouttuyfonate O +
is O +
prepared O +
from O +
the O +
sodium O +
neohouttuyfnoate O +
or O +
its O +
physiologically O +
acceptable O +
salt O +
and O +
the O +
phamacological O +
acceptable O +
auxiliary O +
for O +
injection O -
. O +

Paracetamol O +
Pseudoephedrine O +
desintegration O +
piece O +
and O +
preparation O +
method O +

An O +
oral O +
disintegrating O +
tablet O +
of O +
Shuangpuweima O +
is O +
prepared O +
from O +
acetylaminophenol O -
, O +
pseudoephedrine O +
hydrochloride O -
, O +
chlorpheniramine O -
, O +
disintegrant O -
, O +
filler O +
and O +
flavouring O -
. O +

Angelica O +
polysaccharide O +
and O +
its O +
preparation O +
and O +
use O +
The O +
invention O +
relates O +
to O +
a O +
Chinese O +
angelica O +
polysaccharide O -
, O +
which O +
is O +
made O +
in O +
the O +
following O +
way O -
: O +
dissolve O +
alcohol O +
deposit O +
of O +
Chinese O +
angelica O +
into O +
distilled O +
water O -
, O +
use O +
savage O +
method O +
to O +
more O +
the O +
protein O +
away O +
until O +
there O +
is O +
no O +
protein O +
absorption O +
peak O +
of O +
280 O +
nm O +
by O +
ultraviolet O +
test O -
, O +
centrifugation O +
to O +
clear O +
the O +
deposit O -
; O +
keep O +
the O +
water O -
- O -
phase O +
and O +
add O +
into O +
alcohol O +
for O +
depositing O +
polysaccharide O -
, O +
abandon O +
the O +
supernatant O +
liquid O -
, O +
wash O +
the O +
deposit O +
by O +
alcohol O -
, O +
then O +
freeze O +
and O +
dry O +
it O -
, O +
through O +
gel O +
molecular O +
chromatography O -
, O +
accumulate O +
the O +
separated O +
product O +
with O +
the O +
relative O +
molecule O +
mass O +
between O +
10,000 O -
- O -
110,000 O -
, O +
then O +
freeze O +
and O +
dry O +
it O +
again O +
to O +
acquire O +
the O +
Chinese O +
angelica O +
polysaccharide O -
. O +

The O +
invention O +
has O +
remarkable O +
analgesia O +
for O +
ache O +
caused O +
by O +
chemicals O +
and O +
hot O +
simulation O -
; O +
as O +
well O +
as O +
dysmenorrheal O +
caused O +
by O +
female O +
hormone O -
; O +
and O +
it O +
can O +
be O +
made O +
into O +
drug O +
for O +
analgesia O +
especially O +
that O +
for O +
curing O +
dysmenorrheal O -
. O +

Use O +
of O +
rapamycin O +
in O +
preparation O +
of O +
intraocularly O +
embedded O +
drug O +
The O +
invention O +
relates O +
to O +
the O +
application O +
of O +
rapamycin O +
( O -
RAPA O +
) O +
and O +
medicament O +
capable O +
of O +
self O -
- O -
degrading O +
in O +
preparing O +
eye O +
implantation O +
slow O +
release O +
medicament O -
, O +
the O +
medicament O +
can O +
keep O +
certain O +
reinforcement O +
and O +
shape O +
after O +
complete O +
release O -
, O +
and O +
can O +
be O +
naturally O +
degraded O +
under O +
internal O +
physiological O +
conditions O -
, O +
thus O +
can O +
be O +
absorbed O +
and O +
discharged O +
externally O +
through O +
metabolizing O -
, O +
and O +
no O +
secondary O +
surgery O +
is O +
needed O +
to O +
be O +
taken O +
out O -
. O +

The O +
invention O +
can O +
be O +
applied O +
to O +
the O +
repulsion O +
reaction O +
in O +
cornea O +
transplantation O +
for O +
treating O +
ophthalmology O +
diseases O -
. O +

Anti O +
cancer O +
gene O +
medicinal O +
composition O -
, O +
micromolecule O +
interfere O +
RNA O +
and O +
its O +
screening O +
method O +
The O +
liver O +
cancer O +
resisting O +
gene O +
medicine O +
composition O +
includes O +
antisense O +
fup1 O +
gene O +
and/or O +
small O +
molecular O +
interfering O +
RNA O +
and O +
pharmaceutically O +
acceptable O +
supplementary O +
material O -
. O +

The O +
antisense O +
fup1 B-Gene +
gene O +
has O +
the O +
DNA O +
sequence O +
of O +
SEQ O +
ID O +
No. O +
2 O +
in O +
the O +
sequence O +
list O -
, O +
while O +
the O +
small O +
molecular O +
interfering O +
RNA O +
includes O +
the O +
RNA O +
sequence O +
of O +
SEQ O +
ID O +
No. O +
3 O +
in O +
the O +
sequence O +
list O -
. O +

The O +
present O +
invention O +
also O +
provides O +
the O +
liver O +
cancer O +
resisting O +
gene O +
medicine O +
screening O +
method O +
to O +
design O +
small O +
molecular O +
interfering O +
RNA O +
based O +
on O +
fup1 O +
encoding O +
area O +
via O +
adopting O +
ambion O +
web O +
site O +
provided O +
RNAi O +
design O +
software O -
. O +

The O +
present O +
invention O +
further O +
provides O +
liver O +
cancer O +
resisting O +
small O +
molecule O +
include O +
RNA O +
sequence O +
of O +
SEQ O +
ID O +
No. O +
3 O +
in O +
the O +
sequence O +
list O -
. O +

The O +
present O +
invention O +
adopts O +
gene O +
fup1 O +
high O +
expressed O +
in O +
liver O +
cancer O +
cell O +
as O +
medicine O +
target O +
to O +
design O +
the O +
antagonistic O +
molecule O +
to O +
provide O +
powerful O +
measure O +
for O +
the O +
gene O +
treatment O +
of O +
liver O +
cancer O +
and O +
excellent O +
platform O +
for O +
further O +
screening O +
liver O +
cancer O +
resisting O +
gene O +
medicine O -
. O +

Ethylamine O +
thiourea O +
injection O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
an O +
ethylamine O +
thiourea O +
injection O +
and O +
preparation O +
method O -
, O +
wherein O +
the O +
main O +
medicinal O +
constituent O +
is O +
diaminoethylisothiuramium O +
hydrobromate O -
. O +

By O +
employing O +
the O +
two O +
methods O +
of O +
cushioning O +
liquid O +
and O +
anti O -
- O -
oxidant O -
, O +
the O +
problem O +
of O +
unstable O +
ethylamine O +
thiocarbamide O +
can O +
be O +
solved O +
effectively O -
. O +

The O +
injection O +
has O +
the O +
advantages O +
of O +
simple O +
process O +
for O +
manufacturing O +
and O +
stabilized O +
product O +
quality O -
. O +

New O +
action O +
and O +
application O +
of O +
methylene O +
blue O +
in O +
preventing O +
dental O +
caries O +
The O +
present O +
invention O +
relates O +
to O +
the O +
new O +
action O +
application O +
of O +
methylene O +
blue O +
in O +
preventing O +
dental O +
caries O -
. O +

Methylene O +
blue O +
is O +
used O +
as O +
effective O +
component O +
in O +
preparing O +
dental O +
caries O +
preventing O +
preparation O -
. O +

Method O +
for O +
preparing O +
hard O -
- O -
soluble O +
gel O +
formulation O +
The O +
present O +
invention O +
relates O +
to O +
a O +
preparation O +
method O +
of O +
insoluble O +
medicine O +
gel O +
preparation O -
. O +

The O +
physiological O +
active O +
substance O +
of O +
said O +
gel O +
preparation O +
is O +
insoluble O +
medicine O -
. O +

Its O +
preparation O +
method O +
is O +
characterized O +
by O +
that O +
the O +
ink O +
course O +
of O +
preparation O +
of O +
gel O +
a O +
hydrophilic O +
substance O +
is O +
added O +
so O +
as O +
to O +
raise O +
the O +
solubility O +
of O +
main O +
medicine O +
in O +
water O -
, O +
and O +
can O +
make O +
the O +
main O +
medicine O +
be O +
uniformly O +
diffused O +
in O +
the O +
gel O -
, O +
and O +
the O +
gel O +
stability O +
is O +
good O -
. O +

Use O +
of O +
chitin O -
, O +
chitinous O +
glycan O +
and O +
its O +
derivative O +
biomembrane O +
in O +
medicinal O +
preparation O +
for O +
treaing O +
colpitis O +
and O +
cervicitis O +
An O +
application O +
of O +
the O +
membrane O +
made O +
of O +
chitin O -
, O +
chitosan O -
, O +
or O +
their O +
derivatives O +
in O +
treating O +
vaginitis O +
and O +
cervicitis O +
is O +
disclosed O -
. O +

Said O +
membrane O +
may O +
be O +
replaced O +
by O +
fibrous O +
net O +
or O +
composite O +
material O -
. O +

Anti O -
- O -
cancer O +
analgetic O +
preparation O +
The O +
anticancer O +
analgetic O +
preparation O +
has O +
lappaconitine O +
and O +
vincristine O +
as O +
main O +
active O +
anticancer O +
components O -
. O +

Lappaconitine O +
has O +
the O +
effect O +
of O +
increasing O +
the O +
sensitivity O +
of O +
vincristine O +
in O +
killing O +
cancer O +
cell O -
, O +
so O +
that O +
the O +
preparation O +
of O +
the O +
present O +
invention O +
can O +
reverse O +
the O +
drug O +
resistance O +
of O +
tumor O -
. O +

The O +
present O +
invention O +
has O +
obvious O +
functions O +
of O +
resisting O +
liver O +
cancer O -
, O +
lung O +
cancer O -
, O +
cancer O +
of O +
uterus O +
and O +
breast O +
cancer O -
, O +
stopping O +
pain O -
, O +
etc O -
. O +
and O +
has O +
the O +
feature O +
of O +
less O +
recovery O +
of O +
the O +
blood O +
supply O +
to O +
embolized O +
tumor O +
artery O -
. O +

Compared O +
with O +
similar O +
medicines O -
, O +
the O +
present O +
invention O +
has O +
the O +
advantages O +
of O +
less O +
side O +
effect O -
, O +
high O +
tumor O +
cell O +
killing O +
effect O -
, O +
high O +
stability O -
, O +
low O +
cost O -
, O +
etc O -
. O +

Use O +
of O +
pentacylic O +
triterpene O +
compounds O +
in O +
preparing O +
glycogenic B-Gene +
phosphorylase I-Gene +
inhibitor O +
The O +
present O +
invention O +
relates O +
to O +
application O +
of O +
pentacyclic O +
triterpene O +
compounds O +
in O +
preparing O +
glycogenic B-Gene +
phosphorylase I-Gene +
inhibitor O -
, O +
and O +
includes O +
the O +
application O +
of O +
medicine O +
composition O +
of O +
crataegolic O +
acid O -
, O +
Corosolic O +
acid O -
, O +
oleanolic O +
acid O -
, O +
ursolic O +
acid O -
, O +
betulin O -
, O +
betulic O +
acid O -
, O +
lupeol O +
or O +
their O +
pharmaceutically O +
acceptable O +
salt O +
or O +
ester O +
in O +
preparing O +
medicine O +
for O +
treating O +
diabetes O -
. O +

Oral O +
emulsion O +
combination O +
of O +
' O -
Chuanhuning O -
' O +
An O +
orally O -
- O -
taken O +
composite O +
emulsion O +
of O +
Chuanhuning O +
is O +
prepared O +
from O +
Chuanhuning O -
, O +
surfactant O +
as O +
emulsifier O -
, O +
organic O +
solvent O +
as O +
coemulsifier O +
and O +
oil O -
. O +

It O +
has O +
higher O +
biologic O +
utilization O +
rate O -
. O +

Nanometer O +
preparation O +
of O +
silybin O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
provides O +
a O +
silybin O +
nano O +
medicinal O +
preparation O -
, O +
which O +
comprises O +
liposome O +
nano O +
particles O +
of O +
silybin O -
, O +
the O +
liposome O +
material O +
is O +
the O +
mixture O +
of O +
soya O +
bean O +
lecithin O -
, O +
vitamin O +
E O +
and O +
soyabean O +
oil O +
by O +
the O +
mass O +
ratio O +
of O +
1:2.5:12.5 O -
- O -
1:15:24 O -
, O +
the O +
mass O +
ratio O +
of O +
silybin O +
and O +
lipsome O +
material O +
is O +
1:32 O -
- O -
1:400 O -
, O +
the O +
grain O +
diameter O +
of O +
the O +
liposome O +
nano O +
particles O +
is O +
less O +
than O +
500 O +
nanometer O -
. O +

The O +
invention O +
also O +
discloses O +
the O +
preparing O +
process O +
of O +
the O +
preparation O -
. O +

Vaginal O +
tablet O +
with O +
clindamycin O +
and O +
metronidazole O +
The O +
invention O +
relates O +
to O +
a O +
vaginal O +
tablet O +
of O +
clindamycinum O +
and O +
metronidazole O -
, O +
which O +
uses O +
the O +
salts O +
or O +
esters O +
of O +
clindamycinum O +
and O +
metronidazole O +
as O +
the O +
active O +
constituents O -
, O +
and O +
the O +
conventional O +
tablets O +
as O +
the O +
auxiliary O +
material O -
. O +

Purple O +
bergenia O +
element O +
pentaacetylate O +
and O +
its O +
uses O +
The O +
invention O +
provides O +
a O +
Bergenini O +
penta O -
- O -
acetyl O -
, O +
whose O +
chemical O +
name O +
is O +
( O -
2R,3R,4R,4aS,10bS O -
) O -
-2- O -
( O -
acetoxymethyl O -
) O -
-9-methoxy-6-oxo-2,3,4,4a,6,10b O -
- O -
hexahydr O +
o O +
pyrano O -
[ O -
3,2-c O -
] O -
isochromene-3,4,8,10-tetrayl O +
tetraacetate O -
, O +
and O +
is O +
prepared O +
from O +
Bergenini O +
as O +
lead O +
compound O +
through O +
butanoylation O +
reaction O -
, O +
the O +
hydroxyl O +
on O +
the O +
precursor O +
is O +
blocked O +
so O +
as O +
to O +
enhance O +
the O +
lipophilicity O -
. O +

The O +
Bergenini O +
penta O -
- O -
acetyl O +
can O +
be O +
used O +
for O +
preparing O +
medicine O +
for O +
relieving O +
cough O -
. O +

The O +
invention O +
further O +
provides O +
a O +
compound O +
preparation O +
containing O +
the O +
Bergenini O +
penta O -
- O -
acetyl O -
. O +

Azithromycin O +
gel O +
The O +
present O +
invention O +
relates O +
to O +
an O +
azithromycin O +
gel O -
. O +

Its O +
composition O +
includes O +
( O +
weight O +
portion O -
) O +
1 O -
- O -
5 O +
portions O +
of O +
azithromycin O -
, O +
0.5 O -
- O -
10 O +
portions O +
of O +
skeleton O +
materials O -
, O +
suchas O +
agar O +
and O +
arabic O +
gum O -
, O +
etc O -
. O +

capable O +
of O +
forming O +
gel O -
, O +
25 O -
- O -
35 O +
portions O +
of O +
sweetening O +
agent O +
and O +
80 O -
- O -
120 O +
portions O +
of O +
water O -
. O +

Ointment O +
medicine O +
for O +
treating O +
bedsore O +
The O +
present O +
invention O +
discloses O +
an O +
ointment O +
medicine O +
preparation O +
for O +
curing O +
bed O +
sore O +
with O +
obvious O +
therapeutic O +
effect O -
. O +

Its O +
raw O +
material O +
composition O +
includes O +
( O -
by O +
weight O +
portion O -
) O +
0.1 O -
- O -
5 O +
portions O +
of O +
berberine O -
, O +
20 O -
- O -
40 O +
portions O +
of O +
fluocinonide O +
ointment O -
, O +
0.1 O -
- O -
5 O +
portions O +
of O +
Yunnan O +
white O +
medicine O +
and O +
0.1 O -
- O -
5 O +
portions O +
of O +
sulfonamides O +
anti O -
- O -
inflammatory O +
powder O -
. O +

Soybean O +
isoflavone O +
soft O +
capsule O +
and O +
its O +
preparation O +
process O +
The O +
invention O +
discloses O +
a O +
soybean O +
isoflavone O +
soft O +
capsule O +
and O +
the O +
preparing O +
method O -
, O +
belonging O +
to O +
medical O +
field O -
, O +
with O +
the O +
technique O +
feature O +
being O -
: O +
the O +
material O +
in O +
the O +
capsule O +
comprising O +
soybean O +
isoflavone O -
, O +
phospholipid O -
, O +
calcium O +
salt O -
, O +
vitamin O -
, O +
anti O -
- O -
oxidant O -
, O +
capsule O +
stabilizing O +
agent O +
and O +
deflocculating O +
agent O -
, O +
the O +
capsule O +
shell O +
comprising O +
gelatine O -
, O +
plasticity O +
agent O -
, O +
conservative O -
, O +
hiding O +
agent O -
, O +
coloring O +
matter O -
, O +
corrective O +
and O +
water O -
. O +

The O +
soft O +
capsule O +
prepared O +
by O +
using O +
method O +
in O +
this O +
invention O +
is O +
characterized O +
by O +
the O +
stale O +
quality O -
, O +
safety O -
, O +
convenient O +
usage O -
, O +
ease O +
for O +
body O +
adsorption O -
, O +
and O +
high O +
bioavailability O -
, O +
and O +
particularly O +
be O +
used O +
for O +
regulating O +
the O +
estrogenic O +
hormones O +
for O +
menopausal O +
woman O -
, O +
and O +
for O +
preventing O +
and O +
treating O +
disease O +
relevant O +
with O +
estrogenic O +
hormones O -
. O +

Breviscapine O +
orally O +
disintegrating O +
tablet O +
and O +
preparation O +
method O +
thereof O +
The O +
invention O +
discloses O +
a O +
Breviscapine O +
oral O +
disintegrating O +
tablet O -
, O +
which O +
comprises O +
21.0 O -
- O -
35.0 O +
wt% O +
of O +
Breviscapine O -
, O +
11.0 O -
- O -
15.0.0wt% O +
of O +
sodium O +
carboxymethylstarch O -
, O +
45.0 O -
- O -
60.0 O +
wt% O +
of O +
crystalline O +
cellulose O -
, O +
1.0 O -
- O -
2.0 O +
wt% O +
of O +
magnesium O +
stearate O -
, O +
5.0 O -
- O -
10.0 O +
wt% O +
of O +
miropowdered O +
silica O +
gel O -
, O +
and O +
0.1 O -
- O -
0.5wt% O +
of O +
Aspartame O -
. O +

the O +
relative O +
weight O +
ratio O +
of O +
Breviscapine O +
and O +
sodium O +
carboxymethylstarch O +
is O +
1:0.3 O -
- O -
1:0.7 O -
. O +

Non O -
- O -
metal O +
salt O +
of O +
Glicididazole O +
and O +
its O +
prepn O +
The O +
present O +
invention O +
relates O +
to O +
non O -
- O -
metal O +
salt O +
compounds O +
of O +
glycididazole O -
, O +
including O +
ammonium O +
salt O +
of O +
glycididazole O -
, O +
diethylamine O +
double O +
salt O +
of O +
glycididazole O +
and O +
ethylene O +
diamine O +
double O +
salt O +
of O +
glycididazole O -
, O +
and O +
their O +
preparation O +
process O -
. O +

The O +
present O +
invention O +
provides O +
new O +
glycididazole O +
compounds O +
with O +
improved O +
water O +
solubility O +
and O +
stability O +
for O +
convenient O +
medicinal O +
application O -
. O +

In O +
addition O -
, O +
the O +
non O -
- O -
metal O +
salt O +
compounds O +
of O +
glycididazole O +
are O +
non O -
- O -
sodium O +
ion O +
salt O +
and O +
can O +
avoid O +
sodium O +
accumulation O +
and O +
other O +
bad O +
reaction O +
causing O +
electrolyte O +
metabolism O +
disorder O -
. O +

Stepronin O +
injection O +
and O +
its O +
preparing O +
method O +
The O +
present O +
invention O +
is O +
new O +
preparation O +
form O +
of O +
Stepronin O -
, O +
especially O +
great O +
capacity O +
Stepronin O +
injection O -
, O +
and O +
its O +
preparation O +
process O -
. O +

The O +
injection O +
consists O +
of O +
Stepronin O +
or O +
its O +
metal O +
salt O +
or O +
amino O +
salt O +
as O +
active O +
component O +
and O +
medicinal O +
carrier O -
. O +

Compared O +
with O +
available O +
orally O +
taken O +
Stepronin O +
preparation O -
, O +
the O +
present O +
invention O +
has O +
the O +
advantages O +
of O +
high O +
bioavailability O -
, O +
good O +
medicine O +
absorption O -
, O +
fast O +
medicine O +
dispersion O -
, O +
fast O +
acting O -
, O +
etc O -
. O +

The O +
present O +
invention O +
expands O +
the O +
administration O +
range O +
of O +
Stepronin O +
and O +
raises O +
the O +
clinical O +
administration O +
level O +
of O +
Stepronin O -
. O +

( O -
3R,4R O -
) O -
-trans-3,4-diarylchroman O +
derivatives O +
with O +
estrogenic O +
activity O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
I O +
in O +
which O +
substituents O +
R<2 O -
> O +
and O +
R<3 O -
> O +
are O +
arranged O +
in O +
trans O -
- O -
configuration O -
, O +
Formula O +
( O -
I O -
) O -
, O +
wherein O -
: O +
R<1 O -
> O +
is O +
H O +
or O +
C1-C6 O +
alkyl O -
; O +
C3-C7 O +
cycloalkyl O -
; O +
R<2 O -
> O +
is O +
phenyl O -
, O +
optionally O +
substituted O +
with O +
1 O +
to O +
5 O +
substituents O +
independently O +
selected O +
from O +
the O +
group O +
comprising O +
OH O -
, O +
C1-C6 O +
-alkyl O -
, O +
halogen O -
, O +
nitro O -
, O +
cyano O -
, O +
SH O -
, O +
SR<4 O -
> O -
, O +
trihalo O -
- O -
C1-C6-alkyl O -
, O +
C1-C6 O +
-alkoxy O +
and O +
phenyl O -
, O +
wherein O +
R<4 O -
> O +
is O +
C1-C6 O +
alkyl;R<3 O -
> O +
is O +
phenyl O +
substituted O +
with O +
OR<5 O -
> O +
wherein O +
R<5 O -
> O +
has O +
the O +
Formula O +
( O -
II O -
) O -
, O +
( O -
III O -
) O +
or O +
( O -
IV O -
) O +
, O +
wherein O +
Y O +
is O +
chosen O +
from O +
NHR<4 O -
> O -
, O +
NR<4>2 O -
, O +
NHCOR<4 O -
> O -
, O +
NHSO2R<4 O -
> O -
, O +
CONHR<4 O -
> O -
, O +
CONR<4 O -
> O -
, O +
CONR<4>2 O -
, O +
COOH O -
, O +
COOR<4 O -
> O -
, O +
SO2R<4 O -
> O -
, O +
SOR<4 O -
> O -
, O +
SONHR<4 O -
> O -
, O +
SONR<4>2 O -
, O +
a O +
C3-C7 O +
heterocyclic O +
ring O -
, O +
saturated O +
or O +
unsaturated O -
, O +
containing O +
one O +
or O +
two O +
heteroatoms O +
independently O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
O O -
, O +
S O +
and O +
N O -
, O +
optionally O +
being O +
substituted O +
with O +
1 O +
to O +
3 O +
substituents O +
independently O +
selected O +
from O +
the O +
group O +
comprising O +
H O -
, O +
OH O -
, O +
halogen O -
, O +
nitro O -
, O +
cyano O -
, O +
SH O -
, O +
SR<4 O -
> O -
, O +
trihalo O -
- O -
C1-C6- O +
alkyl O -
, O +
C1-C6-alkyl O +
and O +
C1-C6 O +
-alkoxy O -
, O +
preferably O +
NHR<4 O -
> O -
, O +
NR2<4 O -
> O -
, O +
or O +
a O +
nitrogen O +
heterocycle O -
, O +
wherein O +
R<4 O -
> O +
is O +
as O +
defined O +
above O -
, O +
and O +
the O +
esters O -
, O +
ethers O -
, O +
and O +
salts O +
of O +
the O +
compounds O +
of O +
formula O +
I O -
, O +
optionally O +
along O +
pharmaceutically O +
acceptable O +
excipients O -
, O +
a O +
process O +
for O +
the O +
preparation O +
of O +
the O +
same O -
, O +
and O +
a O +
method O +
of O +
preventing O +
and/or O +
treating O +
estrogen O -
- O -
related O +
disease O +
conditions O +
in O +
a O +
subject O +
using O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
or O +
its O +
salts O -
, O +
optionally O +
along O +
with O +
pharmaceutically O +
acceptable O +
excipients O -
. O +

Tape O +
preparation O +
The O +
present O +
invention O +
provides O +
a O +
tape O +
preparation O +
including O +
a O +
support O +
and O +
an O +
adhesive O +
layer O +
directly O +
or O +
indirectly O +
formed O +
on O +
at O +
least O +
one O +
surface O +
of O +
the O +
support O -
, O +
wherein O +
the O +
adhesive O +
layer O +
contains O +
a O +
rubber O +
adhesive O +
containing O +
at O +
least O +
one O +
kind O +
of O +
rubber O +
polymer O +
and O +
capsaicin O +
as O +
an O +
active O +
ingredient O -
. O +

Since O +
the O +
adhesive O +
layer O +
shows O +
extremely O +
fine O +
adhesive O +
property O +
and O +
superior O +
capsaicin O +
releaseability O -
, O +
a O +
rapid O +
pharmacological O +
effect O +
can O +
be O +
afforded O +
with O +
a O +
small O +
capsaicin O +
content O -
. O +

Micro O -
- O -
powder O +
dom O +
peridone O +
maleate O +
medicinal O +
composition O +
and O +
its O +
preparing O +
method O +
The O +
present O +
invention O +
relates O +
to O +
a O +
medicine O +
composition O +
with O +
domperidone O +
maleate O -
. O +

It O +
is O +
characterized O +
by O +
that O +
said O +
medicine O +
composition O +
is O +
micropowdered O -
, O +
and O +
can O +
be O +
used O +
for O +
invigorating O +
function O +
of O +
gastrointestinal O +
tract O +
and O +
curing O +
the O +
diseases O +
of O +
dyspepsia O +
and O +
nausea O -
- O -
vomiting O -
, O +
etc O -
. O +

Said O +
micropowdered O +
domperidone O +
maleate O +
preparation O +
can O +
raise O +
its O +
bioavailability O -
. O +

Besides O -
, O +
said O +
invention O +
also O +
provides O +
its O +
preparation O +
method O -
. O +

Compound O +
Silybum O +
drip O +
balls O +
and O +
preparation O +
thereof O +
A O +
dripping O +
pill O +
of O +
compound O +
silymarinum O +
is O +
prepared O +
from O +
the O +
silymarinum O +
and O +
the O +
alcohol O +
extract O +
of O +
5 O +
kernels O +
through O +
proportionally O +
mixing O +
it O +
with O +
matrix O +
( O -
polyoxyvinyl O +
monostearate O -
) O -
, O +
heating O +
until O +
the O +
mixture O +
is O +
fused O -
, O +
stirring O -
, O +
and O +
dripping O +
in O +
condensing O +
liquid O -
. O +

Ganciclovir O +
ophthalmic O +
gel O +
and O +
its O +
prepn O -
. O +

method O +
An O +
eye O +
gel O +
of O +
Ganciclovir O +
for O +
treating O +
viral O +
keratitis O +
is O +
proportionally O +
prepared O +
from O +
ganciclovir O +
and O +
eye O +
gel O +
matrix O +
through O +
mixing O +
Ganciclovir O -
, O +
eye O +
gel O +
matrix O +
and O +
water O -
, O +
stirring O -
, O +
regulating O +
pH O +
value O -
, O +
adding O +
water O -
, O +
stirring O +
and O +
sterilizing O -
. O +

Soft O +
capsule O +
of O +
medication O +
composition O -
, O +
and O +
preparation O +
method O +
A O +
composite O +
medicine O +
in O +
the O +
form O +
of O +
softgel O +
is O +
prepared O +
from O +
domperidone O +
and O +
the O +
auxiliary O +
chosen O +
from O +
diluent O -
, O +
cosolvent O -
, O +
solubilizer O +
and O +
surfactant O -
. O +

It O +
has O +
high O +
stability O -
. O +

Its O +
preparing O +
process O +
is O +
also O +
disclosed O -
. O +

Application O +
of O +
medication O +
composition O +
of O +
containing O +
acetamino O +
phenol O +
in O +
treating O +
insufficiency O +
of O +
blood O +
supply O +
for O +
brain O +
An O +
application O +
of O +
the O +
medicinal O +
composition O +
containing O +
paracetamol O -
, O +
propylphenazone O +
and O +
caffeine O +
in O +
treating O +
cerebral O +
ischemia O +
is O +
disclosed O -
. O +

Method O +
for O +
preparing O +
rhubarb O +
sulfur O +
gel O +
agent O +
The O +
invention O +
relates O +
to O +
the O +
process O +
for O +
preparing O +
gelling O +
agent O +
of O +
rhubarb O +
horsetails O +
and O +
sulfur O +
by O +
using O +
free O +
anthraquinone O +
of O +
rhubarb O +
horsetails O +
extract O +
and O +
sulfur O +
as O +
the O +
main O +
constituents O -
, O +
using O +
carbomer O +
as O +
the O +
gel O +
matrix O -
, O +
and O +
using O +
methyl O +
ethylene O +
glycol O +
and O +
urea O +
as O +
the O +
mixed O +
transdermal O +
accelerating O +
agent O -
. O +

The O +
preparation O +
can O +
be O +
used O +
for O +
treating O +
acne O -
. O +

An O +
externally O +
applied O +
medicine O +
for O +
treating O +
hicismus O +
by O +
use O +
of O +
steatite O +
Disclosed O +
is O +
an O +
externally O +
used O +
medicament O +
for O +
treating O +
tragomaschalia O -
, O +
which O +
is O +
prepared O +
from O +
the O +
following O +
raw O +
materials O -
: O +
talcum O +
powder O -
, O +
goldthread O +
root O -
, O +
dandelion O -
, O +
gypsum O -
, O +
camphor O -
, O +
perfume O +
compound O +
and O +
ethanol O -
. O +

Compound O +
medicine O +
composition O +
and O +
its O +
prepn O +
and O +
use O +
The O +
present O +
invention O +
relates O +
to O +
one O +
kind O +
of O +
veterinary O +
medicine O +
composition O +
for O +
eliminating O +
fever O -
, O +
relieving O +
pain O +
and O +
diminishing O +
inflammation O +
and O +
its O +
preparation O +
process O +
and O +
use O -
. O +

The O +
veterinary O +
medicine O +
composition O +
consists O +
of O +
diclofenac O +
sodium O +
and O +
naproxen O +
in O +
the O +
weight O +
ratio O +
of O +
0.1 O -
- O -
10 O -
, O +
preferably O +
0.2 O -
- O -
5 O -
; O +
or O +
consists O +
of O +
diclofenac O +
sodium O +
and O +
barbitone O +
in O +
the O +
weight O +
ratio O +
of O +
0.2 O -
- O -
10 O -
, O +
preferably1 O -
- O -
7.5 O -
. O +

The O +
veterinary O +
medicine O +
composition O +
is O +
used O +
in O +
preventing O +
and O +
treating O +
feverish O +
animal O +
diseases O +
and O +
has O +
synergistic O +
fever O +
eliminating O +
effect O -
, O +
fast O +
acting O +
and O +
less O +
recurrence O -
. O +

Sobering O -
- O -
up O +
beverage O +
A O +
sobering O -
- O -
up O +
beverage O +
is O +
proportionally O +
prepared O +
from O +
8 O +
raw O +
materials O +
including O +
purified O +
water O -
, O +
pear O +
juice O -
, O +
pueraria O +
root O +
( O -
or O +
flower O -
) O -
, O +
ginsenoside O +
Rg3 O -
, O +
rebescensine O +
A O -
, O +
isoliquiritigenin O -
, O +
etc O -
. O +

Chlorhydric O +
acid O +
tranditerol O +
aerosol O +
The O +
invention O +
provides O +
a O +
Tranditerol O +
Hydrochloride O +
aerosol O -
, O +
which O +
comprises O +
( O -
by O +
weight O +
ratio O -
) O +

Tranditerol O +
Hydrochloride O +
0.005 O -
- O -
0.01 O +
part O -
, O +
double O +
solvent O +
5 O -
- O -
10 O +
parts O -
, O +
and O +
propellant O +
90 O -
- O -
95 O +
parts O -
. O +

Preparation O +
method O +
of O +
dexibuprofen O +
amino O +
acid O +
salt O +
and O +
application O +
The O +
invention O +
discloses O +
a O +
nalorphine O +
amino O +
compound O +
and O +
preparing O +
method O +
with O +
structural O +
formula O +
as O +
( O -
I O -
) O -
, O +
wherein O +
the O +
amino O +
can O +
be O +
Arg O -
, O +
Lys O +
or O +
His O -
; O +
the O +
molecular O +
rate O +
of O +
nalorphine O +
and O +
amino O +
is O +
1:1 O -
- O -
1 O -
: O +
5 O +
or O +
5:1 O -
- O -
1:1 O -
. O +

Nifuratel O -
- O -
nystatin O +
vaginal O +
effervescent O -
- O -
tablets O +
The O +
invention O +
relates O +
to O +
a O +
nifungin O -
- O -
canstat O +
vagina O +
effervescent O +
tablet O -
. O +

Wherein O -
, O +
it O +
uses O +
nifungin O +
and O +
canstat O -
, O +
with O +
acid O -
- O -
alkali O +
adding O +
system O -
, O +
and O +
stuff O +
or O +
directly O +
being O +
compressed O +
into O +
tablet O +
or O +
particles O +
then O +
to O +
be O +
compressed O +
into O +
tablet O -
, O +
or O +
uses O +
macrogol O +
to O +
cover O +
the O +
alkali O -
, O +
then O +
to O +
be O +
compressed O +
into O +
tablet O -
. O +

The O +
invention O +
uses O +
the O +
acid O +
alkali O +
system O +
which O +
will O +
generate O +
carbon O +
dioxide O +
gas O +
when O +
meeting O +
water O +
as O +
slaking O +
agent O -
; O +
therefore O -
, O +
the O +
tablet O +
will O +
foam O +
and O +
slake O +
when O +
adsorbs O +
water O +
in O +
vagina O -
, O +
to O +
disperse O +
the O +
elements O +
into O +
vagina O +
completely O -
, O +
as O +
uterine O +
cervix O -
, O +
etc O -
. O +

Aromatic O +
reductive O +
derivative O +
of O +
geldanamycin O +
benzoquinone O -
, O +
preparation O +
method O +
and O +
use O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
geldanamycin O +
type O +
aromatic O +
reduced O +
benzoquinone O +
derivative O +
and O +
its O +
preparation O +
process O +
as O +
well O +
as O +
the O +
medicine O +
composition O +
with O +
the O +
compound O +
as O +
active O +
component O +
and O +
its O +
use O -
. O +

The O +
compound O +
is O +
prepared O +
through O +
fermentation O +
with O -
, O +
say O -
, O +
pseudostreptoverticillium O -
, O +
and O +
it O +
is O +
proved O +
experimentally O +
that O +
the O +
compound O +
may O +
be O +
used O +
in O +
preparing O +
cell O +
period O +
inhibitor O +
and O +
antitumor O +
preparation O -
. O +

Stomatocase O +
treating O +
medicine O +
The O +
stomatocase O +
treating O +
medicine O +
is O +
prepared O +
with O +
five O +
kinds O +
of O +
main O +
materials O -
, O +
including O +
gypsum O -
, O +
cape O +
jasmine O -
, O +
reed O +
rhizome O -
, O +
mint O +
and O +
anemarrhena O +
rhizome O -
, O +
and O +
six O +
kinds O +
of O +
supplementary O +
medicine O +
materials O -
, O +
including O +
rehmannia O +
root O -
, O +
skullcap O +
root O -
, O +
etc O -
. O +

The O +
present O +
invention O +
has O +
unique O +
recipe O -
, O +
obvious O +
treating O +
effect O +
and O +
fast O +
acting O -
. O +

Pediatric O +
paracetamol O +
artifical O +
low O -
- O -
bezoar O +
and O +
chlorphenzmine O +
maleategel O +
preparation O +
and O +
its O +
preparing O +
method O +
The O +
present O +
invention O +
relates O +
to O +
a O +
Xiaoer O +
anfenhuangnamin O +
gel O +
preparation O +
for O +
children O +
and O +
its O +
preparation O +
method O -
. O +

Said O +
gel O +
preparation O +
composition O +
contains O +
( O -
by O +
wt% O -
) O +
0.05 O -
- O -
30 O -
% O +
of O +
acetaminophen O -
, O +
0.005 O -
- O -
1 O -
% O +
of O +
artificial O +
cow O -
- O -
bezoare O -
, O +
0.0005 O -
- O -
0.08 O -
% O +
of O +
chlorpheamine O +
maleate O -
, O +
0.2 O -
- O -
10 O -
% O +
of O +
agar O -
, O +
1 O -
- O -
20 O -
% O +
of O +
cane O +
sugar O -
, O +
1 O -
- O -
10 O -
% O +
of O +
cyclodextrin O +
and O +
45 O -
- O -
90 O -
% O +
of O +
water O -
. O +

Pharmaceutical O +
use O +
of O +
ent O -
- O -
eudesmane O +
alcohol O +
type O +
sesquiterpene O +
for O +
inhibiting O +
hepatitis O +
virus O +
The O +
invention O +
relates O +
to O +
an O +
enantiomorphic O +
amine O +
alkyl O +
sesquiterpene O +
alcohol O +
and O +
glucoside O +
and O +
the O +
medicated O +
salt O +
or O +
solvent O +
thereof O -
, O +
as O +
well O +
as O +
the O +
effect O +
and O +
activity O +
of O +
the O +
composed O +
medicine O +
combination O -
, O +
mainly O +
relating O +
to O +
the O +
medical O +
use O +
in O +
reducing O +
HBV O -
- O -
DNA O +
replication O +
activity O -
. O +

And O +
it O +
has O +
considerably O +
strong O +
inhibiting O +
effect O +
on O +
HBsAG O +
screted O +
by O +
HepG2.2.15 O +
and O +
HBV O -
- O -
DNA O +
replication O +
as O +
compared O +
with O +
positive O +
contrast O +
Lamivudine O -
; O +
and O +
it O +
has O +
obvious O +
inhibition O +
activity O +
to O +
HBV O -
- O -
DNA O +
replication O +
at O +
large O +
dosage O +
( O -
100 O +
mug O -
/ O -
mL O -
) O +
and O +
medium O +
dosage O -
( O -
20 O +
mug O -
/ O -
mL O -
) O +
as O +
contrasted O +
with O +
Lamivudine O -
, O +
and O +
can O +
be O +
expected O +
to O +
apply O +
to O +
preparing O +
medicines O +
for O +
curing O +
HB O +
virus O +
infection O +
disease O -
. O +

Medical O +
usage O +
of O +
milkvetch O -
- O -
root O +
methcoside O +
An O +
application O +
of O +
astragaloside O +
A O +
in O +
preventing O +
and O +
treating O +
acute O +
or O +
chronic O +
nephritis O +
and O +
acute O +
or O +
chronic O +
renal O +
failure O -
, O +
its O +
preparing O +
process O -
, O +
and O +
its O +
medical O +
composition O +
are O +
disclosed O -
. O +

Fat O +
emulsion O +
injection O +
liquid O +
containing O +
soybean O +
oil O -
, O +
medium O +
chain O +
triglyceride O -
, O +
olive O +
oil O +
and O +
fish O +
oil O +
and O +
method O +
for O +
preparing O +
the O +
same O +
The O +
invention O +
relates O +
to O +
an O +
intralipid O +
injection O +
which O +
contains O +
soya O +
oil O -
, O +
middle O +
chain O +
triglyceride O -
, O +
olive O +
oil O -
, O +
and O +
fish O +
oil O -
, O +
wherein O +
it O +
comprises O +
48 O -
- O -
72 O -
g O -
. O +

L O +
soya O +
oil O -
, O +
48 O -
- O -
72g O -
/ O -
L O +
middle O +
chain O +
triglyceride O -
, O +
40 O -
- O -
60g O -
/ O -
L O +
olive O +
oil O -
, O +
and O +
24 O -
- O -
36g O -
/ O -
L O +
fish O +
oil O -
, O +
108 O -
- O -
162 O +
mg O -
/ O -
L O +
dl O -
- O -
alpha O -
- O -
tocofecol O -
, O +
9.6 O -
- O -
14.4g O -
/ O -
L O +
lipovitellin O -
, O +
22.5 O -
- O -
27.5g O -
/ O -
L O +
pure O +
glycerin O -
, O +
240 O -
- O -
360mg O -
/ O -
L O +
sodium O +
oleate O -
, O +
18 O -
- O -
22mg O -
/ O -
L O +
caustic O +
soda O -
, O +
and O +
1L O +
injection O +
water O -
. O +

The O +
ratio O +
between O +
w-6 O +
and O +
w-3 O +
aliphatic O +
acid O +
is O +
3.0 O -
- O -
2.2:1 O -
. O +

The O +
invention O +
optimizes O +
and O +
balances O +
the O +
aliphatic O +
acid O +
mode O -
. O +

Medicament O +
for O +
harmonizing O +
middle O +
energizer O -
, O +
invigorating O +
spleen O +
and O +
regulating O +
stomach O +
function O +
The O +
invention O +
relates O +
to O +
a O +
medicament O +
for O +
spleen O -
- O -
reinforcing O +
and O +
digestion O -
- O -
promoting O +
and O +
process O +
for O +
preparation O -
, O +
wherein O +
the O +
medicament O +
comprises O +
( O -
by O +
weight O +
ratio O -
) O +
wrinkled O +
giant O +
hyssop O +
3 O -
- O -
8 O -
, O +
cape O +
jasmine O +
2 O -
- O -
5 O -
, O +
calcium O +
sulphate O +
3 O -
- O -
8 O -
, O +
licorice O +
root O +
5 O -
- O -
10 O -
, O +
ledebouriella O +
root O +
10 O -
- O -
20 O -
, O +
ginseng O +
3 O -
- O -
8 O -
, O +
poria O +
cocos O +
wolf O +
2 O -
- O -
5 O -
, O +
white O +
atractylodes O +
rhizome O +
2 O -
- O -
5 O -
, O +
dried O +
orange O +
peel O +
2 O -
- O -
5 O -
, O +
cardamorn O +
0.1 O -
- O -
0.2 O -
, O +
clove O +
0.1 O -
- O -
0.2 O -
, O +
sulfur O +
flour O +
0.1 O -
- O -
0.2 O +
and O +
talcum O +
powder O +
0.3 O -
- O -
0.8 O -
. O +

Largngopharyngitis O +
treating O +
medicine O +
composition O +
and O +
its O +
preparation O +
The O +
medicine O +
composition O +
for O +
treating O +
laryngopharyngitis O +
is O +
prepared O +
with O +
rehmannia O +
root O +
5 O -
- O -
100 O +
weight O +
portions O -
, O +
date O +
coating O +
3 O -
- O -
100 O +
weight O +
portions O -
, O +
and O +
tortoise O +
plastron O +
5 O -
- O -
200 O +
weight O +
portions O -
. O +

The O +
preparation O +
process O +
includes O +
the O +
steps O +
of O +
decoction O -
, O +
filtering O -
, O +
concentrating O +
the O +
filtrate O +
to O +
obtain O +
paste O +
of O +
density O +
1.00 O -
- O -
1.15 O -
, O +
dissolving O +
the O +
paste O +
in O +
alcohol O -
, O +
filtering O -
, O +
concentrating O +
the O +
filtrate O +
toobtain O +
dense O +
paste O +
of O +
density O +
1.20 O -
- O -
1.50 O +
while O +
recovering O +
alcohol O -
, O +
and O +
drying O +
to O +
obtain O +
the O +
medicine O +
composition O -
. O +

The O +
medicine O +
composition O +
is O +
used O +
in O +
treating O +
laryngopharyngitis O -
, O +
and O +
has O +
high O +
safety O -
, O +
low O +
cost O -
, O +
high O +
effective O +
component O +
content O +
and O +
high O +
stability O -
. O +

Medicament O +
composition O +
of O +
cefpodoxime O +
proxetil O +
and O +
cyclodextrin O +
and O +
preparation O +
method O +
thereof O +
A O +
medication O +
compound O -
, O +
which O +
include O +
cyclodextrin O +
and O +
cephalosporin O +
ester O -
's O +
clathrate O -
; O +
this O +
invention O +
alao O +
related O +
to O +
the O +
method O +
to O +
produce O +
it O -
. O +

Cerumen O +
softening O +
agent O +
The O +
invention O +
relates O +
to O +
a O +
solvent O +
for O +
softening O +
ear O +
wax O -
, O +
which O +
is O +
prepared O +
from O +
compositions O +
of O +
sodium O +
hydrogen O +
carbonate O -
, O +
water O +
and O +
glycerine O +
through O +
specific O +
processes O -
. O +

The O +
medicament O +
provided O +
by O +
the O +
invention O +
has O +
good O +
effect O +
in O +
softening O +
ear O +
wax O -
, O +
and O +
easy O +
accessibility O +
of O +
raw O +
material O -
. O +

4-methyl O +
cyclopentadecanone O +
and O +
its O +
uses O +
The O +
invention O +
discloses O +
an O +
application O +
of O +
4-methyl O +
cyclopentadecanone O +
in O +
the O +
drug O +
of O +
ischemic O +
cerebrovascular O +
disease O -
, O +
which O +
also O +
treats O +
antirheumatic O -
, O +
rheumatoid O +
disease O +
as O +
well O +
as O +
prevent O +
tumour O -
. O +

Bra O +
technical O +
structure O +
The O +
utility O +
model O +
relates O +
to O +
a O +
bra O +
technical O +
structure O +
simple O +
in O +
structure O +
and O +
convenient O +
for O +
the O +
use O +
of O +
a O +
bra O +
or O +
bra O +
pads O +
filled O +
with O +
medicine O -
, O +
wherein O +
hollow O +
protection O +
layers O +
in O +
contact O +
with O +
the O +
breasts O +
are O +
arranged O +
on O +
the O +
bra O +
or O +
the O +
bra O +
pads O -
, O +
and O +
openings O +
corresponding O +
to O +
the O +
breasts O +
are O +
formed O +
on O +
the O +
two O +
protection O +
layers O -
; O +
medicine O +
materials O +
are O +
arranged O +
in O +
the O +
protective O +
layers O +
after O +
being O +
wrapped O +
by O +
soft O +
and O +
air O +
permeable O +
cloths O -
, O +
so O +
as O +
to O +
permeate O +
through O +
the O +
breasts O +
through O +
the O +
contact O +
between O +
the O +
openings O +
on O +
the O +
protective O +
layers O +
and O +
the O +
breast O +
skins O -
; O +
by O +
wearing O +
the O +
bra O -
, O +
the O +
skin O -
- O -
permeation O +
of O +
the O +
medicine O +
can O +
stimulate O +
the O +
hormone O +
to O +
secrete O -
, O +
and O +
can O +
preserve O +
the O +
excellent O +
shapes O +
of O +
the O +
breasts O -
; O +
in O +
addition O -
, O +
as O +
the O +
medicine O +
has O +
the O +
functions O +
of O +
anti O -
- O -
inflammatory O +
detumescence O +
and O +
blood O +
circulation O +
improvement O -
, O +
the O +
translucency O +
of O +
the O +
breasts O +
can O +
be O +
enhanced O -
, O +
the O +
lump O +
shadow O +
is O +
lessened O -
, O +
and O +
the O +
vascularity O +
gradually O +
becomes O +
normal O -
, O +
and O +
therefore O +
the O +
purposes O +
of O +
health O +
care O -
, O +
breast O +
enlarging O +
and O +
breast O +
rounding O +
and O +
firming O +
are O +
achieved O -
. O +

Drug O +
delivery O +
plaster O +
for O +
reduction O +
of O +
bleeding O +
amount O +
in O +
operation O +
In O +
order O +
to O +
solve O +
the O +
technical O +
problem O +
existing O +
in O +
the O +
process O +
of O +
delivering O +
the O +
drug O +
to O +
the O +
skin O +
for O +
reduction O +
of O +
bleeding O +
amount O +
when O +
an O +
operation O +
is O +
performed O +
at O +
present O -
, O +
the O +
utility O +
model O +
relates O +
to O +
medical O +
supplies O -
, O +
and O +
provides O +
a O +
drug O +
delivery O +
plaster O +
for O +
reduction O +
of O +
the O +
bleeding O +
amount O +
in O +
an O +
operation O -
. O +

The O +
drug O +
delivery O +
plaster O +
comprises O +
a O +
plaster O +
body O -
, O +
and O +
is O +
characterized O +
in O +
that O +
the O +
plaster O +
body O +
is O +
formed O +
by O +
three O +
layers O -
, O +
wherein O +
the O +
surface O +
layer O +
is O +
a O +
bonding O +
layer O +
with O +
viscosity O -
, O +
and O +
a O +
plurality O +
of O +
drug O +
delivery O +
holes O +
are O +
formed O +
in O +
the O +
bonding O +
layer O -
, O +
the O +
intermediate O +
layer O +
is O +
a O +
drug O +
layer O -
, O +
the O +
bottom O +
layer O +
is O +
a O +
heating O +
layer O -
, O +
and O +
heater O +
strips O +
are O +
arranged O +
in O +
the O +
heating O +
layer O -
; O +
a O +
power O +
interface O +
connected O +
with O +
an O +
external O +
power O +
supply O +
is O +
arranged O +
in O +
the O +
bottom O +
surface O +
of O +
the O +
bottom O +
layer O -
. O +

The O +
drug O +
delivery O +
plaster O +
is O +
reasonable O +
in O +
structure O -
, O +
convenient O +
to O +
use O +
and O +
high O +
in O +
drug O +
delivery O +
efficiency O -
, O +
and O +
can O +
be O +
widely O +
applied O +
to O +
surgical O +
operations O -
. O +

New O +
piperazine O +
salt O +
of O +
omeprazol O +
is O +
proton B-Gene +
pump I-Gene +
inhibitor O +
useful O +
to O +
prevent O -
/ O -
treat O +
e.g. O +
peptic O +
ulcer O -
, O +
gastritis O -
, O +
gastroesophageal O +
reflux O -
, O +
acute O +
stress O +
ulcer O +
or O +
dyspepsia O +
Piperazine O +
salt O +
( O -
I O -
) O +
of O +
omeprazole O +
or O +
its O +
enantiomer O +
is O +
new O -
. O +

An O +
independent O +
claim O +
is O +
also O +
included O +
for O +
the O +
preparation O +
of O +
( O -
I O -
) O -
. O +

- O +
ACTIVITY O +
: O +
Gastrointestinal O -
- O -
Gen O -
. O -
; O +
Antiulcer O -
; O +
Antiinflammatory O -
. O +

No O +
biological O +
data O +
given O -
. O +

- O +
MECHANISM O +
OF O +
ACTION O +
: O +
Proton O +
pump O +
inhibitor O -
. O +

No O +
biological O +
data O +
given O -
. O +

Composition O +
for O +
topical O +
application O -
, O +
useful O +
as O +
a O +
cosmetic O +
or O +
dermatological O +
product O -
, O +
contains O +
finely O +
divided O +
barium O +
sulfate O +
Composition O +
for O +
topical O +
application O +
contains O +
barium O +
sulfate O +
with O +
a O +
particle O +
size O +
of O +
1 O -
- O -
30 O +
mu O +
m. O +
An O +
independent O +
claim O +
is O +
also O +
included O +
for O +
preparing O +
a O +
composition O +
as O +
above O +
by O +
adding O +
barium O +
sulfate O +
to O +
known O +
ingredients O +
of O +
conventional O +
cosmetic O +
products O -
. O +

Cosmetic O +
or O +
dermatological O +
preparations O +
for O +
skin O +
care O +
and O +
cleaning O -
, O +
containing O +
apiogalacturonan O +
compounds O +
or O +
extracts O +
thereof O +
from O +
seaweed O -
, O +
together O +
with O +
emulsifiers O +
Preparations O +
containing O +
one O +
or O +
more O +
apiogalacturonans O +
( O -
I O -
) O +
or O +
extract O -
( O -
s O -
) O +
of O +
( O -
I O -
) O +
from O +
Zostera O +
marina O +
and O +
also O +
one O +
or O +
more O +
emulsifiers O -
. O +

Cosmetic O +
or O +
dermatological O +
preparations O +
for O +
skin O +
care O -
, O +
protection O +
and O +
cleaning O -
, O +
containing O +
apiogalacturonan O +
compounds O +
or O +
extracts O +
thereof O +
from O +
seaweed O -
, O +
together O +
with O +
UV O +
light O +
absorbers O +
Preparations O +
containing O +
one O +
or O +
more O +
apiogalacturonans O +
( O -
I O -
) O +
or O +
extract O -
( O -
s O -
) O +
of O +
( O -
I O -
) O +
from O +
Zostera O +
marina O +
and O +
also O +
one O +
or O +
more O +
UV O +
light O +
absorbers O -
. O +

Veterinary O +
rehydration O +
product O +
A O +
composition O +
for O +
the O +
treatment O +
of O +
livestock O +
suffering O +
from O +
disorders O +
such O +
as O +
fluid O +
depletion O -
, O +
acidosis O -
, O +
and O +
imbalances O +
or O +
loss O +
of O +
essential O +
electrolytes O -
, O +
same O +
to O +
be O +
made O +
up O +
in O +
water O +
at O +
point O +
of O +
use O +
as O +
an O +
oral O +
rehydration O +
formulation O -
, O +
comprises O +
an O +
intimate O +
mixture O +
of O +
an O +
energy O +
source O -
, O +
electrolytes O -
, O +
and O +
bicarbonate O +
precursors O -
, O +
which O +
precursors O +
are O +
provided O +
as O +
physiologically O +
acceptable O +
carboxylic O +
acid O +
anions O +
with O +
corresponding O +
physiologically O +
acceptable O +
cations O +
including O +
sodium O -
, O +
the O +
yield O +
of O +
bicarbonate O +
being O +
in O +
excess O +
of O +
30 O +
millimole O -
/ O -
litre O +
( O -
mmol O -
/ O -
1 O -
) O +
of O +
final O +
formulation O -
, O +
and O +
the O +
concentration O +
of O +
sodium O +
being O +
in O +
excess O +
of O +
80 O +
mmol O -
/ O -
1 O +
of O +
final O +
formulation O -
. O +

[ O -
a O -
] O -
-ANNELATED O +
PYRROLE O +
DERIVATIVES O +
AND O +
PHARMACEUTICAL O +
USES O +

THEREOF O +
The O +
present O +
invention O +
concerns O +
heterocyclic O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R1-R7 O -
, O +
B O -
, O +
a O +
and O +
X O +
have O +
the O +
meanings O +
indicated O +
in O +
the O +
description O -
. O +

These O +
compounds O +
can O +
be O +
used O +
for O +
the O +
treatment O +
of O +
rheumatic O +
ailments O +
and O +
for O +
the O +
prevention O +
of O +
allergic O +
illnesses O -
. O +

Method O +
for O +
inhibiting O +
adenylosuccinate B-Gene +
synthetase I-Gene +
activity O +
methylthioadenosine B-Gene +
phosphorylase I-Gene +
deficient O +
cells O +
An O +
in O +
vivo O +
method O +
for O +
depleting O +
mammalian O +
cells O +
of O +
adenosine O +
5'-monophosphate O +
( O -
AMP O -
) O +
useful O +
in O +
the O +
treatment O +
of O +
certain O +
cancers O +
is O +
provided O -
. O +

According O +
to O +
the O +
method O -
, O +
a O +
population O +
of O +
cells O +
is O +
obtained O +
from O +
a O +
host O +
and O +
assayed O +
for O +
loss O +
of O +
methylthioadenosine B-Gene +
phosphorylase I-Gene +
( O -
MTAse B-Gene -
) O +
activity O -
. O +

MTAse B-Gene +
catabolizes O +
methylthioadenosine O +
to O +
adenine O +
for O +
endogenous O +
salvage O +
incorporation O +
into O +
the O +
intracellular O +
AMP O +
pool O -
. O +

The O +
preferred O +
method O +
for O +
assaying O +
loss O +
of O +
MTAse B-Gene +
activity O +
is O +
a O +
hybridization O +
technique O +
for O +
detection O +
of O +
a O +
homozygous O +
loss O +
of O +
the O +
gene O +
which O +
encodes O +
with O +
a O +
therapeutically O +
effective O +
amount O +
of O +
an O +
agent O +
which O +
inhibits O +
the O +
activity O +
of O +
adenylsuccinate B-Gene +
synthetase I-Gene -
, O +
which O +
converts O +
inosine O +
5'-monophosphate O +
to O +
AMP O -
, O +
thus O +
depleting O +
the O +
tumor O +
cells O +
of O +
substrates O +
for O +
de O +
novo O +
AMP O +
production O -
. O +

L O -
- O -
alanosine O +
is O +
the O +
preferred O +
ASS B-Gene +
inhibitory O +
agent O +
for O +
use O +
in O +
the O +
method O +
of O +
the O +
invention O -
. O +

The O +
figure O +
is O +
a O +
nucleotide O +
sequence O +
for O +
genomic O +
MTAse O +
( O -
SEQ O -
. O +
ID O -
. O +

No. O +
1 O -
) O +
wherein O +
the O +
exons O +
are O +
underlined O -
. O +

Use O +
of O +
nk-1 B-Gene +
receptor I-Gene +
antagonists O +
for O +
treating O +
major O +
depressive O +
disorders O +
with O +
anxiety O +
The O +
present O +
invention O +
provides O +
the O +
use O +
of O +
an O +
orally O +
active O -
, O +
long O +
acting O -
, O +
CNS O -
- O -
penetrant O +
NK-1 B-Gene +
receptor I-Gene +
antagonist O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
adapted O +
for O +
oral O +
administration O +
for O +
the O +
treatment O +
or O +
prevention O +
of O +
major O +
depressive O +
disorder O +
with O +
anxiety O +
without O +
concomitant O +
therapy O +
with O +
other O +
anti O -
- O -
depressant O +
or O +
anti O -
- O -
anxiety O +
agents O -
, O +
methods O +
of O +
treatment O +
using O +
such O +
a O +
NK-1 B-Gene +
receptor I-Gene +
antagonist O +
and O +
pharmaceutical O +
compositions O +
comprising O +
the O +
same O -
. O +

Method O +
for O +
antagonizing O +
HEREGUlin O +
or O +
its O +
receptor O +
and O +
use O +
for O +
the O +
inhibition O +
of O +
cancer O +
cells O +
The O +
invention O +
provides O +
a O +
method O +
of O +
inhibiting O +
cancer O +
cell O +
growth O -
, O +
and O +
thereby O +
of O +
treating O +
cancer O +
comprising O +
administering O +
to O +
a O +
mammal O +
afflicted O +
with O +
cancer O +
an O +
effective O +
amount O +
of O +
the O +
compound O +
of O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
the O +
variables O +
of O +
R1+and O +
R2 O +
have O +
the O +
meanings O +
defined O +
in O +
the O +
specification O -
. O +

The O +
present O +
invention O +
also O +
provides O +
novel O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
as O +
well O +
as O +
novel O +
pharmaceutical O +
compositions O +
and O +
intermediates O +
useful O +
for O +
preparing O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
. O +

The O +
figure O +
illustrates O +
the O +
structure O +
and O +
binding O +
activity O +
of O +
compounds O +
of O +
the O +
invention O +
and O +
some O +
of O +
the O +
rifamycin O +
analogs O -
. O +

Compositions O +
and O +
methods O +
for O +
stimulating O +
bone O +
growth O +
Compounds O +
of O +
formulas O +
( O -
1 O -
) O +
and O +
( O -
2 O -
) O -
, O +
wherein O +
the O +
variables O +
of O +
X O -
, O +
Y O +
and O +
R O -
' O +
are O +
herein O +
defined O +
in O +
the O +
specification O -
, O +
promote O +
bone O +
information O +
and O +
are O +
thus O +
useful O +
in O +
treating O +
osteoporosis O -
, O +
bone O +
fracture O +
or O +
deficiency O -
, O +
primary O +
or O +
secondary O +
hyperparathyroidism O -
, O +
periodontal O +
disease O +
or O +
defect O -
, O +
metastatic O +
bone O +
disease O -
, O +
osteolytic O +
bone O +
disease O -
, O +
post O -
- O -
plastic O +
surgery O -
, O +
post O -
- O -
prosthetic O +
joint O +
surgery O -
, O +
and O +
post O -
- O -
dental O +
implantation O -
. O +

The O +
figure O +
shows O +
the O +
structure O +
and O +
activity O +
of O +
several O +
compounds O +
of O +
the O +
invention O +
namely O -
, O +
nevastatin O -
, O +
lovastatin O +
and O +
pravastatin O -
, O +
as O +
tested O +
in O +
the O +
in O +
vitro O +
BMP O -
- O -
promoter O +
based O +
assay O -
. O +

Controlled O +
release O +
compositions O +
for O +
the O +
treatment O +
of O +
hyperlipidemia O +
Lipid O +
lowering O +
dosage O +
units O -
, O +
to O +
be O +
used O +
once O +
a O +
day O -
, O +
produce O +
minimal O +
side O +
effects O -
. O +

They O +
contain O +
a O +
combination O +
of O +
microspheres O +
formulated O +
to O +
co O -
- O -
deliver O +
a O +
HMG B-Gene -
- I-Gene -
CoA I-Gene +
reductase I-Gene +
inhibitor O +
component O +
and O +
a O +
niacin O +
component O -
. O +

Beta B-Gene -
- I-Gene -
catenin I-Gene -
, O +
tcf-4 B-Gene -
, O +
and O +
apc O +
interact O +
to O +
prevent O +
cancer O +
The O +
APC B-Gene +
tumor O +
suppressor O +
protein O +
binds O +
to O +
beta B-Gene +
-catenin I-Gene -
, O +
a O +
protein O +
recently O +
shown O +
to O +
interact O +
with O +
Tcf O -
/ O -
Lef O +
transcription O +
factors O -
. O +

Here O -
, O +
the O +
gene O +
encoding O +
a O +
Tcf B-Gene +
family O +
member O +
that O +
is O +
expressed O +
in O +
colonic O +
epithelium O +
( O -
hTcf-4 B-Gene -
) O +
was O +
cloned O +
and O +
characterized O -
. O +

hTcf-4 B-Gene +
transactivates O +
transcription O +
only O +
when O +
associated O +
with O +
beta O +
-catenin O -
. O +

Nuclei O +
of O +
APC<- B-Gene -
/ O -
- O -
> O +
colon O +
carcinoma O +
cells O +
were O +
found O +
to O +
contain O +
a O +
stable O +
beta B-Gene +
-catenin I-Gene -
- O -
hTCF-4 B-Gene +
complex O +
that O +
was O +
constitutively O +
active O -
, O +
as O +
measured O +
by O +
transcription O +
of O +
a O +
Tcf B-Gene +
reporter O +
gene O -
. O +

Reintroduction O +
of O +
APC B-Gene +
removed O +
beta O +
-catenin O +
from O +
hTcf4 B-Gene +
and O +
abrogated O +
the O +
transcriptional O +
transactivation O -
. O +

Constitutive O +
transcription O +
of O +
TCF B-Gene +
target O +
genes O -
, O +
caused O +
by O +
loss O +
of O +
APC B-Gene +
function O -
, O +
may O +
be O +
a O +
crucial O +
event O +
in O +
the O +
early O +
transformation O +
of O +
colonic O +
epithelium O -
. O +

It O +
is O +
also O +
shown O +
here O +
that O +
the O +
products O +
of O +
mutant O +
APC B-Gene +
genes O +
found O +
in O +
colorectal O +
tumors O +
are O +
defective O +
in O +
regulating O +
beta B-Gene +
-catenin I-Gene -
/ O -
Tcf-4 B-Gene +
transcriptional O +
activation O -
. O +

Furthermore O -
, O +
colorectal O +
tumors O +
with O +
intact O +
APC B-Gene +
genes O +
were O +
shown O +
to O +
contain O +
subtle O +
activating O +
mutations O +
of O +
beta B-Gene +
-catenin I-Gene +
that O +
altered O +
functionally O +
significant O +
phosphorylation O +
sites O -
. O +

These O +
results O +
indicate O +
that O +
regulation O +
of O +
beta B-Gene +
-catenin I-Gene +
is O +
critical O +
to O +
APC O -
's O +
tumor O +
suppressive O +
effect O +
and O +
that O +
this O +
regulation O +
can O +
be O +
circumvented O +
by O +
mutations O +
in O +
either O +
APC B-Gene +
or O +
beta B-Gene +
-catenin I-Gene -
. O +

A O +
method O +
of O +
modulating O +
an O +
immune O +
response O +
in O +
an O +
infected O +
mammal O +
by O +
transmucosal O +
administration O +
of O +
modulating O +
agent O +
Methods O +
and O +
compositions O +
for O +
modulating O +
an O +
immune O +
response O +
in O +
a O +
mammal O +
infected O +
with O +
a O +
bacterium O -
, O +
a O +
virus O -
, O +
or O +
a O +
parasite O +
are O +
provided O -
. O +

The O +
methods O +
and O +
compositions O +
are O +
useful O +
in O +
mammals O +
experiencing O +
an O +
acute O +
infection O +
and O +
in O +
mammals O +
experiencing O +
a O +
chronic O +
infection O -
. O +

The O +
methods O +
and O +
compositions O +
may O +
be O +
used O +
in O +
conjunction O +
with O +
a O +
known O +
treatment O +
for O +
infection O +
of O +
a O +
mammal O +
by O +
an O +
infectious O +
agent O -
. O +

Methods O +
and O +
compositions O +
for O +
transmucosal O +
delivery O +
of O +
a O +
molecule O +
comprising O +
an O +
epitope O +
located O +
in O +
close O +
proximity O +
to O +
the O +
immune O +
response O +
are O +
provided O -
. O +

C-4''-substituted O +
macrolide O +
derivatives O +
This O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
1 O -
) O +
and O +
to O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

The O +
compounds O +
of O +
formula O +
( O -
1 O -
) O +
are O +
potent O +
antibacterial O +
agents O +
that O +
may O +
be O +
used O +
to O +
treat O +
various O +
bacterial O +
infections O +
and O +
disorders O +
related O +
to O +
such O +
infections O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
containing O +
the O +
compounds O +
of O +
formula O +
( O -
1 O -
) O +
and O +
to O +
methods O +
of O +
treating O +
bacterial O +
infections O +
by O +
administering O +
the O +
compounds O +
of O +
formula O +
( O -
1 O -
) O -
. O +

The O +
invention O +
also O +
relates O +
to O +
methods O +
of O +
preparing O +
the O +
compounds O +
of O +
formula O +
( O -
1 O -
) O +
and O +
to O +
intermediates O +
useful O +
in O +
such O +
preparation O -
. O +

Crystalline O +
macrolides O +
and O +
process O +
for O +
their O +
preparation O +
33-Epichloro-33-desoxyascomycin O +
of O +
formula O +
( O -
I O -
) O +
and O +
various O +
tautomeric O +
or O +
solvated O +
forms O +
thereof O -
, O +
in O +
crystalline O +
form O -
, O +
such O +
as O +
Form O +
A O +
and O +
Form O +
B. O +
Their O +
preparation O +
involves O +
appropriately O +
converting O +
amorphous O +
compound O +
of O +
formula O +
( O -
I O -
) O -
, O +
or O +
compound O +
of O +
formula O +
( O -
I O -
) O +
in O +
other O +
than O +
Form O +
A O -
, O +
or O +
compound O +
of O +
formula O +
( O -
I O -
) O +
in O +
other O +
than O +
Form O +
B O -
, O +
respectively O -
, O +
from O +
a O +
solution O +
thereof O +
under O +
crystallization O -
- O -
inducing O +
conditions O +
or O +
conditions O +
inducing O +
preferential O +
crystallization O +
of O +
Form O +
A O +
or O +
B O -
, O +
respectively O -
. O +

Such O +
crystals O +
are O +
particularly O +
indicated O +
for O +
use O +
in O +
the O +
preparation O +
of O +
topical O +
galenical O +
forms O +
of O +
the O +
compound O +
for O +
pharmaceutical O +
use O -
, O +
e.g. O +
creams O -
, O +
emulsions O +
and O +
ointments O -
. O +

Use O +
of O +
taurolidine O +
or O +
taurultam O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
the O +
prevention O +
of O +
metastases O +
The O +
invention O +
provides O +
the O +
use O +
of O +
taurolidine O +
or O +
taurultam O +
solutions O +
to O +
prevent O +
or O +
reduce O +
metastatic O +
growth O -
. O +

This O +
is O +
of O +
particular O +
application O +
in O +
preventing O +
or O +
reducing O +
the O +
incidence O +
of O +
metastatic O +
growth O +
following O +
surgery O -
, O +
particularly O +
following O +
the O +
use O +
of O +
trocars O +
during O +
minimal O +
invasive O +
laparoscopic O +
surgery O -
. O +

metal O +
complexes O +
with O +
antibacterian O +
and O +
fungicidal O +
effects O +
Invented O +
are O +
zinc O +
chelated O +
G B-Gene -
- I-Gene -
CSF I-Gene +
receptor I-Gene +
ligands O -
, O +
pharmaceutical O +
compositions O +
containing O +
these O +
compounds O -
, O +
and O +
methods O +
of O +
using O +
these O +
compounds O +
as O +
agonist O +
of O +
the O +
G B-Gene -
- I-Gene -
CSF I-Gene +
receptor I-Gene -
. O +

Also O +
invented O +
are O +
novel O +
processes O +
used O +
in O +
preparing O +
these O +
compounds O -
. O +

Also O +
invented O +
are O +
novel O +
G B-Gene -
- I-Gene -
CSF I-Gene +
receptor I-Gene +
binding O +
moieties O +
of O +
the O +
invented O +
zinc O +
chelated O +
G B-Gene -
- I-Gene -
CSF I-Gene +
receptor I-Gene +
ligands O -
. O +

Novel O +
optically O +
active O +
aminopentane O +
derivative O +
Novel O +
compounds O +
involving O +
optically O +
pure O +
( O -
- O -
) O -
-1- O -
( O -
benzofuran-2-yl O -
) O -
-2-propylaminopentane O +
represented O +
by O +
formula O +
( O -
I O -
) O -
, O +
which O +
is O +
substantially O +
free O +
from O +
the O +
( O -
+ O -
) O -
-isomer O +
and O +
pharmacologically O +
acceptable O +
acid O +
addition O +
salts O +
thereof O -
. O +

Because O +
of O +
being O +
excellent O +
in O +
the O +
effect O +
of O +
regulatively O +
enhancing O +
neurotransmitters O +
catecholamines O +
( O -
i.e. O -
, O +
CAE O +
( O -
Catecholaminergic O +
Activity O +
Enhancer O -
) O +
effect O -
) O -
, O +
these O +
compounds O +
are O +
useful O +
as O +
psychotropic O +
drugs O +
and O +
remedies O +
for O +
Parkinson O -
's O +
disease O -
, O +
depression O +
and O +
Alzheimer O -
's O +
disease O -
. O +

Thyroid O +
hormone O +
analogues O +
and O +
methods O +
for O +
their O +
preparation O +
Thyroid O +
hormone O +
analogues O +
are O +
disclosed O -
. O +

Methods O +
of O +
using O +
such O +
analogues O +
and O +
pharmaceutical O +
compositions O +
containing O +
them O +
are O +
also O +
disclosed O -
, O +
as O +
are O +
novel O +
procedures O +
for O +
their O +
preparation O -
. O +

Use O +
of O +
citrate O +
in O +
a O +
catheter O +
lock O +
solution O +
This O +
invention O +
relates O +
to O +
an O +
infusion O +
device O +
for O +
a O +
catheter O +
lock O +
solution O -
, O +
to O +
a O +
method O +
of O +
enhancing O +
the O +
patency O +
of O +
catheters O +
in O +
animals O +
and O +
to O +
a O +
catheter O +
lock O +
solution O -
. O +

The O +
device O +
includes O +
a O +
syringe O +
( O -
34 O -
) O +
containing O +
a O +
lock O +
solution O +
comprising O +
a O +
citrate O +
salt O -
. O +

The O +
method O +
for O +
enhancing O +
the O +
patency O +
of O +
catheters O +
includes O +
infusing O +
a O +
lumen O +
( O -
14 O -
, O +
16 O -
) O +
of O +
an O +
indwelling O +
catheter O +
( O -
10 O -
) O +
with O +
a O +
lock O +
solution O +
comprising O +
a O +
citrate O +
salt O -
. O +

In O +
one O +
aspect O +
of O +
the O +
invention O -
, O +
the O +
catheter O +
lock O +
solution O +
includes O +
a O +
citrate O +
salt O +
and O +
a O +
viscosifying O +
agent O -
. O +

The O +
lock O +
solution O +
is O +
prepared O +
to O +
have O +
sufficient O +
viscosity O +
and O +
density O +
to O +
remain O +
in O +
the O +
lumen O +
for O +
a O +
desired O +
amount O +
of O +
time O -
. O +

Nucleic O +
acid O +
constructs O +
for O +
genetic O +
immunisation O +
Recombinant O +
nucleic O +
acid O +
molecules O +
are O +
described O -
. O +

The O +
molecules O +
have O +
a O +
first O +
sequence O +
encoding O +
a O +
Hepatitis B-Gene +
B I-Gene +
virus I-Gene +
core I-Gene +
antigen I-Gene +
and O +
a O +
second O +
sequence O +
encoding O +
at O +
least O +
one O +
T O +
cell O +
epitope O +
inserted O +
within O +
the O +
first O +
sequence O -
. O +

Vectors O +
and O +
compositions O +
containing O +
these O +
molecules O +
are O +
also O +
described O -
. O +

Methods O +
of O +
eliciting O +
an O +
immune O +
response O +
using O +
these O +
molecules O +
are O +
also O +
described O -
. O +

Chlamydia O +
antigen O +
and O +
corresponding O +
dna O +
fragments O +
and O +
uses O +
thereof O +
In O +
summary O +
of O +
this O +
disclosure O -
, O +
the O +
present O +
invention O +
provides O +
a O +
method O +
of O +
nucleic O +
acid O -
, O +
including O +
DNA O -
, O +
immunization O +
of O +
a O +
host O -
, O +
including O +
humans O -
, O +
against O +
disease O +
caused O +
by O +
infection O +
by O +
a O +
strain O +
of O +
Chlamydia O -
, O +
specifically O +
DOLLAR O +
I O -
( O -
C. O +
pneumoniae O -
) O -
, O +
employing O +
a O +
vector O -
, O +
containing O +
a O +
nucleotide O +
sequence O +
encoding O +
an O +
POMP91B O +
precursor O +
protein O +
of O +
a O +
strain O +
of O +
DOLLAR O +
I O -
( O -
Chlamydia O +
pneumoniae O -
) O +
and O +
a O +
promoter O +
to O +
effect O +
expression O +
of O +
the O +
POMP91B O +
precursor O +
gene O +
in O +
the O +
host O -
. O +

Modifications O +
are O +
possible O +
within O +
the O +
scope O +
of O +
this O +
invention O -
. O +

Inhibitors O +
of O +
c B-Gene -
- I-Gene -
jun I-Gene +
n I-Gene -
- I-Gene -
terminal I-Gene +
kinases I-Gene +
( O -
jnk B-Gene -
) O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
or O +
( O -
II O -
) O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
derivative O +
or O +
prodrug O +
thereof O -
; O +
wherein O +
Y O +
is O +
selected O +
from O +
- O -
( O -
CH2 O -
) O -
-Q1 O -
; O +
- O -
( O -
CO O -
) O -
-Q1 O -
; O +
- O -
( O -
CO O -
) O -
NH O -
- O -
Q1 O -
; O +
- O -
( O -
CO O -
) O -
-O O -
- O -
Q1 O -
; O +
- O -
( O -
SO2 O -
) O -
-Q1 O +
or O +
- O -
( O -
SO2 O -
) O -
NH O -
- O -
Q1 O -
; O +
Q1 O +
is O +
a O +
C1-C6 O +
straight O +
chain O +
or O +
branched O +
alkyl O +
or O +
alkenyl O +
group O -
; O +
a O +
5 O -
- O -
7 O +
membered O +
aromatic O +
or O +
non O -
- O -
aromatic O +
carbocyclic O +
or O +
heterocyclic O +
ring O -
; O +
or O +
a O +
9 O -
- O -
14 O +
membered O +
bicyclic O +
or O +
tricyclic O +
aromatic O +
or O +
non O -
- O -
aromatic O +
carbocyclic O +
or O +
heterocyclic O +
ring O +
system O -
, O +
W O +
is O +
N O +
or O +
C O -
; O +
Z O +
is O +
CH O +
or O +
N O -
, O +
which O +
are O +
inhibitors O +
of O +
JNK B-Gene -
, O +
a O +
mammalian O +
protein O +
kinase B-Gene +
involved O +
cell O +
proliferation O -
, O +
cell O +
death O +
and O +
response O +
to O +
extracellular O +
stimuli O -
. O +

The O +
invention O +
also O +
relates O +
to O +
methods O +
for O +
producing O +
these O +
inhibitors O -
. O +

The O +
invention O +
also O +
provides O +
pharmaceutical O +
compositions O +
comprising O +
the O +
inhibitors O +
of O +
the O +
invention O +
and O +
methods O +
of O +
utilizing O +
those O +
compositions O +
in O +
the O +
treatment O +
and O +
prevention O +
of O +
various O +
disorders O -
. O +

Screening O +
methods O +
for O +
compounds O +
which O +
affect O +
melanogenesis O +
Methods O +
of O +
screening O +
for O +
compounds O +
that O +
affect O +
melanogenesis O +
and O +
the O +
function O +
of O +
P B-Gene +
protein I-Gene +
in O +
organisms O -
, O +
cells O -
, O +
or O +
cell O -
- O -
free O +
systems O +
are O +
provided O -
. O +

The O +
invention O +
further O +
relates O +
to O +
the O +
pharmacologic O +
and O +
cosmetic O +
uses O +
of O +
such O +
compounds O +
to O +
reduce O +
or O +
increase O +
the O +
synthesis O +
of O +
melanin O +
in O +
animal O +
and O +
human O +
melanocytes O +
and O +
melanocyte O -
- O -
derived O +
cells O -
. O +

AMINO O +
SUBSTITUTED O +
PYRAZOLOÂ¬1,5-a|-1,5-PYRIMIDINES O +
AND O +
PYRAZOLOÂ¬1,5-a|-1,3,5-TRIAZINES O +
Disclosed O +
are O +
compounds O +
of O +
the O +
formula O -
: O +
( O -
I O -
) O -
, O +
where O +
R?1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
Â¿ O -
, O +
and O +
X O +
are O +
defined O +
herein O -
. O +

These O +
compounds O +
are O +
selective O +
modulators O +
of O +
NPY1 B-Gene +
receptors I-Gene -
. O +

These O +
compounds O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
a O +
number O +
of O +
CNS O +
disorders O -
, O +
metabolic O +
disorders O -
, O +
and O +
peripheral O +
disorders O -
, O +
particularly O +
eating O +
disorders O +
and O +
hypertension O -
. O +

Methods O +
of O +
treatment O +
of O +
such O +
disorders O +
as O +
well O +
as O +
packaged O +
pharmaceutical O +
compositions O +
are O +
also O +
provided O -
. O +

Compounds O +
of O +
the O +
invention O +
are O +
also O +
useful O +
as O +
probes O +
for O +
the O +
localization O +
of O +
NPY1 B-Gene +
receptors I-Gene +
and O +
as O +
standards O +
in O +
assays O +
for O +
NPY1 B-Gene +
receptor I-Gene +
binding O -
. O +

Methods O +
of O +
using O +
the O +
compounds O +
in O +
receptor O +
localization O +
studies O +
are O +
given O -
. O +

Use O +
of O +
the O +
residues O +
from O +
wine O +
production O +
The O +
use O +
of O +
the O +
residues O +
from O +
wine O +
production O +
as O +
active O +
substance O +
preparations O +
in O +
the O +
production O +
of O +
cosmetic O +
and/or O +
pharmaceutical O +
preparations O +
is O +
disclosed O -
. O +

Pharmaceutical O +
preparation O +
containing O +
cytostatic O +
agents O +
and O +
electron O +
acceptors O +
for O +
treating O +
tumor O +
diseases O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
preparation O +
containing O +
at O +
least O +
one O +
active O +
substance O +
that O +
is O +
cytostatically O +
active O -
, O +
at O +
least O +
one O +
biological O +
electron O +
acceptor O -
, O +
and O +
the O +
customary O +
pharmaceutical O +
additives O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
said O +
preparation O +
for O +
treating O +
tumor O +
diseases O -
, O +
in O +
particular O -
, O +
for O +
treating O +
cancer O -
. O +

Novel O +
stromelysin B-Gene +
inhibitors O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
which O +
are O +
suitable O +
for O +
the O +
production O +
of O +
medicaments O +
for O +
the O +
treatment O +
and O +
prophylaxis O +
of O +
diseases O -
, O +
in O +
which O +
an O +
increased O +
activity O +
of O +
matrix B-Gene -
- I-Gene -
degrading I-Gene +
enzymes I-Gene -
, O +
in O +
particular O -
, O +
stromelysin B-Gene -
, O +
are O +
implicated O -
. O +

New O +
gamma O +
selective O +
retinoids O +
New O +
RAR O +
selective O +
retinoid O +
agonists O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
the O +
symbols O +
are O +
as O +
defined O +
in O +
the O +
specification O -
, O +
and O +
pharmaceutically O +
active O +
salts O +
of O +
carboxylic O +
acids O +
of O +
formula O +
( O -
I O -
) O -
, O +
further O +
the O +
invention O +
relates O +
to O +
the O +
use O +
of O +
such O +
retinoic B-Gene +
acid I-Gene +
receptor I-Gene +
agonists O -
, O +
particularly O +
retinoic B-Gene +
acid I-Gene +
receptor I-Gene +
Î· I-Gene -
( O -
RARÎ· B-Gene -
) O +
selective O +
agonists O +
for O +
the O +
treatment O +
of O +
emphysema O +
and O +
associated O +
pulmonary O +
diseases O -
, O +
as O +
well O +
as O +
for O +
the O +
therapy O +
and O +
prophylaxis O +
of O +
dermatological O +
disorders O -
, O +
for O +
the O +
therapy O +
and O +
prophylaxis O +
of O +
malignant O +
and O +
premalignant O +
epithelial O +
lesions O -
, O +
tumours O +
and O +
precancerous O +
changes O +
of O +
the O +
mucous O +
membrane O +
in O +
the O +
mouth O -
, O +
tongue O -
, O +
larynx O -
, O +
oesophagus O -
, O +
bladder O -
, O +
cervix O +
and O +
colon O -
. O +

Method O +
for O +
preparing O +
a O +
fatty O +
substance O +
ester O +
and O +
use O +
thereof O +
in O +
pharmaceutics O -
, O +
cosmetics O +
or O +
food O +
industry O +

The O +
invention O +
concerns O +
a O +
method O +
for O +
preparing O +
a O +
fatty O +
substance O +
ester O -
, O +
characterised O +
in O +
that O +
it O +
consists O +
in O +
subjecting O +
to O +
an O +
esterification O +
reaction O +
at O +
least O +
a O +
fatty O +
substance O +
with O +
at O +
least O +
an O +
alcohol O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
sterols O -
, O +
stanols O -
, O +
4-methylsterols O +
and O +
their O +
hydrogenated O +
homologues O -
, O +
triterpene O +
alcohols O +
and O +
their O +
hydrogenated O +
homologues O -
, O +
and O +
mixtures O +
thereof O -
, O +
in O +
the O +
presence O +
of O +
at O +
least O +
a O +
solid O +
catalyst O +
selected O +
in O +
the O +
group O +
consisting O +
of O +
lanthanide O +
oxides O +
and O +
the O +
mixtures O +
of O +
said O +
oxides O -
. O +

Said O +
method O +
enables O +
to O +
obtain O +
products O +
particularly O +
suited O +
for O +
use O +
in O +
the O +
field O +
of O +
pharmaceutics O -
, O +
in O +
particular O +
dermatology O -
, O +
cosmetics O +
and O +
special O +
food O +
production O +
( O -
functional O +
food O +
products O -
, O +
medicinal O +
food O +
products O +
and O +
dietetic O +
food O +
products O -
) O +

Tetrazole O +
derivatives O +
The O +
present O +
invention O +
is O +
concerned O +
with O +
2H O -
- O -
tetrazole-5-yl O -
- O -
amide O +
derivatives O +
of O +
general O +
formula O +
( O -
I O -
) O +
wherein O +
R1 O +
signifies O +
hydrogen O -
, O +
lower O +
alkyl O -
, O +
- O -
( O -
CHÂ¿2? O -
) O -
n O -
- O -
CF3 O -
, O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
CHF2 O -
, O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
CN O -
, O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
cycloalkyl O -
, O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
O O -
- O -
lower O +
alkyl O -
, O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
O O -
- O -
cycloalkyl O +
or O +
- O -
( O -
CH2 O -
) O -
n O -
- O -
C O -
( O -
O O -
) O -
O O -
- O -
lower O +
alkyl O -
; O +
R?2 O -
Â¿ O +
signifies O +
hydrogen O -
, O +
lower O +
alkyl O -
, O +
lower O +
alkoxy O -
, O +
halogen O -
, O +
-C O -
( O -
O O -
) O -
-lower O +
alkyl O -
, O +
-C O -
( O -
O O -
) O -
OH O -
, O +
-C O -
( O -
O O -
) O -
O O -
- O -
lower O +
alkyl O -
, O +
-NR3R4 O +
or O +
-C O -
( O -
O O -
) O -
-NR3R4 O +
and O +
wherein O +
R?3 O +
and O +
R4 O -
Â¿ O +
may O +
be O +
independently O +
from O +
each O +
other O +
hydrogen O +
or O +
lower O +
alkyl O -
; O +
X O +
signifies O +
-O- O -
, O +
-S- O -
, O +
-CHÂ¿2 O -
? O -
, O +
-OCH2- O +
or O +
two O +
hydrogen O +
atoms O +
not O +
forming O +
a O +
bridge O -
; O +
and O +
n O +
signifies O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O -
; O +
as O +
well O +
as O +
with O +
their O +
pharmaceutically O +
acceptable O +
salts O -
. O +

It O +
has O +
been O +
found O +
that O +
the O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
are O +
group B-Gene +
1 I-Gene +
metabotropic I-Gene +
glutamate I-Gene +
receptor I-Gene +
agonists O +
( O -
mGluR B-Gene -
) O +
and O +
are O +
therefore O +
useful O +
in O +
the O +
treatment O +
of O +
corresponding O +
CNS O -
- O -
disorders O -
. O +

Masp-2 B-Gene -
, O +
a O +
complement O -
- O -
fixing O +
enzyme O -
, O +
and O +
uses O +
for O +
it O +
The O +
present O +
invention O +
relates O +
to O +
substantially O +
pure O +
mannin B-Gene -
- I-Gene -
binding I-Gene +
lectin I-Gene +
associated I-Gene +
serine I-Gene +
protease-2 I-Gene +
( O -
MASP-2 B-Gene -
) O +
polypeptides O +
and O +
fragments O +
thereof O +
as O +
well O +
as O +
nucleic O +
acids O +
encoding O +
such O +
polpeptides O -
. O +

Futhermone O -
, O +
the O +
present O +
invention O +
realates O +
to O +
uses O +
of O +
a O +
substantially O +
pure O +
polypeptide O +
comprising O +
amino O +
acid O +
sequences O +
derived O +
from O +
mannan B-Gene -
- I-Gene -
binding I-Gene +
lectin I-Gene +
associated I-Gene +
serine I-Gene +
protease-2 I-Gene +
( O -
MASP2 B-Gene -
) O +
or O +
a O +
functional O +
homologue O +
thereof O +
for O +
the O +
production O +
of O +
a O +
pharmaceutical O +
composition O +
as O +
well O +
as O +
pharmaceutical O +
compositons O +
comprising O +
MASP-2 B-Gene +
and/or O +
MASP-2 B-Gene +
fragments O -
. O +

In O +
addition O +
the O +
present O +
invetion O +
relates O +
to O +
inhibitors O +
of O +
MASP-2 B-Gene +
and O +
pharmaceutical O +
compositiosn O +
compring O +
such O +
inhibitors O -
. O +

Methods O +
for O +
detecting O +
MASP-2 B-Gene +
nucleic O +
acid O +
expression O +
are O +
included O +
in O +
the O +
invention O -
. O +

Antisense O +
modulation O +
of O +
clusterin O +
expression O +
Antisense O +
compounds O -
, O +
compositions O +
and O +
methods O +
are O +
provided O +
for O +
modulating O +
the O +
expression O +
of O +
clusterin O -
. O +

The O +
compositions O +
comprise O +
antisense O +
compounds O -
, O +
particularly O +
antisense O +
oligonucleotides O -
, O +
targeted O +
to O +
nucleic O +
acids O +
encoding O +
clusterin O -
. O +

Methods O +
of O +
using O +
these O +
compounds O +
for O +
modulation O +
of O +
clusterin O +
expression O +
and O +
for O +
treatment O +
of O +
diseases O +
associated O +
with O +
expression O +
of O +
clusterin O +
are O +
provided O -
. O +

Macrolide O +
antibiotics O +
The O +
present O +
invention O +
relates O +
to O +
11,12 O +
gamma O +
lactone O +
ketolides O +
of O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R O -
, O +
R<1 O -
> O -
, O +
R<2 O -
> O +
and O +
R<3 O -
> O +
are O +
as O +
defined O +
herein O +
and O +
pharmaceutically O +
acceptable O +
salts O +
and O +
solvates O +
thereof O -
, O +
to O +
process O +
for O +
their O +
preparation O +
and O +
their O +
use O +
in O +
therapy O +
or O +
prophylaxis O +
of O +
systemic O +
or O +
topical O +
bacterial O +
infections O +
in O +
a O +
human O +
or O +
animal O +
body O -
. O +

Promoting O +
cell O +
regeneration O +
and/or O +
cell O +
differentiation O +
with O +
non O -
- O -
metabolizable O +
sugar O +
and O +
a O +
polymeric O +
absorbent O +
The O +
invention O +
concerns O +
the O +
use O +
of O +
a O +
combination O +
comprising O +
at O +
least O +
an O +
absorbent O +
and O +
at O +
least O +
a O +
compound O +
selected O +
among O +
the O +
group O +
consisting O +
of O +
non O -
- O -
metabolizable O +
sugars O +
and O +
polyols O +
for O +
preparing O +
a O +
composition O -
, O +
in O +
particular O +
medicinal O -
, O +
for O +
promoting O +
cell O +
regeneration O +
and/or O +
cell O +
differentiation O -
. O +

Use O +
of O +
er B-Gene -
- I-Gene -
beta I-Gene +
selective O +
antagonists O +
as O +
contraceptives O +
The O +
present O +
invention O +
discloses O +
the O +
use O +
of O +
ERSS O -
- O -
selective O +
ligands O +
for O +
production O +
of O +
medicaments O +
for O +
regulating O +
fertility O +
without O +
additional O +
use O +
of O +
a O +
progestin O -
. O +

ERSS O -
- O -
agonists O +
are O +
used O +
for O +
treatment O +
of O +
infertility O +
and O +
ERSS O -
- O -
antagonists O +
for O +
contraception O -
. O +

Sapogenin O +
derivatives O -
, O +
their O +
synthesis O +
and O +
use O +
The O +
invention O +
discloses O +
certain O +
steroidal O +
sapogenins O +
and O +
derivatives O +
thereof O -
, O +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
cognitive O +
dysfunction O -
, O +
non O -
- O -
cognitive O +
neurodegeneration O -
, O +
non O -
- O -
cognitive O +
neuromuscular O +
degeneration O -
, O +
and O +
receptor O +
loss O +
in O +
the O +
absence O +
of O +
cognitive O -
, O +
neural O +
and O +
neuromuscular O +
impairment O -
. O +

Methods O +
of O +
synthesis O -
, O +
treatment O +
and O +
pharmaceutical O +
compositions O +
are O +
also O +
disclosed O -
. O +

PHARMACEUTICAL O +
COMPOSITIONS O +
FOR O +
THE O +
COORDINATED O +
DELIVERY O +
OF O +
NSAIDs O +
The O +
present O +
invention O +
is O +
directed O +
to O +
drug O +
dosage O +
forms O +
that O +
release O +
an O +
agent O +
that O +
raises O +
the O +
pH O +
of O +
a O +
patient O -
's O +
gastrointestinal O +
tract O -
, O +
followed O +
by O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
. O +

The O +
dosage O +
form O +
is O +
designed O +
so O +
that O +
the O +
NSAID O +
is O +
not O +
released O +
until O +
the O +
intragastric O +
pH O +
has O +
been O +
raised O +
to O +
a O +
safe O +
level O -
. O +

The O +
invention O +
also O +
encompasses O +
methods O +
of O +
trating O +
patients O +
by O +
administering O +
this O +
coordinated O +
release O -
, O +
gastroprotective O -
, O +
antiarthitic O -
/ O -
analgesic O +
combination O +
unit O +
dosage O +
form O +
to O +
achieve O +
pain O +
and O +
symptom O +
relief O +
with O +
a O +
reduced O +
risk O +
of O +
developing O +
gastrointestinal O +
damage O +
such O +
as O +
ulcers O -
, O +
erosions O +
and O +
hemorrhages O -
. O +

Improved O +
pharmaceutical O +
composition O +
containing O +
a O +
ppar B-Gene +
alpha I-Gene +
agent O +
and O +
a O +
process O +
for O +
preparing O +
it O +
Oral O +
semi O -
- O -
solid O +
or O +
liquid O +
composition O +
for O +
treating O +
hyperlipidemia O +
or O +
hypercholesterolemia O +
in O +
humans O -
, O +
which O +
comprises O +
at O +
least O +
an O +
effective O +
amount O +
of O +
peroxisome B-Gene +
proliferator I-Gene +
activated I-Gene +
receptor I-Gene +
alpha I-Gene +
agent O +
( O -
PPARa B-Gene -
) O -
, O +
one O +
polyglycolized O +
glyceride O +
and O +
one O +
hydrophilic O +
disintegrating O +
agent O -
. O +

Pharmaceutical O +
formulations O +
for O +
the O +
controlled O +
release O +
of O +
4-amino-6,7-dimethoxy-2- O -
( O -
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl O -
) O -
-5- O -
( O -
2-pyridyl O -
) O -
quinazoline O +
The O +
invention O +
provides O +
a O +
controlled O -
- O -
release O +
pharmaceutical O +
formulation O +
for O +
oral O +
administration O +
comprising O +
4-amino-6,7-dimethoxy-2- O -
( O -
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl O -
) O -
-5- O -
( O -
2-pyridyl O -
) O -
quinazoline O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
; O +
and O +
a O +
pharmaceutically O +
acceptable O +
adjuvant O -
, O +
diluent O +
or O +
carrier O -
; O +
characterized O +
in O +
that O +
the O +
formulation O +
is O +
adapted O +
to O +
release O +
at O +
least O +
50 O -
% O +
by O +
weight O +
of O +
the O +
4-amino-6,7-dimethoxy-2- O -
( O -
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl O -
) O -
-5- O -
( O -
2-pyridyl O -
) O -
-quinazoline O -
, O +
or O +
the O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
after O +
6 O +
hours O +
in O +
Apparatus O +
1 O +
described O +
in O +
the O +
United O +
States O +
Pharmacopoeia O +
24 O +
( O -
2000 O -
) O -
, O +
pp O +
1941 O -
- O -
1943 O -
, O +
having O +
1 O +
litre O +
vessels O -
, O +
baskets O +
of O +
40 O +
mesh O +
( O -
0.4 O +
mm O +
apertures O -
) O -
, O +
a O +
rotation O +
speed O +
of O +
100 O +
rpm O -
, O +
and O +
a O +
dissolution O +
medium O +
consisting O +
of O +
900 O +
ml O +
of O +
0.01 O +
M O +
hydrochloric O +
acid O +
containing O +
0.7 O -
% O +
w O -
/ O -
v O +
sodium O +
chloride O +
at O +
37 O +
DEG O +
C. O +
Formulations O +
according O +
to O +
the O +
invention O +
are O +
suitable O +
for O +
the O +
treatment O +
of O +
BPH O -
. O +

Oxadiazoles O +
having O +
antiproliferative O +
activity O +
Oxadiazole O +
derivatives O +
of O +
general O +
formula O +
( O -
1 O -
) O +
in O +
which O +
X O -
, O +
Y O -
, O +
R O +
and O +
R2 O +
have O +
the O +
meanings O +
defined O +
in O +
the O +
disclosure O -
. O +

The O +
compounds O +
have O +
antiproliferative O +
activity O +
against O +
a O +
number O +
of O +
human O +
tumors O +
cell O +
lines O +
and O +
can O +
therefore O +
be O +
used O +
for O +
the O +
preparation O +
of O +
antitumor O +
medicaments O -
. O +

Pharmaceutical O +
composition O +
that O +
is O +
used O +
to O +
control O +
blood O +
glucose O +
in O +
patients O +
with O +
type O +
2 O +
diabetes O +
The O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
active O +
glimepiride O +
and O +
metformin O +
substances O +
or O +
the O +
salts O +
thereof O -
, O +
such O +
as O +
hydrochloride O -
, O +
succinate O -
, O +
fumarate O -
, O +
etc O -
. O -
, O +
which O +
are O +
used O +
to O +
control O +
blood O +
glucose O +
in O +
patients O +
with O +
type O +
2 O +
diabetes O -
. O +

Clinical O +
studies O -
, O +
which O +
were O +
carried O +
out O +
in O +
order O +
to O +
demonstrate O +
the O +
effectiveness O +
of O +
said O +
combination O -
, O +
have O +
shown O +
that O +
the O +
effect O +
produced O +
by O +
the O +
two O +
drugs O +
is O +
not O +
only O +
additive O +
but O +
also O +
synergetic O +
in O +
comparison O +
with O +
the O +
monotherapy O +
which O +
uses O +
only O +
one O +
of O +
the O +
drugs O +
from O +
the O +
combination O -
. O +

As O +
a O +
result O -
, O +
the O +
use O +
of O +
said O +
combination O +
is O +
suggested O +
as O +
an O +
effective O +
and O +
safe O +
therapy O +
for O +
the O +
control O +
of O +
blood O +
glucose O +
in O +
patients O +
with O +
type O +
2 O +
diabetes O -
. O +

According O +
to O +
the O +
invention O -
, O +
different O +
proportions O +
of O +
the O +
active O +
substances O +
can O +
be O +
used O +
so O +
that O +
the O +
combination O +
suits O +
the O +
different O +
requirements O +
of O +
each O +
patient O -
. O +

Delivery O +
of O +
solid O +
drug O +
compositions O +
This O +
invention O +
relates O +
to O +
the O +
parenteral O +
administration O +
of O +
solid O +
drug O +
compositions O -
. O +

In O +
particular O -
, O +
this O +
invention O +
relates O +
to O +
a O +
syringe O -
- O -
like O +
device O +
for O +
delivering O +
solid O +
drug O +
cylinders O +
including O +
a O +
syringe O +
barrel O -
, O +
a O +
needle O -
, O +
and O +
a O +
microplunger O +
and O +
piston O +
assembly O -
, O +
wherein O +
said O +
microplunger O +
pushes O +
said O +
solid O +
drug O +
cylinder O +
out O +
of O +
said O +
needle O +
and O +
into O +
a O +
patient O +
and O +
said O +
piston O +
pushes O +
on O +
said O +
microplunger O -
. O +

Cascade O +
esters O +
of O +
camptothecins O +
and O +
methods O +
of O +
treating O +
cancer O +
using O +
these O +
compounds O +
Cascade O +
esters O +
of O +
camptothecin O +
are O +
described O -
. O +

Processes O +
for O +
making O +
these O +
compounds O +
and O +
for O +
using O +
them O +
in O +
cancer O +
treatment O +
are O +
also O +
described O -
. O +

Formulation O +
for O +
inwardly O +
transferring O +
nucleic O +
acids O +
into O +
eucaryotic O +
cells O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
formulation O +
for O +
inwardly O +
transferring O +
nucleic O +
acids O +
into O +
eucaryotic O +
cells O -
, O +
characterized O +
in O +
that O +
the O +
formulation O +
has O +
a O +
pH O +
value O +
of O +
6.0 O +
- O +
pH O +
7,4 O -
, O +
and/or O +
an O +
anion O +
concentration O +
of O +
5 O +
- O +
100 O +
mmol O -
/ O -
l O +
and/or O +
a O +
concentration O +
of O +
10 O +
- O +
500 O +
Ã±mol O -
/ O -
l O +
of O +
nonsteroidal O +
antiphlogistics O -
. O +

Compositions O +
for O +
altering O +
mucus O +
secretion O +
A O +
peptide O +
that O +
inhibits O +
mucus O +
secretion O +
in O +
subjects O +
is O +
described O -
, O +
for O +
use O +
in O +
inhibiting O +
mucus O +
secretion O +
by O +
a O +
mucus O +
secreting O +
cell O -
. O +

A O +
pharmaceutical O +
composition O +
comprising O +
a O +
myristoylated O +
polypeptide O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
is O +
also O +
described O -
. O +

4- O -
( O -
3,5-dicyanophenoxy O -
) O +
pyrazole O +
derivatives O +
for O +
use O +
as O +
transcriptase B-Gene +
modulators O +
in O +
the O +
treatment O +
of O +
i.a O -
. O +

hiv O +
This O +
invention O +
relates O +
to O +
the O +
pyrazole O +
derivatives O +
of O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
acceptable O +
salt O -
, O +
solvate O +
or O +
derivatives O +
thereof O -
, O +
to O +
their O +
use O +
in O +
medicine O -
, O +
to O +
compositions O +
containing O +
them O -
, O +
to O +
processes O +
for O +
their O +
preparation O +
and O +
to O +
intermediates O +
used O +
in O +
such O +
processes O -
. O +

The O +
compounds O +
of O +
the O +
invention O +
bind O +
to O +
the O +
enzyme O +
reverse B-Gene +
transcriptase I-Gene +
and O +
are O +
modulators O -
, O +
especially O +
inhibitors O -
, O +
thereof O -
. O +

Reverse B-Gene +
transcriptase I-Gene +
is O +
implicated O +
in O +
the O +
infectious O +
lifecycle O +
of O +
Human O +
Immunodeficiency O +
Virus O +
( O -
HIV O -
) O -
. O +

Compounds O +
which O +
interfere O +
with O +
the O +
function O +
of O +
this O +
enzyme O +
have O +
shown O +
utility O +
in O +
the O +
treatment O +
of O +
conditions O +
caused O +
by O +
HIV O +
and O +
genetically O +
related O +
retroviruses O -
, O +
such O +
as O +
Acquired O +
Immune O +
Deficiency O +
Syndrome O +
( O -
AIDS O -
) O -
. O +

Therapeutic O +
use O +
of O +
fused O +
bicyclic O +
or O +
tricyclic O +
amino O +
acids O +
The O +
compounds O +
of O +
the O +
instant O +
invention O +
are O +
bicyclic O +
or O +
tricyclic O +
amino O +
acids O +
useful O +
in O +
the O +
treatment O +
of O +
fibromylagia O -
. O +

Pharmaceutical O +
compositions O +
containing O +
one O +
or O +
more O +
of O +
the O +
compounds O +
for O +
use O +
in O +
the O +
treatment O +
of O +
fibromyalgia O +
are O +
also O +
included O -
. O +

A O +
method O +
of O +
treating O +
vasomotor O +
symptoms O +
comprising O +
a O +
compound O +
having O +
norepinephrine O +
reuptake O +
inhibitor O +
activity O +
and O +
5-ht2a B-Gene +
antagonistic O +
activity O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
compounds O +
and O +
composition O +
of O +
compounds O +
that O +
modulate O +
norepinephrine O +
levels O +
for O +
the O +
treatment O +
of O +
vasomotor O +
symptoms O +
such O +
as O +
thermoregulatory O +
disorders O -
. O +

Furthermore O -
, O +
the O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
compounds O +
and O +
compositions O +
of O +
compounds O +
having O +
norepinephrine O +
reuptake O +
inhibitor O +
( O -
NRI O -
) O +
activity O +
alone O +
or O +
norepinephrine O +
reuptake O +
inhibitor O +
and O +
serotonin O +
reuptake O +
inhibitor O +
( O -
NRI O -
/ O -
SRI O -
) O +
dual O +
activity O +
in O +
combination O +
with O +
5-HT2a B-Gene +
receptor O +
antagonist O +
activity O -
. O +

Method O +
for O +
counteracting O +
a O +
pathologic O +
change O +
in O +
the O +
beta B-Gene -
- I-Gene -
adrenergic I-Gene +
pathway O +
The O +
invention O +
concerns O +
methods O +
for O +
modulating O +
the O +
ÃŸ B-Gene -
- I-Gene -
adrenergic I-Gene +
pathway O -
. O +

In O +
particular O -
, O +
the O +
invention O +
concerns O +
methods O +
for O +
counteracting O +
a O +
pathologic O +
change O -
, O +
such O +
as O -
, O +
for O +
example O -
, O +
a O +
loss O +
in O +
ÃŸ B-Gene -
- I-Gene -
adrenergic I-Gene +
sensitivity O -
, O +
in O +
the O +
ÃŸ B-Gene -
- I-Gene -
adrenergic I-Gene +
signal O +
transduction O +
pathway O +
by O +
administering O +
an O +
effective O +
amount O +
of O +
a O +
compound O +
capable O +
of O +
inhibiting O +
TGF B-Gene -
- I-Gene -
ÃŸ I-Gene +
signaling O +
through O +
a O +
TGF B-Gene -
- I-Gene -
ÃŸ I-Gene +
receptor I-Gene -
. O +

Compositions O +
and O +
methods O +
for O +
improving O +
the O +
condition O +
of O +
patients O +
suffering O +
from O +
copd O +
and O +
other O +
diseases O +
A O +
food O +
supplement O +
of O +
therapeutic O +
composition O +
is O +
provided O +
suitable O +
for O +
the O +
treatment O +
or O +
prophylaxis O +
of O +
COPD O +
and O +
other O +
acute O +
or O +
chronic O +
diseases O +
in O +
a O +
mammal O -
, O +
especially O +
a O +
human O +
being O -
, O +
comprising O +
at O +
least O +
one O +
of O +
glutamate O -
, O +
other O +
than O +
mono O +
sodium O +
glutamate O -
, O +
and O +
a O +
precursor O +
of O +
glutamate O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
leucine O -
, O +
valine O -
, O +
isoleucine O -
, O +
and O +
a O +
keto O +
acid O +
thereof O -
, O +
in O +
a O +
daily O +
dose O +
for O +
said O +
mammal O +
of O +
at O +
least O +
6 O +
grams O -
, O +
preferably O +
between O +
9 O +
and O +
20 O +
grams O -
, O +
of O +
the O +
total O +
of O +
said O +
glutamate O +
and O +
precursor O +
forms O +
thereof O -
. O +

Human B-Gene +
CLTA-8 I-Gene +
and O +
uses O +
of O +
CTLA-8-related B-Gene +
proteins O +
An O +
antibody O +
that O +
specifically O +
reacts O +
with O +
a O +
protein O +
comprising O +
an O +
amino O +
acid O +
sequence O +
selected O +
from O +
the O +
group O +
consisting O +
of O -
: O +
( O -
a O -
) O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO:2 O -
; O +
( O -
b O -
) O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO:2 O +
from O +
amino O +
acids O +
11 O +
to O +
163 O -
; O +
( O -
c O -
) O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO:2 O +
from O +
amino O +
acids O +
29 O +
to O +
163 O -
; O +
( O -
d O -
) O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO:2 O +
from O +
amino O +
acids O +
31 O +
to O +
163 O -
; O +
and O +
( O -
e O -
) O +
a O +
fragment O +
of O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO:2 O +
having O +
a O +
CTLA-8 B-Gene +
activity O +
chosen O +
from O +
one O +
or O +
more O +
of O +
induction O +
of O +
expression O +
or O +
secretion O +
of O +
Î³ B-Gene -
- I-Gene -
IFN I-Gene -
, O +
IL-6 B-Gene -
, O +
or O +
IL-8 B-Gene -
, O +
or O +
inhibition O +
of O +
angiogenesis O -
. O +

Inhibitors O +
of O +
hepatitis O +
c O +
virus O -
, O +
compositions O +
and O +
treatments O +
using O +
the O +
same O +
The O +
invention O +
relates O +
to O +
methods O +
of O +
inhibiting O +
HCV O +
viral O +
replication O +
activityy O +
comprising O +
contacting O +
an O +
HCV B-Gene +
polymerase I-Gene +
with O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
hydroxamate O +
MMP B-Gene +
inhibitor O -
, O +
and O +
composition O +
comprising O +
the O +
same O -
. O +

Fused O +
pyrido O -
[ O -
3',2':4,5 O -
] O -
thieno O -
[ O -
3,2-d O -
] O -
pyrimidines O +
and O +
pyrido O -
[ O -
3',2':4,5 O -
] O -
furo O -
[ O -
3,2-d O -
] O -
pyrimidines O +
Tricyclic O +
thiophene O -
, O +
furan O +
or O +
pyrrole O +
derivatives O +
( O -
I O -
) O +
are O +
new O -
. O +

Tricyclic O +
thiophene O -
, O +
furan O +
or O +
pyrrole O +
derivatives O +
( O -
I O -
) O +
of O +
formula O +
( O -
Ia O -
) O -
- O -
( O -
Id O -
) O +
and O +
their O +
salts O -
, O +
solvates O -
, O +
metabolites O -
, O +
tautomers O +
and O +
prodrugs O +
are O +
new O -
, O +
other O +
than O +
2-dimethylamino-4,7-diethoxy-8-cyano-9-p O +
henyl O -
- O -
pyrido O -
[ O -
3',2':4,5 O -
] O -
thieno O -
[ O -
3,2-d O -
] O -
pyrimidine O -
, O +
1,4-dihydro-2,2-dimethyl-5-morpholino-10-propylthio-2H O -
- O -
pyrano O -
[ O -
4",3":4 O +
' O -
, O -
5' O -
] O -
pyrido O -
[ O -
3',2':4',5' O -
] O -
thieno O -
[ O -
3,2-d O -
] O -
pyrimidin-8 O -
( O -
9H O -
) O -
-one O -
, O +
1 O -
- O -
-butylthio-1,4-dihydro-2,2-dimethyl-5-morpholino-2H O -
- O -
pyrano O -
[ O -
4",3":4 O -
' O +
, O -
5' O -
] O -
pyrido O -
[ O -
3',2':4',5' O -
] O -
thieno O -
[ O -
3,2-d O -
] O -
pyrimidin-8 O -
( O -
9H O -
) O -
-one O +
and O +
2-methyl-5- O -
( O -
2thienyl O -
) O -
-1,2,3,4-tetrahydro-11H-7-thia-2,6,9,11-tetraaza O +
-benzo O -
[ O -
c O -
] O -
fluorene-8,10-dione O -
. O +

Y O -
' O +
: O +
S O -
, O +
O O +
or O +
N O -
; O +
R1 O -
> O -
H O -
; O +
1 O -
- O -
10C O +
( O -
cyclo O -
) O -
alkyl O -
, O +
2 O -
- O -
12C O +
( O -
cyclo O -
) O -
alkenyl O +
or O +
2 O -
- O -
12C O +
( O -
cyclo O -
) O -
alkynyl O -
, O +
( O -
6 O -
- O -
12C O -
) O -
aryl O -
( O -
1 O -
- O -
5C O -
) O -
alkyl O -
, O +
5- O +
to O +
14-membered O +
mono- O +
or O +
bicyclic O +
heterocyclyl O +
with O +
1 O -
- O -
4 O +
heteroatoms O -
, O +
1 O -
- O -
10C O +
( O -
cyclo O -
) O -
alkoxy O -
, O +
( O -
6 O -
- O -
12C O -
) O -
aryl O -
( O -
1 O -
- O -
5C O -
) O -
alkoxy O -
, O +
2 O -
- O -
12C O +
alkanoyl O -
, O +
benzoyl O +
or O +
1- O +
or O +
2-naphthoyl O -
, O +
alkylthio O -
, O +
alkylsulfinyl O -
, O +
alkoxysulfonyl O +
or O +
alkylsulfonyl O -
, O +
alkoxycarbonyl O -
, O +
alkylcarbamoyl O +
or O +
dialkylcarbamoyl O -
, O +
( O -
hetero O -
) O -
arylthio O -
, O +
( O -
hetero O -
) O -
arylsulfinyl O +
or O +
( O -
hetero O -
) O -
arylsulfonyl O -
, O +
aryloxycarbonyl O -
, O +
arylcarbamoyl O -
, O +
arylamido O -
, O +
N O -
- O -
aryl O -
- O -
N O -
- O -
alkylamido O -
, O +
N O -
- O -
aryl O -
- O -
N O -
- O -
alkylcarbamoyl O -
, O +
aralkoxycarbonyl O +
or O +
aralkylcarbamoyl O +
with O +
1 O -
- O -
5C O +
alkyl O +
or O +
6 O -
- O -
10C O +
aryl O -
, O +
heterocyclylcarbonyl O -
, O +
heterocyclylcarbamoyl O -
, O +
heterocyclylamido O -
, O +
N O -
- O -
heterocyclyl O -
- O -
N O -
- O -
alkylamino O -
, O +
heterocyclylalkoxycarbonyl O +
or O +
heterocyclylalkylcarbamoyl O -
, O +
arylhydrazino O +
or O +
phenyl O +
( O -
all O +
optionally O +
substituted O -
) O -
; O +
1- O +
or O +
2-naphthyl O -
; O +
OH O -
, O +
SH O -
, O +
CHO O -
, O +
COOH O -
, O +
CONH2 O -
, O +
CN O -
, O +
SCN O -
, O +
NO2 O -
, O +
SO3H O -
; O +
with O +
heterocyclyl O +
as O +
above O +
and O +
1 O -
- O -
5C O +
alkyl O -
; O +
halo O -
; O +
NH2 O -
, O +
1 O -
- O -
6C O +
alkylamino O +
or O +
di O -
( O -
1 O -
- O -
5C O +
alkyl O -
) O -
amino O -
, O +
optionally O +
substituted O -
; O +
heterocyclylamino O -
; O +
or O +
La O -
- O -
A O -
- O -
Lb O -
- O -
B O -
; O +
La O +
: O +
a O +
bond O -
, O +
NR O -
' O -
, O +
O O -
, O +
S O -
, O +
SO O -
, O +
SO2 O -
; O +
A O +
: O +
phenyl O +
or O +
naphthyl O +
( O -
both O +
optionally O +
substituted O -
) O +
or O +
heterocyclyl O -
; O +
or O +
a O +
tricyclic O +
group O -
; O +
Lb O +
: O +
a O +
bond O -
, O +
NR O -
' O -
, O +
O O -
, O +
S O -
, O +
SO O -
, O +
SO2 O -
, O +
CHR O -
, O +
CH2O O -
, O +
OCH2 O -
, O +
NR'CO O -
, O +
NR'CS O -
, O +
NR'CONR O -
' O -
, O +
NR'CSNR O -
' O -
, O +
NR'C O -
( O -
NH O -
) O -
, O +
NR'SO O -
, O +
NR'SO2 O -
, O +
N O -
( O -
R' O -
) O -
=S O -
( O -
O O -
) O -
( O -
R O -
' O -
) O -
, O +
NR'C O -
( O -
NHOH O -
) O -
, O +
NHNR O -
' O -
, O +
N O -
( O -
NHR' O -
) O -
CO O -
, O +
NHN= O -
, O +
N O -
( O -
OH O -
) O -
CS O -
, O +
NR'COO O -
, O +
NR'C O -
( O -
S O -
) O -
O O -
, O +
N O -
( O -
OH O -
) O -
CO O -
; O +
B O +
: O +
H O -
; O +
alkyl O +
( O -
optionally O +
substituted O -
) O -
; O +
CONH2 O -
; O +
CONHQ O -
; O +
COOH O -
; O +
COOAlk O -
; O +
COQ O -
; O +
CH2CONH2 O -
; O +
CH2CONHQ O -
; O +
CH2COOH O -
; O +
CH2COOAlk O -
; O +
CH2COQ O -
; O +
phenyl O +
or O +
naphthyl O +
or O +
4- O +
to O +
14-membered O +
mono- O +
or O +
bicyclic O +
heterocyclyl O +
with O +
1 O -
- O -
5 O +
heteroatoms O +
( O -
optionally O +
substituted O +
with O +
oxo O -
) O +
( O -
all O +
optionally O +
substituted O -
) O -
; O +
Alk O +
: O +
alkyl O +
( O -
optionally O +
substituted O -
) O -
; O +
Q O +
: O +
alkyl O -
, O +
aryl O +
or O +
heteroaryl O +
( O -
optionally O +
substituted O -
) O -
; O +
R O -
' O +
: O +
H O +
or O +
Alk O -
; O +
R2 O -
> O -
H O -
, O +
1 O -
- O -
12C O +
alkyl O -
, O +
2 O -
- O -
12C O +
alkenyl O +
or O +
alkynyl O -
; O +
phenyl O -
( O -
1 O -
- O -
6C O -
) O -
alkyl O +
( O -
optionally O +
substituted O -
) O -
; O +
phenacyl O +
( O -
optionally O +
substituted O -
) O -
; O +
COOH O -
, O +
1 O -
- O -
4C O +
alkoxycarbonyl O -
, O +
CONH2 O +
or O +
mono- O +
or O +
di O -
( O -
1 O -
- O -
6C O +
alkyl O -
) O -
carbamoyl O -
; O +
COR O -
' O -
; O +
CN O -
, O +
NO2 O -
, O +
NH2 O -
, O +
mono- O +
or O +
di O -
( O -
1 O -
- O -
6C O +
alkyl O -
) O -
amino O -
, O +
N O -
= O -
N O -
- O -
Ph O -
, O +
N O -
= O -
N O -
- O -
C6H4-R O -
, O +
1,3-diphenyl-4-pyrazolyl O -
, O +
2-thiazolinyl O -
, O +
2-imidazolinyl O +
or O +
3,4,5,6-tetrahydropyrimidinyl O -
; O +
R3 O -
> O -
H O -
; O +
OH O -
, O +
SH O -
, O +
CHO O -
, O +
COOH O -
, O +
CONH2 O -
, O +
CN O -
, O +
SCN O -
, O +
NO2 O -
, O +
halo O -
; O +
NH2 O -
, O +
or O +
SO3H O +
or O +
1 O -
- O -
10C O +
( O -
cyclo O -
) O -
alkyl O -
, O +
2 O -
- O -
12C O +
( O -
cyclo O -
) O -
alkenyl O -
, O +
2 O -
- O -
12C O +
( O -
cyclo O -
) O -
alkynyl O -
, O +
( O -
6 O -
- O -
12C O -
) O -
aryl O -
( O -
1 O -
- O -
5C O -
) O -
alkyl O -
, O +
phenyl O -
, O +
1- O +
or O +
2-naphthyl O -
, O +
pyridyl O +
N O -
- O -
oxide O -
, O +
1 O -
- O -
10C O +
( O -
cyclo O -
) O -
alkoxy O -
, O +
( O -
6 O -
- O -
12C O -
) O -
aryl O -
( O -
1 O -
- O -
5C O -
) O -
alkoxy O -
, O +
2 O -
- O -
12C O +
alkanoyl O -
, O +
benzoyl O +
or O +
1- O +
or O +
2-naphthoyl O -
, O +
alkylthio O -
, O +
alkylsulfinyl O -
, O +
alkoxysulfonyl O +
or O +
alkylsulfonyl O -
, O +
( O -
hetero O -
) O -
arylthio O -
, O +
( O -
hetero O -
) O -
arylsulfinyl O +
or O +
( O -
hetero O -
) O -
arylsulfonyl O -
, O +
alkoxycarbonyl O -
, O +
alkylcarbamoyl O +
or O +
dialkylcarbamoyl O -
, O +
aryloxycarbonyl O -
, O +
arylcarbamoyl O -
, O +
arylamido O -
, O +
N O -
- O -
aryl O -
- O -
N O -
- O -
alkylamido O -
, O +
N O -
- O -
aryl O -
- O -
N O -
- O -
alkylcarbamoyl O -
, O +
aralkoxycarbonyl O +
or O +
aralkylcarbamoyl O +
with O +
1 O -
- O -
5C O +
alkyl O +
or O +
6 O -
- O -
10C O +
aryl O -
, O +
1 O -
- O -
6C O +
alkylamino O +
or O +
di O -
( O -
1 O -
- O -
5C O +
alkyl O -
) O -
amino O -
, O +
6 O -
- O -
10C O +
arylamino O +
or O +
arylhydrazino O +
( O -
all O +
optionally O +
substituted O -
) O -
; O +
R4>2 O -
- O -
14C O +
alkyl O -
, O +
3 O -
- O -
14C O +
cycloalkyl O -
, O +
2 O -
- O -
14C O +
alkenyl O -
, O +
3 O -
- O -
14C O +
cycloalkenyl O -
, O +
2 O -
- O -
14C O +
alkynyl O -
, O +
phenyl O +
or O +
1- O +
or O +
2-naphthyl O -
, O +
4- O +
to O +
14-membered O +
mono- O +
or O +
bicyclic O +
heterocyclyl O +
with O +
1 O -
- O -
5 O +
heteroatoms O +
( O -
all O +
optionally O +
substituted O -
) O -
; O +
SQ1 O -
> O -
, O +
SOQ1 O -
> O -
, O +
SO2Q1 O -
> O -
; O +
OR6 O -
> O +
or O +
NR7 O -
> O -
R8 O -
> O -
; O +
Q1>1 O -
- O -
8C O +
alkyl O -
, O +
2 O -
- O -
8C O +
alkenyl O +
or O +
2 O -
- O -
8C O +
alkynyl O -
, O +
( O -
optionally O +
substituted O -
) O -
; O +
R6>1 O -
- O -
4C O +
n O -
- O -
alkyl O -
, O +
t O -
- O -
Bu O -
, O +
CH2CH2OH O -
, O +
CH2CH2SH O -
, O +
CH2CH2SMe O -
, O +
CH2CF3 O -
, O +
CH2CCl3 O -
, O +
CH2CHF2 O -
, O +
CH2CHCl2 O -
, O +
CH2CH2F O -
, O +
CH2CH2Cl O -
, O +
CH2CH2Br O -
; O +
3 O -
- O -
7C O +
cycloalkyl O -
, O +
2 O -
- O -
5C O +
alkenyl O +
or O +
alkynyl O -
; O +
3 O -
- O -
7C O +
cycloalkenyl O -
; O +
aryl O +
or O +
heteroaryl O -
; O +
1- O +
or O +
2-naphthyl O +
( O -
all O +
optionally O +
substituted O -
) O -
; O +
pyridyl O -
, O +
isoquinolinyl O +

Medicament O +
for O +
local O +
use O +
Pharmaceutical O +
compositions O +
( O -
A O -
) O +
for O +
local O +
application O +
to O +
stop O +
bleeding O -
, O +
close O +
wounds O +
and/or O +
stimulate O +
wound O +
healing O -
, O +
contain O +
fibrinogen B-Gene +
( O -
I B-Gene -
) O +
or O +
fibrin B-Gene +
( O -
Ia B-Gene -
) O -
, O +
thrombin B-Gene +
( O -
II B-Gene -
) O +
and O +
one O +
or O +
more O +
transglutaminases B-Gene +
( O -
III B-Gene -
) O -
, O +
also O +
at O +
least O +
one O +
serpin B-Gene -
- I-Gene -
type I-Gene +
protease I-Gene +
inhibitor O +
( O -
IV O -
) O +
that O +
has O +
no O +
inhibitory O +
action O +
on O +
collagenases B-Gene +
or O +
elastases B-Gene -
, O +
are O +
new O -
. O +

All O +
active O +
ingredients O +
are O +
of O +
allogenic O +
origin O +
( O -
isolated O +
from O +
plasma O +
or O +
tissue O -
, O +
or O +
recombinant O -
) O +
and O +
have O +
been O +
subjected O +
to O +
a O +
virus O +
removal O +
and/or O +
inactivation O +
step O -
, O +
provided O +
that O +
virus O +
inactivation O +
of O +
( O -
IV O -
) O +
is O +
not O +
done O +
in O +
presence O +
of O +
other O +
active O +
ingredients O -
. O +

Independent O +
claims O +
are O +
also O +
included O +
for O +
the O +
following O -
: O +
( O -
a O -
) O +
preparation O +
of O +
a O +
( O -
I O -
) O -
-containing O +
solution O -
, O +
as O +
such O +
or O +
as O +
part O +
of O +
( O -
A O -
) O -
, O +
that O +
can O +
be O +
stored O +
at O +
refrigerator O +
or O +
room O +
temperature O -
; O +
( O -
b O -
) O +
pharmaceutical O +
compositions O +
( O -
B O -
) O +
containing O +
a O +
highly O +
purified O +
( O -
I O -
) O -
- O +
or O +
( O -
I O -
) O +
plus O +
fibronectin O -
- O -
containing O +
composition O +
that O +
has O +
activated O +
prothrombin O +
time O +
and O +
Taipan O +
viper O +
venom O +
prothrombin O +
time O +
at O +
37 O -
[ O -
deg O -
] O -
C O +
of O +
at O +
least O +
200 O +
and O +
300 O +
sec O -
, O +
respectively O -
; O +
( O -
c O -
) O +
a O +
method O +
for O +
preparing O +
pathogen O -
- O -
free O +
( O -
A O -
) O -
; O +
( O -
d O -
) O +
a O +
method O +
for O +
covalent O +
binding O +
of O +
( O -
A O -
) O +
to O +
a O +
biological O +
matrix O -
; O +
( O -
e O -
) O +
a O +
method O +
for O +
preparing O +
a O +
( O -
Ia O -
) O -
-containing O +
gel O +
of O +
20 O -
- O -
90 O -
% O +
water O +
content O -
; O +
( O -
f O -
) O +
a O +
method O +
for O +
solidifying O +
a O +
( O -
Ia O -
) O -
-containing O +
gel O +
with O +
or O +
without O +
removal O +
of O +
water O -
; O +
( O -
g O -
) O +
a O +
freeze O -
- O -
dried O +
( O -
Ia O -
) O -
-containing O +
gel O +
to O +
which O +
a O +
plasticizer O -
, O +
particularly O +
glycol O -
, O +
has O +
been O +
added O +
before O +
solidification O +
and O +
freeze O -
- O -
drying O -
; O +
( O -
h O -
) O +
a O +
method O +
for O +
producing O +
a O +
high O +
viscosity O +
( O -
I O -
) O -
-containing O +
solution O -
; O +
and O +
( O -
i O -
) O +
a O +
method O +
for O +
determining O +
the O +
adhesive O +
capacity O +
of O +
a O +
fibrin O +
clot O +
to O +
a O +
wound O +
bed O -
. O +

Use O +
of O +
4,5-dihydro-1h O -
- O -
pyrazole O +
derivatives O +
having O +
cb1-antagonistic B-Gene +
activity O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
medical O +
use O +
of O +
4,5-dihydro-1H O -
- O -
pyrazole O +
compounds O +
which O +
are O +
potent O +
antagonists O +
of O +
the O +
cannabis O +
CB1-receptor B-Gene -
. O +

Said O +
compounds O +
are O +
particularly O +
suitable O +
in O +
the O +
manufacture O +
of O +
medicaments O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
CB1 B-Gene +
receptor O +
related O +
diseases O +
in O +
juvenile O +
patients O +
and/or O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
drug O +
induced O +
obesity O +
in O +
juvenile O +
as O +
well O +
as O +
in O +
adolescent O +
patients O -
. O +

The O +
compounds O +
have O +
the O +
general O +
formula O +
( O -
1 O -
) O -
, O +
wherein O +
the O +
group O +
Bb O +
represents O +
sulfonyl O +
or O +
carbonyl O -
, O +
and O +
the O +
substituents O +
R O -
, O +
R1 O -
, O +
R2and O +
R3 O -
, O +
and O +
the O +
group O +
Aa O +
are O +
defined O +
as O +
shown O +
in O +
the O +
description O -
. O +

Benzimidazole O +
derivatives O +
and O +
use O +
thereof O +
as O +
peptide B-Gene +
deformylase I-Gene +
inhibitors O +
Benzimidazole O +
compounds O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
acceptable O +
salts O +
or O +
esters O +
thereof O +
are O +
peptide B-Gene +
deformylase I-Gene +
inhibitors O +
useful O +
in O +
the O +
treatment O +
or O +
prevention O +
of O +
infections O +
and O +
other O +
diseases O +
in O +
which O +
peptide B-Gene +
deformylases I-Gene +
are O +
involved O -
, O +
especially O +
in O +
the O +
treatment O +
of O +
bacterial O +
and O +
parasitic O +
infections O -
, O +
for O +
example O +
infections O +
fully O +
or O +
partly O +
caused O +
by O +
microorganisms O +
belonging O +
to O +
Staphylococcus O -
, O +
Enterococcus O -
, O +
Streptococcus O -
, O +
Haemophilus O -
, O +
Moraxella O -
, O +
Escherichia O -
, O +
Mycobacterium O -
, O +
Mycoplasma O -
, O +
Pseudomonas O -
, O +
Chlamydia O -
, O +
Rickettsia O -
, O +
Klebsiella O -
, O +
Shigella O -
, O +
Salmonella O -
, O +
Bordetella O -
, O +
Clostridium O -
, O +
helicobacter O -
, O +
Campylobacter O -
, O +
Legionella O -
, O +
or O +
Neisseria O -
. O +

Oligo O -
- O -
beta- O -
( O -
1,3 O -
) O -
-glucan O +
and O +
monoclonal O +
antibodies O +
against O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
a O +
therapeutical O +
method O +
comprising O +
administration O +
of O +
a O +
composition O +
comprising O +
a O +
monoclonal O +
antibody O +
with O +
an O +
oligo O -
- O -
Î²- O -
( O -
1,3 O -
) O -
-glucan O +
and O -
. O +

a O +
pharmaceutically O +
acceptable O +
carrier O -
, O +
to O +
a O +
human O +
being O +
or O +
to O +
a O +
warm O -
- O -
blood O +
animal O +
suffering O +
from O +
cancer O +
in O +
an O +
amount O +
which O +
is O +
effective O +
to O +
treat O +
the O +
cancer O -
. O +

Treatment O +
of O +
a O +
Hemoglobinopathy O +
Disclosed O +
are O +
methods O +
for O +
treating O +
a O +
patient O +
identified O +
as O +
having O +
a O +
hemoglobinopathy O +
that O +
is O +
characterized O +
by O +
a O +
reduced O +
affinity O +
of O +
hemoglobin B-Gene +
for O +
oxygen O -
. O +

The O +
methods O +
involve O +
providing O +
gaseous O +
nitric O +
oxide O +
and/or O +
carbon O +
monoxide O +
for O +
( O -
i O -
) O +
inhalation O +
by O +
the O +
patient O +
or O +
( O -
ii O -
) O +
ex O +
vivo O +
treatment O +
of O +
the O +
patient O -
's O +
erythrocytes O -
. O +

Alternatively O -
, O +
a O +
nitric O -
- O -
oxide O -
- O -
releasing O +
compound O +
can O +
be O +
administered O +
to O +
the O +
patient O -
. O +

Method O +
of O +
examining O +
sensitivity O +
of O +
cancer O +
cell O +
to O +
anticancer O +
agent O +
In O +
the O +
case O +
where O +
the O +
sensitivity O +
of O +
a O +
cancer O +
cell O +
to O +
a O +
compound O +
can O +
be O +
understood O +
by O +
examining O +
molecules O +
expressed O +
in O +
the O +
cancer O +
cell O +
collected O +
from O +
a O +
cancer O +
patient O +
by O +
biopsy O +
or O +
the O +
like O -
, O +
it O +
is O +
possible O +
to O +
administer O +
the O +
compound O +
selectively O +
to O +
cancer O +
patients O +
on O +
whom O +
the O +
compound O +
can O +
exert O +
its O +
antitumor O +
effect O -
. O +

Thus O -
, O +
it O +
is O +
expected O +
that O +
the O +
therapeutic O +
effect O +
can O +
be O +
enhanced O +
while O +
relieving O +
unnecessary O +
side O +
effects O +
thereby O -
. O +

More O +
specifically O +
speaking O -
, O +
it O +
is O +
found O +
out O +
that O +
the O +
characteristics O +
" O -
low O +
pRB B-Gene -
- O -
expression O -
" O -
, O +
" O -
positive O +
to O +
p16 B-Gene +
expression O -
" O +
and O +
" O -
high O +
cyclin B-Gene +
E I-Gene -
- O -
expression O -
" O +
are O +
usable O +
as O +
a O +
marker O +
for O +
the O +
high O +
sensitivity O +
of O +
cancer O +
cells O +
to O +
this O +
compound O -
. O +

Examination O +
of O +
these O +
characteristics O +
of O +
cancer O +
cells O -
, O +
therefore O -
, O +
the O +
sensitivity O +
of O +
the O +
cancer O +
cells O +
to O +
this O +
compound O +
can O +
be O +
preliminarily O +
understood O -
. O +

Pyridylpyrimidine O +
derivatives O +
as O +
effective O +
compounds O +
against O +
prion O +
infections O +
and O +
prion O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
pyridylpyrimidine O +
derivatives O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
R O +
represents O +
hydrogen O +
or O +
methyl O +
and O +
Z O +
represents O +
nitrogen O +
containing O +
functional O +
groups O -
, O +
the O +
use O +
of O +
the O +
pyridylpyrimidine O +
derivatives O +
as O +
pharmaceutically O +
active O +
agents O -
, O +
especially O +
for O +
the O +
prophylaxis O +
and/or O +
treatment O +
of O +
prion O +
infections O +
and O +
prion O +
diseases O -
, O +
as O +
well O +
as O +
compositions O +
containing O +
at O +
least O +
one O +
pyridylpyrimidine O +
derivative O +
and/or O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Furthermore O -
, O +
the O +
present O +
invention O +
is O +
directed O +
to O +
methods O +
for O +
preventing O +
and/or O +
treating O +
prion O +
infections O +
and O +
prion O +
diseases O +
using O +
said O +
pyridylpyrimidine O +
derivatives O -
. O +

Human O +
cellular O +
protein O +
kinases O -
, O +
phosphatases O +
and O +
cellular O +
signal O +
transduction O +
molecules O +
are O +
disclosed O +
as O +
targets O +
for O +
detecting O -
, O +
preventing O +
and/or O +
treating O +
prion O +
infections O +
and O +
diseases O -
, O +
especially O +
BSE O -
, O +
vCJD O -
, O +
or O +
CJD O +
which O +
can O +
be O +
inhibited O +
by O +
the O +
inventive O +
pyridylpyrimidine O +
derivatives O -
. O +

2-substituted O +
and O +
4-substituted O +
aryl O +
nitrone O +
compouds O +
The O +
present O +
invention O +
provides O +
aryl O +
nitrones O -
, O +
compositions O +
comprising O +
the O +
same O +
and O +
methods O +
of O +
their O +
use O +
for O +
the O +
treatment O +
or O +
prevention O +
of O +
oxidative O -
, O +
ischemic O -
, O +
ischemia O -
/ O -
reperfusion O -
- O -
related O +
and O +
chemokine O +
mediated O +
conditions O -
. O +

Formulations O +
comprising O +
a O +
capsaicinoid O -
, O +
a O +
local O +
anesthetic O +
and/or O +
an O +
antipruritic O +
agent O +
for O +
the O +
treatment O +
of O +
pain O +
Formulations O +
and O +
methods O +
are O +
provided O +
for O +
the O +
treatment O +
of O +
pain O -
, O +
and O +
neuropathic O +
pain O +
in O +
particular O -
. O +

The O +
formulations O +
are O +
eutectic O +
mixtures O +
of O +
a O +
capsaicinoid O +
and O +
a O +
local O +
anesthetic O +
agent O +
and/or O +
anti O -
- O -
pruritic O +
agent O -
. O +

Alkyl O -
- O -
and O +
piperidine O -
- O -
substituted O +
benzimidazole O -
- O -
derivates O +
A O +
compound O +
of O +
general O +
formula O +
( O -
1a O -
) O +
wherein O +
R1 O -
, O +
R5 O -
, O +
R6 O -
, O +
A O -
, O +
B O -
, O +
Y O -
, O +
i O -
, O +
j O +
and O +
m O +
are O +
defined O +
as O +
in O +
the O +
description O +
and O +
claims O -
. O +

It O +
is O +
another O +
object O +
of O +
the O +
present O +
invention O +
to O +
provide O +
pharmaceutical O +
compositions O +
comprising O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
and O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
of O +
the O +
compounds O +
of O +
the O +
present O +
invention O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Oxazole O +
derivatives O +
as O +
histamine B-Gene +
h3 I-Gene +
receptor I-Gene +
agents O -
, O +
preparation O +
and O +
therapeutic O +
uses O +
The O +
present O +
invention O +
discloses O +
novel O +
aryl O +
oxazole O +
compounds O +
of O +
Formula O +
I O +
( O -
I O -
) O -
, O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
which O +
have O +
histamine B-Gene -
- I-Gene -
H3 I-Gene +
receptor I-Gene +
antagonist O +
or O +
inverse O +
agonist O +
activity O -
, O +
as O +
well O +
as O +
methods O +
for O +
preparing O +
and O +
using O +
such O +
compounds O -
. O +

In O +
another O +
embodiment O -
, O +
the O +
invention O +
discloses O +
pharmaceutical O +
compositions O +
comprising O +
compounds O +
of O +
Formula O +
I O +
as O +
well O +
as O +
methods O +
of O +
using O +
these O +
compositions O +
to O +
treat O +
obesity O -
, O +
cognitive O +
deficiencies O -
, O +
narcolepsy O -
, O +
and O +
other O +
histamine B-Gene +
H3 I-Gene +
receptor I-Gene -
- O -
related O +
diseases O -
. O +

Formula O +
I O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
wherein O -
: O +
m O +
is O +
independenlly O +
at O +
each O +
occurrence O +
1 O -
, O +
2 O -
, O +
or O +
3 O -
, O +
Z O +
independently O +
represents O +
carbon O +
( O -
substituted O +
with O +
hydrogen O +
or O +
the O +
optional O +
substituents O +
indicated O +
herein O -
) O +
or O +
nitrogen O -
, O +
provided O +
that O +
when O +
Z O +
is O +
nitrogen O +
then O +
R6 O +
is O +
not O +
attached O +
to O +
Z O -
; O +
R1 O +
and O +
R2 O +
are O +
independently O +
- O -
( O -
C1-C7 O -
) O +
alkyl O -
( O -
optionally O +
substituted O +
with O +
one O +
to O +
three O +
halogens O -
) O -
, O +
or O +
R1 O +
and O +
R2 O +
and O +
the O +
nitrogen O +
to O +
which O +
they O +
are O +
attached O +
form O +
an O +
azetidinyl O +
ring O -
, O +
a O +
pyrrolidinyl O +
ring O -
, O +
or O +
a O +
piperidinyl O +
ring O -
, O +
wherein O +
further O +
the O +
azetidinyl O -
, O +
pyrrolidinyl O -
, O +
or O +
piperidinyl O +
ring O +
so O +
formed O +
may O +
be O +
optionally O +
substituted O +
one O +
to O +
three O +
times O +
with O +
R5 O -
; O +
R6 O +
is O +
independently O +
at O +
each O +
occurrence O +
-H O -
, O +
-halogen O -
, O +
or O +
-CH3 O -
. O +

Pyrimidinylimidazoles O +
as O +
tgf B-Gene -
- I-Gene -
beta I-Gene +
inhibitors O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
possess O +
unexpectedly O +
high O +
affinity O +
for O +
Alk B-Gene +
5 I-Gene +
and/or O +
Alk B-Gene +
4 I-Gene -
, O +
and O +
can O +
be O +
useful O +
as O +
antagonists O +
thereof O +
for O +
preventing O +
and/or O +
treating O +
numerous O +
diseases O -
, O +
including O +
fibrotic O +
disorders O -
. O +

The O +
invention O +
features O +
a O +
compound O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O +
and O +
uses O +
thereof O -
. O +

Compositions O +
and O +
methods O +
comprising O +
vitamin O +
b12 O +
and O +
an O +
impdh B-Gene +
inhibitor O +
for O +
treating O +
viral O -
, O +
inflammatory O +
and O +
proliferative O +
diseases O +
The O +
invention O +
relates O +
generally O +
to O +
novel O +
compositions O +
and O +
methods O +
comprising O +
at O +
least O +
one O +
Vitamin O +
B12 O +
compound O -
, O +
at O +
least O +
one O +
IMPDH B-Gene +
inhibitor O -
, O +
and O +
optionally O +
an O +
interferon O -
. O +

The O +
compositions O +
and O +
methods O +
provide O +
beneficial O +
effects O +
in O +
the O +
treatment O +
of O +
viral O -
, O +
inflammatory O -
, O +
immunodeficiency O -
, O +
IMPDH B-Gene -
- O -
mediated O -
, O +
and O +
proliferative O +
diseases O -
. O +

Compositions O +
and O +
methods O +
for O +
treatment O +
of O +
disease O +
caused O +
by O +
yersinia O +
spp O +
infection O +
The O +
invention O +
generally O +
relates O +
to O +
compositions O +
and O +
methods O +
for O +
treatment O +
of O +
disease O +
caused O +
by O +
Yersinia O +
spp O -
. O +

infection O -
. O +

More O +
specifically O -
, O +
the O +
invention O +
relates O +
to O +
protein B-Gene +
tyrosine I-Gene +
phosphatase I-Gene +
inhibitors O +
and O +
derivatives O +
and O +
analogs O +
thereof O -
, O +
pharmaceutical O +
compositions O +
containing O +
the O +
protein B-Gene +
tyrosine I-Gene +
phosphatase I-Gene +
inhibitors O +
and O +
analogs O -
, O +
methods O +
of O +
making O +
the O +
protein B-Gene +
tyrosine I-Gene +
phosphatase I-Gene +
inhibitors O +
and O +
analogs O +
and O +
methods O +
of O +
use O +
thereof O -
. O +

Biphenyl O +
integrin B-Gene +
antagonists O +
The O +
following O +
invention O +
is O +
directed O +
to O +
pharmaceutical O +
compounds O +
and O +
compositions O +
of O +
the O +
Formula O +
( O -
I O -
) O -
. O +

useful O +
for O +
treating O +
conditions O +
mediated O +
by O +
Î±VÎ²3 B-Gene +
and/or O +
Î±VÎ²5 O +
integrin O -
. O +

Process O +
for O +
the O +
preparation O +
of O +
ibandronate O +
The O +
invention O +
relates O +
to O +
a O +
novel O +
multi O +
step O +
synthesis O +
of O +
3- O -
( O -
N O -
- O -
methyl O -
- O -
N O -
- O -
pentyl O -
) O +
amino O -
- O -
lÂ­hydroxypropane-1 O -
, O +
1-diphosphonic O +
acid O -
, O +
monosodium O +
salt O -
, O +
monohydrate O -
, O +
of O +
Formula O +
( O -
I O -
) O -
. O +

Cosmetic O +
composition O +
comprising O +
phytosterols O -
, O +
isoflavones O +
and O +
methylricinoleate O -
, O +
use O +
as O +
inhibitor O +
of O +
5-alpha B-Gene -
- I-Gene -
reductase I-Gene +
and O +
hair O +
growth O +
The O +
present O +
invention O +
relates O +
to O +
a O +
cosmetic O +
mixture O +
comprising O +
phytosterols O +
in O +
quantities O +
ranging O +
from O +
1 O +
to O +
20 O -
% O +
by O +
weight O -
, O +
isoflavones O +
from O +
0.1 O +
to O +
4 O -
% O +
by O +
weight O +
and O +
methylricinoleate O +
from O +
80 O +
to O +
90 O -
% O +
by O +
weight O -
. O +

Said O +
cosmetic O +
mixture O +
is O +
formulated O +
with O +
excipients O +
normally O +
used O +
in O +
the O +
cosmetic O +
sector O -
, O +
to O +
give O +
a O +
cosmetic O +
formulation O -
. O +

The O +
cosmetic O +
mixture O +
and O +
formulation O +
are O +
capable O +
of O +
inhibiting O +
the O +
enzyme O +
5-alpha B-Gene -
- I-Gene -
reductase I-Gene -
, O +
and O +
thus O +
have O +
inhibitory O +
or O +
retardatory O +
activity O +
towards O +
the O +
growth O +
of O +
body O +
hair O -
. O +

Iridoid O +
glycoside O +
composition O +
The O +
present O +
invention O +
relates O +
to O +
an O +
adjuvants O -
, O +
particularly O +
to O +
the O +
use O +
of O +
a O +
well O -
- O -
characterized O +
plant O +
based O +
iridoid O +
glycoside O +
adjuvant O +
from O +
plant O +
Picrorhiza O +
kurroa O -
, O +
acting O +
as O +
an O +
adjuvant O +
against O +
T O +
-dependent O +
antigen O +
and O +
specifically O +
against O +
HBsAg O +
and O +
typhoid O +
antigens O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
the O +
method O +
of O +
producing O +
the O +
iridoid O +
glycoside O +
adjuvant O +
and O +
the O +
products O +
utilizing O +
such O +
adjuvants O +
for O +
induction O +
of O +
cellular O +
immunity O -
. O +

The O +
adjuvants O +
may O +
be O +
used O +
alone O +
or O +
with O +
specific O +
antigens O -
. O +

The O +
two O +
antigens O +
used O +
in O +
the O +
study O +
represents O +
HBsAg O -
, O +
a O +
recombinant O +
antigen O +
expressed O +
in O +
Pichia O +
pastoris O -
, O +
and O +
typhoid O +
Vi O +
polysaccharide O +
purified O +
from O +
Salmonella O +
typhi O +
broth O -
. O +

These O +
antigens O +
are O +
studied O +
for O +
their O +
immunogenicity O +
with O +
the O +
adjuvant O +
iridoid O +
glycoside O +
adjuvant O -
. O +

Process O +
for O +
the O +
preparation O +
of O +
a O +
taxane O +
derivative O +
The O +
invention O +
relates O +
to O +
an O +
improved O +
process O +
for O +
the O +
synthesis O +
of O +
13- O -
( O -
N O -
- O -
Boc O -
- O -
Î² O -
- O -
isobutylserinyl O -
) O -
-14-Î² O -
- O -
hydroxybaccatin O +
III-1,14-carbonate O +
( O -
I O -
) O -
, O +
wherein O +
carbonation O +
of O +
the O +
1,14-hydroxy O +
groups O +
of O +
the O +
baccatin O +
skeleton O +
is O +
carried O +
out O +
with O +
bis O -
( O -
trichloromethylcarbonate O +
and O +
the O +
7-hydroxy O +
group O +
is O +
protected O +
with O +
a O +
trichloroacetyl O +
group O -
. O +

Use O +
of O +
pyridoxal O +
phosphate O +
derivatives O +
for O +
the O +
treatment O +
of O +
diabetes O +
and O +
related O +
complications O +
Use O +
of O +
a O +
3-acylated O +
pyridoxal O +
analogue O -
, O +
a O +
pharmaceutically O +
acceptable O +
acid O +
addition O +
salt O +
thereof O -
, O +
or O +
a O +
mixture O +
thereof O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
treating O +
insulin O -
- O -
dependent O +
or O +
non O -
- O -
insulin O -
- O -
dependent O +
diabetes O +
mellitus O -
, O +
related O +
conditions O -
, O +
symptoms O +
of O +
insulin O -
- O -
dependent O +
or O +
non O -
- O -
insulin O -
- O -
dependent O +
diabetes O +
mellitus O +
or O +
related O +
conditions O -
, O +
or O +
any O +
combination O +
thereof O +
in O +
a O +
mammal O -
. O +

Alcohol O +
resistant O +
pharmaceutical O +
formulations O +
The O +
present O +
invention O +
provides O +
alcohol O +
resistant O +
oral O +
dosage O +
pharmaceutical O +
forms O +
and O +
methods O +
of O +
using O +
such O +
oral O +
dosage O +
forms O +
to O +
avoid O +
dose O +
dumping O +
if O +
the O +
dosage O +
form O +
is O +
taken O +
together O +
with O +
alcohol O -
. O +

Guanosine O -
- O -
rich O +
oligonucleotides O +
as O +
agents O +
for O +
inducing O +
cell O +
death O +
in O +
eukaryotic O +
cells O +
The O +
present O +
invention O +
relates O +
to O +
guanosine O -
- O -
rich O +
oligonucleotides O +
having O +
the O +
capacity O +
to O +
induce O +
cell O +
death O -
, O +
having O +
characteristics O +
of O +
programmed O +
cell O +
death O -
, O +
in O +
non O -
- O -
quiescent O +
cells O +
of O +
higher O +
eukaryotic O +
organisms O -
. O +

The O +
invention O +
also O +
relates O +
to O +
therapeutic O +
methods O +
involving O +
the O +
administration O +
of O +
these O +
nucleic O +
acid O +
molecules O +
to O +
subjects O +
suffering O +
from O -
, O +
or O +
being O +
predisposed O +
to O -
, O +
disorders O +
involving O +
abnormal O +
cell O +
proliferation O +
and O +
migration O -
. O +

The O +
invention O +
also O +
concerns O +
pharmaceutical O +
compositions O +
comprising O +
the O +
guanosine O -
- O -
rich O +
nucleic O +
acid O +
molecules O -
, O +
in O +
association O +
with O +
suitable O +
carriers O -
. O +

ASSOCIATION O +
OF O +
ÃŸ3 B-Gene +
RECEPTOR I-Gene +
AGONIST O +
AND O +
MONOAMINE O +
REUPTAKE O +
INHIBITORS O -
, O +
PHARMACEUTICAL O +
COMPOSITION O +
AND O +
THERAPEUTIC O +
USE O +
THEREOF O +
The O +
invention O +
concerns O +
the O +
association O +
of O +
at O +
least O +
one O +
ÃŸ3 B-Gene +
adrenergic I-Gene +
receptor I-Gene +
agonist O +
( O -
or O +
ÃŸ3 O +
agonist O -
) O +
with O +
a O +
monoamine O +
reuptake O +
inhibitor O -
. O +

The O +
invention O +
also O +
concerns O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
inventive O +
association O +
and O +
its O +
therapeutic O +
use O -
. O +

Novel O +
memory O +
ctl O +
induction O +
potentiator O +
The O +
present O +
invention O +
relates O +
to O +
a O +
memory O +
CTL O +
induction O +
enhancer O +
comprising O +
a O +
combination O +
of O +
substance O +
( O -
b O -
) O +
with O +
substance O +
( O -
a O -
) O +
and/or O +
substance O +
( O -
c O -
) O -
, O +
wherein O +
substance O +
( O -
a O -
) O +
is O +
an O +
activator O +
of O +
antigen O -
- O -
presenting O +
cells O -
, O +
substance O +
( O -
b O -
) O +
is O +
an O +
inducer O +
of O +
homeostatic O +
proliferation O +
after O +
induction O +
of O +
lymphopenia O -
, O +
and O +
substance O +
( O -
c O -
) O +
is O +
a O +
suppressor O +
of O +
regulatory O +
T O +
cells O -
. O +

Use O +
of O +
tenatoprazole O +
for O +
the O +
treatment O +
of O +
gastroesophageal O +
reflux O +
disease O +
Use O +
of O +
tenatoprazole O +
is O +
claimed O +
in O +
medicines O +
for O +
the O +
treatment O +
of O +
atypical O +
and O +
esophageal O +
symptoms O +
of O +
gastroesophageal O +
reflux O -
, O +
digestive O +
hemorrhages O +
and O +
dyspepsias O -
. O +

- O +
ACTIVITY O +
: O +
Gastrointestinal O -
- O -
Gen O -
; O +
Antiasthmatic O -
; O +
Antitussive O -
; O +
Respiratory O -
- O -
Gen O -
. O -
; O +
Antianginal O -
; O +
Hemostatic O -
. O +

In O +
a O +
test O -
, O +
fourteen O +
patients O +
suffering O +
from O +
gastroesophageal O +
reflux O +
were O +
given O +
a O +
daily O +
dose O +
of O +
tenatoprazole O +
( O -
20 O +
mg O -
) O +
for O +
4 O -
- O -
12 O +
weeks O -
. O +

In O +
twelve O +
cases O -
, O +
the O +
dosage O +
was O +
tolerated O +
perfectly O +
and O +
in O +
the O +
other O +
two O +
cases O +
it O +
was O +
well O -
- O -
tolerated O -
. O +

The O +
effect O +
on O +
the O +
symptoms O +
was O +
very O +
good O -
. O +

- O +
MECHANISM O +
OF O +
ACTION O +
: O +
Proton B-Gene +
pump I-Gene +
inhibitor O -
. O +

Inhibitors O +
of O +
human O +
immunodeficiency O +
virus O +
replication O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
their O +
derivatives O +
comprising O +
a O +
detectable O +
label O -
, O +
their O +
compositions O +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
human O +
immunodeficiency O +
virus O +
( O -
HIV O -
) O +
infection O -
. O +

In O +
particular O -
, O +
the O +
invention O +
provides O +
novel O +
inhibitors O +
of O +
HIV O +
replication O -
, O +
pharmaceutical O +
compositions O +
containing O +
such O +
compounds O +
and O +
methods O +
for O +
using O +
these O +
compounds O +
in O +
the O +
treatment O +
of O +
HIV O +
infection O -
. O +

Modulation O +
of O +
the O +
P2Y2 B-Gene +
receptor I-Gene +
pathway O +
The O +
present O +
invention O +
relates O +
to O +
the O +
field O +
of O +
regulating O +
the O +
activity O +
of O +
the O +
purinergic B-Gene +
receptors I-Gene +
for O +
the O +
modulation O +
of O +
the O +
vascular O +
tone O -
, O +
particularly O +
for O +
the O +
purpose O +
of O +
treatment O +
of O +
haemodynamic O +
conditions O +
by O +
overriding O +
of O +
vasoconstriction O +
activity O -
, O +
such O +
as O +
increases O +
in O +
sympathic O +
vasoconstriction O -
. O +

Modulators O -
, O +
such O +
as O +
UTP O +
analogues O +
as O +
described O +
herein O +
are O +
preferably O +
specific O +
for O +
P2Y2 O -
. O +

Compounds O +
capable O +
of O +
stimulating O +
the O +
P2Y2 B-Gene +
receptor I-Gene +
are O +
suitable O +
for O +
the O +
treatment O +
or O +
prevention O +
wherein O +
inhibition O +
of O +
vasoconstriction O +
activity O +
is O +
desirable O +
such O +
as O +
hypertension O +
and O +
hypertension O +
relates O +
disorders O +
or O +
diseases O -
, O +
whereas O +
compound O +
capable O +
of O +
counteracting O +
the O +
activity O +
of O +
the O +
P2Y2 B-Gene +
receptor I-Gene +
are O +
suitable O +
for O +
the O +
treatment O +
of O +
or O +
prevention O +
wherein O +
inhibition O +
of O +
vasodilatation O +
is O +
desirable O -
. O +

Derivatives O +
of O +
1-phenyl-2-pyridynyl O +
alkylene O +
alcohols O +
as O +
phosphodiesterase B-Gene +
inhibitors O +
The O +
invention O +
relates O +
to O +
inhibitors O +
of O +
the O +
phosphodiesterase B-Gene +
4 I-Gene +
( O -
PDE4 B-Gene -
) O +
enzyme O -
. O +

More O +
particularly O -
, O +
the O +
invention O +
relates O +
to O +
compounds O +
that O +
are O +
derivatives O +
of O +
1-phenyl-2-pyridynyl O +
alkylene O +
alcohols O -
, O +
methods O +
of O +
preparing O +
such O +
compounds O -
, O +
compositions O +
containing O +
them O +
and O +
therapeutic O +
use O +
thereof O -
. O +

Binding O +
interaction O +
of O +
proanthocyanidins O +
with O +
bacteria O +
and O +
bacterial O +
components O +
A O +
composition O +
having O -
: O +
a O +
proanthocyanidin O -
: O +
and O +
a O +
macromolecule O -
, O +
an O +
assembly O +
of O +
macromolecules O -
, O +
a O +
semi O -
- O -
solid O -
, O +
or O +
a O +
solid O +
surface O +
to O +
which O +
the O +
proanthocyanidin O +
is O +
immobilized O -
. O +

A O +
composition O +
having O +
proanthocyanidin O +
compounds O +
having O +
an O +
average O +
degree O +
of O +
polymerization O +
of O +
at O +
least O +
about O +
6 O -
. O +

A O +
method O +
of O +
administering O +
to O +
an O +
immunosuppressed O +
patient O +
or O +
a O +
patient O +
diagnosed O +
with O +
sepsis O +
or O +
septic O +
shock O +
a O +
composition O +
having O +
a O +
proanthocyanidin O -
. O +

A O +
method O +
of O +
administering O +
to O +
a O +
patient O +
diagnosed O +
with O +
a O +
gram O +
negative O +
bacterial O +
infection O +
a O +
composition O +
having O +
proanthocyanidin O +
compounds O +
having O +
an O +
average O +
degree O +
of O +
polymerization O +
of O +
at O +
least O +
about O +
6 O -
. O +

Pharmaceutical O +
composition O +
using O +
aliskiren O +
and O +
avosentan O +
The O +
present O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
and O +
method O +
of O +
achieving O +
a O +
therapeutic O +
effect O +
including O -
, O +
but O +
not O +
limited O +
to O -
, O +
the O +
treatment O +
of O +
hypertension O -
, O +
kidney O +
or O +
heart O +
disease O +
in O +
an O +
animal O -
, O +
preferably O +
a O +
mammal O +
including O +
a O +
human O +
subject O -
, O +
using O +
( O -
i O -
) O +
SPP100 O -
/ O -
aliskiren O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
in O +
combination O +
with O +
( O -
ii O -
) O +
SPP301 O -
/ O -
avosentan O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and O +
( O -
iii O -
) O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

4 O -
- O -
1 O +
bb O +
ligand O +
in O +
inflammatory O +
diseases O +
The O +
invention O +
provides O +
4-IBBL O +
blocking O +
agents O -
, O +
as O +
well O +
as O +
pharmaceutical O +
compositions O +
and O +
articles O +
of O +
manufacture O +
comprising O +
such O +
blocking O +
agents O +
as O +
new O +
therapeutic O +
interventions O +
for O +
sustained O +
inflammation O -
. O +

Thus O -
, O +
the O +
invention O +
also O +
provides O +
methods O +
for O +
reducing O +
sustained O +
production O +
of O +
tumor O +
necrosis O +
factor O -
. O +

Glucose O +
metabolism O +
ameliorating O +
agent O +
A O +
compound O +
of O +
the O +
formula O +
I O -
: O +
wherein O +
R1 O +
is O +
lower O +
alkyl O -
, O +
R2 O +
is O +
hydrogen O +
or O +
lower O +
alkyl O -
, O +
Z O +
is O +
optionally O +
substituted O +
lower O +
alkyl O -
, O +
optionally O +
substituted O +
lower O +
alkenyl O -
, O +
optionally O +
substituted O +
amino O -
, O +
optionally O +
substituted O +
lower O +
alkoxy O -
, O +
optionally O +
substituted O +
carbocyclyl O +
or O +
optionally O +
substituted O +
heterocyclyl O +
can O +
stimulate O +
the O +
glucose O +
metabolism O +
independent O +
of O +
change O +
in O +
body O +
weight O -
. O +

The O +
compound O +
can O +
be O +
used O +
as O +
a O +
glucose O +
metabolism O +
stimulating O +
agent O -
. O +

1-aryl-3-aminoalkoxy O -
- O -
pyrazoles O +
as O +
sigma O +
ligands O +
enhancing O +
analgesic O +
effects O +
of O +
opioids O +
and O +
attenuating O +
the O +
dependency O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
potentiation O +
of O +
the O +
analgesic O +
effect O +
of O +
opioids O +
as O +
well O +
as O +
to O +
attenuation O +
of O +
the O +
addiction O +
thereof O -
. O +

More O +
specifically O -
, O +
the O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
a O +
group O +
of O +
sigma O +
receptor O +
ligands O +
of O +
formula O +
I O +
for O +
the O +
potentiation O +
of O +
the O +
analgesic O +
effect O +
of O +
opioids O +
and O +
at O +
the O +
same O +
time O +
for O +
decreasing O +
of O +
the O +
dependency O +
induced O +
by O +
them O -
. O +

Oxylipins O +
from O +
long O +
chain O +
polyunsaturated O +
fatty O +
acids O +
and O +
methods O +
of O +
making O +
and O +
using O +
the O +
same O +
Disclosed O +
are O +
novel O +
oxylipins O -
, O +
referred O +
to O +
herein O +
as O +
docosanoids O +
and O +
eicosanoids O -
, O +
that O +
are O +
derived O +
from O +
C22 O +
polyunsaturated O +
fatty O +
acids O +
and O +
from O +
C20 O +
polyunsaturated O +
fatty O +
acids O -
, O +
respectively O -
, O +
and O +
methods O +
of O +
making O +
and O +
using O +
such O +
oxylipins O -
. O +

Also O +
disclosed O +
is O +
the O +
use O +
of O +
docosapentaenoic O +
acid O +
( O -
C22:5n-6 O -
) O +
( O -
DPAn-6 O -
) O -
, O +
docosapentaenoic O +
acid O +
( O -
C22:5n-3 O -
) O +
( O -
DPAn-3 O -
) O -
, O +
and O +
docosatetraenoic O +
acid O +
( O -
DTAn-6 O -
: O +
C22:4n-6 O -
) O -
, O +
docosatrienoic O +
acid O +
( O -
C22:3n-3 O -
) O +
( O -
DTrAn-3 O -
) O -
, O +
docosadienoic O +
acid O +
( O -
C22:2n-6 O -
) O +
( O -
DDAn-6 O -
) O -
, O +
eicosatrienoic O +
acid O +
( O -
C20:3n-3 O -
) O +
( O -
ETrAn-3 O -
) O +
eicosapentaenoic O +
acid O +
and O +
arachidonic O +
acid O +
as O +
substrates O +
for O +
the O +
production O +
of O +
novel O +
oxylipins O -
, O +
and O +
to O +
the O +
oxylipins O +
produced O +
thereby O -
. O +

Also O +
disclosed O +
is O +
the O +
use O +
of O +
DPAn-6 O -
, O +
DPAn-3 O -
, O +
DTAn-6 O -
, O +
and/or O +
the O +
oxylipins O +
derived O +
therefrom O -
, O +
and/or O +
novel O +
docosanoids O +
derived O +
from O +
the O +
structures O +
of O +
C22 O +
fatty O +
acids O +
in O +
therapeutic O +
and O +
nutritional O +
or O +
cosmetic O +
applications O -
, O +
and O +
particularly O +
as O +
anti O -
- O -
inflammatory O +
or O +
anti O -
- O -
neurodegenerative O +
compounds O -
. O +

The O +
invention O +
also O +
relates O +
to O +
novel O +
ways O +
of O +
producing O +
long O +
chain O +
polyunsaturated O +
acid O +
( O -
LCPUF O +
A O -
) O -
-rich O +
oils O +
and O +
compositions O +
that O +
contain O +
enhanced O +
and O +
effective O +
amounts O +
of O +
LCPUF O +
A O -
- O -
derived O +
oxylipins O -
, O +
and O +
particularly O -
, O +
docosanoids O -
. O +

Method O +
for O +
optimizing O +
the O +
treatment O +
of O +
chronic O +
myeloid O +
leukemia O +
with O +
abl B-Gene +
tyrosine O +
kinase O +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
evaluating O +
patients O +
to O +
help O +
optimizing O +
the O +
treatment O +
of O +
chronic O +
myeloid O +
leukemia O +
( O -
CML O -
) O +
in O +
a O +
human O +
patient O +
population O -
. O +

More O +
specifically O -
, O +
the O +
method O +
comprises O +
the O +
steps O +
of O +
( O -
a O -
) O +
determining O +
the O +
OCT-1 B-Gene +
Activity O +
in O +
pre O -
- O -
therapy O +
blood O +
of O +
a O +
warm O -
- O -
blooded O +
animal O +
suffering O +
from O +
CML O -
, O +
and O +
( O -
b O -
) O +
administering O +
a O +
daily O +
dose O +
between O +
about O +
500 O +
and O +
1200 O +
mg O +
of O +
Imatinib O +
mesylate O +
to O +
the O +
warm O -
- O -
blooded O +
animal O +
suffering O +
from O +
CML O +
showing O +
an O +
OCT-1 B-Gene +
Activity O +
corresponding O +
to O +
Imatinib O +
intracellular O +
concentration O +
below O +
about O +
6.0 O +
to O +
10.0 O +
ng O -
/ O -
200,000 O +
cells O -
, O +
especially O +
about O +
8.0 O +
to O +
8.5 O +
ng O -
/ O -
200,000 O +
cells O -
. O +

Florfenicol O +
esters O +
for O +
treating O +
bacterial O +
infections O +
The O +
present O +
invention O +
pertains O +
to O +
the O +
use O +
of O +
a O +
composition O +
comprising O +
a O +
florfenicol O +
ester O +
and O +
a O +
pharmaceutically O +
acceptable O +
solvent O +
wherein O +
the O +
florfenicol O +
ester O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
florfenicol O +
acetate O -
, O +
florfenicol O +
propionate O -
, O +
florfenicol O +
butyrate O -
, O +
florfenicol O +
pentanoate O -
, O +
florfenicol O +
heptanoate O -
, O +
florfenicol O +
octanoate O -
, O +
florfenicol O +
nanoate O -
, O +
florfenicol O +
decanoate O -
, O +
florfenicol O +
undecanoate O -
, O +
and O +
florfenicol O +
dodecanoate O -
; O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
treating O +
a O +
bacterial O +
infection O +
that O +
is O +
susceptible O +
to O +
florfenicol O +
in O +
a O +
bovine O +
that O +
can O +
be O +
administered O +
as O +
a O +
single O +
injection O +
in O +
an O +
amount O +
sufficient O +
to O +
treat O +
the O +
infection O +
without O +
requiring O +
a O +
second O +
injection O +

Anti O -
- O -
glycation O +
properties O +
of O +
asicatic O +
acid O +
and O +
madecassic O +
acid O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
the O +
use O +
of O +
compounds O +
from O +
Centella O +
Asiatica O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
Asiatic O +
acid O +
and O +
Madecassic O +
acid O -
, O +
and O +
plant O +
extracts O +
containing O +
both O +
acids O +
in O +
cosmetics O -
, O +
pharmaceuticals O +
and O +
food O +
supplements O +
for O +
preventing O +
the O +
glycation O +
phenomenon O +
and O +
the O +
glycation O +
consequences O +
in O +
tissues O -
, O +
more O +
paticularly O +
for O +
preventing O +
skin O +
aging O -
, O +
enhancing O +
wounds O +
treating O -
, O +
venous O +
insufficiency O +
etc O -
. O +

Poly O +
aromatic O +
sodium B-Gene +
channel I-Gene +
blockers O +
Polyaromatic O +
sodium B-Gene +
channel I-Gene +
blockers O +
represented O +
by O +
the O +
formula O -
: O +
( O +
I O +
) O +
are O +
provided O +
where O +
the O +
structural O +
variables O +
are O +
defined O +
herein O -
. O +

The O +
invention O +
also O +
includes O +
a O +
variety O +
of O +
compositions O -
, O +
combinations O +
and O +
methods O +
of O +
treatment O +
using O +
these O +
inventive O +
sodium B-Gene +
channel I-Gene +
blockers O -
. O +

2-aminopyridine O +
kinase B-Gene +
inhibitors O +
2-Aminopyridine O +
compounds O +
having O +
the O +
structure O +
of O +
Formula O +
I O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O +
of O +
these O +
compounds O -
. O +

Compounds O +
of O +
Formula O +
I O +
inhibit O +
the O +
activity O +
of O +
tyrosine B-Gene +
kinase I-Gene +
enzymes O +
in O +
animals O -
, O +
including O +
humans O -
, O +
and O +
are O +
useful O +
in O +
the O +
treatment O +
and/or O +
prevention O +
of O +
various O +
diseases O +
and O +
conditions O -
. O +

In O +
particular O -
, O +
compounds O +
disclosed O +
herein O +
are O +
inhibitors O +
of O +
kinases O -
, O +
in O +
particular O -
, O +
but O +
not O +
limited O +
to O -
, O +
KDR B-Gene -
, O +
Tie-2 B-Gene -
, O +
F1t3 B-Gene -
, O +
FGFR3 B-Gene -
, O +
Ab1 B-Gene -
, O +
Aurora B-Gene +
A I-Gene -
, O +
c B-Gene -
- I-Gene -
Src I-Gene -
, O +
IGF- B-Gene +
IR I-Gene -
, O +
ALK B-Gene -
, O +
c B-Gene -
- I-Gene -
MET I-Gene -
, O +
RON B-Gene -
, O +
PAK1 B-Gene -
, O +
PAK2 B-Gene -
, O +
and O +
TAK1 B-Gene -
, O +
and O +
can O +
be O +
used O +
in O +
the O +
treatment O +
of O +
proliferative O +
diseases O -
, O +
such O +
as O -
, O +
but O +
not O +
limited O +
to O -
, O +
cancer O -
. O +

The O +
present O +
invention O +
is O +
also O +
directed O +
to O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
of O +
Formula O +
I O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

The O +
present O +
invention O +
is O +
further O +
directed O +
to O +
a O +
method O +
of O +
treating O +
a O +
patient O +
having O +
a O +
condition O +
which O +
is O +
mediated O +
by O +
protein B-Gene +
kinase I-Gene +
activity O +
by O +
administering O +
to O +
the O +
patient O +
a O +
therapeutically O +
effective O +
amount O +
of O +
the O +
above O -
- O -
mentioned O +
pharmaceutical O +
composition O -
. O +

Stabilization O +
of O +
the O +
composition O +
of O +
a O +
mixture O +
Described O +
is O +
a O +
method O +
for O +
slowing O +
the O +
speed O +
of O +
the O +
isomerisation O +
of O +
petasin O +
and O +
neopetasin O +
to O +
isopetasin O -
, O +
and O +
the O +
isomerisation O +
of O +
S O -
- O -
petasin O +
and O +
neo O -
- O -
S O -
- O -
petasin O +
to O +
iso O -
- O -
S O -
- O -
petasin O -
, O +
especially O +
in O +
extracts O +
from O +
plants O +
of O +
the O +
genus O +
Petasites O -
, O +
preferably O +
Petasites O +
hybridus O -
, O +
by O +
the O +
addition O +
of O +
at O +
least O +
one O +
suitable O +
stabilizer O +
and/or O +
the O +
removal O +
of O +
at O +
least O +
one O +
destabilizing O +
substance O -
, O +
e.g. O +
a O +
fatty O +
acid O -
. O +

Enhanced O +
nsaid O +
formulations O +
The O +
application O +
is O +
directed O +
to O +
a O +
composition O +
and O +
its O +
use O +
for O +
treating O +
inflammation O +
comprising O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
active O +
agent O -
, O +
a O +
metasilicate O -
, O +
a O +
first O +
disintegrant O +
and O +
a O +
second O +
disintegrant O -
, O +
resulting O +
in O +
increased O +
absorption O +
of O +
said O +
active O +
in O +
mammals O +
with O +
suppressed O +
vagal O +
systems O +
The O +
preferred O +
composition O +
includes O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
active O -
, O +
sodium O +
bicarbonate O -
, O +
tartaric O +
acid O +
and O +
metasilicate O -
. O +

Tetracyclic O +
compound O +
Provided O +
are O +
a O +
tetracyclic O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
I O -
) O -
: O +
[ O -
in O +
the O +
formula O -
( O -
I O -
) O -
,the O +
formula O +
( O -
A O -
) O +
represents O +
a O +
benzene O +
ring O +
or O +
the O +
like O -
, O +
X O +
represents O +
CH O +
or O +
a O +
nitrogen O +
atom O -
, O +
Q O +
represents O +
-O- O +
or O +
the O +
like O -
, O +
R1 O -
, O +
R2 O -
, O +
and O +
R3 O +
may O +
be O +
the O +
same O +
or O +
different O +
and O +
each O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
, O +
1 O -
, O +
m O -
, O +
and O +
n O +
each O +
represent O +
an O +
integer O +
from O +
one O +
to O +
the O +
maximum O +
substitutable O +
number O +
of O +
substituents O -
, O +
and O +
R4 O +
and O +
R5 O +
may O +
be O +
the O +
same O +
or O +
different O +
and O +
each O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
] O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
the O +
like O -
. O +

Cosmetic O +
composition O +
for O +
sensitive O +
skins O +
Cosmetic O +
composition O +
for O +
sensitive O +
skins O +
comprising O +
hyperoxygenated O +
fatty O +
acids O +
and O +
one O +
or O +
more O +
volatile O +
silicones O -
, O +
together O +
with O +
the O +
use O +
thereof O +
for O +
the O +
prevention O +
of O +
ulcers O +
and O +
the O +
preservation O +
of O +
perilesional O +
skin O -
. O +

Combination O +
of O +
a O +
phosphatidylinositol-3-kinase B-Gene +
( O -
pi3k B-Gene -
) O +
inhibitor O +
and O +
a O +
mtor B-Gene +
inhibitor O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
combination O +
which O +
comprises O +
( O -
a O -
) O +
a O +
phosphoinositide B-Gene +
3-kinase I-Gene +
inhibitor O +
compound O +
of O +
formula O +
( O -
I O -
) O +
and O +
( O -
b O -
) O +
a O +
mTOR B-Gene +
inhibitor O +
for O +
the O +
treatment O +
of O +
a O +
target B-Gene +
of I-Gene +
raparnycin I-Gene +
( I-Gene -
mTOR I-Gene -
) I-Gene +
kinase I-Gene +
dependent O +
disease O -
, O +
especially O +
a O +
cancer O +
disease O -
; O +
a O +
pharmaceutical O +
composition O +
comprising O +
such O +
a O +
combination O -
; O +
the O +
use O +
of O +
such O +
a O +
combination O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
the O +
treatment O +
of O +
a O +
proliferative O +
disease O -
; O +
a O +
commercial O +
package O +
or O +
product O +
comprising O +
such O +
a O +
combination O +
as O +
a O +
combined O +
preparation O +
for O +
simultaneous O -
, O +
separate O +
or O +
sequential O +
use O -
; O +
and O +
to O +
a O +
method O +
of O +
treatment O +
of O +
a O +
warmÂ¬ O +
blooded O +
animal O -
, O +
especially O +
a O +
human O -
. O +

Benzonaphtyridine O +
compounds O +
used O +
as O +
inhibitors O +
of O +
autotaxin O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5,D O -
, O +
Z O -
, O +
X O -
, O +
Y O -
, O +
m O +
and O +
p O +
are O +
defined O +
as O +
cited O +
in O +
claim O +
1 O -
. O +

Said O +
compounds O +
can O +
be O +
used O +
in O +
the O +
treatment O +
of O +
tumours O -
. O +

Topical O +
cosmetic O +
or O +
pharmaceutical O +
composition O +
comprising O +
probiotic O +
lactobacillus O +
strains O +
and O +
use O +
of O +
same O +
A O +
topical O +
composition O +
which O +
is O +
suitable O +
for O +
treating O +
or O +
preventing O +
skin O +
or O +
mucosal O +
infectious O +
disorders O +
or O +
troubles O +
in O +
humans O -
, O +
in O +
particular O +
for O +
treating O +
or O +
preventing O +
urinary O +
tract O +
infections O +
and O +
lower O +
vaginal O +
tract O +
infections O +
in O +
females O +
comprises O +
an O +
oily O +
primary O +
phase O +
and O +
a O +
complementary O +
aqueous O +
phase O +
wherein O +
the O +
oily O +
primary O +
phase O +
consists O +
of O +
a O +
non O +
polar O +
mineral O +
or O +
silicone O +
comprising O +
an O +
efficient O +
amount O +
of O +
at O +
least O +
one O +
viable O +
probiotic O +
bacteria O +
strain O -
, O +
in O +
particular O +
a O +
lactobacillus O +
strain O -
. O +

The O +
composition O +
is O +
also O +
useful O +
for O +
suitable O +
for O +
balancing O +
or O +
restoring O +
skin O +
or O +
mucosal O +
indigenous O +
microflora O +
in O +
humans O -
, O +
in O +
particular O +
for O +
balancing O +
or O +
restoring O +
the O +
local O +
urinary O +
tract O +
and O +
lower O +
vaginal O +
tract O +
bacterial O +
flora O +
in O +
females O -
. O +

Pyrazole O -
- O -
amine O +
compounds O +
useful O +
as O +
kinase O +
inhibitors O +
The O +
present O +
invention O +
provides O +
pyrazole O +
derived O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
useful O +
for O +
treating O +
p38 O +
kinase O -
- O -
associated O +
conditions O -
, O +
where O +
W O -
, O +
X O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O +
and O +
m O +
are O +
as O +
defined O +
herein O -
. O +

The O +
invention O +
further O +
pertains O +
to O +
pharmaceutical O +
compositions O +
containing O +
at O +
least O +
one O +
compound O +
according O +
to O +
the O +
invention O +
useful O +
for O +
treating O +
p38 O +
kinase O -
- O -
associated O +
conditions O -
, O +
and O +
methods O +
of O +
inhibiting O +
the O +
activity O +
of O +
p38 O +
kinase O +
in O +
a O +
mammal O -
. O +

Methods O +
for O +
making O +
valerenic O +
acid O +
derivatives O +
and O +
their O +
use O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compounds O -
, O +
intermediates O +
and O +
methods O +
for O +
making O +
valerenic O +
acid O +
and O +
its O +
derivatives O +
as O +
well O +
as O +
the O +
use O +
of O +
such O +
compounds O +
as O +
GABAA O +
receptor O +
ligands O -
. O +

3- O -
( O -
5-Amino-6-oxo-1,6-dihydropyridazin-3-yl O -
) O -
-biphenyl O +
derivatives O +
as O +
PDE4 B-Gene +
inhibitors O +
New O +
pyridazin-3 O -
( O -
2H O -
) O -
-one O +
derivatives O +
having O +
the O +
chemical O +
structure O +
of O +
formula O +
( O -
I O -
) O +
are O +
disclosed O -
; O +
as O +
well O +
as O +
process O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
comprising O +
them O +
and O +
their O +
use O +
in O +
therapy O +
as O +
inhibitors O +
of O +
the O +
phosphodiesterase B-Gene +
IV I-Gene +
( O -
PDE4 B-Gene -
) O -
. O +

Diazeniumdiolated O +
phosphorylcholine O +
polymers O +
for O +
nitric O +
oxide O +
release O +
The O +
present O +
disclosure O +
in O +
a O +
broad O +
aspect O +
provides O +
for O +
diazeniumdiolated O +
phosphorylcholine O +
polymers O +
and O +
associated O +
methods O +
for O +
achieving O +
nitric O +
oxide O +
release O -
. O +

The O +
present O +
polymers O +
have O +
superior O +
biocompatibility O +
and O +
are O +
useful O +
for O +
coating O +
or O +
fabricating O +
medical O +
devices O +
such O +
as O +
a O +
vascular O +
stent O -
. O +

5,6,7,8-TETRAHYDRO O -
[ O -
1,2,4 O -
] O -
TRIAZOLO O -
[ O -
4,3-a O -
] O -
PYRAZINE O +
DERIVATIVES O +
AS O +
P2X7 O +
MODULATORS O +
The O +
present O +
invention O +
provides O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
wherein O +
A O +
is O +
hydrogen O -
, O +
C1 O -
- O -
4alkyl O -
, O +
C3 O -
- O -
6cycloalkyl O -
, O +
C1 O -
- O -
3alkoxy O -
, O +
C1 O -
- O -
3alkoxy O +
C1 O -
- O -
4alkyl O -
, O +
C1 O -
- O -
2fluoroalkyl O -
, O +
halogen O -
, O +
NR6 O +
R7 O -
, O +
optionally O +
substituted O +
heteroaryl O +
( O -
Het O -
) O -
, O +
or O +
optionally O +
substituted O +
phenyl O -
, O +
and O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O +
and O +
R7 O +
are O +
as O +
defined O +
in O +
the O +
description O -
. O +

The O +
compounds O +
or O +
salts O +
are O +
thought O +
to O +
modulate O +
P2X7 O +
receptor O +
function O +
and O +
to O +
be O +
capable O +
of O +
antagonizing O +
the O +
effects O +
of O +
ATP O +
at O +
the O +
P2X7 O +
receptor O -
. O +

The O +
invention O +
also O +
provides O +
the O +
use O +
of O +
the O +
compound O +
or O +
salt O +
in O +
the O +
treatment O +
or O +
prophylaxis O +
of O -
, O +
for O +
example O -
, O +
inflammatory O +
pain O -
, O +
neuropathic O +
pain O -
, O +
visceral O +
pain O -
, O +
rheumatoid O +
arthritis O -
, O +
osteoarthritis O +
or O +
neurodegenerative O +
disorders O -
. O +

Methods O +
and O +
compositions O +
for O +
treating O +
ophthalmic O +
conditions O +
We O +
describe O +
methods O +
and O +
compositions O +
for O +
treating O +
ophthalmic O +
conditions O +
associated O +
with O +
angiogenesis O -
, O +
vascular O +
leakage O -
, O +
and/or O +
damage O +
to O +
ganglia O -
. O +

Combination O +
of O +
dopamine O +
agonists O +
plus O +
first O +
phase O +
insulin O +
secretagouges O +
for O +
the O +
treatment O +
of O +
metabolic O +
disorders O +
The O +
present O +
invention O +
is O +
directed O +
to O +
a O +
method O +
of O +
treating O +
a O +
metabolic O +
disorder O +
or O +
key O +
elements O +
of O +
a O +
metabolic O +
disorder O +
such O +
method O +
comprising O +
the O +
use O +
of O +
an O +
agent O -
( O -
s O -
) O +
that O +
increases O +
central O +
dopaminergic O +
activity O +
plus O +
a O +
first O -
- O -
phase O +
insulin B-Gene +
secretagouge O -
. O +

2- O +
( O +
lh O -
- O -
pyrazol-4 O +
-ylamino O +
) O +
-pyrimidine O +
as O +
kinase B-Gene +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutical O +
acceptable O +
salts O -
: O +
wherein O +
A1 O -
, O +
A2 O -
, O +
A3 O -
, O +
A4 O -
, O +
X O +
and O +
Y O +
are O +
defined O +
in O +
the O +
description O -
. O +

The O +
present O +
invention O +
relates O +
also O +
to O +
methods O +
of O +
making O +
said O +
compounds O -
, O +
and O +
compositions O +
containing O +
said O +
compounds O +
which O +
are O +
useful O +
for O +
inhibiting O +
kinases O +
such O +
as O +
aurora B-Gene +
and O +
KDR B-Gene -
. O +

The O +
use O +
of O +
lpa O +
for O +
encouraging O +
pregnancy O -
, O +
and O +
fertility O +
agent O +
The O +
objective O +
is O +
to O +
find O +
compounds O +
which O +
have O +
an O +
activity O +
to O +
improve O +
the O +
success O +
rate O +
of O +
pregnancy O +
and O +
implantation O +
in O +
blastocyst O +
transfer O +
in O +
mammals O -
, O +
to O +
provide O +
a O +
method O +
of O +
producing O +
and O +
using O +
the O +
compounds O -
, O +
and O +
to O +
provide O +
a O +
pregnancy O -
- O -
promoting O +
agent O -
. O +

Disclosed O +
is O +
a O +
pregnancy O -
- O -
promoting O +
agent O +
containing O +
one O +
or O +
more O +
lysophosphatidic O +
acids O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
LPA O -
- O -
C16:0 O -
, O +
LPA O -
- O -
C16:1 O -
, O +
LPA O -
- O -
C18:0 O -
, O +
LPA O -
- O -
C18:1 O +
and O +
LPA O -
- O -
C18:2 O -
. O +

Medical O +
use O +
of O +
spla2 O +
hydrolysable O +
liposomes O +
The O +
present O +
invention O +
relates O +
to O +
medical O +
use O +
of O +
liposomes O -
, O +
more O +
particular O +
the O +
first O +
medical O +
use O +
of O +
sPLA2 O +
hydrolysable O +
liposomes O -
. O +

Such O +
liposomes O +
may O +
be O +
used O +
for O +
targeted O +
delivery O +
of O +
therapeutic O +
agents O +
to O +
cancerous O +
tissue O +
and O +
in O +
such O +
embodiments O -
; O +
the O +
therapeutic O +
agents O +
are O +
typically O +
small O +
molecule O +
antitumor O +
agents O -
. O +

Other O +
aspects O +
of O +
the O +
inventions O +
relates O +
to O +
methods O +
of O +
reducing O +
the O +
side O +
effects O +
of O +
therapeutic O +
agents O -
, O +
e.g. O +
reducing O +
nephrotoxicity O -
, O +
neurotoxicity O +
and O +
gastrointestinal O +
toxicity O +
of O +
a O +
therapeutic O +
agent O -
. O +

Yet O +
another O +
aspect O +
of O +
the O +
present O +
invention O +
relate O +
to O +
methods O +
of O +
prolonging O +
the O +
therapeutic O +
effect O +
of O +
a O +
therapeutic O +
agent O -
. O +

Solid O +
pharmaceutical O +
composition O +
for O +
oral O +
administration O +
The O +
present O +
invention O +
relates O +
to O +
a O +
solid O +
pharmaceutical O +
composition O +
for O +
oral O +
administration O -
, O +
containing O +
the O +
following O +
components O +
( O -
A O -
) O +
and O +
( O -
B O -
) O -
: O +
( O -
A O -
) O +
2- O -
[ O -
4- O -
[ O -
2- O -
( O -
benzimidazol-2-ylthio O -
) O -
ethyl O -
] O -
piperazin-1-yl O -
] O -
-N- O -
[ O -
2,4 O +
-bis O -
( O -
methylthio O -
) O -
-6-methyl-3-pyridyl O -
] O -
acetamide O +
( O -
compound O +
a O -
) O +
or O +
an O +
acid O +
addition O +
salt O +
thereof O -
, O +
and O +
( O -
B O -
) O +
organic O +
acid O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
tartaric O +
acid O -
, O +
malic O +
acid O -
, O +
ascorbic O +
acid O +
and O +
benzoic O +
acid O -
. O +

An O +
improvement O +
is O +
achieved O +
in O +
the O +
dissolubility O +
of O +
the O +
compound O +
a O -
, O +
which O +
is O +
useful O +
as O +
a O +
therapeutic O +
agent O +
for O +
hypercholesterolemia O -
, O +
arteriosclerosis O -
, O +
and O +
the O +
like O -
. O +

Inhibitors O +
of O +
long O +
and O +
very O +
long O +
chain O +
fatty O +
acid O +
metabolism O +
as O +
broad O +
spectrum O +
anti O -
- O -
virals O +
The O +
present O +
invention O +
provides O +
methods O +
and O +
compounds O +
for O +
treating O +
viral O +
infections O +
using O +
modulators O +
of O +
host O +
cell O +
enzymes O +
relating O +
to O +
long O +
chain O +
fatty O +
acid O +
and O +
lipid O +
droplet O +
metabolism O -
. O +

It O +
includes O +
a O +
method O +
of O +
treating O +
viral O +
infections O +
using O +
triacsin O +
C O +
and O +
its O +
relatives O -
, O +
analogues O +
and O +
derivatives O +
as O +
well O +
as O +
other O +
inhibitors O +
of O +
long O +
chain O +
fatty O +
acid O +
metabolism O +
and O +
lipid O +
droplet O +
metabolism O -
. O +

Inhibitors O +
of O +
glucose O +
metabolism O +
for O +
use O +
in O +
the O +
treatment O +
of O +
birt O -
- O -
hogg O -
- O -
dubÃ© O +
syndrome O +
A O +
composition O +
comprising O +
an O +
inhibitor O +
of O +
glucose O +
metabolism O +
for O +
use O +
in O +
the O +
treatment O +
of O +
Birt O -
- O -
Hogg O -
- O -
DubÃ© O +
syndrome O -
. O +

The O +
inhibitor O +
of O +
glucose O +
metabolism O +
may O +
be O +
a O +
glycolytic O +
inhibitor O -
. O +

The O +
inhibitor O +
of O +
glucose O +
metabolism O +
may O +
be O +
an O +
inhibitor O +
of O +
pyruvate O +
metabolism O -
. O +

Suitable O +
inhibitors O +
of O +
glucose O +
metabolism O +
include O +
2-deoxy O -
- O -
D- O +
glucose O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O +
or O +
oxamate O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O -
. O +

Treatment O +
of O +
excessive O +
menstrual O +
bleeding O +
associated O +
with O +
uterine O +
fibroids O +
The O +
present O +
invention O +
relates O +
generally O +
to O +
benign O +
gynecological O +
diseases O +
and O +
in O +
particular O +
to O +
a O +
method O +
for O +
reducing O +
heavy O +
menstruation O +
associated O +
with O +
said O +
gynecological O +
diseases O +
following O +
treatment O +
with O +
vascular O +
occlusion O +
methods O +
or O +
thermal O +
related O +
treatment O +
methods O -
. O +

Pharmaceutical O +
composition O +
for O +
the O +
prevention O +
or O +
the O +
treatment O +
of O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
and O +
the O +
method O +
for O +
prevention O +
or O +
treatment O +
of O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
using O +
the O +
same O +
The O +
present O +
invention O +
provides O +
a O +
pharmaceutical O +
composition O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
a O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O +
( O -
NAFLD O -
) O -
, O +
containing O +
an O +
active O +
ingredient O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
Compound O +
1 O +
represented O +
by O +
formula O +
1 O -
, O +
sitagliptin O -
, O +
vildagliptin O -
, O +
linagliptin O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Further O -
, O +
the O +
present O +
invention O +
provides O +
a O +
method O +
for O +
the O +
prevention O +
or O +
treatment O +
of O +
a O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O -
, O +
including O +
administering O +
an O +
effective O +
amount O +
of O +
an O +
active O +
ingredient O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
Compound O +
1 O +
represented O +
by O +
formula O +
1 O -
, O +
sitagliptin O -
, O +
vildagliptin O -
, O +
linagliptin O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
to O +
a O +
mammal O +
including O +
a O +
human O +
in O +
need O +
thereof O -
. O +

Further O -
, O +
the O +
present O +
invention O +
provides O +
use O +
of O +
Compound O +
1 O +
represented O +
by O +
formula O +
1 O -
, O +
sitagliptin O -
, O +
vildagliptin O -
, O +
linagliptin O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
for O +
manufacturing O +
a O +
pharmaceutical O +
composition O +
for O +
the O +
prevention O +
or O +
treatment O +
of O +
a O +
non O -
- O -
alcoholic O +
fatty O +
liver O +
disease O -
. O +

Therapeutic O +
Agent O +
for O +
Migraine O +
Provided O +
are O +
therapeutic O +
and/or O +
preventive O +
agents O +
for O +
migraine O +
which O +
comprise O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
compound O +
having O +
a O +
selective O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
antagonistic O +
activity O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
; O +
therapeutic O +
and/or O +
preventive O +
agents O +
for O +
migraine O +
which O +
comprises O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
compound O +
having O +
a O +
selective O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
antagonistic O +
activity O -
, O +
which O +
has O +
an O +
affinity O +
for O +
the O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
10 O +
times O +
or O +
higher O +
than O +
that O +
for O +
the O +
adenosine B-Gene +
A1 I-Gene +
receptor I-Gene -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
; O +
and O +
the O +
like O -
. O +

Gaseous O +
nitric O +
oxide O -
- O -
sequestering O +
products O +
and O +
processes O +
of O +
preparing O +
same O +
A O +
process O +
of O +
preparing O +
articles O +
having O +
gaseous O +
NO O +
sequestered O +
therein O +
is O +
disclosed O -
, O +
as O +
well O +
as O +
articles O +
prepared O +
thereby O -
. O +

Also O +
disclosed O +
are O +
articles O +
having O +
gaseous O +
NO O +
sequestered O +
therewithin O +
and O +
having O +
reduced O +
amount O +
of O +
oxygen O -
- O -
containing O +
and/or O +
nitrogen O -
- O -
containing O +
reactive O +
species O -
. O +

Also O +
disclosed O +
are O +
processes O +
of O +
preparing O +
packaged O +
articles O +
having O +
a O +
non O -
- O -
gas O +
permeable O +
package O +
that O +
comprises O +
gaseous O +
NO O +
therein O +
and O +
packaged O +
articles O +
made O +
therefrom O -
. O +

Also O +
disclosed O +
are O +
charging O +
devices O +
which O +
can O +
be O +
utilized O +
in O +
the O +
above O -
- O -
described O +
processes O -
. O +

The O +
articles O +
prepared O +
by O +
the O +
above O -
- O -
described O +
processes O +
are O +
preferably O +
medical O +
devices O +
such O +
as O +
indwelling O +
catheters O -
, O +
intubation O +
devices O +
and O +
tampons O -
. O +

Tampons O +
having O +
sequestered O +
therein O +
gaseous O +
NO O -
, O +
uses O +
thereof O +
and O +
processes O +
of O +
preparing O +
same O +
are O +
also O +
disclosed O -
. O +

Pharmaceutical O +
compound O +
for O +
treating O +
status O +
asthmaticus O +
Pharmaceutical O +
composition O +
comprises O +
enoximone O -
, O +
which O +
is O +
administered O +
intravenously O +
in O +
an O +
amount O +
of O +
not O +
> O +
300 O +
mg O +
per O +
day O -
, O +
preferably O +
200 O +
mg O +
per O +
day O -
. O +

An O +
independent O +
claim O +
is O +
also O +
included O +
for O +
a O +
kit O +
comprising O +
the O +
pharmaceutical O +
composition O +
and O +
a O +
drug O +
including O +
beta O +
-2 O +
sympathomimetic O +
agent O -
, O +
catecholamines O -
, O +
aminophylline O -
, O +
corticosteroids O -
, O +
parasympatholytic O +
agent O -
, O +
magnesium O +
sulfate O -
, O +
ketamine O +
and/or O +
S O -
- O -
ketamine O +
for O +
treating O +
status O +
asthmaticus O -
. O +

ACTIVITY O +
: O +
Antiasthmatic O -
. O +

Test O +
details O +
are O +
described O +
but O +
no O +
results O +
given O -
. O +

MECHANISM O +
OF O +
ACTION O +
: O +
None O +
given O -
. O +

New O +
cathepsin O +
s O +
protease O +
inhibitors O -
, O +
useful O +
in O +
the O +
treatment O +
of O +
e.g. O +
autoimmune O +
disorders O -
, O +
allergy O +
and O +
chronic O +
pain O +
conditions O +
Compounds O +
of O +
the O +
formula O +
( O -
I O -
) O +
wherein O +
R2a O +
and O +
R2b O +
are O +
independently O +
H O -
, O +
halo O -
, O +
C1-C4alkyl O -
, O +
C1-C4haloalkyl O +
or O +
C1-C4alkoxy O -
, O +
or O +
R2a O +
and O +
R2b O +
together O +
with O +
the O +
carbon O +
atom O +
to O +
which O +
they O +
are O +
attached O +
form O +
a O +
C3-C6cycloalkyl O -
; O +
R3 O +
is O +
a O +
C5-C10 O +
alkyl O -
, O +
optionally O +
substituted O +
with O +
1 O -
- O -
3 O +
substituents O +
independently O +
selected O +
from O +
halo O -
, O +
C1-C4haloalkyl O -
, O +
C1-C4alkoxy O -
, O +
C1-C4haloalkoxy O -
; O +
or O +
R3 O +
is O +
a O +
C2-C4alkyl O +
chain O +
with O +
at O +
least O +
2 O +
chloro O +
or O +
3 O +
fluoro O +
substituents O -
; O +
or O +
R3 O +
is O +
C3-C7cycloalkylmethyl O -
, O +
optionally O +
substituted O +
with O +
1 O -
- O -
3 O +
substituents O +
independently O +
selected O +
from O +
C1-C4alkyl O -
, O +
halo O -
, O +
C1-C4haloalkyl O -
, O +
C1-C4alkoxy O -
, O +
C1-C4haloalkoxy O -
; O +
R4 O +
is O +
C1-C6alkyl O -
, O +
C1-C6haloalkyl O -
, O +
C1-C6alkoxy O -
, O +
C1-C6haloalkoxy O -
, O +
C1-C6alkylamino O -
, O +
C1- O +
C6dialkylamino O +
or O -
; O +
R4 O +
is O +
Het O +
or O +
Carbocyclyl O -
, O +
either O +
of O +
which O +
is O +
optionally O +
substituted O +
with O +
1 O -
- O -
3 O +
substituents O -
; O +
n O +
is O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
for O +
the O +
use O +
in O +
the O +
prophylaxis O +
or O +
treatment O +
of O +
a O +
disorder O +
characterised O +
by O +
inappropriate O +
expression O +
or O +
activation O +
of O +
cathepsin O +
S. O +

Methods O +
of O +
treating O +
or O +
ameliorating O +
diseases O +
and O +
enhancing O +
performance O +
comprising O +
the O +
use O +
of O +
a O +
magnetic O +
dipole O +
stabilized O +
solution O +
The O +
present O +
invention O +
is O +
directed O +
to O +
methods O +
for O +
treating O +
or O +
ameliorating O +
skin O +
conditions O -
, O +
diabetic O +
conditions O -
, O +
cardiovascular O +
conditions O -
, O +
cancer O -
, O +
infections O +
or O +
metal O +
poisoning O -
, O +
enhancing O +
performance O -
, O +
or O +
providing O +
nutritional O +
support O -
, O +
comprising O +
administering O +
to O +
a O +
subject O +
in O +
need O +
thereof O +
compositions O +
comprising O +
a O +
magnetic O +
dipole O +
stabilized O +
solution O +
( O -
MDSS O -
) O -
. O +

The O +
MDSS O +
solution O +
may O +
include O +
additional O +
components O +
and O +
can O +
be O +
provided O +
in O +
a O +
kit O -
. O +

Stable O +
solid O +
preparations O +
A O +
stable O +
solid O +
dosage O +
form O +
comprising O +
a O +
non O -
- O -
toxic O +
base O +
and O +
an O +
amorphous O +
benzimidazole O +
compound O +
having O +
a O +
proton B-Gene +
pump I-Gene +
inhibitor O +
( O -
PPI O -
) O +
activity O -
. O +

Hetero O +
ring O +
compound O +
[ O -
Problem O -
] O +
A O +
novel O +
and O +
excellent O +
compound O +
which O +
is O +
useful O +
as O +
an O +
agent O +
for O +
preventing O +
and/or O +
treating O +
rejection O +
reactions O +
in O +
various O +
organ O +
transplantations O -
, O +
allergy O +
diseases O -
, O +
autoimmune O +
diseases O -
, O +
and O +
hematologic O +
tumor O -
, O +
and O +
based O +
on O +
a O +
PI3KÎ´ B-Gene +
selective O +
inhibitory O +
action O +
and/or O +
an O +
IL-2 B-Gene +
production O +
inhibitory O +
action O +
and/or O +
a O +
B O +
cell O +
proliferation O +
inhibitory O +
action O +
( O -
including O +
an O +
activation O +
inhibitory O +
action O -
) O -
. O +

[ O -
Means O +
for O +
Solution O -
] O +

The O +
present O +
inventors O +
have O +
investigated O +
a O +
compound O +
having O +
a O +
PI3KÎ´ B-Gene +
selective O +
inhibitory O +
action O +
and/or O +
an O +
IL-2 B-Gene +
production O +
inhibitory O +
action O +
and/or O +
a O +
B O +
cell O +
proliferation O +
inhibitory O +
action O +
( O -
including O +
an O +
activation O +
inhibitory O +
action O -
) O -
, O +
and O +
have O +
found O +
that O +
the O +
heterocyclic O +
compound O +
of O +
the O +
present O +
invention O +
has O +
a O +
PI3KÎ´ B-Gene +
selective O +
inhibitory O +
action O +
and/or O +
and O +
IL-2 B-Gene +
production O +
inhibitory O +
action O +
and/or O +
a O +
B O +
cell O +
proliferation O +
inhibitory O +
action O +
( O -
including O +
an O +
activation O +
inhibitory O +
action O -
) O -
, O +
thereby O +
completing O +
the O +
present O +
invention O -
. O +

Substituted O +
Thiazoles O +
as O +
VEGFR2 O +
kinase O +
Inhibitors O +
This O +
invention O +
relates O +
to O +
substituted O +
thiazoles O +
of O +
formula O +
I O -
: O +
wherein O -
: O +
L O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
-NHC O -
( O -
X O -
) O -
- O -
, O +
-C O -
( O -
X O -
) O -
NH- O -
, O +
-NHC O -
( O -
X O -
) O -
NH- O -
, O +
-C O -
( O -
X O -
) O -
- O -
, O +
-C O -
( O -
X O -
) O -
NH O -
- O -
alkylene- O +
and O +
-NHC O -
( O -
X O -
) O -
-alkylene- O -
, O +
where O +
X O +
is O +
oxygen O +
or O +
sulfur O -
; O +
and O +
Q O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
alkyl O -
, O +
substituted O +
alkyl O -
, O +
aryl O -
, O +
substituted O +
aryl O -
, O +
heteroaryl O -
, O +
substituted O +
heteroaryl O -
, O +
cycloalkyl O -
, O +
substituted O +
cycloalkyl O -
, O +
heterocyclic O +
and O +
substituted O +
heterocyclic O -
, O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
and O +
their O +
use O +
as O +
VEGFR2 O +
( O -
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O -
) O +
kinase O +
inhibitors O +
and O +
in O +
the O +
treatment O +
of O +
diseases O +
capable O +
of O +
treatment O +
by O +
a O +
VEGFR2 O +
kinase O +
inhibitor O -
, O +
particularly O +
cancer O -
. O +

Compounds O +
and O +
pharmaceutical O +
compositions O +
for O +
treating O +
disorders O +
associated O +
with O +
the O +
5-ht1a O +
and O +
5-ht2a O +
receptors O +
This O +
invention O +
is O +
related O +
to O +
the O +
alkyl O -
- O -
piperazine O -
- O -
phenyl O +
4 O +
( O -
3H O -
) O -
-quinazolinones O +
general O +
formula O +
( O -
I O -
) O +
compounds O -
, O +
pharmacologicaly O +
active O +
and O +
able O +
to O +
act O +
on O +
the O +
5-HT1A O +
and O +
5-HT2A O +
serotonin O +
receptors O +
in O +
a O +
manner O +
that O +
promotes O +
the O +
control O -
, O +
relief O +
or O +
cure O +
of O +
disorders O +
associated O +
with O +
these O +
receptors O -
, O +
and O +
pharmaceutical O +
compositions O +
containing O +
the O +
compounds O +
for O +
the O +
treatment O +
of O +
disorders O +
associated O +
with O +
these O +
receptors O -
. O +

These O +
compounds O +
and O +
their O +
pharmaceutical O +
compositions O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
conditions O +
such O +
as O +
depression O -
, O +
anxiety O -
, O +
phobias O -
, O +
addictions O -
, O +
aggressiveness O -
, O +
impulsiveness O -
, O +
panic O -
, O +
psychotic O -
, O +
eating O +
and O +
sleep O +
disorders O -
, O +
obsessive O -
- O -
compulsive O +
disorder O +
and O +
female O +
sexual O +
dysfunctions O -
, O +
among O +
other O +
disorders O +
associated O +
with O +
these O +
receptors O -
. O +

Pyrazole O +
compounds O +
acting O +
against O +
allergic O -
, O +
immune O +
and O +
inflammatory O +
conditions O +
The O +
present O +
invention O +
relates O +
to O +
a O +
pyrazole O +
amide O +
derivative O -
, O +
pharmaceutical O +
compositions O +
containing O +
this O +
compound O +
and O +
to O +
its O +
use O +
in O +
therapy O -
. O +

Nitric O +
oxide O +
amino O +
acid O +
esters O +
for O +
improving O +
vascular O +
circulation O -
, O +
and O +
prophylaxis O +
or O +
treatment O +
of O +
a O +
condition O +
associated O +
with O +
impaired O +
blood O +
circulation O +
Use O +
of O +
nitric O +
oxide O +
amino O +
acid O +
esters O +
for O +
improving O +
vascular O +
circulation O -
, O +
and O +
prophylaxis O +
or O +
treatment O +
of O +
a O +
condition O +
associated O +
with O +
impaired O +
blood O +
circulation O -
, O +
such O +
as O +
peripheral O +
vascular O +
disease O -
. O +

The O +
nitric O +
oxide O +
amino O +
acid O +
esters O +
may O +
be O +
co O -
- O -
administered O +
with O +
an O +
antimicrobial O +
in O +
topical O +
or O +
transdermal O +
compositions O +
for O +
improving O +
vascular O +
circulation O -
, O +
and O +
prophylaxis O +
or O +
treatment O +
of O +
a O +
condition O +
associated O +
with O +
impaired O +
blood O +
circulation O -
. O +

Bicyclic O +
ring O +
system O +
substituted O +
amide O +
functionalised O +
phenols O +
as O +
medicaments O +
This O +
invention O +
relates O +
to O +
bicyclic O +
ring O +
system O +
substituted O +
amide O +
functionalized O +
phenols O +
of O +
general O +
formula O +
1 O -
, O +
their O +
use O +
as O +
inhibitors O +
of O +
CXCR2 B-Gene +
activity O -
, O +
pharmaceutical O +
compositions O +
containing O +
the O +
same O -
, O +
and O +
methods O +
of O +
using O +
the O +
same O +
as O +
agents O +
for O +
treatment O +
and/or O +
prevention O +
of O +
respiratory O +
or O +
gastrointestinal O +
complaints O +
or O +
diseases O -
, O +
inflammatory O +
diseases O +
of O +
the O +
joints O -
, O +
skin O -
, O +
or O +
eyes O -
, O +
diseases O +
of O +
the O +
peripheral O +
or O +
central O +
nervous O +
system O +
or O +
cancers O -
, O +
as O +
well O +
as O +
pharmaceutical O +
compositions O +
which O +
contain O +
these O +
compounds O -
. O +

Composition O +
for O +
the O +
treatment O +
of O +
skin O +
conditions O +
A O +
topical O +
composition O +
for O +
the O +
treatment O +
of O +
skin O +
conditions O -
. O +

The O +
composition O +
comprises O +
an O +
antifungal O +
agent O -
, O +
an O +
anti O -
- O -
inflammatory O +
agent O +
and O +
an O +
antimicrobial O +
agent O +
together O +
with O +
a O +
pharmaceutically O +
acceptable O +
excipient O -
. O +

The O +
anti O -
- O -
inflammatory O +
is O +
present O +
at O +
a O +
concentration O +
of O +
less O +
than O +
0.01%wt O +
of O +
the O +
composition O +
and O +
the O +
antimicrobial O +
agent O +
has O +
the O +
general O +
formula O +
( O -
I O -
) O +
: O +
( O -
Formula O +
( O -
I O -
) O -
) O -
. O +

Heterocyclic O +
compounds O +
for O +
the O +
inhibition O +
of O +
pask B-Gene +
Disclosed O +
herein O +
are O +
new O +
heterocyclic O +
compounds O +
and O +
compositions O +
and O +
their O +
application O +
as O +
pharmaceuticals O +
for O +
the O +
treatment O +
of O +
disease O -
. O +

Methods O +
of O +
inhibiting O +
PAS B-Gene +
Kinase I-Gene +
( O -
PASK B-Gene -
) O +
activity O +
in O +
a O +
human O +
or O +
animal O +
subject O +
are O +
also O +
provided O +
for O +
the O +
treatment O +
of O +
diseases O +
such O +
as O +
diabetes O +
mellitus O -
. O +

COMPOUNDS O +
FOR O +
THE O +
REDUCTION O +
OF O +
ÃŸ B-Gene -
- I-Gene -
AMYLOID I-Gene +
PRODUCTION O +
The O +
present O +
disclosure O +
provides O +
a O +
series O +
of O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O +
which O +
modulate O +
& O -
bgr O -
;- O -
amyloid B-Gene +
peptide O +
( O -
& O -
bgr O -
;- O -
AP B-Gene -
) O +
production O +
and O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
Alzheimer O -
's O +
Disease O +
and O +
other O +
conditions O +
affected O +
by O +
& O -
bgr O -
;- O -
amyloid B-Gene +
peptide O +
( O -
& O -
bgr O -
;- O -
AP B-Gene -
) O +
production O -
. O +

Lin28-mediated B-Gene +
control O +
of O +
let-7 B-Gene +
biogenesis O +
The O +
present O +
embodiments O +
provide O +
for O +
compositions O +
and O +
methods O +
that O +
regulate O +
microRNA O -
- O -
binding O +
protein O -
- O -
mediated O +
miRNA O +
biogenesis O -
; O +
for O +
example O +
Lin28-mediated B-Gene +
biogenesis O +
of O +
let-7 B-Gene -
; O +
and O +
in O +
particular O +
Lin28A B-Gene -
- O -
recruited O +
3 B-Gene -
' I-Gene +
terminal I-Gene +
uridylyl I-Gene +
transferase I-Gene +
( O -
TUTase B-Gene -
) O +
uridylation O +
of O +
pre O -
- O -
let-7 B-Gene -
. O +

A O +
particular O +
embodiment O +
provides O +
compositions O +
and O +
methods O +
for O +
screening O +
for O +
agents O +
that O +
inhibit O +
TUTase B-Gene -
- O -
dependent O +
Lin28A B-Gene -
- O -
mediated O +
repression O +
of O +
let-7 B-Gene +
miRNA O -
. O +

Pyridopyrazine O +
derivatives O +
and O +
their O +
use O +
The O +
present O +
invention O +
provides O +
new O +
pyridopyrazine O +
compounds O +
which O +
are O +
suitable O +
for O +
the O +
treatment O +
or O +
prevention O +
of O +
physiological O +
and/or O +
pathophysiological O +
states O +
mediated O +
and/or O +
modulated O +
by O +
signal O +
transduction O +
pathways O +
and/or O +
enzymes O +
in O +
mammals O +
and O +
in O +
particular O +
in O +
humans O -
. O +

Pyrrolo O +
sulfonamide O +
compounds O +
for O +
modulation O +
of O +
orphan B-Gene +
nuclear I-Gene +
receptor I-Gene +
rar I-Gene -
- I-Gene -
related I-Gene +
orphan I-Gene +
receptor I-Gene -
- I-Gene -
gamma I-Gene +
( O -
rorgamma B-Gene -
, O +
nr1f3 B-Gene -
) O +
activity O +
and O +
for O +
the O +
treatment O +
of O +
chronic O +
inflammatory O +
and O +
autoimmune O +
diseases O +
The O +
invention O +
provides O +
modulators O +
for O +
the O +
orphan O +
nuclear O +
receptor O +
RORy B-Gene +
and O +
methods O +
for O +
treating O +
RORy B-Gene +
mediated O +
diseases O +
by O +
administrating O +
these O +
novel O +
RORy B-Gene +
modulators O +
to O +
a O +
human O +
or O +
a O +
mammal O +
in O +
need O +
thereof O -
. O +

Specifically O -
, O +
the O +
present O +
invention O +
provides O +
pyrrolo O +
sulfonamide O +
compounds O +
of O +
Formula O +
( O -
1 O -
) O +
and O +
the O +
enantiomers O -
, O +
diastereomers O -
, O +
tautomers O -
, O +
solvates O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

Methods O +
and O +
pharmaceutical O +
compositions O +
for O +
the O +
treatment O +
of O +
hormone O -
- O -
refractory O +
prostate O +
cancers O +
The O +
present O +
invention O +
relates O +
to O +
a O +
combination O +
of O +
a O +
curcuminoid O +
and O +
a O +
taxane O +
for O +
use O +
in O +
the O +
treatment O +
of O +
a O +
hormone O -
- O -
refractory O +
prostate O +
cancer O +
( O -
HRPC O -
) O +
in O +
a O +
patient O +
in O +
need O +
thereof O -
. O +

5- O +
or O +
6 O +
- O +
substituted O +
3 O +
- O +
hydroxy O +
- O +
2 O +
( O +
1h O -
) O +
- O +
pyridinones O +
as O +
d B-Gene -
- I-Gene -
amino I-Gene +
acid I-Gene +
oxidase I-Gene +
( O -
daao B-Gene -
) O +
inhibitors O +
in O +
therapy O +
of O +
diseases O +
such O +
as O +
schizophrenia O -
, O +
cognitive O +
disorder O +
and O +
pain O +
The O +
present O +
invention O +
provides O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
wherein O +
R1 O +
is O +
hydrogen O +
or O +
fluorine O -
, O +
one O +
of O +
A O +
and O +
B O +
is O +
R2 O -
, O +
the O +
other O +
is O +
a O +
group O +
-X O -
- O -
Y O -
- O -
R3 O -
. O +

R3 O +
represents O +
a O +
carbocyclic O +
or O +
heterocyclic O +
ring O -
. O +

Further O +
variables O +
are O +
as O +
defined O +
in O +
the O +
specification O -
. O +

Also O +
claimed O +
are- O +
processes O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
their O +
use O +
in O +
therapy O +
of O +
diseases O +
such O +
as O +
schizophrenia O -
, O +
cognitive O +
disorders O +
and O +
pain O +
by O +
modulating O +
the O +
D B-Gene -
- I-Gene -
amino I-Gene +
acid I-Gene +
oxidase I-Gene +
enzyme O +
( O -
DAAO B-Gene -
) O -
. O +

A O +
pharmaceutical O +
composition O +
comprising O +
a O +
menthane O +
carboxylic O +
acid O +
amide O +
Suggested O +
is O +
a O +
pharmaceutical O +
composition O -
, O +
comprising O +
menthane O +
carboxylic O +
acid O -
- O -
N- O -
( O -
4-methoxy O -
- O -
phenyl O -
) O -
-amide O -
. O +

Anti O -
- O -
obesity O +
agent O +
comprising O +
high O -
- O -
purity O +
epa O +
The O +
present O +
invention O +
provides O +
an O +
agent O +
for O +
preventing O +
the O +
increase O +
in O +
a O +
body O +
weight O +
( O -
or O +
for O +
decreasing O +
a O +
body O +
weight O -
) O +
or O +
an O +
anti O -
- O -
obesity O +
agent O +
each O +
comprising O +
at O +
least O +
one O +
component O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
EPA O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
esters O +
and O +
derivatives O +
thereof O +
as O +
an O +
active O +
ingredient O +
for O +
obesity O +
in O +
which O +
the O +
increase O +
in O +
the O +
formation O +
of O +
hepatic O +
lipid O +
or O +
the O +
occurrence O +
of O +
fatty O +
liver O +
is O +
mild O -
, O +
preferably O +
the O +
increase O +
in O +
the O +
formation O +
of O +
hepatic O +
lipid O +
or O +
the O +
occurrence O +
of O +
fatty O +
liver O +
is O +
not O +
observed O -
. O +

Liposome O +
comprising O +
at O +
least O +
a O +
cholesterol O +
derivative O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
galenic O +
form O +
of O +
cholesterol O +
derivative O -
. O +

More O +
particularly O -
, O +
the O +
invention O +
relates O +
to O +
liposomes O +
comprising O +
at O +
least O +
one O +
cholesterol O +
derivative O +
and O +
to O +
compositions O +
comprising O +
said O +
liposomes O -
. O +

Cancer O +
stem O +
cell O +
isolation O +
An O +
objective O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O -
: O +
a O +
cancer O +
stem O +
cell O +
isolated O +
using O +
a O +
cell O +
marker O -
; O +
a O +
substantively O +
homogeneous O +
cancer O +
stem O +
cell O +
population O +
including O +
said O +
cancer O +
stem O +
cell O -
; O +
and O +
a O +
method O +
of O +
preparing O +
said O +
cancer O +
stem O +
cell O +
population O -
. O +

Another O +
objective O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O -
: O +
a O +
method O +
for O +
separating O +
cancer O +
stem O +
cells O +
with O +
a O +
high O +
proliferative O +
potential O +
and O +
those O +
with O +
a O +
low O +
proliferative O +
potential O -
; O +
a O +
method O +
for O +
inducing O +
cancer O +
stem O +
cells O +
to O +
have O +
a O +
different O +
proliferative O +
potential O -
; O +
and O +
cancer O +
stem O +
cells O +
separated O +
or O +
induced O +
by O +
these O +
separation O +
or O +
induction O +
methods O -
. O +

A O +
further O +
objective O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O -
: O +
a O +
method O +
of O +
screening O +
for O +
pharmaceuticals O +
using O +
said O +
cancer O +
stem O +
cell O +
or O +
cancer O +
stem O +
cell O +
population O -
; O +
a O +
method O +
for O +
detecting O +
the O +
presence O +
of O +
said O +
cancer O +
stem O +
cell O +
or O +
cancer O +
stem O +
cell O +
population O +
and O +
for O +
identifying O +
or O +
quantifying O +
the O +
same O -
. O +

The O +
present O +
inventors O +
discovered O +
that O +
highly O +
pure O +
colon O +
cancer O +
stem O +
cells O +
( O -
CSC O -
) O +
can O +
be O +
obtained O +
in O +
a O +
large O +
quantity O -
, O +
and O +
identified O +
two O +
types O +
of O +
states O +
of O +
colon O +
CSCs O +
distinguishable O +
through O +
Lgr5 B-Gene +
expression O -
. O +

Compounds O +
for O +
use O +
in O +
inhibiting O +
HIV O +
capsid O +
assembly O +
The O +
present O +
invention O +
relates O +
a O +
compound O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O +
for O +
use O +
in O +
inhibiting O +
HIV O +
capsid O +
assembly O -
, O +
wherein O +
the O +
compound O +
is O +
a O +
pyrimidine O +
being O +
at O +
least O +
substituted O +
in O +
two O +
positions O -
, O +
preferably O +
in O +
2 O +
and O +
4 O +
position O +
or O +
in O +
4 O +
and O +
6 O +
position O -
, O +
more O +
preferably O +
in O +
2 O +
and O +
4 O +
position O -
. O +

Method O +
for O +
inhibition O +
of O +
deubiquitinating O +
activity O +
A O +
compound O +
of O +
the O +
general O +
structure O +
( O -
I O -
) O +
is O +
capable O +
of O +
abrogating O +
the O +
deubiquitinating O +
( O -
DUB O -
) O +
activity O +
of O +
the O +
19S B-Gene +
RP I-Gene +
DUBs I-Gene -
. O +

The O +
compound O +
can O +
be O +
used O +
for O +
treating O +
cancer O -
, O +
in O +
particular O +
of O +
cancer O +
refractory O +
to O +
treatment O +
by O +
state O -
- O -
of O -
- O -
the O -
- O -
art O +
chemotherapy O -
. O +

Also O +
disclosed O +
are O +
corresponding O +
methods O +
of O +
treatment O +
and O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
compound O -
. O +

Mannosylated O +
compounds O +
useful O +
for O +
the O +
prevention O +
and O +
the O +
treatment O +
of O +
infectious O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
new O +
anti O -
- O -
infectious O +
compounds O +
consisting O +
of O +
( O -
i O -
) O +
a O +
polar O +
head O +
having O +
from O +
one O +
to O +
three O +
mannose O -
, O +
dimannose O +
or O +
trimannose O +
moieties O -
, O +
which O +
is O +
coupled O +
through O +
an O +
appropriate O +
linker O +
to O +
( O -
ii O -
) O +
a O +
single O +
lipid O +
chain O +
of O +
at O +
least O +
17 O +
carbon O +
atoms O +
of O +
length O -
. O +

Pharmaceutical O +
compositions O +
and O +
therapeutic O +
uses O +
thereof O +
are O +
also O +
provided O -
. O +

Inducer O +
of O +
apoptosis O +
This O +
invention O +
relates O +
to O +
the O +
use O +
of O +
a O +
mutant O +
E2 O +
polypeptide O +
to O +
induce O +
apoptosis O +
( O -
a O +
form O +
of O +
programmed O +
cell O +
death O -
) O +
in O +
cells O -
. O +

The O +
mutant O +
E2 O +
derived O +
polypeptide O +
is O +
p53 B-Gene +
binding O +
deficient O -
. O +

Preferably O +
it O +
is O +
unable O +
to O +
bind O +
p53 B-Gene -
; O +
or O +
able O +
to O +
bind O +
p53 B-Gene +
but O +
unable O +
to O +
induce O +
p53-dependent B-Gene +
apoptosis O -
. O +

Anticancer O +
agents O -
; O +
controlling O +
apoptosis O +
Use O +
of O +
endothelin O +
receptor O +
antagonists O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
the O +
treatment O +
of O +
tumour O +
diseases O -
. O +

Substituted O +
isoxazoles O +
and O +
their O +
use O +
as O +
antibiotics O +
Compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
X O +
is O +
O O -
, O +
S O -
, O +
NH O -
, O +
OCO O -
, O +
NH O -
â€” O -
CO O -
, O +
NH O -
â€” O -
COO O -
, O +
NH O -
â€” O -
CO O -
â€” O -
NH O -
, O +
NH O -
â€” O -
CS O +
or O +
NH O -
â€” O -
CS O -
â€” O -
NH O -
; O +
R4 O +
is O +
H O -
, O +
( O -
C1-C3 O -
) O -
-alkyl O +
optionally O +
substituted O +
by O +
halogen O -
, O +
or O +
a O +
C O -
- O -
linked O +
heterocyclic O +
radical O +
selected O +
from O +
several O +
possibilities O -
; O +
R1 O +
and O +
R3 O +
are O +
H O +
or O +
F O -
; O +
and O +
R2 O +
is O +
an O +
N O -
- O -
linked O +
or O +
C O -
- O -
linked O +
heterocyclic O +
radical O -
, O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
microbial O +
infections O +
in O +
human O +
or O +
animal O +
body O -
. O +

Such O +
as O +
4-cyclopentylamino O -
- O -
benzenesulfonic O +
acid O +
2- O -
( O -
3,4-dimethoxy O -
- O -
phenylamino O -
) O -
-1H O -
- O -
benzoimidazol-5-yl O +
ester O -
; O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitors O +
that O +
are O +
aimed O +
to O +
be O +
more O +
active O +
than O +
flavopiridol O +
The O +
present O +
invention O +
discloses O +
and O +
claims O +
benzimidazole O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
in O +
which O +
A O +
is O +
aryl O +
or O +
heteroaryl O -
; O +
R1 O +
is O +
sleceted O +
from O +
optionally O +
substituted O +
alkyl O -
, O +
alkoxy O -
, O +
aryl O +
or O +
heteroaryl O -
, O +
NH O -
- O -
lower O +
alkyl O +
or O +
NH O -
- O -
cycloalkyl O -
, O +
or O +
halogen O -
, O +
NH2 O -
; O +
1-imidazolyl O +
or O +
SO2Me O -
; O +
R2 O +
is O +
selected O +
from O +
optionally O +
substituted O +
â€”CO O -
- O -
alkyl O -
, O +
â€”CO O -
- O -
cycloalkyl O -
, O +
â€”CO O -
- O -
aralkyl O -
, O +
â€”CO O -
- O -
aryl O -
, O +
â€”CO O -
- O -
alkoxy O -
, O +
aryl O +
or O +
aralkyl O -
, O +
or O +
â€”O O -
- O -
amino O -
, O +
CO O -
â€” O -
NHR3 O +
or O +
CO O -
â€” O -
R3R4 O +
wherein O +
R3 O +
and O +
R4 O +
are O +
selecteded O +
independently O +
from O +
hydrogen O -
, O +
alkyl O -
, O +
hydroxyalkyl O -
, O +
alkoxyalkyl O -
, O +
fluoroalkyl O -
, O +
alkynyl O -
, O +
heteroalkyl O -
, O +
alkylheteroalkyl O -
, O +
aryl O -
, O +
aralkyl O +
or O +
together O +
form O +
an O +
alkylene O +
chain O +
optionally O +
containing O +
one O +
to O +
4 O +
heteroatoms O -
; O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
a O +
prodrug O +
thereof O -
; O +
the O +
use O +
of O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
for O +
the O +
treatment O +
of O +
cancer O -
, O +
and O +
pharmaceutical O +
compositions O +
comprising O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
and O +
one O +
or O +
more O +
pharmaceutically O +
acceptable O +
adjuvants O +
or O +
diluents O -
. O +

Acat O +
inhibitors O -
; O +
cardiovascular O +
disorders O -
; O +
restenosis O -
; O +
Alzheimer O -
's O +
disease O +
Compounds O +
represented O +
by O +
the O +
general O +
formula O -
. O +

[ O -
I O -
] O -
: O +
wherein O +
R1 O +
and O +
R2 O +
are O +
each O +
hydrogen O -
, O +
halogen O -
, O +
an O +
optionally O +
substituted O +
linear O +
hydrocarbon O +
group O -
, O +
or O +
hydroxyl O +
which O +
may O +
be O +
substituted O +
with O +
an O +
optionally O +
substituted O +
liner O +
hydrocarbon O +
group O -
, O +
or O +
R1 O +
and O +
R2 O +
together O +
with O +
the O +
carbon O +
atoms O +
adjacent O +
thereto O +
may O +
form O +
an O +
optionally O +
substituted O +
cyclic O +
hydrocarbon O +
or O +
a O +
dihydrofuran O +
ring O +
which O +
may O +
have O +
an O +
oxo O +
group O -
; O +
ring O +
A O +
is O +
a O +
benzene O +
ring O +
which O +
may O +
be O +
further O +
substituted O -
; O +
ring O +
B O +
is O +
an O +
aromatic O +
ring O +
which O +
may O +
be O +
substituted O -
; O +
X O +
is O +
a O +
bond O +
or O +
a O +
spacer O +
whose O +
main O +
chain O +
has O +
1 O +
to O +
6 O +
atoms O -
; O +
Y O +
is O +
carboxyl O +
which O +
may O +
be O +
esterified O -
, O +
carbamoyl O +
which O +
may O +
be O +
substituted O -
, O +
cyano O -
, O +
or O +
an O +
optionally O +
substituted O +
heterocyclic O +
group O +
bearing O +
a O +
hydrogen O +
atom O +
capable O +
of O +
being O +
deprotonated O -
, O +
or O +
salts O +
thereof O -
, O +
which O +
are O +
useful O +
as O +
lipid O -
- O -
rich O +
plaque O +
regressing O +
agents O +
and/or O +
ACAT B-Gene +
inhibitors O -
. O +

administering O +
to O +
humans O +
synergystic O +
mixtures O +
of O +
aromatase B-Gene +
inhibitors O +
and O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
antagonists O +
as O +
antitumor O +
agents O +
A O +
method O +
of O +
treating O +
a O +
human O +
being O +
suffering O +
from O +
a O +
hormone O -
- O -
dependent O +
disorder O +
characterized O +
by O +
the O +
overexpression O +
of O +
EGFR B-Gene -
, O +
comprising O +
administering O +
to O +
said O +
human O +
being O +
an O +
aromatase O +
inhibitor O +
and O +
an O +
EGFR B-Gene +
antagonist O +
or O +
EGFR B-Gene +
inhibitor O -
, O +
in O +
amounts O +
effective O +
to O +
produce O +
a O +
superadditive O +
or O +
synergistic O +
therapeutic O +
effect O -
. O +

Such O +
as O +
[ O -
3- O -
( O -
2-Bromo O -
- O -
ethoxy O -
) O -
-phenyl O -
] O -
- O -
[ O -
4- O -
( O -
3-cyclohexyl-5-methyl O -
- O -
isoxazol-4-yl O -
) O -
-pyrimidin-2-yl O -
] O -
-amine O +
The O +
present O +
invention O +
provides O +
compounds O +
of O +
formula O +
I O -
: O +
or O +
a O +
pharmaceutically O +
acceptable O +
derivative O +
thereof O -
, O +
wherein O +
A O -
- O -
B O +
is O +
N O -
â€” O -
O O +
or O +
O O -
â€” O -
N O +
and O +
G O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
and O +
R4 O +
are O +
as O +
described O +
in O +
the O +
specification O -
. O +

These O +
compounds O +
are O +
inhibitors O +
of O +
protein O +
kinase B-Gene -
, O +
particularly O +
inhibitors O +
of O +
Src B-Gene +
and O +
Lck B-Gene +
kinase O -
. O +

The O +
invention O +
also O +
provides O +
pharmaceutical O +
compositions O +
comprising O +
the O +
inhibitors O +
of O +
the O +
invention O +
and O +
methods O +
of O +
utilizing O +
those O +
compositions O +
in O +
the O +
treatment O +
and O +
prevention O +
of O +
various O +
disorders O -
. O +

Treatment O +
of O +
neovascular O +
opthalmic O +
disease O +
Inhibitors O +
of O +
integrin O -
- O -
linked O +
kinase O +
( O -
ILK O -
) O +
are O +
used O +
in O +
the O +
treatment O +
of O +
various O +
eye O +
diseases O +
with O +
underlining O +
pathology O +
of O +
neovascularization O +
of O +
cornea O -
, O +
iris O -
, O +
retina O +
or O +
choroid O -
. O +

Condom O +
A O +
condom O +
has O +
a O +
vasodilator O +
active O +
compound O +
applied O +
to O +
its O +
external O +
surface O -
, O +
preferably O +
disposed O +
towards O +
the O +
open O +
end O +
of O +
the O +
condom O +
whereby O -
, O +
in O +
use O +
during O +
intercourse O -
, O +
the O +
compound O +
makes O +
contact O +
with O +
the O +
vaginal O +
meatus O +
or O +
proximal O +
region O +
of O +
the O +
vagina O -
, O +
such O +
that O +
the O +
vasodilator O +
is O +
absorbed O +
though O +
the O +
lining O +
of O +
the O +
vagina O +
to O +
stimulate O +
and O +
increase O +
the O +
flow O +
of O +
blood O +
in O +
the O +
labia O +
and O +
through O +
the O +
clitoris O +
to O +
promote O +
engorgement O +
thereof O +
to O +
alleviate O +
symptoms O +
associated O +
with O +
female O +
inorgasmia O +

Combination O +
of O +
an O +
adenosine B-Gene +
A2A I-Gene -
- I-Gene -
receptor I-Gene +
agonist O +
and O +
tiotropium O +
or O +
a O +
derivative O +
thereof O +
for O +
treating O +
obstructive O +
airways O +
and O +
other O +
inflammatory O +
diseases O +
A O +
combination O +
of O +
therapeutic O +
agents O +
useful O +
in O +
the O +
treatment O +
of O +
obstructive O +
airways O +
and O +
other O +
inflammatory O +
diseases O +
comprising O +
( O -
i O -
) O +
an O +
adenosine B-Gene +
A2A I-Gene +
receptor I-Gene +
agonist O -
; O +
and O +
( O -
ii O -
) O +
an O +
anti O -
- O -
cholinergic O +
agent O -
, O +
preferably O +
comprising O +
a O +
member O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
tiotropium O +
and O +
derivatives O +
thereof O -
; O +
the O +
combination O +
being O +
therapeutically O +
effective O +
in O +
the O +
treatment O +
of O +
the O +
diseases O +
when O +
administered O +
by O +
inhalation O -
; O +
as O +
well O +
as O +
to O +
a O +
method O +
of O +
treating O +
the O +
obstructive O +
airways O +
and O +
other O +
inflammatory O +
diseases O +
comprising O +
administering O +
separately O -
, O +
simultaneously O +
or O +
sequentially O +
to O +
the O +
mammal O +
by O +
inhalation O +
a O +
therapeutically O +
effective O +
amount O +
of O +
the O +
combination O +
of O +
therapeutic O +
agents O -
; O +
as O +
well O +
as O +
to O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
together O +
with O +
the O +
combination O +
of O +
therapeutic O +
agents O -
; O +
as O +
well O +
as O +
to O +
a O +
product O +
containing O +
the O +
compounds O +
of O +
the O +
combination O +
for O +
separate O -
, O +
simultaneous O +
or O +
sequential O +
administration O +
by O +
inhalation O +
to O +
a O +
mammal O +
for O +
the O +
treatment O +
of O +
obstructive O +
airways O +
and O +
other O +
inflammatory O +
diseases O -
. O +

It O +
is O +
preferred O +
that O +
the O +
anti O -
- O -
cholinergic O +
agent O +
component O +
be O +
tiotropium O +
bromide O -
. O +

3- O -
( O -
Morpholin-4-ylsulfonyl O -
) O -
-5- O -
( O -
1,3-thiazol-2-yl O -
) O -
-1H O -
- O -
indole-2-carboxamide O -
; O +
inhibiting O -
, O +
modulating O +
and/or O +
regulating O +
signal O +
transduction O +
of O +
both O +
receptor B-Gene +
and I-Gene +
non I-Gene -
- I-Gene -
receptor I-Gene +
tyrosine I-Gene +
kinases I-Gene -
; O +
anticarcinogenic O -
, O +
-diabetic O -
, O +
-arhtritic O -
, O +
-inflammatory O +
agents O -
; O +
psoriasis O -
; O +
angiogenesisinhibitors O -
; O +
liver O +
cirrhosis O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
that O +
are O +
capable O +
of O +
inhibiting O -
, O +
modulating O +
and/or O +
regulating O +
signal O +
transduction O +
of O +
both O +
receptor B-Gene -
- I-Gene -
type I-Gene +
and I-Gene +
non I-Gene -
- I-Gene -
receptor I-Gene +
type I-Gene +
tyrosine I-Gene +
kinases I-Gene -
. O +

The O +
compounds O +
of O +
the O +
instant O +
invention O +
possess O +
a O +
core O +
structure O +
that O +
comprises O +
a O +
sulfonyl O +
indole O +
moiety O -
. O +

The O +
present O +
invention O +
is O +
also O +
related O +
to O +
the O +
pharmaceutically O +
acceptable O +
salts O -
, O +
hydrates O +
and O +
stereoisomers O +
of O +
these O +
compounds O -
. O +

Sprayable O +
compositions O +
comprising O +
a O +
combination O +
of O +
pharmaceutical O +
actives O +
and O +
an O +
oily O +
phase O +
Sprayable O -
, O +
anhydrous O +
and O +
physically O -
/ O -
chemically O +
stable O +
dermatological O -
/ O -
pharmaceutical O +
compositions O -
, O +
well O +
suited O +
for O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
dermatological O +
disorders O -
, O +
notably O +
psoriasis O -
, O +
contain O -
: O +
a O -
) O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
solubilized O +
corticoid O -
, O +
notably O +
dissolved O +
clobetasol O +
propionate O -
; O +
b O -
) O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
solubilized O +
vitamin O +
D O +
derivative O -
, O +
notably O +
dissolved O +
calcitriol O -
; O +
and O +
c O -
) O +
an O +
oily O +
phase O +
which O +
comprises O +
one O +
or O +
more O +
oils O -
; O +
formulated O +
into O +
d O -
) O -
, O +
a O +
sprayable O +
and O +
topically O +
applicable O -
, O +
dermatologically O -
/ O -
pharmaceutically O +
acceptable O +
vehicle O +
therefor O -
. O +

Marker O +
genes O +
Methods O +
are O +
disclosed O +
for O +
fast O +
and O +
accurate O +
readout O +
of O +
kidney O +
toxicity O +
before O +
it O +
occurs O +
and O +
before O +
it O +
is O +
demonstrated O +
by O +
histopathology O +
examination O -
. O +

Ultimately O -
, O +
this O +
approach O +
shall O +
allow O +
earlier O +
compound O +
selection O -
. O +

The O +
twelve O +
genes O +
identified O -
, O +
namely O +
Calbindin B-Gene -
- I-Gene -
D28k I-Gene -
, O +
KIM-1 B-Gene -
, O +
OPN B-Gene -
, O +
EGF B-Gene -
, O +
Clusterin B-Gene -
, O +
VEGF B-Gene -
, O +
OAT B-Gene -
- I-Gene -
K1 I-Gene -
, O +
Aldolase B-Gene +
A I-Gene -
, O +
Aldolase B-Gene +
B I-Gene -
, O +
Podocin B-Gene -
, O +
Alpha-2u B-Gene +
and I-Gene +
C4 I-Gene -
, O +
were O +
grouped O +
and O +
ultimately O +
can O +
be O +
assessed O +
in O +
the O +
form O +
of O +
a O +
kit O +
using O +
PCR O -
, O +
a O +
high O +
throughput O +
technology O -
, O +
in O +
order O +
to O +
characterize O +
and O +
rank O +
new O +
compounds O +
according O +
to O +
their O +
anticipated O +
general O +
kidney O +
toxicity O -
. O +

Also O +
disclosed O +
are O +
methods O +
for O +
identifying O +
agents O +
useful O +
in O +
the O +
treatment O +
of O +
kidney O +
disease O -
, O +
methods O +
for O +
monitoring O +
the O +
efficacy O +
of O +
a O +
treatment O +
for O +
kidney O +
disease O +
and O +
kidney O -
- O -
specific O +
vectors O +
including O +
the O +
sequences O +
of O +
the O +
disclosed O +
genes O -
, O +
and O +
a O +
method O +
for O +
identifying O +
a O +
candidate O +
gene O +
associated O +
with O +
a O +
biological O +
process O +
including O +
kidney O +
function O -
. O +

Composition O +
having O +
antioxidant O +
properties O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
having O +
antioxidant O +
properties O +
comprising O +
at O +
least O +
one O +
compound O +
of O +
the O +
formula O +
I O +
or O +
a O +
cosmetically O -
, O +
dermatologically O +
or O +
pharmacologically O +
tolerated O +
salt O +
or O +
derivative O +
thereof O +
where O +
R1 O +
to O +
R4 O +
can O +
be O +
identical O +
or O +
different O +
and O +
are O +
selected O +
from O +
H O +
C6 O -
- O -
28-alkylcarboxylic O +
acid O +
radicals O +
C6 O -
- O -
28-alkenylcarboxylic O +
acid O +
radicals O +
radicals O +
of O +
the O +
formula O +
II O +
where O +
R5-R8 O -
, O +
independently O +
of O +
one O +
another O -
, O +
are O +
H O -
, O +
hydroxyl O +
or O +
C1 O -
- O -
6-alkoxy O -
, O +
with O +
the O +
proviso O +
that O +
at O +
least O +
one O +
of O +
the O +
radicals O +
R1 O +
to O +
R4 O +
is O +
a O +
radical O +
of O +
the O +
formula O +
II O -
. O +

Composition O +
for O +
use O +
in O +
prophylaxis O +
and O +
or O +
treatment O +
The O +
present O +
invention O +
relates O +
generally O +
to O +
a O +
composition O +
for O +
use O +
in O +
the O +
prophylaxis O +
and/or O +
treatment O +
of O +
pain O -
. O +

More O +
particularly O -
, O +
the O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
for O +
use O +
in O +
the O +
prophylaxis O +
and/or O +
treatment O +
of O +
chronic O +
neuromuscular O +
pain O -
. O +

The O +
composition O +
of O +
the O +
present O +
invention O +
is O +
particularly O +
useful O +
in O +
the O +
prophylaxis O +
and/or O +
treatment O +
of O +
chronic O +
neuromuscular O +
pain O +
such O +
as O -
, O +
for O +
example O -
, O +
fibromylagia O -
, O +
myofascial O +
pain O -
, O +
repetitive O +
strain O +
injury O +
or O +
overuse O +
syndromes O -
, O +
and O +
cytokine O -
- O -
mediated O +
cancer O +
and O +
chemotherapy O +
associated O +
pain O -
. O +

Sensitization O +
of O +
cells O +
to O +
cytotoxic O +
agents O +
using O +
oligonucleotides O +
directed O +
to O +
nucleotide O +
excision O +
repair O +
or O +
transcritpion O +
coupled O +
repair O +
genes O +
This O +
invention O +
relates O +
to O +
the O +
fields O +
of O +
molecular O +
biology O +
and O +
oncology O -
. O +

More O +
particularly O -
, O +
this O +
invention O +
relates O +
to O +
the O +
sensitization O +
of O +
cancerous O +
cells O +
to O +
therapeutic O +
agents O -
. O +

The O +
invention O +
provides O +
methods O -
, O +
compositions O -
, O +
and O +
formulations O +
for O +
potentiating O +
or O +
enhancing O +
the O +
toxicity O +
of O +
various O +
cytotoxins O +
and O +
oxidizing O +
agents O -
, O +
and O +
of O +
reducing O +
the O +
resistance O +
and O +
proliferation O +
rate O +
of O +
cancer O +
cells O -
. O +

It O +
also O +
provides O +
various O +
compositions O +
and O +
therapeutic O +
formulations O +
useful O +
as O +
anticancer O +
agents O -
. O +

5-HT4 O +
receptor O +
antagonists O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
and O +
the O +
use O +
of O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
: O +
X O -
â€” O -
CO O -
â€” O -
CH2-Z O +
wherein O +
X O +
is O +
a O +
monocyclic O +
or O +
polycyclic O +
aromatic O +
group O -
, O +
Z O +
is O +
of O +
sub O -
- O -
formula O +
( O -
h O -
) O -
, O +
( O -
j O -
) O +
or O +
( O -
k O -
) O -
: O +
wherein O +
n1 O +
is O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O -
; O +
n2 O +
is O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O -
; O +
n3is O +
2 O -
, O +
3 O -
, O +
4 O +
or O +
5 O -
; O +
q O +
is O +
0 O -
, O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
p O +
is O +
0 O -
, O +
1 O +
or O +
2 O -
; O +
m O +
is O +
0 O -
, O +
1 O +
or O +
2 O -
; O +
R5 O +
is O +
hydrogen O -
, O +
C1 O -
- O -
2 O +
alkyl O -
, O +
aralkyl O +
or O +
R5 O +
is O +
( O -
CH2 O -
) O -
z O -
- O -
R10 O +
wherein O +
z O +
is O +
2 O +
or O +
3 O +
and O +
R10 O +
is O +
selected O +
from O +
cyano O -
, O +
hydroxyl O -
, O +
C1 O -
- O -
6 O +
alkoxy O -
, O +
phenoxy O -
, O +
C O -
( O -
O O -
) O -
C1 O -
- O -
6 O +
alkyl O -
, O +
COC6H5 O -
, O +
â€”CONR11R12 O -
, O +
NR11COR12 O -
, O +
SO2NR11R12 O +
or O +
NR11SO2R12 O +
wherein O +
R11 O +
and O +
R12 O +
are O +
hydrogen O +
or O +
C1 O -
- O -
6 O +
alkyl O -
; O +
or O +
R5 O +
is O +
straight O +
or O +
branched O +
chain O +
alkylene O +
of O +
chain O +
length O +
1 O -
- O -
6 O +
carbon O +
atoms O +
terminally O +
substituted O +
by O +
aryl O -
, O +
3 O +
to O +
8 O +
membered O +
cycloalkyl O -
, O +
3 O +
to O +
8 O +
membered O +
heterocyclyl O -
, O +
5 O +
or O +
6 O +
membered O +
monocyclic O +
heteroaryl O +
or O +
9 O +
or O +
10 O +
membered O +
fused O +
bicyclic O +
heteroaryl O +
linked O +
through O +
carbon O -
, O +
C2 O -
- O -
7 O +
alkoxycarbonyl O -
, O +
or O +
secondary O +
or O +
tertiary O +
hydroxy O +
substituted O +
C1 O -
- O -
6 O +
alkyl O -
; O +
; O +
and O +
R6 O -
, O +
R7 O +
and O +
R8 O +
are O +
independently O +
hydrogen O +
or O +
C1 O -
- O -
6 O +
alkyl O -
; O +
and O +
R9 O +
is O +
hydrogen O +
or O +
C1 O -
- O -
10alkyl O -
; O +
and O +
their O +
use O +
as O +
pharmaceuticals O +
in O +
the O +
treatment O +
of O +
gastrointestinal O +
disorders O -
, O +
cardiovascular O +
disorders O +
and O +
CNS O +
disorders O -
. O +

Method O +
of O +
manufacturing O +
ferromagnetic O +
particle O +
exothermic O +
elements O +
A O +
method O +
of O +
manufacturing O +
ferromagnetic O +
particle O +
exothermic O +
elements O +
for O +
performing O +
a O +
deposition O +
treatment O +
for O +
causing O +
a O +
treating O +
aqueous O +
solution O +
containing O +
fluorine O +
and O +
iron O +
to O +
contact O +
nucleus O +
particles O -
, O +
to O +
deposit O +
iron O +
hydroxide O +
and O +
form O +
layers O +
around O +
the O +
nucleus O +
particles O -
, O +
and O +
an O +
after O -
- O -
treatment O +
for O +
heating O +
the O +
iron O +
hydroxide O +
layers O +
to O +
change O +
them O +
into O +
ferromagnetic O +
layers O -
, O +
thereby O +
producing O +
ferromagnetic O +
particle O +
exothermic O +
elements O +
with O +
outside O +
of O +
the O +
nucleus O +
particles O +
covered O +
by O +
the O +
ferromagnetic O +
layers O -
, O +
wherein O -
, O +
in O +
time O +
of O +
the O +
deposition O +
treatment O -
, O +
a O +
reaction O +
initiator O +
that O +
reacts O +
with O +
hydrogen O +
fluoride O +
is O +
added O +
to O +
said O +
treating O +
aqueous O +
solution O -
. O +

Aryl O +
boronate O +
functionalized O +
polymers O +
for O +
treating O +
obesity O +
Disclosed O +
are O +
polymers O +
comprising O +
one O +
or O +
more O +
phenyl O +
boronate O +
ester O -
, O +
boronamide O +
or O +
boronate O +
thioester O +
groups O -
. O +

The O +
phenyl O +
boronate O +
ester O -
, O +
boronamide O +
and O +
boronate O +
thioester O +
groups O +
are O +
represented O +
by O +
one O +
of O +
the O +
following O +
structural O +
formulas O -
: O +
Ar O +
in O +
Structural O +
Formulas O +
( O -
I O -
) O +
and O +
( O -
II O -
) O +
is O +
substituted O +
or O +
unsubstituted O -
; O +
and O +
each O +
Z O +
is O +
â€”Oâ€” O -
, O +
â€”NHâ€” O +
or O +
â€”Sâ€” O +
and O +
is O +
independently O +
selected O -
. O +

Pharmaceutically O +
acceptable O +
salts O +
of O +
the O +
polymer O +
are O +
also O +
included O -
. O +

The O +
aryl O +
boronate O +
ester O -
, O +
boronamide O +
or O +
boronate O +
thioester O +
can O +
be O +
cleaved O +
to O +
release O +
the O +
corresponding O +
aryl O +
boronic O +
acid O -
. O +

Also O +
disclosed O +
are O +
pharmaceutical O +
compositions O +
comprising O +
the O +
polymers O +
of O +
the O +
present O +
invention O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
or O +
diluent O -
; O +
and O +
methods O +
of O +
treating O +
a O +
subject O +
for O +
obesity O +
with O +
the O +
polymers O +
of O +
the O +
present O +
invention O -
. O +

2-Aminobicyclo O -
[ O -
3.1.0 O -
] O -
hexane-2,6-dicarboxylic O +
acid O +
derivative O +
One O +
object O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O +
a O +
drug O +
that O +
is O +
effective O +
in O +
treatments O +
for O +
and O +
prevention O +
of O +
psychiatric O +
disorders O +
and O +
in O +
treatments O +
for O +
and O +
prevention O +
of O +
neurological O +
diseases O -
, O +
inhibiting O +
a O +
Group O +
II O +
metabotropic O +
glutamate O +
receptor O -
. O +

The O +
object O +
is O +
solved O +
by O +
a O +
2-amino O -
- O -
bicyclo O -
[ O -
3.1.0 O -
] O -
hexane-2,6-dicarboxylic O +
acid O +
derivative O +
represented O +
by O +
formula O +
[ O -
I O -
] O -
: O +
( O -
wherein O +
R1 O +
and O +
R2 O +
are O +
the O +
same O +
or O +
different O -
, O +
and O +
each O +
represents O +
a O +
hydrogen O +
atom O -
, O +
C1 O -
- O -
10alkyl O +
group O -
, O +
etc O -
; O +
X O +
represents O +
a O +
hydrogen O +
atom O +
or O +
a O +
fluorine O +
atom O -
; O +
and O +
Y O +
represents O +
an O +
amino O +
group O -
, O +
â€”SR3 O -
, O +
â€”S O -
( O -
O O -
) O -
nR7 O -
, O +
â€”SCHR3R4 O -
, O +
â€”S O -
( O -
O O -
) O -
nCHR3R4 O -
, O +
â€”NHCHR3R4 O -
, O +
â€”N O -
( O -
CHR3R4 O -
) O -
( O -
CHR5R6 O -
) O -
, O +
â€”NHCOR3 O +
or O +
â€”OCOR7 O -
) O -
, O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
or O +
a O +
hydrate O +
thereof O +
and O +
so O +
on O -
. O +

Diphosphonate O +
solutions O +
A O +
pharmaceutical O +
product O +
containing O +
pamidronate O +
and O +
other O +
diphosphonate O +
solutions O +
in O +
an O +
appropriate O +
container O -
, O +
a O +
pH O +
of O +
between O +
5 O +
and O +
8 O +
and O +
without O +
organic O +
acid O +
buffer O +
or O +
polyethylen O +
glycol O -
. O +

The O +
container O +
may O +
be O +
treated O +
glass O +
or O +
made O +
of O +
other O +
appropriate O +
material O -
. O +

Coated O +
elastomeric O +
stoppers O +
are O +
also O +
included O -
. O +

A O +
method O +
of O +
producing O +
a O +
pharmaceutical O +
product O +
comprising O +
steps O +
of O +
making O +
a O +
suspension O +
of O +
pamadronic O +
acid O -
, O +
adding O +
sodium O +
hydroxide O -
, O +
to O +
form O +
a O +
solution O +
adjusting O +
the O +
pH O +
to O +
between O +
5 O +
and O +
8 O +
and O +
transferring O +
the O +
solution O +
to O +
a O +
container O -
. O +

Method O +
of O +
controlling O +
damage O +
mediated O +
by O +
alpha O -
, O +
beta O -
- O -
unsaturated O +
aldehydes O +
This O +
invention O +
relates O +
to O +
a O +
method O +
for O +
inhibiting O +
the O +
reaction O +
of O +
an O +
Î± O -
, O -
Î² O -
- O -
unsaturated O +
aldehyde O +
with O +
a O +
biological O +
molecule O -
, O +
the O +
method O +
including O +
the O +
step O +
of O +
administering O +
hydralazine O +
and/or O +
dihydralazine O +
in O +
an O +
amount O +
that O +
is O +
effective O +
to O +
reduce O +
the O +
rate O +
of O +
reaction O +
of O +
the O +
Î± O -
, O -
Î² O -
- O -
unsaturated O +
aldehyde O +
with O +
the O +
biological O +
molecule O -
. O +

Phthalazine O +
derivatives O +
as O +
phosphodiesterase B-Gene +
4 I-Gene +
inhibitors O +
Compounds O +
of O +
formula O +
I O +
wherein O +
R O +
and O +
R1 O +
are O +
as O +
defined O +
in O +
the O +
description O -
. O +

The O +
compounds O +
of O +
formula O +
I O +
are O +
PDE B-Gene +
4 I-Gene +
inhibitors O -
. O +

Peptides O +
and O +
nucleic O +
acids O +
of O +
the O +
cathelicidin O +
family O -
, O +
derived O +
from O +
fish O -
, O +
and O +
uses O +
thereof O +
The O +
invention O +
relates O +
to O +
anti O -
- O -
microbial O +
and O +
immunostimulatory O +
molecules O +
of O +
the O +
cathelicidin O +
family O +
derived O +
from O +
fish O -
. O +

The O +
invention O +
provides O +
a O +
novel O +
cathelicidin O +
molecule O -
, O +
fragments O -
, O +
derivatives O +
and O +
uses O +
thereof O -
, O +
and O +
nucleic O +
acids O +
encoding O +
the O +
same O -
. O +

Having O +
antiinflammatory O -
, O +
anti O -
- O -
pyretic O +
and O +
anti O -
- O -
diarrheal O +
properties O +
According O +
to O +
the O +
invention O +
there O +
is O +
provided O +
a O +
compound O +
the O +
formula O +
I O -
; O +
wherein O +
A O -
, O +
X O -
, O +
B O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O +
and O +
R4 O +
are O +
as O +
defined O +
in O +
the O +
specification O -
. O +

2,3'-bipyridines O +
derivatives O +
as O +
selective O +
cox-2 B-Gene +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
2,3â€²-bipyridines O +
of O +
formula O +
( O -
I O -
) O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
and O +
their O +
medical O +
uses O -
. O +

Inhibitors O +
of O +
cdc25 B-Gene +
phosphatases I-Gene +
A O +
method O +
of O +
inhibiting O +
cdc25 B-Gene +
phosphatases I-Gene +
in O +
warm O -
- O -
blooded O +
animals O +
comprising O +
administering O +
to O +
warm O -
- O -
blooded O +
animals O +
in O +
need O +
thereof O +
an O +
effective O +
amount O +
of O +
a O +
compound O +
of O +
the O +
formula O +
wherein O +
the O +
substituents O +
are O +
defined O +
as O +
in O +
the O +
specification O -
. O +

Therapeutic O +
agent O +
for O +
chronic O +
obstructive O +
pulmonary O +
disease O +
and O +
method O +
for O +
treatment O +
for O +
chronic O +
obstructive O +
pulmonary O +
disease O +
with O +
the O +
same O +
This O +
therapeutic O +
agent O +
for O +
chronic O +
obstructive O +
pulmonary O +
disease O +
comprises O -
, O +
an O +
active O +
ingredient O -
, O +
at O +
least O +
one O +
of O +
a O +
7-aminoquinolinone O +
derivative O +
represented O +
by O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
R1 O +
represents O +
a O +
hydrogen O +
atom O +
or O +
an O +
alkyl O +
group O -
; O +
R2 O +
and O +
R3 O +
each O +
represents O +
a O +
group O +
selected O +
from O +
a O +
hydrogen O +
atom O -
, O +
an O +
acyl O +
group O -
, O +
an O +
alkyl O +
group O +
and O +
an O +
alkenyl O +
group O -
; O +
and O +
R4 O +
and O +
R5 O +
each O +
represents O +
a O +
group O +
selected O +
from O +
a O +
hydrogen O +
atom O -
, O +
an O +
acyl O +
group O -
, O +
an O +
alkyl O +
group O -
, O +
an O +
alkenyl O +
group O +
and O +
an O +
aralkyl O +
group O -
, O +
and O +
its O +
physiologically O +
acceptable O +
salt O -
. O +

Methods O +
of O +
using O +
benzothiophenone O +
derivatives O +
to O +
treat O +
cancer O +
or O +
inflammation O +
Methods O +
of O +
using O +
benzothiophenone O +
derivatives O +
to O +
treat O +
cancer O +
or O +
inflammation O +
in O +
a O +
mammal O +
and O +
pharmaceutical O +
compositions O +
containing O +
such O +
derivatives O +
are O +
disclosed O -
. O +

Use O +
of O +
chemokines O -
, O +
and O +
pharmaceutical O +
preparations O +
containing O +
the O +
same O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
chemokines O +
and/or O +
nucleic O +
acids O +
encoding O +
a O +
chemokine O +
for O +
recruiting O +
mesenchymal O +
precursor O +
and/or O +
stem O +
cells O +
in O +
vivo O +
and O +
in O +
vitro O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
preparations O +
which O +
comprise O +
these O +
substances O +
and O +
which O +
are O +
preferably O +
intended O +
for O +
recruiting O +
mesenchymal O +
precursor O +
and/or O +
stem O +
cells O +
for O +
tissue O +
synthesis O -
. O +

Amorphous O +
antibiotic O +
composition O +
comprising O +
cefditoren O +
pivoxil O +
According O +
to O +
the O +
present O +
invention O -
, O +
there O +
is O +
provided O +
a O +
solid O +
dispersion O +
composition O +
which O +
can O +
maintain O +
amorphous O +
cefditoren O +
pivoxil O +
in O +
a O +
suspension O +
for O +
a O +
long O +
period O +
of O +
time O -
. O +

The O +
present O +
invention O +
is O +
a O +
solid O +
dispersion O +
composition O +
comprising O +
at O +
least O +
0.1 O +
mg O +
of O +
a O +
sugar O +
ester O +
fatty O +
acid O +
on O +
the O +
basis O +
of O +
an O +
amount O +
equivalent O +
to O +
100 O +
mg O +
efficacy O +
of O +
cefditoren O +
pivoxil O -
. O +

Methods O +
of O +
using O +
isothiazole O +
derivatives O +
to O +
treat O +
cancer O +
or O +
inflammation O +
Methods O +
of O +
using O +
substituted O +
3,5-dithio- O -
, O +
disulfinyl O -
- O -
or O +
disulfonyl O -
- O -
isothiazole O +
derivatives O +
to O +
treat O +
cancer O +
or O +
inflammation O +
in O +
a O +
mammal O +
and O +
pharmaceutical O +
compositions O +
containing O +
such O +
derivatives O +
are O +
disclosed O -
. O +

Sulfotransferase B-Gene +
inhibitor O +
The O +
hexuronic O +
acid O +
derivative O +
represented O +
by O +
the O +
following O +
formula O +
1 O +
or O +
a O +
salt O +
thereof O +
is O +
used O +
as O +
an O +
active O +
ingredient O +
of O +
a O +
heparin O -
/ O -
heparan O +
sulfate O +
sulfotransferase B-Gene +
inhibitor O -
. O +

In O +
the O +
formula O -
, O +
each O +
of O +
R1 O -
, O +
R2 O -
, O +
and O +
R3 O +
independently O +
represent O -
( O -
s O -
) O +
SO3 O +
âˆ’ O +
or O +
H O +
which O +
may O +
have O +
a O +
substituent O -
, O +
provided O +
that O +
at O +
least O +
one O +
thereof O +
represents O +
SO3 O +
âˆ’ O -
; O +
X O +
represents O +
OR4 O -
, O +
SR4 O -
, O +
N O -
( O -
R4 O -
) O -
2 O -
, O +
or O +
C O -
( O -
R4 O -
) O -
3 O -
, O +
R4 O +
independently O +
represents O +
H O -
, O +
alkyl O -
, O +
alkenyl O -
, O +
alkynyl O -
, O +
acyl O -
, O +
aryl O -
, O +
or O +
aralkyl O +
group O -
; O +
one O +
of O +
R5 O +
and O +
R6 O +
represents O +
COOH O +
while O +
the O +
other O +
represents O +
H O -
; O +
and O +
the O +
wavy O +
line O +
represents O +
Î± O -
- O -
glycosidic O +
bond O +
or O +
Î² O -
- O -
glycosidic O +
bond O -
. O +

Angiogenesis O +
inhibitor O -
; O +
anticancer O +
agents O -
; O +
antiarthritic O +
agents O -
; O +
psoriasis O +
The O +
invention O +
concerns O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
ring O +
A O +
is O +
phenyl O +
or O +
a O +
5- O +
or O +
6-membered O +
heterocyclic O +
ring O +
as O +
defined O +
herein O -
; O +
Z O +
is O +
â€”Oâ€” O -
, O +
â€”NHâ€” O +
or O +
â€”Sâ€” O -
; O +
m O +
is O +
an O +
integer O +
from O +
0 O +
to O +
5 O +
inclusive O -
; O +
R1 O +
is O +
hydrogen O -
, O +
hydroxy O -
, O +
halogeno O -
, O +
nitro O -
, O +
trifluoromethyl O -
, O +
cyano O -
, O +
C1 O -
- O -
3alkyl O -
, O +
C1 O -
- O -
3alkoxy O -
, O +
C1 O -
- O -
3alkylthio O -
, O +
or O +
â€”NR5R6 O +
( O -
wherein O +
R5 O +
and O +
R6 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
are O +
hydrogen O +
or O +
C1 O -
- O -
3alkyl O -
) O -
; O +
R2 O +
is O +
hydrogen O -
, O +
hydroxy O -
, O +
halogeno O -
, O +
C1 O -
- O -
3alkyl O -
, O +
C1 O -
- O -
3alkoxy O -
, O +
trifluoromethyl O -
, O +
amino O +
or O +
nitro O -
; O +
R3 O +
is O +
hydroxy O -
, O +
halogeno O -
, O +
C1 O -
- O -
3alkyl O -
, O +
C1 O -
- O -
3alkoxy O -
, O +
C1 O -
- O -
3alkanoyloxy O -
, O +
trifluoromethyl O -
, O +
cyano O -
, O +
amino O +
or O +
nitro O -
; O +
provided O +
that O +
when O +
ring O +
A O +
is O +
a O +
5- O +
or O +
6-membered O +
heterocyclic O +
ring O -
, O +
at O +
least O +
one O +
R3 O +
is O +
either O +
hydroxy O +
or O +
halogeno O -
; O +
X1 O +
is O +
â€”Oâ€” O -
, O +
â€”CH2â€” O -
, O +
â€”Sâ€” O -
, O +
â€”SOâ€” O -
, O +
â€”SO2â€” O -
, O +
â€”NR7â€” O -
, O +
â€”NR7COâ€” O -
, O +
â€”CONR7â€” O -
, O +
â€”SO2NR7â€” O +
or O +
â€”NR7SO2â€” O -
, O +
( O -
wherein O +
R7 O +
is O +
hydrogen O -
, O +
C1 O -
- O -
3alkyl O +
or O +
C1 O -
- O -
3alkoxyC2 O -
- O -
3alkyl O -
) O -
; O +
and O +
R4 O +
is O +
selected O +
from O +
a O +
number O +
of O +
groups O +
defined O +
herein O +
comprising O +
an O +
C2 O -
- O -
5alkylene O -
, O +
C3 O -
- O -
5alkenylene O +
or O +
C3 O -
- O -
5alkynylene O +
chain O +
wherein O +
each O +
methylene O +
group O +
( O -
other O +
than O +
that O +
of O +
the O +
Î± O -
- O -
carbon O -
) O +
is O +
optionally O +
substituted O +
by O +
1 O +
substituent O +
independently O +
selected O +
from O +
hydroxy O -
, O +
halogeno O -
, O +
amino O +
and O +
C1 O -
- O -
4alkanoyloxy O -
; O +
provisos O +
are O +
as O +
defined O +
herein O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O -
, O +
to O +
the O +
use O +
of O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
use O +
in O +
the O +
production O +
of O +
an O +
antiangiogenic O +
and/or O +
vascular O +
permeability O +
reducing O +
effect O +
in O +
a O +
warm O -
- O -
blooded O +
animal O +
and O +
to O +
a O +
method O +
for O +
producing O +
an O +
antiangiogenic O +
and/or O +
vascular O +
permeability O +
reducing O +
effect O +
in O +
a O +
warm O -
- O -
blooded O +
animal O +
in O +
need O +
of O +
such O +
treatment O -
. O +

The O +
compounds O +
are O +
useful O +
in O +
disease O +
states O +
such O +
as O +
cancer O -
, O +
rheumatoid O +
arthritis O +
and O +
psoriasis O -
. O +

Preemptive O +
Prophylaxis O +
of O +
Migraine O +
A O +
method O +
of O +
preventing O +
the O +
headache O +
phase O +
of O +
migraine O +
in O +
a O +
human O +
comprises O +
administration O +
of O +
a O +
5HT1 B-Gene +
receptor I-Gene +
agonist O +
or O +
administration O +
of O +
an O +
over O -
- O -
the O -
- O -
counter O +
or O +
nonprescription O +
drug O +
to O +
said O +
human O +
exhibiting O +
prodrome O +
symptoms O +
of O +
migraine O -
. O +

Suitably O -
, O +
the O +
method O +
comprises O +
administration O +
of O +
a O +
migraine O +
headache O +
phase O -
- O -
preventing O +
effective O +
amount O +
of O +
the O +
5HT1 O +
or O +
over O -
- O -
the O -
- O -
counter O +
or O +
nonprescription O +
drug O -
. O +

There O +
is O +
disclosed O +
a O +
preemptive O +
prophylaxis O +
migraine O +
method O +
using O +
the O +
following O +
cognitive O +
tests O -
: O +
Simple O +
Reaction O +
Time O -
; O +
Running O +
Memory O +
Continuous O +
Performance O +
Task O -
; O +
Matching O +
to O +
Sample O -
; O +
Mathematical O +
Processing O +
Task O -
; O +
and O +
interpreting O +
the O +
results O +
as O +
a O +
percent O +
of O +
baseline O +
indicator O +
of O +
need O +
for O +
prophylaxis O -
. O +

Active O +
substance O +
combination O +
comprising O +
a O +
carbinol O +
combined O +
to O +
at O +
least O +
an O +
NSAID O +
The O +
present O +
invention O +
relates O +
to O +
an O +
active O +
substance O +
combination O +
comprising O +
at O +
least O +
one O +
substituted O +
carbinol O +
compound O +
and O +
at O +
least O +
one O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O +
( O -
NSAID O -
) O -
, O +
a O +
medicament O +
comprising O +
said O +
active O +
substance O +
combination O -
, O +
a O +
pharmaceutical O +
formulation O +
comprising O +
said O +
active O +
substance O +
combination O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O -
. O +

2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine O +
derivatives O +
as O +
inhibitors O +
of O +
glucosylceramide O +
Compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
R O +
represents O +
a O +
substituted O +
benzyl O +
group O -
, O +
are O +
useful O +
as O +
inhibitors O +
of O +
glucosylceramide B-Gene +
synthase I-Gene -
. O +

Amino O +
nicotinate O +
derivatives O +
as O +
glucokinase B-Gene +
( O -
GLK B-Gene -
) O +
modulators O +
The O +
invention O +
is O +
related O +
to O +
novel O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
or O +
a O +
salt O -
, O +
solvate O +
or O +
prodrug O +
thereof O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
n O +
and O +
m O +
are O +
as O +
described O +
in O +
the O +
specification O -
, O +
useful O +
in O +
the O +
treatment O +
of O +
a O +
disease O +
or O +
condition O +
mediated O +
through O +
glucokinase B-Gene +
( O -
GLK B-Gene -
) O -
, O +
such O +
as O +
type O +
2 O +
diabetes O -
. O +

The O +
invention O +
also O +
relates O +
to O +
methods O +
for O +
preparing O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
and O +
their O +
use O +
as O +
medicaments O +
in O +
the O +
treatment O +
of O +
diseases O +
mediated O +
by O +
glucokinase B-Gene -
. O +

Treating O +
inflammation O +
with O +
ondansetron O +
and O +
pharmaceutical O +
compositions O +
comprised O +
thereof O +
Inflammatory O +
skin O +
disorders O +
such O +
as O +
rosacea O -
, O +
including O +
a O +
variety O +
of O +
skin O +
diseases O -
, O +
whether O +
or O +
not O +
accompanied O +
by O +
dermatosis O -
, O +
are O +
treated O +
by O +
topically O +
applying O +
onto O +
the O +
affected O +
skin O +
area O -
, O +
a O +
thus O +
effective O +
amount O +
of O +
Ondansetron O -
, O +
or O +
salt O +
or O +
base O +
thereof O -
. O +

Combination O +
Comprising O +
Combretastatin O +
and O +
Anticancer O +
Agents O +
An O +
antitumor O +
combination O +
comprising O +
a O +
stilbene O +
derivative O +
and O +
an O +
anticancer O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
taxanes O -
, O +
alkylating O +
agents O -
, O +
antimetabolites O -
, O +
vinca O +
alkaloids O -
, O +
platinum O +
compounds O -
, O +
epidophylloptoxins O -
, O +
and O +
antibiotics O +
as O +
the O +
active O +
ingredients O +
is O +
provided O -
. O +

Methods O +
of O +
using O +
these O +
pharmaceutical O +
preparations O +
for O +
the O +
treatment O +
of O +
solid O +
carcinomas O +
and O +
the O +
like O +
are O +
also O +
provided O -
. O +

Novel O +
ureido O -
- O -
and O +
amido O -
- O -
pyrazolone O +
derivatives O +
The O +
present O +
invention O +
provides O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
; O +
wherein O +
each O +
of O +
R1 O +
to O +
R4 O +
is O +
independently O +
selected O +
from O +
hydrogen O -
, O +
a O +
halogen O -
, O +
a O +
substituted O +
or O +
unsubstituted O +
cyclic O +
and O +
heterocyclic O +
moiety O -
, O +
substituted O +
or O +
unsubstituted O -
, O +
linear O +
or O +
branched O +
alkyl O -
, O +
alkyloxy O -
, O +
alkylcarbonyl O -
, O +
alkyloxycarbonyl O -
, O +
alkenyl O -
, O +
alkenyloxy O -
, O +
alkenylcarbonyl O -
, O +
alkenyloxycarbonyl O -
, O +
alkynyl O -
, O +
alkynyloxy O -
, O +
alkynylcarbonyl O -
, O +
alkynyloxycarbonyl O -
, O +
aryl O -
, O +
benzyl O -
, O +
arlyoxy O -
, O +
arylcarbonyl O -
, O +
aryloxycarbonyl O +
and O +
sulphur O +
equivalents O +
of O +
said O +
oxy O -
, O +
carbonyl O +
and O +
oxycarbonyl O +
moieties O -
, O +
and O +
A O +
is O +
NH O -
, O +
or O +
( O -
CH2 O -
) O -
n O -
, O +
where O +
n O +
is O +
preferably O +
0 O -
, O +
1 O +
or O +
2 O -
. O +

The O +
invention O +
also O +
relates O +
to O +
methods O +
for O +
preparing O +
the O +
compounds O +
and O +
their O +
uses O +
as O +
CCK B-Gene +
receptor I-Gene +
ligands O +
and O +
CCK B-Gene +
antagonists O -
. O +

Therapy O +
for O +
disease O +
caused O +
by O +
nicotinic B-Gene +
receptors I-Gene -
; O +
cognition O +
activatrors O -
; O +
central O +
nervous O +
system O +
disorders O +
Compounds O +
complying O +
with O +
the O +
general O +
formula O +
in O +
which O +
R O +
either O +
represents O +
a O +
halogen O +
atom O +
or O +
a O +
phenyl O +
group O +
substituted O +
by O +
one O +
or O +
more O +
groups O +
chosen O +
from O +
halogen O +
atoms O +
and O +
( O -
C1-C6 O -
) O -
alkyl O -
, O +
( O -
C1-C6 O -
) O -
alkoxy O -
, O +
nitro O -
, O +
amino O -
, O +
trifluoromethyl O -
, O +
cyano O -
, O +
hydroxy O -
, O +
acetyl O +
or O +
methylenedioxy O +
groups O -
, O +
or O +
represents O +
a O +
pyridinyl O +
group O -
, O +
a O +
thienyl O +
group O -
, O +
an O +
indolyl O +
group O -
, O +
or O +
a O +
pyrimidinyl O +
group O +
optionally O +
substituted O +
by O +
one O +
or O +
more O +
( O -
C1-C6 O -
) O -
alkoxy O +
groups O -
, O +
where O -
, O +
of O +
the O +
two O +
carbon O -
- O -
carbon O +
bonds O +
represented O +
by O +

Prodrugs O +
Of O +
Substituted O +
Amino O +
Heterobicycles O +

Which O +
Modulate O +
The O +
Function O +
Of O +
The O +
Vanilloid-1 B-Gene +
Receptor I-Gene +
( O -
Vr1 B-Gene -
) O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
which O +
are O +
useful O +
as O +
therapeutic O +
compounds O -
, O +
particularly O +
in O +
the O +
treatment O +
of O +
pain O +
and O +
other O +
conditions O +
ameliorated O +
by O +
the O +
modulation O +
of O +
the O +
function O +
of O +
the O +
vanilloid-1 B-Gene +
receptor I-Gene +
( O -
VR1 B-Gene -
) O -
. O +

Treating O +
an O +
inflammatory O +
condition O +
in O +
an O +
individual O +
by O +
administering O +
an O +
agent O +
which O +
inhibits O +
the O +
interaction O +
between O +
a O +
Toll B-Gene -
- I-Gene -
like I-Gene +
receptor I-Gene +
2 I-Gene +
and O +
a O +
high B-Gene +
mobility I-Gene +
group I-Gene +
B I-Gene +
polypeptide I-Gene -
; O +
treating O +
Crohn O -
's O +
disease O -
, O +
sepsis O -
, O +
rheumatoid O +
arthritis O -
, O +
systemic O +
lupus O +
erythematosus O -
, O +
endotoxic O +
shock O -
, O +
allograft O +
rejection O +
The O +
invention O +
features O +
a O +
method O +
of O +
treating O +
an O +
inflammatory O +
condition O +
in O +
an O +
individual O -
, O +
comprising O +
administering O +
an O +
agent O +
inhibits O +
the O +
interaction O +
between O +
a O +
Toll B-Gene -
- I-Gene -
like I-Gene +
receptor I-Gene +
2 I-Gene +
( O -
TLR2 B-Gene -
) O +
and O +
a O +
high B-Gene +
mobility I-Gene +
group I-Gene +
B I-Gene +
( O -
HMGB B-Gene -
) O +
polypeptide O +
to O +
the O +
individual O -
. O +

The O +
invention O +
also O +
features O +
methods O +
for O +
identifying O +
agents O +
that O +
inhibit O +
the O +
interaction O +
between O +
TLR2 B-Gene +
and O +
HMGB B-Gene -
. O +

Growth B-Gene +
hormone I-Gene +
receptor I-Gene +
antagonist O +
cancer O +
treatment O +
The O +
present O +
invention O +
provides O +
methods O +
and O +
compositions O +
for O +
treating O +
tumorigenic O +
cells O +
( O -
e.g. O -
, O +
mammary O +
progenitor O +
cancer O +
cells O -
) O -
, O +
with O +
growth B-Gene +
hormone I-Gene +
receptor I-Gene +
antagonists O +
( O -
e.g. O -
, O +
Pegvisomant O -
) O -
, O +
as O +
well O +
as O +
methods O +
and O +
compositions O +
for O +
screening O +
growth B-Gene +
hormone I-Gene +
receptor I-Gene +
antagonists O +
for O +
their O +
ability O +
serve O +
as O +
anti O -
- O -
neoplastic O +
agents O +
capable O +
of O +
killing O +
tumorigenic O +
cells O -
. O +

The O +
present O +
invention O +
provides O +
methods O +
for O +
identifying O +
tumorigenic O +
cells O -
, O +
methods O +
of O +
obtaining O +
enriched O +
populations O +
of O +
tumorigenic O +
cells O -
, O +
and O +
methods O +
of O +
causing O +
mammary O +
progenitor O +
cells O +
to O +
proliferate O +
and/or O +
differentiate O -
. O +

Chimeric O +
( O -
Double O -
) O +

Decoy O +
The O +
present O +
invention O +
provides O +
a O +
prophylactic O -
, O +
ameliorative O +
or O +
therapeutic O +
medicament O +
for O +
vascular O +
restenosis O -
, O +
ischemic O +
disease O -
, O +
allergic O +
disease O -
, O +
inflammatory O +
disease O -
, O +
autoimmune O +
disease O -
, O +
or O +
cancer O +
metastasis O -
, O +
invasion O +
( O -
cancer O +
metastasis O -
/ O -
invasion O -
) O +
or O +
cachexia O +
based O +
on O +
the O +
inhibitory O +
action O +
on O +
a O +
plural O +
of O +
transcriptional O +
regulatory O +
factor O -
. O +

A O +
chimera O +
( O -
double O -
) O +
decoy O +
of O +
the O +
present O +
invention O +
has O +
plural O +
transcriptional O +
regulatory O +
factor O +
binding O +
sequences O +
in O +
a O +
single O +
molecule O +
thereof O -
. O +

Thus O -
, O +
it O +
is O +
able O +
to O +
inhibit O +
the O +
activity O +
of O +
plural O +
transcriptional O +
regulatory O +
factors O +
with O +
a O +
single O +
molecule O -
. O +

For O +
example O -
, O +
stenosis O +
of O +
an O +
anastomosed O +
site O +
of O +
an O +
artificial O +
blood O +
vessel O +
is O +
caused O +
by O +
thickening O +
of O +
the O +
vascular O +
intima O -
, O +
and O +
this O +
is O +
mainly O +
caused O +
by O +
activation O +
of O +
cell O +
proliferation O +
by O +
an O +
inflammatory O +
reaction O +
occurring O +
at O +
the O +
anastomosed O +
site O -
. O +

Thus O -
, O +
thickening O +
of O +
vessel O +
walls O +
can O +
be O +
inhibited O +
by O +
simultaneously O +
inhibiting O +
two O +
transcriptional O +
regulatory O +
factors O +
involved O +
in O +
inflammation O +
and O +
cell O +
proliferation O +
by O +
using O +
the O +
chimera O +
decoy O +
of O +
the O +
present O +
invention O -
. O +

Triazole O +
Derivative O +
or O +
Salt O +
Thereof O +
[ O -
Problem O -
] O +
There O +
is O +
provided O +
a O +
compound O +
which O +
can O +
be O +
used O +
for O +
therapy O +
of O +
diseases O +
in O +
which O +
11Î² B-Gene -
- I-Gene -
hydroxysteroid I-Gene +
dehydrogenase I-Gene +
type I-Gene +
1 I-Gene +
( O -
11Î² B-Gene -
- I-Gene -
HSD1 I-Gene -
) O +
participates O -
, O +
in O +
particular O +
diabetes O -
, O +
insulin B-Gene +
resistance O -
. O +

[ O -
Means O +
for O +
Solution O -
] O +

It O +
has O +
been O +
found O +
that O +
a O +
triazole O +
derivative O +
wherein O +
the O +
triazole O +
ring O +
is O +
substituted O +
with O +
a O +
trisubstituted O +
methyl O +
group O +
in O +
the O +
2-position O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
has O +
a O +
strong O +
11Î² B-Gene -
- I-Gene -
HSD1 I-Gene +
inhibitory O +
activity O -
. O +

Moreover O -
, O +
the O +
triazole O +
derivative O +
of O +
the O +
invention O +
exhibits O +
an O +
excellent O +
blood O -
- O -
glucose O +
level O -
- O -
lowering O +
action O +
and O +
hence O +
can O +
be O +
used O +
for O +
therapy O +
of O +
diabetes O -
, O +
insulin O +
resistance O -
. O +

Amorphous O +
form O +
of O +
Olanzapine O +
The O +
present O +
invention O +
relates O +
to O +
an O +
amorphous O +
form O +
of O +
olanzapine O +
Formula O +
( O -
I O -
) O -
: O +
and O +
a O +
process O +
for O +
its O +
preparation O -
. O +

The O +
present O +
invention O +
further O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
comprising O +
an O +
amorphous O +
form O +
of O +
olanzapine O +
( O -
I O -
) O -
. O +

The O +
pharmaceutical O +
composition O +
may O +
be O +
used O -
, O +
in O +
particular O -
, O +
for O +
the O +
treatment O +
of O +
psychiatric O -
, O +
psychological O +
or O +
psychotic O +
disorders O -
, O +
anxiety O +
disorders O -
, O +
or O +
gastrointestinal O +
or O +
functional O +
bowel O +
disorders O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
a O +
method O +
of O +
treating O +
said O +
disorders O -
. O +

Heterocycle O -
- O -
Substituted O +
Cyclic O +
Urea O +
Derivatives O -
, O +
Preparation O +
Thereof O +
And O +
Pharmaceutical O +
Use O +

Thereof O +
As O +
Kinase B-Gene +
Inhibitors O +
The O +
disclosure O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
Y O -
, O +
Y1 O -
, O +
Yo O -
, O +
R1 O -
, O +
R2 O -
, O +
R2â€² O -
, O +
p O -
, O +
R3 O -
, O +
R3â€² O -
, O +
A O -
, O +
B O +
and O +
Y2 O +
have O +
the O +
meanings O +
given O +
in O +
the O +
description O -
, O +
and O +
to O +
salts O +
thereof O -
, O +
pharmaceutical O +
compositions O +
comprising O +
said O +
compounds O +
and O +
use O +
thereof O +
as O +
protein B-Gene +
kinase I-Gene +
inhibitors O -
. O +

Delivery O +
of O +
a O +
combination O +
therapy O +
for O +
asthma O +
and O +
chronic O +
obstructive O +
pulmonary O +
disease O +
A O +
method O +
of O +
delivery O +
of O +
a O +
combination O +
therapy O +
to O +
the O +
pulmonary O +
system O +
that O +
includes O +
providing O +
a O +
nebulizer O +
and O +
an O +
aqueous O +
solution O +
comprising O +
a O +
long O -
- O -
acting O +
corticosteroid O -
, O +
a O +
long O -
- O -
acting O +
beta O -
- O -
agonist O -
, O +
and O +
a O +
long O -
- O -
acting O +
anticholinergic O -
, O +
and O +
administering O +
the O +
solution O +
to O +
the O +
patient O +
using O +
the O +
nebulizer O -
. O +

The O +
corticosteroid O +
is O +
budesonide O -
, O +
the O +
beta O -
- O -
agonist O +
is O +
formoterol O +
and O +
the O +
anticholinergic O +
is O +
tiotropium O -
. O +

A O +
pharmaceutical O +
composition O +
is O +
also O +
described O +
for O +
the O +
treatment O +
of O +
respiratory O +
conditions O +
and O +
diseases O +
comprising O +
a O +
long O -
- O -
acting O +
corticosteroid O -
, O +
a O +
long O -
- O -
acting O +
beta O -
- O -
agonist O -
, O +
and O +
a O +
long O -
- O -
acting O +
anticholinergic O -
, O +
and O +
administering O +
the O +
solution O +
to O +
the O +
patient O +
using O +
the O +
nebulizer O -
. O +

Use O +
of O +
acylaminoalkenylene O -
- O -
amide O +
derivatives O +
in O +
functional O +
motility O +
disorders O +
of O +
the O +
viscera O +
The O +
use O +
of O +
a O +
compound O +
of O +
formula O +

I O +
in O +
free O +
form O +
or O +
in O +
the O +
form O +
of O +
a O +
pharmaceutically O +
acceptable O +
salt O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
the O +
treatment O +
of O +
a O +
functional O +
motility O +
disorder O +
of O +
the O +
viscera O -
. O +

New O +
Expression O +
Tools O +
for O +
Multiprotein O +
Applications O +

The O +
present O +
invention O +
relates O +
to O +
polynucleotides O +
for O +
multigene O +
applications O +
comprising O +
a O +
novel O +
functional O +
arrangement O -
, O +
as O +
well O +
as O +
vectors O -
, O +
host O +
cells O -
, O +
and O +
recombinant O +
animals O +
comprising O +
said O +
polynucleotides O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
is O +
directed O +
to O +
methods O +
for O +
generating O +
multigene O +
expression O +
cassettes O -
, O +
methods O +
for O +
producing O +
multiprotein O +
complexes O +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
and O +
methods O +
for O +
producing O +
a O +
vaccine O -
. O +

Furthermore O -
, O +
the O +
present O +
invention O +
encompasses O +
methods O +
for O +
screening O +
protein O +
complex O +
interactions O +
or O +
modifications O +
of O +
proteins O -
, O +
and O +
methods O +
for O +
the O +
in O +
vitro O +
or O +
in O +
vivo O +
screening O +
of O +
candidate O +
compounds O +
capable O +
of O +
protein O +
complex O +
interactions O +
or O +
modifications O +
of O +
proteins O +
or O +
capable O +
of O +
inhibiting O +
protein O +
complex O +
interactions O +
or O +
inhibiting O +
modifications O +
of O +
proteins O -
. O +

Also O -
, O +
the O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
the O +
polynucleotides O -
, O +
vectors O -
, O +
host O +
cells O +
or O +
recombinant O +
animals O +
of O +
the O +
invention O +
for O +
( O -
i O -
) O +
preparing O +
a O +
medicament O +
for O +
gene O +
therapy O -
, O +
for O +
( O -
ii O -
) O +
the O +
recombinant O +
production O +
of O +
multiprotein O +
complexes O -
, O +
( O -
iii O -
) O +
for O +
producing O +
a O +
vaccine O -
, O +
or O +
( O -
iv O -
) O +
for O +
screening O +
compounds O +
of O +
interest O -
. O +

Last O +
but O +
not O +
least O -
, O +
the O +
invention O +
is O +
directed O +
to O +
a O +
kit O +
of O +
parts O +
comprising O +
at O +
least O +
a O +
polynucleotide O -
, O +
a O +
vector O -
, O +
and/or O +
a O +
host O +
cell O +
according O +
to O +
the O +
invention O -
. O +

Boronated O +
Metal O -
- O -
Phthalocyanines O -
, O +
Process O +
For O +
Their O +
Preparation O -
, O +
Pharmaceutical O +
Compositions O +
Comprising O +
Them O +

And O +
Use O +
Thereof O +
The O +
present O +
invention O +
relates O +
to O +
metal O -
- O -
phthalocyanines O +
bearing O +
at O +
least O +
a O +
group O +
containing O +
boron O +
isotopes O +
11B O +
or O +
10B O -
, O +
covalently O +
bound O +
to O +
the O +
axial O +
positions O +
of O +
metal O -
- O -
phthalocyanine O +
nucleus O -
; O +
moreover O +
it O +
refers O +
to O +
the O +
process O +
for O +
their O +
preparation O -
, O +
the O +
pharmaceutical O +
compositions O +
comprising O +
them O +
and O +
their O +
use O +
for O +
the O +
treatment O +
of O +
neoplastic O +
and O +
dysplastic O +
pathologies O +
in O +
PDT O +
and/or O +
BNCT O -
. O +

Antimicrobial O +
photoinactivation O +
using O +
chalcogen O +
analogs O +
of O +
benzo O -
( O -
A O -
) O -
phenoxazinium O +
dyes O +
Compositions O +
and O +
methods O +
for O +
the O +
use O +
of O +
photoactivatable O +
antimicrobial O +
chalcogen O +
analogs O +
of O +
benzophenoxazinium O +
dyes O +
in O +
the O +
treatment O +
of O +
infections O +
are O +
provided O -
. O +

Combinations O +
of O +
Serotonin O +
Reuptake O +
Inhibitors O +
and O +
Imidazoline O +
I O +
2 O +
Agonists O +
The O +
present O +
invention O +
relates O +
to O +
combinations O +
of O +
serotonin O +
reuptake O +
inhibitors O +
and O +
imidazoline O +
I2 O +
agonists O +
as O +
separate O +
chemical O +
units O +
or O +
both O +
properties O +
combined O +
in O +
a O +
single O +
molecule O +
and O +
to O +
the O +
use O +
thereof O +
for O +
the O +
preparation O +
of O +
medicaments O +
for O +
the O +
treatment O +
of O +
depression O -
, O +
obsessive O -
- O -
compulsive O +
disorders O +
( O -
OCDs O -
) O -
, O +
obsessive O -
- O -
compulsive O +
spectrum O +
disorders O +
( O -
OCSDs O -
) O +
and O +
other O +
anxiety O +
states O -
. O +

Inhibition O +
Of O +
Superoxide O +
Dismutase O +
By O +
Tetrathiomolybdate O -
: O +
Identification O +
Of O +
New O +
Anti O -
- O -
Angiogenic O +
And O +
Antitumor O +
Agents O +
Though O +
copper O +
is O +
elevated O +
in O +
the O +
tumor O +
tissue O +
and O +
plasma O +
of O +
patients O +
with O +
various O +
malignancies O -
, O +
the O +
molecular O +
targets O +
for O +
copper O +
binding O +
agents O +
in O +
angiogenesis O +
and O +
tumor O +
progression O +
remain O +
poorly O +
understood O -
. O +

It O +
is O +
disclosed O +
that O +
one O +
anti O -
- O -
angiogenic O +
target O +
for O +
the O +
copper O +
binding O +
agent O +
tetrathiomolybdate O +
is O +
intracellular O +
CuZn O -
- O -
superoxide O +
dismutase O +
( O -
SOD1 O -
) O -
. O +

A O +
second O +
generation O +
tetrathiomolybdate O +
analog O -
, O +
ATN-224 O -
, O +
inhibits O +
endothelial O +
cell O +
( O -
EC O -
) O +
proliferation O +
in O +
vitro O -
, O +
binds O +
to O +
SOD1 O +
and O +
inhibits O +
its O +
activity O +
without O +
displacing O +
bound O +
copper O +
ATN-224 O +
can O +
accumulate O +
in O +
ECs O +
and O +
inhibit O +
CuZnSOD O +
activity O +
with O +
an O +
IC50 O +
similar O +
to O +
the O +
IC50 O +
for O +
EC O +
proliferation O -
, O +
resulting O +
in O +
increased O +
generation O +
of O +
intracellular O +
reactive O +
oxygen O +
species O -
. O +

Inhibition O +
of O +
EC O +
proliferation O +
by O +
ATN-224 O +
in O +
vitro O +
is O +
substantially O +
reversed O +
by O +
a O +
synthetic O +
porphyrin O +
SOD O +
mimetic O -
. O +

Similar O +
results O +
were O +
observed O +
in O +
vivo O -
, O +
where O +
inhibition O +
of O +
angiogenesis O +
by O +
ATN-224 O +
in O +
a O +
Matrigel O +
plug O +
model O +
was O +
also O +
reversed O +
by O +
MnTBAP O -
. O +

Thus O -
, O +
a O +
distinct O +
molecular O +
target O +
for O +
copper O +
depletion O +
therapy O +
has O +
been O +
identified O +
and O +
SOD1 O +
is O +
now O +
validated O +
as O +
a O +
target O +
for O +
anti O -
- O -
angiogenesis O -
. O +

Methods O +
for O +
screening O -
, O +
or O +
designing O -
, O +
such O +
SOD1 O +
inhibitors O +
for O +
use O +
as O +
angiogenesis O +
inhibitors O +
and O +
anti O -
- O -
cancer O +
agents O +
are O +
disclosed O -
. O +

Combinatorial O +
therapy O -
; O +
genetic O +
engineered O +
protein O -
; O +
therapy O +
for O +
autoimmune O +
diaeses O -
; O +
anticancer O +
agents O +
The O +
invention O +
relates O +
to O +
the O +
field O +
of O +
apoptosis O -
. O +

The O +
invention O +
provides O +
novel O +
therapies O -
, O +
for O +
example O -
, O +
novel O +
combinatorial O +
therapies O +
or O +
novel O +
therapeutic O +
compounds O +
that O +
can O +
work O +
alone O -
, O +
sequentially O +
to O -
, O +
or O +
jointly O +
with O +
Apoptin B-Gene -
, O +
especially O +
in O +
those O +
cases O +
wherein O +
p53 B-Gene +
is O +
completely O +
or O +
partially O +
non O -
- O -
functional O -
. O +

Isolated O +
polynucleotides O +
comprising O +
a O +
nucleic O +
acid O +
which O +
operably O +
encodes O +
50 O +
contiguous O +
amino O +
acids O -
, O +
nucleic O +
acids O +
are O +
fragments O +
of O +
a O +
codon O -
- O -
optimized O +
coding O +
region O -
; O +
a O +
carrier O +
The O +
invention O +
is O +
related O +
to O +
polynucleotide O -
- O -
based O +
cytomegalovirus O +
vaccines O -
. O +

In O +
particular O -
, O +
the O +
invention O +
is O +
plasmids O +
operably O +
encoding O +
HCMV O +
antigens O -
, O +
in O +
which O +
the O +
naturally O -
- O -
occurring O +
coding O +
regions O +
for O +
the O +
HCMV O +
antigens O +
have O +
been O +
modified O +
for O +
improved O +
translation O +
in O +
human O +
or O +
other O +
mammalian O +
cells O +
through O +
codon O +
optimization O -
. O +

HCMV O +
antigens O +
which O +
are O +
useful O +
in O +
the O +
invention O +
include O -
, O +
but O +
are O +
not O +
limited O +
to O +
pp65 O -
, O +
glycoprotein O +
B O +
( O -
gB O -
) O -
, O +
IE1 O -
, O +
and O +
fragments O -
, O +
variants O +
or O +
derivatives O +
of O +
either O +
of O +
these O +
antigens O -
. O +

In O +
certain O +
embodiments O -
, O +
sequences O +
have O +
been O +
deleted O -
, O +
e.g. O -
, O +
the O +
Arg435-Lys438 O +
putative O +
kinase B-Gene +
in O +
pp65 O +
and O +
the O +
membrane O +
anchor O +
and O +
endocellular O +
domains O +
in O +
gB. O +
The O +
invention O +
is O +
further O +
directed O +
to O +
methods O +
to O +
induce O +
an O +
immune O +
response O +
to O +
HCMV O +
in O +
a O +
mammal O -
, O +
for O +
example O -
, O +
a O +
human O -
, O +
comprising O +
delivering O +
a O +
plasmid O +
encoding O +
a O +
codon O -
- O -
optimized O +
HCMV O +
antigen O +
as O +
described O +
above O -
. O +

The O +
invention O +
is O +
also O +
directed O +
to O +
pharmaceutical O +
compositions O +
comprising O +
plasmids O +
encoding O +
a O +
codon O -
- O -
optimized O +
HCMV O +
antigen O +
as O +
described O +
above O -
, O +
and O +
further O +
comprising O +
adjuvants O -
, O +
excipients O -
, O +
or O +
immune O +
modulators O -
. O +

N O -
- O -
Hydroxy O +
( O -
2S O -
) O -
-2-hydroxy O +
phenyl O +
or O +
heteroaryl O +
sulfonamide O +
derivatives O -
; O +
for O +
example O -
, O +
N O -
- O -
Hydroxy O +
( O -
2S O -
) O -
-2-hydroxy-3- O -
{ O -
N- O -
[ O -
4- O -
( O -
4- O +
chlorophenoxy O -
) O -
phenyl O -
] O -
, O +
N- O +
methanesulfonylamino O -
} O -
propionamide O -
; O +
for O +
treating O +
disorders O +
related O +
to O +
matrix B-Gene +
metalloproteases I-Gene -
, O +
particularly O +
useful O +
for O +
treating O +
strokes O -
; O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
Formula O +
I O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
and O +
R7 O +
are O +
defined O +
in O +
the O +
specification O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
relates O +
to O +
methods O +
treating O +
disorders O +
related O +
to O +
matrix B-Gene +
metalloproteases I-Gene -
. O +

More O +
particularly O -
, O +
the O +
compounds O +
of O +
the O +
present O +
invention O +
are O +
useful O +
for O +
treating O +
stroke O -
. O +

Polymerizable O +
antimicrobial O +
composition O +
The O +
present O +
invention O +
provides O +
a O +
polymerizable O +
antimicrobial O +
composition O +
and O +
a O +
method O +
for O +
using O +
the O +
same O -
. O +

The O +
polymerizable O +
antimicrobial O +
composition O +
of O +
the O +
invention O +
comprises O +
an O +
antimicrobial O +
compound O -
, O +
a O +
linker O -
, O +
and O +
a O +
polymerizable O +
function O +
group O -
. O +

Topical O +
delivery O +
of O +
codrugs O +
The O +
present O +
invention O +
provides O +
pharmaceutical O +
compositions O +
for O +
topical O +
delivery O +
comprising O +
a O +
suitable O +
carrier O +
and O +
a O +
codrug O +
capable O +
of O +
penetrating O -
, O +
or O +
being O +
transported O +
across O -
, O +
the O +
dermis O -
. O +

The O +
codrug O +
according O +
to O +
the O +
invention O +
comprises O +
a O +
first O +
constituent O +
moiety O +
linked O +
to O +
a O +
second O +
constituent O +
moiety O -
, O +
wherein O +
the O +
second O +
constituent O +
moiety O +
is O +
the O +
same O +
as O -
, O +
or O +
different O +
from O -
, O +
the O +
first O +
constituent O +
moiety O -
. O +

The O +
first O +
and O +
second O +
constituent O +
moieties O +
are O +
so O +
linked O +
that O +
they O +
are O +
easily O +
transported O +
into O +
or O +
across O +
the O +
dermis O -
, O +
into O +
the O +
skin O -
, O +
or O +
into O +
the O +
blood O +
or O +
lymphatic O +
system O -
, O +
and O +
are O +
reconstituted O +
in O +
vivo O +
to O +
form O +
the O +
first O +
and O +
second O +
constituent O +
moieties O -
. O +

Crosslinked O +
Amine O +
Polymers O +
The O +
present O +
invention O +
provides O +
methods O +
and O +
compositions O +
for O +
the O +
treatment O +
of O +
ion O +
imbalances O -
. O +

In O +
particular O -
, O +
the O +
invention O +
provides O +
polymeric O +
and O +
pharmaceutical O +
compositions O +
comprising O +
crosslinked O +
amine O +
polymers O -
. O +

Methods O +
of O +
use O +
of O +
the O +
polymeric O +
and O +
pharmaceutical O +
compositions O +
for O +
therapeutic O +
and/or O +
prophylactic O +
benefits O +
are O +
disclosed O +
herein O -
. O +

Examples O +
of O +
these O +
methods O +
include O +
the O +
treatment O +
of O +
renal O +
diseases O +
and O +
hyperphosphatemia O -
. O +

drug O +
delivery O +
devices O +
comprising O +
capsules O +
containing O +
drugs O +
distributed O +
within O +
an O +
aqueous O +
phase O +
in O +
the O +
interior O +
of O +
the O +
capsule O +
The O +
present O +
invention O +
relates O +
to O +
liposomes O +
for O +
drug O +
delivery O -
, O +
wherein O +
a O +
liposome O +
includes O +
molecules O +
of O +
at O +
least O +
one O +
desired O +
drug O +
distributed O +
within O +
an O +
aqueous O +
phase O +
in O +
the O +
interior O +
of O +
the O +
liposome O +
and O +
wherein O +
the O +
liposome O +
further O +
includes O +
molecules O +
of O +
the O +
same O +
or O +
of O +
another O +
drug O +
attached O +
to O +
either O +
or O +
both O +
sides O +
of O +
the O +
liposomal O +
membrane O -
. O +

More O +
specifically O -
, O +
the O +
invention O +
relates O +
to O +
liposomes O -
, O +
wherein O +
at O +
least O +
a O +
part O +
of O +
the O +
molecules O +
of O +
a O +
desired O +
drug O +
bear O +
a O +
functional O +
group O +
that O +
is O +
reactive O +
with O +
a O +
functional O +
group O +
present O +
in O +
at O +
least O +
one O +
lipid O +
fraction O -
, O +
and O +
wherein O +
the O +
drug O +
is O +
covalently O +
linked O +
to O +
the O +
membrane O +
lipids O +
by O +
chemical O +
bonding O -
, O +
e.g. O +
by O +
ester O +
bonding O +
of O +
a O +
hydroxyl O +
group O +
of O +
a O +
lipid O +
molecule O +
and O +
an O +
acidic O +
residue O +
of O +
the O +
drug O -
. O +

In O +
a O +
preferred O +
embodiment O -
, O +
the O +
desired O +
drug O +
is O +
a O +
glycoprotein B-Gene +
such O +
as O +
erythropoietin B-Gene -
. O +

The O +
invention O +
further O +
relates O +
to O +
a O +
method O +
of O +
manufacture O +
of O +
said O +
liposomes O +
and O +
to O +
pharmaceutical O +
compositions O +
containing O +
them O -
. O +

Hes6 B-Gene +
as O +
a O +
marker O +
of O +
pancreatic O +
endocrine O +
cells O +
The O +
present O +
invention O +
provides O +
methods O +
of O +
identifying O +
endocrine O +
stem O +
and O +
progenitor O +
cells O -
. O +

Novel O +
Benzofurans O +
and O +
Indols O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
X O +
is O +
a O +
fluorine O +
or O +
a O +
chlorine O +
atom O -
; O +
the O +
methyl O +
groups O +
located O +
at O +
the O +
2- O +
and O +
5-position O +
of O +
the O +
piperazine O +
ring O +
are O +
in O +
trans O -
- O -
configuration O +
to O +
each O +
other O -
; O +
Y O +
is O +
NH O +
or O +
O O -
; O +
R1 O +
is O +
selected O +
from O +
hydrogen O -
, O +
chloro O -
, O +
bromo O -
, O +
nitro O -
, O +
methyl O +
or O +
trifluoromethyl O -
; O +
R2 O +
is O +
selected O +
from O +
hydrogen O -
, O +
halo O -
, O +
methyl O -
, O +
trifluoromethyl O -
, O +
methoxy O +
or O +
trifluoromethoxy O -
; O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O -
; O +
The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
containing O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
together O +
with O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

Included O +
are O +
also O +
processes O +
for O +
the O +
preparation O +
of O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
as O +
well O +
as O +
methods O +
for O +
treating O +
mammals O +
suffering O +
from O +
inflammatory O -
, O +
autoimmune O -
, O +
proliferative O +
or O +
hyperproliferative O +
diseases O +
by O +
administering O +
a O +
compound O +
having O +
the O +
formula O +
( O -
I O -
) O +
to O +
said O +
mammal O -
. O +

Topically O +
administrating O +
an O +
inhibitor O +
of O +
Erbb2 B-Gene +
or O +
HER2 B-Gene +
receptor I-Gene +
tyrosine I-Gene +
kinase I-Gene +
activity O +
because O +
of O +
a O +
novel O +
connection O +
between O +
HER2 B-Gene +
and O +
a O +
DNA O +
damage O +
checkpoint O -
; O +
reducing O +
mutagenesis O +
and O +
apoptosis O -
; O +
antitumor O -
, O +
-carcinogenic O -
, O +
-proliferative O +
agents O +
and O +
-inflammatory O +
agents O -
; O +
sunburn O -
; O +
hyperplasia O +
The O +
present O +
invention O +
provides O +
a O +
method O +
for O +
suppression O +
of O +
ultra O +
violet O -
- O -
induced O +
skin O +
pathologies O +
and O +
skin O +
abnormalities O -
, O +
such O +
as O +
abnormal O +
proliferation O +
and O +
mutagenesis O -
, O +
and O +
for O +
inducing O +
apoptosis O +
in O +
cells O +
having O +
Erbb2 B-Gene +
or O +
HER2 B-Gene +
receptors O -
. O +

The O +
method O +
involves O +
administration O +
of O +
Erbb2 B-Gene -
/ O -
HER2 B-Gene +
inhibitors O -
, O +
either O +
before O +
or O +
after O +
exposure O +
to O +
UV O -
. O +

Endogenous O +
Peptide O +
and O +
Active O +
Subfragments O +
Thereof O +
The O +
present O +
invention O +
relates O +
to O +
a O +
substantially O +
pure O +
biologically O +
active O +
consecutive O +
anti O -
- O -
angiogenic O +
polypeptide O +
comprising O +
the O +
central O +
region O +
of O +
human B-Gene +
Histidine I-Gene +
Rich I-Gene +
Glycoprotein I-Gene +
( O -
HRGP B-Gene -
) O -
. O +

Said O +
polypeptide O +
is O +
shown O +
to O +
comprise O +
a O +
potential O +
endogenous O -
, O +
naturally O +
occurring O +
subfragment O +
of O +
human B-Gene +
HRGP I-Gene -
, O +
comprising O +
similar O +
anti O -
- O -
angiogenic O +
activities O +
as O +
the O +
mature O +
protein O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
one O +
or O +
more O +
new O +
biologically O +
active O +
subfragments O +
of O +
human B-Gene +
HRGP I-Gene -
, O +
derived O +
from O +
said O +
central O +
region O -
. O +

Said O +
subfragments O +
are O +
all O +
characterized O +
by O +
having O +
anti O -
- O -
angiogenic O +
activity O -
. O +

One O +
of O +
the O +
active O +
subfragments O +
is O +
referred O +
to O +
as O +
Pep2 B-Gene -
. O +

Enscoped O +
by O +
the O +
present O +
invention O +
are O +
also O +
anti O -
- O -
angiogenic O +
subfragments O +
derived O +
from O +
Pep2 B-Gene -
, O +
one O +
of O +
them O +
comprising O +
a O +
newly O +
identified O +
presently O +
minimal O +
functional O +
entity O -
. O +

Administering O +
vector O +
system O +
that O +
directs O +
regulated O +
erythropoietin B-Gene +
( O -
Epo B-Gene -
) O +
gene O +
therapy O +
in O +
a O +
manner O +
that O +
physiologically O +
corrects O +
the O +
hematocrit O +
levels O +
in O +
a O +
patient O +
in O +
need O +
of O +
anemia O +
treatment O +
Disclosed O +
is O +
a O +
viral O +
vector O +
containing O +
a O +
nucleic O +
acid O +
sequence O +
encoding O +
erythropoietin B-Gene +
( O -
Epo B-Gene -
) O -
, O +
in O +
operable O +
linkage O +
with O +
an O +
HRE B-Gene +
expression O +
control O +
sequence O -
, O +
as O +
well O +
as O +
uses O +
of O +
the O +
vector O -
; O +
for O +
instance O -
, O +
in O +
preparing O +
a O +
medicament O -
. O +

Also O +
provided O +
are O +
methods O +
for O +
treating O +
anemia O -
, O +
can O +
involve O +
administering O +
the O +
vector O +
to O +
a O +
patient O -
, O +
wherein O +
expression O +
of O +
Epo B-Gene +
is O +
physiologically O +
regulated O +
such O +
that O +
hematocrit O +
levels O +
of O +
the O +
patient O +
are O +
corrected O +
and O +
maintained O -
. O +

For O +
prophylaxis O +
or O +
treatment O +
of O +
apoptosis O +
or O +
inflammation O -
- O -
associated O +
disease O -
, O +
diabetes O -
, O +
or O +
chronic O +
obstructive O +
pulmonary O +
disease O +
The O +
present O +
invention O +
provides O +
a O +
method O +
for O +
screening O +
for O +
a O +
prophylactic O +
or O +
therapeutic O +
drug O +
for O +
apoptosis O +
or O +
an O +
inflammation O -
- O -
associated O +
disease O -
, O +
diabetes O +
and O +
complications O +
thereof O +
or O +
a O +
chronic O +
obstructive O +
pulmonary O +
disease O +
( O -
COPD O -
) O -
, O +
namely O -
, O +
a O +
method O +
for O +
screening O +
for O +
a O +
prophylactic O +
or O +
therapeutic O +
drug O +
for O +
apoptosis O +
or O +
an O +
inflammation O -
- O -
associated O +
disease O -
, O +
diabetes O +
and O +
complications O +
thereof O +
or O +
COPD O -
, O +
which O +
includes O +
( O -
1 O -
) O +
comparing O +
the O +
activities O +
of O +
a O +
protein O +
having O +
an O +
amino O +
acid O +
sequence O +
the O +
same O +
as O +
or O +
substantially O +
the O +
same O +
as O +
the O +
amino O +
acid O +
sequence O +
shown O +
by O +
SEQ O +
ID O +
NO O -
: O +
2 O +
or O +
a O +
partial O +
peptide O +
thereof O +
or O +
a O +
salt O +
thereof O -
, O +
between O +
in O +
the O +
presence O +
of O +
a O +
test O +
substance O +
and O +
in O +
the O +
absence O +
of O +
the O +
test O +
substance O -
, O +
or O +
( O -
2 O -
) O +
comparing O +
the O +
expressions O +
of O +
a O +
protein O +
having O +
an O +
amino O +
acid O +
sequence O +
the O +
same O +
as O +
or O +
substantially O +
the O +
same O +
as O +
the O +
amino O +
acid O +
sequence O +
shown O +
by O +
SEQ O +
ID O +
NO O -
: O +
2 O -
, O +
a O +
partial O +
peptide O +
thereof O +
and O +
a O +
salt O +
thereof O +
in O +
the O +
cells O +
having O +
the O +
ability O +
to O +
produce O +
the O +
protein O -
, O +
the O +
partial O +
peptide O +
thereof O +
and O +
the O +
salt O +
thereof O -
, O +
between O +
in O +
the O +
presence O +
of O +
a O +
test O +
substance O +
and O +
in O +
the O +
absence O +
of O +
the O +
test O +
substance O -
. O +

Screening O +
for O +
a O +
compound O +
which O +
inhibits O +
p62 B-Gene -
/ O -
ubiquitin B-Gene +
binding O -
; O +
detecting O +
the O +
formation O +
of O +
inclusion O +
bodies O +
in O +
neurodegenerative O +
diseases O -
; O +
screening O +
for O +
therapeutic O +
agents O +
that O +
disperse O +
the O +
inclusions O +
The O +
application O +
discloses O +
a O +
role O +
of O +
p62 B-Gene +
in O +
aging O -
- O -
related O +
disease O -
, O +
such O +
as O +
development O +
of O +
obesity O -
, O +
type O +
2 O +
diabetes O +
mellitus O -
, O +
non O -
- O -
alcoholic O +
fatty O +
liver O -
, O +
various O +
tumors O -
, O +
increased O +
male O +
mortality O -
, O +
intracellular O +
inclusion O +
named O +
sequestosome O -
, O +
and O +
redox O +
regulation O -
. O +

In O +
particular O +
the O +
application O +
discloses O +
a O +
method O +
of O +
detecting O +
the O +
formation O +
of O +
inclusion O +
bodies O +
in O +
neurodegenerative O +
diseases O -
. O +

The O +
invention O +
further O +
relates O +
to O +
a O +
method O +
of O +
screening O +
for O +
therapeutic O +
agents O +
that O +
disperse O +
the O +
inclusions O -
. O +

Further O -
, O +
transgenic O +
mice O +
containing O +
a O +
mutation O +
in O +
the O +
p62 B-Gene +
gene O +
and O +
having O +
a O +
functionally O +
disrupted O +
p62 B-Gene +
gene O +
locus O +
are O +
also O +
disclosed O -
. O +

Administering O +
( O -
3R,5S O -
) O -
-N O -
- O -
propanesulfonyl-7-chloro-5- O -
( O -
2,3-dimethoxyphenyl O -
) O -
-1- O -
( O -
3-hydroxy-2,2-dimethylpropyl O -
) O -
-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide O -
; O +
cerebral O +
infarction O +
The O +
present O +
invention O +
provides O +
an O +
agent O +
for O +
preventing O +
or O +
treating O +
organ O +
functional O +
disorders O -
, O +
an O +
agent O +
for O +
preventing O +
or O +
treating O +
organ O +
dysfunction O +
and O +
an O +
agent O +
for O +
preventing O +
or O +
treating O +
obesity O +
and O +
deuteropathy O +
thereof O -
, O +
each O +
of O +
which O +
comprises O +
a O +
compound O +
having O +
an O +
effect O +
of O +
increasing O +
ubiquinone O +
or O +
a O +
salt O +
thereof O +
or O +
a O +
prodrug O +
thereof O -
; O +
as O +
well O +
as O +
a O +
ubiquinone O +
increasing O +
agent O +
comprising O +
a O +
compound O +
having O +
a O +
squalene B-Gene +
synthase I-Gene +
inhibitory O +
effect O +
or O +
a O +
salt O +
thereof O +
or O +
a O +
prodrug O +
thereof O -
. O +

Hydrazide O +
Derivatives O +
A O +
compound O +
represented O +
by O +
the O +
following O +
general O +
formula O +
( O -
1 O -
) O +
or O +
a O +
salt O +
thereof O +
or O +
a O +
hydrate O +
of O +
the O +
foregoing O +
is O +
safe O +
while O +
exhibiting O +
suitable O +
physicochemical O +
stability O -
, O +
and O +
is O +
useful O +
as O +
therapeutic O +
or O +
prophylactic O +
agents O +
for O +
diseases O +
associated O +
with O +
thrombus O +
formation O -
. O +

wherein O +
R1a O -
, O +
R1b O -
, O +
R1c O +
and O +
R1d O +
each O +
independently O +
represent O +
hydrogen O -
, O +
etc O -
. O -
, O +
R2 O +
represents O +
optionally O +
substituted O +
phenyl O -
, O +
etc O -
. O -
, O +
R3 O +
represents O +
optionally O +
substituted O +
C6 O -
- O -
10 O +
aryl O -
, O +
etc O -
. O -
, O +
Z1 O -
, O +
Z2 O +
and O +
Z3 O +
each O +
independently O +
represent O +
hydrogen O -
, O +
etc O -
. O -
, O +
Z4 O +
represents O +
hydrogen O -
, O +
etc O -
. O +
and O +
X O +
represents O +
a O +
single O +
bond O +
or O +
â€”COâ€” O -
, O +
etc O -
. O +

Compositions O +
For O +
Treating O +
Flushing O +
And O +
Lipid O -
- O -
Associated O +
Disorders O +
Comprising O +
Niacin O +
Receptor O +
Partial O +
Agonists O +

The O +
invention O +
provides O +
a O +
method O +
of O +
reducing O +
flushing O +
induced O +
by O +
niacin O +
or O +
a O +
niacin O +
analog O +
in O +
a O +
subject O -
, O +
comprising O +
administering O +
to O +
said O +
subject O +
an O +
effective O +
flush O +
reducing O +
amount O +
of O +
a O +
niacin O +
receptor O +
partial O +
agonist O -
. O +

In O +
addition O -
, O +
the O +
invention O +
provides O +
a O +
method O +
of O +
reducing O +
flushing O +
induced O +
by O +
niacin O +
or O +
a O +
niacin O +
analog O +
in O +
a O +
subject O -
, O +
comprising O +
administering O +
to O +
said O +
subject O +
an O +
effective O +
flush O +
reducing O +
amount O +
of O +
a O +
niacin O +
receptor O +
partial O +
agonist O +
and O +
an O +
effective O +
lipid O +
altering O +
amount O +
of O +
niacin O +
or O +
a O +
niacin O +
analog O -
. O +

The O +
invention O +
further O +
provides O +
a O +
method O +
of O +
reducing O +
flushing O +
induced O +
by O +
niacin O +
or O +
a O +
niacin O +
analog O +
in O +
a O +
subject O -
, O +
comprising O +
administering O +
to O +
said O +
subject O +
an O +
effective O +
flush O +
reducing O +
amount O +
of O +
a O +
niacin O +
receptor O +
partial O +
agonist O +
and O +
subsequently O +
administering O +
to O +
said O +
subject O +
an O +
effective O +
lipid O +
altering O +
amount O +
of O +
niacin O +
or O +
a O +
niacin O +
analog O -
. O +

Pharmaceutical O +
Composition O +
Containing O +
Prostaglandin O +
An O +
object O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O +
a O +
stable O +
aqueous O +
pharmaceutical O +
composition O +
which O +
suppresses O +
degradation O +
of O +
prostaglandin O +
F2Î± O +
in O +
a O +
preparation O +
containing O +
prostaglandin O +
F2Î± O -
. O +

The O +
object O +
was O +
attained O +
by O +
formulating O +
a O +
prostaglandin O +
F2Î± O +
derivative O +
into O +
an O +
oil O -
- O -
in O -
- O -
water O +
emulsion O +
together O +
with O +
an O +
oil O -
, O +
for O +
example O -
, O +
medium O +
chain O +
fatty O +
acid O +
triglyceride O -
, O +
a O +
water O -
- O -
soluble O +
polymer O +
and O +
water O -
. O +

Injectable O +
Preparations O +
Of O +
Diclofenac O +
And O +
Its O +
Pharmaceutically O +
Acceptable O +
Salts O +
The O +
present O +
invention O +
provides O +
injectable O +
formulations O +
of O +
water O -
- O -
soluble O +
salts O +
of O +
diclofenac O +
in O +
single O +
doses O +
of O +
less O +
than O +
2 O +
ml O -
, O +
which O +
cause O +
significantly O +
less O +
pain O +
at O +
the O +
site O +
of O +
injection O +
and O +
can O +
be O +
administered O +
by O +
intradeltoid O +
route O -
, O +
in O +
addition O +
to O +
intragluteal O +
and O +
slow O +
intravenous O +
route O -
. O +

More O +
specifically O +
the O +
injectable O +
preparations O +
contain O +
75 O +
mg O +
to O +
100 O +
mg O +
of O +
water O -
- O -
soluble O +
salts O +
of O +
diclofenac O -
, O +
in O +
about O +
1 O +
ml O +
injection O +
solution O +
without O +
significantly O +
raising O +
the O +
viscosity O +
of O +
the O +
injection O +
solution O +
without O +
the O +
use O +
surfactants O -
. O +

The O +
formulations O +
are O +
adjusted O +
to O +
pH O +
6 O +
to O +
10 O +
containing O +
up O +
to O +
100 O +
mg O +
of O +
diclofenac O +
salt O +
in O +
a O +
medium O +
comprising O +
of O +
water O -
, O +
along O +
with O +
one O +
or O +
more O +
co O -
- O -
solvent O -
( O -
s O -
) O -
/ O -
solubiliser O -
( O -
s O -
) O -
, O +
antioxidants O -
, O +
preservatives O -
, O +
buffers O -
, O +
alkali O +
and O +
stabilizers O -
. O +

Synergistic O +
composition O +
for O +
modulating O +
activity O +
of O +
substrate O +
analogs O +
for O +
NAD+ O -
, O +
NADP+ O -
, O +
NADH O +
or O +
NADPH O +
dependent O +
enzymes O +
and O +
process O +
thereof O +
The O +
present O +
disclosure O +
provides O +
a O +
composition O +
for O +
enhancing O +
effect O +
of O +
an O +
inhibitor O +
in O +
inhibiting O +
NAD+ O -
/ O -
NADP+ O +
or O +
NADH O -
/ O -
NADPH O +
dependent O +
enzymes O -
. O +

The O +
inhibition O +
of O +
the O +
NAD+ O -
/ O -
NADP+ O +
or O +
NADH O -
/ O -
NADPH O +
dependent O +
enzymes O +
such O +
as O +
Enoyl O -
- O -
ACP O +
reductase O +
( O -
ENR O -
) O +
by O +
the O +
composition O +
of O +
the O +
present O +
disclosure O +
serves O +
as O +
a O +
target O +
for O +
treating O +
malaria O +
and O +
other O +
infectious O +
diseases O -
. O +

The O +
present O +
disclosure O +
provides O +
composition O +
comprising O +
inhibitor O +
and O +
polyphenol O -
, O +
wherein O +
the O +
polyphenol O +
was O +
found O +
to O +
enhance O +
the O +
inhibitory O +
activity O +
of O +
the O +
inhibitor O -
. O +

The O +
present O +
disclosure O +
provides O +
method O +
for O +
treating O +
an O +
infectious O +
disease O +
comprising O +
administering O +
an O +
effective O +
amount O +
of O +
the O +
composition O +
of O +
the O +
present O +
disclosure O +
to O +
patients O +
in O +
need O +
thereof O -
. O +

The O +
present O +
disclosure O +
further O +
provides O +
a O +
method O +
for O +
identifying O +
a O +
compound O +
that O +
enhances O +
the O +
effect O +
of O +
the O +
inhibitor O -
, O +
a O +
method O +
of O +
determining O +
the O +
antimalarial O +
activity O +
of O +
a O +
compound O +
and O +
use O +
of O +
polyphenol O +
as O +
a O +
bioenhancer O +
that O +
enhances O +
effect O +
of O +
an O +
inhibitor O +
for O +
inhibiting O +
NAD+ O -
/ O -
NADP+ O +
or O +
NADH O -
/ O -
NADPH O +
dependent O +
enzymes O -
. O +

The O +
present O +
disclosure O +
provides O +
a O +
composition O +
comprising O +
inhibitor O +
and O +
a O +
polyphenol O +
wherein O +
the O +
polyphenol O +
enhances O +
effect O +
of O +
the O +
inhibitor O +
for O +
inhibiting O +
aldose O +
reductase O +
for O +
treating O +
complications O +
of O +
diabetes O +
that O +
include O +
diabetic O +
retinopathy O -
, O +
cataract O +
neuropathy O +
and O +
neural O +
complication O -
. O +

e.g. O +
9-Hydroxy-2- O -
( O -
2-methoxy O -
- O -
ethyl O -
) O -
-1,8-dioxo-1,8-dihydro-2H O -
- O -
pyrid O -
[ O -
1,2-a O -
] O -
pyrazi O +
ne-7-carboxylic O +
acid O +
4-fluoro O -
- O -
banzylamide O -
; O +
Human O +
T O +
cell O +
leukemia O +
virus O -
, O +
Feline O +
and O +
Simian O +
immunodeficiency O +
virus O +
inhibitor O -
; O +
side O +
effects O +
reduction O +
[ O -
Object O -
] O +
Is O +
to O +
provide O +
a O +
novel O +
compound O +
having O +
an O +
anti O -
- O -
viral O +
activity O -
, O +
particularly O +
a O +
HIV B-Gene +
integrase I-Gene +
inhibitory O +
activity O -
, O +
and O +
an O +
agent O -
, O +
particularly O +
an O +
anti O -
- O -
HIV O +
agent O -
. O +

[ O -
Solving O +
means O -
] O +
A O +
compound O +
represented O +
by O +
the O +
formula O -
: O +
( O -
wherein O +
Z1 O +
is O +
NR4 O +
( O -
R4 O +
is O +
hydrogen O -
, O +
optionally O +
substituted O +
lower O +
alkyl O +
etc O -
. O -
) O -
, O +
O O +
or O +
CH2 O -
; O +
Z2 O +
is O +
optionally O +
substituted O +
lower O +
alkylene O +
or O +
optionally O +
substituted O +
lower O +
alkenylene O -
, O +
each O +
may O +
be O +
intervened O +
by O +
a O +
heteroatom O +
group O +
selected O +
from O +
group O +
consisting O +
O O -
, O +
S O -
, O +
SO O -
, O +
SO2 O -
, O +
NR5 O +
( O -
R5 O +
is O +
selected O +
independently O +
from O +
the O +
same O +
substituent O +
group O +
of O +
R4 O -
) O -
â€”N O -
â• O +
and O +
â• O -
Nâ€” O -
; O +
R1 O +
is O +
hydrogen O +
or O +
lower O +
alkyl O -
; O +
X O +
is O +
a O +
single O +
bond O -
, O +
a O +
heteroatom O +
group O +
selected O +
from O +
O O -
, O +
S O -
, O +
SO O -
, O +
SO2 O +
and O +
NH O -
, O +
or O +
lower O +
alkylene O +
or O +
lower O +
alkenylene O +
each O +
may O +
be O +
intervened O +
by O +
the O +
heteroatom O +
group O -
; O +
R2 O +
is O +
optionally O +
substituted O +
aryl O -
; O +
R3 O +
is O +
hydrogen O -
, O +
halogen O -
, O +
hydroxy O -
, O +
optionally O +
substituted O +
alkyl O +
group O +
etc O -
. O -
) O +

Crystalline O -
, O +
formed O +
by O +
crystallizing O +
from O +
an O +
aqueous O +
solution O +
without O +
agitation O -
; O +
treating O +
cancer O +
Erlotinib O +
hydrochloride O +
hydrate O +
is O +
formed O +
from O +
an O +
aqueous O +
solution O +
and O +
is O +
useful O +
as O +
a O +
pharmaceutical O +
and O +
as O +
a O +
purification O +
intermediate O -
. O +

Compositions O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
cancer O +
Compositions O +
are O +
provided O +
for O +
the O +
topical O +
treatment O +
of O +
cancer O +
consisting O +
of O +
lotions O -
, O +
creams O -
, O +
sprays O -
, O +
suppositories O +
or O +
slow O -
- O -
release O +
transdermal O +
patches O +
containing O +
lipid O -
- O -
soluble O -
, O +
skin O -
- O -
penetrating O +
organic O +
selenium O +
compounds O +
in O +
combination O +
with O +
inert O +
carriers O +
in O +
therapeutically O +
effective O +
amounts O +
of O +
selenium O +
compound O -
. O +

The O +
selenium O +
compounds O +
are O +
medium O +
linear O +
chain O +
dialkyl O +
diselenides O +
and O +
precursors O +
such O +
as O +
alkyl O +
selenols O -
. O +

Preferred O +
compositions O +
employ O +
R O -
â€” O -
Se O -
â€” O -
Se O -
â€” O -
R O +
compounds O +
where O +
R O +
is O +
from O +
6 O +
to O +
8 O +
carbon O +
atoms O -
, O +
and O +
most O +
specifically O +
di O -
- O -
n O -
- O -
hexyl O +
diselenide O -
. O +

Commonly O +
used O +
carriers O +
may O +
be O +
purified O +
hydrocarbon O +
fractions O -
, O +
oils O -
, O +
with O +
or O +
without O +
added O +
fat O -
- O -
soluble O +
vitamins O -
, O +
water O +
and O +
emulsifying O +
agents O -
. O +

Allele O -
- O -
specific O +
silencing O +
of O +
disease O +
genes O +
The O +
present O +
invention O +
is O +
directed O +
to O +
small O +
interfering O +
RNA O +
molecules O +
( O -
siRNA O -
) O +
targeted O +
against O +
an O +
allele O +
of O +
interest O -
, O +
and O +
methods O +
of O +
using O +
these O +
siRNA O +
molecules O -
. O +

Sirolimus O +
Formulation O +
The O +
present O +
invention O +
relates O +
to O +
a O +
stable O +
pharmaceutical O +
composition O +
comprising O +
sirolimus O -
. O +

The O +
pharmaceutical O +
composition O +
comprises O +
sirolimus O +
in O +
the O +
amorphous O +
form O -
, O +
a O +
fatty O +
acid O +
ester O +
and O +
a O +
pharmaceutically O +
acceptable O +
polymer O +
wherein O +
the O +
fatty O +
acid O +
ester O +
is O +
present O +
at O +
a O +
concentration O +
of O +
less O +
than O +
10 O -
% O +
w O -
/ O -
w O +
compared O +
to O +
the O +
total O +
weight O +
of O +
the O +
composition O -
. O +

N- O -
{ O -
2- O -
[ O -
( O -
( O -
2S O -
) O -
-3- O -
{ O -
[ O -
1- O -
( O -
4-chlorobenzyl O -
) O -
piperidin-4-yl O -
] O -
amino O -
} O -
-2-hydroxy-2-methylpropyl O -
) O -
oxy O -
] O -
-4-hydroxyphenyl O -
} O -
acetamide O +
hemifumarate O -
; O +
chemokine B-Gene +
receptor I-Gene +
1 I-Gene +
modulation O -
; O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
asthma O -
; O +
chemical O +
stability O -
; O +
easy O +
to O +
handle O -
; O +
inhalant O +
formulations O +
The O +
invention O +
provides O +
N- O -
{ O -
2- O -
[ O -
( O -
( O -
2S O -
) O -
-3- O -
{ O -
[ O -
1- O -
( O -
4-chlorobenzyl O -
) O -
piperidin-4-yl O -
] O -
amino O -
} O -
-2-hydroxy-2-methyl O -
- O -
propyl O -
) O -
oxy O -
] O -
-4-hydroxyphenyl O -
} O -
acetamide O +
hemi O -
- O -
fumarate O +
or O +
a O +
solvate O +
thereof O -
, O +
pharmaceutical O +
compositions O +
containing O +
the O +
salt O +
or O +
solvate O +
and O +
use O +
of O +
the O +
salt O +
or O +
solvate O +
in O +
therapy O -
. O +

Weight O +
control O -
; O +
sexual O +
disorders O -
; O +
stomach O +
blotting O -
; O +
gastrointestinal O +
disorders O -
; O +
anticholesterol O +
agents O +
Disclosed O +
is O +
a O +
composition O +
and O +
method O -
, O +
for O +
various O +
conditions O -
, O +
including O +
body O +
weight O +
control O -
, O +
sexual O +
dysfunction O -
, O +
stomach O +
blotting O -
, O +
heartburn O -
, O +
body O +
pain O -
, O +
and O +
controlling O +
cholesterol O -
, O +
arginine O +
is O +
used O +
as O +
active O +
material O -
. O +

The O +
composition O +
is O +
in O +
the O +
form O +
of O +
lotion O -
/ O -
cream O +
applicable O +
to O +
any O +
part O +
of O +
the O +
body O +
and O +
still O +
functional O -
. O +

It O +
does O +
not O +
need O +
to O +
be O +
applied O +
on O +
problematic O +
site O -
. O +

External O +
pharmaceutical O +
composition O +
containing O +
tramadol O +
An O +
analgesic O +
composition O +
for O +
external O +
application O +
for O +
increasing O +
the O +
percutaneous O +
permeability O +
of O +
tramadol O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and O +
for O +
achieving O +
a O +
quick O +
pharmacological O +
effect O -
. O +

The O +
analgesic O +
composition O +
includes O +
tramadol O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
a O +
menthol O +
substance O +
and O +
a O +
pyrrolidone O +
compound O -
. O +

Methods O +
for O +
Improving O +
Drug O +
Disposition O +
The O +
invention O +
provides O +
a O +
method O +
for O +
improving O +
the O +
bioavailability O -
, O +
preferably O -
, O +
oral O +
bioavailability O +
and/or O +
drug O +
disposition O -
, O +
e.g. O +
brain O +
penetration O -
, O +
of O +
an O +
iron O +
chelator O -
, O +
which O +
method O +
comprises O +
co O -
- O -
administering O +
to O +
a O +
mammal O -
, O +
especially O +
a O +
human O -
, O +
in O +
need O +
of O +
such O +
treatment O -
, O +
a O +
combination O +
of O +
an O +
iron O +
chelator O +
and O +
an O +
efflux B-Gene +
protein I-Gene +
inhibitor O -
. O +

Containing O +
phosphodiesterase B-Gene +
inhibitor O +
vardensfil O -
; O +
erectile O +
dysfunction O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
pharmaceutical O +
dosage O +
forms O +
with O +
controlled O +
release O +
of O +
active O +
ingredient O +
which O +
comprise O +
the O +
PDE B-Gene +
5 I-Gene +
inhibitor O +
vardenafil O +
and/or O +
pharmaceutically O +
acceptable O +
salts O -
, O +
hydrates O -
, O +
solvates O +
and/or O +
polymorphic O +
forms O +
thereof O +
as O +
active O +
ingredient O -
, O +
and O +
to O +
the O +
production O +
thereof O -
. O +

The O +
invention O +
further O +
relates O +
to O +
the O +
use O +
of O +
these O +
novel O +
pharmaceutical O +
dosage O +
forms O +
as O +
medicaments O -
, O +
and O +
to O +
their O +
use O +
for O +
producing O +
medicaments O +
for O +
the O +
treatment O +
and/or O +
prevention O +
of O +
disorders O +
in O +
humans O +
and O +
animals O -
. O +

Heterodimers O +
of O +
glutamic O +
acid O +
Compounds O +
of O +
Formula O +
( O -
Ia O -
) O +
wherein O +
R O +
is O +
a O +
C6-C12 O +
substituted O +
or O +
unsubstituted O +
aryl O -
, O +
a O +
C6-C12 O +
substituted O +
or O +
unsubstituted O +
heteroaryl O -
, O +
a O +
C1-C6 O +
substituted O +
or O +
unsubstituted O +
alkyl O +
or O +
â€”NRâ€²Râ€² O -
, O +
Q O +
is O +
C O -
( O -
O O -
) O -
, O +
O O -
, O +
NRâ€² O -
, O +
S O -
, O +
S O -
( O -
O O -
) O -
2 O -
, O +
C O -
( O -
O O -
) O -
2 O +
( O -
CH2 O -
) O -
p O +
Y O +
is O +
C O -
( O -
O O -
) O -
, O +
O O -
, O +
NRâ€² O -
, O +
S O -
, O +
S O -
( O -
O O -
) O -
2 O -
, O +
C O -
( O -
O O -
) O -
2 O +
( O -
CH2 O -
) O -
p O +
Z O +
is O +
H O +
or O +
C1-C4 O +
alkyl O -
, O +
Râ€² O +
is O +
H O -
, O +
C O -
( O -
O O -
) O -
, O +
S O -
( O -
O O -
) O -
2 O -
, O +
C O -
( O -
O O -
) O -
2 O -
, O +
a O +
C6-C12 O +
substituted O +
or O +
unsubstituted O +
aryl O -
, O +
a O +
C6-C12 O +
substituted O +
or O +
unsubstituted O +
heteroaryl O +
or O +
a O +
C1-C6 O +
substituted O +
or O +
unsubstituted O +
alkyl O -
, O +
when O +
substituted O -
, O +
aryl O -
, O +
heteroaryl O +
and O +
alkyl O +
are O +
substituted O +
with O +
halogen O -
, O +
C6-C12 O +
heteroaryl O -
, O +
â€”NRâ€²Râ€² O +
or O +
COOZ O -
, O +
which O +
have O +
diagnostic O +
and O +
therapeutic O +
properties O -
, O +
such O +
as O +
the O +
treatment O +
and O +
management O +
of O +
prostate O +
cancer O +
and O +
other O +
diseases O +
related O +
to O +
NAALADase B-Gene +
inhibition O -
. O +

Radiolabels O +
can O +
be O +
incorporated O +
into O +
the O +
structure O +
through O +
a O +
variety O +
of O +
prosthetic O +
groups O +
attached O +
at O +
the O +
X O +
amino O +
acid O +
side O +
chain O +
via O +
a O +
carbon O +
or O +
hetero O +
atom O +
linkage O -
. O +

E.g. O -
, O +
[ O -
( O -
1- O -
( O -
2-aminoacetyl O -
) O -
-4- O -
{ O -
N- O -
[ O -
( O -
3-fluoro-2-methylphenyl O -
) O -
methyl O -
] O -
carbamoyl O -
} O -
( O -
4-piperidyl O -
) O -
) O -
methoxy O -
] O -
-N- O -
( O -
4-ethylphenyl O -
) O -
carboxamide O -
; O +
smooth O +
muscle O +
myosin O +
or O +
non O -
- O -
muscle O +
myosin O +
modulator O -
; O +
hypotensive O +
agent O -
; O +
asthma O -
, O +
COPD O -
, O +
bronchoconstrictive O +
disease O -
, O +
glaucoma O -
, O +
pre O -
- O -
menstrual O +
cramps O -
, O +
erectile O +
dysfunction O +
Chemical O +
entities O +
that O +
modulate O +
smooth O +
muscle O +
myosin O +
and/or O +
non O -
- O -
muscle O +
myosin O -
, O +
pharmaceutical O +
compositions O +
and O +
methods O +
of O +
treatment O +
of O +
diseases O +
and O +
conditions O +
associated O +
with O +
smooth O +
muscle O +
myosin O +
and/or O +
non O -
- O -
muscle O +
myosin O +
are O +
described O -
. O +

glutamate B-Gene +
receptors I-Gene +
agonists O -
; O +
especially O +
to O +
treat O +
psychotic O +
conditions O -
, O +
including O +
schizophrenia O +
and O +
enhancement O +
of O +
cognition O -
; O +
N- O -
{ O -
-2- O -
[ O -
4- O -
( O -
6-fluoro-3-pyridinyl O -
) O -
phenyl O -
] O -
cyclopropyl O -
} O -
-2-propanesulfonamide O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
solvate O +
or O +
prodrug O +
thereof O -
, O +
are O +
disclosed O -
: O +
wherein O +
R1 O +
is O +
C1 O -
- O -
6alkyl O -
, O +
haloC1 O -
- O -
6alkyl O -
, O +
C2 O -
- O -
6alkenyl O -
, O +
amino O -
, O +
monoC1 O -
- O -
4alkylamino O +
or O +
diC1 O -
- O -
4alkylamino O -
; O +
R2 O +
and O +
R3 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
are O +
hydrogen O -
, O +
halogen O -
, O +
C1 O -
- O -
6alkyl O -
, O +
haloC1 O -
- O -
6alkyl O -
, O +
C1 O -
- O -
4alkoxy O -
, O +
haloC1 O -
- O -
4alkoxy O -
, O +
cyano O -
, O +
amino O -
, O +
monoC1 O -
- O -
4alkylamino O +
or O +
diC1 O -
- O -
4alkylamino O -
; O +
each O +
R4 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
is O +
C1 O -
- O -
6alkyl O -
, O +
halogen O -
, O +
C1 O -
- O -
6alkyl O -
, O +
haloC1 O -
- O -
6alkyl O -
, O +
C1 O -
- O -
4alkoxy O -
, O +
haloC1 O -
- O -
4alkoxy O -
, O +
cyano O -
, O +
nitro O -
, O +
amino O -
, O +
monoC1 O -
- O -
4alkylamino O +
or O +
diC1 O -
- O -
4alkylamino O -
; O +
p O +
is O +
0 O -
, O +
1 O +
or O +
2 O -
; O +
n O +
is O +
1 O +
or O +
2 O -
; O +
R5 O +
and O +
R6 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
are O +
hydrogen O -
, O +
halogen O -
, O +
C1 O -
- O -
6alkyl O -
, O +
haloC1 O -
- O -
6alkyl O -
, O +
C1 O -
- O -
4alkoxy O -
, O +
haloC1 O -
- O -
4alkoxy O -
, O +
cyano O -
, O +
amino O -
, O +
monoC1 O -
- O -
4alkylamino O +
or O +
diC1 O -
- O -
4alkylamino O -
; O +
and O +
Het O +
is O +
thienyl O -
, O +
pyridyl O -
, O +
pyrimidinyl O -
, O +
pyridazinyl O -
, O +
pyrimidinyl O -
, O +
pyrazinyl O -
, O +
imidazolyl O -
, O +
pyrazolyl O -
, O +
pyrrolyl O -
, O +
quinolyl O -
, O +
thiazolyl O +
or O +
furyl O -
, O +
each O +
of O +
which O +
may O +
be O +
substituted O +
by O +
one O +
or O +
more O +
groups O +
independently O +
selected O +
from O +
the O +
list O +
consisting O +
of O +
C1 O -
- O -
6alkyl O -
, O +
C1 O -
- O -
6alkoxy O -
, O +
acetyl O -
, O +
halogen O -
, O +
haloC1 O -
- O -
6alkyl O -
, O +
cyano O -
, O +
nitro O -
, O +
amino O -
, O +
monoC1 O -
- O -
4alkylamino O +
and O +
diC1 O -
- O -
4alkylamino O -
. O +

Methods O +
of O +
preparation O +
of O +
the O +
compounds O -
, O +
and O +
uses O +
thereof O +
in O +
medicine O -
, O +
for O +
example O +
treatment O +
of O +
schizophrenia O -
, O +
are O +
also O +
disclosed O -
. O +

Novel O +
sustained O +
release O +
polymer O +
A O +
polymer O +
and O +
a O +
method O +
for O +
its O +
preparation O +
are O +
provided O -
. O +

The O +
polymer O +
comprises O +
poly O -
( O -
lactide O -
) O -
, O +
poly O -
( O -
lactide O -
/ O -
glycolide O -
) O +
or O +
poly O -
( O -
lactic O +
acid O -
/ O -
glycolic O +
acid O -
) O +
segments O +
bonded O +
by O +
ester O +
linkages O +
to O +
both O +
ends O +
of O +
an O +
alkanediol O +
core O +
unit O -
. O +

The O +
polymer O +
is O +
for O +
use O +
in O +
a O +
controlled O +
release O +
formulation O +
for O +
a O +
medicament O -
, O +
preferably O +
leuprolide O +
acetate O -
. O +

The O +
controlled O +
release O +
formulation O +
is O +
administered O +
to O +
a O +
patient O +
as O +
a O +
subcutaneous O +
depot O +
of O +
a O +
flowable O +
composition O +
comprising O +
the O +
polymer O -
, O +
a O +
biocompatible O +
solvent O -
, O +
and O +
the O +
medicament O -
. O +

Controlled O +
release O +
formulations O +
comprising O +
the O +
polymer O +
release O +
leuprolide O +
for O +
treatment O +
of O +
prostate O +
cancer O +
patients O +
over O +
periods O +
of O +
3 O -
- O -
6 O +
months O -
. O +

mobilizing O +
triacylglycerol O +
in O +
mammals O +
by O +
feeding O +
the O +
mammal O +
a O +
diet O +
that O +
includes O +
betaine O -
, O +
cysteine O +
and O +
choline O +
bitartrate O -
, O +
while O +
restricting O +
methionine O +
intake O -
; O +
reduction O +
of O +
liver O +
disorders O -
; O +
cirrhosis O +
Methods O +
for O +
use O +
in O +
mobilizing O +
triacylglycerol O +
( O -
TAG O -
) O +
in O +
order O +
to O +
elevate O +
apoliprotein B-Gene +
B I-Gene +
and O +
Very O -
- O -
Low O -
- O -
Density O +
Lipoprotein O +
( O -
VLDL O -
) O +
are O +
described O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
method O +
involves O +
providing O +
betaine O +
in O +
an O +
amount O +
of O +
about O +
3 O +
gm O -
/ O -
kg O +
of O +
body O +
weight O +
per O +
day O +
in O +
order O +
to O +
mobilize O +
TAG O -
. O +

In O +
some O +
embodiments O -
, O +
serum O +
VLDL O +
is O +
elevated O +
as O +
a O +
result O +
of O +
mobilizing O +
hepatic O +
TAG O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
method O +
includes O +
restricting O +
methionine O +
intake O +
to O +
less O +
than O +
about O +
1 O +
gm O -
/ O -
kg O +
of O +
body O +
weight O +
per O +
day O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
method O +
includes O +
feeding O +
L O -
- O -
cysteine O +
at O +
a O +
level O +
of O +
at O +
least O +
about O +
3 O +
gm O -
/ O -
kg O +
of O +
body O +
weight O +
per O +
day O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
method O +
includes O +
feeding O +
choline O +
bitartrate O +
at O +
a O +
level O +
of O +
about O +
1.25 O +
gm O -
/ O -
kg O +
of O +
body O +
weight O +
per O +
day O -
. O +

Mobilizing O +
hepatic O +
TAG O +
is O +
effective O +
to O +
reduce O +
hepatic O +
steatosis O -
. O +

Method O +
For O +
Diagnosing O +
Colorectal O +
Cancers O +
Objective O +
methods O +
for O +
detecting O +
and O +
diagnosing O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
are O +
described O +
herein O -
. O +

In O +
one O +
embodiment O -
, O +
the O +
diagnostic O +
method O +
involves O +
the O +
determining O +
an O +
expression O +
level O +
of O +
C10orf3 B-Gene +
that O +
discriminate O +
between O +
CRC O +
and O +
normal O +
cell O -
. O +

The O +
present O +
invention O +
further O +
provides O +
methods O +
of O +
screening O +
for O +
therapeutic O +
agents O +
useful O +
in O +
the O +
treatment O +
of O +
CRC O -
, O +
methods O +
of O +
treating O +
CRC O +
and O +
method O +
of O +
vaccinating O +
a O +
subject O +
against O +
CRC O -
. O +

Treatment O +
for O +
liver O +
disease O +
The O +
present O +
invention O +
is O +
based O +
on O +
the O +
finding O +
that O +
the O +
artificial O +
induction O +
of O +
hepatic O +
stellate O +
cell O +
( O -
HSC O -
) O +
apoptosis O +
in O +
vivo O +
can O +
promote O +
the O +
resolution O +
of O +
liver O +
fibrosis O -
. O +

Thus O -
, O +
the O +
present O +
invention O +
provides O +
methods O +
for O +
treating O +
liver O +
disease O +
in O +
a O +
subject O +
involving O +
administration O +
of O +
an O +
inducer O +
of O +
apoptosis O +
which O +
is O +
capable O +
of O +
selectively O +
inducing O +
hepatic O +
stellate O +
cell O +
apoptosis O +
in O +
the O +
liver O +
of O +
the O +
subject O +
or O +
of O +
an O +
agent O +
which O +
is O +
capable O +
of O +
giving O +
rise O +
to O +
such O +
an O +
inducer O +
in O +
the O +
subject O -
. O +

In O +
addition O -
, O +
the O +
invention O +
provides O +
methods O +
for O +
treating O +
liver O +
fibrosis O +
in O +
a O +
subject O +
comprising O +
the O +
selective O +
delivery O +
of O +
an O +
inducer O +
of O +
apoptosis O +
specifically O +
to O +
the O +
hepatic O +
stellate O +
cells O +
of O +
the O +
subject O +
or O +
of O +
an O +
agent O +
which O +
is O +
capable O +
of O +
giving O +
rise O +
to O +
an O +
inducer O +
of O +
hepatic O +
stellate O +
cell O +
apoptosis O -
. O +

Early O +
Detection O +
and O +
Prognosis O +
of O +
Colon O +
Cancers O +
We O +
have O +
developed O +
a O +
transcriptome O -
- O -
wide O +
approach O +
to O +
identify O +
genes O +
affected O +
by O +
promoter O +
CpG O +
island O +
hypermethylation O +
and O +
transcriptional O +
silencing O +
in O +
colorectal O +
cancer O +
( O -
CRC O -
) O -
. O +

By O +
screening O +
cell O +
lines O +
and O +
validating O +
tumor O +
specific O +
hypermethylation O +
in O +
a O +
panel O +
of O +
primary O +
human O +
CRC O +
samples O -
, O +
we O +
estimate O +
that O +
nearly O +
5 O -
% O +
of O +
all O +
known O +
genes O +
may O +
be O +
promoter O +
methylated O +
in O +
an O +
individual O +
tumor O -
. O +

When O +
directly O +
compared O +
to O +
gene O +
mutations O -
, O +
we O +
find O +
a O +
much O +
larger O +
number O +
of O +
genes O +
hypermethylated O +
in O +
individual O +
tumors O -
, O +
and O +
much O +
higher O +
frequency O +
of O +
hypermethylation O +
within O +
individual O +
genes O +
harboring O +
either O +
genetic O +
or O +
epigenetic O +
changes O -
. O +

Thus O -
, O +
to O +
enumerate O +
the O +
full O +
spectrum O +
of O +
alterations O +
in O +
the O +
human O +
cancer O +
genome O -
, O +
and O +
facilitate O +
the O +
most O +
efficacious O +
grouping O +
of O +
tumors O +
to O +
identify O +
cancer O +
biomarkers O +
and O +
tailor O +
therapeutic O +
approaches O -
, O +
both O +
genetic O +
and O +
epigenetic O +
screens O +
should O +
be O +
undertaken O -
. O +

The O +
genes O +
we O +
identified O +
can O +
be O +
used O +
inter O +
alia O +
diagnostically O +
to O +
detect O +
cancer O -
, O +
pre O -
- O -
cancer O -
, O +
and O +
likelihood O +
of O +
developing O +
cancer O -
. O +

Use O +
of O +
a O +
CB1 B-Gene +
Antagonist O +
for O +
Treating O +
Side O +
Effects O +
and O +
Negative O +
Symptoms O +
of O +
Schizophrenia O +
The O +
present O +
invention O +
discloses O +
and O +
claims O +
a O +
method O +
of O +
treating O +
cognition O +
deficits O +
in O +
a O +
patient O +
suffering O +
from O +
schizophrenia O +
by O +
administering O +
to O +
said O +
patient O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
CB1 B-Gene +
receptor I-Gene +
antagonist O +
as O +
described O +
herein O -
. O +

In O +
another O +
aspect O -
, O +
this O +
invention O +
also O +
discloses O +
and O +
claims O +
a O +
combination O +
of O +
one O +
or O +
more O +
CB1 B-Gene +
receptor I-Gene +
antagonists O +
and O +
of O +
one O +
or O +
more O +
antipsychotic O +
agents O +
useful O +
in O +
the O +
treatment O +
of O +
psychiatric O +
disorders O -
. O +

The O +
combination O +
of O +
this O +
invention O +
provides O +
synergistic O +
results O +
in O +
that O +
the O +
combination O +
improves O +
positive O +
and O +
negative O +
symptoms O +
of O +
schizophrenia O -
, O +
weight O +
gain O +
and O +
catalepsy O -
. O +

1- O -
[ O -
1- O -
( O -
methylsulfonyl O -
) O -
piperidin-4-yl O -
] O -
-3- O -
( O -
adamant-1-yl O -
) O -
urea O -
, O +
1- O -
[ O -
1- O -
( O -
acetyl O -
) O -
piperidin-4-yl O -
] O -
-3- O -
( O -
adamant-1-yl O -
) O -
urea O -
; O +
incipient O +
diabetes O -
, O +
glucose O +
intolerance O -
, O +
obesity O -
, O +
hypertension O -
, O +
high O +
blood O +
pressure O -
, O +
elevated O +
serum O +
cholesterol O -
, O +
reduced O +
high O -
- O -
density O +
lipoproteins O +
and O +
elevated O +
triglyceride O +
levels O +
Compounds O -
, O +
compositions O -
, O +
and O +
methods O +
for O +
inhibiting O +
the O +
onset O +
of O +
metabolic O +
syndrome O +
and O +
treating O +
related O +
disorders O +
in O +
a O +
subject O +
in O +
need O +
of O +
such O +
therapy O +
are O +
disclosed O -
. O +

Controlled O +
Release O +
Formulations O +
The O +
present O +
invention O +
relates O +
to O +
controlled O +
release O +
transmucosal O +
formulations O +
which O +
mediate O +
absorption O +
and O +
methods O +
of O +
use O +
comprising O +
a O +
pharmaceutically O +
active O +
agent O -
, O +
preferably O +
morphine O -
, O +
and O +
a O +
water O +
soluble O +
polymer O -
, O +
chitosan O -
, O +
and O +
preferably O +
one O +
more O +
antioxidants O -
, O +
one O +
or O +
more O +
antimicrobial O +
agents O -
, O +
and O +
water O -
. O +

Method O +
of O +
Treatment O +
by O +
Administration O +
of O +
Rna O +
A O +
method O +
of O +
effecting O +
a O +
treatment O +
response O +
in O +
a O +
target O +
tissue O +
of O +
a O +
subject O -
, O +
comprising O -
: O +
administering O +
to O +
the O +
subject O +
isolated O +
RNA O +
comprising O +
an O +
RNA O +
sequence O +
extractable O +
or O +
extracted O +
from O +
a O +
source O +
tissue O +
such O +
that O +
said O +
treatment O +
response O +
is O +
effected O -
; O +
wherein O +
the O +
RNA O +
is O +
isolated O +
polyA O +
positive O +
RNA O +
in O +
substantially O +
pure O +
form O -
. O +

Two O -
- O -
coat O +
makeup O +
product O -
, O +
its O +
uses O -
, O +
and O +
makeup O +
kit O +
comprising O +
the O +
product O +
A O +
cosmetic O +
makeup O +
product O +
comprising O +
at O +
least O +
two O +
compositions O -
, O +
the O +
first O +
composition O +
comprising O +
a O +
physiologically O +
acceptable O +
medium O +
and O +
the O +
second O +
composition O +
comprising O +
a O +
mixture O +
of O +
at O +
least O +
one O +
high O +
molecular O +
weight O +
polymer O +
having O +
a O +
weight O -
- O -
average O +
molecular O +
mass O +
of O +
greater O +
than O +
or O +
equal O +
to O +
200,000 O +
g O -
/ O -
mol O +
and O +
at O +
least O +
one O +
low O +
molecular O +
weight O +
non O -
- O -
volatile O +
liquid O +
silicone O +
compound O +
having O +
a O +
weight O -
- O -
average O +
molecular O +
mass O +
of O +
less O +
than O +
200,000 O +
g O -
/ O -
mol O -
, O +
wherein O +
the O +
at O +
least O +
one O +
high O +
molecular O +
weight O +
polymer O +
and O +
the O +
at O +
least O +
one O +
low O +
molecular O +
weight O +
non O -
- O -
volatile O +
liquid O +
silicone O +
compound O +
are O +
present O +
in O +
a O +
proportion O +
such O +
that O +
the O +
dynamic O +
viscosity O +
of O +
the O +
mixture O +
at O +
25 O -
Â° O +
C. O -
, O +
measured O +
with O +
a O +
Mettler O +
RM O +
180 O +
rotational O +
viscometer O -
, O +
ranges O +
from O +
0.1 O +
to O +
120 O +
PaÂ·s O -
; O +
a O +
makeup O +
method O +
and O +
a O +
makeup O +
kit O +
comprising O +
the O +
cosmetic O +
makeup O +
product O -
. O +

The O +
cosmetic O +
makeup O +
product O +
may O -
, O +
for O +
example O -
, O +
be O +
a O +
lipstick O -
. O +

Alpha-4 B-Gene +
Integrin I-Gene +
Mediated O +
Cell O +
Adhesion O +
Inhibitors O +
for O +
the O +
Treatment O +
or O +
Prevention O +
of O +
Inflammatory O +
Diseases O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
compositions O +
comprising O +
them O +
and O +
their O +
use O +
in O +
the O +
treatment O +
or O +
prevention O +
of O +
diseases O +
capable O +
of O +
being O +
modulated O +
by O +
the O +
inhibition O +
of O +
cell O +
adhesion O -
. O +

End O -
- O -
Modified O +
Poly O -
( O -
beta O -
- O -
amino O +
esters O -
) O +
and O +
Uses O +
Thereof O +
Poly O -
( O -
beta O -
- O -
amino O +
esters O -
) O +
are O +
end O -
- O -
modified O +
to O +
form O +
materials O +
useful O +
in O +
the O +
medical O +
as O +
well O +
as O +
non O -
- O -
medical O +
field O -
. O +

An O +
amine O -
- O -
terminated O +
poly O -
( O -
beta O -
- O -
amino O +
ester O -
) O +
is O +
reacted O +
with O +
an O +
electrophile O -
, O +
or O +
an O +
acrylate O -
- O -
terminated O +
poly O -
( O -
beta O -
- O -
amino O +
ester O -
) O +
is O +
reacted O +
with O +
a O +
nucleophile O -
. O +

The O +
inventive O +
end O -
- O -
modified O +
polymers O +
may O +
be O +
used O +
in O +
any O +
field O +
where O +
polymers O +
have O +
been O +
found O +
useful O +
including O +
the O +
drug O +
delivery O +
arts O -
. O +

The O +
end O -
- O -
modified O +
polymers O +
are O +
particularly O +
useful O +
in O +
delivery O +
nucleic O +
acids O +
such O +
as O +
DNA O +
or O +
RNA O -
. O +

The O +
invention O +
also O +
provides O +
compositions O +
including O +
the O +
inventive O +
end O -
- O -
modified O +
polymers O -
, O +
methods O +
of O +
preparing O +
the O +
inventive O +
polymers O -
, O +
and O +
method O +
of O +
using O +
the O +
inventive O +
polymers O -
. O +

Using O +
vector O +
comprising O +
nucleotide O +
sequences O +
coding O +
neublastin B-Gene +
as O +
therapeutic O +
treatment O +
for O +
vision O +
defects O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
GFRÎ±3 B-Gene +
agonists O +
for O +
the O +
treatment O +
of O +
disorders O +
of O +
the O +
retina O -
. O +

A O +
preferred O +
GFRÎ±3 B-Gene +
agonist O +
is O +
Neublastin B-Gene -
. O +

Neublastin B-Gene +
may O +
be O +
administered O +
to O +
the O +
eye O +
using O +
protein O +
formulations O -
, O +
in O +
vivo O +
or O +
ex O +
vivo O +
gene O +
therapy O -
, O +
or O +
implantation O +
of O +
encapsulated O +
cells O +
delivering O +
Neublastin B-Gene +
locally O +
to O +
the O +
retina O -
. O +

Preventive O +
and/or O +
Therapeutic O +
Agent O +
for O +
Cancer O +
As O +
the O +
results O +
of O +
intensive O +
studies O +
aiming O +
at O +
providing O +
a O +
gene O +
targeting O +
a O +
cancer O +
cell O +
or O +
a O +
cancer O +
tissue O -
, O +
novel O +
nucleotide O +
sequences O +
showing O +
increased O +
expression O +
in O +
a O +
cancer O +
cell O +
or O +
a O +
cancer O +
tissue O +
compared O +
with O +
normal O +
tissues O +
are O +
identified O -
. O +

As O +
the O +
results O +
of O +
the O +
subsequent O +
studies O -
, O +
genes O +
showing O +
increased O +
expression O +
in O +
a O +
cancer O +
cell O +
or O +
a O +
cancer O +
tissue O +
which O +
are O +
useful O +
as O +
a O +
drug O +
discovery O +
target O +
are O +
found O +
out O -
. O +

Has O +
acceptable O +
biodegradable O +
polymer O -
; O +
polyglycolic O +
acid O -
, O +
polylactic O +
acid O -
; O +
Parkinson O -
's O +
Disease O -
; O +
injectable O +
microspheres O -
, O +
injectable O +
gels O +
and O +
implants O -
; O +
enhanced O +
bioavailability O +
The O +
present O +
invention O +
relates O +
to O +
a O +
long O -
- O -
acting O +
sustained O -
- O -
release O +
dosage O +
form O +
for O +
treatment O +
of O +
Parkinson O +
Disease O -
, O +
comprising O +
a O +
dopamine B-Gene +
receptor I-Gene +
agonist O +
and O +
a O +
pharmaceutically O +
acceptable O +
biodegradable O +
polymer O +
accessories O -
, O +
wherein O +
the O +
content O +
of O +
the O +
dopamine B-Gene +
receptor I-Gene +
agonist O +
in O +
the O +
sustained O -
- O -
release O +
dosage O +
form O +
is O +
5 O -
- O -
50 O -
% O +
by O +
weight O -
, O +
and O +
the O +
content O +
of O +
the O +
pharmaceutically O +
acceptable O +
polymer O +
accessories O +
is O +
50 O -
- O -
95 O -
% O +
by O +
weight O -
. O +

Delivery O +
System O +
For O +
Bioactive O +
Agents O +
on O +
the O +
Basis O +
of O +
a O +
Polymeric O +
Drug O +
Carrier O +
Comprising O +
an O +
Amphiphilic O +
Block O +
Polymer O +
and O +
a O +
Polylacticacid O +
Derivative O +
Delivery O +
system O +
for O +
bioactive O +
agents O +
on O +
the O +
basis O +
of O +
a O +
polymeric O +
drug O +
carrier O +
formed O +
from O +
compositions O +
comprising O +
an O +
amphiphilic O +
block O +
copolymer O +
of O +
a O +
hydrophilic O +
block O +
and O +
a O +
hydrophobic O +
block O +
having O +
a O +
terminal O +
hydroxyl O +
group O +
substituted O +
with O +
a O +
tocopherol O +
or O +
cholesterol O +
group O -
, O +
and O +
a O +
polylactic O +
acide O +
derivative O +
wherein O +
one O +
end O +
of O +
the O +
polylactic O +
acid O +
is O +
covalently O +
bound O +
to O +
at O +
least O +
one O +
carboxyl O +
group O -
. O +

The O +
carboxyl O +
group O +
of O +
the O +
polylactic O +
acid O +
derivative O +
may O +
be O +
fixed O +
with O +
a O +
di- O +
or O +
trivalent O +
metal O +
ion O -
, O +
which O +
is O +
obtained O +
by O +
adding O +
the O +
di- O +
or O +
trivalent O +
metal O +
ion O +
to O +
the O +
polymeric O +
composition O -
. O +

Topical O -
; O +
adenosine O +
5'-monophosphates O +
and O +
salts O +
thereof O -
; O +
arbutins O -
, O +
ellagic O +
acid O -
, O +
4-alkylresorcinols O -
, O +
linolic O +
acid O -
, O +
tranexamic O +
acid O -
, O +
chamomile O +
extracts O -
, O +
ubiquinones O -
; O +
chloasma O -
, O +
freckles O +
A O +
composition O +
for O +
the O +
prevention O +
or O +
alleviation O +
of O +
pigmentation O +
which O +
can O +
produce O +
the O +
higher O +
effect O +
of O +
preventing O +
or O +
alleviating O +
pigmentation O -
. O +

The O +
composition O +
for O +
the O +
prevention O +
or O +
alleviation O +
of O +
pigmentation O +
comprises O +
a O +
combination O +
of O +
( O -
A O -
) O +
at O +
least O +
one O +
member O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
adenosine O +
5â€²-monophosphate O +
and O +
salts O +
thereof O +
with O +
( O -
B O -
) O +
at O +
least O +
one O +
member O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
arbutin O -
, O +
ellagic O +
acid O -
, O +
4-alkylresorcinols O -
, O +
linoleic O +
acid O -
, O +
tranexamic O +
acid O -
, O +
salts O +
of O +
these O -
, O +
Chamomilla O +
recuita O +
extract O -
, O +
and O +
Ubiquinone O -
. O +

Isolated O +
polynucleotide O +
encoding O +
a O +
Regulated O +
in O +
chronic O +
obstructive O +
pulmonary O +
disease O +
Kinase O +
polypeptide O -
; O +
host O +
cell O -
; O +
hybridization O -
; O +
screening O -
; O +
prediction O -
, O +
diagnosis O -
; O +
prognosis O -
; O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
asthma O -
, O +
cancer O -
, O +
diseases O +
of O +
defective O +
cell O +
signaling O +
Reagents O +
which O +
regulate O +
human O +
RC O +
Kinase O +
activity O +
and O +
reagents O +
which O +
bind O +
to O +
human O +
RC O +
Kinase O +
gene O +
products O +
can O +
be O +
used O +
to O +
regulate O +
this O +
protein O +
for O +
therapeutic O +
effects O -
. O +

Such O +
regulation O +
is O +
particularly O +
useful O +
for O +
treating O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
asthma O -
, O +
cancer O -
, O +
and O +
diseases O +
in O +
which O +
cell O +
signaling O +
is O +
defective O -
. O +

siRNA O +
blocks O +
expression O +
of O +
sphingosine B-Gene +
kinase I-Gene -
, O +
potentiates O +
effect O +
of O +
radiation O +
in O +
cancer O +
cells O +
of O +
breast O -
, O +
prostate O -
, O +
colorectal O -
, O +
lung O -
, O +
bladder O -
, O +
head O +
and O +
neck O -
, O +
intestine O -
, O +
ovarian O -
, O +
skin O -
; O +
reduces O +
amount O +
of O +
radiation O +
needed O +
to O +
decrease O +
cancer O +
cell O +
viability O -
, O +
tumor O +
size O +
in O +
vivo O +
The O +
present O +
invention O +
relates O +
to O +
Sphingosine B-Gene +
kinase I-Gene +
inhibitors O +
that O +
are O +
useful O +
for O +
treating O +
various O +
cancers O -
. O +

The O +
invention O +
further O +
relates O +
to O +
compositions O +
and O +
methods O +
of O +
SPK B-Gene +
inhibitors O -
, O +
including O +
siRNAs O -
, O +
which O +
specifically O +
block O +
gene O +
expression O +
of O +
SPK B-Gene +
and O +
potentiates O +
the O +
effect O +
of O +
radiation O +
in O +
the O +
treatment O +
of O +
various O +
cancers O -
. O +

Inhibitory O +
activity O +
against O +
Pin1 B-Gene -
; O +
inhibit O +
peptidyl B-Gene -
- I-Gene -
prolyl I-Gene +
isomerase I-Gene +
activity O +
of O +
Pin1 B-Gene -
; O +
inhibits O +
growth O +
of O +
cancer O +
cells O -
; O +
Ac O -
- O -
Phe O -
- O -
Tyr O -
- O -
phosphoSer- O +
pseudo O +
amide O +
-Pro O -
- O -
Arg O -
- O -
NH2 O -
; O +
Fmoc O -
- O -
bis O -
( O -
POM O -
) O +
phosphoSer- O +
pseudo O +
amide O +
-Pro-2-aminoethyl- O -
( O -
3-indole O -
) O +
and O +
their O +
Phospho- O -
( O -
D O -
) O -
-serine O +
stereoisomers O +
Ac O -
- O -
Phe O -
- O -
Tyr O -
- O -
phosphoSer O -
- O -
Î¨ O -
[ O -
CH O -
â• O -
C O -
] O -
-Pro O -
- O -
Arg O -
- O -
NH2AND O +
Fmoc O -
- O -
bis O -
( O -
pivaloylmethoxy O -
) O -
phosphoSer O -
- O -
Î¨ O -
[ O -
CH O -
â• O -
C O -
] O -
-Pro-2-aminoethyl- O -
( O -
3-indole O -
) O -
; O +
and O +
their O +
Phospho- O -
( O -
D O -
) O -
-serine O +
stereoisomers O +
are O +
novel O +
compounds O -
. O +

Î¨ O +
refers O +
to O +
a O +
pseudo O +
amide O -
. O +

Such O +
novel O +
compounds O +
advantageously O +
may O +
be O +
used O +
as O +
alkene O +
mimics O -
. O +

O O -
- O -
desmethylvenlafaxine O +
succinate O -
; O +
tablet O -
, O +
capsule O -
; O +
sustained O +
release O -
; O +
hydroxypropylmethyl O +
cellulose O +
rate O +
controlling O +
polymer O -
; O +
microcrystalline O +
cellulose O +
binder O -
; O +
depression O -
, O +
bipolar O +
and O +
manic O +
disorders O -
, O +
attention O +
deficit O +
disorder O -
, O +
attention O +
deficit O +
disorder O +
with O +
hyperactivity O -
, O +
Parkinson O -
's O +
disease O +
Methods O +
of O +
preparing O -
, O +
and O +
compositions O +
comprising O -
, O +
derivatives O +
of O +
venlafaxine O +
are O +
disclosed O -
. O +

Also O +
disclosed O +
are O +
methods O +
of O +
treating O +
and O +
preventing O +
diseases O +
and O +
disorders O +
including O -
, O +
but O +
not O +
limited O +
to O -
, O +
affective O +
disorders O +
such O +
as O +
depression O -
, O +
bipolar O +
and O +
manic O +
disorders O -
, O +
attention O +
deficit O +
disorder O -
, O +
attention O +
deficit O +
disorder O +
with O +
hyperactivity O -
, O +
Parkinson O -
's O +
disease O -
, O +
epilepsy O -
, O +
cerebral O +
function O +
disorders O -
, O +
obesity O +
and O +
weight O +
gain O -
, O +
incontinence O -
, O +
dementia O +
and O +
related O +
disorders O -
. O +

Method O +
for O +
Avoiding O +
Edema O +
in O +
the O +
Treatment O +
or O +
Prevention O +
of O +
Ppary O -
- O -
Responsive O +
Diseases O -
, O +
Including O +
Cancer O +
Compounds O -
, O +
compositions O -
, O +
and O +
methods O +
of O +
avoiding O +
edema O +
while O +
treating O +
or O +
preventing O +
PPARÎ³ B-Gene -
- O -
mediated O +
diseases O -
, O +
including O +
cancer O -
, O +
using O +
derivatives O +
and O +
prodrugs O +
are O +
provided O -
. O +

Antiserotonine O +
agents O -
; O +
gastrointestinal O +
disorders O -
; O +
irritable O +
bowel O +
syndrome O -
; O +
central O +
nervous O +
system O +
disorders O -
; O +
Alzheimer O -
's O +
disease O -
; O +
cognition O +
activators O -
; O +
analgesics O -
; O +
cardiovascular O +
disorders O -
; O +
antidiabetic O +
agents O -
; O +
sleep O +
disorders O +
This O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
: O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
wherein O -
: O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
A O +
and O +
m O +
are O +
each O +
as O +
described O +
herein O +
and O +
compositions O +
containing O +
such O +
compounds O +
and O +
the O +
use O +
of O +
such O +
compounds O +
in O +
the O +
treatment O +
of O +
a O +
condition O +
mediated O +
by O +
5-HT4 B-Gene +
agonistic O +
activity O +
such O +
as O -
, O +
but O +
not O +
limited O +
to O -
, O +
gastroesophageal O +
reflux O +
disease O -
, O +
gastrointestinal O +
disease O -
, O +
gastric O +
motility O +
disorder O -
, O +
non O -
- O -
ulcer O +
dyspepsia O -
, O +
functional O +
dyspepsia O -
, O +
irritable O +
bowel O +
syndrome O +
( O -
IBS O -
) O -
, O +
constipation O -
, O +
dyspepsia O -
, O +
esophagitis O -
, O +
gastroesophageral O +
disease O -
, O +
nausea O -
, O +
central O +
nervous O +
system O +
disease O -
, O +
Alzheimer O -
's O +
disease O -
, O +
cognitive O +
disorder O -
, O +
emesis O -
, O +
migraine O -
, O +
neurological O +
disease O -
, O +
pain O -
, O +
cardiovascular O +
disorders O -
, O +
cardiac O +
failure O -
, O +
heart O +
arrhythmia O -
, O +
diabetes O +
and O +
apnea O +
syndrome O -
. O +

Analgesics O -
; O +
antidepressants O -
; O +
neurodegenerative O +
diseases O -
; O +
antiepileptic O +
agents O -
; O +
cognition O +
activators O -
; O +
antitussive O +
agents O -
; O +
incotinence O -
; O +
irritable O +
bowel O +
syndrome O -
; O +
stroke O -
; O +
vision O +
defects O -
; O +
antiinflammatory O +
agents O -
; O +
skin O +
disorders O -
; O +
diarrhea O -
; O +
eating O +
disorders O +
The O +
present O +
invention O +
relates O +
to O +
substituted O +
spiro O +
compounds O -
, O +
to O +
processes O +
for O +
preparing O +
them O -
, O +
to O +
medicaments O +
comprising O +
these O +
compounds O +
and O +
to O +
the O +
use O +
of O +
these O +
compounds O +
for O +
producing O +
medicaments O -
. O +

Antibacterial O +
amide O -
- O -
macrocycles O +
v O +
The O +
invention O +
relates O +
to O +
antibacterial O +
amide O -
- O -
macrocycles O +
of O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
R26 O +
represents O +
hydrogen O -
, O +
halogen O -
, O +
amino O +
or O +
methyl O -
, O +
R7 O +
represents O +
a O +
group O +
of O +
formula O +
( O -
II O -
) O -
, O +
( O -
III O -
) O -
, O +
( O -
IV O -
) O +
or O +
( O -
V O -
) O -
, O +
whereby O +
R1 O +
represents O +
hydrogen O +
or O +
hydroxy O +
and O +
* O +
is O +
the O +
linkage O +
site O +
to O +
the O +
carbon O +
atom O -
, O +
R2 O +
represents O +
hydrogen O +
or O +
methyl O +
and O +
methods O +
for O +
their O +
production O -
, O +
their O +
use O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
diseases O +
as O +
well O +
as O +
their O +
use O +
for O +
the O +
production O +
of O +
medicaments O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
diseases O -
, O +
in O +
particular O +
of O +
bacterial O +
infections O -
. O +

Pharmaceutical O +
Composition O +
for O +
Preventing O +
and O +
Treating O +
Metabolic O +
Bone O +
Diseases O +

Containing O +
Alpha O -
- O -
Arylmethoxyacrylate O +
Derivatives O +

The O +
present O +
invention O +
relates O +
to O +
a O +
use O +
of O +
a O +
specific O +
alpha O -
- O -
arylmethoxyacrylate O +
derivative O -
, O +
or O +
its O +
pharmacologically O +
acceptable O +
salt O +
or O +
solvate O +
for O +
preventing O +
and O +
treating O +
metabolic O +
bone O +
diseases O -
. O +

Plasminogen B-Gene +
Activator I-Gene +
Inhibitor-1 I-Gene +
Inhibitors O +
Inhibitors O +
of O +
plasminogen B-Gene +
activator I-Gene +
inhibitor-1 I-Gene +
( O -
PAI B-Gene -
- I-Gene -
I I-Gene -
) O +
are O +
provided O -
, O +
which O +
may O +
also O +
act O +
as O +
anti O +
cancer O +
agents O -
, O +
of O +
formulae O +
( O -
I O -
- O -
V O -
) O -
. O +

Method O +
for O +
developing O -
, O +
testing O -
, O +
and O +
using O +
associates O +
of O +
macromolecules O +
and O +
complex O +
aggregates O +
for O +
improved O +
payload O +
and O +
controllable O +
de O -
/ O -
association O +
rates O +
This O +
invention O +
describes O +
the O +
principles O +
and O +
procedures O +
suitable O +
for O +
developing O -
, O +
testing O -
, O +
manufacturing O -
, O +
and O +
using O +
combinations O +
of O +
various O +
amphipatic O -
, O +
if O +
necessary O +
modified O -
, O +
macromolecules O +
( O -
such O +
as O +
polypeptides O -
, O +
proteins O -
, O +
etc O -
. O -
) O +
or O +
other O +
chain O +
molecules O +
( O -
such O +
as O +
suitable O -
, O +
e.g. O +
partly O +
hydrophobised O -
, O +
polynucleotides O +
or O +
polysaccharides O -
) O +
with O +
the O +
aggregates O +
which O +
comprise O +
a O +
mixture O +
of O +
polar O +
and/or O +
charged O +
amphipats O +
and O +
form O +
extended O +
surfaces O +
that O +
can O +
be O +
freely O +
suspended O +
or O +
supported O -
. O +

The O +
described O +
methods O +
can O +
be O +
utilised O +
for O +
the O +
optimisation O +
of O +
aggregates O +
that O -
, O +
after O +
association O +
with O +
chain O +
molecules O +
exerting O +
some O +
activity O +
or O +
a O +
useful O +
function O -
, O +
are O +
suitable O +
for O +
the O +
application O +
in O +
vitro O +
or O +
in O +
vivo O -
, O +
for O +
example O -
, O +
in O +
the O +
fields O +
of O +
drug O +
delivery O -
, O +
diagnostics O +
or O +
bio O -
/ O -
catalysis O -
. O +

As O +
special O +
examples O -
, O +
mixtures O +
of O +
vesicular O +
droplets O +
consisting O +
of O +
lipids O +
loaded O +
( O -
associated O -
) O +
with O +
insulin B-Gene -
, O +
interferon B-Gene -
, O +
interleukin B-Gene -
, O +
nerve B-Gene +
growth I-Gene +
factor I-Gene -
, O +
calcitonin B-Gene -
, O +
and O +
an O +
immunoglobulin B-Gene -
, O +
etc O -
. O -
, O +
are O +
described O -
. O +

Broad O +
Spectrum O +
Non O -
- O -
Traditional O +
Preservative O +
System O +
Preservative O +
compositions O +
containing O +
emollient O +
solvents O +
such O +
as O +
octanediol O +
or O +
Symdiol O -
â„¢ O +
or O +
octoxyglycerine O +
monoesters O +
in O +
combination O +
with O +
organic O +
acids O +
such O +
as O +
alpha O +
hydroxyl O +
acids O +
can O +
be O +
used O +
for O +
preventing O +
microbial O +
growth O +
and O +
spoilage O +
in O +
cosmetic O +
and O +
topical O +
skin O +
formulations O +
with O +
the O +
added O +
benefit O +
of O +
providing O +
silky O +
smooth O +
texture O +
to O +
skin O -
. O +

The O +
compositions O +
may O +
optionally O +
contain O +
an O +
essential O +
oil O -
/ O -
component O -
. O +

These O +
preservative O +
compositions O +
are O +
odorless O +
and O +
colorless O +
and O +
small O +
concentrations O +
can O +
be O +
added O +
to O +
cosmetic O -
/ O -
topical O +
formulations O +
to O +
prevent O +
bacterial O -
, O +
yeast O +
and O +
fungal O +
growth O +
within O +
24 O +
to O +
48 O +
hours O +
after O +
contamination O -
. O +

Photochemotherapeutic O +
method O +
using O +
5-aminolevulinic O +
acid O +
and O +
other O +
precursors O +
of O +
endogenous O +
porphyrins O +
Methods O +
of O +
detecting O +
and O +
treating O +
rapidly O +
growing O +
exogenous O +
cells O -
, O +
such O +
as O +
Protista O -
, O +
or O +
parasites O -
, O +
that O +
preferentially O +
accumulate O +
a O +
photoactivatable O +
porphyrin O +
in O +
which O +
5-aminolevulinic O +
acid O +
or O +
precursor O +
thereof O +
is O +
administered O +
to O +
the O +
patient O -
, O +
or O +
contacted O +
to O +
the O +
exogenous O +
cells O -
, O +
in O +
an O +
amount O +
sufficient O +
to O +
induce O +
synthesis O +
fluorescence O +
and/or O +
photosensitizing O +
concentrations O +
of O +
a O +
protoporphyrin O +
IX O +
in O +
the O +
exogenous O +
cells O -
, O +
followed O +
by O +
exposure O +
of O +
the O +
exogenous O +
cells O +
to O +
light O +
of O +
photoactivating O +
wavelengths O -
. O +

Agent O +
for O +
Preventing O -
/ O -
Ameliorating O +
Life O +
Style O -
- O -
Related O +
Diseases O +
Containing O +
Turmeric O +
Essential O +
Oil O +
Component O +
The O +
present O +
invention O +
has O +
its O +
object O +
to O +
provide O +
an O +
agent O +
for O +
preventing O +
and/or O +
ameliorating O +
life O +
style O -
- O -
related O +
diseases O +
which O +
contains O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
substance O +
derived O +
from O +
a O +
safe O +
food O +
material O +
having O +
a O +
long O +
history O +
of O +
being O +
eaten O +
as O +
a O +
food O +
and O +
which O +
is O +
capable O +
of O +
being O +
utilized O +
as O +
functional O +
foods O +
such O +
as O +
health O +
foods O +
or O +
functional O +
health O +
foods O +
( O -
specific O +
health O +
foods O -
, O +
functional O +
nutritive O +
foods O -
) O -
. O +

The O +
agent O +
for O +
preventing O +
and/or O +
ameliorating O +
life O +
style O -
- O -
related O +
diseases O +
according O +
to O +
the O +
invention O +
contains O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
at O +
least O +
one O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
ar O -
- O -
turmerone O -
, O +
Î± O -
- O -
turmerone O -
, O +
Î² O -
- O -
turmerone O -
, O +
curlone O -
, O +
bisacumol O +
and O +
Î² O -
- O -
sesquiphellandrene O -
, O +
or O +
at O +
least O +
one O +
compound O +
selected O +
from O +
among O +
the O +
bisabolane O +
type O +
sesquiterpenoids O +
derived O +
from O +
Curcuma O +
longa O +
L. O -
, O +
and O +
therefore O +
is O +
useful O +
for O +
preventing O +
and/or O +
ameliorating O +
diabetes O -
, O +
visceral O +
fat O +
obesity O -
, O +
metabolic O +
syndrome O +
and O +
obesity O -
, O +
among O +
others O -
. O +

Use O +
of O +
Surfactant O +
Preparations O +
for O +
the O +
Treatment O +
of O +
Surgical O +
Adhesions O +
The O +
invention O +
describes O +
the O +
use O +
of O +
surfactant O +
comprising O +
phospholipids O +
and O +
pulmonary O +
surfactant O +
proteins O +
for O +
the O +
treatment O +
of O +
surgical O +
adhesions O -
. O +

Aldos B-Gene +
as O +
modifiers O +
of O +
the O +
igf B-Gene +
pathway O +
and O +
methods O +
of O +
use O +
Human B-Gene +
ALDO I-Gene +
genes I-Gene +
are O +
identified O +
as O +
modulators O +
of O +
the O +
IGF B-Gene +
pathway O -
, O +
and O +
thus O +
are O +
therapeutic O +
targets O +
for O +
disorders O +
associated O +
with O +
defective O +
IGF B-Gene +
function O -
. O +

Methods O +
for O +
identifying O +
modulators O +
of O +
IGF B-Gene -
, O +
comprising O +
screening O +
for O +
agents O +
that O +
modulate O +
the O +
activity O +
of O +
ALDO B-Gene +
are O +
provided O -
. O +

Systems O +
and O +
methods O +
for O +
delivering O +
drugs O +
A O +
patch O +
pump O +
device O +
generally O +
includes O +
at O +
least O +
one O +
fluid O +
source O -
, O +
a O +
fluid O +
communicator O -
, O +
and O +
an O +
electrochemical O +
actuator O -
. O +

The O +
fluid O +
communicator O +
is O +
in O +
fluid O +
communication O +
with O +
the O +
fluid O +
source O -
. O +

The O +
electrochemical O +
actuator O +
is O +
operative O +
to O +
cause O +
fluid O +
to O +
be O +
delivered O +
from O +
the O +
fluid O +
source O +
into O +
the O +
fluid O +
communicator O -
. O +

Human B-Gene +
dnase I-Gene +
ii I-Gene +
This O +
invention O +
relates O +
to O +
a O +
novel O +
human O +
deoxyribonuclease O -
, O +
referred O +
to O +
as O +
human B-Gene +
DNase I-Gene +
II I-Gene -
. O +

The O +
invention O +
provides O +
nucleic O +
acid O +
sequences O +
encoding O +
human B-Gene +
DNase I-Gene +
II I-Gene -
, O +
thereby O +
enabling O +
the O +
production O +
of O +
human B-Gene +
DNase I-Gene +
II I-Gene +
by O +
recombinant O +
DNA O +
methods O +
in O +
quantities O +
sufficient O +
for O +
clinical O +
use O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
and O +
diagnostic O +
and O +
therapeutic O +
uses O +
of O +
human B-Gene +
DNase I-Gene +
II I-Gene -
. O +

Polyglycerol O +
anti O -
- O -
microbial O +
agents O +
and O +
compositions O +
Polyglycerol O +
anti O -
- O -
microbial O +
agents O +
and O +
compositions O +
are O +
provided O -
. O +

The O +
agents O +
are O +
effective O +
against O +
a O +
variety O +
of O +
pathogens O +
including O +
fungi O -
, O +
Gram O +
positive O +
bacteria O +
and O +
Gram O +
negative O +
bacteria O +
yet O +
are O +
expected O +
to O +
have O +
low O +
human O +
toxicity O +
due O +
in O +
part O +
to O +
their O +
polymeric O +
nature O -
. O +

Applications O +
for O +
the O +
polyglycerol O +
anti O -
- O -
microbial O +
agents O +
and O +
compositions O +
include O +
those O +
involving O +
human O +
and O +
plant O +
contact O -
, O +
such O +
as O +
cosmetics O -
, O +
hair O +
care O +
products O -
, O +
textiles O +
and O +
plant O +
protections O -
, O +
as O +
well O +
as O +
in O +
applications O +
with O +
much O +
less O +
human O +
contact O -
, O +
such O +
as O +
plastics O -
, O +
coatings O -
, O +
wood O -
, O +
paper O +
and O +
other O +
materials O +
of O +
construction O -
. O +

Substituted O +
nitrogen O -
- O -
containing O +
heteroaryl O +
derivatives O +
useful O +
as O +
modulators O +
of O +
the O +
histamine O +
H4 O +
receptor O +
The O +
present O +
invention O +
relates O +
to O +
substituted O +
nitrogen O -
- O -
containing O +
heteroaryl O +
derivatives O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
and O +
methods O +
of O +
using O +
any O +
of O +
these O +
derivatives O +
and O +
compositions O +
for O +
H4 O +
receptor O +
activity O +
modulation O +
and O +
the O +
treatment O +
of O +
states O +
mediated O +
by O +
histamine O +
H4 O +
receptor O +
activity O -
. O +

Novel O +
Spiro O -
- O -
benzo O -
[ O -
c O -
] O -
chromene O +
derivatives O +
useful O +
as O +
modulators O +
of O +
the O +
estrogen B-Gene +
receptors I-Gene +
The O +
present O +
invention O +
is O +
directed O +
to O +
novel O +
spiro O -
- O -
benzo O -
[ O -
C O -
] O -
chromene O +
derivatives O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
disorders O +
mediated O +
by O +
one O +
or O +
more O +
estrogen B-Gene +
receptors I-Gene -
. O +

The O +
compounds O +
of O +
the O +
invention O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
disorders O +
associated O +
with O +
the O +
depletion O +
of O +
estrogen O +
such O +
as O +
hot O +
flashes O -
, O +
vaginal O +
dryness O -
, O +
osteopenia O +
and O +
osteoporosis O -
; O +
hormone O +
sensitive O +
cancers O +
and O +
hyperplasia O +
of O +
the O +
breast O -
, O +
endometrium O -
, O +
cervix O +
and O +
prostate O -
; O +
endometriosis O -
, O +
uterine O +
fibroids O -
, O +
osteoarthritis O +
and O +
as O +
contraceptive O +
agents O -
, O +
alone O +
or O +
in O +
combination O +
with O +
a O +
progestogen O +
or O +
progestogen O +
antagonist O -
. O +

Deuterium O -
- O -
enriched O +
miglustat O +
The O +
present O +
application O +
describes O +
deuterium O -
- O -
enriched O +
miglustat O -
, O +
pharmaceutically O +
acceptable O +
salt O +
forms O +
thereof O -
, O +
and O +
methods O +
of O +
treating O +
using O +
the O +
same O -
. O +

Substituted O +
N O +
[ O -
N- O -
( O -
sulphonylphenyl O -
) O -
sulfonyl O -
- O -
prolyl O -
] O -
-phenylalanine O +
derivatives O +
are O +
antagonists O +
of O +
the O +
very B-Gene +
late I-Gene +
antigen-4 I-Gene +
integrin I-Gene -
; O +
ulcerative O +
colitis O -
, O +
Crohn O -
's O +
disease O -
, O +
asthma O -
, O +
multiple O +
sclerosis O -
, O +
rheumatoid O +
arthritis O +
Substituted O +
Nâ€” O -
[ O -
N- O -
( O -
sulphonylphenyl O -
) O -
sulfonyl O -
- O -
prolyl O -
] O -
-phenylalanine O +
derivatives O +
of O +
the O +
present O +
invention O +
are O +
antagonists O +
of O +
the O +
VLA-4 B-Gene +
integrin I-Gene +
and O +
are O +
useful O +
in O +
the O +
treatment O -
, O +
prevention O +
and O +
suppression O +
of O +
diseases O +
mediated O +
by O +
VLA-4-binding B-Gene +
and O +
cell O +
adhesion O +
and O +
activation O -
. O +

Moreover O -
, O +
the O +
compounds O +
of O +
the O +
present O +
invention O +
demonstrate O +
significant O +
receptor O +
occupancy O +
of O +
VLA-4 B-Gene +
bearing O +
cells O +
after O +
oral O +
administration O +
and O +
are O +
suitable O +
for O +
once- O -
, O +
twice- O -
, O +
or O +
thrice O -
- O -
a O -
- O -
day O +
oral O +
administration O -
. O +

This O +
invention O +
also O +
relates O +
to O +
compositions O +
containing O +
such O +
compounds O +
and O +
methods O +
of O +
treatment O +
using O +
such O +
compounds O -
. O +

Dipeptides O +
for O +
Prevention O +
of O +
Muscle O +
Breakdown O +
and O +
Microbial O +
Infection O +
The O +
subject O +
invention O +
provides O +
dipeptides O +
useful O +
in O +
promoting O +
healthy O +
muscle O +
tissues O +
as O +
well O +
as O +
effective O +
immune O +
responses O -
. O +

The O +
dipeptides O +
of O +
the O +
subject O +
invention O +
are O +
particularly O +
advantageous O +
because O +
they O +
are O +
stable O -
, O +
bioavailable O -
, O +
and O +
can O +
be O +
formulated O +
in O +
an O +
aqueous O +
solution O -
. O +

Targeting O +
Prodrugs O +
for O +
the O +
Treatment O +
of O +
Gastrointestinal O +
Diseases O +
Provided O +
herein O +
are O +
compounds O -
, O +
compositions O +
and O +
methods O +
for O +
decreasing O +
NFÎºB B-Gene +
DNA O -
- O -
binding O +
activity O +
in O +
a O +
patient O +
comprising O +
administering O +
of O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
or O +
composition O +
of O +
the O +
application O +
to O +
the O +
patient O +
to O +
reduce O -
, O +
alleviate O +
or O +
treat O +
various O +
gastrointestinal O +
diseases O -
, O +
such O +
as O +
inflammatory O +
bowel O +
disease O +
( O -
IBD O -
) O -
. O +

Bifunctional O +
Resorcinol O -
, O +
Thioresorcinol O -
, O +
and O +
Dithioresorcinol O +
Derivative O +
Metal O +
Chelating O +
Conjugates O +
The O +
present O +
invention O +
is O +
directed O +
to O +
metal O +
chelating O +
conjugates O +
for O +
use O +
as O +
metallopharmaceutical O +
diagnostic O +
or O +
therapeutic O +
agents O -
. O +

Specifically O -
, O +
conjugates O +
of O +
the O +
present O +
invention O +
include O +
one O +
or O +
more O +
carriers O -
, O +
a O +
linker O -
, O +
and O +
metal O +
coordinating O +
moiety O +
comprising O +
a O +
resorcinol O -
, O +
thioresorcinol O -
, O +
or O +
dithioresorcinol O +
derivative O +
through O +
which O +
the O +
metal O +
coordinating O +
moiety O +
is O +
bonded O +
to O +
the O +
linker O -
. O +

Triazole O +
derivative O +
or O +
a O +
salt O +
thereof O +
[ O -
Problem O -
] O +
To O +
provide O +
a O +
compound O +
which O +
may O +
be O +
used O +
in O +
treating O +
diseases O +
in O +
which O +
11Î² B-Gene -
- I-Gene -
hydroxysteroid I-Gene +
dehydrogenase I-Gene +
type I-Gene +
1 I-Gene +
( O -
11Î² B-Gene -
- I-Gene -
HSD1 I-Gene -
) O +
is O +
concerned O -
, O +
especially O +
diabetes O +
and O +
insulin B-Gene +
resistance O -
. O +

[ O -
Means O +
for O +
Solution O -
] O +

It O +
was O +
found O +
that O +
a O +
triazole O +
derivative O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
in O +
which O +
the O +
3-position O +
of O +
triazole O +
ring O +
is O +
substituted O +
with O +
a O +
trisubstituted O +
methyl O +
group O +
and O +
the O +
5-position O +
is O +
substituted O +
with O +
a O +
lower O +
alkyl O -
, O +
cycloalkyl O +
or O +
the O +
like O -
, O +
has O +
a O +
strong O +
11Î² B-Gene -
- I-Gene -
HSD1-inhibitory I-Gene +
activity O -
. O +

In O +
addition O -
, O +
since O +
the O +
triazole O +
derivative O +
of O +
the O +
present O +
invention O +
shows O +
excellent O +
blood O +
glucose O -
- O -
lowering O +
action O -
, O +
it O +
may O +
be O +
used O +
in O +
the O +
treatment O +
of O +
diabetes O +
and O +
insulin B-Gene +
resistance O -
. O +

Novel O +
Cyclic O +
Urea O +
Derivatives O -
, O +
Preparation O +
Thereof O +
and O +
Pharmaceutical O +
Use O +

Thereof O +
as O +
Kinase B-Gene +
Inhibitors O +
Compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
Ra O -
, O +
Rb O -
, O +
R O -
, O +
X1 O +
and O +
X2 O +
are O +
as O +
defined O +
in O +
the O +
disclosure O -
, O +
pharmaceutical O +
compositions O +
comprising O +
said O +
compounds O -
, O +
processes O +
for O +
making O +
and O +
methods O +
of O +
using O +
the O +
same O +
are O +
provided O -
. O +

Deuterium O -
- O -
enriched O +
pioglitazone O +
The O +
present O +
application O +
describes O +
deuterium O -
- O -
enriched O +
pioglitazone O -
, O +
pharmaceutically O +
acceptable O +
salt O +
forms O +
thereof O -
, O +
and O +
methods O +
of O +
treating O +
using O +
the O +
same O -
. O +

withanolide O +
compounds O +
extracted O +
from O +
a O +
Solanaceae O +
plant O +
as O +
anticancer O +
agents O -
; O +
solvent O +
extraction O +
from O +
Tubocapsicum O +
anomalum O +
A O +
composition O +
for O +
treating O +
cancer O +
cells O +
and O +
a O +
preparation O +
method O +
therefore O +
is O +
provided O -
. O +

The O +
composition O +
includes O +
novel O +
withanolide O +
compounds O +
derived O +
from O +
a O +
Solanaceae O +
plant O -
, O +
which O +
the O +
novel O +
withanolide O +
compounds O +
have O +
the O +
cytotoxicity O +
to O +
the O +
cancer O +
cells O -
. O +

Ginkgolides O +
in O +
the O +
Treatment O +
and O +
Prevention O +
of O +
Ovarian O +
Cancer O +
The O +
present O +
invention O +
is O +
directed O +
to O +
pharmaceutical O +
compositions O +
and O +
nutritional O +
supplements O +
that O +
contain O +
large O +
amount O +
of O +
ginkgolides O -
, O +
particularly O +
ginkgolide O +
A O +
or O +
B O -
, O +
and O +
for O +
which O -
, O +
the O +
other O +
components O +
normally O +
found O +
in O +
Ginkgo O +
biloba O +
extracts O +
have O +
been O +
removed O -
. O +

The O +
compositions O +
may O +
be O +
administered O +
to O +
women O +
to O +
prevent O +
or O +
treat O +
ovarian O +
cancer O -
, O +
particularly O +
non O -
- O -
mucinous O +
ovarian O +
cancer O -
. O +

Short O +
interfering O +
rna O +
as O +
an O +
antiviral O +
agent O +
for O +
hepatitis O +
c O +
Hepatitis O +
C O +
virus O +
( O -
HCV O -
) O +
is O +
a O +
major O +
cause O +
of O +
chronic O +
liver O +
disease O +
and O +
affects O +
over O +
270 O +
million O +
individuals O +
worldwide O -
. O +

The O +
HCV O +
genome O +
is O +
a O +
single O -
- O -
stranded O +
RNA O +
that O +
functions O +
as O +
both O +
a O +
messenger O +
RNA O +
and O +
replication O +
template O -
, O +
making O +
it O +
an O +
attractive O +
target O +
for O +
the O +
study O +
of O +
RNA O +
interference O -
. O +

Double O -
- O -
stranded O +
short O +
interfering O +
RNA O +
( O -
siRNA O -
) O +
molecules O +
designed O +
to O +
target O +
the O +
HCV O +
genome O +
are O +
disclosed O +
herein O -
. O +

20-Alkyl O -
, O +
Gemini O +
Vitamin O +
D3 O +
Compounds O +
and O +
Methods O +
of O +
Use O +
Thereof O +
The O +
invention O +
provides O +
20-alkyl O +
Gemini O +
vitamin O +
D3 O +
compounds O -
, O +
methods O +
for O +
using O +
the O +
compounds O +
to O +
treat O +
vitamin O +
D3 O +
associated O +
states O +
and O +
pharmaceutical O +
compositions O +
containing O +
the O +
compounds O -
. O +

Methods O +
of O +
Identifying O +
and O +
Treating O +
Individuals O +
Exhibiting O +
MDR-1 B-Gene +
Overexpression O +
With O +
Protein B-Gene +
Tyrosine I-Gene +
Kinase I-Gene +
Inhibitors O +
and O +
Combinations O +
Thereof O +
The O +
invention O +
described O +
herein O +
relates O +
to O +
diagnostic O +
and O +
treatment O +
methods O +
and O +
compositions O +
useful O +
in O +
the O +
management O +
of O +
disorders O -
, O +
for O +
example O +
cancers O -
, O +
involving O +
cells O +
that O +
overexpress O +
MDR-1 B-Gene -
, O +
and O +
methods O +
of O +
decreasing O +
the O +
incidence O +
of O +
CNS O +
complications O +
that O +
are O +
often O +
associated O +
with O +
CML O +
patients O +
that O +
have O +
been O +
administered O +
imatinib O +
or O +
other O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitors O -
. O +

Compositions O +
and O +
methods O +
of O +
using O +
capsid B-Gene +
protein O +
from O +
flaviviruses O +
and O +
pestiviruses O +
This O +
invention O +
provides O +
methods O +
of O +
inducing O +
cell O +
death O +
with O +
Flavivirus O +
or O +
Pestivirus O +
capsid B-Gene +
protein O -
, O +
such O +
as O +
West O +
Nile O +
virus O +
( O -
WNV O -
) O +
capsid B-Gene +
protein O -
, O +
and O +
functional O +
fragments O +
thereof O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
of O +
treating O +
patients O +
suffering O +
from O +
diseases O +
characterized O +
by O +
hyperproliferating O +
cells O +
by O +
administering O +
pharmaceutical O +
compositions O +
comprising O +
WNV O +
or O +
other O +
virus O +
including O +
Flavivirus O +
or O +
Pestivirus O +
capsid O +
or O +
other O +
protein O +
or O +
a O +
nucleic O +
acid O +
molecule O +
encoding O +
the O +
same O -
. O +

Methods O +
of O +
identifying O +
compounds O +
which O +
have O +
anti O -
- O -
viral O +
and/or O +
anti O -
- O -
WNV O +
and/or O +
anti O -
- O -
Flavivirus O +
and/or O +
anti O -
- O -
Pestivirus O +
capsid O +
or O +
other O +
protein O +
activity O +
are O +
disclosed O -
. O +

The O +
invention O +
also O +
provides O +
vaccine O +
compositions O +
comprising O +
capsid B-Gene +
or O +
other O +
proteins O -
, O +
or O +
fragments O +
thereof O -
, O +
or O +
nucleic O +
acids O +
encoding O +
same O -
, O +
from O +
WNV O +
or O +
other O +
virus O +
including O +
Flavivirus O +
or O +
Pestivirus O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

The O +
invention O +
also O +
provides O +
diagnostic O +
methods O +
and O +
kits O +
for O +
identifying O +
individuals O +
exposed O +
to O +
WNV O +
or O +
other O +
viruses O +
including O +
Flavivirus O +
or O +
Pestivirus O -
. O +

Herbal O +
composition O +
for O +
treatment O +
of O +
infections O +
caused O +
by O +
dermatophytes O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
herbal O +
composition O +
comprising O +
extract O +
of O +
roots O +
of O +
the O +
plant O +
Murraya O +
koenigii O +
for O +
the O +
treatment O +
of O +
infections O +
caused O +
by O +
dermatophytes O -
, O +
particularly O +
tinea O +
infections O -
, O +
and O +
method O +
of O +
manufacture O +
of O +
said O +
composition O -
. O +

The O +
said O +
herbal O +
composition O +
comprises O +
2-methoxy-3-methyl-9H O -
- O -
carbazole O +
( O -
compound O +
1 O -
) O +
as O +
a O +
bioactive O +
ingredient O -
. O +

Invention O +
also O +
discloses O +
methods O +
for O +
topical O +
application O +
of O +
the O +
said O +
herbal O +
composition O +
for O +
the O +
treatment O +
of O +
infections O +
caused O +
by O +
dermatophytes O -
. O +

VEGF B-Gene +
Inhibition O +
The O +
present O +
invention O +
provides O +
methods O +
for O +
inhibiting O +
VEGF B-Gene +
production O +
or O +
secretion O +
in O +
a O +
subject O +
comprising O +
administering O +
to O +
the O +
subject O +
an O +
effective O +
amount O +
of O +
a O +
compound O +
of O +
Formula O +
I. O +
The O +
invention O +
also O +
provides O +
methods O +
for O +
the O +
treatment O +
or O +
prevention O +
of O +
conditions O +
associated O +
with O +
abnormal O +
levels O +
of O +
VEGF B-Gene +
production O +
or O +
secretion O -
. O +

Medicated O +
sleeve O +
Embodiments O +
of O +
the O +
invention O +
provide O +
a O +
stretchable O +
sleeve O +
having O +
a O +
medicinal O +
section O +
that O +
can O +
be O +
loaded O +
with O +
a O +
medicinal O +
composition O +
and O +
a O +
perforated O +
section O +
comprising O +
a O +
plurality O +
of O +
openings O -
, O +
wherein O +
the O +
medicinal O +
section O +
and O +
the O +
perforated O +
section O +
overlap O -
, O +
and O +
wherein O +
the O +
sleeve O +
is O +
sized O +
so O +
that O +
the O +
interior O +
surface O +
of O +
the O +
medicinal O +
section O +
comfortably O +
fits O +
a O +
body O +
portion O +
and O +
the O +
medicinal O +
section O +
contacts O +
the O +
body O +
portion O +
at O +
the O +
site O +
of O +
pain O -
. O +

Embodiments O +
of O +
the O +
invention O +
also O +
provide O +
methods O +
for O +
preparing O +
a O +
sleeve O +
by O +
applying O +
a O +
medicinal O +
composition O +
to O +
the O +
inner O +
surface O +
of O +
the O +
medicinal O +
section O +
through O +
the O +
openings O +
at O +
the O +
perforated O +
section O -
. O +

Embodiments O +
of O +
the O +
invention O +
also O +
provide O +
methods O +
for O +
relieving O +
pain O +
in O +
a O +
body O +
portion O +
by O +
pulling O +
the O +
sleeve O +
in O +
an O +
outside O -
- O -
out O +
configuration O +
straight O +
up O +
a O +
body O +
portion O +
without O +
having O +
to O +
roll O +
and O +
flip O +
its O +
exterior O +
surface O +
outside O -
. O +

Non O -
- O -
peptidyl O +
agents O +
with O +
pHSP20-like O +
activity O -
, O +
and O +
uses O +
thereof O +
The O +
present O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
modulating O +
smooth O +
muscle O +
cells O -
. O +

The O +
present O +
invention O +
also O +
provides O +
methods O +
of O +
identifying O +
small O +
molecule O +
candidate O +
therapeutic O +
agents O +
for O +
modulating O +
smooth O +
muscle O -
. O +

Methods O +
of O +
treating O +
neurological O +
diseases O +
by O +
regulating O +
migration O +
of O +
neuroblasts O +
in O +
the O +
adult O +
nervous O +
system O +
with O +
tenascin B-Gene -
- I-Gene -
R I-Gene +
This O +
invention O +
provides O +
a O +
method O +
for O +
regulating O +
migration O +
of O +
neuronal O +
progenitor O +
cells O +
in O +
the O +
nervous O +
system O +
of O +
a O +
mammal O -
. O +

The O +
method O +
comprises O +
providing O +
a O +
mammal O +
with O +
TNR B-Gene -
, O +
a O +
biologically O +
active O +
fragment O +
of O +
TNR B-Gene -
, O +
or O +
a O +
TNR B-Gene +
agonist O +
in O +
an O +
amount O +
sufficient O +
to O +
direct O +
migration O +
of O +
the O +
neuronal O +
progenitor O +
cells O -
. O +

The O +
invention O +
provides O +
a O +
method O +
of O +
treating O +
neurological O +
diseases O +
by O +
replenishing O +
diseased O -
, O +
damaged O -
, O +
or O +
destroyed O +
neural O +
cells O +
in O +
the O +
central O +
nervous O +
system O +
or O +
in O +
the O +
peripheral O +
nervous O +
system O -
. O +

Methods O +
for O +
Making O +
and O +
Delivering O +
Rho B-Gene -
- O -
Antagonist O +
Tissue O +
Adhesive O +
Formulations O +
to O +
the O +
Injured O +
Mammalian O +
Central O +
and O +
Peripheral O +
Nervous O +
Systems O +
and O +
uses O +
Thereof O +
The O +
present O +
invention O +
provides O +
methods O +
for O +
making O -
, O +
delivering O +
and O +
using O +
formulations O +
that O +
combine O +
a O +
therapeutically O +
active O +
agent O -
( O -
s O -
) O +
( O -
such O +
as O +
for O +
example O +
a O +
Rho B-Gene +
antagonist O -
( O -
s O -
) O -
) O +
and O +
a O +
flowable O +
carrier O +
component O +
capable O +
of O +
forming O +
a O +
therapeutically O +
acceptable O +
matrix O +
in O +
vivo O +
( O -
such O +
as O +
for O +
example O +
tissue O +
adhesives O -
) O -
, O +
to O +
injured O +
nerves O +
to O +
promote O +
repair O +
and O +
regeneration O +
and O +
regrowth O +
of O +
injured O +
( O -
mammalian O -
) O +
neuronal O +
cells O -
, O +
e.g. O +
for O +
facilitating O +
axon O +
growth O +
at O +
a O +
desired O +
lesion O +
site O -
. O +

Preferred O +
active O +
agents O +
are O +
known O +
Rho B-Gene +
antagonists O +
such O +
as O +
for O +
example O +
C3 O -
, O +
chimeric O +
C3 O +
proteins O -
, O +
etc O -
. O +
or O +
substances O +
selected O +
from O +
among O +
known O +
trans-4-amino O -
( O -
alkyl O -
) O -
-1-pyridylcarbamoylcyclohexane O +
compounds O +
or O +
Rho B-Gene +
kinase I-Gene +
inhibitors O -
. O +

The O +
system O +
for O +
example O +
may O +
deliver O +
an O +
antagonist O -
( O -
s O -
) O +
in O +
a O +
tissue O +
adhesive O +
such O +
as O -
, O +
for O +
example O -
, O +
a O +
fibrin O +
glue O +
or O +
a O +
collagen B-Gene +
gel O +
to O +
create O +
a O +
delivery O +
matrix O +
in O +
situ O -
. O +

A O +
kit O +
and O +
methods O +
of O +
stimulating O +
neuronal O +
regeneration O +
are O +
also O +
included O -
. O +

Rate O -
- O -
controlled O +
particles O +
Rate O -
- O -
controlled O +
particles O -
, O +
comprising O +
compounds O +
of O +
the O +
formula O +
as O +
a O +
solid O +
dispersion O -
. O +

Substituted O +
nitrogen O -
- O -
containing O +
heterobicycles O -
, O +
the O +
preparation O +
thereof O +
and O +
their O +
use O +
as O +
pharmaceutical O +
compositions O +
The O +
present O +
invention O +
relates O +
to O +
new O +
substituted O +
nitrogen O -
- O -
containing O +
heterobicyclic O +
compounds O +
of O +
general O +
formula O +
wherein O +
B O -
, O +
X1 O +
to O +
X3 O +
and O +
R1 O +
to O +
R5 O +
are O +
defined O +
as O +
in O +
claim O +
1 O -
, O +
the O +
tautomers O -
, O +
the O +
enantiomers O -
, O +
the O +
diastereomers O -
, O +
the O +
mixtures O +
thereof O +
and O +
the O +
salts O +
thereof O -
, O +
particularly O +
the O +
physiologically O +
acceptable O +
salts O +
thereof O +
with O +
inorganic O +
or O +
organic O +
acids O +
or O +
bases O -
, O +
which O +
have O +
valuable O +
properties O -
. O +

The O +
compounds O +
of O +
the O +
above O +
general O +
formula O +
I O +
as O +
well O +
as O +
the O +
tautomers O -
, O +
the O +
enantiomers O -
, O +
the O +
diastereomers O -
, O +
the O +
mixtures O +
thereof O +
and O +
the O +
salts O +
thereof O -
, O +
particularly O +
the O +
physiologically O +
acceptable O +
salts O +
thereof O +
with O +
inorganic O +
or O +
organic O +
acids O +
or O +
bases O -
, O +
and O +
their O +
stereoisomers O +
have O +
valuable O +
pharmacological O +
properties O -
, O +
particularly O +
an O +
antithrombotic O +
activity O +
and O +
a O +
factor B-Gene +
Xa I-Gene -
- O -
inhibiting O +
activity O -
. O +

Nebivolol O +
in O +
the O +
treatment O +
of O +
sexual O +
dysfunction O +
The O +
present O +
invention O +
provides O +
methods O +
of O +
treating O +
sexual O +
dysfunction O -
. O +

The O +
methods O +
include O +
administering O +
an O +
effective O +
amount O +
of O +
nebivolol O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
alone O +
or O +
in O +
combination O +
with O +
a O +
second O +
active O +
agent O +
e.g. O +
a O +
PDE-5 B-Gene +
inhibitor O -
, O +
such O +
as O +
sildenafil O +
citrate O -
. O +

The O +
methods O +
of O +
the O +
present O +
invention O +
are O +
particularly O +
suited O +
to O +
the O +
treatment O +
of O +
erectile O +
dysfunction O +
and O +
female O +
sexual O +
arousal O +
disorder O -
. O +

Nitrosation O -
- O -
Inducible O +
Inhibitors O +
Biological O +
Macromolecules O +
Biomacromolecules O +
such O +
as O +
proteins O +
are O +
inactivated O +
by O +
hydrophobic O +
ANSA O +
derivatives O +
of O +
the O +
formula O -
: O +
wherein O +
R1 O +
and O +
R2 O +
are O +
hydrophobic O +
or O +
affinity O +
groups O +
and O +
R3 O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
aminoacyl O +
groups O +
and O +
peptidyl O +
groups O +
upon O +
nitrosation O -
. O +

ANSA O +
derivatives O +
can O +
be O +
designed O +
to O +
selectively O +
kill O +
tumor O +
cells O +
and O +
various O +
pathogens O -
, O +
including O +
bacteria O -
, O +
viruses O -
, O +
and O +
fungi O -
. O +

Agents O +
and O +
Methods O +
for O +
Osteogenic O +
Oxysterols O +
Inhibition O +
of O +
Oxidative O +
Stress O +
on O +
Osteogenic O +
Cellular O +
Differentiation O +
The O +
present O +
invention O +
discloses O +
oxygenic O +
oxygenic O +
oxysterols O -
. O +

Also O +
disclosed O -
, O +
agents O +
and O +
methods O +
for O +
protecting O -
, O +
blocking O +
or O +
rescuing O +
marrow O +
stromal O +
cells O +
from O +
the O +
inhibitory O +
effects O +
of O +
oxidative O +
stress O +
on O +
their O +
osteoblastic O +
cellular O +
differentiation O -
. O +

Exemplary O +
agents O +
include O +
oxysterols O -
, O +
rhBMP2 B-Gene -
, O +
alone O +
or O +
in O +
combination O +
which O +
are O +
demonstrated O +
to O +
specifically O +
combat O +
oxidative O +
stress O +
caused O +
by O +
inflammatory O +
oxidized O +
lipids O -
, O +
such O +
as O +
xanthine O -
/ O -
xanthine O +
oxidase O +
and O +
minimally O +
oxidized O +
LDL O -
. O +

The O +
synergistic O +
effects O +
of O +
oxysterols O +
and O +
bone O +
morphogenic O +
proteins O +
are O +
disclosed O -
. O +

Quinoxaline O +
Derivatives O +
as O +
Antitumor O +
Agents O +

The O +
invention O +
relates O +
to O +
methods O +
of O +
screening O +
for O +
binding O +
partners O -
, O +
especially O +
binding O +
partners O +
essential O +
for O +
the O +
biological O +
activity O +
of O +
erastin O +
( O -
e.g. O +
VDACs O +
such O +
as O +
VDAC3 O -
) O -
. O +

The O +
invention O +
also O +
provides O +
reagents O +
and O +
methods O +
for O +
effective O +
killing O +
of O +
cancer O +
cells O +
with O +
erastin O +
and O +
related O +
compounds O +
or O +
derivatives O -
. O +

Kinesin B-Gene +
inhibitors O +
This O +
invention O +
relates O +
to O +
the O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
shown O +
below O -
. O +

Each O +
variable O +
in O +
formula O +
( O -
I O -
) O +
is O +
defined O +
in O +
the O +
specification O -
. O +

These O +
compounds O +
can O +
be O +
used O +
to O +
treat O +
a O +
kinesin B-Gene +
Eg5 I-Gene +
protein I-Gene -
- O -
mediated O +
disorder O -
. O +

Cancer O +
Related O +
Genes O +
( O -
PRLR B-Gene -
) O +
This O +
invention O +
is O +
in O +
the O +
field O +
of O +
cancer O -
- O -
associated O +
genes O -
. O +

Specifically O +
it O +
relates O +
to O +
methods O +
for O +
detecting O +
cancer O +
or O +
the O +
likelihood O +
of O +
developing O +
cancer O +
based O +
on O +
the O +
presence O +
or O +
absence O +
of O +
expression O +
of O +
a O +
PRLR B-Gene +
gene O +
or O +
protein O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
and O +
molecules O +
for O +
upregulating O +
or O +
downregulating O +
PRLR B-Gene +
gene O +
expression O +
and O +
PRLR B-Gene +
protein O +
activity O -
. O +

Cosmeceutical O +
composition O +
Topical O +
compositions O +
comprising O -
: O +
â€”a O +
physiologically O +
acceptable O +
alkanediol O -
, O +
ether O +
diol O +
or O +
diether O +
alcohol O +
containing O +
up O +
to O +
( O -
8) O +
carbon O +
atoms O -
; O +
â€”water O -
; O +
and O -
â€” O -
optionally O +
an O +
unsaturated O +
fatty O +
alcohol O -
; O +
and O +
optionally O +
further O +
conventional O +
excipients O -
, O +
for O +
use O +
as O +
a O +
cosmeceutical O -
, O +
in O +
particular O +
for O +
use O +
in O +
the O +
repair O +
or O +
maintenance O +
of O +
skin O +
barrier O +
function O -
. O +

They O +
are O +
indicated O +
for O +
use O +
in O +
e.g. O +
moisturizing O +
skin O -
, O +
nail O +
and O +
mucosa O +
and O -
, O +
when O +
an O +
optional O +
pharmaceutically O +
active O +
agent O +
is O +
present O -
, O +
additionally O +
in O +
the O +
treatment O +
of O +
various O +
skin O -
, O +
nail O +
and O +
mucosal O +
diseases O -
. O +

Also O +
disclosed O +
are O +
compositions O +
suitable O +
for O +
topical O +
application O +
to O +
infants O +
and O +
babies O +
for O +
treating O +
dry O +
skin O -
, O +
and O +
soothing O +
skin O +
irritated O +
from O +
diaper O +
rash O +
and O +
scrapes O -
. O +

Drug O +
screening O -
; O +
antagonizing O +
macrophage B-Gene +
migration I-Gene +
inhibitory I-Gene +
factor I-Gene +
( O -
MIF B-Gene -
) O +
using O +
ibudilast O -
; O +
neuropathic O +
pain O -
; O +
identifying O +
agents O +
useful O +
for O +
opiate O +
withdrawal O +
and O +
for O +
treating O +
other O +
addictions O +
and O +
dependence O +
Methods O +
of O +
antagonizing O +
MIF B-Gene +
activity O +
using O +
ibudilast O +
are O +
described O -
. O +

Also O +
described O +
are O +
methods O +
of O +
screening O +
for O +
MIF B-Gene +
antagonists O -
. O +

These O +
agents O +
can O +
be O +
used O +
for O +
treating O +
addictions O -
, O +
including O +
drug O +
and O +
behavioral O +
addictions O -
, O +
as O +
well O +
as O +
for O +
treating O +
neuropathic O +
pain O -
. O +

High O +
penetration O +
composition O +
and O +
uses O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
compositions O +
and O +
uses O +
of O +
novel O +
high O +
penetration O +
compositions O +
or O +
high O +
penetration O +
prodrugs O +
( O -
HPP O -
) O -
, O +
in O +
particular O +
HPPs O +
for O +
4-aminophenol O +
derivatives O -
, O +
which O +
are O +
capable O +
of O +
crossing O +
biological O +
barriers O +
with O +
high O +
penetration O +
efficiency O -
. O +

The O +
HPPs O +
herein O +
are O +
capable O +
of O +
being O +
converted O +
to O +
parent O +
active O +
drugs O +
or O +
drug O +
metabolites O +
after O +
crossing O +
the O +
biological O +
barrier O +
and O +
thus O +
can O +
render O +
treatments O +
for O +
the O +
conditions O +
that O +
the O +
parent O +
drugs O +
or O +
metabolites O +
can O -
. O +

Additionally O -
, O +
due O +
to O +
the O +
ability O +
of O +
penetrating O +
biological O +
barriers O -
, O +
the O +
HPPs O +
herein O +
are O +
capable O +
of O +
reaching O +
areas O +
that O +
parent O +
drugs O +
may O +
not O +
be O +
able O +
to O +
access O +
or O +
to O +
render O +
a O +
sufficient O +
concentration O +
at O +
the O +
target O +
areas O +
and O +
therefore O +
render O +
novel O +
treatments O -
. O +

The O +
HPPs O +
herein O +
can O +
be O +
administered O +
to O +
a O +
subject O +
through O +
various O +
administration O +
routes O -
. O +

For O +
example O -
, O +
the O +
HPPs O +
can O +
be O +
locally O +
delivered O +
to O +
an O +
action O +
site O +
of O +
a O +
condition O +
with O +
a O +
high O +
concentration O +
due O +
to O +
their O +
ability O +
of O +
penetrating O +
biological O +
barriers O +
and O +
thus O +
obviate O +
the O +
need O +
for O +
a O +
systematic O +
administration O -
. O +

For O +
another O +
example O -
, O +
the O +
HPPs O +
herein O +
can O +
be O +
systematically O +
administer O +
to O +
a O +
biological O +
subject O +
and O +
enter O +
the O +
general O +
circulation O +
with O +
a O +
faster O +
rate O -
. O +

Delivery O +
scaffolds O +
and O +
related O +
methods O +
of O +
use O +
The O +
present O +
invention O +
relates O +
to O +
delivery O +
systems O -
. O +

In O +
particular O -
, O +
the O +
present O +
invention O +
provides O +
microporous O +
scaffolds O +
having O +
thereon O +
agents O +
( O -
e.g. O -
, O +
extracellular B-Gene +
matrix I-Gene +
proteins I-Gene -
, O +
exendin-4 B-Gene -
) O +
and O +
biological O +
material O +
( O -
e.g. O -
, O +
pancreatic O +
islet O +
cells O -
) O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
scaffolds O +
are O +
used O +
for O +
transplanting O +
biological O +
material O +
into O +
a O +
subject O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
scaffolds O +
are O +
used O +
in O +
the O +
treatment O +
of O +
diseases O +
( O -
e.g. O -
, O +
type O +
1 O +
diabetes O -
) O -
, O +
and O +
related O +
methods O +
( O -
e.g. O -
, O +
diagnostic O +
methods O -
, O +
research O +
methods O -
, O +
drug O +
screening O -
) O -
. O +

N O -
- O -
Pyrrolidin-3-YL O -
- O -
Amide O +
Derivatives O +
As O +
Serotonin O +
and O +
Noradrenalin O +
Re O -
- O -
Uptake O +
Inhibitors O +
A O +
compound O +
of O +
Formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
and/or O +
veterinarily O +
acceptable O +
derivatives O +
thereof O -
, O +
wherein O -
: O +
R1 O +
is O +
H O -
, O +
C1 O -
- O -
6alkyl O -
, O +
â€”C O -
( O -
A O -
) O -
D O -
, O +
C3 O -
- O -
8cycloalkyl O -
, O +
aryl O -
, O +
het O -
, O +
aryl O -
- O -
C1 O -
- O -
4alkyl O +
or O +
het O -
- O -
C1 O -
- O -
4alkyl O -
, O +
wherein O +
the O +
cycloalkyl O -
, O +
aryl O +
or O +
het O +
groups O +
are O +
optionally O +
substituted O -
; O +
A O +
is O +
S O +
or O +
O O -
; O +
D O +
is O +
H O -
, O +
C1 O -
- O -
6alkyl O -
, O +
aryl O -
, O +
het O -
, O +
aryl O -
- O -
C1 O -
- O -
4alkyl O +
or O +
het O -
- O -
C1 O -
- O -
4alkyl O -
; O +
aryl O +
represents O +
phenyl O -
, O +
naphthyl O -
, O +
anthracyl O +
or O +
phenanthryl O -
; O +
het O +
represents O +
an O +
aromatic O +
or O +
non O -
- O -
aromatic O +
4- O -
, O +
5- O +
or O +
6-membered O +
heterocycle O +
which O +
contains O +
at O +
least O +
one O +
N O -
, O +
O O +
or O +
S O +
heteroatom O -
, O +
optionally O +
fused O +
to O +
a O +
5- O +
or O +
6-membered O +
carbocyclic O +
group O +
or O +
a O +
second O +
4- O -
, O +
5- O +
or O +
6-membered O +
heterocycle O +
which O +
contains O +
at O +
least O +
one O +
N O -
, O +
O O +
or O +
S O +
heteroatom O -
; O +
R2 O +
is O +
aryl1 O +
or O +
het1 O -
, O +
each O +
optionally O +
substituted O -
; O +
n O +
is O +
1 O +
or O +
2 O -
, O +
provided O +
that O +
when O +
n O +
is O +
1 O -
, O +
m O +
is O +
0 O +
or O +
1 O +
and O +
when O +
n O +
is O +
2 O -
, O +
m O +
is O +
0 O -
, O +
wherein O +
if O +
m O +
is O +
0 O -
, O +
then O +
* O +
represents O +
a O +
chiral O +
centre O -
; O +
R3 O +
is O +
( O -
CH2 O -
) O -
aE O -
, O +
wherein O +
a O +
is O +
0 O -
, O +
1 O +
or O +
2 O +
and O +
E O +
is O +
a O +
group O +
selected O +
from O -
: O +
Formula O +
( O -
i O -
) O +
wherein O -
: O +
X O +
is O +
O O -
, O +
S O -
, O +
NR12 O -
, O +
( O -
CH2 O -
) O -
v O +
or O +
a O +
bond O -
; O +
b O +
is O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O -
; O +
c O +
is O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
v O +
is O +
1 O +
or O +
2 O -
; O +
R10 O +
and O +
11 O +
are O +
each O +
independently O +
H O +
or O +
C1 O -
- O -
4 O +
alkyl O -
; O +
and O +
R12 O +
is O +
H O -
, O +
1 O -
- O -
6 O +
alkyl O -
, O +
C O -
( O -
O O -
) O -
C1 O -
- O -
6 O +
alkyl O -
, O +
SO2â€”C1 O -
- O -
6alkyl O -
; O +
and O +
wherein O +
one O +
or O +
more O +
pairs O +
of O +
hydrogen O +
atoms O +
on O +
adjacent O +
carbon O +
or O +
nitrogen O +
atoms O +
may O +
be O +
replaced O +
by O +
a O +
corresponding O +
number O +
of O +
double O +
bonds O -
, O +
provided O +
the O +
ring O +
system O +
is O +
not O +
aromatic O -
; O +
Formula O +
( O -
ii O -
) O +
a O +
carbocyclic O +
spiro O +
group O +
containing O +
6 O +
to O +
12 O +
carbon O +
atoms O -
; O +
Formula O +
( O -
iii O -
) O +
wherein O -
: O +
d O +
is O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O -
; O +
a O +
is O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
f O +
is O +
1 O +
or O +
2 O -
; O +
and O +
R30 O +
is O +
H O +
or O +
C1 O -
- O -
4alkyl O -
; O +
and O +
wherein O +
one O +
or O +
more O +
pairs O +
of O +
hydrogen O +
atoms O +
on O +
adjacent O +
carbon O +
atoms O +
may O +
be O +
replaced O +
by O +
a O +
corresponding O +
number O +
of O +
double O +
bonds O -
, O +
provided O +
the O +
ring O +
system O +
is O +
not O +
aromatic O -
; O +
Formula O +
( O -
iv O -
) O +
wherein O -
: O +
g O +
is O +
0 O -
, O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
J O +
is O +
NR40 O -
; O +
and O +
R40 O +
is O +
C O -
( O -
O O -
) O -
C1 O -
- O -
6 O +
alkyl O -
, O +
S02-C1 O -
- O -
6alkyl O -
; O +
Formula O +
( O -
v O -
) O +
wherein O -
: O +
h O +
is O +
0 O -
, O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
and O +
R50 O +
is O +
H O -
, O +
C1 O -
- O -
8alkyl O -
, O +
C1 O -
- O -
8alkoxy O -
, O +
OH O -
, O +
halo O -
, O +
CF3 O -
, O +
OCF3 O -
, O +
SCF3 O -
, O +
hydroxy O -
- O -
C1 O -
- O -
6alkyl O -
, O +
C1 O -
- O -
4alkoxy O -
- O -
C1 O -
- O -
6alkyl O +
and O +
C1 O -
- O -
4alkyl O -
- O -
S O -
â€” O -
C1 O -
- O -
4alkyl O -
; O +
Formula O +
( O -
vi O -
) O +
â€”CH O -
( O -
cyclopropane O -
) O -
2 O -
; O +
Formula O +
( O -
vii O -
) O +
C1 O -
- O -
6alkyl O -
, O +
substituted O +
by O +
at O +
least O +
one O +
substituent O -
; O +
and O +
Formula O +
( O -
viii O -
) O +
C3 O -
- O -
8cycloalkyl O -
- O -
C1 O -
- O -
6alkyl O -
; O +
wherein O +
the O +
C1 O -
- O -
6alkyl O +
moiety O +
is O +
substituted O +
at O +
any O +
point O +
other O +
than O +
at O +
the O +
junction O +
with O +
the O +
C3 O -
- O -
8cycloalkyl O +
moiety O -
, O +
by O +
at O +
least O +
one O +
substituent O -
. O +

The O +
compounds O +
exhibit O +
activity O +
as O +
both O +
serotonin O +
and/or O +
noradrenaline O +
re O -
- O -
uptake O +
inhibitors O +
and O +
therefore O +
have O +
utility O +
in O +
a O +
variety O +
of O +
therapeutic O +
areas O -
, O +
for O +
example O +
urinary O +
incontinence O -
. O +

Method O +
for O +
treating O +
cancer O -
, O +
rheumatoid O +
arthritis O +
and O +
other O +
medical O +
diseases O +
by O +
utilizing O +
modified O +
virus O +
virions O +
to O +
insert O +
medications O +
into O +
targeted O +
cells O +
A O +
safer O -
, O +
more O +
effective O +
treatment O +
of O +
many O +
medical O +
diseases O +
may O +
be O +
approached O +
by O +
a O +
method O +
utilizing O +
modified O +
viruses O +
as O +
vehicles O +
to O +
transport O +
medically O +
therapeutic O +
drug O +
molecules O +
to O +
specific O +
cells O +
in O +
the O +
body O +
with O +
the O +
intent O +
to O +
have O +
the O +
drug O +
exert O +
an O +
effect O +
only O +
on O +
those O +
cells O +
to O +
which O +
the O +
modified O +
virus O +
delivers O +
the O +
drug O -
. O +

The O +
modified O +
virus O +
or O +
virus O -
- O -
like O +
structures O +
make O +
contact O +
with O +
specific O +
target O +
cells O +
by O +
means O +
of O +
the O +
modified O +
virus O -
's O +
exterior O +
probes O +
or O +
virus O -
- O -
like O +
structures O -
' O +
exterior O +
probes O -
. O +

Once O +
the O +
exterior O +
probes O +
engage O +
a O +
target O +
cell O -
's O +
receptors O -
, O +
the O +
modified O +
virus O +
or O +
virus O -
- O -
like O +
structure O +
inserts O +
into O +
the O +
target O +
cell O +
the O +
quantity O +
of O +
medically O +
therapeutic O +
drug O +
molecules O +
it O +
is O +
carrying O -
. O +

By O +
delivering O +
the O +
medically O +
therapeutic O +
drug O +
only O +
to O +
specific O +
cells O +
in O +
the O +
body O +
it O +
is O +
assured O +
the O +
drug O +
reaches O +
the O +
site O +
in O +
the O +
body O +
it O +
will O +
be O +
most O +
beneficial O +
and O +
the O +
occurrence O +
of O +
unwanted O +
side O +
effects O +
due O +
the O +
drug O +
are O +
significantly O +
minimized O -
. O +

2,4-Substituted O +
Quinazolines O +
as O +
Lipid O +
Kinase B-Gene +
Inhibitors O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
I O -
, O +
which O +
are O +
appropriate O +
for O +
the O +
treatment O +
of O +
kinase O -
, O +
e.g. O +
PI3K B-Gene -
- O -
related O -
, O +
diseases O -
, O +
such O +
as O +
proliferative O +
diseases O -
, O +
inflammatory O +
diseases O -
, O +
obstructive O +
airways O +
disorders O +
and O +
transplantation O +
related O +
diseases O -
. O +

Concentrated O +
Liquid O +
Thyroid O +
Hormone O +
Composition O +
This O +
invention O +
is O +
directed O +
generally O +
to O +
a O +
liquid O +
pharmaceutical O +
composition O +
comprising O +
at O +
least O +
one O +
thyroid O +
hormone O +
( O -
particularly O +
a O +
composition O +
further O +
comprising O +
at O +
least O +
one O +
cyclodextrin O +
compound O -
) O -
, O +
a O +
process O +
for O +
making O +
such O +
a O +
composition O +
and O +
a O +
method O +
of O +
using O +
such O +
a O +
composition O +
to O +
treat O +
a O +
condition O +
associated O +
with O +
impaired O +
thyroid O +
hormone O +
function O -
. O +

Facial O +
blemish O +
removing O +
device O +
A O +
device O +
and O +
method O +
for O +
removing O +
facial O +
blemishes O -
, O +
including O +
sebum O +
that O +
blocks O +
facial O +
pores O -
. O +

The O +
device O +
includes O +
a O +
substantially O +
flat O -
, O +
elongated O +
and O +
rigid O +
element O +
having O +
a O +
first O +
surface O +
and O +
a O +
second O +
surface O -
, O +
and O +
a O +
distal O +
end O +
and O +
a O +
proximal O +
end O -
. O +

The O +
device O +
also O +
includes O +
a O +
base O +
member O +
to O +
which O +
the O +
rigid O +
element O +
is O +
attached O +
such O +
that O +
a O +
collection O +
area O +
is O +
formed O +
between O +
the O +
second O +
surface O +
of O +
the O +
distal O +
end O +
of O +
the O +
rigid O +
element O +
and O +
a O +
portion O +
of O +
the O +
base O +
member O -
. O +

Use O +
of O +
a O +
lactose O -
- O -
derived O +
c O -
- O -
glycoside O +
compound O +
as O +
an O +
agent O +
for O +
activating O +
and O +
regulating O +
cutaneous O +
immunity O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
lactose O -
- O -
derived O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
and O +
to O +
their O +
use O +
as O +
agents O +
for O +
stimulating O +
the O +
immune O +
system O +
of O +
the O +
skin O +
and/or O +
as O +
immunoregulators O -
, O +
and O +
for O +
preparing O +
a O +
composition O +
containing O +
a O +
cosmetically O +
or O +
pharmaceutically O +
acceptable O +
medium O -
, O +
intended O +
in O +
particular O +
to O +
prevent O +
and/or O +
limit O +
the O +
appearance O +
of O +
cutaneous O +
immune O +
imbalances O -
, O +
in O +
particular O +
related O +
to O +
environmental O +
stresses O -
. O +

Substituted O +
heterocycles O +
and O +
their O +
use O +
as O +
chk1 B-Gene -
, O +
pdk1 B-Gene +
and O +
pak B-Gene +
inhibitors O +
The O +
invention O +
relates O +
to O +
novel O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
and O +
to O +
their O +
pharmaceutical O +
compositions O +
and O +
to O +
their O +
methods O +
of O +
use O -
. O +

These O +
novel O +
compounds O +
possess O +
CHK1 B-Gene +
kinase O +
inhibitory O +
activity O -
, O +
PDK1 B-Gene +
inhibitory O +
activity O +
and O +
Pak B-Gene +
kinase I-Gene +
inhibitory O +
activity O +
and O +
are O +
accordingly O +
useful O +
in O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
cancer O -
. O +

M3 B-Gene +
Muscarinic I-Gene +
Acetylcholine I-Gene +
Receptor I-Gene +
Antagonists O +
Muscarinic B-Gene +
Acetylcholine I-Gene +
receptor I-Gene +
antagonists O +
and O +
methods O +
of O +
using O +
them O +
are O +
provided O -
. O +

Compositions O +
and O +
Their O +
Uses O +
Directed O +
to O +
IL-4R O +
Alpha O +
Disclosed O +
herein O +
are O +
compounds O -
, O +
compositions O +
and O +
methods O +
for O +
modulating O +
the O +
expression O +
of O +
IL-4R O +
alpha O +
in O +
a O +
cell O -
, O +
tissue O +
or O +
animal O -
. O +

Also O +
provided O +
are O +
methods O +
of O +
target O +
validation O -
. O +

Also O +
provided O +
are O +
uses O +
of O +
disclosed O +
compounds O +
and O +
compositions O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
treatment O +
of O +
diseases O +
and O +
disorders O +
related O +
to O +
expression O +
of O +
IL O +
4R O -
- O -
Î± O -
, O +
airway O +
hyperresponsiveness O -
, O +
and/or O +
pulmonary O +
inflammation O -
. O +

33 O +
Human O +
Secreted O +
Proteins O +
The O +
present O +
invention O +
relates O +
to O +
33 O +
novel O +
human O +
secreted O +
proteins O +
and O +
isolated O +
nucleic O +
acids O +
containing O +
the O +
coding O +
regions O +
of O +
the O +
genes O +
encoding O +
such O +
proteins O -
. O +

Also O +
provided O +
are O +
vectors O -
, O +
host O +
cells O -
, O +
antibodies O -
, O +
and O +
recombinant O +
methods O +
for O +
producing O +
human O +
secreted O +
proteins O -
. O +

The O +
invention O +
further O +
relates O +
to O +
diagnostic O +
and O +
therapeutic O +
methods O +
useful O +
for O +
diagnosing O +
and O +
treating O +
diseases O -
, O +
disorders O -
, O +
and/or O +
conditions O +
related O +
to O +
these O +
novel O +
human O +
secreted O +
proteins O -
. O +

Controlled O +
Release O +
Complex O +
Formulation O +
For O +
Oral O +
Administration O +
of O +
Medicine O +
For O +
Diabetes O +
and O +
Method O +
For O +
The O +
Preparation O +
Thereof O +
A O +
controlled O +
release O +
combination O +
formulation O +
for O +
oral O +
administration O +
comprising O +
a O -
) O +
a O +
controlled O +
release O +
portion O +
containing O +
metformin O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
, O +
and O +
a O +
combination O +
of O +
a O +
polyethylene O +
oxide O +
and O +
a O +
natural O +
gum O +
as O +
a O +
carrier O +
for O +
controlled O +
release O -
; O +
and O +
b O -
) O +
a O +
rapid O -
- O -
release O +
portion O +
containing O +
a O +
sulfonylurea O -
- O -
based O +
medicine O +
for O +
treating O +
diabetes O +
as O +
an O +
active O +
ingredient O +
coated O +
on O +
the O +
controlled O +
release O +
portion O +
is O +
useful O +
for O +
the O +
treatment O +
of O +
diabetes O -
, O +
for O +
it O +
is O +
capable O +
of O +
maintaining O +
an O +
effective O +
concentration O +
of O +
the O +
medicines O +
in O +
blood O +
at O +
a O +
constant O +
level O -
. O +

Perfluorocarbon O +
conjugate O +
as O +
a O +
blood O +
substitute O +
There O +
are O +
provided O +
disclosures O +
relating O +
to O +
a O +
conjugate O +
of O +
a O +
perfluorocarbon O +
compound O +
and O +
a O +
cationic O +
polymer O +
wherein O +
the O +
conjugate O +
is O +
a O +
blood O +
substitute O -
. O +

Hpv-18-based O +
papillomavirus O +
vaccines O +
Compositions O +
containing O +
one O +
or O +
more O +
early O +
polypeptide O -
( O -
s O -
) O +
of O +
human O +
papillomavirus O +
( O -
HPV O -
) O -
-18 O +
or O +
a O +
nucleic O +
acid O +
encoding O +
one O +
or O +
more O +
early O +
polypeptide O -
( O -
s O -
) O +
of O +
HPV-18 O +
are O +
useful O +
for O +
preventing O +
or O +
treating O +
an O +
infection O +
or O +
a O +
pathological O +
condition O +
caused O +
by O +
at O +
least O +
one O +
papillomavirus O +
other O +
than O +
HPV-18 O -
; O +
the O +
subject O +
compositions O +
are O +
of O +
very O +
special O +
interest O +
in O +
immunotherapy O -
, O +
in O +
particular O +
for O +
preventing O +
or O +
treating O +
HPV O +
persistent O +
infections O +
that O +
might O +
promote O +
cervical O +
intraepithelial O +
neoplasia O +
( O -
CIN O -
) O +
and O +
ultimately O +
cervical O +
cancer O -
. O +

Drug O +
for O +
treating O +
gastric O +
cancer O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
at O +
least O +
one O +
interleukin-17 B-Gene +
inhibitor O +
and/or O +
of O +
at O +
least O +
one O +
IL-17 B-Gene +
receptor I-Gene +
inhibitor O -
, O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
inhibiting O -
, O +
preventing O +
or O +
treating O +
gastric O +
cancer O -
. O +

Cyclodextrin O +
conjugates O +
It O +
has O +
been O +
discovered O +
that O +
the O +
uptake O +
of O +
anionic O +
charged O +
species O +
into O +
cells O +
can O +
be O +
enhanced O +
by O +
noncovalently O +
associating O +
such O +
species O +
with O +
specifically O +
modified O +
forms O +
of O +
cyclodextrin O -
. O +

The O +
invention O +
modified O +
forms O +
of O +
cyclodextrin O +
form O +
well O +
defined O +
stoichiometric O +
complexes O +
with O +
anionic O +
charged O +
molecules O -
. O +

This O +
discovery O +
enables O +
one O +
to O +
produce O +
various O +
compositions O +
containing O +
anionic O +
charged O +
molecules O +
and O +
facilitates O +
methods O +
for O +
enhancing O +
the O +
cellular O +
uptake O +
of O +
double O -
- O -
stranded O +
or O +
hairpin O +
nucleic O +
acid O -
. O +

Substituted O +
2-amino O -
- O -
fused O +
heterocyclic O +
compounds O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O -
, O +
wherein O -
: O +
R1 O -
, O +
R2 O -
, O +
Z1 O -
, O +
t O -
, O +
and O +
ring O +
A O +
are O +
as O +
defined O +
in O +
the O +
specification O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
and O +
methods O +
of O +
treating O +
a O +
condition O +
that O +
is O +
mediated O +
by O +
the O +
modulation O +
of O +
JNK B-Gene -
, O +
such O +
as O +
diabetes O -
, O +
the O +
method O +
comprising O +
administering O +
to O +
a O +
mammal O +
an O +
effective O +
amount O +
of O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O -
. O +

Indazoles O +
Used O +
To O +
Treat O +
Estrogen B-Gene +
Receptor I-Gene +
Beta I-Gene +
Mediated O +
Disorders O +

The O +
present O +
invention O +
relates O +
to O +
novel O +
indazole O +
derivatives O +
having O +
pharmacological O +
activity O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
compositions O +
containing O +
them O +
and O +
uses O +
of O +
these O +
compounds O +
in O +
the O +
treatment O +
of O +
estrogen B-Gene +
receptor I-Gene +
beta I-Gene +
mediated O +
diseases O -
. O +

Site O -
- O -
specific O +
chemical O +
modification O +
of O +
proteins O +
at O +
their O +
n O -
- O -
termini O -
, O +
enabling O +
the O +
formation O +
of O +
homogeneous O +
adducts O +
Site O -
- O -
specific O +
modifications O +
of O +
proteins O +
at O +
their O +
N O -
- O -
termini O +
are O +
provided O -
. O +

In O +
particular O -
, O +
a O +
chemical O +
modification O +
of O +
proteins O +
at O +
their O +
N O -
- O -
termini O +
via O +
a O +
transamination O +
reaction O +
to O +
form O +
homogeneous O +
adducts O +
such O +
as O -
, O +
the O +
corresponding O +
oxime O +
derivatives O +
is O +
provided O -
. O +

Methods O +
of O +
making O +
and O +
using O +
the O +
adducts O +
in O +
radio O -
- O -
labelling O -
, O +
molecular O +
imaging O +
applications O -
, O +
and O +
treatment O +
of O +
disorders O +
such O +
as O +
cancer O -
, O +
Crohn O -
's O +
disease O -
, O +
arthritis O -
, O +
atherothrombosis O +
and O +
plaque O +
rupture O +
are O +
also O +
provided O -
. O +

Early O +
intervention O +
of O +
viral O +
infection O +
with O +
immune O +
activators O +
Symptoms O +
of O +
viral O +
infection O +
are O +
mitigated O +
by O +
administering O +
to O +
a O +
subject O +
exposed O +
to O +
a O +
virus O +
a O +
protective O +
or O +
symptom O -
- O -
mitigating O +
amount O +
of O +
a O +
dsRNA O +
and O +
continuing O +
administration O +
until O +
the O +
subject O -
's O +
symptoms O +
have O +
improved O -
. O +

Antibiotic O +
synergism O +
The O +
present O +
invention O +
relates O +
to O +
antibiotic O +
synergism O +
of O +
pharmaceutical O +
compositions O +
comprising O +
a O +
defensin O +
and O +
a O +
beta O -
- O -
lactam O +
antibiotic O -
. O +

Directional O +
use O +
The O +
invention O +
is O +
directed O +
to O +
a O +
method O +
for O +
oral O +
administration O +
of O +
a O +
liquid O +
containing O +
an O +
active O +
substance O +
to O +
a O +
subject O +
for O +
improved O +
absorption O +
into O +
the O +
subject O -
's O +
bloodstream O +
includes O +
the O +
steps O +
of O +
providing O +
a O +
delivery O +
device O +
containing O +
the O +
liquid O +
and O +
having O +
a O +
mouthpiece O +
for O +
directing O +
the O +
liquid O +
in O +
a O +
defined O +
direction O +
during O +
delivery O -
; O +
directing O +
the O +
mouthpiece O +
toward O +
a O +
localized O +
area O +
of O +
the O +
subject O -
's O +
mouth O +
being O +
especially O +
suitable O +
for O +
increased O +
uptake O +
and O +
faster O +
onset O +
of O +
action O +
of O +
the O +
active O +
substance O +
relative O +
to O +
other O +
areas O +
of O +
and/or O +
the O +
whole O +
mouth O -
; O +
and O +
delivering O +
a O +
measured O +
amount O +
of O +
the O +
liquid O +
directly O +
to O +
the O +
localized O +
area O +
using O +
the O +
delivery O +
device O -
, O +
and O +
a O +
spray O +
device O +
for O +
administering O +
an O +
active O +
substance O +
to O +
the O +
oral O +
cavity O +
of O +
a O +
subject O +
that O +
includes O +
a O +
container O +
capable O +
of O +
holding O +
a O +
liquid O +
containing O +
an O +
active O +
substance O -
, O +
and O +
a O +
mouthpiece O +
being O +
constructed O +
to O +
dispense O +
the O +
liquid O +
containing O +
the O +
substance O +
in O +
a O +
defined O +
direction O +
and O +
directly O +
to O +
a O +
localized O +
area O +
of O +
a O +
subject O -
's O +
mouth O -
, O +
the O +
localized O +
area O +
being O +
the O +
oral O +
vestibule O -
. O +

Cyclopropane O +
amides O +
and O +
analogs O +
exhibiting O +
anti O -
- O -
cancer O +
and O +
anti O -
- O -
proliferative O +
activities O +
Compounds O +
of O +
the O +
present O +
invention O +
find O +
utility O +
in O +
the O +
treatment O +
of O +
mammalian O +
cancers O +
and O +
especially O +
human O +
cancers O +
including O -
, O +
but O +
not O +
limited O +
to O -
, O +
malignant O +
melanomas O -
, O +
solid O +
tumors O -
, O +
glioblastomas O -
, O +
ovarian O +
cancer O -
, O +
pancreatic O +
cancer O -
, O +
prostate O +
cancer O -
, O +
lung O +
cancers O -
, O +
breast O +
cancers O -
, O +
kidney O +
cancers O -
, O +
hepatic O +
cancers O -
, O +
cervical O +
carcinomas O -
, O +
metastasis O +
of O +
primary O +
tumor O +
sites O -
, O +
myeloproliferative O +
diseases O -
, O +
chronic O +
myelogenous O +
leukemia O -
, O +
leukemias O -
, O +
papillary O +
thyroid O +
carcinoma O -
, O +
non O -
- O -
small O +
cell O +
lung O +
cancer O -
, O +
mesothelioma O -
, O +
hypereosinophilic O +
syndrome O -
, O +
gastrointestinal O +
stromal O +
tumors O -
, O +
colonic O +
cancers O -
, O +
ocular O +
diseases O +
characterized O +
by O +
hyperproliferation O +
leading O +
to O +
blindness O +
including O +
various O +
retinopathies O -
, O +
diabetic O +
retinopathy O -
, O +
rheumatoid O +
arthritis O -
, O +
asthma O -
, O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
mastocytosis O -
, O +
mast O +
cell O +
leukemia O -
, O +
and O +
diseases O +
caused O +
by O +
PDGFR B-Gene -
- I-Gene -
Î± I-Gene +
kinase O -
, O +
PDGFR B-Gene -
- I-Gene -
Î² I-Gene +
kinase O -
, O +
c B-Gene -
- I-Gene -
KIT I-Gene +
kinase O -
, O +
cFMS B-Gene +
kinase O -
, O +
c B-Gene -
- I-Gene -
MET I-Gene +
kinase O -
, O +
and O +
oncogenic O +
forms O -
, O +
aberrant O +
fusion O +
proteins O +
and O +
polymorphs O +
of O +
any O +
of O +
the O +
foregoing O +
kinases O -
. O +

Sustained O +
release O +
formulation O +
of O +
melatonin O +
The O +
present O +
invention O +
relates O +
to O +
low O -
- O -
dose O +
formulations O +
of O +
melatonin O -
, O +
and O +
methods O +
of O +
use O +
thereof O -
, O +
which O +
provide O +
a O +
sustained O +
release O +
of O +
melatonin O +
so O +
as O +
to O +
rapidly O +
increase O +
plasma O +
levels O +
of O +
melatonin O -
, O +
maintain O +
a O +
relatively O +
high O +
level O +
( O -
which O +
mimics O +
the O +
endogenous O +
level O +
of O +
a O +
young O +
subject O -
) O +
for O +
approximately O +
5 O -
- O -
6 O +
hours O -
, O +
and O +
then O +
decrease O +
so O +
as O +
to O +
achieve O +
low O +
levels O +
by O +
early O +
morning O +
( O -
rapid O +
washout O -
) O -
, O +
thereby O +
avoiding O +
a O +
" O -
hangover O +
effect O -
" O -
. O +

The O +
sustained O +
release O +
formulations O +
of O +
the O +
invention O +
may O +
be O +
used O +
to O +
treat O +
a O +
variety O +
of O +
sleep O -
- O -
related O +
disorders O -
, O +
including O -
, O +
but O +
not O +
limited O +
to O -
, O +
delayed O +
onset O +
and O +
maintenance O +
forms O +
of O +
insomnia O -
. O +

Iodo O -
- O -
Hexose O +
Compounds O +
Useful O +
to O +
Treat O +
Cancer O +
Methods O +
of O +
treating O +
glioblastoma O +
and O +
pancreatic O +
cancer O +
are O +
provided O +
by O +
the O +
administration O +
of O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
iodo O -
- O -
hexose O +
compound O +
to O +
a O +
subject O +
in O +
need O +
thereof O -
. O +

The O +
subject O +
disclosure O +
includes O +
methods O +
of O +
treating O +
glioblastoma O +
and O +
pancreatic O +
cancer O +
comprising O +
the O +
administration O +
of O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
2-deoxy-2-iodo O -
- O -
D O -
- O -
hexose O +
compound O +
including O +
2-deoxy-2-iodo O -
- O -
D O -
- O -
mannose O -
, O +
2-deoxy-2-iodo O -
- O -
D O -
- O -
glucose O -
, O +
2-deoxy-2-iodo O -
- O -
D O -
- O -
galactose O -
, O +
and/or O +
2-deoxy-2-iodo O -
- O -
D O -
- O -
talose O +
to O +
a O +
subject O +
in O +
need O +
thereof O -
. O +

Novel O +
polymorphous O +
form O +
and O +
the O +
amorphous O +
form O +
of O +
5-chloro O -
- O -
n- O -
( O -
{ O +
( O -
5s O -
) O -
-2-oxo-3 O -
[ O -
4- O -
( O -
3-oxo-4-morpholinyl O -
( O -
-phenyl O -
] O -
-1,3-oxazolidine-5-yl O -
} O -
-methyl O -
) O -
-2-thiophene O +
carboxamide O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
polymorphic O +
form O +
and O +
the O +
amorphous O +
form O +
of O +
5-chloro O -
- O -
N- O -
( O -
{ O -
( O -
5S O -
) O -
-2-oxo-3- O -
[ O -
4- O -
( O -
3-oxo-4-morpholinyl O -
) O -
-phenyl O -
] O -
-1,3-oxazolidin-5-yl O -
} O -
-methyl O -
) O -
-2-thiophene O -
- O -
carboxamide O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
medicaments O +
comprising O +
these O +
forms O -
, O +
and O +
their O +
use O +
in O +
the O +
control O +
of O +
diseases O -
. O +

Assays O +
For O +
Detecting O +
Inhibitors O +
Of O +
Binding O +
Between O +
COX-2 B-Gene +
And O +
PDZ B-Gene +
Proteins I-Gene +

The O +
invention O +
provides O +
an O +
assay O +
for O +
determining O +
whether O +
a O +
test O +
agent O +
is O +
a O +
COX B-Gene +
modulator O -
. O +

In O +
general O +
terms O -
, O +
the O +
assay O +
includes O -
: O +
determining O +
whether O +
a O +
test O +
agent O +
modulates O +
binding O +
of O +
a O +
PDZ B-Gene -
- I-Gene -
containing I-Gene +
polypeptide I-Gene +
to O +
a O +
COX B-Gene +
PL I-Gene -
- I-Gene -
containing I-Gene +
polypeptide I-Gene -
. O +

The O +
PDZ B-Gene -
- I-Gene -
containing I-Gene +
polypeptide I-Gene +
may O +
contain O +
the O +
PDZ B-Gene +
domain I-Gene +
of O +
PDZ B-Gene +
domain I-Gene +
of O +
MAGI1 B-Gene -
, O +
TIP-1 B-Gene -
, O +
MAST2 B-Gene -
, O +
PSD95 B-Gene -
, O +
or O +
SHANK B-Gene -
. O +

The O +
assays O +
may O +
be O +
done O +
in O +
a O +
cell O -
- O -
free O +
environment O +
or O +
in O +
a O +
cellular O +
environment O -
, O +
particularly O +
using O +
a O +
neuronal O +
cell O -
. O +

The O +
invention O +
finds O +
use O +
in O +
a O +
variety O +
of O +
therapeutic O +
applications O -
, O +
including O +
for O +
identifying O +
agents O +
for O +
use O +
in O +
treating O +
cancer O -
, O +
pain O -
, O +
inflammation O +
and O +
neuronal O +
conditions O +
caused O +
by O +
acute O +
insult O -
, O +
e.g. O -
, O +
stroke O -
. O +

Methods O +
for O +
detecting O +
and O +
modulating O +
the O +
sensitivity O +
of O +
tumor O +
cells O +
to O +
anti O -
- O -
mitotic O +
agents O +
and O +
for O +
modulating O +
turmorgenicity O +
Provided O +
herein O +
is O +
a O +
method O +
of O +
screening O +
a O +
tumour O +
cell O +
for O +
resistance O +
to O +
a O +
tubulin B-Gene -
- O -
binding O +
agent O -
, O +
the O +
method O +
comprising O +
detecting O +
the O +
expression O +
of O +
any O +
one O +
or O +
more O +
of O +
class B-Gene +
II I-Gene -
, I-Gene +
class I-Gene +
III I-Gene +
and I-Gene +
class I-Gene +
IVb I-Gene +
Î² I-Gene -
- I-Gene -
tubulin I-Gene +
by O +
the O +
tumour O +
cell O -
, O +
wherein O +
the O +
expression O +
of O +
any O +
one O +
or O +
more O +
of O +
class B-Gene +
II I-Gene -
, I-Gene +
class I-Gene +
III I-Gene +
and I-Gene +
class I-Gene +
IVb I-Gene +
Î² I-Gene -
- I-Gene -
tubulin I-Gene +
indicates O +
that O +
the O +
tumour O +
cell O +
has O +
resistance O +
or O +
potential O +
resistance O +
to O +
the O +
tubulin B-Gene -
- O -
binding O +
agent O -
. O +

Also O +
provided O +
are O +
methods O +
of O +
modulating O +
the O +
sensitivity O +
of O +
a O +
tumour O +
cell O -
. O +

Also O +
provided O +
is O +
a O +
method O +
of O +
modulating O +
the O +
tumorigenesis O +
of O +
a O +
tumour O +
cell O -
. O +

Extracellular O +
matrix O -
/ O -
metastasis O +
modifier O +
genes O +
for O +
the O +
prevention O +
or O +
inhibition O +
of O +
metastasis O +
or O +
growth O +
of O +
tumor O +
and O +
for O +
characterization O +
of O +
tumor O +
Disclosed O +
are O +
methods O +
involving O +
the O +
administration O +
of O +
an O +
extracellular O +
matrix O +
( O -
ECM O -
) O -
/ O -
metastasis O +
modifier O +
gene O -
, O +
e.g. O -
, O +
Anakin B-Gene -
, O +
Necdin B-Gene -
, O +
CentaurinD3 B-Gene +
( O -
CentD3 B-Gene -
) O -
, O +
Csf1r B-Gene -
, O +
Brd4 B-Gene -
, O +
Pi16 B-Gene -
, O +
and O +
Luc7l B-Gene -
, O +
for O +
the O +
prevention O +
or O +
inhibition O +
of O +
metastasis O +
or O +
of O +
tumor O +
growth O -
. O +

Further O +
disclosed O +
are O +
methods O +
of O +
characterizing O +
a O +
tumor O +
or O +
cancer O +
in O +
a O +
subject O +
comprising O +
detecting O +
( O -
i O -
) O +
a O +
single O +
nucleotide O +
polymorphism O +
( O -
SNP O -
) O +
in O +
an O +
Anakin O +
gene O +
or O +
a O +
Brd4 B-Gene +
gene O +
of O +
the O +
subject O -
, O +
( O -
ii O -
) O +
an O +
amino O +
acid O +
substitution O +
in O +
an O +
Anakin O +
protein O +
in O +
the O +
subject O -
, O +
or O +
( O -
iii O -
) O +
a O +
level O +
of O +
expression O +
of O +
an O +
Anakin O +
gene O +
or O +
a O +
Brd4 B-Gene +
gene O +
in O +
the O +
subject O -
. O +

Methods O +
of O +
screening O +
a O +
compound O +
for O +
anti O -
- O -
cancer O +
activity O +
and O +
use O +
of O +
a O +
compound O +
with O +
anti O -
- O -
cancer O +
activity O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
to O +
treat O +
or O +
prevent O +
cancer O +
in O +
a O +
subject O +
are O +
also O +
disclosed O -
. O +

Also O +
disclosed O +
is O +
a O +
method O +
of O +
inhibiting O +
Sipa-1 B-Gene +
in O +
a O +
subject O -
. O +

Composition O +
comprising O +
egg O +
white O -
- O -
chalcanthite O +
for O +
preventing O +
or O +
treating O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
comprising O +
an O +
egg O +
white O -
- O -
chalcanthite O +
component O +
for O +
preventing O +
or O +
treating O +
cancer O -
, O +
and O +
more O +
particularly O -
, O +
to O +
a O +
composition O +
for O +
preventing O +
or O +
treating O +
cancer O -
, O +
which O +
comprises O +
egg O +
white O -
- O -
chalcanthite O +
prepared O +
by O +
mixing O +
a O +
roasted O +
chalcanthite O +
with O +
egg O +
white O +
to O +
reduce O +
the O +
toxicity O +
of O +
the O +
chalcanthite O +
or O +
comprises O +
a O +
mixture O +
of O +
the O +
egg O +
white O -
- O -
chalcanthite O +
and O +
a O +
bamboo O +
salt O -
, O +
and O +
a O +
method O +
for O +
preparing O +
the O +
same O -
. O +

The O +
composition O +
comprising O +
the O +
egg O +
white O -
- O -
chalcanthite O +
exhibits O +
excellent O +
anti O -
- O -
cancer O +
activity O -
, O +
and O +
thus O +
is O +
usefully O +
applicable O +
to O +
pharmaceutical O +
preparations O +
for O +
preventing O +
or O +
treating O +
cancer O +
or O +
the O +
manufacture O +
of O +
health O +
functional O +
foods O -
. O +

Use O +
of O +
spiro O -
- O -
oxindole O +
compounds O +
as O +
therapeutic O +
agents O +
This O +
invention O +
is O +
directed O +
to O +
methods O +
of O +
using O +
spiro O -
- O -
oxindole O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
k O -
, O +
j O -
, O +
Q O -
, O +
R1 O -
, O +
R2a O -
, O +
R2b O -
, O +
R2c O -
, O +
R2d O -
, O +
R3a O -
, O +
R3b O -
, O +
R3c O -
, O +
and O +
R3d O +
are O +
as O +
defined O +
herein O -
, O +
as O +
a O +
stereoisomer O -
, O +
enantiomer O -
, O +
tautomer O +
thereof O +
or O +
mixtures O +
thereof O -
; O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
solvate O +
or O +
prodrug O +
thereof O -
, O +
for O +
the O +
treatment O +
and/or O +
prevention O +
of O +
hypercholesterolemia O -
, O +
benign O +
prostatic O +
hyperplasia O -
, O +
pruritis O +
and O +
cancer O -
. O +

Treating O +
post O -
- O -
seizure O +
patients O +
Patients O +
are O +
subject O +
to O +
a O +
post O -
- O -
seizure O +
treatment O +
regime O +
to O +
separately O +
inhibitor O +
consecutive O +
targets O +
of O +
an O +
epileptogenic O +
cascade O +
comprising O +
neurotransmitter B-Gene +
receptor I-Gene +
signaling O -
, O +
kinase B-Gene -
/ O -
phosphatase B-Gene +
activity O -
, O +
protein O +
translation O -
, O +
and O +
apoptosis O +
or O +
inflammation O -
. O +

Treatment O +
of O +
Statin O +
Side O +
Effects O +
Using O +
Uridine O +
Derivatives O +
The O +
invention O +
relates O +
generally O +
to O +
treatment O +
of O +
muscle O +
pain O +
and/or O +
fatigue O +
and O +
to O +
methods O +
of O +
treatment O +
of O +
side O +
effects O +
of O +
statin O +
therapy O +
which O +
involve O +
the O +
administration O +
of O +
uridine O -
, O +
biological O +
precursors O +
or O +
derivatives O +
or O +
uridine O +
or O +
salts O -
, O +
esters O -
, O +
tautomers O +
or O +
analogues O +
thereof O -
, O +
which O +
are O +
collectively O +
referred O +
to O +
as O +
uridine O +
related O +
compounds O -
. O +

The O +
invention O +
is O +
also O +
directed O +
to O +
compositions O -
, O +
uses O +
and O +
combination O +
packs O +
or O +
kits O +
related O +
to O +
the O +
treatment O +
method O -
. O +

Protein O +
Kinase B-Gene +
Inhibitors O +
and O +
Methods O +
for O +
Using O +
Thereof O +
The O +
invention O +
provides O +
compounds O +
and O +
pharmaceutical O +
compositions O +
thereof O -
, O +
which O +
are O +
useful O +
as O +
protein O +
kinase O +
inhibitors O -
, O +
and O +
methods O +
for O +
using O +
such O +
compounds O +
to O +
treat O -
, O +
ameliorate O +
or O +
prevent O +
a O +
condition O +
associated O +
with O +
abnormal O +
or O +
deregulated O +
kinase O +
activity O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
invention O +
provides O +
methods O +
for O +
using O +
such O +
compounds O +
to O +
treat O -
, O +
ameliorate O +
or O +
prevent O +
diseases O +
or O +
disorders O +
that O +
involve O +
abnormal O +
activation O +
of O +
Alk B-Gene -
, O +
Abl B-Gene -
, O +
Aurora B-Gene -
- I-Gene -
A I-Gene -
, O +
B B-Gene -
- I-Gene -
Raf I-Gene -
, O +
C B-Gene -
- I-Gene -
Raf I-Gene -
, O +
Bcr B-Gene -
- O -
Abl B-Gene -
, O +
BRK B-Gene -
, O +
Blk B-Gene -
, O +
Bmx B-Gene -
, O +
BTK B-Gene -
, O +
C B-Gene -
- I-Gene -
Kit I-Gene -
, O +
CSK B-Gene -
, O +
C B-Gene -
- I-Gene -
Src I-Gene -
, O +
EphB1 B-Gene -
, O +
EphB2 B-Gene -
, O +
EphB4 B-Gene -
, O +
FLT1 B-Gene -
, O +
Fms B-Gene -
, O +
Flt3 B-Gene -
, O +
Fyn B-Gene -
, O +
FRK3 B-Gene -
, O +
JAK2 B-Gene -
, O +
KDR B-Gene -
, O +
Lck B-Gene -
, O +
Lyn B-Gene -
, O +
PDGFRÎ± B-Gene -
, O +
PDGFRÎ² B-Gene -
, O +
PKCÎ± B-Gene -
, O +
SAPK2Î± B-Gene -
, O +
Src B-Gene -
, O +
SIK B-Gene -
, O +
Syk B-Gene -
, O +
Tie2 B-Gene +
and O +
TrkB B-Gene +
kinases O -
. O +

Preservative O -
- O -
free O +
prostaglandin O -
- O -
based O +
ophthalmic O +
solution O +
The O +
present O +
invention O +
provides O +
an O +
ophthalmic O +
solution O +
without O +
an O +
antimicrobial O +
preservative O -
. O +

The O +
solution O +
includes O +
as O +
an O +
active O +
substance O +
at O +
least O +
one O +
prostaglandin O +
and O +
as O +
a O +
solubilizing O +
agent O -
, O +
a O +
surfactant O -
, O +
where O +
the O +
solubilizing O +
agent O +
is O +
polyoxyl-15-hydroxystearate O -
. O +

Methods O +
of O +
Preventing O +
the O +
Serotonin O +
Syndrome O +
and O +
Compositions O +
for O +
Use O +
Therefor O +
The O +
present O +
invention O +
is O +
directed O +
to O +
pharmaceutical O +
compositions O +
and O +
the O +
use O +
thereof O +
for O +
preventing O +
or O +
minimizing O +
the O +
intensity O +
of O +
the O +
serotonin O +
syndrome O -
. O +

The O +
present O +
invention O +
is O +
directed O +
at O +
a O +
method O +
of O +
preventing O +
or O +
minimizing O +
the O +
intensity O +
of O +
the O +
serotonin O +
syndrome O +
in O +
humans O +
which O +
comprises O +
administering O +
proserotonergic O +
agents O +
and O +
serotonin O +
surge O +
protectors O -
, O +
wherein O +
said O +
concurrent O +
administration O +
reduces O +
or O +
prevents O +
serotonin O +
excess O -
, O +
which O +
is O +
the O +
cause O +
of O +
the O +
serotonin O +
syndrome O -
. O +

The O +
present O +
invention O +
is O +
also O +
directed O +
to O +
pharmaceutical O +
compositions O +
comprising O +
proserotonergic O +
agents O +
and O +
serotonin O +
surge O +
protectors O +
useful O +
for O +
carrying O +
out O +
the O +
method O +
of O +
the O +
present O +
invention O -
. O +

Small O +
molecules O +
to O +
induce O +
weight O +
loss O +
or O +
to O +
reduce O +
weight O +
gain O +
Embodiments O +
of O +
the O +
present O +
invention O +
include O +
the O +
use O +
of O +
heterocyclic O +
trialkyl O +
ammonium O -
- O -
containing O +
compounds O +
alone O +
or O +
in O +
combination O +
with O +
alkaline B-Gene +
phosphatase I-Gene +
or O +
other O +
weight O +
loss O -
- O -
inducing O +
drugs O +
or O +
methods O +
to O +
reduce O +
or O +
reverse O +
excess O +
weight O +
gain O +
and O +
obesity O +
as O +
well O +
as O +
reduce O +
the O +
risk O +
of O +
development O +
and O +
help O +
treatment O +
of O +
diseases O +
and O +
unhealthy O +
conditions O +
related O +
to O +
overweight O +
and O +
obesity O -
. O +

Immunostimulatory O +
activity O +
of O +
palindromic O +
immune O +
modulatory O +
oligonucleotides O +
( O -
imo O -
) O +
containing O +
different O +
lengths O +
of O +
palindromic O +
segments O +
The O +
invention O +
provides O +
a O +
palindromic O +
immune O +
modulatory O +
nucleic O +
acid O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
for O +
generating O -
, O +
enhancing O +
and O +
modifying O +
the O +
immune O +
response O +
caused O +
by O +
palindromic O +
immune O +
modulatory O +
compounds O +
used O +
for O +
immunotherapy O +
applications O +

Method O +
for O +
treating O +
onychoschizia O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compositions O +
containing O +
a O +
combination O +
of O +
a O +
herb O +
from O +
the O +
genus O +
Equisetum O +
together O +
with O +
one O +
film O +
forming O +
agent O +
and O +
its O +
use O +
as O +
a O +
nail O +
topical O +
formulation O -
, O +
like O +
nail O +
varnish O -
, O +
cream O -
, O +
gel O -
, O +
lotion O +
or O +
foam O -
. O +

The O +
present O +
invention O +
is O +
further O +
directed O +
to O +
the O +
use O +
of O +
a O +
water O +
soluble O +
film O +
forming O +
agent O +
as O +
an O +
additive O +
in O +
a O +
nail O +
topical O +
formulation O -
. O +

These O +
compositions O +
can O +
be O +
used O +
to O +
treat O +
specific O +
alterations O +
of O +
the O +
ungual O +
structure O -
, O +
with O +
onychoschizia O +
which O +
is O +
a O +
specific O +
alteration O +
of O +
the O +
ungual O +
structure O -
, O +
characterized O +
by O +
lamellar O +
splitting O +
of O +
the O +
nail O +
plate O -
. O +

Warming O +
vapor O +
pad O +
A O +
warming O +
vapor O +
pad O +
to O +
treat O +
respiratory O +
syncytial O +
virus O +
infections O +
in O +
babies O -
, O +
children O +
and O +
adults O +
includes O +
a O +
fabric O +
impregnated O +
with O +
a O +
topical O +
ointment O +
providing O +
medicated O +
vapors O +
to O +
relieve O +
a O +
user O -
's O +
cough O -
, O +
with O +
the O +
fabric O +
being O +
superimposed O +
on O +
an O +
elastic O +
thermal O +
wrap O +
for O +
application O +
as O +
a O +
single O +
layer O +
on O +
the O +
user O -
's O +
chest O -
. O +

Method O +
of O +
inhibiting O +
alveolar O +
bone O +
resorption O +
and O +
periodontal O +
membrane O +
loss O +
and O +
composition O +
for O +
internal O +
use O +
to O +
be O +
used O +
therein O +
Alveolar O +
bone O +
resorption O -
, O +
periodontal O +
membrane O +
loss O -
, O +
and O +
gingival O +
recession O +
can O +
be O +
inhibited O +
by O +
administering O +
500 O +
mg O +
to O +
2000 O +
mg O +
per O +
day O +
of O +
calcium O -
, O +
10 O +
mg O +
to O +
40 O +
mg O +
per O +
day O +
of O +
soy O +
isoflavone O +
aglycone O -
, O +
and O +
vitamin O +
D3 O +
to O +
persons O +
having O +
a O +
tendency O +
for O +
decreased O +
bone O +
density O -
, O +
postmenopausal O +
women O -
, O +
and O +
periodontal O +
disease O +
patients O +
in O +
a O +
maintenance O +
phase O -
; O +
and O +
even O +
an O +
extended O +
period O +
of O +
administration O +
provides O +
a O +
high O +
degree O +
of O +
safety O -
. O +

Amide O +
Compounds O +
Useful O +
in O +
Therapy O +
A O +
compound O +
of O +
Formula O +
( O -
I O -
) O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O -
, O +
wherein O -
, O +
R1 O +
and O +
R2 O +
each O +
independently O +
represent O +
H O -
, O +
halogen O -
, O +
CF3 O -
, O +
C1 O -
- O -
3 O +
alkyl O +
or O +
C1 O -
- O -
3 O +
alkoxy O -
; O +
R3 O +
represents O +
C1 O -
- O -
6 O +
alkyl O -
, O +
C3 O -
- O -
6 O +
cycloalkyl O -
, O +
phenyl O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
Ra O -
) O +
or O +
Het O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
OH O -
, O +
oxo O -
, O +
or O +
C1 O -
- O -
4 O +
alkyl O -
) O -
; O +
R4 O +
represents O +
H O +
or O +
C1 O -
- O -
3 O +
alkyl O -
; O +
R5 O +
represents O +
C1 O -
- O -
6 O +
alkyl O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
Rb O -
) O -
, O +
C3 O -
- O -
6 O +
cycloalkyl O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
oxo O +
or O +
OH O -
) O -
, O +
or O +
Het2 O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
Rd O -
) O -
; O +
oxygen O +
atom O +
or O +
1 O +
sulphur O +
atom O -
, O +
or O +
( O -
c O -
) O +
1 O +
oxygen O +
atom O +
or O +
1 O +
sulphur O +
atom O -
, O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
OH O -
, O +
oxo O +
or O +
C1 O -
- O -
4 O +
alkyl O -
) O -
; O +
and O +
R6 O +
represents O +
C1 O -
- O -
3 O +
alkyl O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
substituents O +
each O +
independently O +
selected O +
from O +
Rf O -
) O -
, O +
C3 O -
- O -
5 O +
cycloalkyl O +
( O -
optionally O +
substituted O +
by O +
one O +
or O +
more O +
halogen O -
) O -
, O +
CN O +
or O +
halogen O -
; O +
where O +
Rf O +
represents O +
halogen O +
or O +
phenyl O -
: O +
and O +
compositions O -
, O +
processes O +
for O +
the O +
preparation O -
, O +
and O +
uses O +
thereof O -
, O +
e.g. O +
in O +
the O +
treatment O +
of O +
endometriosis O +
or O +
uterine O +
fibroids O +

Substituted O +
Heteroarylpiperidine O +
Derivatives O +
As O +
Melanocortin-4 O +
Receptor O +
Modulators O +
The O +
present O +
invention O +
relates O +
to O +
substituted O +
heteroarylpiperidine O +
derivatives O +
as O +
melanocortin-4 O +
receptor O +
modulators O -
. O +

Depending O +
on O +
the O +
structure O +
and O +
the O +
stereochemistry O +
the O +
compounds O +
of O +
the O +
invention O +
are O +
either O +
selective O +
agonists O +
or O +
selective O +
antagonists O +
of O +
the O +
human O +
melanocortin-4 O +
receptor O +
( O -
MC-4R O -
) O -
. O +

The O +
agonists O +
can O +
be O +
used O +
for O +
the O +
treatment O +
of O +
disorders O +
and O +
diseases O +
such O +
as O +
obesity O -
, O +
diabetes O +
and O +
sexual O +
dysfunction O -
, O +
whereas O +
the O +
antagonists O +
are O +
useful O +
for O +
the O +
treatment O +
of O +
disorders O +
and O +
diseases O +
such O +
as O +
cancer O +
cachexia O -
, O +
muscle O +
wasting O -
, O +
anorexia O -
, O +
amyotrophic O +
lateral O +
sclerosis O +
( O -
ALS O -
) O -
, O +
anxiety O +
and O +
depression O -
. O +

Generally O +
all O +
diseases O +
and O +
disorders O +
where O +
the O +
regulation O +
of O +
the O +
MC-4R O +
is O +
involved O +
can O +
be O +
treated O +
with O +
the O +
compounds O +
of O +
the O +
invention O -
. O +

Azole O +
derivatives O +
and O +
fused O +
bicyclic O +
azole O +
derivatives O +
as O +
therapeutic O +
agents O +
This O +
invention O +
provides O +
certain O +
compounds O -
, O +
methods O +
of O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O -
, O +
and O +
their O +
use O +
in O +
treating O +
human O +
or O +
animal O +
disorders O -
. O +

The O +
compounds O +
of O +
the O +
invention O +
are O +
useful O +
as O +
modulators O +
of O +
the O +
interaction O +
between O +
the O +
receptor O +
for O +
advanced O +
glycated O +
end O +
products O +
( O -
RAGE O -
) O +
and O +
its O +
ligands O -
, O +
such O +
as O +
advanced O +
glycated O +
end O +
products O +
( O -
AGEs O -
) O -
, O +
S100 O -
/ O -
calgranulin O -
/ O -
EN O -
- O -
RAGE O -
, O +
Î² O -
- O -
amyloid O +
and O +
amphoterin O -
, O +
and O +
for O +
the O +
management O -
, O +
treatment O -
, O +
control O -
, O +
or O +
as O +
an O +
adjunct O +
treatment O +
for O +
diseases O +
in O +
humans O +
caused O +
by O +
RAGE O -
. O +

Such O +
diseases O +
or O +
disease O +
states O +
include O +
acute O +
and O +
chronic O +
inflammation O -
, O +
the O +
development O +
of O +
diabetic O +
late O +
complications O +
such O +
as O +
increased O +
vascular O +
permeability O -
, O +
nephrdpathy O -
, O +
atherosclerosis O -
, O +
and O +
retinopathy O -
, O +
the O +
development O +
of O +
Alzheimer O -
's O +
disease O -
, O +
erectile O +
dysfunction O -
, O +
and O +
tumor O +
invasion O +
and O +
metastasis O -
. O +

Method O +
of O +
treatment O +
This O +
invention O +
relates O +
to O +
the O +
use O +
of O +
a O +
sulfonamide O +
substituted O +
diphenyl O +
urea O +
compound O +
to O +
treat O +
cystic O +
fibrosis O -
, O +
or O +
the O +
symptoms O +
associated O +
with O +
cystic O +
fibrosis O -
. O +

Methods O +
and O +
materials O +
for O +
genetic O +
analysis O +
of O +
tumors O +
This O +
invention O +
relates O +
generally O +
to O +
methods O +
and O +
materials O +
for O +
rapid O +
detection O +
of O +
mutations O +
for O +
tumor O +
genotyping O -
. O +

Indolo O -
[ O -
3,2-c O -
] O -
quinoline O +
compounds O +
Disclosed O +
herein O +
are O +
indolo O -
[ O -
3,2-c O -
] O -
quinoline O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
wherein O +
R O +
and O +
m O +
are O +
given O +
the O +
definitions O +
as O +
set O +
forth O +
in O +
the O +
Specification O +
and O +
Claims O -
. O +

These O +
compounds O +
can O +
be O +
used O +
to O +
inhibit O +
both O +
growth O +
of O +
cancer O +
cells O +
and O +
activity O +
of O +
telomerase B-Gene -
. O +

Means O +
for O +
improving O +
cognitive O +
functions O +
and O +
memory O +
based O +
on O +
hydrogenated O +
pyrido O -
( O -
4,3-b O -
) O -
indoles O +
( O -
variants O -
) O -
, O +
pharmacological O +
means O +
based O +
thereon O +
and O +
method O +
for O +
the O +
use O +
thereof O +
A O +
means O +
for O +
improving O +
cognitive O +
functions O +
and O +
memory O +
based O +
on O +
hydrogenated O +
pyrido O +
( O -
4,3-b O -
) O +
indoles O +
( O -
variants O -
) O -
, O +
a O +
pharmacological O +
means O +
based O +
thereon O +
and O +
a O +
method O +
for O +
the O +
use O +
thereof O +
relate O +
to O +
the O +
use O +
of O +
chemical O +
compounds O +
in O +
the O +
field O +
of O +
medicine O +
and O +
may O +
be O +
used O +
to O +
extend O +
the O +
arsenal O +
of O +
means O +
which O +
can O +
be O +
utilized O +
for O +
substantial O +
enhancement O +
of O +
memory O +
and O +
activation O +
of O +
the O +
learning O +
process O -
, O +
for O +
the O +
treatment O +
of O +
impaired O +
cognitive O +
functions O +
and O +
memory O +
in O +
the O +
elderly O +
and O +
in O +
mild O +
cognitive O +
impairment O -
, O +
in O +
brain O +
trauma O -
, O +
in O +
chronic O +
cerebrovascular O +
insufficiency O -
, O +
in O +
hypoxic O +
encephalopathies O -
, O +
resulting O +
from O +
chronic O +
alcoholism O +
and O +
in O +
delayed O +
development O +
in O +
children O -
. O +

Said O +
task O +
is O +
resolved O +
by O +
the O +
use O +
of O +
hydrogenated O +
pyrido O +
( O -
[ O -
4 O -
, O +
3-b O -
] O -
) O +
indoles O +
of O +
formula O +
( O -
1 O -
) O +
or O +
formula O +
( O -
2 O -
) O +
as O +
means O +
for O +
improving O +
cognitive O +
functions O +
and O +
memory O -
. O +

Lipophilic O +
drug O +
delivery O +
vehicle O +
and O +
methods O +
of O +
use O +
thereof O +
The O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
delivery O +
of O +
a O +
bioactive O +
agent O +
to O +
an O +
individual O -
. O +

Delivery O +
vehicles O +
are O +
provided O +
that O +
include O +
a O +
bioactive O +
agent O +
in O +
disc O +
shaped O +
particles O +
that O +
include O +
one O +
or O +
more O +
lipid O +
binding O +
polypeptides O +
circumscribing O +
the O +
perimeter O +
of O +
a O +
lipid O +
bilayer O +
in O +
which O +
the O +
bioactive O +
agent O +
is O +
localized O -
. O +

Chimeric O +
lipid O +
binding O +
polypeptides O +
are O +
also O +
provided O +
and O +
may O +
be O +
used O +
to O +
add O +
additional O +
functional O +
properties O +
to O +
the O +
delivery O +
particles O -
. O +

Methods O +
and O +
compositions O +
for O +
treating O +
cancer O +
and O +
modulating O +
signal O +
transduction O +
and O +
metabolism O +
pathways O +
This O +
invention O +
features O +
methods O +
and O +
compositions O +
for O +
treating O +
cancer O +
and O +
modulating O +
signal O +
transduction O +
and O +
metabolism O +
pathways O -
. O +

For O +
example O -
, O +
the O +
methods O +
and O +
compositions O +
of O +
the O +
invention O +
can O +
be O +
used O +
to O +
kill O +
or O +
inhibit O +
the O +
growth O +
or O +
spread O +
of O +
cancer O +
cells O -
. O +

The O +
invention O +
also O +
features O +
a O +
method O +
of O +
identifying O +
a O +
compound O +
that O +
modulates O +
a O +
signal O +
transduction O +
or O +
metabolic O +
pathway O -
. O +

Treatment O +
of O +
Cancer O +
and O +
Inflammatory O +
Disorder O +
Disclosed O +
are O +
extracts O -
, O +
compositions O -
, O +
and O +
methods O +
for O +
treating O +
cancer O +
and O +
inflammatory O +
disorders O -
. O +

Also O +
disclosed O +
are O +
methods O +
for O +
preparing O +
extracts O +
or O +
compounds O +
for O +
treating O +
the O +
disorders O -
. O +

Pyrazinooxazepine O +
derivatives O +
Provided O +
is O +
a O +
compound O +
having O +
a O +
serotonin O +
5-HT2C O +
receptor O +
activating O +
action O -
. O +

A O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
I0 O -
) O -
: O +
wherein O +
each O +
symbol O +
is O +
as O +
defined O +
in O +
the O +
specification O -
, O +
or O +
a O +
salt O +
thereof O -
. O +

Sphingosine-1-phosphate B-Gene +
( I-Gene -
s1p I-Gene -
) I-Gene +
receptor I-Gene +
compounds O +
The O +
invention O +
relates O +
to O +
compounds O -
, O +
in O +
particular O +
2-amino-3,4,5,-trisubstituted O +
thiophenes O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
the O +
uses O +
of O +
said O +
compounds O +
and O +
compositions O +
for O +
diseases O +
related O +
to O +
sphingosine-1-phosphate B-Gene +
( I-Gene -
S1P I-Gene -
) I-Gene +
receptors I-Gene -
, O +
predominantly O +
S1P3 B-Gene +
receptors I-Gene -
. O +

The O +
diseases O +
include O +
cardiovascular O +
diseases O -
, O +
atherosclerosis O -
, O +
cancer O -
, O +
pulmonary O +
oedema O -
, O +
autoimmune O +
disorders O +
and O +
Adult O +
Respiratory O +
Distress O +
Syndrome O -
. O +

RNA O +
INTERFERENCE O +
MEDIATED O +
INHIBITION O +
OF O +
PLATELET B-Gene +
DERIVED I-Gene +
GROWTH I-Gene +
FACTOR I-Gene +
( O -
PDGF B-Gene -
) O +
AND O +
PLATELET B-Gene +
DERIVED I-Gene +
GROWTH I-Gene +
FACTOR I-Gene +
RECEPTOR I-Gene +
( O -
PDGFR B-Gene -
) O +
GENE O +
EXPRESSION O +
USING O +
SHORT O +
INTERFERING O +
NUCLEIC O +
ACID O +
( O -
siNA O -
) O +
This O +
invention O +
relates O +
to O +
compounds O -
, O +
compositions O -
, O +
and O +
methods O +
useful O +
for O +
modulating O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
( O -
PDGF B-Gene -
) O +
and/or O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
PDGFr B-Gene -
) O +
gene O +
expression O +
using O +
short O +
interfering O +
nucleic O +
acid O +
( O -
siNA O -
) O +
molecules O -
. O +

This O +
invention O +
also O +
relates O +
to O +
compounds O -
, O +
compositions O -
, O +
and O +
methods O +
useful O +
for O +
modulating O +
the O +
expression O +
and O +
activity O +
of O +
other O +
genes O +
involved O +
in O +
pathways O +
of O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
( O -
PDGF B-Gene -
) O +
and/or O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
PDGFr B-Gene -
) O +
gene O +
expression O +
and/or O +
activity O +
by O +
RNA O +
interference O +
( O -
RNAi O -
) O +
using O +
small O +
nucleic O +
acid O +
molecules O -
. O +

In O +
particular O -
, O +
the O +
instant O +
invention O +
features O +
small O +
nucleic O +
acid O +
molecules O -
, O +
such O +
as O +
short O +
interfering O +
nucleic O +
acid O +
( O -
siNA O -
) O -
, O +
short O +
interfering O +
RNA O +
( O -
siRNA O -
) O -
, O +
double O -
- O -
stranded O +
RNA O +
( O -
dsRNA O -
) O -
, O +
micro O -
- O -
RNA O +
( O -
miRNA O -
) O -
, O +
and O +
short O +
hairpin O +
RNA O +
( O -
shRNA O -
) O +
molecules O +
and O +
methods O +
used O +
to O +
modulate O +
the O +
expression O +
of O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
( O -
PDGF B-Gene -
) O +
and/or O +
platelet B-Gene +
derived I-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
PDGFr B-Gene -
) O +
genes O -
, O +
such O +
as O +
PDGF B-Gene +
and/or O +
PDGFr B-Gene -
. O +

Rosemary O +
extracts O -
, O +
dietary O +
and O +
pharmaceutical O +
compostions O +
containing O +
them O +
and O +
their O +
uses O +
The O +
present O +
invention O +
refers O +
to O +
rosemary O +
extracts O +
for O +
use O +
as O +
medicament O +
for O +
the O +
treatment O +
of O +
a O +
disorder O +
connected O +
to O +
reduced O +
neurotransmission O -
, O +
as O +
well O +
as O +
to O +
dietary O +
and O +
pharmaceutical O +
compositions O +
containing O +
such O +
rosemary O +
extracts O +
and O +
their O +
uses O -
. O +

Hyperhidrosis O +
treatment O +
Disclosed O +
is O +
a O +
medicinal O +
composition O +
and O +
method O +
of O +
use O +
conspiring O +
topiramate O +
for O +
treating O +
drug O -
- O -
induced O +
excessive O +
sweating O +
( O -
hyperhidrosis O -
) O -
. O +

As O +
a O +
further O +
embodiment O +
of O +
this O +
invention O -
, O +
topiramate O +
may O +
be O +
administered O +
along O +
with O +
another O +
medicament O +
that O +
causes O +
excessive O +
sweating O +
to O +
prevent O +
such O +
excessive O +
sweating O -
. O +

As O +
still O +
a O +
further O +
embodiment O +
of O +
this O +
invention O -
, O +
topiramate O +
may O +
be O +
administered O +
along O +
with O +
another O +
medicament O +
that O +
treats O +
excessive O +
sweating O -
, O +
such O +
that O +
the O +
synergy O +
of O +
the O +
drugs O +
effectively O +
treats O +
the O +
sweating O -
. O +

Method O +
of O +
increasing O +
metabolism O +
The O +
present O +
invention O +
provides O +
a O +
method O +
for O +
increasing O +
metabolism O +
and/or O +
energy O +
expenditure O +
in O +
a O +
subject O -
, O +
e.g. O -
, O +
to O +
treat O +
or O +
prevent O +
obesity O +
and/or O +
a O +
related O +
condition O +
and/or O +
to O +
reduce O +
adiposity O -
, O +
the O +
method O +
comprising O +
increasing O +
the O +
level O +
and/or O +
activity O +
of O +
Hypoxia B-Gene +
Induced I-Gene +
Factor I-Gene +
1Î± I-Gene +
( O -
HIF-1Î± B-Gene -
) O +
in O +
a O +
cell O -
, O +
tissue O +
or O +
organ O +
of O +
the O +
subject O -
, O +
thereby O +
increasing O +
metabolism O +
in O +
the O +
subject O -
. O +

The O +
present O +
invention O +
also O +
provides O +
a O +
method O +
for O +
increasing O +
metabolism O +
in O +
a O +
subject O -
, O +
the O +
method O +
comprising O +
administering O +
an O +
iron O +
chelating O +
agent O +
to O +
the O +
subject O -
, O +
thereby O +
increasing O +
metabolism O +
in O +
the O +
subject O -
. O +

Method O +
for O +
controlling O +
glucose O +
uptake O +
and O +
insulin B-Gene +
sensitivity O +
The O +
invention O +
provides O +
methods O +
for O +
treating O +
diabetes O +
and O +
related O +
disorders O -
, O +
such O +
as O +
metabolic O +
syndromes O +
( O -
which O +
includes O +
insulin B-Gene +
resistance O -
) O -
, O +
by O +
administering O +
an O +
inhibitor O +
of O +
osteopontin B-Gene +
( O -
OPN B-Gene -
) O -
, O +
which O +
includes O +
an O +
antibody O -
, O +
antibody O +
fragment O -
, O +
siRNA O -
, O +
and O +
aptamer O -
. O +

Also O +
disclosed O +
are O +
methods O +
for O +
increasing O +
glucose O +
uptake O +
by O +
cells O +
in O +
a O +
subject O -
, O +
by O +
administering O +
an O +
inhibitor O +
of O +
OPN B-Gene -
. O +

Prophylactic O +
or O +
therapeutic O +
agent O +
for O +
eye O +
disease O +
accompanied O +
by O +
optic O +
nerve O +
disorder O +
The O +
present O +
invention O +
provides O +
a O +
novel O +
pharmaceutical O +
use O +
of O +
2-phenyl-1,2-benzisoselenazol-3 O -
( O -
2H O -
) O -
-one O +
or O +
a O +
salt O +
thereof O -
. O +

2-Phenyl-1,2-benzisoselenazol-3 O -
( O -
2H O -
) O -
-one O +
or O +
a O +
salt O +
thereof O +
exhibits O +
an O +
excellent O +
suppressive O +
effect O +
on O +
retinal O +
ganglion O +
cell O +
death O +
in O +
a O +
pharmacological O +
test O +
using O +
rats O -
, O +
and O +
is O +
therefore O +
useful O +
as O +
a O +
prophylactic O +
or O +
therapeutic O +
agent O +
for O +
an O +
eye O +
disease O +
accompanied O +
by O +
optic O +
nerve O +
disorder O -
. O +

Quinoline O +
compounds O +
suitable O +
for O +
treating O +
disorders O +
that O +
respond O +
to O +
modulation O +
of O +
the O +
serotonin O +
5-ht6 B-Gene +
receptor O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
quinoline O +
compounds O -
. O +

The O +
compounds O +
possess O +
valuable O +
therapeutic O +
properties O +
and O +
are O +
particularly O +
suitable O -
, O +
for O +
treating O +
diseases O +
that O +
respond O +
to O +
modulation O +
of O +
the O +
serotonin O +
5-HT6 B-Gene +
receptor O -
. O +

wherein O +
R O +
is O +
a O +
moiety O +
of O +
the O +
formula O +
wherein O +
A O -
, O +
R1 O +
to O +
R4 O +
are O +
as O +
defined O +
in O +
the O +
claims O +
and O +
the O +
specification O -
, O +
n O +
is O +
0 O -
, O +
1 O +
or O +
2 O -
; O +
m O +
is O +
0 O -
, O +
1 O -
, O +
2 O +
or O +
3 O -
; O +
Ra O -
, O +
Rb O +
are O +
independently O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
halogen O -
, O +
CN O -
, O +
C1-C4-alkyl O -
, O +
C1-C4-haloalkyl O -
, O +
C1-C4-alkoxy O -
, O +
C1-C4-haloalkoxy O -
, O +
C O -
( O -
O O -
) O -
Raa O -
, O +
C O -
( O -
O O -
) O -
NRccRbb O +
and O +
NRccRbb O -
; O +
X O +
is O +
CH2 O -
, O +
C O -
( O -
O O -
) O -
, O +
S O -
, O +
S O -
( O -
O O -
) O +
or O +
S O -
( O -
O O -
) O -
2 O -
; O +
which O +
is O +
located O +
in O +
the O +
3- O +
or O +
4-position O +
of O +
the O +
quinoline O +
ring O -
; O +
Ar O +
is O +
a O +
radical O +
Ar1 O -
, O +
Ar2â€”Ar3 O +
or O +
Ar2â€”O O -
â€” O -
Ar3 O -
, O +
wherein O +
Ar1 O -
, O +
Ar2 O +
and O +
Ar3 O +
are O +
each O +
independently O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
aryl O +
or O +
hetaryl O +
wherein O +
aryl O +
or O +
hetaryl O +
moieties O +
may O +
be O +
unsubstituted O +
or O +
may O +
carry O +
1 O -
, O +
2 O -
, O +
3 O +
substituents O +
Rx O -
, O +
wherein O +
and O +
physiologically O +
tolerated O +
acid O +
addition O +
salts O +
and O +
the O +
N O -
- O -
oxides O +
thereof O -
. O +

Solubilized O +
thiazolopyridines O +
Provided O +
herein O +
are O +
novel O +
sirtuin B-Gene -
- O -
modulating O +
compounds O +
Structural O +
Formula O +
( O -
I O -
) O -
: O +
and O +
methods O +
of O +
use O +
thereof O -
. O +

The O +
sirtuin B-Gene -
- O -
modulating O +
compounds O +
may O +
be O +
used O +
for O +
increasing O +
the O +
lifespan O +
of O +
a O +
cell O -
, O +
and O +
treating O +
and/or O +
preventing O +
a O +
wide O +
variety O +
of O +
diseases O +
and O +
disorders O +
including O -
, O +
for O +
example O -
, O +
diseases O +
or O +
disorders O +
related O +
to O +
aging O +
or O +
stress O -
, O +
diabetes O -
, O +
obesity O -
, O +
neurodegenerative O +
diseases O -
, O +
cardiovascular O +
disease O -
, O +
blood O +
clotting O +
disorders O -
, O +
inflammation O -
, O +
cancer O -
, O +
and/or O +
flushing O +
as O +
well O +
as O +
diseases O +
or O +
disorders O +
that O +
would O +
benefit O +
from O +
increased O +
mitochondrial O +
activity O -
. O +

Also O +
provided O +
are O +
compositions O +
comprising O +
a O +
sirtuin B-Gene -
- O -
modulating O +
compound O +
in O +
combination O +
with O +
another O +
therapeutic O +
agent O -
. O +

Formulations O +
and O +
Methods O +
of O +
Administration O +
of O +
Cephalotaxines O -
, O +
Including O +
Homoharringtonine O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compositions O +
and O +
methods O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
cephalotaxines O -
, O +
for O +
example O -
, O +
homoharringtonine O -
. O +

The O +
invention O +
is O +
also O +
directed O +
to O +
improvements O +
in O +
the O +
purity O -
, O +
manufacturing O +
process O -
, O +
formulation O +
and O +
administration O +
of O +
homoharringtonine O +
for O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
aberrant O +
cellular O +
diseases O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
and O +
compositions O +
for O +
antiparasitic O -
, O +
antifungal O -
, O +
antiviral O +
and O +
antibacterial O +
treatments O -
. O +

Tricyclic O +
compounds O +
for O +
the O +
treatment O +
of O +
inflammatory O +
disorders O +
The O +
present O +
invention O +
provides O +
compounds O +
represented O +
by O +
formula O +
1 O -
: O +
wherein O -
, O +
R1 O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O -
, O +
R8 O -
, O +
R9 O -
, O +
R10 O -
, O +
R11 O -
, O +
R12 O -
, O +
R13 O +
and O +
X O +
are O +
as O +
defined O +
in O +
the O +
specification O -
, O +
in O +
all O +
its O +
stereoisomeric O +
and O +
tautomeric O +
forms O +
and O +
mixtures O +
thereof O +
in O +
all O +
ratios O -
, O +
and O +
its O +
pharmaceutically O +
acceptable O +
salts O -
, O +
pharmaceutically O +
acceptable O +
solvates O -
, O +
pharmaceutically O +
acceptable O +
polymorphs O +
and O +
prodrugs O -
. O +

These O +
compounds O +
are O +
useful O +
for O +
treatment O +
of O +
inflammatory O +
disorders O +
including O +
those O +
caused O +
by O +
elevated O +
levels O +
of O +
proinflammatory O +
cytokines O +
such O +
as O +
Tumor B-Gene +
Necrosis I-Gene +
Factor I-Gene +
( O -
TNF B-Gene -
- I-Gene -
Î± I-Gene +
and/or O +
interleukins B-Gene +
( O -
IL-1Î² B-Gene -
, O +
IL-6 B-Gene -
, O +
IL-8 B-Gene -
) O -
. O +

The O +
invention O +
also O +
relates O +
to O +
processes O +
for O +
the O +
manufacture O +
of O +
compounds O +
of O +
formula O +
1 O +
and O +
pharmaceutical O +
compositions O +
containing O +
them O -
. O +

Methods O +
of O +
treating O +
pre O -
- O -
eclampsia O +
or O +
eclampsia O +
Disclosed O +
herein O +
are O +
methods O +
for O +
treating O +
pre O -
- O -
eclampsia O +
and O +
eclampsia O +
using O +
compounds O +
that O +
increase O +
VEGF B-Gene +
or O +
PlGF B-Gene +
levels O +
or O +
compounds O +
that O +
decrease O +
sFlt-1 B-Gene +
levels O -
. O +

Compounds O +
that O +
inhibit O +
the O +
binding O +
of O +
VEGF B-Gene +
or O +
PlGF B-Gene +
to O +
sFlt1â€”are B-Gene +
also O +
disclosed O +
herein O +
for O +
the O +
treatment O +
of O +
pre O -
- O -
eclampsia O +
or O +
eclampsia O -
. O +

Pre O -
- O -
or O +
post O -
- O -
exposure O +
treatment O +
for O +
filovirus O +
or O +
arenavirus O +
infection O +
The O +
compositions O +
and O +
methods O +
of O +
the O +
invention O +
described O +
herein O +
provide O +
pre- O +
or O +
post O -
- O -
exposure O +
treatments O +
against O +
filovirus O +
or O +
arenavirus O +
infection O +
by O +
expressing O +
one O +
or O +
more O +
genes O +
( O -
e.g. O -
, O +
two O +
ore O +
more O +
genes O -
) O +
from O +
filoviruses O +
or O +
arenaviruses O +
in O +
a O +
delivery O +
vehicle O +
( O -
e.g. O -
, O +
a O +
recombinant O +
viral O +
vector O +
or O +
a O +
liposome O -
) O -
. O +

Formulation O +
with O +
reduced O +
hygroscopicity O +
The O +
invention O +
relates O +
to O +
formulations O +
of O +
hygroscopic O +
solids O +
with O +
a O +
lipophilic O +
coating O +
layer O -
, O +
and O +
a O +
method O +
of O +
production O +
thereof O -
. O +

Pharmaceutical O +
composition O -
, O +
methods O +
for O +
treating O +
and O +
uses O +
thereof O +
The O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
according O +
to O +
the O +
claim O +
1 O +
comprising O +
an O +
SGLT2 B-Gene +
inhibitor O -
, O +
a O +
DPPIV B-Gene +
inhibitor O +
and O +
a O +
third O +
antidiabetic O +
agent O +
which O +
is O +
suitable O +
in O +
the O +
treatment O +
or O +
prevention O +
of O +
one O +
or O +
more O +
conditions O +
selected O +
from O +
type O +
1 O +
diabetes O +
mellitus O -
, O +
type O +
2 O +
diabetes O +
mellitus O -
, O +
impaired O +
glucose O +
tolerance O +
and O +
hyperglycemia O -
. O +

In O +
addition O +
the O +
present O +
invention O +
relates O +
to O +
methods O +
for O +
preventing O +
or O +
treating O +
of O +
metabolic O +
disorders O +
and O +
related O +
conditions O -
. O +

Methods O +
of O +
treating O +
a O +
flaviviridae O +
family O +
viral O +
infection O +
and O +
compositions O +
for O +
treating O +
a O +
flaviviridae O +
family O +
viral O +
infection O +
Briefly O +
described O -
, O +
embodiments O +
of O +
this O +
disclosure O +
include O +
compositions O -
, O +
pharmaceutical O +
compositions O -
, O +
methods O +
of O +
treating O +
a O +
host O +
infected O +
with O +
a O +
virus O +
from O +
the O +
Flaviviridae O +
family O +
of O +
viruses O -
, O +
methods O +
of O +
treating O +
HCV O +
replication O +
in O +
a O +
host O -
, O +
methods O +
of O +
inhibiting O +
the O +
binding O +
of O +
NS4B B-Gene +
polypeptide O +
to O +
the O +
3â€²UTR B-Gene +
of I-Gene +
HCV I-Gene +
negative O +
strand O +
RNA O +
in O +
a O +
host O -
, O +
methods O +
of O +
treating O +
liver O +
fibrosis O +
in O +
a O +
host O -
, O +
and O +
the O +
like O -
. O +

Chiral O +
Complexes O +
of O +
Ascorbic O +
Acid O +
with O +
Natural O +
Antioxidant O +
and O +
Anti O -
- O -
Inflammatory O +
Ketones O +
Including O +
Aloe O -
, O +
Citrus O -
, O +
Ginger O -
, O +
and O +
Mango O +
for O +
Skin O +
and O +
Hair O +
Care O +

This O +
invention O +
relates O +
to O +
certain O +
complexes O +
of O +
ascorbic O +
acid O +
and O +
its O +
derivatives O +
with O +
certain O +
natural O +
antioxidant O +
and O +
anti O -
- O -
inflammatory O +
ketones O +
for O +
topical O +
or O +
oral O +
application O -
; O +
said O +
complexes O +
having O +
general O +
chemical O +
formula O +
( O -
I O -
) O -
, O +
its O +
isomers O -
, O +
and O +
salts O +
thereof O -
, O +
including O +
their O +
optically O +
active O +
or O +
racemic O +
forms O -
. O +

This O +
invention O +
also O +
relates O +
to O +
a O +
method O +
of O +
treatment O +
of O +
skin O +
condition O -
, O +
including O +
dark O +
skin O -
, O +
age O +
spots O -
, O +
acne O -
, O +
inflammation O -
, O +
loss O +
of O +
cellular O +
antioxidants O -
, O +
collagen O +
loss O +
with O +
aging O -
, O +
loss O +
of O +
skin O +
pliability O -
, O +
loss O +
of O +
skin O +
suppleness O -
, O +
skin O +
wrinkles O -
, O +
oxidation O -
, O +
damage O +
from O +
radiation O -
, O +
malfunction O +
of O +
matrix B-Gene +
metalloproteases I-Gene -
, O +
malfunction O +
of O +
tyrosinases B-Gene -
, O +
damage O +
from O +
free O +
radicals O -
, O +
photo O -
- O -
damage O -
, O +
nutritional O +
deficiency O -
, O +
and O +
combinations O +
thereof O -
; O +

Stable O +
Hyaluronan O -
/ O -
Steroid O +
Formulation O +
A O +
pharmaceutical O +
composition O +
comprising O +
in O +
admixture O +
a O +
hyaluronic O +
acid O +
related O +
component O +
( O -
HARC O -
) O +
and O +
a O +
pharmaceutically O +
effective O +
amount O +
of O +
triamcinolone O +
hexacetonide O +
( O -
TAH O -
) O -
. O +

The O +
composition O +
is O +
stable O +
in O +
an O +
accelerated O +
shelf O +
life O +
test O +
in O +
which O +
the O +
composition O +
is O +
heated O +
to O +
80 O -
Â° O +
C. O +
for O +
24 O +
hours O -
. O +

Novel O +
phosphate O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
a O +
production O +
method O +
therefor O +
and O +
a O +
pharmaceutical O +
composition O +
for O +
preventing O +
and O +
treating O +
central O +
nervous O +
system O +
disorders O +
containing O +
the O +
same O +
as O +
an O +
active O +
component O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
{ O -
4- O -
[ O -
2- O -
( O -
dimethylamino O -
) O -
-1- O -
( O -
1-hydroxycyclohexyl O -
) O -
ethyl O -
] O -
phenoxy O -
} O -
phosphate O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
a O +
production O +
method O +
therefor O +
and O +
a O +
pharmaceutical O +
composition O +
for O +
preventing O +
and O +
treating O +
central O +
nervous O +
system O +
disorders O +
which O +
contains O +
the O +
same O +
as O +
an O +
active O +
component O -
. O +

The O +
novel O +
{ O -
4- O -
[ O -
2- O -
( O -
dimethylamino O -
) O -
-1- O -
( O -
1-hydroxycyclohexyl O -
) O -
ethyl O -
] O -
phenoxy O -
} O -
phosphate O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
according O +
to O +
the O +
present O +
invention O +
can O +
beneficially O +
be O +
used O +
to O +
prevent O +
and O +
treat O +
central O +
nervous O +
system O +
disorders O +
since O +
it O +
exhibits O +
an O +
equivalent O +
biological O +
and O +
pharmacological O +
activity O +
to O +
venlafaxine O +
and O +
salts O +
thereof O +
which O +
are O +
known O +
in O +
the O +
field O -
, O +
it O +
has O +
very O +
little O +
toxicity O -
, O +
and O -
, O +
in O +
particular O -
, O +
it O +
is O +
outstandingly O +
soluble O +
in O +
water O +
as O +
compared O +
with O +
prior O -
- O -
art O +
venlafaxine O +
derivatives O -
. O +

Compounds O +
and O +
compositions O +
useful O +
for O +
the O +
treatment O +
of O +
parasitic O +
diseases O +
The O +
invention O +
provides O +
a O +
class O +
of O +
compounds O -
, O +
pharmaceutical O +
compositions O +
comprising O +
such O +
compounds O +
and O +
methods O +
of O +
using O +
such O +
compounds O +
to O +
treat O +
or O +
prevent O +
malaria O -
. O +

2-Aryl O +
Glycinamide O +
Derivatives O +

The O +
disclosure O +
provides O +
compounds O +
of O +
Formula O +
I O -
, O +
including O +
pharmaceutically O +
acceptable O +
salts O -
, O +
their O +
pharmaceutical O +
compositions O -
, O +
and O +
their O +
uses O +
in O +
inhibiting O +
Î² B-Gene -
- I-Gene -
amyloid I-Gene +
peptide I-Gene +
( O -
Î² B-Gene -
- I-Gene -
AP I-Gene -
) O +
production O -
. O +

Xanthophyll O +
composition O +
containing O +
macular O +
pigments O +
and O +
a O +
process O +
for O +
its O +
preparation O +
A O +
xanthophyll O +
composition O +
that O +
contains O +
macular O +
pigments O +
including O +
trans O -
- O -
lutein O +
and O +
zeaxanthin O +
isomers O -
, O +
namely O -
, O +
( O -
R O -
, O -
R O -
) O -
-zeaxanthin O +
and O +
( O -
R O -
, O -
S O -
) O -
-zeaxanthin O -
, O +
derived O +
from O +
the O +
plant O +
extract O -
/ O -
oleoresin O +
containing O +
xanthophylls O -
/ O -
xanthophylls O +
esters O +
which O +
is O +
safe O +
for O +
human O +
consumption O +
and O +
useful O +
for O +
nutrition O +
and O +
health O +
care O -
. O +

The O +
composition O +
has O +
at O +
least O +
80 O -
% O +
by O +
weight O +
that O +
is O +
total O +
xanthophylls O -
, O +
of O +
which O +
the O +
ratio O +
of O +
trans O -
- O -
lutein O +
and O +
zeaxanthin O +
isomers O +
being O +
in O +
the O +
range O +
of O +
about O +
4:1 O +
to O +
about O +
6:1 O +
and O +
the O +
ratio O +
of O +
the O +
isomers O +
of O +
zeaxanthin O +
being O +
in O +
the O +
range O +
of O +
about O +
80 O +
to O +
20:20 O +
to O +
80 O -
. O +

Composition O +
for O +
the O +
treatment O +
of O +
hair O +
loss O +
and O +
baldness O +
A O +
synergistic O +
composition O -
, O +
or O +
the O +
use O +
of O +
that O +
composition O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O -
, O +
or O +
a O +
method O +
of O +
treatment O +
including O +
the O +
use O +
of O +
that O +
composition O -
, O +
for O +
the O +
treatment O +
of O +
hair O +
loss O +
and O +
baldness O -
, O +
for O +
combined O -
, O +
sequential O +
or O +
simultaneous O +
administration O -
, O +
in O +
any O +
form O -
, O +
via O +
any O +
biological O +
route O -
. O +

In O +
its O +
optimal O +
embodiment O +
the O +
composition O +
consists O -
, O +
in O +
the O +
form O +
of O +
a O +
lotion O -
: O +
1600 O -
- O -
2400 O +
IU O -
/ O -
mL O +
Vitamin O +
A O +
Palmitate O -
, O +
0.64%-0.96 O -
% O +
Thiamine O +
Hydrochloride O -
, O +
0.64%-0.96 O -
% O +
Pyridoxine O +
Hydrochloride O -
, O +
4.8%-7.2 O -
% O +
Niacinamide O -
, O +
2.85%-5.2 O -
% O +
D O -
- O -
Panthenol O -
, O +
1.6%-2.4 O -
% O +
L O -
- O -
Arginine O -
, O +
3.6%-4.4 O -
% O +
Methyl O +
Sulphonyl O +
Methane O +
( O -
MSM O -
) O -
, O +
0.08%-0.12 O -
% O +
Ginger O +
Oil O -
, O +
0.08%-0.12 O -
% O +
Cinnamon O +
Oil O -
, O +
0.0996%-0.1494 O -
% O +
Oleoresin O +
Capsicum O -
, O +
1.3%-1.95 O -
% O +
Magnesium O -
, O +
2.4%-3.6 O -
% O +
Zinc O -
, O +
0.192%-0.288 O -
% O +
Manganese O -
, O +
2.6%-3.9 O -
% O +
Urea O -
, O +
2.4%-3.6 O -
% O +
Sodium O +
Glycerophosphate O -
, O +
4.8%-7.2 O -
% O +
L O -
- O -
Lysine O +
HCl O -
, O +
plus O +
Preservatives O -
, O +
Co O -
- O -
solvent O +
( O -
Propylene O +
Glycol O -
) O -
, O +
Fragrances O -
, O +
Anti O -
- O -
Oxidant O -
, O +
Cooling O +
agent O +
( O -
Menthol O -
) O -
, O +
Emulsifier O -
, O +
and O +
Vehicle O +
( O -
Purified O +
water O -
) O -
. O +

Pharmaceutically O +
useful O +
heterocycle O -
- O -
substituted O +
lactams O +
The O +
invention O +
provides O +
compounds O +
that O +
inhibit O +
CK2 B-Gene +
and/or O +
Pim B-Gene +
kinases I-Gene +
and O +
compositions O +
containing O +
such O +
compounds O -
. O +

These O +
compounds O +
and O +
compositions O +
are O +
useful O +
for O +
treating O +
proliferative O +
disorders O +
such O +
as O +
cancer O -
, O +
as O +
well O +
as O +
other O +
kinase O -
- O -
associated O +
conditions O +
including O +
inflammation O -
, O +
pain O -
, O +
infections O -
, O +
and O +
certain O +
immunological O +
disorders O -
. O +

Substituted O +
quinazolines O +
as O +
blood O +
platelet O +
lowering O +
agents O +
This O +
invention O +
relates O +
to O +
the O +
discovery O +
of O +
substituted O +
analogues O +
of O +
the O +
selective O +
platelet O +
lowering O +
agent O +
anagrelide O +
with O +
reduced O +
potential O +
for O +
cardiovascular O +
side O -
- O -
effects O +
which O +
should O +
lead O +
to O +
improved O +
patient O +
compliance O +
and O +
safety O +
in O +
the O +
treatment O +
of O +
myeloproliferative O +
diseases O -
. O +

More O +
specifically O -
, O +
the O +
present O +
invention O +
relates O +
to O +
certain O +
imidazoquinazoline O +
derivatives O +
which O +
have O +
the O +
general O +
formula O +
shown O +
below O +
wherein O +
the O +
substituents O +
have O +
the O +
meanings O +
defined O +
in O +
claim O +
( O -
I O -
) O -
: O +
and O +
which O +
have O +
utility O +
as O +
platelet O +
lowering O +
agents O +
in O +
humans O -
. O +

The O +
compounds O +
of O +
the O +
present O +
invention O +
function O +
by O +
inhibiting O +
megakaryocytopoeisis O +
and O +
hence O +
the O +
formation O +
of O +
blood O +
platelets O -
. O +

Thiophenyl O +
Sulfonamides O +
for O +
the O +
Treatment O +
of O +
Alzheimer O -
's O +
Disease O +
There O +
is O +
provided O +
a O +
series O +
of O +
novel O +
Î±- O -
( O -
N O -
- O -
sulfonamido O -
) O -
acetamide O +
compounds O +
of O +
the O +
Formula O +
( O -
I O -
) O +
wherein O +
R1 O -
, O +
R2 O +
and O +
n O +
are O +
defined O +
herein O -
, O +
which O +
are O +
inhibitors O +
of O +
Î² B-Gene -
- I-Gene -
amyloid I-Gene +
peptide I-Gene +
( O -
Î² B-Gene -
- I-Gene -
AP I-Gene -
) O +
production O +
and O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
Alzheimer O -
's O +
Disease O +
and O +
other O +
conditions O +
affected O +
by O +
anti O -
- O -
amyloid O +
activity O -
. O +

Molecular O +
targets O +
and O +
compounds O -
, O +
and O +
methods O +
to O +
identify O +
the O +
same O -
, O +
useful O +
in O +
the O +
treatment O +
of O +
neurodegenerative O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
methods O +
and O +
assays O +
for O +
identifying O +
agents O +
capable O +
of O +
inhibiting O +
the O +
mutant O +
huntingtin O +
protein O -
, O +
inhibiting O +
or O +
reducing O +
polyglutamine O -
- O -
induced O +
protein O +
aggregation O -
, O +
and/or O +
altering O +
huntingtin B-Gene +
protein O +
conformation O -
, O +
which O +
inhibition O +
is O +
useful O +
in O +
the O +
prevention O -
, O +
amelioration O +
and/or O +
treatment O +
of O +
neurodegenerative O +
diseases O -
, O +
and O +
protein O +
aggregation O +
diseases O +
more O +
generally O -
. O +

In O +
particular O -
, O +
the O +
present O +
invention O +
provides O +
methods O +
and O +
assays O +
for O +
identifying O +
agents O +
for O +
use O +
in O +
the O +
prevention O +
and/or O +
treatment O +
of O +
Huntington O -
's O +
disease O -
. O +

The O +
invention O +
provides O +
polypeptide O +
and O +
nucleic O +
acid O +
TARGETs O +
and O +
siRNA O +
sequences O +
based O +
on O +
these O +

Prophylactic O +
and O +
therapeutic O +
treatment O +
of O +
neuro O -
- O -
degenerative O +
diseases O +
and O +
protein O +
aggregation O +
diseases O +
A O +
composition O +
and O +
method O +
for O +
the O +
treatment O +
of O +
Alzheimer O -
's O +
disease O +
and O +
related O +
amyloid O +
plaque O +
development O +
and O +
reduction O +
of O +
amyloid O +
plaque O -
, O +
amyloidosis O +
and O +
amyotrophic O +
lateral O +
sclerosis O -
, O +
as O +
well O +
as O +
neuro O -
- O -
degenerative O +
diseases O +
and O +
protein O +
aggregation O +
diseases O -
, O +
includes O +
an O +
effective O +
amount O +
of O +
a O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
phytic O +
acid O +
( O -
inositol O +
hexakisphosphate O -
) O -
, O +
a O +
phytate O +
salt O -
, O +
an O +
isomer O +
or O +
hydrolysate O +
of O +
phytic O +
acid O +
or O +
a O +
phytate O +
salt O -
, O +
or O +
a O +
mixture O +
of O +
any O +
combination O +
thereof O -
, O +
being O +
administered O +
to O +
a O +
person O +
in O +
an O +
amount O +
from O +
about O +
0.5 O +
grams O +
to O +
about O +
18.75 O +
grams O +
per O +
day O -
, O +
with O +
or O +
without O +
a O +
dephosphorylating O +
enzyme O -
. O +

Composite O +
material O +
The O +
invention O +
relates O +
to O +
a O +
composite O +
material O -
, O +
a O +
precursor O +
for O +
forming O +
the O +
composite O +
material O +
and O +
a O +
method O +
of O +
forming O +
the O +
composite O +
material O +
from O +
the O +
precursor O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
said O +
composite O +
material O +
and O +
in O +
particular O +
to O +
its O +
use O +
as O +
an O +
antibacterial O +
or O +
antimicrobial O +
agent O -
. O +

Compositions O +
of O +
nanoparticles O +
and O +
methods O +
of O +
making O +
the O +
same O +
Disclosed O +
herein O +
are O +
compositions O +
of O +
nanoparticles O -
. O +

In O +
some O +
embodiments O -
, O +
the O +
nanoparticles O +
are O +
Janus O +
particles O -
, O +
where O +
each O +
particle O +
includes O +
a O +
first O +
component O +
and O +
second O +
component O +
that O +
are O +
exposed O +
to O +
the O +
surface O +
of O +
the O +
particle O -
. O +

Also O -
, O +
disclosed O +
are O +
methods O +
and O +
systems O +
for O +
making O +
a O +
composition O +
of O +
nanoparticles O -
. O +

Finally O -
, O +
a O +
method O +
of O +
treating O +
a O +
mammal O +
by O +
administering O +
a O +
composition O +
of O +
nanoparticles O +
is O +
disclosed O -
. O +

Method O +
of O +
conjugating O +
therapeutic O +
compounds O +
to O +
cell O +
targeting O +
devices O +
via O +
metal O +
complexes O +
The O +
present O +
invention O +
relates O +
to O +
a O +
cell O -
- O -
targeting O +
complex O +
comprising O +
a O +
targeting O +
moiety O +
and O +
a O +
deliverable O +
compound O -
, O +
wherein O +
said O +
targeting O +
moiety O +
and O +
said O +
deliverable O +
compound O +
are O +
joined O +
by O +
means O +
of O +
a O +
( O -
transition O -
) O +
metal O +
ion O +
complex O +
having O +
at O +
least O +
a O +
first O +
reactive O +
moiety O +
for O +
forming O +
a O +
coordination O +
bond O +
with O +
a O +
reactive O +
site O +
of O +
said O +
targeting O +
moiety O +
and O +
having O +
at O +
least O +
a O +
second O +
reactive O +
moiety O +
for O +
forming O +
a O +
coordination O +
bond O +
with O +
a O +
reactive O +
site O +
of O +
said O +
deliverable O +
compound O -
, O +
and O +
wherein O +
said O +
deliverable O +
compound O +
is O +
a O +
therapeutic O +
compound O -
. O +

Inhibition O +
of O +
degradation O +
of O +
extracellular O +
matrix O +
This O +
application O +
relates O +
to O +
a O +
method O +
of O +
inhibiting O +
the O +
degradation O +
of O +
an O +
extracellular O +
matrix O +
associated O +
with O +
islet O +
beta O +
cells O -
, O +
said O +
method O +
comprising O +
contacting O +
said O +
extracellular O +
matrix O +
with O +
an O +
effective O +
amount O +
of O +
a O +
heparanase B-Gene +
inhibitor O -
. O +

Novel O +
Lapachone O +
Compounds O +
And O +
Methods O +
of O +
Use O +

Thereof O +
The O +
present O +
invention O +
provides O +
novel O +
tricyclic O +
spiro O -
- O -
oxathiine O +
naphthoquinone O +
derivatives O -
, O +
a O +
synthetic O +
method O +
for O +
making O +
the O +
derivatives O -
, O +
and O +
the O +
use O +
of O +
the O +
derivatives O +
to O +
induce O +
cell O +
death O +
and/or O +
to O +
inhibit O +
proliferation O +
of O +
cancer O +
or O +
precancerous O +
cells O -
. O +

The O +
naphthoquinone O +
derivatives O +
of O +
the O +
present O +
invention O +
are O +
related O +
to O +
the O +
compound O +
known O +
as O +
Î² O -
- O -
lapachone O +
( O -
3,4-dihydro-2,2-dimethyl-2H O -
- O -
naphtho O -
( O -
1,2-b O -
) O -
pyran-5,6-dione O -
) O -
. O +

2-AMINO-9- O -
[ O -
4- O -
( O -
4-METHOXY O -
- O -
PHENOXY O -
) O -
-PIPERIDIN-1-YL O -
] O -
-4-PHENYL O -
- O -
INDENO O -
[ O -
1,2-D O -
] O -
PYRIMIDIN-5-ONE O +
AND O +
ITS O +
USE O +
AS O +
A O +
HIGHLY O +
SELECTIVE O +
ADENOSINE B-Gene +
A2a I-Gene +
RECEPTOR I-Gene +
ANTAGONIST O +
This O +
invention O +
relates O +
to O +
a O +
novel O +
arylindenopyrimidine O -
, O +
A O -
, O +
and O +
its O +
therapeutic O +
and O +
prophylactic O +
uses O -
. O +

Disorders O +
treated O +
and/or O +
prevented O +
include O +
Parkinson O -
's O +
Disease O -
. O +

Drug O +
Delivery O +
Platforms O +
Comprising O +
Silk O +
Fibroin O +
Hydrogels O +
and O +
Uses O +
Thereof O +

The O +
present O +
specification O +
provides O +
drug O +
delivery O +
platforms O +
useful O +
for O +
the O +
controlled O +
release O +
of O +
a O +
compound O +
over O +
time O +
in O +
an O +
individual O -
. O +

Methods O +
for O +
enhancing O +
muscle O +
performance O +
and O +
tone O +
This O +
disclosure O +
concerns O +
the O +
use O +
of O +
agonists O +
of O +
AMP B-Gene -
- I-Gene -
activated I-Gene +
protein I-Gene +
kinase I-Gene +
( O -
AMPK B-Gene -
) O +
for O +
improving O +
exercise O +
and O +
modifying O +
energy O +
metabolism O +
in O +
a O +
subject O -
. O +

The O +
disclosure O +
also O +
relates O +
to O +
a O +
combination O +
of O +
AMPK B-Gene +
and O +
peroxisome B-Gene +
proliferator I-Gene -
- I-Gene -
activated I-Gene +
receptor I-Gene +
( I-Gene -
PPAR I-Gene -
) I-Gene +
Î´ I-Gene +
agonists O +
for O +
improving O +
exercise O +
performance O +
in O +
a O +
subject O -
, O +
methods O +
for O +
identifying O +
substance O -
- O -
enhanced O +
exercise O +
performance O +
in O +
a O +
subject O -
, O +
and O +
methods O +
for O +
identifying O +
compounds O +
that O +
affect O +
the O +
interaction O +
of O +
PPARÎ´ B-Gene +
with O +
exercise O -
- O -
induced O +
kinases B-Gene -
. O +

Use O +
Of O +
Tranilast O +
And O +
Derivatives O +
Thereof O +

For O +
The O +
Therapy O +
Of O +
Neurological O +
Conditions O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
tranilast O +
and O +
derivatives O +
thereof O +
for O +
the O +
preparation O +
of O +
a O +
pharmaceutical O +
composition O +
for O +
treating O +
and/or O +
preventing O +
a O +
neuronal O +
condition O +
where O +
there O +
is O +
a O +
need O +
of O +
neuroprotection O +
and O +
neuroregeneration O -
. O +

The O +
invention O +
furthermore O +
relates O +
to O +
the O +
use O +
of O +
tranilast O +
and O +
derivatives O +
thereof O +
for O +
the O +
in O +
vitro O +
differentiation O +
of O +
neuronal O +
stem O +
cells O +
and O +
the O +
use O +
of O +
such O +
pre O -
- O -
treated O +
cells O +
for O +
stem O +
cell O +
therapy O +
von O +
neurological O +
conditions O -
. O +

Preparation O +
and O +
enantiomeric O +
separation O +
of O +
7- O -
( O -
3-pyridinyl O -
) O -
-1,7-diazaspiro O -
[ O -
4.4 O -
] O -
nonane O +
and O +
novel O +
salt O +
forms O +
of O +
the O +
racemate O +
and O +
enantiomers O +
A O +
novel O +
scalable O +
synthesis O +
for O +
the O +
preparation O +
of O +
7- O -
( O -
3-pyridinyI O -
) O -
-1,7-diazaspiro O -
[ O -
4.4 O -
) O -
nonane O +
has O +
been O +
developed O -
, O +
and O +
7- O -
( O -
3-pyridinyl O -
) O -
-1,7-diazaspiro O -
[ O -
4.4 O -
] O -
nonane O +
salts O +
have O +
been O +
formed O +
with O +
succinic O +
acid O +
and O +
oxalic O +
acid O -
. O +

Additionally O -
, O +
7- O -
( O -
3-pyridinyl O -
) O -
-1,7-diaza O -
- O -
spiro O -
[ O -
4.4 O -
] O -
nonane O +
has O +
been O +
separated O +
into O +
its O +
stereoisomers O +
via O +
resolution O +
with O +
L O +
and O +
D O +
di O -
- O -
p O -
- O -
toluoyltartaric O +
acids O -
, O +
giving O +
( O -
R O -
) O -
- O +
and O +
( O -
S O -
) O -
-7- O -
( O -
3-pyridinyl O -
) O -
-1,7-diazaspiro O -
[ O -
4.4 O -
] O -
nonane O +
of O +
high O +
enantiomeric O +
purity O -
. O +

Numerous O +
solid O +
salts O +
of O +
the O +
resulting O +
( O -
R O -
) O -
- O +
and O +
( O -
S O -
) O -
-7- O -
( O -
3-pyridinyl O -
) O -
-1,7-diazaspiro O -
[ O -
4.4 O -
} O -
nonane O +
have O +
been O +
prepared O -
. O +

Methods O +
for O +
the O +
preparation O +
of O +
the O +
racemic O +
and O +
enantiomeric O +
salts O -
, O +
pharmaceutical O +
compositions O +
comprising O +
such O +
salts O -
, O +
and O +
uses O +
thereof O +
are O +
disclosed O -
. O +

The O +
salts O +
can O +
be O +
administered O +
to O +
patients O +
susceptible O +
to O +
or O +
suffering O +
from O +
conditions O +
and O +
disorders O -
, O +
such O +
as O +
central O +
nervous O +
system O +
disorders O -
, O +
to O +
treat O +
and/or O +
prevent O +
such O +
disorders O -
. O +

PYRAZOLO O -
[ O -
1,5-a O -
] O -
PYRIMIDINES O +
USEFUL O +
AS O +
JAK2 B-Gene +
INHIBITORS O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
useful O +
as O +
selective O +
inhibitors O +
of O +
JAK2 B-Gene +
kinase O -
. O +

The O +
invention O +
also O +
provides O +
pharmaceutical O +
acceptable O +
compositions O +
comprising O +
said O +
compounds O +
and O +
methods O +
of O +
using O +
the O +
compositions O +
in O +
the O +
treatment O +
of O +
various O +
diseases O -
, O +
conditions O +
or O +
disorders O -
. O +

The O +
invention O +
also O +
provides O +
processes O +
for O +
preparing O +
the O +
compounds O +
of O +
the O +
invention O -
. O +

Thienopyrimidine O +
compounds O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
are O +
A2B O +
receptor O +
antagonists O -
, O +
wherein O +
R1 O +
is O +
optionally O +
substituted O +
aryl O +
or O +
an O +
optionally O +
substituted O +
5- O +
or O +
6-membered O +
heteroaryl O +
ring O -
; O +
R2 O +
and O +
R3 O +
are O +
independently O +
selected O +
from O +
hydrogen O -
, O +
C1-C6 O +
alkyl O -
, O +
C3-C8 O +
cycloalkyl O -
, O +
C3-C8 O +
cycloalkyl- O -
( O -
C1-C6 O -
) O -
-alkyl O -
, O +
aryl- O -
( O -
C1-C6 O -
) O -
-alkyl O +
optionally O +
substituted O +
in O +
the O +
ring O +
part O +
thereof O -
, O +
a O +
5- O +
or O +
6-membered O +
monocyclic O +
heterocyclic O +
group O +
optionally O +
linked O +
via O +
a O +
C1-C6 O +
alkylene O +
chain O +
and O +
optionally O +
substituted O +
in O +
the O +
ring O +
part O +
thereof O -
, O +
benzimidazol-2-yl O -
- O -
methyl O -
, O +
pyrid-3-yl O -
- O -
carbonyl O -
, O +
or O +
( O -
1-methyl O -
- O -
piperidin-4-yl O -
) O -
-carbonyl O -
- O -
methyl O -
; O +
or O +
R2 O +
and O +
R3 O +
taken O +
together O +
with O +
the O +
nitrogen O +
atom O +
to O +
which O +
they O +
are O +
attached O +
form O +
an O +
optionally O +
substituted O +
5- O +
or O +
6-membered O +
ring O -
; O +
R4 O +
is O +
C1-C3 O +
alkyl O -
, O +
C2-C3 O +
alkenyl O -
, O +
â€”N O -
( O -
â€”R5 O -
) O -
â€”R6 O -
, O +
or O +
optionally O +
substituted O +
heteroarylmethylamino O -
; O +
and O +
R5 O +
and O +
R6 O +
are O +
independently O +
selected O +
from O +
hydrogen O +
or O +
C1-C3 O +
alkyl O -
; O +
or O +
R5 O +
and O +
R6 O +
taken O +
together O +
with O +
the O +
nitrogen O +
atom O +
to O +
which O +
they O +
are O +
attached O +
form O +
an O +
optionally O +
substituted O +
4- O +
to O +
6-membered O +
saturated O +
ring O -
. O +

6 O -
- O -
1h O -
- O -
imidazo O -
- O -
quinazoline O +
and O +
quinolines O +
derivatives O -
, O +
new O +
mao B-Gene +
inhibitors O +
and O +
imidazoline O +
receptor O +
ligands O +
The O +
present O +
invention O +
is O +
directed O +
to O +
6- O -
( O -
1H O -
- O -
imidazo-1-yl O -
) O -
-2-aryl O +
and O +
2-heteroaryl O +
quinazoline O +
and O +
quinolines O +
derivatives O -
, O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
their O +
pharmaceutical O +
acceptable O +
salts O +
and O +
solvates O +
and O +
corresponding O +
pharmaceutical O +
compositions O -
, O +
that O +
acts O +
as O +
Monoamine B-Gene +
Oxidase I-Gene +
( O -
MAO B-Gene -
) O +
inhibitors O +
and O +
Imidazoline B-Gene +
Receptor I-Gene +
ligands O -
: O +
wherein O -
: O +
X O +
is O +
independently O +
selected O +
from O +
â€”CH O +
group O +
or O +
a O +
nitrogen O +
atom O +
( O -
â€”N O -
) O -
, O +
W O +
is O +
independently O +
selected O +
from O +
an O +
aryl O +
group O -
, O +
an O +
heteroaryl O +
group O -
, O +
or O +
a O +
benzocondensed O +
heteroaryl O +
group O +
such O +
as O +
1,3-benzodioxole O -
, O +
benzofuran O -
, O +
2,3-dihydrobenzofuran O -
, O +
benzothiophene O -
, O +
2,3-dihydrobenzothiophene O -
, O +
indole O -
, O +
2,3-dihydroindole O -
, O +
benzimidazole O -
, O +
benzoxazole O -
, O +
benzothiazole O -
, O +
2H-3,4-dihydrobenzopyran O -
, O +
[ O -
1,4 O -
] O -
-benzodioxine O -
, O +
2,3-dihydro- O -
[ O -
1,4 O -
] O -
-benzodioxine O +
( O -
1,4-benzodioxan O -
) O -
. O +

R1 O +
is O +
independently O +
selected O +
from O +
hydrogen O +
( O -
â€”H O -
) O -
, O +
C1-C4 O +
alkyl O -
, O +
hydroxymethyl O +
( O -
â€”CH2OH O -
) O -
, O +
aminomethyl O +
( O -
â€”CH2NH2 O -
) O -
, O +
alkylaminomethyl O +
[ O -
CH2NH O -
( O -
R2 O -
) O -
] O -
, O +
or O +
di O -
- O -
alkylaminomethyl O +
[ O -
CH2N O -
( O -
R2 O -
) O -
2 O -
] O -
, O +
trifluoromethyl O +
( O -
â€”CF3 O -
) O -
. O +

Compounds O +
of O +
formula O +
( O -
I O -
) O +
elicited O +
a O +
pharmacological O +
profile O +
suitable O +
for O +
the O +
clinical O +
treatment O +
of O +
depression O +
and O +
related O +
disorders O -
, O +
Parkinson O +
disease O -
, O +
drug O +
abuse O -
, O +
and O +
morphine O +
tolerance O +
and O +
dependence O -
. O +

Multi O -
- O -
phase O +
contraceptive O +
preparation O +
based O +
on O +
a O +
natural O +
estrogen O +
The O +
multiphase O +
preparation O +
having O +
higher O +
contraceptive O +
safety O +
and O +
reduced O +
side O +
effects O +
is O +
based O +
on O +
a O +
combination O +
of O +
a O +
natural O +
oestrogen O +
with O +
dienogest O +
or O +
drospirenon O -
. O +

The O +
multiphase O +
prepration O +
is O +
characterized O +
by O +
a O +
first O +
phase O +
consisting O +
of O +
2 O +
daily O +
dose O +
dose O +
units O +
of O +
3 O +
mg O +
of O +
oestradiol O +
valerate O -
, O +
a O +
second O +
phase O +
consisting O +
of O +
2 O +
groups O +
of O +
daily O +
dose O +
units O -
, O +
wherein O +
a O +
first O +
group O +
is O +
formed O +
by O +
5 O +
daily O +
dose O +
units O +
each O +
containing O +
a O +
combination O +
of O +
2 O +
mg O +
of O +
oestradiol O +
valerate O +
and O +
at O +
least O +
two O +
or O +
three O +
times O +
an O +
ovulation O -
- O -
inhibitory O +
dose O +
of O +
dienogest O +
or O +
drospirenon O +
and O +
a O +
second O +
group O +
is O +
formed O +
by O +
17 O +
daily O +
dose O +
units O +
each O +
containing O +
a O +
combination O +
of O +
2 O +
mg O +
of O +
oestradiol O +
valerate O +
and O +
at O +
least O +
three O +
or O +
four O +
times O +
the O +
ovulation O -
- O -
inhibitory O +
dose O +
of O +
dienogest O +
or O +
drospirenon O -
, O +
a O +
third O +
phase O +
consisting O +
of O +
2 O +
daily O +
dose O +
units O +
of O +
1 O +
mg O +
of O +
oestradiol O +
valerate O -
, O +
and O +
a O +
further O +
phase O +
consisting O +
of O +
2 O +
daily O +
dose O +
units O +
of O +
pharmaceutically O +
acceptable O +
placebo O -
. O +

Substituted O +
Carbamate O +
Derivatives O +
as O +
Modulators O +
of O +
Corticotropin O -
- O -
Releasing O +
Factor O +
Receptor O +
Activity O +

The O +
disclosure O +
provides O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
including O +
their O +
salts O -
, O +
as O +
well O +
as O +
compositions O +
and O +
methods O +
of O +
using O +
the O +
compounds O -
. O +

The O +
compounds O +
are O +
CRF B-Gene +
receptor I-Gene +
antagonists O +
and O +
may O +
be O +
useful O +
for O +
treating O +
disorders O +
associated O +
with O +
abnormal O +
CRF B-Gene +
levels O +
or O +
aberrant O +
functioning O +
of O +
CRF B-Gene +
receptors I-Gene -
. O +

Viscous O +
Terpolymers O +
as O +
Drug O +
Delivery O +
Platform O +
Disclosed O +
are O +
terpolymer O +
compositions O +
of O +
lactide O -
, O +
glycolide O -
, O +
and O +
caprolactone O +
and O +
methods O +
of O +
making O +
such O +
polymers O +
with O +
an O +
initiator O -
. O +

Methods O +
of O +
using O +
the O +
terpolymers O +
as O +
a O +
drug O +
delivery O +
platform O +
are O +
also O +
disclosed O -
. O +

Platelet O +
adhesion O -
- O -
resistant O +
material O +
A O +
platelet O +
adhesion O -
- O -
resistant O +
material O +
is O +
provided O -
, O +
which O +
includes O +
polytriuret O -
- O -
urethane O +
consisting O +
essentially O +
of O +
repeating O +
structural O +
units O +
of O +
formulae O +
( O -
I O -
) O +
to O +
( O -
III O -
) O +
in O +
a O +
random O +
order O -
, O +
in O +
which O +
when O +
the O +
total O +
number O +
of O +
the O +
three O +
repeating O +
structural O +
units O +
in O +
the O +
polytriuret O -
- O -
urethane O +
is O +
100 O -
, O +
the O +
number O +
of O +
the O +
repeating O +
structural O +
units O +
( O -
I O -
) O +
is O +
about O +
5 O +
to O +
about O +
50 O -
: O +
in O +
which O +
each O +
R O +
independently O +
represents O +
a O +
C2-C16 O +
alkylene O +
group O -
, O +
a O +
C6-C30 O +
aromatic O +
group O -
, O +
a O +
C6-C30 O +
alicyclic O +
group O -
; O +
n O +
is O +
an O +
integer O +
of O +
2 O +
to O +
16 O -
; O +
and O +
R1 O +
represents O +
â€” O -
( O -
OCmH2m O -
) O -
p O -
, O +
in O +
which O +
m O +
is O +
an O +
integer O +
of O +
2 O +
to O +
5 O -
, O +
and O +
p O +
is O +
an O +
integer O +
of O +
3 O +
to O +
150 O -
. O +

Mzb1 B-Gene -
, O +
a O +
novel O +
b O +
cell O +
factor O -
, O +
and O +
uses O +
thereof O +
The O +
marginal O +
zone O +
( O -
MZ O -
) O +
and O +
B1 O +
subsets O +
of O +
B O +
cells O -
, O +
which O +
differ O +
from O +
conventional O +
follicular O +
( O -
FO O -
) O +
B O +
cells O +
both O +
developmentally O +
and O +
functionally O -
, O +
are O +
involved O +
in O +
early O +
responses O +
to O +
infectious O +
pathogens O +
and O +
the O +
production O +
of O +
self O -
- O -
reactive O +
antibodies O -
. O +

A O +
novel O +
gene O -
, O +
mzb1 O -
, O +
is O +
expressed O +
at O +
high O +
levels O +
in O +
MZ O +
and O +
B1 O +
B O +
cells O +
but O +
at O +
low O +
level O -
, O +
if O +
at O +
all O -
, O +
in O +
FOB O +
cells O -
. O +

MZB1 B-Gene +
is O +
involved O +
in O +
the O +
regulation O +
of O +
proliferation O -
, O +
BCR B-Gene -
- O -
mediated O +
signal O +
transduction O -
, O +
and O +
antibody O +
production O +
in O +
B O +
cells O -
. O +

Inhibitors O -
, O +
activators O +
and O +
enhancers O +
of O +
MZB1 B-Gene +
expression O +
or O +
activity O +
can O +
be O +
used O +
as O +
immune O +
modulators O +
for O +
research O +
and O +
therapeutic O +
purposes O -
. O +

Methods O +
and O +
Compositions O +
for O +
the O +
Treatment O +
of O +
Chronic O +
Renal O +
Hypertension O +
Methods O +
and O +
compositions O +
for O +
the O +
treating O +
chronic O +
renal O +
hypertension O +
in O +
a O +
subject O +
comprising O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
nitroxide O -
- O -
containing O +
composition O +
to O +
the O +
subject O -
, O +
particularly O +
4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl O +
( O -
Tempol O -
) O -
. O +

Methods O +
and O +
compositions O +
for O +
targeted O +
delivery O +
of O +
gene O +
therapeutic O +
vectors O +
Embodiments O +
of O +
the O +
present O +
invention O +
relate O +
to O +
methods O +
and O +
compositions O +
for O +
tissue- O +
specific O +
delivery O +
of O +
a O +
gene O +
therapeutic O -
, O +
transgenic O +
nucleic O +
acid O +
in O +
mammals O -
. O +

Methods O +
and O +
compositions O +
of O +
the O +
invention O +
include O +
the O +
steps O +
of O +
providing O +
a O +
nucleic O +
acid O +
comprising O +
a O +
transgene O +
flanked O +
by O +
two O +
terminal O +
repeats O +
and O -
, O +
within O +
the O +
same O +
or O +
on O +
a O +
separate O +
nucleic O +
acid O -
, O +
a O +
nucleotide O +
sequence O +
encoding O +
a O +
transposase O -
, O +
wherein O +
the O +
transgene O +
comprises O +
a O +
biotherapeutic O +
gene O -
, O +
contacting O +
the O +
nucleic O +
acid O +
with O +
perfluorocarbon O +
gas O -
- O -
filled O +
microbubbles O +
to O +
form O +
a O +
mixture O -
, O +
introducing O +
the O +
mixture O +
into O +
the O +
bloodstream O +
of O +
a O +
mammal O -
, O +
and O +
focusing O +
ultrasound O +
pulses O +
on O +
a O +
specific O +
tissue O +
of O +
said O +
mammal O -
, O +
wherein O +
said O +
pulses O +
disrupt O +
said O +
microbubbles O +
of O +
said O +
mixture O +
and O +
release O +
said O +
nucleic O +
acid O +
into O +
the O +
bloodstream O +
within O +
the O +
target O +
tissue O -
, O +
thereby O +
enabling O +
uptake O +
of O +
the O +
transgenic O +
nucleic O +
acid O +
into O +
the O +
cells O +
of O +
said O +
target O +
tissue O -
. O +

Use O +
of O +
extracellular O +
rna O +
to O +
measure O +
disease O +
Stable O -
, O +
extracellular O +
microRNAs O +
and O +
methods O +
for O +
isolating O +
and O +
identifying O +
such O +
microRNAs O +
from O +
a O +
body O +
fluid O +
are O +
provided O -
. O +

The O +
extracellular O +
microRNAs O +
isolated O +
from O +
a O +
bodily O +
fluid O +
of O +
a O +
subject O +
can O +
be O +
used O +
to O +
measure O +
disease O +
and O +
provide O +
sensitive O -
, O +
efficient O -
, O +
and O +
non O +
invasive O +
methods O +
for O +
the O +
detection O +
of O +
disease O -
, O +
including O +
cancer O -
. O +

The O +
extracellular O +
microRNAs O +
can O +
be O +
used O +
to O +
develop O +
new O +
therapeutics O +
for O +
the O +
treatment O +
of O +
disease O -
, O +
including O +
cancer O -
. O +

The O +
examples O +
illustrate O +
diagnosis O +
of O +
prostate O +
and O +
ovarian O +
cancer O +
and O +
differential O +
expression O +
of O +
miR-100 B-Gene -
, O +
miR-135b B-Gene -
, O +
miR-141 B-Gene -
, O +
miR-148a B-Gene -
, O +
miR-200a B-Gene -
, O +
miR-200c B-Gene -
, O +
miR-210 B-Gene -
, O +
miR-222 B-Gene -
, O +
miR-375 B-Gene -
, O +
miR-425-Sp B-Gene +
and O +
miR-429 B-Gene -
. O +

Device O +
and O +
methods O +
for O +
treatment O +
and O +
prevention O +
of O +
tendon O +
injuries O +
The O +
present O +
invention O +
relates O +
to O +
treatment O +
and O +
prevention O +
devices O +
and O +
regimens O +
for O +
tendon O +
injury O +
and O +
damage O -
. O +

The O +
invention O +
further O +
provides O +
compositions O +
comprising O +
therapeutic O +
agents O +
and O +
the O +
use O +
of O +
such O +
compositions O +
in O +
methods O +
of O +
treating O +
disorders O -
, O +
injuries O +
and O +
conditions O +
beneficially O +
treated O +
by O +
these O +
agents O -
, O +
particularly O +
those O +
relating O +
to O +
the O +
management O +
of O +
tendon O +
damage O -
. O +

Cd44 B-Gene +
splice O +
variants O +
in O +
neurodegenerative O +
diseases O +
There O +
is O +
provided O +
a O +
method O +
of O +
treating O +
or O +
preventing O +
a O +
neurodegenerative O +
disease O -
, O +
which O +
includes O +
administration O +
of O +
a O +
composition O +
that O +
includes O +
a O +
reagent O +
capable O +
of O +
modulating O +
expression O +
of O +
ribonucleic O +
acid O +
( O -
RNA O -
) O +
encoded O +
by O +
a O +
nucleic O +
acid O -
, O +
wherein O +
the O +
nucleic O +
acid O +
is O +
selected O +
from O +
a O +
group O +
that O +
includes O +
a O +
contiguous O +
nucleotide O +
sequence O +
being O +
at O +
least O +
90 O -
% O +
homologous O +
to O +
at O +
least O +
20 O +
nucleotides O +
of O -
: O +
SEQ O +
ID O +
NO O -
: O +
1 O -
, O +
SEQ O +
ID O +
NO O -
: O +
3 O -
, O +
SEQ O +
ID O +
NO O -
: O +
5 O -
, O +
SEQ O +
ID O +
NO O -
: O +
7 O -
, O +
or O +
any O +
combination O +
thereof O -
. O +

There O +
is O +
further O +
provided O +
a O +
method O +
of O +
treating O +
or O +
preventing O +
a O +
neurodegenerative O +
disease O -
, O +
which O +
includes O +
administration O +
of O +
a O +
composition O +
that O +
includes O +
a O +
reagent O +
capable O +
of O +
modulating O +
expression O +
and/or O +
activity O +
of O +
a O +
polypeptide O -
, O +
wherein O +
the O +
sequence O +
of O +
the O +
polypeptide O +
is O +
selected O +
from O +
a O +
group O +
that O +
includes O +
a O +
contiguous O +
amino O +
acid O +
sequence O +
being O +
at O +
least O +
90 O -
% O +
homologous O +
to O +
at O +
least O +
10 O +
amino O +
acid O +
of O -
: O +
SEQ O +
ID O +
NO O -
: O +
2 O -
, O +
SEQ O +
ID O +
NO O -
: O +
4 O -
, O +
SEQ O +
ID O +
NO O -
: O +
6 O -
, O +
SEQ O +
ID O +
NO O -
: O +
8 O -
, O +
or O +
any O +
combination O +
thereof O -
. O +

Rna O +
interference O +
for O +
the O +
treatment O +
of O +
gain O -
- O -
of O -
- O -
function O +
disorders O +
The O +
present O +
invention O +
relates O +
to O +
the O +
discovery O +
of O +
an O +
effective O +
treatment O +
for O +
a O +
variety O +
of O +
gain O -
- O -
of O -
- O -
function O +
diseases O -
, O +
in O +
particular O -
, O +
Huntington O -
's O +
disease O +
( O -
HD O -
) O -
. O +

The O +
present O +
invention O +
utilizes O +
RNA O +
Interference O +
technology O +
( O -
RNAi O -
) O +
against O +
polymorphic O +
regions O +
in O +
the O +
genes O +
encoding O +
various O +
gain O -
- O -
of O -
- O -
function O +
mutant O +
proteins O +
resulting O +
in O +
an O +
effective O +
treatment O +
for O +
the O +
gain O -
- O -
of O -
- O -
function O +
disease O -
. O +

Compositions O +
comprising O +
cationic O +
microparticles O +
and O +
hcv B-Gene +
e1e2 I-Gene +
dna I-Gene +
and O +
methods O +
of O +
use O +
thereof O +
Immunogenic O +
HCV B-Gene +
E1E2809 I-Gene +
DNA I-Gene +
compositions O +
and O +
methods O +
of O +
using O +
the O +
same O +
are O +
described O -
. O +

The O +
compositions O +
comprise O +
HCV B-Gene +
E1E2809 I-Gene +
DNA I-Gene +
adsorbed O +
to O +
cationic O +
microparticles O -
, O +
such O +
as O +
poly O -
( O -
lactide O -
- O -
co O -
- O -
glycolide O -
) O +
( O -
PLG O -
) O +
microparticles O -
. O +

Pharmaceutical O +
compositions O +
comprising O +
boronic O +
acid O +
compounds O +
Pharmaceutical O +
compositions O +
comprising O +
bortezomib O +
for O +
oral O +
or O +
parenteral O +
administration O -
. O +

Specific O +
aspects O +
relate O +
to O +
stable O -
, O +
sugar O +
free O +
pharmaceutical O +
compositions O +
of O +
bortezomib O -
, O +
including O +
its O +
pharmaceutically O +
acceptable O +
salts O +
or O +
solvates O -
, O +
in O +
the O +
form O +
of O +
ready O -
- O -
to O -
- O -
use O +
solutions O -
, O +
lyophilized O +
forms O -
, O +
or O +
physical O +
admixtures O -
, O +
and O +
the O +
preparation O +
thereof O -
. O +

Other O +
aspects O +
include O +
processes O +
for O +
preparing O +
compositions O +
and O +
methods O +
of O +
using O +
compositions O +
for O +
treating O +
various O +
types O +
of O +
cancers O +
in O +
mammals O -
. O +

minoxidil O +
composition O +
and O +
non O -
- O -
aerosol O -
, O +
non O -
- O -
spray O +
foam O +
method O +
of O +
delivery O +
therefor O +
A O +
foamable O +
composition O +
is O +
described O +
that O +
contains O +
one O +
or O +
more O +
of O -
: O +
minoxidil O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
an O +
aqueous O -
- O -
alcoholic O +
solvent O +
medium O +
which O +
enables O +
said O +
minoxidil O +
or O +
said O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
to O +
be O +
solubilized O -
, O +
a O +
surfactant O -
, O +
such O +
as O +
oleth-20 O -
, O +
a O +
foam O +
stabilizer O -
, O +
such O +
as O +
lauryl O +
glucoside O -
, O +
and O +
a O +
sunscreen O -
. O +

The O +
foamable O +
minoxidil O +
composition O +
is O +
optionally O +
delivered O +
in O +
a O +
measured O +
dosage O +
as O +
a O +
foam O +
using O +
a O +
non O -
- O -
pressurized O +
container O -
, O +
where O +
the O +
foam O +
is O +
produced O +
within O +
the O +
container O +
without O +
use O +
of O +
a O +
propellant O -
. O +

Tricyclic O +
indole O +
derivatives O +
and O +
methods O +
of O +
use O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
Tricyclic O +
Indole O +
Derivatives O -
, O +
compositions O +
comprising O +
at O +
least O +
one O +
Tricyclic O +
Indole O +
Derivatives O -
, O +
and O +
methods O +
of O +
using O +
the O +
Tricyclic O +
Indole O +
Derivatives O +
for O +
treating O +
or O +
preventing O +
a O +
viral O +
infection O +
or O +
a O +
virus O -
- O -
related O +
disorder O +
in O +
a O +
patient O -
. O +

Dispersible O +
phospholipid O +
stabilized O +
microparticles O +
Rapidly O +
dispersing O +
solid O +
dry O +
therapeutic O +
dosage O +
form O +
comprised O +
of O +
a O +
water O +
insoluble O +
compound O +
existing O +
as O +
a O +
nanometer O +
or O +
micrometer O +
particulate O +
solid O +
which O +
is O +
surface O +
stabilized O +
by O +
the O +
presence O +
of O +
at O +
least O +
one O +
phospholipid O -
, O +
the O +
particulate O +
solid O +
being O +
dispersed O +
throughout O +
a O +
bulking O +
matrix O -
. O +

When O +
the O +
dosage O +
form O +
is O +
introduced O +
into O +
an O +
aqueous O +
environment O +
the O +
bulking O +
matrix O +
is O +
substantially O +
completely O +
dissolves O +
within O +
less O +
than O +
2 O +
minutes O +
thereby O +
releasing O +
the O +
water O +
insoluble O +
particulate O +
solid O +
in O +
an O +
unaggregated O +
and/or O +
unagglomerated O +
state O -
. O +

The O +
matrix O +
is O +
composed O +
of O +
a O +
water O +
insoluble O +
substance O +
or O +
therapeutically O +
useful O +
water O +
insoluble O +
or O +
poorly O +
water O +
soluble O +
compound O -
, O +
a O +
phospholipid O +
and O +
optionally O +
also O +
at O +
least O +
one O +
non O -
- O -
ionic O -
, O +
anionic O -
, O +
cationic O -
, O +
or O +
amphipathic O +
surfactant O -
, O +
together O +
with O +
a O +
matrix O +
or O +
bulking O +
agent O +
and O +
if O +
needed O +
a O +
release O +
agent O -
. O +

The O +
volume O +
weighted O +
mean O +
particle O +
size O +
of O +
the O +
water O +
insoluble O +
particle O +
is O +
5 O +
micrometers O +
or O +
less O -
. O +

Screening O +
Method O +
for O +
Identifying O +
Patients O +
at O +
Risk O +
of O +
Adverse O +
Hepatologic O +
Events O +

This O +
present O +
invention O +
provides O +
methods O +
and O +
kits O +
for O +
identifying O +
patients O +
at O +
risk O +
of O +
suffering O +
from O +
a O +
drug O +
induced O +
liver O +
injury O -
, O +
particularly O +
for O +
an O +
antioxidant O +
drug O -
, O +
or O +
for O +
identifying O +
patients O +
who O +
are O +
suffering O +
from O +
early O +
stages O +
of O +
a O +
liver O +
disorder O +
by O +
assessing O +
the O +
levels O +
of O +
apolipoprotein O +
in O +
a O +
sample O +
of O +
the O +
patient O +
and O +
comparing O +
that O +
to O +
a O +
reference O +
value O -
. O +

The O +
reference O +
value O +
is O +
predetermined O +
by O +
identifying O +
a O +
population O +
sample O +
and O +
determining O +
an O +
upper O +
limit O +
of O +
normal O +
value O -
. O +

This O +
value O +
is O +
then O +
used O +
as O +
a O +
reference O +
point O +
for O +
comparison O +
of O +
apolipoprotein O +
levels O +
from O +
patient O +
samples O -
. O +

In O +
one O +
embodiment O -
, O +
apolipoprotein O +
levels O +
are O +
combined O +
with O +
ATL O +
and/or O +
total O +
bilirubin O +
levels O +
for O +
predicting O +
liver O +
damage O -
, O +
hepatotoxicity O +
or O +
hepatic O +
events O +
after O +
drug O +
administration O -
. O +

Modified O +
chloroquines O +
with O +
single O +
ring O +
moiety O +
or O +
fused O +
ring O +
moiety O +
The O +
disclosure O +
provides O +
modified O +
chloroquine O +
compounds O +
having O +
single O +
ring O +
or O +
fused O +
ring O +
moieties O -
. O +

Also O +
provided O +
are O +
pharmaceutical O +
compositions O +
comprising O +
such O +
compounds O -
, O +
methods O +
of O +
using O +
such O +
compounds O +
to O +
inhibit O +
or O +
treat O +
diseases O +
or O +
conditions O +
caused O +
by O +
chloroquine O -
- O -
resistant O +
( O -
CQR O -
) O +
and O +
chloroquine O -
- O -
sensitive O +
( O -
CqS O -
) O +
malaria O +
parasites O +
and O +
other O +
CQ O -
- O -
susceptible O +
microorganisms O -
, O +
and O +
processes O +
and O +
intermediates O +
useful O +
for O +
preparing O +
such O +
compounds O -
. O +

Method O +
and O +
Kit O +
for O +
Assessing O +
a O +
Patient O -
's O +
Genetic O +
Information O -
, O +
Lifestyle O +
and O +
Environment O +
Conditions O -
, O +
and O +
Providing O +
a O +
Tailored O +
Therapeutic O +
Regime O +
A O +
method O +
of O +
determining O +
a O +
personalised O +
therapeutic O +
regime O -
, O +
comprising O -
: O +
receiving O +
genetic O +
information O +
relating O +
to O +
a O +
patient O -
; O +
determining O +
genetic O +
criteria O +
relevant O +
to O +
a O +
personalised O +
therapeutic O +
regime O +
for O +
the O +
patient O +
using O +
the O +
genetic O +
information O -
; O +
receiving O +
personal O +
information O +
relating O +
to O +
the O +
patient O -
; O +
determining O +
personal O +
criteria O +
relevant O +
to O +
the O +
personalised O +
therapeutic O +
regime O +
using O +
the O +
personal O +
information O -
; O +
and O +
combining O +
the O +
genetic O +
criteria O +
and O +
the O +
personal O +
criteria O +
to O +
determine O +
the O +
personalised O +
therapeutic O +
regime O +
for O +
the O +
patient O -
. O +

Methods O +
for O +
enhancing O +
immune O +
response O +
This O +
disclosure O +
demonstrates O +
a O +
novel O +
therapy O +
immunological O +
approach O +
using O +
polyamine O -
- O -
based O +
therapy O +
( O -
PBT O -
) O +
for O +
relieving O +
tumor O -
- O -
induced O +
suppression O +
of O +
the O +
patient O -
's O +
immune O +
system O -
. O +

The O +
demonstration O +
of O +
the O +
pharmacological O +
release O +
from O +
the O +
naturally O +
occurring O +
polyamine O -
- O -
mediated O +
immune O +
suppression O +
offers O +
profound O +
impact O +
on O +
the O +
immunotherapy O +
of O +
cancer O +
together O +
with O +
a O +
variety O +
of O +
diseases O +
caused O +
by O +
the O +
disease O -
- O -
causing O +
vector O -
's O +
ability O +
to O +
evade O +
an O +
immune O +
reaction O -
. O +

This O +
therapeutic O +
approach O +
is O +
equally O +
applicable O +
to O +
disease O +
states O +
whereby O +
immune O +
system O +
suppression O +
by O +
polyamines O +
has O +
been O +
demonstrated O +
including O -
; O +
bacterial O +
infections O -
, O +
parasitic O +
infections O +
including O +
malaria O +
and O +
typanosomiasis O -
, O +
viral O +
infections O -
, O +
peptic O +
ulcers O +
and O +
gastric O +
cancer O +
due O +
to O +
H. O +
Pylori O +
infection O +
together O +
with O +
prevention O +
of O +
pregnancy O -
. O +

With O +
a O +
small O +
molecule O +
drug O -
, O +
used O +
in O +
combination O +
with O +
DFMO O -
, O +
the O +
pharmacological O +
manipulation O +
of O +
polyamine O +
levels O +
for O +
therapeutic O +
benefit O +
in O +
various O +
disease O +
states O +
is O +
possible O -
. O +

Micronutrient O +
Supplement O +
Dispensing O +
Package O +
Provided O +
herein O +
is O +
a O +
prenatal O +
and O +
postpartum O +
multivitamin O +
and O +
mineral O +
supplement O +
package O +
provided O +
in O +
the O +
form O +
of O +
a O +
plurality O +
of O +
solid O +
oral O +
dosage O +
units O +
individually O +
contained O +
in O +
blister O +
packs O +
wherein O +
a O +
portion O +
of O +
the O +
dosage O +
forms O +
are O +
iron O -
- O -
containing O +
while O +
at O +
least O +
half O +
of O +
the O +
dosage O +
units O +
are O +
essentially O +
iron O -
- O -
free O +
and O +
wherein O +
the O +
total O +
amount O +
of O +
iron O +
in O +
the O +
package O +
as O +
sold O +
to O +
purchasers O +
is O +
less O +
than O +
about O +
1300 O +
mg O +
of O +
elemental O +
iron O -
. O +

Alkaloid O +
aminoester O +
derivatives O +
and O +
medicinal O +
composition O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
alkaloid O +
aminoester O +
compounds O +
which O +
act O +
as O +
muscarinic B-Gene +
receptor I-Gene +
antagonists O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
compositions O +
comprising O +
them O -
, O +
and O +
therapeutic O +
uses O +
thereof O -
. O +

Cardenolides O +
for O +
the O +
treatment O +
of O +
ocular O +
cancer O +
The O +
instant O +
invention O +
provides O +
methods O +
of O +
using O +
a O +
class O +
of O +
compounds O +
known O +
as O +
cardenolides O +
in O +
the O +
treatment O +
of O +
proliferative O +
diseases O +
such O +
as O +
cancer O -
. O +

In O +
particular O -
, O +
the O +
instant O +
invention O +
provides O +
methods O +
of O +
treating O +
ocular O +
cancer O +
{ O -
e.g. O -
, O +
retinoblastoma O -
) O +
using O +
intraarterial O +
infusion O +
to O +
administer O +
cardenolides O +
locally O +
to O +
the O +
eye O +
of O +
a O +
subject O +
with O +
an O +
ocular O +
cancer O -
. O +

Novel O +
Saponin O +
Compounds O -
, O +
Methods O +
of O +
Preparation O +
Thereof O -
, O +
Use O +
Thereof O +
and O +
Pharmaceutical O +
Compositions O +

This O +
invention O +
relates O +
to O +
novel O +
saponin O +
compounds O +
of O +
formula O +
II O +
wherein O +
MBz O +
denotes O +
p O -
- O -
methoxybenzoyl O -
, O +
and O +
R O +
is O +
selected O +
from O +
the O +
group O +
comprising O +
C6 O -
- O -
10 O +
aryl O -
, O +
C6 O -
- O -
10 O +
aryl O -
- O -
C1 O -
- O -
4 O +
alkyl- O -
, O +
C1 O -
- O -
18 O +
alkanoyl O -
, O +
C3 O -
- O -
18 O +
alkenyl O -
, O +
C6 O -
- O -
10 O +
aryl O -
- O -
C O -
( O -
O O -
) O -
â€” O -
, O +
C6 O -
- O -
10 O +
aryl O -
- O -
C1 O -
- O -
4 O +
alkyl O -
- O -
C O -
( O -
O O -
) O -
â€” O -
, O +
wherein O +
each O +
of O +
the O +
groups O +
can O +
optionally O +
be O +
substituted O -
. O +

These O +
compounds O +
possess O +
a O +
selective O +
cytostatic O +
activity O -
, O +
useful O -
, O +
e.g. O -
, O +
in O +
the O +
treatment O +
of O +
proliferative O +
diseases O -
. O +

The O +
invention O +
further O +
relates O +
to O +
methods O +
of O +
preparation O +
of O +
the O +
novel O +
compounds O +
and O +
to O +
a O +
pharmaceutical O +
composition O +
containing O +
these O +
compounds O -
. O +

( O -
2-aryloxyacetylamino O -
) O +
phenylpropionic O +
acid O +
derivatives O -
, O +
processes O +
for O +
preparation O +
thereof O +
and O +
use O +
thereof O +
as O +
medicaments O +
The O +
invention O +
relates O +
to O +
substituted O +
( O -
2-aryloxyacetylamino O -
) O -
phenylpropionic O +
acid O +
derivatives O -
, O +
and O +
to O +
the O +
physiologically O +
acceptable O +
salts O +
thereof O -
. O +

The O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
I O +
in O +
which O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O -
, O +
R8 O -
, O +
R9 O +
and O +
A O +
are O +
each O +
defined O +
as O +
specified O -
, O +
and O +
the O +
physiologically O +
compatible O +
salts O +
thereof O -
. O +

The O +
compounds O +
are O +
suitable O -
, O +
for O +
example O -
, O +
for O +
treatment O +
of O +
diabetes O -
. O +

Succinate O +
salt O +
of O +
( O -
2r O -
) O -
-methyl-1-piperazine O +
The O +
present O +
invention O +
relates O +
to O +
a O +
process O +
for O +
the O +
preparation O +
of O +
compounds O +
which O +
are O +
therapeutically O +
active O +
in O +
the O +
central O +
nervous O +
system O -
. O +

In O +
one O +
aspect O -
, O +
the O +
invention O +
relates O +
to O +
a O +
process O +
for O +
the O +
preparation O +
of O +
compounds O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
HA O +
is O +
a O +
pharmaceutically O +
acceptable O +
acid O +
and O +
R1-R4 O +
are O +
each O +
independently O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
hydrogen O -
, O +
halogen O -
, O +
C1-C6-alkyl O -
, O +
C1-C6-alkoxy O -
, O +
and O +
di O -
- O -
C1-C6-alkylamino O -
- O -
C2-C6-alkoxy O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
said O +
compound O +
to O +
manufacture O +
a O +
medicament O +
for O +
the O +
treatment O +
of O +
a O +
serotonin O -
- O -
related O +
disorder O -
. O +

Oligomer O -
- O -
Diarylpiperazine O +
Conjugates O +
The O +
invention O +
relates O +
to O +
( O -
among O +
other O +
things O -
) O +
oligomer O -
- O -
diarylpiperazine O +
conjugates O +
and O +
related O +
compounds O -
. O +

A O +
conjugate O +
of O +
the O +
invention O -
, O +
when O +
administered O +
by O +
any O +
of O +
a O +
number O +
of O +
administration O +
routes O -
, O +
exhibits O +
advantages O +
over O +
previously O +
administered O +
un O -
- O -
conjugated O +
diarylpiperazine O +
compounds O -
. O +

Rna O +
antagonist O +
compounds O +
for O +
the O +
inhibition O +
of O +
expression O +
of O +
mitochondrial B-Gene +
glycerol-3 I-Gene +
phosphate I-Gene +
acyltransferase I-Gene +
1 I-Gene +
( O -
mtgpat1 B-Gene -
) O +
The O +
present O +
invention O +
relates O +
to O +
oligomer O +
compounds O +
( O -
oligomers O -
) O -
, O +
which O +
target O +
mtGPAT1mRNA B-Gene +
in O +
a O +
cell O -
, O +
leading O +
to O +
reduced O +
expression O +
of O +
mtGPAT1 B-Gene -
. O +

Reduction O +
of O +
mtGPAT1 B-Gene +
expression O +
is O +
beneficial O +
for O +
the O +
treatment O +
of O +
certain O +
medical O +
disorders O -
, O +
such O +
as O +
overweight O -
, O +
obesity O -
, O +
fatty O +
liver O -
, O +
hepatosteatosis O -
, O +
non O +
alcoholic O +
fatty O +
liver O +
disease O +
( O -
NAFLD O -
) O -
, O +
non O +
alcoholic O +
steatohepatitis O +
( O -
NASH O -
) O -
, O +
insulin B-Gene +
resistance O -
, O +
and O +
non O +
insulin B-Gene +
dependent O +
diabetes O +
mellitus O +
( O -
NIDDM O -
) O -
. O +

Treatment O +
of O +
delta B-Gene -
- I-Gene -
like I-Gene +
1 I-Gene +
homolog I-Gene +
( O -
dlk1 B-Gene -
) O +
related O +
diseases O +
by O +
inhibition O +
of O +
natural O +
antisense O +
transcript O +
to O +
dlk1 B-Gene +
The O +
present O +
invention O +
relates O +
to O +
antisense O +
oligonucleotides O +
that O +
modulate O +
the O +
expression O +
of O +
and/or O +
function O +
of O +
Delta B-Gene -
- I-Gene -
like I-Gene +
( I-Gene -
1 I-Gene -
) I-Gene +
homolog I-Gene +
( O -
DLK1 B-Gene -
) O -
, O +
in O +
particular O -
, O +
by O +
targeting O +
natural O +
antisense O +
polynucleotides O +
of O +
Delta B-Gene -
- I-Gene -
like I-Gene +
( I-Gene -
1 I-Gene -
) I-Gene +
homolog I-Gene +
( O -
DLK1 B-Gene -
) O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
identification O +
of O +
these O +
antisense O +
oligonucleotides O +
and O +
their O +
use O +
in O +
treating O +
diseases O +
and O +
disorders O +
associated O +
with O +
the O +
expression O +
of O +
( O -
DLK1 B-Gene -
) O -
. O +

Methods O +
and O +
compounds O +
for O +
treatment O +
of O +
neurodegenerative O +
disorders O +
Methods O -
, O +
compounds O +
and O +
compositions O +
for O +
promoting O +
motor O +
neuron O +
survival O +
and O +
the O +
treatment O +
of O +
a O +
neurodegenerative O +
disorders O +
such O +
as O +
Spinal O +
Muscular O +
Atrophy O +
( O -
SMA O -
) O +
are O +
described O +
herein O -
. O +

Method O +
of O +
mitigating O +
adverse O +
drug O +
events O +
using O +
omega-3 O +
fatty O +
acids O +
as O +
a O +
parenteral O +
therapeutic O +
drug O +
vehicle O +
A O +
method O +
of O +
parenterally O +
administering O +
a O +
composition O -
, O +
the O +
method O +
including O +
parenterally O +
administering O +
to O +
a O +
person O +
a O +
composition O +
including O +
at O +
least O +
one O +
omega-3 O +
fatty O +
acid O +
and O +
at O +
least O +
one O +
drug O -
, O +
wherein O +
the O +
at O +
least O +
one O +
omega-3 O +
fatty O +
acid O +
source O +
and O +
the O +
at O +
least O +
one O +
drug O +
are O +
administered O +
simultaneously O -
. O +

Crystalline O +
forms O +
of O +
oxymorphone O +
hydrochloride O +
The O +
present O +
invention O +
is O +
directed O +
to O +
crystalline O +
forms O +
of O +
oxymorphone O +
hydrochloride O -
. O +

Pectin O -
- O -
containing O +
jelly O +
formulation O +
There O +
is O +
disclosed O +
a O +
technique O +
for O +
imparting O +
an O +
appropriate O +
rupture O +
strength O +
and O +
high O +
drug O -
- O -
release O +
properties O +
to O +
a O +
jelly O +
formulation O +
comprising O +
pectin O -
. O +

The O +
jelly O +
formulation O +
of O +
the O +
present O +
invention O +
comprises O +
a O +
drug O -
, O +
pectin O -
, O +
and O +
divalent O +
metal O +
ion O -
, O +
and O +
further O +
comprises O +
a O +
component O +
selected O +
from O +
sucrose O -
, O +
maltitol O +
and O +
C3-C4 O +
alditols O -
, O +
and O +
a O +
component O +
selected O +
from O +
C5-C6 O +
alditols O +
in O +
combination O -
. O +

Pharmaceutical O +
depot O +
for O +
5-fluoro-2- O -
[ O -
[ O -
( O -
1s O -
) O -
-1- O -
( O -
5-fluoro-2-pyridyl O -
) O -
ethyl O -
] O -
amino O -
] O -
-6- O -
[ O -
( O -
5-isopropoxy-1h O -
- O -
pyrazol-3-yl O -
) O -
amino O -
] O -
pyridine-3-carbonitrile O +
A O +
pharmaceutical O +
depot O +
comprising O +
( O -
i O -
) O +
5-fluoro-2- O -
[ O -
[ O -
( O -
1S O -
) O -
-1- O -
( O -
5-fluoro-2-pyridyl O -
) O -
ethyl O -
] O -
amino O -
] O -
-6- O -
[ O -
( O -
5-isopropoxy-1H O -
- O -
pyrazol-3-yl O -
) O -
amino O -
] O -
pyridine-3-carbonitrile O -
, O +
or O +
a O +
pharmaceutically O -
- O -
acceptable O +
salt O +
thereof O -
, O +
as O +
a O +
pharmaceutical O +
agent O +
( O -
PA O -
) O +
and O +
( O -
ii O -
) O +
a O +
polymer O +
which O +
degrades O +
to O +
create O +
an O +
acidic O +
microclimate O -
, O +
wherein O +
the O +
PA O +
is O +
released O +
from O +
the O +
polymer O +
upon O +
polymer O +
degradation O -
. O +

Low O -
- O -
dose O -
, O +
non O -
- O -
irritating O +
nicotine O +
nasal O +
composition O +
to O +
reduce O +
the O +
desire O +
to O +
smoke O +
A O +
composition O +
for O +
administration O +
to O +
the O +
nasal O +
mucosa O +
of O +
a O +
subject O +
comprises O +
a O +
solution O +
of O +
nicotine O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
in O +
a O +
pharmaceutically O +
acceptable O +
solvent O -
. O +

The O +
composition O +
has O +
a O +
nicotine O +
concentration O +
less O +
than O +
0.08 O +
mg O -
/ O -
ml O -
. O +

The O +
composition O +
used O +
alone O +
assists O +
in O +
reduction O +
of O +
the O +
desire O +
of O +
a O +
subject O +
to O +
smoke O +
tobacco O -
. O +

It O +
also O +
reduces O +
the O +
nasal O +
symptoms O +
associated O +
with O +
administration O +
of O +
higher O +
concentrations O +
of O +
nicotine O +
to O +
the O +
nasal O +
mucosa O -
. O +

Inhibitor O +
for O +
elevation O +
of O +
gip B-Gene +
level O +
Provided O +
is O +
a O +
GIP B-Gene -
- O -
increase O +
inhibitor O -
, O +
which O +
is O +
customary O +
used O +
for O +
food O +
production O -
, O +
is O +
excellent O +
in O +
safety O -
, O +
and O +
is O +
useful O +
for O -
, O +
for O +
example O -
, O +
a O +
medicine O +
or O +
a O +
food O -
. O +

The O +
GIP B-Gene -
- O -
increase O +
inhibitor O +
contains O +
catechins O +
as O +
active O +
ingredient O -
. O +

Use O +
of O +
bipolar O +
trans O +
carotenoids O +
as O +
a O +
pretreatment O +
and O +
in O +
the O +
treatment O +
of O +
peripheral O +
vascular O +
disease O +
The O +
subject O +
application O +
relates O +
to O +
methods O +
of O +
treatment O +
of O +
peripheral O +
vascular O +
disease O +
( O -
PVD O -
) O +
as O +
well O +
as O +
ischemic O +
osteonecrosis O -
, O +
peritoneal O +
ischemia O -
, O +
chronic O +
ocular O +
disease O -
, O +
macular O +
degeneration O -
, O +
or O +
diabetic O +
retinopathy O -
, O +
comprising O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
trans O +
carotenoid O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
such O +
carotenoids O +
as O +
pretreatments O +
for O +
mammals O +
at O +
risk O +
of O +
an O +
ischemic O +
event O -
. O +

Cdk B-Gene +
inhibitor O +
salts O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
crystalline O +
form O -
( O -
s O -
) O +
of O +
water O -
- O -
soluble O +
salts O +
and O +
of O +
free O +
base O +
of O +
a O +
cdk B-Gene +
inhibitor O -
. O +

Such O +
crystal O +
salts O +
are O +
for O +
example O +
fumarate O -
, O +
L O -
- O -
malate O -
, O +
maleate O -
, O +
succinate O -
, O +
adipate O -
, O +
malonate O -
, O +
glycolate O -
, O +
phosphate O -
, O +
mesylate O -
, O +
L O -
- O -
lactate O -
, O +
hydrochloride O -
, O +
di O -
- O -
hydrochloride O -
, O +
tri O -
- O -
hydrochloride O -
. O +

Hydrates O +
and O +
polymorphs O +
of O +
such O +
new O +
salt O +
forms O -
, O +
a O +
process O +
for O +
their O +
preparation O -
, O +
their O +
utility O +
in O +
therapy O +
and O +
to O +
the O +
pharmaceutical O +
compositions O +
containing O +
them O +
are O +
also O +
claimed O +
and O +
described O +
in O +
the O +
present O +
application O -
. O +

Substituted O +
spirocyclic O +
amines O +
useful O +
as O +
antidiabetic O +
compounds O +
Substituted O +
spirocyclic O +
amines O +
of O +
structural O +
formula O +
I O +
are O +
selective O +
antagonists O +
of O +
the O +
somatostatin B-Gene +
sub I-Gene -
- I-Gene -
type I-Gene +
receptor I-Gene +
5 I-Gene +
( O -
SSTR5 B-Gene -
) O +
and O +
are O +
useful O +
for O +
the O +
treatment O -
, O +
control O +
or O +
prevention O +
of O +
disorders O +
responsive O +
to O +
antagonism O +
of O +
SSTR5 B-Gene -
, O +
such O +
as O +
Type O +
2 O +
diabetes O -
, O +
insulin B-Gene +
resistance O -
, O +
lipid O +
disorders O -
, O +
obesity O -
, O +
atherosclerosis O -
, O +
metabolic O +
syndrome O -
, O +
depression O -
, O +
and O +
anxiety O -
. O +

Tapentadol O +
for O +
treating O +
pain O +
due O +
to O +
osteoarthritis O +
The O +
use O +
of O +
tapentadol O +
for O +
treating O +
pain O +
due O +
to O +
osteoarthritis O -
. O +

Formulation O +
of O +
a O +
mixture O +
of O +
free O -
- O -
b O -
- O -
ring O +
flavonoids O +
and O +
flavans O +
for O +
use O +
in O +
the O +
prevention O +
and O +
treatment O +
of O +
cognitive O +
decline O +
and O +
age O -
- O -
related O +
memory O +
impairments O +
The O +
present O +
invention O +
provides O +
a O +
novel O +
method O +
for O +
preventing O +
and O +
treating O +
memory O +
and O +
cognitive O +
impairment O +
resulting O +
from O +
oxidative O +
stress O -
, O +
inflammation O +
and O +
the O +
process O +
of O +
aging O -
, O +
as O +
well O +
as O -
, O +
neurodegenerative O +
conditions O -
. O +

The O +
method O +
is O +
comprised O +
of O +
administering O +
a O +
composition O +
comprising O +
a O +
mixture O +
of O +
Free O -
- O -
B O -
- O -
Ring O +
flavonoids O +
and O +
flavans O +
synthesized O +
and/or O +
isolated O +
from O +
a O +
single O +
plant O +
or O +
multiple O +
plants O +
to O +
a O +
host O +
in O +
need O +
thereof O -
. O +

The O +
present O +
also O +
includes O +
a O +
novel O +
method O +
for O +
simultaneously O +
inhibiting O +
expression O +
of O +
pro O -
- O -
inflammatory O +
cytokines O -
, O +
preventing O +
ROS O +
generation O +
and O +
augmenting O +
anti O -
- O -
oxidant O +
defenses O -
. O +

The O +
activity O +
of O +
this O +
composition O +
is O +
conducive O +
to O +
ultimately O +
preserving O +
cognitive O +
function O +
and O +
providing O +
a O +
level O +
of O +
neuroprotection O -
. O +

Optically O +
active O +
pyrazolylaminoquinazoline O -
, O +
and O +
pharmaceutical O +
compositions O +
and O +
methods O +
of O +
use O +
thereof O +
Provided O +
herein O +
is O +
an O +
optically O +
active O +
pyrozolylaminoquinazaline O -
, O +
and O +
pharmaceutical O +
compositions O +
thereof O -
. O +

Also O +
provided O +
herein O +
is O +
a O +
method O +
for O +
treating O -
, O +
preventing O -
, O +
or O +
ameliorating O +
one O +
or O +
more O +
symptoms O +
of O +
a O +
JAK B-Gene -
- O -
mediated O +
condition O -
, O +
disorder O -
, O +
or O +
disease O -
. O +

Further O +
provided O +
herein O +
is O +
a O +
method O +
for O +
treating O -
, O +
preventing O -
, O +
or O +
ameliorating O +
one O +
or O +
more O +
symptoms O +
of O +
a O +
proliferative O +
disease O -
, O +
inflammatory O +
disease O -
, O +
or O +
renal O +
disease O -
. O +

Bace O +
2 O +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
N-1-Benzyl-2-hydroxy-3- O -
( O -
hetero O -
) O -
arylamino O -
- O -
propyl O -
) O -
-isophthalamides O +
of O +
formula O +
I O +
having O +
BACE2 O +
inhibitory O +
activity O +
and O +
their O +
use O +
as O +
therapeutically O +
active O +
substances O -
, O +
their O +
manufacture O +
and O +
pharmaceutical O +
compositions O -
. O +

The O +
active O +
compounds O +
of O +
the O +
present O +
invention O +
are O +
useful O +
in O +
the O +
therapeutic O +
and/or O +
prophylactic O +
treatment O +
of O +
e.g. O +
type O +
2 O +
diabetes O -
. O +

Slow O -
- O -
degrading O +
polymers O +
for O +
undelayed O +
and O +
sustained O +
drug O +
delivery O +
The O +
invention O +
provides O +
polymers O +
and O +
methods O +
for O +
their O +
use O -
. O +

Certain O +
embodiments O +
of O +
the O +
invention O +
provide O +
slow O +
degrading O +
microspheres O +
for O +
undelayed O +
and O +
sustained O +
drug O +
delivery O -
. O +

Ipp B-Gene +
complex O +
as O +
marker O +
for O +
erlotinib O +
treatment O +
The O +
present O +
invention O +
provides O +
biomarkers O +
which O +
are O +
predictive O +
for O +
the O +
clinical O +
benefit O +
of O +
erlotinib O +
hydrochloride O +
treatment O +
in O +
cancer O +
patients O -
. O +

Methods O +
and O +
compositions O +
of O +
mitogen B-Gene -
- I-Gene -
activated I-Gene +
protein I-Gene +
kinase I-Gene +
( O -
mapk B-Gene -
) O +
pathway O +
inhibitors O +
for O +
treating O +
pulmonary O +
fibrosis O +
Methods O +
and O +
compositions O +
of O +
inhibitors O +
of O +
MAPK B-Gene +
kinases I-Gene +
1 I-Gene +
and I-Gene +
2 I-Gene +
( O -
MEK1 B-Gene +
and O +
MEK2 B-Gene -
, O +
or O +
together O -
, O +
MEK1 B-Gene -
/ I-Gene -
2 I-Gene -
) O -
, O +
such O +
as O +
ARRY142886 O -
, O +
and O +
their O +
use O +
in O +
inhibiting O +
MEK1 B-Gene -
/ I-Gene -
2 I-Gene +
kinase B-Gene +
activity O +
in O +
mammals O +
for O +
the O +
treatment O +
and/or O +
reversal O +
of O +
the O +
symptoms O +
of O +
pulmonary O +
fibrosis O -
. O +

MEK1 B-Gene -
/ I-Gene -
2 I-Gene +
inhibitors O +
can O +
selectively O +
inhibit O +
the O +
MAPK B-Gene -
/ O -
ERK B-Gene +
pathway O +
in O +
vivo O +
and O +
prevent O +
TGF B-Gene -
- I-Gene -
Î± I-Gene +
mediated O +
fibrosis O -
. O +

There O +
are O +
several O +
distinct O +
MAPK B-Gene +
pathways O +
that O +
are O +
important O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O -
, O +
differentiation O -
, O +
development O -
, O +
inflammation O -
, O +
survival O -
, O +
and O +
migration O -
. O +

The O +
Ras B-Gene -
- O -
Raf B-Gene -
- O -
MEK B-Gene -
- O -
ERK B-Gene +
pathway O +
( O -
a O +
key O +
component O +
of O +
the O +
MAPK B-Gene +
pathway O -
) O +
via O +
inhibition O +
of O +
MEK1 B-Gene -
/ I-Gene -
2 I-Gene +
is O +
an O +
attractive O +
strategy O +
for O +
therapeutic O +
intervention O +
in O +
idiopathic O +
pulmonary O +
fibrosis O -
, O +
because O +
inhibition O +
of O +
MEK1 B-Gene -
/ I-Gene -
2 I-Gene +
has O +
the O +
potential O +
to O +
block O +
inappropriate O +
signal O +
transduction O +
leading O +
to O +
pulmonary O +
fibrosis O -
, O +
regardless O +
of O +
the O +
upstream O +
position O +
of O +
the O +
aberration O +
causing O +
it O -
. O +

Tricyclic O +
compounds O -
, O +
compositions O -
, O +
and O +
methods O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compounds O +
of O +
Formula O +
I O -
: O +
or O +
salt O +
thereof O -
, O +
which O +
are O +
modulators O +
of O +
the O +
glucocorticoid B-Gene +
receptor I-Gene -
. O +

The O +
compounds O +
and O +
salts O +
of O +
the O +
invention O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
conditions O +
mediated O +
by O +
glucocorticoid B-Gene +
receptor I-Gene +
activity O -
. O +

Imidazo O -
[ O -
1,2 O +
a O -
] O +
pyridine O +
6 O +
carboxamide O +
derivatives O -
, O +
their O +
use O +
for O +
the O +
treatment O +
of O +
colon O +
cancer O +
and O +
their O +
method O +
of O +
manufacture O +
This O +
invention O +
relates O +
to O +
the O +
manufacture O +
of O +
novel O +
chemical O +
compounds O +
which O +
have O +
biological O +
activity O -
, O +
particularly O +
to O +
novel O +
chemical O +
compounds O +
that O +
are O +
cytotoxic O +
against O +
colon O +
cancer O +
cells O +
and O +
colon O +
cancer O +
cell O +
lines O -
. O +

The O +
manufacturing O +
of O +
said O +
chemical O +
compounds O +
displaying O +
anti O -
- O -
cancer O +
properties O +
employs O +
the O +
use O +
of O +
multi O -
- O -
component O +
chemical O +
reactions O -
. O +

The O +
object O +
of O +
this O +
invention O +
is O +
to O +
manufacture O +
and O +
isolate O +
analogues O +
of O +
imidazo O -
[ O -
1,2-a O -
] O -
pyridine O -
, O +
namely O +
compounds O +
of O +
Formula O +
1 O -
, O +
which O +
are O +
cytotoxic O +
against O +
colon O +
cancer O +
cells O -
, O +
while O +
concomitantly O +
being O +
relatively O +
inactive O +
against O +
white O +
blood O +
cells O -
. O +

wherein O -
, O +
R O +
is O +
bromo O -
, O +
methyl O -
, O +
phenyl O -
, O +
nitro O -
, O +
hydrogen O +
or O +
an O +
amide O +
functional O +
group O -
; O +
R1 O +
is O +
benzyl O -
, O +
2,6-dimethylphenyl O +
or O +
cyclohexyl O -
; O +
and O +
R2 O +
is O +
methoxy O -
, O +
benzyloxy O +
or O +
hydroxy O -
. O +

Aminotetrahydroindazoloacetic O +
Acids O +
The O +
invention O +
is O +
concerned O +
with O +
the O +
compounds O +
of O +
formula O +
I O -
: O +
and O +
pharmaceutically O +
acceptable O +
salts O +
and O +
esters O +
thereof O -
, O +
wherein O +
Q O -
, O +
W O -
, O +
X O -
, O +
R1-R5 O +
and O +
n O +
are O +
defined O +
in O +
the O +
detailed O +
description O +
and O +
claims O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
relates O +
to O +
methods O +
of O +
manufacturing O +
and O +
using O +
the O +
compounds O +
of O +
formula O +
I O +
as O +
well O +
as O +
pharmaceutical O +
compositions O +
containing O +
such O +
compounds O -
. O +

The O +
compounds O +
of O +
formula O +
I O +
are O +
antagonists O +
at O +
the O +
CRTH2 B-Gene +
receptor O +
and O +
may O +
be O +
useful O +
in O +
treating O +
diseases O +
and O +
disorders O +
associated O +
with O +
that O +
receptor O +
such O +
as O +
asthma O -
. O +

5-membered O +
heteroaryl O +
derivatives O +
used O +
as O +
sphingosine O +
1- O +
phosphate O +
receptor O +
agonists O +
5-membered O +
heteroaryl O +
derivatives O +
of O +
formula O +
( O -
I O -
) O +
or O +
salts O +
thereof O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
their O +
uses O +
in O +
the O +
treatment O +
of O +
various O +
disorders O +
mediated O +
by O +
S1P1 O +
receptors O +
are O +
disclosed O -
. O +

Ready O +
to O +
Use O +
Ketorolac O +
Formulations O +
Disclosed O +
in O +
certain O +
embodiments O +
is O +
a O +
pharmaceutical O +
composition O +
for O +
parenteral O +
administration O +
comprising O -
: O +
an O +
aqueous O +
solution O +
comprising O +
ketorolac O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
in O +
an O +
amount O +
from O +
about O +
0.1 O +
mg O -
/ O -
mL O +
to O +
about O +
10 O +
mg O -
/ O -
mL O -
; O +
and O +
a O +
pharmaceutically O +
acceptable O +
excipient O -
; O +
wherein O +
the O +
formulation O +
is O +
substantially O +
free O +
of O +
alcohol O -
. O +

Synergistic O +
treatment O +
of O +
cancer O +
using O +
immunomers O +
in O +
conjunction O +
with O +
chemotherapeutic O +
agents O +
The O +
invention O +
relates O +
to O +
the O +
therapeutic O +
use O +
of O +
immunostimulatory O +
oligonucleotides O +
and/or O +
immunomers O +
in O +
combination O +
with O +
chemotherapeutic O +
agents O +
to O +
provide O +
a O +
synergistic O +
therapeutic O +
effect O -
. O +

Gene O +
expression O +
levels O +
of O +
egfr B-Gene -
, O +
vegfr2 B-Gene -
, O +
and O +
ercc1 B-Gene +
associated O +
with O +
clinical O +
outcomes O +
of O +
chemotherapy O +
The O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
identifying O +
a O +
cancer O +
patient O +
suitable O +
for O +
anti O -
- O -
VEGF B-Gene +
therapy O -
. O +

After O +
determining O +
if O +
a O +
patient O +
is O +
likely O +
to O +
be O +
successfully O +
treated O -
, O +
the O +
invention O +
also O +
provides O +
methods O +
for O +
treating O +
the O +
patients O -
. O +

Product O +
for O +
the O +
preparation O +
of O +
dermatological O -
, O +
cosmetic O +
or O +
cosmeceutical O +
compositions O +
intended O +
for O +
skin O +
treatment O +
The O +
present O +
invention O +
relates O +
to O +
a O +
product O +
obtained O +
from O +
gastropod O +
spawn O -
, O +
to O +
be O +
used O +
to O +
prepare O +
dermatological O -
, O +
cosmetic O +
or O +
cosmeceutical O +
compositions O +
designed O +
for O +
skin O +
care O -
; O +
said O +
product O +
has O +
the O +
capacity O +
to O +
activate O +
and O +
mobilise O +
skin O +
stem O +
cells O -
, O +
as O +
well O +
as O +
prevent O +
the O +
loss O +
thereof O +
that O +
takes O +
place O +
as O +
a O +
consequence O +
of O +
chronological O +
and O +
premature O +
ageing O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
the O +
process O +
followed O +
in O +
order O +
to O +
obtain O +
said O +
product O -
. O +

Effective O +
Antitumor O +
Treatments O +
ET-743 O +
is O +
used O +
in O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
an O +
effective O +
treatment O +
of O +
a O +
tumour O +
by O +
combination O +
therapy O +
employing O +
ET-743 O +
with O +
another O +
drug O -
. O +

Transdermal O +
delivery O +
of O +
beneficial O +
substances O +
effected O +
by O +
a O +
hostile O +
biophysical O +
environment O +
The O +
present O +
invention O +
generally O +
relates O +
to O +
the O +
transdermal O +
delivery O +
of O +
substances O +
In O +
one O +
aspect O -
, O +
various O +
methods O +
for O +
the O +
transdermal O +
delivery O +
of O +
beneficial O +
substances O +
are O +
disclosed O -
. O +

By O +
creating O +
a O +
hostile O +
biophysical O +
environment O -
, O +
beneficial O +
substances O +
may O +
be O +
delivered O -
, O +
according O +
to O +
certain O +
embodiments O -
, O +
through O +
the O +
stratum O +
corneum O +
of O +
the O +
skin O +
into O +
the O +
body O -
. O +

Beneficial O +
substances O +
include O -
, O +
but O +
are O +
not O +
limited O +
to O -
, O +
pharmaceutical O +
agents O -
, O +
drugs O -
, O +
vitamins O -
, O +
co O -
- O -
factors O -
, O +
peptides O -
, O +
dietary O +
supplements O -
, O +
and O +
others O -
. O +

The O +
beneficial O +
effects O +
disclosed O +
include O -
, O +
for O +
instance O -
, O +
relief O +
of O +
pain O +
and O +
inflammation O -
, O +
prevention O +
and O +
healing O +
of O +
ulcers O +
of O +
the O +
skin O -
, O +
relief O +
of O +
headache O -
, O +
improved O +
sexual O +
function O +
and O +
enjoyment O -
, O +
growth O +
of O +
hair O +
on O +
the O +
scalp O -
, O +
improving O +
muscle O +
size O +
and/or O +
function O -
, O +
removing O +
body O +
fat O +
and/or O +
cellulite O -
, O +
treating O +
cancer O -
, O +
treating O +
viral O +
infections O +
and O +
others O -
. O +

A O +
hostile O +
biophysical O +
environment O +
may O +
also O +
be O +
used O +
in O +
conjunction O +
with O +
systems O +
and O +
methods O +
for O +
increasing O +
local O +
blood O +
flow O -
, O +
according O +
to O +
one O +
set O +
of O +
embodiments O -
. O +

Low O +
molecular O +
weight O +
cyclin O +
e O +
( O -
lmw O -
- O -
e O -
) O +
as O +
a O +
biomarker O +
for O +
personalization O +
of O +
cancer O +
therapies O +
Methods O +
are O +
disclosed O +
for O +
predicting O +
a O +
patient O +
response O +
to O +
anti O -
- O -
Her2 O +
therapy O +
or O +
anti O -
- O -
aromatase O +
therapy O -
. O +

In O +
certain O +
embodiments O -
, O +
the O +
methods O +
involve O +
the O +
identification O +
of O +
low O +
molecular O +
weight O +
cyclin O +
E O +
( O -
LMW O -
- O -
E O -
) O +
in O +
cancers O -
, O +
such O +
as O +
breast O +
cancer O +
cells O -
, O +
as O +
a O +
predictive O +
and O +
prognostic O +
marker O -
. O +

In O +
further O +
embodiments O -
, O +
LMW O -
- O -
E O +
expression O +
by O +
a O +
cancerous O +
or O +
pre O -
- O -
cancerous O +
cell O +
may O +
be O +
used O +
to O +
predict O +
response O +
to O +
an O +
aromatase O +
inhibitor O +
and/or O +
CDK2 O +
inhibitor O -
, O +
and O +
determination O +
of O +
LMW O -
- O -
E O +
expression O +
may O +
be O +
used O +
in O +
the O +
personalization O +
of O +
cancer O +
therapies O -
. O +

Compound O +
inhibiting O +
in O +
vivo O +
phosphorus O +
transport O +
and O +
medicine O +
containing O +
the O +
same O +
An O +
objective O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O +
compounds O +
that O +
can O +
effectively O +
suppress O +
the O +
concentration O +
of O +
phosphorus O +
in O +
serum O +
to O +
effectively O +
prevent O +
or O +
treat O +
diseases O +
induced O +
by O +
an O +
increase O +
in O +
concentration O +
of O +
phosphate O +
in O +
serum O -
. O +

The O +
compounds O +
according O +
to O +
the O +
present O +
invention O +
are O +
compounds O +
represented O +
by O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutically O +
acceptable O +
salts O +
and O +
solvates O +
thereof O -
: O +
wherein O +
A O +
represents O +
an O +
optionally O +
substituted O +
five- O +
to O +
nine O -
- O -
membered O +
unsaturated O +
carbocyclic O +
moiety O +
or O +
a O +
five- O +
to O +
nine O -
- O -
membered O +
unsaturated O +
heterocyclic O +
moiety O -
, O +
and O +
represents O +
a O +
single O +
bond O +
or O +
a O +
double O +
bond O -
, O +
R5 O +
represents O +
optionally O +
substituted O +
aryl O +
or O +
the O +
like O -
, O +
Z O +
represents O +
â€”N O -
â• O -
CHR6R7 O +
or O +
the O +
like O -
, O +
R6 O +
and O +
R7 O +
represent O +
H O -
, O +
optionally O +
substituted O +
alkyl O -
, O +
optionally O +
substituted O +
aryl O +
or O +
the O +
like O -
, O +
R101 O +
and O +
R102 O +
together O +
form O +
â• O -
O O -
, O +
and O +
R103 O +
and O +
R104 O +
represent O +
H O -
, O +
or O +
R101 O +
and O +
R104 O +
together O +
from O +
a O +
bond O -
, O +
and O +
R102 O +
and O +
R103 O +
together O +
form O +
a O +
bond O -
. O +

Facially O +
Amphiphilic O +
Compounds O -
, O +
Compositions O -
, O +
And O +

Uses O +
Thereof O +

In O +
Treating O +
Cancer O +
The O +
present O +
invention O +
discloses O +
compositions O +
of O +
facially O +
amphiphilic O +
compounds O +
and O +
their O +
use O +
in O +
methods O +
for O +
treating O +
or O +
reducing O +
cancers O +
in O +
animals O -
, O +
such O +
as O +
humans O -
. O +

Quinolinone O +
PDE2 B-Gene +
Inhibitors O +
The O +
present O +
invention O +
is O +
directed O +
to O +
quinolinone O +
compounds O +
which O +
are O +
useful O +
as O +
therapeutic O +
agents O +
for O +
the O +
treatment O +
of O +
central O +
nervous O +
system O +
disorders O +
associated O +
with O +
phosphodiesterase B-Gene +
2 I-Gene +
( O -
PDE2 B-Gene -
) O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
such O +
compounds O +
for O +
treating O +
neurological O +
and O +
psychiatric O +
disorders O -
, O +
such O +
as O +
schizophrenia O -
, O +
psychosis O +
or O +
Huntington O -
's O +
disease O -
, O +
and O +
those O +
associated O +
with O +
striatal O +
hypofunction O +
or O +
basal O +
ganglia O +
dysfunction O -
. O +

Isogenic O +
human O +
cell O +
lines O +
comprising O +
mutated O +
cancer O +
alleles O +
and O +
process O +
using O +
the O +
cell O +
lines O +
Isogenic O +
human O +
cell O +
lines O +
comprising O +
at O +
least O +
one O +
mutated O +
cancer O +
allele O +
under O +
the O +
control O +
of O +
the O +
cell O +
line O +
endogenous O +
promoter O -
, O +
which O +
corresponds O +
to O +
the O +
wild O -
- O -
type O +
cancer O +
allele O +
promoter O +
are O +
disclosed O -
, O +
as O +
well O +
as O +
an O +
in O +
vitro O +
process O +
for O +
determining O +
sensitivity O -
/ O -
resistance O +
of O +
a O +
patient O +
suffering O +
from O +
a O +
tumor O +
to O +
a O +
pharmacological O +
agent O +
comprising O +
the O +
following O +
steps O -
: O +
a O -
) O +
identifying O +
at O +
least O +
one O +
mutated O +
cancer O +
allele O +
in O +
a O +
tissue O +
affected O +
by O +
a O +
tumor O +
of O +
said O +
patient O -
; O +
b O -
) O +
providing O +
an O +
isogenic O +
human O +
cell O +
line O +
representative O +
of O +
the O +
tissue O -
, O +
wherein O +
the O +
cell O +
line O +
comprises O +
at O +
least O +
the O +
identified O +
mutated O +
cancer O +
allele O -
, O +
which O +
is O +
under O +
the O +
control O +
of O +
the O +
cell O +
line O +
endogenous O +
promoter O +
corresponding O +
to O +
the O +
wild O -
- O -
type O +
cancer O +
allele O +
promoter O -
; O +
c O -
) O +
putting O +
in O +
contact O +
said O +
cell O +
line O +
with O +
the O +
pharmacological O +
agent O -
; O +
d O -
) O +
determining O +
a O +
variation O +
of O +
proliferation O -
, O +
apoptosis O +
or O +
cytotoxicity O +
of O +
the O +
cell O +
line O +
in O +
presence O +
of O +
the O +
pharmacological O +
agent O -
; O +
wherein O +
the O +
variation O +
of O +
proliferation O -
, O +
apoptosis O +
car O +
cytotoxicity O +
indicative O +
of O +
the O +
sensitivity O -
/ O -
resistance O +
of O +
the O +
patient O +
tumor O +
to O +
the O +
pharmacological O +
agent O -
. O +

PAR-1 B-Gene +
Activation O +
by O +
Metalloproteinase-1 B-Gene +
( O -
MMP-1 B-Gene -
) O +
Matrix B-Gene +
metalloproteases I-Gene +
( O -
MMPs B-Gene -
) O +
play O +
many O +
important O +
roles O +
in O +
normal O +
and O +
pathological O +
remodeling O +
processes O +
including O +
atherothrombotic O +
disease O -
, O +
inflammation O -
, O +
angiogenesis O +
and O +
cancer O -
. O +

This O +
invention O +
relates O +
to O +
the O +
activation O +
of O +
protease B-Gene -
- I-Gene -
activated I-Gene +
receptor-1 I-Gene +
( O -
PAR-1 B-Gene -
) O +
by O +
endogenous O +
platelet O +
MMP-1 B-Gene +
collagenase B-Gene +
on O +
the O +
surface O +
of O +
platelets O -
. O +

Exposure O +
of O +
platelets O +
to O +
fibrillar O +
collagen O +
converts O +
the O +
surface O -
- O -
bound O +
pro B-Gene -
- I-Gene -
MMP-1 I-Gene +
zymogen O +
to O +
active O +
MMP-1 B-Gene -
, O +
which O +
promotes O +
aggregation O +
through O +
PAR-1 B-Gene -
, O +
MMP-1 B-Gene +
is O +
shown O +
to O +
cleave O +
the O +
PAR-1 B-Gene +
extracellular I-Gene +
domain I-Gene +
at O +
a O +
novel O +
site O -
, O +
which O +
then O +
strongly O +
activates O +
Rho B-Gene -
- O -
GTP O +
signaling O +
pathways O -
, O +
cell O +
shape O +
change O +
and O +
motility O -
, O +
and O +
MAPK B-Gene +
signaling O -
. O +

Blockade O +
of O +
MMP B-Gene -
- O -
PAR B-Gene +
1 I-Gene +
suppresses O +
thrombogenesis O +
under O +
arterial O +
flow O +
conditions O +
and O +
inhibited O +
thrombosis O +
in O +
animals O -
. O +

These O +
studies O +
provide O +
a O +
link O +
between O +
matrix O -
- O -
dependent O +
activation O +
of O +
metalloproteases B-Gene +
and O +
platelet O -
- O -
G B-Gene +
protein I-Gene +
signaling O +
and O +
identify O +
MMP-1 B-Gene -
/ O -
PAR-1 B-Gene +
as O +
a O +
new O +
target O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
arterial O +
thrombosis O +
and O +
other O +
thrombotic O +
diseases O -
. O +

Biomarkers O +
Related O +
to O +
Insulin B-Gene +
Resistance O +
and O +
Methods O +
using O +
the O +
Same O +
Biomarkers O +
relating O +
to O +
glucose O +
disposal O +
rate O -
, O +
insulin B-Gene +
resistance O -
, O +
and/or O +
insulin B-Gene +
resistance O -
- O -
related O +
disorders O +
are O +
provided O -
. O +

Methods O +
based O +
on O +
the O +
same O +
biomarkers O +
are O +
also O +
provided O -
. O +

Compositions O +
and O +
methods O +
for O +
modulating O +
d1-d2 B-Gene +
dopamine I-Gene +
receptor I-Gene +
interaction O +
and O +
function O +
The O +
present O +
invention O +
provides O +
for O +
prevention O +
and/or O +
treatment O +
of O +
neurological O +
or O +
neuropsychiatric O +
disorders O +
involving O +
abnormal O +
D1-D2 B-Gene +
dopamine I-Gene +
receptor I-Gene +
coupling O +
and/or O +
activation O -
. O +

Methods O +
and O +
agents O +
are O +
provided O +
for O +
modulating O +
dopamine O +
receptor O +
function O +
arising O +
from O +
D1-D2 B-Gene +
coupling O +
and/or O +
activation O -
. O +

Agents O +
of O +
the O +
present O +
invention O +
include O +
fragments O +
of O +
D2 B-Gene +
receptor I-Gene +
or O +
D1 B-Gene +
receptor I-Gene +
that O +
can O +
disrupt O +
D1-D2 B-Gene +
coupling O -
. O +

( O -
s O -
) O -
-n O -
- O -
methylnaltrexone O +

This O +
invention O +
relates O +
to O +
S O -
- O -
MNTX O -
, O +
methods O +
of O +
producing O +
S O -
- O -
MNTX O -
, O +
pharmaceutical O +
preparations O +
comprising O +
S O -
- O -
MNTX O +
and O +
methods O +
for O +
their O +
use O -
. O +

Small O +
Molecule O +
Antagonists O +
of O +
Phosphatidylinositol-3,4,5-Triphosphate O +
( O -
PIP3 O -
) O +
and O +
Uses O +
Thereof O +
Disclosed O +
are O +
a O +
new O +
class O +
of O +
non O -
- O -
lipid O +
small O +
molecule O +
inhibitors O +
which O +
interfere O +
with O +
the O +
interaction O +
between O +
PIP3 O +
and O +
pleckstrin O +
homology O +
domains O -
. O +

These O +
molecules O +
target O +
a O +
broad O +
range O +
of O +
PIP3-dependent O +
signaling O +
events O +
in O +
vitro O +
and O +
exert O +
significant O +
anti O -
- O -
tumor O +
activity O +
in O +
vivo O -
. O +

The O +
small O +
molecule O +
inhibitors O +
of O +
the O +
invention O +
can O +
be O +
used O +
alone O +
or O +
together O +
with O +
tumor B-Gene +
necrosis I-Gene +
factor I-Gene +
( O -
TNF B-Gene -
) O -
-related O +
apoptosis O -
- O -
inducing O +
ligand O +
( O -
TRAIL O -
) O +
or O +
other O +
cancer O +
medicament O +
to O +
treat O +
cancer O -
. O +

Small O +
molecule O +
inhibitors O +
of O +
the O +
invention O +
act O +
synergistically O +
in O +
combination O +
with O +
TRAIL O +
in O +
treating O +
cancer O -
. O +

Pharmaceutical O +
compositions O +
and O +
methods O +
for O +
treating O +
cancer O +
are O +
provided O -
. O +

Topical O -
, O +
periocular O -
, O +
or O +
intraocular O +
use O +
of O +
tocotrienols O +
for O +
the O +
treatment O +
of O +
ophthalmic O +
diseases O +
A O +
method O +
for O +
preventing O -
, O +
reducing O -
, O +
ameliorating O +
or O +
treating O +
ophthalmic O +
disorders O +
associated O +
with O +
neurodegenerative O +
diseases O +
or O +
trauma O -
, O +
comprising O +
the O +
topical O -
, O +
periocular O -
, O +
or O +
intraocular O +
application O +
of O +
an O +
ophthalmic O +
formulation O +
comprising O +
a O +
therapeutically O +
effective O +
amount O +
of O +
one O +
or O +
more O +
ophthalmic O +
agents O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
alpha O -
- O -
tocotrienol O -
, O +
beta O -
- O -
tocotrienol O -
, O +
gamma O -
- O -
tocotrienol O -
, O +
delta O -
- O -
tocotrienol O -
, O +
or O +
esters O +
or O +
mixtures O +
thereof O +
is O +
disclosed O -
. O +

Use O +
of O +
tocotrienols O +
for O +
the O +
prevention O -
, O +
reduction O -
, O +
amelioration O +
or O +
treatment O +
of O +
ophthalmic O +
disorders O +
that O +
are O -
, O +
or O +
that O +
are O +
associated O +
with O -
, O +
mitochondrial O +
diseases O +
is O +
also O +
discussed O -
. O +

Topical O +
ophthalmic O +
formulations O +
comprising O +
tocotrienols O +
are O +
also O +
discussed O -
. O +

Method O +
and O +
Pharmaceutical O +
Composition O +
for O +
Use O +
in O +
the O +
Treatment O +
of O +
Neurodegenerative O +
Disorders O +
The O +
invention O +
relates O +
to O +
compounds O +
which O +
activate O +
the O +
BASIGIN O +
signaling O +
pathway O -
, O +
preferably O +
agonists O +
of O +
BASIGIN O -
, O +
for O +
the O +
treatment O +
of O +
neurodegenerative O +
disorders O -
. O +

Microcapsules O +
containing O +
salts O +
for O +
food O +
products O +
A O +
composition O +
for O +
delivering O +
edible O +
salts O +
into O +
food O +
products O +
via O +
microcapsules O +
having O +
a O +
protein O -
- O -
polysaccharide O +
shell O +
matrix O +
and O +
an O +
edible O +
salt O -
- O -
containing O +
active O +
material O -
. O +

A O +
method O +
of O +
treating O +
osteoporosis O +
is O +
also O +
disclosed O -
. O +

Compositions O +
for O +
Inhibiting O +
Growth O +
of O +
Cancer O +
Stem O +
Cells O +

The O +
present O +
invention O +
is O +
a O +
biomarker O +
of O +
chemotherapeutic O +
drug O -
- O -
resistant O +
cancer O +
stem O +
cells O +
and O +
a O +
method O +
of O +
inhibiting O +
the O +
growth O +
of O +
drug O -
- O -
resistant O +
cancer O +
stem O +
cells O -
. O +

In O +
one O +
embodiment O +
the O +
cancer O +
stem O +
cells O +
are O +
testicular O +
cancer O +
germ O +
cells O -
. O +

In O +
another O +
embodiment O +
the O +
present O +
invention O +
is O +
a O +
method O +
of O +
overcoming O +
drug O +
resistance O +
in O +
cancer O +
treatment O +
where O +
the O +
combination O +
of O +
low O +
dose O +
decitabine O +
and O +
administration O +
of O +
a O +
chemotherapeutic O +
drug O +
to O +
which O +
cancer O +
cells O +
were O +
resistant O +
results O +
in O +
successful O +
cancer O +
treatment O -
. O +

Homeopathic O +
Formulations O +
For O +
Treatment O +
Of O +
Herpes O +
Virus O +
Symptoms O +
Compositions O +
and O +
methods O +
of O +
preparing O +
and O +
using O +
such O +
compositions O +
to O +
treat O +
the O +
symptoms O +
of O +
herpes O +
virus O -
. O +

Methods O +
for O +
treating O +
cancer O +
and O +
non O -
- O -
neoplastic O +
conditions O +
Compounds O +
that O +
selectively O +
inhibit O +
pathological O +
production O +
of O +
human B-Gene +
vascular I-Gene +
endothelial I-Gene +
growth I-Gene +
factor I-Gene +
( O -
VEGF B-Gene -
) O +
and O +
compositions O +
comprising O +
such O +
Compounds O +
are O +
described O -
. O +

Compounds O +
that O +
inhibit O +
viral O +
replication O +
or O +
the O +
production O +
of O +
viral O +
RNA O +
or O +
DNA O +
or O +
viral O +
protein O +
and O +
compositions O +
comprising O +
such O +
Compounds O +
are O +
described O -
. O +

Also O +
described O +
are O +
methods O +
of O +
reducing O +
VEGF B-Gene +
using O +
such O +
Compounds O +
and O +
methods O +
for O +
treating O +
cancer O +
and O +
non O -
- O -
neoplastic O +
conditions O +
involving O +
the O +
administration O +
of O +
such O +
Compounds O -
. O +

Further O +
described O +
are O +
methods O +
of O +
inhibiting O +
viral O +
replication O +
or O +
the O +
production O +
of O +
viral O +
RNA O +
or O +
DNA O +
or O +
viral O +
protein O +
using O +
such O +
Compounds O +
and O +
methods O +
for O +
treating O +
viral O +
infections O +
involving O +
the O +
administration O +
of O +
such O +
Compounds O -
. O +

The O +
Compounds O +
may O +
be O +
administered O +
as O +
a O +
single O +
agent O +
therapy O +
or O +
in O +
combination O +
with O +
one O +
or O +
more O +
additional O +
therapies O +
to O +
a O +
human O +
in O +
need O +
of O +
such O +
treatments O -
. O +

Tricyclic O +
and O +
Tetracyclic O +
Systems O +
with O +
Activity O +
on O +
the O +
Central O +
Nervous O +
and O +
Vascular O +
Systems O +

The O +
present O +
invention O +
relates O +
to O +
chemistry O +
and O +
pharmacy O +
and O -
, O +
in O +
particular O -
, O +
to O +
the O +
production O +
of O +
novel O +
molecular O +
entities O -
, O +
tricyclic O +
and O +
tetracyclic O +
derivatives O +
of O +
benzodiazepine O -
, O +
pyridodiazepine O +
and O +
pyrimidodiazepine O +
type O +
fused O +
with O +
1,4-dihydropyridine O +
derivatives O -
, O +
having O +
an O +
effect O +
on O +
the O +
central O -
- O -
nervous O +
and O +
vascular O +
systems O -
. O +

Derivatives O +
containing O +
a O +
dihydropyridine O +
ring O +
are O +
used O -
, O +
by O +
means O +
of O +
reactions O +
with O +
compounds O +
of O +
the O +
ortho O -
- O -
phenylenediamine O -
, O +
ortho O -
- O -
diaminopyridine O +
and O +
ortho O -
- O -
diaminopyrimidine O +
type O -
, O +
and O +
also O +
subsequent O +
conversions O +
to O +
some O +
thereof O -
, O +
to O +
obtain O +
tricyclic O +
and O +
tetracyclic O +
derivatives O +
of O +
general O +
formula O +
I O -
- O -
XII O +
that O +
contain O +
a O +
diazepine O +
or O +
diazepinone O +
nucleus O +
fused O +
to O +
a O +
1,4-dihydropyridine O +
nucleus O -
, O +
in O +
which O +
the O +
A O +
ring O +
is O +
a O +
substituted O +
or O +
unsubstituted O +
benzene O -
, O +
pyridine O +
or O +
pyrimidine O +
ring O -
. O +

These O +
molecular O +
entities O +
exhibit O +
GABAergica O +
and O +
modulating O +
action O +
in O +
the O +
case O +
of O +
calcium O +
channels O +
which O +
can O +
be O +
used O +
in O +
the O +
treatment O +
of O +
cardiovascular O -
, O +
cerebrovascular O -
, O +
neurodegenerative O -
, O +
neuropsychiatric O +
and O +
neurological O +
disorders O -
. O +

Combination O +
therapy O +
using O +
a O +
beta B-Gene +
3 I-Gene +
adrenergic I-Gene +
receptor I-Gene +
agonists O +
and O +
an O +
antimuscarinic O +
agent O +
Described O +
herein O +
is O +
an O +
improved O +
method O +
of O +
treating O +
overactive O +
bladder O -
, O +
wherein O +
the O +
method O +
comprises O +
administering O +
to O +
a O +
patient O +
in O +
need O +
thereof O +
a O +
beta B-Gene +
3 I-Gene +
adrenergic I-Gene +
receptor I-Gene +
agonist O -
, O +
an O +
antimuscarinic O +
agent O -
, O +
and O +
an O +
optional O +
selective O +
M2 B-Gene +
antagonist O -
. O +

Such O +
combination O +
therapy O +
provides O +
improved O +
efficacy O +
and/or O +
reduced O +
side O +
effects O -
. O +

Novel O +
Tetrahydroisoquinoline O +
Compounds O +
The O +
present O +
invention O +
relates O +
to O +
a O +
compound O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
having O +
an O +
excellent O +
DGAT B-Gene +
inhibitory O +
effect O +
and O +
feeding O +
suppressant O +
effect O -
. O +

The O +
present O +
invention O +
provides O +
trans-6- O -
[ O -
3- O -
( O -
2,4-difluoro O -
- O -
phenyl O -
) O -
-ureido O -
] O -
-3,4-dihydro-1H O -
- O -
isoquinoline-2-carboxylic O +
acid O +
4-carboxymethyl O -
- O -
cyclohexyl O +
ester O -
, O +
trans-6- O -
[ O -
3- O -
( O -
2-chloro O -
- O -
phenyl O -
) O -
-ureido O -
] O -
-3,4-dihydro-1H O -
- O -
isoquinoline-2-carboxylic O +
acid O +
4-carboxymethyl O -
- O -
cyclohexyl O +
ester O -
, O +
trans-6- O -
[ O -
3- O -
( O -
2,3-difluoro O -
- O -
phenyl O -
) O -
-ureido O -
] O -
-3,4-dihydro-1H O -
- O -
isoquinoline-2-carboxylic O +
acid O +
4-carboxymethyl O -
- O -
cyclohexyl O +
ester O -
, O +
trans-6- O -
[ O -
3- O -
( O -
2,5-difluoro O -
- O -
phenyl O -
) O -
-ureido O -
] O -
-3,4-dihydro-1H O -
- O -
isoquinoline-2-carboxylic O +
acid O +
4-carboxymethyl O -
- O -
cyclohexyl O +
ester O -
, O +
trans-6- O -
[ O -
3- O -
( O -
2,6-difluoro O -
- O -
phenyl O -
) O -
-ureido O -
] O -
-3,4-dihydro-1H O -
- O -
isoquinoline-2-carboxylic O +
acid O +
4-carboxymethyl O -
- O -
cyclohexyl O +
ester O -
, O +
or O +
the O +
like O -
, O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O -
. O +

Selenium O +
Nanoparticles O +
with O +
Improvded O +
Biological O +
Effects O +
Novel O +
methods O +
for O +
biological O +
effective O -
, O +
stable O +
amorphous O +
and O +
monoclinic O +
selenium O +
nanoparticles O +
are O +
disclosed O -
. O +

They O +
are O +
prepared O +
by O +
reacting O +
selenium O +
source O +
with O +
a O +
reducing O +
agent O +
or O +
an O +
oxidative O +
agent O +
in O +
an O +
aqueous O +
media O +
at O +
a O +
temperature O +
between O +
0 O -
- O -
100 O -
Â° O +
C. O +
in O +
the O +
presence O +
of O +
selenium O +
binding O +
polymer O +
molecules O +
such O +
as O +
poly O -
/ O -
oligopeptide O +
acids O +
or O +
peptone O +
or O +
nucleic O +
acids O +
or O +
poly O -
/ O -
oligosaccharide O +
or O +
their O +
mixtures O -
. O +

Methods O +
of O +
treating O +
or O +
preventing O +
influenza O +
associated O +
illness O +
with O +
oxidative O +
reductive O +
potential O +
water O +
solutions O +
The O +
present O +
invention O +
provides O +
methods O +
of O +
treating O -
, O +
reducing O -
, O +
and/or O +
preventing O +
the O +
incidence O +
of O +
an O +
influenza O +
related O +
viral O +
infection O +
in O +
a O +
patient O +
comprising O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
an O +
oxidative O +
reductive O +
potential O +
( O -
ORP O -
) O +
water O +
solution O -
. O +

The O +
present O +
invention O +
also O +
provides O +
methods O +
of O +
reducing O +
or O +
preventing O +
the O +
incidence O +
of O +
an O +
influenza O +
related O +
viral O +
infection O +
in O +
a O +
patient O +
associated O +
with O +
a O +
medical O +
device O +
comprising O +
contacting O +
the O +
medical O +
device O +
with O +
an O +
effective O +
amount O +
of O +
an O +
ORP O +
water O +
solution O -
. O +

Versatile O +
nanoparticulate O +
biomaterial O +
for O +
controlled O +
delivery O +
and/or O +
containment O +
of O +
therapeutic O +
and O +
diagnostic O +
material O +
The O +
invention O +
provides O +
compositions O +
for O +
controlled O +
delivery O +
and/or O +
containment O +
of O +
therapeutic O +
and/or O +
diagnostic O +
agents O +
comprising O +
the O +
agent O +
or O +
agents O +
encapsulated O +
by O +
a O +
matrix O +
containing O +
chitosan O -
, O +
polyethylene O +
glycol O +
( O -
PEG O -
) O +
and/or O +
polyvinyl O +
alcohol O +
( O -
PVA O -
) O -
, O +
and O +
tetra O -
- O -
methoxy O -
- O -
ortho O -
- O -
silicate O +
( O -
TMOS O -
) O +
or O +
tetra O -
- O -
ethoxy O -
- O -
ortho O -
- O -
silicate O +
( O -
TEOS O -
) O -
, O +
as O +
well O +
as O +
methods O +
for O +
preparing O +
the O +
compositions O -
, O +
and O +
uses O +
of O +
the O +
compositions O +
for O +
therapy O +
and O +
imaging O -
. O +

Compositions O +
of O +
omega O +
fatty O +
acids O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
dental O +
caries O +
resulting O +
from O +
oral O +
infections O +
The O +
present O +
invention O +
discloses O +
compositions O +
of O +
omega O +
polyunsaturated O +
fatty O +
acids O +
for O +
controlling O +
and O +
preventing O +
dental O +
caries O +
resulting O +
from O +
oral O +
infections O -
. O +

The O +
compositions O +
of O +
fatty O +
acids O +
include O +
omega-3 O +
fatty O +
acids O -
, O +
omega-6 O +
fatty O +
acids O -
, O +
and O +
other O +
fatty O +
acids O -
, O +
for O +
their O +
synergistic O +
bioactivity O +
against O +
cariogenic O +
pathogens O -
. O +

The O +
application O +
of O +
this O +
composition O +
can O +
be O +
used O +
for O +
the O +
preparation O +
of O +
drugs O -
, O +
nutritional O +
supplements O -
, O +
food O +
and O +
daily O +
necessities O +
with O +
oral O +
health O +
care O +
and O +
therapeutic O +
effects O -
. O +

Proteostasis O +
regulators O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compounds O +
of O +
Formulae O +
( O -
I O -
) O -
, O +
( O -
II O -
) O -
, O +
( O -
III O -
) O -
, O +
( O -
IV O -
) O -
, O +
( O -
V O -
) O -
, O +
( O -
VI O -
) O -
, O +
( O -
VII O -
) O -
, O +
and O +
( O -
VIII O -
) O -
, O +
pharmaceutical O +
compositions O +
thereof O +
and O +
methods O +
of O +
use O +
thereof O +
in O +
the O +
treatment O +
of O +
conditions O +
associated O +
with O +
a O +
dysfunction O +
in O +
proteostasis O -
. O +

Molecular O +
Predictors O +
of O +
Therapeutic O +
Response O +
to O +
Specific O +
Anti O -
- O -
Cancer O +
Agents O +
Herein O +
is O +
described O +
the O +
use O +
of O +
a O +
collection O +
of O +
50 O +
breast O +
cancer O +
cell O +
lines O +
to O +
match O +
responses O +
to O +
77 O +
conventional O +
and O +
experimental O +
therapeutic O +
agents O +
with O +
transcriptional O -
, O +
proteomic O +
and O +
genomic O +
subtypes O +
found O +
in O +
primary O +
tumors O -
. O +

Almost O +
all O +
compounds O +
produced O +
strong O +
differential O +
responses O +
across O +
the O +
cell O +
lines O +
produced O +
responses O +
that O +
were O +
associated O +
with O +
transcriptional O +
and O +
proteomic O +
subtypes O +
and O +
produced O +
responses O +
that O +
were O +
associated O +
with O +
recurrent O +
genome O +
copy O +
number O +
abnormalities O -
. O +

These O +
associations O +
can O +
now O +
be O +
incorporated O +
into O +
clinical O +
trials O +
that O +
test O +
subtype O +
markers O +
and O +
clinical O +
responses O +
simultaneously O -
. O +

Method O +
of O +
regulating O +
the O +
expression O +
level O +
of O +
survival B-Gene +
of I-Gene +
motor I-Gene +
neuron I-Gene +
1 I-Gene +
( O -
smn1 B-Gene -
) O +
and O +
detecting O +
enzyme O +
activity O +
of O +
ubiquitin B-Gene +
carboxyl I-Gene -
- I-Gene -
terminal I-Gene +
hydrolase I-Gene +
l1 I-Gene +
( O -
uchl1 B-Gene -
) O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
of O +
regulating O +
the O +
expression O +
level O +
of O +
survival B-Gene +
of I-Gene +
motor I-Gene +
neuron I-Gene +
1 I-Gene +
( O -
SMN1 B-Gene -
) O +
comprising O +
administering O +
to O +
a O +
subject O +
in O +
need O +
thereof O +
a O +
therapeutically O +
effective O +
amount O +
of O +
ubiquitin B-Gene +
carboxyl I-Gene -
- I-Gene -
terminal I-Gene +
hydrolase I-Gene +
L1 I-Gene +
( O -
UCHL1 B-Gene -
) O +
regulator O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
a O +
method O +
of O +
detecting O +
enzyme O +
activity O +
of O +
ubiquitin B-Gene +
carboxyl I-Gene -
- I-Gene -
terminal I-Gene +
hydrolase I-Gene +
L1 I-Gene +
( O -
UCHL1 B-Gene -
) O +
in O +
human O +
fibroblasts O +
comprising O +
detecting O +
protein O +
expression O +
level O +
of O +
survival B-Gene +
of I-Gene +
motor I-Gene +
neuron I-Gene +
1 I-Gene +
( O -
SMN1 B-Gene -
) O -
. O +

Anti O -
- O -
miR-1 B-Gene +
Therapy O +
for O +
Wound O +
Healing O +
Methods O +
for O +
modulating O +
gene O +
expression O +
in O +
a O +
skin O +
cell O +
by O +
administering O +
to O +
the O +
cell O +
an O +
amount O +
of O +
a O +
therapeutic O +
composition O +
in O +
an O +
amount O +
sufficient O +
to O +
modulate O +
the O +
expression O +
of O +
miR-1 B-Gene -
, O +
and O +
therapeutic O +
compositions O +
and O +
uses O +
thereof O +
are O +
disclosed O -
. O +

Stable O +
rasagiline O +
composition O +
The O +
present O +
invention O +
provides O +
a O +
stable O +
composition O +
of O +
rasagiline O +
comprising O +
an O +
effective O +
dosage O +
of O +
rasagiline O +
or O +
its O +
pharmaceutically O +
acceptable O +
salts O +
and O +
an O +
antioxidant O +
used O +
as O +
a O +
stabilizer O -
. O +

The O +
dosage O +
forms O +
of O +
the O +
composition O +
are O +
pharmaceutically O +
common O +
transdermal O -
- O -
drug O +
delivery O +
dosage O +
form O +
and O +
mucoadhesive O +
delivery O +
dosage O +
form O -
, O +
such O +
as O +
patch O -
, O +
gel O -
, O +
ointment O -
, O +
cream O -
, O +
cataplasm O -
, O +
film O -
, O +
spray O +
and O +
solution O -
, O +
etc O -
. O +

The O +
composition O +
can O +
be O +
used O +
to O +
prevent O +
or O +
treat O +
mental O +
disorders O -
. O +

Inhibitions O +
of O +
glutaminase O +
c O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
of O +
reducing O +
the O +
production O +
of O +
glutamate O +
from O +
glutamine O +
by O +
glutaminase O +
C O +
in O +
a O +
cell O +
or O +
tissue O -
. O +

The O +
method O +
involves O +
inhibiting O +
glutaminase O +
C O +
activity O +
in O +
the O +
cell O +
or O +
tissue O +
under O +
conditions O +
effective O +
to O +
reduce O +
production O +
of O +
glutamate O +
from O +
glutamine O -
. O +

Compounds O +
for O +
carrying O +
out O +
this O +
method O +
are O +
also O +
disclosed O -
. O +

Novel O +
dental O +
appliances O +
and O +
methods O +
for O +
their O +
fabrication O +
The O +
invention O +
consists O +
of O +
a O +
rapidly O +
crosslinkable O -
, O +
two O -
- O -
component O +
silicone O +
elastomer O +
together O +
with O +
a O +
specially O +
designed O +
tray O +
that O +
serves O +
as O +
a O +
form O +
for O +
the O +
silicone O +
resin O +
and O +
forms O +
an O +
integral O +
portion O +
of O +
a O +
dental O +
appliance O -
. O +

Pegylated O +
polyplexes O +
containing O +
two O +
or O +
more O +
different O +
polymers O +
for O +
polynucleotide O +
delivery O +
The O +
present O +
invention O +
provides O +
polymers O -
, O +
compositions O +
thereof O -
, O +
and O +
polyplexes O +
comprising O +
said O +
polymers O -
. O +

In O +
particular O -
, O +
cationic O +
polymers O -
, O +
pegylated O +
versions O +
thereof O -
, O +
and O +
polynucleotide O +
containing O +
polyplexes O +
comprising O +
such O +
polymers O +
are O +
provided O -
. O +

The O +
invention O +
further O +
provides O +
methods O +
of O +
using O +
said O +
polymers O +
and O +
polyplexes O -
. O +

Bioactive O +
Load O -
- O -
Bearing O +
Composites O +
Methods O +
of O +
preparing O +
bioactive O +
composites O +
are O +
described O -
. O +

Also O +
described O +
are O +
methods O +
of O +
molding O +
such O +
composites O -
. O +

Shaped O +
bodies O +
comprising O +
bioactive O +
composites O +
are O +
further O +
described O -
. O +

Method O +
of O +
treating O +
cancers O +
and O +
a O +
pharmaceutical O +
composition O +
that O +
may O +
be O +
used O +
in O +
practicing O +
said O +
method O +
The O +
method O +
of O +
treating O +
a O +
person O +
having O +
a O +
cancer O +
selected O +
from O +
carcinoma O -
, O +
sarcoma O +
or O +
hematopoietic O +
cancer O +
by O +
administering O +
( O -
a O -
) O +
an O +
effective O +
amount O +
of O +
at O +
least O +
one O +
anti O -
- O -
cancer O +
drug O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
an O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
EGFR B-Gene -
) O +
inhibitor O -
, O +
a O +
vascular B-Gene +
endothelial I-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
VEGFR B-Gene -
) O +
inhibitor O +
and O +
a O +
Raf B-Gene +
kinase O +
inhibitor O +
and O +
( O -
b O -
) O +
an O +
effective O +
amount O +
of O +
5- O -
( O -
4- O -
( O -
6- O -
( O -
4-amino-3,5-dimethyl O -
- O -
phenoxy O -
) O -
-1-methyl-1H O -
- O -
benzimidazol-2-ylmethoxy O -
) O -
-benzyl O -
) O -
-thiazolidine-2,4-dione.dihydrochloride O +
provided O +
that O +
said O +
carcinoma O +
is O +
not O +
lung O +
cancer O +
when O +
an O +
EGFR B-Gene +
inhibitor O +
is O +
erlotinib O -
. O +

The O +
invention O +
also O +
provides O +
a O +
pharmaceutical O +
composition O +
that O +
may O +
be O +
used O +
in O +
practicing O +
said O +
method O -
. O +

Adamantane O +
analogs O +
Provided O +
are O +
compounds O +
that O +
are O +
capable O +
of O +
modulating O +
the O +
activity O +
of O +
the O +
influenza O +
A O +
virus O +
via O +
interaction O +
with O +
the O +
M2 B-Gene +
transmembrane I-Gene +
protein I-Gene -
. O +

Also O +
provided O +
are O +
methods O +
for O +
treating O +
an O +
influenza O +
A O -
- O -
affected O +
disease O +
state O +
or O +
infection O +
comprising O +
administering O +
a O +
composition O +
comprising O +
one O +
or O +
more O +
compounds O +
that O +
have O +
been O +
identified O +
as O +
being O +
capable O +
of O +
interaction O +
with O +
the O +
M2 B-Gene +
protein I-Gene -
. O +

Rapidly O +
disintegrating O +
tablet O +
in O +
oral O +
cavity O +
The O +
present O +
invention O +
provides O +
a O +
method O +
of O +
suppressing O +
the O +
bitter O +
taste O +
of O +
a O +
drug O +
when O +
a O +
rapidly O +
disintegrating O +
tablet O +
in O +
an O +
oral O +
cavity O +
is O +
produced O -
. O +

When O +
a O +
rapidly O +
disintegrating O +
tablet O +
in O +
an O +
oral O +
cavity O +
is O +
produced O -
, O +
the O +
bitter O +
taste O +
of O +
a O +
drug O +
is O +
suppressed O +
by O +
utilizing O +
( O -
a O -
) O +
a O +
granule O +
which O +
contains O +
a O +
drug O +
having O +
a O +
bitter O +
taste O +
and O +
an O +
excipient O +
and O +
in O +
which O +
the O +
bitter O +
taste O +
has O +
not O +
been O +
suppressed O +
and O +
( O -
b O -
) O +
a O +
granule O +
containing O +
a O +
water O +
soluble O +
saccharide O -
. O +

Microgel O +
compositions O +
This O +
invention O +
relates O +
to O +
microgel O +
compositions O -
, O +
and O +
in O +
particular O -
, O +
to O +
gel O +
compositions O +
formed O +
by O +
binding O +
a O +
plurality O +
of O +
individual O +
microgel O +
particles O +
together O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
processes O +
for O +
the O +
preparation O +
of O +
these O +
compositions O +
and O +
their O +
use O +
for O +
particular O +
applications O -
, O +
especially O +
medical O +
applications O +
such O +
as O +
the O +
repair O +
of O +
damaged O -
, O +
degenerated O +
or O +
inappropriately O +
formed O +
load O -
- O -
bearing O +
tissue O +
( O -
such O +
as O -
, O +
for O +
example O -
, O +
intervertebral O +
discs O -
) O -
. O +

Compositions O +
of O +
Apatite O +
and O +
Methods O +
of O +
Use O +
Compositions O +
of O +
apatite O +
derivative O +
crystals O +
are O +
disclosed O +
herein O -
. O +

Also O +
disclosed O +
are O +
methods O +
of O +
using O +
these O +
compositions O +
to O +
treat O +
tooth O +
sensitivity O -
, O +
to O +
use O +
as O +
an O +
anticaries O +
treatment O -
, O +
to O +
use O +
as O +
a O +
restorative O +
material O -
, O +
to O +
use O +
as O +
a O +
tooth O +
surface O +
whitener O -
, O +
and O +
to O +
combat O +
or O +
lessen O +
the O +
side O +
effects O +
of O +
tooth O +
whitening O -
. O +

Inhibiting O +
hepatitis O +
c O +
viral O +
replication O +
with O +
sirna O +
combinations O +
Compositions O +
are O +
disclosed O +
of O +
combinations O +
of O +
small O +
interfering O +
RNAs O +
( O -
siRNA O -
) O +
that O +
can O +
inhibit O +
the O +
replication O +
of O +
hepatitis O +
C O +
virus O +
( O -
HCV O -
) O +
in O +
liver O +
cells O -
, O +
along O +
with O +
methods O +
of O +
co O -
- O -
administering O +
the O +
siRNAs O +
to O +
subjects O -
. O +

Further O -
, O +
methods O +
are O +
disclosed O +
for O +
improving O +
the O +
delivery O +
of O +
nucleic O +
acids O +
to O +
the O +
liver O -
. O +

5-membered O +
heterocycle O +
derivatives O +
and O +
manufacturing O +
process O +
thereof O +
Disclosed O +
are O +
a O +
novel O +
5-membered O +
heterocycle O +
derivatives O +
of O +
Formula O +
I O -
, O +
a O +
tautomer O -
, O +
pharmaceutically O +
acceptable O +
salt O -
, O +
prodrug O +
thereof O +
and O +
a O +
pharmaceutical O +
use O +
thereof O -
. O +

The O +
5-membered O +
heterocycle O +
derivatives O +
of O +
Formula O +
I O -
, O +
a O +
tautomer O -
, O +
pharmaceutically O +
acceptable O +
salt O -
, O +
prodrug O +
thereof O +
and O +
compositions O +
containing O +
them O +
are O +
useful O +
for O +
treating O +
a O +
tumor O -
. O +

Novel O +
uses O +
of O +
adipic O +
acid O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
preventing O +
or O +
treating O +
obesity O -
, O +
diabetes O -
, O +
dyslipidemia O -
, O +
fatty O +
liver O +
or O +
insulin B-Gene +
resistance O +
syndrome O -
, O +
comprising O -
: O +
administering O +
to O +
a O +
mammalian O +
subject O +
in O +
need O +
thereof O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
composition O +
comprising O +
adipic O +
acid O -
. O +

The O +
present O +
composition O +
containing O +
adipic O +
acid O +
as O +
an O +
active O +
ingredient O +
is O +
very O +
effective O +
in O +
preventing O +
or O +
treating O +
obesity O -
, O +
diabetes O -
, O +
dyslipidemia O -
, O +
fatty O +
liver O +
( O -
preferably O -
, O +
non O -
- O -
alcoholic O +
fatty O +
liver O -
) O +
or O +
insulin B-Gene +
resistance O +
syndrome O -
. O +

The O +
composition O +
of O +
the O +
present O +
invention O +
useful O +
as O +
pharmaceuticals O +
compositions O +
or O +
functional O +
food O +
compositions O +
has O +
therapeutic O +
efficacies O +
for O +
obesity O -
, O +
dyslipidemia O +
or O +
fatty O +
liver O -
, O +
and O +
also O +
induces O +
significant O +
decrease O +
in O +
fasting O +
glucose O +
level O +
and O +
blood O +
insulin B-Gene +
level O +
to O +
improve O +
type O +
2 O +
diabetes O -
, O +
insulin B-Gene +
resistance O +
and O +
related O +
metabolic O +
diseases O -
. O +

Cutaneous O +
composition O +
comprising O +
vitamin O +
d O +
analogue O +
and O +
a O +
mixture O +
of O +
solvent O +
and O +
surfactants O +
A O +
pharmaceutical O +
composition O +
comprising O +
a O +
vitamin O +
D O +
derivative O +
or O +
analogue O +
as O +
the O +
active O +
ingredient O +
dissolved O +
in O +
a O +
three O -
- O -
component O +
surfactant O -
- O -
solvent O +
mixture O +
is O +
useful O +
in O +
the O +
treatment O +
of O +
dermal O +
disorders O +
or O +
conditions O -
. O +

Pharmaceutical O +
kit O +
for O +
treating O +
neuronal O +
damages O +
A O +
pharmaceutical O +
kit O +
for O +
treating O +
neuronal O +
damages O +
is O +
disclosed O -
. O +

The O +
pharmaceutical O +
composition O +
of O +
the O +
present O +
invention O +
comprises O -
: O +
a O +
first O +
pharmaceutical O +
composition O +
comprising O +
a O +
first O +
effective O +
amount O +
of O +
a O +
Mg2 O -
+ O -
-containing O +
compound O -
; O +
and O +
a O +
second O +
pharmaceutical O +
composition O +
comprising O +
a O +
second O +
effective O +
amount O +
of O +
a O +
COX-2 B-Gene +
inhibitor O -
. O +

Nucleic O +
acid O +
molecules O +
encoding O +
bank1 B-Gene +
splice O +
variants O +
The O +
present O +
invention O +
relates O +
to O +
a O +
new O +
splice O +
variant O +
of O +
BANK1 B-Gene -
, O +
the O +
use O +
of O +
SNPs O +
in O +
BANK1 B-Gene +
for O +
diagnostics O +
and O +
the O +
use O +
of O +
antagonists O +
to O +
modulate O +
BANK1 B-Gene +
and/or O +
the O +
BANK1 B-Gene +
pathway O -
. O +

Hydrogel O +
materials O +
incorporating O +
eluting O +
ceragenin O +
compound O +
A O +
hydrogel O +
polymer O +
includes O +
a O +
ceragenin O +
compound O -
. O +

The O +
ceragenin O +
compound O +
has O +
a O +
hydrophobicity O -
/ O -
hydrophilicity O +
that O +
produces O +
a O +
release O +
rate O +
in O +
a O +
range O +
of O +
0.1 O -
- O -
100 O +
Î¼g O -
/ O -
ml O +
for O +
at O +
least O +
3 O +
days O -
. O +

Aqueous O +
Pharmaceutical O +
Formulation O +
of O +
Tapentadol O +
for O +
Oral O +
Administration O +
An O +
aqueous O +
pharmaceutical O +
composition O +
containing O +
tapentadol O +
or O +
a O +
physiologically O +
acceptable O +
salt O +
thereof O +
and O +
being O +
adapted O +
for O +
oral O +
administration O -
. O +

The O +
composition O +
has O +
excellent O +
storage O +
stability O +
without O +
relying O +
on O +
the O +
presence O +
of O +
high O +
amounts O +
of O +
preservatives O -
. O +

Promyelocytic B-Gene +
leukemia I-Gene +
protein I-Gene +
as O +
a O +
redox O +
sensor O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
determining O +
the O +
redox O +
status O +
of O +
a O +
cell O +
or O +
tissue O +
comprising O +
a O +
step O +
consisting O +
of O +
determining O +
the O +
level O +
of O +
PML B-Gene +
nuclear O +
bodies O +
in O +
said O +
cell O +
or O +
tissue O -
. O +

Drug O -
- O -
delivery O +
endovascular O +
stent O +
and O +
method O +
of O +
forming O +
the O +
same O +
An O +
intravascular O +
stent O +
and O +
method O +
for O +
inhibiting O +
restenosis O -
, O +
following O +
vascular O +
injury O -
, O +
is O +
disclosed O -
. O +

The O +
stent O +
has O +
an O +
expandable O -
, O +
linked O -
- O -
filament O +
body O +
and O +
a O +
drug O -
- O -
release O +
coating O +
formed O +
on O +
the O +
stent O -
- O -
body O +
filaments O -
, O +
for O +
contacting O +
the O +
vessel O +
injury O +
site O +
when O +
the O +
stent O +
is O +
placed O +
in O -
- O -
situ O +
in O +
an O +
expanded O +
condition O -
. O +

The O +
coating O +
releases O -
, O +
for O +
a O +
period O +
of O +
at O +
least O +
4 O +
weeks O -
, O +
a O +
restenosis O -
- O -
inhibiting O +
amount O +
of O +
a O +
monocyclic O +
triene O +
immunosuppressive O +
compound O +
having O +
an O +
alkyl O +
group O +
substituent O +
at O +
carbon O +
position O +
40 O +
in O +
the O +
compound O -
. O +

The O +
stent O -
, O +
when O +
used O +
to O +
treat O +
a O +
vascular O +
injury O -
, O +
gives O +
good O +
protection O +
against O +
clinical O +
restenosis O -
, O +
even O +
when O +
the O +
extent O +
of O +
vascular O +
injury O +
involves O +
vessel O +
overstretching O +
by O +
more O +
than O +
30 O -
% O +
diameter O -
. O +

Also O +
disclosed O +
is O +
a O +
stent O +
having O +
a O +
drug O -
- O -
release O +
coating O +
composed O +
of O +
( O -
i O -
) O +
10 O +
and O +
60 O +
weight O +
percent O +
poly O -
- O -
dl O -
- O -
Iactide O +
polymer O +
substrate O +
and O +
( O -
ii O -
) O +
40 O -
- O -
90 O +
weight O +
percent O +
of O +
an O +
anti O -
- O -
restenosis O +
compound O -
, O +
and O +
a O +
polymer O +
undercoat O +
having O +
a O +
thickness O +
of O +
between O +
1 O -
- O -
5 O +
microns O -
. O +

Compositions O +
and O +
Methods O +
for O +
Treating O +
Pain O +

The O +
present O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
treating O +
pain O +
in O +
mammals O -
. O +

A O +
composition O +
of O +
the O +
invention O +
comprises O +
one O +
or O +
more O +
anti O -
- O -
inflammatory O +
agents O +
and O +
optionally O +
contains O +
one O +
or O +
more O +
anti O -
- O -
oxidants O +
and O +
immune O +
system O +
boosting O +
agents O -
. O +

Modified O +
release O +
dosage O +
form O +
comprising O +
desvenlafaxine O +
or O +
salts O +
thereof O +
The O +
present O +
invention O +
refers O +
to O +
a O +
modified O +
release O +
pharmaceutical O +
composition O +
comprising O +
desvenlafaxine O +
or O +
salts O +
thereof O -
, O +
a O +
release O +
rate O +
modifying O +
system O +
that O +
controls O +
the O +
release O +
of O +
active O +
agent O -
( O -
s O -
) O +
in O +
both O +
acidic O +
and O +
basic O +
environments O -
. O +

A O +
process O +
of O +
making O +
and O +
method O +
of O +
using O +
the O +
above O -
- O -
described O +
composition O +
is O +
also O +
disclosed O -
. O +

Substituted O +
Carbonyloxymethylphosphoramidate O +
Compounds O +
and O +
Pharmaceutical O +
Compositions O +
for O +
the O +
Treatment O +
of O +
Viral O +
Infections O +
Provided O +
herein O +
are O +
compounds O -
, O +
compositions O +
and O +
methods O +
for O +
the O +
treatment O +
of O +
liver O +
disorders O -
, O +
including O +
HCV O +
infections O -
. O +

In O +
certain O +
embodiments O -
, O +
compounds O +
and O +
compositions O +
of O +
nucleoside O +
derivatives O +
are O +
disclosed O -
, O +
which O +
can O +
be O +
administered O +
either O +
alone O +
or O +
in O +
combination O +
with O +
other O +
anti O -
- O -
viral O +
agents O -
. O +

COMPOUNDS O +
AS O +
RORyT B-Gene +
MODULATORS O +
AND O +
USES O +
THEREOF O +
Heterocyclic O +
compounds O -
, O +
and O +
pharmaceutical O +
compositions O +
thereof O -
, O +
are O +
disclosed O +
as O +
RORÎ³t B-Gene +
modulators O +
that O +
have O +
a O +
formula O +
represented O +
by O +
the O +
following O -
: O +
and O +
wherein O +
n1 O -
, O +
n2 O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
and O +
R4 O +
are O +
as O +
described O +
herein O -
. O +

These O +
compounds O +
may O +
be O +
used O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
a O +
variety O +
of O +
conditions O +
in O +
mammals O +
including O +
humans O -
, O +
including O +
by O +
way O +
of O +
non O -
- O -
limiting O +
example O -
, O +
inflammatory O +
conditions O -
, O +
autoimmune O +
disorders O -
, O +
cancer O -
, O +
and O +
graft O -
- O -
versus O -
- O -
host O +
disease O -
. O +

Method O +
of O +
Achieving O +
Improved O +
Hair O +
Feel O +
A O +
method O +
of O +
achieving O +
improved O +
hair O +
feel O -
. O +

The O +
method O +
comprises O +
applying O +
to O +
hair O +
a O +
composition O +
comprising O -
: O +
( O -
a O -
) O +
a O +
specific O +
cationic O +
guar O +
polymer O -
; O +
( O -
b O -
) O +
a O +
specific O +
cationic O +
copolymer O -
; O +
( O -
c O -
) O +
an O +
anti O -
- O -
dandruff O +
active O -
; O +
( O -
d O -
) O +
a O +
cosmetically O +
acceptable O +
carrier O -
; O +
( O -
e O -
) O +
a O +
surfactant O -
; O +
wherein O +
the O +
weight O +
ratio O +
of O +
( O -
a O -
) O -
: O -
( O -
b O -
) O +
is O +
from O +
about O +
1000:1 O +
to O +
about O +
3.5:1 O -
; O +
and O +
wherein O +
the O +
sum O +
of O +
( O -
a O -
) O -
+ O -
( O -
b O -
) O +
is O +
an O +
amount O +
of O +
from O +
about O +
0.0001 O -
% O +
to O +
about O +
0.7 O -
% O -
, O +
by O +
total O +
weight O +
of O +
the O +
composition O -
. O +

The O +
composition O +
forms O +
coacervate O +
particles O +
upon O +
dilution O +
of O +
the O +
composition O +
with O +
water O +
and O +
the O +
coacervate O +
particles O +
have O +
a O +
squeeze O +
flow O +
viscosity O +
of O +
from O +
about O +
1 O +
cP O +
to O +
about O +
100 O +
cP. O +
The O +
percentage O +
of O +
coacervate O +
particles O +
with O +
a O +
floc O +
size O +
of O +
greater O +
than O +
about O +
20 O +
micron O +
is O +
from O +
about O +
1 O -
% O +
to O +
about O +
60 O -
% O +
and O +
the O +
on O -
- O -
scalp O +
deposition O +
of O +
the O +
anti O -
- O -
dandruff O +
active O +
is O +
at O +
least O +
about O +
1 O +
microgram O -
/ O -
cm2 O -
. O +

Antimicrobial O +
carboline O +
compounds O +
The O +
invention O +
provides O +
compositions O +
comprising O +
carboline O +
compounds O +
for O +
treating O +
infections O +
such O +
as O +
viral O +
conjunctivitis O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
for O +
treating O +
of O +
other O +
infections O -
, O +
including O +
ocular O +
infections O -
. O +

More O +
particularly O -
, O +
the O +
present O +
invention O +
relates O +
to O +
compositions O +
comprising O +
carboline O +
compounds O +
for O +
the O +
treatment O +
of O +
ocular O +
infections O +
such O +
as O +
viral O +
conjunctivitis O -
, O +
particularly O +
those O +
caused O +
by O +
adenovirus O +

Novel O +
iso O -
- O -
ergoline O +
derivatives O +
Provided O +
herein O +
are O +
novel O +
iso O -
- O -
ergoline O +
derivatives O +
and O +
compositions O +
thereof O -
. O +

In O +
other O +
embodiments O -
, O +
provided O +
herein O +
are O +
methods O +
of O +
treatment O -
, O +
prevention O -
, O +
or O +
amelioration O +
of O +
a O +
variety O +
of O +
medical O +
disorders O +
such O +
as O -
, O +
for O +
example O -
, O +
migraine O +
using O +
the O +
compounds O +
and O +
compositions O +
disclosed O +
herein O -
. O +

In O +
still O +
other O +
embodiments O -
, O +
provided O +
herein O +
are O +
methods O +
of O +
agonizing O +
receptors O +
such O +
as O -
, O +
for O +
example O -
, O +
the O +
5-HT1D O +
and/or O +
the O +
5-HT1Breceptor O -
, O +
without O +
agonizing O +
the O +
5-HT2B O +
receptor O +
using O +
the O +
compounds O +
and O +
compositions O +
disclosed O +
herein O -
. O +

In O +
still O +
other O +
embodiments O -
, O +
provided O +
herein O +
are O +
methods O +
of O +
antagonizing O +
or O +
inhibiting O +
activity O +
at O +
receptors O +
such O +
as O -
, O +
for O +
example O -
, O +
the O +
adrenergic O +
alpha2A O +
and/or O +
the O +
alpha2Breceptors O +
using O +
the O +
compounds O +
and O +
compositions O +
disclosed O +
herein O -
. O +

Administration O +
of O +
intravenous O +
ibuprofen O +
to O +
trauma O +
patients O +
A O +
method O +
for O +
treating O +
human O +
patients O +
who O +
require O +
hospitalization O +
for O +
a O +
trauma O +
injury O +
wherein O +
the O +
patients O +
are O +
intravenously O +
administered O +
a O +
first O +
dose O +
of O +
a O +
therapeutically O +
effective O +
dose O +
of O +
ibuprofen O +
intravenously O +
as O +
soon O +
as O +
possible O +
after O +
hospitalization O +
is O +
disclosed O -
. O +

The O +
patients O +
are O +
further O +
treated O +
with O +
intravenous O +
ibuprofen O +
at O +
suitable O +
dosing O +
intervals O +
to O +
the O +
human O +
patient O +
until O +
( O -
a O -
) O +
the O +
patient O +
no O +
longer O +
requires O +
intravenous O +
dosing O +
of O +
ibuprofen O -
. O +

Method O +
and O +
composition O +
for O +
ameliorating O +
the O +
effects O +
for O +
a O +
subject O +
exposed O +
to O +
radiation O +
or O +
other O +
sources O +
of O +
oxidative O +
stress O +
Radiation O -
- O -
oxidative O +
exposure O +
treatment O +
compositions O +
may O +
include O +
a O +
mixture O +
of O +
micronutrient O +
multivitamin O +
and O +
trace O +
elements O -
, O +
a O +
mixture O +
of O +
antioxidants O +
and O +
chemopreventative O +
agents O -
, O +
and O +
optionally O +
a O +
mixture O +
of O +
fatty O +
acids O -
. O +

Methods O +
of O +
treatment O +
of O +
a O +
subject O +
exposed O +
to O +
a O +
radiation O +
source O +
or O +
an O +
oxidative O +
stress O +
with O +
the O +
radiation O -
- O -
oxidative O +
exposure O +
treatment O +
composition O +
may O +
include O +
the O +
step O +
of O +
administering O +
to O +
the O +
subject O +
a O +
daily O +
dose O +
of O +
the O +
radiation O -
- O -
oxidative O +
exposure O +
treatment O +
composition O +
such O +
that O +
the O +
life O +
shortening O +
effects O +
induced O +
by O +
the O +
radiation O +
source O +
or O +
the O +
oxidative O +
stress O +
are O +
ameliorated O -
. O +

Nanoparticles O -
, O +
Compositions O +
Thereof O -
, O +
and O +
Methods O +
of O +
Use O -
, O +
and O +
Methods O +
of O +
Making O +
the O +
Same O +
The O +
disclosure O +
is O +
directed O +
to O +
a O +
nanoparticle O +
comprising O +
a O +
porous O +
framework O +
core O +
including O +
a O +
porous O +
framework O +
material O +
and O +
a O +
compound O -
, O +
and O +
a O +
lipid O +
layer O +
disposed O +
on O +
the O +
surface O +
of O +
the O +
porous O +
framework O +
core O -
. O +

Controlled O +
release O +
hydrocodone O +
A O +
solid O +
oral O +
controlled O -
- O -
release O +
dosage O +
form O +
of O +
hydrocodone O +
is O +
disclosed O -
, O +
the O +
dosage O +
form O +
comprising O +
an O +
analgesically O +
effective O +
amount O +
of O +
hydrocodone O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
controlled O +
release O +
material O -
. O +

Fullerene O +
derivative O +
and O +
composition O +
comprising O +
the O +
same O +
A O +
fullerene O +
derivative O +
represented O +
by O +
the O +
formula O +
( O -
I O -
) O -
: O +
[ O -
wherein O -
, O +
A O +
is O +
a O +
residue O +
of O +
monosaccharides O +
or O +
disaccharides O -
, O +
and O +
Alk O +
is O +
a O +
lower O +
alkylene O +
group O -
, O +
the O +
group O +
represented O +
by O +
the O +
formula O +
( O -
X O -
) O -
: O +
is O +
a O +
fullerene O +
residual O +
skeleton O -
, O +
and O +
n O +
is O +
an O +
integral O +
number O +
of O +
1 O +
or O +
2 O -
] O +
or O +
its O +
salt O +
produces O +
a O +
formulation O +
usable O +
for O +
PDT O +
which O +
has O +
more O +
hydrophilicity O +
and O +
lipophilicity O -
, O +
is O +
expected O +
to O +
have O +
selectivity O +
to O +
tumor O +
cells O +
by O +
cell O +
recognition O -
, O +
shows O +
no O +
toxicity O +
to O +
the O +
cells O +
in O +
a O +
dark O +
place O +
and O +
has O +
a O +
cytocidal O +
effect O +
by O +
light O +
irradiation O -
. O +

Method O +
for O +
producing O +
a O +
tablet O +
made O +
of O +
isomaltulose O -
, O +
isomalt O +
or O +
isomalt O +
variants O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
of O +
producing O +
an O +
improved O +
compressed O +
product O -
, O +
wherein O +
agglomeration O +
of O +
the O +
ingredients O +
is O +
induced O -
. O +

This O +
invention O +
also O +
relates O +
to O +
a O +
compressed O +
product O +
produced O +
by O +
this O +
method O -
. O +

2-Ureido O -
- O -
thiazole O +
derivatives O -
, O +
process O +
for O +
their O +
preparation O -
, O +
and O +
their O +
use O +
as O +
antitumor O +
agents O +
Compounds O +
which O +
are O +
2-ureido-1,3-thiazole O +
derivatives O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
R O +
is O +
a O +
halogen O +
atom O -
, O +
a O +
nitro O +
group O -
, O +
an O +
optionally O +
substituted O +
amino O +
group O +
or O +
it O +
is O +
a O +
group O +
optionally O +
further O +
substituted O -
, O +
selected O +
from O -
: O +
i O -
) O +
straight O +
or O +
branched O +
C1-C6 O +
alkyl O -
; O +
ii O -
) O +
C3-C6 O +
cycloalkyl O -
; O +
iii O -
) O +
aryl O +
or O +
arylalkyl O +
with O +
from O +
1 O +
to O +
6 O +
carbon O +
atoms O +
within O +
the O +
straight O +
or O +
branched O +
alkyl O +
chain O -
; O +
R1 O +
is O +
an O +
optionally O +
substituted O +
group O +
selected O +
from O -
: O +
i O -
) O +
straight O +
or O +
branched O +
C1-C6 O +
alkyl O -
; O +
ii O -
) O +
3 O +
to O +
6 O +
membered O +
carbocycle O +
or O +
5 O +
to O +
7 O +
membered O +
heterocycle O +
ring O -
; O +
iii O -
) O +
aryl O +
or O +
arylcarbonyl O -
; O +
iv O -
) O +
arylalkyl O +
with O +
from O +
1 O +
to O +
6 O +
carbon O +
atoms O +
within O +
the O +
straight O +
or O +
branched O +
alkyl O +
chain O -
; O +
R2 O +
is O +
hydrogen O -
, O +
a O +
straight O +
or O +
branched O +
C1-C6 O +
alkyl O +
or O +
C2-C4 O +
alkenyl O +
or O +
alkynyl O +
group O -
; O +
or O -
, O +
taken O +
together O +
with O +
the O +
nitrogen O +
atom O +
so O +
which O +
they O +
are O +
bonded O -
, O +
R1 O +
and O +
R2 O +
form O +
a O +
substituted O +
or O +
unsubstituted O +
group O +
selected O +
from O -
: O +
i O -
) O +
an O +
optionally O +
benzocondensed O +
or O +
bridged O +
5 O +
to O +
7 O +
membered O +
heterocycle O -
; O +
or O +
ii O -
) O +
a O +
9 O +
to O +
11 O +
membered O +
spiro O -
- O -
heterocyclic O +
compound O -
; O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
; O +
are O +
useful O +
for O +
treating O +
cell O +
proliferative O +
disorders O +
associated O +
with O +
an O +
altered O +
cell O +
dependent O +
kinase O +
activity O -
. O +

Oxalipatinum O +
preparation O +
packaging O +
Flexible O +
impervious O +
bag O +
for O +
medical O +
use O +
containing O +
a O +
pharmaceutical O +
preparation O +
of O +
liquid O +
oxaliplatinum O +
said O +
flexible O +
bag O +
is O +
constructed O +
from O +
plastic O +
materials O -
, O +
with O +
the O +
proviso O +
that O +
any O +
portion O +
to O +
the O +
bag O +
in O +
direct O +
contact O +
with O +
said O +
pharmaceutical O +
preparation O +
of O +
liquid O +
oxaliplatinum O +
does O +
not O +
contain O +
polyvinylchloride O -
- O -
based O +
plastic O +
material O -
. O +

Useful O +
for O +
relieving O +
infertility O +
in O +
females O +
and O +
males O +
Certain O +
novel O +
sterol O +
derivatives O +
can O +
be O +
used O +
for O +
regulating O +
the O +
meiosis O +
in O +
oocytes O +
and O +
in O +
male O +
germ O +
cells O -
. O +

Viricides O -
; O +
human O +
immunodeficiency O +
virus O +
Compounds O +
of O +
the O +
formula O +
I O -
: O +
where O -
; O +
R1 O +
is O +
O O -
, O +
S O -
; O +
R2 O +
is O +
an O +
optionally O +
substituted O +
nitrogen O -
- O -
containing O +
heterocycle O -
, O +
wherein O +
the O +
nitrogen O +
is O +
located O +
at O +
the O +
2 O +
position O +
relative O +
to O +
the O +
( O -
thio O -
) O -
urea O +
bond O -
; O +
R3 O +
is O +
H O -
, O +
C1-C3 O +
alkyl O -
, O +
R4-R7 O +
are O +
independently O +
selected O +
from O +
H O -
, O +
C1-C6 O +
alkyl O -
, O +
C2-C6 O +
alkenyl O -
, O +
C2-C6 O +
alkynyl O -
, O +
haloC1-C6 O +
alkyl O -
, O +
C1-C6 O +
alkanoyl O -
, O +
haloC1-C6 O +
alkanoyl O -
, O +
C1-C6 O +
alkoxy O -
, O +
haloC1-C6 O +
alkoxy O -
, O +
C1-C6 O +
alkyloxy O -
- O -
C1-C6 O +
alkyl O -
, O +
haloC1-C6 O +
alkyloxy O -
- O -
C1-C6 O +
alkyl O +
hydroxy O -
- O -
C1-C6 O +
alkyl O -
, O +
amino O -
- O -
C1-C6 O +
alkyl O -
, O +
carboxy O -
- O -
C1-C6 O +
alkyl O -
, O +
cyano O -
- O -
C1-C6 O +
alkyl O -
, O +
amino O -
, O +
carboxy O -
, O +
carbamoyl O -
, O +
cyano O -
, O +
halo O -
, O +
hydroxy O -
, O +
keto O -
; O +
X O +
is O +
â€” O -
( O -
CH2 O -
) O -
nâˆ’â€”Dâ€” O -
( O -
CH2 O -
) O -
mâ€” O -
; O +
D O +
is O +
â€”Oâ€” O -
, O +
â€”Sâ€” O -
; O +
n O +
and O +
m O +
are O +
independently O +
0 O +
or O +
1 O -
; O +
and O +
prodrugs O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
have O +
utility O +
as O +
inhibitors O +
of O +
HIV-1 B-Gene +
reverse I-Gene +
transcriptase I-Gene -
, O +
particularly O +
drug O +
escape O +
mutants O -
. O +

Diazocine O +
derivatives O +
and O +
their O +
use O +
as O +
tryptase B-Gene +
inhibitors O +
Compounds O +
of O +
the O +
formula O +
I O -
, O +
in O +
which O +
B1 O -
, O +
B2 O -
, O +
R1 O -
, O +
R2 O -
, O +
R6 O -
, O +
R7 O -
, O +
K1 O +
and O +
K2 O +
are O +
as O +
defined O +
in O +
the O +
description O +
are O +
novel O +
effective O +
tryp B-Gene -
- I-Gene -
tase I-Gene +
inhibitors O -
. O +

Active O +
agent O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
anabasine O -
, O +
anatabine O -
, O +
nomicotine O -
, O +
Yerbamate O +
( O -
Ilex O +
paraguariensis O -
) O +
extract O -
, O +
and O +
a O +
liquid O +
extract O +
of O +
tobacco O -
; O +
especially O +
for O +
treating O +
psychological O +
disorders O +
The O +
present O +
invention O +
provides O +
a O +
group O +
of O +
tobacco O +
alkaloids O -
, O +
tobacco O +
extract O -
, O +
YerbamatÃ© O +
extract O -
, O +
and O +
an O +
extract O +
of O +
chewing O +
gum O +
and O +
lozenges O +
which O +
are O +
modulators O +
of O +
monoamine O +
oxidase O +
( O -
MAO O -
) O +
activity O +
( O -
i.e. O -
, O +
compounds O +
and O +
substances O +
which O +
inhibit O +
MAO O +
enzyme O +
and O +
prevent O +
its O +
biological O +
activity O -
) O -
. O +

The O +
MAO O +
inhibitors O +
of O +
the O +
present O +
invention O +
can O +
cause O +
an O +
increase O +
in O +
the O +
level O +
of O +
norepinephrine O -
, O +
dopamine O -
, O +
and O +
serotonin O +
in O +
the O +
brain O +
and O +
other O +
tissues O -
, O +
and O +
thus O +
can O +
cause O +
a O +
wide O +
variety O +
of O +
pharmacological O +
effects O +
mediated O +
by O +
their O +
effects O +
on O +
these O +
compounds O -
. O +

The O +
MAO O +
inhibitors O +
of O +
the O +
present O +
invention O +
are O +
useful O +
for O +
a O +
variety O +
of O +
therapeutic O +
applications O -
, O +
such O +
as O +
the O +
treatment O +
of O +
depression O -
, O +
disorders O +
of O +
attention O +
and O +
focus O -
, O +
mood O +
and O +
emotional O +
disorders O -
, O +
Parkinson O -
's O +
disease O -
, O +
extrapyramidal O +
disorders O -
, O +
hypertension O -
, O +
substance O +
abuse O -
, O +
smoking O +
substitution O -
, O +
anti O -
- O -
depression O +
therapy O -
, O +
eating O +
disorders O -
, O +
withdrawal O +
syndromes O -
, O +
and O +
the O +
cessation O +
of O +
smoking O -
. O +

Phosphate O +
prodrugs O +
of O +
fluoroxindoles O +
The O +
present O +
invention O +
provides O +
novel O +
phosphate O +
derivatives O +
having O +

the O +
general O +
Formula O +
I O +
wherein O +
the O +
wavy O +
bond O +
( O +
) O +
represents O +
the O +
racemate O -
, O +
the O +
( O -
R O -
) O -
-enantiomer O +
or O +
the O +
( O -
S O -
) O -
-enantiomer O +
and O +
A O -
, O +
B O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
m O +
and O +
n O +
are O +
as O +
defined O +
herein O -
, O +
or O +
a O +
nontoxic O +
pharmaceutically O +
acceptable O +
salt O +
or O +
solvate O +
thereof O +
and O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
disorders O +
which O +
are O +
responsive O +
to O +
the O +
opening O +
of O +
potassium O +
channels O -
. O +

Fused O +
indazoles O +
and O +
indoles O +
and O +
their O +
use O +
for O +
the O +
treatment O +
of O +
glaucoma O +
Novel O +
fused O +
indazoles O +
and O +
indoles O +
are O +
disclosed O -
. O +

Also O +
disclosed O +
are O +
methods O +
for O +
the O +
lowering O +
and O +
controlling O +
of O +
normal O +
or O +
elevated O +
intraocular O +
pressure O +
as O +
well O +
as O +
a O +
method O +
for O +
the O +
treatment O +
of O +
glaucoma O +
using O +
compositions O +
containing O +
one O +
or O +
more O +
of O +
the O +
compounds O +
of O +
the O +
present O +
invention O -
. O +

Cosmetic O +
or O +
dermatological O +
composition O +
comprising O +
of O +
a O +
combination O +
of O +
an O +
elastase B-Gene +
inhibitor O +
of O +
the O +
N O -
- O -
acylaminoamide O +
family O +
and O +
at O +
least O +
one O +
antifungal O +
agent O +
or O +
at O +
least O +
one O +
antibacterial O +
agent O +
Cosmetic O +
or O +
dermatological O +
composition O +
characterized O +
in O +
that O +
it O +
comprises O +
a O +
combination O +
of O +
an O +
elastase B-Gene +
inhibitor O +
of O +
the O +
N O -
- O -
acylaminoamide O +
family O +
and O +
at O +
least O +
one O +
antifungal O +
agent O +
or O +
at O +
least O +
one O +
antibacterial O +
agent O -
. O +

useful O +
as O +
a O +
growth O +
factor O +
receptor O +
tyrosine O +
kinase O +
HER2 O +
( O -
Human O +
epidermal O +
growth O +
factor O +
receptor-2 O -
) O +
inhibitor O -
; O +
for O +
treating O +
cancer O +
This O +
invention O +
provides O +
a O +
heterocyclic O +
compound O +
having O +
potent O +
tyrosine O +
kinase O -
- O -
inhibiting O +
activity O +
represented O +
by O +
the O +
formula O -
: O +
wherein O +
m O +
is O +
an O +
integer O +
of O +
1 O +
to O +
3 O -
; O +
n O +
is O +
an O +
integer O +
of O +
1 O +
or O +
2 O -
; O +
R1 O +
is O +
a O +
halogen O +
atom O +
or O +
an O +
optionally O +
halogenated O +
C1 O -
- O -
2 O +
alkyl O +
group O -
; O +
each O +
of O +
R2 O +
and O +
R3 O +
is O -
, O +
same O +
or O +
different O -
, O +
a O +
hydrogen O +
atom O -
, O +
a O +
halogen O +
atom O -
, O +
a O +
lower O +
alkyl O +
group O +
or O +
a O +
lower O +
alkoxy O +
group O -
; O +
R4 O +
is O +
a O +
group O +
represented O +
by O +
the O +
formula O -
: O +
wherein O +
p O +
is O +
an O +
integer O +
of O +
2 O +
to O +
5 O -
; O +
R5 O +
is O +
a O +
C1 O -
- O -
4 O +
alkyl O +
group O +
substituted O +
by O +
alkoxycarbonyl O +
group O -
, O +
carbamoyl O +
group O -
, O +
carbamoyloxy O +
group O -
, O +
alkylsulfonyl O +
group O -
, O +
alkylsulfinyl O +
group O -
, O +
sulfamoyl O +
group O -
, O +
carbamoylamino O +
group O -
, O +
alkylsulfonylamino O +
group O -
, O +
acylamino O +
group O -
, O +
and O +
the O +
like O -
; O +
or O +
a O +
salt O +
thereof O +
and O +
a O +
pharmaceutical O +
composition O +
comprising O +
thereof O -
. O +

To O +
treat O +
and/or O +
prevent O +
hypertension O -
, O +
cardiac O +
hypertrophy O -
, O +
cardiac O +
insufficiency O -
, O +
coronary O +
heart O +
diseases O +
such O +
as O +
angina O +
pectoris O -
, O +
and O +
endothelial O +
dysfunction O +
or O +
endothelial O +
damage O +
as O +
a O +
consequence O +
of O +
atherosclerotic O +
processes O +
or O +
diabetes O +
The O +
invention O +
relates O +
to O +
p O -
- O -
thienylbenzylamides O +
of O +
formula O +
( O -
I O -
) O -
: O +
in O +
which O +
R O -
( O -
1 O -
) O -
, O +
R O -
( O -
2 O -
) O -
, O +
R O -
( O -
3 O -
) O -
, O +
R O -
( O -
4 O -
) O -
, O +
R O -
( O -
5 O -
) O -
, O +
R O -
( O -
6 O -
) O +
and O +
X O +
have O +
the O +
meanings O +
given O +
in O +
the O +
description O -
. O +

The O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
are O +
potent O +
agonists O +
of O +
angiotensin- B-Gene -
( I-Gene -
1 I-Gene -
- I-Gene -
7 I-Gene -
) I-Gene +
receptors I-Gene +
and O +
are O +
useful O +
as O +
pharmaceutically O +
active O +
compounds O +
to O +
treat O +
and/or O +
prevent O +
hypertension O -
; O +
cardiac O +
hypertrophy O -
; O +
cardiac O +
insufficiency O -
; O +
coronary O +
heart O +
diseases O -
, O +
such O +
as O +
angina O +
pectoris O -
; O +
and O +
endothelial O +
dysfunction O +
or O +
endothelial O +
damage O +
as O +
a O +
consequence O -
, O +
for O +
example O -
, O +
of O +
atherosclerotic O +
processes O +
or O +
in O +
association O +
with O +
diabetes O +
mellitus O -
. O +

Prodrug O +
of O +
an O +
estradiol O +
conjugated O +
to O +
a O +
glucuronide O +
sugar O -
; O +
6-oxo-2-methoxyestradiol O -
; O +
3-acetyl-6-oxo-2-methoxyestradiol O -
; O +
and O +
2-methoxyestradiol-6-hydrazone O -
; O +
angiogenesis O +
inhibitor O -
; O +
antiinflammatory O +
for O +
asthma O +
or O +
rheumatoid O +
arthritis O +
A O +
conjugated O +
prodrug O +
of O +
an O +
estradiol O +
compound O +
conjugated O +
to O +
a O +
biological O +
activity O +
modifying O +
agent O -
. O +

Formulation O +
for O +
controlled O +
release O +
of O +
drugs O +
by O +
combining O +
hyrophilic O +
and O +
hydrophobic O +
agents O +
Combinations O +
of O +
hydrophilic O +
and O +
hydrophobic O +
entities O +
in O +
a O +
biodegradable O +
sustained O +
release O +
implant O +
are O +
shown O +
to O +
modulate O +
each O +
other O -
's O +
rate O +
of O +
release O -
. O +

Formulations O +
of O +
a O +
therapeutically O +
active O +
agent O +
and O +
modulator O +
provide O +
controlled O -
, O +
sustained O +
release O +
for O +
an O +
extended O +
period O +
of O +
time O -
. O +

Nitrogen O +
compounds O +
such O +
as O +
1- O -
( O -
( O -
3- O +
Phenylimidazo O -
( O -
5,1-a O -
) O -
-isoquinolin-6-yl O -
) O -
carbonyl O -
) O -
piperidine O -
, O +
that O +
bind O +
preferentially O +
to O +
gamma B-Gene -
- I-Gene -
aminobutyric I-Gene +
acid I-Gene +
( I-Gene -
GABAA I-Gene -
) I-Gene +
receptors I-Gene -
; O +
prophylaxis O +
of O +
nervous O +
system O +
disorders O +
Disclosed O +
are O +
compounds O +
of O +
the O +
formula O -
: O +
and O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
wherein O +
W O -
, O +
Q O -
, O +
X O -
, O +
X1 O -
, O +
Y O +
and O +
Z O +
are O +
as O +
defined O +
herein O -
. O +

These O +
compounds O +
bind O +
with O +
high O +
selectivity O +
and/or O +
high O +
affinity O +
to O +
the O +
benzodiazepine O +
site O +
of O +
GABAA B-Gene +
receptors I-Gene +
and O +
are O +
therefore O +
useful O +
in O +
the O +
treatment O +
of O +
central O +
nervous O +
system O +
( O -
CNS O -
) O +
diseases O +
and O +
as O +
probes O +
for O +
the O +
localization O +
of O +
GABAA B-Gene +
receptors I-Gene +
in O +
tissue O +
samples O -
. O +

Also O +
disclosed O +
are O +
intermediates O +
useful O +
in O +
the O +
preparation O +
of O +
these O +
compounds O -
. O +

Orphan B-Gene +
opioid I-Gene +
receptor I-Gene +
( O -
orl-1 B-Gene -
) O +
ligands O -
; O +
anxiety O -
, O +
depression O -
, O +
neuropathic O +
and O +
acute O +
pain O -
, O +
migraines O -
, O +
asthma O -
, O +
improved O +
cognition O +
The O +
present O +
invention O +
is O +
directed O +
to O +
novel O +
1,3,8-triazaspiro O -
[ O -
4.5 O -
] O -
decan-4-one O +
derivatives O +
of O +
the O +
general O +
formula O +
wherein O +
all O +
variables O +
are O +
as O +
defined O +
herein O -
, O +
useful O +
in O +
the O +
treatment O +
of O +
disorders O +
and O +
conditions O +
mediated O +
by O +
the O +
ORL-1 B-Gene +
G B-Gene -
- I-Gene -
protein I-Gene +
coupled I-Gene +
receptor I-Gene -
. O +

More O +
particularly O -
, O +
the O +
compounds O +
of O +
the O +
present O +
invention O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
disorders O +
and O +
conditions O +
such O +
as O +
anxiety O -
, O +
depression O -
, O +
substance O +
abuse O -
, O +
neuropathic O +
pain O -
, O +
acute O +
pain O -
, O +
migraine O -
, O +
asthma O -
, O +
cough O +
and O +
for O +
improved O +
cognition O -
. O +

N O -
- O -
acylamino O +
benzyl O +
ether O +
derivatives O +
This O +
invention O +
relates O +
to O +
N O -
- O -
acylamino O +
aryl O +
derivatives O +
of O +
the O +
formula O +
where O +
R1 O -
, O +
R21 O -
, O +
R22 O -
, O +
R23 O -
, O +
R24 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O -
, O +
R8 O -
, O +
R O -
, O +
and O +
n O +
are O +
as O +
defined O +
herein O +
and O +
where O +
X O +
is O +
â€”CHRO O -
, O +
â€”OCHRâ€” O -
, O +
â€”CH2Sâ€” O -
, O +
â€”SCH2â€” O -
, O +
â€”CH2CH2â€” O -
, O +
â€”CH O -
â• O -
CHâ€” O +
or O +
â€”Câ‰¡Câ€”. O +
The O +
compounds O +
of O +
the O +
invention O +
are O +
selective O +
monoamine O +
oxidase O +
B O +
inhibitors O -
, O +
and O +
they O +
are O +
therefore O +
useful O +
in O +
the O +
treatment O +
of O +
diseases O +
mediated O +
by O +
monoamine O +
oxidase O +
B O -
, O +
for O +
example O -
, O +
for O +
the O +
treatment O +
of O +
Alzheimer O -
's O +
disease O +
or O +
senile O +
dementia O -
. O +

N- O -
( O -
4-carbamimidoyl O -
- O -
phenyl O -
) O -
-glycine O +
derivatives O +
The O +
invention O +
is O +
concerned O +
with O +
novel O +
N- O -
( O -
4-carbamimidoyl O -
- O -
phenyl O -
) O -
-glycine O +
derivatives O +
of O +
the O +
formula O -
: O +
wherein O +
R1 O -
, O +
E O -
, O +
X1 O +
to O +
X4 O +
and O +
G1 O +
and O +
G2 O +
are O +
as O +
defined O +
in O +
the O +
description O +
and O +
the O +
claims O -
, O +
as O +
well O +
as O +
hydrates O +
or O +
solvates O +
and O +
physiologically O +
usable O +
salts O +
thereof O -
. O +

Compositions O +
and O +
methods O +
for O +
inducing O +
cell O +
death O +
The O +
present O +
invention O +
relates O +
to O +
methods O +
for O +
inducing O +
cell O +
death O +
via O +
activation O +
of O +
the O +
caspase B-Gene -
, O +
SAPK B-Gene -
, O +
and O +
apoptotic O +
signaling O +
cascades O +
in O +
a O +
cell O +
comprising O +
administering O +
to O +
a O +
cell O +
a O +
composition O +
comprising O +
tempo O +
in O +
a O +
amount O +
sufficient O +
to O +
induce O +
death O +
of O +
said O +
cell O -
. O +

Use O +
of O +
the O +
( O -
1S,2R O -
) O +
enantiomer O +
of O +
milnacipran O +
for O +
the O +
preparation O +
of O +
a O +
drug O +
A O +
method O +
for O +
treating O +
or O +
preventing O +
a O +
disorder O +
or O +
a O +
condition O +
by O +
double O +
inhibition O +
of O +
serotonin O +
( O -
5-HT O -
) O +
and O +
noradrenaline O +
( O -
NA O -
) O +
reuptake O +
in O +
a O +
subject O +
in O +
need O +
thereof O -
, O +
while O +
limiting O +
the O +
risks O +
of O +
cardiovascular O +
disturbances O +
and/or O +
organ O +
and/or O +
tissue O +
toxicity O -
, O +
comprising O +
the O +
step O +
of O +
administering O +
to O +
said O +
subject O +
a O +
mixture O +
of O +
enantiomers O +
of O +
milnacipran O +
enriched O +
in O +
the O +
( O -
1S,2R O -
) O +
enantiomer O +
of O +
milnacipran O +
and/or O +
of O +
at O +
least O +
one O +
of O +
its O +
metabolites O -
, O +
as O +
well O +
as O +
their O +
pharmaceutically O -
- O -
acceptable O +
salts O -
. O +

Antidepressants O +
and O +
their O +
analogues O +
as O +
long O -
- O -
acting O +
local O +
anesthetics O +
and O +
analgesics O +
Methods O +
and O +
compositions O +
of O +
antidepressants O +
and O +
analogs O +
thereof O +
for O +
inducing O +
local O +
long O -
- O -
lasting O +
anesthesia O +
and O +
analgesia O +
are O +
provided O -
. O +

The O +
methods O +
and O +
compositions O +
are O +
useful O +
for O +
alleviating O +
acute O +
and O +
chronic O +
pain O -
, O +
particularly O +
useful O +
for O +
treating O +
a O +
localized O +
pain O -
. O +

Uses O +
of O +
galanin O +
GALR2 B-Gene +
receptors O +
This O +
invention O +
provides O +
isolated O +
nucleic O +
acids O +
encoding O +
mammalian B-Gene +
galanin I-Gene +
receptors I-Gene -
, O +
isolated O +
galanin B-Gene +
receptor I-Gene +
proteins O -
, O +
vectors O +
comprising O +
isolated O +
nucleic O +
acid O +
encoding O +
a O +
mammalian B-Gene +
galanin I-Gene +
receptor I-Gene -
, O +
cells O +
comprising O +
such O +
vectors O -
, O +
antibodies O +
directed O +
to O +
a O +
mammalian B-Gene +
galanin I-Gene +
receptor I-Gene -
, O +
nucleic O +
acid O +
probes O +
useful O +
for O +
detecting O +
nucleic O +
acid O +
encoding O +
a O +
mammalian B-Gene +
galanin I-Gene +
receptor I-Gene -
, O +
antisense O +
oligonucleotides O +
complementary O +
to O +
unique O +
sequences O +
of O +
nucleic O +
acid O +
encoding O +
a O +
mammalian B-Gene +
galanin I-Gene +
receptor I-Gene -
, O +
nonhuman O +
transgenic O +
animals O +
which O +
express O +
DNA O +
encoding O +
a O +
normal O +
or O +
a O +
mutant O +
mammalian B-Gene +
galanin I-Gene +
receptor I-Gene -
, O +
as O +
well O +
as O +
methods O +
of O +
determining O +
binding O +
of O +
compounds O +
to O +
mammalian B-Gene +
galanin I-Gene +
receptors I-Gene -
. O +

Preparation O +
and O +
use O +
of O +
carbohydrate O -
- O -
based O +
bicyclic O +
ring O +
structures O +
with O +
antimicrobial O +
and O +
cytostatic O +
activity O +
Novel O +
carbohydrate O -
- O -
based O +
compounds O +
with O +
an O +
attached O +
ring O +
system O +
that O +
have O +
antimicrobial O +
or O +
cytostatic O +
activity O -
. O +

The O +
compounds O +
are O +
administered O +
to O +
humans O +
and O +
animals O +
for O +
the O +
treatment O +
or O +
amelioration O +
of O +
bacterial O -
, O +
fungal O -
, O +
viral O +
or O +
protozoal O +
infections O +
or O +
tumors O -
. O +

The O +
compounds O +
are O +
of O +
the O +
general O +
formula O -
: O +

Injection O +
made O +
from O +
Ixeris O +
Sonchifolia O +
Hance O +
for O +
treatment O +
of O +
cardio O -
- O -
cerebral O +
vascular O +
diseases O +
and O +
fundus O +
diseases O +
and O +
method O +
of O +
producing O +
thereof O +
The O +
invention O +
discloses O +
an O +
injection O +
made O +
from O +
Chinese O +
herb O +
Ixeris O +
Sonchifolia O +
Hance O +
for O +
treatment O +
of O +
cardio O -
- O -
cerebral O +
vascular O +
diseases O +
and O +
fundus O +
diseases O +
and O +
method O +
of O +
producing O +
thereof O -
. O +

The O +
injection O +
is O +
in O +
a O +
form O +
of O +
lyophilized O +
powder O +
in O +
which O +
the O +
rate O +
of O +
flavone O +
to O +
adenosine O +
is O +
5 O +
mg:15 O +
Î¼g O +
or O +
5 O +
mg:30 O +
Î¼g O -
. O +

The O +
flavone O +
and O +
adenosine O +
from O +
Ixeris O +
Sonchifolia O +
Hance O +
is O +
more O +
stable O +
in O +
the O +
lyophilized O +
powder O +
form O +
than O +
in O +
liquid O +
form O +
for O +
injection O +
so O +
that O +
it O +
is O +
easy O +
to O +
control O +
the O +
quality O +
of O +
the O +
product O +
so O +
as O +
to O +
make O +
the O +
medicament O +
safe O +
and O +
effective O -
. O +

It O +
has O +
benefit O +
in O +
store O -
. O +

Reducing O +
risk O +
of O +
thrombotic O +
cardiovascular O +
events O +
such O +
as O +
stroke O -
, O +
myocardial O +
ischemia O -
, O +
myocardial O +
infarction O -
, O +
angina O +
pectoris O -
, O +
and O +
transient O +
ischemic O +
attack O -
; O +
side O +
effect O +
reduction O +
The O +
invention O +
encompasses O +
novel O +
compounds O +
of O +
Formula O +
I O -
, O +
which O +
are O +
nitric O +
oxide O -
- O -
releasing O +
prodrugs O +
of O +
diaryl-2- O -
( O -
5H O -
) O +
furanones O +
useful O +
in O +
the O +
treatment O +
of O +
cyclooxygenase-2 B-Gene +
mediated O +
diseases O -
. O +

The O +
invention O +
also O +
encompasses O +
certain O +
pharmaceutical O +
compositions O +
and O +
methods O +
for O +
treating O +
cyclooxygenase-2 B-Gene +
mediated O +
diseases O +
comprising O +
the O +
use O +
of O +
compounds O +
of O +
Formula O +
I. O +
The O +
above O +
compounds O +
may O +
be O +
used O +
as O +
a O +
combination O +
therapy O +
with O +
low O -
- O -
dose O +
aspirin O +
to O +
treat O +
chronic O +
cyclooxygenase-2 B-Gene +
mediated O +
diseases O +
or O +
conditions O +
while O +
also O +
reducing O +
the O +
risk O +
of O +
thrombotic O +
cardiovascular O +
events O -
. O +

Composition O +
based O +
on O +
ethyl O +
ester O +
of O +
linoleic O +
acid O +
and O +
triethyl O +
ester O +
of O +
citric O +
acid O +
for O +
topical O +
use O +
in O +
the O +
treatment O +
of O +
seborrhea O +
and O +
acne O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
for O +
topical O +
use O +
for O +
treating O +
and O +
improving O +
the O +
aesthetic O +
conditions O +
of O +
the O +
skin O -
, O +
which O +
comprises O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
mixture O +
of O +
ethyllinoleate O +
and O +
triethylcitrate O -
. O +

This O +
composition O +
is O +
active O +
in O +
the O +
treatment O +
of O +
seborrhea O +
and O +
acne O -
. O +

Compounds O +
having O +
prolyl B-Gene +
oligopeptidase I-Gene +
inhibitory O +
activity O -
, O +
methods O +
for O +
their O +
preparation O +
and O +
their O +
use O +
Compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
the O +
symbol O +
aa O +
means O +
a O +
residue O +
of O +
an O +
Î± O -
- O -
amino O +
acid O -
. O +

The O +
invention O +
is O +
also O +
directed O +
to O +
a O +
method O +
for O +
the O +
preparation O +
of O +
the O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
as O +
well O +
as O +
their O +
use O +
as O +
prolyl B-Gene +
oligopeptide I-Gene +
inhibitors O -
, O +
for O +
example O +
for O +
the O +
treatment O +
of O +
Alzheimer O -
's O +
disease O -
. O +

Use O +
of O +
ozone O +
for O +
the O +
treatment O +
of O +
gum O +
disease O +
A O +
method O +
of O +
treating O +
gum O +
disease O -
, O +
includes O +
directing O +
a O +
stream O +
of O +
oxidizing O +
gas O +
onto O +
a O +
diseased O +
gum O +
for O +
a O +
period O +
of O +
time O +
sufficient O +
to O +
kill O +
microorganisms O -
. O +

Melanin B-Gene -
- I-Gene -
concentrating I-Gene +
hormone I-Gene +
antagonist O +
A O +
melanin B-Gene -
- I-Gene -
concentrating I-Gene +
hormone I-Gene +
antagonist O +
comprising O +
a O +
compound O +
of O +
the O +
formula O -
: O +
wherein O +
R O +
is O +
hydrogen O +
atom O +
or O +
a O +
cyclic O +
group O +
which O +
may O +
be O +
substituted O -
; O +
X O +
is O +
a O +
bond O +
or O +
a O +
spacer O +
having O +
a O +
main O +
chain O +
of O +
1 O +
to O +
10 O +
atoms O -
; O +
Y O +
is O +
a O +
spacer O +
having O +
a O +
main O +
chain O +
of O +
1 O +
to O +
6 O +
atoms O -
; O +
ring O +
A O +
is O +
benzene O +
ring O +
which O +
may O +
be O +
further O +
substituted O -
; O +
ring O +
B O +
is O +
a O +
5- O +
to O +
9-membered O +
nitrogen O -
- O -
containing O +
non O -
- O -
aromatic O +
heterocyclic O +
ring O +
which O +
may O +
be O +
further O +
substituted O -
; O +
R1 O +
and O +
R2 O +
are O +
the O +
same O +
or O +
different O +
and O +
are O +
hydrogen O +
atom O -
, O +
a O +
hydrocarbon O +
group O +
which O +
may O +
be O +
substituted O +
or O +
a O +
heterocyclic O +
group O +
which O +
may O +
be O +
substituted O -
; O +
or O +
R1 O +
and O +
R2 O -
, O +
together O +
with O +
the O +
adjacent O +
nitrogen O +
atom O -
, O +
may O +
form O +
a O +
nitrogen O -
- O -
containing O +
heterocyclic O +
ring O +
which O +
may O +
be O +
substituted O -
; O +
or O +
R2 O -
, O +
together O +
with O +
the O +
adjacent O +
nitrogen O +
atom O +
and O +
Y O -
, O +
may O +
form O +
a O +
nitrogen O -
- O -
containing O +
heterocyclic O +
ring O +
which O +
may O +
be O +
substituted O -
; O +
or O +
a O +
salt O +
thereof O +
is O +
useful O +
as O +
a O +
preventive O +
or O +
therapeutic O +
agent O +
for O +
obesity O -
, O +
etc O -
. O +

A O +
polynucleotide O +
comprising O +
a O +
RNA B-Gene +
polymerase I-Gene +
promoter I-Gene -
, O +
able O +
encoding O +
a O +
siRNA O -
; O +
treating O +
cancer O +
and O +
genetic O +
disorders O -
; O +
genetic O +
engineering O -
, O +
inhibit O +
gene O +
expression O +
of O +
a O +
target O +
gene O +
The O +
present O +
invention O +
provides O +
a O +
polynucleotide O +
comprising O +
a O +
RNA B-Gene +
polymerase I-Gene +
III I-Gene +
promoter I-Gene -
, O +
a O +
region O +
encoding O +
a O +
siRNA O -
, O +
and O +
a O +
transcriptional O +
termination O +
element O +
comprising O +
five O +
consecutive O +
thymine O +
residues O -
. O +

The O +
invention O +
also O +
provides O +
for O +
vectors O -
, O +
cells O +
and O +
non O -
- O -
human O +
transgenic O +
animal O +
comprising O +
the O +
polynucleotides O +
of O +
the O +
invention O +
as O +
well O +
as O +
their O +
use O +
in O +
medicaments O +
for O +
various O +
conditions O -
. O +

Recombinant O +
sequence O -
, O +
its O +
preparation O +
and O +
use O +
An O +
isolated O -
, O +
purified O +
or O +
recombinant O +
nucleic O +
acid O +
sequence O +
is O +
disclosed O -
, O +
comprising O -
: O +
( O -
a O -
) O +
a O +
sequence O +
that O +
encodes O +
both O +
an O +
angiogenic O +
factor O +
antagonist O +
and O +
a O +
vascular O +
endothelial O +
structure O +
regulator O -
; O +
( O -
b O -
) O +
a O +
sequence O +
substantially O +
homologous O +
to O +
or O +
that O +
hybridizes O +
to O +
sequence O +
( O -
a O -
) O +
under O +
stringent O +
conditions O -
; O +
or O +
( O -
c O -
) O +
a O +
sequence O +
substantially O +
homologous O +
to O +
or O +
that O +
hybridizes O +
under O +
stringent O +
conditions O +
to O +
the O +
sequence O +
( O -
a O -
) O +
or O +
( O -
b O -
) O +
but O +
for O +
the O +
degeneracy O +
of O +
the O +
genetic O +
code O -
; O +
or O +
( O -
g O -
) O +
an O +
oligonucleotide O +
specific O +
for O +
any O +
of O +
the O +
sequences O +
( O -
a O -
) O -
, O +
( O -
b O -
) O +
or O +
( O -
c O -
) O -
. O +

Particular O +
oligonucleotides O +
( O -
d O -
) O +
are O +
those O +
encoding O +
the O +
vascular O +
endothelial O +
structure O +
regulator O -
. O +

Also O +
described O +
are O +
methods O +
for O +
preparing O +
the O +
recombinant O +
polynucleotide O -
, O +
proteins O +
encoded O +
by O +
such O +
polynucleotides O +
and O +
their O +
use O +
in O +
gene O +
or O +
protein O +
therapy O +
for O +
the O +
treatment O +
of O +
conditions O +
such O +
as O +
cancer O -
. O +

Benzofuran O +
inhibitors O +
of O +
factor O +
VIIa O +
Compounds O +
of O +
Formula O +
I O +
are O +
useful O +
for O +
inhibiting O +
serine O +
protease O +
enzymes O -
, O +
such O +
as O +
TF O -
/ O -
factor O +
VIIa O -
, O +
factor O +
Xa O -
, O +
thrombin O +
and O +
kallikrein O +
and O +
have O +
improved O +
pharmacokinetic O +
properties O -
. O +

These O +
compounds O +
may O +
be O +
used O +
in O +
methods O +
of O +
preventing O +
and/or O +
treating O +
clotting O +
disorders O -
. O +

Infections O +
caused O +
by O +
Gram O +
positive O +
and/or O +
negative O +
pathogens O +
The O +
invention O +
relates O +
to O +
novel O +
tetrahydroisoquinoline O +
derivatives O +
of O +
general O +
formula O +
I O +
and O +
theirs O +
use O +
as O +
active O +
ingredients O +
in O +
the O +
preparation O +
of O +
pharmaceutical O +
compositions O -
. O +

The O +
invention O +
also O +
concerns O +
related O +
aspects O +
including O +
processes O +
for O +
the O +
preparation O +
of O +
the O +
compounds O -
, O +
pharmaceutical O +
compositions O +
containing O +
one O +
or O +
more O +
of O +
those O +
compounds O +
and O +
their O +
use O +
as O +
anti O -
- O -
infectives O -
, O +
wherein O +
R1 O -
, O +
R2 O +
and O +
R3 O +
are O +
as O +
defined O +
in O +
claim O +
1 O -
. O +

Method O +
for O +
use O +
of O +
IGF B-Gene -
- I-Gene -
binding I-Gene +
protein I-Gene +
for O +
selective O +
sensitization O +
of O +
target O +
cells O +
in O +
vivo O +
New O +
methods O +
for O +
the O +
treatment O +
of O +
human O +
disease O +
are O +
provided O -
. O +

IGFBP-3 B-Gene +
is O +
administered O +
together O +
with O +
a O +
co O -
- O -
administered O +
agent O +
to O +
subjects O +
having O +
disease O -
, O +
thereby O +
alleviating O +
the O +
symptoms O +
of O +
the O +
disease O -
, O +
under O +
conditions O +
where O +
administration O +
of O +
IGFBP-3 B-Gene +
alone O +
at O +
the O +
maximum O +
practicable O +
dose O +
has O +
no O +
measurable O +
beneficial O +
effect O +
on O +
the O +
disease O +
condition O -
. O +

Inhibiting O +
cyclin B-Gene -
- I-Gene -
dependent I-Gene +
kinase I-Gene +
complexes I-Gene +
including O +
cdk1 B-Gene -
/ O -
cyclin B-Gene +
B I-Gene -
, O +
cdk2 B-Gene -
/ O -
cyclin B-Gene +
E I-Gene +
and O +
cdk4 B-Gene -
/ O -
cyclin B-Gene +
D1 I-Gene -
; O +
preventing O +
apoptosis O +
The O +
present O +
invention O +
is O +
directed O +
to O +
acyl O +
and O +
sulfonyl O +
derivatives O +
of O +
6,9-disubstituted O +
2- O -
( O -
trans-1,4 O +
-diaminocyclohexyl O -
) O -
-purines O +
of O +
the O +
formula O +
where O +
Z O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
â€”S O -
( O -
O O -
) O -
2â€” O -
, O +
and O +
â€”C O -
( O -
O O -
) O -
â€”. O +

Methods O +
for O +
treating O +
or O +
preventing O +
an O +
inflammatory O +
or O +
metabolic O +
condition O +
or O +
inhibiting O +
JNK B-Gene +
This O +
invention O +
generally O +
relates O +
to O +
methods O +
for O +
treating O +
or O +
preventing O +
a O +
condition O +
responsive O +
to O +
JNK B-Gene +
inhibition O -
, O +
such O +
as O +
a O +
metabolic O +
condition O -
, O +
comprising O +
administering O +
to O +
a O +
patient O +
in O +
need O +
thereof O +
an O +
effective O +
amount O +
of O +
an O +
Anilinopyrimidine O +
Derivative O +
having O +
the O +
following O +
structure O -
: O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
wherein O +
R1 O +
through O +
R6 O +
are O +
as O +
defined O +
herein O -
. O +

Inhibition O +
of O +
systemic O +
infections O +
in O +
humans O +
and O +
vertebrates O +
by O +
dietary O +
fibers O +
The O +
use O +
of O +
a O +
dietary O +
fiber O +
or O +
a O +
mixture O +
of O +
dietary O +
fibers O +
for O +
the O +
manufacture O +
of O +
a O +
composition O -
, O +
being O +
a O +
pharmaceutical O +
composition O +
or O +
a O +
functional O +
food O +
or O +
a O +
functional O +
feed O -
, O +
for O +
the O +
prevention O -
, O +
the O +
inhibition O +
and/or O +
the O +
treatment O +
of O +
systemic O +
infections O +
in O +
humans O +
and O +
in O +
vertebrates O +
caused O +
by O +
pathogenic O +
bacteria O +
is O +
disclosed O -
. O +

A O +
method O +
for O +
the O +
prevention O -
, O +
the O +
inhibition O +
and/or O +
the O +
treatment O +
of O +
systemic O +
infections O +
in O +
humans O +
and O +
in O +
vertebrates O +
caused O +
by O +
pathogenic O +
bacteria O -
, O +
comprising O +
administration O +
to O +
said O +
beings O -
, O +
orally O -
, O +
through O +
tube O +
feeding O +
or O +
rectally O -
, O +
a O +
composition O +
containing O +
an O +
effective O +
amount O +
of O +
a O +
dietary O +
fiber O +
or O +
mixture O +
of O +
dietary O +
fibers O +
is O +
also O +
disclosed O -
. O +

The O +
dietary O +
fiber O +
is O +
preferably O +
a O +
fructan O -
, O +
typically O +
inulin O +
and/or O +
oligofructose O -
, O +
most O +
preferably O +
chicory O +
inulin O +
with O +
an O +
average O +
degree O +
of O +
polymerization O +
( O -
DP O -
) O +
of O +
at O +
least O +
20 O -
. O +

Diazepine O +
compounds O +
as O +
ligands O +
of O +
the O +
melanocortin B-Gene +
1 I-Gene +
and/or I-Gene +
4 I-Gene +
receptors I-Gene +
There O +
is O +
provided O +
novel O +
diazepines O +
that O +
function O +
as O +
agonists O +
at O +
the O +
melanocortin B-Gene +
4 I-Gene +
receptor I-Gene +
and O +
as O +
agonists O +
at O +
the O +
melanocortin B-Gene +
1 I-Gene +
receptor I-Gene -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
methods O +
for O +
their O +
use O +
in O +
treatment O -
, O +
and O +
processes O +
for O +
their O +
preparation O -
. O +

For O +
treatment O +
of O +
rheumatoid O +
arthritis O -
, O +
inflammatory O +
or O +
autoimmune O +
condition O -
, O +
viral O +
infection O -
, O +
cancer O -
; O +
4- O -
{ O -
[ O -
4- O -
( O -
4-chlorophenyl O -
) O -
pyrimidin-2-yl O -
] O -
amino O -
} O -
benzamide O +
Compounds O +
having O +
activity O +
as O +
inhibitors O +
of O +
IKK B-Gene +
are O +
disclosed O -
, O +
particularly O +
IKK-2 B-Gene -
. O +

The O +
compounds O +
of O +
this O +
invention O +
are O +
anilinopyrimidine O +
derivatives O +
having O +
the O +
following O +
structure O -
: O +
wherein O +
R1 O +
and O +
R6 O +
are O +
as O +
defined O +
herein O -
. O +

Such O +
compounds O +
have O +
utility O +
in O +
the O +
treatment O +
of O +
a O +
wide O +
range O +
of O +
conditions O +
that O +
are O +
responsive O +
to O +
IKK B-Gene +
inhibition O -
. O +

Thus O -
, O +
methods O +
of O +
treating O +
such O +
conditions O +
are O +
also O +
disclosed O -
, O +
as O +
are O +
pharmaceutical O +
compositions O +
containing O +
one O +
or O +
more O +
compounds O +
of O +
the O +
above O +
compounds O -
. O +

Adust O +
fatty O +
acid O +
oxidation O -
; O +
stimulant O +
of O +
carnitine B-Gene +
plamitoyl I-Gene +
treansferrase I-Gene +
This O +
invention O +
provides O +
methods O +
and O +
compositions O +
for O +
inducing O +
weight O +
loss O +
and O +
maintaining O +
optimum O +
weight O +
comprising O +
administering O +
an O +
agent O +
that O +
stimulates O +
carnitine B-Gene +
palmitoyl I-Gene +
transferase-1 I-Gene +
( O -
CPT-1 B-Gene -
) O +
activity O +
to O +
the O +
patient O +
in O +
need O -
, O +
including O +
human O +
patients O -
. O +

These O +
methods O +
do O +
not O +
require O +
inhibition O +
of O +
fatty O +
acid O +
synthesis O -
. O +

In O +
particular O -
, O +
this O +
invention O +
provides O +
methods O +
for O +
development O +
of O +
therapeutics O +
that O +
selectively O +
enhance O +
fatty O +
acid O +
oxidation O -
, O +
increase O +
energy O +
production O -
, O +
and O +
reduce O +
adiposity O +
while O +
preserving O +
lean O +
mass O -
, O +
through O +
the O +
pharmacological O +
stimulation O +
of O +
CPT-1 B-Gene +
activity O -
. O +

In O +
a O +
preferred O +
mode O -
, O +
the O +
agent O +
is O +
administered O +
in O +
an O +
amount O +
sufficient O +
to O +
increase O +
fatty O +
acid O +
oxidation O -
. O +

In O +
another O +
preferred O +
mode O -
, O +
the O +
agent O +
is O +
administered O +
in O +
an O +
amount O +
sufficient O +
to O +
antagonize O +
malonyl O +
CoA O +
inhibition O +
of O +
CPT-1 B-Gene -
. O +

In O +
yet O +
another O +
preferred O +
mode O -
, O +
the O +
agent O +
is O +
administered O +
in O +
an O +
amount O +
sufficient O +
to O +
increase O +
malonyl O +
CoA O +
level O -
. O +

Identifying O +
modulators O +
for O +
prevention O +
and O +
treatment O +
of O +
infection O -
, O +
blood O -
, O +
metabolic O -
, O +
cell O +
proliferative O +
and O +
respiratory O +
system O +
disorders O +
The O +
present O +
invention O +
provides O +
a O +
purified O +
polynucleotide O +
encoding O +
a O +
novel O +
polypeptide O -
, O +
designated O +
Fhm O -
, O +
which O +
belongs O +
to O +
the O +
TNF B-Gene +
gene O +
superfamily O -
; O +
to O +
purified O +
Fhm O +
polypeptide O +
molecules O -
; O +
to O +
antibodies O +
that O +
bind O +
Fhm O -
; O +
to O +
materials O +
comprising O +
such O +
molecules O -
; O +
and O +
to O +
methods O +
of O +
using O +
such O +
molecules O -
. O +

Use O +
of O +
phosphodiesterase O +
4 O +
inhibitors O +
such O +
as O +
6,7-dimethoxy-1- O -
[ O -
2- O -
( O -
1,3-dioxocyclohexan-2-yl O -
) O -
pyridin-4-yl O -
] O -
-2,3-bis O -
( O -
hydroxymethyl O -
) O -
naphthalene O +
to O +
treat O +
asthma O -
, O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
atopic O +
dermatitis O -
, O +
allergic O +
rhinitis O -
, O +
psoriasis O -
, O +
rheumatoid O +
arthritis O -
, O +
septic O +
shock O -
, O +
ulcerative O +
colitis O +
The O +
present O +
invention O +
provides O +
a O +
novel O +
a O +
condensed O +
polycyclic O +
compound O +
useful O +
as O +
a O +
phosphodiesterase B-Gene +
4 I-Gene +
inhibitor O -
, O +
which O +
is O +
shown O +
by O +
the O +
formula O +
[ O -
I O -
] O -
: O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and O +
a O +
pharmaceutical O +
composition O +
containing O +
the O +
same O -
. O +

Heparin O +
prodrugs O +
and O +
drug O +
delivery O +
stents O +
formed O +
therefrom O +
A O +
prodrug O +
comprising O +
a O +
heparin O +
and O +
a O +
drug O +
is O +
provided O -
. O +

The O +
prodrug O +
can O +
be O +
used O +
to O +
form O +
a O +
coating O +
on O +
a O +
medical O +
device O -
. O +

The O +
prodrug O +
can O +
also O +
be O +
used O +
with O +
a O +
polymeric O +
material O +
to O +
form O +
a O +
coating O +
on O +
a O +
medical O +
device O -
. O +

The O +
polymeric O +
material O +
can O +
be O +
a O +
hydrophobic O +
polymer O -
, O +
a O +
hydrophilic O +
polymer O -
, O +
a O +
non O -
- O -
fouling O +
polymer O -
, O +
or O +
combinations O +
thereof O -
. O +

The O +
medical O +
device O +
can O +
be O +
implanted O +
in O +
a O +
human O +
being O +
for O +
the O +
treatment O +
of O +
a O +
disease O +
such O +
as O +
atherosclerosis O -
, O +
thrombosis O -
, O +
restenosis O -
, O +
hemorrhage O -
, O +
vascular O +
dissection O +
or O +
perforation O -
, O +
vascular O +
aneurysm O -
, O +
vulnerable O +
plaque O -
, O +
chronic O +
total O +
occlusion O -
, O +
claudication O -
, O +
anastomotic O +
proliferation O +
for O +
vein O +
and O +
artificial O +
grafts O -
, O +
bile O +
duct O +
obstruction O -
, O +
ureter O +
obstruction O -
, O +
tumor O +
obstruction O -
, O +
or O +
combinations O +
thereof O -
. O +

administering O +
a O +
cholinesterase B-Gene +
inhibitor O +
( O +
a O +
dimethoxyindanone O +
derivative O -
) O +
to O +
treat O +
dementia O +
associated O +
with O +
or O +
caused O +
by O +
vascular O +
diseases O +
The O +
invention O +
describes O +
novel O +
methods O +
for O +
treating O +
and O +
preventing O +
dementia O +
caused O +
by O +
vascular O +
diseases O -
; O +
dementia O +
associated O +
with O +
Parkinson O -
's O +
disease O -
; O +
Lewy O +
Body O +
dementia O -
; O +
AIDS O +
dementia O -
; O +
mild O +
cognitive O +
impairments O -
; O +
age O -
- O -
associated O +
memory O +
impairments O -
; O +
cognitive O +
impairments O +
and/or O +
dementia O +
associated O +
with O +
neurologic O +
and/or O +
psychiatric O +
conditions O -
, O +
including O +
epilepsy O -
, O +
brain O +
tumors O -
, O +
brain O +
lesions O -
, O +
multiple O +
sclerosis O -
, O +
Down O -
's O +
syndrome O -
, O +
Rett O -
's O +
syndrome O -
, O +
progressive O +
supranuclear O +
palsy O -
, O +
frontal O +
lobe O +
syndrome O -
, O +
and O +
schizophrenia O +
and O +
related O +
psychiatric O +
disorders O -
; O +
cognitive O +
impairments O +
caused O +
by O +
traumatic O +
brain O +
injury O -
, O +
post O +
coronary O +
artery O +
by O -
- O -
pass O +
graft O +
surgery O -
, O +
electroconvulsive O +
shock O +
therapy O -
, O +
and O +
chemotherapy O -
, O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
of O +
the O +
cholinesterase B-Gene +
inhibitor O +
compounds O +
described O +
herein O -
. O +

The O +
invention O +
also O +
describes O +
novel O +
methods O +
for O +
treating O +
and O +
preventing O +
delirium O -
, O +
Tourette O -
's O +
syndrome O -
, O +
myasthenia O +
gravis O -
, O +
attention O +
deficit O +
hyperactivity O +
disorder O -
, O +
autism O -
, O +
dyslexia O -
, O +
mania O -
, O +
depression O -
, O +
apathy O -
, O +
and O +
myopathy O +
associated O +
with O +
diabetes O +
by O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
of O +
the O +
cholinesterase B-Gene +
inhibitor O +
compounds O +
described O +
herein O -
. O +

The O +
invention O +
also O +
describes O +
novel O +
methods O +
for O +
delaying O +
the O +
onset O +
of O +
Alzheimer O -
's O +
disease O -
, O +
for O +
enhancing O +
cognitive O +
functions O -
, O +
for O +
treating O +
and O +
preventing O +
sleep O +
apnea O -
, O +
for O +
alleviating O +
tobacco O +
withdrawal O +
syndrome O -
, O +
and O +
for O +
treating O +
the O +
dysfunctions O +
of O +
Huntington O -
's O +
Disease O +
by O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
of O +
the O +
cholinesterase B-Gene +
inhibitor O +
compounds O +
described O +
herein O -
. O +

A O +
preferred O +
cholinesterase B-Gene +
inhibitor O +
for O +
use O +
in O +
the O +
methods O +
of O +
the O +
invention O +
is O +
donepezil O +
hydrochloride O +
or O +
ARICEPT O -
Â® O -
. O +

For O +
therapy O +
of O +
oncoses O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
N O -
- O -
substituted O +
indole-3-glyoxylamides O +
of O +
the O +
general O +
formula O +
I O +
as O +
antitumor O +
agents O +
and O +
to O +
a O +
pharmaceutical O +
composition O +
having O +
antitumor O +
action O -
, O +
characterized O +
in O +
that O +
it O +
contains O +
at O +
least O +
one O +
of O +
the O +
compounds O +
of O +
the O +
general O +
formula O +
1 O -
, O +
if O +
appropriate O +
also O +
in O +
the O +
form O +
of O +
the O +
physiologically O +
tolerable O +
acid O +
addition O +
salts O +
or O +
N O -
- O -
oxides O -
. O +

Furthermore O -
, O +
the O +
invention O +
also O +
includes O +
antitumor O +
agents O +
comprising O +
as O +
active O +
compound O +
one O +
or O +
more O +
N O -
- O -
substituted O +
indole-3-glyoxylamides O +
according O +
to O +
the O +
general O +
formula O +
1 O +
and O -
, O +
if O +
appropriate O -
, O +
their O +
physiologically O +
tolerable O +
acid O +
addition O +
salts O +
and O -
, O +
if O +
possible O -
, O +
N O -
- O -
oxides O +
and O +
a O +
pharmaceutically O +
utilizable O +
carrier O +
and/or O +
diluent O +
or O +
auxiliary O +
substance O +
in O +
the O +
form O +
of O +
tablets O -
, O +
coated O +
tablets O -
, O +
capsules O -
, O +
solutions O +
for O +
infusion O +
or O +
ampoules O -
, O +
suppositories O -
, O +
patches O -
, O +
powder O +
preparations O +
which O +
can O +
be O +
employed O +
by O +
inhalation O -
, O +
suspensions O -
, O +
creams O +
and O +
ointments O -
. O +

Epothilone O +
derivatives O +
and O +
their O +
synthesis O +
and O +
use O +
The O +
invention O +
relates O +
to O +
epothilone O +
analog O +
represented O +
by O +
the O +
formula O +
I O +
wherein O +
( O -
i O -
) O +
R2 O +
is O +
absent O +
or O +
oxygen O -
; O +
" O -
a O -
" O +
can O +
be O +
either O +
a O +
single O +
or O +
double O +
bond O -
; O +
" O -
b O -
" O +
can O +
be O +
either O +
absent O +
or O +
a O +
single O +
bond O -
; O +
and O +
" O -
c O -
" O +
can O +
be O +
either O +
absent O +
or O +
a O +
single O +
bond O -
, O +
with O +
the O +
proviso O +
that O +
if O +
R2 O +
is O +
oxygen O +
then O +
" O -
b O -
" O +
and O +
" O -
c O -
" O +
are O +
both O +
a O +
single O +
bond O +
and O +
" O -
a O -
" O +
is O +
a O +
single O +
bond O -
; O +
if O +
R2 O +
is O +
absent O +
then O +
" O -
b O -
" O +
and O +
" O -
c O -
" O +
are O +
absent O +
and O +
" O -
a O -
" O +
is O +
a O +
double O +
bond O -
; O +
and O +
if O +
" O -
a O -
" O +
is O +
a O +
double O +
bond O -
, O +
then O +
R2 O -
, O +
" O -
b O -
" O +
and O +
" O -
c O -
" O +
are O +
absent O -
; O +
R3 O +
is O +
a O +
radical O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
hydrogen O -
; O +
lower O +
alkyl O -
; O +
â€”CH O -
â• O -
CH2 O -
; O +
â€”Câ‰¡CH O -
; O +
â€”CH2F O -
; O +
â€”CH2Cl O -
; O +
â€”CH2â€”OH O -
; O +
â€”CH2â€”Oâ€” O -
( O -
C1-C6-alkyl O -
) O -
; O +
and O +
â€”CH2â€”Sâ€” O -
( O -
C1-C6-alkyl O -
) O -
; O +
R4 O +
and O +
R5 O +
are O +
independently O +
selected O +
from O +
hydrogen O -
, O +
methyl O +
or O +
a O +
protecting O +
group O -
; O +
and O +
R1 O +
is O +
as O +
defined O +
in O +
the O +
specification O -
, O +
or O +
a O +
salt O +
of O +
a O +
compound O +
of O +
the O +
formula O +
I O +
where O +
a O +
salt O -
- O -
forming O +
group O +
is O +
present O -
. O +

A O +
further O +
aspect O +
of O +
the O +
invention O +
is O +
related O +
to O +
the O +
synthesis O +
of O +
epothilone O +
E. O +
These O +
compounds O +
have O +
inter O +
alia O +
microtubuli O +
depolymerisation O +
inhibiting O +
activity O +
and O +
are O +
e.g. O +
useful O +
against O +
proliferative O +
diseases O -
. O +

Modulators O +
of O +
blood O +
glucose O +
levels O -
, O +
triglyceride O +
levels O -
, O +
insulin B-Gene +
levels O +
and O +
non O -
- O -
esterified O +
fatty O +
acid O +
( O -
NEFA O -
) O +
levels O -
; O +
hypoglycemia O +
Compounds O +
are O +
provided O +
which O +
have O +
the O +
structure O +
wherein O +
Q O +
is O +
C O +
or O +
N O -
, O +
A O +
is O +
O O +
or O +
S O -
, O +
Z O +
is O +
O O +
or O +
a O +
bond O -
, O +
X O +
is O +
CH O +
or O +
N O +
and O +
R1 O -
, O +
R2 O -
, O +
R2a O -
, O +
R2b O -
, O +
R2c O -
, O +
R3 O -
, O +
Y O -
, O +
x O -
, O +
m O -
, O +
and O +
n O +
are O +
as O +
defined O +
herein O -
, O +
which O +
compounds O +
are O +
useful O +
as O +
antidiabetic O -
, O +
hypolipidemic O -
, O +
and O +
antiobesity O +
agents O -
. O +

Antidiabetic O +
agents O -
, O +
antilipemic O +
agents O -
, O +
dietetics O -
, O +
anticholesterol O +
agents O -
, O +
hypotensive O +
agents O -
, O +
cardiovascular O +
disorders O -
; O +
( O -
S O -
) O -
-Ethyl O +
2-methoxy-3- O -
[ O -
4- O -
{ O -
3- O -
( O -
4-methanesulfonyloxyphenyl O -
) O +
propylamino O -
} O -
phenyl O -
] O -
propionate O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
antidiabetic O -
, O +
hypolipidemic O -
, O +
antiobesity O +
and O +
hypocholesterolemic O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
their O +
derivatives O -
, O +
their O +
analogs O -
, O +
their O +
tautomeric O +
forms O -
, O +
their O +
stereoisomers O -
, O +
their O +
polymorphs O -
, O +
their O +
pharmaceutically O +
acceptable O +
salts O -
, O +
their O +
pharmaceutically O +
acceptable O +
solvates O +
and O +
pharmaceutically O +
acceptable O +
compositions O +
containing O +
them O -
. O +

Antiproliferative O +
agents O -
; O +
antiinflammatory O +
agents O -
; O +
anticancer O +
agents O -
; O +
diagnosis O -
, O +
therapy O +
The O +
present O +
invention O +
pertains O +
to O +
the O +
use O +
of O +
a O +
compounds O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
use O +
in O +
the O +
treatment O +
of O +
a O +
proliferative O +
condition O -
, O +
wherein O +
the O +
compounds O +
have O +
the O +
following O +
formula O -
: O +
wherein O -
: O +
each O +
of O +
RB2 O -
, O +
RB3 O -
, O +
RB4 O -
, O +
and O +
RB5 O +
is O +
independently O +
â€”H O -
, O +
â€”OH O -
, O +
or O +
â€”OMe O -
; O +
each O +
of O +
R1 O +
and O +
R2 O +
is O +
independently O -
: O +
â€”H O -
, O +
optionally O +
substituted O +
C1 O -
- O -
4alkyl O -
, O +
or O +
optionally O +
substituted O +
C5 O -
- O -
20aryl O -
; O +
RA3 O +
is O +
â€”H O -
, O +
â€”OH O -
, O +
â€”OC O -
( O -
â• O -
O O -
) O -
RE O -
, O +
â€”OS O -
( O -
â• O -
O O -
) O -
2OH O -
, O +
or O +
â€”OP O -
( O -
â• O -
O O -
) O -
( O -
OH O -
) O -
2 O -
; O +
RE O +
is O -
: O +
â€”H O -
, O +
optionally O +
substituted O +
C1 O -
- O -
6alkyl O -
, O +
optionally O +
substituted O +
C3 O -
- O -
20 O +
heterocyclyl O -
, O +
or O +
optionally O +
substituted O +
C5 O -
- O -
20aryl O -
; O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
solvate O -
, O +
amide O -
, O +
ester O -
, O +
ether O -
, O +
chemically O +
protected O +
form O -
, O +
or O +
prodrug O +
thereof O -
. O +

The O +
present O +
invention O +
also O +
pertains O +
to O +
such O +
compounds O -
, O +
pharmaceutical O +
compositions O +
comprising O +
such O +
compounds O -
, O +
and O +
the O +
use O +
of O +
such O +
compounds O +
and O +
compositions O -
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
for O +
both O +
diagnosis O +
and O +
treatment O +
of O -
, O +
for O +
example O -
, O +
proliferative O +
conditions O -
, O +
such O +
as O +
cancer O -
, O +
and O +
inflammatory O +
conditions O -
. O +

Induce O +
cell O +
differentiation O -
; O +
process O +
control O +
The O +
invention O +
features O +
methods O +
for O +
increasing O +
or O +
maintaining O +
the O +
number O +
of O +
functional O +
cells O +
of O +
a O +
predetermined O +
type O -
, O +
for O +
example O -
, O +
insulin B-Gene +
producing O +
cells O +
of O +
the O +
pancreas O -
, O +
blood O +
cells O -
, O +
spleen O +
cells O -
, O +
brain O +
cells O -
, O +
heart O +
cells O -
, O +
vascular O +
tissue O +
cells O -
, O +
cells O +
of O +
the O +
bile O +
duct O -
, O +
or O +
skin O +
cells O -
, O +
in O +
a O +
mammal O +
( O -
e.g. O -
, O +
a O +
human O +
patient O -
) O +
that O +
has O +
injured O +
or O +
damaged O +
cells O +
of O +
the O +
predetermined O +
type O -
. O +

Fluidized O +
bed O +
granulation O -
, O +
compression O +
to O +
form O +
tablets O +
A O +
process O +
for O +
the O +
preparation O +
of O +
an O +
orally O +
administrable O +
calcium O +
composition O +
comprising O +
the O +
steps O +
of O -
: O +
( O -
i O -
) O +
obtaining O +
a O +
physiologically O +
tolerable O +
particulate O +
calcium O +
compound O +
having O +
a O +
mean O +
particle O +
size O +
in O +
the O +
range O +
3 O +
to O +
40 O +
Î¼m O -
, O +
having O +
a O +
crystalline O +
structure O +
and O +
having O +
a O +
surface O +
area O +
of O +
0.1 O +
to O +
1.2 O +
m2 O -
/ O -
g O -
; O +
( O -
ii O -
) O +
mixing O +
the O +
calcium O +
compound O +
with O +
a O +
water O -
- O -
soluble O +
diluent O +
and O +
an O +
aqueous O +
solution O +
of O +
a O +
water O +
soluble O +
binder O +
in O +
a O +
fluid O +
bed O +
granulation O +
apparatus O +
and O +
drying O +
the O +
resulting O +
mixture O +
to O +
produce O +
a O +
first O +
granulate O -
; O +
( O -
iii O -
) O +
optionally O +
mixing O +
the O +
first O +
granulate O +
with O +
one O +
or O +
more O +
further O +
components O +
to O +
produce O +
a O +
second O +
granulate O -
; O +
and O +
( O -
iv O -
) O +
optionally O +
compressing O +
the O +
first O +
or O +
second O +
granulate O +
to O +
form O +
tablets O -
. O +

Methods O +
and O +
compositions O +
for O +
the O +
treatment O +
of O +
diseases O +
of O +
the O +
eye O +
Methods O +
and O +
compositions O +
for O +
prophylaxis O +
and/or O +
treatment O +
of O +
diseases O +
of O +
the O +
eye O +
of O +
a O +
patient O +
resulting O +
angiogenesis O +
in O +
the O +
eye O +
using O +
antagonists O +
of O +
the O +
integrin O +
receptors O +
Î±v O +
Î²3 O +
and/or O +
Î±v O +
Î²5 O -
. O +

The O +
compositions O +
can O +
be O +
nanoparticles O +
and O +
are O +
administered O +
to O +
the O +
eye O +
by O +
injection O +
into O +
the O +
sclera O +
of O +
the O +
eye O -
. O +

4-Deoxy-3,4- O -
[ O -
2-spiro- O -
[ O -
1- O -
[ O -
2- O -
( O -
2-methyl-5-nitro O -
- O -
imidazol-1-yl O -
) O -
ethyl O -
] O -
-piperidin-4-yl O -
] O -
] O -
- O -
( O -
1H O -
) O -
-imidazo- O -
( O -
2,5-dihydro O -
) O -
rifamycin O -
; O +
antibiotic O +
resistance O -
; O +
synergistic O +
effects O +
of O +
covalently O +
linking O +
antibacterial O +
pharmacophores O +
together O -
; O +
pharmacokinetics O -
; O +
aerobic O -
, O +
anaerobic O +
gram O -
- O -
positive O +
and O +
gram O -
- O -
negative O +
bacteria O +
Substituted O +
rifamycin O +
derivatives O +
in O +
which O +
a O +
nitroimidazole O -
, O +
nitrothiazole O +
or O +
nitrofuran O +
pharmacophore O +
is O +
covalently O +
bonded O +
to O +
a O +
rifamycin O -
, O +
methods O +
of O +
using O +
the O +
rifamycin O +
derivatives O -
, O +
and O +
pharmaceutical O +
compositions O +
containing O +
the O +
rifamycin O +
derivatives O +
are O +
disclosed O -
. O +

Methods O +
of O +
synthesizing O +
these O +
substituted O +
rifamycin O +
derivatives O +
are O +
also O +
disclosed O -
. O +

The O +
rifamycin O +
derivatives O +
possess O +
antibacterial O +
activity O -
, O +
and O +
are O +
effective O +
against O +
a O +
number O +
of O +
human O +
and O +
veterinary O +
pathogens O +
in O +
the O +
treatment O +
of O +
bacterial O +
diseases O -
. O +

3- O -
( O -
( O -
1,2,5,6-tetrahydro-2-methyl-5,6-d O +
ioxo-1,2,4-triazine-3-yl O -
) O -
thio O -
) O -
methyl O -
) O -
-7- O -
[ O -
[ O -
[ O -
[ O -
[ O -
( O -
1-methyl O +
ethyl O -
) O -
amino O -
] O -
[ O -
( O -
1-methylethyl O -
) O -
imino O -
] O -
methyl O -
] O -
thio O -
] O -
acetyl O -
] O -
amino O -
] O -
-8-oxo-5-thia-1-aza O -
- O -
bicyclo O +
[ O -
4.2.0 O -
] O -
oct-2-ene-2-carboxylic O +
acid O -
; O +
bioavailibility O -
; O +
stability O -
; O +
pharmacokinetics O -
; O +
antibiotics O -
; O +
infections O +
Disclosed O +
herein O +
are O +
a O +
cephalosporin O +
compound O +
of O +
formula O +
I O -
, O +
wherein O +
R1 O +
is O +
selected O +
from O +
the O +
following O +
groups O -
: O +
wherein O +
R2 O +
is O +
selected O +
from O +
the O +
following O +
groups O -
: O +
the O +
preparation O +
and O +
uses O +
thereof O -
. O +

A O +
method O +
of O +
preparing O +
the O +
cephalosporin O +
compound O +
as O +
disclosed O +
herein O +
comprises O +
reacting O +
a O +
starting O +
cephalosporin O +
comprising O +
a O +
C7 O +
amino O +
group O +
and O +
a O +
C3 O +
thio O -
- O -
methyl O +
moiety O +
substituted O +
with O +
an O +
N O -
- O -
containing O +
heterocyclic O +
group O +
with O +
bromoacetyl O +
bromide O +
and O +
then O +
with O +
a O +
N O -
, O -
Nâ€²-bissubstituted O +
thiourea O -
. O +

Methods O +
of O +
treating O +
an O +
infectious O +
disease O +
are O +
also O +
disclosed O -
, O +
comprising O +
administering O +
to O +
a O +
patient O +
in O +
need O +
thereof O +
the O +
pharmaceutical O +
composition O +
disclosed O +
herein O -
. O +

1-Substituted- O -
[ O -
1H O -
- O -
indene-6,1'-cyclopropane O -
] O -
-4-one O +
derivatives O -
: O +
solid O +
tumors O +
and O +
multi O -
- O -
drug O +
resistant O +
tumors O -
; O +
-cell O +
leukemia O -
, O +
B O -
- O -
cell O +
lymphoma O -
, O +
myeloma O -
, O +
T O -
- O -
cell O +
leukemia O -
, O +
T O -
- O -
cell O +
lymphoma O -
, O +
small O +
leukemia O -
, O +
and O +
small O +
cell O +
lymphoma O +
The O +
present O +
invention O +
provides O +
illudin O +
analogs O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
where O +
R1 O +
is O +
( O -
CH2 O -
) O -
n O -
â€” O -
X O -
â€” O -
Y O +
or O +
H O -
; O +
n O +
is O +
0 O +
to O +
4 O -
; O +
X O +
is O +
O O +
or O +
S O +
or O +
N O +
or O +
absent O -
; O +
and O +
Y O +
is O +
an O +
optionally O +
substituted O +
( O -
C1-C8 O -
) O -
alkyl O -
, O +
( O -
C6-C10 O -
) O -
aryl O -
, O +
( O -
C6-C10 O -
) O -
aryl O -
( O -
C1-C4 O -
) O -
alkyl O +
or O +
cyclo O -
( O -
C3-C6 O -
) O -
alkyl O +
optionally O +
comprising O +
one O +
or O +
more O +
heteroatoms O -
; O +
a O +
monosaccharide O -
, O +
an O +
amino O +
acid O +
residue O -
, O +
or O +
H O +
when O +
n O +
is O +
2 O -
- O -
4 O -
; O +
R2 O +
is O +
absent O -
; O +
or O +
R1 O +
and O +
R2 O +
together O +
comprise O +
a O +
5 O -
- O -
7 O +
membered O +
cyclic O +
ring O -
; O +
R3 O +
is O +
( O -
C1-C4 O -
) O -
alkyl O +
or O +
H O -
; O +
R4 O +
is O +
H O -
, O +
SCH2CO2 O -
( O -
C1-C4 O -
) O -
alkyl O -
, O +
Oâ€” O -
( O -
C5-C12 O -
) O -
aryl O +
or O +
â€”Sâ€” O -
( O -
C5-C12 O -
) O -
aryl O -
; O +
R5 O +
is O +
H O -
, O +
OH O +
or O +
absent O -
; O +
R6 O +
is O +
( O -
C1-C4 O -
) O -
alkyl O +
or O +
absent O -
; O +
R7 O +
is O +
OH O +
or O +
OSi O -
( O -
( O -
C1-C4 O -
) O -
alkyl O -
) O -
3 O -
; O +
or O +
R6 O +
and O +
R7 O +
together O +
are O +
ethylenedioxy O -
; O +
R8 O +
is O +
optionally O +
substituted O +
( O -
C1-C4 O -
) O -
alkyl O -
; O +
and O +
the O +
bonds O +
represented O +
by O +
----- O +
are O +
individually O +
present O +
or O +
absent O -
. O +

The O +
invention O +
further O +
provides O +
dimers O +
comprising O +
analogs O +
of O +
formula O +
( O -
I O -
) O -
. O +

10- O -
( O -
o O -
- O -
Hydroxyphenyl O -
) O -
--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a O -
- O -
triazacyclopenty O -
[ O -
b O -
] O -
fluorene-1,3-diones O +
or O +
the O +
corresponding O +
2,10a O -
- O -
diaza-9 O +
oxafluorenediones O +
or O +
1,10a O -
- O -
diaza-9-thiafluorenediones O -
; O +
antiproliferative O -
, O +
apoptosis O -
- O -
inducing O +
agents O -
; O +
treating O +
color O +
cancer O +
Compounds O +
of O +
the O +
formula O +
( O -
1 O -
) O +
in O +
which O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O +
and O +
X O +
have O +
the O +
meanings O +
indicated O +
in O +
the O +
description O -
, O +
are O +
novel O +
effective O +
compounds O +
with O +
Eg5 B-Gene +
inhibitory O -
, O +
anti O -
- O -
proliferative O +
and/or O +
apoptosis O +
inducing O +
activity O -
. O +

Fasudil O -
- O -
containing O +
preparation O +
and O +
method O +
of O +
improving O +
stability O +
thereof O +
Fasudil O -
- O -
containing O +
preparations O +
that O +
despite O +
the O +
us O +
of O +
a O +
container O +
excelling O +
in O +
the O +
visibility O +
of O +
contents O +
without O +
particularly O +
blocking O +
of O +
light O -
, O +
exhibit O +
high O +
stability O +
against O +
light O -
; O +
and O +
a O +
method O +
of O +
improving O +
the O +
stability O +
of O +
the O +
preparations O +
against O +
light O +
of O +
storing O +
the O +
same O -
. O +

By O +
regulating O +
the O +
pH O +
value O +
of O +
aqueous O +
solution O +
of O +
fasudil O +
charged O +
in O +
a O +
colorless O +
transparent O +
container O +
to O +
â‰¦5.5 O -
, O +
there O +
can O +
be O +
provided O +
fasudil O -
- O -
containing O +
preparations O +
excelling O +
in O +
stability O +
against O +
light O -
; O +
and O +
can O +
be O +
provided O +
a O +
method O +
of O +
improving O +
the O +
stability O +
of O +
the O +
aqueous O +
solution O +
of O +
fasudil O +
against O +
light O -
, O +
or O +
storing O +
the O +
same O -
. O +

Dengue O +
viruses O +
useful O +
for O +
vaccination O +
against O +
Flavivirus O -
; O +
Modified O +
Vaccinia O +
Virus O +
Ankara O +
( O -
MVA O -
) O -
; O +
stable O -
, O +
can O +
easily O +
be O +
produced O +
The O +
present O +
invention O +
relates O +
to O +
NS1 O +
proteins O +
or O +
parts O +
thereof O +
of O +
Flaviviruses O -
, O +
in O +
particular O +
of O +
Dengue O +
viruses O +
useful O +
for O +
vaccination O +
against O +
said O +
Flavivirus O +
and O +
against O +
one O +
or O +
more O +
other O +
Flaviviruses O -
. O +

The O +
invention O +
further O +
concerns O +
the O +
NS1 O +
protein O +
or O +
parts O +
thereof O +
of O +
one O +
Dengue O +
virus O +
serotype O -
, O +
in O +
particular O +
serotype O +
2 O -
, O +
useful O +
for O +
vaccination O +
against O +
Dengue O +
viruses O +
from O +
all O +
serotypes O -
. O +

The O +
invention O +
further O +
concerns O +
DNA O +
comprising O +
an O +
expression O +
cassette O +
coding O +
for O +
a O +
Flavivirus O +
NS1 O +
or O +
parts O +
thereof O -
, O +
vectors O +
comprising O +
said O +
DNA O +
and O +
vaccines O +
containing O +
or O +
expressing O +
a O +
Flavivirus O +
NS1 O -
. O +

inhibition O +
of O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene +
( O -
HSP90 B-Gene -
) O +
comprising O +
administering O +
benzoyl O +
compounds O +
or O +
prodrugs O -
, O -
as O +
antitumor O +
agents O +
The O +
present O +
invention O +
provides O +
Hsp90 B-Gene +
family O +
protein O +
inhibitors O +
comprising O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
benzoyl O +
compound O +
represented O +
by O +
general O +
formula O +
( O -
I O -
) O -
: O +
( O -
wherein O +
n O +
represents O +
an O +
integer O +
of O +
0 O +
to O +
10 O -
; O +
R1 O +
represents O +
substituted O +
or O +
unsubstituted O +
lower O +
alkoxy O -
, O +
substituted O +
or O +
unsubstituted O +
lower O +
alkoxycarbonyl O -
, O +
CONR7R8 O +
or O +
the O +
like O -
; O +
R2 O +
represents O +
substituted O +
or O +
unsubstituted O +
aryl O -
, O +
a O +
substituted O +
or O +
unsubstituted O +
aromatic O +
heterocyclic O +
group O +
or O +
the O +
like O -
; O +
R3 O +
and O +
R5 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
each O +
represent O +
a O +
hydrogen O +
atom O -
, O +
substituted O +
or O +
unsubstituted O +
lower O +
alkyl O -
, O +
substituted O +
or O +
unsubstituted O +
lower O +
alkenyl O +
or O +
the O +
like O -
; O +
and O +
R4 O +
and O +
R6 O -
, O +
which O +
may O +
be O +
the O +
same O +
or O +
different O -
, O +
each O +
represent O +
a O +
hydrogen O +
atom O -
, O +
halogen O -
, O +
substituted O +
or O +
unsubstituted O +
lower O +
alkyl O -
, O +
substituted O +
or O +
unsubstituted O +
aryl O +
or O +
the O +
like O -
) O +
or O +
a O +
prodrug O +
thereof O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
of O +
said O +
benzoyl O +
compound O +
or O +
said O +
prodrug O -
. O +

Isomaltooligosaccharides O +
to O +
inhibit O +
avian O +
pathogenic O +
intestinal O +
bacteria O +
Isomaltooligosaccharides O +
( O -
IMOs O -
) O +
produced O +
by O +
Leuconostoc O +
mesenteroides O +
ATCC O +
13146 O +
fermentation O +
with O +
a O +
sucrose O -
: O -
maltose O +
ratio O +
of O +
2:1 O +
have O +
been O +
discovered O +
to O +
be O +
effective O +
prebiotics O +
in O +
mixed O +
cultures O +
of O +
microbial O +
populations O -
, O +
including O +
cultures O +
from O +
chicken O +
ceca O -
. O +

Surprisingly O +
in O +
mixed O +
microbial O +
cultures O +
this O +
IMO O +
composition O +
proved O +
as O +
effective O +
as O +
FOS O -
. O +

Thus O -
, O +
these O +
IMOs O +
can O +
be O +
used O +
as O +
effective O +
prebiotics O +
for O +
both O +
birds O +
and O +
mammals O -
. O +

Moreover O -
, O +
the O +
IMOs O +
were O +
discovered O +
to O +
be O +
effective O +
non O -
- O -
competitive O +
inhibitors O +
of O +
Î± B-Gene -
- I-Gene -
glucosidase I-Gene -
. O +

These O +
IMOs O +
also O +
will O +
be O +
useful O -
, O +
as O +
an O +
Î± B-Gene -
- I-Gene -
glucosidase I-Gene +
inhibitor O -
, O +
in O +
a O +
therapeutic O +
application O +
for O +
several O +
diseases O -
, O +
including O +
obesity O -
, O +
diabetes O +
mellitus O -
, O +
pre O -
- O -
diabetes O -
, O +
gastritis O -
, O +
gastric O +
ulcer O -
, O +
duodenal O +
ulcer O -
, O +
caries O -
, O +
cancer O -
, O +
viral O +
disease O +
such O +
as O +
hepatitis O +
B O +
and O +
C O -
, O +
HIV O -
, O +
and O +
AIDS O -
. O +

A O +
diet O +
with O +
5 O -
- O -
20 O -
% O +
IMOs O +
was O +
also O +
shown O +
to O +
reduce O +
the O +
abdominal O +
fat O +
tissue O +
in O +
mammals O -
. O +

Detecting O +
a O +
colorectal O +
cancer O +
and/or O +
gastric O +
cancer O -
, O +
detecting O +
selective O +
hybridization O +
of O +
nucleic O +
acid O -
, O +
therapeutic O +
treatment O +
of O +
a O +
cancer O -
, O +
a O +
kit O +
contains O +
oligonucleotide O +
A O +
method O +
of O +
identifying O +
epigenetically O +
silenced O +
genes O -
, O +
e.g. O -
, O +
methylation O +
silenced O +
genes O -
, O +
in O +
cancer O +
cells O +
is O +
provided O -
. O +

In O +
addition O -
, O +
methods O +
of O +
identifying O +
a O +
cancer O +
by O +
detecting O +
epigenetic O +
silencing O +
of O +
gene O +
expression O +
are O +
provided O -
, O +
as O +
are O +
methods O +
of O +
treating O +
a O +
subject O +
having O +
such O +
a O +
cancer O -
, O +
for O +
example O -
, O +
a O +
colorectal O +
cancer O +
and/or O +
gastric O +
cancer O -
. O +

Reagents O +
for O +
practicing O +
such O +
methods O +
also O +
are O +
provided O -
. O +

fewer O +
side O -
- O -
effects O +
by O +
showing O +
no O +
hormone O +
properties O -
; O +
enhancing O +
the O +
learning O +
and O +
memory O -
- O -
retention O -
, O +
treat O +
dementia O +
The O +
present O +
invention O +
relates O +
to O +
cinnamic O +
acid O +
dimers O -
, O +
their O +
preparation O +
and O +
the O +
use O +
thereof O +
for O +
treating O +
neurodegenerative O +
disease O -
, O +
which O +
have O +
excellent O +
effect O +
on O +
enhancing O +
the O +
learning O +
and O +
memory O -
- O -
retention O +
ability O +
in O +
vivo O +
and O +
have O +
fewer O +
side O -
- O -
effects O +
by O +
showing O +
no O +
hormone O +
properties O -
, O +
even O +
when O +
administered O +
for O +
a O +
long O +
period O +
of O +
time O -
, O +
and O +
thus O +
which O +
can O +
be O +
used O +
for O +
neurodegenerative O +
disease O +
including O +
dementia O -
. O +

Using O +
HIV B-Gene +
protease I-Gene +
inhibitors O +
( O -
indinavir O -
, O +
nelfinavir O -
, O +
ritonavir O -
, O +
or O +
saquinavir O -
) O +
alone O +
or O +
in O +
combination O +
with O +
chemotherapy O -
, O +
radiotherapy O -
, O +
or O +
surgery O +
Liposarcomas O +
are O +
treated O +
using O +
HIV B-Gene +
protease I-Gene +
inhibitors O -
, O +
particularly O +
nelfinavir O -
. O +

The O +
protease O +
inhibitors O +
may O +
be O +
used O +
alone O +
or O +
in O +
combination O +
with O +
traditional O +
cancer O +
treatments O -
, O +
such O +
as O +
chemotherapy O -
, O +
radiotherapy O -
, O +
or O +
surgery O -
. O +

combination O +
of O +
N- O -
( O -
1-methylpiperidin-4-yl O -
) O -
-N- O -
( O -
4-fluorophenylmethyl O -
) O -
-N'- O -
( O -
4- O -
( O -
2-methylpropyloxy O -
) O -
phenylmethyl O -
) O -
carbamide O +
andmonoamine O +
oxidase B-Gene +
inhibitor O +
( O -
MAO B-Gene -
- O -
I O +
) O +
selected O +
from O +
tranylcypromine O +
( O -
Parnate O -
) O -
, O +
phenelzine O +
( O -
Nardil O -
) O -
, O +
maprotiline O -
, O +
and O +
isocarboxazid O +
( O -
Marplan O -
) O -
; O +
anti O -
- O -
psychotic O +
agent O -
; O +
dosage O +
form O -
; O +
capsule O +
Disclosed O +
herein O +
are O +
pharmaceutical O +
compositions O +
comprising O +
an O +
inverse O +
serotonin B-Gene +
receptor I-Gene +
agonist O +
or O +
a O +
serotonin B-Gene +
receptor I-Gene +
antagonist O +
and O +
an O +
anti O -
- O -
psychotic O +
agent O -
. O +

Disclosed O +
herein O +
are O +
also O +
methods O +
of O +
treating O +
psychotic O +
disorders O +
using O +
the O +
disclosed O +
pharmaceutical O +
compositions O -
. O +

Substituted O +
5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines O +
Compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
R1 O -
, O +
R2 O -
, O +
m O -
, O +
Q O +
and O +
B O +
have O +
the O +
meanings O +
indicated O +
in O +
Claim O +
1 O -
, O +
are O +
inhibitors O +
of O +
tyrosine B-Gene +
kinases I-Gene -
, O +
in O +
particular O +
Met B-Gene +
kinase O -
, O +
and O +
can O +
be O +
employed O -
, O +
inter O +
alia O -
, O +
for O +
the O +
treatment O +
of O +
tumours O -
. O +

Antiproliferative O +
agents O -
; O +
gene O +
overexpression O +
This O +
invention O +
relates O +
to O +
vitamin O -
- O -
mitomycin O +
conjugates O -
, O +
to O +
a O +
method O +
of O +
using O +
the O +
conjugates O +
to O +
selectively O +
eliminate O +
a O +
population O +
of O +
pathogenic O +
cells O +
in O +
a O +
host O +
animal O +
harboring O +
the O +
pathogenic O +
cells O -
, O +
and O +
to O +
a O +
method O +
of O +
preparation O +
of O +
the O +
conjugates O -
. O +

The O +
conjugate O +
is O +
of O +
the O +
general O +
formula O +
B O -
- O -
L O -
- O -
X O +
wherein O +
the O +
group O +
B O +
is O +
a O +
vitamin O -
, O +
or O +
an O +
analog O +
or O +
a O +
derivative O +
thereof O -
, O +
that O +
binds O +
to O +
a O +
surface O +
accessible O +
vitamin O +
receptor O +
that O +
is O +
uniquely O +
expressed O -
, O +
overexpressed O -
, O +
or O +
preferentially O +
expressed O +
by O +
a O +
population O +
of O +
pathogenic O +
cells O -
, O +
wherein O +
the O +
group O +
L O +
comprises O +
a O +
cleavable O +
linker O -
, O +
and O +
wherein O +
the O +
group O +
X O +
comprises O +
a O +
mitomycin O +
compound O -
, O +
or O +
an O +
analog O +
or O +
a O +
derivative O +
thereof O -
. O +

An O +
additional O +
therapeutic O +
agent O -
, O +
such O +
as O +
a O +
chemotherapeutic O +
agent O -
, O +
can O +
be O +
administered O +
in O +
combination O +
with O +
the O +
conjugate O -
. O +

Such O +
as O +
6-benzenesulfonyl-4-piperazin-1-yl O -
- O -
quinoline O +
hydrochloride O -
; O +
for O +
treatment O +
of O +
central O +
nervous O +
system O +
and/or O +
5- B-Gene +
HT6 I-Gene +
receptor O +
related O +
disorders O -
; O +
for O +
weight O +
gain O -
/ O -
loss O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
P O +
is O +
sulfone O +
or O +
sulfonamide O -
; O +
and O +
A O -
, O +
B O -
, O +
W O -
, O +
X O -
, O +
Y O +
and O +
R3 O +
are O +
as O +
defined O +
in O +
the O +
description O -
; O +
to O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O -
, O +
and O +
to O +
the O +
use O +
of O +
the O +
compounds O +
for O +
the O +
prophylaxis O +
and O +
treatment O +
of O +
medical O +
conditions O +
relating O +
to O +
obesity O -
, O +
type O +
II O +
diabetes O -
, O +
and/or O +
CNS O +
disorders O -
, O +
to O +
achieve O +
reduction O +
of O +
body O +
weight O +
and O +
of O +
body O +
weight O +
gain O -
. O +

Gene O +
repair O +
involving O +
in O +
vivo O +
excision O +
of O +
targeting O +
DNA O +
Methods O +
of O +
modifying O -
, O +
repairing O -
, O +
attenuating O +
and O +
inactivating O +
a O +
gene O +
or O +
other O +
chromosomal O +
DNA O +
in O +
a O +
cell O +
are O +
disclosed O -
. O +

Also O +
disclosed O +
are O +
methods O +
of O +
treating O +
or O +
prophylaxis O +
of O +
a O +
genetic O +
disease O +
in O +
an O +
individual O +
in O +
need O +
thereof O -
. O +

Sustained O +
release O +
portion O +
of O +
unit O +
dose O +
containing O +
guaifenesin O -
, O +
dextromethorphan O +
and O +
a O +
release O -
- O -
delaying O +
matrix O +
contains O +
a O +
hydrophilic O +
polymer O +
and O +
a O +
water O +
insoluble O +
polymer O -
, O +
immediate O +
release O +
portion O +
containing O +
guaifenesin O +
The O +
invention O +
relates O +
to O +
a O +
novel O +
pharmaceutical O +
modified O +
release O +
formulation O +
of O +
guaifenesin O +
and O +
dextromethorphan O -
. O +

The O +
formulation O +
may O +
comprise O +
a O +
hydrophilic O +
polymer O -
, O +
preferably O +
a O +
hydroxypropyl O +
methylcellulose O -
, O +
and O +
a O +
water O -
- O -
insoluble O +
polymer O -
, O +
preferably O +
an O +
acrylic O +
resin O -
, O +
in O +
a O +
ratio O +
range O +
of O +
about O +
one O -
- O -
to O -
- O -
one O +
( O -
1:1 O -
) O +
to O +
about O +
nine O -
- O -
to O -
- O -
one O +
( O -
9:1 O -
) O -
, O +
more O +
preferably O +
a O +
range O +
of O +
about O +
three O -
- O -
to O -
- O -
two O +
( O -
3:2 O -
) O +
to O +
about O +
six O -
- O -
to O -
- O -
one O +
( O -
6:1 O -
) O -
, O +
and O +
most O +
preferably O +
in O +
a O +
range O +
of O +
about O +
two O -
- O -
to O -
- O -
one O +
( O -
2:1 O -
) O +
to O +
about O +
four O -
- O -
to O -
- O -
one O +
( O -
4:1 O -
) O +
by O +
weight O -
. O +

This O +
formulation O +
capable O +
of O +
providing O +
therapeutically O +
effective O +
bioavailability O +
of O +
guaifenesin O +
for O +
at O +
least O +
twelve O +
hours O +
after O +
dosing O +
in O +
a O +
human O +
subject O -
. O +

The O +
invention O +
also O +
relates O +
to O +
a O +
modified O +
release O +
product O +
which O +
has O +
two O +
portions O -
: O +
a O +
first O +
portion O +
having O +
an O +
immediate O +
release O +
formulation O +
of O +
guaifenesin O +
and O +
a O +
second O +
portion O +
having O +
a O +
sustained O +
release O +
formulation O +
of O +
guaifenesin O -
, O +
wherein O +
one O +
or O +
both O +
portions O +
further O +
comprises O +
dextromethorphan O -
. O +

The O +
modified O +
release O +
product O +
has O +
a O +
maximum O +
guaifenesin O +
serum O +
concentration O +
equivalent O +
to O +
that O +
of O +
an O +
immediate O +
release O +
guaifenesin O +
tablet O -
, O +
and O +
is O +
capable O +
of O +
providing O +
therapeutically O +
effective O +
bioavailability O +
of O +
guaifenesin O +
for O +
at O +
least O +
twelve O +
hours O +
after O +
dosing O +
in O +
a O +
human O +
subject O -
. O +

Crystalline O +
forms O +
of O +
rapamycin O +
analogs O +
Provided O +
is O +
a O +
rapamycin O +
analog O +
composition O +
including O +
a O +
crystalline O +
form O +
of O +
a O +
rapamycin O +
analog O -
. O +

The O +
crystal O +
can O +
be O +
a O +
hydrate O -
. O +

dehydrate O -
, O +
solvate O -
, O +
or O +
desolvate O -
. O +

The O +
rampamycin O +
analog O +
can O +
have O +
a O +
structure O +
of O +
Formula O +
1 O -
, O +
which O +
is O +
optionally O +
a O +
prodrug O -
, O +
salt O -
, O +
derivative O -
, O +
or O +
combination O +
thereof O -
: O +

Adenine O +
compound O +
A O +
novel O +
adenine O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
1 O -
) O -
: O +
[ O -
wherein O +
R1 O +
is O +
substituted O +
or O +
unsubstituted O +
alkyl O -
, O +
etc O -
. O -
, O +
X O +
is O +
oxygen O -
, O +
etc O -
. O -
, O +
A1 O +
is O +
4- O +
to O +
8-membered O +
substituted O +
or O +
unsubstituted O +
saturated O +
nitrogen O -
- O -
containing O +
heterocycle O +
containing O +
1 O +
to O +
2 O +
hetero O +
atom O -
( O -
s O -
) O +
selected O +
from O +
1 O +
to O +
2 O +
nitrogen O -
( O -
s O -
) O -
, O +
0 O +
to O +
1 O +
oxygen O +
and O +
0 O +
to O +
1 O +
sulfur O -
, O +
etc O -
. O -
, O +
A2 O +
is O +
substituted O +
or O +
unsubstituted O +
6- O +
to O +
10-membered O +
aryl O -
, O +
etc O -
. O -
, O +
L1 O +
and O +
L2 O +
are O +
independently O +
a O +
straight O +
chain O +
or O +
branched O +
chain O +
alkylene O -
, O +
etc O -
. O -
] O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
which O +
is O +
useful O +
as O +
a O +
medicament O -
. O +

An O +
enzyme O +
in O +
the O +
tryptophan O +
degradation O +
pathway O -
, O +
used O +
to O +
treat O +
neurodegenerative O +
disorders O -
, O +
certain O +
cancers O -
, O +
drug O +
addiction O -
; O +
arylsulfonamides O +
such O +
as O +
3,4-dimethoxy O -
- O -
N- O -
[ O -
5- O -
( O -
4-chlorophenyl O -
) O -
-1,2,4-thiadiazole-3-yl O -
] O -
benzenesulfonamide O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
Formula O +
I O +
below O +
and O +
their O +
tautomers O +
or O +
pharmaceutically O +
acceptable O +
salts O -
, O +
compositions O +
and O +
methods O +
of O +
uses O +
thereof O -
: O +

Administering O +
oligosaccharides O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
comprising O +
prebiotic O +
( O -
prebiotic O +
adjuvant O -
) O +
for O +
decreasing O +
inflammatory O +
process O +
by O +
improving O +
the O +
homeostasis O +
of O +
non O -
- O -
specific O +
immune O +
parameters O +
and O +
of O +
lymphocyte O +
subpopulations O -
. O +

It O +
also O +
relates O +
to O +
the O +
use O +
of O +
a O +
prebiotic O +
formulation O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O +
or O +
a O +
food O +
or O +
petfood O +
composition O +
for O +
decreasing O +
inflammatory O +
process O +
and/or O +
abnormal O +
activation O +
of O +
non O -
- O -
specific O +
immune O +
parameters O -
, O +
such O +
as O +
phagocytes O -
. O +

Selective O +
proton B-Gene +
coupled I-Gene +
folate I-Gene +
transporter I-Gene +
and O +
folate B-Gene +
receptor I-Gene -
, O +
and O +
GARFTase B-Gene +
inhibitor O +
compounds O +
and O +
methods O +
of O +
using O +
the O +
same O +
Fused O +
cyclic O +
pyrimidine O +
compounds O -
, O +
including O +
tautomers O +
thereof O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
prodrugs O -
, O +
solvates O +
and O +
hydrates O +
thereof O -
, O +
are O +
disclosed O +
having O +
the O +
general O +
Formula O +
I O -
: O +
These O +
compounds O +
are O +
useful O +
in O +
methods O +
for O +
treating O +
cancer O -
, O +
selectively O +
targeting O +
cancerous O +
cells O +
via O +
the O +
proton B-Gene +
coupled I-Gene +
folate I-Gene +
transporter I-Gene -
, O +
folate B-Gene +
receptor I-Gene +
alpha I-Gene -
, O +
and/or O +
folate B-Gene +
receptor I-Gene +
beta I-Gene +
pathways O -
, O +
inhibiting O +
GARFTase B-Gene +
in O +
cancerous O +
cells O -
, O +
and O +
selectively O +
targeting O +
activated O +
macrophages O +
in O +
a O +
patient O +
having O +
an O +
autoimmune O +
disease O -
, O +
such O +
as O +
rheumatoid O +
arthritis O -
. O +

Method O +
for O +
restructuring O +
the O +
epidermis O +
using O +
a O +
polyol O -
- O -
glycoside O +
composition O +
A O +
method O +
for O +
restructuring O +
the O +
epidermis O +
with O +
a O +
composition O -
, O +
wherein O +
said O +
composition O +
includes O +
a O +
polyol O -
- O -
glycoside O +
and O +
said O +
polyol O -
- O -
glycoside O +
is O +
obtained O +
by O +
the O +
acetalization O +
of O +
a O +
polyol O +
with O +
a O +
reducing O +
sugar O -
. O +

Fused O +
amino O +
pyridine O +
as O +
HSP90 B-Gene +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
HSP90 B-Gene +
inhibitors O +
containing O +
fused O +
amino O +
pyridine O +
core O +
that O +
are O +
useful O +
as O +
inhibitors O +
of O +
HSP90 B-Gene +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
HSP90 B-Gene +
related O +
diseases O +
and O +
disorders O +
such O +
as O +
cancer O -
, O +
an O +
autoimmune O +
disease O -
, O +
or O +
a O +
neurodegenerative O +
disease O -
. O +

Compounds O +
and O +
compositions O +
for O +
treating O +
cancer O +
The O +
invention O +
relates O +
to O +
compounds O +
and O +
composition O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
cancer O -
. O +

The O +
invention O +
also O +
covers O +
all O +
diseases O +
that O +
may O +
be O +
treated O +
by O +
selective O +
modulation O +
of O +
levels O +
of O +
reactive O +
oxygen O +
species O +
in O +
diseased O +
cells O +
versus O +
normal O +
cells O -
. O +

Methods O +
for O +
the O +
preparation O +
and O +
administration O +
of O +
such O +
compositions O +
are O +
also O +
disclosed O -
. O +

Characterization O +
of O +
GRP94-ligand B-Gene +
interactions O +
and O +
purification O -
, O +
screening O -
, O +
and O +
therapeutic O +
methods O +
relating O +
thereto O +
The O +
presently O +
disclosed O +
subject O +
matter O +
discloses O +
characterization O +
of O +
interactions O +
between O +
ligands O +
and O +
Hsp90 B-Gene +
proteins O -
, O +
including O +
GRP94 B-Gene -
, O +
wherein O +
ligand O +
binding O +
to O +
the O +
N O -
- O -
terminal O +
nucleotide O +
binding O +
domain O +
of O +
GRP94 B-Gene +
elicits O +
a O +
conformational O +
change O +
that O +
converts O +
the O +
GRP94 B-Gene +
from O +
an O +
inactive O +
to O +
an O +
active O +
conformation O -
, O +
and O +
wherein O +
the O +
chaperone O +
and O +
peptide O -
- O -
binding O +
activities O +
of O +
the O +
GRP94 B-Gene +
are O +
markedly O +
stimulated O -
. O +

Also O +
disclosed O +
are O +
purification O -
, O +
screening O -
, O +
and O +
therapeutic O +
methods O +
pertaining O +
to O +
the O +
biological O +
activity O +
of O +
GRP94 B-Gene -
, O +
and O +
in O +
some O +
instances O +
HSP90 O -
, O +
based O +
upon O +
the O +
characterization O +
of O +
ligand O +
interactions O +
of O +
Hsp90 B-Gene +
peptide O -
- O -
binding O +
proteins O -
, O +
including O +
GRP94 B-Gene -
. O +

Wound O +
care O +
device O +
A O +
wound O +
care O +
device O +
for O +
local O +
treatment O +
of O +
pain O +
in O +
a O +
wound O -
, O +
said O +
device O +
comprising O +
an O +
active O +
pain O +
relieving O +
composition O -
, O +
the O +
device O +
being O +
constructed O +
in O +
such O +
a O +
manner O +
that O +
the O +
pain O +
killing O +
agent O +
is O +
released O +
to O +
the O +
wound O +
in O +
such O +
a O +
way O +
that O +
substantially O +
no O +
effective O +
systemic O +
plasma O +
concentration O +
of O +
the O +
pain O +
killing O +
agent O +
can O +
be O +
found O +
and O +
wherein O +
a O +
majority O +
of O +
said O +
pain O +
killing O +
agent O +
is O +
in O +
direct O +
contact O +
with O +
the O +
wound O -
. O +

Thieno- O +
and O +
furo O -
- O -
pyrimidine O +
modulators O +
of O +
the O +
histamine B-Gene +
H4 I-Gene +
receptor I-Gene +
Thieno- O +
and O +
furo O -
- O -
pyrimidine O +
compounds O +
are O +
described O -
, O +
which O +
are O +
useful O +
as O +
H4 B-Gene +
receptor I-Gene +
modulators O -
. O +

Such O +
compounds O +
may O +
be O +
used O +
in O +
pharmaceutical O +
compositions O +
and O +
methods O +
for O +
the O +
modulation O +
of O +
histamine B-Gene +
H4 I-Gene +
receptor I-Gene +
activity O +
and O +
for O +
the O +
treatment O +
of O +
disease O +
states O -
, O +
disorders O -
, O +
and O +
conditions O +
mediated O +
by O +
H4 B-Gene +
receptor I-Gene +
activity O -
, O +
such O +
as O +
inflammation O -
. O +

Polysaccharides O +
with O +
antithrombotic O +
activity O -
, O +
including O +
a O +
covalent O +
bond O +
and O +
an O +
amino O +
chain O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
synthetic O +
polysaccharides O +
with O +
antithrombotic O +
activity O -
, O +
having O +
at O +
least O +
one O +
covalent O +
bond O +
with O +
an O +
amino O +
chain O -
, O +
and O +
to O +
the O +
preparation O +
method O +
thereof O +
and O +
to O +
the O +
therapeutic O +
use O +
thereof O -
. O +

Dietary O +
fiber O +
formulation O +
and O +
method O +
of O +
administration O +
The O +
invention O +
provides O +
dietary O +
fiber O +
formulation O +
and O +
related O +
methods O +
for O +
its O +
administration O -
. O +

In O +
one O +
embodiment O -
, O +
the O +
invention O +
provides O +
a O +
dietary O +
fiber O +
formulation O +
comprising O -
: O +
partially O -
- O -
hydrolyzed O +
guar O +
gum O +
( O -
PHGG O -
) O -
; O +
and O +
fructooligosaccharides O +
( O -
FOS O -
) O -
, O +
wherein O +
the O +
dietary O +
fiber O +
formulation O +
exhibits O +
a O +
prebiotic O +
potential O +
greater O +
than O +
a O +
prebiotic O +
potential O +
of O +
PHGG O +
and O +
FOS O +
individually O -
. O +

Assay O +
for O +
identifying O +
a O +
modulator O +
of O +
HIF B-Gene +
hydroxylase I-Gene +
A O +
novel O +
class O +
of O +
hydroxylases O +
is O +
described O +
having O +
the O +
amino O +
acid O +
sequence O +
of O +
SEQ O +
ID O +
NO O -
: O +
2 O -
, O +
4 O -
, O +
6 O +
and O +
8 O -
, O +
and O +
variants O +
and O +
fragments O +
thereof O +
having O +
HIF O +
hydroxylation O +
activity O -
. O +

The O +
polypeptides O +
of O +
the O +
invention O +
have O +
in O +
particular O +
prolyl O +
hydroxylase O +
activity O -
. O +

An O +
assay O +
method O +
monitors O +
the O +
interaction O +
of O +
the O +
HIF B-Gene +
hydroxylase I-Gene +
with O +
a O +
substrate O -
. O +

Modulators O +
of O +
HIF B-Gene +
hydroxylase I-Gene +
are O +
provided O +
for O +
use O +
in O +
the O +
treatment O +
of O +
a O +
condition O +
associated O +
with O +
increased O +
or O +
decreased O +
HIF O +
levels O +
or O +
activity O +
or O +
for O +
the O +
treatment O +
of O +
a O +
condition O +
where O +
it O +
is O +
desirable O +
to O +
modulate O +
HIF O +
levels O +
or O +
activity O -
. O +

Heteroaryl O +
substituted O +
pyrrolo O -
[ O -
2,3-b O -
] O -
pyridines O +
and O +
pyrrolo O -
[ O -
2,3-b O -
] O -
pyrimidines O +
as O +
Janus B-Gene +
kinase I-Gene +
inhibitors O +
The O +
present O +
invention O +
provides O +
heteroaryl O +
substituted O +
pyrrolo O -
[ O -
2,3-b O -
] O -
pyridines O +
and O +
heteroaryl O +
substituted O +
pyrrolo O -
[ O -
2,3-b O -
] O -
pyrimidines O +
that O +
modulate O +
the O +
activity O +
of O +
Janus B-Gene +
kinases I-Gene +
and O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
diseases O +
related O +
to O +
activity O +
of O +
Janus B-Gene +
kinases I-Gene +
including O -
, O +
for O +
example O -
, O +
immune O -
- O -
related O +
diseases O -
, O +
skin O +
disorders O -
, O +
myeloid O +
proliferative O +
disorders O -
, O +
cancer O -
, O +
and O +
other O +
diseases O -
. O +

Composition O +
for O +
treating O +
mental O +
health O +
disorders O +
A O +
composition O +
of O +
three O +
compounds O +
each O +
selected O +
from O +
a O +
selective O +
re O -
- O -
uptake O +
inhibitor O +
of O +
serotonin O -
, O +
a O +
monoamine O +
oxidase O +
inhibitor O -
, O +
and O +
a O +
phosphodiesterase O +
inhibitor O -
, O +
such O +
that O +
all O +
three O +
compounds O +
are O +
different O +
and O +
are O +
naturally O +
occurring O -
. O +

Methods O +
for O +
recommending O +
neurophysiological O +
disorder O +
therapy O +
Neurophysiologic O +
information O +
such O +
as O +
quantitative O +
electroencephalography O +
( O -
QEEG O -
) O +
is O +
used O +
in O +
a O +
method O +
for O +
classifying O -
, O +
diagnosing O -
, O +
and O +
treating O +
physiologic O +
brain O +
imbalances O -
. O +

Neurophysiologic O +
information O +
is O +
also O +
used O +
to O +
guide O +
sample O +
selection O +
in O +
clinical O +
tests O +
for O +
psychopharmacologic O +
drug O +
candidates O -
. O +

Finally O -
, O +
neurophysiologic O +
information O +
is O +
used O +
for O +
remotely O +
assessing O +
and O +
treating O +
patients O +
with O +
physiologic O +
brain O +
imbalances O -
. O +

Desensitizing O +
drug O +
product O +
Desensitizing O +
drug O +
products O -
, O +
methods O +
of O +
making O +
desensitizing O +
drug O +
products O -
, O +
and O +
methods O +
of O +
using O +
desensitizing O +
drug O +
products O +
including O +
delivery O +
of O +
desensitizing O +
drug O +
products O -
. O +

In O +
one O +
embodiment O -
, O +
the O +
desensitizing O +
drug O +
products O +
are O +
male O +
genital O +
desensitizers O +
that O +
comprise O +
one O +
or O +
anesthetic O +
agents O +
and O +
one O +
or O +
more O +
melting O +
point O +
depressing O +
agents O -
. O +

Remedy O +
for O +
overactive O +
bladder O +
comprising O +
acetic O +
acid O +
anilide O +
derivative O +
as O +
the O +
active O +
ingredient O +
( O -
R O -
) O -
-2- O -
( O -
2-aminothiazol-4-yl O -
) O -
-4â€²- O -
[ O -
2- O -
[ O -
( O -
2-hydroxy-2-phenylethyl O -
) O -
amino O -
] O -
ethyl O -
] O -
acetic O +
acid O +
anilide O +
or O +
its O +
salt O +
shows O +
a O +
potent O +
bladder O +
relaxation O +
effect O +
in O +
" O -
isolated O +
rat O +
bladder O +
smooth O +
muscle O +
relaxation O +
test O -
" O -
, O +
dose O -
- O -
dependently O +
lowers O +
the O +
contraction O +
frequency O +
of O +
rhythmic O +
bladder O +
contractions O +
in O +
" O -
rat O +
rhythmic O +
bladder O +
contraction O +
measurement O +
test O -
" O +
and O -
, O +
moreover O -
, O +
prolongs O +
the O +
urination O +
intervals O +
in O +
" O -
urination O +
functions O +
measurement O +
test O +
on O +
cyclophosphamide O -
- O -
induced O +
overactive O +
bladder O +
model O +
rat O -
" O -
. O +

Owing O +
to O +
these O +
effects O -
, O +
the O +
above O +
compound O +
is O +
useful O +
as O +
a O +
remedy O +
for O +
overactive O +
bladder O -
. O +

Hepatitis O +
C O +
inhibitor O +
tri O -
- O -
peptides O +
Racemates O -
, O +
diastereoisomers O +
and O +
optical O +
isomers O +
of O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
B O +
is O +
H O -
, O +
a O +
C6 O +
or O +
C10 O +
aryl O -
, O +
C7 O -
- O -
16 O +
aralkyl O -
; O +
Het O +
or O +
( O -
lower O +
alkyl O -
) O -
-Het O -
, O +
all O +
of O +
which O +
optionally O +
substituted O +
with O +
C1 O -
- O -
6 O +
alkyl O -
; O +
C1 O -
- O -
6 O +
alkoxy O -
; O +
C1 O -
- O -
6 O +
alkanoyl O -
; O +
hydroxy O -
; O +
hydroxyalkyl O -
; O +
halo O -
; O +
haloalkyl O -
; O +
nitro O -
; O +
cyano O -
; O +
cyanoalkyl O -
; O +
amino O +
optionally O +
substituted O +
with O +
C1 O -
- O -
6 O +
alkyl O -
; O +
amido O -
; O +
or O +
( O -
lower O +
alkyl O -
) O -
amide O -
; O +
or O +
B O +
is O +
an O +
acyl O +
derivative O +
of O +
formula O +
R4â€”C O -
( O -
O O -
) O -
â€” O -
; O +
a O +
carboxyl O +
of O +
formula O +
R4â€”O O -
â€” O -
C O -
( O -
O O -
) O -
â€” O -
; O +
an O +
amide O +
of O +
formula O +
R4â€”N O -
( O -
R5 O -
) O -
â€”C O -
( O -
O O -
) O -
â€” O -
; O +
a O +
thioamide O +
of O +
formula O +
R4â€”N O -
( O -
R5 O -
) O -
â€”C O -
( O -
S O -
) O -
â€” O -
; O +
or O +
a O +
sulfonyl O +
of O +
formula O +
R4â€”SO2 O -
; O +
R5 O +
is O +
H O +
or O +
C1 O -
- O -
6 O +
alkyl O -
; O +
and O +
Y O +
is O +
H O +
or O +
C1 O -
- O -
6 O +
alkyl O -
; O +
R3 O +
is O +
C1 O -
- O -
8 O +
alkyl O -
, O +
C3 O -
- O -
7 O +
cycloalkyl O -
, O +
or O +
C4 O -
- O -
10 O +
alkylcycloalkyl O -
, O +
all O +
optionally O +
substituted O +
with O +
hydroxy O -
, O +
C1 O -
- O -
6 O +
alkoxy O -
, O +
C1 O -
- O -
6 O +
thioalkyl O -
, O +
amido O -
, O +
( O -
lower O +
alkyl O -
) O -
amido O -
, O +
C6 O +
or O +
C10 O +
aryl O -
, O +
or O +
C7 O -
- O -
16 O +
aralkyl O -
; O +
R2 O +
is O +
CH2â€”R20 O -
, O +
NH O -
â€” O -
R20 O -
, O +
O O -
â€” O -
R20 O +
or O +
S O -
â€” O -
R20 O -
, O +
wherein O +
R20 O +
is O +
a O +
saturated O +
or O +
unsaturated O +
C3 O -
- O -
7 O +
cycloalkyl O +
or O +
C4 O -
- O -
10 O +
( O -
alkylcycloalkyl O -
) O -
, O +
all O +
of O +
which O +
being O +
optionally O +
mono- O -
, O +
di- O +
or O +
tri O -
- O -
substituted O +
with O +
R21 O -
, O +
or O +
R20 O +
is O +
a O +
C6 O +
or O +
C10 O +
aryl O +
or O +
C7 O -
- O -
14 O +
aralkyl O +
optionally O +
substituted O -
, O +
or O +
R20 O +
is O +
Het O +
or O +
( O -
lower O +
alkyl O -
) O -
-Het O -
, O +
both O +
optionally O +
substituted O -
, O +
Het O +
or O +
( O -
lower O +
alkyl O -
) O -
-Het O -
; O +
carboxyl O -
; O +
carboxy O -
( O -
lower O +
alkyl O -
) O -
; O +
C6 O +
or O +
C10 O +
aryl O -
, O +
C7 O -
- O -
14 O +
aralkyl O +
or O +
Het O -
, O +
said O +
aryl O -
, O +
aralkyl O +
or O +
Het O +
being O +
optionally O +
substituted O -
; O +
and O +
R1 O +
is O +
H O -
; O +
C1 O -
- O -
6 O +
alkyl O -
, O +
C3 O -
- O -
7 O +
cycloalkyl O -
, O +
C2 O -
- O -
6 O +
alkenyl O -
, O +
or O +
C2 O -
- O -
6 O +
alkynyl O -
, O +
all O +
optionally O +
substituted O +
with O +
halogen O -
; O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
ester O +
thereof O -
. O +

Use O +
of O +
medium O +
chain O +
triglycerides O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
alzheimer O -
's O +
disease O +
and O +
other O +
diseases O +
resulting O +
from O +
reduced O +
neuronal O +
metabolism O +
Methods O +
and O +
compositions O +
for O +
treating O +
or O +
preventing O -
, O +
the O +
occurrence O +
of O +
senile O +
dementia O +
of O +
the O +
Alzheimer O -
's O +
type O -
, O +
or O +
other O +
conditions O +
arising O +
from O +
reduced O +
neuronal O +
metabolism O +
and O +
leading O +
to O +
lessened O +
cognitive O +
function O +
are O +
described O -
. O +

In O +
a O +
preferred O +
embodiment O +
the O +
administration O +
of O +
triglicerides O +
or O +
fatty O +
acids O +
with O +
chain O +
lengths O +
between O +
5 O +
and O +
12 O -
, O +
to O +
said O +
patient O +
at O +
a O +
level O +
produce O +
an O +
improvement O +
in O +
cognitive O +
ability O -
. O +

C6- O +
and O +
c9-substituted O +
chromeno O -
[ O -
4 O -
, O +
3-c O -
] O -
isoxazoline O +
derivatives O +
and O +
their O +
use O +
as O +
anti O -
- O -
depressants O +
The O +
invention O +
concerns O +
substituted O +
tricyclic O +
isoxazoline O +
derivatives O -
, O +
more O +
in O +
particular O +
tricyclic O +
dihydrobenzopyranoisoxazoline O -
, O +
dihydroquinolinoisoxazoline O +
, O +
dihydronaphthalenoisoxazoline O +
and O +
dihydrobenzothiopyranoisoxazoline O +
derivatives O +
substituted O +
on O +
at O +
least O +
one O +
of O +
the O +
C6- O +
and O +
C9-positions O +
of O +
the O +
phenylpart O +
of O +
the O +
tricyclic O +
moiety O +
with O +
a O +
selected O +
radical O -
, O +
according O +
to O +
Formula O +
( O -
I O -
) O +
wherein O +
X O +
= O +
CH2 O -
, O +
N O -
- O -
R7 O -
, O +
S O +
or O +
O O -
, O +
R1 O -
, O +
R2 O -
, O +
R14 O +
and O +
R15 O +
are O +
certain O +
specific O +
substituents O -
, O +
with O +
the O +
proviso O +
that O +
at O +
least O +
one O +
of O +
R14 O +
and O +
R15 O +
is O +
not O +
hydrogen O -
, O +
Pir O +
is O +
preferably O +
an O +
optionally O +
substituted O +
piperidinyl O +
or O +
piperazinyl O +
radical O +
and O +
R3 O +
represents O +
an O +
optionally O +
substituted O +
aromatic O +
homocyclic O +
or O +
heterocyclic O +
ring O +
system O +
including O +
a O +
partially O +
or O +
completely O +
hydrogenated O +
hydrocarbon O +
chain O +
of O +
maximum O +
6 O +
atoms O +
long O +
with O +
which O +
the O +
ring O +
system O +
is O +
attached O +
to O +
the O +
Pir O +
radical O +
and O +
which O +
may O +
contain O +
one O +
or O +
more O +
heteroatoms O +
selected O +
from O +
the O +
group O +
of O +
O O -
, O +
N O +
and O +
S O +
; O +
a O +
process O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
comprising O +
them O +
and O +
their O +
use O +
as O +
a O +
medicine O -
, O +
in O +
particular O +
for O +
the O +
treatment O +
of O +
depression O -
, O +
anxiety O -
, O +
movement O +
disorders O -
, O +
psychosis O -
, O +
Parkinson O -
's O +
disease O +
and O +
body O +
weight O +
disorders O -
.. O +

The O +
compounds O +
according O +
to O +
the O +
invention O +
have O +
surprisingly O +
been O +
shown O +
to O +
have O +
a O +
serotonine O +
( O -
5-HT O -
) O +
reuptake O +
inhibitor O +
activity O +
in O +
combination O +
with O +
additional O +
Î±2-adrenoceptor B-Gene +
antagonist O +
activity O +
and O +
show O +
a O +
strong O +
anti O -
- O -
depressant O +
activity O +
without O +
being O +
sedative O -
. O +

The O +
invention O +
also O +
relates O +
to O +
novel O +
combination O +
of O +
isoxazoline O +
derivatives O +
according O +
to O +
the O +
invention O +
with O +
one O +
or O +
more O +
other O +
compounds O +
selected O +
from O +
the O +
group O +
of O +
antidepressants O -
, O +
anxiolytics O -
, O +
anti O -
- O -
psychotics O +
and O +
anti O -
- O -
Parkinson O -
's O +
disease O +
drugs O +
to O +
improve O +
efficacy O +
and/or O +
onset O +
of O +
action O -
. O +

PREPARATION O +
FOR O +
EXTERNAL O +
PERCUTANEOUS O +
ADMINISTRATION O +
CONTAINING O +
NON O -
- O -
STEROIDAL O +
ANTI O -
- O -
INFLAMMATORY O +
DRUG O +
AND O +
INTERLEUKIN-1Î± B-Gene +
PRODUCTION O +
INHIBITOR O +
A O +
preparation O +
for O +
external O +
percutaneous O +
administration O +
which O +
comprises O +
a O +
non O -
- O -
steroidal O +
anti O -
- O -
inflammatory O +
drug O -
, O +
an O +
alkyl O +
gallate O -
, O +
and O +
a O +
phenolic O +
radial O +
scavenger O +
having O +
a O +
branched O +
lower O +
alkyl O +
group O -
. O +

Also O +
provided O +
is O +
an O +
interleukin-1Î± B-Gene +
production O +
inhibitor O +
which O +
comprises O +
a O +
phenolic O +
radial O +
scavenger O +
having O +
a O +
branched O +
lower O +
alkyl O +
group O +
and/or O +
an O +
alkyl O +
gallate O -
. O +

Tlr7 B-Gene +
ligands O +
for O +
the O +
treatment O +
of O +
hepatitis O +
c O +
This O +
invention O +
relates O +
to O +
methods O +
for O +
treating O +
or O +
preventing O +
hepatitis O +
C O +
virus O +
infections O +
in O +
mammals O +
using O +
Toll B-Gene -
- I-Gene -
Like I-Gene +
Receptor I-Gene +
( I-Gene -
TLR I-Gene -
) I-Gene -
7 I-Gene +
ligands O +
and O +
prodrugs O +
thereof O -
. O +

More O +
particularly O -
, O +
this O +
invention O +
relates O +
to O +
methods O +
of O +
orally O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
one O +
or O +
more O +
prodrugs O +
of O +
TLR7 B-Gene +
ligands O +
for O +
the O +
treatment O +
or O +
prevention O +
of O +
hepatitis O +
C O +
viral O +
infection O -
. O +

Oral O +
administration O +
of O +
these O +
TLR7 B-Gene +
immunomodulating O +
ligands O +
and O +
prodrugs O +
thereof O +
to O +
a O +
mammal O +
provides O +
therapeutically O +
effective O +
amounts O +
and O +
reduced O +
undesirable O +
side O +
effects O -
. O +

Antimycotic O +
nail O +
polish O +
formulations O +
comprising O +
substituted O +
2-aminothiazoles O +
as O +
an O +
active O +
substance O +
The O +
invention O +
relates O +
to O +
a O +
composition O +
comprising O +
( O -
A O -
) O +
a O +
pharmaceutically O +
effective O +
compound O +
from O +
the O +
compound O +
class O +
of O +
antimycotic O +
substituted O +
2-aminothiazoles O -
, O +
and O +
( O -
B O -
) O +
a O +
nail O +
polish O +
formulation O +
of O +
said O +
compound O -
. O +

The O +
invention O +
further O +
relates O +
to O +
antimycotic O +
nail O +
polish O +
formulations O +
for O +
treating O +
onychomycoses O +
and O +
other O +
diseases O +
of O +
the O +
fingernails O +
or O +
toenails O +
caused O +
by O +
fungal O +
infections O -
. O +

The O +
invention O +
particularly O +
relates O +
to O +
antimycotic O +
nail O +
polish O +
formulations O +
that O +
are O +
applied O +
to O +
nails O +
and O +
form O +
a O +
coating O +
from O +
which O +
the O +
antimycotic O +
agent O +
is O +
released O +
and O +
can O +
penetrate O +
into O +
the O +
nail O -
. O +

Said O +
method O +
allows O +
nails O +
of O +
humans O +
and O +
animals O +
to O +
be O +
treated O +
against O +
fungal O +
infections O +
or O +
fungal O +
infections O +
to O +
be O +
prevented O -
. O +

N O -
- O -
acylated-3- O +
( O -
benzoyl O -
) O +
- O +
pyrrolidines O +
as O +
11-beta B-Gene -
- I-Gene -
hsd1 I-Gene +
inhibitors O +
useful O +
for O +
the O +
treatment O +
of O +
metabolic O +
disorders O -
. O +

The O +
use O +
of O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
variable O +
groups O +
are O +
defined O +
within O -
; O +
in O +
the O +
manufacture O +
of O +
medicaments O +
for O +
use O +
in O +
the O +
inhibition O +
of O +
11Î²HSD1 B-Gene -
, O +
processes O +
for O +
making O +
them O -
, O +
certain O +
compounds O +
within O +
the O +
definition O +
of O +
the O +
formula O +
( O -
I O -
) O +
and O +
pharmaceutical O +
compositions O +
comprising O +
them O +
are O +
described O -
. O +

Agent O +
or O +
method O +
for O +
treatment O +
for O +
severe O +
aphasia O +
in O +
chronic O -
- O -
stage O +
cerebrovascular O +
disorder O +
An O +
agent O +
or O +
method O +
for O +
treatments O +
for O +
severe O +
aphasia O +
in O +
chronic O -
- O -
stage O +
cerebrovascular O +
disorders O +
which O +
contains O +
or O +
employs O +
2-oxo-1-pyrrolidineacetamide O +
as O +
an O +
active O +
ingredient O -
. O +

Use O +
of O +
conjugated O +
linolenic O +
acids O +
for O +
reducing O +
body O +
fat O +
mass O +
The O +
present O +
invention O +
discloses O +
the O +
use O +
of O +
conjugated O +
linolenic O +
acids O +
selected O +
from O +
the O +
groups O +
consisting O +
of O +
Cl O +
8:3 O +
( O -
9cis O -
, O +
11 O +
trans O -
, O +
15 O +
cis O -
) O -
octadecatrienoic O +
acid O -
, O +
C18:3 O -
( O -
9cis,13trans,15cis O -
) O -
octadecatrienoic O +
acid O +
and O +
mixtures O +
thereof O +
in O +
the O +
reduction O +
of O +
body O +
fat O +
mass O +
and O +
in O +
the O +
treatment O +
and/or O +
prevention O +
of O +
obesity O -
. O +

These O +
conjugated O +
linolenic O +
acids O +
may O +
be O +
provided O +
in O +
the O +
form O +
of O +
a O +
food O +
supplement O +
or O +
as O +
a O +
component O +
of O +
a O +
prepared O +
food O +
product O -
. O +

Active O +
oxygen O +
eliminator O +
originating O +
in O +
natural O +
material O +
and O +
use O +
of O +
the O +
same O +
An O +
active O +
oxygen O +
eliminator O +
originating O +
in O +
a O +
natural O +
material O +
which O +
comprises O +
water O -
, O +
an O +
organic O +
solvent O -
, O +
an O +
emulsifier O +
and O -
, O +
as O +
the O +
main O +
active O +
ingredients O -
, O +
p O -
- O -
coumalic O +
acid O -
, O +
3,4-di O -
- O -
O O -
- O -
caffeoylquinic O +
acid O -
, O +
3,5-di O -
- O -
O O -
- O -
caffeoylquinic O +
acid O -
, O +
4-hydroxy-3-prenylcinnamic O +
acid O +
and O +
3,5,7-trihydroxy-4'-methoxyflavonol O -
; O +
and O +
a O +
food O +
and O +
a O +
cosmetic O +
containing O +
this O +
active O +
oxygen O +
eliminator O -
. O +

Extracts O +
of O +
scutellaria O +
for O +
the O +
treatment O +
of O +
sars O +
The O +
present O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
having O +
antiviral O +
activity O +
against O +
Coronavirus O -
, O +
and O +
more O +
particularly O +
against O +
those O +
viruses O +
responsible O +
for O +
Severe O +
Acute O +
Respiratory O +
Syndrome O +
( O -
SARS O -
) O -
. O +

In O +
a O +
preferred O +
embodiment O +
it O +
comprises O +
a O +
total O +
standardised O +
extract O +
of O +
a O +
Scutellariae O +
spp O -
. O +

Remedy O +
for O +
urinary O +
disorder O +
It O +
is O +
intended O +
to O +
provide O +
a O +
remedy O +
for O +
urinary O +
disorder O -
. O +

Namely O -
, O +
a O +
remedy O +
for O +
urinary O +
disorder O +
containing O +
a O +
compound O +
which O +
suppresses O +
the O +
GIRK B-Gene +
channel I-Gene +
activated O +
current O +
while O +
showing O +
no O +
suppressive O +
effect O +
on O +
the O +
glycine B-Gene +
receptor I-Gene +
activated O +
current O +
or O +
NMDA B-Gene +
receptor I-Gene +
activated O +
current O -
. O +

Method O +
of O +
treating O +
sepsis O +
Compositions O +
and O +
methods O +
for O +
treating O +
or O +
preventing O +
sepsis O +
in O +
an O +
animal O +
are O +
disclosed O -
. O +

The O +
method O +
comprises O +
administering O +
an O +
electrolyzed O +
saline O +
solution O +
to O +
the O +
animal O -
. O +

In O +
one O +
embodiment O -
, O +
the O +
electrolyzed O +
saline O +
solution O +
comprises O +
ozone O +
and O +
at O +
least O +
one O +
active O +
chlorine O +
species O -
. O +

The O +
electrolyzed O +
saline O +
can O +
further O +
comprise O +
at O +
least O +
one O +
active O +
hydrogen O +
species O -
. O +

Composition O +
against O +
aids O +
virus O +
and O +
method O +
of O +
selectively O +
inactivating O +
virus O -
- O -
infected O +
cells O +
An O +
antiviral O +
composition O +
having O +
an O +
effect O +
of O +
selectively O +
inactivating O +
virus O -
- O -
infected O +
cells O +
which O +
comprises O -
, O +
as O +
the O +
active O +
ingredient O -
, O +
iodine O +
ion O +
or O +
a O +
compound O +
forming O +
iodine O +
ion O -
; O +
a O +
functional O +
food O +
containing O +
the O +
antiviral O +
composition O +
as O +
described O +
above O +
and O +
thus O +
having O +
an O +
antiviral O +
function O +
imparted O +
thereto O -
; O +
and O +
an O +
antiviral O +
drug O +
comprising O +
the O +
antiviral O +
composition O +
as O +
described O +
above O +
and O +
having O +
an O +
effect O +
of O +
selectively O +
inactivating O +
virus O -
- O -
infected O +
cells O -
. O +

Thus O -
, O +
it O +
is O +
intended O +
to O +
provide O +
a O +
novel O +
antiviral O +
composition O +
and O +
so O +
on O +
having O +
a O +
function O +
of O +
selectively O +
inactivating O +
AIDS O +
virus O -
- O -
infected O +
cells O -
, O +
viral O +
cancer O +
cells O -
, O +
etc O -
. O +

Imine O +
derivative O +
and O +
amide O +
derivative O +
A O +
medicine O +
having O +
prostaglandin O +
D2 O +
( O -
PGD2 O -
) O +
production O +
inhibitory O +
activity O +
and O +
having O +
as O +
an O +
active O +
ingredient O +
a O +
substance O +
selected O +
from O +
compounds O +
represented O +
by O +
the O +
general O +
formula O +
( O -
I O -
) O -
: O +
A O -
- O -
Y O -
- O -
B O +
{ O -
wherein O +
A O +
and O +
B O +
each O +
independently O +
represents O +
an O +
optionally O +
substituted O -
, O +
cyclic O +
hydrocarbon O +
or O +
heterocyclic O +
group O -
; O +
and O +
Y O +
represents O +
-CH O -
= O -
N- O -
, O +
-N O -
= O -
CH- O -
, O +
-CONH- O -
, O +
or O +
-NHCO- O -
, O +
provided O +
that O +
the O +
compounds O +
represented O +
by O +
the O +
following O +
formula O +
( O -
I-1 O -
) O +
[ O -
wherein O +
X O +
represents O +
the O +
formula O +
-N O -
= O -
C O -
( O -
R5 O -
) O -
- O +
( O -
wherein O +
the O +
left O -
- O -
side O +
bond O +
is O +
bonded O +
to O +
the O +
benzene O +
ring O +
and O +
the O +
right O -
- O -
side O +
bond O +
is O +
bonded O +
to O +
the O +
nitrogen O +
atom O -
) O +
or O +
the O +
formula O +
-NH O -
- O -
CH O -
( O -
R5 O -
) O -
- O +
( O -
wherein O +
the O +
left O -
- O -
side O +
bond O +
is O +
bonded O +
to O +
the O +
benzene O +
ring O +
and O +
the O +
right O -
- O -
side O +
bond O +
is O +
bonded O +
to O +
the O +
nitrogen O +
atom O -
) O -
; O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
and O +
R4 O +
each O +
independently O +
represents O +
hydrogen O -
, O +
halogeno O -
, O +
or O +
optionally O +
substituted O +
C1 O -
- O -
6 O +
alkyl O +
or O +
hydroxy O -
; O +
R5 O +
represents O +
an O +
optionally O +
substituted O +
C1 O -
- O -
6 O +
alkyl O +
or O +
C6 O -
- O -
10 O +
aryl O +
group O -
; O +
and O +
R O +
represents O +
optionally O +
substituted O +
amino O -
] O +
are O +
excluded O -
} O -
, O +
salts O -
, O +
hydrates O -
, O +
and O +
solvates O -
. O +

Macrolide O +
compositions O +
as O +
therapeutic O +
agent O +
The O +
present O +
invention O +
provides O +
compositions O +
including O +
a O +
macrolide O +
compound O +
that O +
inhibits O +
MHC B-Gene +
class I-Gene +
II I-Gene +
expression O -
. O +

The O +
compositions O +
of O +
the O +
invention O +
are O +
used O +
as O +
an O +
immunosuppressive O +
agent O +
in O +
the O +
treatment O +
prior O +
to O -
, O +
during O +
and/or O +
after O +
organ O +
or O +
tissue O +
transplantation O -
, O +
as O +
well O +
as O +
in O +
the O +
treatment O +
of O +
immune O -
- O -
related O +
disorders O -
. O +

Abnormal O +
cannabidiols O +
for O +
lowering O +
intraocular O +
pressure O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
Abnormal O +
Cannabidiols O +
as O +
potent O +
ocular O +
hypotensives O -
, O +
and O +
are O +
particular O +
suitable O +
for O +
the O +
management O +
of O +
glaucoma O -
. O +

In O +
particular O +
said O +
compounds O +
are O +
represented O +
by O +
formula O +
( O -
I O -
) O +
or O +
formula O +
( O -
II O -
) O +
or O +
formula O +
( O -
III O -
) O -
. O +

These O +
compounds O +
have O +
also O +
been O +
found O +
to O +
be O +
useful O +
in O +
providing O +
neuroprotective O +
effect O +
to O +
the O +
eye O -
. O +

Amino O -
- O -
tropane O +
derivatives O -
, O +
preparation O +
thereof O +
and O +
therapeutic O +
use O +
thereof O +
The O +
invention O +
concerns O +
amino O -
- O -
tropane O +
derivatives O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O -
: O +
Ra O +
R O +
a O -
' O +
et O +
R5 O +
represent O +
hydrogen O +
atoms O +
or O +
alkyl O +
groups O -
; O +
R1 O +
represents O +
a O +
hydrogen O +
atom O +
or O +
an O +
alkyl O -
, O +
cycloalkyl O -
, O +
heterocycloalkyl O +
or O +
aryl O +
group O -
; O +
R2 O +
represents O +
a O +
group O +
of O +
formula O +
- O -
( O -
CH2 O -
) O -
x- O -
( O -
CO O -
) O -
y O -
- O -
Y O +
or O +
- O -
( O -
CO O -
) O -
y- O -
( O -
CH2 O -
) O -
x O -
- O -
Y O -
, O +
wherein O +
Y O +
represents O +
a O +
hydrogen O +
atom O +
or O +
a O +
hydroxy O -
, O +
alkyl O -
, O +
cycloalkyl O -
, O +
alkoxy O -
, O +
aryl O -
, O +
heteroaryl O +
group O +
or O +
NR11R12 O -
; O +
R3 O +
represents O +
1 O +
to O +
3 O +
groups O +
selected O +
among O +
halogen O +
atoms O +
and O +
alkyl O -
, O +
cycloalkyl O +
OR O -
, O +
-NRR O -
' O -
, O +
-CO O -
- O -
NRR O -
' O -
, O +
-NR O -
- O -
CO O -
- O -
R O -
' O -
, O +
-NR O -
- O -
CO O -
- O -
NRR O -
' O -
, O +
-NR O -
- O -
COOR O -
' O -
, O +
-NO2 O -
, O +
-CN O +
and O +
-COOR O +
groups O -
; O +
R4 O +
is O +
selected O +
among O +
a O +
group O +
of O +
formula O +
( O -
a O -
) O -
, O +
( O -
b O -
) O -
, O +
( O -
c O -
) O +
or O +
( O -
d O -
) O -
: O +
or O +
a O +
group O +
of O +
formula O +
-A O -
- O -
R18 O -
, O +
-A O -
- O -
CH O -
= O -
N O -
- O -
R19 O -
, O +
-A O -
- O -
N O -
( O -
R20 O -
) O -
-A'-R19 O -
, O +
-A O -
- O -
CO O -
- O -
N O -
( O -
R2O O -
) O -
-A'-R19 O -
, O +
-A O -
- O -
CH O -
( O -
NH2 O -
) O -
-R19 O -
, O +
-A O -
- O -
N O -
( O -
R20 O -
) O -
-COO O -
- O -
A O -
' O +
or O +
- O -
( O -
CH2 O -
) O -
r O -
- O -
heteroaryl O -
. O +

The O +
invention O +
also O +
concerns O +
a O +
method O +
for O +
preparing O +
said O +
derivatives O +
and O +
the O +
therapeutic O +
use O +
thereof O -
. O +

Donepezyl O +
salts O +
The O +
invention O +
relates O +
to O +
crystalline O +
acid O +
addition O +
salts O +
of O +
donepezil O +
with O +
an O +
organic O +
acid O -
. O +

The O +
acid O +
addition O +
salts O +
have O +
a O +
lower O +
corrosivity O +
compared O +
to O +
the O +
previously O +
known O +
donepezil O +
hydrochloride O -
. O +

The O +
salts O +
can O +
be O +
used O +
for O +
the O +
production O +
of O +
pharmaceutical O +
compositions O +
for O +
the O +
treatment O +
of O +
dementia O -
. O +

Preparation O +
of O +
phenol O -
- O -
amide O +
compounds O +
with O +
antioxidant O +
properties O +
The O +
invention O +
relates O +
to O +
the O +
preparation O +
of O +
compounds O +
comprising O +
at O +
least O +
one O +
phenol O +
function O +
and O +
one O +
amide O +
function O +
derived O +
from O +
amino-2 O +
alkanol-1 O +
having O +
formula O +
( O -
I O -
) O +
and O +
( O -
II O -
) O -
, O +
which O +
have O +
antioxidant O +
and O +
antiradical O +
properties O +
and O +
which O +
are O +
soluble O +
in O +
lipid O +
media O -
. O +

The O +
inventive O +
compounds O +
can O +
be O +
used O +
as O +
cosmetic O +
or O +
pharmaceutical O +
preparations O +
for O +
the O +
prevention O +
of O +
biological O +
degradation O +
caused O +
by O +
free O +
radicals O -
. O +

Therapeutic O +
agent O +
for O +
parkinson O -
's O +
disease O +
A O +
medicine O +
for O +
the O +
prevention O -
, O +
treatment O -
, O +
and/or O +
symptom O +
progress O +
inhibition O +
of O +
Parkinson O -
's O +
disease O +
and/or O +
Parkinson O -
's O +
syndrome O -
. O +

It O +
comprises O +
a O +
combination O +
of O +
( O -
2R O -
) O -
-2-propyloctanoic O +
acid O -
, O +
a O +
salt O +
or O +
solvate O +
thereof O -
, O +
or O +
a O +
prodrug O +
of O +
either O +
with O +
an O +
agent O +
for O +
the O +
prevention O -
, O +
treatment O -
, O +
and/or O +
symptom O +
progress O +
inhibition O +
of O +
Parkinson O -
's O +
disease O +
and/or O +
Parkinson O -
's O +
syndrome O -
. O +

The O +
medicine O +
is O +
highly O +
effective O +
in O +
the O +
prevention O -
, O +
treatment O -
, O +
and/or O +
symptom O +
progress O +
inhibition O +
of O +
Parkinson O -
's O +
disease O +
and/or O +
Parkinson O -
's O +
syndrome O -
. O +

In O +
particular O -
, O +
when O +
the O +
medicinal O +
composition O +
which O +
is O +
for O +
oral O +
administration O -
, O +
which O +
contains O +
( O -
2R O -
) O -
-2-propyloctanoic O +
acid O -
, O +
a O +
salt O +
or O +
solvate O +
thereof O -
, O +
or O +
a O +
prodrug O +
of O +
either O +
as O +
an O +
active O +
ingredient O -
, O +
is O +
administered O +
in O +
combination O +
with O +
a O +
levodopa O +
preparation O -
, O +
levodopa O -
/ O -
benserazide O +
preparation O -
, O +
levodopa O -
/ O -
carbidopa O +
preparation O -
, O +
and/or O +
bromocriptine O +
mesilate O +
in O +
the O +
manner O +
and O +
dose O +
shown O +
in O +
the O +
description O -
, O +
then O +
effects O +
unobtainable O +
with O +
conventional O +
treatments O +
can O +
be O +
produced O -
, O +
such O +
as O +
a O +
dose O +
reduction O -
, O +
alleviation O +
of O +
side O +
effects O -
, O +
and O +
therapeutic O -
- O -
effect O +
enhancement O -
. O +

( O -
( O -
1h O -
- O -
indazol-3-yl O -
) O -
methyl O -
) O +
phenols O +
and O +
( O -
hydroxyphenyl O -
) O -
( O -
1h O -
- O -
indazol-3-yl O -
) O +
methanones O +
as O +
ligands O +
of O +
the O +
estrogen B-Gene +
receptor I-Gene +
This O +
invention O +
provides O +
anti O -
- O -
inflammatory O +
agents O +
of O +
formula O +
( O -
I O -
) O -
, O +
having O +
the O +
structure O -
: O +
formula O +
( O -
I O -
) O -
, O +
formula O +
( O -
II O -
) O -
, O +
wherein O +
A O +
and O +
R1-R10 O +
are O +
as O +
defined O +
in O +
the O +
specification O -
, O +
or O +
a O +
N O -
- O -
oxide O +
thereof O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
or O +
a O +
prodrug O +
thereof O -
. O +

Nitrogen O -
- O -
containing O +
fused O +
ring O +
compound O +
and O +
use O +
thereof O +
An O +
URAT1 B-Gene +
activity O +
inhibitor O +
which O +
contains O +
a O +
nitrogen O -
- O -
containing O +
fused O +
ring O +
compound O +
represented O +
by O +
the O +
following O +
general O +
formula O +
[ O -
1 O -
] O -
: O +
[ O -
1 O -
] O +
wherein O +
each O +
symbol O +
is O +
as O +
defined O +
in O +
the O +
description O -
. O +

This O +
URAT1 B-Gene +
activity O +
inhibitor O +
is O +
useful O +
in O -
, O +
for O +
example O -
, O +
treating O +
pathological O +
conditions O +
in O +
which O +
uric O +
acid O +
participates O +
such O +
as O +
hyperuricemia O -
, O +
gouty O +
node O -
, O +
acute O +
gouty O +
arthritis O -
, O +
chronic O +
gouty O +
arthritis O -
, O +
gouty O +
kidney O -
, O +
urinary O +
calcus O -
, O +
renal O +
dysfunction O -
, O +
coronary O +
artery O +
disease O +
and O +
ischemic O +
heart O +
disease O -
. O +

Indole O +
derivatives O +
for O +
use O +
as O +
ppar B-Gene +
active O +
compounds O +
Compounds O +
are O +
described O +
that O +
are O +
active O +
on O +
at O +
least O +
one O +
of O +
PPARÎ± B-Gene -
, O +
PPARÎ´ B-Gene -
, O +
and O +
PPARÏœ B-Gene -
, O +
which O +
are O +
useful O +
for O +
therapeutic O +
and/or O +
prophylactic O +
methods O +
involving O +
modulation O +
of O +
at O +
least O +
one O +
of O +
PPARÎ± B-Gene -
, O +
PPARÎ´ B-Gene -
, O +
and O +
PPARÏœ. B-Gene +

Method O +
of O +
treating O +
dry O +
eye O +
disorders O +
using O +
13 O -
( O -
s O -
) O -
-hode O +
and O +
its O +
analogs O +
The O +
topical O +
use O +
of O +
13 O -
( O -
S O -
) O -
-HODE O +
and O +
analogs O +
are O +
disclosed O +
for O +
the O +
treatment O +
of O +
dry O +
eye O +
disorders O -
. O +

Therapeutic O +
compositions O +
for O +
intranasal O +
administration O +
of O +
ketorolac O +
Therapeutic O +
compositions O -
, O +
particularly O +
sprayable O +
aqueous O +
compositions O -
, O +
comprise O +
ketorolac O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
in O +
combination O +
with O +
a O +
local O +
anesthetic O -
, O +
such O +
as O +
lidocaine O +
hydrochloride O -
. O +

The O +
compositions O +
are O +
nasally O +
administered O +
to O +
a O +
subject O +
in O +
need O +
thereof O +
to O +
treat O +
pain O +
or O +
inflammation O +
and O +
have O +
the O +
benefit O +
of O +
reduced O +
stinging O +
and O +
improved O +
efficacy O -
, O +
compared O +
to O +
known O +
nasally O +
administered O +
compositions O -
. O +

A O +
tetracycline O +
metal O +
complex O +
in O +
a O +
solid O +
dosage O +
form O +
The O +
present O +
invention O +
is O +
a O +
solid O +
dosage O +
form O +
of O +
a O +
metal O +
complex O +
of O +
tetracycline O +
of O +
Formula O +
( O -
I O -
) O +
for O +
pharmaceutical O +
administration O -
, O +
( O -
I O -
) O +
wherein O +
R1 O +
= O +
Cl O -
, O +
N O -
( O -
CH3 O -
) O -
2 O -
, O +
or O +
H O -
; O +
R2 O +
= O +
CH3 O -
, O +
H O -
, O +
or O +
CH2= O -
; O +
R3 O +
= O +
CH3 O -
, O +
H O -
, O +
OH O -
, O +
or O +
absent O -
; O +
and O +
R4 O +
= O +
OH O +
or O +
H O -
, O +
with O +
the O +
proviso O +
that O +
if O +
R2 O +
is O +
CH3 O +
and O +
R3 O +
is O +
H O -
, O +
then O +
R4 O +
is O +
not O +
OH O -
. O +

Bambuterol O +
and O +
integrin B-Gene +
inhibitor O +
combination O +
The O +
present O +
invention O +
provides O +
novel O +
solid O +
pharmaceutical O +
dosage O +
forms O +
for O +
oral O +
administration O +
comprising O +
a O +
therapeutically O +
active O +
amount O +
of O +
bambuterol O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
a O +
therapeutically O +
effective O +
amount O +
of O +
N- O +
( O -
2-chloro-6-methylbenzoyl O -
) O -
-4- O -
[ O -
( O -
2,6-dichlorobenzoyl O -
) O -
amino O -
] O -
-L O -
- O -
phenylalanine-2- O +
( O -
diethylamino O -
) O +
ethyl O +
ester O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
one O +
or O +
more O +
pharmaceutically O +
acceptable O +
excipients O -
. O +

These O +
novel O +
solid O +
pharmaceutical O +
dosage O +
forms O +
are O +
useful O +
in O +
the O +
treatment O +
or O +
control O +
of O +
asthma O -
. O +

Human O +
monoclonal O +
antibody O +
specific O +
for O +
lipopolysaccharides O +
( O -
lps O -
) O +
of O +
the O +
pseudomonas O +
aeruginosa O +
iats O +
o11 O +
serotype O +
The O +
present O +
invention O +
relates O +
to O +
a O +
human O +
monoclonal O +
antibody O +
specific O +
for O +
the O +
serotype O +
IATS O +
O11 O +
of O +
P. O +
aeruginosa O -
, O +
a O +
hybridoma O +
producing O +
it O -
, O +
nucleic O +
acids O +
encoding O +
it O -
, O +
and O +
host O +
cells O +
transfected O +
therewith O -
. O +

Further O -
, O +
the O +
present O +
invention O +
relates O +
to O +
methods O +
for O +
producing O +
said O +
monoclonal O +
antibody O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
at O +
least O +
one O +
antibody O +
or O +
at O +
least O +
one O +
nucleic O +
acid O +
encoding O +
said O +
antibody O -
. O +

Composition O +
for O +
preventing O +
and/or O +
treating O +
metabolic O +
syndrome O +
and O +
insulin B-Gene +
resistance O +
syndrome O +
It O +
is O +
intended O +
to O +
conveniently O +
and O +
efficiently O +
provide O +
a O +
specific O +
compound O +
originating O +
in O +
a O +
natural O +
material O +
and O +
a O +
composition O +
for O +
preventing O +
and/or O +
treating O +
metabolic O +
syndrome O +
and O +
insulin B-Gene +
resistance O +
syndrome O +
characterized O +
by O +
containing O +
the O +
above O +
compound O +
as O +
the O +
active O +
ingredient O -
. O +

Namely O -
, O +
a O +
composition O +
for O +
preventing O +
and/or O +
treating O +
metabolic O +
syndrome O +
and O +
insulin B-Gene +
resistance O +
syndrome O +
which O +
contains O -
, O +
as O +
the O +
active O +
ingredient O -
, O +
at O +
least O +
one O +
compound O +
selected O +
from O +
among O +
the O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
1 O -
) O -
, O +
the O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
4 O -
) O +
and O +
the O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
5 O -
) O +
or O +
a O +
salt O +
or O +
an O +
ester O +
of O +
the O +
same O -
. O +

4-hydroxy O +
pentanamides O -
, O +
the O +
preparation O +
and O +
use O +
thereof O +
The O +
present O +
invention O +
provides O +
4-hydroxy O +
pentanamides O +
having O +
the O +
following O +
formula O +
( O -
1 O -
) O -
, O +
preparation O +
and O +
use O +
thereof O -
. O +

The O +
said O +
compounds O +
show O +
effective O +
activity O +
of O +
inhibiting O +
BACE O +
and O +
preclude O +
the O +
formation O +
of O +
AÎ² O -
. O +

Thus O +
the O +
said O +
compounds O +
are O +
useful O +
in O +
the O +
manufacture O +
of O +
medicines O +
for O +
treating O +
Alzheimer O -
's O +
Disease O -
. O +

Use O +
of O +
deuterated O +
n- O -
[ O -
2- O -
( O -
5-methoxy-1h O -
- O -
indol-3-yl O -
) O -
-ethyl O -
] O -
acetamides O +
and O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
and O +
medicaments O +
containing O +
said O +
compounds O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
deuterated O +
N- O -
[ O -
2- O -
( O -
5-methoxy-1H O -
- O -
indol-3-yl O -
) O -
ethyl O -
] O -
acetamides O +
or O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
for O +
preventing O -
, O +
treating O -
, O +
or O +
controlling O +
a O +
disorder O -
, O +
disease O -
, O +
or O +
biological O +
function O +
that O +
is O +
related O +
to O +
a O +
relative O +
melatonin O +
deficiency O +
and/or O +
can O +
be O +
treated O +
or O +
influenced O +
by O +
administering O +
melatonin O +
provided O +
that O +
the O +
disease O +
or O +
disorder O +
is O +
not O +
a O +
disorder O +
in O +
the O +
framework O +
of O +
manic O +
depression O -
. O +

The O +
invention O +
further O +
relates O +
to O +
the O +
use O +
of O +
deuterated O +
N- O -
[ O -
2- O -
( O -
5-methoxy-1H O -
- O -
indol-3-yl O -
) O -
ethyl O -
] O -
acetamides O +
or O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
for O +
producing O +
a O +
medicament O -
. O +

Also O +
disclosed O +
is O +
a O +
medicament O +
containing O +
deuterated O +
N- O -
[ O -
2- O -
( O -
5-methoxy-1H O -
- O -
indol-3-yl O -
) O -
ethyl O -
] O -
acetamides O +
or O +
the O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

2-quinolone O +
compounds O +
as O +
inhibitors O +
of O +
phosphodiesterases B-Gene +
There O +
is O +
provided O +
according O +
to O +
the O +
invention O +
novel O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutically O +
acceptable O +
solvates O +
thereof O -
. O +

Novel O +
preventive O +
or O +
remedy O +
for O +
lipid O +
metabolism O +
disorder O -
, O +
obesity O +
and O +
diabetes O +
and O +
use O +
therefor O +
[ O -
PROBLEMS O -
] O +
To O +
provide O +
a O +
preventive O +
or O +
remedy O +
having O +
improved O +
efficacy O +
against O +
lipid O +
metabolism O +
disorder O -
, O +
obesity O +
and O +
diabetes O +
and O +
a O +
method O +
of O +
using O +
the O +
same O -
. O +

[ O -
MEANS O +
FOR O +
SOLVING O +
PROBLEMS O -
] O +
Focusing O +
on O +
the O +
multidrug O +
therapy O -
, O +
a O +
medicine O +
is O +
designed O +
by O +
using O +
a O +
novel O +
phenylpropionic O +
acid O +
derivative O +
serving O +
as O +
a O +
PPARÎ± B-Gene +
activator O +
( O -
for O +
example O -
, O +
( O -
S O -
) O -
-2-ethyl-3- O -
[ O -
4-methoxy-3- O -
[ O -
N- O -
[ O -
[ O -
4- O -
( O -
4-fluorophenoxy O -
) O -
phenyl O -
] O -
methyl O -
] O -
carbamoyl O -
] O -
phenyl O -
] O -
propionic O +
acid O +
( O -
KRP-101 O -
) O -
) O +
together O +
with O +
a O +
statin O +
drug O +
serving O +
as O +
an O +
antihyperlipidemic O +
or O +
blending O +
them O +
to O +
synergistically O +
or O +
additionally O +
enhance O +
the O +
lipid O -
- O -
lowering O +
effect O -
, O +
thereby O +
providing O +
a O +
novel O +
preventive O +
or O +
remedy O +
having O +
improved O +
efficacy O +
against O +
lipid O +
metabolism O +
disorder O -
, O +
obesity O +
and O +
diabetes O +
and O +
a O +
method O +
of O +
using O +
the O +
same O -
. O +

Substituted O +
oxindol O +
derivatives O -
, O +
drugs O +
containing O +
said O +
derivatives O +
and O +
the O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
novel O +
oxindol O +
derivative O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
substituents O +
R1 O -
, O +
R2 O -
, O +
A O -
, O +
B O +
and O +
Y O +
are O +
such O +
as O +
defined O +
in O +
a O +
claim O +
1 O -
. O +

Drugs O +
containing O +
said O +
derivatives O +
and O +
the O +
use O +
thereof O +
for O +
preventing O +
and/or O +
treating O +
vassopress O -
- O -
and O -
/ O -
or O +
oxytocin O -
- O -
dependent O -
- O -
diseases O +
are O +
also O +
disclosed O -
. O +

Antineoplastic O +
preparation O +
The O +
inventive O +
antineoplastic O +
preparation O +
is O +
based O +
on O +
a O +
gluconic O +
acid O +
and O +
exhibits O +
an O +
apoptotic O +
and O +
anti O -
- O -
proliferative O +
effect O +
preserving O +
healthy O +
cells O -
. O +

In O +
the O +
first O +
variant O -
, O +
said O +
preparation O +
is O +
embodied O +
in O +
the O +
form O +
of O +
at O +
least O +
one O +
type O +
of O +
gluconate O -
, O +
wherein O +
a O +
salt O -
- O -
forming O +
agent O +
is O +
selected O +
from O +
a O +
group O +
comprising O +
magnesium O -
, O +
sodium O -
, O +
potassium O -
, O +
Î· O -
- O -
aminobutyric O +
acid O -
, O +
ethylenediamine O +
or O +
the O +
mixture O +
thereof O -
. O +

In O +
the O +
second O +
variant O -
, O +
the O +
perpetration O +
is O +
embodied O +
in O +
the O +
form O +
of O +
a O +
co O -
- O -
ordination O +
compound O +
which O +
is O +
based O +
on O +
a O +
magnesium O +
gluconate O +
in O +
which O +
ligands O +
are O +
selected O +
from O +
a O +
group O +
consisting O +
of O +
a O +
Î· O -
- O -
aminobutyric O +
acid O -
, O +
3-hydroxy O -
- O -
Î· O -
- O -
aminobutyric O +
acid O -
, O +
ethylene O +
diamine O +
tetraacetic O +
acid O +
and O +
an O +
ethylene O +
glycol O +
tetraacetic O +
acid O -
. O +

In O +
the O +
third O +
variant O -
, O +
the O +
composition O +
is O +
embodied O +
in O +
the O +
form O +
of O +
a O +
binary O +
salt O +
selected O +
from O +
a O +
group O +
consisting O +
of O +
a O +
magnesium O +
butyrate O -
- O -
gluconate O -
, O +
magnesium O +
oxybutyrate O -
- O -
gluconate O -
, O +
magnesium O +
glucarate O -
- O -
gluconate O -
, O +
calcium O +
butyrate O -
- O -
gluconate O -
, O +
butyrate O -
- O -
gluconate O +
oxybutyrate O -
- O -
gluconate O -
, O +
calcium O +
glucarate O -
- O -
gluconate O +
and O +
the O +
combination O +
thereof O -
. O +

Perkinson O +
disease O -
- O -
related O +
gene O +
grk5 B-Gene +
and O +
use O +
thereof O +
As O +
a O +
result O +
of O +
a O +
large O +
scale O +
SNP O +
analysis O +
on O +
a O +
group O +
of O +
Perkinson O +
disease O +
patients O +
and O +
a O +
control O +
group O +
of O +
normal O +
persons O -
, O +
it O +
has O +
succeeded O +
in O +
the O +
identification O +
of O +
a O +
gene O +
involved O +
in O +
Perkinson O +
disease O +
( O -
GRK5 B-Gene -
) O -
. O +

It O +
is O +
now O +
found O +
that O +
the O +
increase O +
in O +
the O +
expression O +
of O +
the O +
GRK5 B-Gene +
gene O +
induces O +
the O +
enhancement O +
of O +
the O +
phosphorylation O +
of O +
Î± B-Gene -
- I-Gene -
synuclein I-Gene -
, O +
which O +
in O +
turn O +
induces O +
the O +
enhancement O +
of O +
the O +
formation O +
of O +
a O +
soluble O +
Î± B-Gene -
- I-Gene -
synuclein I-Gene +
oligomer O -
, O +
leading O +
to O +
the O +
development O +
of O +
Perkinson O +
disease O -
. O +

It O +
becomes O +
possible O +
to O +
diagnose O +
Perkinson O +
disease O +
and O +
screen O +
a O +
therapeutic O +
agent O +
for O +
Perkinson O +
disease O +
by O +
using O +
the O +
expression O +
of O +
the O +
GRK5 B-Gene +
gene O -
. O +

Pharmaceutical O +
compositions O +
of O +
antiretrovirals O +
The O +
present O +
invention O +
relates O +
to O +
the O +
stable O +
pharmaceutical O +
dosage O +
forms O +
of O +
combination O +
of O +
antiretroviral O +
agents O -
. O +

More O +
particularly O -
, O +
the O +
present O +
invention O +
relates O +
to O +
stable O +
pharmaceutical O +
dosage O +
forms O +
of O +
Lamivudine O -
, O +
Zidovudine O +
and O +
Nevirapine O -
, O +
prepared O +
by O +
granulation O +
technology O -
. O +

Heterocyclic O +
n O -
- O -
oxides O +
as O +
hypoxic O +
selective O +
protein B-Gene +
kinase I-Gene +
inhibitors O +
The O +
invention O +
relates O +
to O +
novel O +
heterocyclic O +
N O -
- O -
oxides O +
which O +
are O +
useful O +
as O +
hypoxic O +
selective O +
cytotoxic O +
agents O +
that O +
mediate O +
and/or O +
inhibit O +
cell O +
proliferation O -
, O +
for O +
example O -
, O +
through O +
the O +
activity O +
of O +
protein B-Gene +
kinases I-Gene -
. O +

The O +
invention O +
is O +
further O +
related O +
to O +
pharmaceutical O +
compositions O +
containing O +
such O +
compounds O +
and O +
compositions O -
, O +
and O +
to O +
methods O +
of O +
treating O +
cancer O +
as O +
well O +
as O +
other O +
disease O +
states O +
associated O +
with O +
unwanted O +
ahgiogenesis O +
and/or O +
cellular O +
proliferation O +
by O +
administering O +
effective O +
amounts O +
of O +
such O +
compounds O -
. O +

Method O +
for O +
treatment O +
of O +
uterine O +
fibroid O +
tumors O +
Various O +
injectable O +
or O +
insertable O +
uterine O +
fibroid O +
treatment O +
formulations O +
are O +
provided O -
, O +
which O +
comprise O +
a O +
uterine O +
fibroid O +
treatment O +
agent O +
in O +
an O +
amount O +
effective O +
to O +
cause O +
shrinkage O +
or O +
elimination O +
of O +
uterine O +
fibroids O -
. O +

The O +
injectable O +
or O +
insertable O +
formulations O +
are O +
typically O +
solids O -
, O +
semi O -
- O -
solids O +
or O +
high O -
- O -
viscosity O +
fluids O -
. O +

Other O +
aspects O +
of O +
the O +
invention O +
are O +
directed O +
to O +
systems O +
and O +
methods O +
for O +
treatment O +
of O +
uterine O +
fibroids O -
. O +

Substituted O +
benzo O -
( O -
d O -
) O -
isoxazol-3-yl O +
amine O +
compounds O +
as O +
analgesics O +
Disclosed O +
are O +
substituted O +
benzo O -
[ O -
d O -
] O -
isoxazol-3-yl O +
amine O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
which O +
are O +
suitable O +
for O +
the O +
treatment O +
of O +
pain O +
while O +
being O +
provided O +
with O +
an O +
excellent O +
affinity O +
to O +
the O +
KCNQ2 B-Gene -
/ I-Gene -
3 I-Gene +
K+ I-Gene +
channel I-Gene +
and O +
thus O +
being O +
suitable O +
for O +
the O +
treatment O +
of O +
disorders O +
or O +
diseases O +
that O +
are O +
transmitted O +
at O +
least O +
in O +
part O +
through O +
KCNQ2 B-Gene -
/ I-Gene -
3 I-Gene +
K+ I-Gene +
channels I-Gene -
. O +

Compounds O -
, O +
pharmaceutical O +
compositions O +
and O +
methods O +
for O +
their O +
use O +
in O +
treating O +
metabolic O +
disorders O +
The O +
present O +
invention O +
provides O +
compounds O +
useful O -
, O +
for O +
example O -
, O +
for O +
modulating O +
insulin B-Gene +
levels O +
in O +
a O +
subject O -
, O +
having O +
the O +
general O +
formula O +
I O -
: O +
wherein O +
Q O +
is O +
an O +
optionally O +
substituted O +
phenyl O -
; O +
L O +
is O +
a O +
bond O +
or O +
O O -
; O +
P O +
is O +
a O +
benzene O +
or O +
an O +
optionally O +
substituted O +
thiazole O +
ring O -
; O +
and O +
R1 O +
has O +
the O +
values O +
provided O +
herein O -
. O +

The O +
present O +
invention O +
also O +
provides O +
compositions O -
, O +
uses O -
, O +
and O +
methods O +
for O +
use O +
of O +
the O +
compounds O -
, O +
for O +
instance O -
, O +
for O +
treatment O +
of O +
type O +
II O +
diabetes O -
. O +

Combinations O +
of O +
erbb2 B-Gene +
inhibitors O +
with O +
other O +
therapeutic O +
agents O +
in O +
the O +
treatment O +
of O +
cancer O +
This O +
invention O +
relates O +
to O +
a O +
method O +
of O +
treatment O +
of O +
cancer O +
with O +
a O +
combination O +
of O +
an O +
additional O +
therapeutic O +
agent O +
in O +
mammals O -
. O +

This O +
invention O +
also O +
relates O +
to O +
a O +
kit O +
useful O +
in O +
the O +
treatment O +
of O +
abnormal O +
cell O +
growth O +
in O +
mammals O -
, O +
especially O +
humans O -
. O +

Sulindac O +
derivatives O +
for O +
treatment O +
of O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
non O +
steroidal O +
anti O -
- O -
inflammatory O +
compounds O +
( O -
NSAIDs O -
) O +
derivatives O +
of O +
sulindac O -
, O +
for O +
the O +
treatment O -
/ O -
prevention O -
, O +
alone O +
or O +
in O +
combination O -
, O +
of O +
cancer O -
. O +

Heterocyclic O +
containing O +
amines O +
as O +
kinase O +
b O +
inhibitors O +
The O +
invention O +
provides O +
a O +
compound O +
of O +
the O +
formula O +
( O -
I O -
) O +
or O +
a O +
salt O -
, O +
solvate O -
, O +
tautomer O +
or O +
N O -
- O -
oxide O +
thereof O -
; O +
for O +
use O +
as O +
a O +
PKB O +
kinase O +
inhibitor O +
or O +
PKA O +
kinase O +
inhibitor O -
. O +

In O +
formula O +
( O -
I O -
) O -
, O +
A O +
is O +
a O +
saturated O +
hydrocarbon O +
linker O +
group O -
; O +
E O +
is O +
a O +
monocyclic O +
or O +
bicyclic O +
carbocyclic O +
or O +
heterocyclic O +
group O -
; O +
HET O +
is O +
a O +
monocyclic O +
heterocyclic O +
group O -
; O +
R1 O +
is O +
an O +
aryl O +
or O +
heteroaryl O +
group O -
; O +
n O +
is O +
0 O +
to O +
4 O -
; O +
and O +
R2 O -
, O +
R3 O +
and O +
R4 O +
are O +
as O +
defined O +
in O +
the O +
claims O -
, O +
provided O +
that O +
HET O +
is O +
other O +
than O +
an O +
unsubstituted O +
or O +
substituted O +
pyrazole-4-yl O +
group O -
. O +

Fluorescent O +
sulfonamide O +
derivatives O +
having O +
carbonic B-Gene +
anhydrase I-Gene +
inhibiting O +
activity O +
and O +
their O +
use O +
as O +
theapeutic O +
and O +
diagnostic O +
agents O +
The O +
present O +
invention O +
discloses O +
sulfonamide O +
CA B-Gene +
IX I-Gene -
- O -
selective O +
inhibitors O -
, O +
which O +
selectively O +
bind O +
to O +
the O +
enzyme O +
under O +
hypoxic O +
conditions O +
and O +
are O +
able O +
to O +
reverse O +
the O +
tumor O +
acidification O +
mediated O +
by O +
the O +
enzyme O -
. O +

These O +
compounds O +
are O +
useful O +
in O +
anticancer O +
therapies O +
based O +
on O +
tumor O -
- O -
associated O +
CA B-Gene +
isozyme I-Gene +
inhibition O +
as O +
well O +
as O +
for O +
hypoxic O +
tumor O +
imaging O -
. O +

The O +
inhibitors O +
contain O +
a O +
fluorescent O +
moiety O -
, O +
preferably O +
fluorescein O -
. O +

Tablet O +
containing O +
poorly O +
soluble O +
active O +
ingredient O +
Disclosed O +
is O +
a O +
tablet O +
containing O +
about O +
3 O -
- O -
50 O -
% O +
by O +
weight O +
( O -
w O -
/ O -
w O -
) O +
of O +
a O +
poorly O +
soluble O +
active O +
ingredient O +
relative O +
to O +
the O +
total O +
tablet O +
weight O -
, O +
magnesium O +
stearate O +
and O +
a O +
hydroxypropylcellulose O +
having O +
a O +
viscosity O +
of O +
about O +
1 O -
- O -
4 O +
mPaÂ·s O -
. O +

This O +
tablet O +
is O +
suppressed O +
in O +
dissolution O +
variation O +
between O +
lots O -
. O +

Pharmaceutical O +
compositions O +
containing O +
clopidogrel O +
bisulfate O +
Provided O +
is O +
a O +
pharmaceutical O +
composition O +
including O +
clopidogrel O +
bisulfate O +
and O +
a O +
pregelatinized O +
starch O -
. O +

The O +
pharmaceutical O +
composition O +
in O +
which O +
the O +
stability O +
of O +
clopido O +
grel O +
bisulfate O +
is O +
significantly O +
enhanced O +
can O +
be O +
obtained O +
by O +
mixing O +
clopidogrel O +
bisulfate O +
w O +
ith O +
the O +
pregelatinized O +
starch O -
. O +

Compounds O +
and O +
their O +
salts O +
specific O +
to O +
the O +
ppar B-Gene +
receptors O +
and O +
the O +
egf B-Gene +
receptors I-Gene +
and O +
their O +
use O +
in O +
the O +
medical O +
field O +
Therefore O +
the O +
present O +
invention O +
relates O +
specifically O +
to O +
the O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
R1 O +
and O +
R2 O -
, O +
which O +
may O +
be O +
identical O +
or O +
different O -
, O +
are O +
selected O +
from O +
the O +
group O +
comprising O +
H O -
, O +
-CnH2n-1 O -
, O +
a O +
linear O +
or O +
branched O +
alkyl O +
group O +
having O +
from O +
1 O +
to O +
6 O +
carbon O +
atoms O -
, O +
or O +
together O +
form O +
an O +
aromatic O +
or O +
aliphatic O +
ring O +
with O +
5 O +
or O +
6 O +
atoms O -
; O +
R3 O +
is O +
selected O +
from O +
-CO O -
- O -
CH3 O -
, O +
-NHOH O -
, O +
-OH O -
, O +
-OR6 O +
in O +
which O +
R6 O +
is O +
a O +
linear O +
or O +
branched O +
alkyl O +
group O +
having O +
from O +
1 O +
to O +
6 O +
carbon O +
atoms O -
; O +
R4 O +
is O +
selected O +
from O +
H O -
, O +
a O +
linear O +
or O +
branched O +
alkyl O +
group O +
having O +
from O +
1 O +
to O +
6 O +
carbon O +
atoms O -
, O +
phenyl O -
, O +
benzyl O -
, O +
-CF3 O +
or O +
-CF2CF3 O -
, O +
vinyl O +
or O +
allyl O -
; O +
R5 O -
, O +
R7 O -
, O +
R8 O +
are O +
hydrogen O +
atoms O -
; O +
or O +
R3 O +
and O +
R4 O -
, O +
R4 O +
and O +
R5 O -
, O +
or O +
R7 O +
and O +
R8 O +
together O +
form O +
a O +
ring O -
, O +
fused O +
to O +
the O +
benzene O -
, O +
aromatic O +
or O +
aliphatic O +
ring O +
with O +
5 O +
or O +
6 O +
atoms O +
comprising O +
from O +
1 O +
to O +
2 O +
heteroatoms O +
selected O +
independently O +
from O +
the O +
group O +
comprising O +
N O -
, O +
O. O +
and O +
use O +
thereof O +
in O +
the O +
medical O +
field O -
. O +

Simon O +
potato O +
extract O -
, O +
glycosphingolipid O +
derived O +
from O +
simon O +
potato O -
, O +
and O +
process O +
for O +
production O +
of O +
the O +
extract O +
or O +
glycosphingolipid O +
[ O -
PROBLEMS O -
] O +
To O +
provide O +
a O +
process O +
for O +
producing O +
a O +
glycolipid O -
- O -
containing O +
Simon O +
potato O +
extract O +
or O +
a O +
glycosphingolipid O +
from O +
a O +
Simon O +
potato O +
for O +
the O +
purpose O +
of O +
providing O +
an O +
alternative O +
to O +
a O +
livestock O +
brain O +
ganglioside O +
which O +
is O +
free O +
from O +
the O +
risk O +
of O +
BSE O +
or O +
the O +
like O -
, O +
is O +
safe O +
to O +
a O +
human O +
body O +
and O +
can O +
be O +
ingested O +
on O +
a O +
daily O +
basis O -
, O +
and O +
to O +
provide O +
a O +
nerve O +
cell O +
activator O +
comprising O +
a O +
glycolipid O +
or O +
glycosphingolipid O +
derived O +
from O +
a O +
Simon O +
potato O +
and O +
a O +
health O +
food O +
prepared O +
by O +
using O +
the O +
glycolipid O +
or O +
glycosphingolipid O -
. O +

[ O -
MEANS O +
FOR O +
SOLVING O +
PROBLEMS O -
] O +

A O +
Simon O +
potato O +
extract O +
can O +
be O +
produced O +
by O +
immersing O +
a O +
Simon O +
potato O +
in O +
a O +
polar O +
solvent O +
to O +
extract O +
a O +
glycolipid O +
or O +
glycosphingolipid O +
into O +
the O +
polar O +
solvent O +
and O +
then O +
concentrating O +
the O +
resulting O +
immersion O +
fluid O -
. O +

The O +
nerve O +
cell O +
activation O +
effect O +
of O +
the O +
glycolipid O +
or O +
glycosphingolipid O +
is O +
confirmed O +
using O +
an O +
established O +
neuroblast O -
. O +

Hepatitis B-Gene +
c I-Gene +
serine I-Gene +
protease I-Gene +
inhibitors O +
and O +
uses O +
therefor O +
The O +
present O +
invention O +
provides O +
novel O +
compounds O +
which O +
mimic O +
peptides O +
with O +
a O +
C O -
- O -
terminal O +
penultimate O +
proline O -
, O +
such O +
compounds O +
being O +
useful O +
as O +
protease B-Gene +
inhibitors O -
, O +
particularly O +
as O +
inhibitors O +
of O +
serine B-Gene +
proteases I-Gene -
, O +
and O +
more O +
particularly O +
as O +
inhibitors O +
of O +
the O +
NS3 B-Gene +
serine I-Gene +
protease I-Gene +
from O +
hepatitis O +
C. O +
The O +
compounds O +
find O +
utility O +
as O +
antiviral O +
agents O +
directed O +
at O +
hepatitis O +
C. O +
The O +
invention O +
further O +
provides O +
methods O +
of O +
employing O +
such O +
inhibitors O -
, O +
alone O +
or O +
in O +
combination O +
with O +
other O +
therapeutic O +
agents O -
, O +
to O +
treat O +
hepatitis O +
C O +
infection O +
in O +
a O +
subject O +
in O +
need O +
of O +
such O +
treatment O -
. O +

Vaginal O +
treatment O +
composition O +
A O +
vaginal O +
treatment O +
composition O +
that O +
rapidly O +
forms O +
a O +
gel O +
when O +
placed O +
into O +
contact O +
with O +
monovalent O +
or O +
polyvalent O +
cations O -
, O +
such O +
as O +
sodium O +
( O -
Na+ O -
) O +
and O +
calcium O +
( O -
Ca2 O -
+ O -
) O +
cations O +
naturally O +
found O +
in O +
vaginal O +
mucosa O -
, O +
is O +
provided O -
. O +

The O +
gel O +
may O +
form O +
in O +
less O +
than O +
about O +
1 O +
hour O -
, O +
in O +
some O +
embodiments O +
less O +
than O +
about O +
1 O +
minute O -
, O +
and O +
in O +
some O +
embodiments O -
, O +
less O +
than O +
about O +
30 O +
seconds O -
. O +

Among O +
other O +
things O -
, O +
such O +
rapid O +
gelation O +
reduces O +
the O +
likelihood O +
of O +
leakage O +
during O +
use O -
. O +

In O +
addition O -
, O +
because O +
the O +
gel O +
may O +
form O +
intravaginally O -
, O +
it O +
is O +
more O +
likely O +
to O +
retain O +
its O +
structure O +
and O +
shape O +
over O +
an O +
extended O +
period O +
of O +
time O -
. O +

In O +
this O +
manner O -
, O +
the O +
gel O +
may O +
provide O +
the O +
prolonged O +
release O +
of O +
a O +
therapeutic O +
agent O +
that O +
inhibits O +
and/or O +
treats O +
vaginal O +
infection O -
. O +

For O +
instance O -
, O +
the O +
gel O +
may O +
remain O +
within O +
the O +
vagina O +
for O +
about O +
2 O +
to O +
about O +
48 O +
hours O +
to O +
provide O +
the O +
desired O +
effect O -
. O +

Chromane O +
substituted O +
2-alkyl O +
imidazopyridine O +
derivatives O +
and O +
use O +
thereof O +
as O +
acid O +
pump O +
antagonists O +
This O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
: O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
wherein O -
: O +
A O -
, O +
B O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O +
and O +
R7 O +
are O +
each O +
as O +
described O +
herein O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
and O +
compositions O +
containing O +
such O +
compounds O +
and O +
the O +
method O +
and O +
use O +
of O +
such O +
compounds O +
in O +
the O +
treatment O +
of O +
a O +
condition O +
mediated O +
by O +
acid O +
pump O +
antagonistic O +
activity O +
such O +
as O -
, O +
but O +
not O +
limited O +
to O -
, O +
as O +
gastrointestinal O +
disease O -
, O +
gastroesophageal O +
disease O -
, O +
gastroesophageal O +
reflux O +
disease O +
( O -
GERD O -
) O -
, O +
peptic O +
ulcer O -
, O +
gastric O +
ulcer O -
, O +
duodenal O +
ulcer O -
, O +
NSAID O -
- O -
induced O +
ulcers O -
, O +
gastritis O -
, O +
infection O +
of O +
Helicobacter O +
pylori O -
, O +
dyspepsia O -
, O +
functional O +
dyspepsia O -
, O +
Zollinger O -
- O -
Ellison O +
syndrome O -
, O +
non O -
- O -
erosive O +
reflux O +
disease O +
( O -
NERD O -
) O -
, O +
visceral O +
pain O -
, O +
heartburn O -
, O +
nausea O -
, O +
esophagitis O -
, O +
dysphagia O -
, O +
hypersalivation O -
, O +
airway O +
disorders O +
or O +
asthma O -
. O +

Sunscreen O +
and O +
cosmetic O +
compositions O +
for O +
prophylaxis O +
or O +
treatment O +
of O +
skin O +
cancers O +
There O +
are O +
provided O +
sunscreen O +
and O +
cosmetics O +
compositions O +
containing O +
non O -
- O -
steroidal O +
anti- O +
inflammatory O +
drugs O +
( O -
NSAIDs O -
) O +
in O +
the O +
form O +
of O +
metal O +
complexes O +
for O +
the O +
prophylaxis O +
or O +
treatment O +
of O +
cancers O +
of O +
the O +
skin O -
. O +

The O +
ligand O -
( O -
s O -
) O +
of O +
the O +
complex O +
typically O +
independently O +
comprise O +
a O +
carboxylate O -
, O +
or O +
a O +
derivative O +
of O +
a O +
carboxylate O -
, O +
having O +
anti O -
- O -
inflammatory O +
activity O -
. O +

Carboxylate O +
derivatives O +
having O +
anti O -
- O -
inflammatory O +
activity O +
that O +
may O +
be O +
used O +
include O +
hydroxamates O -
, O +
hydroximates O -
, O +
amides O +
and O +
esters O -
. O +

Copper O +
and O +
zinc O +
metal O +
complexes O +
including O +
the O +
NSAIDs O +
indomethacin O +
and O +
acematacin O +
are O +
particularly O +
preferred O -
. O +

7- O -
[ O -
2- O -
[ O -
4- O -
( O -
6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL O -
) O -
-1-PIPERAZINYL O -
] O -
ETHYL O -
] O -
-2- O -
( O -
1-PROPYNYL O -
) O -
-7H O -
- O -
PYRAZOLO- O -
[ O -
4,3-e O -
] O -
- O -
[ O -
1,2,4 O -
] O -
-TRIAZOLO- O -
[ O -
1,5-c O -
] O -
-PYRIMIDIN-5 O +

AMINE O +
The O +
compound O +
having O +
the O +
structural O +
formula O +
I O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
is O +
disclosed O -
, O +
as O +
well O +
as O +
its O +
use O +
in O +
the O +
treatment O +
of O +
central O +
nervous O +
system O +
diseases O -
, O +
in O +
particular O +
Parkinson O -
's O +
disease O -
, O +
Extra O +
Pyramidal O +
Syndrome O -
, O +
restless O +
legs O +
syndrome O +
and O +
attention O +
deficit O +
hyperactivity O +
disorder O -
, O +
pharmaceutical O +
compositions O +
comprising O +
it O -
, O +
and O +
combinations O +
with O +
other O +
agents O -
. O +

Thienopyridine-2-carboxamide O +
derivative O +
Disclosed O +
is O +
a O +
compound O +
represented O +
by O +
the O +
general O +
formula O +
( O -
I O -
) O +
below O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O -
. O +

( O -
In O +
the O +
formula O -
, O +
R1 O +
represents O +
a O +
hydrogen O +
atom O +
or O +
a O +
C1-C6 O +
alkyl O +
group O -
, O +
and O +
R2 O +
represents O +
a O +
substituted O +
cyclic O +
amino O -
. O -
) O +

PYRIDOPYRIMIDINONE O +
INHIBITORS O +
OF O +
PI3KÎ± B-Gene +
The O +
invention O +
is O +
directed O +
to O +
Compounds O +
of O +
Formula O +
I O +
and O +
pharmaceutically O +
acceptable O +
salts O +
or O +
solvates O +
thereof O -
, O +
as O +
well O +
as O +
methods O +
of O +
making O +
and O +
using O +
the O +
compounds O -
. O +

The O +
oral O +
agent O +
for O +
improving O +
and O +
protecting O +
the O +
function O +
of O +
joint O +
comprising O +
hyaluronic O +
acid O -
- O -
phospholipid O +
complexes O +
An O +
oral O +
formulation O +
compring O +
hyaluronid O +
acid- O +
phospholipid O +
complexes O +
as O +
active O +
ingredient O +
and O +
the O +
application O +
of O +
hyaluronic O +
acid- O +
phosphlipid O +
complexes O +
in O +
preparation O +
of O +
the O +
product O +
for O +
improving O +
and O +
protecting O +
the O +
function O +
of O +
joint O -
. O +

Pqs O +
and O +
its O +
conjugates O +
as O +
adjuvants O +
and O +
their O +
uses O +
in O +
pharmaceutical O +
compositions O +
The O +
present O +
invention O +
relates O +
to O +
new O +
adjuvants O +
and O +
the O +
uses O +
in O +
pharmaceutical O +
compositions O -
, O +
like O +
in O +
vaccines O -
. O +

In O +
particular O -
, O +
the O +
present O +
invention O +
provides O +
new O +
compounds O +
useful O +
as O +
adjuvants O +
and/or O +
immunomodulators O +
for O +
prophylactic O +
and/or O +
therapeutic O +
vaccination O +
in O +
the O +
treatment O +
of O +
infectious O +
diseases O -
, O +
inflammatory O +
diseases O -
, O +
autoimmune O +
diseases O -
, O +
tumours O -
, O +
allergies O +
as O +
well O +
as O +
for O +
the O +
control O +
of O +
fertility O +
in O +
human O +
or O +
animal O +
populations O -
. O +

The O +
compounds O +
are O +
particularly O +
useful O +
not O +
only O +
as O +
systemic O -
, O +
but O +
preferably O +
as O +
mucosal O +
adjuvants O -
. O +

In O +
addition O -
, O +
the O +
invention O +
relates O +
to O +
its O +
uses O +
as O +
active O +
ingredients O +
in O +
pharmaceutical O +
compositions O -
. O +

Macrolones O +
A O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
derivative O +
thereof O -
, O +
having O +
antimicrobial O +
activity O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
compositions O +
containing O +
them O +
and O +
to O +
their O +
use O +
in O +
medicine O -
. O +

N4-phenyl O -
- O -
quinaz0line-4 O +
-amine O +
derivatives O +
and O +
related O +
compounds O +
as O +
erbb B-Gene +
type I-Gene +
i I-Gene +
receptor I-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitors O +
for O +
the O +
treatment O +
of O +
hyperproliferative O +
diseases O +
This O +
invention O +
provides O +
compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
wherein O +
B O -
, O +
G O -
, O +
A O -
, O +
E O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
m O +
and O +
n O +
are O +
as O +
defined O +
herein O -
, O +
which O +
are O +
useful O +
as O +
type B-Gene +
I I-Gene +
receptor I-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitors O -
, O +
and O +
methods O +
of O +
use O +
thereof O +
in O +
the O +
treatment O +
of O +
hyperproliferative O +
disorders O +
in O +
mammals O -
. O +

Novel O +
proline O -
- O -
derivative O +
based O +
cosmetological O +
and/or O +
dermatological O +
compositions O +
and O +
uses O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
the O +
necessities O +
of O +
life O -
, O +
and O +
more O +
particularly O +
to O +
the O +
field O +
of O +
cosmetology O +
and O +
dermatology O -
. O +

It O +
relates O +
more O +
particularly O +
to O +
novel O +
cosmetological O +
and/or O +
dermatological O +
compositions O +
which O +
bring O +
about O +
a O +
very O +
significant O +
increase O +
in O +
the O +
deposition O +
of O +
collagen B-Gene +
type I-Gene +
( I-Gene -
III I-Gene -
) I-Gene +
in O +
the O +
extracellular O +
matrix O -
, O +
characterized O +
in O +
that O +
they O +
contain O -
, O +
as O +
active O +
ingredient O -
, O +
a O +
combination O +
of O +
a O +
4-hydroxyproline O +
fatty O +
acid O +
amido O +
ester O -
, O +
of O +
formula O +
( O -
I O -
) O -
: O +
in O +
which O +
R1 O +
and O +
R'1 O +
are O +
identical O +
or O +
different O +
aliphatic O +
chains O +
containing O +
from O +
10 O +
to O +
24 O +
carbon O +
atoms O +
that O +
are O +
in O +
a O +
straight O +
line O +
or O +
branched O -
, O +
and O +
of O +
an O +
extract O +
of O +
the O +
epicarp O +
of O +
the O +
Opuntia O +
ficus O -
- O -
indica O +
( O -
Barbary O +
fig O -
) O +
fruit O +
in O +
an O +
inert O -
, O +
nontoxic O +
excipient O +
or O +
carrier O +
suitable O +
for O +
topical O +
use O -
. O +

Use O +
in O +
the O +
form O +
of O +
a O +
fatty O +
cream O +
or O +
gel O +
for O +
the O +
increased O +
production O +
of O +
collagen B-Gene -
, O +
without O +
amplifying O +
that O +
of O +
procollagen B-Gene +
( I-Gene -
III I-Gene -
) I-Gene +
or O +
of O +
enzymes O +
of O +
the O +
metalloproteinase B-Gene +
family O -
. O +

A O +
g B-Gene +
protein I-Gene -
- I-Gene -
coupled I-Gene +
receptor I-Gene +
antagonist O +
and O +
its O +
use O +
for O +
preventing O +
and O +
treating O +
alzheimer O -
's O +
disease O +
A O +
method O +
of O +
screening O +
reagents O +
for O +
preventing O +
or O +
treating O +
Alzheimer O -
's O +
disease O +
or O +
related O +
neurodegenerative O +
disease O +
is O +
provided O -
. O +

The O +
method O +
comprises O -
: O +
( O -
a O -
) O +
stimulating O +
a O +
receptor O +
and O +
identifying O +
its O +
degree O +
of O +
internalization O -
, O +
wherein O +
the O +
receptor O +
is O +
a O +
G B-Gene +
protein I-Gene -
- I-Gene -
coupled I-Gene +
receptor I-Gene +
combining O +
with O +
PS1 B-Gene -
; O +
( O -
b O -
) O +
stimulating O +
the O +
receptor O +
as O +
step O +
( O -
a O -
) O +
in O +
the O +
presence O +
of O +
a O +
reagent O -
, O +
and O +
identifying O +
its O +
degree O +
of O +
internalization O +
again O -
; O +
( O -
c O -
) O +
comparing O +
the O +
difference O +
between O +
the O +
internalizing O +
degrees O +
of O +
( O -
a O -
) O +
and O +
( O -
b O -
) O -
; O +
( O -
d O -
) O +
repeating O +
steps O +
( O -
a O -
) O -
- O -
( O -
c O -
) O +
if O +
the O +
difference O +
is O +
less O +
than O +
the O +
least O +
value O -
. O +

And O +
use O +
of O +
the O +
receptor O +
antagonist O +
for O +
preparing O +
a O +
drug O +
for O +
preventing O +
or O +
treating O +
Alzheimer O -
's O +
disease O +
or O +
related O +
neurodegenerative O +
disease O +
is O +
provided O -
. O +

The O +
receptor O +
antagonist O +
can O +
be O +
used O +
to O +
inhibit O +
the O +
internalization O +
of O +
the O +
G B-Gene +
protein I-Gene -
- I-Gene -
coupled I-Gene +
receptor I-Gene +
combing O +
with O +
PS1 B-Gene -
. O +

Mutilin O +
derivatives O +
and O +
their O +
use O +
as O +
pharmaceutical O +
14 O -
- O -
0- O -
[ O -
( O -
( O -
( O -
C1.6 O -
) O -
Alkoxy- O -
( O -
C1.6 O -
) O -
alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
( O -
C1 O -
- O -
6 O -
) O -
Mono- O +
or O +
dialkylamino- O -
( O -
C1.6 O -
) O -
alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
Hydroxy- O -
( O -
C1 O -
- O -
6 O -
) O -
-alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
Formyl- O -
( O -
C0.5 O -
) O -
-alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
Guanidino O -
- O -
imino- O -
( O -
C1 O -
- O -
6 O -
) O -
alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
Ureido O -
- O -
imino- O -
( O -
C1 O -
- O -
6 O -
) O -
alky O -
) O -
-phenylsulfany O -
] O -
-acety O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
Thioureido O -
- O -
imino- O -
( O -
C1 O -
- O -
6 O -
) O -
alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O -
, O +
14-O- O -
[ O -
( O -
( O -
lsothioureido O -
- O -
imino- O -
( O -
C1 O -
- O -
6 O -
) O -
alkyl O -
) O -
-phenylsulfanyl O -
) O -
-acetyl O -
] O -
-mutilins O +
and O +
their O +
use O +
as O +
pharmaceuticals O -
. O +

Sulfonamide O +
derivatives O -
, O +
preparation O +
thereof O +
and O +
therapeutic O +
use O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
sulphonamide O +
derivatives O +
corresponding O +
to O +
the O +
general O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
Ar1 O +
represents O +
an O +
aryl O +
optionally O +
substituted O +
with O +
one O +
or O +
more O +
groups O -
, O +
or O +
an O +
optionally O +
substituted O +
heterocyclyl O +
group O -
; O +
T O +
represents O +
a O +
- O -
( O -
CH2 O -
) O -
n- O +
or O +
a O +
group O +
( O -
II O -
) O -
, O +
Ar2 O +
represents O +
an O +
aryl O +
as O +
optionally O +
substituted O +
with O +
one O +
or O +
more O +
groups O -
, O +
or O +
an O +
optionally O +
substituted O +
heterocyclyl O +
group O -
; O +
Ar3 O +
represents O +
an O +
aryl O +
optionally O +
substituted O +
with O +
one O +
or O +
more O +
groups O -
, O +
or O +
else O +
an O +
optionally O +
substituted O +
heterocyclyl O -
, O +
R1 O +
represents O +
a O +
group O +
of O +
formula O +
( O -
A O -
) O +
or O +
( O -
B O -
) O -
: O +
( O -
A O -
) O +
( O -
B O -
) O +
in O +
the O +
form O +
of O +
a O +
base O -
, O +
an O +
addition O +
salt O +
with O +
an O +
acid O -
, O +
a O +
hydrate O +
or O +
a O +
solvate O -
, O +
in O +
the O +
form O +
of O +
enantiomers O -
, O +
diastereoisomers O -
, O +
rotamers O +
or O +
atropoisomers O -
, O +
or O +
mixtures O +
thereof O -
. O +

It O +
also O +
relates O +
to O +
the O +
process O +
for O +
the O +
preparation O +
and O +
also O +
the O +
therapeutic O +
use O +
of O +
the O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
. O +

Topical O +
preparation O +
composition O +
containing O +
a O +
thiourea O +
derivative O +
for O +
preventing O +
or O +
treating O +
pruritic O +
or O +
irritant O +
skin O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
a O +
topical O +
composition O +
comprising O +
a O +
thiourea O +
derivative O -
, O +
which O +
is O +
a O +
vanilloid O +
receptor O +
antagonist O -
, O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
and O +
a O +
pharmaceutical O +
use O +
of O +
the O +
same O -
. O +

The O +
topical O +
composition O +
according O +
to O +
the O +
present O +
invention O +
is O +
excellent O +
in O +
skin O +
permeation O +
and O +
stability O +
and O +
effective O +
in O +
treatment O +
of O +
pruritic O +
or O +
irritant O +
skin O +
diseases O -
. O +

Compositions O +
and O +
methods O +
for O +
effecting O +
controlled O +
posterior O +
vitreous O +
detachment O +
A O +
composition O +
comprises O +
plasmin O +
or O +
an O +
enzymatically O +
equivalent O +
derivative O +
thereof O +
and O +
at O +
least O +
an O +
anti O -
- O -
inflammatory O +
medicament O -
, O +
such O +
as O +
triamcinolone O +
acetonide O -
. O +

The O +
composition O +
can O +
be O +
used O +
to O +
effect O +
or O +
induce O +
a O +
controlled O +
posterior O +
vitreous O +
detachment O +
( O -
' O -
PVD O -
' O -
) O +
to O +
prevent O -
, O +
treat O -
, O +
or O +
ameliorate O +
a O +
potential O +
complication O +
of O +
a O +
pathological O +
ocular O +
condition O -
. O +

Such O +
a O +
composition O +
can O +
be O +
administered O +
intravitreally O -
. O +

Hair O +
grower O +
The O +
invention O +
provides O +
a O +
hair O +
grower O +
having O +
a O +
hair O -
- O -
glowing O +
effect O +
and O +
useful O +
application O +
forms O +
of O +
the O +
hair O +
grower O -
. O +

The O +
invention O +
relates O +
to O +
a O +
hair O +
grower O +
containing O +
as O +
the O +
active O +
ingredient O +
a O +
lithospermic O +
acid O +
derivative O +
represented O +
by O +
the O +
general O +
formula O +
( O -
I O -
) O +
or O +
a O +
salt O +
thereof O -
; O +
and O +
oral O +
preparations O -
, O +
external O +
preparations O -
, O +
and O +
foods O -
, O +
containing O +
the O +
hair O +
grower O -
: O +
( O -
I O -
) O +
wherein O +
R1 O +
and O +
R2 O +
may O +
be O +
the O +
same O +
or O +
different O +
and O +
are O +
each O +
hydrogen O +
or O +
optionally O +
substituted O +
C1 O -
- O -
4 O +
alkyl O -
; O +
and O +
R3 O +
is O +
hydrogen O -
, O +
optionally O +
substituted O +
C1 O -
- O -
4 O +
alkyl O -
, O +
or O +
a O +
group O +
represented O +
by O +
the O +
general O +
formula O +
( O -
II O -
) O -
. O +

Diphenylurea O +
derivatives O +
and O +
their O +
use O +
as O +
chloride B-Gene +
channel I-Gene +
blockers O +
or O +
bkca B-Gene +
channel I-Gene +
modulators O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
diphenylurea O +
derivatives O +
of O +
formula O +
( O -
I O -
) O +
useful O +
as O +
chloride O +
channel O +
blockers O +
or O +
BKCa B-Gene +
channel I-Gene +
modulators O -
. O +

In O +
other O +
aspects O +
the O +
invention O +
relates O +
to O +
the O +
use O +
of O +
these O +
compounds O +
in O +
a O +
method O +
for O +
therapy O -
, O +
and O +
to O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O +
of O +
the O +
invention O -
. O +

Thiazolyldihydroindazoles O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
thiazolyldihydroindazoles O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O +
where O +
the O +
R1 O -
, O +
R2 O +
and O +
R3 O +
radicals O +
are O +
each O +
as O +
defined O +
in O +
the O +
claims O +
and O +
the O +
description O -
, O +
to O +
their O +
tautomers O -
, O +
racemates O -
, O +
enantiomers O -
, O +
diastereomers O +
and O +
mixtures O +
thereof O -
, O +
and O +
where O +
appropriate O +
to O +
their O +
pharmacologically O +
safe O +
acid O +
addition O +
salts O -
, O +
solvates O +
and O +
hydrates O -
, O +
and O +
to O +
processes O +
for O +
preparing O +
these O +
thiazolyldihydroindazoles O +
and O +
to O +
their O +
use O +
as O +
medicaments O -
. O +

Heterocyclic O +
gaba B-Gene +
alpha I-Gene +
subtype I-Gene +
selective I-Gene +
receptor I-Gene +
modulators O +
The O +
present O +
invention O +
provides O +
a O +
compound O +
of O +
the O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutically O +
acceptable O +
salts O -
, O +
solvates O +
or O +
prodrugs O +
thereof O -
, O +
wherein O +
Y O -
, O +
Ar O -
, O +
R1 O +
and O +
R2 O +
are O +
defined O +
herein O -
. O +

Also O +
provided O +
are O +
pharmaceutical O +
compositions O -
, O +
their O +
use O +
and O +
methods O +
of O +
preparing O +
the O +
compounds O -
. O +

1,4:3,6-dianhydromannitol O +
derivatives O +
and O +
use O +
thereof O +
The O +
invention O +
relates O -
, O +
amongst O +
other O +
things O -
, O +
to O +
the O +
use O +
of O +
1,4:3,6-dianhydromannitol O +
derivatives O +
of O +
formulae O +
( O -
Ia O -
) O +
- O +
( O -
I O -
d O -
) O +
as O +
therapeutic O +
agents O -
. O +

3-tetrazolyl O +
indazoles O -
, O +
3-tetrazolyl O +
pyrazolopyridines O -
, O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
novel O +
3-tetrazolyl O +
indazole O +
derivatives O +
and O +
3-tetrazolyl O +
pyrazolo O -
[ O -
3,4-b O -
] O -
-pyridine O +
derivatives O -
, O +
methods O +
for O +
producing O +
the O +
same O -
, O +
the O +
exclusive O +
or O +
combined O +
use O +
thereof O +
for O +
treating O +
and/or O +
preventing O +
diseases O -
, O +
and O +
the O +
use O +
thereof O +
for O +
producing O +
medicaments O +
utilized O +
for O +
the O +
treatment O +
and/or O +
prevention O +
of O +
diseases O -
, O +
particularly O +
cardiovascular O +
diseases O -
. O +

Isatin O +
and O +
its O +
derivatives O +
for O +
use O +
as O +
a O +
medicament O +
The O +
present O +
invention O +
relates O +
to O +
2,3-dioxoindole O +
derivatives O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O +
for O +
use O +
as O +
a O +
medicament O -
, O +
and O +
particularly O +
for O +
use O +
in O +
the O +
prevention O +
or O +
treatment O +
of O +
fever O -
, O +
inflammation O +
or O +
pain O -
, O +
wherein O +
in O +
the O +
general O +
formula O +
( O -
I O -
) O -
; O +
R1 O +
is O +
hydrogen O -
, O +
or O +
( O -
C1-C10 O -
) O +
linear O +
or O +
branched O +
alkyl O +
or O +
hydroxyalkyl O +
group O +
or O +
acyl O +
group O +
containing O +
( O -
C1-C10 O -
) O +
linear O +
or O +
branched O +
alkyl O +
group O -
, O +
R2-R5 O +
are O +
independently O +
hydrogen O -
, O +
halogen O -
, O +
amino O +
group O -
, O +
nitro O +
group O -
, O +
optionally O +
halogen O +
substituted O +
( O -
C1-C10 O -
) O +
alkyl O +
group O -
, O +
( O -
C1-C10 O -
) O +
alkoxy O +
group O +
or O +
hydroxyl O +
group O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
methods O +
for O +
the O +
prevention O +
or O +
treatment O +
of O +
fever O -
, O +
inflammation O +
or O +
pain O -
, O +
wherein O +
a O +
medicament O +
incorporating O +
a O +
pharmacologically O +
effective O +
dose O +
of O +
the O +
above O +
described O +
active O +
ingredient O +
is O +
administered O +
to O +
patients O +
in O +
need O +
of O +
such O +
treatment O -
. O +

Antiperiodontitis O +
agents O -
, O +
and O +
drinks O -
, O +
foods O +
or O +
oral O +
hygiene O +
products O +
containing O +
the O +
agents O +
The O +
invention O +
provides O +
antiperiodontitis O +
agents O +
which O +
originate O +
in O +
plant O +
components O +
free O +
from O +
the O +
anxiety O +
about O +
safety O +
and O +
have O +
no O +
peculiar O +
spice O -
- O -
like O +
aroma O +
or O +
taste O +
and O +
which O +
have O +
high O +
antibacterial O +
effects O +
on O +
bacteria O +
causative O +
of O +
periodontal O +
diseases O +
and O +
can O +
prevent O +
or O +
cure O +
periodontal O +
diseases O -
; O +
and O +
drinks O -
, O +
foods O -
, O +
or O +
oral O +
hygiene O +
products O -
, O +
containing O +
the O +
agents O -
. O +

Antiperiodontitis O +
agents O -
, O +
characterized O +
by O +
containing O +
one O +
or O +
more O +
isothiocyanate O +
compounds O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
Ï‰ O -
- O -
alkenyl O +
isothiocyanate O +
compounds O +
represented O +
by O +
the O +
general O +
formula O +
[ O -
1 O -
] O -
, O +
Ï‰ O -
- O -
alkylthioalkyl O +
isothiocyanate O +
compounds O +
represented O +
by O +
the O +
general O +
formula O +
[ O -
2 O -
] O -
, O +
and O +
Ï‰ O -
- O -
phenylalkyl O +
isothiocyanate O +
compounds O +
represented O +
by O +
the O +
general O +
formula O +
[ O -
3 O -
] O +
and O +
mint O +
essential O +
oil O +
or O +
a O +
mint O +
essential O +
oil O +
component O -
; O +
and O +
drinks O -
, O +
foods O -
, O +
or O +
oral O +
hygiene O +
products O -
, O +
containing O +
the O +
agents O -
: O +
General O +
formula O +
[ O -
1 O -
] O +
: O +
CH2 O -
= O -
CH- O -
( O -
CH2 O -
) O -
m O -
- O -
NCS O +
( O -
wherein O +
m O +
is O +
an O +
integer O +
of O +
1 O +
to O +
10 O -
) O +
General O +
formula O +
[ O -
2 O -
] O +
: O +
R O -
- O -
S- O -
( O -
CH2 O -
) O -
n O -
- O -
NCS O +
( O -
wherein O +
n O +
is O +
an O +
integer O +
of O +
1 O +
to O +
10 O +
and O +
R O +
is O +
straight- O +
or O +
branched O -
- O -
chain O +
alkyl O +
of O +
1 O +
to O +
4 O +
carbon O +
atoms O -
) O -
, O +
and O +
General O +
formula O +
[ O -
3 O -
] O +
: O +
Ph- O -
( O -
CH2 O -
) O -
p O -
- O -
NCS O +
( O -
wherein O +
Ph O +
is O +
phenyl O +
and O +
p O +
is O +
an O +
integer O +
of O +
1 O +
to O +
10 O -
) O -
. O +

Compounds O +
for O +
use O +
as O +
a O +
medicament O +
A O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
( O -
II O -
) O +
for O +
use O +
as O +
a O +
medicament O -
. O +

A O +
pharmaceutical O +
composition O +
the O +
compound O -
. O +

Use O +
of O +
the O +
compound O +
for O +
preparing O +
a O +
medicament O +
for O +
the O +
treatment O +
of O +
a O +
disorder O +
selected O +
from O +
hyperproliferative O +
diseases O -
, O +
autoimmune O +
diseases O -
, O +
and O +
heart O +
diseases O -
. O +

Methods O +
and O +
compositions O +
for O +
modulating O +
hepsin O +
activation O +
of O +
urokinase B-Gene -
- I-Gene -
type I-Gene +
plasminogen I-Gene +
activator I-Gene +
The O +
invention O +
provides O +
methods O +
and O +
compositions O +
for O +
modulating O +
hepsin O +
activity O +
and O +
the O +
uPA B-Gene -
/ O -
plasmin O +
pathway O -
, O +
in O +
particular O +
by O +
regulating O +
pro O -
- O -
uPA B-Gene +
activation O +
by O +
hepsin O -
. O +

4,6-dl- O +
and O +
2,4,6-trisubstituted O +
quinazoline O +
derivatives O +
and O +
pharmaceutical O +
compositions O +
useful O +
for O +
treating O +
viral O +
infections O +
This O +
invention O +
provides O +
the O +
treatment O +
of O +
viral O +
infections O +
with O +
a O +
4,6- O +
disubstituted O +
or O +
2,4,6-trisubstituted O +
quinazoline O +
derivative O +
represented O +
by O +
the O +
structural O +
formula O +
[ O -
( O -
I O -
) O -
] O +
wherein O -
: O +
R2 O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
hydrogen O -
, O +
NR'R O -
' O +
and O +
C1 O -
- O -
7 O +
alkyl O -
; O +
- O +
A O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
a O +
bond O -
, O +
O O -
, O +
S O -
( O -
O O -
) O -
n O -
, O +
C1 O -
- O -
7 O +
alkylene O -
, O +
C2 O -
- O -
7 O +
alkenylene O +
and O +
C2 O -
- O -
7 O +
alkynylene O -
; O +
R4 O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
C1 O -
- O -
7 O +
alkyl O -
, O +
C2 O -
- O -
7 O +
alkenyl O -
, O +
C3 O -
- O -
10 O +
cycloalkyl O -
, O +
C3 O -
- O -
10 O +
cycloalkenyl O -
, O +
aryl O -
, O +
heterocyclic O -
, O +
arylalkyl O -
, O +
heterocyclic O -
- O -
substituted O +
alkyl O +
and O +
cycloalkyl O -
- O -
alkyl O -
; O +
- O +
Y O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
a O +
single O +
bond O -
, O +
C1 O -
- O -
7 O +
alkylene O -
, O +
C2 O -
- O -
7 O +
alkenylene O -
, O +
and O +
C2 O -
- O -
7 O +
alkynylene O -
; O +
n O +
is O +
0 O -
, O +
1 O +
or O +
2 O -
; O +
and O +
R6 O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
halogen O -
, O +
heteroaryl O +
and O +
aryl O -
; O +
a O +
pharmaceutically O +
acceptable O +
addition O +
salt O -
, O +
a O +
stereoisomer O -
, O +
a O +
mono- O +
or O +
a O +
di O -
- O -
Î› O -
/ O -
-oxide O -
, O +
a O +
solvate O +
or O +
a O +
pro O -
- O -
drug O +
thereof O -
. O +

4,6-dl- O +
and O +
2,4,6-trisubstituted O +
quinazoline O +
derivatives O +
useful O +
for O +
treating O +
viral O +
infections O +
This O +
invention O +
provides O +
quinazoline O +
derivatives O +
represented O +
by O +
the O +
structural O +
formula O -
: O +
( O -
I O -
) O -
; O +
wherein O -
: O +
R2 O +
is O +
hydrogen O -
, O +
NR'R O -
' O -
, O +
C1 O -
- O -
7 O +
alkyl O -
, O +
arylC1 O -
- O -
7 O +
alkyl O +
or O +
C3 O -
- O -
10 O +
cycloalkyl O -
; O +
R4 O +
is O +
amino O -
, O +
C1 O -
- O -
7 O +
alkyl O -
, O +
C2 O -
- O -
7 O +
alkenyl O -
, O +
C3 O -
- O -
10 O +
cycloalkyl O -
, O +
C3 O -
- O -
10 O +
cycloalkenyl O -
, O +
aryl O -
, O +
heterocyclic O -
, O +
arylalkyl O -
, O +
heterocyclic O -
- O -
substituted O +
C1 O -
- O -
7 O +
alkyl O +
or O +
C3 O -
- O -
10 O +
cycloalkyl O -
- O -
C1 O -
- O -
7 O +
alkyl O -
; O +
R5 O +
is O +
hydrogen O +
or O +
C1 O -
- O -
7 O +
alkyl O -
, O +
or O +
R5 O +
and O +
R4 O +
together O +
with O +
the O +
nitrogen O +
atom O +
to O +
which O +
they O +
are O +
attached O +
form O +
a O +
heterocyclic O +
ring O -
; O +
Y O +
is O +
a O +
single O +
bond O -
, O +
C1 O -
- O -
7alkylene O -
, O +
C2 O -
- O -
7 O +
alkenylene O +
or O +
C2 O -
- O -
7 O +
alkynylene O -
; O +
R6 O +
is O +
halogen O -
, O +
heteroaryl O +
or O +
aryl O -
; O +
R O -
' O +
and O +
R O -
' O +
are O +
each O +
independently O +
hydrogen O -
, O +
C1 O -
- O -
7 O +
alkyl O -
- O -
carbonyl O +
or O +
C1 O -
- O -
7 O +
alkyl O -
; O +
provided O +
that O +
R4 O +
is O +
not O +
phenyl O +
substituted O +
with O +
morpholino O +
when O +
R2 O +
is O +
H O +
and O +
R5 O +
is O +
H O -
, O +
and O +
provided O +
that O +
when O +
NR4R5 O +
is O +
piperazinyl O -
, O +
said O +
NR4R5 O +
is O +
either O +
non O -
- O -
substituted O +
or O +
substituted O +
with O +
methyl O +
or O +
acetyl O -
; O +
a O +
pharmaceutically O +
acceptable O +
addition O +
salt O -
, O +
a O +
stereoisomer O -
, O +
a O +
mono- O +
or O +
a O +
di O -
- O -
N O -
- O -
oxide O -
, O +
a O +
solvate O +
or O +
a O +
pro O -
- O -
drug O +
thereof O -
, O +
for O +
the O +
treatment O +
of O +
viral O +
infections O -
. O +

Drug O +
combinations O +
for O +
treating O +
airway O +
diseases O +
The O +
invention O +
relates O +
to O +
novel O +
drug O +
combinations O -
, O +
comprising O -
, O +
in O +
addition O +
to O +
one O +
or O +
more O -
, O +
preferably O +
one O -
, O +
compound O +
of O +
general O +
formula O +
( O -
1 O -
) O -
, O +
where O +
the O +
groups O +
R1 O -
, O +
R2 O +
and O +
R3 O +
can O +
have O +
the O +
meanings O +
given O +
in O +
the O +
claims O +
and O +
description O -
, O +
at O +
least O +
one O +
further O +
active O +
ingredient O +
2 O -
, O +
a O +
method O +
for O +
production O +
and O +
use O +
thereof O +
as O +
a O +
drug O -
. O +

Remedy O +
for O +
chronic O +
obstructive O +
pulmonary O +
disease O +
The O +
invention O +
relates O +
to O +
an O +
inhibitor O +
of O +
pulmonary O +
emphysematous O +
lesions O +
containing O +
as O +
an O +
active O +
ingredient O +
a O +
substance O +
having O +
an O +
action O +
of O +
promoting O +
the O +
degradation O +
of O +
CSPG O -
, O +
an O +
action O +
of O +
inhibiting O +
the O +
synthesis O +
of O +
CSPG O -
, O +
or O +
an O +
action O +
of O +
inhibiting O +
the O +
sulfation O +
of O +
CSPG O -
, O +
for O +
example O -
, O +
chondroitinase B-Gene +
ABC O -
, O +
a O +
C6ST O +
antisense O +
agent O -
, O +
a O +
GalNAc O +
antisense O +
agent O +
or O +
the O +
like O -
, O +
an O +
inhibitor O +
of O +
emphysematous O +
lesions O +
suitable O +
for O +
treating O +
or O +
preventing O +
COPD O -
, O +
a O +
therapeutic O +
or O +
preventive O +
agent O +
for O +
COPD O -
, O +
and O +
also O +
relates O +
to O +
a O +
method O +
of O +
inhibiting O +
emphysematous O +
lesions O +
and O +
a O +
method O +
of O +
treating O +
or O +
preventing O +
COPD O -
. O +

Morpholine O +
d3 B-Gene +
dopamine I-Gene +
antagonists O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O +
and O +
R6 O +
are O +
as O +
defined O +
in O +
the O +
specification O -
, O +
to O +
intermediates O +
for O +
their O +
preparation O -
, O +
to O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
to O +
their O +
medicinal O +
use O +
as O +
modulators O +
of O +
the O +
dopamine B-Gene +
D3 I-Gene +
receptor I-Gene -
, O +
particularly O +
as O +
psychotherapeutic O +
agents O -
. O +

2-alkyl-6- O -
( O -
pyrazolopyridin-4-yl O -
) O -
pyridazinone O +
derivative O -
, O +
addition O +
salt O +
thereof O -
, O +
and O +
pde B-Gene +
inhibitor O +
comprising O +
the O +
derivative O +
or O +
the O +
salt O +
as O +
active O +
ingredient O +
[ O -
PROBLEMS O -
] O +
To O +
provide O +
a O +
2-alkyl-6- O -
( O -
pyrazolopyridin- O +
4-yl O -
) O -
pyridazinone O +
derivative O +
which O +
is O +
useful O +
as O +
a O +
pharmaceutical O +
agent O +
having O +
a O +
phosphodiesterase B-Gene -
- O -
inhibiting O +
activity O -
. O +

[ O -
MEANS O +
FOR O +
SOLVING O +
PROBLEMS O -
] O +
A O +
2-alkyl-6- O +
( O -
pyrazolopyridin-4-yl O -
) O -
pyridazinone O +
derivative O +
represented O +
by O +
the O +
general O +
formula O +
( O -
1 O -
) O +
( O -
a O +
specific O +
example O -
: O +
6- O -
( O -
7-methoxy-2- O +
trifluoromethylpyrazolo O -
[ O -
1,5-a O -
] O -
pyridin-4-yl O -
) O -
-5-methyl-2- O -
[ O -
3- O +
[ O -
4- O -
( O -
4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3- O +
yl O -
) O -
phenoxy O -
] O -
propyl O -
] O -
-4,5-dihydro-2H- O +
pyridazin-3-one O -
) O -
. O +

Indazole O +
derivatives O +
as O +
modulators O +
of O +
interleukin- O +
1 O +
receptor O -
- O -
associated O +
kinase O +
The O +
present O +
invention O +
relates O +
to O +
modulators O +
of O +
IRAK B-Gene +
kinases O +
of O +
formula O +
( O -
I O -
) O +
and O +
provides O +
compositions O +
comprising O +
such O +
modulators O -
, O +
as O +
well O +
as O +
methods O +
therewith O +
for O +
treating O +
IRAK- B-Gene +
mediated O +
or O +
IRAK B-Gene +
-associated O +
conditions O +
or O +
diseases O -
. O +

Therapeutical O +
formulation O +
comprising O +
a O +
thiazolidinedione O +
and O +
a O +
nitric O +
oxide O +
scavenger O -
. O +

A O +
therapeutic O +
formulation O +
comprising O +
of O +
Thiazolidinediones O +
as O +
active O +
agents O +
namely O -
, O +
Pioglitazone O +
and O +
Rosiglitazone O -
, O +
characterized O +
in O +
that O +
said O +
Thiazolidinediones O +
are O +
combined O +
or O +
complexated O +
with O +
NO O +
Scavenger O +
to O +
prevent O +
Diabetic O +
Complications O +
arising O +
out O +
of O +
Nitrosative O +
stress O -
. O +

Treatment O +
of O +
fibrosis O +
The O +
present O +
invention O +
relates O +
to O +
methods O +
and O +
compositions O +
for O +
treating O +
fibrosis O -
. O +

In O +
one O +
aspect O +
the O +
invention O +
provides O +
the O +
use O +
of O +
an O +
agent O +
capable O +
of O +
increasing O +
the O +
number O +
of O +
stem O +
cells O +
and/or O +
progenitor O +
cells O +
available O +
to O +
and/or O +
engraftment O +
at O +
a O +
site O +
of O +
fibrosis O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
use O +
in O +
conjunction O +
with O +
an O +
anti- O +
fibrotic O +
agent O +
for O +
the O +
treatment O +
of O +
fibrosis O -
. O +

The O +
anti O -
- O -
fibrotic O +
agent O +
can O +
be O +
supplied O +
to O +
the O +
subject O +
before O -
, O +
at O +
the O +
same O +
time O -
, O +
or O +
after O +
the O +
agent O +
capable O +
of O +
increasing O +
the O +
number O +
of O +
stem O +
cells O +
and/or O +
progenitor O +
cells O +
available O +
to O +
and/or O +
engraftment O +
at O +
a O +
site O +
of O +
fibrosis O -
. O +

The O +
fibrosis O +
may O +
be O +
idiopathic O +
pulmonary O +
fibrosis O -
. O +

The O +
anti O -
- O -
fibrotic O +
agent O +
can O +
be O +
a O +
modulator O +
of O +
RhoA O -
, O +
RhoA O +
GTPases O -
, O +
TGF O -
- O -
Î²l O +
or O +
CTGF O -
, O +
or O +
any O +
other O +
member O +
of O +
the O +
RhoA O +
signalling O +
pathway O -
; O +
or O +
can O +
modulate O +
the O +
effect O +
of O +
suppressor O +
of O +
cytokine O +
signalling O +
1 O +
( O -
SOCS O +
1 O -
) O -
, O +
suppressor O +
of O +
cytokine O +
signalling O +
3 O +
( O -
SOCS O +
3 O -
) O +
or O +
TLR9 O -
; O +
or O +
can O +
be O +
a O +
statin O +
compound O +
or O +
derivative O +
thereof O -
. O +

Enantiomerically O +
pure O +
phosphoindoles O +
as O +
hiv O +
inhibitors O +
3-phosphoindole O +
compounds O +
substantially O +
in O +
the O +
form O +
of O +
a O +
single O +
enantiomer O +
useful O +
for O +
the O +
treatment O +
of O +
Flaviviridae O +
virus O +
infections O -
, O +
and O +
particularly O +
for O +
HLV O +
infections O +
are O +
provided O -
. O +

Also O +
provided O +
are O +
pharmaceutical O +
compositions O +
comprising O +
the O +
3-phosphoindole O +
compounds O +
alone O +
or O +
in O +
combination O +
with O +
one O +
or O +
more O +
other O +
antiviral O +
agents O -
, O +
processes O +
for O +
their O +
preparation O -
, O +
and O +
methods O +
of O +
manufacturing O +
a O +
medicament O +
incorporating O +
these O +
compounds O -
. O +

The O +
3-phosphoindole O +
compounds O +
are O +
of O +
the O +
formula O +
( O -
A O -
) O +
or O +
( O -
B O -
) O +
and O +
the O +
pharmaceutically O +
acceptable O +
salts O -
, O +
solvates O -
, O +
hydrates O -
, O +
or O +
esters O +
thereof O -
. O +

In O +
the O +
formulae O +
X O +
is O +
hydrogen O -
; O +
aryl O +
or O +
heterocyclyl O -
; O +
C2 O -
- O -
6 O +
alkenyl O -
, O +
C2 O -
- O -
6 O +
alkynyl O +
or O +
alkyl O -
; O +
Y O +
is O +
hydrogen O -
, O +
-R O -
, O +
-O O -
- O -
R O -
, O +
-NH O -
- O -
R O -
, O +
or O +
-NRR O -
; O +
Z O +
is O +
-OR O -
, O +
-NHR O -
, O +
-NRR O -
, O +
carboxamido O -
, O +
arnido O -
, O +
carboxyl O -
, O +
carbonyl O -
, O +
or O +
an O +
amino O +
acid O +
residue O -
; O +
R1 O +
is O +
hydrogen O -
, O +
acyl O -
, O +
-S O -
( O -
O O -
) O -
n O -
- O -
R O -
, O +
carboxyl O -
, O +
carbonyl O -
, O +
or O +
an O +
amino O +
acid O +
residue O -
; O +
each O +
R4 O -
' O -
, O +
R5 O -
' O -
, O +
R6 O -
' O +
and O +
R7 O -
' O +
is O +
independently O +
hydrogen O -
, O +
C2 O -
- O -
6 O +
alkenyl O -
, O +
C2 O -
- O -
6 O +
alkynyl O -
, O +
aryl O -
, O +
heterocyclyl O -
, O +
halogen O -
, O +
-CN O -
, O +
-CF3 O -
, O +
-OR O -
, O +
-NHR O -
, O +
-NRR O -
, O +
or O +
-NO2 O -
; O +
n O +
is O +
0 O -
, O +
1 O -
, O +
or O +
2 O -
; O +
and O +
each O +
R O +
is O +
independently O +
hydrogen O -
, O +
alkyl O -
, O +
C2 O -
- O -
6 O +
alkenyl O -
, O +
C2 O -
- O -
6 O +
alkynyl O -
, O +
aryl O -
, O +
or O +
heterocyclyl O -
. O +

Crystalline O +
carbapenem O +
compounds O +
The O +
invention O +
provides O +
crystalline O +
substances O +
each O +
consisting O +
of O +
the O +
carbapenem O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
or O +
a O +
solvate O +
of O +
the O +
compound O -
. O +

The O +
crystalline O +
substances O +
are O +
excellent O +
in O +
handleability O +
and O +
storage O +
stability O -
. O +

Further O -
, O +
the O +
invention O +
also O +
provides O +
solid O +
compositions O +
each O +
containing O +
both O +
the O +
compound O +
of O +
formula O +
( O -
I O -
) O +
and O +
an O +
alkali O +
metal O +
halide O -
. O +

The O +
crystalline O +
substances O +
and O +
the O +
solid O +
compositions O +
exhibit O +
excellent O +
antimicrobial O +
activity O -
. O +

5- O -
[ O -
( O -
2r O -
) O -
- O -
[ O -
2- O -
[ O -
2- O -
[ O -
2- O -
( O -
2,2,2-trifluoroethoxy O -
) O -
phenoxy O -
] O -
ethyl O -
] O -
amino O -
] O -
propyl O -
] O -
-2-methoxybenzenesulfonamide O +
5- O -
[ O -
( O -
2R O -
) O -
- O -
[ O -
2- O -
[ O -
2- O -
[ O -
2- O -
( O -
2,2,2-trifluoroethoxy O -
) O -
phenoxy O -
] O -
ethyl O -
] O -
amino O -
] O -
propyl O -
] O -
-2-methoxybenzenesulfonamide O -
, O +
a O +
pharmaceutical O +
composition O +
containing O +
the O +
compound O -
, O +
and O +
the O +
synthesis O +
method O +
thereof O -
. O +

The O +
compound O +
has O +
strong O +
antagonism O +
toward O +
Î±1-adrenoceptor B-Gene +
and O +
has O +
high O +
selectivity O +
toward O +
smooth O +
muscle O +
of O +
urethra O -
. O +

Thienyl O -
- O -
containing O +
glycopyranosyl O +
derivatives O +
as O +
antidiabetics O +
The O +
invention O +
is O +
directed O +
to O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O +
described O +
herein O -
, O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
or O +
a O +
prodrug O +
thereof O -
, O +
and O +
pharmaceutical O +
compositions O +
and O +
methods O +
of O +
treatment O -
. O +

Aminothiazole O +
macrocycles O -
, O +
their O +
use O +
as O +
antibacterial O +
compounds O +
and O +
processes O +
for O +
their O +
production O +
This O +
invention O +
relates O +
to O +
a O +
novel O +
antibiotic O +
compounds O -
, O +
pharmaceutically O +
acceptable O +
salts O +
and O +
to O +
methods O +
for O +
obtaining O +
such O +
compounds O -
. O +

Use O +
of O +
glucopyranosyloxy- O +
pyrazoles O +
for O +
preventing O +
and O +
treating O +
neurodegenerative O +
disorders O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
a O +
glucopyranosyloxy O -
- O -
pyrazole O +
as O +
defined O +
in O +
claim O +
1 O +
for O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
treating O -
, O +
preventing O +
or O +
slowing O -
, O +
delaying O +
or O +
reversing O +
progression O +
of O +
one O +
or O +
more O +
neurodegenerative O +
disorders O +
in O +
a O +
patient O +
in O +
need O +
thereof O -
. O +

Agent O +
for O +
activating O +
or O +
improving O +
neuronal O +
cell O +
or O +
brain O +
function O +
Disclosed O +
are O -
: O +
an O +
agent O +
for O +
activating O -
, O +
improving O +
or O +
protecting O +
a O +
neuronal O +
cell O -
; O +
an O +
agent O +
for O +
activating O -
, O +
improving O +
or O +
protecting O +
the O +
brain O +
function O -
; O +
and O +
a O +
prophylactic O -
, O +
ameliorating O +
or O +
therapeutic O +
agent O +
for O +
a O +
central O +
or O +
peripheral O +
nerve O +
disease O -
, O +
each O +
of O +
which O +
comprises O +
reduced O +
coenzyme O +
A O +
as O +
an O +
active O +
ingredient O -
. O +

Specifically O +
disclosed O +
are O -
: O +
a O +
prophylactic O -
, O +
ameliorating O +
or O +
therapeutic O +
agent O +
for O +
a O +
central O +
or O +
peripheral O +
nerve O +
disease O -
, O +
which O +
has O +
less O +
adverse O +
side O +
effects O +
and O +
is O +
highly O +
safe O -
; O +
and O +
a O +
method O +
for O +
treating O +
a O +
central O +
or O +
peripheral O +
nerve O +
disease O -
, O +
which O +
is O +
characterized O +
by O +
administering O +
the O +
agent O -
. O +

Methods O +
for O +
the O +
treatment O +
of O +
senile O +
dementia O +
of O +
the O +
alzheimer O -
's O +
type O +
The O +
present O +
invention O +
relates O +
to O +
the O +
diagnosis O -
, O +
risk O +
assessment O -
, O +
prevention O -
, O +
and O +
treatment O +
of O +
Senile O +
Dementia O +
of O +
the O +
Alzheimer O -
's O +
Type O +
( O -
SDAT O -
) O -
. O +

More O +
specifically O +
the O +
present O +
invention O +
relates O +
to O +
the O +
measurement O +
of O +
ethanolamine O +
phospholipids O +
in O +
human O +
serum O -
. O +

Subsets O +
of O +
these O +
molecules O +
are O +
significantly O +
altered O +
in O +
subjects O +
with O +
pathologically O +
confirmed O +
deposits O +
of O +
Î² O -
- O -
amyloid O +
versus O +
subjects O +
without O +
Î² O -
- O -
amyloid O +
deposits O +
and O +
in O +
subjects O +
with O +
a O +
clinical O +
manifestation O +
of O +
dementia O +
consistent O +
with O +
a O +
diagnosis O +
of O +
SDAT O +
versus O +
non O -
- O -
demented O +
controls O -
. O +

Further O -
, O +
the O +
invention O +
relates O +
to O +
the O +
diagnosis O +
of O +
various O +
stages O +
of O +
SDAT O -
, O +
the O +
early O +
detection O +
and O +
prevention O +
of O +
SDAT O +
symptoms O -
, O +
the O +
treatment O +
of O +
SDAT O -
, O +
the O +
differential O +
diagnosis O +
of O +
non O -
- O -
SDAT O +
dementia O -
, O +
and O +
the O +
identification O +
of O +
molecular O +
targets O +
for O +
which O +
chemical O +
or O +
biological O +
treatments O +
can O +
be O +
designed O +
for O +
the O +
therapeutic O +
intervention O +
of O +
SDAT O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
methods O +
of O +
using O +
a O +
molecular O +
diagnostic O +
assay O +
to O +
direct O +
and O +
select O +
the O +
appropriate O +
therapeutic O +
intervention O +
for O +
subjects O +
suffering O +
from O +
dementia O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
small O +
molecules O +
or O +
metabolites O +
that O +
are O +
found O +
to O +
have O +
significantly O +
different O +
abundances O +
between O +
persons O +
with O +
a O +
clinical O +
manifestation O +
of O +
SDAT O +
and O +
normal O -
, O +
non O -
- O -
demented O +
patients O -
. O +

6-benzyl-2,3,4,7-tetrahydro O -
- O -
indolo O +
[ O -
2 O -
, O +
3-c O -
] O +
quinoline O +
compounds O +
useful O +
as O +
pde5 B-Gene +
inhibitors O +
The O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
wherein O +
R1 O +
to O +
R8 O +
and O +
R11 O +
have O +
the O +
meanings O +
as O +
given O +
in O +
the O +
description O -
, O +
the O +
salts O +
thereof O -
, O +
the O +
N O -
- O -
oxides O +
of O +
the O +
compounds O +
and O +
the O +
salts O +
thereof O -
, O +
and O +
the O +
stereoisomers O +
of O +
the O +
compounds O -
, O +
the O +
salts O -
, O +
the O +
N O -
- O -
oxides O +
of O +
the O +
compounds O +
and O +
the O +
N O -
- O -
oxides O +
of O +
the O +
salts O +
thereof O +
are O +
effective O +
inhibitors O +
of O +
the O +
type B-Gene +
5 I-Gene +
phosphodiesterase I-Gene -
. O +

Compositions O +
comprising O +
mkc-733 O +
( O -
pumosetrag O -
) O +
useful O +
for O +
treating O +
irritable O +
bowel O +
syndrome O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
of O +
treating O +
irritable O +
bowel O +
syndrome O +
with O +
constipation O +
( O -
IBS O -
- O -
c O -
) O +
or O +
irritable O +
bowel O +
syndrome O +
with O +
alternating O +
constipation O +
and O +
diarrhea O +
( O -
IBS O -
- O -
a O -
) O +
in O +
a O +
subject O +
in O +
need O +
of O +
treatment O -
. O +

The O +
method O +
comprises O +
administering O +
to O +
said O +
subject O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
thieno O -
[ O -
3,2-b O -
] O +
pyridine O +
compound O +
of O +
Structural O +
Formula O +
I O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
or O +
N O -
- O -
oxide O +
derivative O +
thereof O -
. O +

Method O +
for O +
the O +
treatment O +
of O +
amyloidoses O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
the O +
treatment O +
of O +
an O +
amyloidosis O +
such O +
as O +
Alzheimer O -
's O +
disease O +
in O +
a O +
subject O +
in O +
need O +
thereof O -
, O +
characterized O +
in O +
that O +
it O +
comprises O +
administering O +
an O +
agonist O +
of O +
the O +
P O -
/ O -
Q O +
type O +
voltage B-Gene -
- I-Gene -
gated I-Gene +
presynaptic I-Gene +
calcium I-Gene +
channel I-Gene +
to O +
said O +
subject O -
. O +

Derivatives O +
of O +
benzoxadiazole O +
suitable O +
for O +
the O +
treatment O +
of O +
cell O +
proliferative O +
diseases O +
This O +
invention O +
describes O +
compounds O +
and O +
pharmaceutical O +
compositions O +
useful O +
as O +
ubiquitin B-Gene +
agent O +
inhibitors O -
, O +
particularly O +
ubiquitin B-Gene +
ligase I-Gene +
inhibitors O -
. O +

The O +
compounds O +
and O +
pharmaceutical O +
compositions O +
of O +
the O +
invention O +
are O +
useful O +
as O +
inhibitors O +
of O +
the O +
biochemical O +
pathways O +
of O +
organisms O +
in O +
which O +
ubiquitination O +
is O +
involved O -
, O +
such O +
as O +
signal O +
transduction O +
pathways O -
. O +

The O +
invention O +
also O +
comprises O +
the O +
use O +
of O +
the O +
compounds O +
and O +
pharmaceutical O +
compositions O +
of O +
the O +
invention O +
for O +
the O +
treatment O +
of O +
conditions O +
that O +
require O +
inhibition O +
of O +
ubiquitination O -
. O +

Furthermore O -
, O +
the O +
invention O +
comprises O +
methods O +
of O +
inhibiting O +
ubiquitination O +
in O +
a O +
cell O +
comprising O +
contacting O +
a O +
cell O +
in O +
which O +
inhibition O +
of O +
ubiquitination O +
is O +
desired O +
with O +
a O +
compound O +
or O +
pharmaceutical O +
composition O +
according O +
to O +
the O +
invention O -
. O +

Particularly O -
, O +
the O +
compounds O +
and O +
pharmaceutical O +
compositions O +
are O +
useful O +
to O +
inhibit O +
the O +
ubiquitin O +
ligase O +
activity O +
of O +
TRAF6 B-Gene -
. O +

Compounds O +
to O +
promote O +
regeneration O +
of O +
bone O +
marrow O +
Embodiments O +
of O +
the O +
present O +
invention O +
include O +
the O +
use O +
of O +
heterocyclic O +
trialkyl O +
ammonium O -
- O -
containing O +
compounds O +
to O +
promote O +
regeneration O +
of O +
bone O +
marrow O +
from O +
endogenous O +
or O +
exogenous O +
stem O -
/ O -
progenitor O +
cells O +
and O +
to O +
normalize O +
blood O +
cell O +
and O +
platelet O +
counts O -
. O +

Substituted O +
piperidines O +
for O +
use O +
in O +
the O +
treatment O +
of O +
bacterial O +
infections O +
The O +
present O +
invention O +
relates O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
which O +
are O +
believed O +
to O +
possess O +
antibacterial O +
activity O -
. O +

Compositions O +
containing O +
phosphatidylserine O +
in O +
treating O +
diabetes O +
associated O +
conditions O +
Provided O +
is O +
a O +
pharmaceutical O +
and O +
nutraceutical O +
composition O +
for O +
oral O +
delivery O +
which O +
contains O +
at O +
least O +
60 O +
wt% O +
of O +
glycerophospholipids O +
( O -
GPLs O -
) O -
, O +
in O +
which O +
the O +
ratio O +
of O +
esterified O +
to O +
free O +
phosphatidic O +
acid O +
is O +
between O +
6 O +
and O +
7 O -
, O +
and O +
wherein O +
phosphatidylserine O +
constitutes O +
more O +
than O +
50 O +
wt% O +
of O +
the O +
phosphatidic O +
esters O -
. O +

The O +
composition O +
mitigates O +
diabetes O -
- O -
like O +
conditions O +
and O +
boosts O +
mental O +
and O +
bodily O +
vigor O -
. O +

Sirna O +
against O +
thymidylate B-Gene +
synthase I-Gene +
and O +
uses O +
thereof O +
in O +
cancer O +
treatment O +
regimens O +
Small O +
interfering O +
RNA O +
( O -
siRNA O -
) O +
molecules O +
that O +
target O +
a O +
mammalian B-Gene +
thymidylate I-Gene +
synthase I-Gene +
gene O +
( O -
TS B-Gene -
) O -
, O +
and O +
which O +
are O +
capable O +
of O +
inhibiting O +
the O +
expression O +
of O +
their O +
target O +
gene O -
, O +
are O +
provided O +
The O +
siRNA O +
molecules O +
are O +
also O +
capable O +
of O +
sensitizing O +
cells O +
to O +
the O +
effects O +
of O +
other O +
anti O -
- O -
cancer O +
agents O -
, O +
particularly O +
chemotherapeutic O +
agents O +
that O +
target O +
TS O +
Methods O +
of O +
treating O +
cancer O +
using O +
the O +
TS B-Gene +
siRNA O +
in O +
combination O +
with O +
another O +
anti O -
- O -
cancer O +
agent O +
are O +
also O +
provided O +
Methods O +
of O +
enhancing O +
the O +
effect O +
of O +
a O +
TS B-Gene +
siRNA O +
on O +
cancer O +
cell O +
proliferation O +
by O +
combining O +
the O +
TS B-Gene +
siRNA O +
with O +
a O +
siRNA O +
targeting O +
a O +
cell O +
survival O +
gene O +
such O +
as O +
Bcl-2 B-Gene +
are O +
further O +
provided O -
. O +

5-aminopyrazol-3-yl-3h O -
- O -
imidazo O +
[ O -
4,5-b O -
] O +
pyridine O +
derivatives O +
and O +
their O +
use O +
for O +
the O +
treatment O +
of O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
and O +
to O +
their O +
pharmaceutical O +
compositions O -
, O +
and O +
to O +
their O +
methods O +
of O +
use O -
. O +

These O +
novel O +
compounds O +
provide O +
a O +
treatment O +
for O +
myeloproliferative O +
disorders O +
and O +
cancer O -
. O +

External O +
preparation O +
for O +
skin O +
and O +
external O +
preparation O +
for O +
lips O +
Disclosed O +
are O +
an O +
external O +
preparation O +
for O +
skin O +
for O +
improving O +
wrinkles O +
and O +
sagging O -
, O +
an O +
external O +
preparation O +
for O +
skin O +
for O +
moisture O +
retention O -
, O +
an O +
external O +
preparation O +
for O +
skin O +
for O +
promoting O +
wound O +
healing O +
and O +
an O +
external O +
preparation O +
for O +
lips O -
, O +
each O +
of O +
which O +
contains O +
raspberry O +
ketone O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
. O +

Methods O +
and O +
compositions O +
for O +
the O +
treatment O +
of O +
respiratory O +
disease O +
Disclosed O +
herein O +
are O +
methods O +
and O +
compositions O +
for O +
the O +
treatment O +
of O +
diseases O +
or O +
disorders O +
involving O +
disturbances O +
in O +
glutathione O +
( O -
GSH O -
) O +
metabolism O +
and O +
oxidative O +
stress O -
, O +
especially O +
respiratory O +
diseases O +
or O +
disorders O -
, O +
and O +
most O +
especially O +
asthma O -
. O +

In O +
particular O +
embodiments O -
, O +
methods O +
are O +
disclosed O +
for O +
the O +
treatment O +
of O +
respiratory O +
diseases O +
or O +
disorders O -
, O +
involving O +
the O +
step O +
of O +
administering O +
an O +
agent O +
that O +
inhibits O +
gamma B-Gene +
glutamyl I-Gene +
transpeptidase I-Gene +
( O -
GGT B-Gene -
) O +
activity O +
in O +
lung O +
and O +
airway O +
lining O +
fluid O -
. O +

Phosphate O -
- O -
modified O +
oligonucleotide O +
analogs O +
with O +
immunostimulatory O +
activity O +
The O +
invention O +
relates O +
to O +
oligonucleotides O +
including O +
at O +
least O +
one O +
backbone O +
modification O +
and O +
a O +
pyrimidine O -
- O -
purine O +
dinucleotide O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
and O +
methods O +
of O +
use O +
thereof O -
. O +

Compositions O +
and O +
methods O +
for O +
making O +
therapies O +
delivered O +
by O +
viral O +
vectors O +
reversible O +
for O +
safety O +
or O +
allele O -
- O -
specificity O +
The O +
present O +
invention O +
is O +
directed O +
to O +
compositions O +
methods O +
and O +
kits O +
for O +
regulation O +
of O +
gene O +
therapies O -
, O +
including O -
, O +
without O +
limitation O -
, O +
reversible O +
gene O +
therapies O +
and O +
allele- O +
specific O +
therapies O -
. O +

Triazolyl O +
aminopyrimidine O +
compounds O +
The O +
present O +
invention O +
provides O +
triazolyl O +
aminopyrimidine O +
compounds O +
useful O +
in O +
the O +
treatment O +
of O +
cancer O -
. O +

Potassium B-Gene +
ion I-Gene +
channel I-Gene +
modulators O +
and O +
uses O +
thereof O +
Compounds O +
of O +
general O +
formula O +
( O -
1 O -
) O +
and O +
pharmacologically O +
acceptable O +
salts O +
and O +
pro O -
- O -
drugs O +
thereof O -
: O +
wherein O +
A O +
and O +
B O +
are O +
CH2 O +
or O +
CH2CH2 O -
, O +
R1 O +
is O +
hydrogen O -
, O +
alkyl O -
, O +
cycloalkyl O -
, O +
aryl O -
, O +
aralkyl O +
or O +
heteroaralkyl O -
, O +
D O -
, O +
E O +
and O +
G O +
are O +
CR2 O +
or O +
nitrogen O -
, O +
with O +
the O +
proviso O +
that O +
at O +
least O +
one O +
of O +
D O -
, O +
E O +
and O +
G O +
is O +
nitrogen O -
, O +
R2 O -
, O +
R3 O +
and O +
R4 O +
are O +
hydrogen O -
, O +
alkyl O -
, O +
halogen O -
, O +
haloalkyl O -
, O +
alkoxy O -
, O +
alkoxycarbonyl O -
, O +
carboxyl O -
, O +
hydroxyl O +
or O +
cyano O -
, O +
X O +
is O +
R5SO2 O -
, O +
R5R7NCO O -
, O +
R5R7NSO2or O +
R5SO2NR7CO O -
, O +
Y O +
is O +
R6CO O -
, O +
R6SO2 O -
, O +
R6R7NCO O -
, O +
R6R7NSO2 O -
, O +
R6SO2NR7CO O +
or O +
CO2R8 O -
, O +
R5 O +
and O +
R6 O +
are O +
hydrogen O -
, O +
alkyl O -
, O +
aryl O -
, O +
aralkyl O -
, O +
heteroaryl O +
or O +
heteroaralkyl O -
, O +
R7 O +
is O +
hydrogen O -
, O +
alkyl O -
, O +
aryl O +
or O +
aralkyl O -
, O +
and O +
R8 O +
is O +
alkyl O -
, O +
aryl O -
, O +
aralkyl O -
, O +
alkoxyalkyl O -
, O +
heteroaryl O +
or O +
heteroarylalkyl O -
, O +
are O +
of O +
use O +
inthe O +
prophylaxis O +
or O +
treatment O +
of O +
diseases O +
and O +
conditions O +
in O +
which O +
Kv1.x B-Gene +
channels I-Gene +
are O +
involved O -
, O +
such O +
as O +
lower O +
urinary O +
tract O +
disorders O -
, O +
cardiovascular O +
diseases O -
, O +
inflammatory O +
and O +
immunological O +
diseases O +
and O +
pain O -
. O +

Pyrazolone O +
derivative O +
and O +
pde B-Gene +
inhibitor O +
containing O +
the O +
same O +
as O +
active O +
ingredient O +
Disclosed O +
is O +
a O +
novel O +
pyrazolone O +
derivative O +
represented O +
by O +
the O +
general O +
formula O +
( O -
1 O -
) O +
below O -
, O +
which O +
is O +
useful O +
as O +
a O +
pharmaceutical O +
product O +
having O +
phosphodiesterase B-Gene +
inhibitory O +
activity O -
. O +

( O -
1 O -
) O +
R1 O -
, O +
R2 O -
: O +
C1 O -
- O -
6 O +
alkyl O +
R3 O -
, O +
R4 O -
: O +
H O -
, O +
X O -
, O +
C1 O -
- O -
6 O +
alkoxy O +
Z O -
: O +
O O -
, O +
S O +
A O -
: O +
AA O -
, O +
BB O +
( O -
R5 O -
: O +
H O -
, O +
C1 O -
- O -
6 O +
alkyl O -
; O +
R6 O -
, O +
R7 O -
: O +
C1 O -
- O -
6 O +
alkyl O -
) O +

Quinazoline O +
derivatives O +
as O +
pi3 O +
kinase O +
inhibitors O +
Invented O +
is O +
a O +
method O +
of O +
inhibiting O +
the O +
activity O -
/ O -
function O +
of O +
P13 O +
kinases O +
using O +
quinazoline O +
derivatives O -
. O +

Also O +
invented O +
is O +
a O +
method O +
of O +
treating O +
one O +
or O +
more O +
disease O +
states O +
selected O +
from O -
: O +
autoimmune O +
disorders O -
, O +
inflammatory O +
diseases O -
, O +
cardiovascular O +
diseases O -
, O +
neurodegenerative O +
diseases O -
, O +
allergy O -
, O +
asthma O -
, O +
pancreatitis O -
, O +
multiorgan O +
failure O -
, O +
kidney O +
diseases O -
, O +
platelet O +
aggregation O -
, O +
cancer O -
, O +
sperm O +
motility O -
, O +
transplantation O +
rejection O -
, O +
graft O +
rejection O +
and O +
lung O +
injuries O +
by O +
the O +
administration O +
of O +
quinazoline O +
derivatives O -
. O +

Process O +
for O +
the O +
preparation O +
of O +
a O +
non O -
- O -
corrosive O +
base O +
solution O +
and O +
methods O +
of O +
using O +
same O +
The O +
present O +
invention O +
provides O +
novel O +
methods O +
of O +
making O +
a O +
non O -
- O -
corrosive O +
base O +
solution O +
for O +
use O +
as O +
an O +
alkalinity O +
increasing O +
agent O +
and/or O +
antioxidant O -
. O +

The O +
present O +
invention O +
further O +
provides O +
novel O +
compositions O +
and O +
methods O +
which O +
can O +
be O +
used O +
to O +
provide O +
relief O +
from O +
disorders O +
related O +
to O +
or O +
complicated O +
by O +
acidosis O +
or O +
excessive O +
free O +
radical O +
or O +
other O +
reactive O +
oxygen O +
species O +
production O +
including O -
, O +
but O +
not O +
limited O +
to O -
, O +
gout O -
, O +
Lesch O -
- O -
Nyhan O +
syndrome O -
, O +
hemochromatosis O -
, O +
Alzheimer O -
's O -
, O +
amyotropic O +
lateral O +
sclerosis O -
, O +
arthritis O -
, O +
atherosclerosis O -
, O +
cancer O -
, O +
cataracts O -
, O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
diabetes O -
, O +
cellulitis O -
, O +
coronary O +
artery O +
disease O -
, O +
heart O +
failure O -
, O +
hypertension O -
, O +
inflammatory O +
bowel O +
disease O -
, O +
macular O +
degeneration O -
, O +
multiple O +
sclerosis O -
, O +
Parkinson O -
's O -
, O +
Reynaud O -
's O +
phenomenon O -
, O +
reperfusion O +
injury O -
, O +
pancreatic O +
impairment O -
, O +
skin O +
infections O -
, O +
Hepatitis O +
C O -
, O +
methicillin- O +
resistant O +
Staphylococcus O +
aureus O +
and O +
infection O -
. O +

The O +
compositions O +
and O +
methods O +
of O +
the O +
present O +
invention O +
additionally O +
supply O +
relief O +
from O +
microbial O +
infections O +
including O +
fungal O +
infections O +
as O +
well O +
as O +
prevent O +
secondary O +
infections O -
. O +

Additional O +
compositions O +
and O +
methods O +
are O +
provided O +
which O +
employ O +
a O +
non O -
- O -
corrosive O +
base O +
solution O +
in O +
combination O +
with O +
a O +
second O +
alkalinity O +
increasing O +
agent O +
and/or O +
antioxidant O -
, O +
or O +
other O +
therapeutic O +
agent O +
to O +
yield O +
a O +
more O +
effective O +
treatment O +
tool O +
against O +
acidosis O +
and/or O +
excessive O +
ROS O +
production O +
including O +
free O +
radical O +
production O +
useful O +
to O +
prevent O +
or O +
reduce O +
acidosis O +
and/or O +
excessive O +
ROS O +
production O +
or O +
related O +
symptoms O +
or O +
conditions O +
associated O +
with O +
acidosis O +
and/or O +
excessive O +
free O +
radical O +
production O +
in O +
mammalian O +
subjects O -
. O +

Flavonoid O +
ppar B-Gene +
agonists O +
The O +
present O +
invention O +
relates O +
to O +
PPAR B-Gene +
agonists O -
, O +
and O +
their O +
use O +
in O +
therapy O +
including O +
the O +
treatment O +
of O +
disease O -
. O +

In O +
particular O -
, O +
the O +
invention O +
relates O +
to O +
flavonoid O +
compounds O +
which O +
are O +
PPAR B-Gene -
- I-Gene -
gamma I-Gene +
agonists O +
and/or O +
PPAR B-Gene +
alpha I-Gene -
/ I-Gene -
gamma I-Gene +
dual O +
agonists O -
. O +

2,4 O +
diaminopyrimid'lnes O +
for O +
the O +
treatment O +
of O +
myeloproliferative O +
disorders O +
and O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
and O +
to O +
their O +
salts O -
, O +
pharmaceutical O +
compositions O -
, O +
methods O +
of O +
use O -
, O +
and O +
methods O +
for O +
their O +
preparation O -
. O +

These O +
compounds O +
provide O +
a O +
treatment O +
for O +
myeloproliferative O +
disorders O +
and O +
cancer O -
. O +

Therapeutic O +
agent O +
for O +
cancer O +
with O +
resistance O +
to O +
protease B-Gene +
inhibitor O +
A O +
therapeutic O +
agent O +
for O +
cancers O +
having O +
resistance O +
to O +
protease B-Gene +
inhibitors O +
which O +
contains O -
, O +
as O +
a O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene +
( O -
Hsp90 B-Gene -
) O +
family O +
protein O +
inhibitor O -
, O +
either O +
a O +
benzoyl O +
compound O +
represented O +
by O +
the O +
formula O +
( O -
I O -
) O +
[ O -
wherein O +
n O +
is O +
an O +
integer O +
of O +
1 O -
- O -
5 O -
; O +
R1 O +
represents O +
( O -
un O -
) O -
substituted O +
lower O +
alkyl O -
, O +
CONR7R8 O +
( O -
wherein O +
R7 O +
and O +
R8 O +
are O +
the O +
same O +
or O +
different O +
and O +
each O +
represents O +
hydrogen O -
, O +
( O -
un O -
) O -
substituted O +
lower O +
alkyl O -
, O +
etc O -
. O -
) O -
, O +
etc O -
. O -
; O +
R2 O +
represents O +
( O -
un O -
) O -
substituted O +
aryl O -
, O +
etc O -
. O -
; O +
R3 O +
and O +
R5 O +
are O +
the O +
same O +
or O +
different O +
and O +
each O +
represents O +
hydrogen O -
, O +
( O -
un O -
) O -
substituted O +
lower O +
alkyl O -
, O +
etc O -
. O -
; O +
R4 O +
represents O +
hydrogen O -
, O +
etc O -
. O -
; O +
and O +
R6 O +
represents O +
hydrogen O -
, O +
halogeno O -
, O +
( O -
un O -
) O -
substituted O +
lower O +
alkyl O -
, O +
etc O -
. O -
] O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
of O +
the O +
compound O -
. O +

Anti O -
- O -
bacterial O +
agents O +
The O +
invention O +
relates O +
to O +
novel O +
acylphloroglucinols O +
which O +
have O +
strong O +
growth O +
inhibitory O +
effects O +
on O +
multi O -
- O -
drug O +
resistant O +
strains O +
of O +
bacteria O -
, O +
particularly O +
MRSA O -
. O +

Typically O +
the O +
compounds O +
have O +
a O +
terpene O +
substituent O -
, O +
or O +
a O +
terpene- O +
derived O +
substituent O -
. O +

Methods O +
of O +
isolating O +
the O +
compounds O +
from O +
natural O +
sources O -
, O +
and O +
synthetic O +
methods O +
for O +
forming O +
the O +
compounds O +
are O +
also O +
provided O -
. O +

Combination O +
059 O +

This O +
invention O +
relates O +
to O +
a O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
comprising O +
a O +
MEK B-Gene +
inhibitor O +
and O +
a O +
mTOR B-Gene -
- O -
selective O +
inhibitor O -
, O +
and O +
to O +
methods O +
for O +
the O +
production O +
of O +
an O +
anti O -
- O -
cancer O +
effect O +
in O +
a O +
patient O -
, O +
which O +
is O +
accordingly O +
useful O +
in O +
the O +
treatment O +
of O +
cancer O +
in O +
a O +
patient O -
. O +

More O +
specifically O +
the O +
present O +
invention O +
relates O +
to O -
; O +
a O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
comprising O +
a O +
MEK B-Gene +
inhibitor O +
and O +
a O +
mTOR B-Gene -
- O -
selective O +
inhibitor O -
; O +
a O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
comprising O +
a O +
kit O +
of O +
parts O +
comprising O +
a O +
MEK B-Gene +
inhibitor O +
and O +
a O +
mTOR B-Gene -
- O -
selective O +
inhibitor O -
; O +
use O +
of O +
the O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
in O +
the O +
treatment O +
of O +
cancer O -
; O +
a O +
method O +
of O +
treating O +
cancer O +
comprising O +
administering O +
the O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
to O +
a O +
patient O -
. O +

The O +
combination O +
product O -
, O +
as O +
defined O +
herein O -
, O +
and O +
methods O +
of O +
the O +
invention O +
are O +
also O +
useful O +
in O +
the O +
treatment O +
of O +
other O +
diseases O +
associated O +
with O +
the O +
activity O +
of O +
MEK B-Gene -
, O +
and/or O +
mTOR B-Gene -
. O +

Modulators O +
of O +
the O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
egfr B-Gene -
) O +
pathway O +
for O +
use O +
in O +
the O +
treatment O +
or O +
prevention O +
of O +
substance O +
abuse O +
The O +
present O +
invention O +
provides O +
methods O +
of O +
using O +
modulators O +
of O +
the O +
epidermal B-Gene +
growth I-Gene +
factor I-Gene +
receptor I-Gene +
( O -
EGFR B-Gene -
) O +
pathway O +
for O +
treatment O +
or O +
prevention O +
of O +
substance O +
abuse O +
such O +
as O +
alcohol O +
abuse O -
. O +

The O +
modulators O +
include O +
small O +
molecule O +
inhibitors O +
such O +
as O +
Erlotinib O +
( O -
TARCEVA O -
Â® O -
, O +
N- O -
( O -
3-ethynylphenyl O -
) O -
-6,7-bis O -
( O -
2-methoxyethoxy O -
) O -
-4- O +
quinazolineamine O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
hydrate O +
or O +
prodrug O +
thereof O +
and O +
Gefitinib O +
[ O -
IRES O +
S O +
A O -
Â® O -
, O +
N- O -
( O -
3 O +
-chloro-4-fluoro O -
- O -
phenyl O -
) O -
-7-methoxy-6- O -
( O -
3 O +
-morpholin-4- O +
ylpropoxy O -
) O -
quinazolin-4-amine O -
] O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
hydrate O +
or O +
prodrug O +
thereof O +
and O +
various O +
macromolecular O +
inhibitors O +
of O +
the O +
EGFR B-Gene +
pathway O +
such O +
as O +
siRNAs O +
and O +
antibodies O +
that O +
target O +
genes O +
or O +
proteins O +
in O +
the O +
EGFR B-Gene -
/ O -
ERK B-Gene +
pathway O +
such O +
as O +
one O +
of O +
the O +
EGFR B-Gene -
/ O -
ErbB B-Gene +
protein O +
or O +
a O +
homolog O +
thereof O -
. O +

Inhibition O +
of O +
11 B-Gene +
beta I-Gene -
- I-Gene -
hydroxysteroid I-Gene +
dehydrogenase I-Gene +
type I-Gene +
1 I-Gene +
for O +
ocular O +
neuroprotection O +
A O +
composition O +
comprises O +
a O +
material O +
capable O +
of O +
controlling O +
a O +
level O +
of O +
cortisol O +
in O +
an O +
ocular O +
environment O +
for O +
effecting O +
ocular O +
neuroprotection O +
in O +
subjects O +
in O +
risk O +
of O +
developing O +
or O +
worsening O +
an O +
ocular O +
neurodegenerative O +
condition O -
. O +

Such O +
a O +
composition O +
is O +
injected O +
into O +
or O +
implanted O +
in O +
the O +
subject O -
's O +
posterior O +
segment O +
to O +
provide O +
such O +
neuroprotection O -
. O +

CarboxamidÎ¾ O +
compounds O +
and O +
their O +
use O +
as O +
chemokine B-Gene +
receptor I-Gene +
agonists O +
Chemokine B-Gene +
receptor I-Gene +
antagonists O -
, O +
in O +
particular O -
, O +
compounds O +
of O +
Formula O +
( O -
I- O +
A O -
) O +
that O +
act O +
as O +
antagonists O +
of O +
the O +
chemokine B-Gene +
CCR2 B-Gene +
receptor O -
, O +
including O +
pharmaceutical O +
compositions O +
and O +
uses O +
thereof O +
to O +
treat O +
or O +
prevent O +
diseases O +
associated O +
with O +
monocyte O +
accumulation O -
, O +
lymphocyte O +
accumulation O +
or O +
leukocyte O +
accumulation O +
are O +
described O +
herein O -
. O +

Trail B-Gene +
variants O +
for O +
treating O +
cancer O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
a O +
mutant O +
TRAIL B-Gene +
protein O +
to O +
treat O +
various O +
cancers O +
in O +
mammals O -
. O +

The O +
invention O +
provides O +
a O +
variant O +
TRAIL B-Gene +
protein O -
, O +
which O +
has O +
superior O +
selectivity O +
for O +
the O +
death B-Gene +
receptor I-Gene +
5 I-Gene -
, O +
for O +
treating O +
a O +
mammal O +
diagnosed O +
with O +
cancer O -
. O +

Cucurbitane O +
triterpenoid O +
saponins O -
, O +
pharmaceutical O +
composition O +
thereof O -
, O +
preparation O +
and O +
use O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
the O +
pharmaceutical O +
field O +
and O +
discloses O +
cucurbitane O +
triterpenoid O +
saponins O +
extracted O +
from O +
Momordica O +
charantia O -
, O +
a O +
pharmaceutical O +
composition O +
containing O +
them O +
and O +
their O +
preparation O -
. O +

The O +
invention O +
also O +
discloses O +
the O +
use O +
of O +
such O +
compounds O +
in O +
preparation O +
of O +
medicaments O +
for O +
the O +
treatment O +
of O +
diabetes O -
, O +
obesity O +
and O +
hyperlipaemia O -
. O +

The O +
saponins O +
disclosed O +
in O +
the O +
invention O +
are O +
represented O +
by O +
formula O +
I. O +

Preparations O +
with O +
rosehip O +
extracts O -
, O +
and O +
method O +
of O +
producing O +
rosehip O +
extracts O +
Composition O +
comprising O +
an O +
anti O -
- O -
inflammatory O +
plant O +
extract O +
from O +
rosehips O +
together O +
with O +
a O +
cartilage O -
- O -
protective O +
substance O -
, O +
and O +
a O +
method O +
of O +
producing O +
the O +
rosehip O +
extract O -
. O +

A2b O +
adenosine O +
receptor O +
antagonists O +
for O +
the O +
treatment O +
of O +
cancer O +
Disclosed O +
are O +
methods O +
for O +
treating O +
asthma O -
, O +
inflammatory O +
gastrointestinal O +
tract O +
disorders O -
, O +
cancer O -
, O +
cardiovascular O +
diseases O -
, O +
neurological O +
disorders O -
, O +
and O +
diseases O +
related O +
to O +
undesirable O +
angiogenesis O +
using O +
A2B O +
adenosine O +
receptor O +
antagonists O +
having O +
the O +
structure O +
of O +
Formula O +
( O -
I O -
) O +
or O +
Formula O +
( O -
II O -
) O -
. O +

Aryl O -
- O -
substituted O +
imidazolidine-2,4-diones O -
, O +
method O +
for O +
the O +
production O +
thereof O -
, O +
medicaments O +
containing O +
said O +
compounds O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
the O +
groups O +
R O +
and O +
R O -
' O +
A O -
, O +
D O -
, O +
E O -
, O +
G O -
, O +
L O -
, O +
p O +
and O +
Rl O +
to O +
R1O O +
have O +
the O +
stated O +
meanings O +
and O +
to O +
their O +
physiologically O +
compatible O +
salts O -
. O +

Said O +
compounds O +
are O +
suitable O -
, O +
for O +
example O -
, O +
as O +
anti O -
- O -
obesity O +
drugs O -
. O +

Imidazopyridine O +
compounds O +
The O +
present O +
invention O +
provides O +
imidazopyridines O +
of O +
formula O +
( O -
I O -
) O -
. O +

The O +
compounds O +
show O +
inhibitory O +
activity O +
against O +
protein O +
kinase B-Gene -
, O +
especially O +
VEGFR2 B-Gene -
, O +
FLT3 B-Gene -
, O +
and O +
C B-Gene -
- I-Gene -
KIT I-Gene +
receptors O +
and O +
so O +
on O -
, O +
and O +
can O +
be O +
used O +
for O +
the O +
preparation O +
of O +
the O +
medicament O +
for O +
treating O +
diseases O +
associated O +
with O +
abnormal O +
high O +
level O +
of O +
kinase B-Gene +
activity O -
, O +
such O +
as O +
cancer O -
. O +

Processes O +
for O +
the O +
preparation O +
of O +
bosentan O +
and O +
related O +
compounds O +
Provided O +
herein O +
are O +
novel O -
, O +
commercially O +
viable O +
and O +
industrially O +
advantageous O +
processes O +
for O +
the O +
preparation O +
of O +
substantially O +
pure O +
ethylene O +
glycol O +
sulfonamide O +
compounds O +
such O +
as O +
bosentan O -
. O +

Pyrido O +
[ O -
3 O -
, O +
4-b O -
] O +
indoles O +
and O +
methods O +
of O +
use O +
This O +
disclosure O +
relates O +
to O +
new O +
heterocyclic O +
compounds O +
that O +
may O +
be O +
used O +
to O +
modulate O +
a O +
histamine O +
receptor O +
in O +
an O +
individual O -
. O +

Pyrido O -
[ O -
3,4-b O -
] O -
indoles O +
are O +
described O -
, O +
as O +
are O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O +
and O +
methods O +
of O +
using O +
the O +
compounds O +
in O +
a O +
variety O +
of O +
therapeutic O +
applications O -
, O +
including O +
the O +
treatment O +
of O +
a O +
cognitive O +
disorder O -
, O +
psychotic O +
disorder O -
, O +
neurotransmitter O -
- O -
mediated O +
disorder O +
and/or O +
a O +
neuronal O +
disorder O -
. O +

2-aryl- O +
and O +
2-heteroarylthiazolyl O +
compounds O -
, O +
methods O +
for O +
their O +
preparation O +
and O +
use O +
thereof O +
The O +
present O +
invention O +
discloses O +
fused O +
bicyclic O +
2-aryl- O +
or O +
2-heteroarylthiazolyl O +
compounds O +
and O +
their O +
pharmaceutically O +
acceptable O +
salts O +
and O +
esters O +
thereof O -
, O +
which O +
are O +
useful O +
for O +
inhibiting O +
the O +
growth O +
of O +
cancerous O +
cells O -
, O +
inhibiting O +
human O +
breast O +
carcinoma O +
tumor O +
growth O +
in O +
particular O +
and O +
to O +
treat O +
diseases O +
or O +
disorders O +
associated O +
with O +
securin O -
, O +
including O +
elevated O +
securin O +
levels O -
. O +

Gem O -
- O -
disubstituted O +
and O +
spirocyclic O +
amino O +
pyridines O -
/ O -
pyrimidines O +
as O +
cell O +
cycle O +
inhibitors O +
Compounds O -
, O +
pharmaceutical O +
compositions O +
and O +
methods O +
are O +
provided O +
that O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
CDK4-mediated B-Gene +
disorders O -
, O +
such O +
as O +
cancer O -
. O +

The O +
subject O +
compounds O +
are O +
gem O -
- O -
disubstituted O +
or O +
spirocyclic O +
pyridine O -
, O +
pyrimidine O +
and O +
triazine O +
derivatives O -
. O +

Therapeutic O +
agent O +
for O +
intermittent O +
claudication O +
Disclosed O +
are O -
: O +
a O +
therapeutic O +
agent O +
for O +
intermittent O +
claudication O -
, O +
which O +
comprises O +
a O +
tricyclic O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
[ O -
wherein O +
R1 O +
represents O +
a O +
substituted O +
or O +
unsubstituted O +
lower O +
alkyl O -
] O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
; O +
a O +
therapeutic O +
agent O +
for O +
arterial O +
occlusive O +
intermittent O +
claudication O -
, O +
which O +
comprises O +
a O +
tricyclic O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
; O +
a O +
therapeutic O +
agent O +
for O +
intermittent O +
claudication O -
, O +
which O +
comprises O +
a O +
tricyclic O +
compound O +
represented O +
by O +
formula O +
( O -
IA O -
) O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
; O +
a O +
therapeutic O +
agent O +
for O +
arterial O +
occlusive O +
intermittent O +
claudication O -
, O +
which O +
comprises O +
a O +
tricyclic O +
compound O +
represented O +
by O +
formula O +
( O -
IA O -
) O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O +
as O +
an O +
active O +
ingredient O -
; O +
and O +
others O -
. O +

Indole- O +
3 O +
-glyoxylamide O +
derivatives O +
for O +
use O +
as O +
calcium O +
ion O +
channel O +
modulators O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
are O +
of O +
use O +
in O +
treating O +
a O +
range O +
of O +
conditions O -
, O +
including O +
pain O -
. O +

Method O +
of O +
treating O +
anxious O +
major O +
depressive O +
disorder O +
The O +
invention O +
is O +
directed O +
to O +
using O +
4- O -
{ O -
( O -
3-aminophenyl O -
) O -
[ O -
4- O -
( O -
4-fluorobenzyl O -
) O -
piperazin-1-yl O -
] O -
methyl O -
} O -
-N O -
, O -
N O -
- O -
diethylbenzamide O -
, O +
or O +
enantiomer O +
thereof O -
, O +
or O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and/or O +
mixture O +
thereof O +
to O +
treat O +
anxious O +
major O +
depressive O +
disorder O +
( O -
AMDD O -
) O -
. O +

Cancer O +
drug O +
target O +
and O +
methods O +
of O +
diagnosis O +
and O +
therapy O +
A O +
single O +
nucleotide O +
G O +
> O -
A O +
polymorphism O +
at O +
position O +
-126 O +
in O +
the O +
promoter O +
of O +
the O +
human B-Gene +
myeloid I-Gene +
cell I-Gene +
leukemia-1 I-Gene +
gene I-Gene +
is O +
associated O +
with O +
a O +
reduced O +
predisposition O +
to O +
cancer O +
and O +
an O +
increased O +
responsiveness O +
to O +
pro O -
- O -
apoptotic O +
cancer O +
therapeutic O +
agents O -
. O +

The O +
G>;A O +
polymorphism O +
is O +
in O +
an O +
ELK4 B-Gene +
transcription O +
factor O +
binding O +
site O -
, O +
which O +
results O +
in O +
reduced O +
myeloid B-Gene +
cell I-Gene +
leukemia-1 I-Gene +
gene I-Gene +
expression O -
. O +

Elevated O +
levels O +
of O +
ELK4 B-Gene +
and O +
Mcl-1 B-Gene +
protein O +
and O +
nucleic O +
acids O +
are O +
associated O +
with O +
an O +
increased O +
predisposition O +
to O +
cancer O +
and O +
an O +
decreased O +
responsiveness O +
to O +
pro O -
- O -
apoptotic O +
agents O -
. O +

Reduced O +
levels O +
of O +
ELK4 B-Gene +
and O +
Mcl-1 B-Gene +
protein O +
and O +
nucleic O +
acids O +
are O +
associated O +
with O +
less O +
of O +
a O +
predisposition O +
to O +
cancer O +
and O +
an O +
increased O +
responsiveness O +
to O +
pro O -
- O -
apoptotic O +
cancer O +
therapeutic O +
agents O -
. O +

Methods O +
of O +
cancer O +
diagnosis O +
and/or O +
therapy O +
which O +
target O +
ELK4 B-Gene +
and/or O +
Mcl-1 B-Gene +
protein O +
and/or O +
nucleic O +
acids O +
are O +
particularly O +
applicable O +
to O +
cancers O +
such O +
as O +
glioma O -
, O +
colon O +
cancer O -
, O +
lung O +
cancer O -
, O +
thyroid O +
cancer O -
, O +
kidney O +
cancer O +
and/or O +
melanoma O -
. O +

Such O +
methods O +
and O +
compositions O +
may O +
sensitize O +
or O +
improve O +
responsiveness O +
of O +
cancer O +
cells O +
to O +
pro O -
- O -
apoptotic O +
agents O -
. O +

Benzo O +
[ O -
1 O -
, O +
4 O -
] O +
diazepines O +
substituted O +
at O +
the O +
1-position O +
by O +
a O +
ring O -
, O +
for O +
use O +
as O +
antidepressants O +
It O +
is O +
intended O +
to O +
provide O +
a O +
benzodiazepine O +
compound O +
useful O +
in O +
the O +
production O +
of O +
an O +
antidepressant O +
drug O +
that O +
has O +
a O +
wider O +
therapeutic O +
spectrum O +
and O +
can O +
exert O +
sufficient O +
therapeutic O +
effects O +
in O +
a O +
short O +
period O -
. O +

The O +
benzodiazepine O +
compound O +
of O +
the O +
present O +
invention O +
is O +
represented O +
by O +
the O +
general O +
formula O +
( O -
1 O -
) O -
: O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
and O +
R7 O +
respectively O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
; O +
and O +
R6 O +
represents O +
a O +
substituted O +
phenyl O +
group O +
or O +
the O +
like O -
. O +

4 O -
, O +
6-diphenylpyrid-2 O -
- O -
0nes O +
against O +
cancer O +
A O +
compound O +
for O +
use O +
in O +
the O +
treatment O +
of O +
proliferative O +
disorders O -
, O +
such O +
as O +
cancer O -
, O +
having O +
the O +
following O +
formula O -
: O -
z O +
wherein O -
: O +
R1 O -
, O +
R2 O +
and O +
R3 O +
are O +
independently O +
H O +
or O +
lower O +
alkyl O -
; O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O +
and O +
R8 O +
are O +
independently O +
H O -
, O +
halo O -
, O +
lower O +
alkyl O +
or O +
-O O -
- O -
lower O +
alkyl O -
, O +
provided O +
that O +
at O +
least O +
one O +
is O +
-O O -
- O -
lower O +
alkyl O -
; O +
or O +
at O +
least O +
one O +
pair O +
of O +
R4 O +
to O +
R8 O -
, O +
the O +
members O +
of O +
which O +
pair O +
are O +
adjacent O +
to O +
one O +
another O +
on O +
the O +
ring O -
, O +
are O +
conjoined O +
to O +
form-0- O -
( O -
CR14R15 O -
) O -
n O -
- O -
O- O -
, O +
where O +
n O +
is O +
1 O +
or O +
2 O +
and O +
R14 O +
and O +
R15 O +
are O +
independently O +
H O +
or O +
lower O +
alkyl O -
, O +
and O +
the O +
remainder O +
of O +
R4 O +
to O +
R8 O +
are O +
independently O +
H O -
, O +
halo O -
, O +
lower O +
alkyl O +
or O +
-O O -
- O -
lower O +
alkyl O -
; O +
and O +
R9 O -
, O +
R10 O -
, O +
R11 O -
, O +
R12 O +
and O +
R13 O +
are O +
independently O +
H O -
, O +
halo O -
, O +
lower O +
alkyl O +
or O +
-O O -
- O -
lower O +
alkyl O -
, O +
provided O +
that O +
at O +
least O +
one O +
is O +
-O O -
- O -
lower O +
alkyl O -
; O +
or O +
at O +
least O +
one O +
pair O +
of O +
R9 O +
to O +
R13 O -
, O +
the O +
members O +
of O +
which O +
pair O +
are O +
adjacent O +
to O +
one O +
another O +
on O +
the O +
ring O -
, O +
are O +
conjoined O +
to O +
form O -
- O -
O- O -
( O -
CR16R17 O -
) O -
m O -
- O -
O- O -
, O +
where O +
m O +
is O +
1 O +
or O +
2 O +
and O +
R16 O +
and O +
R17 O +
are O +
independently O +
H O +
or O +
lower O +
alkyl O -
, O +
and O +
the O +
remainder O +
of O +
R9 O +
to O +
R13 O +
are O +
independently O +
H O -
, O +
halo O -
, O +
lower O +
alkyl O +
or O +
-O O -
- O -
lower O +
alkyl O -
. O +

Novel O +
pde B-Gene +
inhibitors O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
processes O +
for O +
their O +
preparation O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
heterocyclic O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
which O +
are O +
phosphodiesterase B-Gene +
inhibitors O +
( O -
PDEs B-Gene -
) O -
, O +
in O +
particular O +
phosphodiesterase B-Gene +
type I-Gene +
4 I-Gene +
inhibitors O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
and O +
processes O +
for O +
their O +
preparation O -
. O +

These O +
novel O +
PDEs B-Gene +
are O +
useful O +
in O +
treating O +
allergic O +
and O +
inflammatory O +
diseases O +
( O -
such O +
as O +
asthma O -
, O +
COPD O -
, O +
allergic O +
rhinitis O -
, O +
allergic O +
conjunctivitis O -
, O +
respiratory O +
distress O +
syndrome O -
, O +
chronic O +
bronchitis O -
, O +
nephritis O -
, O +
rheumatoid O +
spondylitis O -
, O +
osteoarthritis O -
, O +
atopic O +
dermatitis O -
, O +
eosinophilic O +
granuloma O -
, O +
psoriasis O -
, O +
rheumatoid O +
septic O +
shock O -
, O +
ulcerative O +
colitis O -
, O +
multiple O +
sclerosis O -
, O +
chronic O +
inflammation O -
, O +
Crohn O -
's O +
syndrome O +
and O +
central O +
nervous O +
system O -
( O -
CNS O -
) O +
disorders O -
) O +
and O +
for O +
inhibiting O +
the O +
production O +
of O +
Tumor B-Gene +
Necrosis I-Gene +
Factor I-Gene -
( O -
TNF B-Gene -
- I-Gene -
Î± I-Gene -
) O -
. O +

Combination O +
product O +
of O +
receptor B-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitor O +
and O +
fatty B-Gene +
acid I-Gene +
synthase I-Gene +
inhibitor O +
for O +
treating O +
cancer O +
A O +
pharmaceutical O +
combination O +
product O +
is O +
disclosed O +
that O +
comprises O +
a O +
receptor B-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitor O +
and O +
a O +
fatty B-Gene +
acid I-Gene +
synthase I-Gene +
inhibitor O -
, O +
and O +
to O +
the O +
use O +
thereof O +
in O +
the O +
manufacture O +
of O +
a O +
medicament O +
for O +
use O +
in O +
the O +
treatment O +
or O +
prophylaxis O +
of O +
cancer O -
. O +

5h O -
- O -
pyrr0l0 O +
[ O -
2,3-b O -
] O +
pyrazine O +
derivatives O +
for O +
kinase O +
modulation O -
, O +
and O +
indications O +
therefor O +
Compounds O +
active O +
on O +
Fms B-Gene +
and/or O +
Kit B-Gene +
protein I-Gene +
kinases I-Gene +
are O +
described O -
, O +
as O +
well O +
as O +
methods O +
of O +
using O +
such O +
compounds O +
to O +
treat O +
diseases O +
and O +
conditions O +
associated O +
with O +
aberrant O +
activity O +
of O +
Fms B-Gene +
and/or O +
Kit B-Gene +
protein I-Gene +
kinases I-Gene -
. O +

Thiosemicarbazone O +
compounds O +
and O +
use O +
thereof O +
A O +
method O +
of O +
treating O +
a O +
proliferative O +
disease O +
in O +
a O +
vertebrate O -
, O +
the O +
method O +
comprising O +
administering O +
to O +
the O +
vertebrate O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
compound O +
of O +
formula O +
( O -
I O -
) O +
( O -
I O -
) O +
wherein O +
R1 O +
is O +
selected O +
from O +
H O -
, O +
C1 O -
- O -
6 O +
alkyl O -
, O +
C2 O -
- O -
6 O +
alkenyl O +
and O +
phenyl O -
; O +
R2 O +
is O +
selected O +
from O +
H O -
, O +
C1 O -
- O -
6 O +
alkyl O -
, O +
C2 O -
- O -
6 O +
alkenyl O +
and O +
phenyl O -
; O +
wherein O +
R1 O +
and O +
R2 O +
are O +
the O +
same O +
or O +
different O -
, O +
or O +
a O +
salt O -
, O +
hydrate O -
, O +
or O +
iron O +
complex O +
thereof O -
, O +
or O +
a O +
pharmaceutical O +
composition O +
comprising O +
said O +
compound O -
, O +
salt O -
, O +
hydrate O +
or O +
iron O +
complex O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
, O +
diluent O +
or O +
excipient O -
. O +

Deuterated O +
ibudilast O +
This O +
invention O +
relates O +
to O +
novel O +
compounds O +
that O +
are O +
2-alkyl-3-acylpyrazolo O -
[ O -
l,5- O +
a O -
] O -
pyridines O -
, O +
their O +
derivatives O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

More O +
specifically O -
, O +
the O +
invention O +
relates O +
to O +
2-alkyl-3-acylpyrazolo O -
[ O -
l,5-a O -
] O -
pyridine O +
compounds O +
that O +
are O +
derivatives O +
of O +
ibudilast O -
. O +

This O +
invention O +
also O +
provides O +
compositions O +
comprising O +
a O +
compound O +
of O +
this O +
invention O +
and O +
the O +
use O +
of O +
such O +
compositions O +
in O +
methods O +
of O +
treating O +
diseases O +
and O +
conditions O +
that O +
are O +
beneficially O +
treated O +
by O +
administering O +
a O +
phosphodiesterase O +
( O -
PDE O -
) O +
inhibitor O -
, O +
a O +
leukotriene O +
CysLTl O +
( O -
LTD4 O -
) O +
antagonist O -
, O +
an O +
inhibitor O +
of O +
nitric O +
oxide O +
synthase O -
, O +
and/or O +
a O +
glial O +
cell O +
activation O +
suppressant O -
, O +
such O +
as O +
ibudilast O -
. O +

Tricyclic O +
heterocycle O +
derivatives O +
as O +
histamine B-Gene +
h3 I-Gene +
antagonists O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
Tricyclic O +
Heterocylce O +
Derivatives O -
, O +
pharmaceutical O +
compositions O +
comprising O +
the O +
Tricyclic O +
Heterocycle O +
Derivatives O +
and O +
the O +
use O +
of O +
these O +
compounds O +
for O +
treating O +
or O +
preventing O +
allergy O -
, O +
an O +
allergy O -
- O -
induced O +
airway O +
response O -
, O +
congestion O -
, O +
a O +
cardiovascular O +
disease O -
, O +
an O +
inflammatory O +
disease O -
, O +
a O +
gastrointestinal O +
disorder O -
, O +
a O +
neurological O +
disorder O -
, O +
a O +
metabolic O +
disorder O -
, O +
obesity O +
or O +
an O +
obesity O -
- O -
related O +
disorder O -
, O +
diabetes O -
, O +
a O +
diabetic O +
complication O -
, O +
impaired O +
glucose O +
tolerance O +
or O +
impaired O +
fasting O +
glucose O -
. O +

R1 O +
is O +
formula O +
( O -
Ia O -
) O -
, O +
( O -
Ib O -
) O +
or O +
( O -
Ic O -
) O -
; O +
R2 O +
is O +
alkvl O -
, O +
alkenyl O -
, O +
alkynyl O -
, O +
aryl O -
, O +
heteroaryl O -
, O +
cycloalkyl O +
or O +
heterocycloalkyl O -
. O +

any O +
of O +
which O +
can O +
be O +
optionally O +
substituted O +
with O +
R11 O -
; O +
M1 O +
is O +
-CH- O -
. O +

-C O -
( O -
halo O -
) O -
- O +
or O +
-N- O -
; O +
Y O +
is O +
-C O -
( O -
O O -
) O -
- O -
, O +
-S- O -
. O +
-S O -
( O -
O O -
) O -
- O -
, O +
-S O -
( O -
O O -
) O -
2- O -
, O +
-CH2- O +
or O +
-O- O -
, O +
such O +
that O +
Y O +
is O +
not O +
-O- O +
when O +
an O +
adjacent O +
atom O +
is O +
N. O +

Polyglutamine O +
aggregation O +
inhibitor O +
Disclosed O +
is O +
a O +
polyglutamine O +
aggregation O +
inhibitor O +
including O +
a O +
chemical O +
compound O +
represented O +
by O +
any O +
of O +
the O +
following O +
general O +
formulae O +
( O -
1 O -
) O -
- O -
( O -
13 O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

( O -
1 O -
) O +
R3- O -
[ O -
-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y O -
- O -
B O -
( O -
ZR2 O -
) O -
-W- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
2 O -
) O +
R3- O -
[ O -
-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
3 O -
) O +
R3- O -
[ O -
-B O -
( O -
ZR1 O -
) O -
-Y O -
- O -
B O -
( O -
ZR2 O -
) O -
-W- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
4 O -
) O +
R3- O -
[ O -
-X O -
- O -
B O -
( O -
ZR1 O -
) O -
- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
5 O -
) O +
R3- O -
[ O -
-B O -
( O -
ZR2 O -
) O -
-W- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
6 O -
) O +
R3-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-T O -
[ O -
B O -
( O -
ZR2 O -
) O -
-W O -
- O -
R4 O -
] O -
2 O -
; O +
( O -
7 O -
) O +
R3-B O -
( O -
OH O -
) O -
2 O -
; O +
( O -
8) O +
R3-B O -
( O -
ZR1 O -
) O -
-X O -
- O -
B O -
( O -
ZR2 O -
) O -
-R4 O -
; O +
( O -
9 O -
) O +
R3-B O -
( O -
R1 O -
) O -
-O O -
- O -
B O -
( O -
R2 O -
) O -
-R4 O -
; O +
( O -
10 O -
) O +
R3- O -
[ O -
-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y O -
- O -
B O -
( O -
ZR2 O -
) O -
- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
11 O -
) O +
R3- O -
[ O -
-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y O -
- O -
B O -
( O -
ZR2 O -
) O -
-W O -
- O -
Q- O -
] O -
n O -
- O -
R4 O -
; O +
( O -
12 O -
) O +
R3- O -
[ O -
-P O -
- O -
X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y O -
- O -
B O -
( O -
ZR2 O -
) O -
-W- O -
] O -
n O -
- O -
R4 O -
; O +
and O +
( O -
13 O -
) O +
[ O -
R3-X O -
- O -
B O -
( O -
ZR1 O -
) O -
-Y O -
] O -
2B O -
( O -
ZR2 O -
) O +
( O -
wherein O +
the O +
symbols O +
in O +
each O +
formula O +
carry O +
the O +
same O +
definitions O +
as O +
those O +
used O +
in O +
the O +
Specification O -
) O -
. O +

Pyridine O +
derivatives O +
as O +
vegfr-2 B-Gene +
receptor O +
and O +
protein B-Gene +
tyrosine I-Gene +
kinase I-Gene +
inhibitors O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
wherein O +
W O -
, O +
D O -
, O +
E O -
, O +
G O -
, O +
J O -
, O +
L O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O +
and O +
Y O +
are O +
as O +
defined O +
herein O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
hydrates O -
, O +
or O +
solvates O +
thereof O -
, O +
for O +
use O +
-alone O +
or O +
in O +
combination O +
with O +
one O +
or O +
more O +
other O +
pharmaceutically O +
active O +
compounds- O +
in O +
therapy O -
, O +
for O +
treating O +
diseases O +
associated O +
with O +
deregulated O +
angiogenesis O -
, O +
such O +
as O +
cancer O +
and O +
skin O +
and O +
eye O +
diseases O -
. O +

Hybrid O +
tripyrrole O -
- O -
octaarginine O +
compounds O +
and O +
their O +
use O +
as O +
medicament O +
in O +
the O +
treatment O +
of O +
cancer O +
and O +
microbial O +
illnesses O +
Hybrid O +
tripyrrole O -
- O -
octaarginine O +
compounds O -
. O +

Hybrids O +
formed O +
of O +
a O +
tripyrrole O +
group O +
linked O +
to O +
a O +
polyarginine O +
peptide O +
which O +
permit O +
efficient O +
cellular O +
internalisation O +
and O +
promotes O +
greater O +
affinity O +
for O +
DNA O -
. O +

The O +
method O +
of O +
obtainment O +
and O +
uses O +
thereof O -
. O +

Methods O +
for O +
increasing O +
neurogenesis O +
The O +
present O +
invention O +
relates O +
to O +
methods O +
and O +
compounds O +
useful O +
for O +
increasing O +
neurogenesis O -
. O +

Methods O +
and O +
compounds O +
for O +
increasing O +
dopaminergic O +
differentiation O +
are O +
also O +
provided O -
. O +

Methods O +
for O +
treating O +
neurological O +
disorders O +
by O +
increasing O +
neurogenesis O +
are O +
also O +
provided O -
. O +

Macrocyclics O +
pyrimidines O +
as O +
aurora B-Gene +
kinase I-Gene +
inhibitors O +
Macrocyclic O +
derivative O +
compounds O +
that O +
inhibit O +
protein B-Gene +
kinase I-Gene +
enzymes O +
are O +
disclosed O +
along O +
with O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O +
and O +
methods O +
for O +
synthesizing O +
the O +
same O -
. O +

Such O +
compounds O +
have O +
utility O +
in O +
the O +
treatment O +
of O +
proliferative O +
diseases O +
resulting O +
from O +
unregulated O +
and/or O +
disturbed O +
kinase B-Gene +
activity O +
such O +
as O +
cancers O -
, O +
psoriasis O -
, O +
viral O +
and O +
bacterial O +
infections O -
, O +
inflammatory O +
and O +
autoimmune O +
diseases O -
. O +

Antibacterial O +
and/or O +
anti O -
- O -
acne O +
formulations O +
containing O +
salicylic O +
acid O +
or O +
a O +
derivative O +
thereof O +
Antibacterial O +
and/or O +
anti O -
- O -
acne O +
formulation O +
containing O +
( O -
a O -
) O +
salicylic O +
acid O +
or O +
a O +
derivative O +
thereof O +
and O +
( O -
b O -
) O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
derivative O +
thereof O -
: O +
formula O +
( O -
I O -
) O +
wherein O +
each O +
of O +
R1 O +
and O +
R2 O +
is O +
independently O +
selected O +
from O +
methyl O +
and O +
ethyl O +
and O +
R3 O +
is O +
hydrogen O -
. O +

The O +
formulation O +
is O +
particularly O +
active O +
against O +
propionibacteria O -
, O +
and O +
may O +
therefore O +
be O +
used O +
to O +
treat O +
acne O -
. O +

Naringenin O +
complexes O +
and O +
methods O +
of O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
methods O +
of O +
treatment O +
of O +
hepatitis O +
C O -
, O +
dyslipidemia O -
, O +
insulin B-Gene +
resistance O -
, O +
and O +
inflammation O -
, O +
with O +
flavonoid- O +
sugar O +
complexes O -
. O +

Akr1c3 B-Gene +
as O +
a O +
biomarker O -
, O +
methods O +
of O +
selecting O +
and O +
treating O +
patients O +
based O +
upon O +
an O +
akr1c3 B-Gene +
profile O +
and O +
compounds O +
for O +
use O +
therein O +
The O +
invention O +
is O +
based O +
on O +
the O +
finding O +
that O +
the O +
enzyme O +
AKR1C3 B-Gene +
is O +
capable O +
of O +
exhibiting O +
nitroreductase B-Gene +
activity O +
and O +
activating O +
nitroaromatic O +
prodrugs O +
to O +
release O +
the O +
cytotoxic O +
effector O -
. O +

AKR1C3-activated B-Gene +
nitroaromatic O +
prodrugs O +
include O +
dinitrobenzamide O +
mustards O +
such O +
as O +
2- O -
( O -
( O -
2-bromoethyl O -
) O -
-2- O -
{ O -
[ O -
( O -
2-hydroxyethyl O -
) O -
amino O -
] O -
carbonyl O -
} O -
-4,6-dinitroanilino O -
) O -
ethyl O +
methanesulfonate O +
( O -
PR-104A O -
) O -
, O +
and O +
the O +
corresponding O +
pre O -
- O -
prodrug O +
2- O -
[ O -
( O -
2- O -
( O -
bromoethyl O -
) O -
-2,4-dinitro-6- O -
[ O -
[ O -
[ O -
2- O +
( O -
phosphonooxy O -
) O -
ethyl O -
] O -
amino O -
] O -
carbonyl O -
] O -
anilino O -
] O -
ethyl O +
methanesulfonate O +
( O -
PR-104 O -
) O -
. O +

The O +
invention O +
provides O +
methods O +
and O +
procedures O +
to O +
determine O +
drug O +
sensitivity O +
in O +
patients O +
to O +
allow O +
the O +
identification O +
of O +
individualized O +
patient O +
profiles O +
which O +
will O +
aid O +
in O +
treating O +
diseases O +
and O +
disorders O -
, O +
such O +
as O +
cancer O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
of O +
treatment O +
which O +
are O +
based O +
upon O +
such O +
biomarker O -
- O -
related O +
profiles O -
, O +
as O +
well O +
as O +
compounds O +
suitable O +
for O +
use O +
in O +
such O +
methods O +
and O +
compositions O +
comprising O +
" O -
such O +
compounds O -
. O +

Fused O +
heteroaryl O +
diamide O +
compounds O +
useful O +
as O +
mmp-13 B-Gene +
inhibitors O +
Disclosed O +
are O +
compounds O +
and O +
compositions O +
of O +
the O +
formula O +
I O +
as O +
described O +
herein O +
which O +
are O +
inhibitors O +
of O +
MMP-13 B-Gene -
. O +

Also O +
disclosed O +
are O +
methods O +
of O +
using O +
and O +
making O +
compounds O +
of O +
the O +
formula O +
I. O +

Pyrimidine O +
derivative O +
and O +
pyridine O +
derivative O +
both O +
having O +
pi3k B-Gene +
inhibitory O +
activity O +
A O +
pyrimidine O +
derivative O +
or O +
a O +
pyridine O +
derivative O +
represented O +
by O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
of O +
the O +
pyrimidine O +
derivative O +
or O +
the O +
pyridine O +
derivative O -
, O +
which O +
can O +
inhibit O +
the O +
activity O +
of O +
PI3 B-Gene -
K I-Gene +
to O +
control O +
many O +
biological O +
processes O +
including O +
growth O -
, O +
differentiation O -
, O +
survival O -
, O +
proliferation O -
, O +
migration O +
and O +
metabolism O +
of O +
cells O +
and O +
is O +
therefore O +
useful O +
for O +
the O +
prevention O -
/ O -
treatment O +
of O +
diseases O +
including O +
inflammatory O +
diseases O -
, O +
arteriosclerosis O -
, O +
vascular O -
/ O -
cardiovascular O +
diseases O -
, O +
cancer O -
/ O -
tumors O -
, O +
immune O +
diseases O -
, O +
cell O +
proliferative O +
diseases O +
and O +
infectious O +
diseases O -
. O +

Use O +
of O +
sabcomeline O +
for O +
the O +
treatment O +
of O +
add O +
or O +
adhd O +
The O +
present O +
invention O +
relates O +
to O +
the O +
treatment O +
of O +
attention O +
deficit O +
disorder O +
( O -
ADD O -
) O -
, O +
attention O +
deficit O +
hyperactivity O +
disorder O +
( O -
ADHD O -
) O -
, O +
to O +
the O +
treatment O +
of O +
cognitive O +
impairment O +
associated O +
with O +
ADD O +
or O +
ADHD O -
, O +
and O +
to O +
sabcomeline O -
, O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
and O +
compositions O +
comprising O +
sabcomeline O +
for O +
use O +
in O +
said O +
treatments O -
. O +

Oxidized O +
cardiolipin O +
as O +
a O +
novel O +
pro O -
- O -
inflammatory O +
factor O +
Low O +
levels O +
of O +
antibodies O +
reactive O +
with O +
oxidised O +
Cardiolipin O +
( O -
oxCL O -
) O +
in O +
mammals O +
are O +
related O +
to O +
an O +
increased O +
risk O +
of O +
developing O +
cardivacular O +
diseases O -
, O +
auto O -
- O -
immune O +
diseases O +
or O +
inflammatory O +
conditions O -
. O +

High O +
levels O +
can O +
have O +
a O +
protective O +
function O +
and O +
in O +
general O +
there O +
is O +
a O +
negative O +
association O +
between O +
manifestations O +
of O +
these O +
conditions O +
and O +
antibodies O +
against O +
oxCL O -
. O +

Thus O -
, O +
based O +
on O +
their O +
relations O +
methods O +
of O +
monitoring O -
, O +
determining O +
and O +
diagnosing O +
as O +
well O +
as O +
methods O +
of O +
immunisation O +
and O +
therapy O +
of O +
these O +
diseases O +
and O +
conditions O +
are O +
provided O -
. O +

1,3-heterocycles O +
condensed O +
with O +
monoterpene O +
skeleton O -
, O +
their O +
use O +
and O +
pharmaceutical O +
compositions O +
comprising O +
such O +
compounds O +
The O +
invention O +
relates O +
to O +
chiral O +
compounds O +
with O +
monoterpene O +
skeleton O +
of O +
general O +
formula O +
( O -
I O -
) O +
- O +
where O +
in O +
the O +
formula O +
X O +
stands O +
for O +
O O +
or O +
H2 O -
; O +
W O +
stands O +
for O +
O O -
, O +
S O -
, O +
N O -
- O -
R2 O +
or O +
Ph O -
- O -
R3 O -
; O +
Y O +
stands O +
for O +
O O +
or O +
N O -
- O -
R4 O -
; O +
R1 O +
stands O +
for O +
H O -
, O +
C1 O -
- O -
4Alk O +
or O +
( O -
C2 O -
) O -
1 O -
- O -
4-Ph O -
; O +
R2 O +
stands O +
for O +
C1 O -
- O -
4Alk O +
or O +
Ph O -
- O -
R3 O -
; O +
R3 O +
stands O +
for O +
H O -
, O +
C1 O -
- O -
4Alk O -
, O +
C1 O -
- O -
4Alk O -
- O -
O O +
or O +
Hlg O -
; O +
R4 O +
stands O +
for O +
H O +
or O +
Ph O -
; O +
and O +
one O +
of O +
the O +
signs O +
--- O +
means O +
the O +
presence O +
of O +
a O +
double O +
bond O +
and O +
the O +
other O +
means O +
the O +
absense O +
of O +
a O +
double O +
bond O -
, O +
with O +
the O +
proviso O +
that O +
only O +
one O +
of O +
W O +
and O +
Y O +
may O +
simultaneously O +
stand O +
for O +
oxygen O +
- O +
as O +
well O +
as O +
to O +
their O +
prodrugs O +
and O +
salts O +
formed O +
with O +
pharmaceutically O +
acceptable O +
acids O -
. O +

Furthermore O -
, O +
the O +
invention O +
relates O +
to O +
cytostatic O +
pharmaceutical O +
compositions O +
comprising O +
one O +
or O +
more O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
and O +
usual O +
inert O +
pharmaceutical O +
carriers O +
and/or O +
auxiliary O +
agents O -
, O +
to O +
the O +
use O +
of O +
the O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
for O +
preparing O +
cytostatic O +
pharmaceutical O +
compositions O +
as O +
well O +
as O +
to O +
the O +
treatment O +
and/or O +
curing O +
of O +
cancerous O +
illnesses O -
. O +

Pyrrolotriazines O +
as O +
alk B-Gene +
and O +
jak2 B-Gene +
inhibitors O +
The O +
present O +
invention O +
provides O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
salt O +
form O +
thereof O -
, O +
wherein O +
Q1 O -
, O +
Q2 O -
, O +
Q3 O -
, O +
and O +
Q4 O +
are O +
as O +
defined O +
herein O -
. O +

The O +
compound O +
of O +
formula O +
( O -
I O -
) O +
has O +
ALK B-Gene +
and/or O +
JAK2 B-Gene +
inhibitory O +
activity O -
, O +
and O +
may O +
be O +
used O +
to O +
treat O +
proliferative O +
disorders O -
. O +

Process O +
for O +
the O +
preparation O +
of O +
rosuvastatin O +
salts O +
The O +
present O +
invention O +
relates O +
to O +
a O +
new O +
process O +
for O +
the O +
preparation O +
of O +
rosuvastatin O +
[ O -
7- O -
[ O -
4- O -
( O -
4-Fluorophenyl O -
) O -
-6-isopropyl-2- O +
( O -
methanesulphonyl O -
- O -
methyl O -
- O -
amino O -
) O -
-pyrimidin-5-yl O -
] O -
- O -
( O -
3R,51S O -
) O -
- O +
dihydroxy O -
- O -
hept-6-enoic O +
acid O -
] O +
of O +
the O +
formula O +
( O -
I O -
) O +
salts O +
formed O +
with O +
bivalent O +
cations O -
, O +
preferably O +
with O +
calcium O +
or O +
zinc O +
ions O -
, O +
characterized O +
in O +
that O +
rosuvastatin O +
tert O -
.- O -
butylammonium O +
salt O +
is O +
reacted O +
with O +
the O +
appropriate O +
bivalent O +
cation O -
, O +
preferably O +
with O +
calcium O +
or O +
zinc O +
ions O +
in O +
a O +
mixture O +
of O +
a O +
water O +
immiscible O +
or O +
slightly O +
miscible O +
organic O +
solvent O +
and O +
water O +
and O +
the O +
formed O +
salt O +
is O +
isolated O -
. O +

Novel O +
metabolic O +
disease O +
therapy O +
The O +
invention O +
relates O +
to O +
the O +
prevention O +
and O +
treatment O +
of O +
metabolic O +
abnormalities O +
characterized O +
by O +
abnormal O +
glucose O +
metabolism O -
, O +
including O +
diabetes O +
mellitus O +
and O +
new O +
onset O +
diabetes O +
mellitus O +
through O +
the O +
use O +
of O +
fibroblast B-Gene +
activation I-Gene +
protein I-Gene +
( O -
FAP B-Gene -
) O +
selective O +
inhibitors O -
. O +

Bumetanide O -
, O +
furosemide O -
, O +
piretanide O -
, O +
azosemide O -
, O +
and O +
torsemide O +
analogs O -
, O +
compositions O +
and O +
methods O +
of O +
use O +
The O +
present O +
invention O +
provides O +
bumetanide O -
, O +
furosemide O -
, O +
piretanide O -
, O +
azosemide O -
, O +
and O +
torsemide O +
analogs O +
and O +
compositions O +
comprising O +
such O +
analogs O -
. O +

The O +
present O +
invention O +
also O +
provides O +
pharmaceutical O +
compositions O +
containing O +
these O +
bumetanide O -
, O +
furosemide O -
, O +
piretanide O -
, O +
azosemide O -
, O +
and O +
torsemide O +
analogs O +
and O +
methods O +
for O +
their O +
use O -
. O +

All O +
of O +
these O +
analogs O +
are O +
particularly O +
useful O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
conditions O +
that O +
involve O +
the O +
Na+K+Cl- B-Gene +
co I-Gene -
- I-Gene -
transporter I-Gene +
or O +
GABAA B-Gene +
receptor I-Gene +
including O +
but O +
not O +
limited O +
to O +
addictive O +
disorders O -
, O +
Alzheimer O -
's O +
Disease O -
, O +
anxiety O +
disorders O -
, O +
ascites O -
, O +
autism O -
, O +
bipolar O +
disorder O -
, O +
cancer O -
, O +
depression O -
, O +
endothelial O +
corneal O +
dystrophy O -
, O +
edema O -
, O +
epilepsy O -
, O +
glaucoma O -
, O +
Huntington O -
's O +
Disease O -
, O +
insomnia O -
, O +
ischemia O -
, O +
migraine O -
, O +
migraine O +
with O +
aura O -
, O +
neuropathic O +
pain O -
, O +
nociceptive O +
neuralgia O -
, O +
nociceptive O +
pain O -
, O +
ocular O +
diseases O -
, O +
pain O -
, O +
Parkinson O -
's O +
disease O -
, O +
personality O +
disorders O -
, O +
postherpetic O +
neuralgia O -
, O +
psychosis O -
, O +
schizophrenia O -
, O +
seizure O +
disorders O -
, O +
tinnitus O -
, O +
and O +
withdrawal O +
syndromes O -
. O +

C-7 O +
isoxazolinyl O +
quinolone O -
/ O -
naphthyridine O +
derivatives O +
useful O +
as O +
antibacterial O +
agents O +
The O +
present O +
invention O +
relates O +
to O +
C-7 O +
isoxazolyl O +
quinoline O -
/ O -
naphthyridine O +
derivatives O +
useful O +
as O +
antimicrobial O +
compounds O -
, O +
pharmaceutical O +
compositions O +
comprising O +
said O +
derivatives O +
and O +
the O +
use O +
of O +
said O +
derivatives O +
and O +
pharmaceutical O +
compositions O +
as O +
antimicrobial O +
agents O +
against O +
pathogenic O +
microorganisms O -
, O +
particularly O +
against O +
resistant O +
microbes O -
. O +

Method O +
for O +
facilitating O +
extinction O +
training O +
using O +
d O -
- O -
cycloserine O +
Methods O +
are O +
disclosed O +
for O +
improving O +
treatment O +
of O +
various O +
medical O +
conditions O +
via O +
administration O +
of O +
D O -
- O -
cycloserine O +
to O +
facilitate O +
learning O -
. O +

Specifically O -
, O +
by O +
administering O +
D- O +
cycloserine O +
to O +
a O +
patient O +
at O +
a O +
time O +
that O +
is O +
both O +
subsequent O +
to O +
extinction O +
training O +
during O +
the O +
day O +
and O +
within O +
two O +
hours O +
prior O +
to O +
the O +
patient O -
's O +
initial O +
nightly O +
sleep O +
period O +
following O +
the O +
extinction O +
training O -
, O +
the O +
known O +
ability O +
of O +
D O -
- O -
cycloserine O +
to O +
facilitate O +
extinction O +
learning O +
can O +
be O +
enhanced O -
. O +

Therapeutic O +
uses O +
of O +
mastic O +
gum O +
fractions O +
The O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
and O +
formulations O +
comprising O +
polymeric O +
myrcene O -
. O +

More O +
particularly O -
, O +
the O +
invention O +
relates O +
to O +
compositions O +
comprising O +
an O +
isolated O +
fraction O +
of O +
polymeric O +
myrcene O +
in O +
a O +
hydrophobic O +
carrier O +
and O +
formulations O +
which O +
maintain O +
the O +
biological O +
activity O +
of O +
the O +
active O +
polymer O -
. O +

2-indolyl O +
imidazo O +
[ O -
4,5-d O -
] O -
phenanthroline O +
derivatives O +
and O +
their O +
use O +
to O +
inhibit O +
angiogenesis O +
2-Indolyl O +
imidazo O -
[ O -
4,5-d O -
] O -
phenanthroline O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
that O +
are O +
capable O +
of O +
inhibiting O +
angiogenesis O +
are O +
provided O +
Methods O +
of O +
inhibiting O +
angiogenesis O +
using O +
compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
as O +
well O +
as O +
methods O +
and O +
uses O +
of O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
in O +
the O +
treatment O +
of O +
angiogenesis O -
- O -
associated O +
diseases O +
and O +
disorders O +
such O +
as O +
cancer O -
, O +
age- O +
related O +
macular O +
degeneration O +
( O -
AMD O -
) O -
, O +
diabetic O +
retinopathy O +
and O +
retinal O +
vein O +
occlusion O +
are O +
also O +
provided O -
. O +

2 O -
, O +
5-disubstituted O +
tetrazole O +
derivatives O +
and O +
their O +
use O +
as O +
nicotinic B-Gene +
acetylcholine I-Gene +
receptor I-Gene +
modulators O +
This O +
invention O +
relates O +
to O +
novel O +
tetrazole O +
derivatives O +
of O +
formula O +
( O -
I O -
) O -
, O +
which O +
are O +
found O +
to O +
be O +
modulators O +
of O +
the O +
nicotinic B-Gene +
acetylcholine I-Gene +
receptors I-Gene -
. O +

Due O +
to O +
their O +
pharmacological O +
profile O +
the O +
compounds O +
of O +
the O +
invention O +
may O +
be O +
useful O +
for O +
the O +
treatment O +
of O +
diseases O +
or O +
disorders O +
as O +
diverse O +
as O +
those O +
related O +
to O +
the O +
cholinergic O +
system O +
of O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
, O +
the O +
peripheral O +
nervous O +
system O +
( O -
PNS O -
) O -
, O +
diseases O +
or O +
disorders O +
related O +
to O +
smooth O +
muscle O +
contraction O -
, O +
endocrine O +
diseases O +
or O +
disorders O -
, O +
diseases O +
or O +
disorders O +
related O +
to O +
neuro- O +
degeneration O -
, O +
diseases O +
or O +
disorders O +
related O +
to O +
inflammation O -
, O +
pain O -
, O +
and O +
withdrawal O +
symptoms O +
caused O +
by O +
the O +
termination O +
of O +
abuse O +
of O +
chemical O +
substances O -
. O +

A O +
novel O +
medical O +
use O +
of O +
kynurenic O +
acid O -
, O +
its O +
precursors O +
and O +
derivatives O +
The O +
invention O +
relates O +
to O +
the O +
use O +
of O +
kynurenic O +
acid O +
derivatives O +
of O +
general O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R1 O +
is O +
hydroxy O -
, O +
NHR2 O -
, O +
NR2R2 O +
or O +
C1 O -
- O -
10 O +
straight O +
or O +
branched O +
alkoxy O +
or O +
glyceryl O +
group O -
; O +
R2 O +
is O +
hydrogen O +
atom O +
or O +
C1 O -
- O -
10 O +
straight O +
or O +
branched O +
alkyl O +
group O -
; O +
R3-R6 O +
are O +
independently O +
of O +
each O +
other O +
hydrogen O +
atom O -
, O +
halogen O +
atom O -
, O +
C1 O -
- O -
10 O +
alkyl O -
, O +
C2 O -
- O -
10 O +
alkenyl O +
or O +
alkynyl O +
group O +
optionally O +
substituted O +
with O +
a O +
halogen O +
atom O -
, O +
and O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
ester O +
or O +
amide O +
thereof O +
in O +
manufacturing O +
of O +
a O +
drug O +
used O +
in O +
prevention O +
and O +
therapy O +
of O +
pancreas O +
disorders O +
characterized O +
by O +
edema O +
and/or O +
vacuolization O +
and/or O +
destruction O +
of O +
pancreatic O +
tissue O +
and/or O +
pancreas O +
necrosis O +
leading O +
to O +
release O +
of O +
pancreatic O +
Î± O -
- O -
amylase O -
. O +

Prefereably O -
, O +
in O +
the O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
R1 O +
is O +
a O +
hydroxy O -
, O +
NH2 O -
, O +
NH- O -
( O -
C1 O -
- O -
5 O +
straight O +
or O +
branched O +
alkyl O -
) O +
or O +
C1 O -
- O -
5 O +
straight O +
or O +
branched- O +
alkoxy O +
or O +
glyceryl O +
group O -
; O +
R2 O +
is O +
a O +
hydrogen O +
atom O -
; O +
R3-R6 O +
are O +
independently O +
of O +
each O +
other O +
a O +
hydrogen O +
atom O -
, O +
halogen O +
atom O +
or O +
CF3 O +
group O -
. O +

In O +
the O +
most O +
preferred O +
embodiment O -
, O +
the O +
invention O +
concerns O +
the O +
use O +
of O +
kynurenic O +
acid O +
or O +
its O +
pharmaceutically O +
acceptable O +
salt O +
in O +
manufacturing O +
of O +
a O +
drug O +
used O +
in O +
prevention O +
and O +
therapy O +
of O +
pancreas O +
disorders O +
characterized O +
by O +
edema O +
and/or O +
vacuolization O +
and/or O +
destruction O +
of O +
pancreatic O +
tissue O +
and/or O +
pancreas O +
necrosis O +
leading O +
to O +
release O +
of O +
pancreatic B-Gene +
Î± I-Gene -
- I-Gene -
amylase I-Gene -
. O +

Benzoxazoles O +
for O +
the O +
treatment O +
of O +
duchenne O +
muscular O +
dystrophy O +
Compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
X O +
and O +
n O +
are O +
as O +
defined O +
herein O -
, O +
are O +
useful O +
for O +
the O +
treatment O +
or O +
prophylaxis O +
of O +
conditions O +
such O +
as O +
Duchenne O +
muscular O +
dystrophy O -
, O +
Becker O +
muscular O +
dystrophy O -
, O +
and O +
cachexia O -
. O +

Process O +
for O +
the O +
preparation O +
of O +
1- O -
[ O -
[ O -
[ O -
3- O -
[ O -
2- O -
( O -
dimethylamino O -
) O -
ethyl O -
] O -
-1h O -
- O -
indol-5-yl O -
] O -
methyl O -
] O -
sulfonyl O -
] O +
pyrrolidine O +
and O +
its O +
pharmaceutically O +
acceptable O +
salts O +
A O +
process O +
for O +
preparation O +
of O +
1- O -
[ O -
[ O -
[ O -
3- O -
[ O -
2- O -
( O -
dimethylamino O -
) O -
ethyl O -
] O -
-1H O -
- O -
indol-5-yl O -
] O -
methyl O -
] O -
sulfonyl O -
] O -
pyrrolidine O +
of O +
Formula O +
( O -
1 O -
) O -
, O +
which O +
is O +
commonly O +
known O +
as O +
Almotriptan O -
, O +
and O +
its O +
pharmaceutically O +
acceptable O +
salts O +
is O +
provided O -
. O +

The O +
required O +
purity O +
of O +
almotriptan O +
malate O +
free O +
of O +
impurities O +
is O +
attained O +
in O +
three O +
different O +
ways O -
, O +
including O +
by O +
preparing O +
the O +
acid O +
addition O +
salts O +
of O +
amino O +
indole O +
compound O -
, O +
by O +
proceeding O +
through O +
the O +
almotriptan O +
succinate O +
and O +
by O +
specific O +
purification O +
of O +
almotriptan O +
malate O +
from O +
a O +
suitable O +
solvent O -
. O +

Tumor O -
- O -
specific O +
promoter O +
and O +
use O +
thereof O +
As O +
a O +
tumor O -
- O -
specific O +
promoter O -
, O +
a O +
polynucleotide O +
is O +
used O +
which O +
comprises O +
the O +
nucleotide O +
sequence O +
depicted O +
in O +
SEQ O +
ID O +
NO:1 O +
or O +
a O +
nucleotide O +
sequence O +
capable O +
of O +
hybridizing O +
to O +
a O +
nucleotide O +
sequence O +
complementary O +
to O +
the O +
nucleotide O +
sequence O +
depicted O +
in O +
SEQ O +
ID O +
NO:1 O +
under O +
stringent O +
conditions O +
and O +
which O +
has O +
a O +
tumor O -
- O -
specific O +
promoter O +
activity O -
. O +

Stable O +
pharmaceutical O +
compositions O +
with O +
high O +
bioavailability O +
The O +
present O +
invention O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
a O +
strontium O +
compound O +
alone O +
or O +
in O +
combination O +
with O +
vitamin O +
D O +
which O +
is O +
used O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
diseases O +
and O +
conditions O +
associated O +
with O +
abnormal O +
bone O +
resorption O +
and/or O +
effective O +
as O +
a O +
supplement O -
. O +

Preparation O +
for O +
external O +
use O +
Provided O +
is O +
a O +
new O +
external O +
preparation O +
of O +
a O +
tertiary O +
amine O +
compound O +
that O +
exhibits O +
a O +
CXCR4-antagonizing O +
action O -
, O +
said O +
preparation O +
being O +
a O +
nonaqueous O +
preparation O +
containing O +
a O +
tertiary O +
amine O +
compound O +
indicated O +
by O +
general O +
formula O +
( O -
1 O -
) O -
, O +
in O +
solution O +
in O +
a O +
fatty O +
acid O +
ionic O +
liquid O -
. O +

( O -
1 O -
) O +
( O -
In O +
general O +
formula O +
( O -
1 O -
) O -
, O +
R1 O +
through O +
R6 O +
each O +
independently O +
represent O +
either O +
a O +
hydrogen O +
atom O +
or O +
a O +
C1â€“4 O +
lower O +
alkyl O +
group O -
; O +
n O +
1 O +
through O +
n O +
3 O +
are O +
integers O +
from O +
1 O +
to O +
4 O -
, O +
inclusive O -
; O +
A1 O +
and O +
A2 O +
represent O +
substituted O +
or O +
unsubstituted O +
heteroaromatic O +
ring O +
groups O -
; O +
W O +
represents O +
a O +
substituted O +
or O +
unsubstituted O +
phenylene O +
group O -
; O +
X O +
represents O +
an O +
N- O -
( O -
carboxymethyl O -
) O -
methylene O +
group O -
; O +
and O +
D O +
represents O +
a O +
C1â€“5 O +
lower O +
alkylene O +
group O +
substituted O +
with O +
a O +
secondary O +
amino O +
group O +
having O +
a O +
C1â€“4 O +
lower O +
alkyl O +
group O -
. O -
) O +

Fused O +
pyrrolopyridine O +
derivative O +
Disclosed O +
is O +
a O +
fused O +
pyrrolopyridine O +
derivative O +
which O +
is O +
useful O +
as O +
an O +
active O +
ingredient O +
for O +
a O +
pharmaceutical O +
composition O -
, O +
in O +
particular O +
a O +
pharmaceutical O +
composition O +
for O +
prevention O +
or O +
treatment O +
of O +
diseases O +
that O +
are O +
caused O +
by O +
undesirable O +
cytokine O +
signaling O +
or O +
diseases O +
that O +
are O +
caused O +
by O +
abnormal O +
cytokine O +
signaling O -
. O +

The O +
inventors O +
have O +
intensively O +
studied O +
on O +
compounds O +
having O +
JAK B-Gene +
inhibitory O +
activity O -
, O +
and O +
found O +
that O +
the O +
compound O +
of O +
the O +
present O +
invention O -
, O +
namely O +
a O +
fused O +
pyrrolopyridine O +
derivative O +
has O +
excellent O +
JAK B-Gene +
inhibitory O +
activity O +
and O +
is O +
thus O +
useful O +
as O +
an O +
agent O +
for O +
prevention O +
or O +
treatment O +
of O +
diseases O +
that O +
are O +
caused O +
by O +
undesirable O +
cytokine O +
signaling O +
or O +
diseases O +
that O +
are O +
caused O +
by O +
abnormal O +
cytokine O +
signaling O -
. O +

Treatment O +
of O +
non O -
- O -
localized O +
inflammation O +
with O +
pan O -
- O -
hdac B-Gene +
inhibitors O +
Described O +
herein O +
are O +
compositions O +
and O +
methods O +
for O +
treating O +
a O +
subject O +
suffering O +
from O +
a O +
non O -
- O -
localized O +
inflammatory O +
condition O +
( O -
or O +
any O +
symptoms O +
associated O +
with O +
such O +
inflammation O -
) O -
, O +
including O +
systemic O +
inflammation O -
, O +
and O +
inflammatory O +
conditions O +
affecting O +
the O +
large O +
portions O +
of O +
or O +
the O +
whole O +
body O -
, O +
or O +
sepsis O +
by O +
administering O +
to O +
the O +
subject O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
that O +
is O +
a O +
pan O -
- O -
HDAC B-Gene +
inhibitor O -
. O +

Also O +
described O +
herein O +
are O +
methods O +
for O +
decreasing O +
iNOS B-Gene +
and O +
cytokine B-Gene +
expression O +
by O +
administering O +
to O +
the O +
subject O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
that O +
is O +
a O +
pan O -
- O -
HDAC B-Gene +
inhibitor O -
. O +

Sulfonamide O +
compounds O -
, O +
pharmaceutical O +
compositions O +
and O +
uses O +
thereof O +
Compounds O +
are O +
provided O +
according O +
to O +
formula O +
( O -
1 O -
) O -
, O +
wherein O +
W O -
, O +
X O -
, O +
Z O -
, O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
and O +
ml O +
are O +
as O +
defined O +
herein O -
. O +

Provided O +
compounds O +
and O +
pharmaceutical O +
compositions O +
thereof O +
are O +
useful O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
a O +
variety O +
of O +
conditions O +
in O +
mammals O +
including O +
humans O -
, O +
including O +
by O +
way O +
of O +
non- O +
limiting O +
example O -
, O +
pain O -
, O +
inflammation O -
, O +
cognitive O +
disorders O -
, O +
anxiety O -
, O +
depression O -
, O +
and O +
others O -
. O +

Provided O +
compounds O +
and O +
pharmaceutical O +
compositions O +
thereof O +
are O +
also O +
useful O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
a O +
variety O +
of O +
conditions O +
in O +
mammals O +
including O +
humans O -
, O +
including O +
by O +
way O +
of O +
non- O +
limiting O +
example O +
immune O -
- O -
mediated O +
disorders O +
and O +
autoimmune O +
diseases O -
, O +
including O +
multiple O +
sclerosis O -
, O +
type-1 O +
diabetes O +
mellitus O -
, O +
type-2 O +
diabetes O +
mellitus O -
, O +
rheumatoid O +
arthritis O -
, O +
psoriasis O -
, O +
contact O +
dermatitis O -
, O +
obesity O -
, O +
systemic O +
lupus O +
erythematosus O -
, O +
graft O -
- O -
versus O +
host O +
disease O -
, O +
transplant O +
rejection O -
, O +
and O +
others O -
. O +

Anti O -
- O -
hyperglycemic O +
and/or O +
anti O -
- O -
hyperlipidemic O +
agent O +
comprising O +
material O +
containing O +
avian O +
skin O -
- O -
derived O +
sphingomyelin O +
as O +
active O +
ingredient O +
Disclosed O +
is O +
a O +
sphingomyelin O -
- O -
containing O +
material O +
which O +
can O +
be O +
produced O +
in O +
a O +
large O +
quantity O +
at O +
low O +
cost O -
. O +

Also O +
disclosed O +
is O +
an O +
useful O +
use O +
application O +
of O +
a O +
sphingomyelin O -
- O -
containing O +
material O -
. O +

Specifically O +
disclosed O +
is O +
an O +
anti O -
- O -
hyperglycemic O +
and/or O +
anti O -
- O -
hyperlipidemic O +
agent O +
comprising O +
a O +
material O +
containing O +
a O +
sphingomyelin O +
derived O +
from O +
an O +
avain O +
skin O +
as O +
an O +
active O +
ingredient O -
. O +

SUBSTITUTED O +
IMIDAZO O -
[ O -
1,5-a O -
] O -
QUINOXALINES O +
AS O +
INHIBITORS O +
OF O +
PHOSPHODIESTERASE B-Gene +
10 I-Gene +
The O +
invention O +
relates O +
to O +
imidazo O -
[ O -
1,5-a O -
] O -
quinoxaline O +
derivatives O +
which O +
are O +
inhibitors O +
of O +
phosphodiesterase B-Gene +
10 I-Gene +
( O -
PDE10 B-Gene -
) O +
useful O +
in O +
treating O +
central O +
nervous O +
system O +
diseases O +
such O +
as O +
psychosis O +
and O +
also O +
in O +
treating O -
, O +
for O +
example O -
, O +
obesity O -
, O +
type O +
2 O +
diabetes O -
, O +
metabolic O +
syndrome O -
, O +
glucose O +
intolerance O -
, O +
and O +
pain O -
. O +

A O +
novel O +
4-methylbenzenesulphonate O +
salt O +
and O +
a O +
process O +
for O +
preparing O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
salt O +
The O +
invention O +
provides O +
a O +
4-methylbenzenesulphonate O +
salt O +
of O +
the O +
muscarinic O +
antagonist O +
( O -
R O -
) O -
- O +
1- O -
( O -
4-fluorophenethyl O -
) O -
-3- O -
( O -
( O -
S O -
) O -
-2-phenyl-2- O -
( O -
piperidin-1 O +
-yl O -
) O -
propanoyloxy O -
) O -
-1- O +
azoniabicyclo O -
[ O -
2.2.2 O -
] O -
octane O +
and O +
its O +
use O +
in O +
therapy O -
, O -
as O +
well O +
as O +
a O +
process O +
for O +
preparing O +
a O +
pharmaceutical O +
composition O +
comprising O +
the O +
salt O +
and O +
its O +
use O +
in O +
therapy O -
. O +

Liquiritigenin O +
derivatives O -
, O +
preparation O +
methods O +
and O +
uses O +
thereof O +
Liquiritigenin O +
derivatives O -
, O +
preparation O +
methods O +
and O +
uses O +
thereof O +
are O +
disclosed O -
. O +

More O +
specifically O -
, O +
the O +
compounds O +
of O +
formula O +
I O -
, O +
isomers O -
, O +
racemates O -
, O +
enantiomers O -
, O +
diastereomers O -
, O +
enantiomer O +
enrichments O -
, O +
solvates O -
, O +
prodrugs O -
, O +
and O +
esters O +
thereof O +
are O +
disclosed O -
, O +
in O +
which O +
n O +
is O +
0 O +
or O +
1 O -
, O +
R1 O +
is O +
C3 O -
- O -
8 O +
cycloalkyl O +
and O +
R2 O +
is O +
H. O +
The O +
preparation O +
methods O +
for O +
the O +
compounds O +
of O +
formula O +
I O -
, O +

the O +
pharmaceutical O +
compositions O +
comprising O +
the O +
compounds O +
of O +
formula O +
I O -
, O +
and O +
the O +
uses O +
of O +
the O +
compounds O +
of O +
formula O +
I O +
in O +
the O +
manufacture O +
of O +
medicaments O +
for O +
treating O +
and/or O +
preventing O +
cerebral O +
ischemic O +
diseases O -
, O +
neurodegenerative O +
diseases O +
and O +
inflammatory O +
diseases O +
are O +
also O +
disclosed O -
. O +

Conjugates O +
of O +
anticancer O +
chemotherapeutic O +
agent O -
- O -
chlorine O +
derivatives O -
, O +
photosensitizer O +
containing O +
same O +
and O +
composition O +
for O +
treating O +
cancer O +
containing O +
same O +
The O +
present O +
invention O +
relates O +
to O +
conjugates O +
of O +
anticancer O +
chemotherapeutic O +
agent O -
- O -
chlorine O +
derivatives O -
, O +
photosensitizer O +
containing O +
the O +
same O +
and O +
composition O +
for O +
treating O +
cancer O +
containing O +
the O +
same O -
. O +

The O +
conjugates O -
, O +
photosensitizer O +
and O +
composition O +
suppress O +
cancer O +
cell O +
proliferation O +
and O +
enables O +
photodynamic O +
therapy O +
at O +
the O +
same O +
time O +
by O +
conjugating O +
chlorine O +
derivatives O +
with O +
photodynamic O +
activity O +
and O +
an O +
anticancer O +
chemotherapeutic O +
agent O +
with O +
activity O +
of O +
suppressing O +
cell O +
proliferation O -
, O +
as O +
well O +
as O +
being O +
useful O +
in O +
cancer O +
therapy O +
by O +
reducing O +
the O +
toxicity O +
of O +
anticancer O +
chemotherapeutic O +
agent O +
and O +
avoiding O +
chemotherapeutic O +
agent O -
- O -
resistance O -
. O +

Luteinising O +
hormone O +
releasing O +
hormone O +
antagonist O +
with O +
hydantoin O +
structure O +
A O +
decapeptide O +
derivative O +
of O +
formula O +
( O -
I O -
) O +
possessing O +
hydantoin O +
structure O -
, O +
a O +
preparation O +
method O +
thereof O -
, O +
a O +
pharmaceutical O +
composition O +
containing O +
said O +
decapeptide O +
derivative O +
and O +
applications O +
thereof O +
in O +
preparing O +
medications O +
are O +
provided O -
. O +

The O +
decapeptide O +
derivative O +
is O +
a O +
luteinising O +
hormone O +
releasing O +
hormone O +
( O -
LHRH O -
) O +
antagonist O -
, O +
having O +
LHRH O +
receptor O +
antagonist O +
activity O +
and O +
inhibiting O +
pituitary O +
gonadotropin O +
secretion O +
and O +
steroid O +
hormone O +
secretion O +
of O +
sexual O +
glands O -
. O +

Formula O +
( O -
I O -
) O -
, O +
R O -
- O -
Xaa3-Ser O -
- O -
Xaa5- O +
Xaa6- O +
Xaa7- O +
Xaa8-Pro O -
- O -
D O -
- O -
Ala O -
- O -
B O +

CREATINE O +
Î² O -
- O -
ALANINATE O -
: O +
A O +
NOVEL O +
SALT O +
FOR O +
INCREASING O +
ATHLETIC O +
PERFORMANCE O +
Disclosed O +
are O +
creatine O +
Î² O -
- O -
alaninate O -
, O +
compositions O +
and O +
formulations O +
containing O +
same O -
, O +
and O +
methods O +
of O +
use O +
therefor O -
. O +

Aromatic O +
fused O +
heterocyclic O +
derivative O +
and O +
pharmaceutical O +
composition O +
containing O +
same O +
Disclosed O +
is O +
a O +
compound O +
having O +
an O +
activity O +
of O +
modulating O +
a O +
histamine B-Gene -
- I-Gene -
H4 I-Gene +
receptor I-Gene -
. O +

Specifically O +
disclosed O +
is O +
a O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
[ O -
wherein O +
Ra O +
and O +
Rb O +
independently O +
represent O +
a O +
hydrogen O +
atom O -
, O +
a O +
substituted O +
or O +
unsubstituted O +
alkyl O +
group O -
, O +
or O +
the O +
like O -
; O +
X O +
represents O +
-O- O +
or O +
-S O -
( O -
O O -
) O -
p- O -
; O +
p O +
represents O +
an O +
integer O +
of O +
0 O +
to O +
2 O -
; O +
Y O +
represents O +
= O -
O O +
or O +
= O -
S O -
; O +
R1 O +
represents O +
a O +
halogen O +
atom O -
, O +
a O +
substituted O +
or O +
unsubstituted O +
alkyl O +
group O -
, O +
or O +
the O +
like O -
; O +
n O +
represents O +
an O +
integer O +
of O +
0 O +
to O +
4 O -
; O +
and O +
R2 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
a O +
substituted O +
or O +
unsubstituted O +
alkyl O +
group O -
, O +
or O +
the O +
like O -
] O -
, O +
a O +
pharmaceutically O +
acceptable O +
salt O +
of O +
the O +
compound O -
, O +
or O +
a O +
solvate O +
of O +
the O +
compound O +
or O +
the O +
pharmaceutically O +
acceptable O +
salt O -
. O +

Inhibitors O +
of O +
kshv B-Gene +
vil6 I-Gene +
and O +
human B-Gene +
il6 I-Gene +
The O +
invention O +
features O +
compositions O +
comprising O +
microRNAs O +
that O +
are O +
capable O +
of O +
repressing O +
vIL6 B-Gene +
or O +
hIL6 B-Gene -
, O +
and O +
related O +
methods O +
of O +
using O +
the O +
microRNAs O +
for O +
treating O +
Kaposi O -
's O +
sarcoma- O +
associated O +
herpes O +
virus O +
( O -
KSHV O -
) O +
infections O +
or O +
diseases O +
caused O +
by O +
KSHV O -
. O +

Pharmaceutical O +
compositions O +
comprising O +
bi-1356 O +
and O +
metformin O +
The O +
present O +
invention O +
relates O +
to O +
therapeutic O +
uses O +
of O +
pharmaceutical O +
compositions O +
or O +
combinations O +
of O +
a O +
DPP-4 O +
inhibitor O +
with O +
metformin O -
. O +

Use O +
of O +
flubendazole O +
and O +
vinca O +
alkaloids O +
for O +
treatment O +
of O +
hematological O +
diseases O +
Provided O +
are O +
methods O +
for O +
treating O +
a O +
hematological O +
malignancy O +
comprising O +
administering O +
an O +
effective O +
amount O +
of O +
flubendazole O +
alone O +
or O +
in O +
combination O +
with O +
a O +
vinca O +
alkaloid O -
. O +

Also O +
provided O +
are O +
compositions O +
and O +
kits O +
comprising O +
an O +
effective O +
amount O +
of O +
flubendazole O +
and/or O +
a O +
vinca O +
alkaloid O +
for O +
use O +
in O +
the O +
methods O +
of O +
the O +
disclosure O -
. O +

Process O +
for O +
preparation O +
of O +
propargylated O +
aminoindans O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
A O +
process O +
for O +
preparation O +
of O +
propargylated O +
aminoindans O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
comprises O -
: O +
a O -
) O +
reacting O +
an O +
indanone O +
derivative O +
or O +
a O +
salt O +
thereof O +
with O +
propargyl O +
amine O +
or O +
a O +
salt O +
thereof O +
in O +
the O +
presence O +
of O +
a O +
Lewis O +
acid O -
; O +
b O -
) O +
subjecting O +
the O +
resultant O +
reaction O +
mixture O +
to O +
reduction O -
. O +

Thiadiazolidinedioxide O +
p2x7 B-Gene +
receptor I-Gene +
antagonists O +
The O +
invention O +
provides O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
wherein O -
: O +
R1 O +
is O +
C1 O -
- O -
3alkyl O +
or O +
C1fluoroalkyl O -
- O -
CH2 O -
; O +
R2 O +
is O +
hydrogen O -
, O +
C1 O -
- O -
4alkyl O -
, O +
C1fluoroalkyl O -
- O -
CH2- O -
, O +
C3 O -
- O -
6cycloalkyl O -
, O +
C3 O -
- O -
6cycloalkyl O -
- O -
methyl- O -
, O +
optionally O +
substituted O +
benzyl O -
, O +
or O +
optionally O +
substituted O +
heteroaryl- O -
( O -
CH2 O -
) O -
n- O -
, O +
wherein O +
n O +
is O +
0 O +
or O +
1 O -
, O +
wherein O +
in O +
R2 O +
the O +
benzyl O +
is O +
optionally O +
substituted O +
on O +
the O +
ring O +
with O +
one O +
or O +
two O +
substituents O +
independently O +
being O +
methyl O -
, O +
methoxy O -
, O +
fluorine O +
or O +
chlorine O -
, O +
and O +
wherein O +
in O +
R2 O +
the O +
heteroaryl- O -
( O -
CH2 O -
) O -
n- O +
optionally O +
substituted O +
on O +
the O +
heteroaryl O +
ring O +
with O +
one O +
or O +
two O +
substituents O +
independently O +
being O +
C1 O -
- O -
3alkyl O -
, O +
CF3 O -
, O +
methoxy O -
, O +
a O +
halogen O +
atom O -
, O +
or O +
cyano O -
; O +
and O +
wherein O -
: O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O +
and O +
R7 O +
independently O +
are O +
hydrogen O -
, O +
a O +
halogen O +
atom O -
, O +
C1 O -
- O -
4alkyl O -
, O +
trifluoromethyl O -
, O +
or O +
cyano O -
, O +
such O +
that O +
one O +
or O +
both O +
of O +
R3 O +
and O +
R7 O +
is O +
or O +
are O +
a O +
group O +
other O +
than O +
hydrogen O -
. O +

Anti O -
- O -
inflammatory O +
extract O +
The O +
present O +
invention O +
provides O +
anti O -
- O -
inflammatory O +
extracts O +
derived O +
from O +
plants O +
of O +
the O +
Dodonaeoideae O +
subfamily O -
. O +

The O +
present O +
invention O +
also O +
provides O +
a O +
method O +
for O +
preparing O +
an O +
anti O -
- O -
inflammatory O +
extracts O -
. O +

Other O +
aspects O +
of O +
the O +
present O +
invention O +
also O +
relate O +
to O +
pharmaceutical O +
compositions O +
comprising O +
anti O -
- O -
inflammatory O +
extracts O +
and O +
methods O +
of O +
treating O +
or O +
preventing O +
inflammation O +
in O +
a O +
subject O -
. O +

Novel O +
antithrombotic O +
agents O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
derivatives O +
of O +
the O +
general O +
formula O +
( O -
I O -
) O -
, O +
their O +
tautomeric O +
forms O -
, O +
their O +
stereoisomers O -
, O +
their O +
pharmaceutically O +
acceptable O +
salts O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O -
, O +
methods O +
for O +
their O +
preparation O -
, O +
use O +
of O +
these O +
compounds O +
in O +
medicine O +
and O +
the O +
intermediates O +
involved O +
in O +
their O +
preparation O -
. O +

Novel O +
inositol O +
phosphate O +
derivatives O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
the O +
formula O +
( O -
I O -
) O +
wherein O +
R1,R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O +
and O +
R6 O -
, O +
X O +
and O +
n O +
are O +
as O +
defined O +
herein O -
. O +

Preferred O +
compounds O +
are O +
inositol O +
phosphate O +
derivatives O +
wherein O +
R1 O +
is O +
a O +
substituted O +
or O +
unsubstituted O +
phenyl O +
and O +
at O +
least O +
one O +
of O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O +
and O +
R6 O +
is O +
PO3 O +
2- O +
Alternative O +
compounds O +
are O +
inositol O +
phosphate O +
derivatives O +
of O +
the O +
formula O +
( O -
I O -
) O +
wherein O +
R1 O +
is O +
a O +
fiuorophore O +
moiety O +
The O +
compounds O +
are O +
useful O +
alone O +
or O +
in O +
combination O +
with O +
known O +
therapeutic O +
agents O +
for O +
the O +
treatment O +
of O +
diseases O -
, O +
especially O +
cancer O -
. O +

Use O +
of O +
alpha O +
2 O +
adrenergic O +
receptor O +
agonists O +
for O +
treating O +
or O +
preventing O +
psoriasis O +
Methods O +
and O +
kits O +
for O +
treating O +
or O +
preventing O +
psoriasis O +
or O +
a O +
symptom O +
associated O +
with O +
psoriasis O +
in O +
a O +
subject O +
are O +
described O -
. O +

The O +
methods O +
involve O +
topical O +
applications O +
to O +
the O +
subject O +
a O +
therapeutically O +
effective O +
amount O +
of O +
an O +
Î±2 O +
adrenergic O +
receptor O +
agonist O -
, O +
such O +
as O +
brimonidine O -
. O +

Compositions O +
containing O +
salmeterol O -
, O +
fluticasone O +
and O +
cromoglicic O +
acid O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
cromoglicic O +
acid O +
and/or O +
nedocromil O +
salts O +
in O +
pharmaceutically O +
effective O +
amounts O +
in O +
a O +
pharmaceutical O +
composition O +
containing O +
salmeterol O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
as O +
a O +
Î²2-agonisti O +
combined O +
with O +
fluticasone O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
as O +
a O +
corticosteroid O +
for O +
the O +
treatment O +
of O +
the O +
respiratory O +
diseases O -
. O +

Compounds O +
which O +
effecttively O +
remove O +
tumor O +
or O +
cancer O +
cell O +
Compounds O +
which O +
effectively O +
remove O +
tumor O +
or O +
cancer O +
cell O +
and O +
their O +
use O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
tumor O +
or O +
cancer O +
by O +
making O +
immune O +
system O +
find O +
tumor O +
or O +
cancer O +
cell O +
are O +
provided O -
. O +

In O +
detail O -
, O +
by O +
immune O +
identifier O +
of O +
tumor O +
or O +
cancer O +
cell O +
the O +
immune O +
system O +
of O +
organism O +
can O +
find O +
and O +
remove O +
them O +
in O +
time O -
. O +

The O +
substances O +
used O +
for O +
immune O +
identifier O +
are O +
organic O +
molecules O +
( O -
including O +
organometallic O +
compounds O -
) O +
which O +
are O +
adhered O +
to O +
on O +
the O +
surface O +
of O +
the O +
cell O -
. O +

These O +
organic O +
molecules O +
are O +
linked O +
with O +
sugar O +
molecule O -
. O +

Docosahexaenoic O +
acid O +
ethyl O +
esters O +
and/or O +
its O +
derivatives O +
for O +
prevention O +
and/or O +
treatment O +
of O +
age O -
- O -
related O +
macular O +
degeneration O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
containing O +
DHA O +
ethyl O +
esters O +
with O +
over O +
80 O -
% O +
by O +
weight O +
purity O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
age O +
related O +
macular O +
degeneration O -
, O +
that O +
uses O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O +
( O -
PPARÆ´ O -
) O +
as O +
target O -
. O +

Controlled O +
( O -
sustained O -
) O +
release O +
preparation O +
containing O +
quetiapine O +
and O +
preparation O +
method O +
and O +
use O +
thereof O +
The O +
present O +
invention O +
discloses O +
a O +
controlled O +
( O -
sustained O -
) O +
release O +
preparation O +
and O +
preparation O +
method O +
as O +
well O +
as O +
the O +
use O +
thereof O -
. O +

Said O +
preparation O +
contains O +
quetiapine O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
, O +
5 O -
- O -
50 O -
% O +
of O +
polyoxyethylene O +
in O +
amount O +
of O +
total O +
weight O +
of O +
said O +
controlled O +
( O -
sustained O -
) O +
release O +
preparation O -
, O +
and O +
remaining O +
amount O +
of O +
pharmaceutically O +
acceptable O +
excipients O -
. O +

Method O +
of O +
accelerating O +
corneal O +
wound O +
healing O +
The O +
topical O +
ophthalmic O +
use O +
of O +
5,6,7-trihydroxyheptanoic O +
acid O +
and O +
analogs O +
for O +
the O +
acceleration O +
of O +
corneal O +
wound O +
healing O +
in O +
humans O -
, O +
is O +
disclosed O -
. O +

Pharmaceutical O +
compositions O +
containing O +
berberine O +
for O +
treatment O +
or O +
prevention O +
of O +
weight O +
gain O +
and O +
obesity O +
associated O +
with O +
anti O -
- O -
psychotic O +
drugs O +
The O +
compositions O +
and O +
methods O +
disclosed O +
herein O +
are O +
of O +
use O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
weight O +
gain O +
and O +
obesity O -
. O +

In O +
particular O -
, O +
the O +
compositions O +
and O +
methods O +
include O +
treatment O +
of O +
weight O +
gain O +
and O +
obesity O +
with O +
berberine O +
and/or O +
berberine O +
analogs O +
alone O +
or O +
in O +
combination O +
thereof O +
to O +
cause O +
a O +
reduction O +
in O +
an O +
individual O -
's O +
weight O +
or O +
prevent O +
weight O +
gain O +
or O +
obesity O -
. O +

In O +
certain O +
embodiments O -
, O +
the O +
weight O +
gain O +
and O +
obesity O +
are O +
associated O +
with O +
administration O +
of O +
anti O -
- O -
psychotic O +
drugs O -
. O +

In O +
an O +
alternative O +
embodiment O -
, O +
the O +
compositions O +
and O +
methods O +
provide O +
berberine O +
or O +
berberine O +
analogs O +
alone O +
or O +
for O +
coadministration O +
with O +
an O +
anti O -
- O -
psychotic O +
agent O -
. O +

In O +
an O +
additional O +
embodiment O -
, O +
the O +
compositions O +
and O +
methods O +
further O +
include O +
a O +
natural O +
product O -
. O +

The O +
usefulness O +
of O +
the O +
present O +
invention O +
is O +
that O +
berberine O +
and O +
berberine O +
analogs O +
do O +
not O +
have O +
synergistic O +
effects O +
with O +
other O +
drugs O +
and O +
administration O +
results O +
in O +
few O +
side O +
effects O -
. O +

Such O +
characteristics O +
of O +
berberine O +
or O +
berberine O +
analogs O +
are O +
a O +
great O +
improvement O +
able O +
to O +
support O +
the O +
widespread O +
use O +
of O +
the O +
compositions O +
and O +
methods O +
of O +
the O +
present O +
invention O +
as O +
therapeutics O +
for O +
the O +
treatment O +
and O +
prevention O +
of O +
weight O +
gain O +
and O +
obesity O -
. O +

Macrolide O +
inhibitors O +
of O +
mtor B-Gene +
The O +
present O +
invention O +
relates O +
to O +
new O +
macrolide O +
inhibitors O +
of O +
mTOR B-Gene -
, O +
pharmaceutical O +
compositions O +
thereof O -
, O +
and O +
methods O +
of O +
use O +
thereof O +
( O -
Formula O +
I O -
) O -
. O +

Perifosine O +
and O +
capecitabine O +
as O +
a O +
combined O +
treatment O +
for O +
cancer O +
Treatment O +
regimens O +
comprising O +
co O -
- O -
treatment O +
of O +
cancer O +
with O +
perifosine O +
and O +
capecitabine O +
are O +
disclosed O +
herein O -
, O +
as O +
well O +
as O +
pharmaceutical O +
compositions O +
and O +
unit O +
dosage O +
forms O +
thereof O +
formulated O +
to O +
be O +
suitable O +
for O +
use O +
in O +
said O +
treatment O +
regimens O -
. O +

Heterocyclic O +
compounds O +
and O +
their O +
use O +
as O +
pi3k B-Gene +
inhibitors O +
Substituted O +
bicyclic O +
heteroaryls O +
and O +
compositions O +
containing O +
them O -
, O +
for O +
the O +
treatment O +
of O +
general O +
inflammation O -
, O +
arthritis O -
, O +
rheumatic O +
diseases O -
, O +
osteoarthritis O -
, O +
inflammatory O +
bowel O +
disorders O -
, O +
inflammatory O +
eye O +
disorders O -
, O +
inflammatory O +
or O +
unstable O +
bladder O +
disorders O -
, O +
psoriasis O -
, O +
skin O +
complaints O +
with O +
inflammatory O +
components O -
, O +
chronic O +
inflammatory O +
conditions O -
, O +
including O +
but O +
not O +
restricted O +
to O +
autoimmune O +
diseases O +
such O +
as O +
systemic O +
lupus O +
erythematosis O +
( O -
SLE O -
) O -
, O +
myestenia O +
gravis O -
, O +
rheumatoid O +
arthritis O -
, O +
acute O +
disseminated O +
encephalomyelitis O -
, O +
idiopathic O +
thrombocytopenic O +
purpura O -
, O +
multiples O +
sclerosis O -
, O +
Sjoegren O -
's O +
syndrome O +
and O +
autoimmune O +
hemolytic O +
anemia O -
, O +
allergic O +
conditions O +
including O +
all O +
forms O +
of O +
hypersensitivity O -
, O +
The O +
present O +
invention O +
also O +
enables O +
methods O +
for O +
treating O +
cancers O +
that O +
are O +
mediated O -
, O +
dependent O +
on O +
or O +
associated O +
with O +
p110 B-Gene +
activity O -
, O +
including O +
but O +
not O +
restricted O +
to O +
leukemias O -
, O +
such O +
as O +
Acute O +
Myeloid O +
leukaemia O +
( O -
AML O -
) O +
Myelo O -
- O -
dysplastic O +
syndrome O +
( O -
MDS O -
) O +
myelo O -
- O -
proliferative O +
diseases O +
( O -
MPD O -
) O +
Chronic O +
Myeloid O +
Leukemia O +
( O -
CML O -
) O +
T O -
- O -
cell O +
Acute O +
Lymphoblastic O +
leukaemia O +
( O +
T O -
- O -
ALL O -
) O +
B O -
- O -
cell O +
Acute O +
Lymphoblastic O +
leukaemia O +
( O -
B O -
- O -
ALL O -
) O +
Non O +
Hodgkins O +
Lymphoma O +
( O -
NHL O -
) O +
B O -
- O -
cell O +
lymphoma O +
and O +
solid O +
tumors O -
, O +
such O +
as O +
breast O +
cancer O -
. O +

Fully O +
openable O +
multifunction O +
drawer O +
for O +
household O +
appliances O +
The O +
present O +
invention O +
describes O +
a O +
washing O +
machine O +
( O -
1 O -
) O +
comprising O +
an O +
external O +
chassis O +
( O -
11 O -
) O -
, O +
on O +
the O +
front O +
panel O +
( O -
12 O -
) O +
of O +
which O +
are O +
accessible O +
at O +
least O +
one O +
aperture O +
( O -
13 O -
) O -
, O +
equipped O +
with O +
a O +
door O +
( O -
14 O -
) O -
, O +
for O +
the O +
loading O +
and/or O +
unloading O +
of O +
garments O +
into O +
or O +
from O +
the O +
rotary O +
drum O +
inside O +
said O +
chassis O +
( O -
11 O -
) O -
, O +
a O +
soap O +
dispenser O +
( O -
2 O -
) O +
of O +
washing O +
agents O +
assembled O +
on O +
the O +
slidable O +
drawer O +
support O +
structure O +
( O -
21 O -
) O +
able O +
to O +
additionally O +
contain O -
, O +
adjacent O +
to O +
compartments O +
( O -
22 O -
; O +
221 O -
, O +
222 O -
, O +
223 O -
, O +
224 O -
) O -
, O +
one O +
or O +
more O +
receptacles O +
( O -
23 O -
) O -
, O +
able O +
to O +
contain O +
and O +
house O +
various O +
types O +
of O +
useful O +
objects O +
and O +
accessories O -
, O +
and O +
a O +
control O +
panel O +
( O -
26 O -
; O +
261 O -
, O +
262 O -
) O -
. O +

Microsomal O +
prostaglandin B-Gene +
e I-Gene +
syntase-1 I-Gene +
inhibitors O +
This O +
invention O +
relates O +
to O +
piperidine O +
derivatives O -
, O +
to O +
processes O +
for O +
their O +
preparation O -
, O +
to O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
to O +
their O +
use O +
in O +
medicine O -
. O +

Aromatic O +
butan-2-ol O +
compounds O -
, O +
preparation O +
methods O +
and O +
uses O +
thereof O +
Provided O +
are O +
compounds O +
shown O +
by O +
formula O +
I O -
, O +
optical O +
isomers O -
, O +
racemes O -
, O +
diastereoisomers O -
, O +
pharmaceutically O +
acceptable O +
salts O +
or O +
solvates O +
thereof O -
, O +
wherein O +
each O +
substituent O +
has O +
the O +
meaning O +
as O +
defined O +
in O +
the O +
specification O -
. O +

Also O +
provided O +
are O +
their O +
preparation O +
methods O -
, O +
pharmaceutical O +
compositions O +
containing O +
them O +
and O +
uses O +
of O +
said O +
compounds O +
for O +
preparation O +
of O +
drugs O +
useful O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
diseases O +
or O +
disorders O +
caused O +
by O +
the O +
infection O +
of O +
mycobacterium O +
tuberculosis O -
. O +

Cycloamino O +
derivatives O +
as O +
gpr119 B-Gene +
agonists O +
Therapeutic O +
compounds O +
are O +
disclosed O +
having O +
the O +
general O +
formula O +
( O -
I O -
) O +
that O +
are O +
useful O +
for O +
the O +
treatment O +
of O +
metabolic O +
disorders O -
, O +
including O +
type O +
II O +
diabetes O -
. O +

The O +
compounds O +
have O +
activity O +
as O +
agonists O +
of O +
GPR119 B-Gene -
. O +

Compounds O +
having O +
the O +
stereochemistry O +
of O +
formula O +
( O -
la O -
) O +
may O +
also O +
demonstrate O +
DPP B-Gene -
- I-Gene -
IV I-Gene +
inhibitory O +
activity O -
. O +

SUBSTITUTED O +
THIAZOLIDINEDIONE O +
INDAZOLES O -
, O +
INDOLES O +
AND O +
BENZOTRIAZOLES O +
AS O +
ESTROGEN O -
- O -
RELATED O +
RECEPTOR O -
- O -
Î± O +
MODULATORS O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
methods O +
for O +
preparing O +
these O +
compounds O -
, O +
compositions O -
, O +
intermediates O +
and O +
derivatives O +
thereof O +
and O +
for O +
treating O +
a O +
condition O +
including O +
but O +
not O +
limited O +
to O +
ankylosing O +
spondylitis O -
, O +
artherosclerosis O -
, O +
arthritis O +
( O -
such O +
as O +
rheumatoid O +
arthritis O -
, O +
infectious O +
arthritis O -
, O +
childhood O +
arthritis O -
, O +
psoriatic O +
arthritis O -
, O +
reactive O +
arthritis O -
) O -
, O +
bone O -
- O -
related O +
diseases O +
( O -
including O +
those O +
related O +
to O +
bone O +
formation O -
) O -
, O +
breast O +
cancer O +
( O -
including O +
those O +
unresponsive O +
to O +
anti O -
- O -
estrogen O +
therapy O -
) O -
, O +
cardiovascular O +
disorders O -
, O +
cartilage O -
- O -
related O +
disease O +
( O -
such O +
as O +
cartilage O +
injury O -
/ O -
loss O -
, O +
cartilage O +
degeneration O -
, O +
and O +
those O +
related O +
to O +
cartilage O +
formation O -
) O -
, O +
chondrodysplasia O -
, O +
chondrosarcoma O -
, O +
chronic O +
back O +
injury O -
, O +
chronic O +
bronchitis O -
, O +
chronic O +
inflammatory O +
airway O +
disease O -
, O +
chronic O +
obstructive O +
pulmonary O +
disease O -
, O +
diabetes O -
, O +
disorders O +
of O +
energy O +
homeostasis O -
, O +
gout O -
, O +
pseudogout O -
, O +
lipid O +
disorders O -
, O +
metabolic O +
syndrome O -
, O +
multiple O +
myeloma O -
, O +
obesity O -
, O +
osteoarthritis O -
, O +
osteogenesis O +
imperfecta O -
, O +
osteolytic O +
bone O +
metastasis O -
, O +
osteomalacia O -
, O +
osteoporosis O -
, O +
Paget O -
's O +
disease O -
, O +
periodontal O +
disease O -
, O +
polymyalgia O +
rheumatica O -
, O +
Reiter O -
's O +
syndrome O -
, O +
repetitive O +
stress O +
injury O -
, O +
hyperglycemia O -
, O +
elevated O +
blood O +
glucose O +
level O -
, O +
and O +
insulin O +
resistance O -
. O +

Xenon O -
- O -
based O +
inhalable O +
drug O +
for O +
preventing O +
addiction O +
relapses O +
in O +
humans O +
The O +
invention O +
relates O +
to O +
a O +
gas O +
composition O +
containing O +
xenon O +
gas O +
for O +
use O +
in O +
preventing O +
the O +
relapse O +
of O +
a O +
patient O +
who O +
has O +
been O +
weaned O +
from O +
at O +
least O +
one O +
psychotropic O +
product O +
which O +
resulted O +
in O +
said O +
patient O +
becoming O +
habituated O -
, O +
the O +
xenon O +
being O +
administered O +
to O +
the O +
patient O +
by O +
inhalation O -
. O +

The O +
composition O +
of O +
the O +
invention O +
contains O +
an O +
effective O +
volume O +
proportion O +
of O +
xenon O -
, O +
in O +
particular O +
from O +
5 O +
to O +
70 O -
% O +
by O +
volume O +
of O +
xenon O -
. O +

DRAWING O -
: O +
FIG O -
. O +

5 O -
: O +
Nombres O +
de O +
pression O +
sur O +
le O +
levier O -
/ O -
session O +
Number O +
of O +
presses O +
on O +
the O +
lever O -
/ O -
session O +
Levier O +
respectif O +
inactif O +
Respective O +
inactive O +
lever O +
rechute O +
relapse O +

A O +
role O +
for O +
somatostatin O +
to O +
modulate O +
initiation O +
of O +
follicular O +
growth O +
in O +
the O +
human O +
ovary O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
of O +
treating O +
and/or O +
preventing O +
gynecological O +
diseases O -
, O +
by O +
modulating O +
a O +
receptor O +
which O +
is O +
specifically O +
and O +
highly O +
expressed O +
in O +
granulosa O +
cells O +
and O +
oocytes O +
of O +
primates O -
. O +

6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone O -
- O -
based O +
composition O +
and O +
method O +
for O +
the O +
production O +
thereof O +
The O +
invention O +
relates O +
to O +
the O +
pharmaceutical O +
industry O -
, O +
and O +
specifically O +
to O +
a O +
composition O +
based O +
on O +
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone O +
( O -
ubinone O -
, O +
ubiquinone O -
, O +
coenzyme O +
Q10 O -
) O +
in O +
liquid O +
form O -
, O +
which O +
can O +
be O +
used O +
for O +
the O +
prophylaxis O +
and O +
treatment O +
of O +
various O +
illnesses O -
, O +
for O +
restoring O +
fitness O +
for O +
work O -
, O +
and O +
also O +
as O +
a O +
food O +
additive O -
. O +

In O +
addition O +
to O +
the O +
active O +
substance O -
, O +
the O +
composition O +
comprises O +
a O +
nonionic O +
surface O -
- O -
active O +
substance O -
, O +
an O +
antioxidant O -
, O +
a O +
preservative O -
, O +
a O +
fat O -
- O -
soluble O +
emulsion O +
stabilizer O -
, O +
water O -
- O -
soluble O +
cellulose O +
derivatives O -
, O +
a O +
water O -
- O -
soluble O +
emulsion O +
stabilizer O +
and O +
water O -
. O +

The O +
composition O +
is O +
characterized O +
by O +
high O +
bioaccessibility O +
and O +
an O +
extended O +
storage O +
life O -
. O +

The O +
method O +
for O +
producing O +
the O +
composition O +
consists O +
in O +
that O +
the O +
nonionic O +
surface O -
- O -
active O +
substance O +
and O +
the O +
antioxidant O +
are O +
mixed O +
and O +
heated O +
to O +
40 O -
- O -
120 O -
Â° O -
C O -
, O +
the O +
fat O -
- O -
soluble O +
emulsion O +
stabilizer O +
and O +
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone O +
are O +
dissolved O +
in O +
the O +
solution O +
produced O -
, O +
the O +
resultant O +
mixture O +
is O +
cooled O +
to O +
30 O -
- O -
60 O -
Â° O -
Ð¡ O +
and O +
poured O +
under O +
intensive O +
stirring O +
into O +
a O +
mixed O +
solution O -
, O +
preheated O +
to O +
30 O -
- O -
100 O -
Â° O -
Ð¡ O -
, O +
of O +
the O +
water O -
- O -
soluble O +
cellulose O +
derivatives O -
, O +
water O -
- O -
soluble O +
emulsion O +
stabilizer O +
and O +
preservative O +
in O +
water O -
. O +

6- O -
( O -
sulfonylaryl O -
) O -
pyrido O -
[ O -
2,3-d O -
] O -
pyrimidin-7 O -
( O -
8h O -
) O -
-ones O +
for O +
the O +
treatment O +
of O +
cns O +
disorders O +
Provided O +
herein O +
are O +
PAK B-Gene +
inhibitors O +
and O +
methods O +
of O +
utilizing O +
PAK B-Gene +
inhibitors O +
for O +
the O +
treatment O +
of O +
CNS O +
disorders O +
such O +
as O +
neuropsychiatric O +
disoders O -
. O +

Anti O -
- O -
wssv O +
and/or O +
tsv O +
nucleic O +
acid O +
drug O +
An O +
anti O -
- O -
WSSV O +
and/or O +
TSV O +
nucleic O +
acid O +
drug O -
, O +
the O +
active O +
ingredients O +
of O +
which O +
are O +
five O +
nucleic O +
acids O +
whose O +
nucleotide O +
sequences O +
are O +
respectively O +
sequence O +
1 O -
, O +
sequence O +
2 O -
, O +
sequence O +
3 O -
, O +
sequence O +
4 O +
and O +
sequence O +
5 O +
in O +
the O +
sequence O +
list O -
. O +

Amids O +
substituted O +
indazole O +
derivativees O +
as O +
ploy B-Gene -
( I-Gene -
adp I-Gene -
- I-Gene -
ribose I-Gene -
) I-Gene -
polymerase I-Gene +
inhibitors O +
Amide O +
substituted O +
indazoles O +
and O +
benzotriazoles O +
as O +
inhibitors O +
of O +
the O +
enzyme O +
poly B-Gene -
( I-Gene -
ADP I-Gene -
- I-Gene -
ribose I-Gene -
) I-Gene -
polymerase I-Gene -
( O -
PARP B-Gene -
) O -
. O +

The O +
compounds O +
of O +
the O +
present O +
invention O +
are O +
useful O +
as O +
mono O -
- O -
therapies O +
in O +
tumors O +
with O +
specific O +
defects O +
in O +
DNA O -
- O -
repair O +
pathways O -
, O +
as O +
enhancers O +
of O +
certain O +
DNA O -
- O -
damaging O +
agents O +
such O +
as O +
anticancer O +
agents O +
and O +
radiotherapy O -
, O +
for O +
reducing O +
cell O +
necrosis O +
( O -
in O +
stroke O +
and O +
myocardial O +
infarction O -
) O -
, O +
regulating O +
inflammation O +
and O +
tissue O +
injury O -
, O +
treating O +
retroviral O +
infections O -
, O +
and O +
protecting O +
against O +
the O +
toxicity O +
of O +
chemotherapy O -
. O +

Nitrogenated O +
aromatic O +
heterocyclic O +
ring O +
derivative O +
A O +
nitrogenated O +
aromatic O +
heterocyclic O +
ring O +
derivative O +
represented O +
by O +
formula O +
( O -
I O -
) O +
[ O -
wherein O +
R1 O +
and O +
R2 O +
independently O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
; O +
W O +
represents O +
CR3 O +
( O -
wherein O +
R3 O +
represents O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
) O +
or O +
the O +
like O -
; O +
R4 O +
and O +
R5 O +
independently O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
; O +
R9 O +
represents O +
a O +
pyrazolyl O +
group O +
which O +
may O +
have O +
a O +
substituent O -
, O +
or O +
the O +
like O -
; O +
and O +
R12 O +
and O +
R13 O +
independently O +
represent O +
a O +
hydrogen O +
atom O +
or O +
the O +
like O -
] O +
( O -
wherein O +
N- O -
[ O -
2-chloro-4- O -
( O -
6,7-dimethoxy-4- O +
quinolyloxy O -
) O -
phenyl O -
] O -
-N'- O -
( O -
5-methyl-3-isooxazolyl O -
) O -
urea O +
is O +
excluded O +
from O +
the O +
derivative O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
; O +
and O +
a O +
FGFR B-Gene +
inhibitor O +
or O +
the O +
like O +
which O +
comprises O +
the O +
derivative O +
or O +
the O +
pharmaceutically O +
acceptable O +
salt O +
as O +
an O +
active O +
ingredient O -
. O +

Polydeoxyribonucleotides O +
( O -
pdrns O -
) O +
for O +
use O +
in O +
the O +
treatment O +
of O +
metabolic O +
and/or O +
lactic O +
acidosis O +
and O +
polydeoxyribonucleotide O -
- O -
based O +
compositions O +
for O +
the O +
aforesaid O +
use O +
The O +
use O +
of O +
polydeoxyribonucleotides O +
( O -
PDRNs O -
) O +
in O +
the O +
treatment O +
of O +
metabolic O +
and/or O +
lactic O +
acidosis O +
conditions O +
is O +
described O -
. O +

Compositions O +
comprising O +
the O +
synergistic O +
combination O +
of O +
polydeoxyribonucleotides O +
and O +
one O +
methyl O +
amide O -
, O +
such O +
as O +
carnitine O -
, O +
are O +
also O +
described O -
, O +
which O +
are O +
particularly O +
effective O +
in O +
the O +
treatment O +
of O +
metabolic O +
and/or O +
lactic O +
acidosis O +
conditions O -
. O +

The O +
compositions O +
of O +
the O +
invention O +
may O +
include O +
further O +
optional O +
active O +
ingredients O -
, O +
such O +
as O +
a O +
calcium O +
salt O -
, O +
vitamins O +
of O +
the O +
D O +
or O +
B O +
groups O -
, O +
a O +
sodium O +
salt O +
and O +
a O +
potassium O +
salt O -
, O +
preferably O +
used O +
in O +
combination O -
. O +

Novel O +
polymorph O +
of O +
bis O -
[ O -
( O -
e O -
) O -
-7- O -
[ O -
4- O -
( O -
4-fluorophenyl O -
) O -
-6-iso O -
- O -
propyl-2- O -
[ O -
methyl O +
( O -
methylsulfonyl O -
) O -
amino O -
] O -
pyrimidin-5-yl O -
] O -
( O -
3r,5s O -
) O -
-3,5-dihydroxyhept-6-enoic O +
acid O -
] O +
calcium O +
salt O +
Disclosed O +
are O +
novel O +
polymorphic O +
forms O +
of O +
bis O -
[ O -
( O -
E O -
) O -
-7- O -
[ O -
4- O -
( O -
4-fluorophenyl O -
) O -
-6-iso O -
- O -
propyl-2- O -
[ O -
methyl O -
( O -
methylsulfonyl O -
) O -
amino O -
] O -
pyrimidin-5-yl O -
] O +
( O -
3R,5S O -
) O -
-3,5-dihydroxyhept-6-enoic O +
acid O -
] O +
calcium O -
. O +

Composition O +
suppressing O +
matrix B-Gene -
- I-Gene -
metalloproteinase I-Gene +
activity O +
The O +
purpose O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O +
a O +
composition O +
that O +
has O +
the O +
effect O +
of O +
suppressing O +
matrix B-Gene -
- I-Gene -
metalloproteinase I-Gene +
activity O -
. O +

Specifically O -
, O +
the O +
present O +
invention O +
pertains O +
to O +
a O +
composition O +
which O +
suppresses O +
matrix B-Gene -
- I-Gene -
metalloproteinase I-Gene +
activity O +
and O +
contains O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
glucose O -
- O -
metabolism O +
inhibitor O -
. O +

Novel O +
antibiotically O +
active O +
compound O +
and O +
an O +
antibiotic O +
composition O +
comprising O +
the O +
compound O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
antibiotically O +
active O +
compound O +
and O +
to O +
an O +
antibiotic O +
composition O +
comprising O +
the O +
compound O -
, O +
and O +
more O +
specifically O +
relates O +
to O +
a O +
compound O +
that O +
inhibits O +
microorganism O +
protein O +
synthesis O +
and O +
to O +
a O +
use O +
for O +
the O +
compound O -
. O +

Atorbastatin O -
- O -
containing O +
medicinal O +
tablet O +
Provided O +
is O +
a O +
medicinal O +
tablet O -
, O +
particularly O +
an O +
orally O +
disintegrating O +
tablet O -
, O +
in O +
which O +
unpleasant O +
taste O +
of O +
atorbastatin O +
in O +
the O +
oral O +
cavity O +
is O +
reduced O +
( O -
drug O +
compliance O -
) O -
, O +
and O +
which O +
can O +
be O +
dispersed O +
or O +
eluted O +
rapidly O +
in O +
the O +
digestive O +
tract O -
. O +

This O +
medicinal O +
tablet O +
comprises O +
atorbastatin O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and O +
glycyrrhetinic O +
acid O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Isoxazol-3 O -
( O -
2h O -
) O -
-one O +
analogs O +
as O +
plasminogen B-Gene +
inhibitors O +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
fibrinolysis O +
related O +
diseases O +
A O +
compound O +
of O +
formula O +
( O -
I O -
) O -
: O +
wherein O +
R1 O +
is O +
hydrogen O -
; O +
R2 O +
is O +
C1-C10 O +
alkyl O -
, O +
which O +
C1-C10 O +
alkyl O +
comprises O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O +
heteroatoms O -
, O +
selected O +
from O +
O O +
and O +
N O -
, O +
or O +
0 O -
, O +
1 O +
or O +
2 O +
acid O -
, O +
ester O +
or O +
amide O +
functionalities O -
, O +
and O +
said O +
C1-C10 O +
alkyl O +
is O +
substituted O +
by O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O +
CH3 O -
, O +
halogen O +
or O +
CF3 O -
, O +
or O +
-XR20 O -
, O +
wherein O +
X O +
is O +
a O +
bond O +
or O +
_ O -
-CH2- O -
, O +
and O +
R20 O +
is O +
a O +
4 O +
to O +
10 O +
membered O -
, O +
monocyclic O +
or O +
bicyclic O +
heterocyclic O +
aromatic O +
or O +
non O -
- O -
aromatic O +
ring O +
containing O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O +
heteroatoms O +
selected O +
from O +
O O +
and O +
N O -
, O +
and O +
R20 O +
is O +
substituted O +
by O +
0 O -
, O +
1 O -
, O +
2 O -
, O +
3 O +
or O +
4 O +
CH3 O -
, O +
halogen O +
or O +
CF3 O -
, O +
pharmaceutical O +
compositions O -
, O +
medical O +
uses O +
and O +
treatment O +
or O +
prophylaxis O +
of O +
a O +
disease O +
or O +
condition O +
in O +
which O +
modulation O +
of O +
fibrinolysisis O +
is O +
beneficial O -
. O +

Phosphatidylcholine O +
in O +
the O +
treatment O +
ophosphatidylcholinef O +
tumours O +
The O +
present O +
invention O +
regards O +
the O +
use O +
of O +
phosphatidylcholine O +
in O +
the O +
treatment O +
of O +
tumoral O +
pathologies O -
. O +

In O +
particular O -
, O +
the O +
phosphatidylcholine O +
according O +
to O +
the O +
present O +
invention O +
is O +
polyunsaturated O +
phosphatidylcholine O -
. O +

The O +
phosphatidylcholine O +
suitable O +
for O +
the O +
invention O +
can O +
be O +
obtained O +
by O +
extraction O +
from O +
egg O -
- O -
yolk O +
or O +
from O +
soybean O +
seeds O -
. O +

The O +
tumoral O +
pathologies O +
that O +
can O +
be O +
treated O +
according O +
to O +
the O +
invention O +
are O +
in O +
particular O +
hepatoma O +
and O +
mammary O +
tumour O -
. O +

Novel O +
esters O +
of O +
( O -
acyloxymethyl O -
) O -
acrylamide O -
, O +
a O +
pharmaceutical O +
composition O +
containing O +
them O -
, O +
and O +
their O +
use O +
as O +
inhibitors O +
of O +
the O +
thioredoxin O +
- O +
thioredoxin B-Gene +
reductase I-Gene +
system O +
The O +
subject O +
of O +
the O +
present O +
invention O +
are O +
novel O +
esters O +
of O +
( O -
acyloxymethyl O -
) O -
acrylamide O -
, O +
a O +
pharmaceutical O +
composition O +
containing O +
them O +
and O +
their O +
use O +
in O +
the O +
production O +
of O +
drugs O +
for O +
the O +
prophylaxis O +
or O +
treatment O +
of O +
oncogenic O +
diseases O +
and O +
diseases O +
connected O +
with O +
increased O +
cell O +
proliferation O -
. O +

Agent O +
for O +
inducing O +
endogenous O +
interferon O +
The O +
invention O +
relates O +
to O +
medicine O +
and O +
can O +
be O +
used O +
for O +
treating O +
a O +
range O +
of O +
diseases O +
in O +
the O +
treatment O +
of O +
which O +
interferon O +
is O +
used O -
. O +

The O +
agent O +
for O +
inducing O +
endogenous O +
interferon O +
is O +
comprised O +
of O +
the O +
compound O +
6- O -
( O -
3-methoxycarbonyl O +
phenyl O -
) O +
amino-2,4 O -
( O -
1Ð O -
, O +
Ð—Ð O -
) O -
-pyrimidinedione O +
C12H11N3Ðž4 O +
of O +
general O +
formula O -
: O +
( O -
I O -
) O -
. O +

The O +
preparation O +
exhibits O +
greater O +
activity O +
both O +
when O +
injected O +
and O +
when O +
administered O +
orally O -
. O +

Intraesophageal O +
administration O +
of O +
targeted O +
nitroxide O +
agents O +
for O +
protection O +
against O +
ionizing O +
irradiation O -
- O -
induced O +
esophagatis O +
Provided O +
herein O +
are O +
compositions O +
and O +
related O +
methods O +
useful O +
for O +
prevention O +
or O +
mitigation O +
of O +
ionizing O +
radiation O -
- O -
induced O +
esophagitis O -
. O +

The O +
compositions O +
comprise O +
compounds O +
comprising O +
a O +
nitroxide O -
- O -
containing O +
group O +
attached O +
to O +
a O +
mitochondria O -
- O -
targeting O +
group O -
. O +

The O +
compounds O +
can O +
be O +
cross O -
- O -
linked O +
into O +
dimers O +
without O +
loss O +
of O +
activity O -
. O +

The O +
method O +
comprises O +
delivering O +
a O +
compound O -
, O +
as O +
described O +
herein O -
, O +
to O +
a O +
patient O +
in O +
an O +
amount O +
and O +
dosage O +
regimen O +
effective O +
to O +
prevent O +
or O +
mitigate O +
esophageal O +
damage O +
caused O +
by O +
radiation O -
. O +

Therapeutic O +
compositions O +
comprising O +
rilpivirine O +
hcl O +
and O +
tenofovir O +
disoproxil O +
fumarate O +
The O +
invention O +
provides O +
multilayer O +
tablets O +
that O +
contain O +
rilpivirine O +
hydrochloride O -
, O +
emtricitabine O -
, O +
and O +
tenofivir O +
disoproxil O +
fumarate O -
. O +

The O +
tablets O +
are O +
useful O +
for O +
the O +
treatment O +
of O +
HIV O -
. O +

Composition O +
and O +
use O +
of O +
a O +
fermented O +
olive O +
leaf O +
product O +
for O +
the O +
treatment O +
of O +
nail O +
and O +
skin O +
infections O -
. O +

The O +
invention O +
relates O +
to O +
a O +
composition O +
for O +
the O +
treatment O +
of O +
nail O +
infections O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
use O +
of O +
olive O +
leaf O +
product O -
, O +
and O +
oleuropein O +
and O +
derivatives O +
thereof O -
, O +
for O +
the O +
preparation O +
of O +
a O +
product O +
for O +
the O +
treatment O +
of O +
infections O -
, O +
in O +
particular O +
nail O +
infections O -
, O +
more O +
in O +
particular O +
bacterial O +
and/or O +
fungal O +
nail O +
infections O -
. O +

The O +
compositions O +
according O +
to O +
the O +
invention O +
are O +
based O +
on O +
natural O +
products O +
and O +
have O +
a O +
lower O +
chance O +
to O +
induce O +
allergies O +
in O +
users O +
than O +
conventional O +
products O -
. O +

Antifungal O +
composition O +
including O +
polycyclic O +
peptide O +
compound O +
and O +
method O +
for O +
producing O +
same O +
The O +
present O +
invention O +
provides O +
an O +
antifungal O +
composition O +
including O +
as O +
an O +
active O +
ingredient O +
a O +
AN1542 O +
strain O +
( O -
accession O +
number O -
: O +
KCTC O +
12113BP O -
) O +
in O +
a O +
Streptomyces O +
sp. O +
having O +
antifungal O +
activity O -
, O +
an O +
antifungal O +
composition O +
including O +
a O +
compound O +
represented O +
by O +
Formula O +
1 O +
or O +
Formula O +
2 O +
or O +
a O +
strain O +
producing O +
same O +
as O +
an O +
active O +
ingredient O -
, O +
and O +
a O +
method O +
for O +
preparing O +
the O +
compound O -
. O +

The O +
compound O +
or O +
the O +
strain O +
of O +
the O +
present O +
invention O +
exhibits O +
strong O +
antifungal O +
activity O +
to O +
pathogenic O +
microorganisms O +
and O +
antibiotics O -
- O -
tolerant O +
bacteria O -
, O +
and O +
in O +
particular O -
, O +
can O +
be O +
useful O +
in O +
treating O +
contagious O +
diseases O +
due O +
to O +
super O +
bacteria O +
by O +
exhibiting O +
strong O +
antifungal O +
activity O +
to O +
MRSA O -
, O +
QRSA O -
, O +
VRSA O -
, O +
and O +
VRE O -
. O +

Pyrazole O +
derivatives O +
as O +
erk B-Gene +
inhibitors O +
This O +
invention O +
describes O +
substituted O +
pyrazole O +
derivatives O +
of O +
Formula O +
I O -
, O +
and O +
methods O +
of O +
making O +
and O +
using O +
the O +
compounds O -
. O +

These O +
compounds O +
have O +
utility O +
in O +
the O +
treatment O +
of O +
conditions O +
or O +
diseases O +
in O +
which O +
modification O +
of O +
the O +
activity O +
of O +
ERK B-Gene +
would O +
have O +
a O +
positive O +
therapeutic O +
outcome O -
, O +
for O +
instance O +
various O +
cancers O -
, O +
psoriasis O +
and O +
actinic O +
keratosis O -
. O +

Therapeutic O +
eye O +
drop O +
comprising O +
doxycycline O +
and O +
a O +
stabilizer O +
The O +
present O +
invention O +
provides O +
stable O +
aqueous O +
doxycycline O +
aqueous O +
solutions O +
suitable O +
for O +
pharmaceutical O -
, O +
especially O +
ophthalmic O -
, O +
use O -
. O +

The O +
doxycycline O +
aqueous O +
solutions O +
have O +
a O +
pH O +
ranging O +
from O +
4.5 O -
- O -
8 O -
, O +
and O +
contain O +
an O +
antioxidant O +
and O +
a O +
stabilizer O +
such O +
as O +
caffeine O -
, O +
creatine O +
or O +
mixtures O +
thereof O -
. O +

The O +
solutions O +
have O +
improved O +
lifetimes O +
and O +
can O +
be O +
used O +
topically O -
. O +

Dextrin O +
inclusion O +
complex O -
, O +
preparation O +
method O +
thereof O +
and O +
pharmaceutical O +
formulation O +
comprising O +
said O +
inclusion O +
complex O +
A O +
dextrin O +
inclusion O +
complex O +
of O +
total O +
ginsenoside O +
and O +
total O +
flavone O +
of O +
epimedium O +
and O +
the O +
preparation O +
method O +
thereof O +
are O +
disclosed O -
. O +

A O +
pharmaceutical O +
formulation O +
comprising O +
the O +
dextrin O +
inclusion O +
complex O +
and O +
the O +
use O +
of O +
the O +
dextrin O +
inclusion O +
complex O +
in O +
preparing O +
a O +
pharmaceutical O +
formulation O +
are O +
also O +
disclosed O -
. O +

Fucoidan O +
for O +
thrombolysis O -
, O +
derived O +
from O +
seaweed O +
To O +
study O +
different O +
types O +
of O +
thrombolytic O +
agents O -
, O +
both O +
thrombolysis O +
and O +
stimulation O +
of O +
fucoidan O +
were O +
studied O +
in O +
a O +
mouse O +
model O +
of O +
ferric O +
chloride O -
- O -
induced O +
arterial O +
thrombosis O +
and O +
were O +
compared O +
with O +
those O +
of O +
a O +
heparin O +
and O +
tissue B-Gene +
plasminogen I-Gene +
activator I-Gene +
( O -
t B-Gene -
- I-Gene -
PA I-Gene -
) O -
. O +

Thrombosis O +
was O +
induced O +
by O +
applying O +
a O +
filter O +
paper O +
saturated O +
with O +
5 O -
% O +
FeCl3 O +
to O +
the O +
left O +
carotid O +
artery O -
. O +

20 O +
minutes O +
after O +
complete O +
occlusion O -
, O +
several O +
test O +
preparations O +
including O +
a O +
fucoidan O +
source O +
from O +
Undaria O +
pinnatifida O +
sporophylls O +
were O +
intravenously O +
injected O +
to O +
each O +
mouse O +
group O +
by O +
various O +
dosages O +
of O +
10 O -
- O -
200 O +
mg O -
/ O -
kg-1 O -
. O +

To O +
study O +
the O +
stimulation O +
effect O +
of O +
fucoidan O +
with O +
respect O +
to O +
t B-Gene -
- I-Gene -
PA I-Gene -
, O +
fucoidan O +
added O +
in O +
a O +
predetermined O +
amount O +
of O +
t B-Gene -
- I-Gene -
PA I-Gene +
was O +
injected O +
by O +
a O +
dose O +
of O +
1 O -
- O -
10 O +
mg O -
/ O -
kg O -
. O +

Then O -
, O +
the O +
time O +
to O +
reperfusion O +
was O +
measured O -
. O +

As O +
a O +
result O -
, O +
an O +
occluded O +
aorta O +
was O +
dose O -
- O -
dependently O +
reperfused O -
, O +
and O +
the O +
reperfusion O +
was O +
observed O +
at O +
37.5Â±12.4 O +
minutes O +
after O +
the O +
administration O +
of O +
100 O +
mg O -
/ O -
kg-1 O +
of O +
unfractionated O +
fucoidan O -
. O +

The O +
time O +
to O +
reperfusion O +
was O +
retarded O +
to O +
55.0Â±8.0 O +
minutes O +
when O +
a O +
large O +
amount O +
of O +
fucoidan O +
such O +
as O +
1 O +
g O -
/ O -
kg-1 O +
was O +
administered O +
to O +
a O +
mouse O +
provided O +
with O +
low O +
molecular O +
weight O +
fucoidan O +
( O -
LMWF O -
) O -
. O +

Reperfusion O +
occurred O +
at O +
16.67 O +
minutes O +
after O +
administration O +
in O +
a O +
mouse O +
of O +
a O +
control O +
group O +
provided O +
with O +
20 O +
mg O -
/ O -
kg-1 O +
of O +
t B-Gene -
- I-Gene -
PA I-Gene -
. O +

On O +
the O +
contrary O -
, O +
reperfusion O +
was O +
not O +
observed O +
in O +
an O +
occluded O +
mouse O +
provided O +
with O +
heparin O +
( O -
p<0.01 O -
) O -
. O +

The O +
occluded O +
artery O +
was O +
recovered O +
without O +
reperfusion O +
at O +
17.2 O +
minutes O +
after O +
injection O +
if O +
the O +
least O +
amount O +
of O +
fucoidan O +
added O +
in O +
a O +
predetermined O +
amount O +
of O +
t B-Gene -
- I-Gene -
PA I-Gene +
was O +
provided O -
. O +

All O +
the O +
data O +
show O +
that O +
fucoidan O +
can O +
serve O +
as O +
both O +
a O +
thrombolytic O +
agent O +
and O +
a O +
stimulant O +
with O +
respect O +
to O +
thrombolysis O +
activation O +
of O +
t B-Gene -
- I-Gene -
PA I-Gene +
in O +
a O +
thrombosis O +
model O -
, O +
differently O +
from O +
heparin O -
. O +

Treatment O +
of O +
severe O +
persitent O +
asthma O +
with O +
masitinib O +
The O +
present O +
invention O +
relates O +
to O +
the O +
treatment O +
of O +
severe O +
persistent O +
asthma O -
, O +
and O +
in O +
particular O +
severe O +
persistent O +
corticosteroid O -
- O -
dependent O +
or O +
corticosteroid O -
- O -
resistant O +
asthma O -
, O +
comprising O +
administration O +
a O +
tyrosine O +
kinase O +
inhibitor O +
or O +
a O +
mast O +
cell O +
inhibitor O -
, O +
especially O +
masitinib O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Anti O -
- O -
angiogenic O +
compounds O -
, O +
pharmaceutical O +
compositions O +
containing O +
same O -
, O +
and O +
use O +
thereof O +
The O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
A O -
) O +
having O +
an O +
anti O -
- O -
angiogenic O +
and/or O +
anti O -
- O -
tumoral O +
activity O -
, O +
to O +
pharmaceutical O +
compositions O +
comprising O +
same O -
, O +
and O +
to O +
the O +
use O +
thereof O +
for O +
treating O +
cancer O -
. O +

( O -
substituted O -
) O +
N- O -
( O -
CH2 O -
) O -
m O -
- O -
A O -
- O -
Rc O +
where O +
A O +
is O +
a O +
bond O -
, O +
Het- O -
( O -
CH2 O -
) O -
1 O -
- O -
6 O +
or O +
NH- O -
( O -
CH2 O -
) O -
1 O -
- O -
6 O +
and O +
Rc O +
is O +
O O -
- O -
substituted O +
or O +
N O -
- O -
substituted O -
. O +

4-aminoalcoholquinoline O +
derivatives O -
, O +
enantioselective O +
synthesis O +
methods O +
and O +
the O +
use O +
thereof O +
The O +
present O +
invention O +
is O +
intended O +
to O +
provide O +
new O +
antimalarial O +
compounds O +
with O +
a O +
strong O +
antimalarial O +
activity O +
as O +
well O +
as O +
antibacterial O +
activity O +
with O +
few O +
neurological O +
side O +
effects O +
and O +
a O +
new O +
enantioselective O +
pathway O +
to O +
mefloquine O +
amino O -
- O -
analogs O +
allowing O +
the O +
access O +
of O +
such O +
compounds O -
. O +

The O +
present O +
invention O +
relates O +
to O +
new O +
4 O +
-aminoalcohol O +
quinoline O +
derivatives O +
of O +
formula O +
( O -
I O -
) O -
, O +
as O +
well O +
as O +
the O +
synthesis O +
methods O +
and O +
the O +
uses O +
of O +
such O +
derivatives O -
. O +

In O +
which O +
Y O +
is O +
one O +
selected O +
from O +
formulae O +
( O -
II O -
) O +
to O +
( O -
III O -
) O -
. O +

In O +
which O +
Z O +
is O +
selected O +
from O +
formulae O +
( O -
IV O -
) O +
to O +
( O -
VI O -
) O -
, O +
and O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
R4 O -
, O +
R5 O -
, O +
R6 O -
, O +
R7 O +
and O +
n O +
are O +
as O +
defined O +
in O +
the O +
claims O -
. O +

Cell O +
therapy O +
composition O +
for O +
preventing O +
or O +
treating O +
immune O +
disease O +
comprising O +
mesenchymal O +
stem O +
cells O +
and O +
immunoregulatory O +
t O -
- O -
cells O +
as O +
active O +
ingredient O +
The O +
present O +
invention O +
relates O +
to O +
a O +
cell O +
therapy O +
composition O +
for O +
preventing O +
or O +
treating O +
immune O +
disease O +
comprising O +
mesenchymal O +
stem O +
cells O +
and O +
immunoregulatory O +
T O -
- O -
cells O +
as O +
an O +
active O +
ingredient O -
. O +

By O +
infusing O +
mesenchymal O +
stem O +
cells O +
and O +
immunoregulatory O +
T O -
- O -
cells O -
, O +
which O +
are O +
the O +
cellular O +
therapeutic O +
agent O +
of O +
the O +
present O +
invention O -
, O +
into O +
bone O +
marrow O +
transplant O +
animals O -
, O +
rejection O +
to O +
the O +
host O +
is O +
suppressed O +
after O +
the O +
engraftment O +
of O +
transplanted O +
bone O -
- O -
marrow O +
to O +
thus O +
obtain O +
the O +
effect O +
of O +
reducing O +
graft O -
- O -
versus O -
- O -
host O +
disease O +
and O +
immune O +
disease O -
. O +

Moreover O -
, O +
the O +
effect O +
of O +
such O +
GVHD O +
reduction O +
is O +
much O +
greater O +
than O +
the O +
one O +
obtained O +
when O +
only O +
mesenchymal O +
stem O +
cells O +
are O +
infused O -
. O +

Accordingly O -
, O +
the O +
cell O +
therapy O +
composition O +
of O +
the O +
present O +
invention O +
having O +
the O +
above O -
- O -
mentioned O +
effects O +
can O +
be O +
useful O +
in O +
the O +
prevention O +
or O +
treatment O +
of O +
immune O +
disease O -
. O +

Compositions O +
for O +
ameliorating O +
systemic O +
inflammation O +
and O +
methods O +
for O +
making O +
and O +
using O +
them O +
In O +
alternative O +
embodiments O +
the O +
invention O +
provides O +
compositions O -
, O +
e.g. O -
, O +
pharmaceutical O +
compositions O +
and O +
preparations O -
, O +
formulations O -
, O +
kits O +
and O +
other O +
products O +
of O +
manufacture O -
, O +
e.g. O -
, O +
exemplary O +
drug O +
combinations O +
packaged O +
together O +
or O +
separately O +
in O +
blister O +
packs O -
, O +
lidded O +
blisters O +
or O +
blister O +
cards O -
, O +
or O +
wrapped O +
in O +
paper O -
, O +
plastic O +
or O +
cellophane O +
wrappers O +
( O -
e.g. O -
, O +
a O +
shrink O +
wrap O -
) O -
, O +
comprising O +
a O +
combination O +
regimen O +
of O +
at O +
least O +
two O +
active O +
ingredients O +
designed O +
to O +
diminish O +
systemic O +
inflammation O +
by O +
targeting O +
( O -
inhibiting O -
) O +
two O +
different O -
, O +
but O +
convergent O -
, O +
signaling O +
pathways O -
, O +
i.e. O -
, O +
the O +
sympathetic O +
nervous O +
system O +
and O +
the O +
lipid- O +
derived O +
autacoid O +
system O -
; O +
and O +
methods O +
for O +
making O +
and O +
using O +
these O +
compositions O -
. O +

In O +
alternative O +
embodiments O -
, O +
the O +
compositions O +
of O +
the O +
invention O +
( O -
e.g. O -
, O +
the O +
combination O +
of O +
drugs O -
) O +
are O +
used O +
to O +
ameliorate O -
, O +
diminish O -
, O +
treat O -
, O +
block O +
or O +
prevent O +
an O +
inflammatory O +
response O +
secondary O +
to O +
an O +
infection O -
, O +
e.g. O -
, O +
a O +
viral O +
infection O +
and/or O +
a O +
reactivation O -
. O +

Use O +
of O +
poly O -
( O -
4-styrene O +
sulfonic O +
acid O -
- O -
copoly O -
- O -
maleic O +
acid O -
) O +
sodium O +
salt O +
and O +
pharmaceutical O +
composition O +
thereof O +
Use O +
of O +
poly O -
( O -
4-styrene O +
sulfonic O +
acid O -
- O -
copoly O -
- O -
maleic O +
acid O -
) O +
sodium O +
salt O +
in O +
the O +
preparation O +
of O +
pharmaceutical O +
inhibiting O +
infection O +
of O +
HIV-1 O +
and O +
pharmaceutical O +
composition O +
thereof O -
. O +

Said O +
pharmaceutical O +
composition O +
comprises O +
poly O -
( O -
4-styrene O +
sulfonic O +
acid O -
- O -
copoly O -
- O -
maleic O +
acid O -
) O +
sodium O +
salt O +
as O +
active O +
ingredient O +
and O +
conventional O +
pharmaceutical O +
carrier O -
. O +

A O +
COMPOUND O +
FOR O +
INHIBITING O +
HUMAN B-Gene +
11-Î² I-Gene -
- I-Gene -
HYDROXY I-Gene +
STEROID I-Gene +
DEHYDROGENASE I-Gene +
TYPE I-Gene +
1 I-Gene -
, O +
AND O +
A O +
PHARMACEUTICAL O +
COMPOSITION O +
COMPRISING O +
THE O +
SAME O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
compound O -
, O +
or O +
a O +
stereoisomer O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
a O +
pharmaceutical O +
composition O +
for O +
human-11-beta B-Gene -
- I-Gene -
hydroxysteroid I-Gene +
dehydrogenase I-Gene +
type I-Gene +
1 I-Gene +
( O -
11Î² B-Gene -
- I-Gene -
HSD1 I-Gene -
) O +
comprising O +
the O +
same O -
. O +

The O +
invention O +
provides O +
a O +
compound O -
, O +
which O +
has O +
excellent O +
activity O +
and O +
solubility O +
and O +
is O +
more O +
efficiently O +
formulated O +
and O +
delivered O -
, O +
and O +
a O +
pharmaceutical O +
composition O +
for O +
human-11-beta B-Gene -
- I-Gene -
hydroxysteroid I-Gene +
dehydrogenase I-Gene +
type I-Gene +
1 I-Gene +
comprising O +
the O +
same O -
. O +

Method O +
for O +
treatment O +
of O +
xeroderma O +
pigmentosum O +
This O +
invention O +
relates O +
to O +
a O +
method O +
of O +
treating O +
xeroderma O +
pigmentosum O +
and O +
related O +
symptoms O +
in O +
patients O +
by O +
administering O +
a O +
MC1R O +
before O +
or O +
after O +
exposing O +
them O +
to O +
visible O +
light O -
. O +

Pharmaceutical O +
composition O +
for O +
treatment O +
or O +
prophylaxis O +
of O +
neurogenic O +
diseases O +
The O +
present O +
invention O +
provides O +
a O +
pharmaceutical O +
product O +
which O +
has O +
a O +
sufficient O +
curative O +
effect O +
on O +
multiple O +
sclerosis O +
and O +
has O +
excellent O +
autoimmune O +
inhibitory O +
activity O -
, O +
while O +
being O +
reduced O +
in O +
the O +
side O +
effects O +
which O +
steroidal O +
agents O +
and O +
interferon O +
Î² O +
have O -
. O +

The O +
present O +
invention O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
for O +
the O +
treatment O +
or O +
prophylaxis O +
of O +
multiple O +
sclerosis O -
, O +
which O +
contains O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
4- O -
( O -
2-aminopyridin-4-yl O -
) O -
-3- O +
( O -
4-fluorophenyl O -
) O -
-1- O -
( O -
1,4,5,6-tetrahydro-6-oxopyridazin-3-yl O -
) O -
-1H O -
- O -
pyrazole O +
or O +
a O +
pharmacologically O +
acceptable O +
salt O +
thereof O -
. O +

Novel O +
cephalosporin O +
derivative O +
and O +
medical O +
composition O +
containing O +
same O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
cephalosporin O +
derivative O +
indicated O +
in O +
chemical O +
formula O +
1 O +
of O +
the O +
description O -
. O +

In O +
the O +
chemical O +
formula O +
1 O -
, O +
X O -
, O +
Y O -
, O +
L O -
, O +
R1 O -
, O +
R2 O +
are O +
identical O +
as O +
defined O +
in O +
the O +
detailed O +
explanation O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
relates O +
an O +
antibiotic O +
medical O +
composition O +
containing O +
the O +
novel O +
cephalosporin O +
derivative O +
of O +
the O +
chemical O +
formula O +
1 O -
, O +
a O +
prodrug O +
thereof O -
, O +
a O +
hydrate O +
thereof O -
, O +
a O +
solvate O +
thereof O -
, O +
an O +
isomer O +
thereof O -
, O +
and O +
a O +
pharmaceutically O +
permitted O +
salt O +
thereof O -
, O +
as O +
active O +
ingredients O -
. O +

The O +
novel O +
cephalosporin O +
derivative O +
of O +
the O +
chemical O +
formula O +
1 O -
, O +
the O +
prodrug O +
thereof O -
, O +
the O +
hydrate O +
thereof O -
, O +
the O +
solvate O +
thereof O -
, O +
the O +
isomer O +
thereof O -
, O +
and O +
the O +
pharmaceutically O +
permitted O +
salt O +
thereof O +
have O +
a O +
wide O +
antibacterial O +
spectrum O +
for O +
resistant O +
bacteria O -
, O +
have O +
low O +
toxicity O -
, O +
and O +
in O +
particular O -
, O +
show O +
strong O +
antibacterial O +
effect O +
on O +
gram O +
negative O +
bacteria O -
, O +
and O +
is O +
thus O +
useful O +
as O +
an O +
antibiotic O -
. O +

Methods O +
for O +
treating O +
heartburn O +
and/or O +
preventing O +
gastric O +
bleeding O +
or O +
hemorrhage O +
in O +
patients O +
receiving O +
clopidogrel O +
therapy O +
The O +
present O +
invention O +
relates O +
to O +
methods O +
of O +
treating O +
heartburn O +
in O +
a O +
patient O +
receiving O +
clopidogrel O +
therapy O -
. O +

In O +
another O +
aspect O -
, O +
the O +
present O +
invention O +
relates O +
to O +
methods O +
of O +
preventing O +
gastric O +
bleeding O +
or O +
hemorrhage O +
in O +
patients O +
receiving O +
clopidogrel O +
therapy O -
. O +

Solid O +
forms O +
of O +
antiretroviral O +
compounds O +
and O +
anti O -
- O -
oxidative O +
acids O -
, O +
processes O +
for O +
preparation O +
and O +
pharmaceutical O +
compositions O +
thereof O +
Disclosed O +
are O +
solid O +
forms O +
of O +
antiretroviral O +
compounds O +
and O +
anti O -
- O -
oxidative O +
acids O -
, O +
and O +
processes O +
for O +
their O +
preparation O -
. O +

Pharmaceutical O +
compositions O +
using O +
the O +
solid O +
forms O +
are O +
also O +
disclosed O -
. O +

Acadesine O +
derivatives O -
, O +
products O +
and O +
compositions O +
including O +
same O -
, O +
therapeutic O +
uses O +
thereof O -
, O +
and O +
methods O +
for O +
synthesizing O +
same O +
The O +
invention O +
relates O +
to O +
acadesine O +
derivatives O +
as O +
a O +
drug O -
, O +
as O +
well O +
as O +
to O +
said O +
derivatives O +
for O +
the O +
treatment O +
of O +
cancer O +
and O +
particularly O +
for O +
the O +
treatment O +
of O +
chronic O +
myeloid O +
leukemia O +
( O -
CML O -
) O -
. O +

The O +
invention O +
further O +
relates O +
to O +
a O +
product O +
containing O +
said O +
derivatives O +
and O +
at O +
least O +
one O +
second O +
active O +
ingredient O +
as O +
a O +
combination O +
product O +
to O +
be O +
simultaneously O +
or O +
separately O +
administered O -
, O +
or O +
administered O +
over O +
time O -
, O +
in O +
the O +
treatment O +
of O +
cancer O -
, O +
as O +
well O +
as O +
to O +
a O +
pharmaceutical O +
composition O +
including O +
said O +
derivatives O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O -
. O +

Finally O -
, O +
the O +
invention O +
relates O +
to O +
a O +
method O +
for O +
the O +
in O +
vitro O +
inhibition O +
of O +
the O +
proliferation O +
of O +
cells O -
, O +
including O +
contacting O +
a O +
cell O +
with O +
said O +
derivatives O +
in O +
vitro O -
, O +
and O +
to O +
methods O +
for O +
synthesizing O +
said O +
derivatives O -
. O +

2Î± O -
- O -
METHYL O +
AND O +
2Î² O -
- O -
METHYL O +
ANALOGS O +
OF O +
19,26-DINOR-1Î± O -
, O +
25-DIHYDROXYVITAMIN O +
D3 O +
AND O +
THEIR O +
USES O +

This O +
invention O +
discloses O +
2Î± O -
- O -
methyl O +
and O +
2Î² O -
- O -
methyl O +
analogs O +
of O +
19,26-dinor-1Î±,25-dihydroxyvitamin O +
D3 O +
and O +
pharmaceutical O +
uses O +
therefor O -
. O +

These O +
compounds O +
exhibit O +
in O +
vitro O +
biological O +
activities O +
evidencing O +
use O +
as O +
an O +
anti O -
- O -
cancer O +
agent O +
and O +
for O +
the O +
treatment O +
of O +
skin O +
diseases O +
such O +
as O +
psoriasis O +
as O +
well O +
as O +
skin O +
conditions O +
such O +
as O +
wrinkles O -
, O +
slack O +
skin O -
, O +
dry O +
skin O +
and O +
insufficient O +
sebum O +
secretion O -
. O +

These O +
compounds O +
have O +
little O -
, O +
if O +
any O -
, O +
in O +
vivo O +
calcemic O +
activity O +
and O +
therefore O +
may O +
be O +
used O +
to O +
treat O +
autoimmune O +
disorders O +
in O +
humans O +
as O +
well O +
as O +
secondary O +
hyperparathyroidism O +
and O +
renal O +
osteodystrophy O -
. O +

Anti O -
- O -
wrinkle O +
agent O -
, O +
matrix B-Gene +
metalloproteinase I-Gene +
( O -
mmp B-Gene -
) O +
inhibitor O +
and/or O +
laminin O +
5 O +
production O +
promoter O -
, O +
each O +
comprising O +
1-piperidine O +
propionate O +
The O +
purpose O +
of O +
the O +
invention O +
is O +
to O +
provide O +
a O +
novel O +
and O +
effective O +
anti O -
- O -
wrinkle O +
agent O -
. O +

The O +
invention O +
relates O +
to O +
a O +
matrix B-Gene +
metalloproteinase I-Gene +
( O -
MMP B-Gene -
) O +
inhibitor O +
and/or O +
laminin O +
5 O +
production O +
promoter O -
, O +
as O +
well O +
as O +
an O +
anti O -
- O -
wrinkle O +
agent O -
, O +
each O +
of O +
which O +
comprises O +
1-piperidine O +
propionate O +
and/or O +
a O +
salt O +
thereof O -
. O +

Condensed O +
2 O +
- O +
carbamoylpyridazinones O +
as O +
potassium B-Gene +
channel I-Gene +
modulators O +
Disclosed O +
herein O +
are O +
KCNQ B-Gene +
potassium B-Gene +
channels I-Gene +
modulators O +
of O +
formula O +
( O -
I O -
) O +
wherein O +
ring O +
G1 O -
, O +
R1 O -
, O +
and O +
R2 O +
are O +
as O +
defined O +
in O +
the O +
specification O -
. O +

Compositions O +
comprising O +
such O +
compounds O -
; O +
and O +
methods O +
for O +
treating O +
conditions O +
and O +
disorders O +
using O +
such O +
compounds O +
and O +
compositions O +
are O +
also O +
described O -
. O +

Erk B-Gene +
inhibitors O +
for O +
use O +
in O +
treating O +
spinal O +
muscular O +
atrophy O +
The O +
present O +
invention O +
relates O +
to O +
a O +
method O +
for O +
treating O +
spinal O +
muscular O +
atrophy O +
and O +
other O +
related O +
neuromuscular O +
disorders O +
in O +
a O +
subject O +
in O +
need O +
thereof O -
, O +
said O +
method O +
comprising O +
administering O +
a O +
therapeutically O +
effective O +
amount O +
of O +
an O +
ERK B-Gene +
inhibitor O -
, O +
such O +
as O +
Selumetinib O +
to O +
said O +
subject O -
. O +

Skin O +
treatment O +
method O +
River O +
rocks O +
are O +
used O +
in O +
a O +
therapy O +
regime O +
whereby O +
the O +
river O +
rocks O +
are O +
used O +
to O +
absorb O +
excess O +
oils O +
from O +
the O +
skin O +
of O +
a O +
user O -
. O +

In O +
one O +
method O -
, O +
river O +
rocks O +
arc O +
collected O +
from O +
a O +
source O +
( O -
e.g O -
.. O +
river O +
or O +
supplier O -
) O -
, O +
sorted O +
for O +
size O +
and O +
color O -
, O +
engraved O +
with O +
logo O +
or O +
other O +
content O -
, O +
packaged O +
and O +
shipped O +
to O +
customers O +
or O +
retailers O +
with O +
instructions O +
on O +
use O -
. O +

Use O +
comprises O +
placement O +
of O +
the O +
river O +
rocks O +
on O +
oily O +
portions O +
of O +
the O +
user O -
's O +
skin O +
for O +
an O +
appropriate O +
time O +
period O +
allowing O +
the O +
river O +
rock O +
to O +
absorb O +
the O +
excess O +
oils O -
. O +

The O +
river O +
rocks O +
are O +
reusable O +
after O +
being O +
washed O +
with O +
mild O +
soap O +
and O +
water O -
. O +

Thiocarbamate O +
and O +
sulfonamide O +
hydroxamate O +
inhibitors O +
of O +
insulin B-Gene -
- I-Gene -
degrading I-Gene +
enzyme I-Gene +
This O +
disclosure O +
relates O +
to O +
pharmaceutical O +
compositions O +
useful O +
for O +
inhibiting O +
insulin B-Gene -
- I-Gene -
degrading I-Gene +
enzyme I-Gene +
( O -
IDE B-Gene -
) O +
and O +
methods O +
of O +
treating O +
disorders O +
involving O +
the O +
same O +
or O +
peptide O +
substrates O +
of O +
the O +
same O -
. O +

For O +
example O -
, O +
provided O +
herein O +
are O +
methods O +
of O +
treating O +
diabetes O -
, O +
promotion O +
of O +
wound O +
healing O -
, O +
and O +
improvement O +
of O +
memory O -
. O +

Pharmaceutical O +
composition O +
comprising O +
a O +
trpa1 B-Gene +
antagonist O +
and O +
a O +
leukotriene O +
receptor O +
antagonist O +
The O +
present O +
patent O +
application O +
relates O +
to O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
transient B-Gene +
receptor I-Gene +
potential I-Gene +
ankyrin-1 I-Gene +
receptor I-Gene +
( O -
" O -
TRPA1 B-Gene -
" O -
) O +
antagonist O +
and O +
a O +
leukotriene O +
receptor O +
antagonist O -
. O +

Antifungal O +
composition O +
comprising O +
cis O -
- O -
cyclo O -
( O -
l O -
- O -
phe O -
- O -
l O -
- O -
pro O -
) O +
having O +
genus O +
ganoderma O +
fungus O -
- O -
specific O +
antifungal O +
activity O +
The O +
present O +
invention O +
provides O +
an O +
antifungal O +
composition O +
comprising O +
cis O -
- O -
cyclo O -
( O -
L O -
- O -
Phe O -
- O -
L O -
- O -
Pro O -
) O +
as O +
an O +
active O +
ingredient O +
and O +
having O +
Genus O +
Ganoderma O +
fungus O -
- O -
specific O +
antifungal O +
activity O -
, O +
an O +
insecticide O +
composition O -
, O +
and O +
a O +
method O +
for O +
producing O +
an O +
antifungal O +
agent O +
for O +
Genus O +
Ganoderma O +
fungi O -
. O +

The O +
present O +
invention O +
exhibits O +
superior O +
antifungal O +
activity O +
to O +
the O +
Genus O +
Ganoderma O +
fungi O +
( O -
especially O -
, O +
to O +
Ganoderma O +
boninense O +
fungi O -
) O +
and O +
thus O +
can O +
be O +
applied O +
to O +
various O +
industrial O +
fields O +
requiring O +
removal O +
and O +
prevention O +
of O +
Genus O +
Ganoderma O +
fungi O -
, O +
and O +
is O +
economically O +
advantageous O +
in O +
terms O +
of O +
usage O +
due O +
to O +
the O +
antifungal O +
activity O +
even O +
with O +
a O +
small O +
amount O -
. O +

In O +
addition O -
, O +
the O +
present O +
invention O +
provides O +
basic O +
material O +
as O +
a O +
biological O +
agent O +
regarding O +
cis O -
- O -
cyclo O -
( O -
L O -
- O -
Phe O -
- O -
L O -
- O -
Pro O -
) O +
to O +
the O +
insecticide O +
industry O +
which O +
uses O +
biological O +
agents O -
. O +

Tricyclic O +
heterocyclic O +
compounds O +
as O +
kinase B-Gene +
inhibitors O +
There O +
is O +
provided O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
X O -
, O +
R3 O +
and O +
R4 O +
have O +
meanings O +
given O +
in O +
the O +
description O +
( O -
and O +
which O +
compounds O +
are O +
optionally O +
substituted O +
as O +
indicated O +
in O +
the O +
description O -
) O -
, O +
and O +
pharmaceutically O -
- O -
acceptable O +
esters O -
, O +
amides O -
, O +
solvates O +
or O +
salts O +
thereof O -
, O +
which O +
compounds O +
are O +
useful O +
in O +
the O +
treatment O +
of O +
diseases O +
in O +
which O +
inhibition O +
of O +
a O +
protein O +
or O +
lipid O +
kinase O +
( O -
e.g. O +
a O +
PIM B-Gene +
family I-Gene +
kinase O -
, O +
such O +
as O +
PIM-1 B-Gene -
, O +
PIM-2 B-Gene +
and/or O +
PIM-3 B-Gene -
) O +
is O +
desired O +
and/or O +
required O -
, O +
and O +
particularly O +
in O +
the O +
treatment O +
of O +
cancer O +
or O +
a O +
proliferative O +
disease O -
. O +

There O +
is O +
also O +
provided O +
combinations O +
comprising O +
the O +
compounds O +
of O +
formula O +
I. O +

Tricyclic O +
inhibitors O +
of O +
kinases B-Gene +
useful O +
for O +
the O +
treatment O +
of O +
proliferative O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutical O +
acceptable O +
salts O -
, O +
wherein O +
R1 O -
, O +
R2 O -
, O +
R3 O -
, O +
A O -
, O +
B O -
, O +
and O +
n O +
are O +
defined O +
in O +
the O +
description O -
. O +

The O +
present O +
invention O +
relates O +
also O +
to O +
compositions O +
containing O +
said O +
compounds O +
which O +
are O +
useful O +
for O +
inhibiting O +
kinases B-Gene +
such O +
as O +
wee-1 O +
and O +
methods O +
of O +
treating O +
diseases O +
such O +
as O +
cancer O -
. O +

Spirocyclic O +
molecules O +
as O +
protein B-Gene +
kinase I-Gene +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
spirocyclic O +
compounds O +
of O +
formula O +
I O -
, O +
namely O +
spirocyclic O +
( O -
1H O -
- O -
pyrazol-4-yl O -
) O -
-3- O -
( O +
1- O -
( O -
2,6-dichloro-3- O +
fiuorophenyl O -
) O +
ethoxy O -
) O -
pyridin-2-amines O +
having O +
protein B-Gene +
kinase I-Gene +
inhibitory O +
activity O -
, O +
and O +
methods O +
of O +
synthesizing O +
and O +
using O +
such O +
compounds O -
. O +

Preferred O +
compounds O +
are O +
c B-Gene -
- I-Gene -
Met I-Gene +
and/or O +
ALK B-Gene +
inhibitors O +
useful O +
for O +
the O +
treatment O +
of O +
abnormal O +
cell O +
growth O -
, O +
such O +
as O +
cancers O -
. O +

Composition O +
containing O +
5-hydroxyindole O +
compounds O +
or O +
sponge O +
scalarispongia O +
sp. O +
extracts O +
as O +
active O +
ingredients O +
for O +
prevention O +
and O +
treatment O +
of O +
cancer O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
containing O +
5-hydroxyindole O +
compounds O +
or O +
sponge O +
Scalarispongia O +
sp. O +
extracts O +
as O +
active O +
ingredients O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
cancer O +
diseases O -
, O +
and O +
more O +
specifically O -
, O +
the O +
novel O +
compound O +
or O +
the O +
Scalarispongia O +
sp. O +
extract O +
and O +
more O +
specifically O -
, O +
the O +
novel O +
compound O +
or O +
the O +
Scalarispongia O +
sp. O +
extract O +
of O +
the O +
present O +
invention O +
exhibits O +
growth O +
inhibitory O +
activities O +
against O +
various O +
cancer O +
cell O +
lines O +
and O +
is O +
thus O +
useful O +
as O +
a O +
pharmaceutical O +
composition O +
for O +
the O +
prevention O +
and O +
treatment O +
of O +
cancer O +
diseases O -
. O +

Pyridazine O +
derivatives O +
as O +
eaat2 B-Gene +
activators O +
Pyridazine O +
derivatives O +
that O +
activate O +
the O +
excitatory B-Gene +
amino I-Gene +
acid I-Gene +
transporter I-Gene +
2 I-Gene +
( O -
EAAT2 B-Gene -
) O -
, O +
and O +
methods O +
of O +
use O +
thereof O +
for O +
treating O +
or O +
preventing O +
diseases O -
, O +
disorders O -
, O +
and O +
conditions O +
associated O +
with O +
glutamate O +
excitotoxicity O -
. O +

Novel O +
urea O +
derivatives O +
as O +
tec O +
kinase O +
inhibitors O +
and O +
uses O +
thereof O +
Provided O +
are O +
urea O +
compounds O +
of O +
formula O +
( O -
I O -
) O +
as O +
Tec O +
kinase O +
inhibitors O -
, O +
in O +
particular O +
ITK O +
( O -
interleukin-2 O +
inducible O +
tyrosine O +
kinase O -
) O +
inhibitors O -
. O +

Also O +
provided O +
herein O +
are O +
processes O +
for O +
preparing O +
compounds O +
described O +
herein O -
, O +
intermediates O +
used O +
in O +
their O +
synthesis O -
, O +
pharmaceutical O +
compositions O +
thereof O -
, O +
and O +
methods O +
for O +
treating O +
or O +
preventing O +
diseases O -
, O +
conditions O +
and/or O +
disorders O +
mediated O +
by O +
ITK O -
. O +

Methods O +
of O +
treating O +
amyloidoses O +
with O +
vitamin O +
b12 O +
and O +
test O +
for O +
detecting O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptides O +
Embodiments O +
of O +
the O +
invention O +
include O +
methods O +
of O +
using O +
vitamin O +
B12 O +
to O +
influence O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptide O +
aggregation O -
. O +

A O +
preferred O +
method O +
comprises O +
contacting O +
at O +
least O +
one O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptide O +
oligomer O +
formed O +
from O +
a O +
plurality O +
of O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptide O +
monomers O +
with O +
an O +
effective O +
amount O +
of O +
vitamin O +
B12 O -
, O +
the O +
effective O +
amount O +
being O +
sufficient O +
to O +
stimulate O +
dissociation O +
of O +
the O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptide O +
monomers O +
from O +
the O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptide O +
oligomer O +
or O +
fibril O -
. O +

Also O +
provided O +
are O +
methods O +
of O +
treating O +
Alzheimer O -
's O +
disease O +
and O +
diagnostic O +
tests O +
for O +
detecting O +
the O +
presence O +
of O +
amyloid B-Gene -
- I-Gene -
beta I-Gene +
peptides O -
. O +

Nkp30 B-Gene +
receptor O +
targeted O +
therapeutics O +
The O +
invention O +
is O +
directed O +
to O +
T O +
cells O +
and O +
other O +
cells O +
that O +
express O +
chimeric O +
NKp30 B-Gene +
receptors O +
( O -
" O -
chimeric O +
NKp30 O +
T O +
cells O -
" O -
) O -
, O +
methods O +
of O +
making O +
and O +
using O +
chimeric O +
NKp30 O +
T O +
cells O -
, O +
and O +
methods O +
of O +
using O +
these O +
chimeric O +
NKp30 O +
T O +
cells O +
to O +
address O +
diseases O +
and O +
disorders O -
. O +

In O +
one O +
aspect O -
, O +
the O +
disclosure O +
broadly O +
relates O +
to O +
chimeric O +
NKp30 O +
T O +
cells O -
, O +
isolated O +
populations O +
thereof O -
, O +
and O +
compositions O +
comprising O +
the O +
same O -
. O +

In O +
another O +
aspect O -
, O +
said O +
chimeric O +
NKp30 O +
T O +
cells O +
are O +
further O +
designed O +
to O +
express O +
a O +
functional O +
non O -
- O -
TCR O +
receptor O -
. O +

The O +
disclosure O +
also O +
pertains O +
to O +
methods O +
of O +
making O +
said O +
chimeric O +
NKp30 O +
T O +
cells O -
, O +
and O +
methods O +
of O +
reducing O +
or O +
ameliorating O -
, O +
or O +
preventing O +
or O +
treating O -
, O +
diseases O +
and O +
disorders O +
using O +
said O +
chimeric O +
NKp30 O +
T O +
cells O -
, O +
populations O +
thereof O -
, O +
or O +
compositions O +
comprising O +
the O +
same O -
. O +

Combination O +
use O +
of O +
vitamin O +
d O +
and O +
hmg B-Gene +
coa I-Gene +
reductase I-Gene +
inhibitor O +
for O +
treating O +
osteoporosis O +
The O +
present O +
invention O +
provides O +
a O +
method O +
for O +
treating O +
osteoporosis O +
by O +
co- O +
administration O +
of O +
a O +
vitamin O +
D O +
and O +
a O +
3-hydroxy-3-methyl B-Gene -
- I-Gene -
glutaryl I-Gene -
- I-Gene -
Co I-Gene +
A I-Gene +
reductase I-Gene +
( O -
HMG B-Gene +
Co I-Gene +
A I-Gene +
reductase I-Gene -
) O +
inhibitor O -
. O +

Also O +
provided O +
are O +
compositions O +
and O +
kits O +
useful O +
for O +
treating O +
osteoporosis O +
comprising O +
a O +
vitamin O +
D O +
and O +
an O +
HMG B-Gene +
Co I-Gene +
A I-Gene +
reductase I-Gene +
inhibitor O -
. O +

Retinal O +
cyclodextrin O +
acetals O +
and O +
hemiacetals O +
for O +
clarifying O +
skin O +
complexion O +
The O +
present O +
invention O +
discloses O +
certain O +
polyene O +
cyclodextrin O +
acetals O +
and O +
hemiacetals O +
that O +
are O +
effective O +
in O +
providing O +
skin O +
clarification O -
, O +
which O +
is O +
useful O +
for O +
the O +
treatment O +
of O +
acne O -
, O +
and O +
skin O +
disfigurements O +
and O +
skin O +
darkening O +
resulting O +
from O +
acne O -
; O +
skin O +
darkening O +
from O +
cancer O -
, O +
diabetes O -
, O +
radiation O +
treatments O -
, O +
chemotherapy O -
, O +
and O +
sun O -
- O -
burn O -
; O +
mitochondrial O +
and O +
DNA O +
dysfunction O -
; O +
age O +
spots O -
; O +
loss O +
of O +
cellular O +
antioxidants O -
; O +
skin O +
changes O +
associated O +
with O +
aging O +
including O +
collagen O +
loss O -
, O +
loss O +
of O +
skin O +
pliability O -
, O +
loss O +
of O +
skin O +
suppleness O -
, O +
skin O +
wrinkles O +
and O +
fine O +
lines O -
, O +
oxidation O -
, O +
damage O +
from O +
radiation O -
, O +
damage O +
from O +
free O +
radicals O -
, O +
and O +
damage O +
from O +
UV O -
; O +
dry O +
skin O -
; O +
xerosis O -
; O +
ichthyosis O -
; O +
dandruff O -
; O +
brownish O +
spots O -
; O +
keratoses O -
; O +
melasma O -
; O +
lentigines O -
; O +
liver O +
spots O -
; O +
skin O +
pigmentation O +
including O +
pigmented O +
spots O -
, O +
dark O +
circles O +
under O +
the O +
eyes O -
, O +
darkened O +
skin O -
, O +
and O +
blemishes O -
; O +
oily O +
skin O -
; O +
warts O -
; O +
eczema O -
; O +
pruritic O +
skin O -
; O +
psoriasis O -
; O +
inflammatory O +
dermatoses O -
; O +
topical O +
inflammation O -
; O +
disturbed O +
keratinization O -
; O +
scalp O +
dryness O -
, O +
and O +
combinations O +
thereof O -
. O +

Benzoic O +
acid O +
derivatives O +
as O +
eif4e B-Gene +
inhibitors O +
Disclosed O +
are O +
compounds O +
with O +
the O +
formula O +
( O -
I O -
) O -
, O +
where O +
R1 O +
and O +
R2 O +
are O +
as O +
disclosed O +
herein O -
, O +
which O +
are O +
eIF4E B-Gene +
inhibitors O +
useful O +
in O +
the O +
treatment O +
of O +
cancers O -
. O +

Also O +
disclosed O +
are O +
compositions O +
comprising O +
the O +
compounds O -
, O +
as O +
well O +
as O +
methods O +
of O +
treating O +
cancer O +
using O +
the O +
compounds O -
. O +

Amide O +
compounds O -
, O +
compositions O +
and O +
applications O +
thereof O +
The O +
present O +
disclosure O +
relates O +
to O +
substituted O +
amide O +
compounds O +
that O +
are O +
inhibitors O +
of O +
Fatty B-Gene +
Acid I-Gene +
Amide I-Gene +
Hydrolase I-Gene +
( O -
FAAH B-Gene -
) O -
, O +
their O +
stereoisomers O -
, O +
tautomers O -
, O +
prodrugs O -
, O +
polymorphs O -
, O +
solvates O -
, O +
pharmaceutically O +
acceptable O +
salts O -
, O +
and O +
pharmaceutical O +
compositions O +
containing O +
them O -
. O +

These O +
compounds O +
are O +
useful O +
in O +
the O +
treatment O -
, O +
prevention O -
, O +
prophylaxis O -
, O +
management O -
, O +
or O +
adjunct O +
treatment O +
of O +
all O +
medical O +
conditions O +
related O +
to O +
inhibition O +
of O +
Fatty B-Gene +
Acid I-Gene +
Amide I-Gene +
Hydrolase I-Gene +
( O -
FAAH B-Gene -
) O -
, O +
such O +
as O +
pain O +
including O +
acute O +
and O +
post O +
operative O +
pain O -
, O +
chronic O +
pain O -
, O +
cancer O +
pain O -
, O +
cancer O +
chemotherapy O +
induced O +
pain O -
, O +
neuropathic O +
pain O -
, O +
nociceptive O +
pain O -
, O +
inflammatory O +
pain O -
, O +
back O +
pain O -
, O +
pain O +
due O +
to O +
disease O +
of O +
various O +
origin O +
such O +
as O -
: O +
diabetic O +
neuropathy O -
, O +
neurotropic O +
viral O +
disease O +
including O +
human O +
immunodeficient O +
virus O +
( O -
HIV O -
) O -
, O +
herpes O +
zoster O +
such O +
as O +
post O +
herpetic O +
neuralgia O -
; O +
polyneuropathy O -
, O +
neurotoxicity O -
, O +
mechanical O +
nerve O +
injury O -
, O +
carpal O +
tunnel O +
syndrome O -
, O +
immunologic O +
mechanisms O +
like O +
multiple O +
sclerosis O -
; O +
sleep O +
disorders O -
, O +
anxiety O +
and O +
depression O +
disorders O -
, O +
inflammatory O +
disorders O -
, O +
weight O +
and O +
eating O +
disorders O -
, O +
Parkinson O -
's O +
disease O -
, O +
addiction O -
, O +
spasticity O -
, O +
hypertension O +
or O +
other O +
disorders O -
. O +

The O +
disclosure O +
also O +
relates O +
to O +
the O +
process O +
of O +
preparation O +
of O +
the O +
amide O +
compounds O -
. O +

Formula O +
( O -
1 O -
) O -
. O +

The O +
present O +
disclosure O +
also O +
relates O +
to O +
methods O +
for O +
the O +
preparation O +
of O +
such O +
compounds O -
, O +
and O +
to O +
pharmaceutical O +
compositions O +
containing O +
them O -
. O +

Methods O +
of O +
treating O +
fatty O +
liver O +
disease O +
with O +
helminth O -
- O -
derived O +
glycan O -
- O -
containing O +
compounds O +
The O +
present O +
invention O +
provides O +
a O +
compound O +
comprising O +
a O +
helminth O -
- O -
derived O +
glycan O +
and/or O +
glycoconjugate O +
thereof O +
( O -
e.g. O -
, O +
a O +
compound O +
comprising O +
a O +
Lewisx O +
antigen O +
( O -
e.g. O -
, O +
LNFPIII O -
) O -
, O +
a O +
non O -
- O -
Lewisx O +
antigen O +
( O -
e.g. O -
, O +
LNnT O -
, O +
LDN O -
, O +
and O +
LDN O +
derivatives O -
) O -
, O +
or O +
a O +
mixture O +
of O +
Lewisx O +
and O +
non O -
- O -
Lewisx O +
antigens O +
( O -
e.g. O -
, O +
SEA O -
) O -
) O -
, O +
useful O +
as O +
a O +
therapeutic O +
compound O +
for O +
treating O +
or O +
preventing O +
diseases O +
associated O +
with O +
fat O +
accumulation O +
in O +
the O +
liver O -
. O +

The O +
compounds O +
of O +
the O +
invention O +
are O +
useful O +
for O +
treating O +
or O +
preventing O +
the O +
development O +
of O +
a O +
fatty O +
liver O +
disease O +
in O +
a O +
subject O +
that O +
has O +
the O +
disease O +
or O +
is O +
at O +
risk O +
of O +
developing O +
the O +
disease O -
, O +
and O +
inhibiting O +
lipogenesis O +
in O +
hepatocytes O -
. O +

The O +
invention O +
also O +
provides O +
methods O +
of O +
regulating O +
the O +
Erk O -
- O -
c O -
- O -
fos O -
/ O -
AP-1-FXRÎ± O +
signalling O +
pathway O +
by O +
administering O +
a O +
compound O +
comprising O +
a O +
helminth O -
- O -
derived O +
glycan O +
and/or O +
glycoconjugate O +
thereof O +
to O +
a O +
subject O +
with O +
a O +
fatty O +
liver O +
disease O -
, O +
or O +
contacting O +
a O +
hepatocyte O +
with O +
a O +
compound O +
comprising O +
a O +
helminth O -
- O -
derived O +
glycan O +
and/or O +
glycoconjugate O +
thereof O -
. O +

Novel O +
chalcone O +
derivative O +
and O +
anticancer O +
composition O +
comprising O +
same O +
as O +
active O +
ingredient O +
The O +
present O +
invention O +
relates O +
to O +
a O +
novel O +
chalcone O +
derivative O +
and O +
to O +
an O +
anticancer O +
composition O +
comprising O +
same O +
as O +
an O +
active O +
ingredient O -
. O +

Liquid O +
composition O +
of O +
anti O -
- O -
hepatitis O +
b O +
virus O +
Disclosed O +
is O +
an O +
oral O +
liquid O +
for O +
treating O +
a O +
hepatitis O +
B O +
virus O +
infection O -
, O +
and O +
composed O +
of O +
entecavir O -
, O +
sodium O +
diacetate O +
and O +
water O -
. O +

The O +
content O +
of O +
entecavir O +
is O +
0.001 O -
- O -
0.2mg O -
/ O -
ml O -
, O +
and O +
the O +
content O +
of O +
sodium O +
diacetate O +
is O +
0.1 O -
- O -
10mg O -
/ O -
ml O -
. O +

Use O +
of O +
a O +
chemical O +
compound O +
derived O +
from O +
a O +
1,2,3,5-tetrasubstituted O +
pyrole O +
in O +
the O +
preparation O +
of O +
a O +
drug O +
for O +
use O +
in O +
treating O +
inflammatory O +
diseases O +
involving O +
processes O +
of O +
cellular O +
apoptosis O +
The O +
present O +
invention O +
relates O +
to O +
the O +
use O +
of O +
compounds O +
derived O +
from O +
1,2,3,5-tetrasubstituted O +
pyroles O +
in O +
conjunction O +
with O +
pharmaceutically O +
acceptable O +
excipients O +
in O +
the O +
production O +
of O +
a O +
drug O +
that O +
can O +
be O +
used O +
to O +
treat O +
inflammatory O +
diseases O +
involving O +
processes O +
of O +
cellular O +
apoptosis O -
, O +
preferably O +
diseases O +
arising O +
through O +
sepsis O +
caused O +
by O +
Gramâ€‘negative O +
bacteria O -
. O +

Said O +
diseases O +
include O +
acute O +
sepsisâ€‘induced O +
pulmonary O +
diseases O -
, O +
acute O +
sepsisâ€‘induced O +
respiratory O +
distress O +
syndrome O -
, O +
endotoxic O +
or O +
endotoxemic O +
shock O -
, O +
septic O +
peritonitis O +
or O +
trauma O -
. O +

The O +
invention O +
also O +
comprises O +
the O +
pharmaceutical O +
composition O +
for O +
treating O +
said O +
diseases O -
. O +

A O +
new O +
diaza O -
- O -
benzofluoranthene O +
derivative O +
as O +
drug O +
The O +
present O +
invention O +
relates O +
to O +
a O +
new O +
16-tetrazolyl O -
- O -
eburnamenine O +
of O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutically O +
acceptable O +
salt O +
thereof O +
and/or O +
hydrates O +
and/or O +
solvates O +
thereof O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
pharmaceutical O +
compositions O +
containing O +
the O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
hydrates O +
or O +
solvates O +
thereof O +
as O +
active O +
ingredient O -
. O +

The O +
invention O +
also O +
relates O +
to O +
the O +
synthesis O +
of O +
compounds O +
of O +
formula O +
( O -
I O -
) O -
, O +
and O +
the O +
chemical O +
and O +
pharmaceutical O +
manufacture O +
of O +
medicaments O +
containing O +
these O +
compounds O -
, O +
as O +
well O +
as O +
the O +
methods O +
of O +
treatment O +
of O +
mammals O +
- O +
including O +
human O +
- O +
with O +
these O +
compounds O -
. O +

There O +
is O +
still O +
further O +
provided O +
methods O +
for O +
the O +
treatment O +
of O +
neurological O -
, O +
neurodegenerative O +
and O +
psychiatric O +
diseases O +
or O +
conditions O +
as O +
well O +
as O +
comprising O +
the O +
step O +
of O +
administering O +
to O +
human O -
, O +
in O +
need O +
of O +
such O +
treatment O +
and/or O +
prophylaxis O +
a O +
pharmaceutical O +
composition O +
comprising O +
a O +
therapeutically O +
effective O +
amount O +
of O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
pharmaceutically O +
acceptable O +
salts O +
thereof O +
alone O +
or O +
together O +
with O +
at O +
least O +
one O +
and O +
a O +
pharmaceutically O +
acceptable O +
carrier O +
and/or O +
diluent O -
. O +

Hydroxymethylfurfural O +
derivative O +
A O +
hydroxymethylfurfural O +
derivative O +
represented O +
by O +
general O +
formula O +
( O -
A O -
) O -
. O +

In O +
the O +
formula O -
, O +
R O +
is O +
selected O +
from O +
the O +
group O +
consisting O +
of O +
formula O +
( O -
I O -
) O -
, O +
( O -
II O -
) O +
HOOCCH2COCO- O -
, O +
( O -
III O -
) O +
HOOCCH2CH2COCO- O -
, O +
and O +
( O -
IV O -
) O +
a O +
hydrogen O +
atom O -
. O +

Garcinia O +
buchananii O +
baker O +
compounds O -
, O +
compositions O +
and O +
related O +
methods O +
Embodiments O +
of O +
the O +
present O +
disclosure O +
related O +
to O +
compounds O +
and O +
compositions O +
derived O +
from O +
G. O +
buchananii O +
baker O +
and O +
methods O +
thereof O -
. O +

Formulations O +
of O +
( O -
+ O -
) O -
-2- O -
[ O -
1- O -
( O -
3-ethoxy-4-methoxy O -
- O -
phenyl O -
) O -
-2-methanesulfonyl O -
- O -
ethyl O -
] O -
-4-acetyl O +
aminoisoindoline-1,3-dione O +
Pharmaceutical O +
compositions O +
and O +
single O +
unit O +
dosage O +
forms O +
of O +
( O -
+ O -
) O -
-2- O -
[ O -
l- O -
( O -
3-ethox O +
4-mcthoxy O -
- O -
phcnyl O -
) O -
-2-mcthancsulfonyl O -
- O -
cthyl O -
] O -
-4-acctylaminoisoindolinc O -
- O -
l,3-dionc O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
stereoisomer O -
, O +
prodrug O -
, O +
salt O -
, O +
solvate O -
, O +
hydrate O -
, O +
or O +
clathrate O +
5 O +
thereof O -
, O +
are O +
provided O +
herein O -
. O +

Also O +
provided O +
are O +
methods O +
of O +
treating O -
, O +
managing O -
, O +
or O +
preventing O +
various O +
diseases O +
or O +
disorders O -
. O +

The O +
compound O +
is O +
known O +
as O +
Apremilast O +
and O +
has O +
the O +
following O +
structural O +
formula O -
: O +

Formulation O +
and O +
method O +
for O +
treatment O +
of O +
pain O +
and/or O +
inflammation O +
associated O +
with O +
a O +
skin O +
condition O +
Topical O +
formulations O +
comprising O +
an O +
effective O +
amount O +
of O +
menthol O +
in O +
combination O +
with O +
an O +
acidifier O -
, O +
wherein O +
the O +
topical O +
formulation O +
has O +
a O +
pH O +
of O +
about O +
1 O +
to O +
3 O -
, O +
and O +
methods O +
comprising O +
administration O +
of O +
the O +
same O -
, O +
and O +
use O +
of O +
the O +
topical O +
formulations O +
to O +
treat O +
pain O +
and/or O +
inflammation O +
associated O +
with O +
a O +
skin O +
condition O +
are O +
described O -
. O +

For O +
example O -
, O +
the O +
topical O +
formulation O +
relieves O +
pain O -
, O +
redness O -
, O +
swelling O -
, O +
reduces O +
rash O +
and/or O +
itching O +
relating O +
to O +
skin O +
conditions O -
, O +
such O +
as O -
, O +
but O +
not O +
limited O +
to O -
, O +
any O +
kind O +
of O +
envenomation O +
from O +
stings O +
and/or O +
bites O +
from O +
animals O -
, O +
insects O +
and O +
plants O +
in O +
addition O +
to O +
contact O +
dermatitis O -
, O +
burns O -
, O +
urticaria O -
, O +
rash O +
and O +
other O +
forms O +
of O +
dermatitis O -
. O +

Treatment O +
of O +
pain O +
and/or O +
inflammation O +
including O +
activation O +
and/or O +
stimulation O +
and/or O +
blocking O +
and/or O +
reducing O +
the O +
activity O +
of O +
one O +
or O +
more O +
pain O +
receptors O +
to O +
thereby O +
treat O +
the O +
pain O +
and/or O +
inflammation O +
is O +
described O -
. O +

Chinese O +
herbal O +
medicine O +
composition O +
for O +
treating O +
diabetic O +
foot O +
A O +
Chinese O +
herbal O +
medicine O +
composition O +
for O +
treating O +
diabetic O +
foot O -
, O +
consisting O +
of O +
the O +
following O +
raw O +
material O +
medicines O +
in O +
parts O +
by O +
weight O -
: O +
1 O -
- O -
30 O +
parts O +
of O +
scorpion O -
, O +
1 O -
- O -
30 O +
parts O +
of O +
lithargite O -
, O +
1 O -
- O -
30 O +
parts O +
of O +
centipede O -
, O +
1 O -
- O -
20 O +
parts O +
of O +
borneol O -
, O +
1 O -
- O -
20 O +
parts O +
of O +
cirsium O +
japonicum O -
, O +
1 O -
- O -
20 O +
parts O +
of O +
pangolin O -
, O +
1 O -
- O -
20 O +
parts O +
of O +
castor O +
beans O -
, O +
1 O -
- O -
20 O +
parts O +
of O +
garden O +
burnet O -
, O +
and O +
1 O -
- O -
20 O +
parts O +
of O +
safflower O -
. O +

The O +
composition O +
has O +
the O +
effects O +
of O +
clearing O +
heat O +
and O +
detoxicating O -
, O +
eliminating O +
necrotic O +
tissue O +
and O +
promoting O +
granulation O -
, O +
stimulating O +
blood O +
circulation O +
and O +
removing O +
blood O +
stasis O -
, O +
warming O +
and O +
activating O +
arteries O +
and O +
veins O -
, O +
and O +
reducing O +
swelling O +
and O +
stopping O +
pain O -
, O +
and O +
is O +
used O +
to O +
treat O +
nerve O +
patho O -
- O -
type O -
, O +
artery O +
ischemia O -
- O -
type O +
and O +
mixed O -
- O -
type O +
diabetic O +
foot O +
with O +
the O +
symptoms O +
of O +
foot O +
muscular O +
atrophy O -
, O +
deformity O -
, O +
skin O +
infection O -
, O +
purulence O -
, O +
rhagades O +
and O +
ulcers O -
, O +
and O +
toe O +
tip O +
ulcers O +
and O +
gangrene O -
. O +

Effervescent O +
pharmaceutical O +
formulations O +
comprising O +
pregabalin O +
and O +
vitamin O +
b12 O +
The O +
present O +
invention O +
relates O +
to O +
an O +
effervescent O +
pharmaceutical O +
formulation O +
comprising O +
a O +
combination O +
of O +
pregabalin O +
and O +
vitamin O +
B12 O +
and O +
use O +
of O +
this O +
formulation O +
in O +
the O +
treatment O +
of O +
epilepsy O -
, O +
central O +
nervous O +
system O +
disorders O -
, O +
Parkinson O -
's O +
disease O -
; O +
Huntington O -
's O +
disease O -
; O +
tardive O +
dyskinesia O -
; O +
spasticity O -
; O +
cerebral O +
ischemia O -
; O +
postherpetic O +
neuralgia O -
; O +
social O +
phobia O -
; O +
fibromyalgia O +
and O +
spinal O +
cord O +
injury O +
induced O +
chronic O +
pains O -
; O +
neuropathic O +
pains O +
associated O +
with O +
diabetic O +
peripheral O +
neuropathy O +
and O +
common O +
anxiety O +
disorder O +
and O +
in O +
treatment O +
and/or O +
prevention O +
of O +
anemia O +
diseases O +
such O +
as O +
macrocytic O +
anemia O -
, O +
megaloblastic O +
anemia O +
and O +
pernicious O +
anemia O -
. O +

Fatty O +
acids O +
as O +
anti O -
- O -
inflammatory O +
agents O +
A O +
class O +
of O +
enzymatically O +
generated O +
electrophilic O +
fatty O +
acid O +
derivatives O +
( O -
EFADs O -
) O -
, O +
or O +
their O +
enzymatically O +
generated O +
metabolites O -
. O +

The O +
EFAD O -
's O +
and O +
their O +
metabolites O +
have O +
beneficial O +
effects O +
human O +
health O -
. O +

According O +
to O +
the O +
inventors O +
the O +
inventive O +
keto O +
fatty O +
acids O +
or O +
their O +
enzymatically O +
generated O +
metabolites O -
, O +
can O +
inhibit O +
inflammation O +
by O +
giving O +
rise O +
to O +
adaptive O +
signaling O +
molecules O +
in O +
vivo O -
. O +

Ionophore O +
antibiotic O +
suspension O +
An O +
alcohol O +
based O +
suspension O +
formulation O +
including O +
a O +
therapeutically O +
effective O +
amount O +
of O +
at O +
least O +
one O +
ionophore O +
antibiotic O +
in O +
an O +
organic O +
liquid O +
phase O +
including O +
at O +
least O +
one O +
polyol O +
and O +
benzyl O +
alcohol O +
and O +
at O +
least O +
one O +
or O +
more O +
of O +
at O +
least O +
one O +
anionic O +
and/or O +
non O -
- O -
ionic O +
surfactant O -
; O +
at O +
least O +
one O +
stabilising O +
agent O +
or O +
water O +
in O +
an O +
amount O +
of O +
less O +
than O +
or O +
equal O +
to O +
15 O -
% O +
v O -
/ O -
v O +
of O +
the O +
total O +
formulation O -
. O +

Methods O +
of O +
manufacture O +
of O +
the O +
formulation O +
are O +
also O +
described O +
along O +
with O +
methods O +
of O +
use O +
for O +
selected O +
treatments O -
. O +

Bicyclic O +
heterocyclic O +
derivatives O +
as O +
mnk1 B-Gene +
and O +
mnk2 B-Gene +
modulators O +
and O +
uses O +
thereof O +
The O +
present O +
invention O +
relates O +
to O +
certain O +
compounds O +
( O -
e.g. O -
, O +
imidazopyrazine O -
, O +
imidazopyridine O -
, O +
imidazopyridazine O +
and O +
imidazpyrimidine O +
compounds O -
) O +
that O +
act O +
as O +
inhibitors O +
of O +
the O +
MAP B-Gene +
kinase I-Gene +
interacting O +
kinases O +
MNK2a B-Gene -
, O +
MNK2b B-Gene -
, O +
MNK1a B-Gene -
, O +
and O +
MNK1b B-Gene -
. O +

The O +
present O +
invention O +
further O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O -
, O +
and O +
to O +
the O +
use O +
of O +
the O +
compounds O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
the O +
prophylaxis O +
and O +
treatment O +
of O +
diseases O +
( O -
e.g. O -
, O +
proliferative O +
diseases O +
( O -
e.g. O -
, O +
cancer O -
) O -
, O +
inflammatory O +
diseases O -
, O +
Alzheimer O -
's O +
disease O -
) O -
, O +
as O +
well O +
as O +
methods O +
of O +
treating O +
these O +
diseases O -
. O +

Treatment O +
method O +
for O +
steroid O +
responsive O +
dermatoses O +
Invented O +
is O +
a O +
method O +
of O +
treating O +
steroid O +
responsive O +
dermatoses O +
in O +
a O +
mammal O -
, O +
including O +
a O +
human O -
, O +
in O +
need O +
thereof O +
which O +
comprises O +
the O +
administration O +
of O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
selected O +
from O +
the O +
group O +
consisting O +
of O -
: O +
N- O -
{ O -
( O -
1S O -
) O -
-2-Amino-1- O -
[ O -
( O -
3-fluorophenyl O -
) O -
methyl O -
] O -
ethyl O -
} O -
-5-chloro-4- O -
( O -
4-chloro-1-methyl-1H O -
- O -
pyrazol-5-yl O -
) O -
-2-thiophenecarboxamide O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
and O +
the O +
compound O +
N- O -
{ O -
( O -
1S O -
) O -
-2-amino-1- O -
[ O -
( O -
3,4-difluorophenyl O -
) O -
methyl O -
] O -
ethyl O -
} O -
-5-chloro-4- O -
( O -
4-chloro-1-methyl-1H O -
- O -
pyrazol-5-yl O -
) O -
-2- O +
furancarboxamide O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
to O +
such O +
mammal O -
. O +

Pyrrolopyridinone O +
derivatives O +
as O +
ttx O -
- O -
s O +
blockers O +
The O +
present O +
invention O +
relates O +
to O +
pyrrolopyridinone O +
derivatives O +
which O +
have O +
blocking O +
activities O +
of O +
voltage B-Gene +
gated I-Gene +
sodium I-Gene +
channels I-Gene +
as O +
the O +
TTX B-Gene -
- I-Gene -
S I-Gene +
channels I-Gene -
, O +
and O +
which O +
are O +
useful O +
in O +
the O +
treatment O +
or O +
prevention O +
of O +
disorders O +
and O +
diseases O +
in O +
which O +
voltage B-Gene +
gated I-Gene +
sodium I-Gene +
channels I-Gene +
are O +
involved O -
. O +

The O +
invention O +
also O +
relates O +
to O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O +
and O +
the O +
use O +
of O +
these O +
compounds O +
and O +
compositions O +
in O +
the O +
prevention O +
or O +
treatment O +
of O +
such O +
diseases O +
in O +
which O +
voltage B-Gene +
gated I-Gene +
sodium I-Gene +
channels I-Gene +
are O +
involved O -
. O +

Cul4b B-Gene +
as O +
predictive O +
biomarker O +
for O +
cancer O +
treatment O +
The O +
current O +
disclosure O +
describes O +
materials O +
and O +
methods O +
for O +
identifying O +
subjects O +
that O +
would O +
benefit O +
from O +
treatment O +
with O +
a O +
DNA B-Gene +
topoisomerase I-Gene +
1 I-Gene +
inhibitor O -
, O +
based O +
on O +
the O +
levels O +
of O +
cullin B-Gene +
4B I-Gene +
gene O -
, O +
RNA O +
and O +
protein O +
levels O +
in O +
the O +
subject O -
. O +

The O +
disclosure O +
identifies O +
CUL4B B-Gene +
as O +
a O +
predictive O +
biomarker O +
for O +
cancer O +
diagnosis O +
and O +
the O +
subsequent O +
treatment O +
with O +
directed O +
therapeutic O +
agents O -
. O +

The O +
current O +
disclosure O +
also O +
identifies O +
novel O +
therapeutic O +
agents O +
that O +
modulate O +
the O +
level O +
of O +
CUL4B B-Gene +
expression O -
, O +
and O +
sensitize O +
a O +
subject O +
to O +
treatment O +
with O +
a O +
second O +
therapeutic O +
agent O -
. O +

Prophylactic O +
agent O +
and/or O +
therapeutic O +
agent O +
for O +
stress O +
urinary O +
incontinence O +
The O +
problem O +
to O +
be O +
solved O +
by O +
the O +
present O +
invention O +
is O +
to O +
provide O +
an O +
excellent O +
prophylactic O +
agent O +
and/or O +
an O +
excellent O +
therapeutic O +
agent O +
for O +
stress O +
urinary O +
incontinence O -
. O +

The O +
present O +
invention O +
provides O +
a O +
prophylactic O +
agent O +
and/or O +
a O +
therapeutic O +
agent O +
for O +
stress O +
urinary O +
incontinence O -
, O +
which O +
comprises O +
an O +
effective O +
amount O +
of O +
4-piperidyldiphenylpropoxyacetate O +
or O +
a O +
salt O +
thereof O +
and O +
a O +
pharmaceutical O +
carrier O -
. O +

Compositions O +
and O +
methods O +
for O +
modulating O +
hemoglobin B-Gene +
gene O +
family O +
expression O +
Aspects O +
of O +
the O +
invention O +
provide O +
single O +
stranded O +
oligonucleotides O +
for O +
activating O +
or O +
enhancing O +
expression O +
of O +
hemoglobin B-Gene +
genes O +
( O -
HBB B-Gene -
, O +
HBD B-Gene -
, O +
HBEl B-Gene -
, O +
HBG1 B-Gene +
or O +
HBG2 B-Gene -
) O -
. O +

Further O +
aspects O +
provide O +
compositions O +
and O +
kits O +
comprising O +
single O +
stranded O +
oligonucleotides O +
for O +
activating O +
or O +
enhancing O +
expression O +
of O +
hemoglobin B-Gene +
genes O -
. O +

Methods O +
for O +
modulating O +
expression O +
of O +
hemoglobin B-Gene +
genes O +
using O +
the O +
single O +
stranded O +
oligonucleotides O +
are O +
also O +
provided O -
. O +

Further O +
aspects O +
of O +
the O +
invention O +
provide O +
methods O +
for O +
selecting O +
a O +
candidate O +
oligonucleotide O +
for O +
activating O +
or O +
enhancing O +
expression O +
of O +
hemoglobin B-Gene +
genes O -
. O +

Compositions O +
and O +
methods O +
for O +
treatment O +
of O +
peridontitis O +
and O +
rheumatoid O +
arthritis O +
Disclosed O +
are O +
the O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
or O +
its O +
pharmaceutically O +
acceptable O +
salts O -
. O +

The O +
pharmaceutical O +
compositions O +
comprising O +
an O +
effective O +
amount O +
of O +
compounds O +
of O +
Formula O +
( O -
I O -
) O +
useful O +
for O +
the O +
treatment O +
of O +
periodontitis O +
and O +
rheumatoid O +
arthritis O +
may O +
be O +
formulated O +
for O +
oral O -
, O +
buccal O -
, O +
rectal O -
, O +
topical O -
, O +
transdermal O -
, O +
transmucosal O -
, O +
intravenous O -
, O +
parenteral O +
administration O -
, O +
syrup O +
or O +
injection O -
. O +

Polyoxopregnane O +
compounds O +
and O +
use O +
thereof O +
Disclosed O +
are O +
polyoxopregnane O +
compounds O +
and O +
the O +
use O +
of O +
the O +
compounds O +
for O +
the O +
manufacture O +
of O +
medicaments O +
reversing O +
or O +
inhibiting O +
mutidrug O +
resistance O +
of O +
tumor O +
cells O -
. O +

Composition O +
for O +
restricting O +
apoptosis O -
, O +
including O +
mirna O +
of O +
epstein O -
- O -
barr O +
virus O -
, O +
or O +
promoting O +
cell O +
proliferation O +
The O +
present O +
invention O +
relates O +
to O +
uses O +
for O -
: O +
restricting O +
apoptosis O +
of O +
miRNA O +
of O +
Epstein O -
- O -
Barr O +
virus O -
, O +
especially O +
miR B-Gene -
- I-Gene -
BART3 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART3 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART21 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART21 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART18 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART18 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART7 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART7 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART8 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART8 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART9 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART22 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART22 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART19 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART19 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART13 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART13 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART14 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART2 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART1 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART9 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART10 I-Gene -
- I-Gene -
5p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART10 I-Gene -
- I-Gene -
3p I-Gene -
, O +
miR B-Gene -
- I-Gene -
BART14 I-Gene -
- I-Gene -
3p I-Gene +
and O +
their O +
mimics O -
; O +
and O +
promoting O +
cell O +
proliferation O -
. O +

Novel O +
therapeutics O +
for O +
brain O +
cancer O +
Provided O +
herein O +
are O +
novel O +
compositions O +
and O +
methods O +
to O +
inhibit O +
Olig2 B-Gene +
activity O -
. O +

The O +
Olig2 B-Gene +
inhibitors O +
and O +
methods O +
of O +
using O +
the O +
same O +
are O +
useful O -
, O +
inter O +
alia O -
, O +
for O +
treating O +
cancer O -
. O +

In O +
particular O +
the O +
Olig2 B-Gene +
inhibitors O +
may O +
be O +
used O +
to O +
treat O +
glioblastoma O -
. O +

Further O -
, O +
provided O +
are O +
peptide O +
compositions O +
capable O +
of O +
inhibiting O +
Olig B-Gene +
2 I-Gene -
. O +

Neuroendocrine O +
tumor O +
treatment O +
A O +
method O +
for O +
treating O +
a O +
neuroendocrine O +
tumor O -
, O +
particularly O +
pancreatic O +
neuroendocrine O +
tumor O -
, O +
comprising O +
administering O +
to O +
a O +
subject O +
in O +
need O +
thereof O +
a O +
therapeutically O +
effective O +
amount O +
of O +
a O +
compound O +
of O +
formula O +
( O -
I O -
) O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
alone O +
or O +
in O +
combination O +
with O +
at O +
least O +
one O +
therapeutic O +
agent O -
, O +
wherein O +
said O +
neuroendocrine O +
tumor O +
is O +
resistant O +
or O +
refractory O +
to O +
treatment O +
with O +
at O +
least O +
one O +
mTOR B-Gene +
inhibitor O -
; O +
uses O +
of O +
said O +
compounds O +
for O +
the O +
preparation O +
of O +
a O +
medicament O +
for O +
use O +
in O +
the O +
treatment O +
of O +
a O +
neuroendocrine O +
tumor O +
resistant O +
or O +
refractory O +
to O +
treatment O +
with O +
at O +
least O +
one O +
mTOR B-Gene +
inhibitor O -
; O +
uses O +
of O +
said O +
compound O +
for O +
treating O +
said O +
disease O -
; O +
and O +
related O +
pharmaceutical O +
compositions O +
and O +
pharmaceutical O +
package O +
thereof O -
. O +

Method O +
for O +
obtaining O +
high O +
concentrations O +
of O +
the O +
chemical O +
constituent O +
trans O -
- O -
pinocarvyl O +
acetate O +
by O +
hydrodistillation O +
of O +
the O +
aerial O +
parts O +
of O +
microlicia O +
graveolens O +
and O +
obtaining O +
nano O -
- O -
emulsified O +
formulations O +
The O +
method O +
which O +
is O +
the O +
subject O +
matter O +
of O +
the O +
present O +
invention O +
provides O +
a O +
quantitative O +
and O +
qualitative O +
production O +
method O +
for O +
the O +
chemical O +
compound O +
known O +
as O +
trans O -
- O -
pinocarvyl O +
acetate O -
. O +

This O +
compound O +
has O +
relevant O +
applications O +
in O +
the O +
chemical O +
and O +
cosmetic O +
industries O +
for O +
producing O +
perfumes O +
and O +
fragrances O -
. O +

The O +
method O +
which O +
is O +
the O +
subject O +
matter O +
of O +
the O +
present O +
invention O +
also O +
provides O +
nanoemulsions O +
containing O +
essential O +
oil O +
of O +
Microlicia O +
graveolens O -
, O +
thus O +
making O +
its O +
use O +
possible O -
. O +

Novel O +
fatty O +
acid O -
- O -
salicylate O +
conjugates O +
with O +
enhanced O +
therapeutic O +
properties O +
The O +
invention O +
provides O +
compositions O +
and O +
methods O +
for O +
treating O +
or O +
preventing O +
cancer O +
with O +
an O +
inventive O +
composition O -
. O +
' O +

The O +
invention O +
relates O +
to O +
the O +
fields O +
of O +
biomedicine O -
, O +
pharmacology O -
, O +
and O +
molecular O +
biology O -
. O +

Novel O +
heteroaryl O +
and O +
heterocycle O +
compounds O -
, O +
composition O +
and O +
methods O +
thereof O +
Disclosed O +
are O +
novel O +
heteroaryl O +
and O +
heterocycle O +
compounds O +
of O +
formula O +
I-1 O -
, O +
I-2 O +
or O +
I-3 O +
and O +
pharmaceutical O +
compositions O +
comprising O +
them O -
, O +
uses O +
and O +
methods O +
thereof O +
for O +
inhibiting O +
the O +
activity O +
of O +
PI3 B-Gene -
K I-Gene +
and O +
for O +
treating O +
inflammatory O +
and O +
autoimmune O +
diseases O +
and O +
cancer O -
. O +

Benzisoxazole O +
modulators O +
of O +
neurogenesis O +
The O +
present O +
invention O +
relates O +
to O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O +
wherein O +
Ar1 O -
/ O -
Ar2 O +
are O +
phenyl O +
or O +
a O +
5 O +
or O +
6-membered O +
heteroaryl O -
; O +
R1 O -
/ O -
R2 O +
is O +
hydrogen O -
, O +
halogen O -
, O +
lower O +
alkyl O -
, O +
CF3 O +
or O +
lower O +
alkoxy O -
; O +
n O -
, O -
m O +
are O +
1 O +
or O +
2 O -
; O +
or O +
to O +
a O +
pharmaceutically O +
acceptable O +
acid O +
addition O +
salt O -
, O +
to O +
a O +
racemic O +
mixture O +
or O +
to O +
its O +
corresponding O +
enantiomer O +
and/or O +
optical O +
isomers O +
thereof O -
, O +
with O +
the O +
exception O +
of O +
the O +
compound O +
2,1-benzisoxazole,3- O -
( O -
4-chlorophenyl O -
) O -
-5- O -
( O -
1-phenyl-1H O -
- O -
pyrazol-5-yl O -
) O -
- O -
. O +

The O +
compounds O +
may O +
be O +
used O +
for O +
the O +
treatment O +
of O +
schizophrenia O -
, O +
obsessive O -
- O -
compulsive O +
personality O +
disorder O -
, O +
major O +
depression O -
, O +
bipolar O +
disorders O -
, O +
anxiety O +
disorders O -
, O +
normal O +
aging O -
, O +
epilepsy O -
, O +
retinal O +
degeneration O -
, O +
traumatic O +
brain O +
injury O -
, O +
spinal O +
cord O +
injury O -
, O +
post O -
- O -
traumatic O +
stress O +
disorder O -
, O +
panic O +
disorder O -
, O +
Parkinson O -
's O +
disease O -
, O +
dementia O -
, O +
Alzheimer O -
's O +
disease O -
, O +
mild O +
cognitive O +
impairment O -
, O +
chemotherapy O -
- O -
induced O +
cognitive O +
dysfunction O -
, O +
Down O +
syndrome O -
, O +
autism O +
spectrum O +
disorders O -
, O +
hearing O +
loss O -
, O +
tinnitus O -
, O +
spinocerebellar O +
ataxia O -
, O +
amyotrophic O +
lateral O +
sclerosis O -
, O +
multiple O +
sclerosis O -
, O +
Huntington O -
's O +
disease O -
, O +
stroke O -
, O +
radiation O +
therapy O -
, O +
chronic O +
stress O -
, O +
abuse O +
of O +
neuro O -
- O -
active O +
drugs O -
, O +
such O +
as O +
alcohol O -
, O +
opiates O -
, O +
methamphetamine O -
, O +
phencyclidine O +
and O +
cocaine O -
. O +

Substituted O +
naphthyridinedione O +
derivatives O +
as O +
hiv B-Gene +
integrase I-Gene +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
Substituted O +
Naphthyridinedione O +
Derivatives O +
and O +
pharmaceutically O +
acceptable O +
salts O +
thereof O -
. O +

The O +
present O +
invention O +
also O +
relates O +
to O +
compositions O +
comprising O +
at O +
least O +
one O +
Substituted O +
Naphthyridinedione O +
Derivative O -
, O +
and O +
methods O +
of O +
using O +
the O +
Substituted O +
Naphthyridinedione O +
Derivatives O +
for O +
treating O +
or O +
preventing O +
HIV O +
infection O +
in O +
a O +
subject O -
. O +

Piperazinotrizole O +
compound O -
, O +
preparation O +
method O +
therefor O -
, O +
and O +
use O +
thereof O +
in O +
drug O +
preparation O +
Provided O +
is O +
a O +
piperazinotrizole O +
compound O +
represented O +
by O +
general O +
formula O +
I O +
or O +
an O +
isomer O -
, O +
a O +
pharmaceutically O +
acceptable O +
salt O -
, O +
ester O -
, O +
prodrug O +
or O +
hydrate O +
thereof O -
. O +

Also O +
provided O +
are O +
a O +
method O +
for O +
preparing O +
the O +
compound O -
, O +
a O +
drug O +
composition O +
containing O +
the O +
compound O -
, O +
and O +
a O +
use O +
thereof O +
as O +
a O +
high O -
- O -
selectivity O +
poly B-Gene -
( I-Gene -
ADP I-Gene -
- I-Gene -
ribose I-Gene -
) I-Gene +
polymerase-1 O +
( O -
PARP1 B-Gene -
) O +
inhibitor O +
in O +
the O +
preparation O +
of O +
drugs O +
for O +
the O +
prevention O +
and/or O +
treatment O +
of O +
PARP B-Gene -
- O -
related O +
diseases O -
. O +

Orl-1 B-Gene +
receptor O +
antagonists O +
for O +
the O +
treatment O +
of O +
anxiety O +
The O +
use O +
of O +
ORL-1 B-Gene +
receptor O +
antagonists O +
of O +
the O +
formula O +
( O -
I O -
) O +
for O +
the O +
treatment O +
of O +
anxiety O +
disorders O +
is O +
described O -
. O +

( O -
aza- O -
) O -
isoquinolinone O +
derivatives O +
Compounds O +
of O +
the O +
formula O +
( O -
I O -
) O -
, O +
in O +
which O +
R1 O -
, O +
X O -
, O +
Y O +
and O +
n O +
have O +
the O +
meanings O +
indicated O +
in O +
Claim O +
1 O -
, O +
are O +
inhibitors O +
of O +
Tankyrase O -
, O +
and O +
can O +
be O +
employed O -
, O +
inter O +
alia O -
, O +
for O +
the O +
treatment O +
of O +
diseases O +
such O +
as O +
cancer O -
, O +
cardiovascular O +
diseases O -
, O +
central O +
nervous O +
system O +
injury O +
and O +
different O +
forms O +
of O +
inflammation O -
. O +

Buffer O +
substance O +
for O +
the O +
treatment O +
of O +
wounds O +
The O +
invention O +
relates O +
to O +
buffer O +
substances O +
for O +
the O +
phase O -
- O -
appropriate O +
treatment O +
of O +
wounds O -
, O +
said O +
treatment O +
comprising O +
the O +
suppression O +
of O +
fibrin B-Gene +
formation O +
and/or O +
fibrin B-Gene +
cross O -
- O -
linking O -
. O +

The O +
invention O +
further O +
relates O +
to O +
a O +
wound O +
dressing O +
product O +
containing O +
said O +
buffer O +
substances O +
to O +
suppress O +
fibrin B-Gene +
formation O +
and/or O +
fibrin B-Gene +
cross O -
- O -
linking O -
. O +

Therapeutic O +
and O +
diagnostic O +
mirna O +
regulator O +
in O +
kidney O +
disease O +
The O +
present O +
invention O +
discloses O +
a O +
method O +
of O +
diagnosing O +
glomerular O +
kidney O +
disease O +
or O +
the O +
risk O +
of O +
glomerular O +
kidney O +
disease O +
comprising O +
determining O +
the O +
expression O +
level O +
of O +
miRNA O +
miR-193a O -
, O +
wherein O +
said O +
glomerular O +
kidney O +
disease O +
or O +
risk O +
thereof O +
is O +
detected O +
if O +
miR-193a O +
expression O +
levels O +
are O +
increased O +
as O +
compared O +
to O +
a O +
healthy O +
control O -
, O +
method O +
of O +
prophylactically O +
treating O +
a O +
glomerular O +
kidney O +
disease O +
or O +
of O +
reducing O +
the O +
risk O +
of O +
glomerular O +
kidney O +
disease O +
progression O +
in O +
a O +
patient O +
comprising O +
inhibiting O +
miR-193a O +
in O +
a O +
podocyte O +
cell O +
in O +
said O +
patient O +
and O +
suitable O +
means O +
for O +
said O +
methods O -
. O +

Preventive O +
products O +
against O +
pathogenic O +
germs O -
, O +
and O +
method O +
for O +
use O +
thereof O +
The O +
subject O +
of O +
the O +
invention O +
is O +
a O +
group O +
of O +
preventive O +
products O +
to O +
be O +
used O +
against O +
pathogenic O +
germs O -
, O +
and O +
the O +
method O +
for O +
using O +
these O +
products O -
, O +
each O +
product O +
is O +
being O +
a O +
special O +
combined O +
additive O +
for O +
preventive O +
purposes O -
, O +
which O +
could O +
be O +
used O +
as O +
additive O +
or O +
supplementary O +
material O +
in O +
animal O +
feed O +
to O +
produce O +
products O +
primarily O +
for O +
preventing O +
and O +
treating O +
bacterial O +
infection O +
of O +
poultry O -
, O +
which O +
selectively O +
inhibit O +
the O +
propagation O +
of O +
pathogenic O +
germs O +
that O +
generate O +
endo O +
and O +
exo O +
toxins O -
. O +

The O +
product O +
according O +
to O +
the O +
invention O +
suitable O +
primarily O +
for O +
preventing O +
and O +
treating O +
bacterial O +
contamination O +
of O +
poultry O -
. O +

It O +
is O +
charactrised O +
by O +
that O -
, O +
the O +
product O +
is O +
prepared O +
by O +
homogenizing O +
or O +
blending O +
methylglyoxal O +
or O +
its O +
diacetate O -
, O +
i.e. O +
methylglyoxal O +
diacetate O +
with O +
some O +
organic O +
acids O +
and/or O +
in O +
combination O +
with O +
Na O +
salts O +
of O +
organic O +
acids O -
. O +

During O +
the O +
method O +
according O +
to O +
the O +
invention O +
the O +
product O +
is O +
added O +
to O +
the O +
drinking O +
water O +
of O +
the O +
animals O +
and/or O +
mixed O +
in O +
the O +
feed O -
, O +
and O +
in O +
this O +
way O +
it O +
is O +
administered O +
to O +
the O +
animals O -
, O +
and/or O +
used O +
for O +
disinfecting O +
the O +
bedding O +
materials O -
. O +

1,6- O +
diazabicyclo O +
[ O -
3,2,1 O -
] O +
octan- O +
7- O +
one O +
derivatives O +
and O +
their O +
use O +
in O +
the O +
treatment O +
of O +
bacterial O +
infections O +
Compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
their O +
preparation O +
and O +
use O +
in O +
preventing O +
or O +
treating O +
bacterial O +
infections O +
are O +
disclosed O -
. O +

Quinazolinone O +
compounds O +
and O +
derivatives O +
thereof O +
Compounds O +
of O +
Formula O +

I O +
are O +
useful O +
inhibitors O +
of O +
tankyrase O -
. O +

Compounds O +
of O +
Formula O +
I O +
have O +
the O +
following O +
structure O -
: O +
where O +
the O +
definitions O +
of O +
the O +
variables O +
are O +
provided O +
herein O -
. O +

Nootropic O +
compositions O +
for O +
improving O +
memory O +
performance O +
The O +
invention O +
relates O +
to O +
compositions O +
and O +
methods O +
for O +
improving O +
memory O +
and O +
related O +
functions O +
as O +
alertness O -
, O +
attention O -
, O +
concentration O -
, O +
learning O -
, O +
and O +
language O +
processing O -
. O +

More O +
particularly O -
, O +
the O +
invention O +
relates O +
to O +
compositions O +
comprising O +
at O +
least O +
two O +
drugs O +
selected O +
from O +
cinacalcet O -
, O +
baclofen O -
, O +
acamprosate O -
, O +
mexiletine O -
, O +
sulfisoxazole O +
and O +
torasemide O +
useful O +
to O +
enhance O +
memory O +
and O +
related O +
functions O +
in O +
healthy O +
subjects O +
or O +
subjects O +
suffering O +
from O +
conditions O +
or O +
disorders O +
having O +
a O +
negative O +
impact O +
on O +
their O +
memory O -
. O +

Crystal O +
having O +
crystal O +
habits O +
and O +
pharmaceutical O +
composition O +
obtained O +
by O +
processing O +
the O +
crystal O +
An O +
object O +
is O +
to O +
provide O +
means O +
for O +
improving O +
the O +
solubility O +
of O +
luliconazole O -
. O +

Disclosed O +
is O +
a O +
crystal O +
of O +
luliconazole O +
wherein O +
the O +
crystal O +
has O +
such O +
a O +
crystal O +
habit O +
that O +
( O -
021 O -
) O +
plane O +
is O +
a O +
specific O +
crystal O +
growth O +
plane O -
. O +

" O -
novel O +
cross O -
- O -
linkers O +
for O +
hydrogels O -
, O +
hydrogels O +
including O +
these O +
cross O -
- O -
linkers O +
and O +
applications O +
thereof O -
" O +
The O +
present O +
invention O +
relates O +
to O +
novel O +
cross O -
- O -
linkers O +
for O +
hydrogels O -
, O +
in O +
particular O +
for O +
hyaluronan O +
hydrogels O -
, O +
corresponding O +
hydrogels O +
including O +
said O +
cross O -
- O -
linkers O +
and O +
various O +
applications O +
thereof O -
. O +

The O +
cross O +
linker O +
of O +
the O +
invention O +
is O +
a O +
bi- O +
or O +
multifunctional O +
cross O -
- O -
linker O +
comprising O +
or O +
consisting O +
of O +
an O +
aromatic O +
or O +
heteroaromatic O +
ring O +
system O +
with O +
3 O -
- O -
6 O +
C O +
atoms O +
which O +
is O +
coupled O +
via O +
functional O +
groups O +
on O +
at O +
least O +
2 O +
ring O +
positions O +
with O +
at O +
least O +
2 O +
terminal O +
groups O +
capable O +
to O +
form O +
a O +
covalent O +
bond O +
with O +
thiol O +
or O +
amino O +
groups O -
, O +
in O +
particular O +
with O +
thiol O +
groups O +
in O +
a O +
thiol O -
- O -
en O +
reaction O -
. O +

The O +
cross O -
- O -
linker O +
may O +
be O +
charged O +
or O +
uncharged O -
. O +

In O +
a O +
specific O +
embodiment O -
, O +
the O +
terminal O +
groups O +
are O +
coupled O +
to O +
carboxy O +
groups O +
of O +
the O +
aromatic O +
or O +
heteroaromatic O +
ring O +
system O +
via O +
an O +
ester O +
or O +
amide O +
bond O -
. O +

More O +
specifically O -
, O +
the O +
cross O -
- O -
linker O +
of O +
the O +
invention O +
is O +
a O +
derivative O +
of O +
pyridine-3 O -
, O +
5-dicarboxylic O +
acid O +
or O +
a O +
corresponding O +
pyridinium O +
salt O +
thereof O +
wherein O +
2 O +
terminal O +
groups O +
are O +
coupled O +
to O +
the O +
carboxy O +
groups O +
of O +
the O +
pyridine O +
or O +
pyridinium O +
core O +
via O +
an O +
ester O +
or O +
amide O +
bond O -
. O +

In O +
a O +
preferred O +
embodiment O -
, O +
the O +
cross O -
- O -
linker O +
is O +
N3,N5-bis O -
( O -
2-acrylamidoethyl O -
) O +
pyridine-3 O -
, O +
5-dicarboxamide O +
or O +
a O +
3,5-bis O -
( O -
( O -
2-acrylamidoethyl O -
) O +
carbamoyl O -
) O +
-1-methylpyridin O -
- O -
l O -
- O -
ium O -
- O -
halogenide O -
. O +

Dihydroferulic O +
acid O +
and/or O +
dihydrocaffeic O +
acid O +
for O +
use O +
in O +
the O +
treatment O +
of O +
metabolic O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
a O +
composition O +
comprising O +
a O +
compound O +
of O +
the O +
formula O +
I O +
for O +
use O +
as O +
a O +
medicament O -
, O +
wherein O +
R1 O +
is O +
methyl O +
or O +
hydrogen O -
, O +
and O +
wherein O +
R2 O +
is O +
methyl O +
or O +
hydrogen O -
. O +

The O +
invention O +
furthermore O +
relates O +
to O +
food O +
ingredients O +
and O +
food O +
products O +
comprising O +
a O +
compound O +
of O +
the O +
formula O +
I. O +
The O +
invention O +
also O +
relates O +
to O +
processes O +
for O +
producing O +
compounds O +
of O +
the O +
formula O +
I. O +

Na O -
- O -
acyl O +
derivatives O +
of O +
aminoacyl-2-cyanopyrrolidine O -
- O -
inhibitors O +
of O +
prolyl B-Gene +
endopeptidase I-Gene +
and O +
dipeptidyl B-Gene +
peptidase I-Gene -
- I-Gene -
iv I-Gene -
, O +
having O +
hypoglycemic O -
, O +
antihypoxic O -
, O +
neuroprotective O +
action O +
and O +
action O +
of O +
cognitive O +
function O +
improvement O +
The O +
subject O +
of O +
the O +
present O +
invention O +
is O +
nÎ± O -
- O -
acyl O +
derivatives O +
of O +
aminoacyl-2-cyanopyrrolidine O +
- O +
inhibitors O +
of O +
prolyl O +
endopeptidase B-Gene +
and O +
dipeptidyl O +
peptidase B-Gene -
- I-Gene -
iv I-Gene -
, I-Gene +
having O +
hypoglycemic O -
, O +
antihypoxic O -
, O +
neuroprotective O +
action O +
and O +
action O +
of O +
cognitive O +
function O +
improvement O -
. O +

Phenyl O +
1,2-isoxazolyl O +
or O +
phenyl O +
1,2-pyrazole O +
compound O +
and O +
application O +
thereof O +
Disclosed O +
is O +
an O +
application O +
of O +
a O +
phenyl O +
1,2-isoxazolyl O +
or O +
1,2-pyrazole O +
compound O +
of O +
the O +
following O +
structure O +
formula O +
( O -
I O -
) O -
. O +

It O +
is O +
proved O +
through O +
a O +
biological O +
activity O +
test O -
, O +
the O +
compound O +
has O +
an O +
obvious O +
activity O +
of O +
inhibiting O +
the O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene -
. O +

Therefore O -
, O +
the O +
phenyl O +
1,2-isoxazolyl O +
or O +
1,2-pyrazole O +
compound O +
of O +
the O +
present O +
invention O +
can O +
be O +
used O +
as O +
an O +
inhibitor O +
of O +
the O +
heat B-Gene +
shock I-Gene +
protein I-Gene +
90 I-Gene +
for O +
curing O +
cancers O -
. O +

Combination O +
of O +
a O +
6-oxo-1,6-dihydro O -
- O -
pyridazine O +
derivative O +
having O +
anti O -
- O -
cancer O +
activity O +
with O +
a O +
mek O +
inhibitor O +
A O +
pharmaceutical O +
composition O +
comprising O -
: O +
3- O -
( O -
1- O -
{ O -
3- O -
[ O -
5- O -
( O -
1-methyl O -
- O -
piperidin-4-ylmethoxy O -
) O -
-pyrimidin-2-yl O -
] O -
-benzyl O -
} O -
-6-oxo-1,6-dihydro O -
- O -
pyridazin-3-yl O -
) O -
- O +
benzonitrile O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
and/or O +
solvate O +
thereof O +
and O +
N- O -
( O -
( O -
S O -
) O -
-2,3-dihydroxy O -
- O -
propyl O -
) O -
-3- O -
( O -
2-fluoro-4-iodo O -
- O -
phenylamino O -
) O -
-isonicotinamide O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
and/or O +
solvate O +
thereof O -
. O +

5-fluoro O -
- O -
n- O -
( O -
pyridin-2-yl O -
) O -
pyridin-2-amine O +
derivatives O +
containing O +
a O +
sulfone O +
group O +
The O +
present O +
invention O +
relates O +
to O +
5-fluoro O -
- O -
N- O -
( O -
pyridin-2-yl O -
) O -
pyridin-2-amine O +
derivatives O +
containing O +
a O +
sulfone O +
group O +
of O +
general O +
formula O +
( O -
I O -
) O +
as O +
described O +
and O +
defined O +
herein O -
, O +
and O +
methods O +
for O +
their O +
preparation O -
, O +
their O +
use O +
for O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
disorders O -
, O +
in O +
particular O +
of O +
hyper O -
- O -
proliferative O +
disorders O +
and/or O +
virally O +
induced O +
infectious O +
diseases O +
and/or O +
of O +
cardiovascular O +
diseases O -
. O +

The O +
invention O +
further O +
relates O +
to O +
intermediate O +
compounds O +
useful O +
in O +
the O +
preparation O +
of O +
said O +
compounds O +
of O +
general O +
formula O +
( O -
I O -
) O -
. O +

Anthocyanidin O +
complex O +
for O +
the O +
treatment O +
of O +
multiple O +
myeloma O +
The O +
subject O +
matter O +
of O +
the O +
invention O +
is O +
a O +
complex O +
of O +
delphinidin O +
and O +
a O +
sulfoalkyl O +
ether O +
ÃŸ O -
- O -
cyclodextrin O +
for O +
use O +
as O +
a O +
medicinal O +
drug O -
, O +
in O +
particular O +
in O +
the O +
treatment O +
of O +
multiple O +
myeloma O -
. O +

Inhibitors O +
of O +
cyclin B-Gene -
- I-Gene -
dependent I-Gene +
kinase I-Gene +
7 I-Gene +
( O -
cdk7 B-Gene -
) O +
The O +
present O +
invention O +
provides O +
novel O +
compounds O +
of O +
Formula O +
( O -
I O -
) O -
, O +
and O +
pharmaceutically O +
acceptable O +
salts O -
, O +
solvates O -
, O +
hydrates O -
, O +
polymorphs O -
, O +
co O -
- O -
crystals O -
, O +
tautomers O -
, O +
stereoisomers O -
, O +
isotopically O +
labeled O +
derivatives O -
, O +
prodrugs O -
, O +
and O +
compositions O +
thereof O -
. O +

Also O +
provided O +
are O +
methods O +
and O +
kits O +
involving O +
the O +
inventive O +
compounds O +
or O +
compositions O +
for O +
treating O +
or O +
preventing O +
proliferative O +
diseases O +
( O -
e.g. O -
, O +
cancers O +
( O -
e.g. O -
, O +
leukemia O -
, O +
lymphoma O -
, O +
melanoma O -
, O +
multiple O +
myeloma O -
, O +
breast O +
cancer O -
, O +
Ewing O -
's O +
sarcoma O -
, O +
osteosarcoma O -
, O +
brain O +
cancer O -
, O +
neuroblastoma O -
, O +
lung O +
cancer O -
) O -
, O +
benign O +
neoplasms O -
, O +
angiogenesis O -
, O +
inflammatory O +
diseases O -
, O +
autoinflammatory O +
diseases O -
, O +
and O +
autoimmune O +
diseases O -
) O +
in O +
a O +
subject O -
. O +

Treatment O +
of O +
a O +
subject O +
with O +
a O +
proliferative O +
disease O +
using O +
a O +
compound O +
or O +
composition O +
of O +
the O +
invention O +
may O +
inhibit O +
the O +
aberrant O +
activity O +
of O +
a O +
kinase B-Gene -
, O +
such O +
as O +
cyclin B-Gene -
- I-Gene -
dependent I-Gene +
kinase I-Gene +
( O -
CDK B-Gene -
) O +
( O -
e.g. O -
, O +
cyclin B-Gene -
- I-Gene -
dependent I-Gene +
kinase I-Gene +
7 I-Gene +
( O -
CDK7 B-Gene -
) O -
) O -
, O +
and O +
therefore O -
, O +
induce O +
cellular O +
apoptosis O +
and/or O +
inhibit O +
transcription O +
in O +
the O +
subject O -
. O +

Substituted O +
pyrimidinyl O +
and O +
pyridinyl O -
- O -
pyrrolopyridinones O -
, O +
process O +
for O +
their O +
preparation O +
and O +
their O +
use O +
as O +
kinase O +
inhibitors O +
The O +
present O +
invention O +
relates O +
to O +
substituted O +
pyrimidinyl- O +
and O +
pyridinylpyrrolopyridinone O +
compounds O +
which O +
modulate O +
the O +
activity O +
of O +
protein O +
kinases O +
and O +
are O +
therefore O +
useful O +
in O +
treating O +
diseases O +
caused O +
by O +
dysregulated O +
protein O +
kinase O +
activity O -
, O +
in O +
particular O +
RET O +
family O +
kinases O -
. O +

The O +
present O +
invention O +
also O +
provides O +
methods O +
for O +
preparing O +
these O +
compounds O -
, O +
pharmaceutical O +
compositions O +
comprising O +
these O +
compounds O -
, O +
and O +
methods O +
of O +
treating O +
diseases O +
utilizing O +
pharmaceutical O +
compositions O +
containing O +
these O +
compounds O -
. O +

Compositions O -
, O +
uses O +
and O +
methods O +
for O +
treating O +
or O +
preventing O +
dental O +
caries O +
The O +
present O +
invention O +
provides O +
compositions O -
, O +
uses O +
and O +
methods O +
thereof O -
, O +
for O +
inhibiting O +
the O +
growth O +
of O +
caries O -
- O -
causing O +
bacteria O -
. O +

The O +
composition O +
comprises O +
xylitol O -
, O +
sodium O +
citrate O -
, O +
sodium O +
bicarbonate O -
, O +
anionic O +
polymers O +
and O +
acceptable O +
carrier O +
materials O -
. O +

The O +
compositions O +
can O +
tend O +
to O +
be O +
used O +
for O +
treating O +
or O +
preventing O +
a O +
condition O +
caused O +
by O +
caries O -
- O -
causing O +
bacteria O +
The O +
compositions O +
can O +
further O +
tend O +
to O +
be O +
used O +
in O +
patients O +
such O +
as O +
children O -
, O +
adolescents O +
or O +
patients O +
suffering O +
from O +
a O +
heightened O +
susceptibility O +
to O +
toxic O +
substances O -
. O +

Use O +
of O +
pkc412 O +
in O +
the O +
reactivation O +
of O +
latent O +
hiv-1 O +
HIV-1 O +
latency O +
is O +
a O +
major O +
obstacle O +
in O +
HIV-1 O +
eradication O -
. O +

Although O +
current O +
highly O +
active O +
antiretroviral O +
therapy O +
( O -
HAART O -
) O +
has O +
efficiently O +
decreased O +
the O +
viral O +
load O +
in O +
patients O -
, O +
latently O +
infected O +
cells O +
are O +
permanent O +
reservoirs O +
and O +
inevitably O +
lead O +
to O +
viral O +
rebound O +
upon O +
discontinuation O +
of O +
HAART O -
. O +

Therefore O -
, O +
extensive O +
efforts O +
are O +
being O +
directed O +
toward O +
the O +
reactivation O +
of O +
latent O +
HIV O +
reservoirs O +
with O +
the O +
hope O +
that O +
latently O +
infected O +
cells O +
will O +
be O +
eliminated O +
by O +
the O +
host O +
immune O +
system O +
and/or O +
virus O -
- O -
mediated O +
cell O +
lysis O -
. O +

We O +
are O +
currently O +
working O +
on O +
developing O +
strategies O +
to O +
reactivate O +
the O +
latent O +
viral O +
reservoir O +
in O +
order O +
to O +
eliminate O +
them O -
. O +

Through O +
high O -
- O -
throughput O +
screening O -
, O +
an O +
anti- O +
cancer O +
molecule O +
PKC412 O +
that O +
is O +
able O +
to O +
reactivate O +
HIV-1 O +
expression O +
from O +
a O +
HIV-1 O +
latently O +
infected O +
ACH2 O +
cell O +
line O +
and O +
latently O +
infected O +
CD4 O -
+ O +
T O +
cells O +
has O +
been O +
identified O -
. O +

Medical O +
patch O +
[ O -
Problem O -
] O +
To O +
provide O +
a O +
medical O +
patch O +
with O +
an O +
adhesive O +
layer O +
formed O +
thereon O -
, O +
said O +
medical O +
patch O +
containing O +
a O +
large O +
amount O +
of O +
a O +
drug O +
and O +
a O +
dissolution O +
auxiliary O -
, O +
being O +
flexible O +
without O +
losing O +
shape O +
and O +
leaving O +
behind O +
adhesive O +
residue O -
, O +
and O +
exhibiting O +
excellent O +
drug O +
release O +
from O +
the O +
adhesive O +
layer O -
. O +

[ O -
Solution O -
] O +
A O +
medical O +
patch O +
comprising O -
: O +
a O +
drug O +
having O +
a O +
secondary O +
or O +
tertiary O +
amine O +
structure O +
in O +
the O +
molecules O +
thereof O -
; O +
a O +
liquid O +
auxiliary O +
for O +
the O +
drug O -
; O +
and O +
a O +
resin O +
composition O +
formed O +
by O +
cross O -
- O -
linking O +
a O +
copolymerized O +
acrylic O +
resin O +
with O +
an O +
isocyanate O +
group O -
- O -
containing O +
cross O -
- O -
linking O +
agent O +
that O +
has O +
been O +
blocked O -
, O +
said O +
copolymerized O +
acrylic O +
resin O +
having O +
a O +
( O -
meth O -
) O -
acrylate O +
monomer O +
as O +
a O +
main O +
monomer O +
component O +
and O +
having O +
a O +
functional O +
group O +
capable O +
of O +
reacting O +
with O +
the O +
aforementioned O +
isocyanate O +
group O -
- O -
containing O +
cross O -
- O -
linking O +
agent O +
to O +
thereby O +
form O +
a O +
cross O -
- O -
linked O +
structure O -
. O +

The O +
solubility O +
of O +
the O +
drug O +
in O +
a O +
phosphate O +
buffer O +
solution O +
( O -
pH6.4 O -
) O +
is O +
at O +
least O +
0.5wt% O -
. O +

Inhibitor B-Gene +
of I-Gene +
apoptosis I-Gene +
protein I-Gene +
( O -
iap B-Gene -
) O +
antagonists O +
Provided O +
herein O +
are O +
compounds O +
that O +
modulate O +
the O +
activity O +
of O +
inhibitor B-Gene +
of I-Gene +
apoptosis I-Gene +
proteins I-Gene +
( O -
IAPs B-Gene -
) O -
, O +
compositions O +
comprising O +
the O +
compounds O -
, O +
and O +
methods O +
of O +
using O +
the O +
compounds O +
and O +
compositions O +
comprising O +
the O +
compounds O -
. O +

Prevention O +
or O +
treatment O +
agent O +
for O +
hepatic O +
fibrosis O +
In O +
the O +
present O +
invention O -
, O +
a O +
CBP B-Gene -
/ O -
Î² B-Gene -
- I-Gene -
catenin I-Gene +
inhibitor O +
exhibits O +
a O +
superior O +
defibrinating O +
effect O +
with O +
respect O +
to O +
Cre O -
/ O -
loxP O -
/ O -
HCV O -
- O -
MxCre O +
transgenic O +
mice O -
, O +
which O +
are O +
an O +
experimental O +
animal O +
model O +
for O +
hepatic O +
fibrosis O -
, O +
and O +
is O +
useful O +
as O +
a O +
prevention O +
or O +
treatment O +
drug O +
for O +
hepatic O +
fibrosis O -
. O +

Prophylactic O -
/ O -
therapeutic O +
agent O +
for O +
dry O +
eye O +
Provided O +
is O +
a O +
prophylactic O -
/ O -
therapeutic O +
agent O +
for O +
dry O +
eye O -
, O +
which O +
comprises O +
a O +
novel O +
component O +
capable O +
of O +
preventing O +
the O +
deterioration O +
of O +
a O +
tear O +
fluid O +
secretion O +
ability O +
and O +
also O +
capable O +
of O +
inhibiting O +
the O +
generation O +
of O +
active O +
oxygen O +
in O +
tear O +
gland O +
tissues O -
. O +

The O +
prophylactic O -
/ O -
therapeutic O +
agent O +
for O +
dry O +
eye O +
according O +
to O +
the O +
present O +
invention O +
contains O +
a O +
maqui O +
berry O +
extract O +
as O +
an O +
active O +
ingredient O -
. O +

The O +
prophylactic O -
/ O -
therapeutic O +
agent O +
for O +
dry O +
eye O +
according O +
to O +
the O +
present O +
invention O +
may O +
contain O -
, O +
as O +
an O +
active O +
ingredient O -
, O +
a O +
delphinidin O +
glycoside O +
that O +
is O +
extracted O +
from O +
maqui O +
berry O -
. O +

The O +
prophylactic O -
/ O -
therapeutic O +
agent O +
for O +
dry O +
eye O +
according O +
to O +
the O +
present O +
invention O +
may O +
contain O +
at O +
least O +
one O +
component O +
selected O +
from O +
delphinidin-3-sambubioside-5-glucoside O -
, O +
delphinidin-3,5-diglucoside O -
, O +
delphinidin-3-sambubioside O +
and O +
delphinidin-3-glucoside O -
, O +
desirably O +
delphinidin-3,5-diglucoside O -
, O +
as O +
an O +
active O +
ingredient O -
. O +

Pyrazolyl O -
- O -
based O +
carboxamides O +
i O +
as O +
crac B-Gene +
channel I-Gene +
inhibitors O +
The O +
Invention O +
relates O +
to O +
pyrazolyl O -
- O -
based O +
carboxamide O +
compounds O +
of O +
formula O +
( O -
l O -
) O +
useful O +
as O +
ICRAC B-Gene +
inhibitors O -
, O +
to O +
pharmaceutical O +
compositions O +
containing O +
these O +
compounds O +
and O +
to O +
these O +
compounds O +
for O +
the O +
use O +
in O +
the O +
treatment O +
and/or O +
prophylaxis O +
of O +
diseases O +
and/or O +
disorders O -
, O +
in O +
particular O +
inflammatory O +
diseases O +
and/or O +
inflammatory O +
disorders O -
. O +

Pyrrolotriazine O +
derivatives O +
as O +
pi3k O +
inhibitors O +
New O +
pyrrolotriazine O +
derivatives O +
having O +
the O +
chemical O +
structure O +
of O +
formula O +
( O -
I O -
) O +
are O +
disclosed O -
; O +
as O +
well O +
as O +
process O +
for O +
their O +
preparation O -
, O +
pharmaceutical O +
compositions O +
comprising O +
them O +
and O +
their O +
use O +
in O +
therapy O +
as O +
inhibitors O +
of O +
Phosphoinositide O +
3-Kinases O +
( O -
PI3Ks O -
) O +

Compositions O +
for O +
the O +
treatment O +
of O +
inflammatory O +
diseases O +
This O +
invention O +
provides O +
compounds O -
, O +
methods O +
and O +
compositions O +
for O +
the O +
treatment O +
of O +
inflammatory O +
diseases O -
, O +
comprising O +
the O +
timely O +
administration O +
of O +
a O +
provided O +
compound O -
, O +
which O +
has O +
a O +
structure O +
related O +
to O +
an O +
endogenously O +
formed O +
lipid O +
mediator O -
. O +

One O +
embodiment O +
of O +
the O +
present O +
invention O +
is O +
directed O +
to O +
a O +
compound O +
selected O +
from O +
a O +
group O +
having O +
the O +
general O +
formula O +
A. O +

Substituted O +
2-aza O -
- O -
bicyclo O -
[ O -
2.2.1 O -
] O -
heptane-3-carboxylic O +
acid O +
( O -
cyano O -
- O -
methyl O -
) O -
-amides O +
inhibitors O +
of O +
cathepsin O +
c O +
This O +
invention O +
relates O +
to O +
2-Aza O -
- O -
bicyclo O -
[ O -
2.2.1 O -
] O -
heptane-3-carboxylic O +
acid O +
( O -
cyano O -
- O -
methyl O -
) O -
-amides O +
of O +
formula O +
( O -
1 O -
) O +
and O +
their O +
use O +
as O +
inhibitors O +
of O +
Cathepsin O +
C O -
, O +
pharmaceutical O +
compositions O +
containing O +
the O +
same O -
, O +
and O +
methods O +
of O +
using O +
the O +
same O +
as O +
agents O +
for O +
treatment O +
and/or O +
prevention O +
of O +
diseases O +
connected O +
with O +
dipeptidyl O +
peptidase O +
I O +
activity O -
, O +
e.g. O +
respiratory O +
diseases O -
. O +

Pyrazole O -
- O -
amide O +
compound O +
and O +
medicinal O +
uses O +
therefor O +
Provided O +
is O +
a O +
compound O +
as O +
represented O +
by O +
formula O +
[ O -
I O -
] O +
[ O -
in O +
which O +
n O +
indicates O +
1 O +
or O +
2 O -
] O -
, O +
formula O +
[ O -
II O -
] O +
or O +
[ O -
IIh O -
] O -
, O +
or O +
formula O +
[ O -
III O -
] O -
, O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
. O +

Also O +
provided O +
are O +
medicinal O +
uses O +
for O +
the O +
compound O +
or O +
the O +
salt O +
thereof O -
. O +

Methods O +
of O +
treating O -
, O +
reducing O +
the O +
incidence O +
of O -
, O +
and/or O +
preventing O +
ischemic O +
events O +
Methods O +
of O +
treating O -
, O +
reducing O +
the O +
incidence O +
of O -
, O +
and/or O +
preventing O +
an O +
ischemic O +
event O +
in O +
a O +
patient O +
undergoing O +
percutaneous O +
coronary O +
intervention O +
( O -
PCI O -
) O -
, O +
comprising O +
administering O +
to O +
the O +
patient O +
a O +
pharmaceutical O +
composition O +
comprising O +
cangrelor O -
. O +

The O +
method O +
may O +
further O +
comprise O +
administering O +
an O +
additional O +
therapeutic O +
agent O +
to O +
the O +
patient O -
, O +
the O +
additional O +
therapeutic O +
agent O +
comprising O +
a O +
P2Yi2 O +
inhibitor O -
. O +

Pharmaceutical O +
compositions O +
useful O +
for O +
treating O -
, O +
reducing O +
the O +
incidence O +
of O -
, O +
and/or O +
preventing O +
an O +
ischemic O +
event O +
in O +
a O +
patient O +
undergoing O +
PCI O -
. O +

The O +
pharmaceutical O +
compositions O +
comprise O +
cangrelor O -
. O +

Methods O +
of O +
preparing O +
a O +
pharmaceutical O +
composition O +
for O +
treating O -
, O +
reducing O +
the O +
incidence O +
of O -
, O +
and/or O +
preventing O +
an O +
ischemic O +
event O +
in O +
a O +
patient O +
undergoing O +
PCI O -
, O +
comprising O +
admixing O +
cangrelor O +
with O +
one O +
or O +
more O +
pharmaceutically O +
acceptable O +
excipients O -
. O +

An O +
ischemic O +
event O +
may O +
include O +
stent O +
thrombosis O -
, O +
myocardial O +
infarction O -
, O +
ischemia O -
- O -
driven O +
revascularization O -
, O +
and O +
mortality O -
. O +

Compositions O +
for O +
use O +
in O +
treating O +
heavy O +
menstrual O +
bleeding O +
and O +
uterine O +
fibroids O +
The O +
present O +
invention O +
relates O +
to O +
the O +
method O +
of O +
treating O +
heavy O +
menstrual O +
bleeding O +
in O +
a O +
subject O +
with O +
or O +
without O +
uterine O +
fibroids O +
and O +
in O +
need O +
of O +
treatment O +
by O +
administering O +
an O +
effective O +
amount O +
of O +
4- O -
( O -
( O -
R O -
) O -
-2- O -
[ O -
5- O -
( O -
2-fluoro-3-methoxy O -
- O -
phenyl O -
) O -
-3- O -
( O -
2-fluoro-6-trifluoromethyl O -
- O -
benzyl O -
) O -
-4- O +
methyl-2,6-dioxo-3,6-dihydro-2H O -
- O -
pyrimidin O -
- O -
l O -
- O -
yl O -
] O -
-l O -
- O -
phenyl O -
- O -
ethylamino O -
) O -
-butyric O +
acid O +
or O +
a O +
pharmaceutically O +
acceptable O +
salt O +
thereof O -
, O +
in O +
combination O +
with O +
estrogens O +
and O +
progestogens O -
. O +

3-heteroaryl O +
substituted O +
indazoles O +
Compounds O +
of O +
formula O +
( O -
I O -
) O +
which O +
are O +
inhibitors O +
of O +
Bub1 B-Gene +
kinase I-Gene -
, O +
processes O +
for O +
their O +
production O +
and O +
their O +
use O +
as O +
pharmaceuticals O -
. O +

Pharmaceutical O +
composition O +
for O +
treatment O +
of O +
inflammatory O +
bowel O +
disease O +
The O +
purpose O +
of O +
the O +
present O +
invention O +
is O +
to O +
provide O +
a O +
pharmaceutical O +
composition O +
for O +
the O +
treatment O +
of O +
inflammatory O +
bowel O +
disease O +
and O +
a O +
treatment O +
method O +
therefor O -
. O +

A O +
pharmaceutical O +
composition O +
containing O +
siRNA O +
inhibiting O +
the O +
expression O +
of O +
a O +
CD98 B-Gene +
heavy O +
chain O +
was O +
found O +
to O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
inflammatory O +
bowel O +
disease O -
. O +

As O +
a O +
result O -
, O +
a O +
novel O +
treatment O +
method O +
can O +
be O +
provided O +
that O +
uses O +
the O +
siRNA O +
for O +
inflammatory O +
bowel O +
disease O +
for O +
which O +
there O +
has O +
conventionally O +
been O +
no O +
appropriate O +
treatment O +
method O -
. O +

Therapeutic O +
agent O +
for O +
neurodegenerative O +
diseases O +
The O +
present O +
invention O +
relates O +
to O +
a O +
therapeutic O +
agent O +
for O +
neurodegenerative O +
diseases O -
, O +
which O +
contains O +
a O +
compound O +
represented O +
by O +
formula O +
( O -
I O -
) O +
or O +
a O +
salt O +
thereof O -
. O +

( O -
In O +
the O +
formula O -
, O +
Ar1 O +
represents O +
an O +
aromatic O +
group O -
; O +
X O +
represents O +
a O +
single O +
bond O +
or O +
a O +
linking O +
group O -
; O +
R1 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
an O +
aromatic O +
group O +
or O +
an O +
aralkyl O +
group O -
; O +
Y O +
represents O +
CH O -
( O -
R2 O -
) O +
( O -
wherein O +
R2 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
a O +
carbamoyl O +
group O -
, O +
an O +
acyl O +
group O +
or O +
an O +
alkyl O +
group O -
) O -
; O +
Z O +
represents O +
a O +
carbonyl O +
group O +
or O +
CH O -
( O -
R3 O -
) O +
( O -
wherein O +
R3 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
an O +
aromatic O +
group O +
or O +
an O +
aralkyl O +
group O -
) O -
; O +
and O +
Y O +
and O +
Z O +
may O +
combine O +
together O +
and O +
represent O +
C O -
( O -
R2 O -
) O -
=C O -
( O -
R4 O -
) O +
( O -
wherein O +
R2 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
a O +
carbamoyl O +
group O -
, O +
an O +
acyl O +
group O +
or O +
an O +
alkyl O +
group O -
, O +
and O +
R4 O +
represents O +
a O +
hydrogen O +
atom O -
, O +
a O +
hydroxyl O +
group O -
, O +
an O +
aromatic O +
group O +
or O +
an O +
aralkyl O +
group O -
) O -
. O -
) O +

Instantaneous O +
intestinal O +
regulator O +
The O +
present O +
invention O +
provides O +
an O +
instantaneous O +
intestinal O +
regulator O -
, O +
which O -
: O +
contains O +
a O +
Propionibacteriaceae O +
culture O -
, O +
DHNA O +
or O +
an O +
analog O +
thereof O +
as O +
an O +
active O +
ingredient O -
; O +
manifests O +
intestine O -
- O -
regulating O +
effects O +
within O +
one O +
day O +
after O +
being O +
taken O -
; O +
and O +
manifests O +
more O +
pronounced O +
intestine O -
- O -
regulating O +
effects O +
within O +
two O +
days O +
after O +
being O +
taken O -
. O +

The O +
present O +
invention O +
also O +
provides O +
an O +
instantaneous O +
intestinal O +
regulator O -
, O +
which O +
contains O +
a O +
Propionibacteriaceae O +
culture O -
, O +
DHNA O +
or O +
an O +
analog O +
thereof O +
as O +
an O +
active O +
ingredient O +
and O +
maintains O +
the O +
intestine O -
- O -
regulating O +
effects O +
for O +
two O +
weeks O +
after O +
being O +
taken O -
. O +

